7352670
D009599_D006973 NONE nitroprusside_4\NN\0|rebound_34|prevented_14|._44 (r_advmod) hypertensive_1\JJ\10405694|NONE_0
D009599_D006973 NONE snp_2\NNP\11493266|the_4 (r_compound) infusion_3\NN\14589223|NONE_0 (r_pobj) during_0\IN\0|animals_36|increase_71|,_108|showed_148|._164 (r_prep) demonstrated_7\VBD\2137132|NONE_0 (l_dobj) increase_10\NN\13576355|during_71|animals_35|,_37|showed_77|._93 (l_prep) in_11\IN\13603305|a_23|progressive_21|to_18 (l_pobj) pressure_13\NN\11419404|NONE_0
D009599_D007022 CID nitroprusside_19\NN\0|halothane_32|and_11|sodium_7 (l_parataxis) evaluated_24\VBN\670261|NONE_0 (l_nsubjpass) hypotension_22\NN\14057371|(_14|was_12
D009599_D007022 CID snp)-induced_21\VBN\0|NONE_0 (r_amod) hypotension_22\NN\14057371|(_14|was_12
D009599_D007022 CID snp_19\NNP\11493266|and_4 (r_conj) halothane_17\NN\3570838|NONE_0 (r_pobj) of_16\IN\0|the_33|combined_29|hypotensive_20 (r_prep) effects_15\NNS\13245626|NONE_0 (l_amod) hypotensive_14\JJ\10405694|the_13|combined_9|of_20
D012504_D006973 NONE saralasin_7\NN\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) prevented_5\VBN\0|rebound_48|nitroprusside_14|._30 (r_acl) hypertensive_1\JJ\10405694|NONE_0
D012504_D006973 NONE saralasin_20\NN\0|-_9 (r_npadvmod) treated_22\VBN\2376958|the_14 (r_amod) animals_23\NNS\4475|whereas_30|change_18 (r_nsubj) showed_24\VBD\2137132|during_148|animals_112|increase_77|,_40|._16 (r_advcl) demonstrated_7\VBD\2137132|NONE_0 (l_dobj) increase_10\NN\13576355|during_71|animals_35|,_37|showed_77|._93 (l_prep) in_11\IN\13603305|a_23|progressive_21|to_18 (l_pobj) pressure_13\NN\11419404|NONE_0
D006221_D007022 CID halothane_15\NN\3570838|and_21|sodium_25|nitroprusside_32 (r_compound) anesthesia_16\NN\14034177|NONE_0 (l_conj) nitroprusside_19\NN\0|halothane_32|and_11|sodium_7 (l_parataxis) evaluated_24\VBN\670261|NONE_0 (l_nsubjpass) hypotension_22\NN\14057371|(_14|was_12
D006221_D007022 CID halothane_17\NN\3570838|NONE_0 (r_pobj) of_16\IN\0|the_33|combined_29|hypotensive_20 (r_prep) effects_15\NNS\13245626|NONE_0 (l_amod) hypotensive_14\JJ\10405694|the_13|combined_9|of_20
D000809_D007022 NONE angiotensin_6\NN\4522421|in_19 (r_compound) system_7\NN\3575240|the_23|--_14 (l_prep) in_8\IN\13603305|angiotensin_19 (l_pobj) maintenance_10\NN\266806|NONE_0 (l_prep) during_14\IN\0|the_34|of_18 (l_pobj) anesthesia_16\NN\14034177|NONE_0 (l_conj) nitroprusside_19\NN\0|halothane_32|and_11|sodium_7 (l_parataxis) evaluated_24\VBN\670261|NONE_0 (l_nsubjpass) hypotension_22\NN\14057371|(_14|was_12
D000809_D007022 NONE angiotensin_8\NN\4522421|in_19 (r_compound) system_9\NN\3575240|the_23|--_14 (l_prep) in_10\IN\13603305|angiotensin_19 (l_pcomp) antagonizing_11\VBG\1787955|NONE_0 (l_dobj) effects_15\NNS\13245626|NONE_0 (l_amod) hypotensive_14\JJ\10405694|the_13|combined_9|of_20
15145918
D008750_D007022 CID methyldopa_10\NN\2721160|or_9 (r_conj) rilmenidine_6\NN\0|operated_15|,_2 (r_amod) rats_4\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|hypotension_72|._191 (r_prep) elicited_11\VBD\1617192|NONE_0 (l_dobj) hypotension_13\NN\14057371|in_72|._119
D008750_D007022 CID methyldopa_9\NN\2721160|NONE_0 (r_pobj) to_6\IN\0|the_25|hypotensive_21 (r_prep) response_5\NN\11410625|ovx_43|significantly_39|,_28|in_30|._81 (l_amod) hypotensive_4\JJ\10405694|the_4|to_21
D008750_D007022 CID methyldopa_9\NN\2721160|NONE_0 (r_pobj) to_6\IN\0|the_25|hypotensive_21 (r_prep) response_5\NN\11410625|ovx_43|significantly_39|,_28|in_30|._81 (r_dobj) enhanced_2\VBD\227165|NONE_0 (l_prep) in_11\IN\13603305|ovx_73|significantly_69|response_30|,_2|._51 (l_pobj) contrast_12\NN\13854649|NONE_0 (l_prep) to_13\IN\0|NONE_0 (l_pobj) effect_15\NN\34213|NONE_0 (l_prep) on_16\IN\0|no_10 (l_pobj) hypotension_18\NN\14057371|NONE_0
D008750_D007022 CID methyldopa_4\NN\2721160|the_19|enhanced_15|in_23 (r_compound) hypotension_5\NN\14057371|was_24|with_39|._102
D008750_D007022 CID methyldopa_25\NN\2721160|-_10 (r_compound) estrogen_27\NN\14745635|NONE_0 (r_compound) interaction_28\NN\37396|NONE_0 (r_pobj) in_22\IN\13603305|the_30|cardiac_26|autonomic_18 (r_prep) control_21\NN\5190804|NONE_0 (r_pobj) for_17\IN\0|a_7 (r_prep) role_16\NN\719494|NONE_0 (r_dobj) highlight_14\VB\13809920|that_81|estrogen_76|alpha2-_53|but_45|hypotension_16|and_4 (r_conj) downregulates_5\VBZ\0|findings_31|._158 (l_conj) hypotension_12\NN\14057371|that_65|estrogen_60|alpha2-_37|but_29|and_12|highlight_16
D003000_D007022 NONE clonidine_12\NN\2721160|NONE_0 (r_pobj) of_11\IN\0|the_23|hypotensive_19 (r_prep) effect_10\NN\34213|that_51|estrogen_46|negatively_37|and_71|implicates_75 (l_amod) hypotensive_9\JJ\10405694|the_4|of_19
C032302_D007022 CID rilmenidine_6\NN\0|operated_15|,_2 (r_amod) rats_4\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|hypotension_72|._191 (r_prep) elicited_11\VBD\1617192|NONE_0 (l_dobj) hypotension_13\NN\14057371|in_72|._119
C032302_D007022 CID rilmenidine_17\JJ\0|NONE_0 (r_amod) hypotension_18\NN\14057371|NONE_0 (r_pobj) on_16\IN\0|no_10 (r_prep) effect_15\NN\34213|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) contrast_12\NN\13854649|NONE_0 (r_pobj) in_11\IN\13603305|ovx_73|significantly_69|response_30|,_2|._51 (r_prep) enhanced_2\VBD\227165|NONE_0 (l_dobj) response_5\NN\11410625|ovx_43|significantly_39|,_28|in_30|._81 (l_amod) hypotensive_4\JJ\10405694|the_4|to_21
C032302_D007022 CID rilmenidine_17\JJ\0|NONE_0 (r_amod) hypotension_18\NN\14057371|NONE_0
D048288_D007022 NONE i1-imidazoline_7\NNP\0|receptor_15|-_23 (r_punct) mediated_10\VBN\761713|and_28 (r_conj) alpha2-adrenergic_5\JJ\0|in_67 (r_amod) hypotension_11\NN\14057371|NONE_0
D004967_D007022 NONE estrogen_3\NN\14745635|NONE_0 (l_prep) of_4\IN\0|NONE_0 (l_pobj) hypotension_11\NN\14057371|NONE_0
D004967_D007022 NONE estrogen_5\NN\14745635|that_5|negatively_9|effect_46|and_117|implicates_121 (r_nsubj) modulates_7\VBZ\1724459|we_48|have_45|recently_40|._168 (l_dobj) effect_10\NN\34213|that_51|estrogen_46|negatively_37|and_71|implicates_75 (l_amod) hypotensive_9\JJ\10405694|the_4|of_19
D004967_D007022 NONE estrogen_4\NN\14745635|that_5|alpha2-_23|but_31|hypotension_60|and_72|highlight_76 (r_nsubj) downregulates_5\VBZ\0|findings_31|._158 (l_conj) hypotension_12\NN\14057371|that_65|estrogen_60|alpha2-_37|but_29|and_12|highlight_16
D004967_D007022 NONE estrogen_27\NN\14745635|NONE_0 (r_compound) interaction_28\NN\37396|NONE_0 (r_pobj) in_22\IN\13603305|the_30|cardiac_26|autonomic_18 (r_prep) control_21\NN\5190804|NONE_0 (r_pobj) for_17\IN\0|a_7 (r_prep) role_16\NN\719494|NONE_0 (r_dobj) highlight_14\VB\13809920|that_81|estrogen_76|alpha2-_53|but_45|hypotension_16|and_4 (r_conj) downregulates_5\VBZ\0|findings_31|._158 (l_conj) hypotension_12\NN\14057371|that_65|estrogen_60|alpha2-_37|but_29|and_12|highlight_16
D008750_D001523 NONE methyldopa_4\NN\2721160|the_19|enhanced_15|in_23 (r_compound) hypotension_5\NN\14057371|was_24|with_39|._102 (r_nsubjpass) paralleled_10\VBN\2657219|NONE_0 (l_prep) with_11\IN\0|hypotension_39|was_15|._63 (l_pobj) reduction_13\NN\351485|NONE_0 (l_conj) activity_20\NN\30358|further_50|in_32|and_24
11672959
D012460_D056486 CID sulphasalazine_27\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_9 (r_prep) course_24\NN\883297|NONE_0 (r_pobj) of_22\IN\0|the_13|17th_9 (r_prep) day_21\NN\15154774|NONE_0 (r_pobj) on_18\IN\0|NONE_0 (r_prep) beginning_17\VBG\7283608|lady_84|constellation_67|,_2|._99 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) constellation_7\NN\5728678|lady_17|,_65|beginning_67|._166 (l_prep) of_8\IN\0|a_16 (l_pobj) dermatitis_9\NN\14226056|NONE_0 (l_conj) fever_11\NN\14299637|,_2 (l_conj) lymphadenopathy_13\NN\14204950|,_2 (l_conj) hepatitis_15\NN\14127211|and_4
D012460_D003872 CID sulphasalazine_27\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_9 (r_prep) course_24\NN\883297|NONE_0 (r_pobj) of_22\IN\0|the_13|17th_9 (r_prep) day_21\NN\15154774|NONE_0 (r_pobj) on_18\IN\0|NONE_0 (r_prep) beginning_17\VBG\7283608|lady_84|constellation_67|,_2|._99 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) constellation_7\NN\5728678|lady_17|,_65|beginning_67|._166 (l_prep) of_8\IN\0|a_16 (l_pobj) dermatitis_9\NN\14226056|NONE_0
D012460_D008206 CID sulphasalazine_27\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_9 (r_prep) course_24\NN\883297|NONE_0 (r_pobj) of_22\IN\0|the_13|17th_9 (r_prep) day_21\NN\15154774|NONE_0 (r_pobj) on_18\IN\0|NONE_0 (r_prep) beginning_17\VBG\7283608|lady_84|constellation_67|,_2|._99 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) constellation_7\NN\5728678|lady_17|,_65|beginning_67|._166 (l_prep) of_8\IN\0|a_16 (l_pobj) dermatitis_9\NN\14226056|NONE_0 (l_conj) fever_11\NN\14299637|,_2 (l_conj) lymphadenopathy_13\NN\14204950|,_2
D012460_D005334 CID sulphasalazine_27\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_9 (r_prep) course_24\NN\883297|NONE_0 (r_pobj) of_22\IN\0|the_13|17th_9 (r_prep) day_21\NN\15154774|NONE_0 (r_pobj) on_18\IN\0|NONE_0 (r_prep) beginning_17\VBG\7283608|lady_84|constellation_67|,_2|._99 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) constellation_7\NN\5728678|lady_17|,_65|beginning_67|._166 (l_prep) of_8\IN\0|a_16 (l_pobj) dermatitis_9\NN\14226056|NONE_0 (l_conj) fever_11\NN\14299637|,_2
D012460_D001172 NONE sulphasalazine_27\NN\0|NONE_0 (l_prep) for_28\IN\0|oral_20 (l_pobj) arthritis_33\NN\14171682|NONE_0
1664218
C042315_D002289 NONE ci-921_7\NNP\0|NONE_0 (r_punct) (_8\-LRB-\0|343499_5|)_11 (r_punct) nsc_9\NNP\8123696|ii_43|of_34|in_12|._41 (r_appos) study_2\NN\635850|NONE_0 (l_prep) in_12\IN\13603305|ii_55|of_46|nsc_12|._29 (l_pobj) cancer_18\NN\14239425|NONE_0
C042315_D002289 NONE 343499_10\CD\0|(_5|)_6 (r_nummod) nsc_9\NNP\8123696|ii_43|of_34|in_12|._41 (r_appos) study_2\NN\635850|NONE_0 (l_prep) in_12\IN\13603305|ii_55|of_46|nsc_12|._29 (l_pobj) cancer_18\NN\14239425|NONE_0
D000677_D002289 NONE amsacrine_5\NN\0|the_4 (r_compound) analogue_6\NN\4743605|NONE_0 (r_pobj) of_3\IN\0|ii_9|nsc_34|in_46|._75 (r_prep) study_2\NN\635850|NONE_0 (l_prep) in_12\IN\13603305|ii_55|of_46|nsc_12|._29 (l_pobj) cancer_18\NN\14239425|NONE_0
6103707
D005445_D010146 CID flunitrazepam_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|i.m._15 (r_prep) injection_5\NN\320852|NONE_0 (r_pobj) on_3\IN\0|NONE_0 (r_prep) pain_2\NN\14299637|there_10|often_59|._90
16787750
D014635_D003244 CID vpa_4\NNP\0|-_3 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) encephalopathy_7\NN\14084880|NONE_0 (r_pobj) of_3\IN\0|the_18|typical_14 (r_prep) signs_2\NNS\6643763|consciousness_49|,_62|marked_74|._164 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_attr) consciousness_10\NN\5669934|signs_49|,_13|marked_25|._115
D014635_D001855 CID vpa_17\NNP\0|-_3 (r_npadvmod) induced_19\VBN\1627355|,_6|and_23|encephalopathy_39 (r_amod) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45 (r_npadvmod) occur_4\VB\0|NONE_0 (l_prep) in_5\IN\13603305|complications_24|may_10|hepatotoxicity_92|._137 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) including_9\VBG\0|some_15|,_2 (l_pobj) pancreatitis_11\NN\14336539|NONE_0 (l_conj) suppression_15\NN\13489037|haemorrhagic_39|,_14
D014635_D001855 CID vpa_22\NNP\0|-_3 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_compound) encephalopathy_25\NN\14084880|,_45|induced_39|and_16 (r_conj) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45 (r_npadvmod) occur_4\VB\0|NONE_0 (l_prep) in_5\IN\13603305|complications_24|may_10|hepatotoxicity_92|._137 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) including_9\VBG\0|some_15|,_2 (l_pobj) pancreatitis_11\NN\14336539|NONE_0 (l_conj) suppression_15\NN\13489037|haemorrhagic_39|,_14
D014635_D012640 NONE vpa_4\NNP\0|-_3 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) encephalopathy_7\NN\14084880|NONE_0 (r_pobj) of_3\IN\0|the_18|typical_14 (r_prep) signs_2\NNS\6643763|consciousness_49|,_62|marked_74|._164 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_advcl) marked_13\VBD\1296462|signs_74|consciousness_25|,_12|._90 (l_ccomp) slowing_16\VBG\7296428|sometimes_32 (l_dobj) frequency_20\NN\15286249|background_38|,_20 (l_compound) seizure_19\NN\14081375|increased_10|,_17|with_19
D014635_D056486 CID vpa_17\NNP\0|-_3 (r_npadvmod) induced_19\VBN\1627355|,_6|and_23|encephalopathy_39 (r_amod) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45
D014635_D056486 CID vpa_22\NNP\0|-_3 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_compound) encephalopathy_25\NN\14084880|,_45|induced_39|and_16 (r_conj) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45
D014635_D001927 CID acid_1\NN\14818238|encephalopathy--19_13|cases_36|from_53|to_63|._138 (r_nsubj) induced_2\VBD\1627355|NONE_0 (l_advmod) encephalopathy--19_3\NNP\0|acid_13|cases_23|from_40|to_50|._125
D014635_D001927 CID vpa_18\NNP\0|-_3 (r_compound) therapy_20\NN\657604|NONE_0 (r_pobj) to_17\IN\0|in_24 (r_prep) associated_16\VBN\628491|2003_20|-a_15|side_12 (r_acl) effect_15\NN\34213|NONE_0 (r_pobj) to_10\IN\0|acid_63|encephalopathy--19_50|cases_27|from_10|._75 (r_prep) induced_2\VBD\1627355|NONE_0 (l_advmod) encephalopathy--19_3\NNP\0|acid_13|cases_23|from_40|to_50|._125
D014635_D001927 CID vpa_17\NNP\0|-_3 (r_npadvmod) induced_19\VBN\1627355|,_6|and_23|encephalopathy_39 (r_amod) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45 (l_conj) encephalopathy_25\NN\14084880|,_45|induced_39|and_16
D014635_D001927 CID vpa_22\NNP\0|-_3 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_compound) encephalopathy_25\NN\14084880|,_45|induced_39|and_16
D014635_D001927 CID vpa_4\NNP\0|-_3 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) encephalopathy_7\NN\14084880|NONE_0
D014635_D001927 CID vpa_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|causative_17|in_7 (r_prep) effect_7\NN\34213|NONE_0 (l_prep) in_10\IN\13603305|causative_24|of_7 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) encephalopathy_13\JJ\14084880|NONE_0
D014635_D001927 CID vpa_5\NNP\0|-_3 (r_npadvmod) associated_7\VBN\628491|in_26 (r_amod) encephalopathy_8\NN\14084880|NONE_0
D014635_D022124 NONE vpa_4\NNP\0|-_3 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) encephalopathy_7\NN\14084880|NONE_0 (r_pobj) of_3\IN\0|the_18|typical_14 (r_prep) signs_2\NNS\6643763|consciousness_49|,_62|marked_74|._164 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_advcl) marked_13\VBD\1296462|signs_74|consciousness_25|,_12|._90 (l_ccomp) slowing_16\VBG\7296428|sometimes_32 (l_dobj) frequency_20\NN\15286249|background_38|,_20 (l_prep) with_22\IN\0|increased_29|seizure_19|,_2 (l_conj) without_24\IN\0|or_3 (l_pobj) hyperammonemia_25\NN\0|NONE_0
D014635_D010195 CID vpa_17\NNP\0|-_3 (r_npadvmod) induced_19\VBN\1627355|,_6|and_23|encephalopathy_39 (r_amod) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45 (r_npadvmod) occur_4\VB\0|NONE_0 (l_prep) in_5\IN\13603305|complications_24|may_10|hepatotoxicity_92|._137 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) including_9\VBG\0|some_15|,_2 (l_pobj) pancreatitis_11\NN\14336539|NONE_0
D014635_D010195 CID vpa_22\NNP\0|-_3 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_compound) encephalopathy_25\NN\14084880|,_45|induced_39|and_16 (r_conj) hepatotoxicity_20\NN\0|complications_116|may_102|in_92|._45 (r_npadvmod) occur_4\VB\0|NONE_0 (l_prep) in_5\IN\13603305|complications_24|may_10|hepatotoxicity_92|._137 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) including_9\VBG\0|some_15|,_2 (l_pobj) pancreatitis_11\NN\14336539|NONE_0
9931093
C079574_D006973 NONE 139317_14\CD\0|on_7 (r_nummod) fr_13\NNP\14625458|a_22|receptor_20 (l_prep) on_15\IN\0|139317_7 (l_pobj) hypertension_18\NN\14057371|NONE_0
D016559_D007674 NONE 506_5\CD\0|NONE_0 (r_nummod) fk_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_21|clinical_17 (r_prep) utility_2\NN\8186047|is_18|by_33|._79 (r_nsubjpass) complicated_7\VBN\126264|NONE_0 (l_agent) by_8\IN\0|utility_33|is_15|._46 (l_pobj) hypertension_10\NN\14057371|NONE_0 (l_conj) nephrotoxicity_12\NN\0|substantial_29|and_4
D009569_D006973 NONE oxide_44\NN\14818238|,_25|the_23|endothelial_19|nitric_7|(_15|activity_22|._124 (r_compound) synthase_45\NN\0|,_106|the_104|of_89|et-1_78|and_73|converting_58 (r_conj) expression_27\NN\4679549|clarify_141|,_88|we_86|effects_63 (r_dobj) studied_10\VBD\0|NONE_0 (l_advcl) clarify_1\VB\939277|,_53|we_55|effects_78|expression_141 (l_dobj) mechanisms_3\NNS\13446390|to_15 (l_prep) of_4\IN\0|the_15 (l_pobj) hypertension_7\NN\14057371|NONE_0
D016559_D006973 CID 506-induced_3\JJ\0|in_25|._35 (r_nummod) hypertension_4\NN\14057371|NONE_0
D016559_D006973 CID 506_5\CD\0|NONE_0 (r_nummod) fk_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_21|clinical_17 (r_prep) utility_2\NN\8186047|is_18|by_33|._79 (r_nsubjpass) complicated_7\VBN\126264|NONE_0 (l_agent) by_8\IN\0|utility_33|is_15|._46 (l_pobj) hypertension_10\NN\14057371|NONE_0
D016559_D006973 CID 506-induced_6\JJ\0|fk_3 (r_compound) hypertension_7\NN\14057371|NONE_0
D016559_D006973 CID 506_16\CD\0|NONE_0 (r_nummod) fk_15\NNP\0|NONE_0 (r_pobj) of_14\IN\0|the_20|chronic_16|on_10 (r_prep) effects_13\NNS\13245626|clarify_78|,_25|we_23|expression_63 (r_dobj) studied_10\VBD\0|NONE_0 (l_advcl) clarify_1\VB\939277|,_53|we_55|effects_78|expression_141 (l_dobj) mechanisms_3\NNS\13446390|to_15 (l_prep) of_4\IN\0|the_15 (l_pobj) hypertension_7\NN\14057371|NONE_0
D016559_D006973 CID 506-induced_17\JJ\0|NONE_0 (r_nummod) fk_16\NNP\0|in_28 (r_poss) hypertension_18\NN\14057371|NONE_0
D016559_D006973 CID 506-induced_4\JJ\0|fk_3|in_25 (r_nummod) hypertension_5\NN\14057371|d-1_30|._20
230316
D007464_D001927 CID clioquinol_25\NN\2720201|NONE_0 (r_pobj) of_24\IN\0|a_12|high_10|over_14 (r_prep) dose_23\NN\3740161|NONE_0 (r_pobj) of_20\IN\0|the_14 (r_prep) ingestion_19\NN\13440063|NONE_0 (r_pobj) to_17\IN\0|usually_16 (r_prep) related_16\VBN\628491|an_43|acute_40|reversible_34 (r_acl) encephalopathy_14\NN\14084880|NONE_0
D006912_D020258 NONE hydroxyquinolines_3\NNS\0|NONE_0 (r_pobj) of_1\IN\0|:_32|analysis_43 (r_prep) neurotoxicity_0\NN\0|outside_84|._97
D006912_D020258 NONE hydroxyquinolines_13\NNS\0|NONE_0 (r_pobj) to_11\IN\0|possible_30|neurotoxic_21 (r_prep) reactions_10\NNS\13446390|NONE_0 (l_amod) neurotoxic_9\JJ\0|possible_9|to_21
D007464_C538178 NONE clioquinol_13\NN\2720201|many_26|had_13 (l_prep) as_14\IN\14622893|NONE_0 (l_pobj) treatment_15\NN\654885|NONE_0 (l_prep) for_16\IN\0|NONE_0 (l_pobj) enteropathica_18\NN\0|NONE_0
D007464_D009422 NONE clioquinol_25\NN\2720201|NONE_0 (r_pobj) of_24\IN\0|a_12|high_10|over_14 (r_prep) dose_23\NN\3740161|NONE_0 (r_pobj) of_20\IN\0|the_14 (r_prep) ingestion_19\NN\13440063|NONE_0 (r_pobj) to_17\IN\0|usually_16 (r_prep) related_16\VBN\628491|an_43|acute_40|reversible_34 (r_acl) encephalopathy_14\NN\14084880|NONE_0 (r_pobj) of_10\IN\0|disturbance_22 (r_prep) consisted_9\VBD\2603699|the_48|probable_44 (l_nsubj) disturbance_8\NN\407535|of_22
9727773
D001067_D006976 CID suppressants_9\NNS\3247620|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|high_49|of_34|._48 (r_acl) incidence_1\NN\13821570|NONE_0 (l_prep) of_2\IN\0|high_15|associated_34|._82 (l_pobj) hypertension_5\NN\14057371|NONE_0
D001067_D006976 CID suppressant_21\NN\3247620|NONE_0 (r_compound) drugs_22\NNS\14778436|NONE_0 (r_pobj) of_19\IN\0|the_11 (r_prep) intake_18\NN\13440063|NONE_0 (r_pobj) with_16\IN\0|which_26|has_20|been_16 (r_prep) associated_15\VBN\628491|a_58|rare_56|,_17 (r_relcl) disease_10\NN\14061805|hypertension_50|._80 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) hypertension_2\NN\14057371|disease_50|._130
D001067_D006976 CID suppressants_18\NNS\3247620|was_44|,_31|5_29|had_19|._12 (r_dobj) taken_16\VBN\2367363|NONE_0 (l_ccomp) was_9\VBD\0|,_13|5_15|had_25|suppressants_44|._56 (l_nsubj) diagnosis_4\NN\152018|in_18|uncertain_48 (l_prep) of_5\IN\0|the_14 (l_pobj) hypertension_8\NN\14057371|NONE_0
D001067_D006976 CID suppressants_7\NNS\3247620|NONE_0 (r_pobj) of_5\IN\0|unrestricted_26 (r_prep) prescription_4\NN\6786629|NONE_0 (r_pobj) of_2\IN\0|a_9 (r_prep) policy_1\NN\5902545|may_61|to_70|._134 (r_nsubj) lead_9\VB\5155821|NONE_0 (l_prep) to_10\IN\0|policy_70|may_9|._64 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|a_17|high_15 (l_pobj) hypertension_18\NN\14057371|NONE_0
8302922
D000527_D007022 CID e1_5\NNP\0|NONE_0 (r_pobj) during_3\IN\0|epidural_20|blood_11 (r_prep) flow_2\NN\7311115|hypotension_53|._64 (r_nsubj) induced_8\VBD\1627355|NONE_0 (l_dobj) hypotension_9\NN\14057371|flow_53|._11
D000527_D007022 CID e1_6\NNP\0|prostaglandin_14|(_3|)_8|or_10|trimethaphan_13 (r_nmod) pge1_8\NNP\0|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|to_16 (r_dobj) evaluate_1\VB\670261|hypotension_77|during_118 (r_csubj) induced_15\VBN\1627355|,_70|ebf_72|was_76|using_89|._211 (l_dobj) hypotension_16\NN\14057371|evaluate_77|during_41
D000527_D007022 CID pge1_8\NNP\0|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|to_16 (r_dobj) evaluate_1\VB\670261|hypotension_77|during_118 (r_csubj) induced_15\VBN\1627355|,_70|ebf_72|was_76|using_89|._211 (l_dobj) hypotension_16\NN\14057371|evaluate_77|during_41
D000527_D007022 CID pge1_2\NNP\0|NONE_0 (r_dobj) starting_1\VBG\457382|NONE_0 (r_pcomp) after_0\IN\0|significantly_74|compared_88|,_131|and_133|remained_175 (r_prep) decreased_14\VBD\169651|NONE_0 (l_conj) remained_34\VBD\2604760|after_175|significantly_101|compared_87|,_44|and_42 (l_nsubj) degree_28\NN\4916342|constant_43|until_52|._90 (l_prep) of_29\IN\0|the_11|due_15 (l_pobj) hypotension_30\NN\14057371|NONE_0
D000527_D007022 CID pge1_33\NNP\0|NONE_0 (r_pobj) to_32\IN\0|NONE_0 (r_pcomp) due_31\IN\5174653|the_26|of_15 (r_prep) degree_28\NN\4916342|constant_43|until_52|._90 (l_prep) of_29\IN\0|the_11|due_15 (l_pobj) hypotension_30\NN\14057371|NONE_0
D000527_D007022 CID pge1_4\NNP\0|that_5|may_5|preferable_12|decreased_88 (r_nsubj) be_6\VB\14625458|results_30|._92 (l_acomp) preferable_7\JJ\0|that_17|pge1_12|may_7|decreased_76 (l_xcomp) tmp_9\VB\0|NONE_0 (l_prep) for_10\IN\0|to_7 (l_pobj) anaesthesia_12\NN\14034177|NONE_0 (l_amod) hypotensive_11\JJ\10405694|in_24
D007530_D007022 NONE isoflurane_47\JJ\3570838|NONE_0 (r_amod) anaesthesia_48\NN\14034177|NONE_0 (r_pobj) under_46\IN\0|lateral_25|interbody_17 (r_prep) fusion_45\NN\7373277|who_40 (r_dobj) underwent_40\VBD\109660|30_16 (r_relcl) patients_38\NNS\9898892|NONE_0 (r_pobj) in_36\IN\13603305|method_7 (r_prep) using_31\VBG\418025|induced_89|,_19|ebf_17|was_13|._122 (r_advcl) measured_30\VBN\697589|NONE_0 (l_advcl) induced_15\VBN\1627355|,_70|ebf_72|was_76|using_89|._211 (l_dobj) hypotension_16\NN\14057371|evaluate_77|during_41
D014294_D007022 CID trimethaphan_7\RB\0|prostaglandin_20|or_3 (r_conj) e1_5\NNP\0|NONE_0 (r_pobj) during_3\IN\0|epidural_20|blood_11 (r_prep) flow_2\NN\7311115|hypotension_53|._64 (r_nsubj) induced_8\VBD\1627355|NONE_0 (l_dobj) hypotension_9\NN\14057371|flow_53|._11
D014294_D007022 CID trimethaphan_11\NN\0|prostaglandin_27|e1_13|(_10|)_5|or_3 (r_conj) pge1_8\NNP\0|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|to_16 (r_dobj) evaluate_1\VB\670261|hypotension_77|during_118 (r_csubj) induced_15\VBN\1627355|,_70|ebf_72|was_76|using_89|._211 (l_dobj) hypotension_16\NN\14057371|evaluate_77|during_41
D014294_D007022 CID tmp_13\NNP\0|NONE_0 (r_appos) trimethaphan_11\NN\0|prostaglandin_27|e1_13|(_10|)_5|or_3 (r_conj) pge1_8\NNP\0|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|to_16 (r_dobj) evaluate_1\VB\670261|hypotension_77|during_118 (r_csubj) induced_15\VBN\1627355|,_70|ebf_72|was_76|using_89|._211 (l_dobj) hypotension_16\NN\14057371|evaluate_77|during_41
D014294_D007022 CID tmp_4\NNP\0|or_3|product_27 (r_conj) pge1_2\NNP\0|NONE_0 (r_dobj) starting_1\VBG\457382|NONE_0 (r_pcomp) after_0\IN\0|significantly_74|compared_88|,_131|and_133|remained_175 (r_prep) decreased_14\VBD\169651|NONE_0 (l_conj) remained_34\VBD\2604760|after_175|significantly_101|compared_87|,_44|and_42 (l_nsubj) degree_28\NN\4916342|constant_43|until_52|._90 (l_prep) of_29\IN\0|the_11|due_15 (l_pobj) hypotension_30\NN\14057371|NONE_0
D014294_D007022 CID tmp_9\VB\0|NONE_0 (l_prep) for_10\IN\0|to_7 (l_pobj) anaesthesia_12\NN\14034177|NONE_0 (l_amod) hypotensive_11\JJ\10405694|in_24
D014294_D007022 CID tmp_17\NNP\0|because_8|ebf_14 (r_nsubj) decreased_18\VBD\169651|that_93|pge1_88|may_83|preferable_76 (r_advcl) be_6\VB\14625458|results_30|._92 (l_acomp) preferable_7\JJ\0|that_17|pge1_12|may_7|decreased_76 (l_xcomp) tmp_9\VB\0|NONE_0 (l_prep) for_10\IN\0|to_7 (l_pobj) anaesthesia_12\NN\14034177|NONE_0 (l_amod) hypotensive_11\JJ\10405694|in_24
3437726
D003647_D064420 NONE debrisoquine_13\JJ\0|in_26|,_44|constitutes_52|,_93 (r_compound) polymorphism_14\NN\11418750|NONE_0 (r_pobj) of_10\IN\0|the_31|metabolizer_22 (r_prep) phenotype_9\NN\4933544|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) belonging_3\VBG\7526757|NONE_0 (r_acl) patients_2\NNS\9898892|therefore_11|,_2|may_161|reactions_189|treated_204|._259 (r_nsubj) experience_29\VB\5984287|NONE_0 (l_dobj) reactions_32\NNS\13446390|therefore_200|,_191|patients_189|may_28|treated_15|._70
D013034_D064420 NONE sparteine_11\NN\0|/_9 (r_nmod) debrisoquine_13\JJ\0|in_26|,_44|constitutes_52|,_93 (r_compound) polymorphism_14\NN\11418750|NONE_0 (r_pobj) of_10\IN\0|the_31|metabolizer_22 (r_prep) phenotype_9\NN\4933544|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) belonging_3\VBG\7526757|NONE_0 (r_acl) patients_2\NNS\9898892|therefore_11|,_2|may_161|reactions_189|treated_204|._259 (r_nsubj) experience_29\VB\5984287|NONE_0 (l_dobj) reactions_32\NNS\13446390|therefore_200|,_191|patients_189|may_28|treated_15|._70
12789195
D008914_D004194 NONE minoxidil_9\NN\4522904|NONE_0 (r_pobj) of_8\IN\0|the_18|term_9 (r_prep) use_7\NN\407535|NONE_0 (r_pobj) by_2\IN\0|pseudoacromegaly_25|._33 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) pseudoacromegaly_0\NNS\0|by_25|._58
D008914_D004194 NONE minoxidil_15\NN\4522904|NONE_0 (r_pobj) of_14\IN\0|the_18|term_9|at_13 (r_prep) use_13\NN\407535|NONE_0 (r_pobj) from_8\IN\0|that_14 (r_prep) resulted_7\VBD\2633881|a_37|with_27 (r_relcl) patient_3\NN\9898892|we_13|._105 (l_prep) with_4\IN\0|a_10|resulted_27 (l_pobj) pseudoacromegaly_5\NNS\0|NONE_0
D008914_D004194 NONE minoxidil_13\JJ\4522904|NONE_0 (r_amod) use_14\NN\407535|NONE_0 (r_pobj) of_12\IN\0|a_14|side_12 (r_prep) effect_11\NN\34213|NONE_0 (r_pobj) as_8\IN\14622893|the_42|first_38|case_32|of_20 (r_prep) report_5\NN\6470073|this_23|._60 (l_prep) of_6\IN\0|the_22|first_18|case_12|as_20 (l_pobj) pseudoacromegaly_7\NNS\0|NONE_0
12198388
D009388_D012640 CID neostigmine_12\NN\2718084|to_68|,_6|and_4 (r_conj) sensitivity_0\NN\5651971|greater_111|._141 (l_prep) to_1\IN\0|,_62|and_64|neostigmine_68 (l_pobj) endpoints_4\NNS\8566028|NONE_0 (l_compound) convulsion_3\NN\14081375|several_8|induced_21
D009538_D012640 CID nicotine_7\NN\14712692|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|several_29|convulsion_21 (r_acl) endpoints_4\NNS\8566028|NONE_0 (l_compound) convulsion_3\NN\14081375|several_8|induced_21
D009538_D014202 NONE nicotine_3\NN\14712692|animals_26|were_18|,_64|and_66|recorded_119 (r_dobj) administered_2\VBN\2436349|NONE_0 (l_conj) recorded_25\VBN\2225492|animals_145|were_137|nicotine_119|,_55|and_53 (l_nsubjpass) latencies_17\NNS\15269513|were_40|and_54|converted_58|._85 (l_relcl) onset_19\VB\7325190|the_17 (l_prep) of_20\IN\0|to_9 (l_pobj) tremor_21\NN\345926|NONE_0
D009388_D014202 NONE neostigmine_8\JJ\2718084|,_5|or_3 (r_conj) carbachol_5\NN\0|,_2 (r_conj) nicotine_3\NN\14712692|animals_26|were_18|,_64|and_66|recorded_119 (r_dobj) administered_2\VBN\2436349|NONE_0 (l_conj) recorded_25\VBN\2225492|animals_145|were_137|nicotine_119|,_55|and_53 (l_nsubjpass) latencies_17\NNS\15269513|were_40|and_54|converted_58|._85 (l_relcl) onset_19\VB\7325190|the_17 (l_prep) of_20\IN\0|to_9 (l_pobj) tremor_21\NN\345926|NONE_0
D000431_D012640 NONE alcohol_6\NN\7881800|-_7 (r_compound) na_8\TO\14625458|mice_58 (r_aux) ve_9\VB\0|sensitivity_40|was_28|in_15|._58 (l_dobj) mice_23\NNS\2329401|na_58 (l_nmod) prone_13\NNP\0|(_26|wsr_27|)_30 (l_compound) seizure_11\NN\14081375|withdrawal_11|-_7|(_14|wsp_15|and_20|resistant_24
D000431_D012640 NONE ethanol_18\NN\14708720|NONE_0 (r_compound) withdrawal_19\NN\7206096|NONE_0 (r_compound) severity_20\NN\5036394|NONE_0 (r_pobj) with_17\IN\0|that_115|differences_110|may_18|be_14|and_33|implicate_37 (r_prep) associated_16\VBN\628491|results_120|._102 (l_nsubjpass) differences_4\NNS\4723816|that_5|may_92|be_96|with_110|and_143|implicate_147 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) activity_7\NN\30358|NONE_0 (l_conj) sensitivity_10\NN\5651971|cholinergic_38|and_17 (l_prep) to_11\IN\0|postsynaptic_25 (l_pobj) convulsants_13\NNS\0|NONE_0
D000431_D012640 NONE alcohol_26\NN\7881800|NONE_0 (r_compound) withdrawal_27\NN\7206096|NONE_0 (r_pobj) in_25\IN\13603305|cholinergic_23 (r_prep) mechanisms_24\NNS\13446390|NONE_0 (r_dobj) implicate_22\VB\2677097|that_152|differences_147|may_55|be_51|with_37|and_4 (r_conj) associated_16\VBN\628491|results_120|._102 (l_nsubjpass) differences_4\NNS\4723816|that_5|may_92|be_96|with_110|and_143|implicate_147 (l_prep) in_5\IN\13603305|NONE_0 (l_pobj) activity_7\NN\30358|NONE_0 (l_conj) sensitivity_10\NN\5651971|cholinergic_38|and_17 (l_prep) to_11\IN\0|postsynaptic_25 (l_pobj) convulsants_13\NNS\0|NONE_0
D000109_D012640 NONE acetylcholine_4\NN\14807558|hippocampal_12|and_22|sensitivity_49 (r_compound) release_5\NN\3748886|NONE_0 (l_conj) sensitivity_9\NN\5651971|hippocampal_61|acetylcholine_49|and_27 (l_prep) in_10\IN\13603305|cholinergic_35|convulsant_23 (l_pobj) lines_22\NNS\8426461|NONE_0 (l_amod) prone_14\JJ\0|withdrawal_19|resistant_29|selected_39|mouse_48 (l_npadvmod) seizure_12\NN\14081375|-_7|and_14|withdrawal_18
D000109_D012640 NONE acetylcholine_4\NN\14807558|hippocampal_12|and_22|sensitivity_49 (r_compound) release_5\NN\3748886|NONE_0 (l_conj) sensitivity_9\NN\5651971|hippocampal_61|acetylcholine_49|and_27 (l_prep) in_10\IN\13603305|cholinergic_35|convulsant_23 (l_pobj) lines_22\NNS\8426461|NONE_0 (l_amod) resistant_19\JJ\0|withdrawal_48|prone_29|selected_10|mouse_19 (l_npadvmod) seizure_17\NN\14081375|-_7
D000109_D012640 NONE ach_1\NNS\0|also_4|was_9|during_22|._69 (r_nsubjpass) measured_4\VBN\697589|NONE_0 (l_prep) during_5\IN\0|ach_22|also_18|was_13|._47 (l_pobj) testing_6\VBG\639556|NONE_0 (l_prep) for_7\IN\0|NONE_0 (l_pobj) convulsions_11\NNS\14081375|NONE_0
D000109_D012640 NONE ach_2\NNS\0|when_17|was_4|during_17 (r_nsubjpass) measured_4\VBN\697589|,_56|ach_72|was_76|significantly_80|%_107|in_110|,_121|but_123|elevated_148|._174 (l_prep) during_5\IN\0|when_34|ach_17|was_13 (l_pobj) testing_6\VBG\639556|NONE_0 (l_prep) for_7\IN\0|NONE_0 (l_pobj) convulsions_11\NNS\14081375|NONE_0
D000109_D012640 NONE ach_14\NNS\0|measured_72|,_16|was_4|significantly_8|%_35|in_38|,_49|but_51|elevated_76|._102 (r_nsubjpass) elevated_17\JJ\4048568|NONE_0 (l_advcl) measured_4\VBN\697589|,_56|ach_72|was_76|significantly_80|%_107|in_110|,_121|but_123|elevated_148|._174 (l_prep) during_5\IN\0|when_34|ach_17|was_13 (l_pobj) testing_6\VBG\639556|NONE_0 (l_prep) for_7\IN\0|NONE_0 (l_pobj) convulsions_11\NNS\14081375|NONE_0
D002217_D014202 NONE carbachol_5\NN\0|,_2 (r_conj) nicotine_3\NN\14712692|animals_26|were_18|,_64|and_66|recorded_119 (r_dobj) administered_2\VBN\2436349|NONE_0 (l_conj) recorded_25\VBN\2225492|animals_145|were_137|nicotine_119|,_55|and_53 (l_nsubjpass) latencies_17\NNS\15269513|were_40|and_54|converted_58|._85 (l_relcl) onset_19\VB\7325190|the_17 (l_prep) of_20\IN\0|to_9 (l_pobj) tremor_21\NN\345926|NONE_0
D002217_D012640 CID carbachol_9\NN\0|,_2 (r_conj) nicotine_7\NN\14712692|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|several_29|convulsion_21 (r_acl) endpoints_4\NNS\8566028|NONE_0 (l_compound) convulsion_3\NN\14081375|several_8|induced_21
6518066
D008094_D006331 NONE lithium_9\NN\14625458|NONE_0 (r_pobj) to_8\IN\0|screening_30|during_11 (r_prep) exposed_7\VBN\2110927|can_36|assessment_77|._155 (r_csubj) provide_13\VB\2199590|NONE_0 (l_dobj) assessment_18\NN\5732756|exposed_77|can_41|._78 (l_prep) of_19\IN\0|accurate_33|,_25|noninvasive_23 (l_pobj) presence_21\NN\13954253|NONE_0 (l_prep) of_24\IN\0|the_24|or_11|absence_8 (l_pobj) malformations_29\NNS\14213199|NONE_0
D008094_D006331 NONE lithium_25\NN\14625458|-_7 (r_npadvmod) induced_27\VBN\1627355|cardiac_8 (r_amod) malformations_29\NNS\14213199|NONE_0
D008094_D004437 CID lithium_1\NN\14625458|NONE_0 (l_conj) anomaly_6\NN\14501726|maternal_40|and_23|._57
10520387
D004809_D013610 CID ephedrine_9\NN\14712692|NONE_0 (r_pobj) of_8\IN\0|the_8|in_13 (r_prep) use_7\NN\407535|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|marked_19 (r_acl) tachycardia_3\NNS\14110674|however_16|,_9|in_87|,_114|reaching_129|._172
D004809_D013610 CID ephedrine_24\NN\14712692|the_4|/_9|propofol_10|/_18 (r_nmod) mixtures_28\NNS\19613|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) any_21\DT\0|NONE_0 (r_pobj) of_20\IN\0|elderly_17 (r_prep) patients_19\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|the_8|studied_62 (r_prep) use_16\NN\407535|due_93|,_29|we_27|would_24|not_18|._73 (r_dobj) recommend_14\VB\875394|NONE_0 (l_prep) due_0\IN\5174653|,_64|we_66|would_69|not_75|use_93|._166 (l_pobj) risk_3\NN\14541044|to_7 (l_prep) of_4\IN\0|the_9 (l_pobj) tachycardia_6\NN\14110674|NONE_0
D015742_D007022 CID propofol_13\NN\0|doses_22 (l_prep) in_14\IN\13603305|to_12 (l_pobj) order_15\NN\7168131|NONE_0 (l_acl) obtund_17\VB\192051|NONE_0 (l_dobj) response_20\NN\11410625|to_26 (l_amod) hypotensive_19\JJ\10405694|the_4
D015742_D007022 CID propofol_5\NN\0|the_29|of_16 (r_acl) addition_1\NN\3081021|be_45|._149 (r_nsubj) appears_6\VBZ\2604760|NONE_0 (l_xcomp) be_8\VB\14625458|addition_45|._104 (l_attr) method_11\NN\5616786|to_19 (l_prep) of_12\IN\0|an_20|effective_17 (l_pcomp) obtunding_13\VBG\192051|NONE_0 (l_dobj) response_16\NN\11410625|propofol_12 (l_amod) hypotensive_15\JJ\10405694|the_4
D015742_D007022 CID propofol_18\NN\0|response_12 (r_advcl) obtunding_13\VBG\192051|NONE_0 (l_dobj) response_16\NN\11410625|propofol_12 (l_amod) hypotensive_15\JJ\10405694|the_4
D004809_D017202 NONE ephedrine_24\NN\14712692|the_4|/_9|propofol_10|/_18 (r_nmod) mixtures_28\NNS\19613|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) any_21\DT\0|NONE_0 (r_pobj) of_20\IN\0|elderly_17 (r_prep) patients_19\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|the_8|studied_62 (r_prep) use_16\NN\407535|due_93|,_29|we_27|would_24|not_18|._73 (r_dobj) recommend_14\VB\875394|NONE_0 (l_prep) due_0\IN\5174653|,_64|we_66|would_69|not_75|use_93|._166 (l_pobj) risk_3\NN\14541044|to_7 (l_prep) of_4\IN\0|the_9 (l_pobj) tachycardia_6\NN\14110674|NONE_0 (l_acl) inducing_7\VBG\42311|this_17 (l_dobj) ischemia_9\NN\14195315|NONE_0
D004809_D007022 NONE ephedrine_11\NN\14712692|NONE_0 (r_pobj) of_10\IN\0|different_16 (r_prep) doses_9\NNS\3740161|propofol_22 (r_dobj) adding_7\VBG\156601|NONE_0 (l_xcomp) propofol_13\NN\0|doses_22 (l_prep) in_14\IN\13603305|to_12 (l_pobj) order_15\NN\7168131|NONE_0 (l_acl) obtund_17\VB\192051|NONE_0 (l_dobj) response_20\NN\11410625|to_26 (l_amod) hypotensive_19\JJ\10405694|the_4
D004809_D007022 NONE ephedrine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|the_13|propofol_16 (r_prep) addition_1\NN\3081021|be_45|._149 (r_nsubj) appears_6\VBZ\2604760|NONE_0 (l_xcomp) be_8\VB\14625458|addition_45|._104 (l_attr) method_11\NN\5616786|to_19 (l_prep) of_12\IN\0|an_20|effective_17 (l_pcomp) obtunding_13\VBG\192051|NONE_0 (l_dobj) response_16\NN\11410625|propofol_12 (l_amod) hypotensive_15\JJ\10405694|the_4
D015742_D013610 CID propofol_13\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) combination_11\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|the_21|of_13 (r_prep) use_7\NN\407535|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|marked_19 (r_acl) tachycardia_3\NNS\14110674|however_16|,_9|in_87|,_114|reaching_129|._172
D015742_D013610 CID propofol_26\NN\0|the_14|ephedrine_10|/_1|/_8 (r_nmod) mixtures_28\NNS\19613|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) any_21\DT\0|NONE_0 (r_pobj) of_20\IN\0|elderly_17 (r_prep) patients_19\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|the_8|studied_62 (r_prep) use_16\NN\407535|due_93|,_29|we_27|would_24|not_18|._73 (r_dobj) recommend_14\VB\875394|NONE_0 (l_prep) due_0\IN\5174653|,_64|we_66|would_69|not_75|use_93|._166 (l_pobj) risk_3\NN\14541044|to_7 (l_prep) of_4\IN\0|the_9 (l_pobj) tachycardia_6\NN\14110674|NONE_0
D015742_D017202 NONE propofol_26\NN\0|the_14|ephedrine_10|/_1|/_8 (r_nmod) mixtures_28\NNS\19613|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) any_21\DT\0|NONE_0 (r_pobj) of_20\IN\0|elderly_17 (r_prep) patients_19\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|the_8|studied_62 (r_prep) use_16\NN\407535|due_93|,_29|we_27|would_24|not_18|._73 (r_dobj) recommend_14\VB\875394|NONE_0 (l_prep) due_0\IN\5174653|,_64|we_66|would_69|not_75|use_93|._166 (l_pobj) risk_3\NN\14541044|to_7 (l_prep) of_4\IN\0|the_9 (l_pobj) tachycardia_6\NN\14110674|NONE_0 (l_acl) inducing_7\VBG\42311|this_17 (l_dobj) ischemia_9\NN\14195315|NONE_0
6888657
D004054_D009369 NONE des_12\NNP\14749794|-_3 (r_npadvmod) induced_14\VBN\1627355|the_8 (r_amod) tumor_15\NN\14234074|further_37|as_6
D004054_D010911 CID diethylstilbestrol_12\NN\14749794|NONE_0 (r_pobj) with_11\IN\0|chronic_18 (r_prep) treatment_10\NN\654885|NONE_0 (r_pobj) by_8\IN\0|tumors_40|were_33|in_20|implanted_60|._105 (r_agent) induced_3\VBN\1627355|NONE_0 (l_nsubjpass) tumors_1\NNS\14234074|were_7|in_20|by_40|implanted_100|._145
D004054_D010911 CID des_14\NNP\14749794|(_1|,_3|subcutaneously_24|in_39 (r_npadvmod) implanted_21\VBN\1421622|tumors_100|were_93|in_80|by_60|._45 (r_parataxis) induced_3\VBN\1627355|NONE_0 (l_nsubjpass) tumors_1\NNS\14234074|were_7|in_20|by_40|implanted_100|._145
D004967_D010911 NONE estrogen_2\NN\14745635|-_8 (r_npadvmod) induced_4\VBN\1627355|adenohypophyseal_8|in_32 (r_amod) tumors_6\NNS\14234074|NONE_0
15036754
D010755_D012640 NONE organophosphate_0\NNP\14919948|-_15 (r_npadvmod) induced_2\VBN\1627355|and_20|prevention_24|of_35|._63 (r_amod) convulsions_3\NNS\14081375|NONE_0
D003975_D011041 NONE diazepam_3\NN\2830852|when_10|cpa_5|,_2|was_17|immediately_27|after_39 (r_nsubjpass) given_7\VBN\5892096|,_36|treatments_44|,_64|delayed_66|._131 (r_advcl) prevented_16\VBD\0|NONE_0 (l_conj) delayed_18\VBN\439958|given_66|,_30|treatments_22|,_2|._65 (l_conj) shortened_20\VBN\429060|or_3 (l_dobj) occurrence_22\NN\29378|NONE_0 (l_prep) of_23\IN\0|the_15 (l_pobj) signs_25\NNS\6643763|NONE_0 (l_prep) of_26\IN\0|serious_14 (l_pobj) poisoning_27\NN\14034177|NONE_0
D003975_D011041 NONE diazepam_5\NN\2830852|,_2 (r_conj) cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_dobj) occurrence_14\NN\29378|in_81|,_68|cpa_66|and_41|reduced_50|._84 (l_prep) of_15\IN\0|the_15 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_18\IN\0|serious_14 (l_pobj) poisoning_19\NN\14034177|NONE_0
D007531_D064420 NONE dfp_4\NNP\0|-_3 (r_compound) atropine_6\NN\14712692|NONE_0 (r_pobj) with_3\IN\0|rats_13|showed_18|._65 (r_prep) treated_2\VBD\2376958|NONE_0 (l_conj) showed_7\VBD\2137132|rats_31|with_18|._47 (l_dobj) signs_14\NNS\6643763|NONE_0 (l_compound) toxicity_13\NN\13576101|severe_26|typical_19|induced_8
D007531_D064420 NONE dfp_10\NNP\0|NONE_0 (r_compound) toxicity_11\NN\13576101|NONE_0
D007531_D064420 NONE dfp_26\NNP\0|NONE_0 (r_pobj) of_25\IN\0|the_13|in_7 (r_prep) toxicity_24\NN\13576101|thus_17
D000109_D064420 NONE acetylcholine_25\NN\14807558|(_14|ach_15|)_18 (r_nmod) levels_29\NNS\4916342|which_35 (r_dobj) elevates_24\VBZ\2391803|the_40|central_36|nervous_28|(_13|cns_12|)_9|,_8 (r_relcl) system_18\NN\3575240|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) aches_13\NNP\14322699|NONE_0 (r_pobj) with_12\IN\0|their_27|irreversible_21 (r_prep) binding_11\NN\4688246|NONE_0 (r_pobj) of_8\IN\0|the_11 (r_prep) result_7\NN\34213|toxicity_23|._126 (r_attr) is_5\VBZ\0|NONE_0 (l_nsubj) toxicity_2\NN\13576101|result_23|._149
D000109_D064420 NONE ach_27\NNS\0|acetylcholine_15|(_1|)_3 (r_nmod) levels_29\NNS\4916342|which_35 (r_dobj) elevates_24\VBZ\2391803|the_40|central_36|nervous_28|(_13|cns_12|)_9|,_8 (r_relcl) system_18\NN\3575240|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) aches_13\NNP\14322699|NONE_0 (r_pobj) with_12\IN\0|their_27|irreversible_21 (r_prep) binding_11\NN\4688246|NONE_0 (r_pobj) of_8\IN\0|the_11 (r_prep) result_7\NN\34213|toxicity_23|._126 (r_attr) is_5\VBZ\0|NONE_0 (l_nsubj) toxicity_2\NN\13576101|result_23|._149
D010755_D064420 NONE ops_4\NNS\0|NONE_0 (r_pobj) of_3\IN\0|the_19|acute_15 (r_prep) toxicity_2\NN\13576101|result_23|._149
D010755_D064420 NONE op_10\NN\0|-_2 (r_npadvmod) induced_12\VBN\1627355|severe_18|typical_11|toxicity_8 (r_amod) signs_14\NNS\6643763|NONE_0 (l_compound) toxicity_13\NN\13576101|severe_26|typical_19|induced_8
D011220_D064420 NONE 2pam_7\CD\0|and_4|in_5 (r_conj) diazepam_5\NN\2830852|,_2 (r_conj) cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_conj) reduced_22\VBD\441445|in_131|,_118|cpa_116|occurrence_50|and_9|._34 (l_dobj) toxicity_24\NN\13576101|thus_17
D007531_D011041 NONE dfp_10\NNP\0|-_3 (r_compound) atropine_12\NN\14712692|NONE_0 (r_pobj) after_9\IN\0|when_49|cpa_44|,_41|diazepam_39|was_22|immediately_12 (r_prep) given_7\VBN\5892096|,_36|treatments_44|,_64|delayed_66|._131 (r_advcl) prevented_16\VBD\0|NONE_0 (l_conj) delayed_18\VBN\439958|given_66|,_30|treatments_22|,_2|._65 (l_conj) shortened_20\VBN\429060|or_3 (l_dobj) occurrence_22\NN\29378|NONE_0 (l_prep) of_23\IN\0|the_15 (l_pobj) signs_25\NNS\6643763|NONE_0 (l_prep) of_26\IN\0|serious_14 (l_pobj) poisoning_27\NN\14034177|NONE_0
D007531_D011041 NONE dfp_26\NNP\0|NONE_0 (r_pobj) of_25\IN\0|the_13|in_7 (r_prep) toxicity_24\NN\13576101|thus_17 (r_dobj) reduced_22\VBD\441445|in_131|,_118|cpa_116|occurrence_50|and_9|._34 (r_conj) prevented_12\VBD\0|NONE_0 (l_dobj) occurrence_14\NN\29378|in_81|,_68|cpa_66|and_41|reduced_50|._84 (l_prep) of_15\IN\0|the_15 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_18\IN\0|serious_14 (l_pobj) poisoning_19\NN\14034177|NONE_0
D003975_D064420 NONE diazepam_5\NN\2830852|,_2 (r_conj) cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_conj) reduced_22\VBD\441445|in_131|,_118|cpa_116|occurrence_50|and_9|._34 (l_dobj) toxicity_24\NN\13576101|thus_17
C048599_D064420 NONE cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_conj) reduced_22\VBD\441445|in_131|,_118|cpa_116|occurrence_50|and_9|._34 (l_dobj) toxicity_24\NN\13576101|thus_17
D016291_D064420 NONE mk801_2\NNP\0|did_6|not_10|protection_35|._66 (r_nsubj) offer_5\VB\7160883|NONE_0 (l_dobj) protection_8\NN\407535|mk801_35|did_29|not_25|._31 (l_prep) against_9\IN\0|any_26|additional_22 (l_pobj) toxicity_11\NN\13576101|NONE_0
D010755_D004194 NONE organophosphate_0\NNP\14919948|-_15 (r_npadvmod) induced_2\VBN\1627355|and_20|prevention_24|of_35|._63 (r_amod) convulsions_3\NNS\14081375|NONE_0 (l_prep) of_6\IN\0|induced_35|and_15|prevention_11|._28 (l_pobj) damages_8\NNS\13282550|NONE_0
D001285_D011041 NONE atropine_12\NN\14712692|NONE_0 (r_pobj) after_9\IN\0|when_49|cpa_44|,_41|diazepam_39|was_22|immediately_12 (r_prep) given_7\VBN\5892096|,_36|treatments_44|,_64|delayed_66|._131 (r_advcl) prevented_16\VBD\0|NONE_0 (l_conj) delayed_18\VBN\439958|given_66|,_30|treatments_22|,_2|._65 (l_conj) shortened_20\VBN\429060|or_3 (l_dobj) occurrence_22\NN\29378|NONE_0 (l_prep) of_23\IN\0|the_15 (l_pobj) signs_25\NNS\6643763|NONE_0 (l_prep) of_26\IN\0|serious_14 (l_pobj) poisoning_27\NN\14034177|NONE_0
D001285_D011041 NONE atropine_11\NN\14712692|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) combination_9\NN\7951464|NONE_0 (r_pobj) in_8\IN\13603305|and_9|2pam_5 (r_prep) diazepam_5\NN\2830852|,_2 (r_conj) cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_dobj) occurrence_14\NN\29378|in_81|,_68|cpa_66|and_41|reduced_50|._84 (l_prep) of_15\IN\0|the_15 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_18\IN\0|serious_14 (l_pobj) poisoning_19\NN\14034177|NONE_0
D011220_D011041 NONE 2pam_5\CD\0|or_3 (r_conj) diazepam_3\NN\2830852|when_10|cpa_5|,_2|was_17|immediately_27|after_39 (r_nsubjpass) given_7\VBN\5892096|,_36|treatments_44|,_64|delayed_66|._131 (r_advcl) prevented_16\VBD\0|NONE_0 (l_conj) delayed_18\VBN\439958|given_66|,_30|treatments_22|,_2|._65 (l_conj) shortened_20\VBN\429060|or_3 (l_dobj) occurrence_22\NN\29378|NONE_0 (l_prep) of_23\IN\0|the_15 (l_pobj) signs_25\NNS\6643763|NONE_0 (l_prep) of_26\IN\0|serious_14 (l_pobj) poisoning_27\NN\14034177|NONE_0
D011220_D011041 NONE 2pam_7\CD\0|and_4|in_5 (r_conj) diazepam_5\NN\2830852|,_2 (r_conj) cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_dobj) occurrence_14\NN\29378|in_81|,_68|cpa_66|and_41|reduced_50|._84 (l_prep) of_15\IN\0|the_15 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_18\IN\0|serious_14 (l_pobj) poisoning_19\NN\14034177|NONE_0
D001285_D064420 NONE atropine_6\NN\14712692|NONE_0 (r_pobj) with_3\IN\0|rats_13|showed_18|._65 (r_prep) treated_2\VBD\2376958|NONE_0 (l_conj) showed_7\VBD\2137132|rats_31|with_18|._47 (l_dobj) signs_14\NNS\6643763|NONE_0 (l_compound) toxicity_13\NN\13576101|severe_26|typical_19|induced_8
D001285_D064420 NONE atropine_0\NNP\14712692|-_8 (r_compound) mk801_2\NNP\0|did_6|not_10|protection_35|._66 (r_nsubj) offer_5\VB\7160883|NONE_0 (l_dobj) protection_8\NN\407535|mk801_35|did_29|not_25|._31 (l_prep) against_9\IN\0|any_26|additional_22 (l_pobj) toxicity_11\NN\13576101|NONE_0
D001285_D064420 NONE atropine_11\NN\14712692|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) combination_9\NN\7951464|NONE_0 (r_pobj) in_8\IN\13603305|and_9|2pam_5 (r_prep) diazepam_5\NN\2830852|,_2 (r_conj) cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_conj) reduced_22\VBD\441445|in_131|,_118|cpa_116|occurrence_50|and_9|._34 (l_dobj) toxicity_24\NN\13576101|thus_17
C048599_D011041 NONE cpa_1\NN\9761403|when_5|,_3|diazepam_5|was_22|immediately_32|after_44 (r_nsubjpass) given_7\VBN\5892096|,_36|treatments_44|,_64|delayed_66|._131 (r_advcl) prevented_16\VBD\0|NONE_0 (l_conj) delayed_18\VBN\439958|given_66|,_30|treatments_22|,_2|._65 (l_conj) shortened_20\VBN\429060|or_3 (l_dobj) occurrence_22\NN\29378|NONE_0 (l_prep) of_23\IN\0|the_15 (l_pobj) signs_25\NNS\6643763|NONE_0 (l_prep) of_26\IN\0|serious_14 (l_pobj) poisoning_27\NN\14034177|NONE_0
C048599_D011041 NONE cpa_3\NN\9761403|in_15|,_2|occurrence_66|and_107|reduced_116|._150 (r_nsubj) prevented_12\VBD\0|NONE_0 (l_dobj) occurrence_14\NN\29378|in_81|,_68|cpa_66|and_41|reduced_50|._84 (l_prep) of_15\IN\0|the_15 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_18\IN\0|serious_14 (l_pobj) poisoning_19\NN\14034177|NONE_0
2887062
D001971_D000236 NONE bromocriptine_15\JJ\0|of_24 (r_amod) treatment_16\NN\654885|NONE_0 (l_prep) of_17\IN\0|bromocriptine_24 (l_pobj) cells_20\NNS\3080309|NONE_0 (l_compound) adenoma_19\NN\14236226|the_4
D004967_D015175 CID estrogen_8\NN\14745635|-_8 (r_npadvmod) induced_10\VBN\1627355|rat_8|after_26 (r_amod) prolactinomas_12\NNS\0|NONE_0
D004967_D015175 CID estrogen_21\NN\14745635|-_8 (r_npadvmod) induced_23\VBN\1627355|rat_8|prolactinoma_12|h_33|and_35 (r_amod) cells_26\NNS\3080309|NONE_0 (r_pobj) to_20\IN\0|clarify_146|analyses_22|were_13|h_53|._112 (r_prep) applied_19\VBN\0|NONE_0 (l_advcl) clarify_1\VB\939277|analyses_124|were_133|to_146|h_199|._258 (l_dobj) effects_3\NNS\13245626|to_15 (l_prep) on_6\IN\0|the_29|of_17 (l_pobj) cells_8\NNS\3080309|NONE_0 (l_compound) prolactinoma_7\NN\0|in_19
D004967_D015175 CID estrogen_21\NN\14745635|-_8 (r_npadvmod) induced_23\VBN\1627355|rat_8|prolactinoma_12|h_33|and_35 (r_amod) cells_26\NNS\3080309|NONE_0 (l_compound) prolactinoma_25\NN\0|induced_12|rat_4|h_21|and_23
D001971_D015175 NONE bromocriptine_14\NN\0|NONE_0 (r_amod) treatment_15\NN\654885|NONE_0 (r_pobj) after_13\IN\0|induced_26|rat_18 (r_prep) prolactinomas_12\NNS\0|NONE_0
D001971_D015175 NONE bromocriptine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|on_17 (r_prep) effects_3\NNS\13245626|to_15 (l_prep) on_6\IN\0|the_29|of_17 (l_pobj) cells_8\NNS\3080309|NONE_0 (l_compound) prolactinoma_7\NN\0|in_19
D001971_D015175 NONE bromocriptine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|on_17 (r_prep) effects_3\NNS\13245626|to_15 (r_dobj) clarify_1\VB\939277|analyses_124|were_133|to_146|h_199|._258 (r_advcl) applied_19\VBN\0|NONE_0 (l_prep) to_20\IN\0|clarify_146|analyses_22|were_13|h_53|._112 (l_pobj) cells_26\NNS\3080309|NONE_0 (l_compound) prolactinoma_25\NN\0|induced_12|rat_4|h_21|and_23
D001971_D015175 NONE bromocriptine_35\NN\0|NONE_0 (r_pobj) of_34\IN\0|NONE_0 (r_prep) injection_33\NN\320852|NONE_0 (r_pobj) after_32\IN\0|6_4|mg/kg_36 (r_prep) h_31\NN\14622893|clarify_199|analyses_75|were_66|to_53|._59 (r_conj) applied_19\VBN\0|NONE_0 (l_advcl) clarify_1\VB\939277|analyses_124|were_133|to_146|h_199|._258 (l_dobj) effects_3\NNS\13245626|to_15 (l_prep) on_6\IN\0|the_29|of_17 (l_pobj) cells_8\NNS\3080309|NONE_0 (l_compound) prolactinoma_7\NN\0|in_19
D001971_D015175 NONE bromocriptine_35\NN\0|NONE_0 (r_pobj) of_34\IN\0|NONE_0 (r_prep) injection_33\NN\320852|NONE_0 (r_pobj) after_32\IN\0|6_4|mg/kg_36 (r_prep) h_31\NN\14622893|clarify_199|analyses_75|were_66|to_53|._59 (r_conj) applied_19\VBN\0|NONE_0 (l_prep) to_20\IN\0|clarify_146|analyses_22|were_13|h_53|._112 (l_pobj) cells_26\NNS\3080309|NONE_0 (l_compound) prolactinoma_25\NN\0|induced_12|rat_4|h_21|and_23
10669626
D014807_D002114 NONE d_8\JJ\15089472|and_12 (r_conj) growth_5\NN\13526110|NONE_0 (r_nmod) treatment_9\NN\654885|that_26|extent_22|given_61 (r_nsubj) enhance_10\VB\227165|studies_56|._245 (l_prep) given_18\VBN\5892096|that_87|treatment_61|extent_39 (l_advcl) inhibit_24\VB\2510337|doses_21 (l_dobj) carboxylation_27\NN\0|to_17 (l_prep) of_28\IN\0|gamma_20|-_15 (l_pobj) protein_31\NN\14944888|NONE_0 (l_appos) inhibitor_35\NN\20090|matrix_36|gla_29|,_18 (l_compound) calcification_34\NN\13446390|known_24
D014807_D002114 NONE d_30\NN\15089472|-_1 (r_npadvmod) treated_32\VBN\2376958|vitamin_10 (r_amod) rats_33\NNS\2329401|NONE_0 (r_pobj) of_28\IN\0|the_10 (r_prep) media_27\NNS\3575240|NONE_0 (r_pobj) in_25\IN\13603305|at_39 (r_prep) calcification_24\NN\13446390|NONE_0
D014807_D002114 NONE d_15\NN\15089472|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) produced_12\VBN\1617192|serum_14 (r_acl) calcium_11\NN\14625458|NONE_0 (r_pobj) in_9\IN\13603305|the_14 (r_prep) elevation_8\NN\7445480|NONE_0 (r_pobj) on_6\IN\0|no_10 (r_prep) effect_5\NN\34213|because_34|treatment_17 (r_dobj) had_3\VBD\0|is_114|probably_117|best_126|by_141|._245 (r_advcl) explained_27\VBN\831651|NONE_0 (l_agent) by_28\IN\0|had_141|is_27|probably_24|best_15|._104 (l_pobj) hypothesis_30\NN\7162194|NONE_0 (l_acl) inhibits_33\VBZ\2510337|the_29 (l_prep) as_40\IN\14622893|that_58|warfarin_53|activity_31 (l_pobj) inhibitor_43\NN\20090|NONE_0 (l_compound) calcification_42\NN\13446390|a_2
D014807_D002114 NONE d_23\NN\15089472|NONE_0 (r_pobj) between_19\IN\0|the_12 (r_prep) synergy_18\NN\13518963|vitamin_15|,_6 (r_appos) d_15\NN\15089472|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) produced_12\VBN\1617192|serum_14 (r_acl) calcium_11\NN\14625458|NONE_0 (r_pobj) in_9\IN\13603305|the_14 (r_prep) elevation_8\NN\7445480|NONE_0 (r_pobj) on_6\IN\0|no_10 (r_prep) effect_5\NN\34213|because_34|treatment_17 (r_dobj) had_3\VBD\0|is_114|probably_117|best_126|by_141|._245 (r_advcl) explained_27\VBN\831651|NONE_0 (l_agent) by_28\IN\0|had_141|is_27|probably_24|best_15|._104 (l_pobj) hypothesis_30\NN\7162194|NONE_0 (l_acl) inhibits_33\VBZ\2510337|the_29 (l_prep) as_40\IN\14622893|that_58|warfarin_53|activity_31 (l_pobj) inhibitor_43\NN\20090|NONE_0 (l_compound) calcification_42\NN\13446390|a_2
D015055_D002114 NONE carboxyglutamate_8\NN\0|the_10|of_26 (r_compound) residues_9\NNS\20827|although_36|are_31|apparently_35|for_55|as_72 (r_nsubjpass) required_16\VBN\0|that_87|,_54|they_56|are_61|not_65|for_78 (l_prep) as_20\IN\14622893|although_108|residues_72|are_41|apparently_37|for_17 (l_pobj) inhibitor_23\NN\20090|NONE_0 (l_compound) calcification_22\NN\13446390|a_2
D015055_D002114 NONE carboxyglutamate_8\NN\0|the_10|of_26 (r_compound) residues_9\NNS\20827|although_36|are_31|apparently_35|for_55|as_72 (r_nsubjpass) required_16\VBN\0|that_87|,_54|they_56|are_61|not_65|for_78 (r_advcl) required_28\VBN\0|observations_178|._52 (l_prep) for_29\IN\0|that_165|required_78|,_24|they_22|are_17|not_13 (l_pobj) accumulation_31\NN\13497135|NONE_0 (l_prep) at_32\IN\14622893|its_17 (l_pobj) sites_34\NNS\8673395|NONE_0 (l_compound) calcification_33\NN\13446390|NONE_0
D014859_D061205 CID warfarin_0\NNP\2718259|-_8 (r_npadvmod) induced_2\VBN\1627355|artery_8 (r_amod) calcification_4\NN\13446390|is_14|by_29
D014859_D061205 CID warfarin_22\NNP\2718259|NONE_0 (r_pobj) of_21\IN\0|sufficient_17 (r_prep) doses_20\NNS\3740161|inhibit_21 (r_dobj) given_18\VBN\5892096|that_87|treatment_61|extent_39 (r_prep) enhance_10\VB\227165|studies_56|._245 (l_dobj) extent_12\NN\13939892|that_48|treatment_22|given_39 (l_prep) of_13\IN\0|the_11 (l_pobj) calcification_15\NN\13446390|NONE_0
D014859_D061205 CID warfarin_17\NNP\2718259|-_8 (r_npadvmod) treated_19\VBN\2376958|NONE_0 (r_amod) rats_20\NNS\2329401|NONE_0 (r_pobj) in_16\IN\13603305|artery_21 (r_prep) calcification_15\NN\13446390|NONE_0
D014859_D061205 CID warfarin_5\NNP\2718259|NONE_0 (r_pobj) with_4\IN\0|for_12 (r_prep) treatment_0\NN\654885|calcification_57|._167 (r_nsubj) caused_6\VBD\1617192|NONE_0 (l_dobj) calcification_9\NN\13446390|treatment_57|._110 (l_prep) of_10\IN\0|massive_28|focal_20|in_20|and_39|calcification_64 (l_pobj) media_13\NNS\3575240|NONE_0 (l_compound) artery_12\NN\5417975|the_4
D014859_D061205 CID warfarin_20\NNP\2718259|NONE_0 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) of_19\IN\0|4_8 (r_prep) weeks_18\NNS\15113229|even_13 (r_pobj) after_16\IN\0|in_87|,_76|calcification_64|could_50|be_44|in_32|._35 (r_prep) detected_8\VBN\2163746|NONE_0 (l_nsubjpass) calcification_5\NN\13446390|in_23|,_12|could_14|be_20|in_32|after_64|._99
D014859_D061205 CID warfarin_8\NNP\2718259|-_8 (r_npadvmod) induced_10\VBN\1627355|artery_8|in_29 (r_amod) calcification_12\NN\13446390|NONE_0
D014859_D061205 CID warfarin_7\NNP\2718259|NONE_0 (r_pobj) with_6\IN\0|both_20|dietary_15 (r_prep) groups_5\NNS\2137|NONE_0 (r_pobj) of_2\IN\0|concurrent_21 (r_prep) treatment_1\NN\654885|calcification_70|._216 (r_nsubj) produced_8\VBD\1617192|NONE_0 (l_dobj) calcification_11\NN\13446390|treatment_70|._146 (l_prep) of_12\IN\0|massive_28|focal_20|in_20|but_47|calcification_72 (l_pobj) media_15\NNS\3575240|NONE_0 (l_compound) artery_14\NN\5417975|the_4
D014859_D061205 CID warfarin_7\NNP\2718259|NONE_0 (r_pobj) with_6\IN\0|both_20|dietary_15 (r_prep) groups_5\NNS\2137|NONE_0 (r_pobj) of_2\IN\0|concurrent_21 (r_prep) treatment_1\NN\654885|calcification_70|._216 (r_nsubj) produced_8\VBD\1617192|NONE_0 (l_dobj) calcification_11\NN\13446390|treatment_70|._146 (l_conj) calcification_27\NN\13446390|massive_100|focal_92|of_72|in_52|but_25
D014859_D061205 CID warfarin_61\NNP\2718259|-_8 (r_npadvmod) induced_63\VBN\1627355|artery_8 (r_amod) calcification_65\NN\13446390|NONE_0 (r_pobj) to_60\IN\0|NONE_0 (r_prep) resistant_59\JJ\0|that_9 (r_acomp) was_58\VBD\0|the_16 (r_relcl) groups_56\NNS\2137|NONE_0 (r_pobj) of_54\IN\0|NONE_0 (r_prep) either_53\DT\0|NONE_0 (r_pobj) with_52\IN\0|rats_108 (r_prep) compared_51\VBN\644583|ad_20|fed_9 (r_prep) rats_50\NNS\2329401|a_157|between_142|,_69|with_67|,_17 (r_appos) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (r_attr) was_22\VBD\0|NONE_0 (l_advcl) determined_15\VBN\0|,_33|there_35|relationship_47|._381 (l_nsubjpass) explanation_2\NN\6722453|although_13|can_79|not_82|be_86|from_100 (l_prep) for_3\IN\0|the_16 (l_pobj) association_5\NN\8008335|NONE_0 (l_prep) between_6\IN\0|the_16 (l_pobj) calcification_8\NN\13446390|NONE_0
D014859_D061205 CID warfarin_61\NNP\2718259|-_8 (r_npadvmod) induced_63\VBN\1627355|artery_8 (r_amod) calcification_65\NN\13446390|NONE_0 (r_pobj) to_60\IN\0|NONE_0 (r_prep) resistant_59\JJ\0|that_9 (r_acomp) was_58\VBD\0|the_16 (r_relcl) groups_56\NNS\2137|NONE_0 (r_pobj) of_54\IN\0|NONE_0 (r_prep) either_53\DT\0|NONE_0 (r_pobj) with_52\IN\0|rats_108 (r_prep) compared_51\VBN\644583|ad_20|fed_9 (r_prep) rats_50\NNS\2329401|a_157|between_142|,_69|with_67|,_17 (r_appos) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (l_prep) between_25\IN\0|a_15|,_73|with_75|,_125|rats_142 (l_pobj) phosphate_28\NN\15010703|NONE_0 (l_conj) susceptibility_30\NN\13920835|higher_27|serum_20|and_4 (l_prep) to_31\IN\0|NONE_0 (l_pobj) calcification_33\NN\13446390|NONE_0
D014859_D061205 CID warfarin_61\NNP\2718259|-_8 (r_npadvmod) induced_63\VBN\1627355|artery_8 (r_amod) calcification_65\NN\13446390|NONE_0
D014859_D061205 CID warfarin_7\NNP\2718259|-_8 (r_npadvmod) induced_9\VBN\1627355|artery_8 (r_amod) calcification_11\NN\13446390|NONE_0
D014859_D061205 CID warfarin_13\NNP\2718259|vitamin_14|and_4 (r_conj) d_11\NN\15089472|NONE_0 (r_pobj) between_9\IN\0|the_21|possible_17|in_31 (r_prep) synergy_8\NN\13518963|set_41|._62 (l_prep) in_14\IN\13603305|the_52|possible_48|between_31 (l_pobj) calcification_16\NN\13446390|NONE_0
D014859_D061205 CID warfarin_0\NNP\2718259|are_9|also_13|cause_27|,_66|but_68|at_72|._129 (r_nsubjpass) known_3\VBN\0|NONE_0 (l_xcomp) cause_5\VB\7323922|warfarin_27|are_18|also_14|,_39|but_41|at_45|._102 (l_dobj) calcification_6\NN\13446390|to_9 (l_prep) of_7\IN\0|NONE_0 (l_pobj) media_10\NNS\3575240|NONE_0 (l_compound) artery_9\NN\5417975|the_4
D014859_D061205 CID warfarin_20\NNP\2718259|vitamin_15|plus_5 (r_conj) d_18\NNP\15089472|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|NONE_0 (r_acl) rats_14\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|artery_21 (r_prep) calcification_12\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_28\NN\15010703|NONE_0 (r_pobj) between_25\IN\0|a_15|,_73|with_75|,_125|rats_142 (r_prep) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (r_attr) was_22\VBD\0|NONE_0 (l_advcl) determined_15\VBN\0|,_33|there_35|relationship_47|._381 (l_nsubjpass) explanation_2\NN\6722453|although_13|can_79|not_82|be_86|from_100 (l_prep) for_3\IN\0|the_16 (l_pobj) association_5\NN\8008335|NONE_0 (l_prep) between_6\IN\0|the_16 (l_pobj) calcification_8\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_28\NN\15010703|NONE_0 (l_conj) susceptibility_30\NN\13920835|higher_27|serum_20|and_4 (l_prep) to_31\IN\0|NONE_0 (l_pobj) calcification_33\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_28\NN\15010703|NONE_0 (r_pobj) between_25\IN\0|a_15|,_73|with_75|,_125|rats_142 (r_prep) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (l_appos) rats_50\NNS\2329401|a_157|between_142|,_69|with_67|,_17 (l_prep) compared_51\VBN\644583|ad_20|fed_9 (l_prep) with_52\IN\0|rats_108 (l_pobj) either_53\DT\0|NONE_0 (l_prep) of_54\IN\0|NONE_0 (l_pobj) groups_56\NNS\2137|NONE_0 (l_relcl) was_58\VBD\0|the_16 (l_acomp) resistant_59\JJ\0|that_9 (l_prep) to_60\IN\0|NONE_0 (l_pobj) calcification_65\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_42\NN\15010703|NONE_0 (r_pobj) of_40\IN\0|higher_14|in_19 (r_prep) levels_39\NNS\4916342|NONE_0 (r_pobj) with_35\IN\0|a_90|between_75|,_2|,_50|rats_67 (r_prep) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (r_attr) was_22\VBD\0|NONE_0 (l_advcl) determined_15\VBN\0|,_33|there_35|relationship_47|._381 (l_nsubjpass) explanation_2\NN\6722453|although_13|can_79|not_82|be_86|from_100 (l_prep) for_3\IN\0|the_16 (l_pobj) association_5\NN\8008335|NONE_0 (l_prep) between_6\IN\0|the_16 (l_pobj) calcification_8\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_42\NN\15010703|NONE_0 (r_pobj) of_40\IN\0|higher_14|in_19 (r_prep) levels_39\NNS\4916342|NONE_0 (r_pobj) with_35\IN\0|a_90|between_75|,_2|,_50|rats_67 (r_prep) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (l_prep) between_25\IN\0|a_15|,_73|with_75|,_125|rats_142 (l_pobj) phosphate_28\NN\15010703|NONE_0 (l_conj) susceptibility_30\NN\13920835|higher_27|serum_20|and_4 (l_prep) to_31\IN\0|NONE_0 (l_pobj) calcification_33\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_42\NN\15010703|NONE_0 (r_pobj) of_40\IN\0|higher_14|in_19 (r_prep) levels_39\NNS\4916342|NONE_0 (r_pobj) with_35\IN\0|a_90|between_75|,_2|,_50|rats_67 (r_prep) relationship_24\NN\31921|determined_47|,_14|there_12|._334 (l_appos) rats_50\NNS\2329401|a_157|between_142|,_69|with_67|,_17 (l_prep) compared_51\VBN\644583|ad_20|fed_9 (l_prep) with_52\IN\0|rats_108 (l_pobj) either_53\DT\0|NONE_0 (l_prep) of_54\IN\0|NONE_0 (l_pobj) groups_56\NNS\2137|NONE_0 (l_relcl) was_58\VBD\0|the_16 (l_acomp) resistant_59\JJ\0|that_9 (l_prep) to_60\IN\0|NONE_0 (l_pobj) calcification_65\NN\13446390|NONE_0
D010710_D061205 NONE phosphate_18\NN\15010703|higher_13 (r_compound) levels_19\NNS\4916342|NONE_0 (r_pobj) to_15\IN\0|that_88|susceptibility_73|could_17|be_11 (r_prep) related_14\VBN\628491|observation_101|._40 (l_nsubjpass) susceptibility_5\NN\13920835|that_15|could_56|be_62|to_73 (l_prep) to_6\IN\0|increased_25 (l_pobj) calcification_11\NN\13446390|NONE_0
D002118_D002114 NONE calcium_11\NN\14625458|NONE_0 (r_pobj) in_9\IN\13603305|the_14 (r_prep) elevation_8\NN\7445480|NONE_0 (r_pobj) on_6\IN\0|no_10 (r_prep) effect_5\NN\34213|because_34|treatment_17 (r_dobj) had_3\VBD\0|is_114|probably_117|best_126|by_141|._245 (r_advcl) explained_27\VBN\831651|NONE_0 (l_agent) by_28\IN\0|had_141|is_27|probably_24|best_15|._104 (l_pobj) hypothesis_30\NN\7162194|NONE_0 (l_acl) inhibits_33\VBZ\2510337|the_29 (l_prep) as_40\IN\14622893|that_58|warfarin_53|activity_31 (l_pobj) inhibitor_43\NN\20090|NONE_0 (l_compound) calcification_42\NN\13446390|a_2
D014807_D061205 NONE d._11\NNP\0|and_12|vitamin_8 (r_conj) growth_8\NN\13526110|NONE_0 (r_pobj) by_7\IN\0|calcification_29|is_15 (r_agent) accelerated_6\VBN\226566|NONE_0 (l_nsubjpass) calcification_4\NN\13446390|is_14|by_29
D014807_D061205 NONE d_8\JJ\15089472|and_12 (r_conj) growth_5\NN\13526110|NONE_0 (r_nmod) treatment_9\NN\654885|that_26|extent_22|given_61 (r_nsubj) enhance_10\VB\227165|studies_56|._245 (l_dobj) extent_12\NN\13939892|that_48|treatment_22|given_39 (l_prep) of_13\IN\0|the_11 (l_pobj) calcification_15\NN\13446390|NONE_0
D014807_D061205 NONE d_11\NN\15089472|NONE_0 (r_pobj) between_9\IN\0|the_21|possible_17|in_31 (r_prep) synergy_8\NN\13518963|set_41|._62 (l_prep) in_14\IN\13603305|the_52|possible_48|between_31 (l_pobj) calcification_16\NN\13446390|NONE_0
D014807_D061205 NONE d_4\NNP\15089472|NONE_0 (r_pobj) of_2\IN\0|high_11 (r_prep) doses_1\NNS\3740161|are_19|cause_32|._99 (r_nsubjpass) known_6\VBN\0|NONE_0 (l_xcomp) cause_8\VB\7323922|doses_32|are_13|._67 (l_dobj) calcification_9\NN\13446390|to_9|in_34 (l_prep) of_10\IN\0|NONE_0 (l_pobj) media_13\NNS\3575240|NONE_0 (l_compound) artery_12\NN\5417975|the_4
D014807_D061205 NONE d_10\NN\15089472|on_7 (r_compound) dose_11\NN\3740161|NONE_0 (l_prep) on_12\IN\0|d_7 (l_pobj) calcification_14\NN\13446390|NONE_0
D014807_D061205 NONE d_10\NN\15089472|on_7 (r_compound) dose_11\NN\3740161|NONE_0 (r_pobj) of_8\IN\0|the_11|and_42|effect_50 (r_prep) effect_7\NN\34213|NONE_0 (l_conj) effect_17\NN\34213|the_61|of_50|and_8 (l_prep) of_18\IN\0|the_11 (l_pobj) dose_21\NN\3740161|NONE_0 (l_prep) on_22\IN\0|d_7 (l_pobj) elevation_24\NN\7445480|NONE_0 (l_relcl) suggests_30\VBZ\1010118|the_38|of_24|,_8 (l_ccomp) induce_35\VB\1627355|which_34 (l_dobj) calcification_37\NN\13446390|that_33|d_20|may_18|through_14
D014807_D061205 NONE d_20\NNP\15089472|on_7 (r_compound) dose_21\NN\3740161|NONE_0 (r_pobj) of_18\IN\0|the_11 (r_prep) effect_17\NN\34213|the_61|of_50|and_8 (r_conj) effect_7\NN\34213|NONE_0 (l_prep) of_8\IN\0|the_11|and_42|effect_50 (l_pobj) dose_11\NN\3740161|NONE_0 (l_prep) on_12\IN\0|d_7 (l_pobj) calcification_14\NN\13446390|NONE_0
D014807_D061205 NONE d_20\NNP\15089472|on_7 (r_compound) dose_21\NN\3740161|NONE_0 (l_prep) on_22\IN\0|d_7 (l_pobj) elevation_24\NN\7445480|NONE_0 (l_relcl) suggests_30\VBZ\1010118|the_38|of_24|,_8 (l_ccomp) induce_35\VB\1627355|which_34 (l_dobj) calcification_37\NN\13446390|that_33|d_20|may_18|through_14
D014807_D061205 NONE d_33\NN\15089472|that_13|may_2|calcification_20|through_34 (r_nsubj) induce_35\VB\1627355|which_34 (r_ccomp) suggests_30\VBZ\1010118|the_38|of_24|,_8 (r_relcl) elevation_24\NN\7445480|NONE_0 (r_pobj) on_22\IN\0|d_7 (r_prep) dose_21\NN\3740161|NONE_0 (r_pobj) of_18\IN\0|the_11 (r_prep) effect_17\NN\34213|the_61|of_50|and_8 (r_conj) effect_7\NN\34213|NONE_0 (l_prep) of_8\IN\0|the_11|and_42|effect_50 (l_pobj) dose_11\NN\3740161|NONE_0 (l_prep) on_12\IN\0|d_7 (l_pobj) calcification_14\NN\13446390|NONE_0
D014807_D061205 NONE d_33\NN\15089472|that_13|may_2|calcification_20|through_34 (r_nsubj) induce_35\VB\1627355|which_34 (l_dobj) calcification_37\NN\13446390|that_33|d_20|may_18|through_14
D014807_D061205 NONE d_18\NNP\15089472|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|NONE_0 (r_acl) rats_14\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|artery_21 (r_prep) calcification_12\NN\13446390|NONE_0
D014859_D002114 NONE warfarin_22\NNP\2718259|NONE_0 (r_pobj) of_21\IN\0|sufficient_17 (r_prep) doses_20\NNS\3740161|inhibit_21 (r_dobj) given_18\VBN\5892096|that_87|treatment_61|extent_39 (l_advcl) inhibit_24\VB\2510337|doses_21 (l_dobj) carboxylation_27\NN\0|to_17 (l_prep) of_28\IN\0|gamma_20|-_15 (l_pobj) protein_31\NN\14944888|NONE_0 (l_appos) inhibitor_35\NN\20090|matrix_36|gla_29|,_18 (l_compound) calcification_34\NN\13446390|known_24
D014859_D002114 NONE warfarin_5\NNP\2718259|NONE_0 (r_pobj) with_4\IN\0|for_12 (r_prep) treatment_0\NN\654885|calcification_57|._167 (r_nsubj) caused_6\VBD\1617192|NONE_0 (l_dobj) calcification_9\NN\13446390|treatment_57|._110 (l_conj) calcification_23\NN\13446390|massive_92|focal_84|of_64|in_44|and_25
D014859_D002114 NONE warfarin_17\NNP\2718259|concurrent_11 (r_compound) administration_18\NN\1133281|that_25|dramatically_15|extent_42 (r_nsubj) increased_20\VBD\169651|NONE_0 (l_dobj) extent_22\NN\13939892|that_67|administration_42|dramatically_27 (l_prep) of_23\IN\0|the_11 (l_pobj) calcification_24\NN\13446390|NONE_0
D014859_D002114 NONE warfarin_1\NNP\2718259|NONE_0 (r_compound) treatment_2\NN\654885|because_17|effect_17 (r_nsubj) had_3\VBD\0|is_114|probably_117|best_126|by_141|._245 (r_advcl) explained_27\VBN\831651|NONE_0 (l_agent) by_28\IN\0|had_141|is_27|probably_24|best_15|._104 (l_pobj) hypothesis_30\NN\7162194|NONE_0 (l_acl) inhibits_33\VBZ\2510337|the_29 (l_prep) as_40\IN\14622893|that_58|warfarin_53|activity_31 (l_pobj) inhibitor_43\NN\20090|NONE_0 (l_compound) calcification_42\NN\13446390|a_2
D014859_D002114 NONE warfarin_20\NNP\2718259|NONE_0 (r_nmod) d_23\NN\15089472|NONE_0 (r_pobj) between_19\IN\0|the_12 (r_prep) synergy_18\NN\13518963|vitamin_15|,_6 (r_appos) d_15\NN\15089472|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) produced_12\VBN\1617192|serum_14 (r_acl) calcium_11\NN\14625458|NONE_0 (r_pobj) in_9\IN\13603305|the_14 (r_prep) elevation_8\NN\7445480|NONE_0 (r_pobj) on_6\IN\0|no_10 (r_prep) effect_5\NN\34213|because_34|treatment_17 (r_dobj) had_3\VBD\0|is_114|probably_117|best_126|by_141|._245 (r_advcl) explained_27\VBN\831651|NONE_0 (l_agent) by_28\IN\0|had_141|is_27|probably_24|best_15|._104 (l_pobj) hypothesis_30\NN\7162194|NONE_0 (l_acl) inhibits_33\VBZ\2510337|the_29 (l_prep) as_40\IN\14622893|that_58|warfarin_53|activity_31 (l_pobj) inhibitor_43\NN\20090|NONE_0 (l_compound) calcification_42\NN\13446390|a_2
D014859_D002114 NONE warfarin_32\NNP\2718259|that_5|activity_22|as_53 (r_nsubj) inhibits_33\VBZ\2510337|the_29 (l_prep) as_40\IN\14622893|that_58|warfarin_53|activity_31 (l_pobj) inhibitor_43\NN\20090|NONE_0 (l_compound) calcification_42\NN\13446390|a_2
D002118_D061205 NONE calcium_27\NN\14625458|NONE_0 (r_pobj) of_25\IN\0|the_14|,_16|suggests_24 (r_prep) elevation_24\NN\7445480|NONE_0 (r_pobj) on_22\IN\0|d_7 (r_prep) dose_21\NN\3740161|NONE_0 (r_pobj) of_18\IN\0|the_11 (r_prep) effect_17\NN\34213|the_61|of_50|and_8 (r_conj) effect_7\NN\34213|NONE_0 (l_prep) of_8\IN\0|the_11|and_42|effect_50 (l_pobj) dose_11\NN\3740161|NONE_0 (l_prep) on_12\IN\0|d_7 (l_pobj) calcification_14\NN\13446390|NONE_0
D002118_D061205 NONE calcium_27\NN\14625458|NONE_0 (r_pobj) of_25\IN\0|the_14|,_16|suggests_24 (r_prep) elevation_24\NN\7445480|NONE_0 (l_relcl) suggests_30\VBZ\1010118|the_38|of_24|,_8 (l_ccomp) induce_35\VB\1627355|which_34 (l_dobj) calcification_37\NN\13446390|that_33|d_20|may_18|through_14
D002118_D061205 NONE calcium_43\NN\14625458|NONE_0 (r_pobj) on_41\IN\0|its_11 (r_prep) effect_40\NN\34213|NONE_0 (r_pobj) through_38\IN\0|that_47|d_34|may_32|calcification_14 (r_prep) induce_35\VB\1627355|which_34 (r_ccomp) suggests_30\VBZ\1010118|the_38|of_24|,_8 (r_relcl) elevation_24\NN\7445480|NONE_0 (r_pobj) on_22\IN\0|d_7 (r_prep) dose_21\NN\3740161|NONE_0 (r_pobj) of_18\IN\0|the_11 (r_prep) effect_17\NN\34213|the_61|of_50|and_8 (r_conj) effect_7\NN\34213|NONE_0 (l_prep) of_8\IN\0|the_11|and_42|effect_50 (l_pobj) dose_11\NN\3740161|NONE_0 (l_prep) on_12\IN\0|d_7 (l_pobj) calcification_14\NN\13446390|NONE_0
D002118_D061205 NONE calcium_43\NN\14625458|NONE_0 (r_pobj) on_41\IN\0|its_11 (r_prep) effect_40\NN\34213|NONE_0 (r_pobj) through_38\IN\0|that_47|d_34|may_32|calcification_14 (r_prep) induce_35\VB\1627355|which_34 (l_dobj) calcification_37\NN\13446390|that_33|d_20|may_18|through_14
D015055_D061205 NONE carboxylated_36\JJ\515154|that_55|protein_46|indeed_17 (r_acomp) was_31\VBD\0|analysis_50|._33 (r_ccomp) showed_25\VBD\2137132|levels_140|are_111|at_101|,_24|and_22 (r_conj) found_7\VBN\13279262|NONE_0 (l_prep) at_8\IN\14622893|levels_39|are_10|,_77|and_79|showed_101 (l_pobj) sites_9\NNS\8673395|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) calcification_12\NN\13446390|NONE_0
18004067
D000082_D056486 CID paracetamol_15\JJ\0|NONE_0 (r_pobj) of_14\IN\0|therapeutic_18 (r_prep) doses_13\NNS\3740161|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) associated_10\VBN\628491|NONE_0 (r_acl) hepatotoxicity_9\NN\0|NONE_0
D000082_D056486 CID acetaminophen_17\NN\2707683|(_1|)_13 (r_appos) paracetamol_15\JJ\0|NONE_0 (r_pobj) of_14\IN\0|therapeutic_18 (r_prep) doses_13\NNS\3740161|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) associated_10\VBN\628491|NONE_0 (r_acl) hepatotoxicity_9\NN\0|NONE_0
D000082_D056486 CID paracetamol_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|therapeutic_18 (r_prep) doses_13\NNS\3740161|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treated_10\VBN\2376958|NONE_0 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|the_34|of_18 (r_prep) development_5\NN\248977|NONE_0 (l_prep) of_6\IN\0|the_16|in_18 (l_pobj) hepatotoxicity_7\NN\0|NONE_0
D000082_D017114 NONE paracetamol_11\NN\0|at_12 (r_dobj) ingesting_10\VBG\0|regular_28|alcohol_20 (r_acl) consumption_9\NN\13440063|NONE_0 (r_pobj) with_6\IN\0|two_13 (r_prep) patients_5\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|acute_20|liver_14|._92 (r_prep) failure_2\NN\66216|NONE_0
D000431_D017114 NONE alcohol_8\NN\7881800|regular_8|ingesting_20 (r_compound) consumption_9\NN\13440063|NONE_0 (r_pobj) with_6\IN\0|two_13 (r_prep) patients_5\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|acute_20|liver_14|._92 (r_prep) failure_2\NN\66216|NONE_0
D000431_D056486 NONE alcohol_4\NN\7881800|NONE_0 (r_pobj) of_3\IN\0|the_18|possible_14|in_11 (r_prep) role_2\NN\719494|is_118|currently_121|._138 (l_prep) in_5\IN\13603305|the_29|possible_25|of_11 (l_pobj) development_7\NN\248977|NONE_0 (l_prep) of_8\IN\0|the_16 (l_pobj) hepatotoxicity_9\NN\0|NONE_0
D000082_D017093 CID paracetamol_32\JJ\0|NONE_0 (r_advmod) 4_30\CD\13741022|/_15 (r_nummod) day_34\NN\15154774|NONE_0 (r_pobj) with_29\IN\0|while_20|being_14 (r_prep) treated_28\VBN\2376958|consumption_24 (r_advcl) stopping_23\VBG\3323703|who_70|failure_50|within_42|and_4 (r_conj) developed_12\VBD\1753788|who_46|consumers_29|and_8 (l_dobj) failure_14\NN\66216|who_20|within_8|and_46|stopping_50
D000431_D017093 NONE alcohol_9\NN\7881800|NONE_0 (r_pobj) of_8\IN\0|regular_18 (r_prep) consumers_7\NNS\10741590|who_17|and_21|developed_29 (r_attr) were_5\VBD\0|2_15 (l_conj) developed_12\VBD\1753788|who_46|consumers_29|and_8 (l_dobj) failure_14\NN\66216|who_20|within_8|and_46|stopping_50
D000431_D017093 NONE alcohol_24\NN\7881800|NONE_0 (r_compound) consumption_25\NN\13440063|treated_24 (r_dobj) stopping_23\VBG\3323703|who_70|failure_50|within_42|and_4 (r_conj) developed_12\VBD\1753788|who_46|consumers_29|and_8 (l_dobj) failure_14\NN\66216|who_20|within_8|and_46|stopping_50
D000431_D017093 NONE alcohol_10\NN\7881800|NONE_0 (r_pobj) of_9\IN\0|e.g._25|regular_20 (r_prep) consumption_8\NN\13440063|risk_27|,_15 (r_appos) factors_4\NNS\7326557|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) patients_1\NNS\9898892|NONE_0 (r_pobj) in_0\IN\13603305|,_66|failure_74|possible_85|ingested_121|._129 (r_prep) is_14\VBZ\0|NONE_0 (l_nsubj) failure_13\NN\66216|in_74|,_8|possible_11|ingested_47|._55
17439425
D003907_D015431 CID dex_0\NNP\0|sbp_14|+/-_33|mmhg_39|;_43|p_45|._116 (r_nsubj) increased_1\VBD\169651|NONE_0 (l_dep) p_13\NN\14622893|dex_45|sbp_31|+/-_12|mmhg_6|;_2|._71 (l_conj) decreased_18\VBN\169651|0.001_11|)_6|and_4 (l_dobj) thymus_19\NN\11579418|NONE_0 (l_conj) bodyweights_26\NNS\0|(_16|p_15|)_6|and_4
D019820_D006973 NONE xanthine_2\NN\14727670|NONE_0 (r_compound) oxidase_3\NN\14732946|NONE_0 (r_pobj) of_1\IN\0|in_20|._65 (r_prep) role_0\NN\719494|NONE_0 (l_prep) in_4\IN\13603305|of_20|._45 (l_pobj) hypertension_8\NN\14057371|NONE_0
D019820_D006973 NONE xanthine_5\NN\14727670|xo_18|,_21|implicated_32|,_87 (r_compound) oxidase_6\NN\14732946|NONE_0 (r_pobj) of_4\IN\0|the_9|in_92 (r_prep) role_3\NN\719494|we_15|._143 (l_prep) in_22\IN\13603305|the_101|of_92 (l_pobj) hypertension_26\NN\14057371|NONE_0
D019820_D006973 NONE xanthine_5\NN\14727670|xo_18|,_21|implicated_32|,_87 (r_compound) oxidase_6\NN\14732946|NONE_0 (r_pobj) of_4\IN\0|the_9|in_92 (r_prep) role_3\NN\719494|we_15|._143 (l_prep) in_22\IN\13603305|the_101|of_92 (l_pobj) hypertension_26\NN\14057371|NONE_0 (l_appos) ht_30\NNP\0|induced_26
D000493_D006973 NONE allopurinol_0\NNP\3740161|did_12|not_16|ht_32|._34 (r_nsubj) prevent_3\VB\0|NONE_0 (l_dobj) ht_6\NNP\0|allopurinol_32|did_20|not_16|._2
D000493_D006973 NONE allopurinol_8\NN\3740161|that_5|prevent_22 (r_nsubj) failed_9\VBD\0|our_39|previous_35 (r_acl) findings_6\NNS\7951464|together_27 (r_pobj) with_3\IN\0|this_15|,_11|hypertension_99 (r_prep) induced_14\VBN\1627355|,_20|is_48|._94 (l_dobj) hypertension_15\NN\14057371|this_114|,_110|with_99
D000493_D006973 NONE allopurinol_8\NN\3740161|that_5|prevent_22 (r_nsubj) failed_9\VBD\0|our_39|previous_35 (r_acl) findings_6\NNS\7951464|together_27 (r_pobj) with_3\IN\0|this_15|,_11|hypertension_99 (r_prep) induced_14\VBN\1627355|,_20|is_48|._94 (r_ccomp) suggests_17\VBZ\1010118|NONE_0 (l_ccomp) is_21\VBZ\0|induced_48|,_28|._46 (l_attr) determinant_25\NN\5686481|that_32|activity_24|not_12 (l_prep) of_26\IN\0|a_20|major_18|in_9 (l_pobj) ht_29\NNP\0|NONE_0
D003907_D006973 CID dexamethasone_5\NN\2721538|-_13 (r_npadvmod) induced_7\VBN\1627355|in_21 (r_amod) hypertension_8\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone_23\NN\2721538|-_13 (r_npadvmod) induced_25\VBN\1627355|ht_26 (r_amod) hypertension_26\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone_23\NN\2721538|-_13 (r_npadvmod) induced_25\VBN\1627355|ht_26 (r_amod) hypertension_26\NN\14057371|NONE_0 (l_appos) ht_30\NNP\0|induced_26
D003907_D006973 CID dex_28\NN\0|(_1|-_3|)_6 (r_compound) ht_30\NNP\0|induced_26 (r_appos) hypertension_26\NN\14057371|NONE_0
D003907_D006973 CID dex_28\NN\0|(_1|-_3|)_6 (r_compound) ht_30\NNP\0|induced_26
D003907_D006973 CID dex_0\NNP\0|sbp_14|+/-_33|mmhg_39|;_43|p_45|._116 (r_nsubj) increased_1\VBD\169651|NONE_0 (l_dobj) sbp_2\NNP\0|dex_14|+/-_19|mmhg_25|;_29|p_31|._102
D003907_D006973 CID dex_4\NN\0|-_3 (r_compound) ht_6\NNP\0|allopurinol_32|did_20|not_16|._2
D009569_D006973 NONE oxide_16\NN\14818238|-_5 (r_compound) redox_18\NN\13447361|nitric_13 (r_compound) imbalance_19\NN\13934274|NONE_0 (r_pobj) with_14\IN\0|hypertension_46|is_14|._33 (r_prep) associated_13\VBN\628491|NONE_0 (l_nsubjpass) hypertension_3\NN\14057371|is_32|with_46|._79
D009569_D006973 NONE oxide_16\NN\14818238|-_5 (r_compound) redox_18\NN\13447361|nitric_13 (r_compound) imbalance_19\NN\13934274|NONE_0 (r_pobj) with_14\IN\0|hypertension_46|is_14|._33 (r_prep) associated_13\VBN\628491|NONE_0 (l_nsubjpass) hypertension_3\NN\14057371|is_32|with_46|._79 (l_appos) ht_7\NNP\0|induced_25|in_4
18996674
D003042_D011317 CID cocaine_9\NN\3492717|an_21|admitted_18|frequent_9 (r_compound) user_10\NN\7846|a_48|old_38|,_31|,_4 (r_appos) man_4\NN\9605289|to_50|on_83|._153 (r_nsubj) presented_12\VBN\2137132|NONE_0 (l_prep) on_20\IN\0|man_83|to_33|._70 (l_pobj) occasions_23\NNS\5983801|NONE_0 (l_prep) with_24\IN\0|two_23|separate_19 (l_pobj) history_26\NN\15120823|NONE_0 (l_prep) of_27\IN\0|a_10|after_12 (l_pobj) priapism_28\NN\14204950|NONE_0
D003042_D011317 CID cocaine_30\NN\3492717|NONE_0 (r_compound) use_31\NN\407535|NONE_0 (r_pobj) after_29\IN\0|a_22|of_12 (r_prep) history_26\NN\15120823|NONE_0 (l_prep) of_27\IN\0|a_10|after_12 (l_pobj) priapism_28\NN\14204950|NONE_0
D004837_D011317 NONE epinephrine_1\NN\14807929|NONE_0 (l_appos) treatment_6\NN\654885|intracavernous_49|:_23|._50 (l_prep) for_7\IN\0|a_31|invasive_19 (l_pobj) priapism_8\NN\14204950|NONE_0
9653867
D013974_D013971 CID thyroxine_0\NNP\5413241|:_15|case_28|._63 (r_compound) abuse_1\NN\418025|NONE_0 (l_appos) case_5\NN\7283608|thyroxine_28|:_13|._35 (l_prep) of_6\IN\0|an_16|unusual_13 (l_pobj) thyrotoxicosis_7\NN\14059928|NONE_0
D013974_D013971 CID thyroxine_28\NN\5413241|NONE_0 (r_compound) abuse_29\NN\418025|that_64|remains_27|,_12|should_6|be_13|and_27|explored_31 (r_nsubjpass) considered_32\VBN\689344|us_83 (l_advcl) remains_25\VBZ\2684|that_37|,_15|abuse_27|should_33|be_40|and_54|explored_58 (l_nsubj) cause_22\NN\7323922|when_7|obscure_33 (l_prep) for_23\IN\0|a_8 (l_pobj) thyrotoxicosis_24\NN\14059928|NONE_0
D013974_D001068 NONE thyroxine_28\NN\5413241|NONE_0 (r_compound) abuse_29\NN\418025|that_64|remains_27|,_12|should_6|be_13|and_27|explored_31 (r_nsubjpass) considered_32\VBN\689344|us_83 (r_ccomp) reminds_17\VBZ\0|in_115|it_101|derangements_82|and_4|._114 (r_conj) illustrates_3\VBZ\955601|NONE_0 (l_dobj) derangements_5\NNS\14395018|in_33|it_19|and_78|reminds_82|._196 (l_prep) of_6\IN\0|the_17 (l_pobj) function_8\NN\13783581|NONE_0 (l_acl) seen_9\VBN\2106506|thyroid_17 (l_prep) with_13\IN\0|in_18 (l_pcomp) eating_14\VBG\838098|NONE_0 (l_dobj) disorders_15\NNS\14034177|NONE_0
2348231
D010431_D006940 NONE pentoxifylline_0\NNP\3247620|does_25|not_30|hyperemia_72|._144 (r_nsubj) inhibit_6\VB\2510337|NONE_0 (l_dobj) hyperemia_11\NN\14320394|pentoxifylline_72|does_47|not_42|._72
D010431_D006940 NONE trental_2\NNP\3247620|(_1|)_7 (r_appos) pentoxifylline_0\NNP\3247620|does_25|not_30|hyperemia_72|._144 (r_nsubj) inhibit_6\VB\2510337|NONE_0 (l_dobj) hyperemia_11\NN\14320394|pentoxifylline_72|does_47|not_42|._72
D010431_D006940 NONE pentoxifylline_1\NN\3247620|hyperemia_54|and_112|stopped_126 (r_nsubj) inhibits_2\VBZ\2510337|unknown_165|._172 (l_dobj) hyperemia_7\NN\14320394|pentoxifylline_54|and_58|stopped_72
D010431_D006940 NONE pentoxifylline_3\NN\3247620|NONE_0 (r_pobj) of_2\IN\0|neither_13 (r_prep) dose_1\NN\3740161|significantly_23|hyperemia_72|,_81|peak_89|less_160|)_174|._175 (r_nsubj) decreased_5\VBD\169651|NONE_0 (l_dobj) hyperemia_10\NN\14320394|dose_72|significantly_49|,_9|peak_17|less_88|)_102|._103
D010431_D006940 NONE pentoxyifylline_3\NN\0|that_5|does_16|not_21|hyperemia_63|at_78 (r_nsubj) inhibit_6\VB\2510337|we_42|._66 (l_dobj) hyperemia_11\NN\14320394|that_68|pentoxyifylline_63|does_47|not_42|at_15
D013793_D006940 NONE thallium-201_17\NN\0|myocardial_13 (r_nmod) imaging_19\NN\5765159|NONE_0 (r_pobj) for_14\IN\0|NONE_0 (r_prep) implications_13\NNS\5774614|induced_28|coronary_20|:_2 (r_appos) hyperemia_11\NN\14320394|pentoxifylline_72|does_47|not_42|._72
D013793_D006940 NONE thallium-201_22\NN\0|NONE_0 (r_compound) imaging_23\NN\5765159|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_prep) prior_18\RB\10675876|should_18|be_11 (r_advmod) stopped_17\VBN\0|pentoxifylline_126|hyperemia_72|and_14 (r_conj) inhibits_2\VBZ\2510337|unknown_165|._172 (l_dobj) hyperemia_7\NN\14320394|pentoxifylline_54|and_58|stopped_72
C008514_D007383 NONE methylxanthine_12\NN\0|a_2|improve_36 (r_compound) derivative_13\NN\5802185|many_77|are_54|pentoxifylline_43|(_28|trental_27|)_20|,_19|._54 (l_relcl) improve_16\VB\126264|a_38|methylxanthine_36 (l_dobj) claudication_18\NN\14548913|which_31|may_25
D004176_D006940 CID dipyridamole_7\NN\0|-_12 (r_npadvmod) induced_9\VBN\1627355|coronary_8|:_26|implications_28 (r_amod) hyperemia_11\NN\14320394|pentoxifylline_72|does_47|not_42|._72
D004176_D006940 CID dipyridamole_15\JJ\0|-_12 (r_npadvmod) thallium-201_17\NN\0|myocardial_13 (r_nmod) imaging_19\NN\5765159|NONE_0 (r_pobj) for_14\IN\0|NONE_0 (r_prep) implications_13\NNS\5774614|induced_28|coronary_20|:_2 (r_appos) hyperemia_11\NN\14320394|pentoxifylline_72|does_47|not_42|._72
D004176_D006940 CID dipyridamole_3\NN\0|-_12 (r_dep) induced_5\VBN\1627355|coronary_8|like_27 (r_amod) hyperemia_7\NN\14320394|pentoxifylline_54|and_58|stopped_72
D004176_D006940 CID dipyridamole_20\NN\0|-_12 (r_compound) thallium-201_22\NN\0|NONE_0 (r_compound) imaging_23\NN\5765159|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_prep) prior_18\RB\10675876|should_18|be_11 (r_advmod) stopped_17\VBN\0|pentoxifylline_126|hyperemia_72|and_14 (r_conj) inhibits_2\VBZ\2510337|unknown_165|._172 (l_dobj) hyperemia_7\NN\14320394|pentoxifylline_54|and_58|stopped_72
D004176_D006940 CID dipyridamole_7\NN\0|-_12 (r_npadvmod) induced_9\VBN\1627355|the_17 (r_amod) hyperemia_10\NN\14320394|dose_72|significantly_49|,_9|peak_17|less_88|)_102|._103
D004176_D006940 CID dipyridamole_7\NN\0|-_12 (r_npadvmod) induced_9\VBN\1627355|coronary_8 (r_amod) hyperemia_11\NN\14320394|that_68|pentoxyifylline_63|does_47|not_42|at_15
D013806_D006940 NONE theophylline_13\NN\2905612|such_8 (r_pobj) as_12\IN\14622893|other_27 (r_prep) methylxanthines_10\NNS\0|NONE_0 (r_pobj) like_8\IN\5839024|induced_27|coronary_19 (r_prep) hyperemia_7\NN\14320394|pentoxifylline_54|and_58|stopped_72
D013806_D006940 NONE theophylline_21\NN\2905612|NONE_0 (r_pobj) after_20\IN\0|flow_29|lower_6 (r_prep) was_17\VBD\0|while_31 (r_ccomp) peak_13\JJ\13758296|dose_89|significantly_66|hyperemia_17|,_8|less_71|)_85|._86 (r_advcl) decreased_5\VBD\169651|NONE_0 (l_dobj) hyperemia_10\NN\14320394|dose_72|significantly_49|,_9|peak_17|less_88|)_102|._103
C008514_D006940 NONE methylxanthines_10\NNS\0|NONE_0 (r_pobj) like_8\IN\5839024|induced_27|coronary_19 (r_prep) hyperemia_7\NN\14320394|pentoxifylline_54|and_58|stopped_72
D010431_D007383 CID pentoxifylline_6\NN\3247620|many_34|are_11|(_15|trental_16|)_23|,_24|derivative_43|._97 (r_dobj) taking_5\VBG\37396|NONE_0 (l_conj) derivative_13\NN\5802185|many_77|are_54|pentoxifylline_43|(_28|trental_27|)_20|,_19|._54 (l_relcl) improve_16\VB\126264|a_38|methylxanthine_36 (l_dobj) claudication_18\NN\14548913|which_31|may_25
D010431_D007383 CID trental_8\NNP\3247620|many_50|are_27|pentoxifylline_16|(_1|)_7|,_8|derivative_27|._81 (r_npadvmod) taking_5\VBG\37396|NONE_0 (l_conj) derivative_13\NN\5802185|many_77|are_54|pentoxifylline_43|(_28|trental_27|)_20|,_19|._54 (l_relcl) improve_16\VB\126264|a_38|methylxanthine_36 (l_dobj) claudication_18\NN\14548913|which_31|may_25
10807237
D003042_D017542 CID cocaine_0\NN\3492717|NONE_0 (r_compound) use_1\NN\407535|rupture_27|at_35|._95 (r_nsubj) predisposed_2\VBN\680841|NONE_0 (l_dobj) rupture_4\NN\14285662|use_27|at_8|._68
D003042_D000783 NONE cocaine_12\NN\3492717|-_7 (r_npadvmod) related_14\VBN\628491|NONE_0 (r_amod) aneurysms_15\NNS\14057371|NONE_0
D003042_D000783 NONE cocaine_25\NN\3492717|-_7 (r_npadvmod) related_27\VBN\628491|NONE_0 (r_amod) aneurysms_28\NNS\14057371|NONE_0
D003042_D000783 NONE cocaine_0\NN\3492717|NONE_0 (r_compound) use_1\NN\407535|rupture_27|at_35|._95 (r_nsubj) predisposed_2\VBN\680841|NONE_0 (l_prep) at_5\IN\14622893|use_35|rupture_8|._60 (l_conj) in_11\IN\13603305|age_8|and_4 (l_pobj) aneurysms_14\NNS\14057371|NONE_0
3865016
D005047_D017254 NONE etoposide_4\NN\0|NONE_0 (r_nmod) a_7\NNP\13649268|NONE_0 (r_pobj) of_3\IN\0|the_31|concomitant_27 (r_prep) administration_2\NN\1133281|in_55|._129 (r_nsubj) resulted_8\VBD\2633881|NONE_0 (l_prep) in_9\IN\13603305|administration_55|._74 (l_pobj) eradication_10\NN\7334490|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) infiltration_15\NN\975452|NONE_0
D016572_D054218 NONE a_7\NNP\13649268|NONE_0 (r_pobj) of_3\IN\0|a_21|synergistic_19 (r_prep) effect_2\NN\34213|was_38|in_51|in_98|._108 (r_nsubjpass) observed_9\VBN\2163746|NONE_0 (l_prep) in_10\IN\13603305|effect_51|was_13|in_47|._57 (l_pobj) patient_12\NN\9898892|NONE_0 (l_prep) with_13\IN\0|a_10 (l_pobj) leukemia_18\NN\14239918|NONE_0
D016572_D017254 NONE a_7\NNP\13649268|NONE_0 (r_pobj) of_3\IN\0|the_31|concomitant_27 (r_prep) administration_2\NN\1133281|in_55|._129 (r_nsubj) resulted_8\VBD\2633881|NONE_0 (l_prep) in_9\IN\13603305|administration_55|._74 (l_pobj) eradication_10\NN\7334490|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) infiltration_15\NN\975452|NONE_0
D005047_D054218 NONE etoposide_4\NN\0|NONE_0 (r_nmod) a_7\NNP\13649268|NONE_0 (r_pobj) of_3\IN\0|a_21|synergistic_19 (r_prep) effect_2\NN\34213|was_38|in_51|in_98|._108 (r_nsubjpass) observed_9\VBN\2163746|NONE_0 (l_prep) in_10\IN\13603305|effect_51|was_13|in_47|._57 (l_pobj) patient_12\NN\9898892|NONE_0 (l_prep) with_13\IN\0|a_10 (l_pobj) leukemia_18\NN\14239918|NONE_0
3192036
10791295
D001058_D010554 CID apomorphine_2\NN\3786417|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) development_0\NN\248977|-_26|behavior_46|:_54|comparison_56|._103 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_dobj) behavior_6\NN\407535|development_46|-_20|:_8|comparison_10|._57
D001058_D010554 CID apomorphine_3\NN\3786417|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) development_1\NN\248977|-_26|s.c._46|daily_56|)_61|behavior_74|studied_155|._186 (r_nsubj) induced_5\VBN\1627355|NONE_0 (l_dobj) behavior_14\NN\407535|development_74|-_48|s.c._28|daily_18|)_13|studied_81|._112
D001058_D010554 CID apomorphine_5\NN\3786417|repeated_9 (r_compound) treatment_6\NN\654885|in_38|,_23|development_28|evidenced_66|._186 (r_nsubj) induced_7\VBD\1627355|NONE_0 (l_dobj) development_10\NN\248977|in_66|,_51|treatment_28|evidenced_38|._158 (l_prep) of_11\IN\0|a_22|gradual_20 (l_pobj) behavior_13\NN\407535|NONE_0
D001058_D010554 CID apomorphine_5\NN\3786417|repeated_9 (r_compound) treatment_6\NN\654885|in_38|,_23|development_28|evidenced_66|._186 (r_nsubj) induced_7\VBD\1627355|NONE_0 (l_advcl) evidenced_15\VBN\1015244|in_104|,_89|treatment_66|development_38|._120 (l_agent) by_16\IN\0|as_13|and_45|shortened_49 (l_pobj) intensity_19\NN\5090441|NONE_0 (l_prep) of_20\IN\0|the_24|increased_20 (l_pobj) aggressiveness_21\NN\4835724|NONE_0
D001058_D010554 CID apomorphine_14\NN\3786417|NONE_0 (r_preconj) the_13\DT\0|induced_16|aggressive_24 (r_det) behavior_18\NN\407535|NONE_0
1992636
D009853_D000743 CID omeprazole_7\NN\14778019|NONE_0 (r_pobj) of_6\IN\0|the_8 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|hemolytic_17|._37 (r_acl) anemia_1\NN\14189204|NONE_0
D009853_D000743 CID omeprazole_17\NN\14778019|NONE_0 (r_pobj) of_16\IN\0|the_8 (r_prep) use_15\NN\407535|NONE_0 (r_pobj) with_13\IN\0|a_38|serious_36|term_22|adverse_17 (r_prep) reaction_12\NN\13446390|NONE_0 (r_pobj) of_5\IN\0|the_15|first_11|:_67|anemia_79 (r_prep) case_4\NN\7283608|we_20|._90 (l_appos) anemia_20\NN\14189204|the_94|first_90|of_79|:_12
D009853_D000743 CID omeprazole_4\NN\14778019|by_9|is_49 (r_nsubj) caused_5\VBD\1617192|the_34|,_50|but_52|alerted_77 (l_ccomp) is_11\VBZ\0|by_58|omeprazole_49 (l_nsubj) anemia_10\NN\14189204|uncertain_10
D009853_D053609 CID omeprazole_17\NN\14778019|NONE_0 (r_pobj) with_16\IN\0|therapy_8 (r_prep) starting_14\VBG\457382|days_11 (r_pcomp) after_13\IN\0|developed_61|,_43|lethargy_41|._38 (r_prep) weakness_3\NN\14462666|NONE_0 (l_conj) lethargy_5\NN\14014621|developed_20|,_2|after_41|._79
D009853_D004417 CID omeprazole_17\NN\14778019|NONE_0 (r_pobj) with_16\IN\0|therapy_8 (r_prep) starting_14\VBG\457382|days_11 (r_pcomp) after_13\IN\0|developed_61|,_43|lethargy_41|._38 (r_prep) weakness_3\NN\14462666|NONE_0 (l_conj) lethargy_5\NN\14014621|developed_20|,_2|after_41|._79 (l_conj) shortness_8\NN\5129201|,_6|and_4 (l_prep) of_9\IN\0|NONE_0 (l_pobj) breath_10\NN\13440063|NONE_0
9660111
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ\0|the_4 (r_poss) head_23\NN\5225090|in_14 (r_compound) twitches_24\NNS\14360459|does_49|not_44 (r_dobj) potentiate_20\VB\229605|in_108|tri_84|does_67|not_62|hypothermia_33|in_21|and_13|._56 (r_conj) antagonize_11\VB\1787955|NONE_0 (l_dobj) hypothermia_14\VBN\14034177|in_75|tri_51|does_34|not_29|in_12|and_20|potentiate_33|._89
D003000_D010554 NONE clonidine_28\NN\2721160|NONE_0 (r_pobj) by_27\IN\0|in_13 (r_agent) evoked_26\VBN\1617192|the_19 (r_acl) aggressiveness_25\NN\4835724|in_38|as_7
D014299_D006948 CID tri_0\NNP\0|hyperactivity_53|._173 (r_nsubj) increases_5\VBZ\13576355|NONE_0 (l_dobj) hyperactivity_8\NN\14052403|tri_53|._120
D003913_D006948 CID amphetamine_13\NN\3248958|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|the_28|locomotor_24 (r_acl) hyperactivity_8\NN\14052403|tri_53|._120
D012110_D007035 CID reserpine_13\NN\2721160|the_4 (r_compound) hypothermia_14\VBN\14034177|in_75|tri_51|does_34|not_29|in_12|and_20|potentiate_33|._89
D010656_D010554 NONE phenylephrine_7\NN\2682038|NONE_0 (l_acl) evaluated_15\VBN\670261|given_35 (l_conj) aggressiveness_25\NN\4835724|in_38|as_7
D019257_D006948 CID quinpirole_15\NN\0|d_15|-_14|,_2 (r_conj) amphetamine_13\NN\3248958|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|the_28|locomotor_24 (r_acl) hyperactivity_8\NN\14052403|tri_53|._120
D004298_D006948 NONE dopamine_24\NN\14807737|and_12|effects_19 (r_compound) d2_25\NN\0|)_45|-7-hydroxy_44|-_34|(_10|)_17 (r_appos) dipropyloaminotetralin_22\NN\0|and_18|(_14|+_13 (r_conj) quinpirole_15\NN\0|d_15|-_14|,_2 (r_conj) amphetamine_13\NN\3248958|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|the_28|locomotor_24 (r_acl) hyperactivity_8\NN\14052403|tri_53|._120
D014299_D007035 NONE tri_4\NNP\0|in_24|does_17|not_22|hypothermia_51|in_63|and_71|potentiate_84|._140 (r_nsubj) antagonize_11\VB\1787955|NONE_0 (l_dobj) hypothermia_14\VBN\14034177|in_75|tri_51|does_34|not_29|in_12|and_20|potentiate_33|._89
19211690
D017673_D006973 NONE salt_11\NN\14818238|-_4 (r_npadvmod) sensitive_13\JJ\10488309|dahl_10 (r_amod) rats_14\NNS\2329401|NONE_0 (r_pobj) in_9\IN\13603305|of_30 (r_prep) upregulation_5\NN\0|dependent_27|and_4|._70 (r_conj) hypertension_3\NN\14057371|NONE_0
D000809_D006973 NONE angiotensin_25\NN\4522421|the_21|intrarenal_17 (r_compound) system_26\NN\3575240|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) upregulation_19\NN\0|possibly_17 (r_pobj) through_18\IN\0|testosterone_113|to_88|._63 (r_prep) contributes_1\VBZ\126264|NONE_0 (l_prep) to_2\IN\0|testosterone_25|through_88|._151 (l_pobj) development_4\NN\248977|NONE_0 (l_prep) of_5\IN\0|the_16 (l_pobj) hypertension_6\NN\14057371|NONE_0
D013739_D006973 NONE testosterone_0\NN\14747587|-_12 (r_npadvmod) dependent_2\JJ\9627906|and_23|upregulation_27|._97 (r_amod) hypertension_3\NN\14057371|NONE_0
D013739_D006973 NONE testosterone_0\NN\14747587|to_25|through_113|._176 (r_nsubj) contributes_1\VBZ\126264|NONE_0 (l_prep) to_2\IN\0|testosterone_25|through_88|._151 (l_pobj) development_4\NN\248977|NONE_0 (l_prep) of_5\IN\0|the_16 (l_pobj) hypertension_6\NN\14057371|NONE_0
D000809_D007674 NONE angiotensin_25\NN\4522421|the_21|intrarenal_17 (r_compound) system_26\NN\3575240|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) upregulation_19\NN\0|possibly_17 (r_pobj) through_18\IN\0|testosterone_113|to_88|._63 (r_prep) contributes_1\VBZ\126264|NONE_0 (l_prep) to_2\IN\0|testosterone_25|through_88|._151 (l_pobj) development_4\NN\248977|NONE_0 (l_prep) of_5\IN\0|the_16 (l_pobj) hypertension_6\NN\14057371|NONE_0 (l_conj) injury_9\NN\14052046|and_10|in_7
D013739_D007674 NONE testosterone_24\NN\14747587|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) mediated_22\VBN\761713|intrarenal_27 (r_acl) angiotensinogen_21\NN\0|NONE_0 (r_pobj) of_19\IN\0|induced_21 (r_prep) upregulation_18\NN\0|NONE_0 (r_pobj) in_14\IN\13603305|a_20|sexual_18|causes_92 (r_prep) dimorphism_13\NN\11492833|that_23|there_18 (l_relcl) causes_27\VBZ\7323922|a_112|sexual_110|in_92 (l_dobj) increases_28\NNS\13576355|that_17|also_12 (l_prep) in_29\IN\13603305|NONE_0 (l_pobj) bp_30\NNP\0|NONE_0 (l_conj) injury_33\NN\14052046|and_10
D013739_D007674 NONE testosterone_0\NN\14747587|in_25 (r_compound) replacement_1\NN\196485|bp_43|._126 (r_nsubj) increased_6\VBD\169651|NONE_0 (l_npadvmod) bp_7\NNP\0|replacement_43|._83 (l_appos) injury_10\NN\14052046|,_8
D013739_D007674 NONE testosterone_0\NN\14747587|to_25|through_113|._176 (r_nsubj) contributes_1\VBZ\126264|NONE_0 (l_prep) to_2\IN\0|testosterone_25|through_88|._151 (l_pobj) development_4\NN\248977|NONE_0 (l_prep) of_5\IN\0|the_16 (l_pobj) hypertension_6\NN\14057371|NONE_0 (l_conj) injury_9\NN\14052046|and_10|in_7
18410508
D015632_D009422 CID mptp_17\NNP\0|-_4 (r_npadvmod) induced_19\VBN\1627355|of_26 (r_amod) neurodegeneration_20\NN\0|NONE_0
D015632_D009422 CID mptp_8\NNP\0|and_4 (r_conj) meth_6\NNP\2704153|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|the_15|cns_11 (r_acl) damage_3\NN\7296428|because_16|selective_41|for_51
D008694_D020258 NONE methamphetamine_0\NN\2704153|-_15 (r_npadvmod) induced_2\VBN\1627355|neurotoxicity_8 (r_amod) activation_6\NN\13561719|are_11|not_15|by_28|._61 (l_nmod) neurotoxicity_3\NN\0|induced_8
D008694_D020258 NONE meth_6\NNP\2704153|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|the_15|cns_11 (r_acl) damage_3\NN\7296428|because_16|selective_41|for_51 (r_nsubj) is_9\VBZ\0|,_79|we_81|plays_113|._181 (l_prep) for_12\IN\0|because_67|damage_51|selective_10 (l_pobj) system_16\NN\3575240|NONE_0 (l_prep) in_17\IN\13603305|the_23|da_19|neuronal_16 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|mouse_13 (l_pobj) neurotoxicity_21\NN\0|NONE_0
D008694_D020258 NONE meth_6\NNP\2704153|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|the_15|cns_11 (r_acl) damage_3\NN\7296428|because_16|selective_41|for_51 (r_nsubj) is_9\VBZ\0|,_79|we_81|plays_113|._181 (r_advcl) hypothesized_24\VBD\719734|NONE_0 (l_ccomp) plays_28\VBZ\7007684|is_113|,_34|we_32|._68 (l_dobj) role_30\NN\719494|that_24|cx3cr1_15 (l_prep) in_31\IN\13603305|a_7 (l_pobj) neurotoxicity_35\NN\0|NONE_0
D008694_D020258 NONE meth_32\NNP\2704153|-_4 (r_npadvmod) induced_34\VBN\1627355|and_22|activation_37 (r_amod) neurotoxicity_35\NN\0|NONE_0 (r_pobj) in_31\IN\13603305|a_7 (r_prep) role_30\NN\719494|that_24|cx3cr1_15 (r_dobj) plays_28\VBZ\7007684|is_113|,_34|we_32|._68 (r_ccomp) hypothesized_24\VBD\719734|NONE_0 (l_advcl) is_9\VBZ\0|,_79|we_81|plays_113|._181 (l_prep) for_12\IN\0|because_67|damage_51|selective_10 (l_pobj) system_16\NN\3575240|NONE_0 (l_prep) in_17\IN\13603305|the_23|da_19|neuronal_16 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|mouse_13 (l_pobj) neurotoxicity_21\NN\0|NONE_0
D008694_D020258 NONE meth_32\NNP\2704153|-_4 (r_npadvmod) induced_34\VBN\1627355|and_22|activation_37 (r_amod) neurotoxicity_35\NN\0|NONE_0
D008694_D020258 NONE meth_25\NNP\2704153|NONE_0 (r_pobj) with_24\IN\0|mice_136|were_13|and_10|examined_14|._49 (r_prep) treated_23\VBN\2376958|NONE_0 (l_conj) examined_27\VBN\0|mice_150|were_27|with_14|and_4|._35 (l_prep) for_28\IN\0|NONE_0 (l_pobj) neurotoxicity_30\NN\0|NONE_0
D008694_D020258 NONE meth_11\NNP\2704153|or_19|activation_33 (r_compound) neurotoxicity_12\NN\0|that_45|signaling_33|does_23|not_18
D004298_D009422 NONE da_22\NNP\10484858|NONE_0 (r_compound) neurons_23\NNS\5430628|NONE_0 (r_pobj) of_21\IN\0|induced_26 (r_prep) neurodegeneration_20\NN\0|NONE_0
D004298_D009422 NONE da_14\NNP\10484858|the_4|neuronal_3|in_19 (r_compound) system_16\NN\3575240|NONE_0 (r_pobj) for_12\IN\0|because_67|damage_51|selective_10 (r_prep) is_9\VBZ\0|,_79|we_81|plays_113|._181 (l_nsubj) damage_3\NN\7296428|because_16|selective_41|for_51
D004298_D020258 NONE da_14\NNP\10484858|the_4|neuronal_3|in_19 (r_compound) system_16\NN\3575240|NONE_0 (l_prep) in_17\IN\13603305|the_23|da_19|neuronal_16 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|mouse_13 (l_pobj) neurotoxicity_21\NN\0|NONE_0
D004298_D020258 NONE da_14\NNP\10484858|the_4|neuronal_3|in_19 (r_compound) system_16\NN\3575240|NONE_0 (r_pobj) for_12\IN\0|because_67|damage_51|selective_10 (r_prep) is_9\VBZ\0|,_79|we_81|plays_113|._181 (r_advcl) hypothesized_24\VBD\719734|NONE_0 (l_ccomp) plays_28\VBZ\7007684|is_113|,_34|we_32|._68 (l_dobj) role_30\NN\719494|that_24|cx3cr1_15 (l_prep) in_31\IN\13603305|a_7 (l_pobj) neurotoxicity_35\NN\0|NONE_0
D008694_D009422 CID meth_6\NNP\2704153|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|the_15|cns_11 (r_acl) damage_3\NN\7296428|because_16|selective_41|for_51
D008694_D009422 CID meth_32\NNP\2704153|-_4 (r_npadvmod) induced_34\VBN\1627355|and_22|activation_37 (r_amod) neurotoxicity_35\NN\0|NONE_0 (r_pobj) in_31\IN\13603305|a_7 (r_prep) role_30\NN\719494|that_24|cx3cr1_15 (r_dobj) plays_28\VBZ\7007684|is_113|,_34|we_32|._68 (r_ccomp) hypothesized_24\VBD\719734|NONE_0 (l_advcl) is_9\VBZ\0|,_79|we_81|plays_113|._181 (l_nsubj) damage_3\NN\7296428|because_16|selective_41|for_51
D015632_D020258 NONE mptp_8\NNP\0|and_4 (r_conj) meth_6\NNP\2704153|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|the_15|cns_11 (r_acl) damage_3\NN\7296428|because_16|selective_41|for_51 (r_nsubj) is_9\VBZ\0|,_79|we_81|plays_113|._181 (l_prep) for_12\IN\0|because_67|damage_51|selective_10 (l_pobj) system_16\NN\3575240|NONE_0 (l_prep) in_17\IN\13603305|the_23|da_19|neuronal_16 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|mouse_13 (l_pobj) neurotoxicity_21\NN\0|NONE_0
D015632_D020258 NONE mptp_8\NNP\0|and_4 (r_conj) meth_6\NNP\2704153|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|the_15|cns_11 (r_acl) damage_3\NN\7296428|because_16|selective_41|for_51 (r_nsubj) is_9\VBZ\0|,_79|we_81|plays_113|._181 (r_advcl) hypothesized_24\VBD\719734|NONE_0 (l_ccomp) plays_28\VBZ\7007684|is_113|,_34|we_32|._68 (l_dobj) role_30\NN\719494|that_24|cx3cr1_15 (l_prep) in_31\IN\13603305|a_7 (l_pobj) neurotoxicity_35\NN\0|NONE_0
10743446
D002211_D006930 CID capsaicin_16\NN\15032661|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|differential_108|of_87|._42 (r_acl) effects_1\NNS\13245626|NONE_0 (l_prep) of_2\IN\0|differential_21|induced_87|._129 (l_pobj) ketamine_5\NN\3054098|NONE_0 (l_prep) on_8\IN\0|administered_36|and_14|lidocaine_10 (l_pobj) hyperalgesia_12\NN\0|NONE_0
D002211_D006930 CID capsaicin_30\NN\15032661|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|the_137|of_126 (r_acl) effect_4\NN\34213|we_21|have_18|._153 (l_prep) of_5\IN\0|the_11|induced_126 (l_pobj) administration_7\NN\1133281|NONE_0 (l_prep) on_12\IN\0|systemic_50|of_26 (l_pobj) hyperalgesia_27\NN\0|NONE_0
D008012_D010146 NONE lidocaine_11\NN\3681148|and_4 (r_conj) ketamine_9\NN\3054098|NONE_0 (r_pobj) of_8\IN\0|systemic_24|on_26 (r_prep) administration_7\NN\1133281|NONE_0 (l_prep) on_12\IN\0|systemic_50|of_26 (l_pobj) hyperalgesia_27\NN\0|NONE_0 (l_nmod) pain_19\NN\14299637|evoked_18|(_25|static_26|)_32
D007649_D006930 NONE ketamine_5\NN\3054098|NONE_0 (l_prep) on_8\IN\0|administered_36|and_14|lidocaine_10 (l_pobj) hyperalgesia_12\NN\0|NONE_0
D007649_D006930 NONE ketamine_9\NN\3054098|NONE_0 (r_pobj) of_8\IN\0|systemic_24|on_26 (r_prep) administration_7\NN\1133281|NONE_0 (l_prep) on_12\IN\0|systemic_50|of_26 (l_pobj) hyperalgesia_27\NN\0|NONE_0
D007649_D006930 NONE ketamine_0\NN\3054098|area_26|significantly_80|and_94|tended_101 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_dobj) area_4\NN\8630985|ketamine_26|significantly_54|and_68|tended_75 (l_prep) of_5\IN\0|both_14|the_9 (l_pobj) hyperalgesia_13\NN\0|NONE_0
D007649_D006930 NONE ketamine_4\NN\3054098|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|on_26 (r_prep) effects_2\NNS\13245626|mediated_116|._180 (l_prep) on_7\IN\0|the_51|differential_47|of_26 (l_pobj) hyperalgesia_11\NN\0|NONE_0
D007649_D006930 NONE ketamine_4\NN\3054098|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|on_26 (r_prep) effects_2\NNS\13245626|mediated_116|._180 (r_nsubj) suggest_12\VBP\1010118|NONE_0 (l_ccomp) mediated_20\VBN\761713|effects_116|._64 (l_nsubjpass) types_16\NNS\5839024|that_13|are_22|by_35|and_58|have_62 (l_prep) of_17\IN\0|the_14|two_10 (l_pobj) hyperalgesia_18\NN\0|NONE_0
D008012_D006930 NONE lidocaine_7\NN\3681148|administered_26|and_4|on_10 (r_conj) ketamine_5\NN\3054098|NONE_0 (l_prep) on_8\IN\0|administered_36|and_14|lidocaine_10 (l_pobj) hyperalgesia_12\NN\0|NONE_0
D008012_D006930 NONE lidocaine_11\NN\3681148|and_4 (r_conj) ketamine_9\NN\3054098|NONE_0 (r_pobj) of_8\IN\0|systemic_24|on_26 (r_prep) administration_7\NN\1133281|NONE_0 (l_prep) on_12\IN\0|systemic_50|of_26 (l_pobj) hyperalgesia_27\NN\0|NONE_0
D008012_D006930 NONE lidocaine_0\NN\3681148|area_22|significantly_59|._72 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_dobj) area_3\NN\8630985|lidocaine_22|significantly_37|._50 (l_prep) of_4\IN\0|the_9 (l_pobj) hyperalgesia_8\NN\0|NONE_0
D008012_D006930 NONE lidocaine_6\NN\3681148|and_4 (r_conj) ketamine_4\NN\3054098|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|on_26 (r_prep) effects_2\NNS\13245626|mediated_116|._180 (l_prep) on_7\IN\0|the_51|differential_47|of_26 (l_pobj) hyperalgesia_11\NN\0|NONE_0
D008012_D006930 NONE lidocaine_6\NN\3681148|and_4 (r_conj) ketamine_4\NN\3054098|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|on_26 (r_prep) effects_2\NNS\13245626|mediated_116|._180 (r_nsubj) suggest_12\VBP\1010118|NONE_0 (l_ccomp) mediated_20\VBN\761713|effects_116|._64 (l_nsubjpass) types_16\NNS\5839024|that_13|are_22|by_35|and_58|have_62 (l_prep) of_17\IN\0|the_14|two_10 (l_pobj) hyperalgesia_18\NN\0|NONE_0
D002211_D010146 CID capsaicin_30\NN\15032661|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|the_137|of_126 (r_acl) effect_4\NN\34213|we_21|have_18|._153 (l_prep) of_5\IN\0|the_11|induced_126 (l_pobj) administration_7\NN\1133281|NONE_0 (l_prep) on_12\IN\0|systemic_50|of_26 (l_pobj) hyperalgesia_27\NN\0|NONE_0 (l_nmod) pain_19\NN\14299637|evoked_18|(_25|static_26|)_32
D007649_D010146 NONE ketamine_9\NN\3054098|NONE_0 (r_pobj) of_8\IN\0|systemic_24|on_26 (r_prep) administration_7\NN\1133281|NONE_0 (l_prep) on_12\IN\0|systemic_50|of_26 (l_pobj) hyperalgesia_27\NN\0|NONE_0 (l_nmod) pain_19\NN\14299637|evoked_18|(_25|static_26|)_32
D007649_D010146 NONE ketamine_0\NN\3054098|area_26|significantly_80|and_94|tended_101 (r_nsubj) reduced_1\VBD\441445|NONE_0 (l_conj) tended_17\VBD\2604760|ketamine_101|area_75|significantly_21|and_7 (l_xcomp) reduce_19\VB\441445|it_13|._24 (l_dobj) pain_23\NN\14299637|to_23
18442015
D004872_D014456 CID d2_47\NN\0|NONE_0 (r_pobj) of_45\IN\0|NONE_0 (r_prep) coadministration_44\NN\0|NONE_0 (r_pobj) by_43\IN\0|,_182|release_160 (r_prep) induced_42\VBN\1627355|aim_245|examine_221|._57 (l_nsubj) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0 (l_conj) ulcer_37\NN\14211294|gastric_23|and_4|in_6
D002784_D050197 CID cholesterol_49\NN\15058310|vitamin_15|and_4 (r_conj) d2_47\NN\0|NONE_0 (r_pobj) of_45\IN\0|NONE_0 (r_prep) coadministration_44\NN\0|NONE_0 (r_pobj) by_43\IN\0|,_182|release_160 (r_prep) induced_42\VBN\1627355|aim_245|examine_221|._57 (l_nsubj) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0 (l_prep) in_38\IN\13603305|gastric_29|and_10|ulcer_6 (l_pobj) rats_39\NNS\2329401|NONE_0 (l_prep) with_40\IN\0|NONE_0 (l_pobj) atherosclerosis_41\NN\14108324|NONE_0
D002784_D050197 CID cholesterol_23\NN\15058310|vitamin_15|and_4 (r_conj) d2_21\NN\0|kg_34|induce_22 (r_dobj) containing_19\VBG\2632940|NONE_0 (l_advcl) induce_25\VB\1627355|kg_56|d2_22 (l_dobj) atherosclerosis_26\NN\14108324|to_10
D002784_D050197 CID cholesterol_10\NN\15058310|serum_21|,_8 (r_conj) calcium_7\NN\14625458|such_14 (r_pobj) as_5\IN\14622893|elevated_42|atherosclerotic_33|,_7 (r_prep) parameters_2\NNS\5858936|were_95|in_109|._132 (l_amod) atherosclerotic_1\JJ\0|elevated_9|,_26|as_33
D002784_D050197 CID cholesterol_10\NN\15058310|serum_21|,_8 (r_conj) calcium_7\NN\14625458|such_14 (r_pobj) as_5\IN\14622893|elevated_42|atherosclerotic_33|,_7 (r_prep) parameters_2\NNS\5858936|were_95|in_109|._132 (r_nsubjpass) obtained_18\VBN\2210855|NONE_0 (l_prep) in_19\IN\13603305|parameters_109|were_14|._23 (l_pobj) rats_21\NNS\2329401|NONE_0 (l_amod) atherosclerotic_20\JJ\0|NONE_0
D002118_D050197 NONE calcium_7\NN\14625458|such_14 (r_pobj) as_5\IN\14622893|elevated_42|atherosclerotic_33|,_7 (r_prep) parameters_2\NNS\5858936|were_95|in_109|._132 (l_amod) atherosclerotic_1\JJ\0|elevated_9|,_26|as_33
D002118_D050197 NONE calcium_7\NN\14625458|such_14 (r_pobj) as_5\IN\14622893|elevated_42|atherosclerotic_33|,_7 (r_prep) parameters_2\NNS\5858936|were_95|in_109|._132 (r_nsubjpass) obtained_18\VBN\2210855|NONE_0 (l_prep) in_19\IN\13603305|parameters_109|were_14|._23 (l_pobj) rats_21\NNS\2329401|NONE_0 (l_amod) atherosclerotic_20\JJ\0|NONE_0
D006632_D050197 NONE histamine_19\NN\14739004|mast_10|,_17|peroxide_25 (r_compound) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0 (l_prep) in_38\IN\13603305|gastric_29|and_10|ulcer_6 (l_pobj) rats_39\NNS\2329401|NONE_0 (l_prep) with_40\IN\0|NONE_0 (l_pobj) atherosclerosis_41\NN\14108324|NONE_0
D006632_D050197 NONE histamine_6\NN\14739004|NONE_0 (r_pobj) of_5\IN\0|a_23|positive_21|to_13 (r_prep) correlation_4\NN\13841213|moreover_21|,_13|was_60|in_70|._99 (r_nsubjpass) found_14\VBN\13279262|NONE_0 (l_prep) in_15\IN\13603305|moreover_91|,_83|correlation_70|was_10|._29 (l_pobj) rats_18\NNS\2329401|NONE_0 (l_amod) atherosclerotic_17\JJ\0|those_6
D006632_D050197 NONE histamine_18\NN\14739004|and_18|permeability_36 (r_compound) release_19\NN\3748886|produce_108|,_28|lpo_26|,_12|ameliorated_53|._85 (r_conj) generation_16\NN\7942152|NONE_0 (l_ccomp) produce_2\VB\7555863|,_80|lpo_82|,_96|release_108|ameliorated_161|._193 (l_nsubj) atherosclerosis_0\NN\14108324|could_16|ulcer_50|via_56
D010634_D014456 NONE luminal_16\JJ\2792049|hemoglobin_8|and_27|areas_37 (r_amod) content_18\NN\7951464|microvascular_47|,_21 (l_conj) areas_21\NNS\8630985|luminal_37|hemoglobin_29|and_10 (l_compound) ulcer_20\NN\14211294|NONE_0
D010634_D014456 NONE luminal_22\JJ\2792049|hemoglobin_8 (r_amod) content_24\NN\7951464|lpo_38|and_23 (r_conj) generation_20\NN\7942152|histamine_23|,_6 (r_conj) release_17\NN\3748886|gastric_39|acid_31|back_26|-_22|,_12 (r_conj) diffusion_14\NN\13518963|NONE_0 (r_pobj) including_9\VBG\0|increased_31|ulcerogenic_21|,_2 (r_prep) factors_7\NNS\7326557|NONE_0 (r_pobj) with_4\IN\0|ulcers_19 (r_prep) accompanied_3\VBN\0|were_152|also_157|in_171|._184 (l_nsubj) ulcers_2\NNS\14211294|with_19
D006632_D014456 NONE histamine_19\NN\14739004|mast_10|,_17|peroxide_25 (r_compound) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0 (l_conj) ulcer_37\NN\14211294|gastric_23|and_4|in_6
D006632_D014456 NONE histamine_10\NN\14739004|,_23|permeability_39 (r_compound) concentration_11\NN\4916342|mucosal_34|lpo_26|,_12 (l_conj) permeability_14\NN\4940146|histamine_39|,_16 (l_conj) content_18\NN\7951464|microvascular_47|,_21 (l_conj) areas_21\NNS\8630985|luminal_37|hemoglobin_29|and_10 (l_compound) ulcer_20\NN\14211294|NONE_0
D006632_D014456 NONE histamine_16\NN\14739004|,_17|generation_23 (r_compound) release_17\NN\3748886|gastric_39|acid_31|back_26|-_22|,_12 (r_conj) diffusion_14\NN\13518963|NONE_0 (r_pobj) including_9\VBG\0|increased_31|ulcerogenic_21|,_2 (r_prep) factors_7\NNS\7326557|NONE_0 (r_pobj) with_4\IN\0|ulcers_19 (r_prep) accompanied_3\VBN\0|were_152|also_157|in_171|._184 (l_nsubj) ulcers_2\NNS\14211294|with_19
D006632_D014456 NONE histamine_6\NN\14739004|NONE_0 (r_pobj) of_5\IN\0|a_23|positive_21|to_13 (r_prep) correlation_4\NN\13841213|moreover_21|,_13|was_60|in_70|._99 (l_prep) to_7\IN\0|a_36|positive_34|of_13 (l_conj) to_11\IN\0|hemorrhage_15|and_4 (l_pobj) ulcer_12\NN\14211294|NONE_0
D006632_D014456 NONE histamine_18\NN\14739004|and_18|permeability_36 (r_compound) release_19\NN\3748886|produce_108|,_28|lpo_26|,_12|ameliorated_53|._85 (r_conj) generation_16\NN\7942152|NONE_0 (l_ccomp) produce_2\VB\7555863|,_80|lpo_82|,_96|release_108|ameliorated_161|._193 (l_dobj) ulcer_5\NN\14211294|atherosclerosis_50|could_34|via_6
D002784_D014456 CID cholesterol_49\NN\15058310|vitamin_15|and_4 (r_conj) d2_47\NN\0|NONE_0 (r_pobj) of_45\IN\0|NONE_0 (r_prep) coadministration_44\NN\0|NONE_0 (r_pobj) by_43\IN\0|,_182|release_160 (r_prep) induced_42\VBN\1627355|aim_245|examine_221|._57 (l_nsubj) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0 (l_conj) ulcer_37\NN\14211294|gastric_23|and_4|in_6
D004872_D006471 CID d2_47\NN\0|NONE_0 (r_pobj) of_45\IN\0|NONE_0 (r_prep) coadministration_44\NN\0|NONE_0 (r_pobj) by_43\IN\0|,_182|release_160 (r_prep) induced_42\VBN\1627355|aim_245|examine_221|._57 (l_nsubj) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0
D014700_D050197 NONE verapamil_3\NN\2938514|NONE_0 (r_pobj) of_2\IN\0|protective_18|on_13|._73 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) on_4\IN\0|protective_31|of_13|._60 (l_pobj) ulcers_7\NNS\14211294|NONE_0 (l_prep) in_8\IN\13603305|gastric_27|hemorrhagic_19 (l_pobj) rats_11\NNS\2329401|NONE_0 (l_amod) atherosclerotic_10\JJ\0|severe_7
D014700_D050197 NONE verapamil_28\NN\2938514|NONE_0 (r_pobj) by_27\IN\0|that_26|could_21|be_15|in_13 (r_agent) ameliorated_26\VBN\126264|produce_161|,_81|lpo_79|,_65|release_53|._32 (r_relcl) generation_16\NN\7942152|NONE_0 (l_ccomp) produce_2\VB\7555863|,_80|lpo_82|,_96|release_108|ameliorated_161|._193 (l_nsubj) atherosclerosis_0\NN\14108324|could_16|ulcer_50|via_56
D002784_D006471 CID cholesterol_49\NN\15058310|vitamin_15|and_4 (r_conj) d2_47\NN\0|NONE_0 (r_pobj) of_45\IN\0|NONE_0 (r_prep) coadministration_44\NN\0|NONE_0 (r_pobj) by_43\IN\0|,_182|release_160 (r_prep) induced_42\VBN\1627355|aim_245|examine_221|._57 (l_nsubj) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0
D014700_D006471 NONE verapamil_3\NN\2938514|NONE_0 (r_pobj) of_2\IN\0|protective_18|on_13|._73 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) on_4\IN\0|protective_31|of_13|._60 (l_pobj) ulcers_7\NNS\14211294|NONE_0 (l_amod) hemorrhagic_6\JJ\0|gastric_8|in_19
D014700_D006471 NONE verapamil_15\NN\2938514|NONE_0 (r_pobj) by_12\IN\0|dependently_24 (r_agent) ameliorated_11\VBN\126264|ulcer_63|._43 (r_acomp) were_7\VBD\0|NONE_0 (l_nsubj) ulcer_2\NN\14211294|ameliorated_63|._106 (l_amod) hemorrhagic_1\JJ\0|this_5|and_18|parameters_42
D014700_D006471 NONE verapamil_28\NN\2938514|NONE_0 (r_pobj) by_27\IN\0|that_26|could_21|be_15|in_13 (r_agent) ameliorated_26\VBN\126264|produce_161|,_81|lpo_79|,_65|release_53|._32 (r_relcl) generation_16\NN\7942152|NONE_0 (l_ccomp) produce_2\VB\7555863|,_80|lpo_82|,_96|release_108|ameliorated_161|._193 (l_dobj) ulcer_5\NN\14211294|atherosclerosis_50|could_34|via_6 (l_amod) hemorrhagic_4\JJ\0|gastric_8
D004872_D050197 CID d2_47\NN\0|NONE_0 (r_pobj) of_45\IN\0|NONE_0 (r_prep) coadministration_44\NN\0|NONE_0 (r_pobj) by_43\IN\0|,_182|release_160 (r_prep) induced_42\VBN\1627355|aim_245|examine_221|._57 (l_nsubj) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0 (l_prep) in_38\IN\13603305|gastric_29|and_10|ulcer_6 (l_pobj) rats_39\NNS\2329401|NONE_0 (l_prep) with_40\IN\0|NONE_0 (l_pobj) atherosclerosis_41\NN\14108324|NONE_0
D004872_D050197 CID d2_21\NN\0|kg_34|induce_22 (r_dobj) containing_19\VBG\2632940|NONE_0 (l_advcl) induce_25\VB\1627355|kg_56|d2_22 (l_dobj) atherosclerosis_26\NN\14108324|to_10
D006632_D006471 NONE histamine_19\NN\14739004|mast_10|,_17|peroxide_25 (r_compound) release_20\NN\3748886|,_22|by_160 (l_conj) peroxide_23\NN\14780040|mast_35|histamine_25|,_8 (l_appos) permeability_31\NN\4940146|lipid_58 (l_prep) in_32\IN\13603305|generation_50|microvascular_27 (l_pcomp) modulating_33\VBG\1724459|NONE_0 (l_dobj) hemorrhage_35\NN\14285662|NONE_0
D006632_D006471 NONE histamine_6\NN\14739004|NONE_0 (r_pobj) of_5\IN\0|a_23|positive_21|to_13 (r_prep) correlation_4\NN\13841213|moreover_21|,_13|was_60|in_70|._99 (l_prep) to_7\IN\0|a_36|positive_34|of_13 (l_pobj) hemorrhage_9\NN\14285662|and_11|to_15
D006632_D006471 NONE histamine_18\NN\14739004|and_18|permeability_36 (r_compound) release_19\NN\3748886|produce_108|,_28|lpo_26|,_12|ameliorated_53|._85 (r_conj) generation_16\NN\7942152|NONE_0 (l_ccomp) produce_2\VB\7555863|,_80|lpo_82|,_96|release_108|ameliorated_161|._193 (l_dobj) ulcer_5\NN\14211294|atherosclerosis_50|could_34|via_6 (l_amod) hemorrhagic_4\JJ\0|gastric_8
D014700_D014456 NONE verapamil_3\NN\2938514|NONE_0 (r_pobj) of_2\IN\0|protective_18|on_13|._73 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) on_4\IN\0|protective_31|of_13|._60 (l_pobj) ulcers_7\NNS\14211294|NONE_0
D014700_D014456 NONE verapamil_6\NN\2938514|NONE_0 (r_pobj) of_5\IN\0|the_22|protective_18|on_13 (r_prep) effect_4\NN\34213|additionally_29|,_17|was_40|._53 (l_prep) on_7\IN\0|the_35|protective_31|of_13 (l_pobj) model_10\NN\5888929|NONE_0 (l_compound) ulcer_9\NN\14211294|this_5
D014700_D014456 NONE verapamil_15\NN\2938514|NONE_0 (r_pobj) by_12\IN\0|dependently_24 (r_agent) ameliorated_11\VBN\126264|ulcer_63|._43 (r_acomp) were_7\VBD\0|NONE_0 (l_nsubj) ulcer_2\NN\14211294|ameliorated_63|._106
D014700_D014456 NONE verapamil_28\NN\2938514|NONE_0 (r_pobj) by_27\IN\0|that_26|could_21|be_15|in_13 (r_agent) ameliorated_26\VBN\126264|produce_161|,_81|lpo_79|,_65|release_53|._32 (r_relcl) generation_16\NN\7942152|NONE_0 (l_ccomp) produce_2\VB\7555863|,_80|lpo_82|,_96|release_108|ameliorated_161|._193 (l_dobj) ulcer_5\NN\14211294|atherosclerosis_50|could_34|via_6
6286738
D002762_D054559 CID d3_5\NNP\0|NONE_0 (r_pobj) of_3\IN\0|large_23|parenteral_17|(_14|d3_45|)_47 (r_prep) doses_2\NNS\3740161|were_55|with_71|._246 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|doses_71|were_16|._175 (l_pobj) hypercalcemia_21\NN\14299637|NONE_0 (l_conj) hyperphosphatemia_23\NN\0|prolonged_25|,_2
D002762_D054559 CID d3_15\NNP\0|large_68|parenteral_62|of_45|(_31|)_2 (r_appos) doses_2\NNS\3740161|were_55|with_71|._246 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|doses_71|were_16|._175 (l_pobj) hypercalcemia_21\NN\14299637|NONE_0 (l_conj) hyperphosphatemia_23\NN\0|prolonged_25|,_2
D002762_D054559 CID d3_30\NNP\0|NONE_0 (r_pobj) of_28\IN\0|large_16 (r_prep) increases_27\NNS\13576355|,_12|and_10 (r_conj) hyperphosphatemia_23\NN\0|prolonged_25|,_2
D002762_D064420 NONE d3_1\NN\0|in_12|._25 (r_compound) toxicity_2\NN\13576101|NONE_0
D002762_D064420 NONE d3_3\NNP\0|NONE_0 (r_compound) toxicity_4\NN\13576101|NONE_0
D002762_D064420 NONE d3_3\NNP\0|NONE_0 (r_compound) toxicity_4\NN\13576101|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) signs_0\NNS\6643763|were_29|not_34|in_47 (r_nsubjpass) observed_7\VBN\2163746|;_41|however_43|,_50|cows_61|commonly_66|signs_92|died_139|._143 (r_ccomp) developed_18\VBN\1753788|NONE_0 (l_dobj) signs_20\NNS\6643763|observed_92|;_51|however_49|,_42|cows_31|commonly_26|died_47|._51 (l_prep) of_21\IN\0|severe_13 (l_pobj) toxicity_24\NN\13576101|NONE_0
D002762_D064420 NONE d3_23\NNP\0|and_12|cows_25 (r_compound) toxicity_24\NN\13576101|NONE_0 (r_pobj) of_21\IN\0|severe_13 (r_prep) signs_20\NNS\6643763|observed_92|;_51|however_49|,_42|cows_31|commonly_26|died_47|._51 (r_dobj) developed_18\VBN\1753788|NONE_0 (l_ccomp) observed_7\VBN\2163746|;_41|however_43|,_50|cows_61|commonly_66|signs_92|died_139|._143 (l_nsubjpass) signs_0\NNS\6643763|were_29|not_34|in_47 (l_prep) of_1\IN\0|NONE_0 (l_pobj) toxicity_4\NN\13576101|NONE_0
D002762_D064420 NONE d3_23\NNP\0|and_12|cows_25 (r_compound) toxicity_24\NN\13576101|NONE_0
D002762_D064420 NONE d3_7\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_21|extreme_17|in_14|and_38|margin_50 (r_prep) toxicity_4\NN\13576101|of_15
D002762_D064420 NONE d3_22\NNP\0|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) doses_19\NNS\3740161|NONE_0 (r_pobj) between_18\IN\0|NONE_0 (r_prep) safety_17\NN\13920835|NONE_0 (r_pobj) of_16\IN\0|the_15|low_11 (r_prep) margin_15\NN\13903079|the_71|extreme_67|of_50|in_36|and_12 (r_conj) toxicity_4\NN\13576101|of_15
D002762_D064420 NONE d3_38\NNP\0|that_13|can_3|not_6|be_10|prevent_33|injected_57 (r_nsubjpass) used_42\VBN\0|because_224|,_41|we_39|._76 (r_ccomp) concluded_35\VBD\628491|NONE_0 (l_prep) because_0\IN\0|,_183|we_185|used_224|._300 (l_pobj) toxicity_4\NN\13576101|of_15
D002762_D010319 NONE d3_7\NNP\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) treated_4\VBN\2376958|the_9 (r_acl) cows_3\NNS\2402010|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) none_0\NN\15228378|signs_48|during_68 (r_nsubj) showed_8\VBD\2137132|;_55|however_57|,_64|%_68|signs_109|during_129|._147 (l_dobj) signs_9\NNS\6643763|none_48|during_20 (l_prep) of_10\IN\0|NONE_0 (l_pobj) fever_12\NN\14299637|NONE_0
D002762_D010319 NONE d3_7\NNP\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) treated_4\VBN\2376958|the_9 (r_acl) cows_3\NNS\2402010|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) none_0\NN\15228378|signs_48|during_68 (r_nsubj) showed_8\VBD\2137132|;_55|however_57|,_64|%_68|signs_109|during_129|._147 (r_ccomp) developed_26\VBD\1753788|NONE_0 (l_dobj) signs_28\NNS\6643763|showed_109|;_54|however_52|,_45|%_41|during_20|._38 (l_prep) of_29\IN\0|clinical_15 (l_pobj) fever_31\NN\14299637|NONE_0
D002762_D010319 NONE d3_7\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_21|extreme_17|in_14|and_38|margin_50 (r_prep) toxicity_4\NN\13576101|of_15 (l_conj) margin_15\NN\13903079|the_71|extreme_67|of_50|in_36|and_12 (l_prep) of_16\IN\0|the_15|low_11 (l_pobj) safety_17\NN\13920835|NONE_0 (l_prep) between_18\IN\0|NONE_0 (l_pobj) doses_19\NNS\3740161|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) d3_22\NNP\0|NONE_0 (l_relcl) prevent_24\VBP\0|vitamin_16 (l_dobj) fever_26\NN\14299637|that_18
D002762_D010319 NONE d3_7\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_21|extreme_17|in_14|and_38|margin_50 (r_prep) toxicity_4\NN\13576101|of_15 (l_conj) margin_15\NN\13903079|the_71|extreme_67|of_50|in_36|and_12 (l_prep) of_16\IN\0|the_15|low_11 (l_pobj) safety_17\NN\13920835|NONE_0 (l_prep) between_18\IN\0|NONE_0 (l_pobj) doses_19\NNS\3740161|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) d3_22\NNP\0|NONE_0 (l_relcl) prevent_24\VBP\0|vitamin_16 (l_dobj) fever_26\NN\14299637|that_18 (l_relcl) induce_30\VBP\1627355|milk_26|and_15|doses_11 (l_dobj) fever_32\NN\14299637|that_17
D002762_D010319 NONE d3_7\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_21|extreme_17|in_14|and_38|margin_50 (r_prep) toxicity_4\NN\13576101|of_15 (r_pobj) because_0\IN\0|,_183|we_185|used_224|._300 (r_prep) concluded_35\VBD\628491|NONE_0 (l_ccomp) used_42\VBN\0|because_224|,_41|we_39|._76 (l_xcomp) prevent_45\VB\0|that_46|d3_33|can_30|not_27|be_23|injected_24 (l_dobj) fever_47\NN\14299637|practically_28|to_16
D002762_D010319 NONE d3_22\NNP\0|NONE_0 (l_relcl) prevent_24\VBP\0|vitamin_16 (l_dobj) fever_26\NN\14299637|that_18
D002762_D010319 NONE d3_22\NNP\0|NONE_0 (l_relcl) prevent_24\VBP\0|vitamin_16 (l_dobj) fever_26\NN\14299637|that_18 (l_relcl) induce_30\VBP\1627355|milk_26|and_15|doses_11 (l_dobj) fever_32\NN\14299637|that_17
D002762_D010319 NONE d3_22\NNP\0|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) doses_19\NNS\3740161|NONE_0 (r_pobj) between_18\IN\0|NONE_0 (r_prep) safety_17\NN\13920835|NONE_0 (r_pobj) of_16\IN\0|the_15|low_11 (r_prep) margin_15\NN\13903079|the_71|extreme_67|of_50|in_36|and_12 (r_conj) toxicity_4\NN\13576101|of_15 (r_pobj) because_0\IN\0|,_183|we_185|used_224|._300 (r_prep) concluded_35\VBD\628491|NONE_0 (l_ccomp) used_42\VBN\0|because_224|,_41|we_39|._76 (l_xcomp) prevent_45\VB\0|that_46|d3_33|can_30|not_27|be_23|injected_24 (l_dobj) fever_47\NN\14299637|practically_28|to_16
D002762_D010319 NONE d3_38\NNP\0|that_13|can_3|not_6|be_10|prevent_33|injected_57 (r_nsubjpass) used_42\VBN\0|because_224|,_41|we_39|._76 (r_ccomp) concluded_35\VBD\628491|NONE_0 (l_prep) because_0\IN\0|,_183|we_185|used_224|._300 (l_pobj) toxicity_4\NN\13576101|of_15 (l_conj) margin_15\NN\13903079|the_71|extreme_67|of_50|in_36|and_12 (l_prep) of_16\IN\0|the_15|low_11 (l_pobj) safety_17\NN\13920835|NONE_0 (l_prep) between_18\IN\0|NONE_0 (l_pobj) doses_19\NNS\3740161|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) d3_22\NNP\0|NONE_0 (l_relcl) prevent_24\VBP\0|vitamin_16 (l_dobj) fever_26\NN\14299637|that_18
D002762_D010319 NONE d3_38\NNP\0|that_13|can_3|not_6|be_10|prevent_33|injected_57 (r_nsubjpass) used_42\VBN\0|because_224|,_41|we_39|._76 (r_ccomp) concluded_35\VBD\628491|NONE_0 (l_prep) because_0\IN\0|,_183|we_185|used_224|._300 (l_pobj) toxicity_4\NN\13576101|of_15 (l_conj) margin_15\NN\13903079|the_71|extreme_67|of_50|in_36|and_12 (l_prep) of_16\IN\0|the_15|low_11 (l_pobj) safety_17\NN\13920835|NONE_0 (l_prep) between_18\IN\0|NONE_0 (l_pobj) doses_19\NNS\3740161|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) d3_22\NNP\0|NONE_0 (l_relcl) prevent_24\VBP\0|vitamin_16 (l_dobj) fever_26\NN\14299637|that_18 (l_relcl) induce_30\VBP\1627355|milk_26|and_15|doses_11 (l_dobj) fever_32\NN\14299637|that_17
D002762_D010319 NONE d3_38\NNP\0|that_13|can_3|not_6|be_10|prevent_33|injected_57 (r_nsubjpass) used_42\VBN\0|because_224|,_41|we_39|._76 (l_xcomp) prevent_45\VB\0|that_46|d3_33|can_30|not_27|be_23|injected_24 (l_dobj) fever_47\NN\14299637|practically_28|to_16
D002762_D006934 CID d3_5\NNP\0|NONE_0 (r_pobj) of_3\IN\0|large_23|parenteral_17|(_14|d3_45|)_47 (r_prep) doses_2\NNS\3740161|were_55|with_71|._246 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|doses_71|were_16|._175 (l_pobj) hypercalcemia_21\NN\14299637|NONE_0
D002762_D006934 CID d3_15\NNP\0|large_68|parenteral_62|of_45|(_31|)_2 (r_appos) doses_2\NNS\3740161|were_55|with_71|._246 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|doses_71|were_16|._175 (l_pobj) hypercalcemia_21\NN\14299637|NONE_0
D002762_D006934 CID d3_30\NNP\0|NONE_0 (r_pobj) of_28\IN\0|large_16 (r_prep) increases_27\NNS\13576355|,_12|and_10 (r_conj) hyperphosphatemia_23\NN\0|prolonged_25|,_2 (r_conj) hypercalcemia_21\NN\14299637|NONE_0
603022
D005702_D062787 NONE hydrobromide_1\RB\0|was_89|in_98|._177 (r_nsubjpass) used_16\VBN\0|NONE_0 (l_prep) in_17\IN\13603305|hydrobromide_98|was_9|._79 (l_pobj) patient_19\JJ\9898892|NONE_0 (l_acl) demonstrating_20\NN\2137132|a_10 (l_dobj) effects_22\NNS\13245626|NONE_0 (l_prep) of_23\IN\0|central_16 (l_pobj) overdosage_28\NN\0|NONE_0
D012601_D062787 CID scopolamine_24\NN\14712692|(_12|hyoscine_13|)_21 (r_nmod) overdosage_28\NN\0|NONE_0
D012601_D062787 CID hyoscine_26\NN\14712692|scopolamine_13|(_1|)_8 (r_nmod) overdosage_28\NN\0|NONE_0
1601297
D003042_D009203 CID cocaine_3\NN\3492717|the_4 (r_compound) abusers_4\NNS\9633969|NONE_0 (r_pobj) of_1\IN\0|and_23|none_27 (r_prep) eleven_0\CD\13745420|evidence_63|._172 (r_nsubj) had_10\VBD\0|NONE_0 (l_dobj) evidence_12\NN\5816287|eleven_63|._109 (l_prep) of_13\IN\0|ecg_13 (l_pobj) injury_16\NN\14052046|NONE_0 (l_acl) defined_17\VBN\2604760|significant_30|myocardial_18 (l_prep) as_18\IN\14622893|NONE_0 (l_pobj) infarction_20\NN\14204950|NONE_0
D003042_D007511 NONE cocaine_3\NN\3492717|the_4 (r_compound) abusers_4\NNS\9633969|NONE_0 (r_pobj) of_1\IN\0|and_23|none_27 (r_prep) eleven_0\CD\13745420|evidence_63|._172 (r_nsubj) had_10\VBD\0|NONE_0 (l_dobj) evidence_12\NN\5816287|eleven_63|._109 (l_prep) of_13\IN\0|ecg_13 (l_pobj) injury_16\NN\14052046|NONE_0 (l_acl) defined_17\VBN\2604760|significant_30|myocardial_18 (l_prep) as_18\IN\14622893|NONE_0 (l_pobj) infarction_20\NN\14204950|NONE_0 (l_conj) ischemia_22\NN\14195315|myocardial_23|,_2
D003042_D012559 NONE cocaine_7\NN\3492717|-_7 (r_npadvmod) abusing_9\VBG\2514187|99_11 (r_amod) patients_10\NNS\9898892|NONE_0 (r_pobj) of_5\IN\0|(_6|)_2 (r_prep) ecg_3\NNP\7000195|the_24 (r_appos) electrocardiograms_1\NNS\7000195|were_56|with_70|._112 (r_nsubjpass) compared_12\VBN\644583|NONE_0 (l_prep) with_13\IN\0|electrocardiograms_70|were_14|._42 (l_pobj) ecgs_15\NNS\7000195|NONE_0 (l_prep) of_16\IN\0|the_9 (l_pobj) controls_19\NNS\5190804|NONE_0 (l_amod) schizophrenic_18\JJ\10490141|50_3
D003042_D009202 NONE cocaine_8\NN\3492717|hospitalized_13 (r_compound) abusers_9\NNS\9633969|NONE_0 (r_pobj) in_5\IN\13603305|myocardial_18 (r_prep) injury_4\NN\14052046|NONE_0
D003042_D009202 NONE cocaine_3\NN\3492717|the_4 (r_compound) abusers_4\NNS\9633969|NONE_0 (r_pobj) of_1\IN\0|and_23|none_27 (r_prep) eleven_0\CD\13745420|evidence_63|._172 (r_nsubj) had_10\VBD\0|NONE_0 (l_dobj) evidence_12\NN\5816287|eleven_63|._109 (l_prep) of_13\IN\0|ecg_13 (l_pobj) injury_16\NN\14052046|NONE_0
D003042_D002037 CID cocaine_3\NN\3492717|the_4 (r_compound) abusers_4\NNS\9633969|NONE_0 (r_pobj) of_1\IN\0|and_23|none_27 (r_prep) eleven_0\CD\13745420|evidence_63|._172 (r_nsubj) had_10\VBD\0|NONE_0 (l_dobj) evidence_12\NN\5816287|eleven_63|._109 (l_prep) of_13\IN\0|ecg_13 (l_pobj) injury_16\NN\14052046|NONE_0 (l_acl) defined_17\VBN\2604760|significant_30|myocardial_18 (l_prep) as_18\IN\14622893|NONE_0 (l_pobj) infarction_20\NN\14204950|NONE_0 (l_conj) ischemia_22\NN\14195315|myocardial_23|,_2 (l_conj) block_27\NN\21939|,_20|and_18
8643971
D017239_D064420 NONE paclitaxel_16\NN\0|escalating_11|combined_17 (r_compound) doses_17\NNS\3740161|NONE_0 (r_pobj) of_14\IN\0|the_26|and_13|toxicity_9 (r_prep) response_11\NN\11410625|to_17 (l_conj) toxicity_13\NN\13576101|the_17|and_4|of_9
D017239_D064420 NONE paclitaxel_5\NN\0|escalating_11 (r_compound) doses_6\NNS\3740161|levels_41|,_5|and_7|permitted_66 (r_dobj) incorporate_3\VBP\1461328|NONE_0 (l_conj) permitted_17\VBN\797697|levels_107|doses_66|,_61|and_59 (l_advcl) permits_20\VBZ\6479665|escalations_64|are_26|._7 (l_nsubj) toxicity_19\NN\13576101|if_3
D002945_D064420 NONE cisplatin_23\NN\0|NONE_0 (r_pobj) with_19\IN\0|with_26 (r_prep) combined_18\VBN\2630189|escalating_28|paclitaxel_17 (r_acl) doses_17\NNS\3740161|NONE_0 (r_pobj) of_14\IN\0|the_26|and_13|toxicity_9 (r_prep) response_11\NN\11410625|to_17 (l_conj) toxicity_13\NN\13576101|the_17|and_4|of_9
D017239_D006258 NONE paclitaxel_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|ii_9 (r_prep) study_5\NN\635850|a_13|plus_20|cisplatin_25|._103 (r_dobj) phase_1\NN\15113229|NONE_0 (l_conj) cisplatin_9\NN\0|a_38|study_25|plus_5|._78 (l_prep) as_10\IN\14622893|NONE_0 (l_pobj) therapy_14\NN\657604|NONE_0 (l_prep) for_15\IN\0|line_13|:_25|results_39 (l_pobj) cancers_19\NNS\14239425|NONE_0
D017239_D006258 NONE paclitaxel_13\NN\0|NONE_0 (r_pobj) of_9\IN\0|an_44|group_12 (r_prep) study_8\NN\635850|NONE_0 (r_pobj) of_2\IN\0|preliminary_20 (r_prep) results_1\NNS\34213|rate_159|used_253|._353 (r_nsubj) reported_27\VBD\831651|NONE_0 (l_dobj) rate_32\NN\13815152|results_159|used_94|._194 (l_prep) in_33\IN\13603305|a_20|%_16|response_14|,_37|and_39 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_prep) with_35\IN\0|NONE_0 (l_pobj) cancer_39\NN\14239425|NONE_0
D017239_D006258 NONE taxol_15\NNP\0|agent_18 (r_appos) paclitaxel_13\NN\0|NONE_0 (r_pobj) of_9\IN\0|an_44|group_12 (r_prep) study_8\NN\635850|NONE_0 (r_pobj) of_2\IN\0|preliminary_20 (r_prep) results_1\NNS\34213|rate_159|used_253|._353 (r_nsubj) reported_27\VBD\831651|NONE_0 (l_dobj) rate_32\NN\13815152|results_159|used_94|._194 (l_prep) in_33\IN\13603305|a_20|%_16|response_14|,_37|and_39 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_prep) with_35\IN\0|NONE_0 (l_pobj) cancer_39\NN\14239425|NONE_0
D017239_D006258 NONE paclitaxel_43\NN\0|the_4|cisplatin_11 (r_nmod) combination_46\NN\7951464|has_12|been_16|successfully_26|and_39|improved_61 (r_nsubjpass) used_49\VBN\0|results_253|rate_94|._100 (r_conj) reported_27\VBD\831651|NONE_0 (l_dobj) rate_32\NN\13815152|results_159|used_94|._194 (l_prep) in_33\IN\13603305|a_20|%_16|response_14|,_37|and_39 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_prep) with_35\IN\0|NONE_0 (l_pobj) cancer_39\NN\14239425|NONE_0
D017239_D006258 NONE paclitaxel_16\NN\0|escalating_11|combined_17 (r_compound) doses_17\NNS\3740161|NONE_0 (l_acl) combined_18\VBN\2630189|escalating_28|paclitaxel_17 (l_prep) with_24\IN\0|with_26 (l_pobj) support_30\NN\407535|NONE_0 (l_prep) in_31\IN\13603305|granulocyte_46|factor_15 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|NONE_0 (l_pobj) head_38\NN\5225090|NONE_0 (l_conj) carcinoma_41\NN\14239918|untreated_52|advanced_34|inoperable_25|and_9
D017239_D006258 NONE paclitaxel_0\NNP\0|cisplatin_11|regimen_48|warranted_128 (r_nsubj) is_3\VBZ\0|NONE_0 (l_attr) regimen_9\NN\5898568|paclitaxel_48|cisplatin_37|warranted_80 (l_prep) for_10\IN\0|an_32|effective_29|line_13|and_49 (l_pobj) head_13\NN\5225090|NONE_0 (l_conj) cancer_16\NN\14239425|advanced_23|and_9
D017239_D010051 NONE paclitaxel_13\NN\0|NONE_0 (r_pobj) of_9\IN\0|an_44|group_12 (r_prep) study_8\NN\635850|NONE_0 (r_pobj) of_2\IN\0|preliminary_20 (r_prep) results_1\NNS\34213|rate_159|used_253|._353 (r_nsubj) reported_27\VBD\831651|NONE_0 (l_conj) used_49\VBN\0|results_253|rate_94|._100 (l_conj) improved_54\VBN\126264|combination_61|has_49|been_45|successfully_35|and_22 (l_dobj) duration_57\NN\15113229|has_43|significantly_39 (l_prep) in_58\IN\13603305|median_25|response_18 (l_pobj) patients_61\NNS\9898892|NONE_0 (l_compound) cancer_60\NN\14239425|ovarian_8
D017239_D010051 NONE taxol_15\NNP\0|agent_18 (r_appos) paclitaxel_13\NN\0|NONE_0 (r_pobj) of_9\IN\0|an_44|group_12 (r_prep) study_8\NN\635850|NONE_0 (r_pobj) of_2\IN\0|preliminary_20 (r_prep) results_1\NNS\34213|rate_159|used_253|._353 (r_nsubj) reported_27\VBD\831651|NONE_0 (l_conj) used_49\VBN\0|results_253|rate_94|._100 (l_conj) improved_54\VBN\126264|combination_61|has_49|been_45|successfully_35|and_22 (l_dobj) duration_57\NN\15113229|has_43|significantly_39 (l_prep) in_58\IN\13603305|median_25|response_18 (l_pobj) patients_61\NNS\9898892|NONE_0 (l_compound) cancer_60\NN\14239425|ovarian_8
D017239_D010051 NONE paclitaxel_43\NN\0|the_4|cisplatin_11 (r_nmod) combination_46\NN\7951464|has_12|been_16|successfully_26|and_39|improved_61 (r_nsubjpass) used_49\VBN\0|results_253|rate_94|._100 (l_conj) improved_54\VBN\126264|combination_61|has_49|been_45|successfully_35|and_22 (l_dobj) duration_57\NN\15113229|has_43|significantly_39 (l_prep) in_58\IN\13603305|median_25|response_18 (l_pobj) patients_61\NNS\9898892|NONE_0 (l_compound) cancer_60\NN\14239425|ovarian_8
D002945_D010051 NONE cisplatin_45\NN\0|the_15|paclitaxel_11 (r_compound) combination_46\NN\7951464|has_12|been_16|successfully_26|and_39|improved_61 (r_nsubjpass) used_49\VBN\0|results_253|rate_94|._100 (l_conj) improved_54\VBN\126264|combination_61|has_49|been_45|successfully_35|and_22 (l_dobj) duration_57\NN\15113229|has_43|significantly_39 (l_prep) in_58\IN\13603305|median_25|response_18 (l_pobj) patients_61\NNS\9898892|NONE_0 (l_compound) cancer_60\NN\14239425|ovarian_8
D002945_D006258 NONE cisplatin_9\NN\0|a_38|study_25|plus_5|._78 (l_prep) as_10\IN\14622893|NONE_0 (l_pobj) therapy_14\NN\657604|NONE_0 (l_prep) for_15\IN\0|line_13|:_25|results_39 (l_pobj) cancers_19\NNS\14239425|NONE_0
D002945_D006258 NONE cisplatin_45\NN\0|the_15|paclitaxel_11 (r_compound) combination_46\NN\7951464|has_12|been_16|successfully_26|and_39|improved_61 (r_nsubjpass) used_49\VBN\0|results_253|rate_94|._100 (r_conj) reported_27\VBD\831651|NONE_0 (l_dobj) rate_32\NN\13815152|results_159|used_94|._194 (l_prep) in_33\IN\13603305|a_20|%_16|response_14|,_37|and_39 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_prep) with_35\IN\0|NONE_0 (l_pobj) cancer_39\NN\14239425|NONE_0
D002945_D006258 NONE cisplatin_23\NN\0|NONE_0 (r_pobj) with_19\IN\0|with_26 (r_prep) combined_18\VBN\2630189|escalating_28|paclitaxel_17 (l_prep) with_24\IN\0|with_26 (l_pobj) support_30\NN\407535|NONE_0 (l_prep) in_31\IN\13603305|granulocyte_46|factor_15 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|NONE_0 (l_pobj) head_38\NN\5225090|NONE_0 (l_conj) carcinoma_41\NN\14239918|untreated_52|advanced_34|inoperable_25|and_9
D002945_D006258 NONE cisplatin_2\NN\0|paclitaxel_11|regimen_37|warranted_117 (r_advmod) is_3\VBZ\0|NONE_0 (l_attr) regimen_9\NN\5898568|paclitaxel_48|cisplatin_37|warranted_80 (l_prep) for_10\IN\0|an_32|effective_29|line_13|and_49 (l_pobj) head_13\NN\5225090|NONE_0 (l_conj) cancer_16\NN\14239425|advanced_23|and_9
9523805
D008012_D009422 CID lidocaine_16\NN\3681148|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) than_14\IN\0|a_50|lower_48|with_32 (r_prep) incidence_9\NN\13821570|transient_63|neurologic_53|after_33|:_10|._61 (r_appos) symptoms_2\NNS\5823932|NONE_0
D008012_D009422 CID lidocaine_12\NN\3681148|spinal_10 (r_amod) anesthesia_14\NN\14034177|that_77|symptoms_51|frequently_35|but_11|are_15 (r_dobj) follow_11\VBP\1835496|evidence_71|._70 (l_nsubj) symptoms_6\NNS\5823932|that_26|frequently_16|anesthesia_51|but_62|are_66
D008012_D009422 CID lidocaine_12\NN\3681148|spinal_10 (r_amod) anesthesia_14\NN\14034177|that_77|symptoms_51|frequently_35|but_11|are_15 (r_dobj) follow_11\VBP\1835496|evidence_71|._70 (l_nsubj) symptoms_6\NNS\5823932|that_26|frequently_16|anesthesia_51|but_62|are_66 (l_appos) tnss_8\NNS\0|transient_31|neurologic_21|(_1|)_4
D008012_D009422 CID lidocaine_13\NN\3681148|NONE_0 (l_conj) bupivacaine_15\NN\0|and_4 (l_prep) with_16\IN\0|NONE_0 (l_pobj) respect_17\NN\5817845|NONE_0 (l_prep) to_18\IN\0|NONE_0 (l_pobj) duration_19\NN\15113229|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) action_21\NN\30358|NONE_0 (l_conj) risk_24\NN\14541044|and_13 (l_prep) of_25\IN\0|relative_14 (l_pobj) tnss_26\NNS\0|NONE_0
D008012_D009422 CID lidocaine_6\NN\3681148|tnss_22 (r_dobj) receiving_5\VBG\2210855|30_12 (l_dobj) tnss_8\NNS\0|lidocaine_22
D008012_D009422 CID lidocaine_6\NN\3681148|tnss_22 (r_dobj) receiving_5\VBG\2210855|30_12 (r_acl) patients_4\NNS\9898892|:_13|,_45|patients_55|them_100|,_104|and_106|had_152 (r_nsubj) had_21\VBD\0|NONE_0 (l_conj) had_31\VBD\0|:_165|patients_152|,_107|patients_97|them_52|,_48|and_46 (l_dobj) tnss_32\NNS\0|none_46|._4
D008012_D009422 CID lidocaine_5\NN\3681148|NONE_0 (r_xcomp) preferable_3\JJ\0|prilocaine_18|may_7|has_65|._127 (r_acomp) be_2\VB\14625458|NONE_0 (l_advcl) has_12\VBZ\13888491|prilocaine_83|may_72|preferable_65|._62 (l_dobj) duration_15\NN\15113229|because_25|it_17 (l_conj) incidence_21\NN\13821570|a_41|similar_39|of_22|but_12 (l_prep) of_22\IN\0|a_18|lower_16 (l_pobj) tnss_23\NNS\0|NONE_0
D011318_D009422 CID prilocaine_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|a_18|lower_16|than_32 (r_prep) incidence_9\NN\13821570|transient_63|neurologic_53|after_33|:_10|._61 (r_appos) symptoms_2\NNS\5823932|NONE_0
D011318_D009422 CID prilocaine_11\JJ\0|accordingly_66|,_55|present_49|,_42|study_15|._102 (l_prep) with_12\IN\0|NONE_0 (l_pobj) lidocaine_13\NN\3681148|NONE_0 (l_conj) bupivacaine_15\NN\0|and_4 (l_prep) with_16\IN\0|NONE_0 (l_pobj) respect_17\NN\5817845|NONE_0 (l_prep) to_18\IN\0|NONE_0 (l_pobj) duration_19\NN\15113229|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) action_21\NN\30358|NONE_0 (l_conj) risk_24\NN\14541044|and_13 (l_prep) of_25\IN\0|relative_14 (l_pobj) tnss_26\NNS\0|NONE_0
D011318_D009422 CID prilocaine_15\NN\0|NONE_0 (r_dobj) receiving_14\VBG\2210855|30_12 (r_acl) patients_13\NNS\9898892|:_68|patients_55|,_10|them_45|,_49|and_51|had_97 (r_nsubj) had_21\VBD\0|NONE_0 (l_nsubj) patients_4\NNS\9898892|:_13|,_45|patients_55|them_100|,_104|and_106|had_152 (l_acl) receiving_5\VBG\2210855|30_12 (l_dobj) tnss_8\NNS\0|lidocaine_22
D011318_D009422 CID prilocaine_15\NN\0|NONE_0 (r_dobj) receiving_14\VBG\2210855|30_12 (r_acl) patients_13\NNS\9898892|:_68|patients_55|,_10|them_45|,_49|and_51|had_97 (r_nsubj) had_21\VBD\0|NONE_0 (l_conj) had_31\VBD\0|:_165|patients_152|,_107|patients_97|them_52|,_48|and_46 (l_dobj) tnss_32\NNS\0|none_46|._4
D011318_D009422 CID prilocaine_0\NNP\0|may_11|preferable_18|has_83|._145 (r_nsubj) be_2\VB\14625458|NONE_0 (l_advcl) has_12\VBZ\13888491|prilocaine_83|may_72|preferable_65|._62 (l_dobj) duration_15\NN\15113229|because_25|it_17 (l_conj) incidence_21\NN\13821570|a_41|similar_39|of_22|but_12 (l_prep) of_22\IN\0|a_18|lower_16 (l_pobj) tnss_23\NNS\0|NONE_0
D002045_D009422 NONE bupivacaine_13\NN\0|and_4 (r_conj) prilocaine_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|a_18|lower_16|than_32 (r_prep) incidence_9\NN\13821570|transient_63|neurologic_53|after_33|:_10|._61 (r_appos) symptoms_2\NNS\5823932|NONE_0
D002045_D009422 NONE bupivacaine_19\NN\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) infrequent_17\JJ\0|NONE_0 (r_acomp) are_16\VBP\13600404|that_92|symptoms_66|frequently_50|anesthesia_15|but_4 (r_conj) follow_11\VBP\1835496|evidence_71|._70 (l_nsubj) symptoms_6\NNS\5823932|that_26|frequently_16|anesthesia_51|but_62|are_66
D002045_D009422 NONE bupivacaine_19\NN\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) infrequent_17\JJ\0|NONE_0 (r_acomp) are_16\VBP\13600404|that_92|symptoms_66|frequently_50|anesthesia_15|but_4 (r_conj) follow_11\VBP\1835496|evidence_71|._70 (l_nsubj) symptoms_6\NNS\5823932|that_26|frequently_16|anesthesia_51|but_62|are_66 (l_appos) tnss_8\NNS\0|transient_31|neurologic_21|(_1|)_4
D002045_D009422 NONE bupivacaine_15\NN\0|and_4 (l_prep) with_16\IN\0|NONE_0 (l_pobj) respect_17\NN\5817845|NONE_0 (l_prep) to_18\IN\0|NONE_0 (l_pobj) duration_19\NN\15113229|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) action_21\NN\30358|NONE_0 (l_conj) risk_24\NN\14541044|and_13 (l_prep) of_25\IN\0|relative_14 (l_pobj) tnss_26\NNS\0|NONE_0
D002045_D009422 NONE bupivacaine_30\NN\0|NONE_0 (r_dobj) receiving_29\VBG\2210855|30_12 (r_acl) patients_28\NNS\9898892|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) none_25\NN\15228378|tnss_46|._50 (r_nsubj) had_31\VBD\0|:_165|patients_152|,_107|patients_97|them_52|,_48|and_46 (r_conj) had_21\VBD\0|NONE_0 (l_nsubj) patients_4\NNS\9898892|:_13|,_45|patients_55|them_100|,_104|and_106|had_152 (l_acl) receiving_5\VBG\2210855|30_12 (l_dobj) tnss_8\NNS\0|lidocaine_22
D002045_D009422 NONE bupivacaine_30\NN\0|NONE_0 (r_dobj) receiving_29\VBG\2210855|30_12 (r_acl) patients_28\NNS\9898892|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) none_25\NN\15228378|tnss_46|._50 (r_nsubj) had_31\VBD\0|:_165|patients_152|,_107|patients_97|them_52|,_48|and_46 (l_dobj) tnss_32\NNS\0|none_46|._4
16167916
D020849_D054556 CID raloxifene_11\NN\0|NONE_0 (r_compound) treatment_12\NN\654885|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_pcomp) due_9\IN\5174653|venous_23 (r_amod) thromboembolism_8\NN\14100769|NONE_0
8092427
-1_D007645 NONE bpo_8\NNP\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) negative_6\JJ\7204401|skin_10 (r_amod) test_5\NN\5798043|patients_19 (r_attr) were_3\VBD\0|;_30|49_32|also_52|negative_57|,_72|and_74|44_78|._98 (r_ccomp) were_17\VBD\0|NONE_0 (l_acomp) negative_19\JJ\7204401|were_57|;_27|49_25|also_5|,_15|and_17|44_21|._41 (l_prep) to_20\IN\0|NONE_0 (l_pobj) mdm_21\NNP\0|NONE_0
D047090_D004342 NONE lactam_12\NN\0|NONE_0 (r_amod) antibiotics_13\NNS\2716205|NONE_0 (r_pobj) to_9\IN\0|suspected_29|allergic_19 (r_prep) reactions_8\NNS\13446390|NONE_0
D047090_D004342 NONE lactam_31\NN\0|NONE_0 (r_amod) antibiotics_32\NNS\2716205|NONE_0 (r_pobj) to_28\IN\0|whether_26|patients_18 (r_prep) allergic_27\JJ\0|to_30
D047090_D004342 NONE lactam_31\NN\0|NONE_0 (r_amod) antibiotics_32\NNS\2716205|NONE_0 (r_pobj) to_28\IN\0|whether_26|patients_18 (r_prep) allergic_27\JJ\0|to_30 (r_ccomp) establish_24\VB\2426171|history_112|,_105|with_94|,_79|rast_77|was_12|had_63|._182 (r_xcomp) used_22\VBN\0|NONE_0 (l_conj) had_33\VBD\0|history_175|,_168|with_157|,_142|rast_140|was_75|establish_63|._119 (l_dobj) responses_37\NNS\11410625|or_30|were_33 (l_amod) allergic_36\JJ\0|selective_20|immediate_10|to_19
D047090_D004342 NONE lactam_12\NN\0|NONE_0 (r_amod) antibiotics_13\NNS\2716205|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) allergic_8\JJ\0|NONE_0
D010400_D004342 NONE pg_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|good_15 (r_prep) tolerance_15\NN\5032565|NONE_0 (r_pobj) with_13\IN\0|immediate_21|ax_11 (r_prep) allergy_12\NN\14533203|NONE_0
D010400_D004342 NONE pg_13\NNP\0|who_19|have_15 (r_dobj) tolerated_12\VBN\802318|allergic_27 (r_relcl) patients_9\NNS\9898892|NONE_0 (l_amod) allergic_8\JJ\0|tolerated_27
D000658_D004342 CID amoxicillin_4\NNP\3910033|NONE_0 (r_pobj) to_3\IN\0|immediate_29|allergic_19|._14 (r_prep) reactions_2\NNS\13446390|NONE_0
D000658_D004342 CID amoxicillin_39\NNP\3910033|NONE_0 (r_pobj) to_38\IN\0|selective_39|immediate_29|allergic_19 (r_prep) responses_37\NNS\11410625|or_30|were_33 (r_dobj) had_33\VBD\0|history_175|,_168|with_157|,_142|rast_140|was_75|establish_63|._119 (r_conj) used_22\VBN\0|NONE_0 (l_xcomp) establish_24\VB\2426171|history_112|,_105|with_94|,_79|rast_77|was_12|had_63|._182 (l_ccomp) allergic_27\JJ\0|to_30
D000658_D004342 CID amoxicillin_39\NNP\3910033|NONE_0 (r_pobj) to_38\IN\0|selective_39|immediate_29|allergic_19 (r_prep) responses_37\NNS\11410625|or_30|were_33 (l_amod) allergic_36\JJ\0|selective_20|immediate_10|to_19
D000658_D004342 CID ax_41\NN\3265032|NONE_0 (r_appos) amoxicillin_39\NNP\3910033|NONE_0 (r_pobj) to_38\IN\0|selective_39|immediate_29|allergic_19 (r_prep) responses_37\NNS\11410625|or_30|were_33 (r_dobj) had_33\VBD\0|history_175|,_168|with_157|,_142|rast_140|was_75|establish_63|._119 (r_conj) used_22\VBN\0|NONE_0 (l_xcomp) establish_24\VB\2426171|history_112|,_105|with_94|,_79|rast_77|was_12|had_63|._182 (l_ccomp) allergic_27\JJ\0|to_30
D000658_D004342 CID ax_41\NN\3265032|NONE_0 (r_appos) amoxicillin_39\NNP\3910033|NONE_0 (r_pobj) to_38\IN\0|selective_39|immediate_29|allergic_19 (r_prep) responses_37\NNS\11410625|or_30|were_33 (l_amod) allergic_36\JJ\0|selective_20|immediate_10|to_19
D000658_D004342 CID ax_11\NNP\3265032|immediate_10|with_11 (r_compound) allergy_12\NN\14533203|NONE_0
D000658_D004342 CID ax_3\NN\3265032|NONE_0 (r_pobj) with_2\IN\0|challenge_16 (r_prep) tests_1\NNS\5798043|were_14|in_29|establish_53|and_115|were_168 (r_nsubjpass) performed_5\VBN\0|NONE_0 (l_advcl) establish_14\VB\2426171|tests_53|were_39|in_24|and_62|were_115 (l_dobj) diagnosis_16\NN\152018|to_17|,_46 (l_prep) of_17\IN\0|the_14 (l_pobj) reaction_20\NN\13446390|NONE_0
D000658_D004342 CID ax_22\NN\3265032|NONE_0 (r_pobj) to_21\IN\0|immediate_28|allergic_18 (r_prep) reaction_20\NN\13446390|NONE_0
D000658_D004342 CID ax_38\NN\3265032|NONE_0 (r_pobj) for_37\IN\0|NONE_0 (r_prep) rast_36\NNP\0|both_19|skin_14|and_4 (r_conj) test_34\NN\5798043|28_15|)_12 (r_appos) %_30\NN\0|in_15|(_3|negative_39|._47 (r_nsubj) were_39\VBD\0|tests_168|were_154|in_139|establish_115|and_53 (r_conj) performed_5\VBN\0|NONE_0 (l_advcl) establish_14\VB\2426171|tests_53|were_39|in_24|and_62|were_115 (l_dobj) diagnosis_16\NN\152018|to_17|,_46 (l_prep) of_17\IN\0|the_14 (l_pobj) reaction_20\NN\13446390|NONE_0
D000658_D004342 CID ax_6\NN\3265032|-_2 (r_npadvmod) allergic_8\JJ\0|tolerated_27
D010406_D004342 NONE penicillin_50\NN\2716866|other_6 (r_compound) derivatives_51\NNS\5802185|NONE_0 (r_pobj) with_48\IN\0|cross_15|-_10 (r_prep) reacting_47\VBG\2367363|NONE_0 (r_acomp) were_44\VBD\0|responses_33|or_3 (r_conj) had_33\VBD\0|history_175|,_168|with_157|,_142|rast_140|was_75|establish_63|._119 (r_conj) used_22\VBN\0|NONE_0 (l_xcomp) establish_24\VB\2426171|history_112|,_105|with_94|,_79|rast_77|was_12|had_63|._182 (l_ccomp) allergic_27\JJ\0|to_30
D010406_D004342 NONE penicillin_50\NN\2716866|other_6 (r_compound) derivatives_51\NNS\5802185|NONE_0 (r_pobj) with_48\IN\0|cross_15|-_10 (r_prep) reacting_47\VBG\2367363|NONE_0 (r_acomp) were_44\VBD\0|responses_33|or_3 (r_conj) had_33\VBD\0|history_175|,_168|with_157|,_142|rast_140|was_75|establish_63|._119 (l_dobj) responses_37\NNS\11410625|or_30|were_33 (l_amod) allergic_36\JJ\0|selective_20|immediate_10|to_19
D010400_D007645 NONE pg_32\NNP\0|NONE_0 (r_pobj) to_31\IN\0|of_12|%_3|)_2 (r_prep) 44_24\CD\0|were_78|;_48|49_46|also_26|negative_21|,_6|and_4|._20 (r_conj) were_17\VBD\0|NONE_0 (l_acomp) negative_19\JJ\7204401|were_57|;_27|49_25|also_5|,_15|and_17|44_21|._41 (l_prep) to_20\IN\0|NONE_0 (l_pobj) mdm_21\NNP\0|NONE_0
11807648
D014148_D012640 CID tamca_5\NN\0|whether_8|action_29|incorporated_39 (r_nsubj) retains_6\VBZ\2700867|to_23 (l_dobj) action_9\NN\30358|whether_37|tamca_29|incorporated_10 (l_amod) convulsive_8\JJ\0|its_4
D014148_D012640 CID tamca_4\NN\0|:_16|fs_14 (r_appos) findings_0\NNS\7951464|activity_54|._119 (r_nsubj) caused_5\VBD\1617192|NONE_0 (l_dobj) activity_8\NN\30358|findings_54|._65 (l_relcl) associated_11\VBN\628491|paroxysmal_36|brain_25 (l_prep) with_12\IN\0|which_21|was_15 (l_pobj) behaviours_15\NNS\14006945|NONE_0 (l_amod) convulsive_14\JJ\0|distinct_9
D014148_D012640 CID tamca_10\CD\0|NONE_0 (r_pobj) of_9\IN\0|increasing_25 (r_prep) concentration_8\NN\4916342|NONE_0 (r_pobj) with_6\IN\0|degree_35|._38 (r_prep) increased_5\VBD\169651|NONE_0 (l_nsubj) degree_1\NN\4916342|with_35|._73 (l_prep) of_2\IN\0|the_11 (l_pobj) seizures_4\NNS\14081375|NONE_0
D014148_D012640 CID tamca_0\NN\0|seizures_25|evoked_116|._193 (r_advmod) evoked_1\VBD\1617192|NONE_0 (l_dobj) seizures_3\NNS\14081375|tamca_25|evoked_91|._168
D014148_D012640 CID tamca_0\NN\0|seizures_25|evoked_116|._193 (r_advmod) evoked_1\VBD\1617192|NONE_0 (l_advcl) evoked_24\VBD\1617192|tamca_116|seizures_91|._77 (l_dobj) episodes_26\NNS\7283608|while_70|concentration_53|)_20|only_18 (l_prep) of_27\IN\0|brief_15 (l_pobj) potentials_32\NNS\14481929|NONE_0 (l_amod) convulsive_31\JJ\0|correlated_11|in_22
D014148_D012640 CID tamca_16\NN\0|(_6|0.5_7|mg_11|/_13 (r_nmod) ml_21\NNS\13616054|NONE_0 (r_pobj) of_15\IN\0|the_25|lowest_21 (r_prep) concentration_14\NN\4916342|while_17|)_33|only_35|episodes_53 (r_nsubj) evoked_24\VBD\1617192|tamca_116|seizures_91|._77 (r_advcl) evoked_1\VBD\1617192|NONE_0 (l_dobj) seizures_3\NNS\14081375|tamca_25|evoked_91|._168
D014148_D012640 CID tamca_16\NN\0|(_6|0.5_7|mg_11|/_13 (r_nmod) ml_21\NNS\13616054|NONE_0 (r_pobj) of_15\IN\0|the_25|lowest_21 (r_prep) concentration_14\NN\4916342|while_17|)_33|only_35|episodes_53 (r_nsubj) evoked_24\VBD\1617192|tamca_116|seizures_91|._77 (l_dobj) episodes_26\NNS\7283608|while_70|concentration_53|)_20|only_18 (l_prep) of_27\IN\0|brief_15 (l_pobj) potentials_32\NNS\14481929|NONE_0 (l_amod) convulsive_31\JJ\0|correlated_11|in_22
D014148_D012640 CID acid_1\NN\14818238|action_28|._44 (r_nsubj) retains_2\VBZ\2700867|NONE_0 (l_dobj) action_5\NN\30358|acid_28|._16 (l_amod) convulsive_4\JJ\0|its_4|within_18
D014148_D004827 NONE acid_10\NN\14818238|in_5 (r_dobj) containing_8\VBG\2632940|fibrin_16 (r_acl) sealants_7\NNS\14705533|NONE_0 (r_pobj) of_5\IN\0|cortical_21 (r_prep) application_4\NN\947128|NONE_0 (r_dobj) following_2\VBG\8180190|epileptic_19|._84 (r_prep) seizures_1\NNS\14081375|NONE_0
D014148_D004827 NONE tamca_2\NN\0|however_9|,_2|has_6|been_10|cause_24|._48 (r_nsubjpass) shown_5\VBN\2137132|NONE_0 (l_xcomp) cause_7\VB\7323922|however_33|,_26|tamca_24|has_18|been_14|._24 (l_dobj) seizures_9\NNS\14081375|to_19
3101906
D007654_D003643 NONE ketoconazole_9\JJ\0|NONE_0 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) with_8\IN\0|probably_20 (r_prep) associated_7\VBN\628491|the_26|three_22 (r_acl) deaths_5\NNS\7296428|NONE_0
D007654_D056486 CID ketoconazole_9\JJ\0|NONE_0 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) with_8\IN\0|probably_20 (r_prep) associated_7\VBN\628491|the_26|three_22 (r_acl) deaths_5\NNS\7296428|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) two_1\CD\13741022|NONE_0 (r_pobj) in_0\IN\13603305|drug_79|had_84|been_88|after_103|._162 (r_prep) continued_15\VBN\2367363|NONE_0 (l_prep) after_16\IN\0|in_103|drug_24|had_19|been_15|._59 (l_pobj) onset_18\NN\7325190|NONE_0 (l_prep) of_19\IN\0|the_10 (l_pobj) jaundice_20\NN\14299637|NONE_0 (l_conj) symptoms_23\NNS\5823932|and_10 (l_prep) of_24\IN\0|other_15 (l_pobj) hepatitis_25\NN\14127211|NONE_0
D007654_D056486 CID ketoconazole_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|term_15 (r_prep) treatment_16\NN\654885|NONE_0 (r_pobj) during_13\IN\0|monitoring_69|is_11|prevent_48|._87 (r_prep) advised_12\VBN\813978|NONE_0 (l_nsubjpass) monitoring_3\NN\879759|is_58|during_69|prevent_117|._156 (l_prep) for_7\IN\0|clinical_57|at_21 (l_pobj) evidence_8\NN\5816287|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) hepatitis_10\NN\14127211|NONE_0
D007654_D056486 CID ketoconazole_18\NN\0|NONE_0 (r_pobj) with_17\IN\0|term_15 (r_prep) treatment_16\NN\654885|NONE_0 (r_pobj) during_13\IN\0|monitoring_69|is_11|prevent_48|._87 (r_prep) advised_12\VBN\813978|NONE_0 (l_advcl) prevent_20\VB\0|monitoring_117|is_59|during_48|._39 (l_dobj) injury_24\NN\14052046|to_36
D007654_D007565 CID ketoconazole_9\JJ\0|NONE_0 (r_compound) treatment_10\NN\654885|NONE_0 (r_pobj) with_8\IN\0|probably_20 (r_prep) associated_7\VBN\628491|the_26|three_22 (r_acl) deaths_5\NNS\7296428|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) two_1\CD\13741022|NONE_0 (r_pobj) in_0\IN\13603305|drug_79|had_84|been_88|after_103|._162 (r_prep) continued_15\VBN\2367363|NONE_0 (l_prep) after_16\IN\0|in_103|drug_24|had_19|been_15|._59 (l_pobj) onset_18\NN\7325190|NONE_0 (l_prep) of_19\IN\0|the_10 (l_pobj) jaundice_20\NN\14299637|NONE_0
17244258
D003520_D003556 CID cyclophosphamide_9\NN\0|-_16 (r_npadvmod) induced_11\VBN\1627355|in_17 (r_amod) cystitis_12\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_1\NN\0|-_16 (r_npadvmod) induced_3\VBN\1627355|in_17 (r_amod) cystitis_4\NN\14566129|NONE_0
26094
D008750_D001523 NONE dopa_13\NN\14601829|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) occurring_10\VBG\0|NONE_0 (r_acl) depressions_9\NNS\14373582|NONE_0 (r_pobj) of_8\IN\0|a_21|significant_19|treated_40 (r_prep) number_7\NN\5107765|NONE_0 (l_acl) treated_14\VBD\2376958|a_61|significant_59|of_40 (l_dobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) histories_18\NNS\15120823|NONE_0 (l_amod) psychiatric_17\JJ\0|NONE_0
D008750_D003866 CID dopa_13\NN\14601829|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) occurring_10\VBG\0|NONE_0 (r_acl) depressions_9\NNS\14373582|NONE_0
1428568
D015784_D003866 NONE betaxolol_4\NN\0|that_5|could_10|less_19 (r_nsubj) be_6\VB\14625458|results_37|._68 (l_attr) less_7\JJR\14187378|that_24|betaxolol_19|could_9 (l_prep) of_8\IN\0|than_24 (l_pobj) inducer_12\NN\14778436|NONE_0 (l_compound) depression_10\NN\14373582|a_2|-_10
D013999_D003866 CID timolol_6\NN\2832168|NONE_0 (r_compound) 0.5%/12h_7\CD\0|NONE_0 (r_pobj) with_5\IN\0|patients_29|chronically_20|,_21|suffering_23 (r_prep) treated_4\VBN\2376958|,_93|were_95|in_109|._121 (l_advcl) suffering_9\VBG\14322699|patients_52|chronically_43|with_23|,_2 (l_prep) from_10\IN\0|diagnosed_16 (l_pobj) depression_11\NN\14373582|NONE_0
D013999_D003866 CID timolol_15\NN\2832168|NONE_0 (r_compound) treatment_16\NN\654885|NONE_0 (r_pobj) under_14\IN\0|the_13 (r_prep) patients_13\NNS\9898892|in_59|,_6|values_61|._142 (r_nsubj) presented_17\VBD\2137132|NONE_0 (l_dobj) values_20\NNS\5941423|in_120|,_67|patients_61|._81 (l_compound) depression_19\NN\14373582|higher_7|measured_18|0.001_75
D013999_D003866 CID timolol_14\NN\2832168|NONE_0 (r_pobj) than_13\IN\0|of_24 (r_prep) less_7\JJR\14187378|that_24|betaxolol_19|could_9 (l_prep) of_8\IN\0|than_24 (l_pobj) inducer_12\NN\14778436|NONE_0 (l_compound) depression_10\NN\14373582|a_2|-_10
D013999_D005901 NONE timolol_6\NN\2832168|NONE_0 (r_compound) 0.5%/12h_7\CD\0|NONE_0 (r_pobj) with_5\IN\0|patients_29|chronically_20|,_21|suffering_23 (r_prep) treated_4\VBN\2376958|,_93|were_95|in_109|._121 (l_nsubj) patients_2\NNS\9898892|chronically_9|with_29|,_50|suffering_52 (l_amod) glaucomatous_1\JJ\0|eight_6
20722491
D005472_D009369 NONE 5-fu_1\CD\0|,_5|have_7|mainstay_21|._139 (r_nsubj) been_5\VBN\0|NONE_0 (l_attr) mainstay_7\NN\10677713|5-fu_21|,_16|have_14|._118 (l_prep) of_8\IN\0|the_13|for_95 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) for_10\IN\0|NONE_0 (l_pobj) tumors_13\NNS\14234074|NONE_0
C110904_D007674 NONE capecitabine_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_11|in_16 (r_prep) safety_8\NN\13920835|NONE_0 (l_prep) in_11\IN\13603305|the_27|of_16 (l_pobj) populations_13\NNS\7942152|NONE_0 (l_prep) as_15\IN\14622893|special_25 (l_pobj) patients_16\NNS\9898892|such_8 (l_prep) with_17\IN\0|NONE_0 (l_pobj) disease_24\NN\14061805|NONE_0
C110904_D007674 NONE capecitabine_0\NNP\0|profile_43|and_51|given_62|._136 (r_nsubj) has_1\VBZ\13888491|NONE_0 (l_conj) given_11\VBN\5892096|capecitabine_62|profile_19|and_11|._74 (l_prep) to_13\IN\0|can_20|be_16|safely_7 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) dysfunctions_22\NNS\14204950|NONE_0
D005472_D001943 NONE 5-fu_1\CD\0|,_5|have_7|mainstay_21|._139 (r_nsubj) been_5\VBN\0|NONE_0 (l_attr) mainstay_7\NN\10677713|5-fu_21|,_16|have_14|._118 (l_prep) of_8\IN\0|the_13|for_95 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) for_10\IN\0|NONE_0 (l_pobj) tumors_13\NNS\14234074|NONE_0 (l_prep) including_15\VBG\0|several_22|solid_14|,_2|,_54 (l_pobj) colorectal_16\NN\0|NONE_0 (l_conj) breast_18\NN\5225090|,_2 (l_conj) cancers_23\NNS\14239425|and_18
C110904_D014839 CID capecitabine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_41|reported_23|toxic_14 (r_prep) effects_5\NNS\13245626|diarrhea_28|._89 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_attr) diarrhea_9\NN\14299637|effects_28|._61 (l_appos) nausea_11\NN\14299637|,_2 (l_conj) vomiting_13\NN\116687|,_2
C110904_D013280 CID capecitabine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_41|reported_23|toxic_14 (r_prep) effects_5\NNS\13245626|diarrhea_28|._89 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_attr) diarrhea_9\NN\14299637|effects_28|._61 (l_appos) nausea_11\NN\14299637|,_2 (l_conj) vomiting_13\NN\116687|,_2 (l_conj) stomatitis_15\JJ\14336539|,_2
C110904_D003967 CID capecitabine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_41|reported_23|toxic_14 (r_prep) effects_5\NNS\13245626|diarrhea_28|._89 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_attr) diarrhea_9\NN\14299637|effects_28|._61
C110904_D009325 CID capecitabine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_41|reported_23|toxic_14 (r_prep) effects_5\NNS\13245626|diarrhea_28|._89 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_attr) diarrhea_9\NN\14299637|effects_28|._61 (l_appos) nausea_11\NN\14299637|,_2
C110904_D008107 NONE capecitabine_0\NNP\0|profile_43|and_51|given_62|._136 (r_nsubj) has_1\VBZ\13888491|NONE_0 (l_conj) given_11\VBN\5892096|capecitabine_62|profile_19|and_11|._74 (l_prep) to_13\IN\0|can_20|be_16|safely_7 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) dysfunctions_22\NNS\14204950|NONE_0
D005472_D015179 NONE 5-fu_1\CD\0|,_5|have_7|mainstay_21|._139 (r_nsubj) been_5\VBN\0|NONE_0 (l_attr) mainstay_7\NN\10677713|5-fu_21|,_16|have_14|._118 (l_prep) of_8\IN\0|the_13|for_95 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) for_10\IN\0|NONE_0 (l_pobj) tumors_13\NNS\14234074|NONE_0 (l_prep) including_15\VBG\0|several_22|solid_14|,_2|,_54 (l_pobj) colorectal_16\NN\0|NONE_0 (l_conj) breast_18\NN\5225090|,_2 (l_conj) cancers_23\NNS\14239425|and_18
C110904_D060831 CID capecitabine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_41|reported_23|toxic_14 (r_prep) effects_5\NNS\13245626|diarrhea_28|._89 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_attr) diarrhea_9\NN\14299637|effects_28|._61 (l_appos) nausea_11\NN\14299637|,_2 (l_conj) vomiting_13\NN\116687|,_2 (l_conj) stomatitis_15\JJ\14336539|,_2 (l_conj) syndrome_20\NN\5870365|and_14
D005472_D006258 NONE 5-fu_1\CD\0|,_5|have_7|mainstay_21|._139 (r_nsubj) been_5\VBN\0|NONE_0 (l_attr) mainstay_7\NN\10677713|5-fu_21|,_16|have_14|._118 (l_prep) of_8\IN\0|the_13|for_95 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) for_10\IN\0|NONE_0 (l_pobj) tumors_13\NNS\14234074|NONE_0 (l_prep) including_15\VBG\0|several_22|solid_14|,_2|,_54 (l_pobj) colorectal_16\NN\0|NONE_0 (l_conj) breast_18\NN\5225090|,_2 (l_conj) cancers_23\NNS\14239425|and_18
9855119
D016559_D007674 NONE fk506_28\NN\0|type_13|chronic_8|(_18|n_19|)_24|,_25|and_27|nephropathy_47 (r_compound) nephropathy_29\NN\14573196|,_53|normal_51|n_34|,_29
D016559_D007674 NONE fk506_28\NN\0|type_13|chronic_8|(_18|n_19|)_24|,_25|and_27|nephropathy_47 (r_compound) nephropathy_29\NN\14573196|,_53|normal_51|n_34|,_29 (l_conj) nephropathy_41\NN\14573196|type_60|chronic_55|fk506_47|(_29|n_28|)_23|,_22|and_20
D016559_D007674 NONE fk506_40\NN\0|(_18|n_19|)_25 (r_compound) nephropathy_41\NN\14573196|type_60|chronic_55|fk506_47|(_29|n_28|)_23|,_22|and_20 (r_conj) nephropathy_29\NN\14573196|,_53|normal_51|n_34|,_29
D016559_D007674 NONE fk506_40\NN\0|(_18|n_19|)_25 (r_compound) nephropathy_41\NN\14573196|type_60|chronic_55|fk506_47|(_29|n_28|)_23|,_22|and_20
D016559_D007674 NONE fk506_18\NN\0|type_27|chronic_8 (r_compound) nephropathy_19\NN\14573196|of_93|,_67|biopsies_57|,_11|respectively_13|._25
D016559_D007674 NONE fk506_1\NNP\0|NONE_0 (r_compound) nephropathy_2\NN\14573196|of_22|,_75
D016559_D007674 NONE fk506_12\NN\0|NONE_0 (r_compound) nephropathy_13\NN\14573196|the_28|type_19|chronic_14|,_17|included_25|,_52
D016559_D007674 NONE fk506_12\NN\0|NONE_0 (r_compound) nephropathy_13\NN\14573196|the_28|type_19|chronic_14|,_17|included_25|,_52 (r_compound) group_14\NN\2137|NONE_0 (r_pobj) in_6\IN\13603305|NONE_0 (r_prep) patients_5\NNS\9898892|NONE_0 (r_pobj) of_4\IN\0|the_28|serum_24|creatinine_18 (r_prep) levels_3\NNS\4916342|higher_123|._203 (r_nsubj) were_22\VBD\0|NONE_0 (l_acomp) higher_24\JJR\0|levels_123|._80 (l_prep) than_25\IN\0|statistically_21 (l_pobj) those_26\DT\0|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) group_34\NN\2137|NONE_0 (l_compound) fk506-nephropathy_33\NNP\0|the_25|type_13|(_24|p_25|)_33
D016559_D007674 NONE fk506-nephropathy_33\NNP\0|the_25|type_13|(_24|p_25|)_33 (r_compound) group_34\NN\2137|NONE_0 (r_pobj) in_27\IN\13603305|NONE_0 (r_prep) those_26\DT\0|NONE_0 (r_pobj) than_25\IN\0|statistically_21 (r_prep) higher_24\JJR\0|levels_123|._80 (r_acomp) were_22\VBD\0|NONE_0 (l_nsubj) levels_3\NNS\4916342|higher_123|._203 (l_prep) of_4\IN\0|the_28|serum_24|creatinine_18 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) group_14\NN\2137|NONE_0 (l_compound) nephropathy_13\NN\14573196|the_28|type_19|chronic_14|,_17|included_25|,_52
D016559_D007674 NONE fk506-nephropathy_33\NNP\0|the_25|type_13|(_24|p_25|)_33
D016559_D007674 NONE fk506_5\NNP\0|chronic_8 (r_compound) nephropathy_6\NN\14573196|that_19|primarily_21|of_31|,_108
D016559_D007674 NONE fk506_5\NNP\0|chronic_8 (r_compound) nephropathy_6\NN\14573196|that_19|primarily_21|of_31|,_108 (r_nsubj) consists_7\VBZ\2603699|study_50|and_98|suggests_102|._226 (r_ccomp) demonstrates_2\VBZ\2137132|NONE_0 (l_conj) suggests_21\VBZ\1010118|study_152|consists_102|and_4|._124 (l_ccomp) is_29\VBZ\0|NONE_0 (l_nsubj) nephropathy_28\NN\14573196|that_29|condition_17
D016559_D007674 NONE fk506_27\NN\0|type_13|chronic_8 (r_compound) nephropathy_28\NN\14573196|that_29|condition_17 (r_nsubj) is_29\VBZ\0|NONE_0 (r_ccomp) suggests_21\VBZ\1010118|study_152|consists_102|and_4|._124 (r_conj) demonstrates_2\VBZ\2137132|NONE_0 (l_ccomp) consists_7\VBZ\2603699|study_50|and_98|suggests_102|._226 (l_nsubj) nephropathy_6\NN\14573196|that_19|primarily_21|of_31|,_108
D016559_D007674 NONE fk506_27\NN\0|type_13|chronic_8 (r_compound) nephropathy_28\NN\14573196|that_29|condition_17
D003404_D007674 NONE creatinine_2\NN\0|the_10|serum_6|of_18 (r_compound) levels_3\NNS\4916342|higher_123|._203 (l_prep) of_4\IN\0|the_28|serum_24|creatinine_18 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) group_14\NN\2137|NONE_0 (l_compound) nephropathy_13\NN\14573196|the_28|type_19|chronic_14|,_17|included_25|,_52
D003404_D007674 NONE creatinine_2\NN\0|the_10|serum_6|of_18 (r_compound) levels_3\NNS\4916342|higher_123|._203 (r_nsubj) were_22\VBD\0|NONE_0 (l_acomp) higher_24\JJR\0|levels_123|._80 (l_prep) than_25\IN\0|statistically_21 (l_pobj) those_26\DT\0|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) group_34\NN\2137|NONE_0 (l_compound) fk506-nephropathy_33\NNP\0|the_25|type_13|(_24|p_25|)_33
D016559_D005923 CID fk506_1\NNP\0|NONE_0 (r_compound) nephropathy_2\NN\14573196|of_22|,_75 (r_nsubj) consisted_3\VBD\2603699|arteriolopathy_65|(_80|of_99|;_121|biopsies_126|._244 (r_ccomp) angiodegeneration_17\NN\0|NONE_0 (l_appos) biopsies_24\NNS\5739043|consisted_126|arteriolopathy_61|(_46|of_27|;_5|._118 (l_conj) glomerulosclerosis_29\NN\0|20_30|)_19|,_18
D016559_D005355 NONE fk506_1\NNP\0|NONE_0 (r_compound) nephropathy_2\NN\14573196|of_22|,_75 (r_nsubj) consisted_3\VBD\2603699|arteriolopathy_65|(_80|of_99|;_121|biopsies_126|._244 (r_ccomp) angiodegeneration_17\NN\0|NONE_0 (l_appos) biopsies_24\NNS\5739043|consisted_126|arteriolopathy_61|(_46|of_27|;_5|._118 (l_conj) glomerulosclerosis_29\NN\0|20_30|)_19|,_18 (l_conj) form_37\NN\6286395|focal_64|segmental_58|(_29|biopsies_26|)_18|and_16 (l_prep) of_38\IN\0|the_17|striped_13 (l_pobj) fibrosis_40\NN\14204950|NONE_0
D016559_D005922 NONE fk506_28\NN\0|type_13|chronic_8|(_18|n_19|)_24|,_25|and_27|nephropathy_47 (r_compound) nephropathy_29\NN\14573196|,_53|normal_51|n_34|,_29 (r_conj) findings_17\NNS\7951464|,_43|recurrent_41|iga_31|n_14|._105 (r_conj) nephropathy_9\NN\14573196|n_21
D016559_D005922 NONE fk506_40\NN\0|(_18|n_19|)_25 (r_compound) nephropathy_41\NN\14573196|type_60|chronic_55|fk506_47|(_29|n_28|)_23|,_22|and_20 (r_conj) nephropathy_29\NN\14573196|,_53|normal_51|n_34|,_29 (r_conj) findings_17\NNS\7951464|,_43|recurrent_41|iga_31|n_14|._105 (r_conj) nephropathy_9\NN\14573196|n_21
16755009
D003975_D000647 CID diazepam-_0\NN\0|NONE_0 (l_appos) amnesia_7\NN\5669934|,_34|._53
D003975_D000647 CID diazepam_16\NN\2830852|(_22|mg/kg_17|)_6|and_4 (r_conj) scopolamine_8\NN\14712692|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) induced_6\VBN\1627355|the_12 (r_acl) amnesia_5\NN\5669934|furthermore_30|,_19|dce_17|._77
D012601_D000647 CID scopolamine-_2\NN\0|served_40 (r_nmod) amnesia_7\NN\5669934|,_34|._53
D012601_D000647 CID scopolamine_8\NN\14712692|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) induced_6\VBN\1627355|the_12 (r_acl) amnesia_5\NN\5669934|furthermore_30|,_19|dce_17|._77
D002784_D003072 NONE cholesterol_30\NN\15058310|activity_53 (r_nsubj) lowering_31\VBG\351638|,_14 (r_conj) property_28\NN\32613|memory_17 (r_dobj) improving_27\VBG\126264|a_127|useful_125|for_111 (r_acl) remedy_9\NN\258854|to_15 (l_prep) for_10\IN\0|a_16|useful_14|improving_111 (l_pobj) management_12\NN\1123598|NONE_0 (l_prep) of_13\IN\0|the_15 (l_pobj) dysfunctions_15\NNS\14204950|NONE_0
D010936_D000647 NONE dce_2\NNP\0|furthermore_13|,_2|amnesia_17|._94 (r_nsubj) reversed_3\VBD\109660|NONE_0 (l_dobj) amnesia_5\NN\5669934|furthermore_30|,_19|dce_17|._77
D010936_D003072 NONE dce_2\NNP\0|therefore_11|,_2|may_4|be_17|._228 (r_nsubj) prove_4\VB\2604760|NONE_0 (l_xcomp) be_6\VB\14625458|therefore_28|,_19|dce_17|may_13|._211 (l_attr) remedy_9\NN\258854|to_15 (l_prep) for_10\IN\0|a_16|useful_14|improving_111 (l_pobj) management_12\NN\1123598|NONE_0 (l_prep) of_13\IN\0|the_15 (l_pobj) dysfunctions_15\NNS\14204950|NONE_0
19843802
D004837_D006973 CID epinephrine_5\NN\14807929|NONE_0 (r_pobj) of_4\IN\0|a_8|injected_15 (r_prep) bolus_3\NN\13899404|however_11|,_4|crisis_86|._92 (r_nsubj) provoked_11\VBD\1617192|NONE_0 (l_dobj) crisis_14\NN\14411243|however_97|,_90|bolus_86|._6 (l_amod) hypertensive_13\JJ\10405694|a_2
6534871
D007545_D009203 CID isoproterenol_8\NN\3740161|-_13 (r_npadvmod) induced_10\VBN\1627355|myocardial_8 (r_amod) infarction_12\NN\14204950|NONE_0
7449470
D004317_D066126 NONE doxorubicin_3\NN\2716866|late_11|,_7|late_5|._26 (r_compound) cardiotoxicity_4\NN\0|NONE_0
D004317_D066126 NONE adriamycin_11\NNS\0|NONE_0 (r_pobj) of_10\IN\0|the_8|as_14 (r_prep) use_9\NN\407535|which_17 (r_dobj) limits_7\VBZ\5123416|a_27|major_25 (r_relcl) complication_5\NN\1073995|toxicity_20|._75 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) toxicity_1\NN\13576101|complication_20|._95
11419773
D002110_D008945 NONE caffeine_34\NN\14712692|NONE_0 (r_pobj) of_33\IN\0|a_21|high_19 (r_prep) concentration_32\NN\4916342|NONE_0 (r_dobj) containing_29\VBG\2632940|a_40|"_38|energy_29|"_23|guarana_21|health_13 (r_acl) drink_28\NN\7578363|NONE_0 (r_dobj) consuming_20\VBG\1168468|NONE_0 (r_pcomp) after_19\IN\0|who_51|fibrillation_13 (r_prep) developed_15\VBD\1753788|a_64|old_54|with_44 (r_relcl) woman_6\NN\9605289|we_26|._196 (l_prep) with_7\IN\0|a_20|old_10|developed_44 (l_pobj) prolapse_13\NN\14548343|NONE_0
D002110_D014693 CID caffeine_34\NN\14712692|NONE_0 (r_pobj) of_33\IN\0|a_21|high_19 (r_prep) concentration_32\NN\4916342|NONE_0 (r_dobj) containing_29\VBG\2632940|a_40|"_38|energy_29|"_23|guarana_21|health_13 (r_acl) drink_28\NN\7578363|NONE_0 (r_dobj) consuming_20\VBG\1168468|NONE_0 (r_pcomp) after_19\IN\0|who_51|fibrillation_13 (r_prep) developed_15\VBD\1753788|a_64|old_54|with_44 (l_dobj) fibrillation_18\NN\14361664|who_38|after_13
D002110_D001145 NONE caffeine_0\NN\14712692|-_8 (r_nsubj) induced_2\VBN\1627355|cardiac_8|:_26|danger_44|._73 (r_amod) arrhythmia_4\NN\14103288|NONE_0
6287825
D007538_D009422 NONE isoniazid_0\NNP\2716205|agent_32|._64 (r_nsubj) was_1\VBD\0|NONE_0 (l_attr) agent_5\NN\7347|isoniazid_32|._32 (l_prep) in_6\IN\13603305|the_24|frequent_15 (l_pobj) neuropathy_10\NN\14204950|NONE_0
D013831_D044342 NONE thiamine_7\NN\15090742|NONE_0 (r_pobj) of_6\IN\0|nutritional_23 (r_prep) deficiency_5\NN\14449126|to_15
D013831_D010523 CID thiamine_7\NN\15090742|NONE_0 (r_pobj) of_6\IN\0|nutritional_23 (r_prep) deficiency_5\NN\14449126|to_15 (r_pobj) due_2\IN\5174653|peripheral_22 (r_prep) neuropathy_1\NNS\14204950|common_72|%_84|and_87|presented_91|._147
D013831_D010523 CID thiamine_7\NN\15090742|NONE_0 (r_pobj) of_6\IN\0|nutritional_23 (r_prep) deficiency_5\NN\14449126|to_15 (r_pobj) due_2\IN\5174653|peripheral_22 (r_prep) neuropathy_1\NNS\14204950|common_72|%_84|and_87|presented_91|._147 (r_nsubj) was_10\VBD\0|NONE_0 (l_conj) presented_17\VBN\2137132|neuropathy_91|common_19|%_7|and_4|._56 (l_prep) as_19\IN\14622893|NONE_0 (l_pobj) neuropathy_25\NN\14204950|mainly_36
D012256_D044342 NONE riboflavin_9\NN\15090742|and_4 (r_conj) thiamine_7\NN\15090742|NONE_0 (r_pobj) of_6\IN\0|nutritional_23 (r_prep) deficiency_5\NN\14449126|to_15
D012256_D010523 CID riboflavin_9\NN\15090742|and_4 (r_conj) thiamine_7\NN\15090742|NONE_0 (r_pobj) of_6\IN\0|nutritional_23 (r_prep) deficiency_5\NN\14449126|to_15 (r_pobj) due_2\IN\5174653|peripheral_22 (r_prep) neuropathy_1\NNS\14204950|common_72|%_84|and_87|presented_91|._147
D012256_D010523 CID riboflavin_9\NN\15090742|and_4 (r_conj) thiamine_7\NN\15090742|NONE_0 (r_pobj) of_6\IN\0|nutritional_23 (r_prep) deficiency_5\NN\14449126|to_15 (r_pobj) due_2\IN\5174653|peripheral_22 (r_prep) neuropathy_1\NNS\14204950|common_72|%_84|and_87|presented_91|._147 (r_nsubj) was_10\VBD\0|NONE_0 (l_conj) presented_17\VBN\2137132|neuropathy_91|common_19|%_7|and_4|._56 (l_prep) as_19\IN\14622893|NONE_0 (l_pobj) neuropathy_25\NN\14204950|mainly_36
19820426
C558899_D066126 NONE ritonavir_10\NNS\4013993|NONE_0 (r_compound) therapy_11\NN\657604|/_11 (r_appos) lopinavir_8\NNS\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) related_6\VBN\628491|cardiac_17 (r_acl) toxicity_5\NN\13576101|NONE_0
C558899_D001919 CID ritonavir_15\NNS\4013993|,_17|agent_48 (r_compound) therapy_16\NN\657604|/_11 (r_appos) lopinavir_13\NNS\0|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) related_11\VBN\628491|dilated_23 (r_acl) cardiomyopathy_10\NN\14103288|complete_33|heart_24|and_12 (r_conj) block_7\NN\21939|one_42|,_107|developed_130|._156 (r_dobj) developed_4\VBD\1753788|NONE_0 (l_advcl) developed_29\VBD\1753788|one_172|block_130|,_23|._26 (l_dobj) bradycardia_31\NNS\14110674|while_36|twin_20
C558899_D002311 CID ritonavir_15\NNS\4013993|,_17|agent_48 (r_compound) therapy_16\NN\657604|/_11 (r_appos) lopinavir_13\NNS\0|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) related_11\VBN\628491|dilated_23 (r_acl) cardiomyopathy_10\NN\14103288|complete_33|heart_24|and_12
C558899_D006327 CID ritonavir_15\NNS\4013993|,_17|agent_48 (r_compound) therapy_16\NN\657604|/_11 (r_appos) lopinavir_13\NNS\0|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) related_11\VBN\628491|dilated_23 (r_acl) cardiomyopathy_10\NN\14103288|complete_33|heart_24|and_12 (r_conj) block_7\NN\21939|one_42|,_107|developed_130|._156
9766615
D003024_D015430 NONE clozapine_40\NN\3713736|seizure_29|(_11|)_9 (r_appos) threshold_37\NN\15265518|effects_100|,_31|and_33|agranulocytosis_37 (r_dobj) lowered_35\VBD\1850315|are_148|in_133|,_101 (l_nsubj) effects_21\NNS\13245626|threshold_100|,_131|and_133|agranulocytosis_137 (l_conj) effects_24\NNS\13245626|cardiovascular_40|,_18|,_57 (l_conj) gain_27\NN\13576355|anticholinergic_32|,_9
D003024_D015430 NONE clozapine_46\NN\3713736|NONE_0 (r_appos) agranulocytosis_44\NN\14189204|effects_137|threshold_37|,_6|and_4 (r_conj) lowered_35\VBD\1850315|are_148|in_133|,_101 (l_nsubj) effects_21\NNS\13245626|threshold_100|,_131|and_133|agranulocytosis_137 (l_conj) effects_24\NNS\13245626|cardiovascular_40|,_18|,_57 (l_conj) gain_27\NN\13576355|anticholinergic_32|,_9
D003024_D012640 NONE clozapine_40\NN\3713736|seizure_29|(_11|)_9 (r_appos) threshold_37\NN\15265518|effects_100|,_31|and_33|agranulocytosis_37 (l_compound) seizure_36\NN\14081375|(_18|clozapine_29|)_38
D003024_D012640 NONE clozapine_46\NN\3713736|NONE_0 (r_appos) agranulocytosis_44\NN\14189204|effects_137|threshold_37|,_6|and_4 (r_conj) lowered_35\VBD\1850315|are_148|in_133|,_101 (l_dobj) threshold_37\NN\15265518|effects_100|,_31|and_33|agranulocytosis_37 (l_compound) seizure_36\NN\14081375|(_18|clozapine_29|)_38
D003024_D001480 NONE clozapine_40\NN\3713736|seizure_29|(_11|)_9 (r_appos) threshold_37\NN\15265518|effects_100|,_31|and_33|agranulocytosis_37 (r_dobj) lowered_35\VBD\1850315|are_148|in_133|,_101 (r_conj) associated_13\VBN\628491|agents_41|risk_21|,_10|but_8|._229 (r_conj) have_4\VBP\7846|NONE_0 (l_dobj) risk_7\NN\14541044|agents_20|,_11|but_13|associated_21|._250 (l_prep) of_8\IN\0|a_13|lower_11 (l_pobj) eps_9\NNP\0|NONE_0
D003024_D001480 NONE clozapine_46\NN\3713736|NONE_0 (r_appos) agranulocytosis_44\NN\14189204|effects_137|threshold_37|,_6|and_4 (r_conj) lowered_35\VBD\1850315|are_148|in_133|,_101 (r_conj) associated_13\VBN\628491|agents_41|risk_21|,_10|but_8|._229 (r_conj) have_4\VBP\7846|NONE_0 (l_dobj) risk_7\NN\14541044|agents_20|,_11|but_13|associated_21|._250 (l_prep) of_8\IN\0|a_13|lower_11 (l_pobj) eps_9\NNP\0|NONE_0
D003024_D000380 CID clozapine_40\NN\3713736|seizure_29|(_11|)_9 (r_appos) threshold_37\NN\15265518|effects_100|,_31|and_33|agranulocytosis_37 (r_dobj) lowered_35\VBD\1850315|are_148|in_133|,_101 (l_conj) agranulocytosis_44\NN\14189204|effects_137|threshold_37|,_6|and_4
D003024_D000380 CID clozapine_46\NN\3713736|NONE_0 (r_appos) agranulocytosis_44\NN\14189204|effects_137|threshold_37|,_6|and_4
D003024_D012735 NONE clozapine_40\NN\3713736|seizure_29|(_11|)_9 (r_appos) threshold_37\NN\15265518|effects_100|,_31|and_33|agranulocytosis_37 (r_dobj) lowered_35\VBD\1850315|are_148|in_133|,_101 (l_nsubj) effects_21\NNS\13245626|threshold_100|,_131|and_133|agranulocytosis_137 (l_conj) effects_24\NNS\13245626|cardiovascular_40|,_18|,_57 (l_conj) gain_27\NN\13576355|anticholinergic_32|,_9 (l_conj) dysfunction_30\NN\14204950|weight_20|,_9
D003024_D012735 NONE clozapine_46\NN\3713736|NONE_0 (r_appos) agranulocytosis_44\NN\14189204|effects_137|threshold_37|,_6|and_4 (r_conj) lowered_35\VBD\1850315|are_148|in_133|,_101 (l_nsubj) effects_21\NNS\13245626|threshold_100|,_131|and_133|agranulocytosis_137 (l_conj) effects_24\NNS\13245626|cardiovascular_40|,_18|,_57 (l_conj) gain_27\NN\13576355|anticholinergic_32|,_9 (l_conj) dysfunction_30\NN\14204950|weight_20|,_9
16330766
C040029_D009437 NONE gabapentin_11\NN\2718469|NONE_0 (l_appos) drug_14\NN\14778436|,_4 (l_amod) effective_15\JJ\0|a_7 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_compound) pain_18\NN\14299637|neuropathic_12
D002211_D006930 CID capsaicin_32\NN\15032661|-_9 (r_npadvmod) induced_34\VBN\1627355|secondary_8 (r_amod) hyperalgesia_36\NN\0|normal_44|and_32
C040029_D006930 NONE gabapentin_15\NN\2718469|-_10 (r_npadvmod) induced_17\VBN\1627355|the_15|of_19|in_37 (r_amod) modulation_18\NN\7044917|using_107|,_36|we_34|._138 (l_prep) in_22\IN\13603305|the_52|induced_37|of_18 (l_pobj) response_23\NN\11410625|NONE_0 (l_prep) to_24\IN\0|NONE_0 (l_pobj) stimulation_27\NN\242808|NONE_0 (l_prep) of_28\IN\0|nociceptive_35|mechanical_23 (l_pobj) skin_30\NN\5237755|NONE_0 (l_conj) hyperalgesia_36\NN\0|normal_44|and_32
6640832
D004317_D002277 NONE adriamycin_2\NNS\0|early_15|._43 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) carcinoma_6\NN\14239918|NONE_0
D004317_D001749 NONE adriamycin_2\NNS\0|early_15|._43 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) carcinoma_6\NN\14239918|NONE_0
D004317_D001749 NONE adriamycin_0\NNP\0|was_25|intravesically_42|within_57|after_69|._128 (r_nsubjpass) administered_7\VBN\2436349|NONE_0 (l_prep) after_12\IN\0|adriamycin_69|was_44|intravesically_27|within_12|._59 (l_pobj) resection_14\NN\671351|NONE_0 (l_prep) of_15\IN\0|transurethral_24 (l_pobj) tumors_25\NNS\14234074|NONE_0
8421099
D015282_D002764 NONE octreotide_25\NN\0|in_19 (r_compound) therapy_26\NN\657604|NONE_0 (r_pobj) during_24\IN\0|the_71|successive_67|of_46 (r_prep) formation_15\NN\7938773|NONE_0 (l_prep) of_16\IN\0|the_25|successive_21|during_46 (l_pobj) sludge_18\NN\14591635|NONE_0 (l_conj) gallstones_20\NNS\9230768|bile_13|,_2 (l_conj) cholecystitis_23\NN\14336539|,_6|and_4
D015282_D000172 NONE octreotide_12\NN\0|somatostatin_21|(_1|)_10 (r_appos) analog_10\NN\4743605|NONE_0 (r_pobj) of_8\IN\0|the_22|term_13|on_36 (r_prep) effects_7\NNS\13245626|NONE_0 (l_prep) on_14\IN\0|the_58|term_49|of_36 (l_pobj) function_16\NN\13783581|NONE_0 (l_prep) in_20\IN\13603305|gallbladder_45|and_24|formation_10 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_compound) acromegalic_22\JJ\0|chinese_8
D015282_D000172 NONE octreotide_26\NN\0|the_24|somatostatin_20 (r_appos) analog_25\NN\4743605|NONE_0 (r_pobj) of_22\IN\0|sc_13 (r_prep) injection_21\NN\320852|NONE_0 (r_pobj) with_19\IN\0|in_56|day_90|for_94 (r_prep) treated_18\VBN\2376958|20_43|chinese_40|with_23 (r_acl) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|20_20|chinese_17|treated_23 (l_pobj) acromegaly_17\NNS\14366759|NONE_0
D015282_D000172 NONE octreotide_25\NN\0|in_19 (r_compound) therapy_26\NN\657604|NONE_0 (l_prep) in_27\IN\13603305|octreotide_19 (l_pobj) patients_30\NNS\9898892|NONE_0 (l_compound) acromegalic_29\JJ\0|chinese_8
D015282_D000172 NONE octreotide_16\NN\0|term_5|of_19 (r_compound) therapy_17\NN\657604|NONE_0 (l_prep) of_18\IN\0|term_24|octreotide_19 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_compound) acromegalic_19\JJ\0|NONE_0
D015282_D042882 CID octreotide_12\NN\0|somatostatin_21|(_1|)_10 (r_appos) analog_10\NN\4743605|NONE_0 (r_pobj) of_8\IN\0|the_22|term_13|on_36 (r_prep) effects_7\NNS\13245626|NONE_0 (l_prep) on_14\IN\0|the_58|term_49|of_36 (l_pobj) function_16\NN\13783581|NONE_0 (l_conj) formation_19\NN\7938773|gallbladder_35|and_14|in_10 (l_compound) gallstone_18\NN\9230768|NONE_0
D015282_D042882 CID octreotide_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) treatment_1\NN\654885|NONE_0 (r_pobj) during_0\IN\0|,_32|patients_37|sludge_56|had_67|._136 (r_prep) developed_7\VBD\1753788|NONE_0 (l_conj) had_11\VBD\0|during_67|,_35|patients_30|sludge_11|._69 (l_dobj) gallstones_12\NNS\9230768|10_7|,_10|and_12|developed_18
D015282_D042882 CID octreotide_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|in_14 (r_prep) withdrawal_1\NN\7206096|NONE_0 (l_prep) in_4\IN\13603305|of_14 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) without_7\IN\0|10_12 (l_pobj) gallstones_8\NNS\9230768|NONE_0
D015282_D042882 CID octreotide_25\NN\0|in_19 (r_compound) therapy_26\NN\657604|NONE_0 (r_pobj) during_24\IN\0|the_71|successive_67|of_46 (r_prep) formation_15\NN\7938773|NONE_0 (l_prep) of_16\IN\0|the_25|successive_21|during_46 (l_pobj) sludge_18\NN\14591635|NONE_0 (l_conj) gallstones_20\NNS\9230768|bile_13|,_2
D015282_D041881 CID octreotide_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) treatment_1\NN\654885|NONE_0 (r_pobj) during_0\IN\0|,_32|patients_37|sludge_56|had_67|._136 (r_prep) developed_7\VBD\1753788|NONE_0 (l_conj) had_11\VBD\0|during_67|,_35|patients_30|sludge_11|._69 (l_conj) developed_16\VBD\1753788|10_25|gallstones_18|,_8|and_6 (l_dobj) cholecystitis_18\NN\14336539|1_18|requiring_14
7453952
D011188_D003919 NONE potassium_48\NN\14625458|the_11 (r_compound) level_49\NN\4916342|NONE_0 (r_pobj) in_45\IN\13603305|an_13 (r_prep) elevation_44\NN\7445480|the_82|lithium_78|in_56|and_7 (r_conj) concentration_31\NN\4916342|NONE_0 (r_pobj) between_28\IN\0|the_10 (r_prep) ratio_27\NN\13815152|NONE_0 (r_pobj) of_25\IN\0|a_12 (r_prep) reduction_24\NN\351485|NONE_0 (r_pobj) by_22\IN\0|in_125|,_103|attenuation_97|was_16|._157 (r_agent) accompanied_21\VBN\0|NONE_0 (l_nsubjpass) attenuation_6\NN\7427337|in_28|,_6|was_81|by_97|._254 (l_prep) of_7\IN\0|the_16 (l_pobj) syndrome_17\NN\5870365|NONE_0
D000584_D011141 NONE amiloride_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11|on_13 (r_prep) effect_1\NN\34213|was_154|in_171|,_178|treated_192|._209 (l_prep) on_4\IN\0|the_24|of_13 (l_pobj) polydipsia_8\NN\14040660|and_24|on_28 (l_conj) polyuria_10\NN\14113228|induced_23|and_4
D000584_D011141 NONE amiloride_5\NN\0|acute_6|to_25 (r_compound) administration_6\NN\1133281|that_21|might_82|patients_102|but_111|result_157 (l_prep) to_7\IN\0|acute_31|amiloride_25 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0 (l_conj) polyuria_16\NN\14113228|and_4
D000584_D011141 NONE amiloride_23\JJ\0|prolonged_10 (r_compound) supplementation_24\NN\5108947|would_16|in_29|and_56|be_66 (r_nsubj) result_26\VB\34213|that_178|administration_157|might_75|patients_55|but_46 (r_conj) relieve_18\VB\205885|it_125|is_122|._125 (l_nsubj) administration_6\NN\1133281|that_21|might_82|patients_102|but_111|result_157 (l_prep) to_7\IN\0|acute_31|amiloride_25 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0 (l_conj) polyuria_16\NN\14113228|and_4
D008094_D011141 NONE lithium_5\NN\14625458|-_7 (r_npadvmod) induced_7\VBN\1627355|and_19|polyuria_23 (r_amod) polydipsia_8\NN\14040660|and_24|on_28 (l_conj) polyuria_10\NN\14113228|induced_23|and_4
D008094_D011141 NONE lithium_14\NN\14625458|the_4|in_22 (r_compound) concentration_15\NN\4916342|NONE_0 (r_pobj) on_12\IN\0|polydipsia_28|and_4 (r_conj) on_4\IN\0|the_24|of_13 (l_pobj) polydipsia_8\NN\14040660|and_24|on_28 (l_conj) polyuria_10\NN\14113228|induced_23|and_4
D008094_D011141 NONE lithium_8\NN\14625458|-_7 (r_npadvmod) treated_10\VBN\2376958|suffering_17 (r_amod) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0 (l_conj) polyuria_16\NN\14113228|and_4
D008094_D011141 NONE lithium_29\NN\14625458|elevated_9 (r_compound) levels_30\NNS\4916342|NONE_0 (r_pobj) in_27\IN\13603305|supplementation_29|would_13|and_27|be_37 (r_prep) result_26\VB\34213|that_178|administration_157|might_75|patients_55|but_46 (r_conj) relieve_18\VB\205885|it_125|is_122|._125 (l_nsubj) administration_6\NN\1133281|that_21|might_82|patients_102|but_111|result_157 (l_prep) to_7\IN\0|acute_31|amiloride_25 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0 (l_conj) polyuria_16\NN\14113228|and_4
D000584_D059606 NONE amiloride_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11|on_13 (r_prep) effect_1\NN\34213|was_154|in_171|,_178|treated_192|._209 (l_prep) on_4\IN\0|the_24|of_13 (l_pobj) polydipsia_8\NN\14040660|and_24|on_28
D000584_D059606 NONE amiloride_5\NN\0|acute_6|to_25 (r_compound) administration_6\NN\1133281|that_21|might_82|patients_102|but_111|result_157 (l_prep) to_7\IN\0|acute_31|amiloride_25 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0
D000584_D059606 NONE amiloride_23\JJ\0|prolonged_10 (r_compound) supplementation_24\NN\5108947|would_16|in_29|and_56|be_66 (r_nsubj) result_26\VB\34213|that_178|administration_157|might_75|patients_55|but_46 (r_conj) relieve_18\VB\205885|it_125|is_122|._125 (l_nsubj) administration_6\NN\1133281|that_21|might_82|patients_102|but_111|result_157 (l_prep) to_7\IN\0|acute_31|amiloride_25 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0
D008094_D059606 NONE lithium_5\NN\14625458|-_7 (r_npadvmod) induced_7\VBN\1627355|and_19|polyuria_23 (r_amod) polydipsia_8\NN\14040660|and_24|on_28
D008094_D059606 NONE lithium_14\NN\14625458|the_4|in_22 (r_compound) concentration_15\NN\4916342|NONE_0 (r_pobj) on_12\IN\0|polydipsia_28|and_4 (r_conj) on_4\IN\0|the_24|of_13 (l_pobj) polydipsia_8\NN\14040660|and_24|on_28
D008094_D059606 NONE lithium_8\NN\14625458|-_7 (r_npadvmod) treated_10\VBN\2376958|suffering_17 (r_amod) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0
D008094_D059606 NONE lithium_29\NN\14625458|elevated_9 (r_compound) levels_30\NNS\4916342|NONE_0 (r_pobj) in_27\IN\13603305|supplementation_29|would_13|and_27|be_37 (r_prep) result_26\VB\34213|that_178|administration_157|might_75|patients_55|but_46 (r_conj) relieve_18\VB\205885|it_125|is_122|._125 (l_nsubj) administration_6\NN\1133281|that_21|might_82|patients_102|but_111|result_157 (l_prep) to_7\IN\0|acute_31|amiloride_25 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|treated_17 (l_prep) from_13\IN\0|NONE_0 (l_pobj) polydipsia_14\NN\14040660|NONE_0
D000584_D003919 NONE amiloride_13\NN\0|NONE_0 (r_pobj) by_12\IN\0|the_53|induced_41|like_14|in_13 (r_prep) syndrome_11\NN\5870365|NONE_0
D000584_D003919 NONE amiloride_19\NN\0|NONE_0 (r_pobj) by_18\IN\0|the_53|induced_41|like_14 (r_prep) syndrome_17\NN\5870365|NONE_0
D008094_D003919 CID lithium_3\NN\14625458|-_7 (r_npadvmod) induced_5\VBN\1627355|the_12|like_27|by_41|in_54 (r_amod) syndrome_11\NN\5870365|NONE_0
D008094_D003919 CID lithium_9\NN\14625458|-_7 (r_npadvmod) induced_11\VBN\1627355|the_12|like_27|by_41 (r_amod) syndrome_17\NN\5870365|NONE_0
D008094_D003919 CID lithium_30\NN\14625458|the_4|in_22|and_71|elevation_78 (r_compound) concentration_31\NN\4916342|NONE_0 (r_pobj) between_28\IN\0|the_10 (r_prep) ratio_27\NN\13815152|NONE_0 (r_pobj) of_25\IN\0|a_12 (r_prep) reduction_24\NN\351485|NONE_0 (r_pobj) by_22\IN\0|in_125|,_103|attenuation_97|was_16|._157 (r_agent) accompanied_21\VBN\0|NONE_0 (l_nsubjpass) attenuation_6\NN\7427337|in_28|,_6|was_81|by_97|._254 (l_prep) of_7\IN\0|the_16 (l_pobj) syndrome_17\NN\5870365|NONE_0
D018021_D011141 NONE licl_37\NNP\0|NONE_0 (r_pobj) with_36\IN\0|chronically_20 (r_prep) treated_35\VBN\2376958|effect_192|was_38|in_21|,_14|._17 (r_conj) investigated_30\VBN\644583|NONE_0 (l_nsubjpass) effect_1\NN\34213|was_154|in_171|,_178|treated_192|._209 (l_prep) on_4\IN\0|the_24|of_13 (l_pobj) polydipsia_8\NN\14040660|and_24|on_28 (l_conj) polyuria_10\NN\14113228|induced_23|and_4
D018021_D059606 NONE licl_37\NNP\0|NONE_0 (r_pobj) with_36\IN\0|chronically_20 (r_prep) treated_35\VBN\2376958|effect_192|was_38|in_21|,_14|._17 (r_conj) investigated_30\VBN\644583|NONE_0 (l_nsubjpass) effect_1\NN\34213|was_154|in_171|,_178|treated_192|._209 (l_prep) on_4\IN\0|the_24|of_13 (l_pobj) polydipsia_8\NN\14040660|and_24|on_28
3564823
D008012_D020301 NONE lidocaine_11\NN\3681148|precluded_37|,_2|was_10|,_36|with_38|,_76|counteract_81|._105 (r_nsubjpass) given_13\VBN\5892096|NONE_0 (l_advcl) counteract_24\VB\2367363|precluded_118|,_83|lidocaine_81|was_71|,_45|with_43|,_5|._24 (l_dobj) vasospasm_26\NN\0|to_18
D008012_D013035 NONE lidocaine_7\NN\3681148|NONE_0 (r_pobj) by_6\IN\0|spasm_15|._12 (r_prep) relieved_5\VBN\205885|NONE_0 (l_nsubj) spasm_4\NN\14299637|by_15|._27
D013874_D002545 NONE pentothal_12\NNS\2792049|following_66|,_9|was_10|intravenously_14|minimize_39|._66 (r_nsubjpass) infused_15\VBN\606335|NONE_0 (l_advcl) minimize_17\VB\441445|following_105|,_48|pentothal_39|was_29|intravenously_25|._27 (l_dobj) ischaemia_19\NN\14195315|to_21
2304736
D011224_D014550 CID prazosin_0\NN\2698769|-_8 (r_npadvmod) induced_2\VBN\1627355|stress_8|._27 (r_amod) incontinence_4\NN\13473097|NONE_0
D011224_D014550 CID prazosin_8\NN\2698769|to_3 (r_pobj) due_6\IN\5174653|a_38|of_31 (r_amod) case_1\NN\7283608|is_85|._97 (l_prep) of_2\IN\0|a_7|due_31 (l_pobj) incontinence_5\NN\13473097|NONE_0
D011224_D014550 CID prazosin_8\NN\2698769|while_13 (r_dobj) taking_7\VBG\37396|who_43|with_31 (r_advcl) present_2\VBP\28270|NONE_0 (l_prep) with_3\IN\0|who_12|taking_31 (l_pobj) incontinence_5\NN\13473097|NONE_0
D011224_D014549 NONE prazosin_8\NN\2698769|while_13 (r_dobj) taking_7\VBG\37396|who_43|with_31 (r_advcl) present_2\VBP\28270|NONE_0 (r_relcl) patients_0\NNS\9898892|should_68|medication_105|before_116|,_142|resolve_175|._226 (r_nsubj) change_10\VB\7283608|NONE_0 (l_advcl) resolve_22\VB\4616059|patients_175|should_107|medication_70|before_59|,_33|._51 (l_nsubj) incontinence_20\NN\13473097|because_14|may_13|spontaneously_25|with_39
4071154
D007213_D001201 CID indomethacin_24\NN\3828465|we_136|have_133|case_117|._20 (r_advcl) reported_2\VBN\831651|NONE_0 (l_dobj) case_4\NN\7283608|we_19|have_16|indomethacin_117|._137 (l_prep) in_12\IN\13603305|a_57|of_50 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_10 (l_pobj) cirrhosis_16\NN\14116321|NONE_0 (l_conj) ascites_18\NNS\14204950|,_2
D007213_D006947 CID indomethacin_24\NN\3828465|we_136|have_133|case_117|._20 (r_advcl) reported_2\VBN\831651|NONE_0 (l_dobj) case_4\NN\7283608|we_19|have_16|indomethacin_117|._137 (l_prep) of_5\IN\0|a_7|in_50 (l_pobj) failure_9\NN\66216|NONE_0 (l_prep) with_10\IN\0|acute_29|oliguric_23|renal_14 (l_pobj) hyperkalemia_11\NN\14299637|NONE_0
D007213_D051437 NONE indomethacin_0\NNP\3828465|-_12 (r_npadvmod) induced_2\VBN\1627355|renal_8|:_27|recurrence_29|._54 (r_amod) insufficiency_4\NN\14462946|NONE_0
D007213_D051437 NONE indomethacin_24\NN\3828465|we_136|have_133|case_117|._20 (r_advcl) reported_2\VBN\831651|NONE_0 (l_dobj) case_4\NN\7283608|we_19|have_16|indomethacin_117|._137 (l_prep) of_5\IN\0|a_7|in_50 (l_pobj) failure_9\NN\66216|NONE_0
D007213_D011660 CID indomethacin_24\NN\3828465|we_136|have_133|case_117|._20 (r_advcl) reported_2\VBN\831651|NONE_0 (l_dobj) case_4\NN\7283608|we_19|have_16|indomethacin_117|._137 (l_prep) in_12\IN\13603305|a_57|of_50 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_10 (l_pobj) cirrhosis_16\NN\14116321|NONE_0 (l_conj) ascites_18\NNS\14204950|,_2 (l_conj) pulmonale_22\NN\0|,_10|and_8
D007213_D005355 CID indomethacin_24\NN\3828465|we_136|have_133|case_117|._20 (r_advcl) reported_2\VBN\831651|NONE_0 (l_dobj) case_4\NN\7283608|we_19|have_16|indomethacin_117|._137 (l_prep) in_12\IN\13603305|a_57|of_50 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_10 (l_pobj) cirrhosis_16\NN\14116321|NONE_0
D007213_D009846 CID indomethacin_18\NN\3828465|NONE_0 (r_pobj) of_17\IN\0|a_14|single_12 (r_prep) dose_16\NN\3740161|exposure_21 (r_pobj) to_13\IN\0|recurrence_40 (r_punct) caused_19\VBD\1617192|restoration_107|withdrawal_63|,_53|._46 (l_dobj) recurrence_20\NN\7342049|to_40 (l_prep) of_21\IN\0|NONE_0 (l_pobj) oliguria_24\NN\14299637|NONE_0
3800626
D010423_D020425 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|fibrous_8 (r_amod) myopathy_12\NNS\14204950|to_31 (r_pobj) due_6\IN\5174653|compression_43|of_20|._43 (r_prep) neuropathy_1\NN\14204950|NONE_0 (l_prep) of_2\IN\0|compression_23|due_20|._63 (l_pobj) nerve_5\NN\5475681|NONE_0
D010423_D005355 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|fibrous_8 (r_amod) myopathy_12\NNS\14204950|to_31
D010423_D005355 CID pentazocine_13\NN\2707683|repeated_9 (r_compound) injection_14\NN\320852|NONE_0 (r_pobj) of_11\IN\0|a_33|common_31|,_25|known_18|side_12 (r_prep) effect_10\NN\34213|myopathy_38|._40 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) myopathy_1\NN\14204950|effect_38|._78
D010423_D005355 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|documented_23|fibrous_8|of_25 (r_amod) myopathy_12\NNS\14204950|NONE_0
D010423_D005355 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|documented_23|fibrous_8|of_25 (r_amod) myopathy_12\NNS\14204950|NONE_0 (r_pobj) with_6\IN\0|a_20|old_10|bilaterally_84|and_96|history_113 (r_prep) woman_5\NN\9605289|NONE_0 (r_pobj) in_0\IN\13603305|,_163|examination_183|lesion_223|,_293|in_295|._330 (r_prep) showed_32\VBD\2137132|NONE_0 (l_prep) in_51\IN\13603305|in_295|,_132|examination_112|lesion_72|,_2|._35 (l_pobj) addition_52\NN\3081021|NONE_0 (l_prep) to_53\IN\0|NONE_0 (l_pobj) myopathy_56\NN\14204950|NONE_0
D010423_D009135 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|fibrous_8 (r_amod) myopathy_12\NNS\14204950|to_31
D010423_D009135 CID pentazocine_13\NN\2707683|repeated_9 (r_compound) injection_14\NN\320852|NONE_0 (r_pobj) of_11\IN\0|a_33|common_31|,_25|known_18|side_12 (r_prep) effect_10\NN\34213|myopathy_38|._40 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) myopathy_1\NN\14204950|effect_38|._78
D010423_D009135 CID pentazocine_10\NN\2707683|-_11 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_compound) myopathy_13\NN\14204950|NONE_0
D010423_D009135 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|documented_23|fibrous_8|of_25 (r_amod) myopathy_12\NNS\14204950|NONE_0
D010423_D009135 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|documented_23|fibrous_8|of_25 (r_amod) myopathy_12\NNS\14204950|NONE_0 (r_pobj) with_6\IN\0|a_20|old_10|bilaterally_84|and_96|history_113 (r_prep) woman_5\NN\9605289|NONE_0 (r_pobj) in_0\IN\13603305|,_163|examination_183|lesion_223|,_293|in_295|._330 (r_prep) showed_32\VBD\2137132|NONE_0 (l_prep) in_51\IN\13603305|in_295|,_132|examination_112|lesion_72|,_2|._35 (l_pobj) addition_52\NN\3081021|NONE_0 (l_prep) to_53\IN\0|NONE_0 (l_pobj) myopathy_56\NN\14204950|NONE_0
D010423_D009408 CID pentazocine_8\NN\2707683|-_11 (r_advmod) induced_10\VBN\1627355|fibrous_8 (r_amod) myopathy_12\NNS\14204950|to_31 (r_pobj) due_6\IN\5174653|compression_43|of_20|._43 (r_prep) neuropathy_1\NN\14204950|NONE_0 (l_prep) of_2\IN\0|compression_23|due_20|._63 (l_pobj) nerve_5\NN\5475681|NONE_0
D010423_D009408 CID pentazocine_10\NN\2707683|-_11 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_compound) myopathy_13\NN\14204950|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) affected_8\VBN\126264|fibrotic_16 (r_acl) muscle_7\NN\5289601|to_12 (r_pobj) due_4\IN\5174653|compression_23 (r_amod) neuropathy_3\NN\14204950|however_21|,_14|has_75|not_79|previously_83|been_94|._107
15804801
D017239_D003323 CID paclitaxel_6\NN\0|-_10 (r_compound) eluting_8\VBG\1270199|a_13 (r_amod) stent_9\NN\4493505|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) implantation_3\NN\13526110|NONE_0 (r_pobj) after_2\IN\0|coronary_18|._48 (r_prep) aneurysm_1\NN\14057371|NONE_0
D017239_D003323 CID paclitaxel_22\NN\0|-_10 (r_compound) eluting_24\VBG\1270199|a_13 (r_amod) stent_25\NN\4493505|NONE_0 (r_dobj) receiving_20\VBG\2210855|months_13 (r_pcomp) after_19\IN\0|who_72|aneurysm_47|in_38 (r_prep) developed_8\VBD\1753788|a_22|old_12 (l_dobj) aneurysm_11\NN\14057371|who_25|in_9|after_47
11773892
D016559_D007674 CID tacrolimus_5\NN\0|and_4 (r_conj) cyclosporine_3\VBP\0|the_27|calcineurin_23 (r_appos) inhibitors_2\NNS\20090|are_39|both_43|be_57|._71 (r_nsubjpass) known_8\VBN\0|NONE_0 (l_xcomp) be_10\VB\14625458|inhibitors_57|are_18|both_14|._14 (l_acomp) nephrotoxic_11\JJ\0|to_6
D003404_D006530 NONE creatinine_13\NN\0|higher_26|preoperative_19|,_17|percentage_29|,_77|requirement_97 (r_compound) levels_14\NNS\4916342|compared_95|,_65|patients_50|._186 (l_appos) percentage_18\NN\13815742|higher_55|preoperative_48|creatinine_29|,_12|,_48|requirement_68 (l_prep) of_19\IN\0|a_21|greater_19 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) syndrome_23\NN\5870365|NONE_0
D003404_D006530 NONE creatinine_42\NN\0|higher_108|percentage_101|for_78|in_65|,_28|and_26 (r_conj) requirement_27\NN\1129920|higher_123|preoperative_116|creatinine_97|,_80|percentage_68|,_20 (r_appos) levels_14\NNS\4916342|compared_95|,_65|patients_50|._186 (l_appos) percentage_18\NN\13815742|higher_55|preoperative_48|creatinine_29|,_12|,_48|requirement_68 (l_prep) of_19\IN\0|a_21|greater_19 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) syndrome_23\NN\5870365|NONE_0
D003404_D006530 NONE creatinine_11\NN\0|patients_70|and_11|are_15|._59 (r_dobj) have_4\VBP\7846|NONE_0 (l_conj) are_13\VBP\13600404|patients_85|creatinine_15|and_4|._44 (l_acomp) likely_15\JJ\0|NONE_0 (l_xcomp) have_17\VB\7846|more_15 (l_dobj) syndrome_19\NN\5870365|to_20
D016572_D007674 CID cyclosporine_3\VBP\0|the_27|calcineurin_23 (r_appos) inhibitors_2\NNS\20090|are_39|both_43|be_57|._71 (r_nsubjpass) known_8\VBN\0|NONE_0 (l_xcomp) be_10\VB\14625458|inhibitors_57|are_18|both_14|._14 (l_acomp) nephrotoxic_11\JJ\0|to_6
D003404_D007676 NONE creatinine_20\NN\0|,_18 (r_conj) crf_16\NNP\0|,_25|crf_20|;_2 (r_conj) controls_7\NNS\5190804|three_14|:_2|>_65|;_81|and_83|n=45_93 (l_conj) crf_10\NNP\0|,_5|;_18|crf_20
D003404_D007676 NONE creatinine_20\NN\0|,_18 (r_conj) crf_16\NNP\0|,_25|crf_20|;_2 (r_conj) controls_7\NNS\5190804|three_14|:_2|>_65|;_81|and_83|n=45_93 (l_conj) crf_10\NNP\0|,_5|;_18|crf_20 (l_conj) esrd_12\NNP\0|no_10|or_3
D003404_D007676 NONE creatinine_20\NN\0|,_18 (r_conj) crf_16\NNP\0|,_25|crf_20|;_2
D003404_D007676 NONE creatinine_20\NN\0|,_18 (r_conj) crf_16\NNP\0|,_25|crf_20|;_2 (r_conj) controls_7\NNS\5190804|three_14|:_2|>_65|;_81|and_83|n=45_93 (r_appos) groups_5\NNS\2137|NONE_0 (l_conj) n=45_32\JJ\0|three_107|:_95|controls_93|>_28|;_12|and_10 (l_nmod) esrd_30\NNS\0|._10
D003404_D007676 NONE creatinine_13\NN\0|higher_26|preoperative_19|,_17|percentage_29|,_77|requirement_97 (r_compound) levels_14\NNS\4916342|compared_95|,_65|patients_50|._186 (r_dobj) had_9\VBD\0|NONE_0 (l_nsubj) patients_8\NNS\9898892|compared_45|,_15|levels_50|._236 (l_nmod) crf_5\NNP\0|esrd_8
D003404_D007676 NONE creatinine_13\NN\0|higher_26|preoperative_19|,_17|percentage_29|,_77|requirement_97 (r_compound) levels_14\NNS\4916342|compared_95|,_65|patients_50|._186 (r_dobj) had_9\VBD\0|NONE_0 (l_nsubj) patients_8\NNS\9898892|compared_45|,_15|levels_50|._236 (l_compound) esrd_7\NNP\0|crf_8
D003404_D007676 NONE creatinine_42\NN\0|higher_108|percentage_101|for_78|in_65|,_28|and_26 (r_conj) requirement_27\NN\1129920|higher_123|preoperative_116|creatinine_97|,_80|percentage_68|,_20 (r_appos) levels_14\NNS\4916342|compared_95|,_65|patients_50|._186 (r_dobj) had_9\VBD\0|NONE_0 (l_nsubj) patients_8\NNS\9898892|compared_45|,_15|levels_50|._236 (l_nmod) crf_5\NNP\0|esrd_8
D003404_D007676 NONE creatinine_42\NN\0|higher_108|percentage_101|for_78|in_65|,_28|and_26 (r_conj) requirement_27\NN\1129920|higher_123|preoperative_116|creatinine_97|,_80|percentage_68|,_20 (r_appos) levels_14\NNS\4916342|compared_95|,_65|patients_50|._186 (r_dobj) had_9\VBD\0|NONE_0 (l_nsubj) patients_8\NNS\9898892|compared_45|,_15|levels_50|._236 (l_compound) esrd_7\NNP\0|crf_8
D003404_D007676 NONE creatinine_16\NN\0|NONE_0 (r_pobj) of_14\IN\0|an_12|compared_20|,_61|and_63 (r_prep) increase_13\NN\13576355|that_8|postoperatively_84|factors_122|respectively_204 (r_nsubj) were_31\VBD\0|analysis_175|._116 (l_attr) factors_34\NNS\7326557|that_130|increase_122|postoperatively_38|respectively_82 (l_prep) for_35\IN\0|independent_25|risk_13|with_35 (l_pobj) development_37\NN\248977|NONE_0 (l_prep) of_38\IN\0|the_16 (l_pobj) crf_39\NNP\0|NONE_0
D003404_D007676 NONE creatinine_16\NN\0|NONE_0 (r_pobj) of_14\IN\0|an_12|compared_20|,_61|and_63 (r_prep) increase_13\NN\13576355|that_8|postoperatively_84|factors_122|respectively_204 (r_nsubj) were_31\VBD\0|analysis_175|._116 (l_attr) factors_34\NNS\7326557|that_130|increase_122|postoperatively_38|respectively_82 (l_prep) for_35\IN\0|independent_25|risk_13|with_35 (l_pobj) development_37\NN\248977|NONE_0 (l_prep) of_38\IN\0|the_16 (l_pobj) crf_39\NNP\0|NONE_0 (l_conj) esrd_41\NNP\0|or_3
D003404_D007676 NONE creatinine_11\NN\0|patients_70|and_11|are_15|._59 (r_dobj) have_4\VBP\7846|NONE_0 (l_nsubj) patients_0\NNS\9898892|creatinine_70|and_81|are_85|._129 (l_relcl) develop_2\VBP\1753788|NONE_0 (l_dobj) esrd_3\NNS\0|who_12
D003404_D007676 NONE creatinine_6\NN\0|NONE_0 (r_pobj) of_4\IN\0|an_12|at_20|postoperatively_37 (r_prep) increase_3\NN\13576355|however_12|,_5|predictive_70|._114 (r_nsubj) is_11\VBZ\0|NONE_0 (l_acomp) predictive_13\JJ\0|however_82|,_75|increase_70|._44 (l_prep) of_14\IN\0|more_16 (l_pobj) development_16\NN\248977|NONE_0 (l_prep) of_17\IN\0|the_16 (l_pobj) crf_18\NNP\0|NONE_0
D003404_D007676 NONE creatinine_6\NN\0|NONE_0 (r_pobj) of_4\IN\0|an_12|at_20|postoperatively_37 (r_prep) increase_3\NN\13576355|however_12|,_5|predictive_70|._114 (r_nsubj) is_11\VBZ\0|NONE_0 (l_acomp) predictive_13\JJ\0|however_82|,_75|increase_70|._44 (l_prep) of_14\IN\0|more_16 (l_pobj) development_16\NN\248977|NONE_0 (l_prep) of_17\IN\0|the_16 (l_pobj) crf_18\NNP\0|NONE_0 (l_conj) esrd_20\NNP\0|or_3
17466854
D008775_D006261 CID methylprednisolone_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_19|and_22|gentamicin_26 (r_prep) administration_1\NN\1133281|was_87|to_99|._175 (r_nsubjpass) related_15\VBN\628491|NONE_0 (l_prep) to_16\IN\0|administration_99|was_12|._76 (l_pobj) incidence_19\NN\13821570|NONE_0 (l_prep) of_20\IN\0|a_17|high_15 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_prep) including_23\VBG\0|side_13 (l_pobj) nausea_24\NN\14299637|NONE_0 (l_conj) vomiting_26\NN\116687|,_2 (l_conj) headache_29\NN\5829480|,_6|and_4
D008775_D020250 CID methylprednisolone_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_19|and_22|gentamicin_26 (r_prep) administration_1\NN\1133281|was_87|to_99|._175 (r_nsubjpass) related_15\VBN\628491|NONE_0 (l_prep) to_16\IN\0|administration_99|was_12|._76 (l_pobj) incidence_19\NN\13821570|NONE_0 (l_prep) of_20\IN\0|a_17|high_15 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_prep) including_23\VBG\0|side_13 (l_pobj) nausea_24\NN\14299637|NONE_0 (l_conj) vomiting_26\NN\116687|,_2
D005839_D006261 CID gentamicin_5\NN\2716866|the_45|of_26|and_4 (r_conj) administration_1\NN\1133281|was_87|to_99|._175 (r_nsubjpass) related_15\VBN\628491|NONE_0 (l_prep) to_16\IN\0|administration_99|was_12|._76 (l_pobj) incidence_19\NN\13821570|NONE_0 (l_prep) of_20\IN\0|a_17|high_15 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_prep) including_23\VBG\0|side_13 (l_pobj) nausea_24\NN\14299637|NONE_0 (l_conj) vomiting_26\NN\116687|,_2 (l_conj) headache_29\NN\5829480|,_6|and_4
D008775_D002386 NONE methylprednisolone_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_19 (r_prep) administration_11\NN\1133281|NONE_0 (r_pobj) after_9\IN\0|the_51|of_37 (r_prep) incidence_3\NN\13821570|to_14|and_94|gentamicin_98|._184 (r_dobj) assess_1\VB\5220461|NONE_0 (l_conj) gentamicin_15\NN\2716866|to_112|incidence_98|and_4|._86 (l_prep) at_24\IN\14622893|into_37 (l_pobj) end_26\NN\8568978|NONE_0 (l_prep) of_27\IN\0|the_8 (l_pobj) surgery_30\NN\6045562|NONE_0 (l_compound) cataract_29\NN\14252864|routine_8
D005839_D020250 CID gentamicin_5\NN\2716866|the_45|of_26|and_4 (r_conj) administration_1\NN\1133281|was_87|to_99|._175 (r_nsubjpass) related_15\VBN\628491|NONE_0 (l_prep) to_16\IN\0|administration_99|was_12|._76 (l_pobj) incidence_19\NN\13821570|NONE_0 (l_prep) of_20\IN\0|a_17|high_15 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_prep) including_23\VBG\0|side_13 (l_pobj) nausea_24\NN\14299637|NONE_0 (l_conj) vomiting_26\NN\116687|,_2
D005839_D002386 NONE gentamicin_15\NN\2716866|to_112|incidence_98|and_4|._86 (l_prep) at_24\IN\14622893|into_37 (l_pobj) end_26\NN\8568978|NONE_0 (l_prep) of_27\IN\0|the_8 (l_pobj) surgery_30\NN\6045562|NONE_0 (l_compound) cataract_29\NN\14252864|routine_8
8590259
C016986_D015814 CID apraclonidine_8\NN\0|-_13 (r_npadvmod) treated_10\VBN\2376958|NONE_0 (r_amod) eyes_11\NNS\5945642|NONE_0 (r_pobj) for_7\IN\0|statistically_26|throughout_31|and_52|significant_75 (r_prep) significant_6\JJ\0|effects_27|._187 (r_acomp) were_4\VBD\0|NONE_0 (l_nsubj) effects_3\NNS\13245626|significant_27|._214 (l_amod) hypotensive_2\JJ\10405694|the_11|ocular_7
C016986_D015814 CID apraclonidine_31\NN\0|NONE_0 (r_pobj) of_28\IN\0|topical_23 (r_prep) administration_27\NN\1133281|NONE_0 (r_pobj) after_25\IN\0|three_12 (r_prep) hours_24\NNS\15118228|NONE_0 (r_pobj) from_22\IN\0|also_54|statistically_49|for_23 (r_prep) significant_18\JJ\0|statistically_101|for_75|throughout_44|and_23 (r_conj) significant_6\JJ\0|effects_27|._187 (r_acomp) were_4\VBD\0|NONE_0 (l_nsubj) effects_3\NNS\13245626|significant_27|._214 (l_amod) hypotensive_2\JJ\10405694|the_11|ocular_7
14568327
D015632_D004409 NONE mptp_7\NNP\0|-_4 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) parkinsonism_10\NN\14085708|NONE_0 (r_pobj) of_6\IN\0|different_16 (r_prep) types_5\NNS\5839024|NONE_0 (r_pobj) with_3\IN\0|monkeys_8 (r_prep) using_0\VBG\418025|,_71|study_85|degree_105|._259 (r_advcl) evaluated_15\VBD\670261|NONE_0 (l_dobj) degree_17\NN\4916342|using_105|,_34|study_20|._154 (l_relcl) involved_38\VBN\2676054|the_123 (l_prep) in_39\IN\13603305|to_121|severity_75|may_16|be_12 (l_pobj) development_41\NN\248977|NONE_0 (l_prep) of_42\IN\0|the_16 (l_pobj) lids_43\NNS\5313679|NONE_0
D015632_D004409 NONE mptp_8\NNP\0|acute_19|,_13|onset_29 (r_compound) exposure_9\NN\5042871|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) monkeys_0\NNS\2469914|prior_94|dyskinesia_144|days_173|._210 (r_nsubj) developed_24\VBD\1753788|NONE_0 (l_dobj) dyskinesia_25\RB\14084880|monkeys_144|prior_50|days_29|._66
D015632_D004409 NONE mptp_8\NNP\0|term_5 (r_compound) exposure_9\NN\5042871|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) monkeys_3\NNS\2469914|in_13|,_2|,_36|slow_38|symptom_43|and/or_63|duration_83|prior_92 (r_nsubj) progression_13\NN\8457976|resistant_91|developed_138|._207 (r_nsubj) were_24\VBD\0|NONE_0 (l_acomp) resistant_26\JJ\0|progression_91|developed_47|._116 (l_prep) to_27\IN\0|more_15 (l_pcomp) developing_28\VBG\13541167|NONE_0 (l_dobj) lids_29\NNS\5313679|NONE_0
D015632_D004409 NONE mptp_8\NNP\0|term_5 (r_compound) exposure_9\NN\5042871|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) monkeys_3\NNS\2469914|in_13|,_2|,_36|slow_38|symptom_43|and/or_63|duration_83|prior_92 (r_nsubj) progression_13\NN\8457976|resistant_91|developed_138|._207 (r_nsubj) were_24\VBD\0|NONE_0 (l_parataxis) developed_34\VBD\1753788|progression_138|resistant_47|._69 (l_nsubj) dyskinesia_33\NN\14084880|(_7|e.g._6|,_2|sooner_24|)_79
D007980_D010302 NONE levodopa_34\NN\14604959|NONE_0 (r_compound) therapy_35\NN\657604|NONE_0 (r_pobj) of_33\IN\0|NONE_0 (r_prep) duration_32\NN\15113229|to_7|and_4 (r_conj) response_29\NN\11410625|rate_51|,_24|symptom_22|,_6|and_4 (r_conj) severity_26\NN\5036394|to_46|may_59|be_63|in_75 (r_nsubjpass) involved_38\VBN\2676054|the_123 (r_relcl) degree_17\NN\4916342|using_105|,_34|study_20|._154 (r_dobj) evaluated_15\VBD\670261|NONE_0 (l_advcl) using_0\VBG\418025|,_71|study_85|degree_105|._259 (l_prep) with_3\IN\0|monkeys_8 (l_pobj) types_5\NNS\5839024|NONE_0 (l_prep) of_6\IN\0|different_16 (l_pobj) parkinsonism_10\NN\14085708|NONE_0
D007980_D004409 CID levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|in_20 (r_amod) dyskinesias_5\NNS\14084880|NONE_0
D007980_D004409 CID levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_3\NNS\14084880|problem_35|._108
D007980_D004409 CID levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_3\NNS\14084880|problem_35|._108 (l_appos) lids_5\NNPS\5313679|induced_21|(_1|)_4
D007980_D004409 CID levodopa_34\NN\14604959|NONE_0 (r_compound) therapy_35\NN\657604|NONE_0 (r_pobj) of_33\IN\0|NONE_0 (r_prep) duration_32\NN\15113229|to_7|and_4 (r_conj) response_29\NN\11410625|rate_51|,_24|symptom_22|,_6|and_4 (r_conj) severity_26\NN\5036394|to_46|may_59|be_63|in_75 (r_nsubjpass) involved_38\VBN\2676054|the_123 (l_prep) in_39\IN\13603305|to_121|severity_75|may_16|be_12 (l_pobj) development_41\NN\248977|NONE_0 (l_prep) of_42\IN\0|the_16 (l_pobj) lids_43\NNS\5313679|NONE_0
D007980_D004409 CID levodopa_22\NN\14604959|NONE_0 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) initiation_20\NN\7450842|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_prep) prior_18\RB\10675876|monkeys_94|dyskinesia_50|days_79|._116 (r_advmod) developed_24\VBD\1753788|NONE_0 (l_dobj) dyskinesia_25\RB\14084880|monkeys_144|prior_50|days_29|._66
D007980_D004409 CID levodopa_33\JJ\14604959|daily_6 (r_compound) administration_34\NN\1133281|NONE_0 (r_pobj) of_31\IN\0|11_15 (r_prep) days_30\NNS\15140892|monkeys_173|prior_79|dyskinesia_29|._37 (r_npadvmod) developed_24\VBD\1753788|NONE_0 (l_dobj) dyskinesia_25\RB\14084880|monkeys_144|prior_50|days_29|._66
D007980_D004409 CID levodopa_22\NN\14604959|NONE_0 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) initiation_20\NN\7450842|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_prep) prior_18\RB\10675876|in_105|,_94|monkeys_92|,_56|slow_54|symptom_49|and/or_29|duration_9 (r_advmod) progression_13\NN\8457976|resistant_91|developed_138|._207 (r_nsubj) were_24\VBD\0|NONE_0 (l_acomp) resistant_26\JJ\0|progression_91|developed_47|._116 (l_prep) to_27\IN\0|more_15 (l_pcomp) developing_28\VBG\13541167|NONE_0 (l_dobj) lids_29\NNS\5313679|NONE_0
D007980_D004409 CID levodopa_22\NN\14604959|NONE_0 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) initiation_20\NN\7450842|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_prep) prior_18\RB\10675876|in_105|,_94|monkeys_92|,_56|slow_54|symptom_49|and/or_29|duration_9 (r_advmod) progression_13\NN\8457976|resistant_91|developed_138|._207 (r_nsubj) were_24\VBD\0|NONE_0 (l_parataxis) developed_34\VBD\1753788|progression_138|resistant_47|._69 (l_nsubj) dyskinesia_33\NN\14084880|(_7|e.g._6|,_2|sooner_24|)_79
D007980_D004409 CID levodopa_42\JJ\14604959|chronic_8 (r_compound) administration_43\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|146_9 (r_prep) days_39\NNS\15140892|NONE_0 (r_pobj) than_37\IN\0|no_10 (r_prep) sooner_36\RBR\9738708|(_31|e.g._30|,_26|dyskinesia_24|)_55 (r_advmod) developed_34\VBD\1753788|progression_138|resistant_47|._69 (r_parataxis) were_24\VBD\0|NONE_0 (l_acomp) resistant_26\JJ\0|progression_91|developed_47|._116 (l_prep) to_27\IN\0|more_15 (l_pcomp) developing_28\VBG\13541167|NONE_0 (l_dobj) lids_29\NNS\5313679|NONE_0
D007980_D004409 CID levodopa_42\JJ\14604959|chronic_8 (r_compound) administration_43\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|146_9 (r_prep) days_39\NNS\15140892|NONE_0 (r_pobj) than_37\IN\0|no_10 (r_prep) sooner_36\RBR\9738708|(_31|e.g._30|,_26|dyskinesia_24|)_55 (r_advmod) developed_34\VBD\1753788|progression_138|resistant_47|._69 (l_nsubj) dyskinesia_33\NN\14084880|(_7|e.g._6|,_2|sooner_24|)_79
D007980_D004409 CID levodopa_24\VB\14604959|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) prior_22\RB\10675876|to_92|lids_81|with_65 (r_advmod) develop_9\VB\1753788|the_18 (l_dobj) lids_10\NNS\5313679|to_11|with_16|prior_81
D007980_D004409 CID levodopa_24\VB\14604959|NONE_0 (r_pobj) to_23\IN\0|NONE_0 (r_prep) prior_22\RB\10675876|to_92|lids_81|with_65 (r_advmod) develop_9\VB\1753788|the_18 (r_acl) propensity_7\NN\7498854|NONE_0 (r_pobj) in_5\IN\13603305|distinct_21 (r_prep) differences_4\NNS\4723816|data_22|and_140|demonstrate_144|._230 (r_dobj) suggest_2\VBP\1010118|NONE_0 (l_conj) demonstrate_26\VB\2137132|data_166|differences_144|and_4|._86 (l_dobj) value_28\NN\5856066|NONE_0 (l_prep) for_32\IN\0|the_26|of_16 (l_pcomp) studying_34\VBG\5808794|NONE_0 (l_dobj) pathophysiology_36\NN\0|further_21 (l_prep) of_37\IN\0|the_20 (l_pobj) lids_38\NNS\5313679|NONE_0
D007980_D010300 NONE levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|in_20 (r_amod) dyskinesias_5\NNS\14084880|NONE_0 (l_prep) in_6\IN\13603305|induced_20 (l_pobj) monkeys_8\NNS\2469914|NONE_0 (l_amod) parkinsonian_7\JJ\0|NONE_0
D007980_D010300 NONE levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_3\NNS\14084880|problem_35|._108 (r_nsubj) present_7\VBP\28270|NONE_0 (l_dobj) problem_10\NN\14408086|dyskinesias_35|._73 (l_prep) for_11\IN\0|a_16|major_14 (l_pobj) management_16\NN\1123598|NONE_0 (l_prep) of_17\IN\0|the_25|term_16 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_nmod) disease_20\NN\14061805|(_8|pd_9|)_11
D007980_D010300 NONE levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|(_20|lids_21|)_25 (r_amod) dyskinesias_3\NNS\14084880|problem_35|._108 (r_nsubj) present_7\VBP\28270|NONE_0 (l_dobj) problem_10\NN\14408086|dyskinesias_35|._73 (l_prep) for_11\IN\0|a_16|major_14 (l_pobj) management_16\NN\1123598|NONE_0 (l_prep) of_17\IN\0|the_25|term_16 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_nmod) pd_22\NNP\14625458|disease_9|(_1|)_2
D015632_D010302 CID mptp_7\NNP\0|-_4 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) parkinsonism_10\NN\14085708|NONE_0
9522143
D011318_D034381 CID prilocaine_2\NN\0|NONE_0 (r_dobj) given_1\VBN\5892096|p_117 (r_acl) patients_0\NNS\9898892|likely_36|._135 (r_nsubj) were_3\VBD\0|NONE_0 (l_acomp) likely_5\JJ\0|patients_36|._99 (l_xcomp) develop_7\VB\1753788|more_15 (l_xcomp) hearing_8\VBG\1184814|to_11 (l_dobj) loss_9\NN\13252973|NONE_0
D011318_D034381 CID prilocaine_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|loss_44|db_3|._44 (r_prep) was_7\VBD\0|NONE_0 (l_nsubj) loss_3\NN\13252973|db_41|after_44|._88
D002045_D034381 CID bupivacaine_19\NN\0|NONE_0 (r_pobj) than_16\IN\0|10_14 (r_prep) loss_9\NN\13252973|NONE_0
D002045_D034381 CID bupivacaine_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|15_6 (r_prep) db_15\NN\14622893|and_7 (r_conj) prilocaine_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|loss_44|db_3|._44 (r_prep) was_7\VBD\0|NONE_0 (l_nsubj) loss_3\NN\13252973|db_41|after_44|._88
15233872
D007545_D009203 CID isoproterenol_7\NN\3740161|-_13 (r_npadvmod) induced_9\VBN\1627355|myocardial_8|in_30 (r_amod) infarction_11\NN\14204950|NONE_0
C007145_D009203 NONE crataegus_5\NNP\11585340|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) tincture_3\NN\14984973|NONE_0 (r_pobj) of_2\IN\0|cardioprotective_24|on_25|._79 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) on_6\IN\0|cardioprotective_49|of_25|._54 (l_pobj) infarction_11\NN\14204950|NONE_0
C007145_D009203 NONE tcr_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_22|protective_18|on_7 (r_prep) effect_9\NN\34213|to_30 (l_prep) on_12\IN\0|the_29|protective_25|of_7 (l_pobj) infarction_16\NN\14204950|NONE_0
1378968
D008094_D007676 CID lithium_8\NN\14625458|-_7 (r_npadvmod) induced_10\VBN\1627355|chronic_8|renal_16|in_30 (r_amod) failure_13\NN\66216|NONE_0
D008094_D051437 NONE lithium_2\NN\14625458|-_7 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) nephropathy_5\NN\14573196|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) rats_0\NNS\2329401|were_38|to_53|,_128|in_130|._221 (r_nsubjpass) subjected_7\VBN\137313|NONE_0 (l_prep) in_26\IN\13603305|rats_130|were_92|to_77|,_2|._91 (l_pobj) attempt_28\NN\407535|NONE_0 (l_acl) induce_30\VB\1627355|an_14 (l_dobj) hyperfiltration_32\NN\0|to_21 (l_conj) progression_35\NN\8457976|glomerular_39|and_12 (l_prep) of_36\IN\0|further_20 (l_pobj) failure_38\NN\66216|NONE_0
D008094_D051437 NONE lithium_21\NN\14625458|pretreated_8 (r_nmod) rats_23\NNS\2329401|NONE_0 (r_pobj) in_20\IN\13603305|plasma_25|creatinine_18 (r_prep) levels_19\NNS\4916342|NONE_0 (r_dobj) decrease_16\NN\7296428|to_20|gfr_8 (r_conj) increase_13\VB\13576355|in_18|._77 (r_xcomp) tended_11\VBD\2604760|hp_66|accentuante_53|and_12 (r_conj) failed_1\VBD\0|NONE_0 (l_xcomp) accentuante_3\NN\0|hp_13|and_41|tended_53 (l_dobj) progression_4\NN\8457976|to_15 (l_prep) of_5\IN\0|NONE_0 (l_pobj) failure_7\NN\66216|NONE_0
D008094_D007674 NONE lithium_2\NN\14625458|-_7 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) nephropathy_5\NN\14573196|NONE_0
D008094_D007674 NONE li_4\NNP\14625458|-_2 (r_npadvmod) induced_6\VBN\1627355|,_19|reduced_56|,_63 (r_amod) nephropathy_7\NN\14573196|that_16|is_57|with_71
D008094_D005921 NONE lithium_0\NN\14625458|also_8|proteinuria_20|in_58|._90 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_prep) in_7\IN\13603305|lithium_58|also_50|proteinuria_38|._32 (l_pobj) absence_8\NN\14449405|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) glomerulosclerosis_10\NN\0|NONE_0
D003404_D051437 NONE creatinine_18\NN\0|plasma_7|in_18 (r_compound) levels_19\NNS\4916342|NONE_0 (r_dobj) decrease_16\NN\7296428|to_20|gfr_8 (r_conj) increase_13\VB\13576355|in_18|._77 (r_xcomp) tended_11\VBD\2604760|hp_66|accentuante_53|and_12 (r_conj) failed_1\VBD\0|NONE_0 (l_xcomp) accentuante_3\NN\0|hp_13|and_41|tended_53 (l_dobj) progression_4\NN\8457976|to_15 (l_prep) of_5\IN\0|NONE_0 (l_pobj) failure_7\NN\66216|NONE_0
D008094_D006973 CID lithium_0\NN\14625458|also_8|proteinuria_20|in_58|._90 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_dobj) proteinuria_3\NN\14299637|lithium_20|also_12|in_38|._70 (l_conj) hypertension_6\NN\14057371|and_13
D008094_D006973 CID li_4\NNP\14625458|-_2 (r_npadvmod) induced_6\VBN\1627355|,_19|reduced_56|,_63 (r_amod) nephropathy_7\NN\14573196|that_16|is_57|with_71 (r_nsubjpass) associated_19\VBN\628491|results_93|._62 (l_prep) with_20\IN\0|that_87|nephropathy_71|is_14 (l_pobj) proteinuria_21\NN\14299637|NONE_0 (l_conj) hypertension_25\NN\14057371|and_22
D008094_D011507 CID lithium_0\NN\14625458|also_8|proteinuria_20|in_58|._90 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_dobj) proteinuria_3\NN\14299637|lithium_20|also_12|in_38|._70
D008094_D011507 CID li_4\NNP\14625458|-_2 (r_npadvmod) induced_6\VBN\1627355|,_19|reduced_56|,_63 (r_amod) nephropathy_7\NN\14573196|that_16|is_57|with_71 (r_nsubjpass) associated_19\VBN\628491|results_93|._62 (l_prep) with_20\IN\0|that_87|nephropathy_71|is_14 (l_pobj) proteinuria_21\NN\14299637|NONE_0
3503576
D003676_D014786 NONE deferoxamine_26\NN\0|NONE_0 (r_pobj) with_23\IN\0|who_42|were_38|therapy_8 (r_prep) receiving_19\VBG\2210855|dependent_26 (r_relcl) anemia_16\NN\14189204|NONE_0 (r_pobj) with_12\IN\0|89_12 (r_prep) patients_11\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|neurotoxicity_40|was_26|previously_22|._133 (r_prep) documented_6\VBN\1000214|NONE_0 (l_nsubjpass) neurotoxicity_3\NN\0|was_14|previously_18|in_40|._173
D003676_D000740 NONE deferoxamine_26\NN\0|NONE_0 (r_pobj) with_23\IN\0|who_42|were_38|therapy_8 (r_prep) receiving_19\VBG\2210855|dependent_26 (r_relcl) anemia_16\NN\14189204|NONE_0
D007501_D006311 NONE iron_20\NN\14625458|chelation_5 (r_compound) therapy_22\NN\657604|who_34|were_30|with_8 (r_dobj) receiving_19\VBG\2210855|dependent_26 (r_relcl) anemia_16\NN\14189204|NONE_0 (r_pobj) with_12\IN\0|89_12 (r_prep) patients_11\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|neurotoxicity_40|was_26|previously_22|._133 (r_prep) documented_6\VBN\1000214|NONE_0 (l_nsubjpass) neurotoxicity_3\NN\0|was_14|previously_18|in_40|._173
D003676_D064420 NONE deferoxamine_9\NN\0|NONE_0 (r_compound) doses_10\NNS\3740161|since_66|18_60|were_38|initially_33|in_6 (r_dobj) receiving_8\VBG\2210855|,_84|therapy_86|was_94|with_108|,_207|and_209|demonstrated_269 (r_advcl) restarted_24\VBN\1857717|NONE_0 (l_conj) demonstrated_55\VBN\2137132|receiving_269|,_185|therapy_183|was_175|with_161|,_62|and_60 (l_nsubjpass) toxicity_53\NN\13576101|with_43|was_9|._25
D007501_D014786 NONE iron_20\NN\14625458|chelation_5 (r_compound) therapy_22\NN\657604|who_34|were_30|with_8 (r_dobj) receiving_19\VBG\2210855|dependent_26 (r_relcl) anemia_16\NN\14189204|NONE_0 (r_pobj) with_12\IN\0|89_12 (r_prep) patients_11\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|neurotoxicity_40|was_26|previously_22|._133 (r_prep) documented_6\VBN\1000214|NONE_0 (l_nsubjpass) neurotoxicity_3\NN\0|was_14|previously_18|in_40|._173
D003676_D006311 NONE deferoxamine_8\NN\0|NONE_0 (r_compound) therapy_9\NN\657604|NONE_0 (r_dobj) receiving_7\VBG\2210855|NONE_0 (r_acl) patients_6\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|serial_41|of_26|._42 (r_prep) studies_1\NNS\635850|NONE_0 (l_prep) of_2\IN\0|serial_15|in_26|._68 (l_pobj) neurotoxicity_4\NN\0|NONE_0
D003676_D006311 NONE deferoxamine_26\NN\0|NONE_0 (r_pobj) with_23\IN\0|who_42|were_38|therapy_8 (r_prep) receiving_19\VBG\2210855|dependent_26 (r_relcl) anemia_16\NN\14189204|NONE_0 (r_pobj) with_12\IN\0|89_12 (r_prep) patients_11\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|neurotoxicity_40|was_26|previously_22|._133 (r_prep) documented_6\VBN\1000214|NONE_0 (l_nsubjpass) neurotoxicity_3\NN\0|was_14|previously_18|in_40|._173
D003676_D006311 NONE deferoxamine_9\NN\0|NONE_0 (r_compound) doses_10\NNS\3740161|since_66|18_60|were_38|initially_33|in_6 (r_dobj) receiving_8\VBG\2210855|,_84|therapy_86|was_94|with_108|,_207|and_209|demonstrated_269 (r_advcl) restarted_24\VBN\1857717|NONE_0 (l_prep) with_25\IN\0|receiving_108|,_24|therapy_22|was_14|,_99|and_101|demonstrated_161 (l_pobj) doses_27\NNS\3740161|NONE_0 (l_prep) depending_36\VBG\2604760|lower_47|,_36|mg/kg_23 (l_prep) on_37\IN\0|NONE_0 (l_pobj) degree_39\NN\4916342|NONE_0 (l_prep) of_40\IN\0|the_11 (l_pobj) abnormality_42\NN\14034177|NONE_0
D003676_D006311 NONE deferoxamine_14\NN\0|not_14 (r_dobj) receiving_13\VBG\2210855|and_8 (r_conj) receiving_10\VBG\2210855|individual_20 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|deterioration_53|,_24|serially_9|,_63|respectively_65|,_77|provided_79|._191 (r_prep) demonstrated_5\VBD\2137132|NONE_0 (l_prep) provided_18\VBD\2199590|deterioration_132|,_103|serially_88|in_79|,_16|respectively_14|,_2|._112 (l_pcomp) convincing_19\JJ\766418|NONE_0 (l_dobj) evidence_20\NN\5816287|NONE_0 (l_prep) for_21\IN\0|NONE_0 (l_pobj) relation_28\NN\2137|NONE_0 (l_prep) between_29\IN\0|a_28|cause_26 (l_pobj) administration_31\NN\1133281|NONE_0 (l_conj) ototoxicity_33\NN\0|deferoxamine_32|and_4
D003676_D006311 NONE deferoxamine_30\NN\0|and_28|ototoxicity_32 (r_compound) administration_31\NN\1133281|NONE_0 (l_conj) ototoxicity_33\NN\0|deferoxamine_32|and_4
D007501_D000740 NONE iron_20\NN\14625458|chelation_5 (r_compound) therapy_22\NN\657604|who_34|were_30|with_8 (r_dobj) receiving_19\VBG\2210855|dependent_26 (r_relcl) anemia_16\NN\14189204|NONE_0
7628595
D002955_D064420 NONE acid_9\NN\14818238|folinic_8|in_21 (r_compound) supplementation_10\NN\5108947|vitamin_29|and_17 (l_prep) in_11\IN\13603305|folinic_29|acid_21 (l_pcomp) preventing_12\VBG\0|NONE_0 (l_dobj) toxicity_14\NN\13576101|NONE_0
D015215_D001855 CID zidovudine_20\NNP\3834836|(_11|zdv)-induced_12|marrow_30 (r_nmod) suppression_25\NN\13489037|NONE_0
D015215_D001855 CID zdv)-induced_22\VBN\0|zidovudine_12|(_1|marrow_18 (r_amod) suppression_25\NN\13489037|NONE_0
D015215_D001855 CID zdv_7\NNP\3834836|NONE_0 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) of_6\IN\0|folinic_29|acid_21 (r_prep) supplementation_5\NN\5108947|vitamin_29|and_17 (r_conj) b12_1\NN\0|does_52|not_57|useful_66|,_158|excluded_232|._240 (r_nsubj) seem_11\VB\2604760|NONE_0 (l_oprd) useful_12\JJ\0|b12_66|does_14|not_9|,_92|excluded_166|._174 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) preventing_14\VBG\0|NONE_0 (l_conj) reducing_16\VBG\13447361|or_3 (l_dobj) myelotoxicity_20\NN\0|in_14
D015215_D001855 CID zdv_17\NNP\3834836|-_3 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) myelotoxicity_20\NN\0|in_14
D015215_D015658 NONE zdv_21\NNP\3834836|to_18|alone_19 (r_dobj) receive_19\VB\2210855|virus_81|were_19 (r_xcomp) randomized_17\VBN\278117|NONE_0 (l_nsubjpass) virus_5\NN\9312843|were_62|receive_81 (l_appos) patients_8\NNS\9898892|five_49|human_44|immunodeficiency_38 (l_amod) hiv)-infected_7\VBN\0|(_1|with_23
D005492_D001855 NONE folate_8\JJ\15090742|and_14|development_18 (r_compound) levels_9\NNS\4916342|vitamin_22|or_10 (l_conj) development_11\NN\248977|folate_18|and_4 (l_prep) of_12\IN\0|NONE_0 (l_pobj) myelosuppression_13\NN\0|NONE_0
D015215_D064420 NONE zidovudine_16\NN\3834836|NONE_0 (r_pobj) of_15\IN\0|hematologic_21 (r_prep) toxicity_14\NN\13576101|NONE_0
D014805_D001855 NONE b12_13\NN\0|NONE_0 (l_conj) supplementation_17\NN\5108947|vitamin_29|and_17 (l_prep) in_18\IN\13603305|folinic_29|acid_21 (l_pcomp) preventing_19\VBG\0|NONE_0 (l_dobj) suppression_25\NN\13489037|NONE_0
D014805_D001855 NONE b12_6\NN\0|NONE_0 (l_conj) levels_9\NNS\4916342|vitamin_22|or_10 (l_conj) development_11\NN\248977|folate_18|and_4 (l_prep) of_12\IN\0|NONE_0 (l_pobj) myelosuppression_13\NN\0|NONE_0
D014805_D001855 NONE b12_1\NN\0|does_52|not_57|useful_66|,_158|excluded_232|._240 (r_nsubj) seem_11\VB\2604760|NONE_0 (l_oprd) useful_12\JJ\0|b12_66|does_14|not_9|,_92|excluded_166|._174 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) preventing_14\VBG\0|NONE_0 (l_conj) reducing_16\VBG\13447361|or_3 (l_dobj) myelotoxicity_20\NN\0|in_14
D014805_D064420 NONE b12_6\NN\0|NONE_0 (l_conj) supplementation_10\NN\5108947|vitamin_29|and_17 (l_prep) in_11\IN\13603305|folinic_29|acid_21 (l_pcomp) preventing_12\VBG\0|NONE_0 (l_dobj) toxicity_14\NN\13576101|NONE_0
D002955_D001855 NONE acid_16\NN\14818238|folinic_8|in_21 (r_compound) supplementation_17\NN\5108947|vitamin_29|and_17 (l_prep) in_18\IN\13603305|folinic_29|acid_21 (l_pcomp) preventing_19\VBG\0|NONE_0 (l_dobj) suppression_25\NN\13489037|NONE_0
D002955_D001855 NONE acid_4\NN\14818238|folinic_8|of_21 (r_compound) supplementation_5\NN\5108947|vitamin_29|and_17 (r_conj) b12_1\NN\0|does_52|not_57|useful_66|,_158|excluded_232|._240 (r_nsubj) seem_11\VB\2604760|NONE_0 (l_oprd) useful_12\JJ\0|b12_66|does_14|not_9|,_92|excluded_166|._174 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) preventing_14\VBG\0|NONE_0 (l_conj) reducing_16\VBG\13447361|or_3 (l_dobj) myelotoxicity_20\NN\0|in_14
16298782
D019331_D034381 NONE name_2\NN\6284225|loss_40|in_45|,_72|but_74|gave_78|._129 (r_nsubj) reduced_3\VBN\441445|NONE_0 (l_dobj) loss_8\NN\13252973|name_40|in_5|,_32|but_34|gave_38|._89
D009569_D006319 NONE no_17\DT\7204911|NONE_0 (r_pobj) of_16\IN\0|the_15 (r_prep) production_15\NN\30358|as_41|mechanism_23 (r_dobj) involves_13\VBZ\2676054|ototoxicity_73|problem_41|and_33|,_30 (r_conj) is_2\VBZ\0|,_90|we_92|assess_103|._206 (r_ccomp) need_20\VBP\13920835|NONE_0 (l_xcomp) assess_22\VB\5220461|is_103|,_13|we_11|._103 (l_dobj) use_24\NN\407535|to_14 (l_prep) for_28\IN\0|the_25|of_17 (l_pobj) prevention_30\NN\1073995|NONE_0 (l_prep) of_31\IN\0|the_15 (l_pobj) loss_37\NN\13252973|NONE_0
D009569_D006319 NONE no_26\DT\7204911|NONE_0 (r_det) inhibitors_27\NNS\20090|NONE_0 (r_pobj) of_25\IN\0|the_8|for_17 (r_prep) use_24\NN\407535|to_14 (l_prep) for_28\IN\0|the_25|of_17 (l_pobj) prevention_30\NN\1073995|NONE_0 (l_prep) of_31\IN\0|the_15 (l_pobj) loss_37\NN\13252973|NONE_0
D019331_D006311 NONE ester_6\NN\14727670|NONE_0 (l_appos) protector_10\NN\10466918|arginine_35|methyl_26|:_14|._40 (l_prep) against_11\IN\0|a_22|potential_20 (l_pobj) ototoxicity_13\NN\0|NONE_0
D019331_D006316 NONE ester_13\NN\14727670|the_56|nitric_52|(_39 (r_appos) oxide_2\NN\14818238|may_60|as_68|,_144|but_146|needed_170 (r_nsubj) act_20\VB\6479665|NONE_0 (l_prep) as_21\IN\14622893|oxide_68|may_8|,_76|but_78|needed_102 (l_pobj) otoprotectant_23\NN\0|NONE_0 (l_prep) against_24\IN\0|an_17 (l_pobj) loss_29\NN\13252973|NONE_0
D019331_D006316 NONE name_17\NN\6284225|no_47|inhibitor_43|arginine_25|methyl_16|(_3|)_4 (r_appos) ester_13\NN\14727670|the_56|nitric_52|(_39 (r_appos) oxide_2\NN\14818238|may_60|as_68|,_144|but_146|needed_170 (r_nsubj) act_20\VB\6479665|NONE_0 (l_prep) as_21\IN\14622893|oxide_68|may_8|,_76|but_78|needed_102 (l_pobj) otoprotectant_23\NN\0|NONE_0 (l_prep) against_24\IN\0|an_17 (l_pobj) loss_29\NN\13252973|NONE_0
D005839_D006316 NONE gentamicin_32\NN\2716866|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_agent) caused_30\VBN\1617192|frequency_23|hearing_13 (r_acl) loss_29\NN\13252973|NONE_0
D005839_D006311 NONE gentamicin_12\NN\2716866|NONE_0 (r_compound) ototoxicity_13\NN\0|NONE_0
D000617_D006319 NONE aminoglycoside_32\NN\0|-_14 (r_npadvmod) induced_34\VBN\1627355|hearing_22 (r_amod) loss_37\NN\13252973|NONE_0
D009569_D006311 NONE no_17\DT\7204911|NONE_0 (r_pobj) of_16\IN\0|the_15 (r_prep) production_15\NN\30358|as_41|mechanism_23 (r_dobj) involves_13\VBZ\2676054|ototoxicity_73|problem_41|and_33|,_30 (r_conj) is_2\VBZ\0|,_90|we_92|assess_103|._206 (l_nsubj) ototoxicity_1\NN\0|problem_32|and_40|,_43|involves_73
D009569_D006311 NONE no_17\DT\7204911|NONE_0 (r_pobj) of_16\IN\0|the_15 (r_prep) production_15\NN\30358|as_41|mechanism_23 (r_dobj) involves_13\VBZ\2676054|ototoxicity_73|problem_41|and_33|,_30 (l_nsubj) mechanism_12\NN\13446390|as_18|production_23 (l_compound) ototoxic_11\JJ\0|their_6
D009569_D006311 NONE no_26\DT\7204911|NONE_0 (r_det) inhibitors_27\NNS\20090|NONE_0 (r_pobj) of_25\IN\0|the_8|for_17 (r_prep) use_24\NN\407535|to_14 (r_dobj) assess_22\VB\5220461|is_103|,_13|we_11|._103 (r_xcomp) need_20\VBP\13920835|NONE_0 (l_ccomp) is_2\VBZ\0|,_90|we_92|assess_103|._206 (l_nsubj) ototoxicity_1\NN\0|problem_32|and_40|,_43|involves_73
D009569_D006311 NONE no_26\DT\7204911|NONE_0 (r_det) inhibitors_27\NNS\20090|NONE_0 (r_pobj) of_25\IN\0|the_8|for_17 (r_prep) use_24\NN\407535|to_14 (r_dobj) assess_22\VB\5220461|is_103|,_13|we_11|._103 (r_xcomp) need_20\VBP\13920835|NONE_0 (l_ccomp) is_2\VBZ\0|,_90|we_92|assess_103|._206 (l_conj) involves_13\VBZ\2676054|ototoxicity_73|problem_41|and_33|,_30 (l_nsubj) mechanism_12\NN\13446390|as_18|production_23 (l_compound) ototoxic_11\JJ\0|their_6
D005839_D034381 CID gentamicin_4\NN\2716866|-_10 (r_npadvmod) induced_6\VBN\1627355|hearing_8 (r_amod) loss_8\NN\13252973|name_40|in_5|,_32|but_34|gave_38|._89
D009569_D006316 NONE oxide_2\NN\14818238|may_60|as_68|,_144|but_146|needed_170 (r_nsubj) act_20\VB\6479665|NONE_0 (l_prep) as_21\IN\14622893|oxide_68|may_8|,_76|but_78|needed_102 (l_pobj) otoprotectant_23\NN\0|NONE_0 (l_prep) against_24\IN\0|an_17 (l_pobj) loss_29\NN\13252973|NONE_0
D009569_D006316 NONE no_4\NNP\7204911|inhibitor_4|arginine_22|methyl_31|(_44|name_47|)_51 (r_intj) ester_13\NN\14727670|the_56|nitric_52|(_39 (r_appos) oxide_2\NN\14818238|may_60|as_68|,_144|but_146|needed_170 (r_nsubj) act_20\VB\6479665|NONE_0 (l_prep) as_21\IN\14622893|oxide_68|may_8|,_76|but_78|needed_102 (l_pobj) otoprotectant_23\NN\0|NONE_0 (l_prep) against_24\IN\0|an_17 (l_pobj) loss_29\NN\13252973|NONE_0
D000617_D006311 NONE aminoglycoside_32\NN\0|-_14 (r_npadvmod) induced_34\VBN\1627355|hearing_22 (r_amod) loss_37\NN\13252973|NONE_0 (r_pobj) of_31\IN\0|the_15 (r_prep) prevention_30\NN\1073995|NONE_0 (r_pobj) for_28\IN\0|the_25|of_17 (r_prep) use_24\NN\407535|to_14 (r_dobj) assess_22\VB\5220461|is_103|,_13|we_11|._103 (r_xcomp) need_20\VBP\13920835|NONE_0 (l_ccomp) is_2\VBZ\0|,_90|we_92|assess_103|._206 (l_nsubj) ototoxicity_1\NN\0|problem_32|and_40|,_43|involves_73
D000617_D006311 NONE aminoglycoside_32\NN\0|-_14 (r_npadvmod) induced_34\VBN\1627355|hearing_22 (r_amod) loss_37\NN\13252973|NONE_0 (r_pobj) of_31\IN\0|the_15 (r_prep) prevention_30\NN\1073995|NONE_0 (r_pobj) for_28\IN\0|the_25|of_17 (r_prep) use_24\NN\407535|to_14 (r_dobj) assess_22\VB\5220461|is_103|,_13|we_11|._103 (r_xcomp) need_20\VBP\13920835|NONE_0 (l_ccomp) is_2\VBZ\0|,_90|we_92|assess_103|._206 (l_conj) involves_13\VBZ\2676054|ototoxicity_73|problem_41|and_33|,_30 (l_nsubj) mechanism_12\NN\13446390|as_18|production_23 (l_compound) ototoxic_11\JJ\0|their_6
6538499
D004317_D009202 CID adr_8\NNP\0|-_3 (r_npadvmod) induced_10\VBN\1627355|cardiac_8|morphological_16 (r_amod) alterations_13\NNS\7283608|NONE_0
D004317_D002286 NONE adr_6\NNP\0|the_4|antitumor_4|in_23|tumor_64 (r_compound) activity_8\NN\30358|treatment_45|did_35|not_31|._55 (l_relcl) tumor_16\NN\14234074|the_68|adr_64|antitumor_60|in_41
D004317_D064420 NONE adriamycin_6\JJ\0|effect_37|400_7|._27 (l_dobj) toxicity_7\NN\13576101|NONE_0
D011092_D064420 NONE 400_4\CD\0|effect_30|adriamycin_7|._34 (r_nummod) glycol_3\NN\14766364|NONE_0 (l_advcl) adriamycin_6\JJ\0|effect_37|400_7|._27 (l_dobj) toxicity_7\NN\13576101|NONE_0
D004317_D007939 NONE adr_6\NNP\0|the_4|antitumor_4|in_23|tumor_64 (r_compound) activity_8\NN\30358|treatment_45|did_35|not_31|._55 (l_prep) in_9\IN\13603305|the_27|adr_23|antitumor_19|tumor_41 (l_pobj) leukemia_11\NN\14239918|and_9
12653683
D000450_D009404 NONE aldosterone_38\NN\14751863|NONE_0 (r_pobj) by_37\IN\0|the_15 (r_prep) regulation_36\NN\6652242|NONE_0 (r_pobj) from_34\IN\0|to_10|after_35 (r_prep) escape_33\VB\46177|NONE_0 (r_xcomp) appears_31\VBZ\2604760|in_169|,_156|expression_144|is_110|in_97|,_6|but_4|._64 (r_conj) increased_11\VBN\169651|NONE_0 (l_prep) in_12\IN\13603305|in_72|,_59|expression_47|is_13|,_91|but_93|appears_97|._161 (l_pobj) phase_16\NN\15113229|NONE_0 (l_prep) of_17\IN\0|the_21|early_12 (l_pobj) model_20\NN\5888929|NONE_0 (l_prep) of_21\IN\0|the_23|experimental_19 (l_pobj) syndrome_26\NN\5870365|NONE_0
D012964_D009404 NONE sodium_1\NN\14625458|epithelial_11|(_15|enac_16|)_20|subunit_22|._123 (r_compound) channel_2\NN\6251781|NONE_0 (l_appos) subunit_6\NN\13604718|epithelial_33|sodium_22|(_7|enac_6|)_2|._101 (l_appos) mrna_7\NN\14832193|NONE_0 (l_conj) expression_10\NN\4679549|and_12 (l_prep) in_11\IN\13603305|protein_19 (l_pobj) rats_12\NNS\2329401|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) syndrome_19\NN\5870365|NONE_0
D012964_D009404 NONE sodium_6\NN\14625458|NONE_0 (r_compound) excretion_7\NN\13466586|in_51|,_17|is_10|during_23|._60 (r_nsubjpass) decreased_9\VBN\169651|NONE_0 (l_prep) in_0\IN\13603305|,_34|excretion_51|is_61|during_74|._111 (l_pobj) syndrome_3\NN\5870365|NONE_0
D000450_D011507 NONE aldosterone_9\NN\14751863|and_26|proteinuria_30 (r_compound) concentration_10\NN\4916342|sodium_37|,_21 (l_conj) proteinuria_12\NN\14299637|aldosterone_30|and_4
D011692_D009404 CID aminonucleoside_15\RB\0|-_15 (r_advmod) induced_17\VBN\1627355|puromycin_26|nephrotic_8 (r_amod) syndrome_19\NN\5870365|NONE_0
D011692_D009404 CID aminonucleoside_12\NN\0|we_74|abundance_58|in_13|._48 (l_pobj) syndrome_16\NN\5870365|NONE_0
D011692_D009404 CID pan)-induced_14\VBN\0|nephrotic_13 (r_amod) syndrome_16\NN\5870365|NONE_0
D011692_D009404 CID pan_22\NNP\3101986|-_3 (r_npadvmod) induced_24\VBN\1627355|nephrotic_8|in_27 (r_amod) syndrome_26\NN\5870365|NONE_0
D011692_D011507 CID pan_28\NNP\3101986|NONE_0 (r_pobj) of_26\IN\0|a_14|single_12 (r_prep) dose_25\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treated_21\VBN\2376958|male_25|dawley_12 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_15\IN\13603305|courses_99|were_13|._79 (r_prep) studied_14\VBN\0|NONE_0 (l_nsubjpass) courses_2\NNS\883297|were_86|in_99|._178 (l_prep) of_3\IN\0|the_17|time_13 (l_pobj) excretion_6\NN\13466586|NONE_0 (l_conj) concentration_10\NN\4916342|sodium_37|,_21 (l_conj) proteinuria_12\NN\14299637|aldosterone_30|and_4
D012964_D011507 NONE sodium_5\NN\14625458|,_16|concentration_37 (r_compound) excretion_6\NN\13466586|NONE_0 (l_conj) concentration_10\NN\4916342|sodium_37|,_21 (l_conj) proteinuria_12\NN\14299637|aldosterone_30|and_4
D012964_D011507 NONE sodium_4\NN\14625458|NONE_0 (r_compound) excretion_5\NN\13466586|NONE_0 (r_pobj) of_2\IN\0|the_13|and_28|appearance_36 (r_prep) kinetics_1\NNS\6100236|comparable_76|._117 (l_conj) appearance_8\NN\4723816|the_49|of_36|and_8 (l_prep) of_9\IN\0|the_15 (l_pobj) proteinuria_10\NN\14299637|NONE_0
3615541
D000661_D006948 CID amphetamine_6\NN\3248958|-_11 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) hyperactivity_9\NN\14052403|NONE_0
D002116_D006948 NONE calcitonin_12\NN\5413241|intracerebral_14 (r_compound) injections_13\NNS\320852|NONE_0 (r_pobj) by_10\IN\0|the_52|of_37 (r_prep) antagonism_4\NN\24720|NONE_0 (l_prep) of_5\IN\0|the_15|by_37 (l_pobj) hyperactivity_9\NN\14052403|NONE_0
20084309
D008874_D000402 NONE mz_42\NNP\0|NONE_0 (r_compound) use_43\NN\407535|NONE_0 (r_pobj) by_41\IN\0|NONE_0 (r_agent) caused_40\VBN\1617192|NONE_0 (r_acl) hypoxia_39\NN\14035298|to_3 (r_pobj) due_37\JJ\5174653|was_152|;_113|patients_109|hypoxia_75|due_67|._31 (r_prep) presented_20\VBD\2137132|NONE_0 (l_prep) due_23\IN\5174653|was_85|;_46|patients_42|hypoxia_8|due_67|._98 (l_pobj) obstruction_27\NN\4341686|to_16
D008874_D009202 NONE mz_38\NNP\0|the_4 (r_compound) dose_39\NN\3740161|)_13|and_11 (r_conj) mr_34\NNP\6339416|mitral_22|(_1 (r_appos) regurgitation_32\NN\7406350|of_20|,_9 (r_conj) duration_26\NN\15113229|to_88|influence_76 (r_dobj) test_7\VB\5798043|analyses_22|were_13|._148 (l_dobj) influence_9\NN\5190804|to_12|duration_76 (l_prep) of_10\IN\0|the_14 (l_pobj) variables_13\NNS\2452|NONE_0 (l_appos) age_15\NN\4916342|the_24|clinical_20|:_2|,_37 (l_conj) sex_17\NN\13440063|,_2 (l_conj) stroke_19\UH\556313|,_2 (l_conj) mp_23\NNP\10249459|,_18 (l_amod) myocardiopathy_21\NN\14103288|(_15|)_18
D008874_D009202 NONE mz_38\NNP\0|the_4 (r_compound) dose_39\NN\3740161|)_13|and_11 (r_conj) mr_34\NNP\6339416|mitral_22|(_1 (r_appos) regurgitation_32\NN\7406350|of_20|,_9 (r_conj) duration_26\NN\15113229|to_88|influence_76 (r_dobj) test_7\VB\5798043|analyses_22|were_13|._148 (l_dobj) influence_9\NN\5190804|to_12|duration_76 (l_prep) of_10\IN\0|the_14 (l_pobj) variables_13\NNS\2452|NONE_0 (l_appos) age_15\NN\4916342|the_24|clinical_20|:_2|,_37 (l_conj) sex_17\NN\13440063|,_2 (l_conj) stroke_19\UH\556313|,_2 (l_conj) mp_23\NNP\10249459|,_18
D008874_D009202 NONE mz_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|high_11 (r_prep) doses_15\NNS\3740161|severe_32|mr_25|,_23|(_18|%_12|associated_24 (r_appos) mp_8\NNP\10249459|NONE_0
D008874_D020521 NONE mz_38\NNP\0|the_4 (r_compound) dose_39\NN\3740161|)_13|and_11 (r_conj) mr_34\NNP\6339416|mitral_22|(_1 (r_appos) regurgitation_32\NN\7406350|of_20|,_9 (r_conj) duration_26\NN\15113229|to_88|influence_76 (r_dobj) test_7\VB\5798043|analyses_22|were_13|._148 (l_dobj) influence_9\NN\5190804|to_12|duration_76 (l_prep) of_10\IN\0|the_14 (l_pobj) variables_13\NNS\2452|NONE_0 (l_appos) age_15\NN\4916342|the_24|clinical_20|:_2|,_37 (l_conj) sex_17\NN\13440063|,_2 (l_conj) stroke_19\UH\556313|,_2
D008874_D000860 CID mz_42\NNP\0|NONE_0 (r_compound) use_43\NN\407535|NONE_0 (r_pobj) by_41\IN\0|NONE_0 (r_agent) caused_40\VBN\1617192|NONE_0 (r_acl) hypoxia_39\NN\14035298|to_3 (r_pobj) due_37\JJ\5174653|was_152|;_113|patients_109|hypoxia_75|due_67|._31 (r_prep) presented_20\VBD\2137132|NONE_0 (l_dobj) hypoxia_22\NN\14035298|was_77|;_38|patients_34|due_8|due_75|._106
D008874_D000860 CID mz_42\NNP\0|NONE_0 (r_compound) use_43\NN\407535|NONE_0 (r_pobj) by_41\IN\0|NONE_0 (r_agent) caused_40\VBN\1617192|NONE_0 (r_acl) hypoxia_39\NN\14035298|to_3
D008874_D008944 NONE mz_38\NNP\0|the_4 (r_compound) dose_39\NN\3740161|)_13|and_11 (r_conj) mr_34\NNP\6339416|mitral_22|(_1 (r_appos) regurgitation_32\NN\7406350|of_20|,_9
D008874_D008944 NONE mz_38\NNP\0|the_4 (r_compound) dose_39\NN\3740161|)_13|and_11 (r_conj) mr_34\NNP\6339416|mitral_22|(_1
D008874_D008944 NONE mz_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|high_11 (r_prep) doses_15\NNS\3740161|severe_32|mr_25|,_23|(_18|%_12|associated_24 (r_appos) mp_8\NNP\10249459|NONE_0 (l_nmod) mr_6\NNP\6339416|severe_7|,_2|(_7|%_13|doses_25|associated_49
1786266
D000928_D001480 NONE antidepressant_3\NN\3740161|,_18|and_20|findings_54 (r_compound) use_4\NN\407535|rabbit_32|,_17|._47 (r_conj) syndrome_1\NN\5870365|NONE_0
15325671
D017239_D001943 NONE paclitaxel_2\NN\0|._163 (l_conj) melphalan_4\NN\2722458|combined_21|,_2 (l_conj) cyclophosphamide_9\NN\0|and_14 (l_conj) thiotepa_11\NNS\2722458|dose_23|,_2 (l_conj) carboplatin_14\VB\0|,_6|and_4 (l_dobj) regimen_22\NN\5898568|in_33 (l_prep) for_23\IN\0|a_38|triple_36|sequential_29|dose_13 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) cancer_28\NN\14239425|NONE_0
D003520_D001943 NONE cyclophosphamide_9\NN\0|-_16 (r_npadvmod) based_11\VBN\0|dose_22|for_19 (r_amod) chemotherapy_12\NN\661091|NONE_0 (l_prep) for_13\IN\0|dose_41|based_19 (l_pobj) cancer_16\NN\14239425|NONE_0
D003520_D001943 NONE cyclophosphamide_9\NN\0|and_14 (l_conj) thiotepa_11\NNS\2722458|dose_23|,_2 (l_conj) carboplatin_14\VB\0|,_6|and_4 (l_dobj) regimen_22\NN\5898568|in_33 (l_prep) for_23\IN\0|a_38|triple_36|sequential_29|dose_13 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) cancer_28\NN\14239425|NONE_0
D003520_D001943 NONE cyclophosphamide_16\NN\0|as_17 (r_dobj) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (r_acl) cancer_12\NN\14239425|NONE_0
D008558_D001943 NONE melphalan_4\NN\2722458|combined_21|,_2 (l_conj) cyclophosphamide_9\NN\0|and_14 (l_conj) thiotepa_11\NNS\2722458|dose_23|,_2 (l_conj) carboplatin_14\VB\0|,_6|and_4 (l_dobj) regimen_22\NN\5898568|in_33 (l_prep) for_23\IN\0|a_38|triple_36|sequential_29|dose_13 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) cancer_28\NN\14239425|NONE_0
D003520_D066126 NONE cyclophosphamide_9\NN\0|-_16 (r_npadvmod) based_11\VBN\0|dose_22|for_19 (r_amod) chemotherapy_12\NN\661091|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) association_4\NN\8008335|NONE_0 (r_pobj) in_3\IN\13603305|toxicity_18|._94 (r_prep) observed_2\VBD\2163746|NONE_0 (l_nsubj) toxicity_1\NN\13576101|in_18|._112
D003520_D066126 NONE cyclophosphamide_3\NN\0|-_16 (r_npadvmod) related_5\VBN\628491|transient_27|cardiac_8|(_25|%_28|)_29 (r_amod) toxicity_7\NN\13576101|NONE_0
D003520_D003920 NONE cyclophosphamide_16\NN\0|as_17 (r_dobj) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (r_acl) cancer_12\NN\14239425|NONE_0 (l_conj) characteristics_44\NNS\5849040|responsive_247|metastatic_236|breast_225|receiving_211|and_31 (l_appos) presence_46\NN\13954253|the_44|following_40|pretreatment_30|:_2 (l_appos) history_60\NN\15120823|of_75|,_16 (l_conj) smoking_62\NN\831191|prior_23|cardiac_17|,_2 (l_conj) mellitus_65\NN\0|,_11
D016190_D001943 NONE carboplatin_14\VB\0|,_6|and_4 (l_dobj) regimen_22\NN\5898568|in_33 (l_prep) for_23\IN\0|a_38|triple_36|sequential_29|dose_13 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) cancer_28\NN\14239425|NONE_0
D018943_D006973 NONE anthracyclines_70\NNS\0|NONE_0 (r_pobj) of_69\IN\0|prior_10|,_17|and_19|irradiation_40 (r_prep) use_68\NN\407535|diabetes_25|,_8 (r_conj) mellitus_65\NN\0|,_11 (r_conj) smoking_62\NN\831191|prior_23|cardiac_17|,_2 (r_conj) history_60\NN\15120823|of_75|,_16 (r_appos) presence_46\NN\13954253|the_44|following_40|pretreatment_30|:_2 (l_prep) of_47\IN\0|,_59|history_75 (l_pobj) electrocardiogram_48\NN\7000195|NONE_0 (l_appos) abnormalities_52\NNS\14034177|(_6|ekg_5 (l_appos) hypertension_56\NN\14057371|,_7|age_5
D003520_D006973 NONE cyclophosphamide_16\NN\0|as_17 (r_dobj) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (r_acl) cancer_12\NN\14239425|NONE_0 (l_conj) characteristics_44\NNS\5849040|responsive_247|metastatic_236|breast_225|receiving_211|and_31 (l_appos) presence_46\NN\13954253|the_44|following_40|pretreatment_30|:_2 (l_prep) of_47\IN\0|,_59|history_75 (l_pobj) electrocardiogram_48\NN\7000195|NONE_0 (l_appos) abnormalities_52\NNS\14034177|(_6|ekg_5 (l_appos) hypertension_56\NN\14057371|,_7|age_5
D013852_D001943 NONE thiotepa_11\NNS\2722458|dose_23|,_2 (l_conj) carboplatin_14\VB\0|,_6|and_4 (l_dobj) regimen_22\NN\5898568|in_33 (l_prep) for_23\IN\0|a_38|triple_36|sequential_29|dose_13 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) cancer_28\NN\14239425|NONE_0
D018943_D001943 NONE anthracyclines_70\NNS\0|NONE_0 (r_pobj) of_69\IN\0|prior_10|,_17|and_19|irradiation_40 (r_prep) use_68\NN\407535|diabetes_25|,_8 (r_conj) mellitus_65\NN\0|,_11 (r_conj) smoking_62\NN\831191|prior_23|cardiac_17|,_2 (r_conj) history_60\NN\15120823|of_75|,_16 (r_appos) presence_46\NN\13954253|the_44|following_40|pretreatment_30|:_2 (r_appos) characteristics_44\NNS\5849040|responsive_247|metastatic_236|breast_225|receiving_211|and_31 (r_conj) cancer_12\NN\14239425|NONE_0
D018943_D006333 NONE anthracyclines_70\NNS\0|NONE_0 (r_pobj) of_69\IN\0|prior_10|,_17|and_19|irradiation_40 (r_prep) use_68\NN\407535|diabetes_25|,_8 (r_conj) mellitus_65\NN\0|,_11 (r_conj) smoking_62\NN\831191|prior_23|cardiac_17|,_2 (r_conj) history_60\NN\15120823|of_75|,_16 (r_appos) presence_46\NN\13954253|the_44|following_40|pretreatment_30|:_2 (r_appos) characteristics_44\NNS\5849040|responsive_247|metastatic_236|breast_225|receiving_211|and_31 (r_conj) cancer_12\NN\14239425|NONE_0 (l_acl) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (l_prep) as_17\IN\14622893|cyclophosphamide_17 (l_pobj) part_18\NN\31921|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) regimen_26\NN\5898568|NONE_0 (l_acl) assess_28\VB\5220461|a_41|triple_39|sequential_32|dose_16 (l_dobj) association_29\NN\8008335|to_10 (l_prep) between_30\IN\0|NONE_0 (l_pobj) presence_31\NN\13954253|NONE_0 (l_prep) of_32\IN\0|NONE_0 (l_pobj) failure_36\NN\66216|NONE_0
D018943_D006333 NONE anthracyclines_70\NNS\0|NONE_0 (r_pobj) of_69\IN\0|prior_10|,_17|and_19|irradiation_40 (r_prep) use_68\NN\407535|diabetes_25|,_8 (r_conj) mellitus_65\NN\0|,_11 (r_conj) smoking_62\NN\831191|prior_23|cardiac_17|,_2 (r_conj) history_60\NN\15120823|of_75|,_16 (r_appos) presence_46\NN\13954253|the_44|following_40|pretreatment_30|:_2 (r_appos) characteristics_44\NNS\5849040|responsive_247|metastatic_236|breast_225|receiving_211|and_31 (r_conj) cancer_12\NN\14239425|NONE_0 (l_acl) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (l_prep) as_17\IN\14622893|cyclophosphamide_17 (l_pobj) part_18\NN\31921|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) regimen_26\NN\5898568|NONE_0 (l_acl) assess_28\VB\5220461|a_41|triple_39|sequential_32|dose_16 (l_dobj) association_29\NN\8008335|to_10 (l_prep) between_30\IN\0|NONE_0 (l_pobj) presence_31\NN\13954253|NONE_0 (l_prep) of_32\IN\0|NONE_0 (l_pobj) failure_36\NN\66216|NONE_0 (l_appos) chf_38\NNP\0|peritransplant_41|heart_15
D003520_D006333 CID cyclophosphamide_16\NN\0|as_17 (r_dobj) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (l_prep) as_17\IN\14622893|cyclophosphamide_17 (l_pobj) part_18\NN\31921|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) regimen_26\NN\5898568|NONE_0 (l_acl) assess_28\VB\5220461|a_41|triple_39|sequential_32|dose_16 (l_dobj) association_29\NN\8008335|to_10 (l_prep) between_30\IN\0|NONE_0 (l_pobj) presence_31\NN\13954253|NONE_0 (l_prep) of_32\IN\0|NONE_0 (l_pobj) failure_36\NN\66216|NONE_0
D003520_D006333 CID cyclophosphamide_16\NN\0|as_17 (r_dobj) receiving_13\VBG\2210855|responsive_36|metastatic_25|breast_14|and_180|characteristics_211 (l_prep) as_17\IN\14622893|cyclophosphamide_17 (l_pobj) part_18\NN\31921|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) regimen_26\NN\5898568|NONE_0 (l_acl) assess_28\VB\5220461|a_41|triple_39|sequential_32|dose_16 (l_dobj) association_29\NN\8008335|to_10 (l_prep) between_30\IN\0|NONE_0 (l_pobj) presence_31\NN\13954253|NONE_0 (l_prep) of_32\IN\0|NONE_0 (l_pobj) failure_36\NN\66216|NONE_0 (l_appos) chf_38\NNP\0|peritransplant_41|heart_15
D003520_D006333 CID cyclophosphamide_16\NN\0|with_17 (r_dobj) following_14\VBG\8180190|six_66|grade_12|._95 (r_prep) developed_8\VBD\1753788|NONE_0 (l_dobj) grade_11\NN\7975026|six_54|following_12|._107 (l_appos) chf_13\NNP\0|reversible_19
D003520_D006333 CID cyclophosphamide_5\NN\0|NONE_0 (r_pobj) during_3\IN\0|ekg_15 (r_prep) monitoring_2\NN\879759|did_46|not_50|development_66|._77 (r_nsubj) predict_8\VB\916909|NONE_0 (l_dobj) development_10\NN\248977|monitoring_66|did_20|not_16|._11 (l_compound) chf_9\NNP\0|NONE_0
D018943_D003920 NONE anthracyclines_70\NNS\0|NONE_0 (r_pobj) of_69\IN\0|prior_10|,_17|and_19|irradiation_40 (r_prep) use_68\NN\407535|diabetes_25|,_8 (r_conj) mellitus_65\NN\0|,_11
2802551
D000666_D007674 CID b_5\NN\1355326|chronic_21|in_17 (r_compound) nephrotoxicity_6\NN\0|status_41|._22
D000666_D007674 CID b_5\NNP\1355326|NONE_0 (r_pobj) of_3\IN\0|the_26|nephrotoxic_22 (r_prep) potential_2\NN\14481929|for_63|)_74 (l_amod) nephrotoxic_1\JJ\0|the_4|of_22
D012964_D007674 NONE sodium_0\NN\14625458|NONE_0 (r_compound) status_1\NN\24720|nephrotoxicity_41|._63 (r_nsubj) influences_2\VBZ\5190804|NONE_0 (l_dobj) nephrotoxicity_6\NN\0|status_41|._22
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN\0|that_5|metabolite_41 (r_nsubj) is_11\VBZ\0|NONE_0 (l_attr) metabolite_14\NN\20090|that_46|chloroacetaldehyde_41 (l_relcl) carried_23\VBN\1850315|an_83|important_80|of_59|,_28 (l_prep) in_25\IN\13603305|study_22|was_16|out_4 (l_pobj) order_26\NN\7168131|NONE_0 (l_acl) elucidate_28\VB\939277|NONE_0 (l_prep) in_33\IN\13603305|to_29|role_12 (l_pobj) development_35\NN\248977|NONE_0 (l_prep) of_36\IN\0|the_16 (l_pobj) cystitis_38\NN\14566129|NONE_0
C004656_D006470 CID caa_9\NNP\0|NONE_0 (r_appos) chloroacetaldehyde_7\NN\0|that_5|metabolite_41 (r_nsubj) is_11\VBZ\0|NONE_0 (l_attr) metabolite_14\NN\20090|that_46|chloroacetaldehyde_41 (l_relcl) carried_23\VBN\1850315|an_83|important_80|of_59|,_28 (l_prep) in_25\IN\13603305|study_22|was_16|out_4 (l_pobj) order_26\NN\7168131|NONE_0 (l_acl) elucidate_28\VB\939277|NONE_0 (l_prep) in_33\IN\13603305|to_29|role_12 (l_pobj) development_35\NN\248977|NONE_0 (l_prep) of_36\IN\0|the_16 (l_pobj) cystitis_38\NN\14566129|NONE_0
C004656_D006470 CID caa_32\NNP\0|NONE_0 (r_pobj) of_31\IN\0|the_9 (r_prep) role_30\NN\719494|to_17|in_12 (r_dobj) elucidate_28\VB\939277|NONE_0 (l_prep) in_33\IN\13603305|to_29|role_12 (l_pobj) development_35\NN\248977|NONE_0 (l_prep) of_36\IN\0|the_16 (l_pobj) cystitis_38\NN\14566129|NONE_0
C004656_D001745 NONE caa_4\NNP\0|that_5|after_4|administration_15|does_30|not_35|to_50 (r_nsubj) contribute_10\VB\126264|data_61|._28 (l_prep) to_11\IN\0|that_55|caa_50|after_46|administration_35|does_20|not_15 (l_pobj) damage_13\NN\7296428|NONE_0
C004656_D003556 CID chloroacetaldehyde_7\NN\0|that_5|metabolite_41 (r_nsubj) is_11\VBZ\0|NONE_0 (l_attr) metabolite_14\NN\20090|that_46|chloroacetaldehyde_41 (l_relcl) carried_23\VBN\1850315|an_83|important_80|of_59|,_28 (l_prep) in_25\IN\13603305|study_22|was_16|out_4 (l_pobj) order_26\NN\7168131|NONE_0 (l_acl) elucidate_28\VB\939277|NONE_0 (l_prep) in_33\IN\13603305|to_29|role_12 (l_pobj) development_35\NN\248977|NONE_0 (l_prep) of_36\IN\0|the_16 (l_pobj) cystitis_38\NN\14566129|NONE_0
C004656_D003556 CID caa_9\NNP\0|NONE_0 (r_appos) chloroacetaldehyde_7\NN\0|that_5|metabolite_41 (r_nsubj) is_11\VBZ\0|NONE_0 (l_attr) metabolite_14\NN\20090|that_46|chloroacetaldehyde_41 (l_relcl) carried_23\VBN\1850315|an_83|important_80|of_59|,_28 (l_prep) in_25\IN\13603305|study_22|was_16|out_4 (l_pobj) order_26\NN\7168131|NONE_0 (l_acl) elucidate_28\VB\939277|NONE_0 (l_prep) in_33\IN\13603305|to_29|role_12 (l_pobj) development_35\NN\248977|NONE_0 (l_prep) of_36\IN\0|the_16 (l_pobj) cystitis_38\NN\14566129|NONE_0
C004656_D003556 CID caa_32\NNP\0|NONE_0 (r_pobj) of_31\IN\0|the_9 (r_prep) role_30\NN\719494|to_17|in_12 (r_dobj) elucidate_28\VB\939277|NONE_0 (l_prep) in_33\IN\13603305|to_29|role_12 (l_pobj) development_35\NN\248977|NONE_0 (l_prep) of_36\IN\0|the_16 (l_pobj) cystitis_38\NN\14566129|NONE_0
11532387
D004298_D001480 NONE dopamine_26\NN\14807737|a_12 (r_compound) antagonist_27\NN\7846|,_23 (r_appos) risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D004298_D001480 NONE dopamine_26\NN\14807737|a_12 (r_compound) antagonist_27\NN\7846|,_23 (r_appos) risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_advcl) suggesting_29\VBG\1010118|mechanism_158|may_102|have_98|been_93|to_80|,_2|._90 (l_dobj) influence_32\NN\5190804|NONE_0 (l_prep) in_37\IN\13603305|the_55|pathophysiologic_51|of_24 (l_pobj) development_39\NN\248977|NONE_0 (l_prep) of_40\IN\0|the_16 (l_pobj) rs_41\NN\13635336|NONE_0
D012701_D001480 NONE serotonin_24\NN\14807737|-_9 (r_compound) dopamine_26\NN\14807737|a_12 (r_compound) antagonist_27\NN\7846|,_23 (r_appos) risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D012701_D001480 NONE serotonin_24\NN\14807737|-_9 (r_compound) dopamine_26\NN\14807737|a_12 (r_compound) antagonist_27\NN\7846|,_23 (r_appos) risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_advcl) suggesting_29\VBG\1010118|mechanism_158|may_102|have_98|been_93|to_80|,_2|._90 (l_dobj) influence_32\NN\5190804|NONE_0 (l_prep) in_37\IN\13603305|the_55|pathophysiologic_51|of_24 (l_pobj) development_39\NN\248977|NONE_0 (l_prep) of_40\IN\0|the_16 (l_pobj) rs_41\NN\13635336|NONE_0
D012701_D001480 NONE serotonin_35\NN\14807737|the_4 (r_compound) system_36\NN\3575240|NONE_0 (r_pobj) of_33\IN\0|the_31|pathophysiologic_27|in_24 (r_prep) influence_32\NN\5190804|NONE_0 (r_dobj) suggesting_29\VBG\1010118|mechanism_158|may_102|have_98|been_93|to_80|,_2|._90 (r_advcl) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D012701_D001480 NONE serotonin_35\NN\14807737|the_4 (r_compound) system_36\NN\3575240|NONE_0 (r_pobj) of_33\IN\0|the_31|pathophysiologic_27|in_24 (r_prep) influence_32\NN\5190804|NONE_0 (l_prep) in_37\IN\13603305|the_55|pathophysiologic_51|of_24 (l_pobj) development_39\NN\248977|NONE_0 (l_prep) of_40\IN\0|the_16 (l_pobj) rs_41\NN\13635336|NONE_0
D018967_D013375 CID risperidone_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|dose_15 (r_prep) reduction_7\NN\351485|NONE_0 (r_pobj) during_5\IN\0|emergent_25|rabbit_16|._36 (r_prep) syndrome_4\NN\5870365|NONE_0
D018967_D013375 CID risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D004298_D013375 NONE dopamine_26\NN\14807737|a_12 (r_compound) antagonist_27\NN\7846|,_23 (r_appos) risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D012701_D013375 NONE serotonin_24\NN\14807737|-_9 (r_compound) dopamine_26\NN\14807737|a_12 (r_compound) antagonist_27\NN\7846|,_23 (r_appos) risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D012701_D013375 NONE serotonin_35\NN\14807737|the_4 (r_compound) system_36\NN\3575240|NONE_0 (r_pobj) of_33\IN\0|the_31|pathophysiologic_27|in_24 (r_prep) influence_32\NN\5190804|NONE_0 (r_dobj) suggesting_29\VBG\1010118|mechanism_158|may_102|have_98|been_93|to_80|,_2|._90 (r_advcl) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D018967_D001480 CID risperidone_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|dose_15 (r_prep) reduction_7\NN\351485|NONE_0 (r_pobj) during_5\IN\0|emergent_25|rabbit_16|._36 (r_prep) syndrome_4\NN\5870365|NONE_0
D018967_D001480 CID risperidone_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|dose_15 (r_prep) reduction_6\NN\351485|NONE_0 (r_pobj) during_4\IN\0|patient_21|rs_3|._36 (r_prep) developed_2\VBN\1753788|NONE_0 (l_dobj) rs_3\NN\13635336|patient_18|during_3|._39
D018967_D001480 CID risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_nsubjpass) mechanism_2\NN\13446390|may_56|have_60|been_65|to_78|,_156|suggesting_158|._248 (l_prep) of_3\IN\0|the_25|underlying_21|in_26 (l_pobj) rs_7\NN\13635336|NONE_0
D018967_D001480 CID risperidone_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_28|pharmacological_24 (r_prep) profile_19\NN\6999802|NONE_0 (r_pobj) to_16\IN\0|mechanism_78|may_22|have_18|been_13|,_78|suggesting_80|._170 (r_prep) related_15\VBN\628491|NONE_0 (l_advcl) suggesting_29\VBG\1010118|mechanism_158|may_102|have_98|been_93|to_80|,_2|._90 (l_dobj) influence_32\NN\5190804|NONE_0 (l_prep) in_37\IN\13603305|the_55|pathophysiologic_51|of_24 (l_pobj) development_39\NN\248977|NONE_0 (l_prep) of_40\IN\0|the_16 (l_pobj) rs_41\NN\13635336|NONE_0
7420681
D005839_D051437 CID sulfate_25\NN\15010703|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) day_22\NN\15154774|5_8|mg_6|/_4|/_1 (r_appos) kg_20\NNS\13717155|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|62_61|with_49|and_4 (r_conj) patients_5\NNS\9898892|in_18|,_5|were_160|up_174|prospectively_177|for_191|._311 (r_nsubjpass) followed_36\VBN\1835496|NONE_0 (l_prep) for_39\IN\0|in_209|,_196|patients_191|were_31|up_17|prospectively_14|._120 (l_pobj) development_41\NN\248977|NONE_0 (l_prep) of_42\IN\0|the_16 (l_pobj) failure_47\NN\66216|NONE_0
D005839_D051437 CID gentamicin_23\NN\2716866|-_10 (r_npadvmod) treated_25\VBN\2376958|the_15 (r_amod) patients_26\NNS\9898892|NONE_0 (r_pobj) of_21\IN\0|of_14|%_3|)_2 (r_prep) 16_14\CD\13745420|five_56|failure_62|._69 (r_nsubj) had_27\VBD\0|NONE_0 (l_dobj) failure_29\NN\66216|five_118|16_62|._7
D005839_D051437 CID gentamicin_2\NN\2716866|thus_6|,_2|was_11|with_26|was_79|._93 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|thus_32|,_28|gentamicin_26|was_15|was_53|._67 (l_pobj) failure_7\NN\66216|NONE_0
D014031_D007674 NONE tobramycin_3\JJ\2716866|NONE_0 (r_pobj) of_2\IN\0|clinical_24|and_14|gentamicin_18|._28 (r_prep) nephrotoxicity_1\NN\0|NONE_0
D014031_D007674 NONE sulfate_4\NN\15010703|gentamicin_34|and_15 (r_conj) sulfate_1\NN\15010703|demonstrate_43|._121 (r_nsubj) continue_5\VBP\2367363|NONE_0 (l_xcomp) demonstrate_7\VB\2137132|sulfate_43|._78 (l_dobj) ototoxicity_8\NN\0|to_15 (l_conj) nephrotoxicity_10\NN\0|and_4|in_15
D005839_D007674 NONE gentamicin_5\NN\2716866|clinical_42|of_18|and_4|._10 (r_conj) nephrotoxicity_1\NN\0|NONE_0
D005839_D007674 NONE sulfate_1\NN\15010703|demonstrate_43|._121 (r_nsubj) continue_5\VBP\2367363|NONE_0 (l_xcomp) demonstrate_7\VB\2137132|sulfate_43|._78 (l_dobj) ototoxicity_8\NN\0|to_15 (l_conj) nephrotoxicity_10\NN\0|and_4|in_15
D014031_D006311 NONE sulfate_4\NN\15010703|gentamicin_34|and_15 (r_conj) sulfate_1\NN\15010703|demonstrate_43|._121 (r_nsubj) continue_5\VBP\2367363|NONE_0 (l_xcomp) demonstrate_7\VB\2137132|sulfate_43|._78 (l_dobj) ototoxicity_8\NN\0|to_15
D005839_D006311 NONE sulfate_1\NN\15010703|demonstrate_43|._121 (r_nsubj) continue_5\VBP\2367363|NONE_0 (l_xcomp) demonstrate_7\VB\2137132|sulfate_43|._78 (l_dobj) ototoxicity_8\NN\0|to_15
D000617_D051437 NONE aminoglycoside_43\NN\0|-_14 (r_npadvmod) related_45\VBN\628491|renal_8|,_21|defined_23 (r_amod) failure_47\NN\66216|NONE_0
D014031_D051437 CID sulfate_28\NN\15010703|gentamicin_33|or_14|for_8 (r_conj) sulfate_25\NN\15010703|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) day_22\NN\15154774|5_8|mg_6|/_4|/_1 (r_appos) kg_20\NNS\13717155|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|62_61|with_49|and_4 (r_conj) patients_5\NNS\9898892|in_18|,_5|were_160|up_174|prospectively_177|for_191|._311 (r_nsubjpass) followed_36\VBN\1835496|NONE_0 (l_prep) for_39\IN\0|in_209|,_196|patients_191|were_31|up_17|prospectively_14|._120 (l_pobj) development_41\NN\248977|NONE_0 (l_prep) of_42\IN\0|the_16 (l_pobj) failure_47\NN\66216|NONE_0
D014031_D051437 CID tobramycin_9\RB\2716866|-_10 (r_npadvmod) treated_11\VBN\2376958|the_15 (r_amod) patients_12\NNS\9898892|NONE_0 (r_pobj) of_7\IN\0|33_9|(_6|15_5|)_2|and_35 (r_prep) %_5\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) five_0\CD\13741022|16_56|failure_118|._125 (r_nsubj) had_27\VBD\0|NONE_0 (l_dobj) failure_29\NN\66216|five_118|16_62|._7
D014031_D051437 CID tobramycin_16\JJ\2716866|often_13|as_7 (r_acomp) was_15\VBD\0|thus_85|,_81|gentamicin_79|was_68|with_53|._14 (r_advcl) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|thus_32|,_28|gentamicin_26|was_15|was_53|._67 (l_pobj) failure_7\NN\66216|NONE_0
12905102
D003024_D003693 CID clozapine_2\NN\3713736|NONE_0 (r_amod) treatment_3\NN\654885|NONE_0 (r_pobj) during_1\IN\0|:_26|factors_58|._65 (r_prep) delirium_0\NN\14391660|NONE_0
D003024_D003693 CID clozapine_7\NN\3713736|NONE_0 (r_compound) treatment_8\NN\654885|NONE_0 (r_pobj) during_6\IN\0|incidence_40|for_13 (r_prep) factors_3\NNS\7326557|clarification_64|._77 (l_prep) for_4\IN\0|incidence_27|during_13 (l_pobj) delirium_5\NN\14391660|NONE_0
D003024_D003693 CID clozapine_13\NN\3713736|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|all_33|adult_29|psychiatric_23 (r_acl) inpatients_10\NNS\10405694|to_34 (r_dobj) identify_6\VB\699815|we_41|records_11|,_74|reviewed_76|._203 (r_xcomp) used_1\VBD\0|NONE_0 (l_conj) reviewed_20\VBD\644583|we_117|records_87|identify_76|,_2|._127 (l_advcl) score_25\VB\5736149|records_11|,_40|and_42|tested_46 (l_dobj) incidence_26\NN\13821570|to_9 (l_prep) of_29\IN\0|and_13|severity_9 (l_pobj) delirium_30\NN\14391660|NONE_0
D003024_D003693 CID clozapine_7\NN\3713736|-_9 (r_npadvmod) treated_9\VBN\2376958|NONE_0 (r_amod) inpatients_10\NNS\10405694|NONE_0 (r_pobj) of_6\IN\0|10_5 (r_prep) %_5\NN\0|NONE_0 (r_pobj) in_3\IN\13603305|delirium_19|was_10|,_39|in_54|._113 (r_prep) found_2\VBN\13279262|NONE_0 (l_nsubjpass) delirium_0\NNP\14391660|was_9|in_19|,_58|in_73|._132
D003024_D001523 NONE clozapine_13\NN\3713736|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|all_33|adult_29|psychiatric_23 (r_acl) inpatients_10\NNS\10405694|to_34 (l_amod) psychiatric_9\JJ\0|all_10|adult_6|treated_23
8864707
D010672_D004827 NONE phenytoin_10\NNP\3550533|NONE_0 (r_compound) overdosages_11\NNS\0|NONE_0 (r_pobj) after_9\IN\0|resonance_60|of_40|in_22|._27 (r_prep) volumetry_2\NN\0|NONE_0 (l_prep) in_6\IN\13603305|resonance_38|of_18|after_22|._49 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_amod) epileptic_7\JJ\10595647|NONE_0
D010672_D062787 CID phenytoin_10\NNP\3550533|NONE_0 (r_compound) overdosages_11\NNS\0|NONE_0
D010672_D062787 CID phenytoin_3\JJ\3550533|NONE_0 (r_compound) overdosage_4\NN\0|that_15|does_11|not_16|necessarily_20|in_39|and_61|is_68
D010672_D062787 CID phenytoin_17\JJ\3550533|NONE_0 (r_compound) medication_18\NN\3247620|that_15|cause_24 (r_nsubj) was_19\VBD\0|it_41|unlikely_35 (r_ccomp) is_14\VBZ\0|that_83|overdosage_68|does_57|not_52|necessarily_48|in_29|and_7 (r_conj) result_8\VB\34213|we_59|._140 (l_nsubj) overdosage_4\NN\0|that_15|does_11|not_16|necessarily_20|in_39|and_61|is_68
D010672_D012640 NONE phenytoin_15\JJ\3550533|serum_10|and_23|volume_38 (r_compound) levels_17\NNS\4916342|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) elevation_13\NN\7445480|seizure_18|,_2 (r_conj) duration_11\NN\15113229|NONE_0 (l_compound) seizure_10\NN\14081375|,_16|elevation_18
D010672_D002526 NONE phenytoin_11\JJ\3550533|and_21|atrophy_36 (r_compound) medication_12\NN\3247620|NONE_0 (l_conj) atrophy_15\NN\14299637|phenytoin_36|and_15
D010672_D002526 NONE phenytoin_3\JJ\3550533|NONE_0 (r_compound) overdosage_4\NN\0|that_15|does_11|not_16|necessarily_20|in_39|and_61|is_68 (r_nsubj) result_8\VB\34213|we_59|._140 (l_prep) in_9\IN\13603305|that_54|overdosage_39|does_28|not_23|necessarily_19|and_22|is_29 (l_pobj) atrophy_11\NN\14299637|NONE_0
D010672_D002526 NONE phenytoin_3\JJ\3550533|NONE_0 (r_compound) overdosage_4\NN\0|that_15|does_11|not_16|necessarily_20|in_39|and_61|is_68 (r_nsubj) result_8\VB\34213|we_59|._140 (l_conj) is_14\VBZ\0|that_83|overdosage_68|does_57|not_52|necessarily_48|in_29|and_7 (l_ccomp) was_19\VBD\0|it_41|unlikely_35 (l_attr) cause_22\NN\7323922|that_39|medication_24 (l_prep) of_23\IN\0|the_15|only_11 (l_pobj) atrophy_25\NN\14299637|NONE_0
D010672_D002526 NONE phenytoin_17\JJ\3550533|NONE_0 (r_compound) medication_18\NN\3247620|that_15|cause_24 (r_nsubj) was_19\VBD\0|it_41|unlikely_35 (r_ccomp) is_14\VBZ\0|that_83|overdosage_68|does_57|not_52|necessarily_48|in_29|and_7 (r_conj) result_8\VB\34213|we_59|._140 (l_prep) in_9\IN\13603305|that_54|overdosage_39|does_28|not_23|necessarily_19|and_22|is_29 (l_pobj) atrophy_11\NN\14299637|NONE_0
D010672_D002526 NONE phenytoin_17\JJ\3550533|NONE_0 (r_compound) medication_18\NN\3247620|that_15|cause_24 (r_nsubj) was_19\VBD\0|it_41|unlikely_35 (l_attr) cause_22\NN\7323922|that_39|medication_24 (l_prep) of_23\IN\0|the_15|only_11 (l_pobj) atrophy_25\NN\14299637|NONE_0
8372922
20003049
C031942_D013921 NONE argatroban_4\NN\0|NONE_0 (l_prep) in_5\IN\13603305|elevation_31|._108 (l_pobj) patient_9\NN\9898892|NONE_0 (l_prep) with_10\IN\0|a_29|transplant_19 (l_pobj) history_13\NN\15120823|NONE_0 (l_prep) of_14\IN\0|a_20|suspected_18 (l_pobj) thrombocytopenia_18\NN\14189204|NONE_0
C031942_D013921 NONE argatroban_20\NN\0|in_112|,_89|patient_58|was_17|during_41|._69 (r_oprd) administered_19\VBN\2436349|NONE_0 (l_nsubjpass) patient_11\JJ\9898892|in_54|,_31|was_41|argatroban_58|during_99|._127 (l_prep) with_12\IN\0|a_37|old_27|ill_12 (l_pobj) history_15\NN\15120823|NONE_0 (l_prep) of_16\IN\0|a_20|suspected_18 (l_pobj) hitt_17\NNP\0|NONE_0
C031942_D013927 NONE argatroban_4\NN\0|NONE_0 (l_prep) in_5\IN\13603305|elevation_31|._108 (l_pobj) patient_9\NN\9898892|NONE_0 (l_prep) with_10\IN\0|a_29|transplant_19 (l_pobj) history_13\NN\15120823|NONE_0 (l_prep) of_14\IN\0|a_20|suspected_18 (l_pobj) thrombocytopenia_18\NN\14189204|NONE_0 (l_prep) with_19\IN\0|induced_25 (l_pobj) thrombosis_20\NN\14100769|NONE_0
C031942_D013927 NONE argatroban_20\NN\0|in_112|,_89|patient_58|was_17|during_41|._69 (r_oprd) administered_19\VBN\2436349|NONE_0 (l_nsubjpass) patient_11\JJ\9898892|in_54|,_31|was_41|argatroban_58|during_99|._127 (l_prep) with_12\IN\0|a_37|old_27|ill_12 (l_pobj) history_15\NN\15120823|NONE_0 (l_prep) of_16\IN\0|a_20|suspected_18 (l_pobj) hitt_17\NNP\0|NONE_0
C031942_D008107 NONE argatroban_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|high_20 (r_prep) concentrations_2\NNS\4916342|were_29|in_43|,_83|and_85|observed_157|is_196|._258 (r_nsubjpass) measured_6\VBN\697589|NONE_0 (l_conj) is_42\VBZ\0|concentrations_196|were_167|in_153|,_113|and_111|observed_39|._62 (l_attr) minutes_46\NNS\6502378|)_52 (l_appos) minutes_52\NNS\6502378|39_26|51_23|[_12|]_31 (l_prep) with_53\IN\0|<_19|=_14|181_12 (l_pobj) impairment_55\NN\7296428|NONE_0
C031942_D008107 NONE argatroban_25\JJ\0|half_11|t(1/2_22 (r_amod) life_27\NN\13954253|a_35|prolonged_33|)_12|of_14 (r_npadvmod) plasma_24\NN\5398023|was_52|published_66 (r_nsubjpass) observed_36\VBN\2163746|concentrations_157|were_128|in_114|,_74|and_72|is_39|._101 (r_conj) measured_6\VBN\697589|NONE_0 (l_conj) is_42\VBZ\0|concentrations_196|were_167|in_153|,_113|and_111|observed_39|._62 (l_attr) minutes_46\NNS\6502378|)_52 (l_appos) minutes_52\NNS\6502378|39_26|51_23|[_12|]_31 (l_prep) with_53\IN\0|<_19|=_14|181_12 (l_pobj) impairment_55\NN\7296428|NONE_0
C031942_D001778 NONE argatroban_3\JJ\0|correlation_22|versus_25 (r_amod) concentration_4\NN\4916342|contributed_146|._196 (r_nsubj) suggest_14\VBP\1010118|NONE_0 (l_ccomp) contributed_24\VBN\126264|concentration_146|._50 (l_prep) to_25\IN\0|that_73|levels_49|may_21|have_17 (l_pobj) coagulopathy_30\NN\0|NONE_0
C031942_D001778 NONE argatroban_21\NN\0|prolonged_36|elevated_26|of_10 (r_amod) levels_18\NNS\4916342|that_24|may_28|have_32|to_49 (r_nsubj) contributed_24\VBN\126264|concentration_146|._50 (l_prep) to_25\IN\0|that_73|levels_49|may_21|have_17 (l_pobj) coagulopathy_30\NN\0|NONE_0
C031942_D001778 NONE argatroban_8\JJ\0|in_25 (r_amod) concentration_9\NN\4916342|to_29|plasma_18|and_36|extended_40 (r_dobj) measure_6\VB\168237|the_20|first_16 (l_conj) extended_16\VBN\153263|to_69|plasma_58|concentration_40|and_4 (l_dobj) coagulopathy_17\NN\0|NONE_0
C031942_D016638 NONE argatroban_20\NN\0|in_112|,_89|patient_58|was_17|during_41|._69 (r_oprd) administered_19\VBN\2436349|NONE_0 (l_nsubjpass) patient_11\JJ\9898892|in_54|,_31|was_41|argatroban_58|during_99|._127 (l_amod) ill_10\JJ\14052403|a_25|old_15|with_12
D006493_D013927 NONE heparin_15\NN\2718259|-_7 (r_npadvmod) induced_17\VBN\1627355|with_25 (r_amod) thrombocytopenia_18\NN\14189204|NONE_0 (l_prep) with_19\IN\0|induced_25 (l_pobj) thrombosis_20\NN\14100769|NONE_0
D006493_D013927 NONE heparin_18\NN\2718259|-_7 (r_npadvmod) induced_20\VBN\1627355|(_25|hit_26 (r_amod) thrombocytopenia_21\NN\14189204|NONE_0 (r_pobj) of_17\IN\0|a_10 (r_prep) history_16\NN\15120823|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) for_12\IN\0|NONE_0 (r_prep) anticoagulation_11\NN\657604|NONE_0 (r_pobj) of_10\IN\0|an_22|alternative_19 (r_prep) method_9\NN\5616786|inhibitors_41|or_96|hit_99|._165 (r_dobj) provide_6\VBP\2199590|NONE_0 (l_conj) hit_26\VB\36762|inhibitors_140|method_99|or_3|._66 (l_prep) with_27\IN\0|undergoing_23 (l_pobj) thrombosis_28\NN\14100769|NONE_0
D006493_D013927 NONE heparin_18\NN\2718259|-_7 (r_npadvmod) induced_20\VBN\1627355|(_25|hit_26 (r_amod) thrombocytopenia_21\NN\14189204|NONE_0 (r_pobj) of_17\IN\0|a_10 (r_prep) history_16\NN\15120823|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) for_12\IN\0|NONE_0 (r_prep) anticoagulation_11\NN\657604|NONE_0 (r_pobj) of_10\IN\0|an_22|alternative_19 (r_prep) method_9\NN\5616786|inhibitors_41|or_96|hit_99|._165 (r_dobj) provide_6\VBP\2199590|NONE_0 (l_conj) hit_26\VB\36762|inhibitors_140|method_99|or_3|._66 (l_prep) with_27\IN\0|undergoing_23 (l_pobj) thrombosis_28\NN\14100769|NONE_0 (l_appos) hitt_30\NNP\0|NONE_0
D006493_D013921 NONE heparin_15\NN\2718259|-_7 (r_npadvmod) induced_17\VBN\1627355|with_25 (r_amod) thrombocytopenia_18\NN\14189204|NONE_0
D006493_D013921 NONE heparin_18\NN\2718259|-_7 (r_npadvmod) induced_20\VBN\1627355|(_25|hit_26 (r_amod) thrombocytopenia_21\NN\14189204|NONE_0
D006493_D013921 NONE heparin_18\NN\2718259|-_7 (r_npadvmod) induced_20\VBN\1627355|(_25|hit_26 (r_amod) thrombocytopenia_21\NN\14189204|NONE_0 (l_appos) hit_23\NNP\36762|induced_26|(_1
D006493_D013921 NONE heparin_18\NN\2718259|-_7 (r_npadvmod) induced_20\VBN\1627355|(_25|hit_26 (r_amod) thrombocytopenia_21\NN\14189204|NONE_0 (r_pobj) of_17\IN\0|a_10 (r_prep) history_16\NN\15120823|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) for_12\IN\0|NONE_0 (r_prep) anticoagulation_11\NN\657604|NONE_0 (r_pobj) of_10\IN\0|an_22|alternative_19 (r_prep) method_9\NN\5616786|inhibitors_41|or_96|hit_99|._165 (r_dobj) provide_6\VBP\2199590|NONE_0 (l_conj) hit_26\VB\36762|inhibitors_140|method_99|or_3|._66
D006493_D013921 NONE heparin_18\NN\2718259|-_7 (r_npadvmod) induced_20\VBN\1627355|(_25|hit_26 (r_amod) thrombocytopenia_21\NN\14189204|NONE_0 (r_pobj) of_17\IN\0|a_10 (r_prep) history_16\NN\15120823|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) patients_13\NNS\9898892|NONE_0 (r_pobj) for_12\IN\0|NONE_0 (r_prep) anticoagulation_11\NN\657604|NONE_0 (r_pobj) of_10\IN\0|an_22|alternative_19 (r_prep) method_9\NN\5616786|inhibitors_41|or_96|hit_99|._165 (r_dobj) provide_6\VBP\2199590|NONE_0 (l_conj) hit_26\VB\36762|inhibitors_140|method_99|or_3|._66 (l_prep) with_27\IN\0|undergoing_23 (l_pobj) thrombosis_28\NN\14100769|NONE_0 (l_appos) hitt_30\NNP\0|NONE_0
17111419
D002125_C536214 NONE gluconate_5\NN\0|NONE_0 (r_pobj) with_2\IN\0|empirical_20 (r_prep) treatment_1\NN\654885|was_45|,_58|and_60|subsided_91 (r_nsubjpass) initiated_7\VBN\1617192|NONE_0 (l_conj) subsided_13\VBD\223500|treatment_91|was_46|,_33|and_31 (l_nsubj) contractions_11\NNS\358931|slowly_13|over_29|._64
D002034_D006996 NONE bumetanide_9\NN\0|that_5|loop_16 (r_nsubj) is_10\VBZ\0|upon_69|,_31|it_29|was_26|._58 (l_attr) loop_12\NN\3323703|that_21|bumetanide_16 (l_relcl) cause_16\VB\7323922|a_25|diuretic_18 (l_dobj) hypocalcemia_18\NN\14299637|that_27|may_22
D002118_D006996 NONE calcium_9\NN\14625458|NONE_0 (r_compound) chelation_10\NN\29677|NONE_0 (r_pobj) to_8\IN\0|a_18|severe_16|by_21|resulting_53 (r_prep) reaction_7\NN\13446390|NONE_0 (l_acl) resulting_15\VBG\2633881|a_71|severe_69|to_53|by_32 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) hypocalcemia_19\NN\14299637|NONE_0
D049994_D006996 NONE diuretic_13\NN\3247620|a_7|cause_18 (r_amod) loop_12\NN\3323703|that_21|bumetanide_16 (l_relcl) cause_16\VB\7323922|a_25|diuretic_18 (l_dobj) hypocalcemia_18\NN\14299637|that_27|may_22
C102006_D064420 NONE citrate_1\JJ\14850483|severe_7 (r_compound) toxicity_2\NN\13576101|donation_51|._59
C102006_D064420 NONE citrate_6\JJ\14850483|severe_7 (r_compound) toxicity_7\NN\13576101|NONE_0
C102006_D064420 NONE citrate_22\JJ\14850483|NONE_0 (r_compound) toxicity_23\NN\13576101|NONE_0
C102006_D006996 CID citrate_13\NN\14850483|NONE_0 (r_compound) anticoagulant_14\NN\3740161|NONE_0 (r_pobj) by_11\IN\0|a_39|severe_37|to_21|resulting_32 (r_prep) reaction_7\NN\13446390|NONE_0 (l_acl) resulting_15\VBG\2633881|a_71|severe_69|to_53|by_32 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) hypocalcemia_19\NN\14299637|NONE_0
C102006_D006996 CID citrate_22\JJ\14850483|NONE_0 (r_compound) toxicity_23\NN\13576101|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_pcomp) due_20\IN\5174653|severe_17 (r_amod) reactions_19\NNS\13446390|NONE_0 (r_dobj) prevent_17\VB\0|to_8 (r_xcomp) help_16\VB\407535|that_112|screening_99|is_18 (r_xcomp) recommended_14\VBN\875394|we_109|._68 (l_nsubjpass) screening_4\NN\6887726|that_13|is_81|help_99 (l_prep) for_5\IN\0|careful_18 (l_pobj) medications_6\NNS\3247620|NONE_0 (l_conj) conditions_9\NNS\14512817|and_15 (l_acl) predisposing_10\VBG\680841|underlying_22 (l_prep) to_11\IN\0|NONE_0 (l_pobj) hypocalcemia_12\NN\14299637|NONE_0
2070391
D008012_D010146 CID lidocaine_6\NN\3681148|as_10 (r_dobj) using_4\VBG\418025|in_18|._77 (r_acl) reduction_0\NN\351485|NONE_0 (l_prep) in_1\IN\13603305|using_18|._95 (l_pobj) pain_3\NN\14299637|NONE_0
D008012_D010146 CID lidocaine_11\NN\3681148|NONE_0 (r_pobj) of_10\IN\0|the_14 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|NONE_0 (r_acl) pain_5\NN\14299637|that_5|is_48|to_59
D008012_D010146 CID lidocaine_14\NN\3681148|NONE_0 (r_pobj) of_13\IN\0|the_7 (r_prep) ph_12\NN\5038959|to_14|into_16 (r_dobj) adjust_10\VB\126264|a_24|buffering_22 (r_relcl) solution_8\NN\14586258|NONE_0 (r_pobj) of_5\IN\0|the_13 (r_prep) addition_4\NN\3081021|if_7|would_90|pain_103|during_108 (r_nsubj) reduce_20\VB\441445|to_116 (l_dobj) pain_21\NN\14299637|if_110|addition_103|would_13|during_5
D008012_D010146 CID lidocaine_13\NN\3681148|in_10|and_30|lidocaine_43 (r_dobj) receiving_11\VBG\2210855|NONE_0 (r_pcomp) after_10\IN\0|to_33|severity_17 (r_prep) quantify_5\VB\947077|patients_23|were_14|._136 (l_dobj) severity_7\NN\5036394|to_16|after_17 (l_prep) of_8\IN\0|the_13 (l_pobj) pain_9\NN\14299637|NONE_0
D008012_D010146 CID lidocaine_20\NN\3681148|lidocaine_43|in_33|and_13 (r_conj) receiving_11\VBG\2210855|NONE_0 (r_pcomp) after_10\IN\0|to_33|severity_17 (r_prep) quantify_5\VB\947077|patients_23|were_14|._136 (l_dobj) severity_7\NN\5036394|to_16|after_17 (l_prep) of_8\IN\0|the_13 (l_pobj) pain_9\NN\14299637|NONE_0
D008012_D010146 CID lidocaine_6\NN\3681148|NONE_0 (r_pobj) for_4\IN\0|the_20|mean_16|pain_11 (r_prep) score_3\NN\5736149|lower_47|._135 (l_compound) pain_2\NN\14299637|the_9|mean_5|for_11
D008012_D010146 CID lidocaine_16\NN\3681148|NONE_0 (r_pobj) for_14\IN\0|the_15|mean_11|(_23|+/-_28|,_51|p_53|)_61 (r_prep) score_13\NN\5736149|NONE_0 (r_pobj) than_10\IN\0|significantly_20 (r_prep) lower_9\JJR\2831724|score_47|._88 (r_acomp) was_7\VBD\0|NONE_0 (l_nsubj) score_3\NN\5736149|lower_47|._135 (l_compound) pain_2\NN\14299637|the_9|mean_5|for_11
D008012_D010146 CID lidocaine_5\NN\3681148|NONE_0 (r_pobj) of_3\IN\0|the_18|ph_14 (r_prep) adjustment_2\NN\7357388|can_33|be_37|easily_53|in_60|._194 (r_nsubjpass) accomplished_8\VBN\484166|NONE_0 (l_prep) in_10\IN\13603305|adjustment_60|can_27|be_23|easily_7|._134 (l_pobj) laboratory_13\NN\4602044|NONE_0 (l_prep) before_14\IN\0|the_31|catheterization_27 (l_pobj) injection_15\NN\320852|NONE_0 (l_prep) in_18\IN\13603305|and_12|results_8 (l_pobj) reduction_20\NN\351485|NONE_0 (l_prep) of_21\IN\0|a_12 (l_pobj) pain_23\NN\14299637|NONE_0
2611118
D004008_D056486 CID diclofenac_23\NNP\0|NONE_0 (r_pobj) by_22\IN\0|,_42|commonly_35|,_27|hepatitis_18|._13 (r_agent) induced_21\VBN\1627355|tolerated_112|,_103|abnormalities_88|have_56|been_51|and_37 (r_conj) recorded_13\VBN\2225492|NONE_0 (l_nsubjpass) abnormalities_7\NNS\14034177|tolerated_24|,_15|have_32|been_37|and_51|induced_88 (l_prep) of_8\IN\0|asymptomatic_27 (l_pobj) function_10\NN\13783581|NONE_0
D004008_D056486 CID diclofenac_23\NNP\0|NONE_0 (r_pobj) by_22\IN\0|,_42|commonly_35|,_27|hepatitis_18|._13 (r_agent) induced_21\VBN\1627355|tolerated_112|,_103|abnormalities_88|have_56|been_51|and_37 (l_nsubj) hepatitis_20\NN\14127211|,_24|commonly_17|,_9|by_18|._31
D004008_D006521 NONE sodium_6\NN\14625458|diclofenac_11 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|chronic_25|active_17|._41 (r_acl) hepatitis_2\NN\14127211|NONE_0
D004008_D006521 NONE sodium_13\NN\14625458|NONE_0 (r_pobj) with_11\IN\0|months_15|progressed_29 (r_prep) therapy_10\NN\657604|NONE_0 (r_pobj) after_7\IN\0|patient_53|hepatitis_10|,_99|finding_103|._134 (r_prep) developed_3\VBD\1753788|NONE_0 (l_dobj) hepatitis_6\NN\14127211|patient_43|after_10|,_109|finding_113|._144
2484011
D002395_D011596 NONE catecholamine_18\NN\5407119|turnover_14|and/or_28|metabolism_35 (r_compound) rate_20\NN\13815152|NONE_0 (r_pobj) of_17\IN\0|a_20|probable_18|by_49|and_70|increase_86 (r_prep) decrease_16\NN\7296428|results_75|._224 (l_conj) increase_29\NN\13576355|a_106|probable_104|of_86|by_37|and_16 (l_relcl) account_38\VB\6647206|a_66|resulting_64|in_45 (l_prep) for_39\IN\0|which_18|may_12 (l_pobj) depression_42\NN\14373582|NONE_0
D000547_D011596 CID amantadine_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) readministration_0\NN\0|,_30|after_32|,_66|motility_78|from_87|in_118|with_133|._205 (r_nsubj) increased_12\VBN\169651|NONE_0 (l_prep) with_21\IN\0|readministration_133|,_103|after_101|,_67|motility_55|from_46|in_15|._72 (l_pobj) exception_22\NN\5706954|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) mice_28\NNS\2329401|NONE_0 (l_relcl) occurred_33\VBD\0|the_46|c_37 (l_nsubj) suppression_30\NN\13489037|where_6 (l_prep) of_31\IN\0|NONE_0 (l_pobj) motility_32\NN\4773351|NONE_0
D000547_D011596 CID amantadine_45\NN\0|NONE_0 (r_pobj) by_44\IN\0|in_14 (r_agent) caused_43\VBN\1617192|a_24|behavioral_22 (r_acl) depression_42\NN\14373582|NONE_0
D000588_D011596 NONE amines_6\NNS\14951377|NONE_0 (r_pobj) of_3\IN\0|the_24|biochemical_20 (r_prep) results_2\NNS\34213|decrease_75|._299 (r_nsubj) suggest_13\VBP\1010118|NONE_0 (l_dobj) decrease_16\NN\7296428|results_75|._224 (l_conj) increase_29\NN\13576355|a_106|probable_104|of_86|by_37|and_16 (l_relcl) account_38\VB\6647206|a_66|resulting_64|in_45 (l_prep) for_39\IN\0|which_18|may_12 (l_pobj) depression_42\NN\14373582|NONE_0
D009638_D011596 NONE norepinephrine_35\NN\14807929|NONE_0 (r_pobj) of_34\IN\0|o_14|-_13 (r_prep) methylation_33\NN\0|NONE_0 (r_pobj) in_30\IN\13603305|a_21|resulting_19|account_45 (r_prep) increase_29\NN\13576355|a_106|probable_104|of_86|by_37|and_16 (l_relcl) account_38\VB\6647206|a_66|resulting_64|in_45 (l_prep) for_39\IN\0|which_18|may_12 (l_pobj) depression_42\NN\14373582|NONE_0
D000547_D003866 NONE amantadine_4\JJ\0|depressed_11|locomotor_21 (r_nmod) activity_7\NN\30358|NONE_0 (l_amod) depressed_5\JJ\1819147|amantadine_11|locomotor_10
9754849
D003932_D002819 NONE heroine_30\NN\5929008|previously_19 (r_dobj) abusing_29\VBG\2514187|an_24 (r_acl) inpatient_27\NN\10405694|NONE_0 (r_pobj) in_25\IN\13603305|rapid_71|to_54 (r_prep) adjustment_15\NN\7357388|NONE_0 (r_pobj) by_13\IN\0|both_25|transiently_20 (r_agent) induced_12\VBN\1627355|movements_27 (r_xcomp) choreoathetoid_8\JJ\0|this_38|report_23|and_4|._178 (l_dobj) movements_9\NNS\191142|induced_27
D003042_D002819 CID cocaine_12\NN\3492717|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) intoxications_10\NNS\14034177|NONE_0 (r_pobj) during_9\IN\0|to_40|abnormalities_14 (r_prep) be_5\VB\14625458|hyperkinesias_27|are_13|._86 (r_xcomp) known_3\VBN\0|NONE_0 (l_nsubjpass) hyperkinesias_1\NNS\0|are_14|be_27|._113
D003042_D002819 CID cocaine_32\NN\3492717|and_4 (r_conj) heroine_30\NN\5929008|previously_19 (r_dobj) abusing_29\VBG\2514187|an_24 (r_acl) inpatient_27\NN\10405694|NONE_0 (r_pobj) in_25\IN\13603305|rapid_71|to_54 (r_prep) adjustment_15\NN\7357388|NONE_0 (r_pobj) by_13\IN\0|both_25|transiently_20 (r_agent) induced_12\VBN\1627355|movements_27 (r_xcomp) choreoathetoid_8\JJ\0|this_38|report_23|and_4|._178 (l_dobj) movements_9\NNS\191142|induced_27
D008691_D002819 CID methadone_7\NN\3808564|NONE_0 (r_pobj) to_6\IN\0|rapid_17 (r_prep) adjustment_5\NN\7357388|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|choreoathetoid_25|._45 (r_acl) movements_1\NNS\191142|NONE_0
D008691_D002819 CID methadone_24\NN\3808564|NONE_0 (r_pobj) to_16\IN\0|rapid_17|in_54 (r_prep) adjustment_15\NN\7357388|NONE_0 (r_pobj) by_13\IN\0|both_25|transiently_20 (r_agent) induced_12\VBN\1627355|movements_27 (r_xcomp) choreoathetoid_8\JJ\0|this_38|report_23|and_4|._178 (l_dobj) movements_9\NNS\191142|induced_27
D003042_D020820 NONE cocaine_12\NN\3492717|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) intoxications_10\NNS\14034177|NONE_0 (r_pobj) during_9\IN\0|to_40|abnormalities_14 (r_prep) be_5\VB\14625458|hyperkinesias_27|are_13|._86 (l_attr) abnormalities_8\NNS\14034177|to_26|during_14
D003042_D006948 CID cocaine_12\NN\3492717|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) intoxications_10\NNS\14034177|NONE_0 (r_pobj) during_9\IN\0|to_40|abnormalities_14 (r_prep) be_5\VB\14625458|hyperkinesias_27|are_13|._86 (r_xcomp) known_3\VBN\0|NONE_0 (l_nsubjpass) hyperkinesias_1\NNS\0|are_14|be_27|._113
354896
D008012_D003866 NONE lidocaine_8\NN\3681148|NONE_0 (r_pobj) of_7\IN\0|a_21|single_19|50-mg_12|in_13 (r_prep) bolus_6\NN\13899404|NONE_0 (r_pobj) of_2\IN\0|intravenous_27 (r_prep) administration_1\NN\1133281|in_82|._176 (r_nsubj) resulted_15\VBD\2633881|NONE_0 (l_prep) in_16\IN\13603305|administration_82|._94 (l_pobj) depression_18\NN\14373582|NONE_0
D008012_D006323 CID lidocaine_0\NN\3681148|-_9 (r_npadvmod) induced_2\VBN\1627355|cardiac_8|._24 (r_amod) asystole_4\NN\14204950|NONE_0
D008012_D001919 NONE lidocaine_29\NN\3681148|NONE_0 (r_pobj) to_28\IN\0|a_20|true_18 (r_prep) idiosyncrasy_27\NN\4763925|,_41|thus_39|,_35|this_33|probably_28|._25 (r_dobj) represented_24\VBD\2664769|patient_144|conditions_109|;_27|and_25 (r_conj) had_2\VBD\0|NONE_0 (l_dobj) conditions_6\NNS\14512817|patient_35|;_82|and_84|represented_109 (l_relcl) predisposed_10\VBN\680841|no_51|apparent_48|associated_39 (l_prep) to_12\IN\0|which_33|might_27|have_21|him_4 (l_pobj) development_14\NN\248977|NONE_0 (l_prep) of_15\IN\0|the_16 (l_pobj) bradyarrhythmias_16\NNS\0|NONE_0
20619828
D002997_-1 NONE clomipramine_0\NNP\4482543|in_22 (r_compound) exposure_1\NN\5042871|changes_74|inflexibility_164|._357 (r_nsubj) produced_5\VBD\1617192|NONE_0 (l_npadvmod) inflexibility_25\NN\5023741|exposure_164|changes_90|._193
D002997_-1 NONE clomipramine_0\NNP\4482543|in_22 (r_compound) exposure_1\NN\5042871|changes_74|inflexibility_164|._357 (r_nsubj) produced_5\VBD\1617192|NONE_0 (l_npadvmod) inflexibility_25\NN\5023741|exposure_164|changes_90|._193 (l_appos) impairment_41\NN\7296428|,_126|behavioral_124|(_99|perseveration_98|,_17 (l_conj) hoarding_51\NN\4217882|working_54|memory_46|(_28|paradigm_11|,_2 (l_conj) dysfunction_55\NN\14204950|,_22|and_20
D002997_D060845 CID clomipramine_0\NNP\4482543|in_22 (r_compound) exposure_1\NN\5042871|changes_74|inflexibility_164|._357 (r_nsubj) produced_5\VBD\1617192|NONE_0 (l_npadvmod) inflexibility_25\NN\5023741|exposure_164|changes_90|._193 (l_appos) impairment_41\NN\7296428|,_126|behavioral_124|(_99|perseveration_98|,_17 (l_conj) hoarding_51\NN\4217882|working_54|memory_46|(_28|paradigm_11|,_2
D002997_D008569 CID clomipramine_0\NNP\4482543|in_22 (r_compound) exposure_1\NN\5042871|changes_74|inflexibility_164|._357 (r_nsubj) produced_5\VBD\1617192|NONE_0 (l_npadvmod) inflexibility_25\NN\5023741|exposure_164|changes_90|._193 (l_appos) impairment_41\NN\7296428|,_126|behavioral_124|(_99|perseveration_98|,_17
D002997_D001008 CID clomipramine_0\NNP\4482543|in_22 (r_compound) exposure_1\NN\5042871|changes_74|inflexibility_164|._357 (r_nsubj) produced_5\VBD\1617192|NONE_0 (l_dobj) changes_10\NNS\7283608|exposure_74|inflexibility_90|._283 (l_relcl) include_12\VBP\0|significant_52|behavioral_40 (l_dobj) anxiety_14\NN\14373582|that_22
18329269
D006220_D002375 CID haloperidol_36\NN\3713736|-_11 (r_npadvmod) induced_38\VBN\1627355|rat_16|catalepsy_8|for_24 (r_amod) model_40\NN\5888929|NONE_0 (l_compound) catalepsy_39\NN\14023236|rat_24|induced_8|for_16
D006220_D010300 NONE haloperidol_36\NN\3713736|-_11 (r_npadvmod) induced_38\VBN\1627355|rat_16|catalepsy_8|for_24 (r_amod) model_40\NN\5888929|NONE_0 (l_prep) for_41\IN\0|rat_40|induced_24|catalepsy_16 (l_pobj) disease_44\NN\14061805|NONE_0
18752389
D019821_D017114 NONE simvastatin_21\NN\3676175|40_12|mg_15|/_17 (r_nmod) day_25\NN\15154774|NONE_0 (r_pobj) from_20\IN\0|NONE_0 (r_prep) conversion_19\NN\7359599|weeks_12 (r_pobj) after_18\IN\0|transplantation_25|simvastatin_47 (r_prep) necessitating_13\VBG\0|fulminant_26|hepatic_16 (r_acl) failure_12\NN\66216|who_32
C492458_D017093 NONE ezetimibe_2\NN\0|-_9 (r_npadvmod) induced_4\VBN\1627355|hepatic_8|necessitating_24|._59 (r_amod) failure_6\NN\66216|NONE_0
C492458_D017093 NONE ezetimibe_13\NN\0|-_9 (r_npadvmod) induced_15\VBN\1627355|liver_8|resulted_27 (r_amod) failure_17\NN\66216|NONE_0
C532833_D056486 NONE acid_25\NN\14818238|NONE_0 (r_pobj) of_22\IN\0|the_20 (r_prep) glucuronidation_21\NN\0|may_23|have_19|,_43|resulting_45 (r_dobj) inhibited_19\VBN\2510337|ezetimibe_140|glucuronidation_110|and_13|._132 (l_advcl) resulting_27\VBG\2633881|may_68|have_64|glucuronidation_45|,_2 (l_prep) in_28\IN\13603305|NONE_0 (l_pobj) exposure_31\NN\5042871|NONE_0 (l_conj) hepatotoxicity_34\NN\0|increased_46|simvastatin_36|and_15
D015283_D003866 NONE escitalopram_2\NNP\0|and_4|(_13|taking_28|)_49 (r_conj) simvastatinezetimibe_0\NNP\0|were_76|,_93|and_95|excluded_145 (l_relcl) taking_7\VBG\37396|and_32|escitalopram_28|(_15|)_21 (l_prep) for_8\IN\0|which_21|she_15|was_11 (l_pobj) depression_9\NN\14373582|NONE_0
C492458_D056486 CID ezetimibe_17\NN\0|the_34|combination_30 (r_appos) agent_14\NN\7347|or_19 (r_conj) ezetimibe_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|however_59|,_52|events_38|have_31|not_26|been_22|widely_17|._61 (r_prep) published_8\VBN\1621555|NONE_0 (l_nsubjpass) events_3\NNS\23100|however_21|,_14|have_7|not_12|been_16|widely_21|with_38|._99 (l_amod) hepatotoxic_2\JJ\0|NONE_0
C492458_D056486 CID simvastatinezetimibe_0\NNP\0|were_76|,_93|and_95|excluded_145 (r_nsubjpass) discontinued_12\VBN\0|NONE_0 (l_conj) excluded_21\VBN\471711|simvastatinezetimibe_145|were_69|,_52|and_50 (l_nsubjpass) causes_17\NNS\7323922|were_25|._38 (l_prep) of_18\IN\0|other_23|potential_17 (l_pobj) hepatotoxicity_19\NN\0|NONE_0
C492458_D056486 CID simvastatinezetimibe_7\NN\0|-_20 (r_npadvmod) induced_9\VBN\1627355|the_25 (r_amod) hepatotoxicity_10\NN\0|NONE_0
C492458_D056486 CID ezetimibe_10\NN\0|NONE_0 (r_pobj) with_7\IN\0|potential_25 (r_prep) hepatotoxicity_6\NN\0|NONE_0
C492458_D003866 NONE simvastatinezetimibe_0\NNP\0|were_76|,_93|and_95|excluded_145 (l_relcl) taking_7\VBG\37396|and_32|escitalopram_28|(_15|)_21 (l_prep) for_8\IN\0|which_21|she_15|was_11 (l_pobj) depression_9\NN\14373582|NONE_0
C108606_D056486 NONE ezetimibe_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|however_59|,_52|events_38|have_31|not_26|been_22|widely_17|._61 (r_prep) published_8\VBN\1621555|NONE_0 (l_nsubjpass) events_3\NNS\23100|however_21|,_14|have_7|not_12|been_16|widely_21|with_38|._99 (l_amod) hepatotoxic_2\JJ\0|NONE_0
C108606_D056486 NONE ezetimibe_0\NNP\0|glucuronidation_30|and_127|inhibited_140|._272 (r_nsubj) undergoes_1\VBZ\109660|NONE_0 (l_conj) inhibited_19\VBN\2510337|ezetimibe_140|glucuronidation_110|and_13|._132 (l_advcl) resulting_27\VBG\2633881|may_68|have_64|glucuronidation_45|,_2 (l_prep) in_28\IN\13603305|NONE_0 (l_pobj) exposure_31\NN\5042871|NONE_0 (l_conj) hepatotoxicity_34\NN\0|increased_46|simvastatin_36|and_15
C108606_D056486 NONE ezetimibe_17\NN\0|of_21 (r_compound) inhibition_18\NN\1068773|NONE_0 (r_pobj) by_16\IN\0|the_35|increased_31|simvastatin_21 (r_prep) exposure_15\NN\5042871|that_99|mechanism_90 (r_attr) is_11\VBZ\0|we_83|._76 (l_nsubj) mechanism_4\NN\13446390|that_9|exposure_90 (l_prep) of_5\IN\0|the_14 (l_pobj) hepatotoxicity_10\NN\0|NONE_0
D014530_D056486 NONE diphosphate_6\NN\0|ugt_38|in_43 (r_compound) glucoronosyltransferases_7\NNS\0|NONE_0 (r_pobj) by_4\IN\0|extensive_26 (r_prep) glucuronidation_3\NN\0|ezetimibe_30|and_97|inhibited_110|._242 (r_dobj) undergoes_1\VBZ\109660|NONE_0 (l_conj) inhibited_19\VBN\2510337|ezetimibe_140|glucuronidation_110|and_13|._132 (l_advcl) resulting_27\VBG\2633881|may_68|have_64|glucuronidation_45|,_2 (l_prep) in_28\IN\13603305|NONE_0 (l_pobj) exposure_31\NN\5042871|NONE_0 (l_conj) hepatotoxicity_34\NN\0|increased_46|simvastatin_36|and_15
D019821_D056486 NONE simvastatin_9\NN\3676175|NONE_0 (r_pobj) with_8\IN\0|panel_26|had_20|been_16|for_17|._87 (r_prep) maintained_7\VBN\0|NONE_0 (l_prep) for_10\IN\0|panel_43|had_37|been_33|with_17|._70 (l_pobj) months_12\NNS\15113229|NONE_0 (l_prep) before_13\IN\0|18_10 (l_pobj) conversion_15\NN\7359599|NONE_0 (l_prep) without_16\IN\0|the_15 (l_pobj) evidence_17\NN\5816287|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) hepatotoxicity_19\NN\0|NONE_0
D019821_D056486 NONE simvastatin_30\NN\3676175|increased_10|and_21|hepatotoxicity_36 (r_amod) exposure_31\NN\5042871|NONE_0 (l_conj) hepatotoxicity_34\NN\0|increased_46|simvastatin_36|and_15
D019821_D056486 NONE simvastatin_14\NN\3676175|the_14|increased_10|by_21 (r_amod) exposure_15\NN\5042871|that_99|mechanism_90 (r_attr) is_11\VBZ\0|we_83|._76 (l_nsubj) mechanism_4\NN\13446390|that_9|exposure_90 (l_prep) of_5\IN\0|the_14 (l_pobj) hepatotoxicity_10\NN\0|NONE_0
D015283_D056486 NONE escitalopram_2\NNP\0|and_4|(_13|taking_28|)_49 (r_conj) simvastatinezetimibe_0\NNP\0|were_76|,_93|and_95|excluded_145 (r_nsubjpass) discontinued_12\VBN\0|NONE_0 (l_conj) excluded_21\VBN\471711|simvastatinezetimibe_145|were_69|,_52|and_50 (l_nsubjpass) causes_17\NNS\7323922|were_25|._38 (l_prep) of_18\IN\0|other_23|potential_17 (l_pobj) hepatotoxicity_19\NN\0|NONE_0
C492458_D017114 CID mg_33\NN\13717155|/_2 (r_nummod) day_35\NN\15154774|10_22|mg_19|-_17 (r_npadvmod) ezetimibe_31\NN\0|to_21 (r_dobj) simvastatin_27\NN\3676175|transplantation_72|after_47 (r_advcl) necessitating_13\VBG\0|fulminant_26|hepatic_16 (r_acl) failure_12\NN\66216|who_32
8996652
D005665_D006311 NONE furosemide_19\NN\3214670|particularly_33|and_4 (r_conj) aminoglycosides_17\NNS\0|a_81|prolonged_79|and_54|dose_37|,_15 (r_appos) administration_7\NN\1133281|NONE_0 (r_pobj) to_4\IN\0|closely_16 (r_prep) related_3\JJ\628491|ototoxicity_29|._122 (r_oprd) appeared_1\VBD\2604760|NONE_0 (l_nsubj) ototoxicity_0\NN\0|related_29|._151
D005665_D006311 NONE furosemide_19\NN\3214670|particularly_33|and_4 (r_conj) aminoglycosides_17\NNS\0|a_81|prolonged_79|and_54|dose_37|,_15 (r_appos) administration_7\NN\1133281|NONE_0 (l_conj) dose_11\NN\3740161|a_44|prolonged_42|and_17|,_22|aminoglycosides_37 (l_prep) of_12\IN\0|higher_18|total_11 (l_pobj) drugs_14\NNS\14778436|NONE_0 (l_compound) ototoxic_13\JJ\0|NONE_0
D000617_D006311 NONE aminoglycosides_17\NNS\0|a_81|prolonged_79|and_54|dose_37|,_15 (r_appos) administration_7\NN\1133281|NONE_0 (r_pobj) to_4\IN\0|closely_16 (r_prep) related_3\JJ\628491|ototoxicity_29|._122 (r_oprd) appeared_1\VBD\2604760|NONE_0 (l_nsubj) ototoxicity_0\NN\0|related_29|._151
D000617_D006311 NONE aminoglycosides_17\NNS\0|a_81|prolonged_79|and_54|dose_37|,_15 (r_appos) administration_7\NN\1133281|NONE_0 (l_conj) dose_11\NN\3740161|a_44|prolonged_42|and_17|,_22|aminoglycosides_37 (l_prep) of_12\IN\0|higher_18|total_11 (l_pobj) drugs_14\NNS\14778436|NONE_0 (l_compound) ototoxic_13\JJ\0|NONE_0
19759529
D006220_D006948 NONE haloperidol_5\NN\3713736|clozapine_39 (r_nmod) antipsychotics_16\NNS\4470232|effective_20|._66 (r_nsubj) were_17\VBD\0|NONE_0 (l_acomp) effective_18\JJ\0|antipsychotics_20|._46 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) models_22\NNS\5888929|NONE_0 (l_prep) of_23\IN\0|all_17|these_13 (l_pobj) hyperactivity_24\NN\14052403|NONE_0
-1_D006948 NONE ssr103800_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|the_44|potential_40|like_16|involving_66 (r_prep) properties_10\NNS\32613|,_23|with_25 (r_dobj) investigating_4\VBG\575741|NONE_0 (l_prep) with_14\IN\0|properties_25|,_2 (l_pobj) focus_17\NN\5704266|NONE_0 (l_prep) on_18\IN\0|a_19|particular_17|,_26 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) hyperactivity_21\NN\14052403|NONE_0
-1_D006948 NONE ssr103800_3\NNP\0|(_10|mg/kg_17|p.o._23|)_27|blocked_29|induced_51 (r_nmod) hyperactivity_12\NN\14052403|NONE_0
-1_D006948 NONE ssr103800_3\NNP\0|(_10|mg/kg_17|p.o._23|)_27|blocked_29|induced_51 (r_nmod) hyperactivity_12\NN\14052403|NONE_0 (r_punct) that_2\IN\0|results_15|and_120|reversed_134|._193 (r_dobj) showed_1\VBD\2137132|NONE_0 (l_conj) reversed_26\VBD\109660|results_149|that_134|and_14|._59 (l_dobj) hyperactivity_28\NN\14052403|partially_31
-1_D006948 NONE ssr103800_3\NNP\0|in_13|,_2|affect_20|or_64|observed_77|)_119 (r_nsubj) failed_4\VBD\0|NONE_0 (l_xcomp) affect_6\VB\26192|in_33|,_22|ssr103800_20|or_44|observed_57|)_99 (l_dobj) hyperactivity_7\NN\14052403|to_10
-1_D002375 NONE ssr103800_6\NNP\0|however_30|,_23|unlike_21|,_2|did_10|not_14|catalepsy_26|retention_37|up_64|together_84 (r_nsubj) produce_9\VB\7555863|NONE_0 (l_dobj) catalepsy_10\NN\14023236|however_56|,_49|unlike_47|,_28|ssr103800_26|did_16|not_12|retention_11|up_38|together_58
D016202_D012559 NONE aspartate_15\NNP\0|n_11|-_10 (r_appos) methyl_11\NN\14617189|the_16|glutamate_12|(_19|nmda_20|)_24 (r_nmod) receptor_19\NN\5225602|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) antagonists_5\NNS\7846|that_5|symptoms_93 (r_nsubj) produce_20\VBP\7555863|the_87 (l_dobj) symptoms_24\NNS\5823932|that_98|antagonists_93 (l_amod) like_23\JJ\5839024|in_14 (l_npadvmod) schizophrenic_21\JJ\10490141|-_13
D016202_D012559 NONE nmda_17\NNP\0|the_36|glutamate_32|methyl_20|(_1|)_4 (r_nmod) receptor_19\NN\5225602|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) antagonists_5\NNS\7846|that_5|symptoms_93 (r_nsubj) produce_20\VBP\7555863|the_87 (l_dobj) symptoms_24\NNS\5823932|that_98|antagonists_93 (l_amod) like_23\JJ\5839024|in_14 (l_npadvmod) schizophrenic_21\JJ\10490141|-_13
D016202_D012559 NONE nmda_41\NNP\0|its_4 (r_compound) receptor_42\NN\5225602|NONE_0 (r_pobj) via_39\IN\0|a_45|of_28 (r_prep) dysfunctioning_34\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_9 (r_prep) idea_31\NN\5809192|NONE_0 (r_pobj) to_29\IN\0|however_150|,_143|observation_137|has_8|._81 (r_prep) led_28\VBN\3202760|NONE_0 (l_nsubj) observation_3\NN\996969|however_13|,_6|has_129|to_137|._218 (l_relcl) produce_20\VBP\7555863|the_87 (l_dobj) symptoms_24\NNS\5823932|that_98|antagonists_93 (l_amod) like_23\JJ\5839024|in_14 (l_npadvmod) schizophrenic_21\JJ\10490141|-_13
D004298_D006948 NONE dopamine_15\NN\14807737|(_21|dat(-/-_22|)_29 (r_compound) transporter_16\NN\4490091|NONE_0 (r_pobj) in_14\IN\13603305|naturally_19 (r_prep) observed_13\VBN\2163746|in_90|,_79|ssr103800_77|affect_57|or_13|)_42 (r_conj) failed_4\VBD\0|NONE_0 (l_xcomp) affect_6\VB\26192|in_33|,_22|ssr103800_20|or_44|observed_57|)_99 (l_dobj) hyperactivity_7\NN\14052403|to_10
D000661_D006948 CID amphetamine_30\NN\3248958|either_27|drug_20|or_24|mice_38 (r_appos) challenge_26\NN\13927383|NONE_0 (r_dobj) involving_23\VBG\2676054|the_110|potential_106|like_82|of_66 (r_prep) properties_10\NNS\32613|,_23|with_25 (r_dobj) investigating_4\VBG\575741|NONE_0 (l_prep) with_14\IN\0|properties_25|,_2 (l_pobj) focus_17\NN\5704266|NONE_0 (l_prep) on_18\IN\0|a_19|particular_17|,_26 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) hyperactivity_21\NN\14052403|NONE_0
D000661_D006948 CID amphetamine_10\NN\3248958|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) induced_8\VBN\1627355|NONE_0 (r_acl) hyperactivity_7\NN\14052403|to_10
D003024_D006948 NONE clozapine_12\NN\3713736|haloperidol_39 (r_nmod) antipsychotics_16\NNS\4470232|effective_20|._66 (r_nsubj) were_17\VBD\0|NONE_0 (l_acomp) effective_18\JJ\0|antipsychotics_20|._46 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) models_22\NNS\5888929|NONE_0 (l_prep) of_23\IN\0|all_17|these_13 (l_pobj) hyperactivity_24\NN\14052403|NONE_0
D016291_D006948 CID mk-801_32\NNP\0|NONE_0 (r_punct) )_33\-RRB-\0|(_27|ie_26|,_24|and_10 (r_punct) amphetamine_30\NN\3248958|either_27|drug_20|or_24|mice_38 (r_appos) challenge_26\NN\13927383|NONE_0 (r_dobj) involving_23\VBG\2676054|the_110|potential_106|like_82|of_66 (r_prep) properties_10\NNS\32613|,_23|with_25 (r_dobj) investigating_4\VBG\575741|NONE_0 (l_prep) with_14\IN\0|properties_25|,_2 (l_pobj) focus_17\NN\5704266|NONE_0 (l_prep) on_18\IN\0|a_19|particular_17|,_26 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) hyperactivity_21\NN\14052403|NONE_0
D016291_D006948 CID mk-801_23\NNP\0|NONE_0 (r_punct) and_24\CC\0|results_135|that_120|reversed_14|._73 (r_cc) showed_1\VBD\2137132|NONE_0 (l_dobj) that_2\IN\0|results_15|and_120|reversed_134|._193 (l_punct) hyperactivity_12\NN\14052403|NONE_0
D016291_D006948 CID mk-801_23\NNP\0|NONE_0 (r_punct) and_24\CC\0|results_135|that_120|reversed_14|._73 (r_cc) showed_1\VBD\2137132|NONE_0 (l_conj) reversed_26\VBD\109660|results_149|that_134|and_14|._59 (l_dobj) hyperactivity_28\NN\14052403|partially_31
C094645_D006948 NONE aripiprazole_14\NN\0|(_27|olanzapine_26|,_16|and_4|)_12 (r_conj) clozapine_12\NN\3713736|haloperidol_39 (r_nmod) antipsychotics_16\NNS\4470232|effective_20|._66 (r_nsubj) were_17\VBD\0|NONE_0 (l_acomp) effective_18\JJ\0|antipsychotics_20|._46 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) models_22\NNS\5888929|NONE_0 (l_prep) of_23\IN\0|all_17|these_13 (l_pobj) hyperactivity_24\NN\14052403|NONE_0
D004298_D012559 NONE dopamine_8\NN\14807737|NONE_0 (r_compound) neurotransmission_9\NN\0|NONE_0 (r_pobj) in_7\IN\13603305|NONE_0 (r_prep) dysfunction_6\NN\14204950|NONE_0 (r_pobj) with_5\IN\0|schizophrenia_44|has_30|been_26|initially_21|._46 (r_prep) associated_4\VBN\628491|NONE_0 (l_nsubjpass) schizophrenia_0\NNP\14398067|has_14|been_18|initially_23|with_44|._90
D018698_D012559 NONE glutamate_8\NN\15010703|the_4|methyl_12|(_31|nmda_32|)_36 (r_nmod) receptor_19\NN\5225602|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) antagonists_5\NNS\7846|that_5|symptoms_93 (r_nsubj) produce_20\VBP\7555863|the_87 (l_dobj) symptoms_24\NNS\5823932|that_98|antagonists_93 (l_amod) like_23\JJ\5839024|in_14 (l_npadvmod) schizophrenic_21\JJ\10490141|-_13
D016202_D006948 NONE nmda_40\NNP\0|(_5|ie_4|,_2|)_15|and_17|dat(-/-_21 (r_compound) nr1(neo-/-_41\NNP\0|transgenic_26|)_23 (r_appos) mice_36\NNS\2329401|either_65|drug_58|amphetamine_38|or_14 (r_conj) challenge_26\NN\13927383|NONE_0 (r_dobj) involving_23\VBG\2676054|the_110|potential_106|like_82|of_66 (r_prep) properties_10\NNS\32613|,_23|with_25 (r_dobj) investigating_4\VBG\575741|NONE_0 (l_prep) with_14\IN\0|properties_25|,_2 (l_pobj) focus_17\NN\5704266|NONE_0 (l_prep) on_18\IN\0|a_19|particular_17|,_26 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) hyperactivity_21\NN\14052403|NONE_0
D016202_D006948 NONE nmda_19\NNP\0|the_20|competitive_12|receptor_5|,_24 (r_compound) antagonist_21\NN\7846|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|ssr103800_51|(_41|mg/kg_34|p.o._28|)_24|blocked_22 (r_acl) hyperactivity_12\NN\14052403|NONE_0
D016202_D006948 NONE nmda_19\NNP\0|the_20|competitive_12|receptor_5|,_24 (r_compound) antagonist_21\NN\7846|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|ssr103800_51|(_41|mg/kg_34|p.o._28|)_24|blocked_22 (r_acl) hyperactivity_12\NN\14052403|NONE_0 (r_punct) that_2\IN\0|results_15|and_120|reversed_134|._193 (r_dobj) showed_1\VBD\2137132|NONE_0 (l_conj) reversed_26\VBD\109660|results_149|that_134|and_14|._59 (l_dobj) hyperactivity_28\NN\14052403|partially_31
D016202_D006948 NONE nmda_30\NNP\0|nr1(neo-/-_5|)_15 (r_nmod) mice_33\NNS\2329401|NONE_0 (r_pobj) of_29\IN\0|spontaneous_26 (r_prep) hyperactivity_28\NN\14052403|partially_31 (r_dobj) reversed_26\VBD\109660|results_149|that_134|and_14|._59 (r_conj) showed_1\VBD\2137132|NONE_0 (l_dobj) that_2\IN\0|results_15|and_120|reversed_134|._193 (l_punct) hyperactivity_12\NN\14052403|NONE_0
D016202_D006948 NONE nmda_30\NNP\0|nr1(neo-/-_5|)_15 (r_nmod) mice_33\NNS\2329401|NONE_0 (r_pobj) of_29\IN\0|spontaneous_26 (r_prep) hyperactivity_28\NN\14052403|partially_31
C076029_D006948 NONE olanzapine_10\NN\0|(_1|,_10|and_22|aripiprazole_26|)_38 (r_nmod) clozapine_12\NN\3713736|haloperidol_39 (r_nmod) antipsychotics_16\NNS\4470232|effective_20|._66 (r_nsubj) were_17\VBD\0|NONE_0 (l_acomp) effective_18\JJ\0|antipsychotics_20|._46 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) models_22\NNS\5888929|NONE_0 (l_prep) of_23\IN\0|all_17|these_13 (l_pobj) hyperactivity_24\NN\14052403|NONE_0
8170551
D000086_D053040 NONE acetazolamide_0\RB\0|-_13 (r_npadvmod) induced_2\VBN\1627355|:_23|implications_25|._78 (r_amod) nephrolithiasis_3\NN\14115914|NONE_0
D000086_D053040 NONE acetazolamide_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|a_15 (r_prep) complication_3\NN\1073995|nephrolithiasis_21|but_30|preclude_43|._59 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) nephrolithiasis_0\NNP\14115914|complication_21|but_51|preclude_64|._80
D000086_D007669 CID acetazolamide_3\NN\0|NONE_0 (r_pobj) on_2\IN\0|three_15 (r_prep) patients_1\NNS\9898892|calculi_48|._55 (r_nsubj) developed_8\VBN\1753788|NONE_0 (l_dobj) calculi_10\NNS\9416076|patients_48|._7
D000086_D009468 NONE acetazolamide_0\RB\0|-_13 (r_npadvmod) induced_2\VBN\1627355|:_23|implications_25|._78 (r_amod) nephrolithiasis_3\NN\14115914|NONE_0 (l_appos) implications_5\NNS\5774614|induced_25|:_2|._53 (l_prep) for_6\IN\0|NONE_0 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|NONE_0 (l_pobj) disorders_10\NNS\14034177|NONE_0
10342929
D000806_D000799 CID inhibitors_4\NNS\20090|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_pcomp) due_1\IN\5174653|._56 (r_prep) angioedema_0\NNP\14316714|NONE_0
D000806_D000799 CID inhibitor_13\NN\20090|ace_5|)_2 (r_compound) treatment_14\NN\654885|incidence_77|(_16|patients_42|._50 (r_nsubj) is_15\VBZ\0|NONE_0 (l_nsubj) incidence_2\NN\13821570|(_61|treatment_77|patients_119|._127 (l_prep) of_3\IN\0|the_24|estimated_20|during_14 (l_pobj) angioedema_4\NN\14316714|NONE_0
15275829
D009538_D012640 CID nicotine_11\NN\14712692|-_8 (r_npadvmod) induced_13\VBN\1627355|and_17|hypolocomotion_21 (r_amod) seizures_14\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_2\NN\14712692|NONE_0 (r_pobj) of_1\IN\0|to_12 (r_prep) binding_0\NN\4688246|series_76|._189 (r_nsubj) elicits_10\VBZ\1617192|NONE_0 (l_dobj) series_12\NN\8456993|binding_76|._113 (l_prep) of_13\IN\0|a_9 (l_pobj) behaviors_17\NNS\407535|NONE_0 (l_relcl) go_19\VBP\15291801|dependent_25 (l_prep) to_29\IN\0|that_57|from_49|,_2 (l_pobj) seizures_30\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_9\NN\14712692|-_8 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) seizures_12\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_10\NN\14712692|NONE_0 (r_pobj) of_9\IN\0|the_12|at_17 (r_prep) effects_8\NNS\13245626|NONE_0 (r_pobj) to_6\IN\0|less_15 (r_prep) sensitive_5\JJ\10488309|mice_15|,_54|measured_56|._179 (r_acomp) were_3\VBD\0|NONE_0 (l_advcl) measured_16\VBN\697589|mice_71|sensitive_56|,_2|._123 (l_conj) measured_30\VBN\697589|as_62|,_21|and_19|at_15 (l_prep) as_31\IN\14622893|NONE_0 (l_pobj) sensitivity_32\NN\5651971|NONE_0 (l_prep) to_33\IN\0|NONE_0 (l_pobj) seizures_37\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_34\NN\14712692|-_8 (r_npadvmod) induced_36\VBN\1627355|NONE_0 (r_amod) seizures_37\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_7\NN\14712692|-_8 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) seizures_10\NNS\14081375|NONE_0
D009538_D012640 CID nicotine_15\NN\14712692|-_8 (r_npadvmod) induced_17\VBN\1627355|and_17|hypolocomotion_21 (r_amod) seizures_18\NNS\14081375|NONE_0
D009538_D014202 NONE nicotine_2\NN\14712692|NONE_0 (r_pobj) of_1\IN\0|to_12 (r_prep) binding_0\NN\4688246|series_76|._189 (r_nsubj) elicits_10\VBZ\1617192|NONE_0 (l_dobj) series_12\NN\8456993|binding_76|._113 (l_prep) of_13\IN\0|a_9 (l_pobj) behaviors_17\NNS\407535|NONE_0 (l_relcl) go_19\VBP\15291801|dependent_25 (l_prep) from_20\IN\0|that_8|,_47|to_49 (l_pobj) exploration_22\NN\309647|NONE_0 (l_conj) sedation_24\NN\14034177|altered_21|,_2 (l_conj) tremors_27\NNS\345926|,_6|and_4
D000109_D006948 NONE acetylcholine_5\NN\14807558|alpha3_27|nicotinic_10|receptor_14 (r_compound) subunits_7\NNS\13604718|necessary_13|for_23|._79 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_prep) for_10\IN\0|subunits_23|necessary_10|._56 (l_pobj) seizures_14\NNS\14081375|NONE_0 (l_conj) hypolocomotion_16\NN\0|induced_21|and_4
D009538_D006948 NONE nicotine_11\NN\14712692|-_8 (r_npadvmod) induced_13\VBN\1627355|and_17|hypolocomotion_21 (r_amod) seizures_14\NNS\14081375|NONE_0 (l_conj) hypolocomotion_16\NN\0|induced_21|and_4
D009538_D006948 NONE nicotine_9\NN\14712692|-_8 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) seizures_12\NNS\14081375|NONE_0 (r_pobj) in_8\IN\13603305|the_19|beta4_15|and_29|hypolocomotion_33 (r_prep) subunits_7\NNS\13604718|NONE_0 (l_conj) hypolocomotion_14\NN\0|the_52|beta4_48|in_33|and_4
D009538_D006948 NONE nicotine_15\NN\14712692|-_8 (r_npadvmod) induced_17\VBN\1627355|and_17|hypolocomotion_21 (r_amod) seizures_18\NNS\14081375|NONE_0 (l_conj) hypolocomotion_20\NN\0|induced_21|and_4
D000109_D003643 NONE acetylcholine_5\NN\14807558|nicotinic_10|(_24|nachrs_25|)_31 (r_compound) receptors_6\NNS\5225602|NONE_0 (r_pobj) to_3\IN\0|of_12 (r_prep) binding_0\NN\4688246|series_76|._189 (r_nsubj) elicits_10\VBZ\1617192|NONE_0 (l_dobj) series_12\NN\8456993|binding_76|._113 (l_prep) of_13\IN\0|a_9 (l_pobj) behaviors_17\NNS\407535|NONE_0 (l_relcl) go_19\VBP\15291801|dependent_25 (l_prep) to_29\IN\0|that_57|from_49|,_2 (l_pobj) seizures_30\NNS\14081375|NONE_0 (l_conj) death_32\NN\7296428|and_4
D000109_D012640 NONE acetylcholine_5\NN\14807558|alpha3_27|nicotinic_10|receptor_14 (r_compound) subunits_7\NNS\13604718|necessary_13|for_23|._79 (r_nsubj) are_8\VBP\13600404|NONE_0 (l_prep) for_10\IN\0|subunits_23|necessary_10|._56 (l_pobj) seizures_14\NNS\14081375|NONE_0
D000109_D012640 NONE acetylcholine_5\NN\14807558|nicotinic_10|(_24|nachrs_25|)_31 (r_compound) receptors_6\NNS\5225602|NONE_0 (r_pobj) to_3\IN\0|of_12 (r_prep) binding_0\NN\4688246|series_76|._189 (r_nsubj) elicits_10\VBZ\1617192|NONE_0 (l_dobj) series_12\NN\8456993|binding_76|._113 (l_prep) of_13\IN\0|a_9 (l_pobj) behaviors_17\NNS\407535|NONE_0 (l_relcl) go_19\VBP\15291801|dependent_25 (l_prep) to_29\IN\0|that_57|from_49|,_2 (l_pobj) seizures_30\NNS\14081375|NONE_0
D000109_D014202 NONE acetylcholine_5\NN\14807558|nicotinic_10|(_24|nachrs_25|)_31 (r_compound) receptors_6\NNS\5225602|NONE_0 (r_pobj) to_3\IN\0|of_12 (r_prep) binding_0\NN\4688246|series_76|._189 (r_nsubj) elicits_10\VBZ\1617192|NONE_0 (l_dobj) series_12\NN\8456993|binding_76|._113 (l_prep) of_13\IN\0|a_9 (l_pobj) behaviors_17\NNS\407535|NONE_0 (l_relcl) go_19\VBP\15291801|dependent_25 (l_prep) from_20\IN\0|that_8|,_47|to_49 (l_pobj) exploration_22\NN\309647|NONE_0 (l_conj) sedation_24\NN\14034177|altered_21|,_2 (l_conj) tremors_27\NNS\345926|,_6|and_4
D009538_D003643 NONE nicotine_2\NN\14712692|NONE_0 (r_pobj) of_1\IN\0|to_12 (r_prep) binding_0\NN\4688246|series_76|._189 (r_nsubj) elicits_10\VBZ\1617192|NONE_0 (l_dobj) series_12\NN\8456993|binding_76|._113 (l_prep) of_13\IN\0|a_9 (l_pobj) behaviors_17\NNS\407535|NONE_0 (l_relcl) go_19\VBP\15291801|dependent_25 (l_prep) to_29\IN\0|that_57|from_49|,_2 (l_pobj) seizures_30\NNS\14081375|NONE_0 (l_conj) death_32\NN\7296428|and_4
9812111
D006220_D011595 NONE haloperidol_12\NN\3713736|phase_23|,_16 (r_appos) a_7\NNP\13649268|who_20 (r_dobj) completed_5\VBD\352826|the_20|60_16 (r_relcl) patients_3\NNS\9898892|NONE_0 (r_pobj) for_0\IN\0|efficacious_73|._233 (r_prep) was_13\VBD\0|NONE_0 (l_acomp) efficacious_14\JJ\0|for_73|._160 (l_prep) to_17\IN\0|and_13|superior_9 (l_pobj) haloperidol_22\NN\3713736|NONE_0 (l_prep) for_25\IN\0|both_38|dose_29|and_12|placebo_8 (l_pobj) scores_26\NNS\13757724|NONE_0 (l_prep) on_27\IN\0|NONE_0 (l_conj) on_36\IN\0|factor_11|and_4 (l_pobj) agitation_38\NN\14373582|NONE_0
D006220_D011595 NONE haloperidol_22\NN\3713736|NONE_0 (l_prep) for_25\IN\0|both_38|dose_29|and_12|placebo_8 (l_pobj) scores_26\NNS\13757724|NONE_0 (l_prep) on_27\IN\0|NONE_0 (l_conj) on_36\IN\0|factor_11|and_4 (l_pobj) agitation_38\NN\14373582|NONE_0
D006220_D000544 NONE haloperidol_11\NN\3713736|NONE_0 (l_prep) for_12\IN\0|NONE_0 (l_pobj) psychosis_13\NN\14380140|NONE_0 (l_prep) in_17\IN\13603305|and_25|behaviors_10 (l_pobj) disease_20\NN\14061805|NONE_0
D006220_D000544 NONE haloperidol_17\NN\3713736|NONE_0 (r_pobj) of_16\IN\0|two_10 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) of_13\IN\0|the_30|and_17|effects_8 (r_prep) efficacy_9\NN\5199286|to_15|in_66 (r_dobj) compare_7\VB\4744814|goal_26|._169 (l_prep) in_20\IN\13603305|to_81|efficacy_66 (l_pobj) treatment_22\NN\654885|NONE_0 (l_prep) in_28\IN\13603305|the_52|of_38 (l_pobj) patients_29\NNS\9898892|NONE_0 (l_prep) with_30\IN\0|NONE_0 (l_pobj) disease_33\NN\14061805|NONE_0
D006220_D000544 NONE haloperidol_20\NN\3713736|(_11|a_4|)_3|,_2|,_39|and_41|haloperidol_45 (r_appos) phase_16\NN\15113229|trial_7 (r_preconj) in_0\IN\13603305|,_166|were_168|in_182|._224 (r_prep) compared_48\VBN\644583|NONE_0 (l_prep) in_49\IN\13603305|in_182|,_16|were_14|._42 (l_pobj) outpatients_51\NNS\10405694|NONE_0 (l_prep) with_52\IN\0|71_15 (l_pobj) disease_55\NN\14061805|NONE_0
D006220_D000544 NONE haloperidol_34\NN\3713736|(_56|a_49|)_48|,_47|haloperidol_45|,_6|and_4 (r_conj) phase_16\NN\15113229|trial_7 (r_preconj) in_0\IN\13603305|,_166|were_168|in_182|._224 (r_prep) compared_48\VBN\644583|NONE_0 (l_prep) in_49\IN\13603305|in_182|,_16|were_14|._42 (l_pobj) outpatients_51\NNS\10405694|NONE_0 (l_prep) with_52\IN\0|71_15 (l_pobj) disease_55\NN\14061805|NONE_0
D006220_D000544 NONE haloperidol_6\NN\3713736|NONE_0 (r_pobj) with_5\IN\0|window_16 (r_prep) observed_4\VBN\2163746|may_26|also_30|to_41|._139 (r_nsubj) apply_9\VB\0|NONE_0 (l_prep) to_10\IN\0|observed_41|may_15|also_11|._98 (l_pobj) neuroleptics_12\NNS\4470232|NONE_0 (l_acl) used_13\VBN\0|other_19 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_compound) disease_17\NN\14061805|alzheimer_12|with_17
D006220_D019958 NONE haloperidol_11\NN\3713736|NONE_0 (l_prep) for_12\IN\0|NONE_0 (l_pobj) psychosis_13\NN\14380140|NONE_0 (l_conj) behaviors_16\NNS\407535|and_15|in_10
D006220_D019958 NONE haloperidol_17\NN\3713736|NONE_0 (r_pobj) of_16\IN\0|two_10 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) of_13\IN\0|the_30|and_17|effects_8 (r_prep) efficacy_9\NN\5199286|to_15|in_66 (r_dobj) compare_7\VB\4744814|goal_26|._169 (l_prep) in_20\IN\13603305|to_81|efficacy_66 (l_pobj) treatment_22\NN\654885|NONE_0 (l_prep) of_23\IN\0|the_14|in_38 (l_pobj) psychosis_24\NN\14380140|NONE_0 (l_conj) behaviors_27\NNS\407535|and_15
D006220_D019958 NONE haloperidol_6\NN\3713736|NONE_0 (r_pobj) with_5\IN\0|window_16 (r_prep) observed_4\VBN\2163746|may_26|also_30|to_41|._139 (r_nsubj) apply_9\VB\0|NONE_0 (l_prep) to_10\IN\0|observed_41|may_15|also_11|._98 (l_pobj) neuroleptics_12\NNS\4470232|NONE_0 (l_acl) used_13\VBN\0|other_19 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|alzheimer_29|disease_17 (l_pobj) psychosis_20\NN\14380140|NONE_0 (l_conj) behaviors_23\NNS\407535|and_15
D006220_D011618 NONE haloperidol_11\NN\3713736|NONE_0 (l_prep) for_12\IN\0|NONE_0 (l_pobj) psychosis_13\NN\14380140|NONE_0
D006220_D011618 NONE haloperidol_17\NN\3713736|NONE_0 (r_pobj) of_16\IN\0|two_10 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) of_13\IN\0|the_30|and_17|effects_8 (r_prep) efficacy_9\NN\5199286|to_15|in_66 (r_dobj) compare_7\VB\4744814|goal_26|._169 (l_prep) in_20\IN\13603305|to_81|efficacy_66 (l_pobj) treatment_22\NN\654885|NONE_0 (l_prep) of_23\IN\0|the_14|in_38 (l_pobj) psychosis_24\NN\14380140|NONE_0
D006220_D011618 NONE haloperidol_12\NN\3713736|phase_23|,_16 (r_appos) a_7\NNP\13649268|who_20 (r_dobj) completed_5\VBD\352826|the_20|60_16 (r_relcl) patients_3\NNS\9898892|NONE_0 (r_pobj) for_0\IN\0|efficacious_73|._233 (r_prep) was_13\VBD\0|NONE_0 (l_acomp) efficacious_14\JJ\0|for_73|._160 (l_prep) to_17\IN\0|and_13|superior_9 (l_pobj) haloperidol_22\NN\3713736|NONE_0 (l_prep) for_25\IN\0|both_38|dose_29|and_12|placebo_8 (l_pobj) scores_26\NNS\13757724|NONE_0 (l_prep) on_27\IN\0|NONE_0 (l_pobj) factor_34\NN\7326557|and_7|on_11 (l_compound) psychosis_33\NN\14380140|the_35|brief_31|scale_6
D006220_D011618 NONE haloperidol_22\NN\3713736|NONE_0 (l_prep) for_25\IN\0|both_38|dose_29|and_12|placebo_8 (l_pobj) scores_26\NNS\13757724|NONE_0 (l_prep) on_27\IN\0|NONE_0 (l_pobj) factor_34\NN\7326557|and_7|on_11 (l_compound) psychosis_33\NN\14380140|the_35|brief_31|scale_6
D006220_D011618 NONE haloperidol_6\NN\3713736|NONE_0 (r_pobj) with_5\IN\0|window_16 (r_prep) observed_4\VBN\2163746|may_26|also_30|to_41|._139 (r_nsubj) apply_9\VB\0|NONE_0 (l_prep) to_10\IN\0|observed_41|may_15|also_11|._98 (l_pobj) neuroleptics_12\NNS\4470232|NONE_0 (l_acl) used_13\VBN\0|other_19 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|alzheimer_29|disease_17 (l_pobj) psychosis_20\NN\14380140|NONE_0
D006220_D001480 CID haloperidol_8\NN\3713736|NONE_0 (r_pobj) for_7\IN\0|a_32|favorable_30|therapeutic_20|in_16 (r_prep) profile_6\NN\6999802|results_42|,_46|developed_68|._117 (r_dobj) indicated_2\VBD\952524|NONE_0 (l_advcl) developed_22\VBD\1753788|results_110|profile_68|,_22|._49 (l_acomp) moderate_23\JJ\9605289|although_30|subgroup_19 (l_prep) to_24\TO\0|NONE_0 (l_pobj) signs_27\NNS\6643763|NONE_0
9351491
D018967_D010302 CID risperidone_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) subjects_7\NNS\6598915|NONE_0 (r_pobj) in_6\IN\13603305|parkinsonism_26|was_13|and_65|observed_73|._111 (r_prep) observed_5\VBN\2163746|NONE_0 (l_nsubjpass) parkinsonism_3\NN\14085708|was_13|in_26|and_91|observed_99|._137
D006220_D010302 CID haloperidol_16\NN\3713736|(_10|%_7|)_6|and_4 (r_conj) risperidone_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) subjects_7\NNS\6598915|NONE_0 (r_pobj) in_6\IN\13603305|parkinsonism_26|was_13|and_65|observed_73|._111 (r_prep) observed_5\VBN\2163746|NONE_0 (l_nsubjpass) parkinsonism_3\NN\14085708|was_13|in_26|and_91|observed_99|._137
D018967_D011618 NONE risperidone_6\NN\0|pharmacologic_14 (r_poss) profile_9\NN\6999802|that_33|may_8|efficacy_29|and_70|decreased_74 (r_nsubj) produce_11\VB\7555863|studies_67|have_59 (l_dobj) efficacy_13\NN\5199286|that_62|profile_29|may_21|and_41|decreased_45 (l_prep) for_14\IN\0|improved_18 (l_pobj) symptoms_17\NNS\5823932|NONE_0
8829025
D016559_D007674 NONE tacrolimus_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) associated_10\VBN\628491|the_19 (r_acl) nephrotoxicity_9\NN\0|NONE_0
D009543_D006973 NONE nifedipine_23\NN\2938514|who_19|were_15 (r_dobj) receiving_22\VBG\2210855|hypertensive_31 (r_relcl) patients_19\NNS\9898892|NONE_0 (l_amod) hypertensive_18\JJ\10405694|receiving_31
D009543_D006973 NONE nifedipine_33\NN\2938514|not_14 (r_dobj) receiving_32\VBG\2210855|nonhypertensive_29 (r_acl) patients_30\NNS\9898892|NONE_0 (r_dobj) comprising_28\VBG\2604760|the_10 (r_acl) other_27\JJ\0|one_82|comprising_72|,_10|and_8 (r_conj) group_16\NN\2137|groups_83|were_43|over_29|,_6|._144 (l_acl) comprising_17\VBG\2604760|one_10|,_62|and_64|other_72 (l_dobj) patients_19\NNS\9898892|NONE_0 (l_amod) hypertensive_18\JJ\10405694|receiving_31
D009543_D006973 NONE nifedipine_5\NN\2938514|NONE_0 (r_pobj) of_4\IN\0|the_29|observed_25|positive_16|on_14 (r_prep) impact_3\NN\7339329|should_110|factor_133|._202 (r_nsubj) be_18\VB\14625458|NONE_0 (l_attr) factor_21\NN\7326557|impact_133|should_23|._69 (l_prep) in_22\IN\13603305|an_20|important_17 (l_pcomp) selecting_23\VBG\697589|NONE_0 (l_xcomp) treat_27\VB\7570720|agent_9 (l_dobj) hypertension_28\NN\14057371|to_9
D009543_D007674 NONE nifedipine_5\NN\2938514|NONE_0 (r_pobj) of_4\IN\0|the_29|observed_25|positive_16|on_14 (r_prep) impact_3\NN\7339329|should_110|factor_133|._202 (l_prep) on_6\IN\0|the_43|observed_39|positive_30|of_14 (l_pcomp) reducing_7\VBG\13447361|NONE_0 (l_dobj) nephrotoxicity_9\NN\0|NONE_0
D016559_D006973 CID tacrolimus_5\NNS\0|NONE_0 (r_dobj) receiving_4\VBG\2210855|NONE_0 (r_acl) patients_3\NNS\9898892|NONE_0 (r_pobj) of_2\IN\0|two_11 (r_prep) groups_1\NNS\2137|were_40|over_54|,_77|group_83|._227 (r_nsubjpass) compared_7\VBN\644583|NONE_0 (l_appos) group_16\NN\2137|groups_83|were_43|over_29|,_6|._144 (l_acl) comprising_17\VBG\2604760|one_10|,_62|and_64|other_72 (l_dobj) patients_19\NNS\9898892|NONE_0 (l_amod) hypertensive_18\JJ\10405694|receiving_31
D016559_D006973 CID tacrolimus_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) associated_10\VBN\628491|the_19 (r_acl) nephrotoxicity_9\NN\0|NONE_0 (r_dobj) reducing_7\VBG\13447361|NONE_0 (r_pcomp) on_6\IN\0|the_43|observed_39|positive_30|of_14 (r_prep) impact_3\NN\7339329|should_110|factor_133|._202 (r_nsubj) be_18\VB\14625458|NONE_0 (l_attr) factor_21\NN\7326557|impact_133|should_23|._69 (l_prep) in_22\IN\13603305|an_20|important_17 (l_pcomp) selecting_23\VBG\697589|NONE_0 (l_xcomp) treat_27\VB\7570720|agent_9 (l_dobj) hypertension_28\NN\14057371|to_9
2670794
D002216_D011665 NONE captopril_9\NNP\2673637|(_1|)_9 (r_appos) enzyme_7\NN\14723628|on_19 (r_dobj) converting_6\VBG\126264|NONE_0 (l_prep) on_11\IN\0|enzyme_19 (l_pobj) insufficiency_15\NN\14462946|NONE_0
D002216_D011665 NONE captopril_2\NNP\2673637|NONE_0 (r_pobj) of_1\IN\0|(_13|mg/kg_16|)_21|,_22|inhibitor_27|,_75 (r_prep) injection_0\NN\320852|insufficiency_120|._151 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) insufficiency_23\NN\14462946|injection_120|._31
D014148_D004211 CID acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (l_prep) of_1\IN\0|by_60 (l_pobj) coagulation_3\NN\13518963|NONE_0
D014148_D004211 CID amca_16\NNP\0|tranexamic_17 (r_appos) acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (l_prep) of_1\IN\0|by_60 (l_pobj) coagulation_3\NN\13518963|NONE_0
D000809_D051437 NONE angiotensin_5\NN\4522421|NONE_0 (l_acl) converting_6\VBG\126264|NONE_0 (l_prep) on_11\IN\0|enzyme_19 (l_pobj) insufficiency_15\NN\14462946|NONE_0
D000809_D051437 NONE angiotensin_11\NN\4522421|NONE_0 (r_pobj) of_10\IN\0|an_13 (r_prep) inhibitor_9\NN\20090|of_27|(_14|mg/kg_11|)_6|,_5|,_48 (r_appos) injection_0\NN\320852|insufficiency_120|._151 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) insufficiency_23\NN\14462946|injection_120|._31
D002216_D007674 NONE captopril_17\NNP\2673637|NONE_0 (r_pobj) by_16\IN\0|damage_84|was_14|._12 (r_agent) prevented_15\VBN\0|NONE_0 (l_nsubjpass) damage_1\NN\7296428|was_70|by_84|._96
D002216_D007674 NONE captopril_0\NNP\2673637|may_10|,_13|by_15|,_36|increase_49|,_136|diminishing_146|._306 (r_nsubj) reduce_8\VB\441445|NONE_0 (l_advcl) diminishing_26\VBG\169651|captopril_146|may_136|,_133|by_131|,_110|increase_97|,_10|._160 (l_prep) with_36\IN\0|thereby_73|aggregation_49|,_2 (l_pobj) result_38\NN\34213|NONE_0 (l_acl) deposited_44\VBN\1340439|the_36 (l_conj) produced_52\VBN\1617192|that_71|fibrin_61|will_54|be_49|and_36 (l_nsubjpass) damage_49\NN\7296428|will_7|be_12
D002216_D051437 NONE captopril_9\NNP\2673637|(_1|)_9 (r_appos) enzyme_7\NN\14723628|on_19 (r_dobj) converting_6\VBG\126264|NONE_0 (l_prep) on_11\IN\0|enzyme_19 (l_pobj) insufficiency_15\NN\14462946|NONE_0
D002216_D051437 NONE captopril_2\NNP\2673637|NONE_0 (r_pobj) of_1\IN\0|(_13|mg/kg_16|)_21|,_22|inhibitor_27|,_75 (r_prep) injection_0\NN\320852|insufficiency_120|._151 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) insufficiency_23\NN\14462946|injection_120|._31
D002216_D004211 NONE captopril_9\NNP\2673637|(_1|)_9 (r_appos) enzyme_7\NN\14723628|on_19 (r_dobj) converting_6\VBG\126264|NONE_0 (r_acl) angiotensin_5\NN\4522421|NONE_0 (r_pobj) of_4\IN\0|an_13 (r_prep) inhibitor_3\NN\20090|NONE_0 (r_pobj) of_1\IN\0|due_98|._141 (r_prep) effects_0\NNS\13245626|NONE_0 (l_amod) due_16\IN\5174653|of_98|._43 (l_pobj) coagulation_19\NN\13518963|to_17
D014148_D051437 NONE acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_dobj) rise_22\NN\7324673|induction_139|resembling_42|._97 (l_prep) to_23\IN\0|NONE_0 (l_pobj) insufficiency_27\NN\14462946|NONE_0
D014148_D051437 NONE amca_16\NNP\0|tranexamic_17 (r_appos) acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_dobj) rise_22\NN\7324673|induction_139|resembling_42|._97 (l_prep) to_23\IN\0|NONE_0 (l_pobj) insufficiency_27\NN\14462946|NONE_0
D000809_D004211 NONE angiotensin_5\NN\4522421|NONE_0 (r_pobj) of_4\IN\0|an_13 (r_prep) inhibitor_3\NN\20090|NONE_0 (r_pobj) of_1\IN\0|due_98|._141 (r_prep) effects_0\NNS\13245626|NONE_0 (l_amod) due_16\IN\5174653|of_98|._43 (l_pobj) coagulation_19\NN\13518963|to_17
D014508_D007674 NONE urea_9\NN\14727670|and_5|in_9 (r_pobj) in_7\IN\13603305|an_12 (r_prep) increase_6\NN\13576355|NONE_0 (r_pobj) by_4\IN\0|as_13 (r_agent) reflected_3\VBN\923793|renal_16 (r_advcl) damage_1\NN\7296428|was_70|by_84|._96
D014148_D014947 NONE acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_advcl) resembling_28\VBG\2657219|induction_181|rise_42|._55 (l_ccomp) occurring_30\VBG\0|NONE_0 (l_prep) after_31\IN\0|that_15 (l_pobj) trauma_32\NN\14052046|NONE_0
D014148_D014947 NONE amca_16\NNP\0|tranexamic_17 (r_appos) acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_advcl) resembling_28\VBG\2657219|induction_181|rise_42|._55 (l_ccomp) occurring_30\VBG\0|NONE_0 (l_prep) after_31\IN\0|that_15 (l_pobj) trauma_32\NN\14052046|NONE_0
D000809_D011665 NONE angiotensin_5\NN\4522421|NONE_0 (l_acl) converting_6\VBG\126264|NONE_0 (l_prep) on_11\IN\0|enzyme_19 (l_pobj) insufficiency_15\NN\14462946|NONE_0
D000809_D011665 NONE angiotensin_11\NN\4522421|NONE_0 (r_pobj) of_10\IN\0|an_13 (r_prep) inhibitor_9\NN\20090|of_27|(_14|mg/kg_11|)_6|,_5|,_48 (r_appos) injection_0\NN\320852|insufficiency_120|._151 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) insufficiency_23\NN\14462946|injection_120|._31
D014148_D018805 NONE acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_advcl) resembling_28\VBG\2657219|induction_181|rise_42|._55 (l_ccomp) occurring_30\VBG\0|NONE_0 (l_prep) after_31\IN\0|that_15 (l_pobj) trauma_32\NN\14052046|NONE_0 (l_conj) sepsis_34\NN\14174549|or_3|in_7
D014148_D018805 NONE amca_16\NNP\0|tranexamic_17 (r_appos) acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_advcl) resembling_28\VBG\2657219|induction_181|rise_42|._55 (l_ccomp) occurring_30\VBG\0|NONE_0 (l_prep) after_31\IN\0|that_15 (l_pobj) trauma_32\NN\14052046|NONE_0 (l_conj) sepsis_34\NN\14174549|or_3|in_7
D014148_D011665 NONE acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_dobj) rise_22\NN\7324673|induction_139|resembling_42|._97 (l_prep) to_23\IN\0|NONE_0 (l_pobj) insufficiency_27\NN\14462946|NONE_0
D014148_D011665 NONE amca_16\NNP\0|tranexamic_17 (r_appos) acid_14\NN\14818238|and_15 (r_conj) thrombin_11\NN\14735953|NONE_0 (r_pobj) of_10\IN\0|in_39 (r_prep) injection_9\NN\320852|NONE_0 (r_pobj) by_8\IN\0|of_60 (r_prep) induction_0\NN\7450842|rise_139|resembling_181|._236 (r_nsubj) gives_21\VBZ\5020358|NONE_0 (l_dobj) rise_22\NN\7324673|induction_139|resembling_42|._97 (l_prep) to_23\IN\0|NONE_0 (l_pobj) insufficiency_27\NN\14462946|NONE_0
1728522
D019980_D056486 CID acid_9\NN\14818238|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) combination_4\NN\7951464|to_3 (r_pobj) due_2\JJ\5174653|granulomatous_24|._53 (r_prep) hepatitis_1\NN\14127211|NONE_0
D019980_D056486 CID acid_11\NN\14818238|-_4 (r_npadvmod) induced_13\VBN\1627355|clavulanic_16 (r_amod) hepatitis_14\NN\14127211|NONE_0
D019980_D006099 CID acid_9\NN\14818238|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) combination_4\NN\7951464|to_3 (r_pobj) due_2\JJ\5174653|granulomatous_24|._53 (r_prep) hepatitis_1\NN\14127211|NONE_0
D019980_D006099 CID acid_11\NN\14818238|-_4 (r_npadvmod) induced_13\VBN\1627355|clavulanic_16 (r_amod) hepatitis_14\NN\14127211|NONE_0 (r_pobj) with_7\IN\0|a_10 (r_prep) patient_6\NN\9898892|NONE_0 (r_pobj) of_4\IN\0|the_9|with_64 (r_prep) case_3\NN\7283608|we_14|._104 (l_prep) with_15\IN\0|the_73|of_64 (l_pobj) granulomas_18\NNS\14235200|NONE_0
7890216
D014580_D042882 NONE acid_13\NN\14818238|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) response_9\NN\11410625|of_51|:_2|._37 (r_appos) composition_0\NN\5075602|NONE_0 (l_prep) of_1\IN\0|:_49|response_51|._88 (l_pobj) stones_4\NNS\19128|NONE_0
D015282_D000172 NONE octreotide_0\NNP\0|,_49|stones_72|in_79|._100 (l_appos) treatment_4\NN\654885|,_15 (l_prep) for_5\IN\0|an_23|effective_20 (l_pobj) acromegaly_6\NNS\14366759|NONE_0
D015282_D000172 NONE octreotide_28\NN\0|NONE_0 (r_pobj) in_26\IN\13603305|direct_28 (r_prep) methods_25\NNS\5616786|NONE_0 (r_pobj) by_21\IN\0|is_97|,_24|this_22|was_17|treated_48|._93 (r_agent) investigated_20\VBN\644583|NONE_0 (l_conj) treated_29\VBD\2376958|is_145|,_72|this_70|was_65|by_48|._45 (l_dobj) patients_31\NNS\9898892|with_9 (l_compound) acromegalic_30\JJ\0|NONE_0
D002118_D042882 NONE calcium_41\NN\14625458|NONE_0 (r_dobj) containing_40\VBG\2632940|some_17|gall_12 (r_acl) stones_39\NNS\19128|a_36|blocked_34|cystic_26|and_14 (r_conj) duct_35\NN\5248181|at_57|patients_36|will_27|._44 (r_dobj) have_31\VB\7846|in_190|,_177|octreotide_175|stones_151|are_144 (r_conj) induced_4\VBN\1627355|NONE_0 (l_dobj) stones_6\NNS\19128|in_39|,_26|octreotide_24|are_7|have_151
D002118_D042882 NONE calcium_41\NN\14625458|NONE_0 (r_dobj) containing_40\VBG\2632940|some_17|gall_12 (r_acl) stones_39\NNS\19128|a_36|blocked_34|cystic_26|and_14 (r_conj) duct_35\NN\5248181|at_57|patients_36|will_27|._44 (r_dobj) have_31\VB\7846|in_190|,_177|octreotide_175|stones_151|are_144 (r_conj) induced_4\VBN\1627355|NONE_0 (l_ccomp) are_7\VBP\13600404|in_46|,_33|octreotide_31|stones_7|have_144 (l_prep) in_18\IN\13603305|generally_58|small_48|although_10|,_2|,_45 (l_pobj) common_19\JJ\8673395|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) disease_24\NN\14061805|NONE_0
D002118_D042882 NONE calcium_41\NN\14625458|NONE_0 (r_dobj) containing_40\VBG\2632940|some_17|gall_12 (r_acl) stones_39\NNS\19128|a_36|blocked_34|cystic_26|and_14
D015282_D042882 CID octreotide_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|gall_20|bladder_15 (r_acl) stones_4\NNS\19128|NONE_0
D015282_D042882 CID octreotide_0\NNP\0|,_49|stones_72|in_79|._100 (r_nsubj) induces_8\VBZ\1627355|NONE_0 (l_dobj) stones_11\NNS\19128|octreotide_72|,_23|in_7|._28
D015282_D042882 CID octreotide_28\NN\0|NONE_0 (r_pobj) in_26\IN\13603305|direct_28 (r_prep) methods_25\NNS\5616786|NONE_0 (r_pobj) by_21\IN\0|is_97|,_24|this_22|was_17|treated_48|._93 (r_agent) investigated_20\VBN\644583|NONE_0 (l_conj) treated_29\VBD\2376958|is_145|,_72|this_70|was_65|by_48|._45 (l_prep) with_32\IN\0|patients_9 (l_pobj) stones_34\NNS\19128|NONE_0
D015282_D042882 CID octreotide_3\NN\0|in_15|,_2|stones_24|are_31|have_175 (r_advmod) induced_4\VBN\1627355|NONE_0 (l_dobj) stones_6\NNS\19128|in_39|,_26|octreotide_24|are_7|have_151
D015282_D042882 CID octreotide_3\NN\0|in_15|,_2|stones_24|are_31|have_175 (r_advmod) induced_4\VBN\1627355|NONE_0 (l_ccomp) are_7\VBP\13600404|in_46|,_33|octreotide_31|stones_7|have_144 (l_prep) in_18\IN\13603305|generally_58|small_48|although_10|,_2|,_45 (l_pobj) common_19\JJ\8673395|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) disease_24\NN\14061805|NONE_0
D015282_D042882 CID octreotide_3\NN\0|in_15|,_2|stones_24|are_31|have_175 (r_advmod) induced_4\VBN\1627355|NONE_0 (l_conj) have_31\VB\7846|in_190|,_177|octreotide_175|stones_151|are_144 (l_dobj) duct_35\NN\5248181|at_57|patients_36|will_27|._44 (l_conj) stones_39\NNS\19128|a_36|blocked_34|cystic_26|and_14
D002784_D042882 NONE cholesterol_21\NN\15058310|71_12|and_8 (r_conj) %_17\NN\0|that_22|they_17 (r_dobj) contained_15\VBD\2632940|analysis_89|,_19|._43 (r_ccomp) showed_12\VBD\2137132|NONE_0 (l_nsubj) analysis_1\NN\633864|,_70|contained_89|._132 (l_prep) of_2\IN\0|chemical_18 (l_pobj) stones_4\NNS\19128|NONE_0
D002784_D042882 NONE cholesterol_36\NN\15058310|NONE_0 (r_nsubj) rich_37\JJ\7942152|that_35|stones_24 (r_acomp) were_35\VBD\0|NONE_0 (r_ccomp) suggesting_31\VBG\1010118|after_139|,_112|five_110|dissolution_13|,_2|._50 (r_advcl) showed_12\VBD\2137132|NONE_0 (l_dobj) dissolution_29\NN\13518963|after_126|,_99|five_97|,_11|suggesting_13|._63 (l_compound) stone_28\NN\19128|either_48|partial_41|gall_5
D002784_D042882 NONE cholesterol_14\NN\15058310|,_6|and_4|rich_12 (r_conj) multiple_11\JJ\5859630|,_2 (r_conj) small_9\JJ\5220461|generally_10|although_38|,_46|in_48|,_93 (r_acomp) are_7\VBP\13600404|in_46|,_33|octreotide_31|stones_7|have_144 (r_ccomp) induced_4\VBN\1627355|NONE_0 (l_dobj) stones_6\NNS\19128|in_39|,_26|octreotide_24|are_7|have_151
D002784_D042882 NONE cholesterol_14\NN\15058310|,_6|and_4|rich_12 (r_conj) multiple_11\JJ\5859630|,_2 (r_conj) small_9\JJ\5220461|generally_10|although_38|,_46|in_48|,_93 (r_acomp) are_7\VBP\13600404|in_46|,_33|octreotide_31|stones_7|have_144 (l_prep) in_18\IN\13603305|generally_58|small_48|although_10|,_2|,_45 (l_pobj) common_19\JJ\8673395|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) disease_24\NN\14061805|NONE_0
D002784_D042882 NONE cholesterol_14\NN\15058310|,_6|and_4|rich_12 (r_conj) multiple_11\JJ\5859630|,_2 (r_conj) small_9\JJ\5220461|generally_10|although_38|,_46|in_48|,_93 (r_acomp) are_7\VBP\13600404|in_46|,_33|octreotide_31|stones_7|have_144 (r_ccomp) induced_4\VBN\1627355|NONE_0 (l_conj) have_31\VB\7846|in_190|,_177|octreotide_175|stones_151|are_144 (l_dobj) duct_35\NN\5248181|at_57|patients_36|will_27|._44 (l_conj) stones_39\NNS\19128|a_36|blocked_34|cystic_26|and_14
9390208
D002955_D064420 NONE leucovorin_19\NN\0|dose_14|and_4|(_11|mfl_12|)_15|:_16|benefit_33 (r_conj) 5-fu_17\CD\0|NONE_0 (l_conj) benefit_26\NN\13278375|dose_47|and_37|leucovorin_33|(_22|mfl_21|)_18|:_17 (l_conj) toxicity_32\NN\13576101|low_50|palliative_46|and_27
D005472_D001943 NONE 5-fu_17\CD\0|NONE_0 (r_pobj) of_13\IN\0|48-hour_28|continuous_20 (r_prep) infusion_12\NN\14589223|of_86|._107 (r_conj) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|infusion_86|._193 (l_pobj) cancer_6\NN\14239425|NONE_0
D005472_D001943 NONE 5-fu_34\CD\0|NONE_0 (r_pobj) of_33\IN\0|continuous_20 (r_prep) infusion_32\NN\14589223|1_17|and_15 (r_conj) day_28\NN\15154774|NONE_0 (r_pobj) on_27\IN\0|from_148|,_114|we_112|patients_98|by_27|,_12|m2_4|,_52|with_63|,_78|m2_87|for_91|._115 (r_prep) treated_8\VBD\2376958|NONE_0 (l_dobj) patients_10\NNS\9898892|from_50|,_16|we_14|by_71|,_86|m2_94|on_98|,_150|with_161|,_176|m2_185|for_189|._213 (l_prep) with_11\IN\0|13_12 (l_pobj) cancer_18\NN\14239425|NONE_0
D002955_D001943 NONE leucovorin_19\NN\0|dose_14|and_4|(_11|mfl_12|)_15|:_16|benefit_33 (r_conj) 5-fu_17\CD\0|NONE_0 (r_pobj) of_13\IN\0|48-hour_28|continuous_20 (r_prep) infusion_12\NN\14589223|of_86|._107 (r_conj) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|infusion_86|._193 (l_pobj) cancer_6\NN\14239425|NONE_0
D002955_D001943 NONE leucovorin_43\NN\0|together_14 (r_pobj) with_42\IN\0|from_211|,_177|we_175|patients_161|by_90|,_75|m2_67|on_63|,_11|,_15|m2_24|for_28|._52 (r_prep) treated_8\VBD\2376958|NONE_0 (l_dobj) patients_10\NNS\9898892|from_50|,_16|we_14|by_71|,_86|m2_94|on_98|,_150|with_161|,_176|m2_185|for_189|._213 (l_prep) with_11\IN\0|13_12 (l_pobj) cancer_18\NN\14239425|NONE_0
D008942_D064420 NONE mitoxantrone_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|treated_33|metastatic_25|breast_14 (r_prep) cancer_6\NN\14239425|NONE_0 (r_pobj) of_1\IN\0|infusion_86|._193 (r_prep) treatment_0\NN\654885|NONE_0 (l_conj) infusion_12\NN\14589223|of_86|._107 (l_prep) of_13\IN\0|48-hour_28|continuous_20 (l_pobj) 5-fu_17\CD\0|NONE_0 (l_conj) benefit_26\NN\13278375|dose_47|and_37|leucovorin_33|(_22|mfl_21|)_18|:_17 (l_conj) toxicity_32\NN\13576101|low_50|palliative_46|and_27
C085788_D064420 NONE mfl_21\NNP\0|dose_26|and_16|leucovorin_12|(_1|)_3|:_4|benefit_21 (r_appos) 5-fu_17\CD\0|NONE_0 (l_conj) benefit_26\NN\13278375|dose_47|and_37|leucovorin_33|(_22|mfl_21|)_18|:_17 (l_conj) toxicity_32\NN\13576101|low_50|palliative_46|and_27
C085788_D064420 NONE regimen_2\NN\5898568|benefit_35|and_43|induces_47|._92 (r_nsubj) achieves_3\VBZ\2524171|NONE_0 (l_conj) induces_8\VBZ\1627355|regimen_47|benefit_12|and_4|._45 (l_dobj) toxicity_10\NN\13576101|at_9
D008942_D001943 NONE mitoxantrone_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|treated_33|metastatic_25|breast_14 (r_prep) cancer_6\NN\14239425|NONE_0
D008942_D001943 NONE mitoxantrone_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|from_121|,_87|we_85|patients_71|,_15|m2_23|on_27|,_79|with_90|,_105|m2_114|for_118|._142 (r_prep) treated_8\VBD\2376958|NONE_0 (l_dobj) patients_10\NNS\9898892|from_50|,_16|we_14|by_71|,_86|m2_94|on_98|,_150|with_161|,_176|m2_185|for_189|._213 (l_prep) with_11\IN\0|13_12 (l_pobj) cancer_18\NN\14239425|NONE_0
C085788_D001943 NONE mfl_21\NNP\0|dose_26|and_16|leucovorin_12|(_1|)_3|:_4|benefit_21 (r_appos) 5-fu_17\CD\0|NONE_0 (r_pobj) of_13\IN\0|48-hour_28|continuous_20 (r_prep) infusion_12\NN\14589223|of_86|._107 (r_conj) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|infusion_86|._193 (l_pobj) cancer_6\NN\14239425|NONE_0
D005472_D064420 NONE 5-fu_17\CD\0|NONE_0 (l_conj) benefit_26\NN\13278375|dose_47|and_37|leucovorin_33|(_22|mfl_21|)_18|:_17 (l_conj) toxicity_32\NN\13576101|low_50|palliative_46|and_27
7088431
D004054_D014625 CID diethylstilbestrol_21\NN\14749794|NONE_0 (r_pobj) to_20\IN\0|in_9 (r_prep) exposed_17\VBN\2110927|young_12 (r_acl) women_16\NNS\9605289|NONE_0 (r_pobj) in_14\IN\13603305|follow_10|-_4 (r_prep) up_13\NN\153263|NONE_0 (r_pobj) at_10\IN\14622893|cases_58 (r_prep) detected_9\VBD\2163746|are_76|._88 (l_nsubj) cases_1\NNS\7283608|at_58 (l_prep) of_2\IN\0|two_10 (l_pobj) adenocarcinoma_5\NN\14242337|NONE_0 (l_prep) of_6\IN\0|clear_26|cell_20 (l_pobj) vagina_8\NN\5250659|NONE_0
D004054_D018262 CID des_6\NNP\14749794|-_3 (r_npadvmod) exposed_8\VBN\2110927|under_18 (r_amod) offspring_9\NN\10235549|NONE_0 (r_pobj) in_5\IN\13603305|of_29|._42 (r_prep) development_0\NN\248977|NONE_0 (l_prep) of_1\IN\0|in_29|._71 (l_pobj) adenocarcinoma_4\NN\14242337|NONE_0
D004054_D018262 CID diethylstilbestrol_21\NN\14749794|NONE_0 (r_pobj) to_20\IN\0|in_9 (r_prep) exposed_17\VBN\2110927|young_12 (r_acl) women_16\NNS\9605289|NONE_0 (r_pobj) in_14\IN\13603305|follow_10|-_4 (r_prep) up_13\NN\153263|NONE_0 (r_pobj) at_10\IN\14622893|cases_58 (r_prep) detected_9\VBD\2163746|are_76|._88 (l_nsubj) cases_1\NNS\7283608|at_58 (l_prep) of_2\IN\0|two_10 (l_pobj) adenocarcinoma_5\NN\14242337|NONE_0 (l_prep) of_6\IN\0|clear_26|cell_20 (l_pobj) vagina_8\NN\5250659|NONE_0
18417364
D009538_D009759 CID nicotine_0\NN\14712692|-_8 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) nystagmus_3\NN\337486|with_21|._47
D009538_D009759 CID nicotine_3\NN\14712692|-_8 (r_npadvmod) induced_5\VBN\1627355|(_18|nin_19|)_22 (r_amod) nystagmus_6\NN\337486|NONE_0
D009538_D009759 CID nicotine_3\NN\14712692|-_8 (r_npadvmod) induced_5\VBN\1627355|(_18|nin_19|)_22 (r_amod) nystagmus_6\NN\337486|NONE_0 (l_appos) nin_8\NNP\0|induced_19|(_1|)_3
D010100_D009759 NONE oxygen_4\NN\14622893|dependent_13|(_23|bold_24|)_28|activity_30|in_46 (r_nmod) levels_12\NNS\4916342|NONE_0 (r_pobj) with_2\IN\0|nin_15|._107 (r_prep) correlated_1\VBD\2657219|NONE_0 (l_nsubj) nin_0\NNP\0|with_15|._122
9869257
D012601_D000647 CID scopolamine_36\NN\14712692|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|NONE_0 (r_acl) amnesia_27\NN\5669934|NONE_0
C098725_D000647 CID s-(-)-et-126_41\NNP\0|the_28|m1-selective_24 (r_appos) antagonist_40\NN\7846|both_76|the_71|non_67|selective_63|antimuscarinic_53|drug_38|and_21 (r_conj) scopolamine_36\NN\14712692|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) induced_28\VBN\1627355|NONE_0 (r_acl) amnesia_27\NN\5669934|NONE_0
C087567_D000647 NONE pg-9_8\NNP\0|in_37|,_2|before_46|,_73|prevented_75|._203 (r_nsubj) administered_18\VBN\2436349|NONE_0 (l_conj) prevented_26\VBN\0|in_112|,_77|pg-9_75|before_29|,_2|._128 (l_dobj) amnesia_27\NN\5669934|NONE_0
C087567_D000647 NONE pg-9_6\NNP\0|per_18|,_27|i.c.v._29|)_35 (r_nmod) microg_11\NN\0|in_48|,_13|also_30|able_35|,_80|demonstrating_82|._134 (r_nsubj) was_17\VBD\0|NONE_0 (l_acomp) able_19\JJ\0|in_83|,_48|microg_35|also_5|,_45|demonstrating_47|._99 (l_xcomp) prevent_21\VB\0|NONE_0 (l_dobj) amnesia_25\NN\5669934|to_33
3015567
D009599_D007022 CID nitroprusside_0\NNP\0|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hypotension_3\NN\14057371|secretion_24|._180
D009599_D007022 CID nitroprusside_7\RB\0|-_13 (r_advmod) induced_9\VBN\1627355|NONE_0 (r_amod) hypotension_10\NN\14057371|NONE_0
D003345_D007022 NONE corticosterone_18\NN\14752057|a_9|between_21 (r_compound) level_19\NN\4916342|NONE_0 (r_pobj) at_15\IN\14622893|NONE_0 (r_prep) occurs_14\VBZ\0|suppression_96|is_16|and_4|._66 (r_conj) observed_12\VBN\2163746|NONE_0 (l_nsubjpass) suppression_0\NN\13489037|is_80|and_92|occurs_96|._162 (l_appos) secretion_3\NN\13526110|of_9 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) response_5\NN\11410625|NONE_0 (l_prep) to_6\IN\0|NONE_0 (l_pobj) hypotension_10\NN\14057371|NONE_0
8739323
D008466_D007674 NONE nitrogranulogen_8\NN\0|such_8 (r_pobj) as_7\IN\14622893|anticancer_22 (r_prep) drugs_5\NNS\14778436|NONE_0 (r_pobj) of_3\IN\0|the_23|nephrotoxic_19|5-fu_86|administered_118|mtx_156 (r_prep) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D008466_D007674 NONE ng_10\NNP\13717155|,_3|methotrexate_5 (r_appos) nitrogranulogen_8\NN\0|such_8 (r_pobj) as_7\IN\14622893|anticancer_22 (r_prep) drugs_5\NNS\14778436|NONE_0 (r_pobj) of_3\IN\0|the_23|nephrotoxic_19|5-fu_86|administered_118|mtx_156 (r_prep) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D005472_D003556 NONE 5-fu_20\CD\0|NONE_0 (r_pobj) with_19\IN\0|when_14 (r_prep) combined_18\VBN\2630189|it_40|did_37|not_33|complication_18|._26 (r_advcl) cause_14\VB\7323922|cy_62|cystitis_40|in_31|,_17|but_15 (r_conj) caused_1\VBD\1617192|NONE_0 (l_dobj) cystitis_3\NN\14566129|cy_22|in_9|,_23|but_25|cause_40
D008727_D007674 NONE methotrexate_13\NNP\2722166|ng_5|,_2 (r_conj) nitrogranulogen_8\NN\0|such_8 (r_pobj) as_7\IN\14622893|anticancer_22 (r_prep) drugs_5\NNS\14778436|NONE_0 (r_pobj) of_3\IN\0|the_23|nephrotoxic_19|5-fu_86|administered_118|mtx_156 (r_prep) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D008727_D007674 NONE mtx_15\NNP\0|,_4 (r_appos) methotrexate_13\NNP\2722166|ng_5|,_2 (r_conj) nitrogranulogen_8\NN\0|such_8 (r_pobj) as_7\IN\14622893|anticancer_22 (r_prep) drugs_5\NNS\14778436|NONE_0 (r_pobj) of_3\IN\0|the_23|nephrotoxic_19|5-fu_86|administered_118|mtx_156 (r_prep) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D008727_D007674 NONE mtx_33\NNP\0|the_179|nephrotoxic_175|of_156|5-fu_70|administered_38 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D008727_D007674 NONE mtx_6\NNP\0|NONE_0 (r_pobj) of_5\IN\0|that_20|+_7 (r_prep) nephrotoxicity_4\NN\0|studies_22|is_55|._83
D003520_D006470 CID cy_0\NNP\0|cystitis_22|in_31|,_45|but_47|cause_62 (r_nsubj) caused_1\VBD\1617192|NONE_0 (l_dobj) cystitis_3\NN\14566129|cy_22|in_9|,_23|but_25|cause_40
D005472_D007674 NONE 5-fluorouracil_18\CD\0|(_15|)_20|and_22|cyclophosphamide_26 (r_punct) 5-fu_20\CD\0|the_109|nephrotoxic_105|of_86|administered_32|mtx_70 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D005472_D007674 NONE 5-fu_20\CD\0|the_109|nephrotoxic_105|of_86|administered_32|mtx_70 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D005472_D007674 NONE 5-fu_35\CD\0|[_7|+_2 (r_conj) mtx_33\NNP\0|the_179|nephrotoxic_175|of_156|5-fu_70|administered_38 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D005472_D007674 NONE 5-fu_8\CD\0|lower_34 (r_nsubj) is_13\VBZ\0|studies_77|nephrotoxicity_55|._28 (r_ccomp) indicate_2\VBP\952524|NONE_0 (l_dobj) nephrotoxicity_4\NN\0|studies_22|is_55|._83
D003520_D007674 NONE cyclophosphamide_23\NN\0|5-fluorouracil_26|(_11|)_6|and_4 (r_conj) 5-fu_20\CD\0|the_109|nephrotoxic_105|of_86|administered_32|mtx_70 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D003520_D007674 NONE cy_25\NNP\0|NONE_0 (r_appos) cyclophosphamide_23\NN\0|5-fluorouracil_26|(_11|)_6|and_4 (r_conj) 5-fu_20\CD\0|the_109|nephrotoxic_105|of_86|administered_32|mtx_70 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D003520_D007674 NONE cy_37\NNP\0|+_2 (r_conj) 5-fu_35\CD\0|[_7|+_2 (r_conj) mtx_33\NNP\0|the_179|nephrotoxic_175|of_156|5-fu_70|administered_38 (r_appos) action_2\NN\30358|was_186|in_200|._229 (l_amod) nephrotoxic_1\JJ\0|the_4|of_19|5-fu_105|administered_137|mtx_175
D003520_D007674 NONE cy_10\NNP\0|+_2|administered_3 (r_conj) 5-fu_8\CD\0|lower_34 (r_nsubj) is_13\VBZ\0|studies_77|nephrotoxicity_55|._28 (r_ccomp) indicate_2\VBP\952524|NONE_0 (l_dobj) nephrotoxicity_4\NN\0|studies_22|is_55|._83
D005472_D006470 NONE 5-fu_20\CD\0|NONE_0 (r_pobj) with_19\IN\0|when_14 (r_prep) combined_18\VBN\2630189|it_40|did_37|not_33|complication_18|._26 (r_advcl) cause_14\VB\7323922|cy_62|cystitis_40|in_31|,_17|but_15 (r_conj) caused_1\VBD\1617192|NONE_0 (l_dobj) cystitis_3\NN\14566129|cy_22|in_9|,_23|but_25|cause_40
D003520_D003556 CID cy_0\NNP\0|cystitis_22|in_31|,_45|but_47|cause_62 (r_nsubj) caused_1\VBD\1617192|NONE_0 (l_dobj) cystitis_3\NN\14566129|cy_22|in_9|,_23|but_25|cause_40
D008727_D006470 NONE mtx_22\NNP\0|and_4 (r_conj) 5-fu_20\CD\0|NONE_0 (r_pobj) with_19\IN\0|when_14 (r_prep) combined_18\VBN\2630189|it_40|did_37|not_33|complication_18|._26 (r_advcl) cause_14\VB\7323922|cy_62|cystitis_40|in_31|,_17|but_15 (r_conj) caused_1\VBD\1617192|NONE_0 (l_dobj) cystitis_3\NN\14566129|cy_22|in_9|,_23|but_25|cause_40
D008727_D003556 NONE mtx_22\NNP\0|and_4 (r_conj) 5-fu_20\CD\0|NONE_0 (r_pobj) with_19\IN\0|when_14 (r_prep) combined_18\VBN\2630189|it_40|did_37|not_33|complication_18|._26 (r_advcl) cause_14\VB\7323922|cy_62|cystitis_40|in_31|,_17|but_15 (r_conj) caused_1\VBD\1617192|NONE_0 (l_dobj) cystitis_3\NN\14566129|cy_22|in_9|,_23|but_25|cause_40
20880751
D018698_D004409 NONE glutamate_28\NN\15010703|ionotropic_28|,_19|and_21|systems_59 (r_compound) receptors_29\NNS\5225602|dopamine_66|receptor_57|,_40 (l_conj) systems_36\NNS\3575240|ionotropic_87|glutamate_59|,_40|and_38 (l_prep) in_37\IN\13603305|dopaminergic_38|neurotransmitter_25 (l_pobj) pathophysiology_39\NN\0|NONE_0 (l_prep) of_40\IN\0|the_20 (l_pobj) dyskinesias_44\NNS\14084880|NONE_0
D004298_D004409 NONE dopamine_9\NN\14807737|this_5 (r_compound) precursor_10\NN\14580897|NONE_0 (r_pobj) of_7\IN\0|the_18|term_9 (r_prep) use_6\NN\407535|however_23|,_16|is_31|by_46|._94 (r_nsubjpass) complicated_12\VBN\126264|NONE_0 (l_agent) by_13\IN\0|however_69|,_62|use_46|is_15|._48 (l_pobj) fluctuations_16\NNS\7345593|NONE_0 (l_conj) dyskinesias_18\NNS\14084880|disabling_27|and_4
D004298_D004409 NONE dopamine_21\NN\14807737|receptor_9|,_26|receptors_66 (r_compound) subtypes_23\NNS\0|promising_124|of_108|,_20 (l_conj) receptors_29\NNS\5225602|dopamine_66|receptor_57|,_40 (l_conj) systems_36\NNS\3575240|ionotropic_87|glutamate_59|,_40|and_38 (l_prep) in_37\IN\13603305|dopaminergic_38|neurotransmitter_25 (l_pobj) pathophysiology_39\NN\0|NONE_0 (l_prep) of_40\IN\0|the_20 (l_pobj) dyskinesias_44\NNS\14084880|NONE_0
D007980_D004409 CID levodopa_0\NNP\14604959|-_8|dyskinesias_17|:_65|filling_67|._99 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesias_3\NNS\14084880|levodopa_17|-_9|:_48|filling_50|._82
D007980_D004409 CID levodopa_17\NN\14604959|-_8 (r_npadvmod) induced_19\VBN\1627355|underlying_20 (r_amod) dyskinesias_20\NNS\14084880|a_44|key_42
D007980_D004409 CID levodopa_41\NN\14604959|-_8 (r_npadvmod) induced_43\VBN\1627355|NONE_0 (r_amod) dyskinesias_44\NNS\14084880|NONE_0
D007980_D010300 NONE levodopa_0\NNP\14604959|-_8|dyskinesias_17|:_65|filling_67|._99 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesias_3\NNS\14084880|levodopa_17|-_9|:_48|filling_50|._82 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pobj) disease_9\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_0\NNP\14604959|drug_31|._76 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) drug_5\NN\14778436|levodopa_31|._45 (l_prep) for_6\IN\0|the_24|effective_15 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) disease_12\NN\14061805|NONE_0
20098969
D008694_D006212 NONE methamphetamine_0\NN\2704153|stimulant_46|._215 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) stimulant_7\NN\5816287|methamphetamine_46|._169 (l_relcl) increases_9\VBZ\13576355|a_42|addictive_35|,_26|powerful_24 (l_conj) produce_16\VB\7555863|that_57|wakefulness_42|and_8 (l_dobj) effects_18\NNS\13245626|can_18 (l_prep) as_20\IN\14622893|other_19 (l_pobj) dysrhythmias_22\NNS\0|such_16 (l_conj) hypertension_24\NN\14057371|cardiac_22|,_2 (l_conj) hallucinations_26\NNS\14376855|,_2
D008694_D001523 NONE methamphetamine_0\NN\2704153|stimulant_46|._215 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) stimulant_7\NN\5816287|methamphetamine_46|._169 (l_relcl) increases_9\VBZ\13576355|a_42|addictive_35|,_26|powerful_24 (l_conj) produce_16\VB\7555863|that_57|wakefulness_42|and_8 (l_dobj) effects_18\NNS\13245626|can_18 (l_prep) as_20\IN\14622893|other_19 (l_pobj) dysrhythmias_22\NNS\0|such_16 (l_conj) hypertension_24\NN\14057371|cardiac_22|,_2 (l_conj) hallucinations_26\NNS\14376855|,_2 (l_conj) behavior_30\NN\407535|,_14|and_12
D008694_-1 NONE methamphetamine_3\NN\2704153|NONE_0 (r_dobj) abusing_2\VBG\2514187|dental_16 (r_acl) patients_1\NNS\9898892|can_33|with_45|._136 (r_nsubj) present_5\VB\28270|NONE_0 (l_prep) with_6\IN\0|patients_45|can_12|._91 (l_pobj) hygiene_9\NN\14494893|NONE_0 (l_conj) xerostomia_11\NN\14536438|poor_19|oral_14|,_2 (l_conj) caries_14\NNS\13456715|,_10 (l_appos) mouth_18\NN\5610008|rampant_22|(_7|,_7|and_9|wear_29
D008694_-1 NONE methamphetamines_23\NNS\2704153|who_19|may_15|be_11 (r_dobj) abusing_22\VBG\2514187|NONE_0 (r_relcl) patients_18\NNS\9898892|NONE_0 (r_dobj) manage_17\VBP\2524171|practitioners_28|and_4 (r_conj) recognize_15\VBP\686447|to_29 (r_ccomp) help_12\VB\407535|case_64|was_17|._91 (r_advcl) presented_10\VBN\2137132|NONE_0 (l_nsubjpass) case_2\NN\7283608|was_47|help_64|._155 (l_acl) showing_3\VBG\6887726|this_19|clinical_14 (l_dobj) manifestations_5\NNS\7321772|NONE_0 (l_prep) of_6\IN\0|oral_20 (l_pobj) mouth_8\NN\5610008|NONE_0
D008694_D003731 CID methamphetamine_3\NN\2704153|NONE_0 (r_dobj) abusing_2\VBG\2514187|dental_16 (r_acl) patients_1\NNS\9898892|can_33|with_45|._136 (r_nsubj) present_5\VB\28270|NONE_0 (l_prep) with_6\IN\0|patients_45|can_12|._91 (l_pobj) hygiene_9\NN\14494893|NONE_0 (l_conj) xerostomia_11\NN\14536438|poor_19|oral_14|,_2 (l_conj) caries_14\NNS\13456715|,_10
D008694_D003731 CID methamphetamine_5\NN\2704153|NONE_0 (r_pobj) of_4\IN\0|her_8|for_19 (r_prep) use_3\NN\407535|she_17|and_38|experienced_50|._122 (r_dobj) reported_1\VBD\831651|NONE_0 (l_conj) experienced_12\VBN\2108377|she_67|use_50|and_12|._72 (l_dobj) episodes_16\NNS\7283608|had_38|not_34|started_20
D008694_D001145 NONE methamphetamine_0\NN\2704153|stimulant_46|._215 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) stimulant_7\NN\5816287|methamphetamine_46|._169 (l_relcl) increases_9\VBZ\13576355|a_42|addictive_35|,_26|powerful_24 (l_conj) produce_16\VB\7555863|that_57|wakefulness_42|and_8 (l_dobj) effects_18\NNS\13245626|can_18 (l_prep) as_20\IN\14622893|other_19 (l_pobj) dysrhythmias_22\NNS\0|such_16
D008694_D006973 NONE methamphetamine_0\NN\2704153|stimulant_46|._215 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) stimulant_7\NN\5816287|methamphetamine_46|._169 (l_relcl) increases_9\VBZ\13576355|a_42|addictive_35|,_26|powerful_24 (l_conj) produce_16\VB\7555863|that_57|wakefulness_42|and_8 (l_dobj) effects_18\NNS\13245626|can_18 (l_prep) as_20\IN\14622893|other_19 (l_pobj) dysrhythmias_22\NNS\0|such_16 (l_conj) hypertension_24\NN\14057371|cardiac_22|,_2
D008694_D014987 NONE methamphetamine_3\NN\2704153|NONE_0 (r_dobj) abusing_2\VBG\2514187|dental_16 (r_acl) patients_1\NNS\9898892|can_33|with_45|._136 (r_nsubj) present_5\VB\28270|NONE_0 (l_prep) with_6\IN\0|patients_45|can_12|._91 (l_pobj) hygiene_9\NN\14494893|NONE_0 (l_conj) xerostomia_11\NN\14536438|poor_19|oral_14|,_2
D008694_D057085 NONE methamphetamine_3\NN\2704153|NONE_0 (r_dobj) abusing_2\VBG\2514187|dental_16 (r_acl) patients_1\NNS\9898892|can_33|with_45|._136 (r_nsubj) present_5\VB\28270|NONE_0 (l_prep) with_6\IN\0|patients_45|can_12|._91 (l_pobj) hygiene_9\NN\14494893|NONE_0 (l_conj) xerostomia_11\NN\14536438|poor_19|oral_14|,_2 (l_conj) caries_14\NNS\13456715|,_10 (l_conj) wear_25\NN\14561618|rampant_51|(_36|mouth_29|,_22|and_20
16428221
D008774_D019969 NONE methylphenidate_20\NN\4320126|in_23 (r_compound) intake_21\NN\13440063|NONE_0 (r_pobj) after_19\IN\0|in_49|stroke_25|has_18|been_14|._40 (r_prep) reported_18\VBN\831651|vasculitis_109|is_64|well_61|,_46|and_44 (r_conj) documented_8\VBN\1000214|NONE_0 (l_nsubjpass) vasculitis_1\NN\14336539|is_45|well_48|,_63|and_65|reported_109 (l_acl) associated_2\VBN\628491|cerebral_20 (l_prep) with_3\IN\0|NONE_0 (l_pobj) abuse_5\NN\418025|NONE_0
D008774_D002544 NONE methylphenidate_20\NN\4320126|in_23 (r_compound) intake_21\NN\13440063|NONE_0 (r_pobj) after_19\IN\0|in_49|stroke_25|has_18|been_14|._40 (r_prep) reported_18\VBN\831651|vasculitis_109|is_64|well_61|,_46|and_44 (l_nsubjpass) stroke_15\NN\556313|in_24|has_7|been_11|after_25|._65
D008774_D002544 NONE methylphenidate_14\NN\4320126|NONE_0 (r_pobj) with_13\IN\0|who_16|was_12|due_21|and_42|suffered_46 (r_prep) treated_12\VBN\2376958|a_29|old_19 (l_conj) suffered_19\VBD\2110220|who_62|was_58|with_46|due_25|and_4 (l_prep) from_20\IN\0|NONE_0 (l_pobj) strokes_23\NNS\556313|NONE_0
D008774_D020293 CID methylphenidate_4\NN\4320126|oral_5|in_23 (r_compound) intake_5\NN\13440063|NONE_0 (r_dobj) following_2\VBG\8180190|cerebral_20|:_49|report_58|._64 (r_prep) vasculitis_1\NNS\14336539|NONE_0
D008774_D020293 CID methylphenidate_20\NN\4320126|in_23 (r_compound) intake_21\NN\13440063|NONE_0 (r_pobj) after_19\IN\0|in_49|stroke_25|has_18|been_14|._40 (r_prep) reported_18\VBN\831651|vasculitis_109|is_64|well_61|,_46|and_44 (r_conj) documented_8\VBN\1000214|NONE_0 (l_nsubjpass) vasculitis_1\NN\14336539|is_45|well_48|,_63|and_65|reported_109
D008774_D014657 NONE methylphenidate_3\NN\4320126|that_5|should_36|be_43|in_57 (l_dobj) vasculitis_5\NN\14336539|NONE_0
D008774_D014657 NONE methylphenidate_18\NN\4320126|NONE_0 (r_compound) therapy_19\NN\657604|NONE_0 (r_pobj) of_17\IN\0|a_10 (r_prep) history_16\NN\15120823|neurological_28|and_6 (r_conj) symptoms_13\NNS\5823932|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) patients_10\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|that_62|methylphenidate_57|should_21|be_14 (r_prep) considered_8\VBN\689344|we_63|._90 (l_nsubjpass) methylphenidate_3\NN\4320126|that_5|should_36|be_43|in_57 (l_dobj) vasculitis_5\NN\14336539|NONE_0
D008774_D006948 NONE methylphenidate_14\NN\4320126|NONE_0 (r_pobj) with_13\IN\0|who_16|was_12|due_21|and_42|suffered_46 (r_prep) treated_12\VBN\2376958|a_29|old_19 (l_prep) due_15\IN\5174653|who_37|was_33|with_21|and_21|suffered_25 (l_pobj) hyperactivity_17\NN\14052403|to_3
220563
C023470_D010523 CID maleate_1\NN\2718811|NONE_0 (l_conj) neuropathy_4\NN\14204950|perhexiline_35|and_15|._10
C023470_D010523 CID maleate_12\NN\2718811|and_39|in_43 (r_pobj) with_10\IN\0|a_26|of_11|for_101 (r_prep) complication_7\NN\1073995|NONE_0 (r_pobj) as_5\IN\14622893|neuropathy_26|has_15|been_11|._179 (r_prep) noted_4\VBN\1009240|NONE_0 (l_nsubjpass) neuropathy_1\NN\14204950|has_11|been_15|as_26|._205
C023470_D000787 NONE maleate_12\NN\2718811|and_39|in_43 (r_pobj) with_10\IN\0|a_26|of_11|for_101 (r_prep) complication_7\NN\1073995|NONE_0 (l_prep) for_30\IN\0|a_127|of_112|with_101 (l_pobj) treatment_33\NN\654885|NONE_0 (l_prep) of_34\IN\0|the_27|prophylactic_23 (l_pobj) pectoris_36\NN\0|NONE_0
9721172
D011241_D002779 NONE prednisone_6\NN\2721538|ursodeoxycholic_22|,_2 (l_conj) tacrolimus_10\VB\0|,_11|and_9 (l_conj) disease_14\NN\14061805|then_33|,_18
D007052_D001649 NONE ibuprofen_30\JJ\3828465|NONE_0 (r_compound) use_31\NN\407535|NONE_0 (r_pobj) with_29\IN\0|child_168|;_33|this_31|was_26|temporally_22|._18 (r_prep) associated_28\VBN\628491|NONE_0 (l_nsubjpass) child_3\NN\9622049|;_135|this_137|was_142|temporally_146|with_168|._186 (l_relcl) developed_5\VBD\1753788|a_31|healthy_18|described_116 (l_dobj) syndrome_15\NN\5870365|who_69
D016559_D002779 NONE tacrolimus_10\VB\0|,_11|and_9 (l_conj) disease_14\NN\14061805|then_33|,_18
D011241_D005355 NONE prednisone_6\NN\2721538|ursodeoxycholic_22|,_2 (r_conj) acid_4\NN\14818238|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) therapy_1\NN\657604|NONE_0 (r_pobj) despite_0\IN\7501545|unrelenting_104|,_115|with_117|._175 (r_prep) was_15\VBD\0|NONE_0 (l_prep) with_18\IN\0|despite_117|unrelenting_13|,_2|._58 (l_pobj) cirrhosis_19\NN\14116321|NONE_0
D014580_D005355 NONE acid_4\NN\14818238|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) therapy_1\NN\657604|NONE_0 (r_pobj) despite_0\IN\7501545|unrelenting_104|,_115|with_117|._175 (r_prep) was_15\VBD\0|NONE_0 (l_prep) with_18\IN\0|despite_117|unrelenting_13|,_2|._58 (l_pobj) cirrhosis_19\NN\14116321|NONE_0
D007052_D013262 CID ibuprofen_30\JJ\3828465|NONE_0 (r_compound) use_31\NN\407535|NONE_0 (r_pobj) with_29\IN\0|child_168|;_33|this_31|was_26|temporally_22|._18 (r_prep) associated_28\VBN\628491|NONE_0 (l_nsubjpass) child_3\NN\9622049|;_135|this_137|was_142|temporally_146|with_168|._186 (l_relcl) described_23\VBN\1001294|a_147|healthy_134|developed_116 (l_nsubjpass) syndrome_21\NN\5870365|after_22|is_9
D016559_D005355 NONE tacrolimus_10\VB\0|,_11|and_9 (r_conj) prednisone_6\NN\2721538|ursodeoxycholic_22|,_2 (r_conj) acid_4\NN\14818238|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) therapy_1\NN\657604|NONE_0 (r_pobj) despite_0\IN\7501545|unrelenting_104|,_115|with_117|._175 (r_prep) was_15\VBD\0|NONE_0 (l_prep) with_18\IN\0|despite_117|unrelenting_13|,_2|._58 (l_pobj) cirrhosis_19\NN\14116321|NONE_0
D014580_D002779 NONE acid_4\NN\14818238|NONE_0 (l_conj) prednisone_6\NN\2721538|ursodeoxycholic_22|,_2 (l_conj) tacrolimus_10\VB\0|,_11|and_9 (l_conj) disease_14\NN\14061805|then_33|,_18
7919560
D000667_D009205 CID ampicillin_7\NN\3910033|NONE_0 (r_pobj) by_6\IN\0|multiforme_51|._13 (r_agent) caused_5\VBN\1617192|NONE_0 (l_nsubj) multiforme_1\NN\0|by_51|._64 (l_conj) myocarditis_4\NN\14338942|erythema_41|and_21
D000667_D009205 CID ampicillin_12\NN\3910033|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) caused_10\VBN\1617192|a_63|of_56 (r_acl) case_3\NN\7283608|to_12|._81 (l_prep) of_4\IN\0|a_7|caused_56 (l_pobj) multiforme_6\NNS\0|NONE_0 (l_conj) myocarditis_9\NN\14338942|erythema_41|and_21
D000667_D004892 CID ampicillin_7\NN\3910033|NONE_0 (r_pobj) by_6\IN\0|multiforme_51|._13 (r_agent) caused_5\VBN\1617192|NONE_0 (l_nsubj) multiforme_1\NN\0|by_51|._64
D000667_D004892 CID ampicillin_12\NN\3910033|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) caused_10\VBN\1617192|a_63|of_56 (r_acl) case_3\NN\7283608|to_12|._81 (l_prep) of_4\IN\0|a_7|caused_56 (l_pobj) multiforme_6\NNS\0|NONE_0
D010406_D004342 NONE penicillins_11\NNS\2716866|NONE_0 (r_pobj) to_10\IN\0|myocarditis_61|manifestation_25|._14 (r_prep) is_2\VBZ\0|NONE_0 (l_attr) manifestation_7\NN\7321772|myocarditis_36|to_25|._39 (l_prep) of_8\IN\0|a_35|rare_33 (l_pobj) allergy_9\NN\14533203|NONE_0
D010406_D009205 NONE penicillins_11\NNS\2716866|NONE_0 (r_pobj) to_10\IN\0|myocarditis_61|manifestation_25|._14 (r_prep) is_2\VBZ\0|NONE_0 (l_nsubj) myocarditis_1\NN\14338942|manifestation_36|to_61|._75
D000667_D018805 NONE ampicillin_8\NN\3910033|NONE_0 (r_pobj) with_7\IN\0|boy_16|was_12|and_16|gentamicin_20|._62 (r_prep) treated_6\VBN\2376958|NONE_0 (l_conj) gentamicin_10\NN\2716866|boy_36|was_32|with_20|and_4|._42 (l_prep) because_11\IN\0|NONE_0 (l_pobj) septicemia_14\NN\14189204|of_13
D005839_D018805 NONE gentamicin_10\NN\2716866|boy_36|was_32|with_20|and_4|._42 (l_prep) because_11\IN\0|NONE_0 (l_pobj) septicemia_14\NN\14189204|of_13
2425813
D011239_D009133 CID prednisolone_14\NN\2721538|NONE_0 (r_pobj) of_13\IN\0|the_32|subcutaneous_28 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) following_9\VBG\8180190|enlargement_55|in_15|._57 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) enlargement_1\NN\363260|in_40|following_55|._112 (l_conj) wastage_4\NN\13458571|liver_29|and_11
D011239_D006529 CID prednisolone_14\NN\2721538|NONE_0 (r_pobj) of_13\IN\0|the_32|subcutaneous_28 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) following_9\VBG\8180190|enlargement_55|in_15|._57 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) enlargement_1\NN\363260|in_40|following_55|._112
12695819
D016559_D009422 NONE tacrolimus_17\NNS\0|NONE_0 (l_relcl) developed_19\VBD\1753788|NONE_0 (l_dobj) complications_21\NNS\1073995|who_25
D016559_D020258 NONE tacrolimus_7\NN\0|-_10 (r_npadvmod) induced_9\VBN\1627355|in_22 (r_amod) neurotoxicity_10\NN\0|NONE_0
D016559_D020258 NONE tacrolimus_15\NN\0|-_10 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) neurotoxicity_18\NN\0|NONE_0
6133211
D012460_D000013 NONE sulphasalazine_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|who_13 (r_dobj) received_12\VBD\2210855|inflammatory_31|bowel_18 (r_relcl) disease_10\NN\14061805|NONE_0 (r_pobj) with_7\IN\0|two_12 (r_prep) mothers_6\NNS\10399491|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) born_3\VBN\0|three_15|,_2|,_115 (r_acl) infants_1\NNS\9918248|were_126|have_140|._171 (r_nsubjpass) found_20\VBN\13279262|NONE_0 (l_xcomp) have_22\VB\7846|infants_140|were_14|._31 (l_dobj) anomalies_25\NNS\14501726|to_25
D012460_D015212 NONE sulphasalazine_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|who_13 (r_dobj) received_12\VBD\2210855|inflammatory_31|bowel_18 (r_relcl) disease_10\NN\14061805|NONE_0
2355241
D007980_D002543 NONE levodopa_23\NN\14604959|NONE_0 (r_pobj) of_22\IN\0|the_23|hypotensive_19|and_12|mechanism_30 (r_prep) effect_21\NN\34213|incidence_119|may_28|._108 (r_dobj) reflect_18\VB\923793|NONE_0 (l_nsubj) incidence_2\NN\13821570|may_91|effect_119|._227 (l_prep) of_3\IN\0|the_18|low_14|as_24 (l_pobj) haemorrhage_5\NN\14285662|NONE_0
D009638_D003643 NONE noradrenaline_31\NN\14807929|reduced_8|in_21 (r_amod) levels_32\NNS\4916342|to_25 (r_pobj) due_28\IN\5174653|a_24|hypotensive_22 (r_amod) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (r_conj) effect_21\NN\34213|incidence_119|may_28|._108 (r_dobj) reflect_18\VB\923793|NONE_0 (l_nsubj) incidence_2\NN\13821570|may_91|effect_119|._227 (l_prep) as_6\IN\14622893|the_42|low_38|of_24 (l_pobj) cause_8\NN\7323922|NONE_0 (l_prep) of_9\IN\0|a_8|in_9 (l_pobj) death_10\NN\7296428|NONE_0
D007980_D007022 CID levodopa_23\NN\14604959|NONE_0 (r_pobj) of_22\IN\0|the_23|hypotensive_19|and_12|mechanism_30 (r_prep) effect_21\NN\34213|incidence_119|may_28|._108 (l_amod) hypotensive_20\JJ\10405694|the_4|of_19|and_31|mechanism_49
D007980_D007022 CID levodopa_23\NN\14604959|NONE_0 (r_pobj) of_22\IN\0|the_23|hypotensive_19|and_12|mechanism_30 (r_prep) effect_21\NN\34213|incidence_119|may_28|._108 (l_conj) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (l_amod) hypotensive_26\JJ\10405694|a_2|due_22
D007980_D010300 NONE levodopa_23\NN\14604959|NONE_0 (r_pobj) of_22\IN\0|the_23|hypotensive_19|and_12|mechanism_30 (r_prep) effect_21\NN\34213|incidence_119|may_28|._108 (r_dobj) reflect_18\VB\923793|NONE_0 (l_nsubj) incidence_2\NN\13821570|may_91|effect_119|._227 (l_prep) as_6\IN\14622893|the_42|low_38|of_24 (l_pobj) cause_8\NN\7323922|NONE_0 (l_prep) in_11\IN\13603305|a_17|of_9 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) disease_16\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_23\NN\14604959|NONE_0 (r_pobj) of_22\IN\0|the_23|hypotensive_19|and_12|mechanism_30 (r_prep) effect_21\NN\34213|incidence_119|may_28|._108 (l_conj) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (l_amod) due_28\IN\5174653|a_24|hypotensive_22 (l_pobj) levels_32\NNS\4916342|to_25 (l_prep) in_33\IN\13603305|reduced_29|noradrenaline_21 (l_pobj) brain_36\NN\5462674|NONE_0 (l_amod) parkinsonian_35\JJ\0|the_4
D009638_D002543 NONE noradrenaline_31\NN\14807929|reduced_8|in_21 (r_amod) levels_32\NNS\4916342|to_25 (r_pobj) due_28\IN\5174653|a_24|hypotensive_22 (r_amod) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (r_conj) effect_21\NN\34213|incidence_119|may_28|._108 (r_dobj) reflect_18\VB\923793|NONE_0 (l_nsubj) incidence_2\NN\13821570|may_91|effect_119|._227 (l_prep) of_3\IN\0|the_18|low_14|as_24 (l_pobj) haemorrhage_5\NN\14285662|NONE_0
D009638_D010300 NONE noradrenaline_31\NN\14807929|reduced_8|in_21 (r_amod) levels_32\NNS\4916342|to_25 (r_pobj) due_28\IN\5174653|a_24|hypotensive_22 (r_amod) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (r_conj) effect_21\NN\34213|incidence_119|may_28|._108 (r_dobj) reflect_18\VB\923793|NONE_0 (l_nsubj) incidence_2\NN\13821570|may_91|effect_119|._227 (l_prep) as_6\IN\14622893|the_42|low_38|of_24 (l_pobj) cause_8\NN\7323922|NONE_0 (l_prep) in_11\IN\13603305|a_17|of_9 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) disease_16\NN\14061805|NONE_0
D009638_D010300 NONE noradrenaline_31\NN\14807929|reduced_8|in_21 (r_amod) levels_32\NNS\4916342|to_25 (l_prep) in_33\IN\13603305|reduced_29|noradrenaline_21 (l_pobj) brain_36\NN\5462674|NONE_0 (l_amod) parkinsonian_35\JJ\0|the_4
D009638_D007022 NONE noradrenaline_31\NN\14807929|reduced_8|in_21 (r_amod) levels_32\NNS\4916342|to_25 (r_pobj) due_28\IN\5174653|a_24|hypotensive_22 (r_amod) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (r_conj) effect_21\NN\34213|incidence_119|may_28|._108 (l_amod) hypotensive_20\JJ\10405694|the_4|of_19|and_31|mechanism_49
D009638_D007022 NONE noradrenaline_31\NN\14807929|reduced_8|in_21 (r_amod) levels_32\NNS\4916342|to_25 (r_pobj) due_28\IN\5174653|a_24|hypotensive_22 (r_amod) mechanism_27\NN\13446390|the_53|hypotensive_49|of_30|and_18 (l_amod) hypotensive_26\JJ\10405694|a_2|due_22
D007980_D003643 NONE levodopa_23\NN\14604959|NONE_0 (r_pobj) of_22\IN\0|the_23|hypotensive_19|and_12|mechanism_30 (r_prep) effect_21\NN\34213|incidence_119|may_28|._108 (r_dobj) reflect_18\VB\923793|NONE_0 (l_nsubj) incidence_2\NN\13821570|may_91|effect_119|._227 (l_prep) as_6\IN\14622893|the_42|low_38|of_24 (l_pobj) cause_8\NN\7323922|NONE_0 (l_prep) of_9\IN\0|a_8|in_9 (l_pobj) death_10\NN\7296428|NONE_0
17608141
D008070_D005334 NONE lipopolysaccharide_0\JJ\0|NONE_0 (r_compound) pretreatment_1\NN\0|did_13|not_17|temperature_43|later_107|._112 (r_nsubj) affect_4\VB\26192|NONE_0 (l_dobj) temperature_8\NN\13575869|pretreatment_43|did_30|not_26|later_64|._69 (l_conj) hyperthermia_13\NN\14034177|the_55|basal_51|body_45|or_28
D008070_D020258 NONE lipopolysaccharide_11\NN\0|NONE_0 (r_compound) pretreatment_12\NN\0|NONE_0 (r_pobj) by_10\IN\0|nigrostriatal_49|dopaminergic_35|in_8 (r_prep) neurotoxicity_7\NN\0|attenuation_66|methamphetamine_51|-_36|._56
D008070_D020258 NONE lipopolysaccharide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|the_10|,_21|factor_59 (r_prep) roles_7\NNS\719494|in_31|,_18|we_16|._161 (l_appos) factor_17\NN\7326557|the_69|of_59|,_38 (l_conj) treatment_19\NN\654885|a_44|inflammatory_38|,_2 (l_prep) in_20\IN\13603305|NONE_0 (l_pcomp) modulating_21\VBG\1724459|NONE_0 (l_dobj) neurotoxicity_28\NN\0|NONE_0
D008070_D020258 NONE lipopolysaccharide_8\NN\0|systemic_9|in_32 (r_compound) pretreatment_9\NN\0|NONE_0 (l_prep) in_10\IN\13603305|systemic_41|lipopolysaccharide_32 (l_pcomp) exerting_11\VBG\1158872|NONE_0 (l_dobj) protection_13\NN\407535|NONE_0 (l_prep) against_14\IN\0|effective_21 (l_pobj) neurotoxicity_20\NN\0|NONE_0
D008694_D020258 NONE methamphetamine_2\NN\2704153|attenuation_15|-_15|neurotoxicity_51|._107 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (l_dobj) neurotoxicity_7\NN\0|attenuation_66|methamphetamine_51|-_36|._56
D008694_D020258 NONE methamphetamine_23\NN\2704153|-_15 (r_npadvmod) induced_25\VBN\1627355|the_20|nigrostriatal_8|dopamine_22 (r_amod) neurotoxicity_28\NN\0|NONE_0
D008694_D020258 NONE methamphetamine_15\NN\2704153|-_15 (r_npadvmod) induced_17\VBN\1627355|nigrostriatal_8|dopamine_22 (r_amod) neurotoxicity_20\NN\0|NONE_0
D004298_D020258 NONE dopamine_27\NN\14807737|the_42|induced_22|nigrostriatal_14 (r_compound) neurotoxicity_28\NN\0|NONE_0
D004298_D020258 NONE dopamine_19\NN\14807737|induced_22|nigrostriatal_14 (r_compound) neurotoxicity_20\NN\0|NONE_0
D008694_D009422 NONE methamphetamine_10\NN\2704153|-_15 (r_npadvmod) induced_12\VBN\1627355|dopaminergic_8|terminal_21 (r_amod) damage_15\NN\7296428|NONE_0
D008694_D005334 CID methamphetamine_10\NN\2704153|-_15 (r_npadvmod) elicited_12\VBN\1617192|NONE_0 (r_amod) hyperthermia_13\NN\14034177|the_55|basal_51|body_45|or_28
1130930
D002512_D007683 CID sodium_23\NN\14625458|NONE_0 (r_pobj) of_21\IN\0|a_14 (r_prep) combination_20\NN\7951464|while_28|they_22|were_17|and_34|gentamicin_38 (r_dobj) receiving_18\VBG\2210855|patients_117|necrosis_84|,_18|._76 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) necrosis_5\NN\11444117|patients_33|,_66|receiving_84|._160
D005839_D007683 CID sulfate_26\NN\15010703|NONE_0 (r_compound) therapy_27\NN\657604|NONE_0 (r_dobj) gentamicin_25\NN\2716866|while_66|they_60|were_55|combination_38|and_4 (r_conj) receiving_18\VBG\2210855|patients_117|necrosis_84|,_18|._76 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) necrosis_5\NN\11444117|patients_33|,_66|receiving_84|._160
D005839_D007674 NONE gentamicin_5\NN\2716866|combined_21 (r_compound) regimen_6\NN\5898568|NONE_0 (r_pobj) of_1\IN\0|._42 (r_prep) nephrotoxicity_0\NN\0|NONE_0
D002512_D051437 NONE sodium_23\NN\14625458|NONE_0 (r_pobj) of_21\IN\0|a_14 (r_prep) combination_20\NN\7951464|while_28|they_22|were_17|and_34|gentamicin_38 (r_dobj) receiving_18\VBG\2210855|patients_117|necrosis_84|,_18|._76 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) necrosis_5\NN\11444117|patients_33|,_66|receiving_84|._160 (l_acl) characterized_7\VBN\609683|acute_24|tubular_18|,_2 (l_agent) by_9\IN\0|NONE_0 (l_pobj) failure_13\NN\66216|clinically_35
D005839_D009846 NONE sulfate_26\NN\15010703|NONE_0 (r_compound) therapy_27\NN\657604|NONE_0 (r_dobj) gentamicin_25\NN\2716866|while_66|they_60|were_55|combination_38|and_4 (r_conj) receiving_18\VBG\2210855|patients_117|necrosis_84|,_18|._76 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) necrosis_5\NN\11444117|patients_33|,_66|receiving_84|._160 (l_acl) characterized_7\VBN\609683|acute_24|tubular_18|,_2 (l_agent) by_9\IN\0|NONE_0 (l_pobj) failure_13\NN\66216|clinically_35
D005839_D051437 NONE sulfate_26\NN\15010703|NONE_0 (r_compound) therapy_27\NN\657604|NONE_0 (r_dobj) gentamicin_25\NN\2716866|while_66|they_60|were_55|combination_38|and_4 (r_conj) receiving_18\VBG\2210855|patients_117|necrosis_84|,_18|._76 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) necrosis_5\NN\11444117|patients_33|,_66|receiving_84|._160 (l_acl) characterized_7\VBN\609683|acute_24|tubular_18|,_2 (l_agent) by_9\IN\0|NONE_0 (l_pobj) failure_13\NN\66216|clinically_35
D002512_D009846 NONE sodium_23\NN\14625458|NONE_0 (r_pobj) of_21\IN\0|a_14 (r_prep) combination_20\NN\7951464|while_28|they_22|were_17|and_34|gentamicin_38 (r_dobj) receiving_18\VBG\2210855|patients_117|necrosis_84|,_18|._76 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) necrosis_5\NN\11444117|patients_33|,_66|receiving_84|._160 (l_acl) characterized_7\VBN\609683|acute_24|tubular_18|,_2 (l_agent) by_9\IN\0|NONE_0 (l_pobj) failure_13\NN\66216|clinically_35
D002512_D007674 NONE cephalothin_3\NN\2996840|-_11 (r_compound) gentamicin_5\NN\2716866|combined_21 (r_compound) regimen_6\NN\5898568|NONE_0 (r_pobj) of_1\IN\0|._42 (r_prep) nephrotoxicity_0\NN\0|NONE_0
8649546
D007980_D004409 CID levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) dyskinesia_5\NN\14084880|NONE_0
D007980_D004409 CID levodopa_14\RB\14604959|-_8 (r_npadvmod) induced_16\VBN\1627355|ballistic_8|in_41 (r_amod) dyskinesia_20\NN\14084880|that_101|administration_96|may_51
D011433_D004409 NONE propranolol_7\NN\0|NONE_0 (r_pcomp) by_6\IN\0|of_31|._37 (r_prep) improvement_0\NN\7359599|NONE_0 (l_prep) of_1\IN\0|by_31|._68 (l_pobj) dyskinesia_5\NN\14084880|NONE_0
D011433_D004409 NONE propranolol_18\NN\0|patients_102|._65 (r_dobj) received_14\VBN\2210855|NONE_0 (l_nsubj) patients_1\NNS\9898892|propranolol_102|._167 (l_acl) suffering_2\VBG\14322699|seven_15 (l_prep) with_10\IN\0|from_30 (l_pobj) dyskinesia_13\NN\14084880|NONE_0
D011433_D010300 NONE propranolol_7\NN\0|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) disease_11\NN\14061805|NONE_0
D011433_D010300 NONE propranolol_18\NN\0|patients_102|._65 (r_dobj) received_14\VBN\2210855|NONE_0 (l_nsubj) patients_1\NNS\9898892|propranolol_102|._167 (l_acl) suffering_2\VBG\14322699|seven_15 (l_prep) from_3\IN\0|with_30 (l_pobj) disease_6\NN\14061805|NONE_0
D011433_D010300 NONE propranolol_18\NN\0|patients_102|._65 (r_dobj) received_14\VBN\2210855|NONE_0 (l_nsubj) patients_1\NNS\9898892|propranolol_102|._167 (l_acl) suffering_2\VBG\14322699|seven_15 (l_prep) from_3\IN\0|with_30 (l_pobj) disease_6\NN\14061805|NONE_0 (l_appos) pd_8\NNP\14625458|parkinson_21|(_1|)_2
D007980_D010300 NONE levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) dyskinesia_5\NN\14084880|NONE_0 (r_pobj) of_1\IN\0|by_31|._68 (r_prep) improvement_0\NN\7359599|NONE_0 (l_prep) by_6\IN\0|of_31|._37 (l_pcomp) propranolol_7\NN\0|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) disease_11\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_14\RB\14604959|-_8 (r_npadvmod) induced_16\VBN\1627355|ballistic_8|in_41 (r_amod) dyskinesia_20\NN\14084880|that_101|administration_96|may_51 (l_prep) in_21\IN\13603305|induced_41|ballistic_33 (l_pobj) pd_22\NNP\14625458|NONE_0
9406968
D001127_D011141 NONE vasopressin_4\NN\5407119|NONE_0 (r_pobj) of_2\IN\0|the_15 (r_prep) expression_1\NN\4679549|gene_41|was_103|in_120|polyuria_154|using_164|._227 (r_nsubjpass) investigated_22\VBN\644583|NONE_0 (l_parataxis) polyuria_29\NN\14113228|expression_154|gene_113|was_51|in_34|using_10|._73
D001127_D011141 NONE avp_6\NNP\0|(_1|)_3|in_10 (r_nmod) gene_8\NN\8459252|expression_41|was_62|in_79|polyuria_113|using_123|._186 (r_nsubjpass) investigated_22\VBN\644583|NONE_0 (l_parataxis) polyuria_29\NN\14113228|expression_154|gene_113|was_51|in_34|using_10|._73
D014667_D003919 NONE vasopressin_5\NN\5407119|in_17 (r_compound) gene_6\NN\8459252|NONE_0 (l_prep) in_7\IN\13603305|vasopressin_17 (l_pobj) nuclei_12\NNS\5445668|NONE_0 (l_prep) of_13\IN\0|the_42|paraventricular_38 (l_pobj) rat_20\NN\2329401|NONE_0 (l_compound) insipidus_19\NN\0|the_29|diabetes_9
D008094_D003919 NONE lithium_15\NN\14625458|-_7 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) diabetes_18\NN\14075199|the_20|insipidus_9 (r_compound) rat_20\NN\2329401|NONE_0 (l_compound) insipidus_19\NN\0|the_29|diabetes_9
D008094_D003919 NONE li_35\NNP\14625458|-_2 (r_npadvmod) induced_37\VBN\1627355|NONE_0 (r_amod) diabetes_38\NN\14075199|the_15|insipidus_9 (r_compound) rat_40\NN\2329401|NONE_0 (l_compound) insipidus_39\NN\0|the_24|diabetes_9
D001127_D003681 NONE avp_19\NNP\0|NONE_0 (r_pobj) of_17\IN\0|the_14|upregulation_22 (r_prep) elevation_16\NN\7445480|NONE_0 (r_pobj) to_14\IN\0|that_82|dehydration_77|may_15 (r_prep) contribute_13\VB\126264|results_87|._149 (l_nsubj) dehydration_4\NN\14536438|that_5|may_62|to_77
D001127_D003681 NONE avp_24\NNP\0|gene_4|in_20 (r_compound) expression_26\NN\4679549|NONE_0 (r_pobj) of_23\IN\0|the_17 (r_prep) upregulation_22\NN\0|the_36|of_22 (r_conj) elevation_16\NN\7445480|NONE_0 (r_pobj) to_14\IN\0|that_82|dehydration_77|may_15 (r_prep) contribute_13\VB\126264|results_87|._149 (l_nsubj) dehydration_4\NN\14536438|that_5|may_62|to_77
D008094_D003681 NONE li_35\NNP\14625458|-_2 (r_npadvmod) induced_37\VBN\1627355|NONE_0 (r_amod) diabetes_38\NN\14075199|the_15|insipidus_9 (r_compound) rat_40\NN\2329401|NONE_0 (r_pobj) of_33\IN\0|the_8 (r_prep) son_32\NN\10285938|the_16|and_8 (r_conj) pvn_29\NN\0|NONE_0 (r_pobj) in_27\IN\13603305|avp_20|gene_16 (r_prep) expression_26\NN\4679549|NONE_0 (r_pobj) of_23\IN\0|the_17 (r_prep) upregulation_22\NN\0|the_36|of_22 (r_conj) elevation_16\NN\7445480|NONE_0 (r_pobj) to_14\IN\0|that_82|dehydration_77|may_15 (r_prep) contribute_13\VB\126264|results_87|._149 (l_nsubj) dehydration_4\NN\14536438|that_5|may_62|to_77
D008094_D011141 NONE lithium_26\NN\14625458|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) rats_24\NNS\2329401|NONE_0 (r_pobj) in_23\IN\13603305|expression_120|gene_79|was_17|polyuria_34|using_44|._107 (r_prep) investigated_22\VBN\644583|NONE_0 (l_parataxis) polyuria_29\NN\14113228|expression_154|gene_113|was_51|in_34|using_10|._73
D008094_D011141 NONE li)-induced_28\JJ\0|(_1|,_20 (r_amod) polyuria_29\NN\14113228|expression_154|gene_113|was_51|in_34|using_10|._73
D018021_D011141 CID licl_9\NNP\0|that_15|for_18 (r_dobj) contained_8\VBD\2632940|a_12 (r_relcl) diet_6\NN\7560652|NONE_0 (r_dobj) consuming_4\VBG\1168468|the_21|male_17|wistar_12 (r_acl) rats_3\NNS\2329401|polyuria_84|._92 (r_nsubj) developed_19\VBN\1753788|NONE_0 (l_dobj) polyuria_21\NN\14113228|rats_84|._8
D001127_D003919 NONE avp_19\NNP\0|NONE_0 (r_pobj) of_17\IN\0|the_14|upregulation_22 (r_prep) elevation_16\NN\7445480|NONE_0 (l_conj) upregulation_22\NN\0|the_36|of_22 (l_prep) of_23\IN\0|the_17 (l_pobj) expression_26\NN\4679549|NONE_0 (l_prep) in_27\IN\13603305|avp_20|gene_16 (l_pobj) pvn_29\NN\0|NONE_0 (l_conj) son_32\NN\10285938|the_16|and_8 (l_prep) of_33\IN\0|the_8 (l_pobj) rat_40\NN\2329401|NONE_0 (l_compound) insipidus_39\NN\0|the_24|diabetes_9
D001127_D003919 NONE avp_24\NNP\0|gene_4|in_20 (r_compound) expression_26\NN\4679549|NONE_0 (l_prep) in_27\IN\13603305|avp_20|gene_16 (l_pobj) pvn_29\NN\0|NONE_0 (l_conj) son_32\NN\10285938|the_16|and_8 (l_prep) of_33\IN\0|the_8 (l_pobj) rat_40\NN\2329401|NONE_0 (l_compound) insipidus_39\NN\0|the_24|diabetes_9
3187073
D005472_D002637 CID 5-fu_6\CD\0|NONE_0 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) on_5\IN\0|NONE_0 (r_prep) patients_4\NNS\9898892|that_5|should_27|under_37|and_61|discontinued_94 (r_nsubj) be_9\VB\14625458|it_55|is_52|._117 (l_conj) discontinued_19\VBN\0|that_99|patients_94|should_67|under_57|and_33 (l_advcl) observed_26\VBN\2163746|that_78|treatment_69|should_59|be_52 (l_nsubjpass) pain_22\NN\14299637|if_9|is_24
D005472_D013610 NONE 5-fu_6\CD\0|NONE_0 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) on_5\IN\0|NONE_0 (r_prep) patients_4\NNS\9898892|that_5|should_27|under_37|and_61|discontinued_94 (r_nsubj) be_9\VB\14625458|it_55|is_52|._117 (l_conj) discontinued_19\VBN\0|that_99|patients_94|should_67|under_57|and_33 (l_advcl) observed_26\VBN\2163746|that_78|treatment_69|should_59|be_52 (l_nsubjpass) pain_22\NN\14299637|if_9|is_24 (l_conj) tachyarrhythmia_24\NN\0|chest_14|or_3
17400887
D013726_D020078 NONE terbutaline_6\JJ\0|neonatal_9|in_22 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) after_4\IN\0|neuroinflammation_47|:_44|implications_46|._69 (r_prep) abnormalities_3\NNS\14034177|NONE_0 (l_nmod) neuroinflammation_0\NN\0|after_47|:_91|implications_93|._116
D013726_D001523 NONE terbutaline_6\JJ\0|neonatal_9|in_22 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) after_4\IN\0|neuroinflammation_47|:_44|implications_46|._69 (r_prep) abnormalities_3\NNS\14034177|NONE_0
D013726_D001321 CID terbutaline_6\JJ\0|neonatal_9|in_22 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) after_4\IN\0|neuroinflammation_47|:_44|implications_46|._69 (r_prep) abnormalities_3\NNS\14034177|NONE_0 (l_appos) implications_11\NNS\5774614|neuroinflammation_93|after_46|:_2|._23 (l_prep) for_12\IN\0|NONE_0 (l_pobj) autism_13\NN\14304060|NONE_0
D013726_D001321 CID terbutaline_0\NNP\0|has_72|been_76|with_92|._148 (r_nsubjpass) associated_13\VBN\628491|NONE_0 (l_prep) with_14\IN\0|terbutaline_92|has_20|been_16|._56 (l_pobj) concordance_16\NN\13968547|NONE_0 (l_prep) for_17\IN\0|increased_22 (l_pobj) autism_18\NN\14304060|NONE_0
D013726_D007752 NONE terbutaline_0\NNP\0|has_72|been_76|with_92|._148 (l_appos) agonist_4\NN\0|,_23|,_36 (l_acl) used_5\VBN\0|a_29|beta2-adrenoceptor_27 (l_xcomp) arrest_7\VB\88481|NONE_0 (l_dobj) labor_9\NN\7974025|to_18
9522152
D002045_D009461 NONE bupivacaine_11\NN\0|NONE_0 (r_pobj) of_7\IN\0|intrathecal_22 (r_prep) injection_6\NN\320852|NONE_0 (r_dobj) following_4\VBG\8180190|a_33|transient_31|neurological_21|._94 (r_acl) deficit_3\NN\5113133|NONE_0
D002045_D009461 NONE bupivacaine_21\NN\0|NONE_0 (r_pobj) with_14\IN\0|unilateral_30|spinal_19 (r_prep) anaesthesia_13\NN\14034177|NONE_0 (r_pobj) after_10\IN\0|that_14 (r_prep) occurred_9\VBD\0|transient_36|neurological_26 (r_relcl) deficit_7\NN\5113133|NONE_0
17562951
C044834_D003920 NONE iodixanol_35\NN\0|NONE_0 (r_pobj) with_34\IN\0|iopamidol_40 (r_prep) with_23\IN\0|dl_32|%_21|,_68|increases_82 (r_prep) were_14\VBD\0|in_58|,_33|scr_31|>_17|._175 (r_conj) increases_6\VBZ\13576355|NONE_0 (l_prep) in_0\IN\13603305|,_25|scr_27|>_41|were_58|._233 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) diabetes_3\NNS\14075199|NONE_0
C044834_D003920 NONE iodixanol_25\NN\0|or_3 (r_conj) iopamidol_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_33|intraarterial_29|to_26|,_47 (r_prep) administration_21\NN\1133281|NONE_0 (r_pobj) after_18\IN\0|rate_101|not_28|different_10|with_88|._121 (r_prep) is_14\VBZ\0|NONE_0 (l_prep) with_32\IN\0|rate_189|not_116|different_98|after_88|._33 (l_conj) without_34\IN\0|or_3 (l_pobj) mellitus_36\NN\0|NONE_0
D000111_D003920 NONE acetylcysteine_16\NN\0|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) use_12\NN\407535|contrast_48|,_33|presence_31|,_2 (r_appos) volume_5\NN\33615|in_26|,_11|,_62|scr_78|,_81|and_83|estimated_87|._155 (l_appos) presence_7\NN\13954253|contrast_17|,_2|,_29|use_31 (l_prep) of_8\IN\0|NONE_0 (l_pobj) mellitus_10\NN\0|NONE_0
D007479_D007674 CID iopamidol_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_33|intraarterial_29|to_26|,_47 (r_prep) administration_21\NN\1133281|NONE_0 (r_pobj) after_18\IN\0|rate_101|not_28|different_10|with_88|._121 (r_prep) is_14\VBZ\0|NONE_0 (l_nsubj) rate_1\NN\13815152|not_73|different_91|after_101|with_189|._222 (l_prep) of_2\IN\0|the_9|,_31|defined_33|,_63 (l_pobj) nephropathy_6\NN\14573196|NONE_0
C044834_D007674 CID iodixanol_25\NN\0|or_3 (r_conj) iopamidol_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_33|intraarterial_29|to_26|,_47 (r_prep) administration_21\NN\1133281|NONE_0 (r_pobj) after_18\IN\0|rate_101|not_28|different_10|with_88|._121 (r_prep) is_14\VBZ\0|NONE_0 (l_nsubj) rate_1\NN\13815152|not_73|different_91|after_101|with_189|._222 (l_prep) of_2\IN\0|the_9|,_31|defined_33|,_63 (l_pobj) nephropathy_6\NN\14573196|NONE_0
D007479_D051436 NONE iopamidol_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|a_51|multicenter_49|,_38|randomized_36|,_26|blind_17|in_27 (r_prep) comparison_12\NN\635850|study_49|rate_111|._206 (l_prep) in_17\IN\13603305|a_78|multicenter_76|,_65|randomized_63|,_53|blind_44|of_27 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) disease_22\NN\14061805|NONE_0
C044834_D051436 NONE iodixanol_16\NN\0|and_4 (r_conj) iopamidol_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|a_51|multicenter_49|,_38|randomized_36|,_26|blind_17|in_27 (r_prep) comparison_12\NN\635850|study_49|rate_111|._206 (l_prep) in_17\IN\13603305|a_78|multicenter_76|,_65|randomized_63|,_53|blind_44|of_27 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) disease_22\NN\14061805|NONE_0
D007479_D003920 NONE iopamidol_24\NN\0|with_40 (r_pobj) with_23\IN\0|dl_32|%_21|,_68|increases_82 (r_prep) were_14\VBD\0|in_58|,_33|scr_31|>_17|._175 (r_conj) increases_6\VBZ\13576355|NONE_0 (l_prep) in_0\IN\13603305|,_25|scr_27|>_41|were_58|._233 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) diabetes_3\NNS\14075199|NONE_0
D007479_D003920 NONE iopamidol_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_33|intraarterial_29|to_26|,_47 (r_prep) administration_21\NN\1133281|NONE_0 (r_pobj) after_18\IN\0|rate_101|not_28|different_10|with_88|._121 (r_prep) is_14\VBZ\0|NONE_0 (l_prep) with_32\IN\0|rate_189|not_116|different_98|after_88|._33 (l_conj) without_34\IN\0|or_3 (l_pobj) mellitus_36\NN\0|NONE_0
12574103
D003907_D006973 CID dexamethasone_1\NN\2721538|prenatal_9 (r_compound) programs_2\NNS\5833840|and_22|injury_32|in_39|._49 (r_compound) hypertension_3\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone_11\NN\2721538|if_12|increase_39 (r_nsubj) programmed_12\VBD\794981|to_39 (l_dobj) increase_15\NN\13576355|if_51|dexamethasone_39 (l_prep) in_16\IN\13603305|a_23|progressive_21 (l_pobj) pressure_18\NN\11419404|NONE_0
D003907_D006973 CID dexamethasone_5\NN\2721538|that_23|on_14 (r_dobj) received_3\VBD\2210855|male_15 (r_relcl) rats_1\NNS\2329401|had_99|pressures_118|at_128 (r_nsubj) elevated_23\VBN\4048568|;_43|group_56|did_62|not_66|reduction_77|._107 (l_dobj) pressures_25\NNS\11419404|rats_118|had_19|at_10
D003907_D006973 CID dexamethasone_5\NN\2721538|that_14|in_30 (r_nsubj) results_8\VBZ\34213|study_48|._135 (l_prep) in_9\IN\13603305|that_44|dexamethasone_30 (l_pobj) reduction_11\NN\351485|NONE_0 (l_prep) in_12\IN\13603305|a_12 (l_pobj) number_14\NN\5107765|NONE_0 (l_conj) glomerulosclerosis_16\NN\0|glomerular_19|,_2|administered_42 (l_conj) hypertension_19\NN\14057371|,_6|and_4
D003907_D005921 NONE dexamethasone_3\NN\2721538|rats_11|on_14|had_45|._105 (r_dobj) given_2\VBN\5892096|NONE_0 (l_advcl) had_11\VBD\0|rats_56|dexamethasone_45|on_31|._60 (l_dobj) glomeruli_13\NNS\5425910|NONE_0 (l_prep) with_14\IN\0|more_15|than_24 (l_pobj) glomerulosclerosis_15\NN\0|NONE_0
D003907_D005921 NONE dexamethasone_5\NN\2721538|that_14|in_30 (r_nsubj) results_8\VBZ\34213|study_48|._135 (l_prep) in_9\IN\13603305|that_44|dexamethasone_30 (l_pobj) reduction_11\NN\351485|NONE_0 (l_prep) in_12\IN\13603305|a_12 (l_pobj) number_14\NN\5107765|NONE_0 (l_conj) glomerulosclerosis_16\NN\0|glomerular_19|,_2|administered_42
D003907_D007674 CID dexamethasone_1\NN\2721538|prenatal_9 (r_compound) programs_2\NNS\5833840|and_22|injury_32|in_39|._49 (r_compound) hypertension_3\NN\14057371|NONE_0 (l_conj) injury_6\NN\14052046|programs_32|and_10|in_7|._17
D003907_D007674 CID dexamethasone_11\NN\2721538|if_12|increase_39 (r_nsubj) programmed_12\VBD\794981|to_39 (l_dobj) increase_15\NN\13576355|if_51|dexamethasone_39 (l_prep) in_16\IN\13603305|a_23|progressive_21 (l_pobj) pressure_18\NN\11419404|NONE_0 (l_conj) injury_21\NN\14052046|blood_25|and_10
D003907_D007674 CID dexamethasone_4\NN\2721538|offspring_31|on_14 (r_dobj) administered_3\VBN\2436349|reduction_65|compared_96|._271 (r_csubj) had_11\VBD\0|NONE_0 (l_dobj) reduction_15\NN\351485|administered_65|compared_31|._206 (l_prep) in_16\IN\13603305|a_16|%_12 (l_pobj) number_18\NN\5107765|NONE_0
D003907_D007674 CID dexamethasone_5\NN\2721538|that_23|on_14 (r_dobj) received_3\VBD\2210855|male_15 (r_relcl) rats_1\NNS\2329401|had_99|pressures_118|at_128 (r_nsubj) elevated_23\VBN\4048568|;_43|group_56|did_62|not_66|reduction_77|._107 (r_ccomp) have_37\VB\7846|NONE_0 (l_dobj) reduction_39\NN\351485|elevated_77|;_34|group_21|did_15|not_11|._30 (l_prep) in_40\IN\13603305|a_12 (l_pobj) number_42\NN\5107765|NONE_0
D003907_D007674 CID dexamethasone_5\NN\2721538|that_14|in_30 (r_nsubj) results_8\VBZ\34213|study_48|._135 (l_prep) in_9\IN\13603305|that_44|dexamethasone_30 (l_pobj) reduction_11\NN\351485|NONE_0 (l_prep) in_12\IN\13603305|a_12 (l_pobj) number_14\NN\5107765|NONE_0
18023325
D004221_D010243 NONE disulfiram_24\NN\3740161|dose_5 (r_compound) intoxication_25\NN\14034177|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) caused_19\VBN\1617192|severe_48|acute_41|sensorimotor_35|axonal_22 (r_acl) polyneuropathy_18\NN\0|NONE_0 (r_dobj) superimposed_13\VBN\1494310|this_68|case_57|and_4|._104 (r_conj) was_1\VBD\0|NONE_0 (l_attr) case_3\NN\7283608|this_11|and_53|superimposed_57|._161 (l_prep) of_4\IN\0|a_7 (l_pobj) palsy_6\JJ\14557898|NONE_0
D004221_D014826 CID disulfiram_6\NN\3740161|acute_6 (r_compound) intoxication_7\NN\14034177|NONE_0 (r_pobj) after_4\IN\0|acute_23|fold_11|._35 (r_prep) palsy_3\JJ\14557898|NONE_0
D004221_D014826 CID disulfiram_6\NN\3740161|a_2 (r_compound) overdose_7\NN\84738|NONE_0 (r_pobj) by_4\IN\0|NONE_0 (r_agent) caused_3\VBN\1617192|acute_28|peripheral_22 (r_acl) neuropathy_2\NN\14204950|rare_51|and_56|is_66 (r_nsubj) is_8\VBZ\0|NONE_0 (l_conj) is_13\VBZ\0|neuropathy_66|rare_15|and_10 (l_attr) report_15\NN\6470073|there_12|._40 (l_acl) leading_18\VBG\4339291|no_16|of_6 (l_prep) to_19\IN\0|NONE_0 (l_pobj) palsy_22\JJ\14557898|NONE_0
D004221_D010523 CID disulfiram_6\NN\3740161|a_2 (r_compound) overdose_7\NN\84738|NONE_0 (r_pobj) by_4\IN\0|NONE_0 (r_agent) caused_3\VBN\1617192|acute_28|peripheral_22 (r_acl) neuropathy_2\NN\14204950|rare_51|and_56|is_66
D004221_D062787 NONE disulfiram_6\NN\3740161|a_2 (r_compound) overdose_7\NN\84738|NONE_0
D004221_D011115 NONE disulfiram_24\NN\3740161|dose_5 (r_compound) intoxication_25\NN\14034177|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) caused_19\VBN\1617192|severe_48|acute_41|sensorimotor_35|axonal_22 (r_acl) polyneuropathy_18\NN\0|NONE_0
12369736
C103477_D009069 NONE 55562_1\CD\0|side_21|,_26 (r_nummod) gr_0\NNP\0|shell_60|prior_66|attenuated_101|._163 (r_nsubj) administered_11\VBN\2436349|NONE_0 (l_conj) attenuated_23\VBD\224901|gr_101|shell_41|prior_35|._62 (l_dobj) hyperactivity_29\NN\14052403|dependently_61
C103477_D009069 NONE 55562_38\CD\0|NONE_0 (r_nummod) gr_37\NNP\0|the_32|5-ht1b_28|receptor_21|(_1|)_8 (r_appos) antagonist_35\NN\7846|NONE_0 (r_pobj) of_31\IN\0|inhibitory_36 (r_prep) effects_30\NNS\13245626|NONE_0 (r_pobj) in_26\IN\13603305|NONE_0 (r_prep) consisting_25\VBG\2603699|core_24|,_20|this_18|and_95|agonist_99|respectively_119 (r_acl) modification_24\NN\191142|the_40|accumbens_36|,_21|but_19 (r_conj) shell_17\NN\2703275|NONE_0 (r_pobj) into_14\IN\0|NONE_0 (r_prep) microinjected_13\VBN\0|5-ht1b_24|receptor_17 (r_acl) ligands_12\NNS\20090|NONE_0 (r_pobj) by_9\IN\0|hyperlocomotion_28|is_12|._230 (r_agent) modified_8\VBN\109660|findings_58|induced_27 (l_nsubjpass) hyperlocomotion_6\NN\0|is_16|by_28|._258
D003042_D009069 CID cocaine_14\NN\3492717|-_7 (r_npadvmod) induced_16\VBN\1627355|the_12|locomotor_8|in_32 (r_amod) hyperactivity_18\NN\14052403|NONE_0
D003042_D009069 CID cocaine_34\NN\3492717|NONE_0 (r_pobj) by_33\IN\0|NONE_0 (r_agent) induced_32\VBN\1627355|the_28|locomotor_24 (r_acl) hyperactivity_31\NN\14052403|NONE_0
D003042_D009069 CID cocaine_18\NN\3492717|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) prior_16\RB\10675876|gr_66|shell_6|attenuated_35|._97 (r_advmod) administered_11\VBN\2436349|NONE_0 (l_conj) attenuated_23\VBD\224901|gr_101|shell_41|prior_35|._62 (l_dobj) hyperactivity_29\NN\14052403|dependently_61
D003042_D009069 CID cocaine_4\NN\3492717|that_5 (r_nsubj) induced_5\VBN\1627355|findings_31|modified_27 (r_ccomp) indicate_2\VBP\952524|NONE_0 (l_ccomp) modified_8\VBN\109660|findings_58|induced_27 (l_nsubjpass) hyperlocomotion_6\NN\0|is_16|by_28|._258
C065046_D009069 CID 93129_44\CD\0|(_4|)_5 (r_nummod) cp_43\NNP\0|,_9 (r_appos) agonist_41\NN\0|core_123|,_119|this_117|consisting_99|and_4|respectively_20 (r_conj) modification_24\NN\191142|the_40|accumbens_36|,_21|but_19 (r_conj) shell_17\NN\2703275|NONE_0 (r_pobj) into_14\IN\0|NONE_0 (r_prep) microinjected_13\VBN\0|5-ht1b_24|receptor_17 (r_acl) ligands_12\NNS\20090|NONE_0 (r_pobj) by_9\IN\0|hyperlocomotion_28|is_12|._230 (r_agent) modified_8\VBN\109660|findings_58|induced_27 (l_nsubjpass) hyperlocomotion_6\NN\0|is_16|by_28|._258
8953972
D004837_D006323 CID epinephrine_0\NN\14807929|role_25 (r_nsubj) has_1\VBZ\13888491|;_55|however_57|,_64|by_70 (l_dobj) role_4\NN\719494|epinephrine_25 (l_prep) in_5\IN\13603305|a_14|proven_12 (l_pobj) arrest_7\NN\88481|NONE_0
D004837_D013345 CID epinephrine_8\NN\14807929|NONE_0 (r_pobj) of_7\IN\0|prehospital_16 (r_prep) use_6\NN\407535|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|fatal_28|intracranial_22|._46 (r_acl) bleeding_2\NN\14285662|NONE_0
D004837_D012128 NONE epinephrine_26\NN\14807929|to_27 (r_dobj) administer_24\VB\2436349|onset_108|paramedics_27|._35 (r_xcomp) led_16\VBD\3202760|NONE_0 (l_nsubj) onset_2\NN\7325190|paramedics_81|administer_108|._143 (l_prep) of_3\IN\0|the_17|sudden_13 (l_pobj) distress_5\NN\7494363|NONE_0
D004837_D005076 NONE epinephrine_26\NN\14807929|to_27 (r_dobj) administer_24\VB\2436349|onset_108|paramedics_27|._35 (r_xcomp) led_16\VBD\3202760|NONE_0 (l_nsubj) onset_2\NN\7325190|paramedics_81|administer_108|._143 (l_prep) of_3\IN\0|the_17|sudden_13 (l_pobj) distress_5\NN\7494363|NONE_0 (l_conj) rash_7\JJ\14321469|respiratory_22|,_2
D004837_D004342 NONE epinephrine_0\NN\14807929|role_25 (r_nsubj) has_1\VBZ\13888491|;_55|however_57|,_64|by_70 (r_ccomp) use_14\NN\407535|should_87|be_94|with_104|._116 (l_prep) by_15\IN\0|has_70|;_15|however_13|,_6 (l_pobj) paramedics_16\NNS\10398624|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) reaction_22\NN\13446390|NONE_0
D004837_D006973 NONE epinephrine_0\NN\14807929|role_25 (r_nsubj) has_1\VBZ\13888491|;_55|however_57|,_64|by_70 (r_ccomp) use_14\NN\407535|should_87|be_94|with_104|._116 (l_prep) by_15\IN\0|has_70|;_15|however_13|,_6 (l_pobj) paramedics_16\NNS\10398624|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) reaction_22\NN\13446390|NONE_0 (l_conj) hypertension_25\NN\14057371|suspected_39|allergic_29|and_11
20588063
D011692_D009401 CID aminonucleoside_17\JJ\0|puromycin_10 (r_amod) nephrosis_18\NN\14304060|NONE_0
D011692_D009401 CID aminonucleoside_2\JJ\0|NONE_0 (r_amod) nephrosis_3\NN\14304060|(_10|pan_11|)_14
9293063
D003613_D006222 CID danazol_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|term_15 (r_prep) treatment_10\NN\654885|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) association_5\NN\8008335|NONE_0 (r_pobj) in_4\IN\13603305|NONE_0 (r_prep) occurring_3\VBG\0|duct_15|._62 (r_acl) hamartoma_2\NN\14234074|NONE_0
D003613_D006222 CID danazol_20\NN\0|term_5 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) on_16\IN\0|who_13|had_9 (r_prep) been_15\VBN\0|a_18 (r_relcl) patient_12\NN\9898892|NONE_0 (r_pobj) in_10\IN\13603305|which_16 (r_prep) developed_9\VBD\1753788|duct_21 (r_relcl) hamartoma_7\NN\14234074|NONE_0
D003613_D001650 CID danazol_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|term_15 (r_prep) treatment_10\NN\654885|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) association_5\NN\8008335|NONE_0 (r_pobj) in_4\IN\13603305|NONE_0 (r_prep) occurring_3\VBG\0|duct_15|._62 (r_acl) hamartoma_2\NN\14234074|NONE_0
D003613_D001650 CID danazol_20\NN\0|term_5 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) on_16\IN\0|who_13|had_9 (r_prep) been_15\VBN\0|a_18 (r_relcl) patient_12\NN\9898892|NONE_0 (r_pobj) in_10\IN\13603305|which_16 (r_prep) developed_9\VBD\1753788|duct_21 (r_relcl) hamartoma_7\NN\14234074|NONE_0
6634932
D010042_D017180 CID ouabain_20\RB\0|-_7 (r_npadvmod) induced_22\VBN\1627355|ventricular_8 (r_amod) tachycardias_24\NNS\14110674|NONE_0
C002616_D017180 NONE um-272_0\NNP\0|(_7|n_8|,_9|n_10|-_11|)_31|,_32|agent_62 (r_punct) dimethylpropranolol_6\NNP\0|,_55|was_57|sublingually_74|to_87|._140 (r_nsubjpass) administered_15\VBN\2436349|NONE_0 (l_prep) to_17\IN\0|dimethylpropranolol_87|,_32|was_30|sublingually_13|._53 (l_pobj) dogs_18\NNS\2083346|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) tachycardias_24\NNS\14110674|NONE_0
C002616_D017180 NONE dimethylpropranolol_6\NNP\0|,_55|was_57|sublingually_74|to_87|._140 (r_nsubjpass) administered_15\VBN\2436349|NONE_0 (l_prep) to_17\IN\0|dimethylpropranolol_87|,_32|was_30|sublingually_13|._53 (l_pobj) dogs_18\NNS\2083346|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) tachycardias_24\NNS\14110674|NONE_0
C002616_D017180 NONE um-272_1\NNP\0|sublingual_11|tachycardia_29|sinus_44|._70 (r_punct) converted_2\VBD\126264|NONE_0 (l_dobj) tachycardia_4\NN\14110674|sublingual_40|um-272_29|sinus_15|._41
15602202
D017963_D009395 CID azithromycin_6\PRP\2716205|NONE_0 (r_pobj) by_5\IN\0|nephritis_18|._15 (r_prep) induced_4\VBN\1627355|NONE_0 (l_nsubj) nephritis_3\NN\14113228|by_18|._33
D017963_D009395 CID azithromycin_10\RB\2716205|-_12 (r_advmod) induced_12\VBN\1627355|,_7|acute_9|interstitial_15 (r_amod) nephritis_16\NN\14113228|girl_74|is_69|with_57|,_43|._9
8638206
D001279_D010243 CID atracurium_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|prolonged_14|in_14 (r_prep) use_4\NN\407535|NONE_0 (r_pobj) after_2\IN\0|persistent_21|._67 (r_prep) paralysis_1\NN\14557898|NONE_0
D001279_D010243 CID besylate_1\NN\0|has_114|also_118|been_123|with_139|,_164|but_166|used_180 (r_nsubjpass) associated_22\VBN\628491|NONE_0 (l_prep) with_23\IN\0|besylate_139|has_25|also_21|been_16|,_25|but_27|used_41 (l_pobj) paralysis_25\NN\14557898|NONE_0
D001279_D010243 CID atracurium_5\NN\0|-_10 (r_npadvmod) related_7\VBN\628491|persisting_18 (r_amod) paralysis_8\NN\14557898|NONE_0
D014673_D010243 CID bromide_21\NN\14904359|such_19 (r_pobj) as_19\IN\14622893|based_17 (r_prep) nmbas_17\NNS\0|reports_116|have_44|often_34|,_32|used_50|._90 (r_dobj) involved_13\VBN\2676054|NONE_0 (l_nsubj) reports_0\NNS\6470073|have_72|often_82|nmbas_116|,_148|used_166|._206 (l_prep) of_1\IN\0|after_24 (l_pobj) paralysis_3\NN\14557898|NONE_0
-1_D010243 NONE benzylisoquinolinium_7\NN\0|a_15|acting_7|eliminated_34 (r_amod) nmba_8\NNP\0|atracurium_57|,_38|,_66 (r_appos) besylate_1\NN\0|has_114|also_118|been_123|with_139|,_164|but_166|used_180 (r_nsubjpass) associated_22\VBN\628491|NONE_0 (l_prep) with_23\IN\0|besylate_139|has_25|also_21|been_16|,_25|but_27|used_41 (l_pobj) paralysis_25\NN\14557898|NONE_0
15632880
D011188_D006947 NONE k(+_7\NNP\0|NONE_0 (r_appos) hyperkalemia_5\NN\14299637|who_14
D011188_D006947 NONE potassium_17\NN\14625458|higher_22|baseline_15|and_17|doses_57 (r_compound) levels_18\NNS\4916342|,_52|and_54|were_58 (r_dobj) had_13\VBD\0|patients_81|older_40|,_2|._167 (r_conj) were_4\VBD\0|NONE_0 (l_nsubj) patients_0\NNS\9898892|older_41|,_79|had_81|._248 (l_relcl) developed_2\VBD\1753788|NONE_0 (l_dobj) hyperkalemia_3\NN\14299637|who_14
D011188_D006947 NONE potassium_22\NN\14625458|NONE_0 (r_compound) supplement_23\NN\6365467|lower_25|baseline_19 (r_compound) doses_24\NNS\3740161|higher_79|baseline_72|potassium_57|and_40 (r_conj) levels_18\NNS\4916342|,_52|and_54|were_58 (r_dobj) had_13\VBD\0|patients_81|older_40|,_2|._167 (r_conj) were_4\VBD\0|NONE_0 (l_nsubj) patients_0\NNS\9898892|older_41|,_79|had_81|._248 (l_relcl) developed_2\VBD\1753788|NONE_0 (l_dobj) hyperkalemia_3\NN\14299637|who_14
D013148_D051437 CID spironolactone_0\NNP\2721160|-_14|insufficiency_29|._90 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) insufficiency_4\NN\14462946|spironolactone_29|-_15|._61
D013148_D051437 CID spironolactone_9\NN\2721160|NONE_0 (r_pobj) of_8\IN\0|the_8 (r_prep) use_7\NN\407535|NONE_0 (r_dobj) evaluating_5\VBG\670261|a_39|previous_37|randomized_28|controlled_17 (r_acl) trial_4\NN\786195|risk_84|._138 (r_nsubj) reported_14\VBD\831651|NONE_0 (l_dobj) risk_17\NN\14541044|trial_84|._54 (l_prep) of_18\IN\0|a_11|low_9 (l_pobj) hyperkalemia_19\NN\14299637|NONE_0 (l_conj) insufficiency_26\NN\14462946|(_15|%_13|)_12|and_10
D013148_D051437 CID spironolactone_21\NN\2721160|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) treated_19\VBN\2376958|failure_17 (r_acl) patients_18\NNS\9898892|NONE_0 (r_pobj) in_15\IN\13603305|renal_20 (r_prep) insufficiency_14\NN\14462946|and_10
D013148_D051437 CID spironolactone_13\NN\2721160|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) discontinuation_11\NN\209943|seven_38|due_34|._88 (r_dobj) required_10\VBD\0|NONE_0 (l_prep) due_14\IN\5174653|seven_72|discontinuation_34|._54 (l_pobj) hyperkalemia_16\NN\14299637|to_3 (l_conj) failure_24\NN\66216|(_18|n_17|)_11|or_9
D013148_D051437 CID spironolactone_0\NNP\2721160|-_14 (r_npadvmod) induced_2\VBN\1627355|and_21 (r_amod) hyperkalemia_3\NN\14299637|renal_17 (r_nmod) insufficiency_6\NN\14462946|common_23|in_30|reported_62|._81
D011188_D003920 NONE potassium_17\NN\14625458|higher_22|baseline_15|and_17|doses_57 (r_compound) levels_18\NNS\4916342|,_52|and_54|were_58 (r_dobj) had_13\VBD\0|patients_81|older_40|,_2|._167 (r_conj) were_4\VBD\0|NONE_0 (l_acomp) older_5\JJR\0|patients_41|,_38|had_40|._207 (l_conj) likely_8\JJ\0|and_9 (l_xcomp) have_10\VB\7846|more_15 (l_dobj) diabetes_11\NNS\14075199|to_8
D011188_D003920 NONE potassium_22\NN\14625458|NONE_0 (r_compound) supplement_23\NN\6365467|lower_25|baseline_19 (r_compound) doses_24\NNS\3740161|higher_79|baseline_72|potassium_57|and_40 (r_conj) levels_18\NNS\4916342|,_52|and_54|were_58 (r_dobj) had_13\VBD\0|patients_81|older_40|,_2|._167 (r_conj) were_4\VBD\0|NONE_0 (l_acomp) older_5\JJR\0|patients_41|,_38|had_40|._207 (l_conj) likely_8\JJ\0|and_9 (l_xcomp) have_10\VB\7846|more_15 (l_dobj) diabetes_11\NNS\14075199|to_8
D013148_D006333 NONE spironolactone_0\NNP\2721160|-_14|insufficiency_29|._90 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) insufficiency_4\NN\14462946|spironolactone_29|-_15|._61 (l_prep) in_7\IN\13603305|renal_37|and_17|hyperkalemia_13 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) failure_11\NN\66216|NONE_0
D013148_D006333 NONE spironolactone_9\NN\2721160|NONE_0 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_compound) failure_12\NN\66216|NONE_0
D013148_D006333 NONE spironolactone_11\NN\2721160|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) benefits_9\NNS\13278375|since_10|were_27 (r_nsubjpass) reported_13\VBN\831651|because_92|treatments_84|have_55 (r_advcl) changed_6\VBN\0|,_58|prevalence_64|may_98|in_109|._137 (l_nsubj) treatments_1\NNS\654885|because_8|have_29|reported_84 (l_prep) for_2\IN\0|NONE_0 (l_pobj) failure_4\NN\66216|NONE_0
D013148_D006333 NONE spironolactone_21\NN\2721160|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) treated_19\VBN\2376958|failure_17 (r_acl) patients_18\NNS\9898892|NONE_0 (l_compound) failure_17\NN\66216|treated_17
D013148_D006333 NONE spironolactone_12\NN\2721160|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treated_10\VBN\2376958|failure_17 (r_acl) patients_9\NNS\9898892|NONE_0 (l_compound) failure_8\NN\66216|treated_17
D049971_D051437 NONE thiazide_31\NN\3214670|than_19 (r_amod) diuretics_32\NNS\3247620|NONE_0 (r_pobj) with_30\IN\0|to_14|be_11 (r_prep) treated_29\VBN\2376958|more_18 (r_xcomp) likely_26\JJ\0|NONE_0 (r_acomp) were_24\VBD\0|doses_29|,_6|and_4 (r_conj) required_16\VBD\0|patients_112|weight_45|,_2|._113 (r_conj) had_5\VBD\0|NONE_0 (l_nsubj) patients_0\NNS\9898892|weight_67|,_110|required_112|._225 (l_relcl) developed_2\VBD\1753788|NONE_0 (l_dobj) insufficiency_4\NN\14462946|who_20
D013148_D006947 CID spironolactone_0\NNP\2721160|-_14|insufficiency_29|._90 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) insufficiency_4\NN\14462946|spironolactone_29|-_15|._61 (l_conj) hyperkalemia_6\NN\14299637|renal_24|and_4|in_13
D013148_D006947 CID spironolactone_9\NN\2721160|NONE_0 (r_pobj) of_8\IN\0|the_8 (r_prep) use_7\NN\407535|NONE_0 (r_dobj) evaluating_5\VBG\670261|a_39|previous_37|randomized_28|controlled_17 (r_acl) trial_4\NN\786195|risk_84|._138 (r_nsubj) reported_14\VBD\831651|NONE_0 (l_dobj) risk_17\NN\14541044|trial_84|._54 (l_prep) of_18\IN\0|a_11|low_9 (l_pobj) hyperkalemia_19\NN\14299637|NONE_0
D013148_D006947 CID spironolactone_21\NN\2721160|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) treated_19\VBN\2376958|failure_17 (r_acl) patients_18\NNS\9898892|NONE_0 (r_pobj) in_15\IN\13603305|renal_20 (r_prep) insufficiency_14\NN\14462946|and_10 (r_conj) hyperkalemia_11\NN\14299637|NONE_0
D013148_D006947 CID spironolactone_13\NN\2721160|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) discontinuation_11\NN\209943|seven_38|due_34|._88 (r_dobj) required_10\VBD\0|NONE_0 (l_prep) due_14\IN\5174653|seven_72|discontinuation_34|._54 (l_pobj) hyperkalemia_16\NN\14299637|to_3
D013148_D006947 CID spironolactone_0\NNP\2721160|-_14 (r_npadvmod) induced_2\VBN\1627355|and_21 (r_amod) hyperkalemia_3\NN\14299637|renal_17
D003404_D051437 NONE creatinine_14\NN\0|lower_53|baseline_47|body_38|and_26 (r_conj) weight_9\NN\5009170|patients_67|,_43|required_45|._158 (r_dobj) had_5\VBD\0|NONE_0 (l_nsubj) patients_0\NNS\9898892|weight_67|,_110|required_112|._225 (l_relcl) developed_2\VBD\1753788|NONE_0 (l_dobj) insufficiency_4\NN\14462946|who_20
D011188_D051437 NONE k(+_7\NNP\0|NONE_0 (r_appos) hyperkalemia_5\NN\14299637|who_14 (r_dobj) developed_4\VBD\1753788|NONE_0 (r_relcl) patients_2\NNS\9898892|cases_11|(_77 (r_attr) were_1\VBD\0|NONE_0 (l_nsubj) cases_0\NNS\7283608|patients_11|(_88 (l_appos) l_13\NN\13616054|NONE_0 (l_conj) insufficiency_17\NN\14462946|>_21|meq_16|/_13|)_11|or_9
6386793
D000639_D014786 CID amitriptyline_27\NN\4482543|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) than_25\IN\0|significantly_34|with_15 (r_prep) less_22\JJR\14187378|incidence_121|._43 (r_acomp) were_20\VBD\0|NONE_0 (l_nsubj) incidence_2\NN\13821570|less_121|._164 (l_prep) of_3\IN\0|the_22|overall_18 (l_pobj) effects_5\NNS\13245626|NONE_0 (l_conj) frequency_8\NN\15286249|side_21|and_8 (l_prep) of_11\IN\0|the_27|and_13|severity_9 (l_pobj) vision_13\NN\5767733|NONE_0
D004308_D014987 NONE dothiepin_24\JJ\0|NONE_0 (r_pobj) with_23\IN\0|significantly_19|than_15 (r_prep) less_22\JJR\14187378|incidence_121|._43 (r_acomp) were_20\VBD\0|NONE_0 (l_nsubj) incidence_2\NN\13821570|less_121|._164 (l_prep) of_3\IN\0|the_22|overall_18 (l_pobj) effects_5\NNS\13245626|NONE_0 (l_conj) frequency_8\NN\15286249|side_21|and_8 (l_prep) of_11\IN\0|the_27|and_13|severity_9 (l_pobj) vision_13\NN\5767733|NONE_0 (l_conj) mouth_16\NN\5610008|blurred_20|,_6
D000928_D003866 NONE antidepressant_8\NN\3740161|an_13|effective_10|associated_20 (r_amod) drug_9\NN\14778436|to_34 (l_acl) associated_10\VBN\628491|an_33|effective_30|antidepressant_20 (l_prep) with_11\IN\0|NONE_0 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) than_15\IN\0|fewer_19|side_13 (l_pobj) amitriptyline_16\NN\4482543|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) treatment_19\NN\654885|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) outpatients_22\NNS\10405694|NONE_0 (l_amod) depressed_21\JJ\1819147|NONE_0
D000639_D014987 CID amitriptyline_27\NN\4482543|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) than_25\IN\0|significantly_34|with_15 (r_prep) less_22\JJR\14187378|incidence_121|._43 (r_acomp) were_20\VBD\0|NONE_0 (l_nsubj) incidence_2\NN\13821570|less_121|._164 (l_prep) of_3\IN\0|the_22|overall_18 (l_pobj) effects_5\NNS\13245626|NONE_0 (l_conj) frequency_8\NN\15286249|side_21|and_8 (l_prep) of_11\IN\0|the_27|and_13|severity_9 (l_pobj) vision_13\NN\5767733|NONE_0 (l_conj) mouth_16\NN\5610008|blurred_20|,_6
D004308_D003866 NONE hydrochloride_12\NN\14817592|NONE_0 (r_pobj) of_10\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_7\NN\5199286|NONE_0 (r_pobj) of_5\IN\0|a_21|blind_12|in_54|._99 (r_prep) study_4\NN\635850|NONE_0 (l_prep) in_13\IN\13603305|a_75|blind_66|of_54|._45 (l_pobj) treatment_15\NN\654885|NONE_0 (l_prep) of_16\IN\0|the_14 (l_pobj) disorder_19\NN\14034177|NONE_0
D004308_D003866 NONE dothiepin_10\JJ\0|in_51|,_2|were_28|to_42|._97 (r_nsubjpass) compared_14\VBN\644583|NONE_0 (l_prep) to_15\IN\0|in_93|,_44|dothiepin_42|were_14|._55 (l_pobj) placebo_16\NN\3740161|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) treatment_19\NN\654885|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) outpatients_23\NNS\10405694|NONE_0 (l_amod) depressed_22\JJ\1819147|33_3
D004308_D003866 NONE dothiepin_0\JJ\0|effective_41|,_100|and_102|were_111 (r_nsubj) were_3\VBD\0|NONE_0 (l_acomp) effective_5\JJ\0|dothiepin_41|,_59|and_61|were_70 (l_prep) in_6\IN\13603305|equally_18 (l_pcomp) alleviating_7\VBG\205885|NONE_0 (l_dobj) symptoms_9\NNS\5823932|NONE_0 (l_prep) of_10\IN\0|the_13 (l_pobj) illness_12\NN\14052046|NONE_0
D004308_D003866 NONE dothiepin_0\NNP\0|thus_10|was_15|be_28|._159 (r_nsubjpass) found_3\VBN\13279262|NONE_0 (l_xcomp) be_5\VB\14625458|dothiepin_28|thus_18|was_13|._131 (l_attr) drug_9\NN\14778436|to_34 (l_acl) associated_10\VBN\628491|an_33|effective_30|antidepressant_20 (l_prep) with_11\IN\0|NONE_0 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) than_15\IN\0|fewer_19|side_13 (l_pobj) amitriptyline_16\NN\4482543|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) treatment_19\NN\654885|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) outpatients_22\NNS\10405694|NONE_0 (l_amod) depressed_21\JJ\1819147|NONE_0
D004308_D014786 NONE dothiepin_24\JJ\0|NONE_0 (r_pobj) with_23\IN\0|significantly_19|than_15 (r_prep) less_22\JJR\14187378|incidence_121|._43 (r_acomp) were_20\VBD\0|NONE_0 (l_nsubj) incidence_2\NN\13821570|less_121|._164 (l_prep) of_3\IN\0|the_22|overall_18 (l_pobj) effects_5\NNS\13245626|NONE_0 (l_conj) frequency_8\NN\15286249|side_21|and_8 (l_prep) of_11\IN\0|the_27|and_13|severity_9 (l_pobj) vision_13\NN\5767733|NONE_0
D000639_D003866 NONE amitriptyline_12\NN\4482543|and_4 (r_conj) dothiepin_10\JJ\0|in_51|,_2|were_28|to_42|._97 (r_nsubjpass) compared_14\VBN\644583|NONE_0 (l_prep) to_15\IN\0|in_93|,_44|dothiepin_42|were_14|._55 (l_pobj) placebo_16\NN\3740161|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) treatment_19\NN\654885|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) outpatients_23\NNS\10405694|NONE_0 (l_amod) depressed_22\JJ\1819147|33_3
D000639_D003866 NONE amitriptyline_2\NN\4482543|and_4 (r_conj) dothiepin_0\JJ\0|effective_41|,_100|and_102|were_111 (r_nsubj) were_3\VBD\0|NONE_0 (l_acomp) effective_5\JJ\0|dothiepin_41|,_59|and_61|were_70 (l_prep) in_6\IN\13603305|equally_18 (l_pcomp) alleviating_7\VBG\205885|NONE_0 (l_dobj) symptoms_9\NNS\5823932|NONE_0 (l_prep) of_10\IN\0|the_13 (l_pobj) illness_12\NN\14052046|NONE_0
D000639_D003866 NONE amitriptyline_16\NN\4482543|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) treatment_19\NN\654885|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) outpatients_22\NNS\10405694|NONE_0 (l_amod) depressed_21\JJ\1819147|NONE_0
2673163
D003042_D002532 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0
D003042_D002532 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0
D003042_D002532 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0
D003042_D002532 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0
D003042_D002532 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0
D003042_D020521 NONE cocaine_3\NN\3492717|NONE_0 (r_compound) use_4\NN\407535|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|._27 (r_acl) stroke_0\NN\556313|NONE_0
D003042_D020521 NONE cocaine_6\NN\3492717|NONE_0 (r_compound) use_7\NN\407535|in_16|was_4|to_16|and_26|review_30 (r_nsubjpass) related_9\VBN\628491|eight_39 (l_prep) to_10\IN\0|in_32|use_16|was_12|and_10|review_14 (l_pobj) stroke_11\NN\556313|NONE_0
D003042_D020521 NONE cocaine_2\NN\3492717|by_12 (r_compound) use_3\NN\407535|stroke_24|._68 (r_dobj) followed_1\VBD\1835496|NONE_0 (l_nsubj) stroke_0\NN\556313|use_24|._92
D003042_D020521 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0
D003042_D020521 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_nsubj) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24
D003042_D020521 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_nsubj) stroke_35\NN\556313|occurs_38|;_6|may_7|route_22
D003042_D020521 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163
D003042_D020521 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_conj) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (l_prep) in_65\IN\13603305|(_4|)_2|,_28 (l_pobj) stroke_69\NN\556313|NONE_0
D003042_D020521 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (l_ccomp) increasing_17\VBG\169651|data_82 (l_nsubj) incidence_9\NN\13821570|that_22|is_43 (l_prep) of_10\IN\0|the_23|apparent_19 (l_pobj) stroke_11\NN\556313|NONE_0
D003042_D020521 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24
D003042_D020521 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_nsubj) stroke_35\NN\556313|occurs_38|;_6|may_7|route_22
D003042_D020521 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163
D003042_D020521 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_conj) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (l_prep) in_65\IN\13603305|(_4|)_2|,_28 (l_pobj) stroke_69\NN\556313|NONE_0
D003042_D020521 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (l_ccomp) increasing_17\VBG\169651|data_82 (l_nsubj) incidence_9\NN\13821570|that_22|is_43 (l_prep) of_10\IN\0|the_23|apparent_19 (l_pobj) stroke_11\NN\556313|NONE_0
D003042_D020521 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_nsubj) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24
D003042_D020521 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_nsubj) stroke_35\NN\556313|occurs_38|;_6|may_7|route_22
D003042_D020521 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163
D003042_D020521 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_conj) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (l_prep) in_65\IN\13603305|(_4|)_2|,_28 (l_pobj) stroke_69\NN\556313|NONE_0
D003042_D020521 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (l_ccomp) increasing_17\VBG\169651|data_82 (l_nsubj) incidence_9\NN\13821570|that_22|is_43 (l_prep) of_10\IN\0|the_23|apparent_19 (l_pobj) stroke_11\NN\556313|NONE_0
D003042_D020521 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_nsubj) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24
D003042_D020521 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_nsubj) stroke_35\NN\556313|occurs_38|;_6|may_7|route_22
D003042_D020521 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163
D003042_D020521 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163 (l_conj) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (l_prep) in_65\IN\13603305|(_4|)_2|,_28 (l_pobj) stroke_69\NN\556313|NONE_0
D003042_D020521 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (l_ccomp) increasing_17\VBG\169651|data_82 (l_nsubj) incidence_9\NN\13821570|that_22|is_43 (l_prep) of_10\IN\0|the_23|apparent_19 (l_pobj) stroke_11\NN\556313|NONE_0
D003042_D020521 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (l_nsubj) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24
D003042_D020521 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (l_nsubj) stroke_35\NN\556313|occurs_38|;_6|may_7|route_22
D003042_D020521 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163
D003042_D020521 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0
D003042_D002544 CID cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_dobj) that_77\DT\0|follow_246|;_204|frequency_45|._27 (l_prep) of_78\IN\0|NONE_0 (l_pobj) infarction_80\NN\14204950|NONE_0
D003042_D002544 CID cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_dobj) that_77\DT\0|follow_246|;_204|frequency_45|._27 (l_prep) of_78\IN\0|NONE_0 (l_pobj) infarction_80\NN\14204950|NONE_0
D003042_D002544 CID cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_dobj) that_77\DT\0|follow_246|;_204|frequency_45|._27 (l_prep) of_78\IN\0|NONE_0 (l_pobj) infarction_80\NN\14204950|NONE_0
D003042_D002544 CID cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_dobj) that_77\DT\0|follow_246|;_204|frequency_45|._27 (l_prep) of_78\IN\0|NONE_0 (l_pobj) infarction_80\NN\14204950|NONE_0
D003042_D002544 CID cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (r_nsubj) exceeds_76\VBZ\0|NONE_0 (l_dobj) that_77\DT\0|follow_246|;_204|frequency_45|._27 (l_prep) of_78\IN\0|NONE_0 (l_pobj) infarction_80\NN\14204950|NONE_0
D003042_D001165 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0 (l_conj) malformations_59\NNS\14213199|intracranial_41|and_18
D003042_D001165 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0 (l_conj) malformations_59\NNS\14213199|intracranial_41|and_18
D003042_D001165 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_nmod) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0 (l_conj) malformations_59\NNS\14213199|intracranial_41|and_18
D003042_D001165 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0 (l_conj) malformations_59\NNS\14213199|intracranial_41|and_18
D003042_D001165 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (l_advcl) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (l_prep) with_54\IN\0|after_43|use_29|is_25|frequently_22 (l_pobj) aneurysms_56\NNS\14057371|NONE_0 (l_conj) malformations_59\NNS\14213199|intracranial_41|and_18
D003042_D020300 NONE cocaine_14\NN\3492717|NONE_0 (r_compound) use_15\NN\407535|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) related_12\VBN\628491|NONE_0 (r_acl) stroke_11\NN\556313|NONE_0 (r_pobj) of_10\IN\0|the_23|apparent_19 (r_prep) incidence_9\NN\13821570|that_22|is_43 (r_nsubj) increasing_17\VBG\169651|data_82 (r_ccomp) indicate_2\VBP\952524|;_87|(_89|stroke_112|primarily_126|in_136 (r_ccomp) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_prep) of_73\IN\0|stroke_163|the_14 (l_pobj) hemorrhage_75\NN\14285662|NONE_0
D003042_D020300 NONE cocaine_22\NN\3492717|-_7 (r_npadvmod) associated_24\VBN\628491|2_11|)_10 (r_amod) stroke_25\NN\556313|indicate_112|;_25|(_23|primarily_14|in_24 (r_nsubj) occurs_26\VBZ\0|;_32|stroke_38|may_45|route_60 (r_ccomp) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_prep) of_73\IN\0|stroke_163|the_14 (l_pobj) hemorrhage_75\NN\14285662|NONE_0
D003042_D020300 NONE cocaine_41\NN\3492717|NONE_0 (r_compound) administration_42\NN\1133281|NONE_0 (r_pobj) of_40\IN\0|any_10 (r_prep) route_39\NN\8593262|occurs_60|;_28|stroke_22|may_15 (r_dobj) follow_37\VB\1835496|;_42|frequency_201|that_246|._273 (r_ccomp) exceeds_76\VBZ\0|NONE_0 (l_nsubj) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_prep) of_73\IN\0|stroke_163|the_14 (l_pobj) hemorrhage_75\NN\14285662|NONE_0
D003042_D020300 NONE cocaine_49\NN\3492717|NONE_0 (r_compound) use_50\NN\407535|after_14|is_4|frequently_7|with_29 (r_nsubjpass) associated_53\VBN\628491|4_42|;_70|and_72|5_77 (r_advcl) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_prep) of_73\IN\0|stroke_163|the_14 (l_pobj) hemorrhage_75\NN\14285662|NONE_0
D003042_D020300 NONE cocaine_66\NN\3492717|-_7 (r_npadvmod) associated_68\VBN\628491|NONE_0 (r_amod) stroke_69\NN\556313|NONE_0 (r_pobj) in_65\IN\13603305|(_4|)_2|,_28 (r_prep) 5_63\CD\13741022|4_119|associated_77|;_7|and_5 (r_conj) stroke_47\NN\556313|the_149|of_163 (r_nmod) frequency_72\NN\15286249|follow_201|;_159|that_45|._72 (l_prep) of_73\IN\0|stroke_163|the_14 (l_pobj) hemorrhage_75\NN\14285662|NONE_0
19803309
D013390_D009224 NONE suxamethonium_29\NN\0|NONE_0 (r_pobj) of_27\IN\0|a_16|standard_14|for_29 (r_prep) dose_26\NN\3740161|NONE_0 (r_pobj) following_23\VBG\8180190|life_32|spasm_6 (r_prep) threatening_20\VBG\2603699|who_19 (r_ccomp) developed_18\VBD\1753788|a_51|old_41|healthy_26|,_6 (r_relcl) primigravida_15\NN\10144838|NONE_0 (r_pobj) in_8\IN\13603305|an_42|undiagnosed_39|of_22 (r_prep) case_4\NN\7283608|we_25|._206 (l_prep) of_5\IN\0|an_20|undiagnosed_17|in_22 (l_pobj) congenita_7\NN\0|NONE_0
D013390_D014313 CID suxamethonium_29\NN\0|NONE_0 (r_pobj) of_27\IN\0|a_16|standard_14|for_29 (r_prep) dose_26\NN\3740161|NONE_0 (r_pobj) following_23\VBG\8180190|life_32|spasm_6 (r_prep) threatening_20\VBG\2603699|who_19 (l_dobj) spasm_22\NN\14299637|life_26|following_6
234669
D002245_D014693 NONE dioxide_32\NN\14971519|)_13|and_11 (r_conj) po2_28\NNP\0|(_1 (r_appos) oxygen_26\NN\14622893|NONE_0 (r_pobj) of_25\IN\0|ph_25 (r_prep) pressures_24\NNS\11419404|when_20|were_51|within_61 (r_nsubjpass) kept_37\VBN\0|during_200|,_164|threshold_133|was_123|by_111|._25 (r_advcl) reduced_11\VBN\441445|NONE_0 (l_nsubjpass) threshold_9\NN\15265518|during_67|,_31|was_10|by_22|kept_133|._158 (l_compound) fibrillation_8\NN\14361664|the_16|ventricular_12
D002245_D014693 NONE co2_34\NNP\14836127|carbon_16 (r_appos) dioxide_32\NN\14971519|)_13|and_11 (r_conj) po2_28\NNP\0|(_1 (r_appos) oxygen_26\NN\14622893|NONE_0 (r_pobj) of_25\IN\0|ph_25 (r_prep) pressures_24\NNS\11419404|when_20|were_51|within_61 (r_nsubjpass) kept_37\VBN\0|during_200|,_164|threshold_133|was_123|by_111|._25 (r_advcl) reduced_11\VBN\441445|NONE_0 (l_nsubjpass) threshold_9\NN\15265518|during_67|,_31|was_10|by_22|kept_133|._158 (l_compound) fibrillation_8\NN\14361664|the_16|ventricular_12
C093415_D014693 NONE po2_28\NNP\0|(_1 (r_appos) oxygen_26\NN\14622893|NONE_0 (r_pobj) of_25\IN\0|ph_25 (r_prep) pressures_24\NNS\11419404|when_20|were_51|within_61 (r_nsubjpass) kept_37\VBN\0|during_200|,_164|threshold_133|was_123|by_111|._25 (r_advcl) reduced_11\VBN\441445|NONE_0 (l_nsubjpass) threshold_9\NN\15265518|during_67|,_31|was_10|by_22|kept_133|._158 (l_compound) fibrillation_8\NN\14361664|the_16|ventricular_12
D000628_D012131 NONE aminophylline_2\NN\2905612|NONE_0 (r_pobj) of_1\IN\0|for_34|._100 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) for_6\IN\0|of_34|._66 (l_pcomp) initiating_7\VBG\1617192|NONE_0 (l_prep) during_10\IN\0|fibrillation_13 (l_pobj) failure_12\NN\66216|NONE_0
D000628_D012131 NONE aminophylline_3\NN\2905612|NONE_0 (r_pobj) of_2\IN\0|the_12|and_94|during_98 (r_prep) effects_1\NNS\13245626|were_133|in_146|._177 (l_conj) during_16\IN\0|the_110|of_98|and_4 (l_pobj) failure_18\NN\66216|NONE_0
D000628_D012131 NONE aminophylline_30\NN\2905612|NONE_0 (r_pobj) of_29\IN\0|NONE_0 (r_prep) infusion_28\NN\14589223|produced_89|pc02_43|,_2|in_35|._135 (r_nsubj) resulted_31\VBD\2633881|NONE_0 (l_advcl) produced_4\VBN\1617192|pc02_46|,_87|infusion_89|in_124|._224 (l_nsubjpass) failure_2\NN\66216|when_17|was_8|by_21
D000628_D012131 NONE aminophylline_24\NN\2905612|pharmacologic_35|,_15|,_13 (r_appos) agents_21\NNS\7347|that_134|contribute_103|,_16|may_36|role_59 (r_nsubj) play_27\VB\7007684|experiments_194|._23 (l_advcl) contribute_8\VB\126264|that_31|,_87|agents_103|may_139|role_162 (l_prep) to_9\IN\0|although_37|factors_23|may_15 (l_pobj) incidence_12\NN\13821570|NONE_0 (l_prep) of_13\IN\0|the_24|increased_20 (l_pobj) arrhythmias_15\NNS\14103288|NONE_0 (l_prep) in_16\IN\13603305|ventricular_24 (l_pobj) failure_18\NN\66216|NONE_0
D010100_D014693 NONE oxygen_26\NN\14622893|NONE_0 (r_pobj) of_25\IN\0|ph_25 (r_prep) pressures_24\NNS\11419404|when_20|were_51|within_61 (r_nsubjpass) kept_37\VBN\0|during_200|,_164|threshold_133|was_123|by_111|._25 (r_advcl) reduced_11\VBN\441445|NONE_0 (l_nsubjpass) threshold_9\NN\15265518|during_67|,_31|was_10|by_22|kept_133|._158 (l_compound) fibrillation_8\NN\14361664|the_16|ventricular_12
D000628_D014693 CID aminophylline_2\NN\2905612|NONE_0 (r_pobj) of_1\IN\0|for_34|._100 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) for_6\IN\0|of_34|._66 (l_pcomp) initiating_7\VBG\1617192|NONE_0 (l_dobj) fibrillation_9\NN\14361664|during_13
D000628_D014693 CID aminophylline_3\NN\2905612|NONE_0 (l_prep) on_4\IN\0|NONE_0 (l_pobj) threshold_8\NN\15265518|NONE_0 (l_compound) fibrillation_7\NN\14361664|the_16|during_23
D000628_D014693 CID aminophylline_4\NN\2905612|NONE_0 (r_pobj) of_3\IN\0|the_13 (r_prep) infusion_2\NN\14589223|NONE_0 (r_pobj) during_0\IN\0|,_36|threshold_67|was_77|by_89|kept_200|._225 (r_prep) reduced_11\VBN\441445|NONE_0 (l_nsubjpass) threshold_9\NN\15265518|during_67|,_31|was_10|by_22|kept_133|._158 (l_compound) fibrillation_8\NN\14361664|the_16|ventricular_12
D000628_D014693 CID aminophylline_30\NN\2905612|NONE_0 (r_pobj) of_29\IN\0|NONE_0 (r_prep) infusion_28\NN\14589223|produced_89|pc02_43|,_2|in_35|._135 (r_nsubj) resulted_31\VBD\2633881|NONE_0 (l_prep) in_32\IN\13603305|produced_124|pc02_78|,_37|infusion_35|._100 (l_pobj) decrease_36\NN\7296428|NONE_0 (l_prep) in_37\IN\13603305|an_25|greater_17 (l_pobj) threshold_40\NN\15265518|NONE_0 (l_compound) fibrillation_39\NN\14361664|to_23
D000628_D007040 NONE aminophylline_30\NN\2905612|NONE_0 (r_pobj) of_29\IN\0|NONE_0 (r_prep) infusion_28\NN\14589223|produced_89|pc02_43|,_2|in_35|._135 (r_nsubj) resulted_31\VBD\2633881|NONE_0 (l_advcl) produced_4\VBN\1617192|pc02_46|,_87|infusion_89|in_124|._224 (l_agent) by_5\IN\0|when_38|failure_21|was_13 (l_pobj) hypoventilation_6\NN\0|NONE_0
D000628_D001145 NONE aminophylline_24\NN\2905612|pharmacologic_35|,_15|,_13 (r_appos) agents_21\NNS\7347|that_134|contribute_103|,_16|may_36|role_59 (r_nsubj) play_27\VB\7007684|experiments_194|._23 (l_advcl) contribute_8\VB\126264|that_31|,_87|agents_103|may_139|role_162 (l_prep) to_9\IN\0|although_37|factors_23|may_15 (l_pobj) incidence_12\NN\13821570|NONE_0 (l_prep) of_13\IN\0|the_24|increased_20 (l_pobj) arrhythmias_15\NNS\14103288|NONE_0
3985451
D014859_D003286 NONE warfarin_12\NN\2718259|chronic_8 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) on_10\IN\0|a_18|old_8|sustained_32 (r_prep) man_9\NN\9605289|NONE_0 (l_relcl) sustained_15\VBD\2679899|a_50|old_40|on_32 (l_conj) developed_21\VBD\1753788|who_38|tear_9|and_4 (l_dobj) pain_23\NN\14299637|NONE_0 (l_conj) contracture_27\NN\369802|increasing_30|and_14
D014859_D003286 NONE warfarin_12\RB\2718259|-_8 (r_npadvmod) induced_14\VBN\1627355|peripheral_8 (r_amod) neuropathy_16\NN\14204950|NONE_0 (r_pobj) of_11\IN\0|the_21|common_12 (r_prep) form_10\NN\6286395|palsy_33 (r_dobj) represents_6\VBZ\2664769|;_73|it_75|is_78|by_95|._232 (r_ccomp) characterized_20\VBN\609683|NONE_0 (l_agent) by_21\IN\0|represents_95|;_22|it_20|is_17|._137 (l_pobj) pain_23\NN\14299637|NONE_0 (l_conj) degrees_30\NNS\4916342|severe_44|in_32|,_10 (l_conj) contracture_39\NN\369802|varying_61|of_45|,_14|and_12
D014859_D010523 NONE warfarin_12\RB\2718259|-_8 (r_npadvmod) induced_14\VBN\1627355|peripheral_8 (r_amod) neuropathy_16\NN\14204950|NONE_0
D014859_D020428 CID warfarin_0\NNP\2718259|-_8 (r_npadvmod) induced_2\VBN\1627355|iliopsoas_8|with_29|._64 (r_amod) hemorrhage_4\NN\14285662|NONE_0 (l_prep) with_5\IN\0|induced_29|iliopsoas_21|._35 (l_pobj) palsy_9\JJ\14557898|NONE_0
D014859_D020428 CID warfarin_12\RB\2718259|-_8 (r_npadvmod) induced_14\VBN\1627355|peripheral_8 (r_amod) neuropathy_16\NN\14204950|NONE_0 (r_pobj) of_11\IN\0|the_21|common_12 (r_prep) form_10\NN\6286395|palsy_33 (r_dobj) represents_6\VBZ\2664769|;_73|it_75|is_78|by_95|._232 (l_nsubj) palsy_5\JJ\14557898|form_33
D014859_D006470 NONE warfarin_0\NNP\2718259|-_8 (r_npadvmod) induced_2\VBN\1627355|iliopsoas_8|with_29|._64 (r_amod) hemorrhage_4\NN\14285662|NONE_0
D014859_D009135 CID warfarin_12\NN\2718259|chronic_8 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) on_10\IN\0|a_18|old_8|sustained_32 (r_prep) man_9\NN\9605289|NONE_0 (l_relcl) sustained_15\VBD\2679899|a_50|old_40|on_32 (l_dobj) tear_19\NN\13771404|who_29|and_5|developed_9
D014859_D010146 NONE warfarin_12\NN\2718259|chronic_8 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) on_10\IN\0|a_18|old_8|sustained_32 (r_prep) man_9\NN\9605289|NONE_0 (l_relcl) sustained_15\VBD\2679899|a_50|old_40|on_32 (l_conj) developed_21\VBD\1753788|who_38|tear_9|and_4 (l_dobj) pain_23\NN\14299637|NONE_0
D014859_D010146 NONE warfarin_12\RB\2718259|-_8 (r_npadvmod) induced_14\VBN\1627355|peripheral_8 (r_amod) neuropathy_16\NN\14204950|NONE_0 (r_pobj) of_11\IN\0|the_21|common_12 (r_prep) form_10\NN\6286395|palsy_33 (r_dobj) represents_6\VBZ\2664769|;_73|it_75|is_78|by_95|._232 (r_ccomp) characterized_20\VBN\609683|NONE_0 (l_agent) by_21\IN\0|represents_95|;_22|it_20|is_17|._137 (l_pobj) pain_23\NN\14299637|NONE_0
D014859_D015417 NONE warfarin_12\RB\2718259|-_8 (r_npadvmod) induced_14\VBN\1627355|peripheral_8 (r_amod) neuropathy_16\NN\14204950|NONE_0 (r_pobj) of_11\IN\0|the_21|common_12 (r_prep) form_10\NN\6286395|palsy_33 (r_dobj) represents_6\VBZ\2664769|;_73|it_75|is_78|by_95|._232 (r_ccomp) characterized_20\VBN\609683|NONE_0 (l_agent) by_21\IN\0|represents_95|;_22|it_20|is_17|._137 (l_pobj) pain_23\NN\14299637|NONE_0 (l_conj) degrees_30\NNS\4916342|severe_44|in_32|,_10 (l_prep) of_31\IN\0|varying_16|,_31|and_33|contracture_45 (l_pobj) impairment_35\NN\7296428|NONE_0
19356053
D020123_D009404 NONE sirolimus_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_15|and_13|development_21 (r_prep) initiation_14\NN\7450842|NONE_0 (l_conj) development_19\NN\248977|the_36|of_21|and_8 (l_prep) of_20\IN\0|the_16 (l_pobj) proteinuria_24\NN\14299637|NONE_0 (l_compound) range_23\NN\5123416|NONE_0 (l_amod) nephrotic_21\JJ\0|-_9
D003404_D011507 NONE creatinine_22\NN\0|,_17|estimate_22 (r_compound) ratios_23\NNS\13815152|turbidometric_61|or_35|protein_19 (r_conj) measurement_16\NN\407535|NONE_0 (r_pobj) by_14\IN\0|in_86|,_69|magnitude_63|was_38|on_25|._111 (r_agent) assessed_9\VBN\670261|NONE_0 (l_nsubjpass) magnitude_5\NN\4916342|in_23|,_6|was_25|on_38|by_63|._174 (l_prep) of_6\IN\0|the_14 (l_pobj) proteinuria_7\NN\14299637|NONE_0
D003404_D011507 NONE creatinine_22\NN\0|,_17|estimate_22 (r_compound) ratios_23\NNS\13815152|turbidometric_61|or_35|protein_19 (l_appos) estimate_26\NN\5802185|creatinine_22|,_5 (l_prep) of_27\IN\0|an_12|day_24 (l_pobj) grams_28\NNS\13717155|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) proteinuria_30\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_19 (r_prep) administration_5\NN\1133281|to_28 (r_pobj) following_3\VBG\8180190|significant_24|._72 (r_prep) proteinuria_2\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_8 (r_prep) use_14\NN\407535|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) linked_11\VBN\628491|significant_24 (r_acl) proteinuria_10\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_11\NN\0|NONE_0 (r_compound) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|substantial_24 (r_acl) proteinuria_8\NN\14299637|who_26
D020123_D011507 CID sirolimus_12\NN\0|and_18|proteinuria_22 (r_compound) therapy_13\NN\657604|NONE_0 (l_conj) proteinuria_15\NN\14299637|sirolimus_22|and_4
D020123_D011507 CID sirolimus_12\NN\0|and_18|proteinuria_22 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) of_11\IN\0|the_17 (r_prep) commencement_10\NN\15180528|NONE_0 (r_pobj) between_8\IN\0|the_31|close_27|temporal_21 (r_prep) association_7\NN\8008335|in_36|,_21|sirolimus_85|as_95|._141 (r_nsubj) implicated_16\VBN\2677097|NONE_0 (l_prep) as_18\IN\14622893|in_131|,_116|association_95|sirolimus_10|._46 (l_pobj) etiology_22\NN\7326557|NONE_0 (l_prep) of_23\IN\0|the_25|likely_16 (l_pobj) proteinuria_25\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_17\NN\0|in_121|,_106|association_85|as_10|._56 (r_dobj) implicated_16\VBN\2677097|NONE_0 (l_nsubj) association_7\NN\8008335|in_36|,_21|sirolimus_85|as_95|._141 (l_prep) between_8\IN\0|the_31|close_27|temporal_21 (l_pobj) commencement_10\NN\15180528|NONE_0 (l_prep) of_11\IN\0|the_17 (l_pobj) therapy_13\NN\657604|NONE_0 (l_conj) proteinuria_15\NN\14299637|sirolimus_22|and_4
D020123_D011507 CID sirolimus_17\NN\0|in_121|,_106|association_85|as_10|._56 (r_dobj) implicated_16\VBN\2677097|NONE_0 (l_prep) as_18\IN\14622893|in_131|,_116|association_95|sirolimus_10|._46 (l_pobj) etiology_22\NN\7326557|NONE_0 (l_prep) of_23\IN\0|the_25|likely_16 (l_pobj) proteinuria_25\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_15|and_13|development_21 (r_prep) initiation_14\NN\7450842|NONE_0 (l_conj) development_19\NN\248977|the_36|of_21|and_8 (l_prep) of_20\IN\0|the_16 (l_pobj) proteinuria_24\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_5\NN\0|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) with_4\IN\0|proteinuria_37|strongly_9|compared_28|._80 (r_prep) correlated_1\VBD\2657219|NONE_0 (l_nsubj) proteinuria_0\NNP\14299637|strongly_28|with_37|compared_65|._117
D020123_D011507 CID sirolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) discontinuation_4\NN\209943|in_18|,_2|in_38|,_51|but_53|resolution_61|._87 (r_nsubj) resulted_7\VBD\2633881|NONE_0 (l_conj) resolution_14\NN\6470073|in_79|,_63|discontinuation_61|in_23|,_10|but_8|._26 (l_prep) of_16\IN\0|not_16|,_2 (l_pobj) proteinuria_17\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_0\NNP\0|or_18|aggravates_21|._113 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_conj) aggravates_3\VBZ\126264|sirolimus_21|or_3|._92 (l_dobj) proteinuria_7\NN\14299637|in_12
D020123_D011507 CID sirolimus_10\NN\0|when_5|is_10 (r_nsubjpass) withdrawn_12\VBN\1835496|does_36|not_31|,_20 (r_advcl) resolve_7\VB\4616059|proteinuria_38|may_26|,_15|but_13|._36 (r_conj) improve_2\VB\126264|NONE_0 (l_nsubj) proteinuria_0\NNP\14299637|may_12|,_23|but_25|resolve_38|._74
D020123_D007674 NONE sirolimus_0\NNP\0|agent_42|,_73|and_75|have_83|._155 (r_nsubj) is_1\VBZ\0|NONE_0 (l_conj) have_13\VB\7846|sirolimus_83|agent_41|,_10|and_8|._72 (l_dobj) nephrotoxicity_15\NN\0|may_14
7802851
D000525_D003866 CID alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_prep) of_18\IN\0|adverse_30|(_12|%_9|)_2|;_53|and_55|effects_69 (l_pobj) depression_19\NN\14373582|NONE_0
D000525_D008569 CID alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_conj) effects_31\NNS\13245626|adverse_99|(_81|%_78|)_71|of_69|;_16|and_14 (l_appos) sedation_34\NN\14034177|more_32|side_27|-_23|,_15 (l_conj) irritability_36\NN\7552087|particularly_23|,_2 (l_conj) memory_39\NN\5926676|,_11
D000525_D016584 NONE alprazolam_3\NN\2830852|NONE_0 (r_pobj) of_2\IN\0|the_13|in_26|,_60|and_62|effect_75 (r_prep) efficacy_1\NN\5199286|were_139|._152 (l_prep) in_6\IN\13603305|the_39|of_26|,_34|and_36|effect_49 (l_pobj) disorder_8\NN\14034177|NONE_0
D000525_D016584 NONE alprazolam_20\NN\2830852|in_115|were_19|._21 (r_xcomp) randomised_18\VBN\278117|NONE_0 (l_prep) in_0\IN\13603305|were_96|alprazolam_115|._136 (l_pobj) london_1\NNP\0|NONE_0 (l_conj) patients_5\NNS\9898892|and_16 (l_relcl) met_7\VBD\0|toronto_25|154_17 (l_dobj) criteria_11\NNS\13577171|who_16 (l_prep) for_12\IN\0|iii_13 (l_pobj) disorder_14\NN\14034177|NONE_0
D000525_D001259 CID alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_conj) effects_31\NNS\13245626|adverse_99|(_81|%_78|)_71|of_69|;_16|and_14 (l_appos) sedation_34\NN\14034177|more_32|side_27|-_23|,_15 (l_conj) irritability_36\NN\7552087|particularly_23|,_2 (l_conj) memory_39\NN\5926676|,_11 (l_conj) loss_42\NN\13252973|impaired_24|,_9 (l_conj) ataxia_44\NN\14084880|weight_16|and_4
D000525_D001523 NONE alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_prep) of_18\IN\0|adverse_30|(_12|%_9|)_2|;_53|and_55|effects_69 (l_pobj) depression_19\NN\14373582|NONE_0 (l_conj) enuresis_21\NN\13496972|,_2 (l_conj) disinhibition_23\NN\0|,_2 (l_conj) aggression_25\NN\4657876|and_4
D000525_D001523 NONE alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_conj) effects_31\NNS\13245626|adverse_99|(_81|%_78|)_71|of_69|;_16|and_14 (l_appos) sedation_34\NN\14034177|more_32|side_27|-_23|,_15 (l_conj) irritability_36\NN\7552087|particularly_23|,_2
D000525_D015431 CID alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_conj) effects_31\NNS\13245626|adverse_99|(_81|%_78|)_71|of_69|;_16|and_14 (l_appos) sedation_34\NN\14034177|more_32|side_27|-_23|,_15 (l_conj) irritability_36\NN\7552087|particularly_23|,_2 (l_conj) memory_39\NN\5926676|,_11 (l_conj) loss_42\NN\13252973|impaired_24|,_9
D000525_D000379 NONE alprazolam_3\NN\2830852|NONE_0 (r_pobj) of_2\IN\0|the_13|in_26|,_60|and_62|effect_75 (r_prep) efficacy_1\NN\5199286|were_139|._152 (l_prep) in_6\IN\13603305|the_39|of_26|,_34|and_36|effect_49 (l_pobj) disorder_8\NN\14034177|NONE_0 (l_prep) with_9\IN\0|panic_15 (l_pobj) agoraphobia_10\NNP\14381416|NONE_0
D000525_D000379 NONE alprazolam_20\NN\2830852|in_115|were_19|._21 (r_xcomp) randomised_18\VBN\278117|NONE_0 (l_prep) in_0\IN\13603305|were_96|alprazolam_115|._136 (l_pobj) london_1\NNP\0|NONE_0 (l_conj) patients_5\NNS\9898892|and_16 (l_relcl) met_7\VBD\0|toronto_25|154_17 (l_dobj) criteria_11\NNS\13577171|who_16 (l_prep) for_12\IN\0|iii_13 (l_pobj) disorder_14\NN\14034177|NONE_0 (l_prep) with_15\IN\0|panic_15 (l_pobj) agoraphobia_16\NNP\14381416|NONE_0
D000525_D004775 CID alprazolam_5\NN\2830852|NONE_0 (r_compound) patients_6\NNS\9898892|compared_43|,_13|reactions_32|._208 (r_nsubj) developed_7\VBD\1753788|NONE_0 (l_dobj) reactions_10\NNS\13446390|compared_75|,_45|patients_32|._176 (l_prep) of_18\IN\0|adverse_30|(_12|%_9|)_2|;_53|and_55|effects_69 (l_pobj) depression_19\NN\14373582|NONE_0 (l_conj) enuresis_21\NN\13496972|,_2
6503301
D003606_D008545 NONE dacarbazine_6\NN\0|(_20|dtic_21|)_25|for_27 (r_compound) therapy_7\NN\657604|NONE_0 (l_prep) for_11\IN\0|dacarbazine_27|(_7|dtic_6|)_2 (l_pobj) melanoma_12\NN\14252320|NONE_0
D003606_D008545 NONE dtic_9\NNP\8337324|dacarbazine_21|(_1|)_4|for_6 (r_appos) therapy_7\NN\657604|NONE_0 (l_prep) for_11\IN\0|dacarbazine_27|(_7|dtic_6|)_2 (l_pobj) melanoma_12\NN\14252320|NONE_0
D003606_D008545 NONE dacarbazine_14\NN\0|(_12|dtic_13|)_17|for_27 (r_nmod) therapy_18\NN\657604|case_88|after_25|is_21|._32 (l_prep) for_19\IN\0|dacarbazine_27|(_15|dtic_14|)_10 (l_pobj) melanoma_20\NN\14252320|NONE_0
D003606_D008545 NONE dtic_16\NNP\8337324|dacarbazine_13|(_1|)_4|for_14 (r_nmod) therapy_18\NN\657604|case_88|after_25|is_21|._32 (l_prep) for_19\IN\0|dacarbazine_27|(_15|dtic_14|)_10 (l_pobj) melanoma_20\NN\14252320|NONE_0
D003606_D006504 CID dacarbazine_6\NN\0|(_20|dtic_21|)_25|for_27 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) after_5\IN\0|occlusive_24|liver_14|._45 (r_prep) disease_4\NN\14061805|NONE_0
D003606_D006504 CID dtic_9\NNP\8337324|dacarbazine_21|(_1|)_4|for_6 (r_appos) therapy_7\NN\657604|NONE_0 (r_pobj) after_5\IN\0|occlusive_24|liver_14|._45 (r_prep) disease_4\NN\14061805|NONE_0
D003606_D006504 CID dacarbazine_14\NN\0|(_12|dtic_13|)_17|for_27 (r_nmod) therapy_18\NN\657604|case_88|after_25|is_21|._32 (r_nsubjpass) reported_22\VBN\831651|NONE_0 (l_nsubjpass) case_1\NN\7283608|after_63|therapy_88|is_109|._120 (l_prep) of_2\IN\0|a_7 (l_pobj) disease_6\NN\14061805|NONE_0 (l_prep) of_7\IN\0|occlusive_18|with_13 (l_pobj) liver_9\NN\5298729|NONE_0
D003606_D006504 CID dtic_16\NNP\8337324|dacarbazine_13|(_1|)_4|for_14 (r_nmod) therapy_18\NN\657604|case_88|after_25|is_21|._32 (r_nsubjpass) reported_22\VBN\831651|NONE_0 (l_nsubjpass) case_1\NN\7283608|after_63|therapy_88|is_109|._120 (l_prep) of_2\IN\0|a_7 (l_pobj) disease_6\NN\14061805|NONE_0 (l_prep) of_7\IN\0|occlusive_18|with_13 (l_pobj) liver_9\NN\5298729|NONE_0
3714122
D010755_D020258 NONE organophosphate_33\NN\14919948|n'-diisopropylphosphorodiamidofluoridate_56|)_16|,_15 (r_appos) mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0 (l_prep) of_7\IN\0|neuropathic_34|and_15|inhibition_11 (l_pobj) esterase_9\NN\0|NONE_0 (l_amod) neurotoxic_8\JJ\0|or_20|enzyme_41
D010755_D020258 NONE organophosphate_33\NN\14919948|n'-diisopropylphosphorodiamidofluoridate_56|)_16|,_15 (l_amod) neurotoxic_32\JJ\0|a_2
C005238_D013118 CID mipafox_5\NNP\0|NONE_0 (r_pobj) of_4\IN\0|less_12|inhibited_49 (r_prep) dosages_3\NNS\13576355|in_13|,_2|degree_176|in_198|._223 (r_nsubj) produced_39\VBN\1617192|NONE_0 (l_dobj) degree_41\NN\4916342|in_189|,_178|dosages_176|in_22|._47 (l_prep) of_42\IN\0|this_12 (l_pobj) damage_44\NN\7296428|NONE_0
C005238_D009422 NONE mipafox_7\NN\0|-_7 (r_npadvmod) induced_9\VBN\1627355|neuropathic_8|in_27 (r_amod) damage_11\NN\7296428|neurotoxic_63|esterase_52|and_32
C005238_D009422 NONE mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0
C005238_D009422 NONE mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0 (l_prep) of_7\IN\0|neuropathic_34|and_15|inhibition_11 (l_pobj) esterase_9\NN\0|NONE_0 (l_conj) enzyme_13\NN\14723628|neurotoxic_41|or_21 (l_compound) target_12\NN\7258332|(_14|nte_15|)_18 (l_compound) neuropathy_11\NN\14204950|NONE_0
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|)_40|,_41|organophosphate_56 (r_appos) mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|)_40|,_41|organophosphate_56 (r_appos) mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0 (l_prep) of_7\IN\0|neuropathic_34|and_15|inhibition_11 (l_pobj) esterase_9\NN\0|NONE_0 (l_conj) enzyme_13\NN\14723628|neurotoxic_41|or_21 (l_compound) target_12\NN\7258332|(_14|nte_15|)_18 (l_compound) neuropathy_11\NN\14204950|NONE_0
C005238_D009422 NONE mipafox_18\NNP\0|NONE_0 (r_compound) exposure_19\NN\5042871|shortly_22|after_14|can_9|damage_33|later_62 (r_nsubj) predict_21\VB\916909|NONE_0 (l_dobj) damage_23\NN\7296428|shortly_55|after_47|exposure_33|can_24|later_29
D010755_D009422 NONE organophosphate_33\NN\14919948|n'-diisopropylphosphorodiamidofluoridate_56|)_16|,_15 (r_appos) mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0
D010755_D009422 NONE organophosphate_33\NN\14919948|n'-diisopropylphosphorodiamidofluoridate_56|)_16|,_15 (r_appos) mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0 (l_prep) of_7\IN\0|neuropathic_34|and_15|inhibition_11 (l_pobj) esterase_9\NN\0|NONE_0 (l_conj) enzyme_13\NN\14723628|neurotoxic_41|or_21 (l_compound) target_12\NN\7258332|(_14|nte_15|)_18 (l_compound) neuropathy_11\NN\14204950|NONE_0
C005238_D020258 NONE mipafox_7\NN\0|-_7 (r_npadvmod) induced_9\VBN\1627355|neuropathic_8|in_27 (r_amod) damage_11\NN\7296428|neurotoxic_63|esterase_52|and_32 (r_conj) inhibition_5\NN\1068773|NONE_0 (l_amod) neurotoxic_3\JJ\0|esterase_11|and_31|damage_63
C005238_D020258 NONE mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0 (l_prep) of_7\IN\0|neuropathic_34|and_15|inhibition_11 (l_pobj) esterase_9\NN\0|NONE_0 (l_amod) neurotoxic_8\JJ\0|or_20|enzyme_41
C005238_D020258 NONE mipafox_24\NNP\0|NONE_0 (l_appos) organophosphate_33\NN\14919948|n'-diisopropylphosphorodiamidofluoridate_56|)_16|,_15 (l_amod) neurotoxic_32\JJ\0|a_2
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|)_40|,_41|organophosphate_56 (r_appos) mipafox_24\NNP\0|NONE_0 (r_pobj) to_23\IN\0|acutely_16 (r_prep) exposed_22\VBN\2110927|NONE_0 (r_acl) rats_20\NNS\2329401|NONE_0 (r_pobj) in_19\IN\13603305|correlation_124|was_13|._110 (r_prep) examined_18\VBN\0|NONE_0 (l_nsubjpass) correlation_1\NN\13841213|was_111|in_124|._234 (l_prep) between_2\IN\0|the_16 (l_pobj) damage_4\NN\7296428|NONE_0 (l_prep) of_7\IN\0|neuropathic_34|and_15|inhibition_11 (l_pobj) esterase_9\NN\0|NONE_0 (l_amod) neurotoxic_8\JJ\0|or_20|enzyme_41
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NNP\0|)_40|,_41|organophosphate_56 (r_appos) mipafox_24\NNP\0|NONE_0 (l_appos) organophosphate_33\NN\14919948|n'-diisopropylphosphorodiamidofluoridate_56|)_16|,_15 (l_amod) neurotoxic_32\JJ\0|a_2
2559236
D004317_D000419 CID adriamycin_7\NNS\0|NONE_0 (r_pobj) of_6\IN\0|a_14|single_12|and_14 (r_prep) dose_5\NN\3740161|rats_25|were_20|divided_39|._137 (r_dobj) given_2\VBN\5892096|NONE_0 (l_advcl) divided_12\VBD\140123|rats_64|were_59|dose_39|._98 (l_prep) into_13\IN\0|later_14 (l_pobj) groups_15\NNS\2137|NONE_0 (l_acl) matched_16\VBN\2664769|four_12 (l_prep) for_17\IN\0|NONE_0 (l_pobj) albuminuria_18\NN\14299637|NONE_0
D004656_D009401 NONE enalapril_10\NN\2673637|enzyme_23 (r_appos) inhibitor_6\NN\20090|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_58|in_71|with_93|._130 (r_nsubjpass) assessed_12\VBN\670261|NONE_0 (l_prep) with_18\IN\0|effect_93|was_35|in_22|._37 (l_pobj) nephrosis_21\NN\14304060|NONE_0
D004656_D009401 NONE enalapril_17\NN\2673637|NONE_0 (r_pobj) of_16\IN\0|the_11|on_13 (r_prep) effect_15\NN\34213|to_14 (l_prep) on_18\IN\0|the_24|of_13 (l_pobj) progression_19\NN\8457976|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) injury_22\NN\14052046|NONE_0 (l_prep) in_23\IN\13603305|renal_13 (l_pobj) nephrosis_25\NN\14304060|NONE_0
D004656_D007674 NONE enalapril_17\NN\2673637|NONE_0 (r_pobj) of_16\IN\0|the_11|on_13 (r_prep) effect_15\NN\34213|to_14 (l_prep) on_18\IN\0|the_24|of_13 (l_pobj) progression_19\NN\8457976|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) injury_22\NN\14052046|NONE_0
D004317_D009401 CID adriamycin_20\NNS\0|established_12 (r_amod) nephrosis_21\NN\14304060|NONE_0
D004317_D009401 CID adriamycin_24\JJ\0|NONE_0 (r_amod) nephrosis_25\NN\14304060|NONE_0
D004656_D000419 NONE enalapril_7\DT\2673637|that_5|pressure_33|2_51|vs._53 (r_nsubj) reduced_8\JJ\441445|studies_30|._290 (l_prep) vs._16\IN\0|that_58|enalapril_53|pressure_20|2_2 (l_pobj) hg_21\NNP\14625458|NONE_0 (l_conj) pressure_36\NN\11419404|mm_65|,_60|group_58|,_45|p_43|)_27|and_25 (l_appos) +/-_39\SYM\0|glomerular_34|capillary_23|(_4|(_73|+/-_78|)_106|or_108|gfr_111 (l_prep) without_53\IN\0|54_47|1_40|vs._38 (l_pcomp) reducing_54\VBG\13447361|NONE_0 (l_dobj) albuminuria_55\NN\14299637|NONE_0
D004656_D000419 NONE enalapril_1\NN\2673637|NONE_0 (r_compound) treatment_2\NN\654885|NONE_0 (r_nsubj) reduced_3\VBN\441445|blood_8|without_23|._62 (r_amod) pressure_5\NN\11419404|NONE_0 (l_prep) without_6\IN\0|reduced_23|blood_15|._39 (l_pcomp) reducing_7\VBG\13447361|NONE_0 (l_dobj) albuminuria_8\NN\14299637|in_12
D004317_D007674 NONE adriamycin_9\NNS\0|-_10 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) nephropathy_12\NN\14573196|NONE_0
D004317_D007674 NONE adriamycin_24\JJ\0|NONE_0 (r_amod) nephrosis_25\NN\14304060|NONE_0 (r_pobj) in_23\IN\13603305|renal_13 (r_prep) injury_22\NN\14052046|NONE_0
10739826
D003276_D054556 CID contraceptives_5\NNS\3183080|NONE_0 (l_conj) risk_8\NN\14541044|newer_34|oral_28|and_8 (l_prep) of_9\IN\0|the_9 (l_pobj) thromboembolism_11\NN\14100769|NONE_0
D003276_D054556 CID contraceptives_17\NNS\3183080|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0
D003276_D054556 CID contraceptives_17\NNS\3183080|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3|associated_5
D003276_D054556 CID oc_19\NNP\0|newer_27|oral_21 (r_appos) contraceptives_17\NNS\3183080|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0
D003276_D054556 CID oc_19\NNP\0|newer_27|oral_21 (r_appos) contraceptives_17\NNS\3183080|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3|associated_5
D003276_D054556 CID oc_27\NNP\0|,_6|users_26 (r_compound) use_28\NN\407535|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) patterns_25\NNS\5726345|NONE_0 (r_pobj) between_24\IN\0|studies_130|did_20|not_16|._76 (r_prep) distinguish_23\VB\618878|NONE_0 (l_nsubj) studies_2\NNS\635850|did_110|not_114|between_130|._206 (l_relcl) assessed_4\VBD\670261|the_33|epidemiological_29 (l_dobj) risk_6\NN\14541044|that_18 (l_prep) of_7\IN\0|the_9 (l_pobj) thromboembolism_9\NN\14100769|NONE_0
D003276_D054556 CID oc_27\NNP\0|,_6|users_26 (r_compound) use_28\NN\407535|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) patterns_25\NNS\5726345|NONE_0 (r_pobj) between_24\IN\0|studies_130|did_20|not_16|._76 (r_prep) distinguish_23\VB\618878|NONE_0 (l_nsubj) studies_2\NNS\635850|did_110|not_114|between_130|._206 (l_relcl) assessed_4\VBD\670261|the_33|epidemiological_29 (l_dobj) risk_6\NN\14541044|that_18 (l_prep) of_7\IN\0|the_9 (l_pobj) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3|associated_5
D003276_D054556 CID oc_12\NNP\0|NONE_0 (r_pobj) of_9\IN\0|repeat_13 (r_prep) users_8\NNS\7846|NONE_0 (r_pobj) for_6\IN\0|the_31|adjusted_27|rate_18|of_7 (r_prep) ratio_3\NN\13815152|%_64|repeat_90|,_129|was_142|._278 (l_prep) of_4\IN\0|the_24|adjusted_20|rate_11|for_7 (l_pobj) vte_5\NN\0|NONE_0
12627929
C067311_D054556 CID docetaxel_9\NNS\0|NONE_0 (r_pobj) of_8\IN\0|the_16|in_29 (r_prep) combination_7\NN\7951464|NONE_0 (r_pobj) with_5\IN\0|venous_23 (r_prep) thromboembolism_4\NN\14100769|NONE_0
C067311_D054556 CID docetaxel_26\NNS\0|NONE_0 (r_pobj) with_25\IN\0|who_17|were_13|alone_15 (r_prep) treated_24\VBN\2376958|advanced_55|independent_37|prostate_25 (r_relcl) cancer_21\NN\14239425|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) patients_14\NNS\9898892|NONE_0 (r_pobj) in_13\IN\13603305|the_46|of_32 (r_prep) frequency_6\NN\15286249|to_16 (l_prep) of_7\IN\0|the_14|in_32 (l_pobj) thromboembolism_9\NN\14100769|NONE_0
C067311_D054556 CID docetaxel_26\NNS\0|NONE_0 (r_pobj) with_25\IN\0|who_17|were_13|alone_15 (r_prep) treated_24\VBN\2376958|advanced_55|independent_37|prostate_25 (r_relcl) cancer_21\NN\14239425|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) patients_14\NNS\9898892|NONE_0 (r_pobj) in_13\IN\13603305|the_46|of_32 (r_prep) frequency_6\NN\15286249|to_16 (l_prep) of_7\IN\0|the_14|in_32 (l_pobj) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3
C067311_D054556 CID docetaxel_6\NNS\0|who_13|alone_10 (r_dobj) received_5\VBD\2210855|23_16 (r_relcl) patients_3\NNS\9898892|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) none_0\NN\15228378|vte_59|,_62|developed_135|._158 (r_nsubj) developed_8\VBN\1753788|NONE_0 (l_dobj) vte_9\NNP\0|none_59|,_3|developed_76|._99
C067311_D054556 CID docetaxel_6\NNS\0|who_13|alone_10 (r_dobj) received_5\VBD\2210855|23_16 (r_relcl) patients_3\NNS\9898892|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) none_0\NN\15228378|vte_59|,_62|developed_135|._158 (r_nsubj) developed_8\VBN\1753788|NONE_0 (l_advcl) developed_25\VBD\1753788|none_135|vte_76|,_73|._23 (l_dobj) vte_26\NNP\0|whereas_81|9_73
C067311_D054556 CID docetaxel_22\NNS\0|who_13 (r_dobj) received_21\VBD\2210855|47_22|(_10|%_7|)_6 (r_relcl) patients_15\NNS\9898892|NONE_0 (r_pobj) of_13\IN\0|plus_44|thalidomide_49 (r_prep) 9_12\CD\13741022|whereas_8|vte_73 (r_nsubj) developed_25\VBD\1753788|none_135|vte_76|,_73|._23 (r_advcl) developed_8\VBN\1753788|NONE_0 (l_dobj) vte_9\NNP\0|none_59|,_3|developed_76|._99
C067311_D054556 CID docetaxel_22\NNS\0|who_13 (r_dobj) received_21\VBD\2210855|47_22|(_10|%_7|)_6 (r_relcl) patients_15\NNS\9898892|NONE_0 (r_pobj) of_13\IN\0|plus_44|thalidomide_49 (r_prep) 9_12\CD\13741022|whereas_8|vte_73 (r_nsubj) developed_25\VBD\1753788|none_135|vte_76|,_73|._23 (l_dobj) vte_26\NNP\0|whereas_81|9_73
C067311_D054556 CID docetaxel_5\NNS\0|the_31|of_18 (r_relcl) addition_1\NN\3081021|significantly_73|frequency_101|._117 (r_nsubj) increases_13\VBZ\13576355|NONE_0 (l_dobj) frequency_15\NN\15286249|addition_101|significantly_28|._16 (l_prep) of_16\IN\0|the_14 (l_pobj) vte_17\NNP\0|NONE_0
D013792_D011471 NONE thalidomide_11\NN\4166841|and_4 (r_conj) docetaxel_9\NNS\0|NONE_0 (r_pobj) of_8\IN\0|the_16|in_29 (r_prep) combination_7\NN\7951464|NONE_0 (l_prep) in_12\IN\13603305|the_45|of_29 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) cancer_20\NN\14239425|NONE_0
D013792_D011471 NONE thalidomide_32\NN\4166841|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) combination_30\NN\7951464|NONE_0 (r_pobj) in_29\IN\13603305|or_3 (r_conj) alone_27\RB\0|who_32|were_28|with_15 (r_advmod) treated_24\VBN\2376958|advanced_55|independent_37|prostate_25 (r_relcl) cancer_21\NN\14239425|NONE_0
D013792_D011471 NONE thalidomide_3\NN\4166841|NONE_0 (r_pobj) of_2\IN\0|the_13|docetaxel_18 (r_prep) addition_1\NN\3081021|significantly_73|frequency_101|._117 (l_relcl) docetaxel_5\NNS\0|the_31|of_18 (l_prep) in_6\IN\13603305|to_13 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) cancer_11\NN\14239425|NONE_0
D013792_D054556 CID thalidomide_11\NN\4166841|and_4 (r_conj) docetaxel_9\NNS\0|NONE_0 (r_pobj) of_8\IN\0|the_16|in_29 (r_prep) combination_7\NN\7951464|NONE_0 (r_pobj) with_5\IN\0|venous_23 (r_prep) thromboembolism_4\NN\14100769|NONE_0
D013792_D054556 CID thalidomide_32\NN\4166841|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) combination_30\NN\7951464|NONE_0 (r_pobj) in_29\IN\13603305|or_3 (r_conj) alone_27\RB\0|who_32|were_28|with_15 (r_advmod) treated_24\VBN\2376958|advanced_55|independent_37|prostate_25 (r_relcl) cancer_21\NN\14239425|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) patients_14\NNS\9898892|NONE_0 (r_pobj) in_13\IN\13603305|the_46|of_32 (r_prep) frequency_6\NN\15286249|to_16 (l_prep) of_7\IN\0|the_14|in_32 (l_pobj) thromboembolism_9\NN\14100769|NONE_0
D013792_D054556 CID thalidomide_32\NN\4166841|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) combination_30\NN\7951464|NONE_0 (r_pobj) in_29\IN\13603305|or_3 (r_conj) alone_27\RB\0|who_32|were_28|with_15 (r_advmod) treated_24\VBN\2376958|advanced_55|independent_37|prostate_25 (r_relcl) cancer_21\NN\14239425|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) patients_14\NNS\9898892|NONE_0 (r_pobj) in_13\IN\13603305|the_46|of_32 (r_prep) frequency_6\NN\15286249|to_16 (l_prep) of_7\IN\0|the_14|in_32 (l_pobj) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3
D013792_D054556 CID thalidomide_24\NN\4166841|of_49|plus_5 (r_conj) 9_12\CD\13741022|whereas_8|vte_73 (r_nsubj) developed_25\VBD\1753788|none_135|vte_76|,_73|._23 (r_advcl) developed_8\VBN\1753788|NONE_0 (l_dobj) vte_9\NNP\0|none_59|,_3|developed_76|._99
D013792_D054556 CID thalidomide_24\NN\4166841|of_49|plus_5 (r_conj) 9_12\CD\13741022|whereas_8|vte_73 (r_nsubj) developed_25\VBD\1753788|none_135|vte_76|,_73|._23 (l_dobj) vte_26\NNP\0|whereas_81|9_73
D013792_D054556 CID thalidomide_3\NN\4166841|NONE_0 (r_pobj) of_2\IN\0|the_13|docetaxel_18 (r_prep) addition_1\NN\3081021|significantly_73|frequency_101|._117 (r_nsubj) increases_13\VBZ\13576355|NONE_0 (l_dobj) frequency_15\NN\15286249|addition_101|significantly_28|._16 (l_prep) of_16\IN\0|the_14 (l_pobj) vte_17\NNP\0|NONE_0
C067311_D011471 NONE docetaxel_9\NNS\0|NONE_0 (r_pobj) of_8\IN\0|the_16|in_29 (r_prep) combination_7\NN\7951464|NONE_0 (l_prep) in_12\IN\13603305|the_45|of_29 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) cancer_20\NN\14239425|NONE_0
C067311_D011471 NONE docetaxel_26\NNS\0|NONE_0 (r_pobj) with_25\IN\0|who_17|were_13|alone_15 (r_prep) treated_24\VBN\2376958|advanced_55|independent_37|prostate_25 (r_relcl) cancer_21\NN\14239425|NONE_0
C067311_D011471 NONE docetaxel_5\NNS\0|the_31|of_18 (l_prep) in_6\IN\13603305|to_13 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) cancer_11\NN\14239425|NONE_0
8919272
D014635_D009422 NONE valproate_10\NN\0|NONE_0 (l_dobj) disorders_43\NNS\14034177|application_183|polfa_119|at_111|to_59|._67
D014635_D009422 NONE valproate_49\NNP\0|(_2|"_1|"_24|)_25 (r_amod) encephalopathy_50\JJ\14084880|cerebellum_30 (r_appos) damage_46\NN\7296428|NONE_0 (r_dobj) indicating_44\VBG\952524|revealed_32|neurological_23 (r_acl) disorders_43\NNS\14034177|application_183|polfa_119|at_111|to_59|._67
D014635_D056486 NONE valproate_15\NNP\0|NONE_0 (r_amod) encephalopathy_16\NNP\14084880|NONE_0 (r_pobj) of_14\IN\0|the_16 (r_prep) development_13\NN\248977|NONE_0 (r_pobj) upon_11\IN\0|influence_56|mainly_23|,_2 (r_prep) hyperammonemia_9\NN\0|is_65|._77 (l_nsubj) influence_2\NN\5190804|mainly_33|,_54|upon_56 (l_prep) of_3\IN\0|the_23|possible_19|,_21 (l_pobj) damage_6\NN\7296428|NONE_0
D014635_D001927 CID valproate_11\NN\0|NONE_0 (l_nsubj) features_1\NNS\5849040|to_92|._99 (l_prep) of_2\IN\0|morphological_23|after_18 (l_pobj) encephalopathy_3\NN\14084880|NONE_0
D014635_D001927 CID valproate_10\NN\0|NONE_0 (l_dobj) disorders_43\NNS\14034177|application_183|polfa_119|at_111|to_59|._67 (l_acl) indicating_44\VBG\952524|revealed_32|neurological_23 (l_dobj) damage_46\NN\7296428|NONE_0 (l_appos) encephalopathy_50\JJ\14084880|cerebellum_30
D014635_D001927 CID valproate_49\NNP\0|(_2|"_1|"_24|)_25 (r_amod) encephalopathy_50\JJ\14084880|cerebellum_30
D014635_D001927 CID valproate_15\NNP\0|NONE_0 (r_amod) encephalopathy_16\NNP\14084880|NONE_0
D014635_D002526 NONE valproate_10\NN\0|NONE_0 (l_dobj) disorders_43\NNS\14034177|application_183|polfa_119|at_111|to_59|._67 (l_acl) indicating_44\VBG\952524|revealed_32|neurological_23 (l_dobj) damage_46\NN\7296428|NONE_0
D014635_D002526 NONE valproate_49\NNP\0|(_2|"_1|"_24|)_25 (r_amod) encephalopathy_50\JJ\14084880|cerebellum_30 (r_appos) damage_46\NN\7296428|NONE_0
D014635_D022124 NONE valproate_15\NNP\0|NONE_0 (r_amod) encephalopathy_16\NNP\14084880|NONE_0 (r_pobj) of_14\IN\0|the_16 (r_prep) development_13\NN\248977|NONE_0 (r_pobj) upon_11\IN\0|influence_56|mainly_23|,_2 (r_prep) hyperammonemia_9\NN\0|is_65|._77
18439803
D010862_D012640 CID pilocarpine_10\NN\14712692|-_11 (r_npadvmod) induced_12\VBN\1627355|in_16 (r_amod) seizure_13\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine_23\NN\14712692|-_11 (r_npadvmod) induced_25\VBN\1627355|NONE_0 (r_amod) seizure_26\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine_13\NN\14712692|-_11 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) seizure_16\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine_12\NN\14712692|-_11 (r_npadvmod) induced_14\VBN\1627355|in_18 (r_amod) increases_15\NNS\13576355|that_54|vpu_49|could_45|drastically_39 (r_dobj) reduce_11\VB\441445|the_39 (r_relcl) finding_6\NN\43195|,_6 (r_appos) vpa_3\NNP\0|NONE_0 (r_pobj) like_2\IN\5839024|therefore_11|,_2|should_113|,_127|for_146|._241 (r_prep) account_21\VB\6647206|NONE_0 (l_prep) for_27\IN\0|therefore_157|,_148|like_146|should_33|,_19|._95 (l_pobj) activity_30\NN\30358|partly_31|,_25 (l_acl) observed_31\VBN\2163746|its_28|anticonvulsant_24 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) seizure_36\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine_33\NN\14712692|-_11 (r_npadvmod) induced_35\VBN\1627355|in_16 (r_amod) seizure_36\NN\14081375|NONE_0
D000596_D012640 NONE acid_7\NN\14818238|hippocampal_18 (r_compound) neurotransmitters_8\NNS\14807410|NONE_0 (r_pobj) on_4\IN\0|acute_43|of_29|in_44|._82 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) in_9\IN\13603305|acute_87|of_73|on_44|._38 (l_pobj) seizure_13\NN\14081375|NONE_0
D000596_D012640 NONE acid_26\NN\14818238|inhibitory_17 (r_compound) neurotransmitters_27\NNS\14807410|NONE_0 (r_pobj) of_23\IN\0|the_14 (r_prep) reduction_22\NN\351485|that_9|minor_71|and_77|offset_81 (r_nsubj) was_28\VBD\0|based_178|it_78|is_75|._87 (r_ccomp) suggested_19\VBN\1010118|NONE_0 (l_prep) based_0\VBN\0|it_100|is_103|was_178|._265 (l_prep) on_1\IN\0|NONE_0 (l_pobj) finding_3\NN\43195|NONE_0 (l_acl) protect_9\VB\1127795|the_35 (l_dobj) animals_11\NNS\4475|that_35|vpu_30|could_18 (l_prep) against_12\IN\0|the_12 (l_pobj) seizure_16\NN\14081375|NONE_0
C108761_D012640 NONE n-(2-propylpentanoyl)urea_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|acute_14|on_29|in_73|._111 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) in_9\IN\13603305|acute_87|of_73|on_44|._38 (l_pobj) seizure_13\NN\14081375|NONE_0
C108761_D012640 NONE vpu_0\NNS\0|potent_13|,_28|exhibiting_30|._196 (r_nsubj) was_1\VBD\0|NONE_0 (l_advcl) exhibiting_7\VBG\2632167|vpu_30|potent_17|,_2|._166 (l_dobj) dose_11\NN\3740161|was_121 (l_prep) of_16\IN\0|the_35|median_31|effective_24|ed(50_8|)_2 (l_pobj) mg/kg_18\NNS\0|NONE_0 (l_prep) in_19\IN\13603305|49_9 (l_pcomp) protecting_20\VBG\1127795|NONE_0 (l_prep) against_22\IN\0|rats_5 (l_pobj) seizure_26\NN\14081375|NONE_0
C108761_D012640 NONE vpu_5\NNPS\0|that_5|could_12|animals_30 (r_nsubj) protect_9\VB\1127795|the_35 (l_dobj) animals_11\NNS\4475|that_35|vpu_30|could_18 (l_prep) against_12\IN\0|the_12 (l_pobj) seizure_16\NN\14081375|NONE_0
C108761_D012640 NONE vpu_8\NNP\0|that_5|could_4|drastically_10|increases_49 (r_nsubj) reduce_11\VB\441445|the_39 (r_relcl) finding_6\NN\43195|,_6 (r_appos) vpa_3\NNP\0|NONE_0 (r_pobj) like_2\IN\5839024|therefore_11|,_2|should_113|,_127|for_146|._241 (r_prep) account_21\VB\6647206|NONE_0 (l_prep) for_27\IN\0|therefore_157|,_148|like_146|should_33|,_19|._95 (l_pobj) activity_30\NN\30358|partly_31|,_25 (l_acl) observed_31\VBN\2163746|its_28|anticonvulsant_24 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) seizure_36\NN\14081375|NONE_0
D001224_D012640 NONE aspartate_40\NN\0|and_4 (r_conj) glutamate_38\NN\15010703|NONE_0 (r_pobj) of_37\IN\0|a_23|pronounced_21 (r_prep) reduction_36\NN\351485|NONE_0 (r_pobj) by_33\IN\0|NONE_0 (r_agent) offset_32\VBN\15180528|that_90|reduction_81|minor_10|and_4 (r_conj) was_28\VBD\0|based_178|it_78|is_75|._87 (r_ccomp) suggested_19\VBN\1010118|NONE_0 (l_prep) based_0\VBN\0|it_100|is_103|was_178|._265 (l_prep) on_1\IN\0|NONE_0 (l_pobj) finding_3\NN\43195|NONE_0 (l_acl) protect_9\VB\1127795|the_35 (l_dobj) animals_11\NNS\4475|that_35|vpu_30|could_18 (l_prep) against_12\IN\0|the_12 (l_pobj) seizure_16\NN\14081375|NONE_0
D001224_D012640 NONE aspartate_19\NN\0|and_4 (r_conj) glutamate_17\NN\15010703|NONE_0 (r_pobj) in_16\IN\13603305|induced_18 (r_prep) increases_15\NNS\13576355|that_54|vpu_49|could_45|drastically_39 (r_dobj) reduce_11\VB\441445|the_39 (r_relcl) finding_6\NN\43195|,_6 (r_appos) vpa_3\NNP\0|NONE_0 (r_pobj) like_2\IN\5839024|therefore_11|,_2|should_113|,_127|for_146|._241 (r_prep) account_21\VB\6647206|NONE_0 (l_prep) for_27\IN\0|therefore_157|,_148|like_146|should_33|,_19|._95 (l_pobj) activity_30\NN\30358|partly_31|,_25 (l_acl) observed_31\VBN\2163746|its_28|anticonvulsant_24 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) seizure_36\NN\14081375|NONE_0
D014635_D012640 NONE vpa_5\NNP\0|NONE_0 (r_pobj) than_4\IN\0|more_12 (r_prep) potent_3\JJ\0|vpu_13|,_15|exhibiting_17|._183 (r_acomp) was_1\VBD\0|NONE_0 (l_advcl) exhibiting_7\VBG\2632167|vpu_30|potent_17|,_2|._166 (l_dobj) dose_11\NN\3740161|was_121 (l_prep) of_16\IN\0|the_35|median_31|effective_24|ed(50_8|)_2 (l_pobj) mg/kg_18\NNS\0|NONE_0 (l_prep) in_19\IN\13603305|49_9 (l_pcomp) protecting_20\VBG\1127795|NONE_0 (l_prep) against_22\IN\0|rats_5 (l_pobj) seizure_26\NN\14081375|NONE_0
D014635_D012640 NONE vpa_32\NNP\0|NONE_0 (r_pobj) for_31\IN\0|the_24|corresponding_20 (r_prep) value_30\NN\5856066|whereas_26|mg/kg_22 (r_nsubj) was_33\VBD\0|dose_121 (r_advcl) exhibiting_7\VBG\2632167|vpu_30|potent_17|,_2|._166 (l_dobj) dose_11\NN\3740161|was_121 (l_prep) of_16\IN\0|the_35|median_31|effective_24|ed(50_8|)_2 (l_pobj) mg/kg_18\NNS\0|NONE_0 (l_prep) in_19\IN\13603305|49_9 (l_pcomp) protecting_20\VBG\1127795|NONE_0 (l_prep) against_22\IN\0|rats_5 (l_pobj) seizure_26\NN\14081375|NONE_0
D014635_D012640 NONE vpa_7\NNP\0|and_4 (r_conj) vpu_5\NNPS\0|that_5|could_12|animals_30 (r_nsubj) protect_9\VB\1127795|the_35 (l_dobj) animals_11\NNS\4475|that_35|vpu_30|could_18 (l_prep) against_12\IN\0|the_12 (l_pobj) seizure_16\NN\14081375|NONE_0
D014635_D012640 NONE vpa_3\NNP\0|NONE_0 (r_pobj) like_2\IN\5839024|therefore_11|,_2|should_113|,_127|for_146|._241 (r_prep) account_21\VB\6647206|NONE_0 (l_prep) for_27\IN\0|therefore_157|,_148|like_146|should_33|,_19|._95 (l_pobj) activity_30\NN\30358|partly_31|,_25 (l_acl) observed_31\VBN\2163746|its_28|anticonvulsant_24 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) seizure_36\NN\14081375|NONE_0
D018698_D012640 NONE glutamate_38\NN\15010703|NONE_0 (r_pobj) of_37\IN\0|a_23|pronounced_21 (r_prep) reduction_36\NN\351485|NONE_0 (r_pobj) by_33\IN\0|NONE_0 (r_agent) offset_32\VBN\15180528|that_90|reduction_81|minor_10|and_4 (r_conj) was_28\VBD\0|based_178|it_78|is_75|._87 (r_ccomp) suggested_19\VBN\1010118|NONE_0 (l_prep) based_0\VBN\0|it_100|is_103|was_178|._265 (l_prep) on_1\IN\0|NONE_0 (l_pobj) finding_3\NN\43195|NONE_0 (l_acl) protect_9\VB\1127795|the_35 (l_dobj) animals_11\NNS\4475|that_35|vpu_30|could_18 (l_prep) against_12\IN\0|the_12 (l_pobj) seizure_16\NN\14081375|NONE_0
D018698_D012640 NONE glutamate_17\NN\15010703|NONE_0 (r_pobj) in_16\IN\13603305|induced_18 (r_prep) increases_15\NNS\13576355|that_54|vpu_49|could_45|drastically_39 (r_dobj) reduce_11\VB\441445|the_39 (r_relcl) finding_6\NN\43195|,_6 (r_appos) vpa_3\NNP\0|NONE_0 (r_pobj) like_2\IN\5839024|therefore_11|,_2|should_113|,_127|for_146|._241 (r_prep) account_21\VB\6647206|NONE_0 (l_prep) for_27\IN\0|therefore_157|,_148|like_146|should_33|,_19|._95 (l_pobj) activity_30\NN\30358|partly_31|,_25 (l_acl) observed_31\VBN\2163746|its_28|anticonvulsant_24 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) seizure_36\NN\14081375|NONE_0
1720453
D007069_D064420 NONE ifosfamide_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|60_8|g_5|/_4 (r_prep) m2_13\NN\13357178|NONE_0 (r_pobj) of_9\IN\0|the_27|higher_23|cumulative_16|,_24|age_36|,_67|and_69|predominance_75 (r_prep) dose_8\NN\3740161|NONE_0 (r_pobj) with_4\IN\0|toxicity_24|was_15|._156 (r_prep) correlated_3\VBN\2657219|NONE_0 (l_nsubjpass) toxicity_1\NN\13576101|was_9|with_24|._180
D007069_C535700 NONE ifosfamide_7\JJ\0|renal_11|in_26 (r_amod) toxicity_9\NN\13576101|NONE_0 (r_pobj) of_6\IN\0|term_15|follow_10|-_4 (r_prep) up_5\NN\153263|for_52|:_84|society_103|._139 (r_nsubj) treated_12\VBN\2376958|NONE_0 (l_prep) for_13\IN\0|up_52|:_32|society_51|._87 (l_pobj) tumors_16\NNS\14234074|NONE_0
D007069_C535700 NONE ifosfamide_19\JJ\0|the_9|same_5|chemotherapy_11|(_33|society_48|mmt_121|)_128 (r_compound) protocol_21\NN\6652242|who_51|have_47 (r_dobj) received_16\VBN\2210855|the_103|renal_99|of_84|with_69|in_35|and_13 (r_relcl) function_2\NN\13783581|were_241|year_256|after_261|._294 (l_prep) with_6\IN\0|the_34|renal_30|of_15|in_34|and_56|received_69 (l_pobj) tumors_9\NNS\14234074|NONE_0
D007069_C535700 NONE ifosfamide_19\JJ\0|the_9|same_5|chemotherapy_11|(_33|society_48|mmt_121|)_128 (r_compound) protocol_21\NN\6652242|who_51|have_47 (l_appos) society_24\NNP\7950920|the_57|same_53|ifosfamide_48|chemotherapy_37|(_15|mmt_73|)_80 (l_prep) of_25\IN\0|international_22 (l_pobj) study_31\NNP\635850|NONE_0 (l_compound) tumor_30\NNP\14234074|oncology_31|malignant_22|mesenchymal_12
D007069_C535700 NONE ifosfamide_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_13|in_14 (r_prep) efficacy_16\NN\5199286|NONE_0 (l_prep) in_19\IN\13603305|the_27|of_14 (l_pobj) treatment_21\NN\654885|NONE_0 (l_prep) of_22\IN\0|the_14|in_22 (l_pobj) tumors_24\NNS\14234074|NONE_0
D010710_D011507 NONE phosphate_25\NN\15010703|tubular_10 (r_nmod) reabsorption_27\NN\13526110|creatinine_40|,_20 (r_conj) clearance_23\NN\5089947|,_13 (r_conj) osmolarity_20\NN\0|urinary_12|,_2 (r_conj) ph_18\NN\5038959|,_10 (r_conj) aminoaciduria_15\JJ\14299637|,_2 (r_conj) proteinuria_13\NN\14299637|,_2
D010710_D064420 NONE phosphate_51\NN\15010703|NONE_0 (r_compound) reabsorption_52\NN\13526110|elevated_52|beta_43|2_38|and_18 (r_conj) microglobulinuria_48\NN\0|NONE_0 (r_pobj) with_44\IN\0|five_14 (r_prep) patients_43\NNS\9898892|group_20|._78 (r_dobj) included_41\VBD\0|identified_187|:_154|first_148|patients_128|;_23|and_21 (r_conj) included_13\VBD\0|NONE_0 (l_dobj) patients_15\NNS\9898892|identified_59|:_26|first_20|;_105|and_107|included_128 (l_relcl) developed_25\VBD\1753788|four_47|(_33|%_31|)_6 (l_dobj) toxicity_27\NN\13576101|who_20
D007069_D009369 NONE ifosfamide_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|60_8|g_5|/_4 (r_prep) m2_13\NN\13357178|NONE_0 (r_pobj) of_9\IN\0|the_27|higher_23|cumulative_16|,_24|age_36|,_67|and_69|predominance_75 (r_prep) dose_8\NN\3740161|NONE_0 (l_conj) predominance_31\NN\14441825|the_102|higher_98|cumulative_91|of_75|,_51|age_39|,_8|and_6 (l_prep) of_32\IN\0|a_15 (l_pobj) involvement_35\NN\1080366|NONE_0 (l_compound) tumor_34\NN\14234074|vesicoprostatic_16
D003404_D011507 NONE creatinine_22\NN\0|,_20|reabsorption_40 (r_compound) clearance_23\NN\5089947|,_13 (r_conj) osmolarity_20\NN\0|urinary_12|,_2 (r_conj) ph_18\NN\5038959|,_10 (r_conj) aminoaciduria_15\JJ\14299637|,_2 (r_conj) proteinuria_13\NN\14299637|,_2
D003404_D000608 NONE creatinine_22\NN\0|,_20|reabsorption_40 (r_compound) clearance_23\NN\5089947|,_13 (r_conj) osmolarity_20\NN\0|urinary_12|,_2 (r_conj) ph_18\NN\5038959|,_10 (r_conj) aminoaciduria_15\JJ\14299637|,_2
D003404_D006030 NONE creatinine_22\NN\0|,_20|reabsorption_40 (r_compound) clearance_23\NN\5089947|,_13 (r_conj) osmolarity_20\NN\0|urinary_12|,_2 (r_conj) ph_18\NN\5038959|,_10 (r_conj) aminoaciduria_15\JJ\14299637|,_2 (r_conj) proteinuria_13\NN\14299637|,_2 (r_conj) glucosuria_11\NN\14267841|and_26|electrolytes_14|,_2
D010710_D006030 NONE phosphate_25\NN\15010703|tubular_10 (r_nmod) reabsorption_27\NN\13526110|creatinine_40|,_20 (r_conj) clearance_23\NN\5089947|,_13 (r_conj) osmolarity_20\NN\0|urinary_12|,_2 (r_conj) ph_18\NN\5038959|,_10 (r_conj) aminoaciduria_15\JJ\14299637|,_2 (r_conj) proteinuria_13\NN\14299637|,_2 (r_conj) glucosuria_11\NN\14267841|and_26|electrolytes_14|,_2
D007069_D007674 CID ifosfamide_7\JJ\0|renal_11|in_26 (r_amod) toxicity_9\NN\13576101|NONE_0
D010710_D000608 NONE phosphate_25\NN\15010703|tubular_10 (r_nmod) reabsorption_27\NN\13526110|creatinine_40|,_20 (r_conj) clearance_23\NN\5089947|,_13 (r_conj) osmolarity_20\NN\0|urinary_12|,_2 (r_conj) ph_18\NN\5038959|,_10 (r_conj) aminoaciduria_15\JJ\14299637|,_2
D010710_D005198 NONE phosphate_51\NN\15010703|NONE_0 (r_compound) reabsorption_52\NN\13526110|elevated_52|beta_43|2_38|and_18 (r_conj) microglobulinuria_48\NN\0|NONE_0 (r_pobj) with_44\IN\0|five_14 (r_prep) patients_43\NNS\9898892|group_20|._78 (r_dobj) included_41\VBD\0|identified_187|:_154|first_148|patients_128|;_23|and_21 (r_conj) included_13\VBD\0|NONE_0 (l_dobj) patients_15\NNS\9898892|identified_59|:_26|first_20|;_105|and_107|included_128 (l_relcl) developed_25\VBD\1753788|four_47|(_33|%_31|)_6 (l_dobj) toxicity_27\NN\13576101|who_20 (l_acl) resulting_28\VBG\2633881|major_15 (l_prep) in_29\IN\13603305|NONE_0 (l_pobj) syndrome_32\NN\5870365|NONE_0
D010710_D005198 NONE phosphate_51\NN\15010703|NONE_0 (r_compound) reabsorption_52\NN\13526110|elevated_52|beta_43|2_38|and_18 (r_conj) microglobulinuria_48\NN\0|NONE_0 (r_pobj) with_44\IN\0|five_14 (r_prep) patients_43\NNS\9898892|group_20|._78 (r_dobj) included_41\VBD\0|identified_187|:_154|first_148|patients_128|;_23|and_21 (r_conj) included_13\VBD\0|NONE_0 (l_dobj) patients_15\NNS\9898892|identified_59|:_26|first_20|;_105|and_107|included_128 (l_relcl) developed_25\VBD\1753788|four_47|(_33|%_31|)_6 (l_dobj) toxicity_27\NN\13576101|who_20 (l_acl) resulting_28\VBG\2633881|major_15 (l_prep) in_29\IN\13603305|NONE_0 (l_pobj) syndrome_32\NN\5870365|NONE_0 (l_appos) tdfs_34\NNP\0|fanconi_20|(_1|)_4
9245658
D009538_D013927 NONE nicotine_0\NN\14712692|does_9|not_14|enhance_28|._59 (r_nsubj) appear_3\VB\2604760|NONE_0 (l_xcomp) enhance_5\VB\227165|nicotine_28|does_19|not_14|._31 (l_dobj) thrombosis_6\NN\14100769|to_11
D009538_D050197 CID nicotine_7\NN\14712692|that_5|could_9|role_22|,_58 (r_nsubj) play_9\VB\7007684|studies_61|but_45|is_71 (l_dobj) role_11\NN\719494|that_27|nicotine_22|could_13|,_36 (l_prep) in_12\IN\13603305|a_7 (l_pcomp) accelerating_13\VBG\226566|NONE_0 (l_dobj) atherosclerosis_14\NN\14108324|NONE_0
D009538_D002318 CID nicotine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|the_9|in_12|._53 (r_prep) role_1\NN\719494|NONE_0 (l_prep) in_4\IN\13603305|the_21|of_12|._41 (l_pobj) disease_9\NN\14061805|NONE_0
D009538_D002318 CID nicotine_0\NNP\14712692|system_43|and_50|contribute_72 (r_nsubj) activates_1\VBZ\1641914|NONE_0 (l_conj) contribute_11\VB\126264|nicotine_72|system_29|and_22 (l_prep) to_12\IN\0|in_29|could_17|._25 (l_pobj) disease_14\NN\14061805|NONE_0
9746003
D002220_D009207 CID carbamazepine_9\NN\0|NONE_0 (l_conj) two_11\CD\13741022|and_4 (l_prep) of_12\IN\0|NONE_0 (l_pobj) jerks_16\NNS\10322238|NONE_0
D002220_D009207 CID carbamazepine_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) withdrawal_21\NN\7206096|NONE_0 (r_pobj) on_20\IN\0|which_15 (r_prep) resolved_19\VBD\352826|these_39|developed_33|myoclonic_23|,_8 (r_relcl) jerks_16\NNS\10322238|NONE_0
D020888_D004832 CID vigabatrin_5\VBP\0|and_4 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) seizures_9\NNS\14081375|NONE_0
D020888_D004832 CID vigabatrin_2\NN\0|and_4 (r_conj) carbamazepine_0\NNP\0|are_29|in_49|._76 (r_nsubjpass) contraindicated_4\VBN\872886|NONE_0 (l_prep) in_5\IN\13603305|carbamazepine_49|are_20|._27 (l_pobj) seizures_8\NNS\14081375|NONE_0
D002220_D004832 CID carbamazepine_3\NN\0|NONE_0 (l_conj) vigabatrin_5\VBP\0|and_4 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) seizures_9\NNS\14081375|NONE_0
D002220_D004832 CID carbamazepine_0\NNP\0|are_29|in_49|._76 (r_nsubjpass) contraindicated_4\VBN\872886|NONE_0 (l_prep) in_5\IN\13603305|carbamazepine_49|are_20|._27 (l_pobj) seizures_8\NNS\14081375|NONE_0
18081909
C026098_D001927 CID levetiracetam_3\NN\0|NONE_0 (r_pcomp) by_2\IN\0|encephalopathy_23|added_17|._35 (r_prep) induced_1\VBN\1627355|NONE_0 (l_nsubj) encephalopathy_0\JJ\14084880|by_23|added_40|._58
C026098_D001927 CID levetiracetam_7\FW\0|a_2|(_14|lev)-induced_15 (r_amod) encephalopathy_10\JJ\14084880|NONE_0
C026098_D001927 CID lev)-induced_9\VBN\0|a_17|levetiracetam_15|(_1 (r_amod) encephalopathy_10\JJ\14084880|NONE_0
C026098_C562694 NONE lev_15\NNP\13685678|NONE_0 (r_pobj) with_14\IN\0|man_77|was_12|)_17|added_19|._53 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_65|with_77|)_94|added_96|._130 (l_acl) suffering_5\VBG\14322699|a_18|old_8 (l_prep) from_6\IN\0|with_25 (l_pobj) epilepsy_8\NN\14085708|NONE_0
C026098_D012640 NONE lev_15\NNP\13685678|NONE_0 (r_pobj) with_14\IN\0|man_77|was_12|)_17|added_19|._53 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_65|with_77|)_94|added_96|._130 (l_acl) suffering_5\VBG\14322699|a_18|old_8 (l_prep) with_9\IN\0|from_25 (l_pobj) seizures_11\NNS\14081375|NONE_0
C026098_D012640 NONE lev_3\NNP\13685678|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) discontinuation_1\NN\209943|improved_60 (r_pobj) following_0\VBG\8180190|NONE_0 (l_preconj) improved_9\VBN\126264|discontinuation_60 (l_conj) decreased_13\VBD\169651|and_22 (l_nsubj) frequency_12\NN\15286249|._19 (l_compound) seizure_11\NN\14081375|NONE_0
D014635_C562694 NONE valproate_22\VB\0|NONE_0 (r_xcomp) added_20\VBN\156601|man_96|was_31|with_19|)_2|._34 (r_conj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_65|with_77|)_94|added_96|._130 (l_acl) suffering_5\VBG\14322699|a_18|old_8 (l_prep) from_6\IN\0|with_25 (l_pobj) epilepsy_8\NN\14085708|NONE_0
D014635_C562694 NONE vpa_24\NNP\0|to_14|(_1|)_3|(_5|mg_11|)_13 (r_dobj) valproate_22\VB\0|NONE_0 (r_xcomp) added_20\VBN\156601|man_96|was_31|with_19|)_2|._34 (r_conj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_65|with_77|)_94|added_96|._130 (l_acl) suffering_5\VBG\14322699|a_18|old_8 (l_prep) from_6\IN\0|with_25 (l_pobj) epilepsy_8\NN\14085708|NONE_0
D014635_D001927 CID valproate_6\VB\0|NONE_0 (r_xcomp) added_4\VBN\156601|encephalopathy_40|by_17|._18 (r_conj) induced_1\VBN\1627355|NONE_0 (l_nsubj) encephalopathy_0\JJ\14084880|by_23|added_40|._58
D014635_D012640 NONE valproate_22\VB\0|NONE_0 (r_xcomp) added_20\VBN\156601|man_96|was_31|with_19|)_2|._34 (r_conj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_65|with_77|)_94|added_96|._130 (l_acl) suffering_5\VBG\14322699|a_18|old_8 (l_prep) with_9\IN\0|from_25 (l_pobj) seizures_11\NNS\14081375|NONE_0
D014635_D012640 NONE vpa_24\NNP\0|to_14|(_1|)_3|(_5|mg_11|)_13 (r_dobj) valproate_22\VB\0|NONE_0 (r_xcomp) added_20\VBN\156601|man_96|was_31|with_19|)_2|._34 (r_conj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_65|with_77|)_94|added_96|._130 (l_acl) suffering_5\VBG\14322699|a_18|old_8 (l_prep) with_9\IN\0|from_25 (l_pobj) seizures_11\NNS\14081375|NONE_0
20520283
C522667_D001480 CID asenapine_21\NN\0|NONE_0 (r_pobj) of_19\IN\0|10_4|at_17 (r_prep) %_18\NN\0|34_11|,_8|and_6 (r_conj) %_14\NN\0|15_15|and_11|%_5|,_4|respectively_81 (r_appos) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|as_16|aes_13 (r_prep) occurred_5\VBD\0|symptoms_25|._120 (r_advcl) reported_2\VBD\831651|NONE_0 (l_nsubj) symptoms_1\NNS\5823932|occurred_25|._145
C522667_D001480 CID asenapine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) similar_7\JJ\0|that_18|efficacy_13 (r_acomp) was_6\VBD\0|analyses_33 (r_ccomp) indicated_3\VBD\952524|;_66|contrasts_76|were_86|in_96|._138 (r_ccomp) seen_16\VBN\2106506|NONE_0 (l_prep) in_17\IN\13603305|indicated_96|;_30|contrasts_20|were_10|._42 (l_pobj) aes_18\NNS\0|NONE_0 (l_appos) symptoms_22\NNS\5823932|,_28
C522667_D001714 NONE asenapine_0\NNP\0|is_10|by_22|in_59|._205 (r_nsubjpass) approved_2\VBN\803325|NONE_0 (l_prep) in_9\IN\13603305|asenapine_59|is_49|by_37|._146 (l_pobj) adults_10\NNS\7846|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_conj) of_17\IN\0|treatment_30|or_3 (l_pobj) episodes_21\NNS\7283608|NONE_0 (l_amod) manic_18\JJ\0|associated_24
C522667_D001714 NONE asenapine_0\NNP\0|is_10|by_22|in_59|._205 (r_nsubjpass) approved_2\VBN\803325|NONE_0 (l_prep) in_9\IN\13603305|asenapine_59|is_49|by_37|._146 (l_pobj) adults_10\NNS\7846|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_conj) of_17\IN\0|treatment_30|or_3 (l_pobj) episodes_21\NNS\7283608|NONE_0 (l_acl) associated_22\VBN\628491|manic_24 (l_prep) with_23\IN\0|NONE_0 (l_pobj) disorder_26\NN\14034177|NONE_0
C522667_D011618 NONE asenapine_0\NNP\0|is_10|by_22|in_59|._205 (r_nsubjpass) approved_2\VBN\803325|NONE_0 (l_prep) in_9\IN\13603305|asenapine_59|is_49|by_37|._146 (l_pobj) adults_10\NNS\7846|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_conj) of_17\IN\0|treatment_30|or_3 (l_pobj) episodes_21\NNS\7283608|NONE_0 (l_acl) associated_22\VBN\628491|manic_24 (l_prep) with_23\IN\0|NONE_0 (l_pobj) disorder_26\NN\14034177|NONE_0 (l_prep) with_27\IN\0|bipolar_19|i_11 (l_conj) without_29\IN\0|or_3 (l_pobj) features_31\NNS\5849040|NONE_0 (l_amod) psychotic_30\JJ\10595647|NONE_0
D006220_D001480 CID haloperidol_29\NN\3713736|mg_8|,_2 (r_conj) bid_27\NN\7160883|NONE_0 (r_pobj) at_22\IN\14622893|10_21|of_17 (r_prep) %_18\NN\0|34_11|,_8|and_6 (r_conj) %_14\NN\0|15_15|and_11|%_5|,_4|respectively_81 (r_appos) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|as_16|aes_13 (r_prep) occurred_5\VBD\0|symptoms_25|._120 (r_advcl) reported_2\VBD\831651|NONE_0 (l_nsubj) symptoms_1\NNS\5823932|occurred_25|._145
D006220_D001480 CID haloperidol_11\NN\3713736|and_4 (r_conj) asenapine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) similar_7\JJ\0|that_18|efficacy_13 (r_acomp) was_6\VBD\0|analyses_33 (r_ccomp) indicated_3\VBD\952524|;_66|contrasts_76|were_86|in_96|._138 (r_ccomp) seen_16\VBN\2106506|NONE_0 (l_prep) in_17\IN\13603305|indicated_96|;_30|contrasts_20|were_10|._42 (l_pobj) aes_18\NNS\0|NONE_0 (l_appos) symptoms_22\NNS\5823932|,_28
C522667_D012559 NONE asenapine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|and_11|safety_7|in_13|._112 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_5\IN\13603305|and_24|safety_20|of_13|._99 (l_pobj) trial_12\NN\786195|NONE_0 (l_prep) in_13\IN\13603305|placebo-_42|controlled_17 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) exacerbation_17\NN\374224|NONE_0 (l_prep) of_18\IN\0|acute_19 (l_pobj) schizophrenia_19\NN\14398067|NONE_0
C522667_D012559 NONE asenapine_0\NNP\0|is_10|by_22|in_59|._205 (r_nsubjpass) approved_2\VBN\803325|NONE_0 (l_prep) in_9\IN\13603305|asenapine_59|is_49|by_37|._146 (l_pobj) adults_10\NNS\7846|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_pobj) treatment_13\NN\654885|or_27|of_30 (l_prep) of_14\IN\0|acute_16 (l_pobj) schizophrenia_15\NN\14398067|NONE_0
C522667_D012559 NONE asenapine_22\NN\0|NONE_0 (r_pobj) with_21\IN\0|dose_15 (r_prep) treatment_20\NN\654885|NONE_0 (r_pobj) to_16\IN\0|in_93|,_63|patients_57|were_23|randomly_18|at_39|,_64|asenapine_66|)_154|._155 (r_prep) assigned_15\VBN\2475922|NONE_0 (l_nsubjpass) patients_9\NNS\9898892|in_36|,_6|were_34|randomly_39|to_57|at_96|,_121|asenapine_123|)_211|._212 (l_prep) with_10\IN\0|458_13 (l_pobj) schizophrenia_12\NN\14398067|NONE_0
C522667_D012559 NONE asenapine_32\NN\0|in_159|,_129|patients_123|were_89|randomly_84|to_66|at_27|,_2|)_88|._89 (r_dep) assigned_15\VBN\2475922|NONE_0 (l_nsubjpass) patients_9\NNS\9898892|in_36|,_6|were_34|randomly_39|to_57|at_96|,_121|asenapine_123|)_211|._212 (l_prep) with_10\IN\0|458_13 (l_pobj) schizophrenia_12\NN\14398067|NONE_0
D006220_D012559 NONE haloperidol_9\NN\3713736|-_11 (r_npadvmod) controlled_11\VBN\0|placebo-_25|in_17 (r_amod) trial_12\NN\786195|NONE_0 (l_prep) in_13\IN\13603305|placebo-_42|controlled_17 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) exacerbation_17\NN\374224|NONE_0 (l_prep) of_18\IN\0|acute_19 (l_pobj) schizophrenia_19\NN\14398067|NONE_0
D006220_D012559 NONE haloperidol_41\NN\3713736|,_5|or_3 (r_conj) placebo_38\NN\3740161|mg_8|,_2 (r_conj) bid_36\NN\7160883|NONE_0 (r_pobj) at_33\IN\14622893|verify_54 (r_prep) asenapine_32\NN\0|in_159|,_129|patients_123|were_89|randomly_84|to_66|at_27|,_2|)_88|._89 (r_dep) assigned_15\VBN\2475922|NONE_0 (l_nsubjpass) patients_9\NNS\9898892|in_36|,_6|were_34|randomly_39|to_57|at_96|,_121|asenapine_123|)_211|._212 (l_prep) with_10\IN\0|458_13 (l_pobj) schizophrenia_12\NN\14398067|NONE_0
7504976
D002231_D002779 CID carbimazole_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|hepatitis_18 (r_agent) induced_6\VBN\1627355|patients_37|._38 (l_nsubj) hepatitis_5\NN\14127211|by_18
D002231_D002779 CID omercazole_11\NN\0|(_4|)_10 (r_appos) carbimazole_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|hepatitis_18 (r_agent) induced_6\VBN\1627355|patients_37|._38 (l_nsubj) hepatitis_5\NN\14127211|by_18
D002231_D002779 CID carbimazole_12\NN\0|others_67|._11 (l_amod) mixed_4\JJ\140123|a_2|)_32|following_44 (l_conj) cholestatic_6\JJ\0|(_1
D002231_D056486 CID carbimazole_16\NN\0|NONE_0 (r_pobj) between_15\IN\0|cross_17|-_12 (r_prep) reactivity_14\NN\5652926|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) one_10\CD\13741022|NONE_0 (r_pobj) including_9\VBG\0|four_11 (r_prep) cases_8\NNS\7283608|hepatitis_45|by_27|:_7|._82 (r_appos) induced_2\VBN\1627355|NONE_0 (l_nsubj) hepatitis_1\NN\14127211|by_18|:_38|cases_45|._127
D002231_D056486 CID carbimazole_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|hepatitis_18 (r_agent) induced_6\VBN\1627355|patients_37|._38 (l_nsubj) hepatitis_5\NN\14127211|by_18
D002231_D056486 CID omercazole_11\NN\0|(_4|)_10 (r_appos) carbimazole_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|hepatitis_18 (r_agent) induced_6\VBN\1627355|patients_37|._38 (l_nsubj) hepatitis_5\NN\14127211|by_18
D002231_D056486 CID carbimazole_12\NN\0|others_67|._11 (l_amod) following_11\VBG\8180190|a_46|mixed_44|)_12 (l_compound) hepatitis_10\NN\14127211|NONE_0
D002231_D056486 CID carbimazole_21\NN\0|experienced_96|had_13|._11 (r_dobj) replaced_20\VBN\1631072|NONE_0 (l_nsubj) experienced_7\VBD\2108377|had_83|carbimazole_96|._107 (l_dobj) hepatitis_10\NN\14127211|one_63|further_32|)_57
C019269_D056486 NONE benzylthiouracil_18\NN\0|and_4 (r_conj) carbimazole_16\NN\0|NONE_0 (r_pobj) between_15\IN\0|cross_17|-_12 (r_prep) reactivity_14\NN\5652926|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) one_10\CD\13741022|NONE_0 (r_pobj) including_9\VBG\0|four_11 (r_prep) cases_8\NNS\7283608|hepatitis_45|by_27|:_7|._82 (r_appos) induced_2\VBN\1627355|NONE_0 (l_nsubj) hepatitis_1\NN\14127211|by_18|:_38|cases_45|._127
C019269_D056486 NONE benzylthiouracil_14\NNP\0|NONE_0 (r_pobj) after_13\IN\0|which_15 (r_prep) appeared_12\VBD\2604760|a_28|cytolytic_26 (r_relcl) hepatitis_10\NN\14127211|one_63|further_32|)_57
C019269_D056486 NONE ne_17\NNP\14622893|NONE_0 (r_appos) benzylthiouracil_14\NNP\0|NONE_0 (r_pobj) after_13\IN\0|which_15 (r_prep) appeared_12\VBD\2604760|a_28|cytolytic_26 (r_relcl) hepatitis_10\NN\14127211|one_63|further_32|)_57
11007689
D016559_D057049 CID tacrolimus_2\NN\0|-_10 (r_npadvmod) associated_4\VBN\628491|thrombotic_11 (r_amod) microangiopathy_6\NN\0|and_37|._15
D016559_D057049 CID tacrolimus_6\NN\0|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) switching_4\VBG\191142|as_13|,_2|has_24|been_28|be_45|._118 (r_nsubjpass) reported_9\VBN\831651|NONE_0 (l_xcomp) be_11\VB\14625458|as_58|,_47|switching_45|has_21|been_17|._73 (l_attr) option_15\NN\6480506|to_27 (l_prep) in_16\IN\13603305|a_28|viable_26|therapeutic_19 (l_pobj) setting_18\NN\8567235|NONE_0 (l_prep) of_19\IN\0|the_12 (l_pobj) tma_23\NNP\0|NONE_0
D016559_D057049 CID tacrolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_32|widespread_23 (r_prep) application_4\NN\947128|NONE_0 (r_pobj) with_0\IN\0|,_75|tma_99|has_103|also_107|been_112|._127 (r_prep) recognized_18\VBN\686447|NONE_0 (l_nsubjpass) tma_14\NNP\0|with_99|,_24|has_4|also_8|been_13|._28
D016559_D057049 CID tacrolimus_11\NN\0|-_10 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) tma_14\NNP\0|with_99|,_24|has_4|also_8|been_13|._28
D016559_D057049 CID tacrolimus_18\NN\0|and_4 (r_conj) cyclosporine_16\NN\0|NONE_0 (r_pobj) to_15\IN\0|sequentially_13 (r_prep) exposed_13\VBN\2110927|NONE_0 (r_acl) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|the_22|of_7 (r_prep) recurrence_8\NN\7342049|NONE_0 (l_prep) of_9\IN\0|the_15|in_7 (l_pobj) tma_10\NNP\0|NONE_0
D016559_D057049 CID tacrolimus_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) introduction_0\NN\235435|in_78|._149 (r_nsubj) resulted_8\VBD\2633881|NONE_0 (l_prep) in_9\IN\13603305|introduction_78|._71 (l_pobj) recurrence_11\NN\7342049|NONE_0 (l_prep) of_12\IN\0|the_15|and_7|loss_26 (l_pobj) tma_13\NNP\0|NONE_0
D016559_D057049 CID tacrolimus_7\NN\0|NONE_0 (r_pobj) to_6\IN\0|who_35|are_31|from_18 (r_prep) switched_3\VBN\138508|NONE_0 (r_relcl) patients_0\NNS\9898892|should_72|be_79|closely_82|for_100|._143 (r_nsubjpass) monitored_14\VBN\2169352|NONE_0 (l_prep) for_15\IN\0|patients_100|should_28|be_21|closely_18|._43 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_20\IN\0|the_23|and_13|symptoms_9 (l_pobj) tma_22\NNP\0|NONE_0
D016572_D057049 CID cyclosporine_0\NN\0|NONE_0 (l_conj) microangiopathy_6\NN\0|and_37|._15
D016572_D057049 CID cyclosporine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_8 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|thrombotic_33|tma_5 (r_acl) microangiopathy_4\NN\0|NONE_0
D016572_D057049 CID cyclosporine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_8 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|thrombotic_33|tma_5 (r_acl) microangiopathy_4\NN\0|NONE_0 (l_appos) tma_6\NNP\0|thrombotic_28|associated_5
D016572_D057049 CID cyclosporine_20\NN\0|-_12 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) tma_23\NNP\0|NONE_0
D016572_D057049 CID cyclosporine_16\NN\0|NONE_0 (r_pobj) to_15\IN\0|sequentially_13 (r_prep) exposed_13\VBN\2110927|NONE_0 (r_acl) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|the_22|of_7 (r_prep) recurrence_8\NN\7342049|NONE_0 (l_prep) of_9\IN\0|the_15|in_7 (l_pobj) tma_10\NNP\0|NONE_0
D016572_D057049 CID cyclosporine_13\NN\0|-_12 (r_npadvmod) induced_15\VBN\1627355|responded_17 (r_amod) tma_16\NNP\0|who_35
D016572_D057049 CID cyclosporine_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_15|in_16 (r_prep) withdrawal_21\NN\7206096|NONE_0 (r_pobj) to_19\IN\0|that_15 (r_prep) responded_18\VBD\2367363|induced_17 (r_relcl) tma_16\NNP\0|who_35
D016572_D057049 CID cyclosporine_5\NN\0|NONE_0 (r_pobj) from_4\IN\0|who_17|are_13|to_18 (r_prep) switched_3\VBN\138508|NONE_0 (r_relcl) patients_0\NNS\9898892|should_72|be_79|closely_82|for_100|._143 (r_nsubjpass) monitored_14\VBN\2169352|NONE_0 (l_prep) for_15\IN\0|patients_100|should_28|be_21|closely_18|._43 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_20\IN\0|the_23|and_13|symptoms_9 (l_pobj) tma_22\NNP\0|NONE_0
8682684
D000082_D007022 CID acetaminophen_0\NNP\2707683|-_13 (r_npadvmod) induced_2\VBN\1627355|._19 (r_amod) hypotension_3\NN\14057371|NONE_0
D000082_D007022 CID acetaminophen_2\RB\2707683|however_9|,_2|has_14|been_18|produce_39|._119 (r_nsubjpass) demonstrated_5\VBN\2137132|NONE_0 (l_xcomp) produce_7\VB\7555863|however_48|,_41|acetaminophen_39|has_25|been_21|._80 (l_dobj) symptoms_8\NNS\5823932|to_11 (l_prep) including_12\VBG\0|of_16|,_2|,_21|in_23 (l_pobj) hypotension_13\NN\14057371|NONE_0
D000082_D007022 CID acetaminophen_18\NN\2707683|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) after_15\IN\0|in_65|episodes_47|reproducibly_23 (r_prep) developed_14\VBN\1753788|two_83|ill_68 (l_nsubj) episodes_10\NNS\7283608|in_18|reproducibly_24|after_47 (l_prep) of_11\IN\0|transient_19 (l_pobj) hypotension_12\NN\14057371|NONE_0
D000082_D007022 CID acetaminophen_9\NN\2707683|for_27|clinicians_23|to_12|in_14 (r_dobj) consider_8\VB\689344|the_27 (l_prep) in_10\IN\13603305|for_41|clinicians_37|to_26|acetaminophen_14 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) hypotension_13\NN\14057371|NONE_0
D000082_D002318 NONE acetaminophen_3\NN\2707683|NONE_0 (r_pobj) for_2\IN\0|the_14|produce_21 (r_prep) potential_1\NN\14481929|low_73|._76 (l_acl) produce_5\VB\7555863|the_35|for_21 (l_dobj) toxicities_7\NNS\13576101|to_26
D000082_D000707 NONE acetaminophen_2\RB\2707683|however_9|,_2|has_14|been_18|produce_39|._119 (r_nsubjpass) demonstrated_5\VBN\2137132|NONE_0 (l_xcomp) produce_7\VB\7555863|however_48|,_41|acetaminophen_39|has_25|been_21|._80 (l_dobj) symptoms_8\NNS\5823932|to_11 (l_prep) of_9\IN\0|,_14|including_16|,_37|in_39 (l_pobj) anaphylaxis_10\NN\14533203|NONE_0
D000082_D016638 NONE acetaminophen_18\NN\2707683|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) after_15\IN\0|in_65|episodes_47|reproducibly_23 (r_prep) developed_14\VBN\1753788|two_83|ill_68 (r_relcl) patients_6\NNS\9898892|article_37|._111 (l_amod) ill_5\JJ\14052403|two_15|developed_68
15737522
D002443_D001660 CID ceftriaxone_0\NN\2996840|-_11 (r_npadvmod) associated_2\VBN\628491|biliary_11|in_35|._66 (r_amod) pseudolithiasis_4\NN\0|NONE_0
D002443_D001660 CID ceftriaxone_5\NN\2996840|that_5|pseudolithiasis_21 (r_nsubj) leads_6\VBZ\5155821|it_34|is_31|well_28|._41 (l_xcomp) pseudolithiasis_8\NN\0|that_26|ceftriaxone_21
D002443_D001660 CID ceftriaxone_19\CD\2996840|,_21|had_33 (r_compound) treatment_20\NN\654885|NONE_0 (r_dobj) receiving_18\VBG\2210855|paediatric_29|surgical_18 (r_acl) patients_17\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) pseudolithiasis_13\NN\0|NONE_0
19767176
D010100_D009410 NONE oxygen_5\NN\14622893|reactive_9 (r_compound) species_6\NNS\7992450|NONE_0 (r_pobj) of_3\IN\0|as_35|activation_38 (r_prep) production_2\NN\30358|both_6|,_2|have_73|been_78|in_94|._202 (r_nsubjpass) implicated_17\VBN\2677097|NONE_0 (l_prep) in_18\IN\13603305|both_100|,_96|production_94|have_21|been_16|._108 (l_pobj) damage_21\NN\7296428|NONE_0
D010100_D009410 NONE oxygen_9\NN\14622893|reactive_9|and_15|activation_19|of_30 (r_compound) species_10\NNS\7992450|NONE_0 (r_pobj) of_7\IN\0|the_15 (r_prep) generation_6\NN\7942152|that_9|role_87|compared_156 (r_nsubj) plays_17\VBZ\7007684|data_95|might_90|._123 (l_dobj) role_21\NN\719494|that_96|generation_87|compared_69 (l_prep) in_22\IN\13603305|a_20|central_13 (l_pobj) damage_27\NN\7296428|NONE_0
C020972_D013226 NONE dithiocarbamate_1\NN\0|cortex_38|._88 (r_nsubj) protects_2\VBZ\1127795|NONE_0 (l_dobj) cortex_5\NN\5462674|dithiocarbamate_38|._50 (l_prep) in_6\IN\13603305|the_20|piriform_16 (l_pobj) model_11\NN\5888929|NONE_0 (l_amod) epilepticus_10\NN\0|the_23|pilocarpine_19|status_7
C020972_D013226 NONE pdtc_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|the_11|on_8 (r_prep) effect_1\NN\34213|was_97|in_111|._152 (l_prep) on_4\IN\0|the_19|of_8 (l_pobj) loss_10\NN\13252973|NONE_0 (l_amod) associated_8\VBN\628491|status_19|cell_11|in_21 (l_npadvmod) epilepticus_6\NN\0|-_11
C020972_D013226 NONE pdtc_4\NNP\0|NONE_0 (r_pobj) with_1\IN\0|before_20 (r_prep) treatment_0\NN\654885|epilepticus_58|significantly_70|rate_108|to_113|._120 (r_nsubj) increased_11\VBD\169651|NONE_0 (l_advmod) epilepticus_9\NN\0|treatment_58|significantly_12|rate_50|to_55|._62
C020972_D013226 NONE pdtc_4\NNP\0|mg/kg_6|(_5|low_6|-_9 (r_nmod) dose_8\NN\3740161|NONE_0 (r_pobj) of_1\IN\0|)_26 (r_prep) administration_0\NN\1133281|did_43|not_47|effects_63|._135 (r_nsubj) exert_12\VB\1158872|NONE_0 (l_dobj) effects_14\NNS\13245626|administration_63|did_20|not_16|._72 (l_prep) on_15\IN\0|major_14 (l_pobj) development_17\NN\248977|NONE_0 (l_prep) of_18\IN\0|the_16 (l_pobj) epilepticus_21\NN\0|NONE_0
C020972_D013226 NONE pdtc_16\NNP\0|-_4 (r_npadvmod) treated_18\VBN\2376958|NONE_0 (r_amod) rats_19\NNS\2329401|and_17 (r_conj) vehicle-_14\NN\0|NONE_0 (r_pobj) in_13\IN\13603305|decrease_79|was_15|following_34|._62 (r_prep) identified_12\VBN\699815|NONE_0 (l_prep) following_20\VBG\8180190|decrease_113|was_49|in_34|._28 (l_pobj) epilepticus_22\NN\0|NONE_0
D010862_D013226 CID pilocarpine_8\NN\14712692|the_4|status_12|epilepticus_19 (r_amod) model_11\NN\5888929|NONE_0 (l_amod) epilepticus_10\NN\0|the_23|pilocarpine_19|status_7
D010862_D013226 CID pilocarpine_23\NN\14712692|the_21|rat_17|fractionated_13 (r_compound) model_24\NN\5888929|NONE_0 (r_pobj) in_19\IN\13603305|effect_111|was_14|._41 (r_prep) evaluated_18\VBN\670261|NONE_0 (l_nsubjpass) effect_1\NN\34213|was_97|in_111|._152 (l_prep) on_4\IN\0|the_19|of_8 (l_pobj) loss_10\NN\13252973|NONE_0 (l_amod) associated_8\VBN\628491|status_19|cell_11|in_21 (l_npadvmod) epilepticus_6\NN\0|-_11
D010100_D012640 NONE oxygen_9\NN\14622893|reactive_9|and_15|activation_19|of_30 (r_compound) species_10\NNS\7992450|NONE_0 (r_pobj) of_7\IN\0|the_15 (r_prep) generation_6\NN\7942152|that_9|role_87|compared_156 (r_nsubj) plays_17\VBZ\7007684|data_95|might_90|._123 (l_dobj) role_21\NN\719494|that_96|generation_87|compared_69 (l_prep) in_22\IN\13603305|a_20|central_13 (l_pobj) damage_27\NN\7296428|NONE_0 (l_amod) associated_25\VBN\628491|neuronal_11|in_27 (l_npadvmod) seizure_23\NN\14081375|-_7
C020972_D009410 NONE pdtc_10\NNP\0|the_40|kappab_33|and_16 (r_conj) inhibitor_7\NN\20090|in_29|,_16|cortex_54|,_60|affect_81|._107 (r_nsubj) protected_11\VBD\1127795|NONE_0 (l_advcl) affect_20\VB\26192|in_110|,_97|inhibitor_81|cortex_27|,_21|._26 (l_dobj) loss_23\NN\13252973|whereas_41|it_33|did_30|not_26
10193204
D001241_D013927 NONE acid_36\NN\14818238|while_22|mg/kg_14|,_26|control_39|,_46|showed_48 (r_dobj) acetylsalicylic_35\JJ\0|in_153|,_133|administration_127|inhibition_61|,_8|._90 (r_advcl) showed_20\VBD\2137132|NONE_0 (l_dobj) inhibition_22\NN\1068773|in_92|,_72|administration_66|,_53|acetylsalicylic_61|._151 (l_prep) of_23\IN\0|the_15|by_14|,_28|respectively_30 (l_pobj) thrombosis_24\NN\14100769|NONE_0
D001241_D013927 NONE asa_38\NNP\0|NONE_0 (r_appos) acid_36\NN\14818238|while_22|mg/kg_14|,_26|control_39|,_46|showed_48 (r_dobj) acetylsalicylic_35\JJ\0|in_153|,_133|administration_127|inhibition_61|,_8|._90 (r_advcl) showed_20\VBD\2137132|NONE_0 (l_dobj) inhibition_22\NN\1068773|in_92|,_72|administration_66|,_53|acetylsalicylic_61|._151 (l_prep) of_23\IN\0|the_15|by_14|,_28|respectively_30 (l_pobj) thrombosis_24\NN\14100769|NONE_0
D004837_D001791 NONE epinephrine_21\NN\14807929|plus_5 (r_conj) collagen_19\NN\15026716|NONE_0 (r_pobj) by_18\IN\0|in_34 (r_agent) induced_17\VBN\1627355|the_28|experimental_24 (r_acl) thrombosis_16\NN\14100769|NONE_0 (r_pobj) on_13\IN\0|the_27|of_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42
D004837_D001791 NONE ep_23\NN\0|NONE_0 (r_appos) epinephrine_21\NN\14807929|plus_5 (r_conj) collagen_19\NN\15026716|NONE_0 (r_pobj) by_18\IN\0|in_34 (r_agent) induced_17\VBN\1627355|the_28|experimental_24 (r_acl) thrombosis_16\NN\14100769|NONE_0 (r_pobj) on_13\IN\0|the_27|of_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42
C009438_D001791 NONE tetrandrine_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|on_33|._98 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_5\IN\0|of_33|._65 (l_pobj) thrombosis_7\NN\14100769|NONE_0 (l_prep) in_8\IN\13603305|experimental_24 (l_pobj) mice_9\NNS\2329401|NONE_0 (l_conj) aggregation_13\NN\31264|and_19
C009438_D001791 NONE tet_10\NNP\15157225|NONE_0 (r_pobj) of_9\IN\0|the_12|on_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42
C009438_D001791 NONE tet_14\NNP\15157225|in_80|,_2|dose_35|dependently_40|._51 (r_nsubj) showed_17\VBD\2137132|NONE_0 (l_prep) in_0\IN\13603305|,_78|tet_80|dose_115|dependently_120|._131 (l_pobj) aggregations_5\NNS\31264|NONE_0
C060802_D001778 NONE fan_12\NNP\3183080|and_4 (r_conj) tet_10\NNP\15157225|NONE_0 (r_pobj) of_9\IN\0|the_12|on_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42 (l_conj) coagulation_33\NN\13518963|platelet_31|and_10
C009438_D001778 NONE tet_10\NNP\15157225|NONE_0 (r_pobj) of_9\IN\0|the_12|on_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42 (l_conj) coagulation_33\NN\13518963|platelet_31|and_10
D004837_D001778 NONE epinephrine_21\NN\14807929|plus_5 (r_conj) collagen_19\NN\15026716|NONE_0 (r_pobj) by_18\IN\0|in_34 (r_agent) induced_17\VBN\1627355|the_28|experimental_24 (r_acl) thrombosis_16\NN\14100769|NONE_0 (r_pobj) on_13\IN\0|the_27|of_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42 (l_conj) coagulation_33\NN\13518963|platelet_31|and_10
D004837_D001778 NONE ep_23\NN\0|NONE_0 (r_appos) epinephrine_21\NN\14807929|plus_5 (r_conj) collagen_19\NN\15026716|NONE_0 (r_pobj) by_18\IN\0|in_34 (r_agent) induced_17\VBN\1627355|the_28|experimental_24 (r_acl) thrombosis_16\NN\14100769|NONE_0 (r_pobj) on_13\IN\0|the_27|of_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42 (l_conj) coagulation_33\NN\13518963|platelet_31|and_10
C060802_D001791 NONE fangchinoline_4\NN\0|and_4 (r_conj) tetrandrine_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|on_33|._98 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_5\IN\0|of_33|._65 (l_pobj) thrombosis_7\NN\14100769|NONE_0 (l_prep) in_8\IN\13603305|experimental_24 (l_pobj) mice_9\NNS\2329401|NONE_0 (l_conj) aggregation_13\NN\31264|and_19
C060802_D001791 NONE fan_12\NNP\3183080|and_4 (r_conj) tet_10\NNP\15157225|NONE_0 (r_pobj) of_9\IN\0|the_12|on_15 (r_prep) effects_8\NNS\13245626|to_19 (r_dobj) investigate_6\VB\644583|study_24|was_18|,_119|and_121|in_168 (r_advcl) undertaken_4\VBN\1641914|NONE_0 (l_conj) in_34\IN\13603305|study_192|was_186|investigate_168|,_49|and_47 (l_nsubj) aggregation_30\NN\31264|vitro_37|._42
C060802_D001791 NONE fan_16\NNP\3183080|and_4 (r_conj) tet_14\NNP\15157225|in_80|,_2|dose_35|dependently_40|._51 (r_nsubj) showed_17\VBD\2137132|NONE_0 (l_prep) in_0\IN\13603305|,_78|tet_80|dose_115|dependently_120|._131 (l_pobj) aggregations_5\NNS\31264|NONE_0
C060802_D013927 NONE fangchinoline_4\NN\0|and_4 (r_conj) tetrandrine_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|on_33|._98 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_5\IN\0|of_33|._65 (l_pobj) thrombosis_7\NN\14100769|NONE_0
C060802_D013927 NONE fan_12\NNP\3183080|and_4 (r_conj) tet_10\NNP\15157225|NONE_0 (r_pobj) of_9\IN\0|the_12|on_15 (r_prep) effects_8\NNS\13245626|to_19 (l_prep) on_13\IN\0|the_27|of_15 (l_pobj) thrombosis_16\NN\14100769|NONE_0
C060802_D013927 NONE fan_17\NNP\3183080|and_4 (r_conj) tet_15\NNP\15157225|NONE_0 (r_pobj) of_14\IN\0|the_36|(_17|mg/kg_13|i.p._6|)_2 (r_prep) administration_7\NN\1133281|in_26|,_6|inhibition_66|,_119|acetylsalicylic_127|._217 (r_nsubj) showed_20\VBD\2137132|NONE_0 (l_dobj) inhibition_22\NN\1068773|in_92|,_72|administration_66|,_53|acetylsalicylic_61|._151 (l_prep) of_23\IN\0|the_15|by_14|,_28|respectively_30 (l_pobj) thrombosis_24\NN\14100769|NONE_0
C009438_D013927 NONE tetrandrine_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|on_33|._98 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_5\IN\0|of_33|._65 (l_pobj) thrombosis_7\NN\14100769|NONE_0
C009438_D013927 NONE tet_10\NNP\15157225|NONE_0 (r_pobj) of_9\IN\0|the_12|on_15 (r_prep) effects_8\NNS\13245626|to_19 (l_prep) on_13\IN\0|the_27|of_15 (l_pobj) thrombosis_16\NN\14100769|NONE_0
C009438_D013927 NONE tet_15\NNP\15157225|NONE_0 (r_pobj) of_14\IN\0|the_36|(_17|mg/kg_13|i.p._6|)_2 (r_prep) administration_7\NN\1133281|in_26|,_6|inhibition_66|,_119|acetylsalicylic_127|._217 (r_nsubj) showed_20\VBD\2137132|NONE_0 (l_dobj) inhibition_22\NN\1068773|in_92|,_72|administration_66|,_53|acetylsalicylic_61|._151 (l_prep) of_23\IN\0|the_15|by_14|,_28|respectively_30 (l_pobj) thrombosis_24\NN\14100769|NONE_0
D004837_D013927 CID epinephrine_21\NN\14807929|plus_5 (r_conj) collagen_19\NN\15026716|NONE_0 (r_pobj) by_18\IN\0|in_34 (r_agent) induced_17\VBN\1627355|the_28|experimental_24 (r_acl) thrombosis_16\NN\14100769|NONE_0
D004837_D013927 CID ep_23\NN\0|NONE_0 (r_appos) epinephrine_21\NN\14807929|plus_5 (r_conj) collagen_19\NN\15026716|NONE_0 (r_pobj) by_18\IN\0|in_34 (r_agent) induced_17\VBN\1627355|the_28|experimental_24 (r_acl) thrombosis_16\NN\14100769|NONE_0
7083920
D000638_D013617 NONE amiodarone_13\NN\2715941|for_21 (r_compound) treatment_14\NN\654885|NONE_0 (l_prep) for_15\IN\0|amiodarone_21 (l_pobj) tachycardia_17\NNS\14110674|NONE_0
D000638_D006345 NONE amiodarone_13\NN\2715941|for_21 (r_compound) treatment_14\NN\654885|NONE_0 (r_pobj) under_12\IN\0|in_50|without_63 (r_prep) occurring_11\VBG\0|a_32|reversible_30|hisian_13 (l_prep) without_21\IN\0|under_63|in_13 (l_pobj) abnormalities_25\NNS\14034177|NONE_0
D000638_D006327 CID amiodarone_13\NN\2715941|for_21 (r_compound) treatment_14\NN\654885|NONE_0 (r_pobj) under_12\IN\0|in_50|without_63 (r_prep) occurring_11\VBG\0|a_32|reversible_30|hisian_13 (r_acl) block_10\NN\21939|NONE_0
D000638_D001282 NONE amiodarone_3\NN\2715941|NONE_0 (r_compound) discontinuation_4\NN\209943|days_22 (r_pobj) after_2\IN\0|,_32|electrograms_45|flutter_72|._122 (r_prep) showed_9\VBD\2137132|NONE_0 (l_dobj) flutter_11\NN\331950|after_72|,_40|electrograms_27|._50
8558192
D002945_D064420 NONE cisplatin_9\NN\0|-_9 (r_npadvmod) based_11\VBN\0|NONE_0 (r_amod) chemotherapy_12\NN\661091|NONE_0 (r_pobj) with_8\IN\0|patients_54 (r_prep) pretreated_7\VBN\0|assessable_50|._86 (r_csubj) were_13\VBD\0|NONE_0 (l_acomp) assessable_14\JJ\0|pretreated_50|._36 (l_prep) for_15\IN\0|NONE_0 (l_pobj) toxicity_16\NN\13576101|NONE_0
C030852_D064420 NONE vnb_0\NNP\0|was_4|well_8|and_23|occurred_81 (r_nsubjpass) tolerated_3\VBN\802318|NONE_0 (l_conj) occurred_13\VBD\0|vnb_81|was_77|well_73|and_58 (l_nsubj) toxicity_12\NN\13576101|instances_40|._17
C030852_D064420 NONE vnb_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|further_19|in_7 (r_prep) evaluation_10\NN\874067|given_64|,_10|is_41|._53 (r_nsubjpass) warranted_17\VBN\1012073|NONE_0 (l_prep) given_0\VBN\5892096|,_54|evaluation_64|is_105|._117 (l_pobj) profile_4\NN\6999802|NONE_0 (l_conj) toxicity_7\NN\13576101|its_40|tolerance_26|and_8
C030852_C562729 NONE vinorelbine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|ii_9|in_15|._63 (r_prep) trial_2\NN\786195|NONE_0 (l_prep) in_5\IN\13603305|ii_24|of_15|._48 (l_pobj) carcinoma_10\NN\14239918|NONE_0
C030852_C562729 NONE vinorelbine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|toxic_14 (r_prep) effects_7\NNS\13245626|the_28|response_24|and_10|administered_29 (r_conj) rate_4\NN\13815152|to_25|._123 (l_acl) administered_13\VBN\2436349|the_57|response_53|and_39|effects_29 (l_prep) as_14\IN\14622893|NONE_0 (l_pobj) agent_17\NN\7347|NONE_0 (l_prep) in_18\IN\13603305|a_15|single_13 (l_pobj) carcinoma_23\NN\14239918|NONE_0
C030852_C562729 NONE vnb_11\NNP\0|(_1|)_3 (r_appos) vinorelbine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|toxic_14 (r_prep) effects_7\NNS\13245626|the_28|response_24|and_10|administered_29 (r_conj) rate_4\NN\13815152|to_25|._123 (l_acl) administered_13\VBN\2436349|the_57|response_53|and_39|effects_29 (l_prep) as_14\IN\14622893|NONE_0 (l_pobj) agent_17\NN\7347|NONE_0 (l_prep) in_18\IN\13603305|a_15|single_13 (l_pobj) carcinoma_23\NN\14239918|NONE_0
C030852_C562729 NONE vnb_4\NNP\0|that_5|agent_17 (r_nsubj) is_5\VBZ\0|data_23|._67 (l_attr) agent_8\NN\7347|that_22|vnb_17 (l_prep) in_9\IN\13603305|an_16|active_13 (l_pobj) carcinoma_14\NN\14239918|NONE_0
19299179
D015662_D008100 NONE trimoxazole_35\NN\0|for_22 (r_amod) treatment_36\NN\654885|here_229|,_225|we_223|cases_209|._17 (r_dobj) report_3\VBP\6470073|NONE_0 (l_dobj) cases_5\NNS\7283608|here_20|,_16|we_14|treatment_209|._226 (l_conj) in_20\IN\13603305|two_113|of_103|and_4 (l_pobj) lesions_23\NNS\14204950|,_61 (l_acl) mimicking_24\VBG\1742886|one_20|patient_16 (l_dobj) formation_27\NN\7938773|NONE_0 (l_compound) abscess_26\NN\14299637|liver_6|on_18
D015662_D009894 NONE trimoxazole_25\NN\0|NONE_0 (r_punct) ._26\.\0|pneumonia_133|is_54|generally_51|with_33 (r_punct) treated_18\VBN\2376958|NONE_0 (l_nsubjpass) pneumonia_1\NN\14145095|is_79|generally_82|with_100|._133 (l_appos) infection_9\NN\14052046|pneumocystis_53|(_30|pcp_29|)_26|,_25|,_37
D015662_D015658 NONE trimoxazole_11\NN\0|dose_8|for_22|--_73|report_77 (r_amod) treatment_12\NN\654885|NONE_0 (l_prep) for_13\IN\0|dose_30|trimoxazole_22|--_51|report_55 (l_pobj) pneumonia_15\NN\14145095|NONE_0 (l_prep) in_16\IN\13603305|pneumocystis_23 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_amod) infected_19\VBN\2316868|NONE_0
D015662_D015658 NONE trimoxazole_25\NN\0|NONE_0 (r_punct) ._26\.\0|pneumonia_133|is_54|generally_51|with_33 (r_punct) treated_18\VBN\2376958|NONE_0 (l_nsubjpass) pneumonia_1\NN\14145095|is_79|generally_82|with_100|._133 (l_appos) infection_9\NN\14052046|pneumocystis_53|(_30|pcp_29|)_26|,_25|,_37 (l_prep) in_10\IN\13603305|a_33|common_31|opportunistic_24 (l_pobj) individuals_14\NNS\7347|NONE_0 (l_amod) infected_13\VBN\2316868|NONE_0
D015662_D015658 NONE trimoxazole_35\NN\0|for_22 (r_amod) treatment_36\NN\654885|here_229|,_225|we_223|cases_209|._17 (r_dobj) report_3\VBP\6470073|NONE_0 (l_dobj) cases_5\NNS\7283608|here_20|,_16|we_14|treatment_209|._226 (l_prep) of_6\IN\0|two_10|and_99|in_103 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_amod) infected_11\VBN\2316868|immunocompromised_22|developed_22
D015662_D011020 NONE trimoxazole_11\NN\0|dose_8|for_22|--_73|report_77 (r_amod) treatment_12\NN\654885|NONE_0 (l_prep) for_13\IN\0|dose_30|trimoxazole_22|--_51|report_55 (l_pobj) pneumonia_15\NN\14145095|NONE_0
D015662_D011020 NONE trimoxazole_25\NN\0|NONE_0 (r_punct) ._26\.\0|pneumonia_133|is_54|generally_51|with_33 (r_punct) treated_18\VBN\2376958|NONE_0 (l_nsubjpass) pneumonia_1\NN\14145095|is_79|generally_82|with_100|._133
D015662_D011020 NONE trimoxazole_25\NN\0|NONE_0 (r_punct) ._26\.\0|pneumonia_133|is_54|generally_51|with_33 (r_punct) treated_18\VBN\2376958|NONE_0 (l_nsubjpass) pneumonia_1\NN\14145095|is_79|generally_82|with_100|._133 (l_appos) pcp_3\NNP\10480253|pneumocystis_24|(_1|)_3|,_4|infection_29|,_66
D015662_D011020 NONE trimoxazole_35\NN\0|for_22 (r_amod) treatment_36\NN\654885|here_229|,_225|we_223|cases_209|._17 (l_prep) for_37\IN\0|trimoxazole_22 (l_pobj) pcp_38\NNP\10480253|NONE_0
D015662_D002779 NONE trimoxazole_11\NN\0|dose_8|for_22|--_73|report_77 (r_amod) treatment_12\NN\654885|NONE_0 (r_pobj) after_5\IN\0|severe_36|._115 (r_prep) cholestasis_4\NN\14052403|NONE_0
D015662_D002780 CID trimoxazole_35\NN\0|for_22 (r_amod) treatment_36\NN\654885|here_229|,_225|we_223|cases_209|._17 (r_dobj) report_3\VBP\6470073|NONE_0 (l_dobj) cases_5\NNS\7283608|here_20|,_16|we_14|treatment_209|._226 (l_prep) of_6\IN\0|two_10|and_99|in_103 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_relcl) developed_14\VBD\1753788|immunocompromised_44|infected_22 (l_dobj) cholestasis_17\NN\14052403|who_34|,_11
19889778
12639165
D013988_D007565 CID ticlopidine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) following_4\VBG\8180190|patients_28|jaundice_9|and_37|showed_41|._166 (r_prep) developed_2\VBD\1753788|NONE_0 (l_dobj) jaundice_3\NN\14299637|patients_19|following_9|and_46|showed_50|._175
D013988_D056486 CID ticlopidine_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|cholestatic_8|._29 (r_amod) hepatitis_4\NN\14127211|NONE_0
D013988_D056486 CID ticlopidine_5\NN\0|-_11 (r_npadvmod) induced_7\VBN\1627355|cholestatic_8 (r_amod) hepatitis_9\NN\14127211|NONE_0
D013988_D056486 CID ticlopidine_8\NN\0|following_12 (r_advmod) receiving_7\VBG\2210855|NONE_0 (r_pcomp) after_6\IN\0|patients_51|hepatitis_10|,_71|with_73|._124 (r_prep) developed_2\VBD\1753788|NONE_0 (l_dobj) hepatitis_5\NN\14127211|patients_41|after_10|,_81|with_83|._134
D013988_D056486 CID ticlopidine_10\NN\0|a_46|rare_44|of_26 (r_advmod) complication_5\NN\1073995|hepatitis_20 (r_attr) is_2\VBZ\0|;_60|cases_70|have_76|been_81|but_95|few_99|._128 (l_nsubj) hepatitis_1\NN\14127211|complication_20
D013988_D056486 CID ticlopidine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) following_4\VBG\8180190|patients_28|jaundice_9|and_37|showed_41|._166 (r_prep) developed_2\VBD\1753788|NONE_0 (l_conj) showed_9\VBD\2137132|patients_69|jaundice_50|following_41|and_4|._125 (l_dobj) characteristics_14\NNS\5849040|NONE_0 (l_prep) of_15\IN\0|the_44|clinical_40|,_24|resolved_32 (l_pobj) hepatitis_17\NN\14127211|NONE_0
D013988_D056486 CID ticlopidine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_22|rare_20|adverse_15|be_24 (r_prep) effect_6\NN\34213|hepatitis_28|._49 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) hepatitis_1\NN\14127211|effect_28|._77
D013988_D002779 CID ticlopidine_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|cholestatic_8|._29 (r_amod) hepatitis_4\NN\14127211|NONE_0
D013988_D002779 CID ticlopidine_5\NN\0|-_11 (r_npadvmod) induced_7\VBN\1627355|cholestatic_8 (r_amod) hepatitis_9\NN\14127211|NONE_0
D013988_D002779 CID ticlopidine_8\NN\0|following_12 (r_advmod) receiving_7\VBG\2210855|NONE_0 (r_pcomp) after_6\IN\0|patients_51|hepatitis_10|,_71|with_73|._124 (r_prep) developed_2\VBD\1753788|NONE_0 (l_dobj) hepatitis_5\NN\14127211|patients_41|after_10|,_81|with_83|._134
D013988_D002779 CID ticlopidine_10\NN\0|a_46|rare_44|of_26 (r_advmod) complication_5\NN\1073995|hepatitis_20 (r_attr) is_2\VBZ\0|;_60|cases_70|have_76|been_81|but_95|few_99|._128 (l_nsubj) hepatitis_1\NN\14127211|complication_20
D013988_D002779 CID ticlopidine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) following_4\VBG\8180190|patients_28|jaundice_9|and_37|showed_41|._166 (r_prep) developed_2\VBD\1753788|NONE_0 (l_conj) showed_9\VBD\2137132|patients_69|jaundice_50|following_41|and_4|._125 (l_dobj) characteristics_14\NNS\5849040|NONE_0 (l_prep) of_15\IN\0|the_44|clinical_40|,_24|resolved_32 (l_pobj) hepatitis_17\NN\14127211|NONE_0
D013988_D002779 CID ticlopidine_4\NN\0|-_11 (r_npadvmod) induced_6\VBN\1627355|this_17 (r_amod) cholestasis_7\NN\14052403|NONE_0
D013988_D002779 CID ticlopidine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_22|rare_20|adverse_15|be_24 (r_prep) effect_6\NN\34213|hepatitis_28|._49 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) hepatitis_1\NN\14127211|effect_28|._77
12063090
D004177_D059350 NONE metamizol_9\NN\0|and_4|in_10 (r_conj) morphine_7\NN\2707683|NONE_0 (r_pobj) between_6\IN\0|a_26|significant_24 (r_prep) interaction_5\NN\37396|findings_28|,_70|suggesting_72|._154 (r_dobj) show_2\VBP\429048|NONE_0 (l_advcl) suggesting_15\VBG\1010118|findings_100|interaction_72|,_2|._82 (l_ccomp) be_20\VB\14625458|NONE_0 (l_acomp) useful_21\JJ\0|that_31|combination_21|could_9 (l_prep) for_22\IN\0|NONE_0 (l_pobj) treatment_24\NN\654885|NONE_0 (l_prep) of_25\IN\0|the_14 (l_pobj) pain_27\NN\14299637|NONE_0
D009020_D059350 NONE morphine_7\NN\2707683|NONE_0 (r_pobj) between_6\IN\0|a_26|significant_24 (r_prep) interaction_5\NN\37396|findings_28|,_70|suggesting_72|._154 (r_dobj) show_2\VBP\429048|NONE_0 (l_advcl) suggesting_15\VBG\1010118|findings_100|interaction_72|,_2|._82 (l_ccomp) be_20\VB\14625458|NONE_0 (l_acomp) useful_21\JJ\0|that_31|combination_21|could_9 (l_prep) for_22\IN\0|NONE_0 (l_pobj) treatment_24\NN\654885|NONE_0 (l_prep) of_25\IN\0|the_14 (l_pobj) pain_27\NN\14299637|NONE_0
D004177_D003248 NONE metamizol_0\NNP\0|antinociception_31|._91 (r_nsubj) potentiates_1\VBZ\229605|NONE_0 (l_dobj) antinociception_3\NN\0|metamizol_31|._60 (l_conj) constipation_6\NN\14299637|morphine_33|but_8
D004177_D003248 NONE metamizol_20\NN\0|NONE_0 (r_pobj) with_16\IN\0|the_91|antinociceptive_87|of_46|in_32 (r_prep) effects_7\NNS\13245626|work_52|(_121|day_129|)_144|rats_146|._150 (l_amod) antinociceptive_4\NN\0|the_4|of_41|with_87|in_119 (l_conj) constipating_6\JJ\440786|and_4
D004177_D003248 NONE metamizol_20\NN\0|did_10|not_14|constipation_46 (r_nsubj) potentiate_23\VB\229605|NONE_0 (l_dobj) constipation_27\NN\14299637|metamizol_46|did_36|not_32
D002606_D010146 NONE charcoal_25\NN\14633206|NONE_0 (r_compound) meal_26\NN\7570720|the_13 (r_compound) test_27\NN\5798043|was_5|evaluate_17|._48 (r_nsubjpass) used_29\VBN\0|on_171|,_156|effects_138|were_130|using_116|,_75|model_38 (r_conj) assessed_8\VBN\670261|NONE_0 (l_conj) model_21\NN\5888929|on_133|,_118|effects_100|were_92|using_78|,_37|used_38 (l_amod) induced_18\VBN\1627355|impairment_19|,_35|and_37 (l_npadvmod) pain_16\NN\14299637|-_4
D009020_D003248 CID morphine_2\NN\2707683|but_25|constipation_33 (r_compound) antinociception_3\NN\0|metamizol_31|._60 (l_conj) constipation_6\NN\14299637|morphine_33|but_8
D009020_D003248 CID morphine_15\NN\2707683|NONE_0 (r_pobj) of_11\IN\0|the_16 (r_prep) combination_10\NN\7951464|NONE_0 (r_pobj) of_8\IN\0|the_45|antinociceptive_41|with_46|in_78 (r_prep) effects_7\NNS\13245626|work_52|(_121|day_129|)_144|rats_146|._150 (l_amod) antinociceptive_4\NN\0|the_4|of_41|with_87|in_119 (l_conj) constipating_6\JJ\440786|and_4
D009020_D003248 CID morphine_4\NN\2707683|in_23|,_2|transit_34|after_65|,_98|respectively_100|,_112|suggesting_114|._183 (r_nsubj) inhibited_5\VBD\2510337|NONE_0 (l_advcl) suggesting_23\VBG\1010118|in_137|,_116|morphine_114|transit_80|after_49|,_16|respectively_14|,_2|._69 (l_ccomp) develop_28\VB\1753788|NONE_0 (l_prep) to_29\IN\0|that_31|tolerance_26|did_16|not_12 (l_pobj) effects_32\NNS\13245626|NONE_0 (l_amod) constipating_31\JJ\440786|the_4
D009020_D003248 CID morphine_10\NN\2707683|NONE_0 (r_pobj) by_9\IN\0|regardless_12 (r_agent) produced_8\VBN\1617192|NONE_0 (r_acl) that_7\DT\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) similar_5\JJ\0|intestinal_19 (r_amod) transit_4\NN\4365484|combination_33|,_80|suggesting_82|._156 (r_dobj) inhibited_2\VBD\2510337|NONE_0 (l_advcl) suggesting_18\VBG\1010118|combination_115|transit_82|,_2|._74 (l_ccomp) potentiate_23\VB\229605|NONE_0 (l_dobj) constipation_27\NN\14299637|metamizol_46|did_36|not_32
D009020_D003248 CID morphine_24\NN\2707683|-_8 (r_npadvmod) induced_26\VBN\1627355|NONE_0 (r_amod) constipation_27\NN\14299637|metamizol_46|did_36|not_32
9672936
D008614_D010149 NONE pethidine_0\NNP\0|-_9 (r_npadvmod) associated_2\VBN\628491|in_19|._93 (r_amod) seizure_3\NN\14081375|NONE_0 (l_prep) in_4\IN\13603305|associated_19|._74 (l_pobj) adolescent_7\JJ\9622049|NONE_0 (l_acl) receiving_8\VBG\2210855|a_21|healthy_19 (l_prep) for_10\IN\0|pethidine_10 (l_pobj) control_13\NN\5190804|NONE_0 (l_compound) pain_12\NN\14299637|postoperative_14
D008614_D010149 NONE pethidine_9\NN\0|for_10 (r_dobj) receiving_8\VBG\2210855|a_21|healthy_19 (l_prep) for_10\IN\0|pethidine_10 (l_pobj) control_13\NN\5190804|NONE_0 (l_compound) pain_12\NN\14299637|postoperative_14
D008614_D010149 NONE pethidine_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|a_64|healthy_62|old_46|received_37|standard_28|intermittent_19|via_13 (r_prep) doses_9\NNS\3740161|for_65|._109 (r_nsubj) pump_21\NN\3736970|NONE_0 (l_prep) for_22\IN\0|doses_65|._44 (l_pobj) management_23\NN\1123598|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) control_27\NN\5190804|NONE_0 (l_compound) pain_26\NN\14299637|postoperative_14
D008614_D012640 CID pethidine_0\NNP\0|-_9 (r_npadvmod) associated_2\VBN\628491|in_19|._93 (r_amod) seizure_3\NN\14081375|NONE_0
D008614_D012640 CID pethidine_9\NN\0|for_10 (r_dobj) receiving_8\VBG\2210855|a_21|healthy_19 (r_acl) adolescent_7\JJ\9622049|NONE_0 (r_pobj) in_4\IN\13603305|associated_19|._74 (r_prep) seizure_3\NN\14081375|NONE_0
1749407
D003042_D009203 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|myocardial_8|:_29|observations_40|._84 (r_amod) infarction_4\NN\14204950|NONE_0
D003042_D009203 CID cocaine_13\NN\3492717|by_9|may_8|in_19 (r_nsubj) result_15\VB\34213|several_49|possible_41 (l_prep) in_16\IN\13603305|by_28|cocaine_19|may_11 (l_pobj) infarction_19\NN\14204950|NONE_0
D003042_D009203 CID cocaine_26\NN\3492717|-_7 (r_npadvmod) induced_28\VBN\1627355|in_17 (r_amod) increase_29\NN\13576355|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) associated_24\VBN\628491|myocardial_25|oxygen_14 (r_acl) demand_23\NN\6513366|NONE_0 (r_pobj) in_20\IN\13603305|an_12 (r_prep) increase_19\NN\13576355|NONE_0 (r_pobj) from_17\IN\0|in_112|,_41|infarction_22|may_11|._110 (r_prep) result_16\VB\34213|NONE_0 (l_nsubj) infarction_14\NN\14204950|in_90|,_19|may_11|from_22|._132
D003042_D013035 NONE cocaine_16\NN\3492717|-_7 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) vasoconstriction_19\NN\1149911|NONE_0 (r_pobj) of_15\IN\0|the_10 (r_prep) locus_14\NN\8645963|speculative_50|._61 (r_nsubj) remains_20\VBZ\2684|with_122|,_102|findings_87|circumstantial_66|,_52|and_50 (r_conj) are_8\VBP\13600404|NONE_0 (l_prep) with_0\IN\0|,_20|findings_35|circumstantial_56|,_70|and_72|remains_122 (l_pobj) regard_1\NN\5817845|NONE_0 (l_prep) to_2\IN\0|NONE_0 (l_pobj) spasm_3\NN\14299637|NONE_0
D010100_D009203 NONE oxygen_22\NN\14622893|myocardial_11|associated_14 (r_compound) demand_23\NN\6513366|NONE_0 (r_pobj) in_20\IN\13603305|an_12 (r_prep) increase_19\NN\13576355|NONE_0 (r_pobj) from_17\IN\0|in_112|,_41|infarction_22|may_11|._110 (r_prep) result_16\VB\34213|NONE_0 (l_nsubj) infarction_14\NN\14204950|in_90|,_19|may_11|from_22|._132
D003042_D013927 NONE cocaine_11\NN\3492717|NONE_0 (r_pobj) of_10\IN\0|a_29|primary_27|,_20|thrombotic_18 (r_prep) effect_9\NN\34213|NONE_0 (l_amod) thrombotic_8\JJ\0|a_11|primary_9|,_2|of_18
4812392
D001379_D011565 NONE azathioprine_4\NN\3740161|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) psoriasis_2\NN\14219661|NONE_0
D001379_D011565 NONE azathioprine_0\JJ\3740161|NONE_0 (r_det) treatment_1\NN\654885|%_26|out_29|._79 (r_nsubj) benefited_2\VBD\2210855|NONE_0 (l_prep) out_8\IN\66636|treatment_29|%_3|._50 (l_prep) of_9\IN\0|NONE_0 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) suffering_12\VBG\14322699|29_12 (l_prep) from_13\IN\0|NONE_0 (l_pobj) psoriasis_15\NN\14219661|NONE_0
D001379_D056486 NONE azathioprine_9\JJ\3740161|NONE_0 (r_amod) therapy_10\NN\657604|if_16|is_8|detected_60 (r_nsubjpass) continued_12\VBN\2367363|biopsies_78|should_69|be_62|at_48|._90 (l_advcl) detected_20\VBN\2163746|if_76|therapy_60|is_52 (l_nsubjpass) damage_17\NN\7296428|so_25|that_22|may_7|be_11|at_23
18343374
D002996_D012170 CID clomiphene_6\NN\3329880|-_10 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) ovulation_9\NN\13526110|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|central_31|vein_15|._44 (r_acl) occlusion_3\NN\14081375|NONE_0
D002996_D012170 CID citrate_12\NN\14850483|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|central_31|vein_15 (r_acl) occlusion_8\NN\14081375|NONE_0
D002996_D012170 CID cc_14\NN\13616054|clomiphene_20|(_1|)_2 (r_appos) citrate_12\NN\14850483|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|central_31|vein_15 (r_acl) occlusion_8\NN\14081375|NONE_0
D002996_D012170 CID cc_13\NN\13616054|NONE_0 (r_pobj) with_12\IN\0|ovulation_20 (r_prep) induction_11\NN\7450842|NONE_0 (r_pobj) after_9\IN\0|central_31|vein_15 (r_prep) occlusion_8\NN\14081375|outcome_41|)_24|:_23|._43
D002996_D012170 CID cc_18\NN\13616054|NONE_0 (r_pobj) of_17\IN\0|eight_14 (r_prep) courses_16\NNS\883297|NONE_0 (r_pobj) after_14\IN\0|result(s_80|:_71|woman_47|occlusion_10|._25 (r_prep) developed_9\VBD\1753788|NONE_0 (l_dobj) occlusion_13\NN\14081375|result(s_70|:_61|woman_37|after_10|._35
D002996_D012170 CID cc_15\NN\13616054|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|NONE_0 (r_pobj) after_12\IN\0|vein_15 (r_prep) occlusion_11\NN\14081375|NONE_0
D002996_D014786 CID cc_10\NN\13616054|NONE_0 (r_pobj) of_9\IN\0|the_33|thromboembolic_29 (r_prep) complications_8\NNS\1073995|NONE_0 (r_pobj) on_5\IN\0|a_27|of_18 (r_prep) search_1\NN\407535|does_67|not_72|complication_107|,_119|is_170|._185 (r_nsubj) include_13\VB\0|NONE_0 (l_advcl) is_26\VBZ\0|search_170|does_103|not_98|complication_63|,_51|._15 (l_nsubj) disturbance_22\NN\407535|although_21|not_31|uncommon_35
D002996_D014786 CID cc_24\NN\13616054|NONE_0 (r_compound) intake_25\NN\13440063|NONE_0 (r_pobj) after_23\IN\0|mild_24|visual_19 (r_prep) disturbance_22\NN\407535|although_21|not_31|uncommon_35
D002996_D007247 NONE cc_9\NN\13616054|NONE_0 (r_pobj) with_8\IN\0|patients_9 (r_prep) treating_5\VBG\2376958|NONE_0 (l_dobj) patients_7\NNS\9898892|with_9 (l_compound) infertility_6\NN\14034177|NONE_0
D002996_D013923 NONE cc_10\NN\13616054|NONE_0 (r_pobj) of_9\IN\0|the_33|thromboembolic_29 (r_prep) complications_8\NNS\1073995|NONE_0 (l_compound) thromboembolic_7\JJ\0|the_4|of_29
D002996_D013923 NONE cc_24\NN\13616054|NONE_0 (r_compound) intake_25\NN\13440063|NONE_0 (r_pobj) after_23\IN\0|mild_24|visual_19 (r_prep) disturbance_22\NN\407535|although_21|not_31|uncommon_35 (r_nsubj) is_26\VBZ\0|search_170|does_103|not_98|complication_63|,_51|._15 (r_advcl) include_13\VB\0|NONE_0 (l_nsubj) search_1\NN\407535|does_67|not_72|complication_107|,_119|is_170|._185 (l_prep) on_5\IN\0|a_27|of_18 (l_pobj) complications_8\NNS\1073995|NONE_0 (l_compound) thromboembolic_7\JJ\0|the_4|of_29
6203452
D001761_D002277 NONE bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|microangiopathy_45|after_165|._228 (l_prep) with_2\IN\0|five_14 (l_pobj) carcinoma_3\NN\14239918|NONE_0
D002945_D013921 NONE cisplatin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|,_14|bleomycin_16 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_conj) anemia_15\NN\14189204|(_66|by_51|,_29|)_36 (l_conj) thrombocytopenia_19\JJ\14189204|microangiopathic_47|hemolytic_30|,_14|and_12
D002945_D013921 NONE cisplatin_30\VB\0|and_25|anemia_33|and_40|thrombocytopenia_44 (r_amod) nephrotoxicity_31\NN\0|NONE_0 (l_conj) thrombocytopenia_36\NN\14189204|cisplatin_44|and_19|anemia_11|and_4
D002945_D051437 NONE cisplatin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|,_14|bleomycin_16 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_agent) by_9\IN\0|(_15|,_22|anemia_51|)_87 (l_pobj) insufficiency_11\NN\14462946|NONE_0
D002945_D051437 NONE cisplatin_30\VB\0|and_25|anemia_33|and_40|thrombocytopenia_44 (r_amod) nephrotoxicity_31\NN\0|NONE_0 (r_pobj) to_29\IN\0|because_38|failure_24|may_16|be_12 (r_prep) ascribed_28\VBN\670261|diagnosis_166|may_117|be_113|or_102|missed_99|,_31|._112 (l_nsubjpass) failure_25\NN\66216|because_14|may_8|be_12|to_24
D001761_D000743 NONE bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_conj) anemia_15\NN\14189204|(_66|by_51|,_29|)_36
D014748_D057049 NONE alkaloid_31\NN\14727670|a_8 (r_amod) vinca_30\JJ\11567411|,_8|and_6 (r_conj) bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183
D002945_D007674 CID cisplatin_30\VB\0|and_25|anemia_33|and_40|thrombocytopenia_44 (r_amod) nephrotoxicity_31\NN\0|NONE_0
D002945_D002277 NONE cisplatin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|,_14|bleomycin_16 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|microangiopathy_45|after_165|._228 (l_prep) with_2\IN\0|five_14 (l_pobj) carcinoma_3\NN\14239918|NONE_0
D014748_D051437 NONE alkaloid_31\NN\14727670|a_8 (r_amod) vinca_30\JJ\11567411|,_8|and_6 (r_conj) bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_agent) by_9\IN\0|(_15|,_22|anemia_51|)_87 (l_pobj) insufficiency_11\NN\14462946|NONE_0
D001761_D013921 NONE bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_conj) anemia_15\NN\14189204|(_66|by_51|,_29|)_36 (l_conj) thrombocytopenia_19\JJ\14189204|microangiopathic_47|hemolytic_30|,_14|and_12
D002945_D000743 NONE cisplatin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|,_14|bleomycin_16 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_conj) anemia_15\NN\14189204|(_66|by_51|,_29|)_36
D014748_D002277 NONE alkaloid_31\NN\14727670|a_8 (r_amod) vinca_30\JJ\11567411|,_8|and_6 (r_conj) bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|microangiopathy_45|after_165|._228 (l_prep) with_2\IN\0|five_14 (l_pobj) carcinoma_3\NN\14239918|NONE_0
D002945_D001855 NONE cisplatin_30\VB\0|and_25|anemia_33|and_40|thrombocytopenia_44 (r_amod) nephrotoxicity_31\NN\0|NONE_0 (l_conj) thrombocytopenia_36\NN\14189204|cisplatin_44|and_19|anemia_11|and_4 (l_prep) to_37\IN\0|NONE_0 (l_pobj) suppression_43\NN\13489037|NONE_0
D014748_D000743 NONE alkaloid_31\NN\14727670|a_8 (r_amod) vinca_30\JJ\11567411|,_8|and_6 (r_conj) bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_conj) anemia_15\NN\14189204|(_66|by_51|,_29|)_36
D014748_D013921 NONE alkaloid_31\NN\14727670|a_8 (r_amod) vinca_30\JJ\11567411|,_8|and_6 (r_conj) bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_conj) anemia_15\NN\14189204|(_66|by_51|,_29|)_36 (l_conj) thrombocytopenia_19\JJ\14189204|microangiopathic_47|hemolytic_30|,_14|and_12
D001761_D051437 NONE bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183 (l_acl) characterized_8\VBN\609683|thrombotic_28 (l_agent) by_9\IN\0|(_15|,_22|anemia_51|)_87 (l_pobj) insufficiency_11\NN\14462946|NONE_0
D001761_D057049 NONE bleomycin_26\NNS\0|with_16|,_2 (r_conj) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183
D002945_D057049 NONE cisplatin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|,_14|bleomycin_16 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) after_21\IN\0|patients_165|microangiopathy_120|._63 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) microangiopathy_6\NN\0|patients_45|after_120|._183
D002945_D000740 NONE cisplatin_30\VB\0|and_25|anemia_33|and_40|thrombocytopenia_44 (r_amod) nephrotoxicity_31\NN\0|NONE_0 (l_conj) anemia_34\NN\14189204|cisplatin_33|and_8|and_7|thrombocytopenia_11
11279304
D003630_D006333 CID dnr_16\NNP\0|NONE_0 (r_pobj) given_15\VBN\5892096|heart_14 (r_acl) failure_14\NN\66216|NONE_0
D003630_D066126 NONE daunorubicin_36\NN\0|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) treated_33\VBN\2376958|acute_15 (r_acl) leukemia_32\NN\14239918|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) patients_29\NNS\9898892|NONE_0 (r_pobj) in_28\IN\13603305|induced_23 (r_prep) cardiotoxicity_27\NN\0|NONE_0
D003630_D066126 NONE dnr)-containing_38\NN\0|NONE_0 (r_compound) regimen_39\NNS\5898568|a_32|(_17 (r_appos) daunorubicin_36\NN\0|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) treated_33\VBN\2376958|acute_15 (r_acl) leukemia_32\NN\14239918|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) patients_29\NNS\9898892|NONE_0 (r_pobj) in_28\IN\13603305|induced_23 (r_prep) cardiotoxicity_27\NN\0|NONE_0
D018943_D015470 NONE anthracycline_24\NN\0|-_13 (r_advmod) induced_26\VBN\1627355|in_23 (r_amod) cardiotoxicity_27\NN\0|NONE_0 (l_prep) in_28\IN\13603305|induced_23 (l_pobj) patients_29\NNS\9898892|NONE_0 (l_prep) with_30\IN\0|NONE_0 (l_pobj) leukemia_32\NN\14239918|NONE_0
D018943_D006331 NONE anthracycline_4\NN\0|conventional_13 (r_amod) therapy_5\NN\657604|NONE_0 (r_pobj) of_2\IN\0|the_19 (r_prep) cardiotoxicity_1\NN\0|need_66|._164 (r_nsubj) highlights_6\VBZ\13809920|NONE_0 (l_dobj) need_8\NN\13920835|cardiotoxicity_66|._98 (l_acl) search_10\VB\407535|a_10 (l_prep) for_11\IN\0|to_10 (l_pobj) methods_12\NNS\5616786|NONE_0 (l_relcl) are_14\VBP\13600404|NONE_0 (l_acomp) sensitive_16\JJ\10488309|that_16 (l_conj) capable_18\JJ\0|highly_21|and_4 (l_prep) of_19\IN\0|NONE_0 (l_pcomp) predicting_20\VBG\916909|NONE_0 (l_dobj) dysfunction_22\NN\14204950|NONE_0
D003630_D015470 NONE daunorubicin_36\NN\0|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) treated_33\VBN\2376958|acute_15 (r_acl) leukemia_32\NN\14239918|NONE_0
D003630_D015470 NONE dnr)-containing_38\NN\0|NONE_0 (r_compound) regimen_39\NNS\5898568|a_32|(_17 (r_appos) daunorubicin_36\NN\0|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) treated_33\VBN\2376958|acute_15 (r_acl) leukemia_32\NN\14239918|NONE_0
D003630_D015470 NONE dnr_9\NNP\0|-_3 (r_npadvmod) containing_11\VBG\2632940|a_6 (r_amod) regimen_12\NN\5898568|NONE_0 (r_pobj) with_7\IN\0|patients_42|were_13|._29 (r_prep) treated_6\VBN\2376958|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_29|with_42|._71 (l_prep) with_2\IN\0|thirteen_18 (l_pobj) leukemia_4\NN\14239918|NONE_0
D018943_D066126 NONE anthracycline_7\NN\0|-_13 (r_advmod) induced_9\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_10\NN\0|NONE_0
D018943_D066126 NONE anthracyclines_0\NNS\0|drugs_44|,_49|but_51|cause_71 (r_nsubj) are_1\VBP\13600404|NONE_0 (l_conj) cause_9\VBP\7323922|anthracyclines_71|drugs_27|,_22|but_20 (l_dobj) cardiotoxicity_13\NN\0|they_35|frequently_30|._14
D018943_D066126 NONE anthracycline_4\NN\0|conventional_13 (r_amod) therapy_5\NN\657604|NONE_0 (r_pobj) of_2\IN\0|the_19 (r_prep) cardiotoxicity_1\NN\0|need_66|._164
D018943_D066126 NONE anthracycline_24\NN\0|-_13 (r_advmod) induced_26\VBN\1627355|in_23 (r_amod) cardiotoxicity_27\NN\0|NONE_0
D018943_D066126 NONE anthracycline_16\NN\0|-_13 (r_advmod) induced_18\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_19\NN\0|NONE_0
20067456
D017367_D012735 NONE inhibitor_16\NN\20090|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|male_24|sexual_19 (r_acl) dysfunction_9\NN\14204950|NONE_0
D017367_D012735 NONE inhibitor_28\NN\20090|NONE_0 (r_pobj) by_23\IN\0|determine_121|,_50|is_58|._150 (r_agent) induced_22\VBN\1627355|NONE_0 (l_csubj) determine_1\VB\0|by_121|,_171|is_179|._271 (l_dobj) safety_3\NN\13920835|to_17 (l_prep) of_6\IN\0|the_24|and_13|efficacy_9 (l_pobj) bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0
D017367_D012735 NONE inhibitor_28\NN\20090|NONE_0 (r_pobj) by_23\IN\0|determine_121|,_50|is_58|._150 (r_agent) induced_22\VBN\1627355|NONE_0 (l_csubj) determine_1\VB\0|by_121|,_171|is_179|._271 (l_dobj) safety_3\NN\13920835|to_17 (l_prep) of_6\IN\0|the_24|and_13|efficacy_9 (l_pobj) bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0 (l_appos) sd_20\NN\0|male_25|sexual_20|(_1|)_2
D017367_D012735 NONE inhibitor_28\NN\20090|NONE_0 (r_pobj) by_23\IN\0|determine_121|,_50|is_58|._150 (r_agent) induced_22\VBN\1627355|NONE_0 (l_advcl) is_35\VBZ\0|determine_179|by_58|,_8|._92 (l_nsubj) sd_34\NN\0|as_3|effect_20|have_70
D017367_D012735 NONE ssri_30\NNP\2718811|a_42|selective_40|serotonin_30|reuptake_20|(_1|)_4 (r_appos) inhibitor_28\NN\20090|NONE_0 (r_pobj) by_23\IN\0|determine_121|,_50|is_58|._150 (r_agent) induced_22\VBN\1627355|NONE_0 (l_csubj) determine_1\VB\0|by_121|,_171|is_179|._271 (l_dobj) safety_3\NN\13920835|to_17 (l_prep) of_6\IN\0|the_24|and_13|efficacy_9 (l_pobj) bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0
D017367_D012735 NONE ssri_30\NNP\2718811|a_42|selective_40|serotonin_30|reuptake_20|(_1|)_4 (r_appos) inhibitor_28\NN\20090|NONE_0 (r_pobj) by_23\IN\0|determine_121|,_50|is_58|._150 (r_agent) induced_22\VBN\1627355|NONE_0 (l_csubj) determine_1\VB\0|by_121|,_171|is_179|._271 (l_dobj) safety_3\NN\13920835|to_17 (l_prep) of_6\IN\0|the_24|and_13|efficacy_9 (l_pobj) bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0 (l_appos) sd_20\NN\0|male_25|sexual_20|(_1|)_2
D017367_D012735 NONE ssri_30\NNP\2718811|a_42|selective_40|serotonin_30|reuptake_20|(_1|)_4 (r_appos) inhibitor_28\NN\20090|NONE_0 (r_pobj) by_23\IN\0|determine_121|,_50|is_58|._150 (r_agent) induced_22\VBN\1627355|NONE_0 (l_advcl) is_35\VBZ\0|determine_179|by_58|,_8|._92 (l_nsubj) sd_34\NN\0|as_3|effect_20|have_70
D017367_D012735 NONE ssris_42\NNS\2718811|NONE_0 (r_pobj) of_41\IN\0|a_21|common_19|side_12|-_8 (r_prep) effect_40\NN\34213|as_23|sd_20|have_50 (r_attr) is_35\VBZ\0|determine_179|by_58|,_8|._92 (r_advcl) induced_22\VBN\1627355|NONE_0 (l_csubj) determine_1\VB\0|by_121|,_171|is_179|._271 (l_dobj) safety_3\NN\13920835|to_17 (l_prep) of_6\IN\0|the_24|and_13|efficacy_9 (l_pobj) bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0
D017367_D012735 NONE ssris_42\NNS\2718811|NONE_0 (r_pobj) of_41\IN\0|a_21|common_19|side_12|-_8 (r_prep) effect_40\NN\34213|as_23|sd_20|have_50 (r_attr) is_35\VBZ\0|determine_179|by_58|,_8|._92 (r_advcl) induced_22\VBN\1627355|NONE_0 (l_csubj) determine_1\VB\0|by_121|,_171|is_179|._271 (l_dobj) safety_3\NN\13920835|to_17 (l_prep) of_6\IN\0|the_24|and_13|efficacy_9 (l_pobj) bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0 (l_appos) sd_20\NN\0|male_25|sexual_20|(_1|)_2
D017367_D012735 NONE ssris_42\NNS\2718811|NONE_0 (r_pobj) of_41\IN\0|a_21|common_19|side_12|-_8 (r_prep) effect_40\NN\34213|as_23|sd_20|have_50 (r_attr) is_35\VBZ\0|determine_179|by_58|,_8|._92 (l_nsubj) sd_34\NN\0|as_3|effect_20|have_70
D017367_D012735 NONE ssri_21\NNP\2718811|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) type_19\NN\5839024|,_2 (r_appos) sd_17\NN\0|NONE_0
D017367_D012735 NONE ssris_10\NNS\2718811|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) induced_8\VBN\1627355|an_35|effective_32|for_12 (r_acl) treatment_4\NN\654885|bupropion_26|._38 (l_prep) for_5\IN\0|an_23|effective_20|induced_12 (l_pobj) sd_7\NN\0|NONE_0
D016642_D012735 NONE bupropion_5\NN\0|NONE_0 (l_prep) on_6\IN\0|the_25|adjunctive_21 (l_pobj) dysfunction_9\NN\14204950|NONE_0
D016642_D012735 NONE bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0
D016642_D012735 NONE bupropion_8\NN\0|NONE_0 (l_prep) on_15\IN\0|adjunctive_44|sr_4 (l_pobj) dysfunction_18\NN\14204950|NONE_0 (l_appos) sd_20\NN\0|male_25|sexual_20|(_1|)_2
D016642_D012735 NONE bupropion_8\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_24|and_13|efficacy_9 (r_prep) safety_3\NN\13920835|to_17 (r_dobj) determine_1\VB\0|by_121|,_171|is_179|._271 (r_csubj) induced_22\VBN\1627355|NONE_0 (l_advcl) is_35\VBZ\0|determine_179|by_58|,_8|._92 (l_nsubj) sd_34\NN\0|as_3|effect_20|have_70
D016642_D012735 NONE bupropion_0\NN\0|treatment_26|._64 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) treatment_4\NN\654885|bupropion_26|._38 (l_prep) for_5\IN\0|an_23|effective_20|induced_12 (l_pobj) sd_7\NN\0|NONE_0
8231633
D015764_D012640 NONE bepridil_31\NN\0|NONE_0 (r_pcomp) with_30\IN\0|less_16 (r_prep) pronounced_29\VBN\0|modified_132|;_23|effect_16|._24 (r_acomp) was_27\VBD\0|NONE_0 (l_ccomp) modified_8\VBN\109660|;_109|effect_116|pronounced_132|._156 (l_conj) decreased_13\VBD\169651|was_60|not_56|significantly_52|but_29 (l_dobj) time_15\NN\7308889|blockers_23 (l_relcl) obtain_19\VB\2210855|the_23|of_14 (l_dobj) convulsions_23\NNS\14081375|to_30
D002045_D064420 NONE bupivacaine_6\NN\0|-_11 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) toxicity_9\NN\13576101|NONE_0
D002045_D064420 NONE bupivacaine_15\NN\0|-_11 (r_npadvmod) induced_17\VBN\1627355|acute_8 (r_amod) toxicity_19\NN\13576101|NONE_0
D002045_D012640 CID bupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_24|convulsant_20 (r_prep) activity_2\NN\30358|NONE_0 (r_nsubj) was_5\VBD\0|not_4|significantly_8|but_31|decreased_60 (r_auxpass) modified_8\VBN\109660|;_109|effect_116|pronounced_132|._156 (l_conj) decreased_13\VBD\169651|was_60|not_56|significantly_52|but_29 (l_dobj) time_15\NN\7308889|blockers_23 (l_relcl) obtain_19\VB\2210855|the_23|of_14 (l_dobj) convulsions_23\NNS\14081375|to_30
D002045_D012640 CID bupivacaine_20\NN\0|-_11 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) convulsions_23\NNS\14081375|to_30
D002118_D012640 NONE calcium_10\NN\14625458|NONE_0 (r_compound) channel_11\NN\6251781|NONE_0 (r_compound) blockers_12\NNS\10101634|time_23 (r_nsubj) decreased_13\VBD\169651|was_60|not_56|significantly_52|but_29 (l_dobj) time_15\NN\7308889|blockers_23 (l_relcl) obtain_19\VB\2210855|the_23|of_14 (l_dobj) convulsions_23\NNS\14081375|to_30
D002118_D064420 NONE calcium_2\NN\14625458|NONE_0 (r_compound) channel_3\NN\6251781|on_17 (r_compound) blockers_4\NNS\10101634|NONE_0 (l_prep) on_5\IN\0|channel_17 (l_pobj) toxicity_9\NN\13576101|NONE_0
D002118_D064420 NONE calcium_11\NN\14625458|NONE_0 (r_compound) channel_12\NN\6251781|on_17 (r_compound) blockers_13\NNS\10101634|NONE_0 (l_prep) on_14\IN\0|channel_17 (l_pobj) toxicity_19\NN\13576101|NONE_0
2549018
D005473_D009771 NONE fluoxetine_3\NN\4169152|for_11 (r_dobj) receiving_2\VBG\2210855|five_14 (l_prep) for_4\IN\0|fluoxetine_11 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) disorder_10\NN\14034177|NONE_0
D005473_D017109 CID fluoxetine_0\NNP\4169152|-_10 (r_npadvmod) induced_2\VBN\1627355|:_17|implications_44|._56 (r_amod) akathisia_3\NN\0|NONE_0
D005473_D017109 CID fluoxetine_3\NN\4169152|for_11 (r_dobj) receiving_2\VBG\2210855|five_14 (r_acl) patients_1\NNS\9898892|akathisia_111|._120 (r_nsubj) developed_14\VBD\1753788|NONE_0 (l_dobj) akathisia_15\NN\0|patients_111|._9
D005473_D017109 CID fluoxetine_2\NN\4169152|-_10 (r_npadvmod) induced_4\VBN\1627355|the_23|typical_19|of_17 (r_amod) symptoms_5\NNS\5823932|indistinguishable_111|._172 (r_nsubj) were_23\VBD\0|NONE_0 (l_acomp) indistinguishable_24\JJ\0|symptoms_111|._61 (l_prep) from_25\IN\0|NONE_0 (l_pobj) those_26\DT\0|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) akathisia_31\NN\0|NONE_0
D005473_D017109 CID fluoxetine_17\NN\4169152|-_10 (r_advmod) induced_19\VBN\1627355|NONE_0 (r_amod) akathisia_20\NN\0|NONE_0 (r_pobj) of_16\IN\0|the_13 (r_prep) symptoms_15\NNS\5823932|that_9|identical_46|,_55|milder_75 (r_nsubj) were_21\VBD\0|patients_130|._40 (r_ccomp) reported_12\VBD\831651|NONE_0 (l_nsubj) patients_1\NNS\9898892|were_130|._170 (l_relcl) experienced_4\VBN\2108377|three_23 (l_dobj) akathisia_8\NN\0|who_40|had_36
D005473_D017109 CID fluoxetine_17\NN\4169152|-_10 (r_advmod) induced_19\VBN\1627355|NONE_0 (r_amod) akathisia_20\NN\0|NONE_0
D005473_D017109 CID fluoxetine_9\NN\4169152|NONE_0 (r_pobj) of_8\IN\0|a_21|common_19|side_12 (r_prep) effect_7\NN\34213|to_20 (r_attr) be_3\VB\14625458|akathisia_22|and_38|responded_52|._152 (r_xcomp) appeared_1\VBD\2604760|NONE_0 (l_nsubj) akathisia_0\NNP\0|be_22|and_60|responded_74|._174
D005473_D017109 CID fluoxetine_4\NN\4169152|-_10 (r_advmod) induced_6\VBN\1627355|NONE_0 (r_amod) akathisia_7\NN\0|that_24|may_10|be_14|by_24|be_214
D005473_D017109 CID fluoxetine_4\NN\4169152|-_10 (r_advmod) induced_6\VBN\1627355|NONE_0 (r_amod) akathisia_7\NN\0|that_24|may_10|be_14|by_24|be_214 (r_nsubjpass) caused_10\VBN\1617192|authors_57|._209 (l_conj) be_36\VB\14625458|that_238|akathisia_214|may_204|be_200|by_190 (l_nsubj) pathophysiology_21\NN\0|that_9|"_97|may_99|identical_106 (l_prep) of_22\IN\0|the_20 (l_pobj) akathisia_26\NN\0|NONE_0
D005473_D017109 CID fluoxetine_23\NN\4169152|-_10 (r_advmod) induced_25\VBN\1627355|and_18|jitteriness_56 (r_amod) akathisia_26\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_20 (r_prep) pathophysiology_21\NN\0|that_9|"_97|may_99|identical_106 (r_nsubj) be_36\VB\14625458|that_238|akathisia_214|may_204|be_200|by_190 (r_conj) caused_10\VBN\1617192|authors_57|._209 (l_nsubjpass) akathisia_7\NN\0|that_24|may_10|be_14|by_24|be_214
D005473_D017109 CID fluoxetine_23\NN\4169152|-_10 (r_advmod) induced_25\VBN\1627355|and_18|jitteriness_56 (r_amod) akathisia_26\NN\0|NONE_0
D000928_D017109 NONE antidepressant_29\NN\3740161|-_14 (r_npadvmod) induced_31\VBN\1627355|tricyclic_25|"_8 (r_amod) jitteriness_33\NN\7523905|induced_56|and_38 (r_conj) akathisia_26\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_20 (r_prep) pathophysiology_21\NN\0|that_9|"_97|may_99|identical_106 (r_nsubj) be_36\VB\14625458|that_238|akathisia_214|may_204|be_200|by_190 (r_conj) caused_10\VBN\1617192|authors_57|._209 (l_nsubjpass) akathisia_7\NN\0|that_24|may_10|be_14|by_24|be_214
D000928_D017109 NONE antidepressant_29\NN\3740161|-_14 (r_npadvmod) induced_31\VBN\1627355|tricyclic_25|"_8 (r_amod) jitteriness_33\NN\7523905|induced_56|and_38 (r_conj) akathisia_26\NN\0|NONE_0
D011433_D017109 NONE propranolol_22\NN\0|the_31|adrenergic_22|,_11|reduction_18 (r_acl) antagonist_21\NN\7846|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) to_14\IN\0|generally_25|well_5 (r_prep) responded_12\VBD\2367363|akathisia_74|be_52|and_14|._100 (r_conj) appeared_1\VBD\2604760|NONE_0 (l_nsubj) akathisia_0\NNP\0|be_22|and_60|responded_74|._174
D005473_D001008 NONE fluoxetine_2\NN\4169152|-_10 (r_npadvmod) induced_4\VBN\1627355|the_23|typical_19|of_17 (r_amod) symptoms_5\NNS\5823932|indistinguishable_111|._172 (l_prep) of_6\IN\0|the_40|typical_36|induced_17 (l_pobj) restlessness_7\NN\4773351|NONE_0 (l_conj) pacing_10\NN\15122011|,_11 (l_conj) movements_13\NNS\191142|constant_29|,_14 (l_conj) anxiety_22\NN\14373582|purposeless_55|of_33|,_13|and_11
D005473_D003865 NONE fluoxetine_3\NN\4169152|for_11 (r_dobj) receiving_2\VBG\2210855|five_14 (l_prep) for_4\IN\0|fluoxetine_11 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) disorder_10\NN\14034177|NONE_0 (l_conj) depression_13\NN\14373582|obsessive_39|compulsive_29|or_9
3997294
D000638_D013617 NONE amiodarone_11\NN\2715941|NONE_0 (l_prep) for_28\IN\0|(_69|dose_60|,_2 (l_pobj) control_29\NN\5190804|NONE_0 (l_prep) of_30\IN\0|NONE_0 (l_pobj) tachyarrhythmias_32\NNS\0|NONE_0
D000638_D010490 CID amiodarone_9\NN\2715941|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) during_8\IN\0|pleural_48|and_15|neuropathy_11 (r_prep) effusion_5\NN\6880249|NONE_0
D000638_D011014 CID amiodarone_14\NN\2715941|NONE_0 (r_compound) pneumonitis_15\NN\14336539|NONE_0
D000638_D011014 CID amiodarone_20\NN\2715941|NONE_0 (r_pobj) of_19\IN\0|immediate_21|,_13|and_15|prompt_19 (r_prep) withdrawal_18\NN\7206096|review_121|need_62|,_12|._90 (r_dobj) indicates_7\VBZ\952524|NONE_0 (l_dobj) need_9\NN\13920835|review_59|,_50|withdrawal_62|._152 (l_prep) for_10\IN\0|the_9 (l_pobj) diagnosis_12\NN\152018|NONE_0 (l_prep) of_13\IN\0|early_16 (l_pobj) pneumonitis_15\NN\14336539|NONE_0
D000638_D010996 CID amiodarone_9\NN\2715941|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) during_8\IN\0|pleural_48|and_15|neuropathy_11 (r_prep) effusion_5\NN\6880249|NONE_0
D000638_D009422 NONE amiodarone_9\NN\2715941|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) during_8\IN\0|pleural_48|and_15|neuropathy_11 (r_prep) effusion_5\NN\6880249|NONE_0 (l_conj) neuropathy_7\NN\14204950|pleural_37|and_4|during_11
D013256_D011014 NONE steroid_26\NN\14727670|continued_10 (r_compound) therapy_27\NN\657604|but_22|ensure_11 (r_conj) prompt_23\JJ\7011209|immediate_40|of_19|,_6|and_4 (r_conj) withdrawal_18\NN\7206096|review_121|need_62|,_12|._90 (r_dobj) indicates_7\VBZ\952524|NONE_0 (l_dobj) need_9\NN\13920835|review_59|,_50|withdrawal_62|._152 (l_prep) for_10\IN\0|the_9 (l_pobj) diagnosis_12\NN\152018|NONE_0 (l_prep) of_13\IN\0|early_16 (l_pobj) pneumonitis_15\NN\14336539|NONE_0
D000638_D002318 NONE amiodarone_11\NN\2715941|NONE_0 (r_pobj) with_10\IN\0|patient_68|was_12|._133 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubjpass) patient_1\NN\9898892|was_56|with_68|._201 (l_prep) with_2\IN\0|a_10|and_24|pacemaker_38 (l_pobj) disease_4\NN\14061805|NONE_0
2265898
C009265_D012640 NONE levodopa_38\JJ\14604959|a_12|carbidopa_10 (r_compound) preparation_39\NN\407535|had_147|;_47|both_45|had_40|been_36|;_11|and_13|had_22|._116 (r_dobj) receiving_34\VBG\2210855|NONE_0 (l_conj) had_43\VBD\0|had_169|;_69|both_67|had_62|been_58|preparation_22|;_11|and_9|._94 (l_dobj) onset_45\NN\7325190|both_13 (l_prep) of_46\IN\0|the_10 (l_pobj) seizures_50\NNS\14081375|NONE_0
C009265_D001523 NONE levodopa_38\JJ\14604959|a_12|carbidopa_10 (r_compound) preparation_39\NN\407535|had_147|;_47|both_45|had_40|been_36|;_11|and_13|had_22|._116 (r_dobj) receiving_34\VBG\2210855|NONE_0 (l_conj) had_43\VBD\0|had_169|;_69|both_67|had_62|been_58|preparation_22|;_11|and_9|._94 (l_dobj) onset_45\NN\7325190|both_13 (l_prep) of_46\IN\0|the_10 (l_pobj) seizures_50\NNS\14081375|NONE_0 (l_nmod) hallucinosis_47\NN\14373582|,_35|were_43
C009265_D004827 CID carbidopa_6\NN\0|NONE_0 (l_nsubj) epilepsy_1\NN\14085708|/_27|administration_38|in_53|._84
C009265_D007676 NONE levodopa_38\JJ\14604959|a_12|carbidopa_10 (r_compound) preparation_39\NN\407535|had_147|;_47|both_45|had_40|been_36|;_11|and_13|had_22|._116 (r_dobj) receiving_34\VBG\2210855|NONE_0 (l_ccomp) had_11\VBD\0|;_100|both_102|had_107|been_111|preparation_147|;_158|and_160|had_169|._263 (l_dobj) failure_14\NN\66216|presented_43|:_34|patients_27|,_7|on_9|but_40|begun_53
1147734
D011441_D006521 CID propylthiouracil_29\NN\14727670|NONE_0 (r_pobj) of_28\IN\0|the_19 (r_prep) administration_27\NN\1133281|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_agent) caused_24\VBN\1617192|chronic_38|active_30|(_23|aggressive_22|)_12 (r_acl) hepatitis_23\NN\14127211|NONE_0
D011441_D008107 NONE propylthiouracil_4\NN\14727670|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|liver_14|._26 (r_acl) disease_1\NN\14061805|NONE_0
14659530
D012701_D008881 NONE serotonin_24\NN\14807737|NONE_0 (r_compound) release_25\NN\3748886|NONE_0 (r_pobj) with_22\IN\0|negative_21 (r_prep) correlation_21\NN\13841213|(_34|cgrp_33|)_29|and_13 (r_conj) concentration_18\NN\4916342|plasma_46|calcitonin_39|related_23 (r_appos) peptide_14\NN\14724264|NONE_0 (r_pobj) in_8\IN\13603305|strong_16 (r_prep) increase_7\NN\13576355|induced_32|migraine_24|:_9|._128 (r_appos) attack_4\NN\955060|NONE_0 (l_compound) migraine_3\JJ\14326607|induced_8|:_15|increase_24|._152
D012701_D008881 NONE serotonin_24\NN\14807737|peptide_42|concentration_27|5-ht_32|)_36 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (r_dobj) investigate_8\VB\644583|aim_32|._241 (l_conj) attack_40\NN\955060|to_212|changes_197|and_33 (l_compound) migraine_39\JJ\14326607|the_20|delayed_16|genuine_8|provoked_16
D012701_D008881 NONE 5-hydroxytriptamine_26\NN\0|NONE_0 (r_punct) ,_27\,\0|NONE_0 (r_punct) 5-ht_28\CD\0|peptide_74|concentration_59|serotonin_32|)_4 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (r_dobj) investigate_8\VB\644583|aim_32|._241 (l_conj) attack_40\NN\955060|to_212|changes_197|and_33 (l_compound) migraine_39\JJ\14326607|the_20|delayed_16|genuine_8|provoked_16
D012701_D008881 NONE 5-ht_28\CD\0|peptide_74|concentration_59|serotonin_32|)_4 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (r_dobj) investigate_8\VB\644583|aim_32|._241 (l_conj) attack_40\NN\955060|to_212|changes_197|and_33 (l_compound) migraine_39\JJ\14326607|the_20|delayed_16|genuine_8|provoked_16
D012701_D008881 NONE 5-ht_8\CD\0|NONE_0 (r_nummod) content_9\NN\7951464|be_18 (r_nsubj) tended_10\VBD\2604760|NONE_0 (l_xcomp) be_12\VB\14625458|content_18 (l_prep) in_14\IN\13603305|to_12|lower_6 (l_pobj) subjects_15\NNS\6598915|NONE_0 (l_relcl) experienced_17\VBD\2108377|NONE_0 (l_dobj) attack_20\NN\955060|who_27 (l_compound) migraine_19\JJ\14326607|a_2
D012701_D008881 NONE serotonin_1\NN\14807737|NONE_0 (r_compound) content_2\NN\7951464|significantly_18|p<0.01_33|after_41|but_97|observed_126 (r_nsubj) decreased_3\VBD\169651|NONE_0 (l_prep) after_8\IN\0|content_41|significantly_23|p<0.01_8|but_56|observed_85 (l_pobj) nitroglycerin_9\NN\15015501|NONE_0 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) subjects_11\NNS\6598915|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) attack_15\NN\955060|NONE_0 (l_compound) migraine_14\JJ\14326607|no_3
D012701_D008881 NONE serotonin_1\NN\14807737|NONE_0 (r_compound) content_2\NN\7951464|significantly_18|p<0.01_33|after_41|but_97|observed_126 (r_nsubj) decreased_3\VBD\169651|NONE_0 (l_conj) observed_21\VBN\2163746|content_126|significantly_108|p<0.01_93|after_85|but_29 (l_prep) in_22\IN\13603305|change_20|was_13|._32 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) attack_26\NN\955060|NONE_0 (l_compound) migraine_25\JJ\14326607|NONE_0
D012701_D008881 NONE serotonin_3\NN\14807737|from_18 (r_compound) release_4\NN\3748886|in_23|,_12|does_23|not_28|migraine_40 (r_nsubj) provoke_9\VB\1617192|,_16|it_18|may_21|even_25|headache_45|._100 (l_dobj) migraine_10\NN\14326607|in_63|,_52|release_40|does_17|not_12
D009569_D008881 NONE no_0\RB\7204911|-_2 (r_intj) induced_2\VBN\1627355|migraine_8|:_23|increase_32|._160 (r_amod) attack_4\NN\955060|NONE_0 (l_compound) migraine_3\JJ\14326607|induced_8|:_15|increase_24|._152
D015740_D008881 NONE peptide_14\NN\14724264|NONE_0 (r_pobj) in_8\IN\13603305|strong_16 (r_prep) increase_7\NN\13576355|induced_32|migraine_24|:_9|._128 (r_appos) attack_4\NN\955060|NONE_0 (l_compound) migraine_3\JJ\14326607|induced_8|:_15|increase_24|._152
D015740_D008881 NONE cgrp_16\NN\0|(_1|)_4|and_20|correlation_33 (r_nmod) concentration_18\NN\4916342|plasma_46|calcitonin_39|related_23 (r_appos) peptide_14\NN\14724264|NONE_0 (r_pobj) in_8\IN\13603305|strong_16 (r_prep) increase_7\NN\13576355|induced_32|migraine_24|:_9|._128 (r_appos) attack_4\NN\955060|NONE_0 (l_compound) migraine_3\JJ\14326607|induced_8|:_15|increase_24|._152
D015740_D008881 NONE peptide_17\NN\14724264|concentration_15|serotonin_42|5-ht_74|)_78 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (r_dobj) investigate_8\VB\644583|aim_32|._241 (l_conj) attack_40\NN\955060|to_212|changes_197|and_33 (l_compound) migraine_39\JJ\14326607|the_20|delayed_16|genuine_8|provoked_16
D015740_D008881 NONE cgrp_19\NN\0|(_1|)_4|and_20 (r_nmod) concentration_21\NN\4916342|peptide_15|serotonin_27|5-ht_59|)_63 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (r_dobj) investigate_8\VB\644583|aim_32|._241 (l_conj) attack_40\NN\955060|to_212|changes_197|and_33 (l_compound) migraine_39\JJ\14326607|the_20|delayed_16|genuine_8|provoked_16
D015740_D008881 NONE cgrp_1\NN\0|plasma_7 (r_compound) concentration_2\NN\4916342|significantly_24|p<0.01_39|during_47|and_74|returned_78|._134 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_prep) during_8\IN\0|concentration_47|significantly_23|p<0.01_8|and_27|returned_31|._87 (l_pobj) attack_11\NN\955060|NONE_0 (l_compound) migraine_10\JJ\14326607|the_4
D015740_D008881 NONE cgrp_1\NN\0|plasma_7 (r_compound) concentration_2\NN\4916342|significantly_24|p<0.01_39|during_47|and_74|returned_78|._134 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_conj) returned_13\VBD\1835496|concentration_78|significantly_54|p<0.01_39|during_31|and_4|._56 (l_prep) after_16\IN\0|to_12 (l_pobj) cessation_18\NN\7365849|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) migraine_21\NN\14326607|NONE_0
D015740_D008881 NONE cgrp_3\NNP\0|plasma_7 (r_compound) concentrations_4\NNS\4916342|however_21|,_14|change_25|._101 (r_nsubj) failed_5\VBD\0|NONE_0 (l_xcomp) change_7\VB\7283608|however_46|,_39|concentrations_25|._76 (l_prep) during_8\IN\0|to_10 (l_conj) in_12\IN\13603305|headache_13|and_4 (l_pobj) subjects_14\NNS\6598915|NONE_0 (l_prep) with_15\IN\0|the_13 (l_pobj) attack_18\NN\955060|NONE_0 (l_compound) migraine_17\JJ\14326607|no_3
D015740_D008881 NONE cgrp_1\NNP\0|basal_6 (r_compound) concentration_2\NN\4916342|higher_32|and_39|platelet_43|._129 (r_nsubj) was_3\VBD\0|NONE_0 (l_conj) platelet_7\NN\5432736|concentration_43|higher_11|and_4|._86 (l_ccomp) tended_10\VBD\2604760|NONE_0 (l_xcomp) be_12\VB\14625458|content_18 (l_prep) in_14\IN\13603305|to_12|lower_6 (l_pobj) subjects_15\NNS\6598915|NONE_0 (l_relcl) experienced_17\VBD\2108377|NONE_0 (l_dobj) attack_20\NN\955060|who_27 (l_compound) migraine_19\JJ\14326607|a_2
D015740_D008881 NONE cgrp_7\NN\0|plasma_7 (r_compound) concentration_8\NN\4916342|that_17|with_25 (r_nsubj) correlates_9\VBZ\5857459|the_40 (l_prep) with_10\IN\0|that_42|concentration_25 (l_pobj) timing_12\NN\5044673|NONE_0 (l_prep) of_15\IN\0|the_24|and_13|severity_9 (l_pobj) headache_18\NN\5829480|NONE_0 (l_compound) migraine_17\JJ\14326607|a_2
D015740_D008881 NONE cgrp_7\NN\0|plasma_7 (r_compound) concentration_8\NN\4916342|that_17|with_25 (r_nsubj) correlates_9\VBZ\5857459|the_40 (r_acl) fact_4\NN\5816287|in_19|,_6|relationship_117|._155 (r_nsubj) suggests_19\VBZ\1010118|NONE_0 (l_dobj) relationship_22\NN\31921|in_136|,_123|fact_117|._38 (l_prep) between_23\IN\0|a_22|direct_20 (l_pobj) cgrp_24\NN\0|NONE_0 (l_conj) migraine_26\NN\14326607|and_4
D015740_D008881 NONE cgrp_24\NN\0|NONE_0 (r_pobj) between_23\IN\0|a_22|direct_20 (r_prep) relationship_22\NN\31921|in_136|,_123|fact_117|._38 (r_dobj) suggests_19\VBZ\1010118|NONE_0 (l_nsubj) fact_4\NN\5816287|in_19|,_6|relationship_117|._155 (l_acl) correlates_9\VBZ\5857459|the_40 (l_prep) with_10\IN\0|that_42|concentration_25 (l_pobj) timing_12\NN\5044673|NONE_0 (l_prep) of_15\IN\0|the_24|and_13|severity_9 (l_pobj) headache_18\NN\5829480|NONE_0 (l_compound) migraine_17\JJ\14326607|a_2
D015740_D008881 NONE cgrp_24\NN\0|NONE_0 (l_conj) migraine_26\NN\14326607|and_4
D015740_D008881 NONE cgrp_21\NN\0|the_16|concomitant_12|in_13 (r_compound) release_22\NN\3748886|the_38|and_25 (r_conj) headache_17\NN\5829480|provoke_45|,_29|it_27|may_24|even_20|._55 (r_dobj) counteract_15\VB\2367363|NONE_0 (l_ccomp) provoke_9\VB\1617192|,_16|it_18|may_21|even_25|headache_45|._100 (l_dobj) migraine_10\NN\14326607|in_63|,_52|release_40|does_17|not_12
D005996_D008881 NONE nitroglycerin_43\NN\15015501|NONE_0 (r_pobj) by_42\IN\0|NONE_0 (r_agent) provoked_41\VBN\1617192|the_36|delayed_32|genuine_24|migraine_16 (r_acl) attack_40\NN\955060|to_212|changes_197|and_33 (l_compound) migraine_39\JJ\14326607|the_20|delayed_16|genuine_8|provoked_16
D005996_D008881 NONE nitroglycerin_16\NN\15015501|the_4 (r_compound) application_17\NN\947128|NONE_0 (r_pobj) after_14\IN\0|min_15|and_4 (r_conj) before_12\RB\0|blood_65|was_59|from_45|times_14|,_46|and_48|min_63 (r_advmod) collected_2\VBN\2281093|NONE_0 (l_conj) min_23\NN\15154774|blood_128|was_122|from_108|times_77|before_63|,_17|and_15 (l_prep) after_24\IN\0|60_15|;_64|subjects_69|._78 (l_pobj) beginning_26\NN\7283608|NONE_0 (l_prep) of_27\IN\0|the_14 (l_pobj) attack_30\NN\955060|NONE_0 (l_compound) migraine_29\JJ\14326607|the_4|mean_17
D005996_D008881 NONE nitroglycerin_9\NN\15015501|NONE_0 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) subjects_11\NNS\6598915|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) attack_15\NN\955060|NONE_0 (l_compound) migraine_14\JJ\14326607|no_3
D005996_D008881 NONE nitroglycerin_9\NN\15015501|NONE_0 (r_pobj) after_8\IN\0|content_41|significantly_23|p<0.01_8|but_56|observed_85 (r_prep) decreased_3\VBD\169651|NONE_0 (l_conj) observed_21\VBN\2163746|content_126|significantly_108|p<0.01_93|after_85|but_29 (l_prep) in_22\IN\13603305|change_20|was_13|._32 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) attack_26\NN\955060|NONE_0 (l_compound) migraine_25\JJ\14326607|NONE_0
D015740_D006261 NONE peptide_17\NN\14724264|concentration_15|serotonin_42|5-ht_74|)_78 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (l_prep) during_31\IN\0|in_126 (l_pobj) headache_34\NN\5829480|NONE_0
D015740_D006261 NONE cgrp_19\NN\0|(_1|)_4|and_20 (r_nmod) concentration_21\NN\4916342|peptide_15|serotonin_27|5-ht_59|)_63 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (l_prep) during_31\IN\0|in_126 (l_pobj) headache_34\NN\5829480|NONE_0
D015740_D006261 NONE cgrp_3\NNP\0|plasma_7 (r_compound) concentrations_4\NNS\4916342|however_21|,_14|change_25|._101 (r_nsubj) failed_5\VBD\0|NONE_0 (l_xcomp) change_7\VB\7283608|however_46|,_39|concentrations_25|._76 (l_prep) during_8\IN\0|to_10 (l_pobj) headache_10\NN\5829480|and_9|in_13
D015740_D006261 NONE cgrp_7\NN\0|plasma_7 (r_compound) concentration_8\NN\4916342|that_17|with_25 (r_nsubj) correlates_9\VBZ\5857459|the_40 (l_prep) with_10\IN\0|that_42|concentration_25 (l_pobj) timing_12\NN\5044673|NONE_0 (l_prep) of_15\IN\0|the_24|and_13|severity_9 (l_pobj) headache_18\NN\5829480|NONE_0
D015740_D006261 NONE cgrp_24\NN\0|NONE_0 (r_pobj) between_23\IN\0|a_22|direct_20 (r_prep) relationship_22\NN\31921|in_136|,_123|fact_117|._38 (r_dobj) suggests_19\VBZ\1010118|NONE_0 (l_nsubj) fact_4\NN\5816287|in_19|,_6|relationship_117|._155 (l_acl) correlates_9\VBZ\5857459|the_40 (l_prep) with_10\IN\0|that_42|concentration_25 (l_pobj) timing_12\NN\5044673|NONE_0 (l_prep) of_15\IN\0|the_24|and_13|severity_9 (l_pobj) headache_18\NN\5829480|NONE_0
D015740_D006261 NONE cgrp_21\NN\0|the_16|concomitant_12|in_13 (r_compound) release_22\NN\3748886|the_38|and_25 (r_conj) headache_17\NN\5829480|provoke_45|,_29|it_27|may_24|even_20|._55
D012701_D006261 NONE serotonin_24\NN\14807737|peptide_42|concentration_27|5-ht_32|)_36 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (l_prep) during_31\IN\0|in_126 (l_pobj) headache_34\NN\5829480|NONE_0
D012701_D006261 NONE 5-hydroxytriptamine_26\NN\0|NONE_0 (r_punct) ,_27\,\0|NONE_0 (r_punct) 5-ht_28\CD\0|peptide_74|concentration_59|serotonin_32|)_4 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (l_prep) during_31\IN\0|in_126 (l_pobj) headache_34\NN\5829480|NONE_0
D012701_D006261 NONE 5-ht_28\CD\0|peptide_74|concentration_59|serotonin_32|)_4 (r_nmod) content_30\NN\7951464|NONE_0 (r_pobj) in_10\IN\13603305|during_126 (r_prep) changes_9\NNS\7283608|to_15|and_164|attack_197 (l_prep) during_31\IN\0|in_126 (l_pobj) headache_34\NN\5829480|NONE_0
D012701_D006261 NONE serotonin_3\NN\14807737|from_18 (r_compound) release_4\NN\3748886|in_23|,_12|does_23|not_28|migraine_40 (r_nsubj) provoke_9\VB\1617192|,_16|it_18|may_21|even_25|headache_45|._100 (r_ccomp) counteract_15\VB\2367363|NONE_0 (l_dobj) headache_17\NN\5829480|provoke_45|,_29|it_27|may_24|even_20|._55
D005996_D006261 NONE nitroglycerin_43\NN\15015501|NONE_0 (r_pobj) by_42\IN\0|NONE_0 (r_agent) provoked_41\VBN\1617192|the_36|delayed_32|genuine_24|migraine_16 (r_acl) attack_40\NN\955060|to_212|changes_197|and_33 (r_conj) investigate_8\VB\644583|aim_32|._241 (l_dobj) changes_9\NNS\7283608|to_15|and_164|attack_197 (l_prep) during_31\IN\0|in_126 (l_pobj) headache_34\NN\5829480|NONE_0
9034419
C047426_D003865 NONE venlafaxine_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|an_12 (r_prep) overdose_10\NN\84738|woman_36|in_24|._54 (r_dobj) took_8\VBD\2367363|NONE_0 (l_nsubj) woman_4\NN\9605289|overdose_36|in_60|._90 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) depression_7\NN\14373582|NONE_0
C047426_D012640 CID venlafaxine_4\NNP\0|a_2 (r_amod) overdose_5\NN\84738|NONE_0 (r_pobj) from_2\IN\0|NONE_0 (r_prep) resulting_1\VBG\2633881|._37 (r_acl) seizure_0\NN\14081375|NONE_0
C047426_D012640 CID venlafaxine_5\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_14|tablets_24 (r_prep) ingestion_2\NN\13440063|NONE_0 (r_pobj) after_0\IN\0|,_51|patient_57|seizure_101|._108 (r_prep) experienced_11\VBD\2108377|NONE_0 (l_dobj) seizure_15\NN\14081375|after_101|,_50|patient_44|._7
C047426_D012640 CID venlafaxine_11\NNP\0|NONE_0 (r_amod) overdose_12\NN\84738|NONE_0 (r_pobj) of_10\IN\0|the_24|first_20|reported_14|resulted_29 (r_prep) case_9\NN\7283608|to_45|,_29|this_27|._67 (l_relcl) resulted_14\VBD\2633881|the_53|first_49|reported_43|of_29 (l_prep) in_15\IN\13603305|that_14 (l_pobj) seizure_18\NN\14081375|NONE_0
C047426_D012640 CID venlafaxine_1\NNP\0|the_4|in_21 (r_amod) overdose_2\NN\84738|in_33|but_76|elicited_80|._108 (r_nsubj) resulted_6\VBD\2633881|NONE_0 (l_prep) in_7\IN\13603305|overdose_33|but_43|elicited_47|._75 (l_pobj) episode_10\NN\7283608|NONE_0 (l_prep) of_11\IN\0|a_17|single_15 (l_pobj) seizure_13\NN\14081375|NONE_0
C047426_D062787 CID venlafaxine_4\NNP\0|a_2 (r_amod) overdose_5\NN\84738|NONE_0
C047426_D062787 CID venlafaxine_5\NNP\0|NONE_0 (r_amod) overdose_6\NN\84738|NONE_0
C047426_D062787 CID venlafaxine_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|an_12 (r_prep) overdose_10\NN\84738|woman_36|in_24|._54
C047426_D062787 CID venlafaxine_11\NNP\0|NONE_0 (r_amod) overdose_12\NN\84738|NONE_0
C047426_D062787 CID venlafaxine_1\NNP\0|the_4|in_21 (r_amod) overdose_2\NN\84738|in_33|but_76|elicited_80|._108
18560792
D004298_D006349 NONE dopamine_33\NN\14807737|ergot_6 (r_compound) agonists_34\NNS\0|NONE_0 (r_pobj) to_29\IN\0|when_32|treatment_23|is_13 (r_prep) converted_28\VBN\126264|that_62|improvement_43|usual_28 (r_advcl) is_22\VBZ\0|NONE_0 (r_ccomp) reveals_17\VBZ\2137132|with_19|and_4 (r_conj) treated_13\VBN\2376958|the_69|high_65|of_50 (r_acl) frequency_5\NN\15286249|study_24|._197 (l_prep) of_6\IN\0|the_19|high_15|treated_50 (l_pobj) regurgitation_9\NN\7406350|NONE_0
D010479_D006349 NONE pergolide_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|disease_53|._14 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubj) disease_2\NN\14061805|with_53|._67
D010479_D006349 NONE pergolide_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|with_30 (r_acl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|abnormalities_33|have_19|been_14|._64 (r_prep) reported_5\VBN\831651|NONE_0 (l_nsubjpass) abnormalities_2\NNS\14034177|have_14|been_19|in_33|._97
D010479_D006349 NONE pergolide_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_9 (r_prep) role_10\NN\719494|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) suggestive_7\JJ\0|a_49|restrictive_47|of_27|,_2 (r_amod) pattern_2\NN\5726345|,_70|was_72|in_85|patients_100|._141 (l_prep) of_3\IN\0|a_22|restrictive_20|,_25|suggestive_27 (l_pobj) regurgitation_5\NN\7406350|NONE_0
D010479_D006349 NONE pergolide_0\NNP\0|was_10|in_27|,_69|resulting_71|returned_206|._252 (r_nsubjpass) discontinued_2\VBN\0|NONE_0 (l_prep) in_3\IN\13603305|pergolide_27|was_17|,_42|resulting_44|returned_179|._225 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|10_12 (l_pobj) disease_9\NN\14061805|NONE_0
D010479_D006349 NONE pergolide_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|and_15|reveals_19 (r_prep) treated_13\VBN\2376958|the_69|high_65|of_50 (r_acl) frequency_5\NN\15286249|study_24|._197 (l_prep) of_6\IN\0|the_19|high_15|treated_50 (l_pobj) regurgitation_9\NN\7406350|NONE_0
D004298_D010300 NONE dopamine_33\NN\14807737|ergot_6 (r_compound) agonists_34\NNS\0|NONE_0 (r_pobj) to_29\IN\0|when_32|treatment_23|is_13 (r_prep) converted_28\VBN\126264|that_62|improvement_43|usual_28 (r_advcl) is_22\VBZ\0|NONE_0 (r_ccomp) reveals_17\VBZ\2137132|with_19|and_4 (r_conj) treated_13\VBN\2376958|the_69|high_65|of_50 (r_acl) frequency_5\NN\15286249|study_24|._197 (l_prep) of_6\IN\0|the_19|high_15|treated_50 (l_pobj) regurgitation_9\NN\7406350|NONE_0 (l_prep) in_10\IN\13603305|restrictive_32|valve_20 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_compound) pd_11\NNP\14625458|NONE_0
D010479_D010300 NONE pergolide_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|disease_53|._14 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubj) disease_2\NN\14061805|with_53|._67 (l_prep) in_3\IN\13603305|valvular_23|heart_14 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|NONE_0 (l_pobj) disease_8\NN\14061805|NONE_0
D010479_D010300 NONE pergolide_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|with_30 (r_acl) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|treated_30 (l_pobj) disease_11\NN\14061805|NONE_0
D010479_D010300 NONE pergolide_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|with_30 (r_acl) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|treated_30 (l_pobj) disease_11\NN\14061805|NONE_0 (l_appos) pd_13\NNP\14625458|parkinson_21|(_1|)_2
D010479_D010300 NONE pergolide_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|patients_36 (r_prep) treated_7\VBN\2376958|were_23|attend_39|._111 (l_nsubj) patients_2\NNS\9898892|with_36 (l_compound) pd_1\NNP\14625458|all_4|in_12
D010479_D010300 NONE pergolide_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|and_15|reveals_19 (r_prep) treated_13\VBN\2376958|the_69|high_65|of_50 (r_acl) frequency_5\NN\15286249|study_24|._197 (l_prep) of_6\IN\0|the_19|high_15|treated_50 (l_pobj) regurgitation_9\NN\7406350|NONE_0 (l_prep) in_10\IN\13603305|restrictive_32|valve_20 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_compound) pd_11\NNP\14625458|NONE_0
D010479_D006333 NONE pergolide_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_9 (r_prep) role_10\NN\719494|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) suggestive_7\JJ\0|a_49|restrictive_47|of_27|,_2 (r_amod) pattern_2\NN\5726345|,_70|was_72|in_85|patients_100|._141 (r_nsubjpass) observed_15\VBN\2163746|NONE_0 (l_dobj) patients_22\NNS\9898892|pattern_100|,_30|was_28|in_15|._41 (l_prep) including_23\VBG\0|NONE_0 (l_pobj) two_24\CD\13741022|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) failure_27\NN\66216|NONE_0
D010479_D006333 NONE pergolide_0\NNP\0|was_10|in_27|,_69|resulting_71|returned_206|._252 (r_nsubjpass) discontinued_2\VBN\0|NONE_0 (l_advcl) resulting_11\VBG\2633881|pergolide_71|was_61|in_44|,_2|returned_135|._181 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) grade_16\NN\7975026|NONE_0 (l_prep) at_20\IN\14622893|a_37|lower_35|regurgitation_29|p=0.01_8 (l_pobj) transthoracic_23\NN\0|NONE_0 (l_conj) patients_28\NNS\9898892|the_54|second_50|echocardiography_29|and_12 (l_prep) with_29\IN\0|the_17|two_13 (l_pobj) failure_31\NN\66216|NONE_0
16181582
D014635_D004827 NONE valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) encephalopathy_3\NN\14084880|syndrome_25|._93 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) syndrome_7\NN\5870365|encephalopathy_25|._68 (l_relcl) manifest_10\VB\6479665|a_25|rare_23 (l_prep) in_11\RP\13603305|that_18|may_13 (l_pobj) individuals_15\NNS\7347|NONE_0 (l_amod) epileptic_14\JJ\10595647|normal_7
D014635_D001927 CID valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|._22 (r_amod) encephalopathy_3\NN\14084880|NONE_0
D014635_D001927 CID valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) encephalopathy_3\NN\14084880|syndrome_25|._93
D014635_D001927 CID valproate_3\NN\0|-_9 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) encephalopathy_6\NN\14084880|NONE_0
869641
D015103_D001919 NONE dihydroxyphenylserine_21\NN\0|l_17|-_16|,_11 (r_conj) dopa_15\NNP\14601829|NONE_0 (r_pobj) by_12\IN\0|in_93|,_82|bradycardia_73|was_27|significantly_23|had_42|._123 (r_agent) enhanced_11\VBN\227165|NONE_0 (l_nsubjpass) bradycardia_4\NN\14110674|in_20|,_9|was_46|significantly_50|by_73|had_115|._196
D004298_D007022 NONE dopamine_3\NN\14807737|-_8|beta_9|-_13 (r_compound) oxidase_7\NN\14732946|a_16 (r_compound) inhibitor_8\NN\20090|fla-63_32|,_26|,_9|did_11|not_15|effect_28|._103 (r_nsubj) have_12\VB\7846|NONE_0 (l_dobj) effect_14\NN\34213|fla-63_60|,_54|inhibitor_28|,_19|did_17|not_13|._75 (l_prep) on_15\IN\0|any_11 (l_pobj) hypotension_17\NN\14057371|NONE_0
D005406_D001919 NONE fla-63_0\NN\0|,_6|inhibitor_32|,_41|did_43|not_47|effect_60|._135 (r_mark) have_12\VB\7846|NONE_0 (l_dobj) effect_14\NN\34213|fla-63_60|,_54|inhibitor_28|,_19|did_17|not_13|._75 (l_prep) on_15\IN\0|any_11 (l_pobj) hypotension_17\NN\14057371|NONE_0 (l_appos) effect_24\NN\34213|the_49|,_34 (l_amod) bradycardia_19\NN\14110674|of_39
D007980_D001919 NONE dopa_9\NN\14601829|NONE_0 (r_pobj) by_6\IN\0|of_37|via_10|._48 (r_prep) mediation_0\NN\7148192|NONE_0 (l_prep) of_1\IN\0|by_37|via_47|._85 (l_pobj) bradycardia_5\NNP\14110674|NONE_0
D007980_D001919 NONE dopa_15\NNP\14601829|NONE_0 (r_pobj) by_12\IN\0|in_93|,_82|bradycardia_73|was_27|significantly_23|had_42|._123 (r_agent) enhanced_11\VBN\227165|NONE_0 (l_nsubjpass) bradycardia_4\NN\14110674|in_20|,_9|was_46|significantly_50|by_73|had_115|._196
D007980_D001919 NONE dopa_28\NNP\14601829|NONE_0 (r_pobj) of_25\IN\0|bradycardia_39 (r_prep) effect_24\NN\34213|the_49|,_34 (l_amod) bradycardia_19\NN\14110674|of_39
D007980_D001919 NONE dopa_4\NNP\14601829|however_11|,_4|bradycardia_18|._110 (r_nsubj) restored_5\VBD\1631072|NONE_0 (l_dobj) bradycardia_7\NN\14110674|however_29|,_22|dopa_18|._92
D007980_D001919 NONE dopa_6\NNP\14601829|that_7|bradycardia_21|through_33 (r_nsubj) enhances_7\VBZ\227165|it_28|is_25|._70 (l_dobj) bradycardia_9\NN\14110674|that_28|dopa_21|through_12
D004298_D001919 NONE dopamine_12\NN\14807737|central_8|in_19 (r_compound) formation_13\NN\7938773|NONE_0 (r_pobj) via_10\IN\0|of_47|by_10|._38 (r_prep) mediation_0\NN\7148192|NONE_0 (l_prep) of_1\IN\0|by_37|via_47|._85 (l_pobj) bradycardia_5\NNP\14110674|NONE_0
D004298_D001919 NONE dopamine_3\NN\14807737|-_8|beta_9|-_13 (r_compound) oxidase_7\NN\14732946|a_16 (r_compound) inhibitor_8\NN\20090|fla-63_32|,_26|,_9|did_11|not_15|effect_28|._103 (r_nsubj) have_12\VB\7846|NONE_0 (l_dobj) effect_14\NN\34213|fla-63_60|,_54|inhibitor_28|,_19|did_17|not_13|._75 (l_prep) on_15\IN\0|any_11 (l_pobj) hypotension_17\NN\14057371|NONE_0 (l_appos) effect_24\NN\34213|the_49|,_34 (l_amod) bradycardia_19\NN\14110674|of_39
D005406_D007022 NONE fla-63_0\NN\0|,_6|inhibitor_32|,_41|did_43|not_47|effect_60|._135 (r_mark) have_12\VB\7846|NONE_0 (l_dobj) effect_14\NN\34213|fla-63_60|,_54|inhibitor_28|,_19|did_17|not_13|._75 (l_prep) on_15\IN\0|any_11 (l_pobj) hypotension_17\NN\14057371|NONE_0
D009638_D001919 CID norepinephrine_8\NN\14807929|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) caused_5\VBN\1617192|reflex_19 (r_acl) bradycardia_4\NN\14110674|in_20|,_9|was_46|significantly_50|by_73|had_115|._196
D009638_D001919 CID norepinephrine_35\NN\14807929|NONE_0 (r_pobj) to_34\IN\0|reflex_17 (r_prep) responses_33\NNS\11410625|heart_21|or_10 (r_conj) rate_30\NN\13815152|blood_22|,_8 (r_conj) pressure_27\NN\11419404|NONE_0 (r_pobj) on_25\IN\0|no_10 (r_prep) effect_24\NN\34213|NONE_0 (r_dobj) had_22\VBD\0|in_135|,_124|bradycardia_115|was_69|significantly_65|by_42|._81 (r_conj) enhanced_11\VBN\227165|NONE_0 (l_nsubjpass) bradycardia_4\NN\14110674|in_20|,_9|was_46|significantly_50|by_73|had_115|._196
D009638_D001919 CID norepinephrine_10\NN\14807929|NONE_0 (r_pobj) by_9\IN\0|in_18 (r_agent) caused_8\VBN\1617192|the_16 (r_acl) bradycardia_7\NN\14110674|however_29|,_22|dopa_18|._92
D009638_D001919 CID norepinephrine_18\NN\14807929|NONE_0 (r_pobj) to_17\IN\0|the_23|reflex_19 (r_prep) bradycardia_16\NN\14110674|NONE_0
D007980_D007022 NONE dopa_28\NNP\14601829|NONE_0 (r_pobj) of_25\IN\0|bradycardia_39 (r_prep) effect_24\NN\34213|the_49|,_34 (r_appos) hypotension_17\NN\14057371|NONE_0
D006916_D001919 NONE 5-htp_0\NNP\0|pressure_37|and_61|decreased_65|._115 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_conj) decreased_13\VBD\169651|5-htp_65|pressure_28|and_4|._50 (l_dobj) bradycardia_16\NN\14110674|NONE_0
7423039
D004317_D066126 CID adriamycin_3\JJ\0|NONE_0 (r_amod) cardiotoxicity_4\NN\0|NONE_0
D004317_D066126 CID adriamycin_4\NNS\0|NONE_0 (r_pobj) of_3\IN\0|the_24|cardiotoxic_20 (r_prep) effects_2\NNS\13245626|were_22|in_35|._93 (l_amod) cardiotoxic_1\JJ\0|the_4|of_20
8386779
D010208_D007172 NONE papaverine_25\NN\3800001|3_15|:_8 (r_appos) drugs_21\NNS\14778436|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) combination_18\NN\7951464|NONE_0 (r_pobj) of_16\IN\0|0.2_8 (r_prep) ml._15\NN\0|total_89|._65 (r_dobj) received_13\VBD\2210855|NONE_0 (l_nsubj) total_1\NN\3553|ml._89|._154 (l_prep) of_2\IN\0|a_8 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_relcl) presented_7\VBD\2137132|38_28|consecutive_25 (l_prep) with_11\IN\0|who_28|to_14 (l_pobj) impotence_12\NN\4723816|NONE_0
D017693_D007172 NONE bicarbonate_1\NN\14798450|pain_30|induced_35|._96 (r_nsubj) alleviates_2\VBZ\205885|NONE_0 (l_advcl) induced_5\VBN\1627355|bicarbonate_35|pain_5|._61 (l_agent) by_6\IN\0|NONE_0 (l_pobj) injections_8\NNS\320852|NONE_0 (l_prep) for_9\IN\0|intracavernous_26 (l_pobj) dysfunction_11\NN\14204950|NONE_0
D017693_D004414 NONE bicarbonate_1\NN\14798450|pain_30|induced_35|._96 (r_nsubj) alleviates_2\VBZ\205885|NONE_0 (l_dobj) pain_4\NN\14299637|bicarbonate_30|induced_5|._66
D017693_D004414 NONE bicarbonate_43\NN\14798450|NONE_0 (r_pobj) of_41\IN\0|the_13 (r_prep) addition_40\NN\3081021|NONE_0 (r_pobj) without_38\IN\0|or_3 (r_conj) with_36\IN\0|intracorporeal_26 (r_prep) injections_35\NNS\320852|NONE_0 (r_pobj) following_33\VBG\8180190|incidence_25 (r_prep) comparing_27\VBG\635850|a_19|randomized_17 (r_acl) study_26\NN\635850|in_162|,_28|we_26|medications._154 (r_dobj) performed_23\VBD\0|NONE_0 (l_prep) in_0\IN\13603305|,_134|we_136|study_162|medications._316 (l_pobj) attempt_2\NN\407535|NONE_0 (l_acl) determine_4\VB\0|an_14 (l_ccomp) be_13\VB\14625458|to_81 (l_nsubj) pain_7\NN\14299637|whether_15|could_47|due_56
D017693_D004414 NONE bicarbonate_43\NN\14798450|NONE_0 (r_pobj) of_41\IN\0|the_13 (r_prep) addition_40\NN\3081021|NONE_0 (r_pobj) without_38\IN\0|or_3 (r_conj) with_36\IN\0|intracorporeal_26 (r_prep) injections_35\NNS\320852|NONE_0 (r_pobj) following_33\VBG\8180190|incidence_25 (r_prep) comparing_27\VBG\635850|a_19|randomized_17 (l_dobj) incidence_29\NN\13821570|following_25 (l_prep) of_30\IN\0|the_14 (l_pobj) pain_32\NN\14299637|NONE_0
D017693_D004414 NONE bicarbonate_6\NN\14798450|NONE_0 (r_pobj) without_4\IN\0|the_16|19_12|added_27 (r_prep) patients_3\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|of_90|due_105|,_126|complained_192|._217 (r_prep) complained_16\VBD\0|NONE_0 (l_prep) of_17\IN\0|of_90|due_15|,_36|complained_102|._127 (l_pobj) pain_19\NN\14299637|NONE_0
D017693_D004414 NONE bicarbonate_6\NN\14798450|NONE_0 (r_pobj) without_4\IN\0|the_16|19_12|added_27 (r_prep) patients_3\NNS\9898892|NONE_0 (r_pobj) of_0\IN\0|of_90|due_105|,_126|complained_192|._217 (r_prep) complained_16\VBD\0|NONE_0 (l_advcl) complained_40\VBD\0|of_192|of_102|due_87|,_66|._25 (l_prep) of_41\IN\0|while_75|1_64 (l_pobj) pain_43\NN\14299637|NONE_0
D017693_D004414 NONE bicarbonate_39\NN\14798450|who_20 (r_dobj) received_37\VBD\2210855|the_20|19_16|(_9|%_7|)_6 (r_relcl) men_31\NNS\8208016|NONE_0 (r_pobj) of_28\IN\0|only_7 (r_prep) 1_27\CD\13741022|while_11|of_64 (r_nsubj) complained_40\VBD\0|of_192|of_102|due_87|,_66|._25 (r_advcl) complained_16\VBD\0|NONE_0 (l_prep) of_17\IN\0|of_90|due_15|,_36|complained_102|._127 (l_pobj) pain_19\NN\14299637|NONE_0
D017693_D004414 NONE bicarbonate_39\NN\14798450|who_20 (r_dobj) received_37\VBD\2210855|the_20|19_16|(_9|%_7|)_6 (r_relcl) men_31\NNS\8208016|NONE_0 (r_pobj) of_28\IN\0|only_7 (r_prep) 1_27\CD\13741022|while_11|of_64 (r_nsubj) complained_40\VBD\0|of_192|of_102|due_87|,_66|._25 (l_prep) of_41\IN\0|while_75|1_64 (l_pobj) pain_43\NN\14299637|NONE_0
11569530
C063968_D016171 NONE e4031_19\NNP\0|and_4 (r_conj) cisapride_17\NN\0|,_2 (r_conj) terodiline_15\NN\0|,_2 (r_conj) terfenadine_13\NN\0|tdp_23|were_19|:_2 (r_appos) investigated_11\VBN\644583|NONE_0 (l_nsubjpass) tdp_9\NNP\0|were_4|:_21|terfenadine_23
D020117_D016171 CID cisapride_17\NN\0|,_2 (r_conj) terodiline_15\NN\0|,_2 (r_conj) terfenadine_13\NN\0|tdp_23|were_19|:_2 (r_appos) investigated_11\VBN\644583|NONE_0 (l_nsubjpass) tdp_9\NNP\0|were_4|:_21|terfenadine_23
D020117_D016171 CID cisapride_14\JJ\0|,_2 (r_conj) terodiline_12\NN\0|,_2 (r_conj) terfenadine_10\NN\0|the_12|(_1|)_34 (r_appos) clinic_8\NN\8053905|NONE_0 (r_pobj) in_6\IN\13603305|that_20|have_15|tdp_4 (r_prep) shown_4\VBN\2137132|NONE_0 (l_dobj) tdp_5\NNP\0|that_16|have_11|in_4
D016593_D016171 CID terfenadine_19\NN\0|the_17|(_6|)_26 (r_appos) market_16\NN\407535|NONE_0 (r_pobj) from_14\IN\0|of_17 (r_prep) withdrawal_10\NN\7206096|NONE_0 (r_pobj) to_9\IN\0|that_13|has_8 (r_prep) led_8\VBN\3202760|a_23|side_21|-_17 (r_relcl) effect_5\NN\34213|tdp_14|._100 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) tdp_0\NNP\0|effect_14|._114
D016593_D016171 CID terfenadine_13\NN\0|tdp_23|were_19|:_2 (r_appos) investigated_11\VBN\644583|NONE_0 (l_nsubjpass) tdp_9\NNP\0|were_4|:_21|terfenadine_23
D016593_D016171 CID terfenadine_10\NN\0|the_12|(_1|)_34 (r_appos) clinic_8\NN\8053905|NONE_0 (r_pobj) in_6\IN\13603305|that_20|have_15|tdp_4 (r_prep) shown_4\VBN\2137132|NONE_0 (l_dobj) tdp_5\NNP\0|that_16|have_11|in_4
C010637_D016171 CID terodiline_21\NN\0|e.g._21|and_4 (r_conj) terfenadine_19\NN\0|the_17|(_6|)_26 (r_appos) market_16\NN\407535|NONE_0 (r_pobj) from_14\IN\0|of_17 (r_prep) withdrawal_10\NN\7206096|NONE_0 (r_pobj) to_9\IN\0|that_13|has_8 (r_prep) led_8\VBN\3202760|a_23|side_21|-_17 (r_relcl) effect_5\NN\34213|tdp_14|._100 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) tdp_0\NNP\0|effect_14|._114
C010637_D016171 CID terodiline_15\NN\0|,_2 (r_conj) terfenadine_13\NN\0|tdp_23|were_19|:_2 (r_appos) investigated_11\VBN\644583|NONE_0 (l_nsubjpass) tdp_9\NNP\0|were_4|:_21|terfenadine_23
C010637_D016171 CID terodiline_12\NN\0|,_2 (r_conj) terfenadine_10\NN\0|the_12|(_1|)_34 (r_appos) clinic_8\NN\8053905|NONE_0 (r_pobj) in_6\IN\13603305|that_20|have_15|tdp_4 (r_prep) shown_4\VBN\2137132|NONE_0 (l_dobj) tdp_5\NNP\0|that_16|have_11|in_4
6308277
D010433_D012640 CID pentylenetetrezol_30\NN\0|NONE_0 (r_pobj) of_29\IN\0|the_20|convulsant_16|in_21|tests_30 (r_prep) dose_28\NN\3740161|did_29|not_25 (r_dobj) alter_25\VB\0|in_132|,_106|acetaminophen_104|did_72|not_68|seizures_53|and_12|._122 (r_conj) modify_15\VB\109660|NONE_0 (l_dobj) seizures_17\NNS\14081375|in_79|,_53|acetaminophen_51|did_19|not_15|and_41|alter_53|._175
D000082_D064420 NONE acetaminophen_5\NN\2707683|NONE_0 (r_pobj) by_4\IN\0|in_21|._16 (r_prep) reduction_0\NN\351485|NONE_0 (l_prep) in_1\IN\13603305|by_21|._37 (l_pobj) toxicity_3\NN\13576101|NONE_0
D000082_D064420 NONE acetaminophen_26\NN\2707683|NONE_0 (r_pobj) of_25\IN\0|the_13 (r_prep) presence_24\NN\13954253|that_9|(_26|micrograms_30|toxicity_61 (r_nsubj) reduced_33\VBD\441445|the_70 (l_dobj) toxicity_36\NN\13576101|that_70|presence_61|(_35|micrograms_31
D002110_D012640 CID caffeine_23\NN\14712692|NONE_0 (r_pobj) of_22\IN\0|the_19|ip_30|and_34|onset_42 (r_prep) administration_21\NN\1133281|NONE_0 (l_conj) onset_33\NN\7325190|the_61|of_42|ip_12|and_8 (l_prep) of_34\IN\0|the_10|by_21|;_45|and_47|pretreatment_54 (l_pobj) convulsions_36\NNS\14081375|NONE_0
D002110_D012640 CID caffeine_23\NN\14712692|NONE_0 (r_pobj) of_22\IN\0|the_19|ip_30|and_34|onset_42 (r_prep) administration_21\NN\1133281|NONE_0 (r_pobj) between_19\IN\0|the_13 (r_prep) interval_18\NN\33615|that_67|pretreatment_58|reduced_181 (r_dobj) increased_16\VBD\169651|studies_83|._298 (l_conj) reduced_54\VBD\441445|that_248|pretreatment_239|interval_181 (l_dobj) incidence_56\NN\13821570|(_70|ip_88|)_90 (l_prep) of_57\IN\0|the_14 (l_pobj) seizures_59\NNS\14081375|NONE_0
D002110_D012640 CID caffeine_65\NN\14712692|NONE_0 (r_pobj) of_64\IN\0|the_13 (r_prep) presence_63\NN\13954253|NONE_0 (r_pobj) in_61\IN\13603305|NONE_0 (r_prep) produced_60\VBN\1617192|audiogenic_20 (r_acl) seizures_59\NNS\14081375|NONE_0 (r_pobj) of_57\IN\0|the_14 (r_prep) incidence_56\NN\13821570|(_70|ip_88|)_90 (r_dobj) reduced_54\VBD\441445|that_248|pretreatment_239|interval_181 (r_conj) increased_16\VBD\169651|studies_83|._298 (l_dobj) interval_18\NN\33615|that_67|pretreatment_58|reduced_181 (l_prep) between_19\IN\0|the_13 (l_pobj) administration_21\NN\1133281|NONE_0 (l_conj) onset_33\NN\7325190|the_61|of_42|ip_12|and_8 (l_prep) of_34\IN\0|the_10|by_21|;_45|and_47|pretreatment_54 (l_pobj) convulsions_36\NNS\14081375|NONE_0
D002110_D012640 CID caffeine_65\NN\14712692|NONE_0 (r_pobj) of_64\IN\0|the_13 (r_prep) presence_63\NN\13954253|NONE_0 (r_pobj) in_61\IN\13603305|NONE_0 (r_prep) produced_60\VBN\1617192|audiogenic_20 (r_acl) seizures_59\NNS\14081375|NONE_0
D002110_D012640 CID caffeine_12\NN\14712692|NONE_0 (r_pobj) after_7\IN\0|the_40|of_26 (r_prep) frequency_1\NN\15286249|was_68|from_80|by_94|._110 (l_prep) of_2\IN\0|the_14|after_26 (l_pobj) seizures_6\NNS\14081375|NONE_0
D002110_D012640 CID caffeine_4\NN\14712692|NONE_0 (r_pobj) of_3\IN\0|the_12 (r_prep) absence_2\NN\14449405|NONE_0 (r_pobj) in_0\IN\13603305|,_26|acetaminophen_28|did_60|not_64|seizures_79|and_120|alter_132|._254 (r_prep) modify_15\VB\109660|NONE_0 (l_dobj) seizures_17\NNS\14081375|in_79|,_53|acetaminophen_51|did_19|not_15|and_41|alter_53|._175
D002110_D064420 NONE caffeine_2\NN\14712692|NONE_0 (r_compound) toxicity_3\NN\13576101|NONE_0
D002110_D064420 NONE caffeine_11\NN\14712692|NONE_0 (r_pobj) of_10\IN\0|the_24|stimulatory_20|on_12 (r_prep) effects_9\NNS\13245626|to_27 (r_dobj) augment_6\VB\153263|because_42|salicylates_34|have_22|been_17 (r_xcomp) reported_4\VBN\831651|,_66|attention_68|was_78|on_90|._199 (r_advcl) focused_18\VBN\628491|NONE_0 (l_prep) on_19\IN\0|reported_90|,_24|attention_22|was_12|._109 (l_pobj) possibility_21\NN\5944958|NONE_0 (l_acl) reduced_33\VBD\441445|the_70 (l_dobj) toxicity_36\NN\13576101|that_70|presence_61|(_35|micrograms_31
D002110_D064420 NONE caffeine_38\NN\14712692|NONE_0 (r_pobj) of_37\IN\0|the_17|cns_13 (r_prep) toxicity_36\NN\13576101|that_70|presence_61|(_35|micrograms_31
D000082_D012640 NONE acetaminophen_11\NN\2707683|NONE_0 (r_pobj) with_10\IN\0|:_18|1_16|)_29 (r_prep) pretreatment_9\NN\0|that_9|interval_58|reduced_239 (r_nsubj) increased_16\VBD\169651|studies_83|._298 (l_dobj) interval_18\NN\33615|that_67|pretreatment_58|reduced_181 (l_prep) between_19\IN\0|the_13 (l_pobj) administration_21\NN\1133281|NONE_0 (l_conj) onset_33\NN\7325190|the_61|of_42|ip_12|and_8 (l_prep) of_34\IN\0|the_10|by_21|;_45|and_47|pretreatment_54 (l_pobj) convulsions_36\NNS\14081375|NONE_0
D000082_D012640 NONE acetaminophen_11\NN\2707683|NONE_0 (r_pobj) with_10\IN\0|:_18|1_16|)_29 (r_prep) pretreatment_9\NN\0|that_9|interval_58|reduced_239 (r_nsubj) increased_16\VBD\169651|studies_83|._298 (l_conj) reduced_54\VBD\441445|that_248|pretreatment_239|interval_181 (l_dobj) incidence_56\NN\13821570|(_70|ip_88|)_90 (l_prep) of_57\IN\0|the_14 (l_pobj) seizures_59\NNS\14081375|NONE_0
D000082_D012640 NONE acetaminophen_49\NN\2707683|NONE_0 (r_pobj) with_48\IN\0|2_16|)_28 (r_prep) pretreatment_47\NN\0|the_64|of_54|by_33|;_9|and_7 (r_conj) onset_33\NN\7325190|the_61|of_42|ip_12|and_8 (l_prep) of_34\IN\0|the_10|by_21|;_45|and_47|pretreatment_54 (l_pobj) convulsions_36\NNS\14081375|NONE_0
D000082_D012640 NONE acetaminophen_49\NN\2707683|NONE_0 (r_pobj) with_48\IN\0|2_16|)_28 (r_prep) pretreatment_47\NN\0|the_64|of_54|by_33|;_9|and_7 (r_conj) onset_33\NN\7325190|the_61|of_42|ip_12|and_8 (r_conj) administration_21\NN\1133281|NONE_0 (r_pobj) between_19\IN\0|the_13 (r_prep) interval_18\NN\33615|that_67|pretreatment_58|reduced_181 (r_dobj) increased_16\VBD\169651|studies_83|._298 (l_conj) reduced_54\VBD\441445|that_248|pretreatment_239|interval_181 (l_dobj) incidence_56\NN\13821570|(_70|ip_88|)_90 (l_prep) of_57\IN\0|the_14 (l_pobj) seizures_59\NNS\14081375|NONE_0
D000082_D012640 NONE acetaminophen_21\NN\2707683|NONE_0 (r_pobj) by_20\IN\0|frequency_94|was_26|from_14|._16 (r_agent) reduced_14\VBN\441445|NONE_0 (l_nsubjpass) frequency_1\NN\15286249|was_68|from_80|by_94|._110 (l_prep) of_2\IN\0|the_14|after_26 (l_pobj) seizures_6\NNS\14081375|NONE_0
D000082_D012640 NONE acetaminophen_6\FW\2707683|in_28|,_2|did_32|not_36|seizures_51|and_92|alter_104|._226 (r_nsubj) modify_15\VB\109660|NONE_0 (l_dobj) seizures_17\NNS\14081375|in_79|,_53|acetaminophen_51|did_19|not_15|and_41|alter_53|._175
16574712
D018817_D003072 CID mdma_0\NN\3054098|polydrug_5 (r_compound) users_2\NNS\7846|impairments_46|._120 (r_nsubj) show_3\VBP\429048|NONE_0 (l_dobj) impairments_9\NNS\7296428|users_46|._74 (l_acl) coupled_10\VBN\1295275|specific_39|central_30|executive_22 (l_prep) with_11\IN\0|NONE_0 (l_pobj) processes_17\NNS\407535|NONE_0
D018817_D008569 NONE mdma_12\NNP\3054098|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) users_10\NNS\7846|NONE_0 (r_pobj) in_9\IN\13603305|in_59|deficits_28|have_19|been_14|._61 (r_prep) reported_8\VBN\831651|NONE_0 (l_nsubjpass) deficits_5\NNS\5113133|in_31|have_9|been_14|in_28|._89
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\CD\0|(_1|ecstasy_35 (r_intj) mdma_12\NNP\3054098|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) users_10\NNS\7846|NONE_0 (r_pobj) in_9\IN\13603305|in_59|deficits_28|have_19|been_14|._61 (r_prep) reported_8\VBN\831651|NONE_0 (l_nsubjpass) deficits_5\NNS\5113133|in_31|have_9|been_14|in_28|._89
D018817_D008569 NONE ecstasy_16\NN\13985818|(_36|3,4-methylenedioxymethamphetamine_35 (r_appos) mdma_12\NNP\3054098|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) users_10\NNS\7846|NONE_0 (r_pobj) in_9\IN\13603305|in_59|deficits_28|have_19|been_14|._61 (r_prep) reported_8\VBN\831651|NONE_0 (l_nsubjpass) deficits_5\NNS\5113133|in_31|have_9|been_14|in_28|._89
6773726
D005996_D003920 NONE nitroglycerin_3\NN\15015501|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_66|in_79|._201 (r_nsubjpass) compared_12\VBN\644583|NONE_0 (l_prep) in_13\IN\13603305|effect_79|was_13|._122 (l_pobj) subjects_16\NNS\6598915|NONE_0 (l_appos) subjects_20\NNS\6598915|5_31|normal_29|,_14 (l_amod) diabetic_19\JJ\10595647|12_3|without_18|,_46|and_48|subjects_63
D005996_D003920 NONE nitroglycerin_3\NN\15015501|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_66|in_79|._201 (r_nsubjpass) compared_12\VBN\644583|NONE_0 (l_prep) in_13\IN\13603305|effect_79|was_13|._122 (l_pobj) subjects_16\NNS\6598915|NONE_0 (l_appos) subjects_20\NNS\6598915|5_31|normal_29|,_14 (l_conj) subjects_28\NNS\6598915|12_66|diabetic_63|without_45|,_17|and_15 (l_amod) diabetic_27\JJ\10595647|5_2|with_18
D005996_D003920 NONE nitroglycerin_19\NN\15015501|NONE_0 (r_pobj) after_18\IN\0|the_40|in_27 (r_prep) decrease_13\NN\7296428|the_35|in_22|and_8 (r_conj) increase_7\NN\13576355|NONE_0 (r_pobj) of_5\IN\0|magnitude_26 (r_prep) course_4\NN\883297|similar_106|,_178|occurred_270|._329 (r_nsubj) were_20\VBD\0|NONE_0 (l_acomp) similar_21\JJ\0|course_106|,_72|occurred_164|._223 (l_prep) in_22\IN\13603305|NONE_0 (l_pobj) subjects_27\NNS\6598915|NONE_0 (l_amod) normal_24\JJ\5667196|the_4|without_29 (l_conj) diabetic_26\JJ\10595647|and_4
D005996_D003920 NONE nitroglycerin_19\NN\15015501|NONE_0 (r_pobj) after_18\IN\0|the_40|in_27 (r_prep) decrease_13\NN\7296428|the_35|in_22|and_8 (r_conj) increase_7\NN\13576355|NONE_0 (r_pobj) of_5\IN\0|magnitude_26 (r_prep) course_4\NN\883297|similar_106|,_178|occurred_270|._329 (r_nsubj) were_20\VBD\0|NONE_0 (l_advcl) occurred_47\VBD\0|course_270|similar_164|,_92|._59 (l_prep) in_48\IN\13603305|whereas_99|increase_82 (l_pobj) subjects_51\NNS\6598915|NONE_0 (l_amod) diabetic_50\JJ\10595647|the_4|with_18
D005996_D009422 NONE nitroglycerin_3\NN\15015501|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_66|in_79|._201 (r_nsubjpass) compared_12\VBN\644583|NONE_0 (l_prep) in_13\IN\13603305|effect_79|was_13|._122 (l_pobj) subjects_16\NNS\6598915|NONE_0 (l_appos) subjects_20\NNS\6598915|5_31|normal_29|,_14 (l_prep) without_21\IN\0|12_21|diabetic_18|,_28|and_30|subjects_45 (l_pobj) neuropathy_23\NN\14204950|NONE_0
D005996_D009422 NONE nitroglycerin_3\NN\15015501|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_66|in_79|._201 (r_nsubjpass) compared_12\VBN\644583|NONE_0 (l_prep) in_13\IN\13603305|effect_79|was_13|._122 (l_pobj) subjects_16\NNS\6598915|NONE_0 (l_appos) subjects_20\NNS\6598915|5_31|normal_29|,_14 (l_conj) subjects_28\NNS\6598915|12_66|diabetic_63|without_45|,_17|and_15 (l_prep) with_29\IN\0|5_20|diabetic_18 (l_pobj) neuropathy_31\NN\14204950|NONE_0
D005996_D009422 NONE nitroglycerin_19\NN\15015501|NONE_0 (r_pobj) after_18\IN\0|the_40|in_27 (r_prep) decrease_13\NN\7296428|the_35|in_22|and_8 (r_conj) increase_7\NN\13576355|NONE_0 (r_pobj) of_5\IN\0|magnitude_26 (r_prep) course_4\NN\883297|similar_106|,_178|occurred_270|._329 (r_nsubj) were_20\VBD\0|NONE_0 (l_acomp) similar_21\JJ\0|course_106|,_72|occurred_164|._223 (l_prep) in_22\IN\13603305|NONE_0 (l_pobj) subjects_27\NNS\6598915|NONE_0 (l_prep) without_28\IN\0|the_33|normal_29 (l_pobj) neuropathy_30\NN\14204950|NONE_0
D005996_D009422 NONE nitroglycerin_19\NN\15015501|NONE_0 (r_pobj) after_18\IN\0|the_40|in_27 (r_prep) decrease_13\NN\7296428|the_35|in_22|and_8 (r_conj) increase_7\NN\13576355|NONE_0 (r_pobj) of_5\IN\0|magnitude_26 (r_prep) course_4\NN\883297|similar_106|,_178|occurred_270|._329 (r_nsubj) were_20\VBD\0|NONE_0 (l_advcl) occurred_47\VBD\0|course_270|similar_164|,_92|._59 (l_prep) in_48\IN\13603305|whereas_99|increase_82 (l_pobj) subjects_51\NNS\6598915|NONE_0 (l_prep) with_52\IN\0|the_22|diabetic_18 (l_pobj) neuropathy_54\NN\14204950|NONE_0
D005996_D007022 CID nitroglycerin_5\NN\15015501|NONE_0 (r_pobj) by_4\IN\0|postural_21 (r_prep) hypotension_3\NN\14057371|NONE_0
D005996_D003929 NONE nitroglycerin_5\NN\15015501|NONE_0 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) neuropathy_9\NN\14204950|NONE_0
15130900
D003520_D001749 CID cyclophosphamide_12\NN\0|NONE_0 (r_pobj) to_11\IN\0|and_13|relation_9 (r_prep) risks_8\NNS\14541044|wegener_26|:_2 (r_appos) granulomatosis_6\NN\0|NONE_0 (r_pobj) in_3\IN\13603305|urinary_23|bladder_15|._67 (r_prep) cancer_2\NN\14239425|NONE_0
D003520_D001749 CID cyclophosphamide_16\NN\0|NONE_0 (r_pobj) to_15\IN\0|its_13|,_19|in_21 (r_prep) relation_14\NN\2137|to_63|and_53|characterise_49|,_10|and_8 (r_conj) assess_3\VB\5220461|:_5|._131 (l_conj) characterise_5\VB\651991|to_14|and_4|,_39|and_41|relation_49 (l_dobj) risk_7\NN\14541044|NONE_0 (l_prep) of_8\IN\0|the_9 (l_pobj) cancer_10\NN\14239425|NONE_0
D003520_D001749 CID cyclophosphamide_18\NN\0|NONE_0 (l_conj) cancer_21\NN\14239425|and_12
D003520_D001749 CID cyclophosphamide_12\NN\0|NONE_0 (r_pobj) in_11\IN\13603305|every_21|10_15|g_12|(_20|or_21 (r_prep) increment_10\NN\29677|NONE_0 (r_pobj) for_6\IN\0|risk_31|._96 (r_prep) doubled_5\VBD\247390|NONE_0 (l_nsubj) risk_1\NN\14541044|for_31|._127 (l_prep) of_2\IN\0|the_9 (l_pobj) cancer_4\NN\14239425|NONE_0
D003520_D001749 CID cyclophosphamide_9\NN\0|NONE_0 (r_pobj) between_8\IN\0|a_29|response_22|and_25|risk_33 (r_prep) relationship_7\NN\31921|results_33|._201 (l_conj) risk_12\NN\14541044|a_62|response_55|between_33|and_8 (l_prep) of_13\IN\0|the_9|,_17|risks_35 (l_pobj) cancer_15\NN\14239425|NONE_0
D003520_D014890 NONE cyclophosphamide_12\NN\0|NONE_0 (r_pobj) to_11\IN\0|and_13|relation_9 (r_prep) risks_8\NNS\14541044|wegener_26|:_2 (r_appos) granulomatosis_6\NN\0|NONE_0
D003520_D014890 NONE cyclophosphamide_16\NN\0|NONE_0 (r_pobj) to_15\IN\0|its_13|,_19|in_21 (r_prep) relation_14\NN\2137|to_63|and_53|characterise_49|,_10|and_8 (l_prep) in_18\IN\13603305|its_34|to_21|,_2 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) granulomatosis_23\NN\0|NONE_0
D003520_D014890 NONE cyclophosphamide_9\NN\0|NONE_0 (r_pobj) between_8\IN\0|a_29|response_22|and_25|risk_33 (r_prep) relationship_7\NN\31921|results_33|._201 (l_conj) risk_12\NN\14541044|a_62|response_55|between_33|and_8 (l_conj) risks_19\NNS\14541044|the_44|of_35|,_18 (l_conj) possibility_28\NN\5944958|high_57|cumulative_52|in_35|,_15|and_13 (l_prep) of_29\IN\0|the_16 (l_pobj) factors_31\NNS\7326557|NONE_0 (l_acl) operating_32\VBG\2439501|risk_13 (l_prep) before_34\IN\0|NONE_0 (l_pobj) granulomatosis_37\NN\0|even_22
150790
D007538_D001523 NONE isoniazid_22\NN\2716205|NONE_0 (r_pobj) of_21\IN\0|the_31|therapeutic_27 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|difficulties_13 (r_prep) sleeping_15\VBG\14024882|,_6|and_4 (r_conj) irritability_12\NN\7552087|,_2
D011736_D002653 NONE pyridoxine_1\JJ\15090742|-_10 (r_advmod) dependent_3\JJ\9627906|a_13|behavioral_10|unmasked_30|._51 (r_amod) disorder_5\NN\14034177|NONE_0
D007538_D012893 NONE isoniazid_22\NN\2716205|NONE_0 (r_pobj) of_21\IN\0|the_31|therapeutic_27 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|difficulties_13 (r_prep) sleeping_15\VBG\14024882|,_6|and_4 (l_dobj) difficulties_16\NNS\621627|after_13
D011736_D006948 NONE pyridoxine_3\NN\15090742|NONE_0 (r_pobj) of_2\IN\0|periodic_20 (r_prep) withdrawal_1\NN\7206096|was_25|with_40|._71 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|withdrawal_40|was_15|._31 (l_pobj) return_7\NN\6479665|NONE_0 (l_prep) of_8\IN\0|NONE_0 (l_pobj) hyperkinesis_10\NN\0|NONE_0
D007538_D006948 CID isoniazid_22\NN\2716205|NONE_0 (r_pobj) of_21\IN\0|the_31|therapeutic_27 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|difficulties_13 (r_prep) sleeping_15\VBG\14024882|,_6|and_4 (r_conj) irritability_12\NN\7552087|,_2 (r_conj) hyperkinesis_10\NN\0|NONE_0
D007538_D002653 CID isoniazid_8\NN\2716205|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) unmasked_6\VBD\853195|a_43|dependent_30|behavioral_20|._21 (r_acl) disorder_5\NN\14034177|NONE_0
D007538_D002653 CID isoniazid_22\NN\2716205|NONE_0 (r_pobj) of_21\IN\0|the_31|therapeutic_27 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|difficulties_13 (r_prep) sleeping_15\VBG\14024882|,_6|and_4 (r_conj) irritability_12\NN\7552087|,_2 (r_conj) hyperkinesis_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|girl_35|deterioration_15|,_2|._108 (r_prep) had_5\VBD\0|NONE_0 (l_dobj) deterioration_7\NN\14560612|girl_20|,_13|with_15|._123
3719553
D011241_D004342 NONE prednisone_3\NNP\2721538|oral_25|and_4 (r_conj) diphenhydramine_1\NN\2720725|ineffective_36|in_48|._101 (r_nsubj) were_4\VBD\0|NONE_0 (l_prep) in_6\IN\13603305|diphenhydramine_48|ineffective_12|._53 (l_pcomp) preventing_7\VBG\0|NONE_0 (l_dobj) recurrence_9\NN\7342049|NONE_0 (l_prep) of_10\IN\0|the_15 (l_pobj) reaction_13\NN\13446390|NONE_0
D005472_D007674 NONE 5-fluorouracil_11\CD\0|an_88|allergic_85|consisting_67 (r_punct) reaction_2\NN\13446390|in_100|._214 (r_nsubj) occurred_12\VBD\0|NONE_0 (l_prep) in_13\IN\13603305|reaction_100|._114 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) carcinoma_18\NN\14239918|NONE_0 (l_prep) of_19\IN\0|recurrent_20 (l_pobj) cavity_22\NN\9304750|NONE_0 (l_conj) cirrhosis_24\NN\14116321|the_17|oral_13|,_2 (l_conj) function_32\NN\13783581|,_39|and_37
D005472_D005355 NONE 5-fluorouracil_11\CD\0|an_88|allergic_85|consisting_67 (r_punct) reaction_2\NN\13446390|in_100|._214 (r_nsubj) occurred_12\VBD\0|NONE_0 (l_prep) in_13\IN\13603305|reaction_100|._114 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) carcinoma_18\NN\14239918|NONE_0 (l_prep) of_19\IN\0|recurrent_20 (l_pobj) cavity_22\NN\9304750|NONE_0 (l_conj) cirrhosis_24\NN\14116321|the_17|oral_13|,_2
D005472_D000799 CID 5-fluorouracil_11\CD\0|an_88|allergic_85|consisting_67 (r_punct) reaction_2\NN\13446390|in_100|._214 (l_acl) consisting_3\VBG\2603699|an_21|allergic_18|5-fluorouracil_67 (l_prep) of_4\IN\0|NONE_0 (l_pobj) edema_6\NN\14315192|angioneurotic_14
D005472_D009062 NONE 5-fluorouracil_11\CD\0|an_88|allergic_85|consisting_67 (r_punct) reaction_2\NN\13446390|in_100|._214 (r_nsubj) occurred_12\VBD\0|NONE_0 (l_prep) in_13\IN\13603305|reaction_100|._114 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) carcinoma_18\NN\14239918|NONE_0 (l_prep) of_19\IN\0|recurrent_20 (l_pobj) cavity_22\NN\9304750|NONE_0
D005472_D004342 NONE 5-fluorouracil_3\CD\0|NONE_0 (r_punct) infusion_4\NN\14589223|NONE_0 (r_pobj) to_2\IN\0|allergic_18|._26 (r_prep) reaction_1\NN\13446390|NONE_0
D005472_D004342 NONE 5-fluorouracil_11\CD\0|an_88|allergic_85|consisting_67 (r_punct) reaction_2\NN\13446390|in_100|._214
D002945_D005355 NONE cisplatin_27\NN\0|-_9 (r_advmod) induced_29\VBN\1627355|impaired_8|renal_17 (r_amod) function_32\NN\13783581|,_39|and_37 (r_conj) cirrhosis_24\NN\14116321|the_17|oral_13|,_2
D002945_D009062 NONE cisplatin_27\NN\0|-_9 (r_advmod) induced_29\VBN\1627355|impaired_8|renal_17 (r_amod) function_32\NN\13783581|,_39|and_37 (r_conj) cirrhosis_24\NN\14116321|the_17|oral_13|,_2 (r_conj) cavity_22\NN\9304750|NONE_0
D002945_D004342 NONE cisplatin_27\NN\0|-_9 (r_advmod) induced_29\VBN\1627355|impaired_8|renal_17 (r_amod) function_32\NN\13783581|,_39|and_37 (r_conj) cirrhosis_24\NN\14116321|the_17|oral_13|,_2 (r_conj) cavity_22\NN\9304750|NONE_0 (r_pobj) of_19\IN\0|recurrent_20 (r_prep) carcinoma_18\NN\14239918|NONE_0 (r_pobj) with_16\IN\0|a_10 (r_prep) patient_15\NN\9898892|NONE_0 (r_pobj) in_13\IN\13603305|reaction_100|._114 (r_prep) occurred_12\VBD\0|NONE_0 (l_nsubj) reaction_2\NN\13446390|in_100|._214
D002945_D000799 NONE cisplatin_27\NN\0|-_9 (r_advmod) induced_29\VBN\1627355|impaired_8|renal_17 (r_amod) function_32\NN\13783581|,_39|and_37 (r_conj) cirrhosis_24\NN\14116321|the_17|oral_13|,_2 (r_conj) cavity_22\NN\9304750|NONE_0 (r_pobj) of_19\IN\0|recurrent_20 (r_prep) carcinoma_18\NN\14239918|NONE_0 (r_pobj) with_16\IN\0|a_10 (r_prep) patient_15\NN\9898892|NONE_0 (r_pobj) in_13\IN\13603305|reaction_100|._114 (r_prep) occurred_12\VBD\0|NONE_0 (l_nsubj) reaction_2\NN\13446390|in_100|._214 (l_acl) consisting_3\VBG\2603699|an_21|allergic_18|5-fluorouracil_67 (l_prep) of_4\IN\0|NONE_0 (l_pobj) edema_6\NN\14315192|angioneurotic_14
D004155_D004342 NONE diphenhydramine_1\NN\2720725|ineffective_36|in_48|._101 (r_nsubj) were_4\VBD\0|NONE_0 (l_prep) in_6\IN\13603305|diphenhydramine_48|ineffective_12|._53 (l_pcomp) preventing_7\VBG\0|NONE_0 (l_dobj) recurrence_9\NN\7342049|NONE_0 (l_prep) of_10\IN\0|the_15 (l_pobj) reaction_13\NN\13446390|NONE_0
D002945_D007674 NONE cisplatin_27\NN\0|-_9 (r_advmod) induced_29\VBN\1627355|impaired_8|renal_17 (r_amod) function_32\NN\13783581|,_39|and_37
12090760
D015215_D000740 CID azidothymidine_9\RB\0|-_14 (r_advmod) induced_11\VBN\1627355|NONE_0 (r_amod) anemia_12\NN\14189204|and_7|in_11
D015215_D000740 CID azidothymidine_0\NNP\0|anemia_29|can_44|be_48|by_60|and_152|interleukin_156|._170 (r_nsubjpass) reversed_8\VBN\109660|NONE_0 (l_nsubjpass) anemia_3\NN\14189204|azidothymidine_29|can_15|be_19|by_31|and_123|interleukin_127|._141
D015215_D000740 CID azt)-induced_2\VBN\0|(_1|in_20 (r_compound) anemia_3\NN\14189204|azidothymidine_29|can_15|be_19|by_31|and_123|interleukin_127|._141
15120741
D010862_D012640 CID pilocarpine_5\NN\14712692|systemic_9 (r_compound) injection_6\NN\320852|similar_38|,_23|se_37|,_143|but_145|identified_208 (r_nsubj) causes_7\VBZ\7323922|NONE_0 (l_dobj) se_11\NNP\14724645|similar_75|,_60|injection_37|,_106|but_108|identified_171 (l_conj) development_16\NN\248977|status_41|epilepticus_34|(_22|)_19|and_17 (l_prep) of_17\IN\0|the_25|eventual_21 (l_pobj) seizures_19\NNS\14081375|NONE_0
D001640_D013226 NONE bicuculline_5\NN\0|mg(2+)-free_38 (r_pobj) in_0\IN\13603305|,_52|conditions_54|,_112|stimulation_125|in_159|._278 (r_prep) resulted_21\VBD\2633881|NONE_0 (l_prep) in_22\IN\13603305|in_159|,_107|conditions_105|,_47|stimulation_34|._119 (l_pobj) spike_26\NN\7307895|NONE_0 (l_relcl) experience_41\VB\5984287|a_103|single_101|population_94|in_77 (l_dobj) se_42\NNP\14724645|that_24|did_19|not_15
D008274_D013226 NONE mg(2+)-free_1\JJ\0|bicuculline_38 (r_pobj) in_0\IN\13603305|,_52|conditions_54|,_112|stimulation_125|in_159|._278 (r_prep) resulted_21\VBD\2633881|NONE_0 (l_prep) in_22\IN\13603305|in_159|,_107|conditions_105|,_47|stimulation_34|._119 (l_pobj) spike_26\NN\7307895|NONE_0 (l_relcl) experience_41\VB\5984287|a_103|single_101|population_94|in_77 (l_dobj) se_42\NNP\14724645|that_24|did_19|not_15
D010862_D013226 CID pilocarpine_5\NN\14712692|systemic_9 (r_compound) injection_6\NN\320852|similar_38|,_23|se_37|,_143|but_145|identified_208 (r_nsubj) causes_7\VBZ\7323922|NONE_0 (l_dobj) se_11\NNP\14724645|similar_75|,_60|injection_37|,_106|but_108|identified_171 (l_nmod) epilepticus_9\NN\0|status_7|(_12|)_15|and_17|development_34
D010862_D013226 CID pilocarpine_5\NN\14712692|systemic_9 (r_compound) injection_6\NN\320852|similar_38|,_23|se_37|,_143|but_145|identified_208 (r_nsubj) causes_7\VBZ\7323922|NONE_0 (l_dobj) se_11\NNP\14724645|similar_75|,_60|injection_37|,_106|but_108|identified_171
D010862_D013226 CID pilocarpine_34\NN\14712692|-_11 (r_npadvmod) treated_36\VBN\2376958|NONE_0 (r_amod) mice_37\NNS\2329401|control_37|and_24 (r_conj) mice_32\NNS\2329401|NONE_0 (r_pobj) from_30\IN\0|granule_14 (r_prep) cells_29\NNS\3080309|NONE_0 (r_pobj) in_27\IN\13603305|a_26|single_24|population_17|experience_77 (r_prep) spike_26\NN\7307895|NONE_0 (l_relcl) experience_41\VB\5984287|a_103|single_101|population_94|in_77 (l_dobj) se_42\NNP\14724645|that_24|did_19|not_15
D018698_D013226 NONE glutamate_37\NN\15010703|NONE_0 (r_compound) receptor_38\NN\5225602|ionotropic_21 (r_compound) antagonists_39\NNS\7846|NONE_0 (r_pobj) by_35\IN\0|which_19|were_13 (r_agent) blocked_34\VBN\1476483|s_23|,_13 (r_relcl) duration_30\NN\15113229|NONE_0 (r_pobj) of_25\IN\0|repetitive_27 (r_prep) afterdischarges_24\NNS\0|negative_34|dc_25|and_15 (r_conj) shifts_21\NNS\7446404|NONE_0 (r_pobj) by_18\IN\0|,_25|at_23|,_2 (r_prep) followed_11\VBD\1835496|in_68|,_53|stimulation_43|in_22|._169 (r_advcl) resulted_6\VBD\2633881|NONE_0 (l_prep) in_0\IN\13603305|,_15|stimulation_25|in_46|followed_68|._237 (l_pobj) survivors_2\NNS\9630641|NONE_0 (l_compound) se_1\NNP\14724645|NONE_0
D018698_D013226 NONE glutamate_1\NN\15010703|focal_6|of_27|at_53 (r_compound) photostimulation_2\NN\0|in_96|._187 (r_nsubj) resulted_15\VBD\2633881|NONE_0 (l_prep) in_16\IN\13603305|photostimulation_96|._91 (l_pobj) responses_18\NNS\11410625|NONE_0 (l_prep) of_19\IN\0|population_21 (l_pobj) duration_24\NN\15113229|NONE_0 (l_prep) in_25\IN\13603305|s_11|but_28|groups_42 (l_pobj) slices_26\NNS\13285176|NONE_0 (l_prep) from_27\IN\0|NONE_0 (l_pobj) survivors_29\NNS\9630641|NONE_0 (l_compound) se_28\NNP\14724645|NONE_0
14765563
D011803_D003128 CID quinine_7\NN\2721948|NONE_0 (r_dobj) containing_6\VBG\2632940|NONE_0 (r_acl) products_5\NNS\3076708|that_5|may_28|complications_53|status_104|in_145 (r_nsubj) produce_9\VB\7555863|reports_53|._127 (l_dobj) status_18\NN\24720|that_109|products_104|may_76|complications_51|in_41 (l_conj) seizures_20\NNS\14081375|altered_23|mental_15|,_2|,_18 (l_conj) coma_23\NN\5678932|,_6|and_4
D011803_D012640 CID quinine_7\NN\2721948|NONE_0 (r_dobj) containing_6\VBG\2632940|NONE_0 (r_acl) products_5\NNS\3076708|that_5|may_28|complications_53|status_104|in_145 (r_nsubj) produce_9\VB\7555863|reports_53|._127 (l_dobj) status_18\NN\24720|that_109|products_104|may_76|complications_51|in_41 (l_conj) seizures_20\NNS\14081375|altered_23|mental_15|,_2|,_18
D011803_D002493 NONE quinine_7\NN\2721948|NONE_0 (r_dobj) containing_6\VBG\2632940|NONE_0 (r_acl) products_5\NNS\3076708|that_5|may_28|complications_53|status_104|in_145 (r_nsubj) produce_9\VB\7555863|reports_53|._127 (l_dobj) complications_11\NNS\1073995|that_58|products_53|may_25|status_51|in_92
D011803_D020922 NONE quinine_23\NN\2721948|banned_76|,_2|available_18|._79 (r_nsubj) is_24\VBZ\0|NONE_0 (l_advcl) banned_8\VBD\2480923|,_74|quinine_76|available_94|._155 (l_dobj) use_10\NN\407535|although_67|administration_26|due_29 (l_prep) for_11\IN\0|its_8 (l_pobj) cramps_14\NNS\14299637|NONE_0
D011803_D003221 CID quinine_7\NN\2721948|NONE_0 (r_dobj) containing_6\VBG\2632940|NONE_0 (r_acl) products_5\NNS\3076708|that_5|may_28|complications_53|status_104|in_145 (r_nsubj) produce_9\VB\7555863|reports_53|._127 (l_dobj) complications_11\NNS\1073995|that_58|products_53|may_25|status_51|in_92 (l_prep) including_13\VBG\0|neurological_28|,_2|,_19 (l_pobj) confusion_14\NN\13972797|NONE_0
10835440
D009553_D007022 CID nimodipine_2\NNP\0|the_16|intravenous_12|west_11|european_16|stroke_25|(_38|inwest_39|)_45 (r_compound) trial_6\NN\786195|correlation_23|._137 (r_nsubj) found_10\VBD\13279262|NONE_0 (l_dobj) correlation_12\NN\13841213|trial_23|._114 (l_prep) between_13\IN\0|a_14 (l_pobj) reduction_17\NN\351485|NONE_0 (l_prep) in_18\IN\13603305|induced_18|and_23|outcome_42 (l_pobj) pressure_20\NN\11419404|NONE_0
D009553_D007022 CID nimodipine_14\NN\0|-_10 (r_npadvmod) induced_16\VBN\1627355|in_18|and_41|outcome_60 (r_amod) reduction_17\NN\351485|NONE_0 (l_prep) in_18\IN\13603305|induced_18|and_23|outcome_42 (l_pobj) pressure_20\NN\11419404|NONE_0
D009553_D007022 CID nimodipine_0\NNP\0|NONE_0 (r_compound) treatment_1\NN\654885|in_19|._165 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_prep) in_3\IN\13603305|treatment_19|._146 (l_pobj) reduction_7\NN\351485|NONE_0 (l_prep) in_8\IN\13603305|a_38|significant_22 (l_pobj) bp_10\NNP\0|NONE_0
D009553_D002544 NONE nimodipine_34\NN\0|1_18|mg_16|/_14 (r_parataxis) h_28\NN\14622893|to_33|placebo_22|,_7 (r_appos) receive_19\VB\2210855|methods_113|were_32|consecutively_27|._102 (r_advcl) allocated_17\VBN\2228698|NONE_0 (l_nsubjpass) methods_0\NNS\5616786|were_81|consecutively_86|receive_113|._215 (l_appos) patients_2\NNS\9898892|:_2 (l_prep) with_3\IN\0|(_45|within_46|)_61 (l_pobj) diagnosis_6\NN\152018|NONE_0 (l_prep) of_7\IN\0|a_21|clinical_19 (l_pobj) stroke_9\NN\556313|NONE_0
D009553_D002544 NONE nimodipine_49\NN\0|(_53|dose_48|)_44|n=101_30|or_22 (r_conj) nimodipine_34\NN\0|1_18|mg_16|/_14 (r_parataxis) h_28\NN\14622893|to_33|placebo_22|,_7 (r_appos) receive_19\VB\2210855|methods_113|were_32|consecutively_27|._102 (r_advcl) allocated_17\VBN\2228698|NONE_0 (l_nsubjpass) methods_0\NNS\5616786|were_81|consecutively_86|receive_113|._215 (l_appos) patients_2\NNS\9898892|:_2 (l_prep) with_3\IN\0|(_45|within_46|)_61 (l_pobj) diagnosis_6\NN\152018|NONE_0 (l_prep) of_7\IN\0|a_21|clinical_19 (l_pobj) stroke_9\NN\556313|NONE_0
D009553_D020521 NONE nimodipine_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|after_56|._74 (r_prep) effect_0\NN\34213|NONE_0 (l_prep) after_9\IN\0|of_56|._18 (l_pobj) stroke_11\NN\556313|NONE_0
D009553_D020521 NONE nimodipine_2\NNP\0|the_16|intravenous_12|west_11|european_16|stroke_25|(_38|inwest_39|)_45 (r_compound) trial_6\NN\786195|correlation_23|._137 (l_compound) stroke_5\NNP\556313|the_41|intravenous_37|nimodipine_25|west_14|european_9|(_13|inwest_14|)_20
D009553_D020521 NONE nimodipine_2\NNP\0|the_16|intravenous_12|west_11|european_16|stroke_25|(_38|inwest_39|)_45 (r_compound) trial_6\NN\786195|correlation_23|._137 (r_nsubj) found_10\VBD\13279262|NONE_0 (l_dobj) correlation_12\NN\13841213|trial_23|._114 (l_prep) between_13\IN\0|a_14 (l_pobj) reduction_17\NN\351485|NONE_0 (l_conj) outcome_27\NN\7291312|induced_60|in_42|and_19 (l_prep) in_28\IN\13603305|an_23|unfavorable_20 (l_pobj) stroke_30\NN\556313|NONE_0
D009553_D020521 NONE nimodipine_14\NN\0|-_10 (r_npadvmod) induced_16\VBN\1627355|in_18|and_41|outcome_60 (r_amod) reduction_17\NN\351485|NONE_0 (r_pobj) between_13\IN\0|a_14 (r_prep) correlation_12\NN\13841213|trial_23|._114 (r_dobj) found_10\VBD\13279262|NONE_0 (l_nsubj) trial_6\NN\786195|correlation_23|._137 (l_compound) stroke_5\NNP\556313|the_41|intravenous_37|nimodipine_25|west_14|european_9|(_13|inwest_14|)_20
D009553_D020521 NONE nimodipine_14\NN\0|-_10 (r_npadvmod) induced_16\VBN\1627355|in_18|and_41|outcome_60 (r_amod) reduction_17\NN\351485|NONE_0 (l_conj) outcome_27\NN\7291312|induced_60|in_42|and_19 (l_prep) in_28\IN\13603305|an_23|unfavorable_20 (l_pobj) stroke_30\NN\556313|NONE_0
D009553_D020521 NONE nimodipine_15\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_31|intravenous_27 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) after_7\IN\0|neurological_23|after_61 (r_prep) worsening_6\VBG\13457378|NONE_0 (l_prep) after_16\IN\0|neurological_84|after_61 (l_pobj) stroke_18\NN\556313|NONE_0
18464113
D006514_D006509 CID antigen_14\NN\20090|(_8|hbsag_9|)_14|seropositive_16|cancer_29|undergoing_45 (r_nmod) patients_20\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|virus_19 (r_prep) reactivation_8\NN\0|NONE_0 (l_compound) virus_7\NN\9312843|in_19 (l_compound) b_6\NNP\1355326|NONE_0
D006514_D006509 CID hbsag_16\NNP\0|antigen_9|(_1|)_5|seropositive_7|cancer_20|undergoing_36 (r_nmod) patients_20\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|virus_19 (r_prep) reactivation_8\NN\0|NONE_0 (l_compound) virus_7\NN\9312843|in_19 (l_compound) b_6\NNP\1355326|NONE_0
D019259_D056486 NONE lamivudine_3\NN\3834836|the_17|prophylactic_13 (r_compound) group_4\NN\2137|NONE_0 (r_pobj) in_0\IN\13603305|hepatitis_44|were_54|patient_78|._119 (r_prep) observed_8\VBN\2163746|NONE_0 (l_nsubjpass) hepatitis_6\NN\14127211|in_44|were_10|patient_34|._75
D006514_D009369 NONE antigen_14\NN\20090|(_8|hbsag_9|)_14|seropositive_16|cancer_29|undergoing_45 (r_nmod) patients_20\NNS\9898892|NONE_0 (l_compound) cancer_19\NN\14239425|antigen_29|(_21|hbsag_20|)_15|seropositive_13|undergoing_16
D006514_D009369 NONE hbsag_16\NNP\0|antigen_9|(_1|)_5|seropositive_7|cancer_20|undergoing_36 (r_nmod) patients_20\NNS\9898892|NONE_0 (l_compound) cancer_19\NN\14239425|antigen_29|(_21|hbsag_20|)_15|seropositive_13|undergoing_16
D019259_D006509 NONE lamivudine_0\NNP\3834836|NONE_0 (l_prep) for_1\IN\0|._154 (l_pobj) prevention_3\NN\1073995|NONE_0 (l_prep) of_4\IN\0|the_15 (l_pobj) reactivation_8\NN\0|NONE_0 (l_compound) virus_7\NN\9312843|in_19 (l_compound) b_6\NNP\1355326|NONE_0
D019259_D006509 NONE lamivudine_20\NN\3834836|in_133|,_120|patients_111|prior_11|compared_31|._100 (r_dobj) received_16\VBD\2210855|NONE_0 (l_nsubj) patients_5\NNS\9898892|in_22|,_9|lamivudine_111|prior_122|compared_142|._211 (l_relcl) have_7\VBP\7846|cancer_20 (l_dobj) malignancies_11\NNS\14070360|who_33 (l_prep) with_12\IN\0|solid_37 (l_pobj) infection_15\NN\14052046|NONE_0
D019259_D006509 NONE lamivudine_34\NN\3834836|who_20|did_16|not_12 (r_dobj) receive_33\VB\2210855|historical_37|control_26 (r_relcl) group_29\NN\2137|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) compared_25\VBN\644583|in_164|,_151|patients_142|lamivudine_31|prior_20|._69 (r_prep) received_16\VBD\2210855|NONE_0 (l_nsubj) patients_5\NNS\9898892|in_22|,_9|lamivudine_111|prior_122|compared_142|._211 (l_relcl) have_7\VBP\7846|cancer_20 (l_dobj) malignancies_11\NNS\14070360|who_33 (l_prep) with_12\IN\0|solid_37 (l_pobj) infection_15\NN\14052046|NONE_0
D019259_D019337 NONE lamivudine_20\NN\3834836|in_133|,_120|patients_111|prior_11|compared_31|._100 (r_dobj) received_16\VBD\2210855|NONE_0 (l_nsubj) patients_5\NNS\9898892|in_22|,_9|lamivudine_111|prior_122|compared_142|._211 (l_relcl) have_7\VBP\7846|cancer_20 (l_dobj) malignancies_11\NNS\14070360|who_33
D019259_D019337 NONE lamivudine_34\NN\3834836|who_20|did_16|not_12 (r_dobj) receive_33\VB\2210855|historical_37|control_26 (r_relcl) group_29\NN\2137|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) compared_25\VBN\644583|in_164|,_151|patients_142|lamivudine_31|prior_20|._69 (r_prep) received_16\VBD\2210855|NONE_0 (l_nsubj) patients_5\NNS\9898892|in_22|,_9|lamivudine_111|prior_122|compared_142|._211 (l_relcl) have_7\VBP\7846|cancer_20 (l_dobj) malignancies_11\NNS\14070360|who_33
D019259_D009369 NONE lamivudine_0\NNP\3834836|NONE_0 (l_prep) for_1\IN\0|._154 (l_pobj) prevention_3\NN\1073995|NONE_0 (l_prep) of_4\IN\0|the_15 (l_pobj) reactivation_8\NN\0|NONE_0 (l_prep) in_9\IN\13603305|virus_19 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_compound) cancer_19\NN\14239425|antigen_29|(_21|hbsag_20|)_15|seropositive_13|undergoing_16
D019259_D009369 NONE lamivudine_20\NN\3834836|in_133|,_120|patients_111|prior_11|compared_31|._100 (r_dobj) received_16\VBD\2210855|NONE_0 (l_nsubj) patients_5\NNS\9898892|in_22|,_9|lamivudine_111|prior_122|compared_142|._211 (l_compound) cancer_4\NN\14239425|have_20
D019259_D009369 NONE lamivudine_34\NN\3834836|who_20|did_16|not_12 (r_dobj) receive_33\VB\2210855|historical_37|control_26 (r_relcl) group_29\NN\2137|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) compared_25\VBN\644583|in_164|,_151|patients_142|lamivudine_31|prior_20|._69 (r_prep) received_16\VBD\2210855|NONE_0 (l_nsubj) patients_5\NNS\9898892|in_22|,_9|lamivudine_111|prior_122|compared_142|._211 (l_compound) cancer_4\NN\14239425|have_20
D019259_D009369 NONE lamivudine_5\NN\3834836|that_18|significantly_11|incidence_39|during_110 (r_nsubj) decreases_7\VBZ\7296428|study_58|._127 (l_dobj) incidence_9\NN\13821570|that_57|lamivudine_39|significantly_28|during_71 (l_prep) of_10\IN\0|the_14 (l_pobj) reactivation_12\NN\0|NONE_0 (l_conj) morbidity_15\NN\13826959|hbv_29|and_12 (l_prep) in_16\IN\13603305|overall_18 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_compound) cancer_17\NN\14239425|NONE_0
2924746
D005481_D015430 NONE hfde_21\NNP\0|-_4 (r_npadvmod) induced_23\VBN\1627355|NONE_0 (r_amod) seizures_24\NNS\14081375|NONE_0 (r_pobj) against_20\IN\0|continuously_24 (r_prep) protective_19\JJ\0|administration_97|and_41|was_45|._117 (r_acomp) was_17\VBD\0|NONE_0 (l_conj) was_26\VBD\0|administration_142|protective_45|and_4|._72 (l_advcl) measured_30\VBN\697589|toxic_9 (l_agent) by_31\IN\0|as_12|over_15 (l_pobj) gain_33\NN\13576355|NONE_0
D005481_D012640 CID ether_4\NN\14840755|NONE_0 (r_pobj) by_2\IN\0|seizures_17|found_44|._153 (r_prep) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|found_61|._170
D005481_D012640 CID ether_4\NN\14840755|NONE_0 (r_pobj) by_2\IN\0|seizures_17|found_44|._153 (r_prep) induced_1\VBN\1627355|NONE_0 (l_conj) found_10\VBN\13279262|seizures_61|by_44|._109 (l_xcomp) be_12\VB\14625458|were_19|also_14 (l_prep) than_21\IN\0|to_52|measure_29 (l_pobj) seizures_22\NNS\14081375|NONE_0
D005481_D012640 CID hfde_6\NNP\0|hexafluorodiethyl_25 (r_appos) ether_4\NN\14840755|NONE_0 (r_pobj) by_2\IN\0|seizures_17|found_44|._153 (r_prep) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|found_61|._170
D005481_D012640 CID hfde_6\NNP\0|hexafluorodiethyl_25 (r_appos) ether_4\NN\14840755|NONE_0 (r_pobj) by_2\IN\0|seizures_17|found_44|._153 (r_prep) induced_1\VBN\1627355|NONE_0 (l_conj) found_10\VBN\13279262|seizures_61|by_44|._109 (l_xcomp) be_12\VB\14625458|were_19|also_14 (l_prep) than_21\IN\0|to_52|measure_29 (l_pobj) seizures_22\NNS\14081375|NONE_0
D005481_D012640 CID hfde_21\NNP\0|-_4 (r_npadvmod) induced_23\VBN\1627355|NONE_0 (r_amod) seizures_24\NNS\14081375|NONE_0
D002220_D015430 NONE cbz_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|oral_20|as_7|h_40 (r_prep) administration_1\NN\1133281|protective_97|and_138|was_142|._214 (r_nsubj) was_17\VBD\0|NONE_0 (l_conj) was_26\VBD\0|administration_142|protective_45|and_4|._72 (l_advcl) measured_30\VBN\697589|toxic_9 (l_agent) by_31\IN\0|as_12|over_15 (l_pobj) gain_33\NN\13576355|NONE_0
D002220_D012640 NONE cbz_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_prep) protection_18\NN\407535|NONE_0 (r_pobj) of_17\IN\0|a_25|sensitive_18 (r_prep) measure_16\NN\168237|to_23|than_29 (r_attr) be_12\VB\14625458|were_19|also_14 (r_xcomp) found_10\VBN\13279262|seizures_61|by_44|._109 (r_conj) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|found_61|._170
D002220_D012640 NONE cbz_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_prep) protection_18\NN\407535|NONE_0 (r_pobj) of_17\IN\0|a_25|sensitive_18 (r_prep) measure_16\NN\168237|to_23|than_29 (r_attr) be_12\VB\14625458|were_19|also_14 (l_prep) than_21\IN\0|to_52|measure_29 (l_pobj) seizures_22\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|oral_20|as_7|h_40 (r_prep) administration_1\NN\1133281|protective_97|and_138|was_142|._214 (r_nsubj) was_17\VBD\0|NONE_0 (l_acomp) protective_19\JJ\0|administration_97|and_41|was_45|._117 (l_prep) against_20\IN\0|continuously_24 (l_pobj) seizures_24\NNS\14081375|NONE_0
D005492_D064420 NONE folate_17\JJ\15090742|tissue_7 (r_compound) concentrations_18\NNS\4916342|and_18 (r_conj) plasma_14\NN\5398023|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) effect_12\NN\34213|,_6|and_4 (r_conj) toxicity_9\NN\13576101|,_2
D019946_D015430 NONE glycol_13\NN\14766364|a_28|common_26|,_12 (r_appos) vehicle_10\NN\3100490|in_49|,_11|,_25|by_27|,_50|was_52|exhibit_65|._145 (r_nsubjpass) found_22\VBN\13279262|NONE_0 (l_xcomp) exhibit_24\VB\6733939|in_114|,_76|vehicle_65|,_40|by_38|,_15|was_13|._80 (l_dobj) properties_26\NNS\32613|to_22 (l_prep) against_27\IN\0|protective_22 (l_pobj) seizures_29\NNS\14081375|NONE_0 (l_conj) gain_33\NN\13576355|induced_38|and_21
D019946_D012640 NONE glycol_13\NN\14766364|a_28|common_26|,_12 (r_appos) vehicle_10\NN\3100490|in_49|,_11|,_25|by_27|,_50|was_52|exhibit_65|._145 (r_nsubjpass) found_22\VBN\13279262|NONE_0 (l_xcomp) exhibit_24\VB\6733939|in_114|,_76|vehicle_65|,_40|by_38|,_15|was_13|._80 (l_dobj) properties_26\NNS\32613|to_22 (l_prep) against_27\IN\0|protective_22 (l_pobj) seizures_29\NNS\14081375|NONE_0
D002220_D064420 NONE carbamazepine_1\NN\0|in_24|:_34|efficacy_36|._109 (r_compound) treatment_2\NN\654885|NONE_0 (l_appos) efficacy_7\NN\5199286|carbamazepine_36|in_12|:_2|._73 (l_conj) toxicity_9\NN\13576101|,_2
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\NNP\0|NONE_0 (r_dobj) bolus_9\NN\13899404|a_36|study_26|)_51 (r_appos) phase_1\NN\15113229|was_87|in_96|._160 (r_nsubjpass) done_15\VBN\0|NONE_0 (l_prep) in_16\IN\13603305|phase_96|was_9|._64 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) in_19\IN\13603305|55_12 (l_pobj) status_22\NN\24720|NONE_0 (l_prep) with_23\IN\0|good_24|performance_19 (l_pobj) tumors_25\NNS\14234074|NONE_0
C027260_D009369 NONE pirarubicin_12\NNP\0|NONE_0 (r_appos) 4'-0-tetrahydropyranyladriamycin_10\NNP\0|NONE_0 (r_dobj) bolus_9\NN\13899404|a_36|study_26|)_51 (r_appos) phase_1\NN\15113229|was_87|in_96|._160 (r_nsubjpass) done_15\VBN\0|NONE_0 (l_prep) in_16\IN\13603305|phase_96|was_9|._64 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) in_19\IN\13603305|55_12 (l_pobj) status_22\NN\24720|NONE_0 (l_prep) with_23\IN\0|good_24|performance_19 (l_pobj) tumors_25\NNS\14234074|NONE_0
10721819
D004294_D001919 CID domperidone_26\NN\0|NONE_0 (r_pobj) by_24\IN\0|that_24|was_19|partly_15 (r_agent) reduced_23\VBN\441445|an_26|mg/kg_33|)_38 (r_relcl) effect_19\NN\34213|while_62|tachycardia_56|was_44|to_31|,_5 (r_npadvmod) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (l_prep) to_14\IN\0|while_31|tachycardia_25|was_13|,_26|effect_31 (l_pobj) bradycardia_16\NNS\14110674|NONE_0
D001971_D007022 CID bromocriptine_5\NN\0|in_29|,_14|hypotension_50|._77 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hypotension_14\NN\14057371|in_79|,_64|bromocriptine_50|._27
D001971_D007022 CID bromocriptine_0\NNP\0|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hypotension_3\NN\14057371|unaffected_16|,_56|reversed_80|._182
D007545_D007022 NONE isoproterenol_7\JJ\3740161|NONE_0 (r_compound) pretreatment_8\NN\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_prep) unaffected_5\JJ\0|hypotension_16|,_40|reversed_64|._166 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) hypotension_3\NN\14057371|unaffected_16|,_56|reversed_80|._182
D004298_D013610 NONE dopamine_27\NN\14807737|NONE_0 (r_compound) d2_28\NN\0|peripheral_20 (r_compound) receptors_29\NNS\5225602|NONE_0 (r_pobj) at_25\IN\14622893|the_32|of_16 (r_prep) bradycardia_21\NN\14110674|to_12 (r_dobj) mask_19\VB\3122748|to_22|and_7 (r_conj) predominate_16\VB\0|that_84|,_80|in_78|,_54|tachycardia_40 (r_xcomp) appears_14\VBZ\2604760|they_86|._102 (l_nsubj) tachycardia_11\NN\14110674|that_44|,_40|in_38|,_14|predominate_40
D007545_D006332 CID isoproterenol_0\JJ\3740161|for_27 (r_compound) pretreatment_1\NN\0|hypertrophy_40|without_52|._108 (r_nsubj) caused_5\VBD\1617192|NONE_0 (l_dobj) hypertrophy_7\NN\14365950|pretreatment_40|without_12|._68
D007545_D001919 CID isoproterenol_7\JJ\3740161|NONE_0 (r_compound) pretreatment_8\NN\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_prep) unaffected_5\JJ\0|hypotension_16|,_40|reversed_64|._166 (r_acomp) was_4\VBD\0|NONE_0 (l_advcl) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (l_prep) to_14\IN\0|while_31|tachycardia_25|was_13|,_26|effect_31 (l_pobj) bradycardia_16\NNS\14110674|NONE_0
D007545_D001919 CID isoproterenol_5\JJ\3740161|15-day_7 (r_compound) pretreatment_6\NN\0|that_26|not_13|but_32|reversed_36 (r_nsubj) abolished_9\VBD\0|results_61|._221 (l_conj) reversed_11\VBD\109660|that_62|pretreatment_36|not_23|but_4 (l_prep) to_16\IN\0|tachycardia_12|,_14|effect_19 (l_pobj) bradycardia_17\NNP\14110674|NONE_0
D001971_D013610 CID bromocriptine_9\NN\0|-_13 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) tachycardia_12\NN\14110674|NONE_0
D001971_D013610 CID bromocriptine_5\NN\0|-_13 (r_npadvmod) induced_7\VBN\1627355|,_19|persisted_27|,_56 (r_amod) tachycardia_8\NN\14110674|that_27
D001971_D013610 CID bromocriptine_13\NN\0|-_13 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) tachycardia_16\NN\14110674|whether_86|pretreatment_68|could_36|in_12
D001971_D013610 CID bromocriptine_5\NN\0|in_29|,_14|hypotension_50|._77 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hypotension_14\NN\14057371|in_79|,_64|bromocriptine_50|._27 (l_conj) tachycardia_16\NN\14110674|significant_28|and_4
D001971_D013610 CID bromocriptine_0\NNP\0|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hypotension_3\NN\14057371|unaffected_16|,_56|reversed_80|._182 (r_nsubj) was_4\VBD\0|NONE_0 (l_advcl) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (l_nsubjpass) tachycardia_11\NN\14110674|while_6|was_12|to_25|,_51|effect_56
D001971_D013610 CID bromocriptine_12\NN\0|-_13 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) tachycardia_15\NN\14110674|to_12|,_26|effect_31
D001971_D013610 CID bromocriptine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_24|central_20 (r_prep) tachycardia_11\NN\14110674|that_44|,_40|in_38|,_14|predominate_40
D001971_D001919 NONE bromocriptine_0\NNP\0|-_13 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hypotension_3\NN\14057371|unaffected_16|,_56|reversed_80|._182 (r_nsubj) was_4\VBD\0|NONE_0 (l_advcl) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (l_prep) to_14\IN\0|while_31|tachycardia_25|was_13|,_26|effect_31 (l_pobj) bradycardia_16\NNS\14110674|NONE_0
D001971_D001919 NONE bromocriptine_12\NN\0|-_13 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) tachycardia_15\NN\14110674|to_12|,_26|effect_31 (r_dobj) reversed_11\VBD\109660|that_62|pretreatment_36|not_23|but_4 (l_prep) to_16\IN\0|tachycardia_12|,_14|effect_19 (l_pobj) bradycardia_17\NNP\14110674|NONE_0
D001971_D001919 NONE bromocriptine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_24|central_20 (r_prep) tachycardia_11\NN\14110674|that_44|,_40|in_38|,_14|predominate_40 (r_nsubj) appears_14\VBZ\2604760|they_86|._102 (l_xcomp) predominate_16\VB\0|that_84|,_80|in_78|,_54|tachycardia_40 (l_conj) mask_19\VB\3122748|to_22|and_7 (l_dobj) bradycardia_21\NN\14110674|to_12
D004294_D007022 NONE domperidone_26\NN\0|NONE_0 (r_pobj) by_24\IN\0|that_24|was_19|partly_15 (r_agent) reduced_23\VBN\441445|an_26|mg/kg_33|)_38 (r_relcl) effect_19\NN\34213|while_62|tachycardia_56|was_44|to_31|,_5 (r_npadvmod) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (r_advcl) was_4\VBD\0|NONE_0 (l_nsubj) hypotension_3\NN\14057371|unaffected_16|,_56|reversed_80|._182
D004298_D001919 NONE dopamine_27\NN\14807737|NONE_0 (r_compound) d2_28\NN\0|peripheral_20 (r_compound) receptors_29\NNS\5225602|NONE_0 (r_pobj) at_25\IN\14622893|the_32|of_16 (r_prep) bradycardia_21\NN\14110674|to_12
D007545_D013610 NONE isoproterenol_7\NN\3740161|NONE_0 (l_prep) on_8\IN\0|NONE_0 (l_pobj) tachycardia_12\NN\14110674|NONE_0
D007545_D013610 NONE isoproterenol_10\NN\3740161|NONE_0 (r_pobj) with_9\IN\0|prolonged_23 (r_prep) pretreatment_8\NN\0|whether_18|could_32|tachycardia_68|in_80 (r_nsubj) abolish_12\VB\0|to_67 (l_dobj) tachycardia_16\NN\14110674|whether_86|pretreatment_68|could_36|in_12
D007545_D013610 NONE isoproterenol_7\JJ\3740161|NONE_0 (r_compound) pretreatment_8\NN\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_prep) unaffected_5\JJ\0|hypotension_16|,_40|reversed_64|._166 (r_acomp) was_4\VBD\0|NONE_0 (l_advcl) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (l_nsubjpass) tachycardia_11\NN\14110674|while_6|was_12|to_25|,_51|effect_56
D007545_D013610 NONE isoproterenol_5\JJ\3740161|15-day_7 (r_compound) pretreatment_6\NN\0|that_26|not_13|but_32|reversed_36 (r_nsubj) abolished_9\VBD\0|results_61|._221 (l_conj) reversed_11\VBD\109660|that_62|pretreatment_36|not_23|but_4 (l_dobj) tachycardia_15\NN\14110674|to_12|,_26|effect_31
D004294_D013610 NONE domperidone_26\NN\0|NONE_0 (r_pobj) by_24\IN\0|that_24|was_19|partly_15 (r_agent) reduced_23\VBN\441445|an_26|mg/kg_33|)_38 (r_relcl) effect_19\NN\34213|while_62|tachycardia_56|was_44|to_31|,_5 (r_npadvmod) reversed_13\VBN\109660|hypotension_80|unaffected_64|,_24|._102 (l_nsubjpass) tachycardia_11\NN\14110674|while_6|was_12|to_25|,_51|effect_56
18754075
D019386_D005923 NONE alendronate_10\JJ\3740161|bisphosphonate_16|in_28 (r_nmod) administration_12\NN\1133281|NONE_0 (l_prep) in_13\IN\13603305|bisphosphonate_44|alendronate_28 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) glomerulosclerosis_19\NN\0|NONE_0
D019386_D011507 CID alendronate_10\JJ\3740161|bisphosphonate_16|in_28 (r_nmod) administration_12\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|massive_44|and_24|failure_8|._107 (r_prep) proteinuria_1\NN\14299637|NONE_0
D013256_D009404 NONE steroid_19\NN\14727670|NONE_0 (r_compound) therapy_20\NN\657604|NONE_0 (r_pobj) to_18\IN\0|man_100|was_30|initially_26|well_5|._18 (r_prep) responding_16\VBG\2367363|NONE_0 (l_nsubj) man_5\NN\9605289|was_70|initially_74|well_95|to_100|._118 (l_prep) with_6\IN\0|a_27|old_17|japanese_13|due_24 (l_pobj) syndrome_8\NN\5870365|NONE_0
D004164_D011507 NONE bisphosphonate_8\NN\0|alendronate_16|in_44 (r_nmod) administration_12\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|massive_44|and_24|failure_8|._107 (r_prep) proteinuria_1\NN\14299637|NONE_0
D004164_D011507 NONE bisphosphonates_11\NNS\0|that_41|intravenous_27|can_16|proteinuria_30 (r_nsubj) aggravate_13\VB\126264|report_81|._45 (l_dobj) proteinuria_14\NN\14299637|that_71|intravenous_57|bisphosphonates_30|can_14
D019386_D058186 CID alendronate_10\JJ\3740161|bisphosphonate_16|in_28 (r_nmod) administration_12\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|massive_44|and_24|failure_8|._107 (r_prep) proteinuria_1\NN\14299637|NONE_0 (l_conj) failure_5\NN\66216|massive_36|and_16|after_8|._115
D019386_D058186 CID sodium_9\NN\14625458|,_22 (r_nmod) administration_11\NN\1133281|within_63|amount_20|rapidly_62|up_70|with_83|._107 (r_nsubj) increased_19\VBD\169651|NONE_0 (l_prep) with_25\IN\0|within_146|administration_83|amount_63|rapidly_21|up_13|._24 (l_pobj) failure_28\NN\66216|NONE_0
D004164_D058186 NONE bisphosphonate_8\NN\0|alendronate_16|in_44 (r_nmod) administration_12\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|massive_44|and_24|failure_8|._107 (r_prep) proteinuria_1\NN\14299637|NONE_0 (l_conj) failure_5\NN\66216|massive_36|and_16|after_8|._115
D004164_D058186 NONE bisphosphonate_6\NN\0|NONE_0 (r_pobj) of_3\IN\0|14_8 (r_prep) days_2\NNS\15140892|NONE_0 (r_pobj) within_0\IN\0|administration_63|amount_83|rapidly_125|up_133|with_146|._170 (r_prep) increased_19\VBD\169651|NONE_0 (l_prep) with_25\IN\0|within_146|administration_83|amount_63|rapidly_21|up_13|._24 (l_pobj) failure_28\NN\66216|NONE_0
D004164_D058186 NONE bisphosphonates_11\NNS\0|that_41|intravenous_27|can_16|proteinuria_30 (r_nsubj) aggravate_13\VB\126264|report_81|._45 (l_dobj) proteinuria_14\NN\14299637|that_71|intravenous_57|bisphosphonates_30|can_14 (l_conj) failure_18\NN\66216|and_16
D013256_D005923 NONE steroid_19\NN\14727670|NONE_0 (r_compound) therapy_20\NN\657604|NONE_0 (r_pobj) to_18\IN\0|man_100|was_30|initially_26|well_5|._18 (r_prep) responding_16\VBG\2367363|NONE_0 (l_nsubj) man_5\NN\9605289|was_70|initially_74|well_95|to_100|._118 (l_amod) due_9\IN\5174653|a_51|old_41|japanese_37|with_24 (l_pobj) glomerulosclerosis_13\NN\0|to_19
D004164_D005923 NONE bisphosphonate_8\NN\0|alendronate_16|in_44 (r_nmod) administration_12\NN\1133281|NONE_0 (l_prep) in_13\IN\13603305|bisphosphonate_44|alendronate_28 (l_pobj) patient_15\NN\9898892|NONE_0 (l_prep) with_16\IN\0|a_10 (l_pobj) glomerulosclerosis_19\NN\0|NONE_0
6747681
D002330_D005910 NONE bcnu_3\NNP\0|arterial_9|for_18|._82 (r_compound) chemotherapy_4\NN\661091|NONE_0 (l_prep) for_5\IN\0|arterial_27|bcnu_18|._64 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|NONE_0 (l_pobj) gliomas_9\NNS\14236743|NONE_0
D002330_D005910 NONE bcnu_7\NNP\0|(_5|)_43 (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_29|rapid_25|systemic_19 (r_prep) clearance_5\NN\5089947|of_22 (r_pobj) because_0\IN\0|,_87|administration_104|should_119|advantage_148|._228 (r_prep) provide_17\VB\2199590|NONE_0 (l_dobj) advantage_20\NN\5154517|because_148|,_61|administration_44|should_29|._80 (l_prep) over_21\IN\5867413|a_24|substantial_22 (l_pobj) administration_23\NN\1133281|NONE_0 (l_prep) for_24\IN\0|intravenous_27 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14 (l_pobj) gliomas_29\NNS\14236743|NONE_0
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_29|rapid_25|systemic_19 (r_prep) clearance_5\NN\5089947|of_22 (r_pobj) because_0\IN\0|,_87|administration_104|should_119|advantage_148|._228 (r_prep) provide_17\VB\2199590|NONE_0 (l_dobj) advantage_20\NN\5154517|because_148|,_61|administration_44|should_29|._80 (l_prep) over_21\IN\5867413|a_24|substantial_22 (l_pobj) administration_23\NN\1133281|NONE_0 (l_prep) for_24\IN\0|intravenous_27 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14 (l_pobj) gliomas_29\NNS\14236743|NONE_0
D000431_D014786 NONE ethanol_11\NN\14708720|the_4 (r_compound) diluent_12\NN\14778436|NONE_0 (r_pobj) of_9\IN\0|the_18 (r_prep) concentration_8\NN\4916342|after_10|was_37 (r_nsubjpass) lowered_14\VBN\1850315|frequency_86|._7 (r_advcl) decreased_5\VBD\169651|NONE_0 (l_nsubj) frequency_1\NN\15286249|lowered_86|._93 (l_prep) of_2\IN\0|the_14 (l_pobj) loss_4\NN\13252973|NONE_0
D002330_D001254 NONE bcnu_29\NNP\0|arterial_9 (r_compound) therapy_30\NN\657604|NONE_0 (r_pobj) of_25\IN\0|eight_14 (r_prep) courses_24\NNS\883297|patients_126|._38 (r_dobj) received_20\VBD\2210855|NONE_0 (l_nsubj) patients_3\NNS\9898892|courses_126|._164 (l_prep) to_8\IN\0|four_37|with_23 (l_pobj) astrocytomas_10\NN\0|NONE_0
2522601
D002220_D051437 CID carbamazepine_2\NN\0|NONE_0 (r_pobj) to_1\IN\0|presenting_17|._100 (r_prep) hypersensitivity_0\NN\14531772|NONE_0 (l_acl) presenting_3\VBG\2137132|to_17|._83 (l_prep) with_4\IN\0|NONE_0 (l_pobj) reaction_7\NN\13446390|NONE_0 (l_conj) failure_15\NN\66216|a_60|leukemoid_58|,_40|eosinophilia_38
D002220_D051437 CID carbamazepine_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) hypersensitivity_6\NN\14531772|in_8|with_44 (r_nsubj) presented_9\VBN\2137132|a_52|,_39|reaction_60 (r_relcl) patient_3\NN\9898892|we_12|._165 (l_conj) reaction_17\NN\13446390|a_112|presented_60|,_21 (l_conj) eosinophilia_19\NN\14299637|a_29|severe_27|leukemoid_20|,_2 (l_conj) hyponatremia_21\NN\14299637|,_2 (l_conj) failure_25\NN\66216|,_12|and_10
D002220_D004802 NONE carbamazepine_2\NN\0|NONE_0 (r_pobj) to_1\IN\0|presenting_17|._100 (r_prep) hypersensitivity_0\NN\14531772|NONE_0 (l_acl) presenting_3\VBG\2137132|to_17|._83 (l_prep) with_4\IN\0|NONE_0 (l_pobj) reaction_7\NN\13446390|NONE_0 (l_conj) eosinophilia_9\NN\14299637|a_22|leukemoid_20|,_2|failure_38
D002220_D004802 NONE carbamazepine_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) hypersensitivity_6\NN\14531772|in_8|with_44 (r_nsubj) presented_9\VBN\2137132|a_52|,_39|reaction_60 (r_relcl) patient_3\NN\9898892|we_12|._165 (l_conj) reaction_17\NN\13446390|a_112|presented_60|,_21 (l_conj) eosinophilia_19\NN\14299637|a_29|severe_27|leukemoid_20|,_2
D002220_D004342 CID carbamazepine_2\NN\0|NONE_0 (r_pobj) to_1\IN\0|presenting_17|._100 (r_prep) hypersensitivity_0\NN\14531772|NONE_0
D002220_D004342 CID carbamazepine_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) hypersensitivity_6\NN\14531772|in_8|with_44
D002220_D007955 CID carbamazepine_2\NN\0|NONE_0 (r_pobj) to_1\IN\0|presenting_17|._100 (r_prep) hypersensitivity_0\NN\14531772|NONE_0 (l_acl) presenting_3\VBG\2137132|to_17|._83 (l_prep) with_4\IN\0|NONE_0 (l_pobj) reaction_7\NN\13446390|NONE_0
D002220_D007955 CID carbamazepine_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) hypersensitivity_6\NN\14531772|in_8|with_44 (r_nsubj) presented_9\VBN\2137132|a_52|,_39|reaction_60 (r_relcl) patient_3\NN\9898892|we_12|._165 (l_conj) reaction_17\NN\13446390|a_112|presented_60|,_21
D002220_D007010 CID carbamazepine_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) hypersensitivity_6\NN\14531772|in_8|with_44 (r_nsubj) presented_9\VBN\2137132|a_52|,_39|reaction_60 (r_relcl) patient_3\NN\9898892|we_12|._165 (l_conj) reaction_17\NN\13446390|a_112|presented_60|,_21 (l_conj) eosinophilia_19\NN\14299637|a_29|severe_27|leukemoid_20|,_2 (l_conj) hyponatremia_21\NN\14299637|,_2
D002220_D003873 CID carbamazepine_2\NN\0|NONE_0 (r_pobj) to_1\IN\0|presenting_17|._100 (r_prep) hypersensitivity_0\NN\14531772|NONE_0 (l_acl) presenting_3\VBG\2137132|to_17|._83 (l_prep) with_4\IN\0|NONE_0 (l_pobj) reaction_7\NN\13446390|NONE_0 (l_conj) eosinophilia_9\NN\14299637|a_22|leukemoid_20|,_2|failure_38 (l_conj) erythroderma_11\NN\14219661|,_2
D002220_D003873 CID carbamazepine_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) hypersensitivity_6\NN\14531772|in_8|with_44 (r_nsubj) presented_9\VBN\2137132|a_52|,_39|reaction_60 (l_prep) with_10\IN\0|in_52|hypersensitivity_44 (l_pobj) erythroderma_12\NN\14219661|NONE_0
11426838
C050232_D064420 NONE tolylguanidine_22\NN\0|the_51|agonist_13|)_19|and_21|bd1031_58 (r_nmod) dtg_24\NNP\0|the_93|putative_89|,_69 (r_appos) antagonists_9\NNS\7846|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) provided_5\VBN\2199590|the_15 (r_acl) protection_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) contrast_1\NN\13854649|NONE_0 (r_pobj) in_0\IN\13603305|each_251|toxicity_280|._299 (r_prep) worsened_37\VBD\146138|NONE_0 (l_dobj) toxicity_40\NN\13576101|in_280|each_29|._19
C050232_D064420 NONE dtg_24\NNP\0|the_93|putative_89|,_69 (r_appos) antagonists_9\NNS\7846|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) provided_5\VBN\2199590|the_15 (r_acl) protection_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) contrast_1\NN\13854649|NONE_0 (r_pobj) in_0\IN\13603305|each_251|toxicity_280|._299 (r_prep) worsened_37\VBD\146138|NONE_0 (l_dobj) toxicity_40\NN\13576101|in_280|each_29|._19
D003042_D064420 NONE cocaine_42\NN\3492717|NONE_0 (r_pobj) of_41\IN\0|the_24|behavioral_20 (r_prep) toxicity_40\NN\13576101|in_280|each_29|._19
C093337_D012640 NONE bd1063_12\NNP\0|,_2 (r_conj) bd1018_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|treatment_18|significantly_30 (r_punct) attenuated_17\VBD\224901|induced_19|and_39|lethality_43 (r_amod) convulsions_21\NNS\14081375|studies_102|._25
D009838_D012640 NONE oligodeoxynucleotide_23\NN\0|sigma_30|,_15 (r_appos) receptors_19\NNS\5225602|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) antagonism_16\NN\24720|NONE_0 (r_dobj) involved_15\VBD\2676054|the_18|novel_14 (r_acl) ligands_14\NNS\20090|NONE_0 (r_pobj) of_11\IN\0|the_25|cocaine_16 (r_prep) effects_10\NNS\13245626|that_22|was_128|also_132|attenuate_160 (r_nsubjpass) shown_29\VBN\2137132|the_174 (l_xcomp) attenuate_32\VB\224901|that_182|effects_160|was_32|also_28 (l_dobj) effects_38\NNS\13245626|to_68|significantly_65 (l_amod) convulsive_34\JJ\0|the_4|stimulatory_25|of_45
-1_D012640 NONE bd1018_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|treatment_18|significantly_30 (r_punct) attenuated_17\VBD\224901|induced_19|and_39|lethality_43 (r_amod) convulsions_21\NNS\14081375|studies_102|._25
-1_D012640 NONE lr132_15\NNS\0|,_5|or_3 (r_conj) bd1063_12\NNP\0|,_2 (r_conj) bd1018_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|treatment_18|significantly_30 (r_punct) attenuated_17\VBD\224901|induced_19|and_39|lethality_43 (r_amod) convulsions_21\NNS\14081375|studies_102|._25
D003042_D012640 CID cocaine_18\NN\3492717|-_7 (r_npadvmod) induced_20\VBN\1627355|attenuated_19|and_20|lethality_24 (r_amod) convulsions_21\NNS\14081375|studies_102|._25
D003042_D012640 CID cocaine_9\NN\3492717|the_9|of_16 (r_compound) effects_10\NNS\13245626|that_22|was_128|also_132|attenuate_160 (r_nsubjpass) shown_29\VBN\2137132|the_174 (l_xcomp) attenuate_32\VB\224901|that_182|effects_160|was_32|also_28 (l_dobj) effects_38\NNS\13245626|to_68|significantly_65 (l_amod) convulsive_34\JJ\0|the_4|stimulatory_25|of_45
D003042_D012640 CID cocaine_40\NN\3492717|NONE_0 (r_pobj) of_39\IN\0|the_49|convulsive_45|stimulatory_20 (r_prep) effects_38\NNS\13245626|to_68|significantly_65 (l_amod) convulsive_34\JJ\0|the_4|stimulatory_25|of_45
-1_D064420 NONE bd1031_32\NN\0|the_109|agonist_71|tolylguanidine_58|)_39|and_37 (r_conj) dtg_24\NNP\0|the_93|putative_89|,_69 (r_appos) antagonists_9\NNS\7846|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) provided_5\VBN\2199590|the_15 (r_acl) protection_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) contrast_1\NN\13854649|NONE_0 (r_pobj) in_0\IN\13603305|each_251|toxicity_280|._299 (r_prep) worsened_37\VBD\146138|NONE_0 (l_dobj) toxicity_40\NN\13576101|in_280|each_29|._19
-1_D064420 NONE 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_34\NN\0|the_41|novel_37|agonist_16 (r_appos) bd1031_32\NN\0|the_109|agonist_71|tolylguanidine_58|)_39|and_37 (r_conj) dtg_24\NNP\0|the_93|putative_89|,_69 (r_appos) antagonists_9\NNS\7846|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) provided_5\VBN\2199590|the_15 (r_acl) protection_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) contrast_1\NN\13854649|NONE_0 (r_pobj) in_0\IN\13603305|each_251|toxicity_280|._299 (r_prep) worsened_37\VBD\146138|NONE_0 (l_dobj) toxicity_40\NN\13576101|in_280|each_29|._19
19957053
D004809_D002534 NONE ephedrine_3\JJ\14712692|but_8 (r_conj) phenylephrine_0\NNP\2682038|oxygenation_53|._105 (r_nsubj) reduces_4\VBZ\441445|NONE_0 (l_dobj) oxygenation_7\NN\13518963|phenylephrine_53|._52
D004809_D007022 NONE ephedrine_3\JJ\14712692|but_8 (r_conj) phenylephrine_0\NNP\2682038|oxygenation_53|._105 (r_nsubj) reduces_4\VBZ\441445|NONE_0 (l_dobj) oxygenation_7\NN\13518963|phenylephrine_53|._52 (l_prep) following_8\VBG\8180190|frontal_25|lobe_17 (l_dobj) hypotension_12\NN\14057371|NONE_0
D004809_D007022 NONE ephedrine_7\JJ\14712692|and_4 (r_conj) phenylephrine_5\NN\2682038|NONE_0 (r_pobj) of_4\IN\0|the_11|on_31 (r_prep) effect_3\NN\34213|we_16|following_77|._117 (r_dobj) describe_1\VBP\1001294|NONE_0 (l_prep) following_16\VBG\8180190|we_93|effect_77|._40 (l_dobj) hypotension_20\NN\14057371|NONE_0
D004809_D007022 NONE ephedrine_18\JJ\14712692|while_6|oxygenation_33 (r_nsubj) maintains_19\VBZ\0|utilization_124|impact_35|)_18|._75 (r_advcl) has_10\VBZ\13888491|NONE_0 (l_nsubj) utilization_1\NN\407535|impact_89|)_106|maintains_124|._199 (l_acl) correct_5\VB\138508|the_36|of_20 (l_dobj) hypotension_6\NN\14057371|to_11
D010656_D007022 NONE phenylephrine_0\NNP\2682038|oxygenation_53|._105 (r_nsubj) reduces_4\VBZ\441445|NONE_0 (l_dobj) oxygenation_7\NN\13518963|phenylephrine_53|._52 (l_prep) following_8\VBG\8180190|frontal_25|lobe_17 (l_dobj) hypotension_12\NN\14057371|NONE_0
D010656_D007022 NONE phenylephrine_5\NN\2682038|NONE_0 (r_pobj) of_4\IN\0|the_11|on_31 (r_prep) effect_3\NN\34213|we_16|following_77|._117 (r_dobj) describe_1\VBP\1001294|NONE_0 (l_prep) following_16\VBG\8180190|we_93|effect_77|._40 (l_dobj) hypotension_20\NN\14057371|NONE_0
D010656_D007022 NONE phenylephrine_3\NN\2682038|NONE_0 (r_pobj) of_2\IN\0|the_16|correct_20 (r_prep) utilization_1\NN\407535|impact_89|)_106|maintains_124|._199 (l_acl) correct_5\VB\138508|the_36|of_20 (l_dobj) hypotension_6\NN\14057371|to_11
D010656_D002534 CID phenylephrine_0\NNP\2682038|oxygenation_53|._105 (r_nsubj) reduces_4\VBZ\441445|NONE_0 (l_dobj) oxygenation_7\NN\13518963|phenylephrine_53|._52
12684739
D004298_D019966 NONE dopamine_47\NN\14807737|(_7 (r_appos) accumbens_43\NNS\0|given_250|,_94|we_92|effects_76|._30 (r_oprd) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0
D004298_D019966 NONE da_49\NNP\10484858|nacc_16|)_12|(_1|)_2 (r_appos) dopamine_47\NN\14807737|(_7 (r_appos) accumbens_43\NNS\0|given_250|,_94|we_92|effects_76|._30 (r_oprd) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0
D003042_D005128 NONE cocaine_37\NN\3492717|-_7 (r_npadvmod) induced_39\VBN\1627355|in_18 (r_amod) increases_40\NNS\13576355|NONE_0 (r_pobj) on_36\IN\0|chronic_21|dose_9 (r_prep) gvg_35\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) effects_28\NNS\13245626|given_174|,_18|we_16|accumbens_76|._106 (r_dobj) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0
D003042_D005128 NONE cocaine_37\NN\3492717|-_7 (r_npadvmod) induced_39\VBN\1627355|in_18 (r_amod) increases_40\NNS\13576355|NONE_0 (r_pobj) on_36\IN\0|chronic_21|dose_9 (r_prep) gvg_35\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) effects_28\NNS\13245626|given_174|,_18|we_16|accumbens_76|._106 (r_dobj) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0 (l_appos) vfd_17\NNP\0|visual_22|field_15|associated_5
D004298_D005128 NONE dopamine_47\NN\14807737|(_7 (r_appos) accumbens_43\NNS\0|given_250|,_94|we_92|effects_76|._30 (r_oprd) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0
D004298_D005128 NONE dopamine_47\NN\14807737|(_7 (r_appos) accumbens_43\NNS\0|given_250|,_94|we_92|effects_76|._30 (r_oprd) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0 (l_appos) vfd_17\NNP\0|visual_22|field_15|associated_5
D004298_D005128 NONE da_49\NNP\10484858|nacc_16|)_12|(_1|)_2 (r_appos) dopamine_47\NN\14807737|(_7 (r_appos) accumbens_43\NNS\0|given_250|,_94|we_92|effects_76|._30 (r_oprd) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0
D004298_D005128 NONE da_49\NNP\10484858|nacc_16|)_12|(_1|)_2 (r_appos) dopamine_47\NN\14807737|(_7 (r_appos) accumbens_43\NNS\0|given_250|,_94|we_92|effects_76|._30 (r_oprd) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0 (l_appos) vfd_17\NNP\0|visual_22|field_15|associated_5
D020888_D005128 CID gvg_35\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) effects_28\NNS\13245626|given_174|,_18|we_16|accumbens_76|._106 (r_dobj) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0
D020888_D005128 CID gvg_35\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) effects_28\NNS\13245626|given_174|,_18|we_16|accumbens_76|._106 (r_dobj) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0 (l_conj) risk_11\NN\14541044|substance_34|and_18 (l_prep) of_12\IN\0|the_19|increased_15 (l_pobj) defects_15\NNS\14462666|NONE_0 (l_appos) vfd_17\NNP\0|visual_22|field_15|associated_5
D020888_D019966 NONE gvg_35\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) effects_28\NNS\13245626|given_174|,_18|we_16|accumbens_76|._106 (r_dobj) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0
D003042_D019966 NONE cocaine_37\NN\3492717|-_7 (r_npadvmod) induced_39\VBN\1627355|in_18 (r_amod) increases_40\NNS\13576355|NONE_0 (r_pobj) on_36\IN\0|chronic_21|dose_9 (r_prep) gvg_35\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) effects_28\NNS\13245626|given_174|,_18|we_16|accumbens_76|._106 (r_dobj) explored_26\VBD\789138|NONE_0 (l_prep) given_0\VBN\5892096|,_156|we_158|effects_174|accumbens_250|._280 (l_pobj) success_3\NN\7283608|NONE_0 (l_prep) for_4\IN\0|its_24|preclinical_20 (l_pcomp) treating_5\VBG\2376958|NONE_0 (l_dobj) abuse_7\NN\418025|NONE_0
17919553
C106791_D064420 NONE telithromycin_15\NNS\0|based_78|,_2|cause_31|,_71|and_73|suggested_99 (r_nsubj) was_16\VBD\0|NONE_0 (l_prep) based_0\VBN\0|,_76|telithromycin_78|cause_109|,_149|and_151|suggested_177 (l_prep) on_1\IN\0|NONE_0 (l_pobj) score_3\NN\5736149|NONE_0 (l_prep) on_6\IN\0|a_13|of_5 (l_pobj) scale_13\NN\7260623|NONE_0 (l_compound) probability_12\NN\33615|the_34 (l_compound) reaction_11\NN\13446390|NONE_0
C106791_D056486 CID telithromycin_6\NNS\0|NONE_0 (r_relcl) exposure_4\NN\5042871|NONE_0 (r_pobj) after_3\IN\0|acute_23|hepatitis_17|._31 (r_prep) attack_2\NN\955060|NONE_0 (l_compound) hepatitis_1\NNP\14127211|acute_6|after_17|._48
C106791_D056486 CID telithromycin_19\NNS\0|NONE_0 (r_compound) usage_20\NN\407535|NONE_0 (r_pobj) after_18\IN\0|suffered_82|,_17|"_16|that_14|._25 (r_prep) occurred_17\VBD\0|NONE_0 (l_ccomp) suffered_3\VBN\2110220|,_65|"_66|that_68|after_82|._107 (l_dobj) episode_6\NN\7283608|patient_32|had_24 (l_prep) of_7\IN\0|a_19|previous_17 (l_pobj) hepatitis_10\NN\14127211|NONE_0
C106791_D056486 CID telithromycin_15\NNS\0|based_78|,_2|cause_31|,_71|and_73|suggested_99 (r_nsubj) was_16\VBD\0|NONE_0 (l_attr) cause_19\NN\7323922|based_109|,_33|telithromycin_31|,_40|and_42|suggested_68 (l_prep) of_20\IN\0|the_19|probable_15 (l_pobj) hepatitis_22\NN\14127211|NONE_0
C106791_D056486 CID telithromycin_15\NNS\0|based_78|,_2|cause_31|,_71|and_73|suggested_99 (r_nsubj) was_16\VBD\0|NONE_0 (l_conj) suggested_30\VBD\1010118|based_177|,_101|telithromycin_99|cause_68|,_28|and_26 (l_dobj) hepatitis_35\NN\14127211|findings_38|._9
C106791_D056486 CID telithromycin_21\NNS\0|who_15|time_25 (r_dobj) prescribed_20\VBD\748282|the_28|attending_24 (r_relcl) physician_18\NN\10305802|NONE_0 (r_pobj) to_15\IN\0|if_46|incident_31|had_22|been_18 (r_prep) communicated_14\VBN\2231661|recurrence_88|might_57|have_51|been_46|._84 (r_advcl) avoided_7\VBN\0|NONE_0 (l_nsubjpass) recurrence_0\NN\7342049|might_31|have_37|been_42|communicated_88|._172 (l_prep) of_1\IN\0|NONE_0 (l_pobj) attack_3\NN\955060|NONE_0 (l_compound) hepatitis_2\NN\14127211|NONE_0
C106791_D056486 CID telithromycin_14\NNS\0|NONE_0 (r_pobj) of_13\IN\0|the_19 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) with_10\IN\0|probably_20 (r_prep) associated_9\VBN\628491|a_35|of_28 (r_acl) case_4\NN\7283608|here_17|we_12|._84 (l_prep) of_5\IN\0|a_7|associated_28 (l_pobj) hepatitis_7\NN\14127211|NONE_0
7248170
D010634_D005355 NONE phenobarbitone_0\NNP\2792049|-_14 (r_npadvmod) induced_2\VBN\1627355|of_20|:_43|relationship_49|._103 (r_amod) enlargement_3\NN\363260|NONE_0 (l_appos) relationship_12\NN\31921|induced_49|of_29|:_6|._54 (l_prep) to_13\TO\0|its_17 (l_pobj) cirrhosis_18\NN\14116321|NONE_0
D010634_D008103 CID phenobarbitone_60\NN\2792049|-_14 (r_npadvmod) primed_62\VBN\406243|the_19 (r_amod) rat_63\NN\2329401|NONE_0 (r_pobj) in_58\IN\13603305|ascites_213|tetrachloride_37|intragastrically_17|increased_37|._194 (r_prep) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_nsubj) yield_1\NN\913705|greater_120|,_138|albumin_147 (l_prep) of_2\IN\0|the_10 (l_pobj) cirrhosis_4\NN\14116321|NONE_0 (l_prep) of_5\IN\0|severe_17 (l_pobj) liver_7\NN\5298729|NONE_0
D010634_D008103 CID phenobarbitone_88\NN\2792049|-_14 (r_npadvmod) induced_90\VBN\1627355|the_19|of_20 (r_amod) enlargement_91\NN\363260|NONE_0 (r_pobj) of_86\IN\0|the_9 (r_prep) peak_85\NN\13758296|NONE_0 (r_pobj) at_83\IN\14622893|calibrating_42 (r_prep) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_nsubj) yield_1\NN\913705|greater_120|,_138|albumin_147 (l_prep) of_2\IN\0|the_10 (l_pobj) cirrhosis_4\NN\14116321|NONE_0 (l_prep) of_5\IN\0|severe_17 (l_pobj) liver_7\NN\5298729|NONE_0
D002251_D013163 NONE tetrachloride_55\NN\14818238|ascites_176|intragastrically_20|in_37|increased_74|._231 (r_advmod) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2
D002251_D013163 NONE tetrachloride_82\NN\14818238|the_41|initial_37|"_29|"_17|dose_15 (r_advmod) calibrating_77\VBG\296178|at_42 (r_dative) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2
D010634_D001201 NONE phenobarbitone_60\NN\2792049|-_14 (r_npadvmod) primed_62\VBN\406243|the_19 (r_amod) rat_63\NN\2329401|NONE_0 (r_pobj) in_58\IN\13603305|ascites_213|tetrachloride_37|intragastrically_17|increased_37|._194 (r_prep) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407
D010634_D001201 NONE phenobarbitone_88\NN\2792049|-_14 (r_npadvmod) induced_90\VBN\1627355|the_19|of_20 (r_amod) enlargement_91\NN\363260|NONE_0 (r_pobj) of_86\IN\0|the_9 (r_prep) peak_85\NN\13758296|NONE_0 (r_pobj) at_83\IN\14622893|calibrating_42 (r_prep) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407
D002251_D008103 CID tetrachloride_55\NN\14818238|ascites_176|intragastrically_20|in_37|increased_74|._231 (r_advmod) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_nsubj) yield_1\NN\913705|greater_120|,_138|albumin_147 (l_prep) of_2\IN\0|the_10 (l_pobj) cirrhosis_4\NN\14116321|NONE_0 (l_prep) of_5\IN\0|severe_17 (l_pobj) liver_7\NN\5298729|NONE_0
D002251_D008103 CID tetrachloride_82\NN\14818238|the_41|initial_37|"_29|"_17|dose_15 (r_advmod) calibrating_77\VBG\296178|at_42 (r_dative) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_nsubj) yield_1\NN\913705|greater_120|,_138|albumin_147 (l_prep) of_2\IN\0|the_10 (l_pobj) cirrhosis_4\NN\14116321|NONE_0 (l_prep) of_5\IN\0|severe_17 (l_pobj) liver_7\NN\5298729|NONE_0
D010634_D006529 CID phenobarbitone_0\NNP\2792049|-_14 (r_npadvmod) induced_2\VBN\1627355|of_20|:_43|relationship_49|._103 (r_amod) enlargement_3\NN\363260|NONE_0 (l_prep) of_4\IN\0|induced_20|:_23|relationship_29|._83 (l_pobj) liver_6\NN\5298729|NONE_0
D010634_D006529 CID phenobarbitone_60\NN\2792049|-_14 (r_npadvmod) primed_62\VBN\406243|the_19 (r_amod) rat_63\NN\2329401|NONE_0 (r_pobj) in_58\IN\13603305|ascites_213|tetrachloride_37|intragastrically_17|increased_37|._194 (r_prep) given_56\VBN\5892096|NONE_0 (l_conj) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (l_prep) by_72\IN\0|was_30|from_16 (l_pcomp) giving_73\VBG\1085793|NONE_0 (l_prep) at_83\IN\14622893|calibrating_42 (l_pobj) peak_85\NN\13758296|NONE_0 (l_prep) of_86\IN\0|the_9 (l_pobj) enlargement_91\NN\363260|NONE_0 (l_prep) of_92\IN\0|the_39|induced_20 (l_pobj) liver_94\NN\5298729|NONE_0
D010634_D006529 CID phenobarbitone_88\NN\2792049|-_14 (r_npadvmod) induced_90\VBN\1627355|the_19|of_20 (r_amod) enlargement_91\NN\363260|NONE_0 (l_prep) of_92\IN\0|the_39|induced_20 (l_pobj) liver_94\NN\5298729|NONE_0
D002251_D006529 NONE tetrachloride_15\NN\14818238|-_13 (r_advmod) induced_17\VBN\1627355|carbon_21 (r_amod) cirrhosis_18\NN\14116321|NONE_0 (r_pobj) to_13\TO\0|its_17 (r_prep) relationship_12\NN\31921|induced_49|of_29|:_6|._54 (r_appos) enlargement_3\NN\363260|NONE_0 (l_prep) of_4\IN\0|induced_20|:_23|relationship_29|._83 (l_pobj) liver_6\NN\5298729|NONE_0
D002251_D006529 NONE tetrachloride_55\NN\14818238|ascites_176|intragastrically_20|in_37|increased_74|._231 (r_advmod) given_56\VBN\5892096|NONE_0 (l_conj) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (l_prep) by_72\IN\0|was_30|from_16 (l_pcomp) giving_73\VBG\1085793|NONE_0 (l_prep) at_83\IN\14622893|calibrating_42 (l_pobj) peak_85\NN\13758296|NONE_0 (l_prep) of_86\IN\0|the_9 (l_pobj) enlargement_91\NN\363260|NONE_0 (l_prep) of_92\IN\0|the_39|induced_20 (l_pobj) liver_94\NN\5298729|NONE_0
D002251_D006529 NONE tetrachloride_82\NN\14818238|the_41|initial_37|"_29|"_17|dose_15 (r_advmod) calibrating_77\VBG\296178|at_42 (r_dative) giving_73\VBG\1085793|NONE_0 (l_prep) at_83\IN\14622893|calibrating_42 (l_pobj) peak_85\NN\13758296|NONE_0 (l_prep) of_86\IN\0|the_9 (l_pobj) enlargement_91\NN\363260|NONE_0 (l_prep) of_92\IN\0|the_39|induced_20 (l_pobj) liver_94\NN\5298729|NONE_0
D010634_D001284 NONE phenobarbitone_60\NN\2792049|-_14 (r_npadvmod) primed_62\VBN\406243|the_19 (r_amod) rat_63\NN\2329401|NONE_0 (r_pobj) in_58\IN\13603305|ascites_213|tetrachloride_37|intragastrically_17|increased_37|._194 (r_prep) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2 (l_conj) atrophy_44\NN\14299637|2_33|,_17|and_15|after_42
D010634_D001284 NONE phenobarbitone_88\NN\2792049|-_14 (r_npadvmod) induced_90\VBN\1627355|the_19|of_20 (r_amod) enlargement_91\NN\363260|NONE_0 (r_pobj) of_86\IN\0|the_9 (r_prep) peak_85\NN\13758296|NONE_0 (r_pobj) at_83\IN\14622893|calibrating_42 (r_prep) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2 (l_conj) atrophy_44\NN\14299637|2_33|,_17|and_15|after_42
D002251_D001201 NONE tetrachloride_55\NN\14818238|ascites_176|intragastrically_20|in_37|increased_74|._231 (r_advmod) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407
D002251_D001201 NONE tetrachloride_82\NN\14818238|the_41|initial_37|"_29|"_17|dose_15 (r_advmod) calibrating_77\VBG\296178|at_42 (r_dative) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407
D010634_D013163 NONE phenobarbitone_60\NN\2792049|-_14 (r_npadvmod) primed_62\VBN\406243|the_19 (r_amod) rat_63\NN\2329401|NONE_0 (r_pobj) in_58\IN\13603305|ascites_213|tetrachloride_37|intragastrically_17|increased_37|._194 (r_prep) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2
D010634_D013163 NONE phenobarbitone_88\NN\2792049|-_14 (r_npadvmod) induced_90\VBN\1627355|the_19|of_20 (r_amod) enlargement_91\NN\363260|NONE_0 (r_pobj) of_86\IN\0|the_9 (r_prep) peak_85\NN\13758296|NONE_0 (r_pobj) at_83\IN\14622893|calibrating_42 (r_prep) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2
D002251_D005355 NONE tetrachloride_15\NN\14818238|-_13 (r_advmod) induced_17\VBN\1627355|carbon_21 (r_amod) cirrhosis_18\NN\14116321|NONE_0
D002251_D001284 NONE tetrachloride_55\NN\14818238|ascites_176|intragastrically_20|in_37|increased_74|._231 (r_advmod) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2 (l_conj) atrophy_44\NN\14299637|2_33|,_17|and_15|after_42
D002251_D001284 NONE tetrachloride_82\NN\14818238|the_41|initial_37|"_29|"_17|dose_15 (r_advmod) calibrating_77\VBG\296178|at_42 (r_dative) giving_73\VBG\1085793|NONE_0 (r_pcomp) by_72\IN\0|was_30|from_16 (r_prep) increased_65\VBN\169651|ascites_250|tetrachloride_74|intragastrically_54|in_37|._157 (r_conj) given_56\VBN\5892096|NONE_0 (l_nsubj) ascites_20\VBZ\14204950|tetrachloride_176|intragastrically_196|in_213|increased_250|._407 (l_conj) albumin_27\NN\14736972|yield_147|greater_27|,_9 (l_conj) splenomegaly_35\JJ\14366759|plasma_35|less_20|,_2 (l_conj) atrophy_44\NN\14299637|2_33|,_17|and_15|after_42
17242861
D010862_D012640 NONE pilocarpine_4\NN\14712692|-_11 (r_npadvmod) induced_6\VBN\1627355|,_16|model_20|,_51 (r_amod) seizures_7\NNS\14081375|NONE_0
D010862_D012640 NONE pilocarpine_4\NN\14712692|-_11 (r_npadvmod) induced_6\VBN\1627355|,_16|model_20|,_51 (r_amod) seizures_7\NNS\14081375|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) susceptibility_2\NN\13920835|NONE_0 (r_pobj) for_1\IN\0|NONE_0 (r_prep) qtls_0\NNS\0|have_92|not_97|been_101|,_114|and_116|used_149 (r_nsubjpass) reported_19\VBN\831651|NONE_0 (l_conj) used_27\VBN\0|qtls_149|have_57|not_52|been_48|,_35|and_33 (l_xcomp) localize_29\VB\2694933|css_37|have_33|not_28|previously_24|been_13|._37 (l_dobj) genes_32\NNS\8459252|to_35 (l_compound) susceptibility_31\NN\13920835|NONE_0 (l_compound) seizure_30\NN\14081375|NONE_0
D010862_D012640 NONE pilocarpine_9\NN\14712692|-_11 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) seizures_12\NNS\14081375|NONE_0
D010862_D012640 NONE pilocarpine_23\NN\14712692|-_11 (r_npadvmod) induced_25\VBN\1627355|NONE_0 (r_amod) seizures_26\NNS\14081375|NONE_0
D010862_D004833 CID pilocarpine_4\NN\14712692|-_11 (r_npadvmod) induced_6\VBN\1627355|,_16|model_20|,_51 (r_amod) seizures_7\NNS\14081375|NONE_0 (l_appos) model_10\NN\5888929|induced_20|,_4|,_31 (l_prep) of_11\IN\0|a_8 (l_pobj) epilepsy_14\NN\14085708|NONE_0
15278670
D004737_D012640 NONE enflurane_12\NN\3299929|and_4 (r_conj) sevoflurane_10\NN\0|NONE_0 (r_pobj) between_9\IN\0|the_25|convulsive_21 (r_prep) threshold_8\NN\15265518|NONE_0 (l_amod) convulsive_7\JJ\0|the_4|between_21
D004737_D012640 NONE enflurane_14\NN\3299929|or_3 (r_conj) sevoflurane_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|higher_22 (r_prep) concentrations_10\NNS\4916342|when_12|were_43|and_61|decreased_99 (r_nsubjpass) administered_16\VBN\2436349|rise_102|marked_67|._126 (l_conj) decreased_23\VBD\169651|when_111|concentrations_99|were_56|and_38 (l_nsubj) pressure_20\NN\11419404|significantly_34|in_48|,_67|and_69|in_73 (l_prep) at_21\IN\14622893|the_19|blood_15 (l_pobj) convulsions_22\NNS\14081375|NONE_0
D004737_D012640 NONE enflurane_37\NN\3299929|0.8_14|and_9 (r_conj) %_33\NN\0|NONE_0 (r_pobj) in_31\IN\13603305|pressure_73|significantly_39|in_25|,_6|and_4 (r_conj) decreased_23\VBD\169651|when_111|concentrations_99|were_56|and_38 (l_nsubj) pressure_20\NN\11419404|significantly_34|in_48|,_67|and_69|in_73 (l_prep) at_21\IN\14622893|the_19|blood_15 (l_pobj) convulsions_22\NNS\14081375|NONE_0
D008012_D003866 NONE lidocaine_10\JJ\3681148|NONE_0 (r_compound) toxicity_11\NN\13576101|NONE_0 (r_pobj) of_9\IN\0|the_22|convulsive_18 (r_prep) effect_8\NN\34213|that_40|sevoflurane_35|but_29|carries_33 (r_dobj) reduces_5\VBZ\441445|it_33|is_30|._103 (l_conj) carries_13\VBZ\315986|that_73|sevoflurane_68|effect_33|but_4 (l_prep) due_16\IN\5174653|risk_5 (l_pcomp) to_17\IN\0|NONE_0 (l_pobj) depression_19\NN\14373582|NONE_0
C009250_D064420 NONE sevoflurane_4\NN\0|that_5|effect_35|but_64|carries_68 (r_nsubj) reduces_5\VBZ\441445|it_33|is_30|._103 (l_dobj) effect_8\NN\34213|that_40|sevoflurane_35|but_29|carries_33 (l_prep) of_9\IN\0|the_22|convulsive_18 (l_pobj) toxicity_11\NN\13576101|NONE_0
C009250_D003866 NONE sevoflurane_4\NN\0|that_5|effect_35|but_64|carries_68 (r_nsubj) reduces_5\VBZ\441445|it_33|is_30|._103 (l_conj) carries_13\VBZ\315986|that_73|sevoflurane_68|effect_33|but_4 (l_prep) due_16\IN\5174653|risk_5 (l_pcomp) to_17\IN\0|NONE_0 (l_pobj) depression_19\NN\14373582|NONE_0
D008012_D012640 CID lidocaine_5\NN\3681148|-_9 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) convulsions_8\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_5\NN\3681148|-_9 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) convulsions_8\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_16\NN\3681148|(_19|mg.kg(-1).min(-1_22|)_38 (r_compound) infusion_17\NN\14589223|NONE_0 (r_pobj) with_15\IN\0|threshold_51|+/-_18|)_2|)_44|,_45|increasing_47|._155 (r_prep) was_8\VBD\0|NONE_0 (l_nsubj) threshold_2\NN\15265518|+/-_33|)_49|with_51|)_95|,_96|increasing_98|._206 (l_amod) convulsive_1\JJ\0|the_4|(_21|mean_22|)_33
D008012_D012640 CID lidocaine_10\JJ\3681148|NONE_0 (r_compound) toxicity_11\NN\13576101|NONE_0 (r_pobj) of_9\IN\0|the_22|convulsive_18 (r_prep) effect_8\NN\34213|that_40|sevoflurane_35|but_29|carries_33 (l_amod) convulsive_7\JJ\0|the_4|of_18
C009250_D012640 NONE sevoflurane_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_12|on_15|._47 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_4\IN\0|the_27|of_15|._32 (l_pobj) convulsions_8\NNS\14081375|NONE_0
C009250_D012640 NONE sevoflurane_3\NN\0|NONE_0 (l_prep) on_4\IN\0|NONE_0 (l_pobj) convulsions_8\NNS\14081375|NONE_0
C009250_D012640 NONE sevoflurane_40\NN\0|NONE_0 (r_pobj) of_39\IN\0|the_28|tidal_20 (r_prep) concentration_38\NN\4916342|when_19|%_36 (r_nsubj) was_41\VBD\0|mg._58|)_50 (r_relcl) l(-1_31\NN\0|NONE_0 (r_pobj) to_26\IN\0|significantly_14 (r_prep) increasing_24\VBG\169651|threshold_98|+/-_65|)_49|with_47|)_3|,_2|._108 (r_advcl) was_8\VBD\0|NONE_0 (l_nsubj) threshold_2\NN\15265518|+/-_33|)_49|with_51|)_95|,_96|increasing_98|._206 (l_amod) convulsive_1\JJ\0|the_4|(_21|mean_22|)_33
C009250_D012640 NONE sevoflurane_10\NN\0|NONE_0 (r_pobj) between_9\IN\0|the_25|convulsive_21 (r_prep) threshold_8\NN\15265518|NONE_0 (l_amod) convulsive_7\JJ\0|the_4|between_21
C009250_D012640 NONE sevoflurane_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|higher_22 (r_prep) concentrations_10\NNS\4916342|when_12|were_43|and_61|decreased_99 (r_nsubjpass) administered_16\VBN\2436349|rise_102|marked_67|._126 (l_conj) decreased_23\VBD\169651|when_111|concentrations_99|were_56|and_38 (l_nsubj) pressure_20\NN\11419404|significantly_34|in_48|,_67|and_69|in_73 (l_prep) at_21\IN\14622893|the_19|blood_15 (l_pobj) convulsions_22\NNS\14081375|NONE_0
C009250_D012640 NONE sevoflurane_28\NN\0|NONE_0 (r_pobj) in_25\IN\13603305|pressure_48|significantly_14|,_19|and_21|in_25 (r_prep) decreased_23\VBD\169651|when_111|concentrations_99|were_56|and_38 (l_nsubj) pressure_20\NN\11419404|significantly_34|in_48|,_67|and_69|in_73 (l_prep) at_21\IN\14622893|the_19|blood_15 (l_pobj) convulsions_22\NNS\14081375|NONE_0
C009250_D012640 NONE sevoflurane_4\NN\0|that_5|effect_35|but_64|carries_68 (r_nsubj) reduces_5\VBZ\441445|it_33|is_30|._103 (l_dobj) effect_8\NN\34213|that_40|sevoflurane_35|but_29|carries_33 (l_amod) convulsive_7\JJ\0|the_4|of_18
D001030_D012640 NONE apamin_0\NNP\0|tendency_21|)_106|but_108|was_117 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) tendency_7\NN\6193203|apamin_21|)_85|but_87|was_96 (l_acl) decrease_9\VB\7296428|a_14 (l_dobj) threshold_12\NN\15265518|to_27 (l_amod) convulsive_11\JJ\0|the_4|(_21|+/-_27|)_59
D008012_D064420 NONE lidocaine_10\JJ\3681148|NONE_0 (r_compound) toxicity_11\NN\13576101|NONE_0
3856631
D001663_D052016 NONE bilirubin_10\NN\14756039|NONE_0 (r_amod) elevations_11\NNS\7445480|transient_43|serum_33|and_14|,_10|neutropenia_12 (r_conj) transaminase_8\NN\15077571|toxicities_44|._65 (l_appos) neutropenia_13\NN\14196405|transient_55|serum_45|and_26|elevations_12|,_2 (l_conj) mucositis_16\NN\0|,_6|and_4
D008727_D054198 NONE methotrexate_18\NNP\2722166|a_24|dose_17|intravenous_12|designed_30 (r_compound) regimen_19\NN\5898568|NONE_0 (r_pobj) with_12\IN\0|children_88|were_13|._191 (r_prep) treated_11\VBN\2376958|NONE_0 (l_nsubjpass) children_1\NNS\9622049|were_75|with_88|._279 (l_prep) with_2\IN\0|twenty_16|developed_38 (l_pobj) leukemia_5\NN\14239918|NONE_0
D008727_D054198 NONE methotrexate_28\NNP\2722166|csf_4|of_28 (r_compound) concentrations_29\NNS\4916342|without_31 (r_dobj) maintain_26\VB\0|to_15|and_4 (r_conj) achieve_24\VB\2524171|that_21|was_16 (r_xcomp) designed_22\VBN\1631534|a_54|dose_47|intravenous_42|methotrexate_30 (r_relcl) regimen_19\NN\5898568|NONE_0 (r_pobj) with_12\IN\0|children_88|were_13|._191 (r_prep) treated_11\VBN\2376958|NONE_0 (l_nsubjpass) children_1\NNS\9622049|were_75|with_88|._279 (l_prep) with_2\IN\0|twenty_16|developed_38 (l_pobj) leukemia_5\NN\14239918|NONE_0
D008727_D054198 NONE methotrexate_4\NN\2722166|treatment_29|._125 (r_nsubj) is_5\VBZ\0|NONE_0 (l_attr) treatment_8\NN\654885|methotrexate_29|._96 (l_prep) for_9\IN\0|an_23|effective_20 (l_pobj) induction_11\NN\7450842|NONE_0 (l_prep) after_14\IN\0|the_27|of_13 (l_pobj) relapse_16\NN\66636|NONE_0 (l_prep) in_17\IN\13603305|meningeal_18 (l_pobj) leukemia_20\NN\14239918|NONE_0
D001663_D064420 NONE bilirubin_10\NN\14756039|NONE_0 (r_amod) elevations_11\NNS\7445480|transient_43|serum_33|and_14|,_10|neutropenia_12 (r_conj) transaminase_8\NN\15077571|toxicities_44|._65 (r_attr) were_5\VBD\0|NONE_0 (l_nsubj) toxicities_3\NNS\13576101|transaminase_44|._109
D008727_D002493 NONE methotrexate_18\NNP\2722166|a_24|dose_17|intravenous_12|designed_30 (r_compound) regimen_19\NN\5898568|NONE_0 (r_pobj) with_12\IN\0|children_88|were_13|._191 (r_prep) treated_11\VBN\2376958|NONE_0 (l_nsubjpass) children_1\NNS\9622049|were_75|with_88|._279 (l_relcl) developed_7\VBD\1753788|twenty_54|with_38 (l_dobj) disease_9\NN\14061805|who_24
D008727_D002493 NONE methotrexate_28\NNP\2722166|csf_4|of_28 (r_compound) concentrations_29\NNS\4916342|without_31 (r_dobj) maintain_26\VB\0|to_15|and_4 (r_conj) achieve_24\VB\2524171|that_21|was_16 (r_xcomp) designed_22\VBN\1631534|a_54|dose_47|intravenous_42|methotrexate_30 (r_relcl) regimen_19\NN\5898568|NONE_0 (r_pobj) with_12\IN\0|children_88|were_13|._191 (r_prep) treated_11\VBN\2376958|NONE_0 (l_nsubjpass) children_1\NNS\9622049|were_75|with_88|._279 (l_relcl) developed_7\VBD\1753788|twenty_54|with_38 (l_dobj) disease_9\NN\14061805|who_24
D001663_D009503 NONE bilirubin_10\NN\14756039|NONE_0 (r_amod) elevations_11\NNS\7445480|transient_43|serum_33|and_14|,_10|neutropenia_12 (r_conj) transaminase_8\NN\15077571|toxicities_44|._65 (l_appos) neutropenia_13\NN\14196405|transient_55|serum_45|and_26|elevations_12|,_2
D008727_D008577 NONE methotrexate_10\NNP\2722166|NONE_0 (r_pobj) with_5\IN\0|meningeal_19 (r_prep) leukemia_4\NN\14239918|NONE_0
15957009
D014236_D008569 NONE metrifonate_15\NN\0|(_47|3_46|mg/kg_37|,_32|intraperitoneally_30|and_4|p.o._23 (r_conj) ro4368554_2\NNP\0|both_6|,_2|deficits_116|)_214|._215 (r_nsubj) reversed_24\VBD\109660|NONE_0 (l_dobj) deficits_26\NNS\5113133|both_122|,_118|ro4368554_116|)_98|._99
D012701_D008569 NONE 5-ht(6_45\CD\0|,_18|possibly_16|,_8|other_6|receptor_8 (r_compound) antagonists_48\NNS\7846|that_125|mechanisms_115|may_104|be_100|in_88|and_38 (r_conj) involved_31\VBN\2676054|NONE_0 (r_ccomp) suggesting_25\VBG\1010118|in_145|,_132|improve_103|,_63|it_61|cholinergic_47|,_2|._147 (r_advcl) reversed_16\VBD\109660|NONE_0 (l_dobj) cholinergic_18\JJ\0|in_98|,_85|improve_56|,_16|it_14|,_45|suggesting_47|._194 (l_conj) deficit_23\NN\5113133|a_40|and_26
D012601_D008569 CID scopolamine_29\NN\14712692|NONE_0 (r_pobj) by_28\IN\0|NONE_0 (r_agent) induced_27\VBN\1627355|memory_16 (r_acl) deficits_26\NNS\5113133|both_122|,_118|ro4368554_116|)_98|._99
C507242_D008569 NONE ro4368554_5\NN\0|antagonist_11|performance_26|in_38|._108 (r_nsubj) restores_6\VBZ\1631072|NONE_0 (l_prep) in_9\IN\13603305|antagonist_49|ro4368554_38|performance_12|._70 (l_pobj) models_13\NNS\5888929|NONE_0 (l_prep) of_14\IN\0|cholinergic_36|in_21 (l_pobj) deficiency_16\NN\14449126|NONE_0
C507242_D008569 NONE ro4368554_2\NNP\0|both_6|,_2|deficits_116|)_214|._215 (r_nsubj) reversed_24\VBD\109660|NONE_0 (l_dobj) deficits_26\NNS\5113133|both_122|,_118|ro4368554_116|)_98|._99
C507242_D008569 NONE ro4368554_4\NN\0|although_9|did_10|not_14|deficit_51 (r_nsubj) improve_7\VB\126264|in_42|,_29|,_40|it_42|cholinergic_56|,_101|suggesting_103|._250 (r_advcl) reversed_16\VBD\109660|NONE_0 (l_dobj) cholinergic_18\JJ\0|in_98|,_85|improve_56|,_16|it_14|,_45|suggesting_47|._194 (l_conj) deficit_23\NN\5113133|a_40|and_26
C507242_D008569 NONE ro4368554_39\NN\0|NONE_0 (r_pobj) by_38\IN\0|the_34|of_17 (r_prep) facilitation_34\NN\13920835|NONE_0 (r_pobj) in_32\IN\13603305|that_37|mechanisms_27|may_16|be_12|and_50|antagonists_88 (r_prep) involved_31\VBN\2676054|NONE_0 (r_ccomp) suggesting_25\VBG\1010118|in_145|,_132|improve_103|,_63|it_61|cholinergic_47|,_2|._147 (r_advcl) reversed_16\VBD\109660|NONE_0 (l_dobj) cholinergic_18\JJ\0|in_98|,_85|improve_56|,_16|it_14|,_45|suggesting_47|._194 (l_conj) deficit_23\NN\5113133|a_40|and_26
D014364_D008569 NONE trp_31\NNP\0|NONE_0 (r_compound) depletion_32\NN\351638|and_8|(_10|mg/kg_14|,_19|i.p._21|,_25|and_27|mg/kg_33 (r_conj) scopolamine_29\NN\14712692|NONE_0 (r_pobj) by_28\IN\0|NONE_0 (r_agent) induced_27\VBN\1627355|memory_16 (r_acl) deficits_26\NNS\5113133|both_122|,_118|ro4368554_116|)_98|._99
15188772
D004837_D009202 NONE epinephrine_15\NN\14807929|NONE_0 (r_pobj) of_14\IN\0|8_5 (r_prep) mg_13\NN\13717155|woman_59|markers_225|._255 (r_nsubj) developed_16\VBN\1753788|NONE_0 (l_dobj) markers_44\NNS\21939|woman_284|mg_225|._30 (l_prep) of_45\IN\0|stunning_194|elevated_29|biochemical_20 (l_pobj) necrosis_47\NN\11444117|NONE_0
D004837_D017682 CID epinephrine_15\NN\14807929|NONE_0 (r_pobj) of_14\IN\0|8_5 (r_prep) mg_13\NN\13717155|woman_59|markers_225|._255 (r_nsubj) developed_16\VBN\1753788|NONE_0 (l_dobj) markers_44\NNS\21939|woman_284|mg_225|._30 (l_amod) stunning_18\JJ\269140|elevated_165|biochemical_174|of_194
D004837_D062787 NONE epinephrine_12\NN\14807929|accidental_22|iatrogenic_11 (r_amod) overdose_13\NN\84738|to_37
D004837_D018487 NONE epinephrine_12\NN\14807929|accidental_22|iatrogenic_11 (r_amod) overdose_13\NN\84738|to_37 (r_pobj) due_8\IN\5174653|severe_70|left_52|ventricular_47|systolic_35|._49 (r_prep) dysfunction_7\NN\14204950|NONE_0
D004837_D018487 NONE epinephrine_15\NN\14807929|NONE_0 (r_pobj) of_14\IN\0|8_5 (r_prep) mg_13\NN\13717155|woman_59|markers_225|._255 (r_nsubj) developed_16\VBN\1753788|NONE_0 (l_dobj) markers_44\NNS\21939|woman_284|mg_225|._30 (l_amod) stunning_18\JJ\269140|elevated_165|biochemical_174|of_194 (l_relcl) characterized_21\VBN\609683|myocardial_29 (l_conj) left_32\VBD\8621598|that_85|was_80|by_62|,_51|and_53 (l_dobj) dysfunction_37\NN\14204950|NONE_0
D002395_D009202 NONE catecholamine_0\NN\5407119|-_13 (r_npadvmod) induced_2\VBN\1627355|due_23 (r_amod) cardiomyopathy_3\NN\14103288|has_66|been_70|for_86|._122
D002395_D009202 NONE catecholamines_10\NNS\5407119|NONE_0 (r_pobj) of_8\IN\0|chronic_15 (r_prep) excess_7\NN\5119367|to_11 (r_pobj) due_4\IN\5174653|induced_23 (r_prep) cardiomyopathy_3\NN\14103288|has_66|been_70|for_86|._122
17615423
C413408_D012206 CID atazanavir_16\NNS\0|,_6|and_4 (r_conj) amiodarone_13\NN\2715941|,_2 (r_conj) simvastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|concomitant_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|acute_20|renal_14 (r_amod) failure_5\NN\66216|severe_38|and_16|._79 (r_conj) rhabdomyolysis_1\NN\0|NONE_0
C413408_D012206 CID atazanavir_14\NNS\0|,_6|and_4 (l_acl) resulting_15\VBG\2633881|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) rhabdomyolysis_17\NN\0|NONE_0
D019821_D015658 NONE simvastatin_0\NNP\3676175|patient_33|human_43|virus_66 (r_nmod) medications_11\NNS\3247620|were_12|all_17|temporarily_21|and_46|given_66 (l_compound) virus_10\NN\9312843|simvastatin_66|patient_33|human_23
C413408_D058186 CID atazanavir_16\NNS\0|,_6|and_4 (r_conj) amiodarone_13\NN\2715941|,_2 (r_conj) simvastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|concomitant_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|acute_20|renal_14 (r_amod) failure_5\NN\66216|severe_38|and_16|._79
C413408_D058186 CID atazanavir_14\NNS\0|,_6|and_4 (l_acl) resulting_15\VBG\2633881|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) rhabdomyolysis_17\NN\0|NONE_0 (l_conj) failure_21\NN\66216|and_16
D000638_D012206 CID amiodarone_13\NN\2715941|,_2 (r_conj) simvastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|concomitant_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|acute_20|renal_14 (r_amod) failure_5\NN\66216|severe_38|and_16|._79 (r_conj) rhabdomyolysis_1\NN\0|NONE_0
D000638_D012206 CID amiodarone_11\NN\2715941|,_2 (l_conj) atazanavir_14\NNS\0|,_6|and_4 (l_acl) resulting_15\VBG\2633881|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) rhabdomyolysis_17\NN\0|NONE_0
D000638_D058186 CID amiodarone_13\NN\2715941|,_2 (r_conj) simvastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|concomitant_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|acute_20|renal_14 (r_amod) failure_5\NN\66216|severe_38|and_16|._79
D000638_D058186 CID amiodarone_11\NN\2715941|,_2 (l_conj) atazanavir_14\NNS\0|,_6|and_4 (l_acl) resulting_15\VBG\2633881|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) rhabdomyolysis_17\NN\0|NONE_0 (l_conj) failure_21\NN\66216|and_16
D000638_D015658 NONE amiodarone_2\NN\2715941|,_2 (r_conj) simvastatin_0\NNP\3676175|patient_33|human_43|virus_66 (r_nmod) medications_11\NNS\3247620|were_12|all_17|temporarily_21|and_46|given_66 (l_compound) virus_10\NN\9312843|simvastatin_66|patient_33|human_23
D019821_D058186 CID simvastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|concomitant_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|acute_20|renal_14 (r_amod) failure_5\NN\66216|severe_38|and_16|._79
D019821_D058186 CID simvastatin_9\NN\3676175|NONE_0 (l_conj) amiodarone_11\NN\2715941|,_2 (l_conj) atazanavir_14\NNS\0|,_6|and_4 (l_acl) resulting_15\VBG\2633881|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) rhabdomyolysis_17\NN\0|NONE_0 (l_conj) failure_21\NN\66216|and_16
D019821_D012206 CID simvastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|concomitant_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|acute_20|renal_14 (r_amod) failure_5\NN\66216|severe_38|and_16|._79 (r_conj) rhabdomyolysis_1\NN\0|NONE_0
D019821_D012206 CID simvastatin_9\NN\3676175|NONE_0 (l_conj) amiodarone_11\NN\2715941|,_2 (l_conj) atazanavir_14\NNS\0|,_6|and_4 (l_acl) resulting_15\VBG\2633881|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) rhabdomyolysis_17\NN\0|NONE_0
D019821_D012206 CID simvastatin_14\NN\3676175|NONE_0 (r_amod) metabolism_15\NN\13526110|that_25 (r_dobj) inhibit_13\VBP\2510337|concomitant_23 (r_relcl) drugs_11\NNS\14778436|NONE_0 (r_pobj) of_9\IN\0|the_13 (r_prep) presence_8\NN\13954253|NONE_0 (r_pobj) in_6\IN\13603305|risk_36|is_13|._72 (r_prep) increased_5\VBN\169651|NONE_0 (l_nsubjpass) risk_1\NN\14541044|is_23|in_36|._108 (l_prep) of_2\IN\0|the_9 (l_pobj) rhabdomyolysis_3\NN\0|NONE_0
12584269
D016559_D007674 CID fk506_14\NNP\0|whereas_8|was_15|better_19 (r_nsubjpass) tolerated_19\VBN\802318|study_103|effect_58|,_36|._9 (r_advcl) demonstrated_3\VBD\2137132|NONE_0 (l_dobj) effect_7\NN\34213|study_45|,_22|tolerated_58|._67 (l_amod) nephrotoxic_6\JJ\0|a_14|synergistic_12|of_19
D020123_D005355 NONE srl_3\NNP\0|fk506_11 (r_compound) combination_4\NN\7951464|degree_44|compared_66|._97 (r_nsubj) showed_5\VBD\2137132|NONE_0 (l_dobj) degree_10\NN\4916342|combination_44|compared_22|._53 (l_prep) of_11\IN\0|only_32|a_27|higher_14 (l_pobj) fibrosis_12\NN\14204950|NONE_0
D016572_D007674 CID csa_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|a_33|synergistic_31|nephrotoxic_19 (r_prep) effect_7\NN\34213|study_45|,_22|tolerated_58|._67 (l_amod) nephrotoxic_6\JJ\0|a_14|synergistic_12|of_19
D020123_D007674 CID srl_5\NN\0|act_13|,_70|is_95|._108 (r_nsubj) seems_6\VBZ\2604760|these_31|nephrotoxic_21|,_10|but_8 (r_conj) are_1\VBP\13600404|NONE_0 (l_acomp) nephrotoxic_2\JJ\0|these_10|,_11|but_13|seems_21
D020123_D007674 CID srl_5\NN\0|act_13|,_70|is_95|._108 (r_nsubj) seems_6\VBZ\2604760|these_31|nephrotoxic_21|,_10|but_8 (l_xcomp) act_8\VB\6479665|srl_13|,_57|is_82|._95 (l_advcl) displaying_10\VBG\2137132|to_19|differently_12 (l_dobj) effects_14\NNS\13245626|NONE_0 (l_amod) nephrotoxic_13\JJ\0|only_11|minor_6
D020123_D007674 CID srl_7\NN\0|where_6|was_4|with_17 (r_nsubjpass) combined_9\VBN\2630189|treatment_34 (l_prep) with_10\IN\0|where_23|srl_17|was_13 (l_pobj) indications_14\NNS\33020|NONE_0 (l_prep) of_15\IN\0|a_36|calcineurin_34|inhibitor_22 (l_pobj) effect_19\NN\34213|NONE_0 (l_amod) nephrotoxic_18\JJ\0|a_14|synergistic_12
D020123_D007674 CID srl_11\NNP\0|plus_5 (r_conj) csa_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|a_33|synergistic_31|nephrotoxic_19 (r_prep) effect_7\NN\34213|study_45|,_22|tolerated_58|._67 (l_amod) nephrotoxic_6\JJ\0|a_14|synergistic_12|of_19
D020123_D007674 CID srl_16\NNP\0|plus_5 (r_conj) fk506_14\NNP\0|whereas_8|was_15|better_19 (r_nsubjpass) tolerated_19\VBN\802318|study_103|effect_58|,_36|._9 (r_advcl) demonstrated_3\VBD\2137132|NONE_0 (l_dobj) effect_7\NN\34213|study_45|,_22|tolerated_58|._67 (l_amod) nephrotoxic_6\JJ\0|a_14|synergistic_12|of_19
D016559_D005355 NONE fk506_1\NNP\0|srl_11 (r_nmod) combination_4\NN\7951464|degree_44|compared_66|._97 (r_nsubj) showed_5\VBD\2137132|NONE_0 (l_dobj) degree_10\NN\4916342|combination_44|compared_22|._53 (l_prep) of_11\IN\0|only_32|a_27|higher_14 (l_pobj) fibrosis_12\NN\14204950|NONE_0
14976857
D011405_D054092 NONE propafenone_26\NN\0|a_2 (r_compound) overdose_27\NN\84738|NONE_0 (r_pobj) by_24\IN\0|was_26|probably_22 (r_agent) precipitated_23\VBN\1642924|shunt_123|in_72|,_19|and_17|._38 (r_conj) occurred_9\VBD\0|NONE_0 (l_nsubj) shunt_1\NN\5248181|in_51|,_104|and_106|precipitated_123|._161 (l_prep) via_4\IN\0|this_20|of_9 (l_pobj) ovale_8\NN\0|NONE_0
D011405_D004437 NONE propafenone_9\NN\0|in_21 (r_compound) overdose_10\NN\84738|NONE_0 (l_prep) in_11\IN\13603305|propafenone_21 (l_pobj) woman_14\NN\9605289|NONE_0 (l_prep) with_15\IN\0|a_14|young_12 (l_pobj) anomaly_18\NN\14501726|NONE_0
D011405_-1 NONE propafenone_9\NN\0|in_21 (r_compound) overdose_10\NN\84738|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|transient_46|like_14|._71 (r_acl) syndrome_6\NN\5870365|NONE_0
D011405_D062787 NONE propafenone_9\NN\0|in_21 (r_compound) overdose_10\NN\84738|NONE_0
D011405_D062787 NONE propafenone_26\NN\0|a_2 (r_compound) overdose_27\NN\84738|NONE_0
11166519
D003042_D012640 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) induced_3\VBN\1627355|acute_14|:_16|sensitivity_31|._70 (r_amod) seizures_4\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_22\NN\3492717|NONE_0 (r_pobj) of_21\IN\0|a_19|single_17 (r_prep) injection_20\NN\320852|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|behavioral_20 (r_acl) seizures_15\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_14\NN\3492717|-_7 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) seizures_17\NNS\14081375|NONE_0
6209318
D008801_D014202 CID mexiletine_16\NN\2715941|the_4 (r_amod) group_17\NN\2137|NONE_0 (r_pobj) in_14\IN\13603305|more_14|than_24 (r_prep) frequent_13\JJ\2556126|effects_70|._58 (r_acomp) were_11\VBD\0|NONE_0 (l_nsubj) effects_3\NNS\13245626|frequent_70|._128 (l_appos) tremor_6\JJ\345926|recognized_38|side_27|,_15|,_36
D008801_D012817 CID mexiletine_16\NN\2715941|the_4 (r_amod) group_17\NN\2137|NONE_0 (r_pobj) in_14\IN\13603305|more_14|than_24 (r_prep) frequent_13\JJ\2556126|effects_70|._58 (r_acomp) were_11\VBD\0|NONE_0 (l_nsubj) effects_3\NNS\13245626|frequent_70|._128 (l_appos) tremor_6\JJ\345926|recognized_38|side_27|,_15|,_36 (l_conj) problems_9\NNS\14408086|particularly_41|and_21
D008801_D009203 NONE mexiletine_9\NN\2715941|perlongets_20 (r_pobj) of_8\IN\0|the_27|sustained_23|release_13 (r_prep) form_7\NN\6286395|NONE_0 (r_pobj) of_3\IN\0|the_27|antiarrhythmic_23 (r_prep) effects_2\NNS\13245626|were_73|in_88|._180 (r_nsubjpass) evaluated_16\VBN\670261|NONE_0 (l_prep) in_17\IN\13603305|effects_88|were_15|._92 (l_pobj) trial_23\NN\786195|NONE_0 (l_prep) in_24\IN\13603305|a_29|blind_20|placebo_14 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|630_13 (l_pobj) infarction_31\NN\14204950|NONE_0
D008801_D009203 NONE perlongets_13\NNP\0|mexiletine_20 (r_pobj) of_8\IN\0|the_27|sustained_23|release_13 (r_prep) form_7\NN\6286395|NONE_0 (r_pobj) of_3\IN\0|the_27|antiarrhythmic_23 (r_prep) effects_2\NNS\13245626|were_73|in_88|._180 (r_nsubjpass) evaluated_16\VBN\670261|NONE_0 (l_prep) in_17\IN\13603305|effects_88|were_15|._92 (l_pobj) trial_23\NN\786195|NONE_0 (l_prep) in_24\IN\13603305|a_29|blind_20|placebo_14 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|630_13 (l_pobj) infarction_31\NN\14204950|NONE_0
D008801_D001145 NONE mexiletine_1\NN\2715941|international_14|antiarrhythmic_23|coronary_38|:_52|report_57|._96 (r_nmod) trial_6\NN\786195|NONE_0 (l_appos) report_9\NNP\6470073|international_71|mexiletine_57|antiarrhythmic_34|coronary_19|:_5|._39 (l_prep) on_10\IN\0|i._10 (l_pobj) arrhythmia_11\NN\14103288|NONE_0
D008801_D003643 NONE mexiletine_6\NN\2715941|the_4|(_17|%_21|)_22 (r_amod) group_7\NN\2137|NONE_0 (r_pobj) in_4\IN\13603305|more_12|than_31 (r_prep) deaths_3\NNS\7296428|there_16
20196116
D000995_D017114 CID antituberculosis_0\NNP\0|therapy_17|-_24|failure_45|profile_65|._110 (r_nsubj) induced_3\VBN\1627355|NONE_0 (l_dobj) failure_6\NN\66216|antituberculosis_45|therapy_28|-_21|profile_20|._65
D000995_D017114 CID antituberculosis_0\NN\0|(_25|failure_54 (r_compound) therapy_1\NN\657604|alf_85|._102 (l_appos) failure_6\NN\66216|antituberculosis_54|(_29
D000995_D017114 CID antituberculosis_0\NN\0|(_25|failure_54 (r_compound) therapy_1\NN\657604|alf_85|._102 (l_appos) failure_6\NN\66216|antituberculosis_54|(_29 (l_appos) alf_10\NNP\0|att)-associated_41|acute_25|liver_19|(_5|)_3
D000995_D017114 CID antituberculosis_0\NN\0|(_25|failure_54 (r_compound) therapy_1\NN\657604|alf_85|._102 (r_nsubj) is_12\VBZ\0|NONE_0 (l_attr) alf_18\NNP\0|therapy_85|._17
D001663_D001927 NONE bilirubin_11\NN\14756039|:_8 (l_appos) time_21\NN\7308889|serum_46|(_30|dl_17|)_15|,_14 (l_conj) encephalopathy_37\NN\14084880|prothrombin_70|prolongation_48|,_19|and_17
20477932
D003042_D064420 NONE cocaine_6\NN\3492717|including_17 (r_compound) toxicity_7\NN\13576101|NONE_0
D003042_D064420 NONE cocaine_24\NN\3492717|the_14|and_4 (r_conj) brain_22\NN\5462674|induced_18|-_25 (r_nmod) behaviour_27\NN\14006945|NONE_0 (r_pobj) in_20\IN\13603305|oxidative_17 (r_prep) status_19\NN\24720|NONE_0 (r_pobj) between_17\IN\0|the_16 (r_prep) association_16\NN\8008335|an_40|in_28|but_8 (r_conj) increase_10\NN\13576355|NONE_0 (r_pobj) including_8\VBG\0|cocaine_17 (r_prep) toxicity_7\NN\13576101|NONE_0
C052342_D008569 NONE topiramate_22\NN\0|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_prep) prevention_20\NN\1073995|of_52|,_6|and_4 (r_conj) involvement_9\NN\1080366|and_34|learning_30|:_2 (r_appos) memory_2\NN\5926676|cocaine_15|._129 (l_conj) learning_4\VBG\5701944|and_4|:_28|involvement_30 (l_dobj) impairments_5\NNS\7296428|NONE_0
D003042_D008569 CID cocaine_0\NN\3492717|memory_15|._144 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) memory_2\NN\5926676|cocaine_15|._129 (l_conj) learning_4\VBG\5701944|and_4|:_28|involvement_30 (l_dobj) impairments_5\NNS\7296428|NONE_0
D003042_D007859 CID cocaine_0\NN\3492717|memory_15|._144 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) memory_2\NN\5926676|cocaine_15|._129 (l_conj) learning_4\VBG\5701944|and_4|:_28|involvement_30 (l_dobj) impairments_5\NNS\7296428|NONE_0
C052342_D007859 NONE topiramate_22\NN\0|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_prep) prevention_20\NN\1073995|of_52|,_6|and_4 (r_conj) involvement_9\NN\1080366|and_34|learning_30|:_2 (r_appos) memory_2\NN\5926676|cocaine_15|._129 (l_conj) learning_4\VBG\5701944|and_4|:_28|involvement_30 (l_dobj) impairments_5\NNS\7296428|NONE_0
D003042_D019970 NONE cocaine_43\NN\3492717|NONE_0 (r_compound) administration_44\NN\1133281|NONE_0 (r_pobj) of_42\IN\0|an_22|experimental_19|in_26 (r_prep) model_41\NN\5888929|NONE_0 (r_pobj) in_38\IN\13603305|therefore_228|activity_209|were_15|._58 (r_prep) evaluated_37\VBN\670261|NONE_0 (l_nsubjpass) activity_2\NN\30358|therefore_19|were_194|in_209|._267 (l_appos) stress_5\NN\7083732|nfkappab_29|,_12|,_172 (l_conj) synthase_10\NN\0|oxidative_40|,_24 (l_conj) therapy_31\NN\657604|neuronal_135|nitric_126|oxide_119|(_104|activity_97|,_24 (l_prep) for_32\IN\0|a_30|proposed_17 (l_pobj) addiction_34\NN\14034177|NONE_0
D009569_D019970 NONE oxide_9\NN\14818238|neuronal_16|nitric_7|(_15|activity_22|,_95|therapy_119 (r_compound) synthase_10\NN\0|oxidative_40|,_24 (l_conj) therapy_31\NN\657604|neuronal_135|nitric_126|oxide_119|(_104|activity_97|,_24 (l_prep) for_32\IN\0|a_30|proposed_17 (l_pobj) addiction_34\NN\14034177|NONE_0
C052342_D019970 NONE topiramate_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|the_11 (r_prep) effect_24\NN\34213|spatial_43|and_26|memory_22|as_7 (r_conj) learning_17\NN\5701944|nnos_24|)_20|,_10 (r_conj) activity_14\NN\30358|neuronal_38|nitric_29|oxide_22|(_7|,_73|therapy_97 (r_conj) synthase_10\NN\0|oxidative_40|,_24 (l_conj) therapy_31\NN\657604|neuronal_135|nitric_126|oxide_119|(_104|activity_97|,_24 (l_prep) for_32\IN\0|a_30|proposed_17 (l_pobj) addiction_34\NN\14034177|NONE_0
7265370
C020743_D053040 NONE dyazide_3\RB\0|NONE_0 (r_compound) therapy_4\NN\657604|nephrolithiasis_37|._7 (r_dobj) complicating_2\VBG\126264|NONE_0 (l_nsubj) nephrolithiasis_1\JJ\14115914|therapy_37|._44
C020743_D053040 NONE triamterene_16\JJ\0|NONE_0 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_13\IN\0|4_8|for_43 (r_prep) years_12\NNS\15144371|NONE_0 (r_pobj) after_10\IN\0|case_57|is_21|in_9|._73 (r_prep) reported_6\VBN\831651|NONE_0 (l_nsubjpass) case_1\NN\7283608|is_36|in_48|after_57|._130 (l_prep) of_2\IN\0|a_7 (l_pobj) nephrolithiasis_4\NN\14115914|NONE_0
D014223_D053040 CID triamterene_0\JJ\0|NONE_0 (r_compound) nephrolithiasis_1\JJ\14115914|therapy_37|._44
D014223_D053040 CID triamterene_3\JJ\0|NONE_0 (r_compound) nephrolithiasis_4\NN\14115914|NONE_0
D014223_D053040 CID triamterene_2\JJ\0|NONE_0 (r_compound) nephrolithiasis_3\NN\14115914|NONE_0
D014223_D006973 NONE triamterene_3\JJ\0|NONE_0 (r_compound) nephrolithiasis_4\NN\14115914|NONE_0 (r_pobj) of_2\IN\0|a_7 (r_prep) case_1\NN\7283608|is_36|in_48|after_57|._130 (r_nsubjpass) reported_6\VBN\831651|NONE_0 (l_prep) after_10\IN\0|case_57|is_21|in_9|._73 (l_pobj) years_12\NNS\15144371|NONE_0 (l_prep) for_18\IN\0|4_51|of_43 (l_pobj) hypertension_19\NN\14057371|NONE_0
C020743_D006973 NONE triamterene_16\JJ\0|NONE_0 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_13\IN\0|4_8|for_43 (r_prep) years_12\NNS\15144371|NONE_0 (l_prep) for_18\IN\0|4_51|of_43 (l_pobj) hypertension_19\NN\14057371|NONE_0
424937
D008750_D056486 CID methyldopa_6\NN\2721160|NONE_0 (r_pobj) by_5\IN\0|patterns_35|._13 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubj) patterns_0\NNS\5726345|by_35|._48 (l_prep) of_1\IN\0|NONE_0 (l_pobj) injury_3\NN\14052046|NONE_0
D008750_D056486 CID methyldopa_22\NN\2721160|-_10 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) hepatitis_25\NN\14127211|NONE_0
D008750_D056486 CID methyldopa_14\NN\2721160|NONE_0 (r_pobj) between_13\IN\0|the_24|causal_20 (r_prep) relationship_12\NN\31921|in_52|in_24|,_13|was_56|with_67|._141 (r_nsubjpass) proved_19\VBN\2604760|NONE_0 (l_prep) with_20\IN\0|in_119|in_91|,_80|relationship_67|was_11|._74 (l_pobj) recurrence_22\NN\7342049|NONE_0 (l_prep) of_23\IN\0|the_15|within_13|to_43 (l_pobj) hepatitis_24\NN\14127211|NONE_0
D008750_D017114 NONE methyldopa_22\NN\2721160|-_10 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) hepatitis_25\NN\14127211|NONE_0 (r_pobj) of_21\IN\0|a_16|prior_14 (r_prep) episode_20\NN\7283608|NONE_0 (r_pobj) after_17\IN\0|when_50|drug_41|was_36|accidentally_32|year_5 (r_prep) recommenced_14\VBN\348746|patient_83|hepatitis_41|._72 (r_advcl) developed_6\VBD\1753788|NONE_0 (l_dobj) hepatitis_8\NN\14127211|patient_42|recommenced_41|._113
D008750_D017093 NONE methyldopa_17\NN\2721160|who_20|had_16|been_12|for_11 (r_dobj) taking_16\VBG\37396|,_15|,_29 (r_relcl) another_11\DT\0|resolution_92|over_103 (r_nsubj) showed_22\VBD\2137132|having_94|in_77|,_59|and_57 (r_conj) presented_5\VBN\2137132|patient_21|,_9|._168 (l_prep) in_6\IN\13603305|having_17|,_18|and_20|showed_77 (l_pobj) failure_8\NN\66216|NONE_0
D008750_D008107 NONE methyldopa_7\NN\2721160|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) related_5\VBN\628491|liver_14 (r_acl) disease_4\NN\14061805|NONE_0
D008750_D008107 NONE methyldopa_14\NN\2721160|NONE_0 (l_conj) dysfunction_17\NN\14204950|and_12
20470218
D008727_D056784 NONE methotrexate_32\NN\2722166|dose_5|(_22|n_23|2_27|)_28|,_29|syndrome_31 (r_compound) toxicity_33\NN\13576101|posterior_131|reversible_121|leukoencephalopathy_110|(_81|n_80|)_74|,_73|stroke_71|,_25 (r_conj) syndrome_6\NN\5870365|complications_64|._211 (l_compound) leukoencephalopathy_5\JJ\0|posterior_21|reversible_11|(_29|n_30|)_36|,_37|stroke_39|,_85|toxicity_110
D008727_D020521 NONE methotrexate_32\NN\2722166|dose_5|(_22|n_23|2_27|)_28|,_29|syndrome_31 (r_compound) toxicity_33\NN\13576101|posterior_131|reversible_121|leukoencephalopathy_110|(_81|n_80|)_74|,_73|stroke_71|,_25 (r_conj) syndrome_6\NN\5870365|complications_64|._211 (l_conj) stroke_13\NN\556313|posterior_60|reversible_50|leukoencephalopathy_39|(_10|n_9|)_3|,_2|,_46|toxicity_71
D008727_D064420 NONE methotrexate_32\NN\2722166|dose_5|(_22|n_23|2_27|)_28|,_29|syndrome_31 (r_compound) toxicity_33\NN\13576101|posterior_131|reversible_121|leukoencephalopathy_110|(_81|n_80|)_74|,_73|stroke_71|,_25
D008727_D004833 NONE methotrexate_32\NN\2722166|dose_5|(_22|n_23|2_27|)_28|,_29|syndrome_31 (r_compound) toxicity_33\NN\13576101|posterior_131|reversible_121|leukoencephalopathy_110|(_81|n_80|)_74|,_73|stroke_71|,_25 (r_conj) syndrome_6\NN\5870365|complications_64|._211 (l_conj) stroke_13\NN\556313|posterior_60|reversible_50|leukoencephalopathy_39|(_10|n_9|)_3|,_2|,_46|toxicity_71 (l_conj) epilepsy_22\NN\14085708|(_23|n_22|5_18|)_17|,_16
D008727_D007177 NONE methotrexate_32\NN\2722166|dose_5|(_22|n_23|2_27|)_28|,_29|syndrome_31 (r_compound) toxicity_33\NN\13576101|posterior_131|reversible_121|leukoencephalopathy_110|(_81|n_80|)_74|,_73|stroke_71|,_25 (l_conj) syndrome_40\NN\5870365|dose_36|methotrexate_31|(_9|n_8|2_4|)_3|,_2 (l_prep) of_41\IN\0|,_55|and_57|events_80 (l_pobj) secretion_45\NN\13526110|NONE_0
15572383
D004317_D011507 CID adriamycin_10\NNS\0|NONE_0 (r_pobj) by_9\IN\0|after_50|,_26|proteinuria_24|was_12|._82 (r_agent) induced_8\VBN\1627355|NONE_0 (l_nsubjpass) proteinuria_6\NN\14299637|after_26|,_2|was_12|by_24|._106
D004317_D011507 CID adriamycin_3\NNS\0|NONE_0 (l_pobj) proteinuria_7\NN\14299637|anticipated_49|,_38|._72
D004317_D011507 CID adriamycin_12\NNS\0|ace_70|positively_66|with_44 (r_advcl) correlated_4\VBD\2657219|NONE_0 (l_prep) with_5\IN\0|ace_26|positively_22|adriamycin_44 (l_pobj) rise_8\NN\7324673|NONE_0 (l_prep) in_9\IN\13603305|the_18|relative_14 (l_pobj) proteinuria_10\NN\14299637|NONE_0
D004317_D009404 NONE adriamycin_3\NNS\0|NONE_0 (l_pobj) proteinuria_7\NN\14299637|anticipated_49|,_38|._72 (l_amod) nephrotic_5\JJ\0|elicited_9|range_10|,_27|damage_48
D004317_D005923 NONE adriamycin_3\NNS\0|NONE_0 (l_pobj) proteinuria_7\NN\14299637|anticipated_49|,_38|._72 (l_conj) damage_11\NN\7296428|elicited_57|nephrotic_48|range_38|,_21 (l_conj) glomerulosclerosis_15\NN\0|renal_41|interstitial_35|and_15
D004317_D007674 NONE adriamycin_12\NNS\0|-_10 (r_advmod) induced_14\VBN\1627355|renal_8 (r_amod) damage_16\NN\7296428|NONE_0
D004317_D007674 NONE adriamycin_23\NNS\0|NONE_0 (r_pobj) of_22\IN\0|a_19|single_17|in_14 (r_prep) injection_21\NN\320852|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|the_29|of_16 (r_acl) severity_13\NN\5036394|NONE_0 (l_prep) of_14\IN\0|the_13|induced_16 (l_pobj) damage_16\NN\7296428|NONE_0
D004317_D007674 NONE adriamycin_3\NNS\0|NONE_0 (l_pobj) proteinuria_7\NN\14299637|anticipated_49|,_38|._72 (l_conj) damage_11\NN\7296428|elicited_57|nephrotic_48|range_38|,_21
D004317_D007674 NONE adriamycin_10\NNS\0|-_10 (r_advmod) induced_12\VBN\1627355|renal_8|in_21 (r_amod) damage_14\NN\7296428|NONE_0
7582165
D000305_D004342 NONE corticosteroids_5\NNS\14745635|NONE_0 (r_pobj) to_4\IN\0|allergic_19|:_18|diagnosis_20|._46 (r_prep) reactions_3\NNS\13446390|NONE_0
D010248_D004342 NONE paramethasone_3\NN\0|NONE_0 (r_pobj) from_2\IN\0|NONE_0 (r_prep) different_1\JJ\0|NONE_0 (r_amod) corticosteroids_0\NNS\14745635|also_45|reactions_76 (r_nsubj) produced_5\VBD\1617192|;_53|however_55|,_62|few_66|were_78|._92 (l_dobj) reactions_7\NNS\13446390|corticosteroids_76|also_31 (l_compound) hypersensitivity_6\NN\14531772|in_27
D010248_D004342 NONE paramethasone_16\NN\0|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) caused_14\VBN\1617192|a_17|pseudo_15|-_9 (r_acl) allergy_13\NN\14533203|NONE_0
18208574
D006493_D013927 CID heparin_12\NN\2718259|-_7 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_15\NN\14189204|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) patients_10\NNS\9898892|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) thrombosis_8\NN\14100769|density_37|._60
D006493_D013927 CID heparin_12\NN\2718259|-_7 (r_npadvmod) induced_14\VBN\1627355|a_19|step_13|assay_39 (r_amod) thrombocytopenia_15\NN\14189204|NONE_0 (l_appos) assay_20\NN\5733583|a_58|step_52|induced_39 (l_prep) with_21\IN\0|(_20|hit_19|)_16|antigen_14 (l_pobj) thrombosis_22\NN\14100769|NONE_0
D006493_D013927 CID heparin_33\JJ\2718259|a_7|high_5 (r_compound) concentration_34\NN\4916342|NONE_0 (r_pobj) of_30\IN\0|inhibition_27 (r_prep) characteristics_29\NNS\5849040|correlate_172|;_41|assay_35|._47 (r_dobj) utilizes_26\VBZ\0|NONE_0 (l_advcl) correlate_1\VB\5857459|;_131|assay_137|characteristics_172|._219 (l_dobj) density_3\NN\4941325|to_21 (l_prep) of_7\IN\0|optical_39|and_23|inhibition_11 (l_pobj) thrombocytopenia_15\NN\14189204|NONE_0 (l_appos) assay_20\NN\5733583|a_58|step_52|induced_39 (l_prep) with_21\IN\0|(_20|hit_19|)_16|antigen_14 (l_pobj) thrombosis_22\NN\14100769|NONE_0
D006493_D013921 CID heparin_12\NN\2718259|-_7 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_15\NN\14189204|NONE_0
D006493_D013921 CID heparin_12\NN\2718259|-_7 (r_npadvmod) induced_14\VBN\1627355|a_19|step_13|assay_39 (r_amod) thrombocytopenia_15\NN\14189204|NONE_0
D006493_D013921 CID heparin_12\NN\2718259|-_7 (r_npadvmod) induced_14\VBN\1627355|a_19|step_13|assay_39 (r_amod) thrombocytopenia_15\NN\14189204|NONE_0 (l_appos) assay_20\NN\5733583|a_58|step_52|induced_39 (l_nmod) hit_17\NN\36762|(_1|)_3|antigen_5|with_19
D006493_D013921 CID heparin_33\JJ\2718259|a_7|high_5 (r_compound) concentration_34\NN\4916342|NONE_0 (r_pobj) of_30\IN\0|inhibition_27 (r_prep) characteristics_29\NNS\5849040|correlate_172|;_41|assay_35|._47 (r_dobj) utilizes_26\VBZ\0|NONE_0 (l_advcl) correlate_1\VB\5857459|;_131|assay_137|characteristics_172|._219 (l_dobj) density_3\NN\4941325|to_21 (l_prep) of_7\IN\0|optical_39|and_23|inhibition_11 (l_pobj) thrombocytopenia_15\NN\14189204|NONE_0
D006493_D013921 CID heparin_33\JJ\2718259|a_7|high_5 (r_compound) concentration_34\NN\4916342|NONE_0 (r_pobj) of_30\IN\0|inhibition_27 (r_prep) characteristics_29\NNS\5849040|correlate_172|;_41|assay_35|._47 (r_dobj) utilizes_26\VBZ\0|NONE_0 (l_advcl) correlate_1\VB\5857459|;_131|assay_137|characteristics_172|._219 (l_dobj) density_3\NN\4941325|to_21 (l_prep) of_7\IN\0|optical_39|and_23|inhibition_11 (l_pobj) thrombocytopenia_15\NN\14189204|NONE_0 (l_appos) assay_20\NN\5733583|a_58|step_52|induced_39 (l_nmod) hit_17\NN\36762|(_1|)_3|antigen_5|with_19
D006493_D013921 CID heparin_21\NN\2718259|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) exposure_19\NN\5042871|NONE_0 (r_pobj) after_18\IN\0|with_83 (r_prep) patients_0\NNS\9898892|were_243|in_257|._269 (l_prep) with_1\IN\0|after_83 (l_pobj) decrease_6\NN\7296428|NONE_0 (l_conj) thrombocytopenia_11\NNP\14189204|%_32|in_21|or_3|)_32
D006493_D013921 CID heparin_48\NN\2718259|NONE_0 (r_pobj) of_47\IN\0|high_19 (r_prep) concentration_46\NN\4916342|NONE_0 (r_pobj) with_44\IN\0|50_14 (r_prep) inhibition_43\NN\1068773|who_77|assay_41 (r_dobj) had_24\VBD\0|,_6|]_118 (r_relcl) heparin_21\NN\2718259|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) exposure_19\NN\5042871|NONE_0 (r_pobj) after_18\IN\0|with_83 (r_prep) patients_0\NNS\9898892|were_243|in_257|._269 (l_prep) with_1\IN\0|after_83 (l_pobj) decrease_6\NN\7296428|NONE_0 (l_conj) thrombocytopenia_11\NNP\14189204|%_32|in_21|or_3|)_32
19884587
D009582_D008850 CID nitrofurantoins_0\NNS\2716205|were_16|with_32|aor_69|._273 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|nitrofurantoins_32|were_16|aor_37|._241 (l_pobj) anophthalmia_4\NN\0|NONE_0 (l_conj) microphthalmos_6\NNS\0|or_3
D009582_D002971 CID nitrofurantoins_0\NNS\2716205|were_16|with_32|aor_69|._273 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_appos) aor_8\NNP\0|nitrofurantoins_69|were_53|with_37|._204 (l_appos) aor_26\NNP\0|(_64|=_59|3.7_57|;_54|ci_48|,_35|syndrome_10|aor_114 (l_conj) lip_58\NN\5301392|(_92|=_87|4.2_85|;_82|ci_76|)_65|,_64|defects_48|(_40|aor_39|;_30|ci_24|)_13|,_12|and_10
D009582_D002972 CID nitrofurantoins_0\NNS\2716205|were_16|with_32|aor_69|._273 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_appos) aor_8\NNP\0|nitrofurantoins_69|were_53|with_37|._204 (l_appos) aor_26\NNP\0|(_64|=_59|3.7_57|;_54|ci_48|,_35|syndrome_10|aor_114 (l_conj) lip_58\NN\5301392|(_92|=_87|4.2_85|;_82|ci_76|)_65|,_64|defects_48|(_40|aor_39|;_30|ci_24|)_13|,_12|and_10 (l_prep) with_59\IN\0|cleft_10 (l_pobj) palate_61\NN\8660339|NONE_0
D004917_D000014 NONE erythromycins_4\NNS\2716866|,_2|,_33|used_44|,_75 (r_conj) penicillins_2\NNS\2716866|reassuringly_14|,_2|were_90|not_95|with_110|._133 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|reassuringly_124|,_112|penicillins_110|were_20|not_15|._23 (l_pobj) defects_22\NNS\14462666|NONE_0
D009582_D000014 CID nitrofurantoins_2\NNS\2716205|and_4 (r_conj) sulfonamides_0\NNS\2716205|were_33|with_49|,_75|indicating_77|._118 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|sulfonamides_49|were_16|,_26|indicating_28|._69 (l_pobj) defects_8\NNS\14462666|NONE_0
D013449_D000014 CID sulfonamides_0\NNS\2716205|were_33|with_49|,_75|indicating_77|._118 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|sulfonamides_49|were_16|,_26|indicating_28|._69 (l_pobj) defects_8\NNS\14462666|NONE_0
D009582_D018636 CID nitrofurantoins_0\NNS\2716205|were_16|with_32|aor_69|._273 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_appos) aor_8\NNP\0|nitrofurantoins_69|were_53|with_37|._204 (l_appos) syndrome_24\NN\5870365|(_54|=_49|3.7_47|;_44|ci_38|,_25|aor_10|aor_124
D010406_D000014 NONE penicillins_2\NNS\2716866|reassuringly_14|,_2|were_90|not_95|with_110|._133 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|reassuringly_124|,_112|penicillins_110|were_20|not_15|._23 (l_pobj) defects_22\NNS\14462666|NONE_0
D009582_D006344 CID nitrofurantoins_0\NNS\2716205|were_16|with_32|aor_69|._273 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_appos) aor_8\NNP\0|nitrofurantoins_69|were_53|with_37|._204 (l_appos) aor_26\NNP\0|(_64|=_59|3.7_57|;_54|ci_48|,_35|syndrome_10|aor_114 (l_appos) defects_41\NNS\14462666|(_44|=_39|4.2_37|;_34|ci_28|)_17|,_16|(_8|aor_9|;_18|ci_24|)_35|,_36|and_38|lip_48
D009582_D000853 CID nitrofurantoins_0\NNS\2716205|were_16|with_32|aor_69|._273 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|nitrofurantoins_32|were_16|aor_37|._241 (l_pobj) anophthalmia_4\NN\0|NONE_0
D013449_D018636 CID sulfonamides_0\NNS\2716205|were_13|with_29 (r_nsubjpass) associated_2\VBN\628491|;_52|%_56|confidence_58|ci_79|,_82|1.3_84|)_91|,_92|syndrome_117 (r_ccomp) interval_17\NN\33615|NONE_0 (l_appos) syndrome_30\NN\5870365|associated_117|;_65|%_61|confidence_59|ci_38|,_35|1.3_33|)_26|,_25
D013449_D000757 CID sulfonamides_0\NNS\2716205|were_13|with_29 (r_nsubjpass) associated_2\VBN\628491|;_52|%_56|confidence_58|ci_79|,_82|1.3_84|)_91|,_92|syndrome_117 (l_prep) with_3\IN\0|sulfonamides_29|were_16 (l_pobj) aor_9\NNP\0|NONE_0 (l_amod) anencephaly_4\NNS\14465048|(_12|adjusted_13|or_22|[_25|]_29|3.4_33
D002511_D000014 NONE cephalosporins_7\NNS\2716866|,_6|and_4 (r_conj) erythromycins_4\NNS\2716866|,_2|,_33|used_44|,_75 (r_conj) penicillins_2\NNS\2716866|reassuringly_14|,_2|were_90|not_95|with_110|._133 (r_nsubjpass) associated_18\VBN\628491|NONE_0 (l_prep) with_19\IN\0|reassuringly_124|,_112|penicillins_110|were_20|not_15|._23 (l_pobj) defects_22\NNS\14462666|NONE_0
17343925
D012906_D034381 CID smoking_3\NN\831191|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) influence_1\NN\5190804|has_64|not_68|been_72|,_86|associated_125|._163 (r_nsubjpass) estimated_13\VBN\637259|NONE_0 (l_advcl) associated_20\VBN\628491|influence_125|has_61|not_57|been_53|,_39|._38 (l_prep) with_21\IN\0|although_48|smoking_39|has_31|been_27|positively_22 (l_pcomp) hearing_22\VBG\1184814|NONE_0 (l_dobj) loss_23\NN\13252973|NONE_0
D012906_D034381 CID smoking_16\NN\831191|although_9|has_8|been_12|positively_17|with_39 (r_nsubjpass) associated_20\VBN\628491|influence_125|has_61|not_57|been_53|,_39|._38 (l_prep) with_21\IN\0|although_48|smoking_39|has_31|been_27|positively_22 (l_pcomp) hearing_22\VBG\1184814|NONE_0 (l_dobj) loss_23\NN\13252973|NONE_0
8387218
D016049_D018149 CID didanosine_24\NN\2725367|NONE_0 (r_dobj) ceasing_23\VBG\0|NONE_0 (r_pcomp) on_22\IN\0|to_10 (r_prep) returned_19\VBN\1835496|,_32|did_30|not_26|treatment_14|and_4|._40 (r_conj) require_16\VB\0|patients_100|curves_63|but_29|were_19 (r_conj) developed_2\VBD\1753788|NONE_0 (l_dobj) curves_5\VBZ\13863771|patients_37|but_34|were_44|require_63
D015215_D015658 NONE zidovudine_17\NNP\3834836|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) intolerant_15\JJ\0|hiv_34|positive_21|azt_26 (r_amod) individuals_14\NNS\7347|NONE_0 (l_amod) positive_13\JJ\6321702|hiv_13|intolerant_21|azt_47
D015215_D015658 NONE azt_19\NNP\3834836|hiv_60|positive_47|intolerant_26 (r_appos) individuals_14\NNS\7347|NONE_0 (l_amod) positive_13\JJ\6321702|hiv_13|intolerant_21|azt_47
D015215_D064420 NONE zidovudine_17\NNP\3834836|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) intolerant_15\JJ\0|hiv_34|positive_21|azt_26 (r_amod) individuals_14\NNS\7347|NONE_0 (r_pobj) in_9\IN\13603305|ddi_5 (r_prep) didanosine_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|the_21|and_13|toxicity_9|)_86 (r_prep) use_1\NN\407535|NONE_0 (l_conj) toxicity_3\NN\13576101|the_12|and_4|of_9|)_95
D015215_D064420 NONE azt_19\NNP\3834836|hiv_60|positive_47|intolerant_26 (r_appos) individuals_14\NNS\7347|NONE_0 (r_pobj) in_9\IN\13603305|ddi_5 (r_prep) didanosine_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|the_21|and_13|toxicity_9|)_86 (r_prep) use_1\NN\407535|NONE_0 (l_conj) toxicity_3\NN\13576101|the_12|and_4|of_9|)_95
D016049_D003920 NONE didanosine_24\NN\2725367|NONE_0 (r_dobj) ceasing_23\VBG\0|NONE_0 (r_pcomp) on_22\IN\0|to_10 (r_prep) returned_19\VBN\1835496|,_32|did_30|not_26|treatment_14|and_4|._40 (r_conj) require_16\VB\0|patients_100|curves_63|but_29|were_19 (r_conj) developed_2\VBD\1753788|NONE_0 (l_dobj) curves_5\VBZ\13863771|patients_37|but_34|were_44|require_63 (l_amod) characteristic_6\JJ\5849040|tolerance_17 (l_prep) of_7\IN\0|NONE_0 (l_pobj) diabetes_8\NNS\14075199|NONE_0
D016049_D064420 NONE didanosine_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|the_21|and_13|toxicity_9|)_86 (r_prep) use_1\NN\407535|NONE_0 (l_conj) toxicity_3\NN\13576101|the_12|and_4|of_9|)_95
D016049_D064420 NONE ddi_7\NN\2725367|in_5 (r_appos) didanosine_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|the_21|and_13|toxicity_9|)_86 (r_prep) use_1\NN\407535|NONE_0 (l_conj) toxicity_3\NN\13576101|the_12|and_4|of_9|)_95
D016049_D015658 NONE didanosine_5\NN\2725367|NONE_0 (l_prep) in_9\IN\13603305|ddi_5 (l_pobj) individuals_14\NNS\7347|NONE_0 (l_amod) positive_13\JJ\6321702|hiv_13|intolerant_21|azt_47
D016049_D015658 NONE ddi_7\NN\2725367|in_5 (r_appos) didanosine_5\NN\2725367|NONE_0 (l_prep) in_9\IN\13603305|ddi_5 (l_pobj) individuals_14\NNS\7347|NONE_0 (l_amod) positive_13\JJ\6321702|hiv_13|intolerant_21|azt_47
1639466
D004656_D006973 NONE enalapril_33\NN\2673637|-_9 (r_npadvmod) treated_35\VBN\2376958|(_8|n_9|=_11|,_15|or_17|treated_33 (r_amod) 8)_39\CD\0|untreated_64|hypertensive_54|(_32|8)_27 (r_appos) controls_27\NNS\5190804|three_37|:_25 (r_appos) groups_23\NNS\2137|NONE_0 (r_pobj) to_21\IN\0|after_95|were_23|randomly_18|._117 (r_prep) assigned_20\VBN\2475922|NONE_0 (l_prep) after_2\IN\0|were_72|randomly_77|to_95|._212 (l_pobj) clipping_3\VBG\6400510|weeks_12 (l_prep) of_4\IN\0|NONE_0 (l_pobj) artery_7\NN\5417975|NONE_0 (l_appos) rats_10\NNS\2329401|one_31|renal_27|,_15|(_5|hg_19|)_21 (l_amod) hypertensive_9\JJ\10405694|NONE_0
D004656_D006973 NONE enalapril_33\NN\2673637|-_9 (r_npadvmod) treated_35\VBN\2376958|(_8|n_9|=_11|,_15|or_17|treated_33 (r_amod) 8)_39\CD\0|untreated_64|hypertensive_54|(_32|8)_27 (r_appos) controls_27\NNS\5190804|three_37|:_25 (l_amod) hypertensive_26\JJ\10405694|untreated_10|(_22|8)_27|8)_54
D004656_D006973 NONE enalapril_25\NN\2673637|-_9 (r_npadvmod) treated_27\VBN\2376958|the_14 (r_amod) group_28\NN\2137|NONE_0 (r_pobj) in_23\IN\13603305|(_31|+/-_37|compared_58 (r_prep) lower_22\JJR\2831724|in_105|,_94|size_81|higher_72|in_65|but_4|._130 (l_prep) compared_37\VBN\644583|in_58|(_27|+/-_21 (l_prep) with_38\IN\0|NONE_0 (l_pobj) controls_41\NNS\5190804|NONE_0 (l_amod) hypertensive_40\JJ\10405694|the_4|(_22|+/-_28|)_47
D002118_D000419 NONE calcium_8\NN\14625458|the_4|nitrendipine_24 (r_compound) channel_9\NN\6251781|NONE_0 (l_appos) nitrendipine_11\NN\0|the_28|calcium_24 (l_conj) angiotensin_14\NN\4522421|blocker_28|or_7 (l_acl) converting_15\VBG\126264|the_16 (l_prep) on_19\IN\0|enalapril_10 (l_pobj) pressure_21\NN\11419404|NONE_0 (l_conj) albuminuria_23\NN\14299637|blood_16|,_2
D004656_D005921 NONE enalapril_14\JJ\2673637|NONE_0 (r_compound) treatment_15\NN\654885|NONE_0 (r_pobj) after_13\IN\0|excretion_48|did_15|not_11|._25 (r_prep) change_12\VB\7283608|flow_69|,_55|but_53 (l_nsubj) excretion_7\NN\13466586|did_33|not_37|after_48|._73 (l_conj) glomerulosclerosis_9\NN\0|albumin_22|and_4
D009568_D005921 NONE nitrendipine_9\NN\0|-_12 (r_npadvmod) treated_11\VBN\2376958|the_17 (r_amod) group_12\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|furthermore_66|,_55|index_34|was_28|significantly_24|compared_34|._109 (r_prep) increased_6\VBN\169651|NONE_0 (l_nsubjpass) index_3\NN\13850304|furthermore_32|,_21|was_6|significantly_10|in_34|compared_68|._143 (l_compound) glomerulosclerosis_2\NN\0|NONE_0
D009568_D000419 CID nitrendipine_11\NN\0|the_28|calcium_24 (l_conj) angiotensin_14\NN\4522421|blocker_28|or_7 (l_acl) converting_15\VBG\126264|the_16 (l_prep) on_19\IN\0|enalapril_10 (l_pobj) pressure_21\NN\11419404|NONE_0 (l_conj) albuminuria_23\NN\14299637|blood_16|,_2
D009568_D000419 CID nitrendipine_5\NN\0|-_12 (r_npadvmod) treated_7\VBN\2376958|the_17|group_8 (r_amod) albuminuria_9\NN\14299637|NONE_0
D009568_D006978 NONE nitrendipine_7\NN\0|adverse_46|of_31|._70 (l_prep) on_8\IN\0|blocker_21 (l_pobj) nephrosclerosis_9\NN\14113228|NONE_0 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) rats_11\NNS\2329401|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) hypertension_14\NN\14057371|NONE_0
D009568_D006978 NONE nitrendipine_11\NN\0|the_28|calcium_24 (r_appos) channel_9\NN\6251781|NONE_0 (r_pobj) with_6\IN\0|a_19|6-week_17 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_224|in_236|._295 (r_nsubjpass) studied_35\VBN\0|NONE_0 (l_prep) in_36\IN\13603305|effect_236|was_12|._59 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_prep) with_38\IN\0|NONE_0 (l_pobj) kidney_41\NN\5333259|NONE_0 (l_appos) hypertension_46\NN\14057371|two_34|-_31|,_24
D000809_D000419 NONE angiotensin_14\NN\4522421|blocker_28|or_7 (l_acl) converting_15\VBG\126264|the_16 (l_prep) on_19\IN\0|enalapril_10 (l_pobj) pressure_21\NN\11419404|NONE_0 (l_conj) albuminuria_23\NN\14299637|blood_16|,_2
D009568_D009400 CID nitrendipine_7\NN\0|adverse_46|of_31|._70 (l_prep) on_8\IN\0|blocker_21 (l_pobj) nephrosclerosis_9\NN\14113228|NONE_0
D002118_D009400 NONE calcium_4\NN\14625458|the_4 (r_compound) channel_5\NN\6251781|NONE_0 (r_pobj) of_2\IN\0|adverse_15|nitrendipine_31|._101 (r_prep) effect_1\NN\34213|NONE_0 (l_appos) nitrendipine_7\NN\0|adverse_46|of_31|._70 (l_prep) on_8\IN\0|blocker_21 (l_pobj) nephrosclerosis_9\NN\14113228|NONE_0
D002118_D006978 NONE calcium_4\NN\14625458|the_4 (r_compound) channel_5\NN\6251781|NONE_0 (r_pobj) of_2\IN\0|adverse_15|nitrendipine_31|._101 (r_prep) effect_1\NN\34213|NONE_0 (l_appos) nitrendipine_7\NN\0|adverse_46|of_31|._70 (l_prep) on_8\IN\0|blocker_21 (l_pobj) nephrosclerosis_9\NN\14113228|NONE_0 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) rats_11\NNS\2329401|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) hypertension_14\NN\14057371|NONE_0
D002118_D006978 NONE calcium_8\NN\14625458|the_4|nitrendipine_24 (r_compound) channel_9\NN\6251781|NONE_0 (r_pobj) with_6\IN\0|a_19|6-week_17 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_224|in_236|._295 (r_nsubjpass) studied_35\VBN\0|NONE_0 (l_prep) in_36\IN\13603305|effect_236|was_12|._59 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_prep) with_38\IN\0|NONE_0 (l_pobj) kidney_41\NN\5333259|NONE_0 (l_appos) hypertension_46\NN\14057371|two_34|-_31|,_24
D004656_D000419 NONE enalapril_18\NN\2673637|on_10 (r_dobj) converting_15\VBG\126264|the_16 (l_prep) on_19\IN\0|enalapril_10 (l_pobj) pressure_21\NN\11419404|NONE_0 (l_conj) albuminuria_23\NN\14299637|blood_16|,_2
D004656_D006978 NONE enalapril_18\NN\2673637|on_10 (r_dobj) converting_15\VBG\126264|the_16 (r_acl) angiotensin_14\NN\4522421|blocker_28|or_7 (r_conj) nitrendipine_11\NN\0|the_28|calcium_24 (r_appos) channel_9\NN\6251781|NONE_0 (r_pobj) with_6\IN\0|a_19|6-week_17 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_224|in_236|._295 (r_nsubjpass) studied_35\VBN\0|NONE_0 (l_prep) in_36\IN\13603305|effect_236|was_12|._59 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_prep) with_38\IN\0|NONE_0 (l_pobj) kidney_41\NN\5333259|NONE_0 (l_appos) hypertension_46\NN\14057371|two_34|-_31|,_24
D009568_D006973 NONE nitrendipine_42\NN\0|-_12|n_22 (r_advmod) treated_44\VBN\2376958|treated_33|(_25|n_24|=_22|,_18|or_16 (r_conj) 8)_39\CD\0|untreated_64|hypertensive_54|(_32|8)_27 (r_appos) controls_27\NNS\5190804|three_37|:_25 (r_appos) groups_23\NNS\2137|NONE_0 (r_pobj) to_21\IN\0|after_95|were_23|randomly_18|._117 (r_prep) assigned_20\VBN\2475922|NONE_0 (l_prep) after_2\IN\0|were_72|randomly_77|to_95|._212 (l_pobj) clipping_3\VBG\6400510|weeks_12 (l_prep) of_4\IN\0|NONE_0 (l_pobj) artery_7\NN\5417975|NONE_0 (l_appos) rats_10\NNS\2329401|one_31|renal_27|,_15|(_5|hg_19|)_21 (l_amod) hypertensive_9\JJ\10405694|NONE_0
D009568_D006973 NONE nitrendipine_42\NN\0|-_12|n_22 (r_advmod) treated_44\VBN\2376958|treated_33|(_25|n_24|=_22|,_18|or_16 (r_conj) 8)_39\CD\0|untreated_64|hypertensive_54|(_32|8)_27 (r_appos) controls_27\NNS\5190804|three_37|:_25 (l_amod) hypertensive_26\JJ\10405694|untreated_10|(_22|8)_27|8)_54
D009568_D006973 NONE nitrendipine_5\NN\0|-_12 (r_npadvmod) treated_7\VBN\2376958|the_17|group_8 (r_amod) albuminuria_9\NN\14299637|NONE_0 (r_pobj) in_3\IN\13603305|in_13|,_2|from_56|progressively_72|to_86|compared_100|._162 (r_prep) increased_10\VBD\169651|NONE_0 (l_prep) compared_20\VBN\644583|in_113|,_102|in_100|from_44|progressively_28|to_14|._62 (l_prep) with_21\IN\0|NONE_0 (l_pobj) hr_26\NN\15154774|NONE_0 (l_prep) in_27\IN\13603305|mg/24_9 (l_pobj) controls_30\NNS\5190804|NONE_0 (l_amod) hypertensive_29\JJ\10405694|the_4
D009568_D006973 NONE nitrendipine_9\NN\0|-_12 (r_npadvmod) treated_11\VBN\2376958|the_17 (r_amod) group_12\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|furthermore_66|,_55|index_34|was_28|significantly_24|compared_34|._109 (r_prep) increased_6\VBN\169651|NONE_0 (l_prep) compared_13\VBN\644583|furthermore_100|,_89|index_68|was_62|significantly_58|in_34|._75 (l_prep) with_14\IN\0|NONE_0 (l_pobj) controls_17\NNS\5190804|NONE_0 (l_amod) hypertensive_16\JJ\10405694|the_4|(_22|0.38_23|)_56
D009568_D006973 NONE nitrendipine_9\NN\0|-_12 (r_npadvmod) treated_11\VBN\2376958|the_17|(_14|+/-_20|)_39 (r_amod) group_12\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|in_40|,_29|size_16|higher_7|but_61|lower_65|._195 (r_prep) was_5\VBD\0|NONE_0 (l_conj) lower_22\JJR\2831724|in_105|,_94|size_81|higher_72|in_65|but_4|._130 (l_prep) compared_37\VBN\644583|in_58|(_27|+/-_21 (l_prep) with_38\IN\0|NONE_0 (l_pobj) controls_41\NNS\5190804|NONE_0 (l_amod) hypertensive_40\JJ\10405694|the_4|(_22|+/-_28|)_47
D000809_D006978 NONE angiotensin_14\NN\4522421|blocker_28|or_7 (r_conj) nitrendipine_11\NN\0|the_28|calcium_24 (r_appos) channel_9\NN\6251781|NONE_0 (r_pobj) with_6\IN\0|a_19|6-week_17 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_224|in_236|._295 (r_nsubjpass) studied_35\VBN\0|NONE_0 (l_prep) in_36\IN\13603305|effect_236|was_12|._59 (l_pobj) rats_37\NNS\2329401|NONE_0 (l_prep) with_38\IN\0|NONE_0 (l_pobj) kidney_41\NN\5333259|NONE_0 (l_appos) hypertension_46\NN\14057371|two_34|-_31|,_24
16858720
D014859_D006470 NONE warfarin_1\JJ\2718259|-_8 (r_compound) drug_3\NN\14778436|a_11 (r_compound) interaction_4\NN\37396|could_12|have_18|to_35|in_54|considered_145|._179 (r_nsubj) contributed_7\VBN\126264|NONE_0 (l_prep) to_8\IN\0|interaction_35|could_23|have_17|in_19|considered_110|._144 (l_pobj) haemorrhage_10\NN\14285662|NONE_0
D014859_D006470 NONE warfarin_1\JJ\2718259|-_8 (r_compound) drug_3\NN\14778436|a_11 (r_compound) interaction_4\NN\37396|could_12|have_18|to_35|in_54|considered_145|._179 (r_nsubj) contributed_7\VBN\126264|NONE_0 (l_conj) considered_34\VBN\689344|interaction_145|could_133|have_127|to_110|in_91|._34 (l_nsubjpass) complication_32\NN\1073995|was_13|being_28 (l_amod) bleeding_31\VBG\14285662|the_4
D014859_D006470 NONE warfarin_19\JJ\2718259|the_4 (r_compound) patients_20\NNS\9898892|NONE_0 (r_pobj) of_17\IN\0|24_9|(_6|41_5|)_2 (r_prep) %_15\NN\0|and_28|in_32 (r_pobj) in_11\IN\13603305|interaction_54|could_42|have_36|to_19|considered_91|._125 (r_prep) contributed_7\VBN\126264|NONE_0 (l_prep) to_8\IN\0|interaction_35|could_23|have_17|in_19|considered_110|._144 (l_pobj) haemorrhage_10\NN\14285662|NONE_0
D014859_D006470 NONE warfarin_19\JJ\2718259|the_4 (r_compound) patients_20\NNS\9898892|NONE_0 (r_pobj) of_17\IN\0|24_9|(_6|41_5|)_2 (r_prep) %_15\NN\0|and_28|in_32 (r_pobj) in_11\IN\13603305|interaction_54|could_42|have_36|to_19|considered_91|._125 (r_prep) contributed_7\VBN\126264|NONE_0 (l_conj) considered_34\VBN\689344|interaction_145|could_133|have_127|to_110|in_91|._34 (l_nsubjpass) complication_32\NN\1073995|was_13|being_28 (l_amod) bleeding_31\VBG\14285662|the_4
D014859_D002543 CID warfarin_4\NN\2718259|NONE_0 (r_pobj) by_3\IN\0|influence_18 (r_agent) induced_2\VBN\1627355|cerebral_21|._61 (r_acl) haemorrhage_1\NN\14285662|NONE_0
D014859_D002543 CID warfarin_9\RB\2718259|-_8 (r_npadvmod) induced_11\VBN\1627355|cerebral_8 (r_amod) haemorrhages_13\NNS\14285662|NONE_0
D014859_D002543 CID warfarin_16\JJ\2718259|to_3 (r_pobj) due_14\IN\5174653|to_97|frequency_81|._104 (r_prep) evaluate_1\VB\670261|NONE_0 (l_dobj) frequency_3\NN\15286249|to_16|due_81|._185 (l_prep) of_8\IN\0|the_43|,_30|severity_28 (l_pobj) haemorrhages_13\NNS\14285662|NONE_0
D014859_D002543 CID warfarin_18\JJ\2718259|-_8 (r_compound) drug_20\NN\14778436|in_18 (r_compound) interactions_21\NNS\37396|and_18 (r_conj) warfarin_16\JJ\2718259|to_3 (r_pobj) due_14\IN\5174653|to_97|frequency_81|._104 (r_prep) evaluate_1\VB\670261|NONE_0 (l_dobj) frequency_3\NN\15286249|to_16|due_81|._185 (l_prep) of_8\IN\0|the_43|,_30|severity_28 (l_pobj) haemorrhages_13\NNS\14285662|NONE_0
D014859_D002543 CID warfarin_8\JJ\2718259|NONE_0 (r_nmod) interactions_13\NNS\37396|whether_35|could_13|have_19|haemorrhage_44 (r_nsubj) caused_16\VBN\1617192|to_71 (l_dobj) haemorrhage_19\NN\14285662|whether_79|interactions_44|could_31|have_25
D014859_D002543 CID warfarin_10\JJ\2718259|-_8 (r_compound) drug_12\NN\14778436|and_13 (r_conj) warfarin_8\JJ\2718259|NONE_0 (r_nmod) interactions_13\NNS\37396|whether_35|could_13|have_19|haemorrhage_44 (r_nsubj) caused_16\VBN\1617192|to_71 (l_dobj) haemorrhage_19\NN\14285662|whether_79|interactions_44|could_31|have_25
D014859_D002543 CID warfarin_17\JJ\2718259|NONE_0 (r_compound) treatment_18\NN\654885|NONE_0 (r_pobj) to_16\IN\0|NONE_0 (r_prep) related_15\VBN\628491|NONE_0 (r_amod) as_14\IN\14622893|among_69|were_14|._32 (r_prep) assessed_13\VBN\670261|NONE_0 (l_prep) among_0\IN\0|were_55|as_69|._101 (l_pobj) patients_2\NNS\9898892|NONE_0 (l_prep) with_3\IN\0|593_13 (l_pobj) haemorrhage_5\NN\14285662|NONE_0
D014859_D002543 CID warfarin_0\NNP\2718259|-_8 (r_npadvmod) induced_2\VBN\1627355|cerebral_8 (r_amod) haemorrhages_4\NNS\14285662|problem_34|._67
D014859_D002543 CID warfarin_4\RB\2718259|-_8 (r_npadvmod) related_6\VBN\628491|cerebral_8 (r_amod) haemorrhages_8\NNS\14285662|NONE_0
D014859_D002543 CID warfarin_26\NN\2718259|NONE_0 (r_pobj) with_25\IN\0|to_12 (r_prep) interact_24\VB\2367363|NONE_0 (r_xcomp) known_22\VBN\0|NONE_0 (r_acl) drugs_21\NNS\14778436|when_17 (r_dobj) prescribing_20\VBG\748282|if_39|caution_28|had_20|been_16 (r_advcl) taken_18\VBN\2367363|proportion_107|might_54|have_48|been_43|._60 (r_advcl) prevented_12\VBN\0|NONE_0 (l_nsubjpass) proportion_2\NN\13824815|might_53|have_59|been_64|taken_107|._167 (l_prep) of_3\IN\0|a_25|significant_23 (l_pobj) haemorrhages_8\NNS\14285662|NONE_0
3173179
D002216_D006973 NONE captopril_13\NN\2673637|NONE_0 (r_pobj) of_12\IN\0|the_17|and_13|withdrawal_21 (r_prep) introduction_11\NN\235435|NONE_0 (l_conj) withdrawal_16\NN\7206096|the_38|of_21|and_8 (l_prep) in_19\IN\13603305|the_28|of_13 (l_pobj) woman_23\NN\9605289|NONE_0 (l_prep) with_24\IN\0|a_32|asymptomatic_19 (l_pobj) hypertension_26\NN\14057371|NONE_0
D002216_D009203 NONE captopril_13\NN\2673637|NONE_0 (r_pobj) of_12\IN\0|the_17|and_13|withdrawal_21 (r_prep) introduction_11\NN\235435|NONE_0 (r_pobj) with_9\IN\0|in_41|infarction_21 (r_prep) coincided_8\VBD\2604477|a_38 (l_nsubj) infarction_7\NN\14204950|in_20|with_21
D014700_D009203 CID verapamil_0\NNP\2938514|as_21|._122 (r_compound) withdrawal_1\NN\7206096|NONE_0 (l_prep) as_2\IN\14622893|verapamil_21|._101 (l_pobj) cause_5\NN\7323922|NONE_0 (l_prep) of_6\IN\0|a_17|possible_15 (l_pobj) infarction_8\NN\14204950|NONE_0
D014700_D009203 CID verapamil_18\NN\2938514|NONE_0 (r_pobj) of_17\IN\0|the_15|in_13 (r_prep) withdrawal_16\NN\7206096|the_38|of_21|and_8 (r_conj) introduction_11\NN\235435|NONE_0 (r_pobj) with_9\IN\0|in_41|infarction_21 (r_prep) coincided_8\VBD\2604477|a_38 (l_nsubj) infarction_7\NN\14204950|in_20|with_21
D014700_D006973 NONE verapamil_0\NNP\2938514|as_21|._122 (r_compound) withdrawal_1\NN\7206096|NONE_0 (l_prep) as_2\IN\14622893|verapamil_21|._101 (l_pobj) cause_5\NN\7323922|NONE_0 (l_prep) of_6\IN\0|a_17|possible_15 (l_pobj) infarction_8\NN\14204950|NONE_0 (l_prep) in_9\IN\13603305|myocardial_22|with_24 (l_pobj) woman_12\NN\9605289|NONE_0 (l_amod) hypertensive_11\JJ\10405694|a_2
D014700_D006973 NONE verapamil_18\NN\2938514|NONE_0 (r_pobj) of_17\IN\0|the_15|in_13 (r_prep) withdrawal_16\NN\7206096|the_38|of_21|and_8 (l_prep) in_19\IN\13603305|the_28|of_13 (l_pobj) woman_23\NN\9605289|NONE_0 (l_prep) with_24\IN\0|a_32|asymptomatic_19 (l_pobj) hypertension_26\NN\14057371|NONE_0
12202650
D002211_D063806 NONE capsaicin_0\NN\15032661|-_9 (r_npadvmod) induced_2\VBN\1627355|muscle_8 (r_amod) pain_4\NN\14299637|excitability_16|._60
D002211_D010146 CID capsaicin_0\NNS\15032661|was_23|into_36|induce_64|._100 (r_nsubjpass) injected_7\VBN\81072|NONE_0 (l_advcl) induce_13\VB\1627355|capsaicin_64|was_41|into_28|._36 (l_dobj) pain_14\NN\14299637|to_10|in_5
1833784
D015647_D006948 NONE 38393_17\CD\0|NONE_0 (r_nummod) skf_16\NNP\0|the_15|d1_11 (r_appos) agonist_15\NN\0|whereas_15|effect_25 (r_nsubj) had_18\VBD\0|with_99|,_35|._13 (r_advcl) pretreatment_0\NN\0|NONE_0 (l_prep) with_1\IN\0|,_64|had_99|._112 (l_pobj) agonist_4\NN\0|NONE_0 (l_appos) hyperactivity_10\NN\14052403|the_46|d2_42
-1_D006948 NONE phno_5\NNP\0|NONE_0 (r_npadvmod) enhanced_6\VBN\227165|induced_18 (r_amod) hyperactivity_10\NN\14052403|the_46|d2_42
C534628_D006948 NONE 23390_12\CD\0|NONE_0 (r_nummod) sch_11\NNP\0|the_28|selective_24|d1_14 (r_appos) antagonist_10\NN\7846|NONE_0 (r_pobj) by_6\IN\0|hyperactivity_26|was_12 (r_agent) blocked_5\VBN\1476483|,_48|antagonist_67|and_89|fluphenazine_114|._126 (l_nsubjpass) hyperactivity_3\NN\14052403|was_14|by_26
D004298_D006948 NONE dopamine_8\NN\14807737|and_7 (r_conj) d1_5\NN\0|NONE_0 (r_nmod) receptors_9\NNS\5225602|NONE_0 (r_pobj) of_4\IN\0|an_15|in_32 (r_prep) involvement_3\NN\1080366|NONE_0 (l_prep) in_10\IN\13603305|an_47|of_32 (l_pcomp) mediating_11\VBG\761713|NONE_0 (l_dobj) hyperactivity_15\NN\14052403|NONE_0
D009538_D006948 CID nicotine_12\NN\14712692|-_8 (r_npadvmod) induced_14\VBN\1627355|in_22 (r_amod) hyperactivity_15\NN\14052403|NONE_0
D009538_D006948 CID nicotine_0\NNP\14712692|increase_42|,_125|but_127|had_131|._230 (r_nsubj) caused_5\VBD\1617192|NONE_0 (l_dobj) increase_8\NN\13576355|nicotine_42|,_83|but_85|had_89|._188 (l_prep) in_9\IN\13603305|a_23|significant_21|habituated_40 (l_pobj) activity_11\NN\30358|NONE_0
D009538_D006948 CID nicotine_0\NN\14712692|-_8 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) hyperactivity_3\NN\14052403|was_14|by_26
D009538_D006948 CID nicotine_7\NN\14712692|-_8 (r_npadvmod) induced_9\VBN\1627355|enhanced_18 (r_amod) hyperactivity_10\NN\14052403|the_46|d2_42
D009538_D006948 CID nicotine_5\NN\14712692|acute_6 (r_compound) injection_6\NN\320852|that_20|hyperactivity_31 (r_nsubj) induces_7\VBZ\1627355|results_47|._77 (l_dobj) hyperactivity_10\NN\14052403|that_51|injection_31
D020891_D006948 NONE raclopride_18\NN\0|NONE_0 (l_ccomp) blocked_5\VBN\1476483|,_48|antagonist_67|and_89|fluphenazine_114|._126 (l_nsubjpass) hyperactivity_3\NN\14052403|was_14|by_26
D005476_D006948 NONE fluphenazine_23\NN\3713736|blocked_114|,_66|antagonist_47|and_25|._12 (r_conj) raclopride_18\NN\0|NONE_0 (l_ccomp) blocked_5\VBN\1476483|,_48|antagonist_67|and_89|fluphenazine_114|._126 (l_nsubjpass) hyperactivity_3\NN\14052403|was_14|by_26
3371379
D014700_D020258 CID verapamil_0\NNP\2938514|-_9|neurotoxicity_32|._45 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) neurotoxicity_4\NN\0|verapamil_32|-_23|._13
D014700_D020258 CID verapamil_11\NN\2938514|NONE_0 (r_pobj) with_10\IN\0|combined_19 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) after_7\IN\0|of_31 (r_prep) signs_3\NNS\6643763|NONE_0 (l_prep) of_4\IN\0|after_31 (l_pobj) neurotoxicity_6\NN\0|NONE_0
D002118_D020258 NONE calcium_19\NN\14625458|NONE_0 (r_compound) entry_20\NN\6502378|the_12 (r_compound) blocker_21\NN\10101634|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) discontinuation_16\NN\209943|NONE_0 (r_pobj) after_15\IN\0|complete_18 (r_prep) recovery_14\NN\7357388|patients_107|._59 (r_dobj) showed_12\VBD\2137132|NONE_0 (l_nsubj) patients_1\NNS\9898892|recovery_107|._166 (l_prep) with_2\IN\0|two_13 (l_pobj) signs_3\NNS\6643763|NONE_0 (l_prep) of_4\IN\0|after_31 (l_pobj) neurotoxicity_6\NN\0|NONE_0
D002220_D020258 CID carbamazepine_3\NN\0|NONE_0 (r_compound) neurotoxicity_4\NN\0|verapamil_32|-_23|._13
D002220_D020258 CID carbamazepine_5\JJ\0|NONE_0 (r_compound) neurotoxicity_6\NN\0|NONE_0
20080419
D010862_D004827 CID pilocarpine_24\NN\14712692|NONE_0 (r_pobj) by_23\IN\0|in_15 (r_agent) induced_22\VBN\1627355|a_20|of_12 (r_acl) model_19\NN\5888929|NONE_0 (l_prep) of_20\IN\0|a_8|induced_12 (l_pobj) epilepsy_21\NN\14085708|NONE_0
10457883
16938416
C032109_D050197 NONE esters_38\NNS\14727670|reported_107|administered_82|dose_64|testosterone_50|)_6|and_8|atherosclerosis_19 (r_appos) therapy_33\NN\657604|NONE_0 (l_conj) atherosclerosis_42\NN\14108324|reported_126|administered_101|dose_83|testosterone_69|esters_19|)_13|and_11
D004967_D050197 NONE estrogen_30\NN\14745635|-_8 (r_compound) testosterone_32\NN\14747587|reported_57|administered_32|dose_14|esters_50|)_56|and_58|atherosclerosis_69 (r_compound) therapy_33\NN\657604|NONE_0 (l_conj) atherosclerosis_42\NN\14108324|reported_126|administered_101|dose_83|testosterone_69|esters_19|)_13|and_11
D013739_D050197 CID testosterone_3\NN\14747587|is_13|with_27|._71 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|testosterone_27|is_14|._44 (l_pobj) atherosclerosis_7\NN\14108324|NONE_0
D013739_D050197 CID testosterone_32\NN\14747587|reported_57|administered_32|dose_14|esters_50|)_56|and_58|atherosclerosis_69 (r_compound) therapy_33\NN\657604|NONE_0 (l_conj) atherosclerosis_42\NN\14108324|reported_126|administered_101|dose_83|testosterone_69|esters_19|)_13|and_11
D013739_D050197 CID testosterone_7\NN\14747587|dose_5 (r_compound) therapy_8\NN\657604|that_28|may_8|adversely_12|atherosclerosis_29|and_69|indicate_73 (r_nsubj) affect_11\VB\26192|results_66|._120 (l_dobj) atherosclerosis_12\NN\14108324|that_57|therapy_29|may_21|adversely_17|and_40|indicate_44
D002784_D003920 NONE cholesterol_9\NN\15058310|,_17|pressure_34 (r_compound) level_10\NN\4916342|,_14 (r_conj) diabetes_7\NNS\14075199|NONE_0
D000431_D003920 NONE alcohol_17\NN\7881800|NONE_0 (r_compound) use_18\NN\407535|systolic_36|blood_27|,_13|or_11 (r_conj) pressure_14\NN\11419404|cholesterol_34|,_17 (r_conj) level_10\NN\4916342|,_14 (r_conj) diabetes_7\NNS\14075199|NONE_0
17612891
D003024_D012559 NONE clozapine_16\NN\3713736|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) commencement_14\NN\15180528|NONE_0 (r_pobj) after_13\IN\0|male_64|onset_21|._31 (r_prep) developed_7\VBD\1753788|NONE_0 (l_nsubj) male_4\NN\15388|onset_43|after_64|._95 (l_prep) with_5\IN\0|a_19|old_9 (l_pobj) schizophrenia_6\NN\14398067|NONE_0
D003024_D009205 CID clozapine_4\NN\3713736|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|acute_18|._25 (r_acl) myocarditis_1\NN\14338942|NONE_0
D003024_D009205 CID clozapine_10\NN\3713736|NONE_0 (r_pobj) of_9\IN\0|the_17 (r_prep) commencement_8\NN\15180528|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|a_28|of_21 (r_acl) case_1\NN\7283608|is_72|,_84|highlighting_86|._150 (l_prep) of_2\IN\0|a_7|associated_21 (l_pobj) myocarditis_4\NN\14338942|NONE_0
D003024_D009205 CID clozapine_16\NN\3713736|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) commencement_14\NN\15180528|NONE_0 (r_pobj) after_13\IN\0|male_64|onset_21|._31 (r_prep) developed_7\VBD\1753788|NONE_0 (l_dobj) onset_10\NN\7325190|male_43|after_21|._52 (l_prep) of_11\IN\0|a_15|sudden_13 (l_pobj) myocarditis_12\NN\14338942|NONE_0
D003024_D009205 CID clozapine_11\NN\3713736|NONE_0 (r_pobj) of_10\IN\0|the_8 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|an_40|recognized_24 (r_acl) complication_5\NN\1073995|myocarditis_42|._49 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) myocarditis_0\NNP\14338942|complication_42|._91
D003024_D011618 NONE clozapine_2\NN\3713736|NONE_0 (r_pobj) considering_0\VBG\689344|standard_44 (r_csubj) remains_3\VBZ\2684|,_61|there_63|need_82|._180 (l_attr) standard_6\NN\13577171|considering_44 (l_prep) in_7\IN\13603305|the_18|gold_14 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) psychosis_11\NN\14380140|NONE_0
12716030
D006493_D006470 NONE heparin_7\VBN\2718259|in_47|,_2|volume_30|._109 (r_nsubj) enhanced_8\VBD\227165|NONE_0 (l_dobj) volume_11\NN\33615|in_77|,_32|heparin_30|._79 (l_prep) over_13\IN\5867413|the_29|hematoma_25|3.4-fold_9 (l_pobj) that_14\DT\0|NONE_0 (l_acl) seen_15\VBN\2106506|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) control_17\NN\5190804|NONE_0 (l_dobj) animals_19\NNS\4475|NONE_0 (l_conj) bleeding_22\NN\14285662|ich_20|and_8
D006493_D002543 NONE heparin_7\VBN\2718259|in_47|,_2|volume_30|._109 (r_nsubj) enhanced_8\VBD\227165|NONE_0 (l_prep) in_0\IN\13603305|,_45|heparin_47|volume_77|._156 (l_pobj) induction_2\NN\7450842|NONE_0 (l_compound) ich_1\NNP\0|using_14
D006493_D002543 NONE heparin_7\VBN\2718259|in_47|,_2|volume_30|._109 (r_nsubj) enhanced_8\VBD\227165|NONE_0 (l_dobj) volume_11\NN\33615|in_77|,_32|heparin_30|._79 (l_prep) over_13\IN\5867413|the_29|hematoma_25|3.4-fold_9 (l_pobj) that_14\DT\0|NONE_0 (l_acl) seen_15\VBN\2106506|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) control_17\NN\5190804|NONE_0 (l_dobj) animals_19\NNS\4475|NONE_0 (l_compound) ich_18\NNP\0|and_12|bleeding_20
D006493_D006406 CID heparin_7\VBN\2718259|in_47|,_2|volume_30|._109 (r_nsubj) enhanced_8\VBD\227165|NONE_0 (l_dobj) volume_11\NN\33615|in_77|,_32|heparin_30|._79 (l_compound) hematoma_10\NN\14317720|the_4|3.4-fold_16|over_25
16274958
D017255_D055154 CID acitretin_3\NN\0|recurrent_24|and_4|._9 (r_conj) dysphonia_1\NN\14400677|NONE_0
D017255_D055154 CID acitretin_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|while_22|she_16|was_12 (r_agent) treated_13\VBN\2376958|we_69|case_55|._20 (r_advcl) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_14|treated_55|._75 (l_prep) of_4\IN\0|the_9 (l_pobj) woman_6\NN\9605289|NONE_0 (l_acl) complaining_7\VBG\0|a_8 (l_prep) of_8\IN\0|NONE_0 (l_pobj) dysphonia_9\NN\14400677|NONE_0
D017255_D055154 CID acitretin_10\NN\0|-_9 (r_advmod) induced_12\VBN\1627355|NONE_0 (r_amod) dysphonia_13\NN\14400677|NONE_0
19631624
D002188_D007859 NONE cannabis_12\NN\13112664|NONE_0 (r_compound) users_13\NNS\7846|NONE_0 (r_pobj) in_11\IN\13603305|frontocortical_28 (r_prep) hypoactivity_10\NN\0|parahippocampal_49|and_19 (r_conj) hyperactivity_7\NN\14052403|in_40|:_18|._63 (r_appos) deficits_0\NNS\5113133|NONE_0 (l_prep) in_1\IN\13603305|:_22|hyperactivity_40|._103 (l_pobj) learning_2\NN\5701944|NONE_0 (l_conj) memory_4\NN\5926676|and_4
D018817_D008569 CID ecstasy_5\NN\13985818|NONE_0 (r_compound) users_6\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|learning_29|and_17|correlates_34 (r_prep) deficits_3\NNS\5113133|NONE_0
D018817_D008569 CID ecstasy_6\NN\13985818|NONE_0 (r_compound) users_7\NNS\7846|that_13|impairments_14 (r_nsubj) display_8\VBP\6879180|it_50|has_47|been_43|consistently_38|._54 (l_dobj) impairments_9\NNS\7296428|that_27|users_14 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) performance_14\NN\6619065|NONE_0 (l_nmod) learning_11\NN\5701944|NONE_0 (l_conj) memory_13\NN\5926676|and_4
D002188_D006948 NONE cannabis_12\NN\13112664|NONE_0 (r_compound) users_13\NNS\7846|NONE_0 (r_pobj) in_11\IN\13603305|frontocortical_28 (r_prep) hypoactivity_10\NN\0|parahippocampal_49|and_19 (r_conj) hyperactivity_7\NN\14052403|in_40|:_18|._63
D018817_D020258 NONE ecstasy_1\NN\13985818|-_7 (r_npadvmod) specific_3\JJ\5817396|these_14 (r_amod) effects_4\NNS\13245626|may_8|be_12|to_23|._120 (r_nsubjpass) related_7\VBN\628491|NONE_0 (l_prep) to_8\IN\0|effects_23|may_15|be_11|._97 (l_pobj) vulnerability_10\NN\14540765|NONE_0 (l_prep) to_16\IN\0|the_58|of_40 (l_pobj) effects_19\NNS\13245626|NONE_0 (l_amod) neurotoxic_18\JJ\0|the_4|of_19
D018817_D020258 NONE ecstasy_21\NN\13985818|NONE_0 (r_pobj) of_20\IN\0|the_23|neurotoxic_19 (r_prep) effects_19\NNS\13245626|NONE_0 (l_amod) neurotoxic_18\JJ\0|the_4|of_19
D018817_D006948 NONE ecstasy_13\NN\13985818|-_7 (r_npadvmod) specific_15\JJ\5817396|in_23 (r_amod) hyperactivity_16\NN\14052403|analysis_79|,_42|left_44|._132
D002188_D008569 NONE cannabis_12\NN\13112664|NONE_0 (r_compound) users_13\NNS\7846|NONE_0 (r_pobj) in_11\IN\13603305|frontocortical_28 (r_prep) hypoactivity_10\NN\0|parahippocampal_49|and_19 (r_conj) hyperactivity_7\NN\14052403|in_40|:_18|._63 (r_appos) deficits_0\NNS\5113133|NONE_0 (l_prep) in_1\IN\13603305|:_22|hyperactivity_40|._103 (l_pobj) learning_2\NN\5701944|NONE_0 (l_conj) memory_4\NN\5926676|and_4
D018817_D007859 CID ecstasy_5\NN\13985818|NONE_0 (r_compound) users_6\NNS\7846|NONE_0 (r_pobj) in_4\IN\13603305|learning_29|and_17|correlates_34 (r_prep) deficits_3\NNS\5113133|NONE_0
D018817_D007859 CID ecstasy_6\NN\13985818|NONE_0 (r_compound) users_7\NNS\7846|that_13|impairments_14 (r_nsubj) display_8\VBP\6879180|it_50|has_47|been_43|consistently_38|._54 (l_dobj) impairments_9\NNS\7296428|that_27|users_14 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) performance_14\NN\6619065|NONE_0 (l_nmod) learning_11\NN\5701944|NONE_0 (l_conj) memory_13\NN\5926676|and_4
1732369
D004317_D009202 CID doxorubicin_0\NNP\2716866|agent_56|._109 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_6\NN\7347|doxorubicin_56|._53 (l_acl) known_7\VBN\0|an_47|effective_44|anticancer_34|chemotherapeutic_23 (l_xcomp) cause_9\VB\7323922|NONE_0 (l_dobj) cardiomyopathy_13\NN\14103288|to_27
D004280_D006331 NONE dobutamine_21\NN\0|NONE_0 (r_compound) infusion_22\NN\14589223|differentiate_12 (r_dobj) using_20\VBG\418025|develop_126|,_31|study_20|was_14|._150 (r_xcomp) performed_19\VBN\0|NONE_0 (l_advcl) develop_1\VB\1753788|,_95|study_106|was_112|using_126|._276 (l_dobj) test_7\NN\5798043|to_56 (l_prep) for_8\IN\0|a_50|sensitive_43|echocardiographic_33|screening_15 (l_pobj) damage_10\NN\7296428|NONE_0
D004317_D009369 NONE doxorubicin_13\NN\2716866|-_11 (r_npadvmod) treated_15\VBN\2376958|asymptomatic_25|term_13|of_28 (r_amod) survivors_19\NNS\9630641|NONE_0 (l_prep) of_20\IN\0|asymptomatic_53|treated_28|term_15 (l_pobj) cancer_22\NN\14239425|NONE_0
D004317_D009369 NONE doxorubicin_13\NN\2716866|to_3 (r_pobj) due_11\IN\5174653|cardiac_15 (r_amod) damage_10\NN\7296428|NONE_0 (r_pobj) for_8\IN\0|a_50|sensitive_43|echocardiographic_33|screening_15 (r_prep) test_7\NN\5798043|to_56 (r_dobj) develop_1\VB\1753788|,_95|study_106|was_112|using_126|._276 (r_advcl) performed_19\VBN\0|NONE_0 (l_xcomp) using_20\VBG\418025|develop_126|,_31|study_20|was_14|._150 (l_xcomp) differentiate_24\VB\618878|infusion_12 (l_dobj) survivors_29\NNS\9630641|to_40 (l_prep) of_30\IN\0|asymptomatic_33|term_15|treated_20 (l_pobj) cancer_32\NN\14239425|NONE_0
D004317_D009369 NONE doxorubicin_35\NN\2716866|NONE_0 (r_pobj) with_34\IN\0|from_17 (r_prep) treated_33\VBN\2376958|asymptomatic_53|term_35|of_20 (r_acl) survivors_29\NNS\9630641|to_40 (l_prep) of_30\IN\0|asymptomatic_33|term_15|treated_20 (l_pobj) cancer_32\NN\14239425|NONE_0
D004317_D006331 NONE doxorubicin_13\NN\2716866|to_3 (r_pobj) due_11\IN\5174653|cardiac_15 (r_amod) damage_10\NN\7296428|NONE_0
D004317_D006331 NONE doxorubicin_35\NN\2716866|NONE_0 (r_pobj) with_34\IN\0|from_17 (r_prep) treated_33\VBN\2376958|asymptomatic_53|term_35|of_20 (r_acl) survivors_29\NNS\9630641|to_40 (r_dobj) differentiate_24\VB\618878|infusion_12 (r_xcomp) using_20\VBG\418025|develop_126|,_31|study_20|was_14|._150 (r_xcomp) performed_19\VBN\0|NONE_0 (l_advcl) develop_1\VB\1753788|,_95|study_106|was_112|using_126|._276 (l_dobj) test_7\NN\5798043|to_56 (l_prep) for_8\IN\0|a_50|sensitive_43|echocardiographic_33|screening_15 (l_pobj) damage_10\NN\7296428|NONE_0
D004280_D009369 NONE dobutamine_0\NNP\0|echocardiography_18|:_34|indicator_48|._167 (r_nsubj) stress_1\VBP\7083732|NONE_0 (l_appos) indicator_6\NN\6636259|dobutamine_48|echocardiography_30|:_14|._119 (l_prep) of_7\IN\0|a_22|sensitive_20 (l_pobj) function_10\NN\13783581|NONE_0 (l_prep) in_11\IN\13603305|diminished_31|myocardial_20 (l_pobj) survivors_19\NNS\9630641|NONE_0 (l_prep) of_20\IN\0|asymptomatic_53|treated_28|term_15 (l_pobj) cancer_22\NN\14239425|NONE_0
D004280_D009369 NONE dobutamine_21\NN\0|NONE_0 (r_compound) infusion_22\NN\14589223|differentiate_12 (r_dobj) using_20\VBG\418025|develop_126|,_31|study_20|was_14|._150 (l_xcomp) differentiate_24\VB\618878|infusion_12 (l_dobj) survivors_29\NNS\9630641|to_40 (l_prep) of_30\IN\0|asymptomatic_33|term_15|treated_20 (l_pobj) cancer_32\NN\14239425|NONE_0
3629586
D002511_D006402 NONE cephalosporin_15\JJ\2716866|in_29 (r_amod) hematotoxicity_16\NN\0|NONE_0
D002511_D006402 NONE cephalosporin_0\JJ\2716866|NONE_0 (r_amod) antibiotics_1\NNS\2716205|variety_20|characterized_124|._137 (r_nsubj) cause_2\VBP\7323922|NONE_0 (l_dobj) variety_4\NN\7951464|antibiotics_20|characterized_104|._117 (l_prep) of_5\IN\0|a_10|,_34 (l_pobj) disturbances_7\NNS\407535|NONE_0
D002511_D006402 NONE cephalosporin_4\NN\2716866|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) rechallenge_1\VB\0|NONE_0 (r_pobj) upon_0\IN\0|,_42|syndrome_60|was_69|in_84 (r_prep) reproduced_10\VBN\1621555|;_30|dogs_71|period_117|compared_140|._207 (l_nsubjpass) syndrome_8\NN\5870365|upon_60|,_18|was_9|in_24
D002511_D006402 NONE cephalosporin_20\NN\2716866|-_13 (r_advmod) induced_22\VBN\1627355|the_18|blood_8|described_25 (r_amod) dyscrasias_24\NNS\14052046|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) similar_17\JJ\0|NONE_0 (r_amod) hematotoxicity_16\NN\0|that_84|administration_75|can_11|and_86|provides_95
D002511_D006402 NONE cephalosporin_20\NN\2716866|-_13 (r_advmod) induced_22\VBN\1627355|the_18|blood_8|described_25 (r_amod) dyscrasias_24\NNS\14052046|NONE_0
D015790_D009503 CID cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_dobj) incidence_21\NN\13821570|in_132|,_99|administration_81|thrombocytopenia_38|._84 (l_prep) of_22\IN\0|a_27|dependent_20 (l_pobj) anemia_23\NN\14189204|NONE_0 (l_conj) neutropenia_25\NN\14196405|,_2
C021341_D064420 NONE cefazedone_12\NN\0|or_3 (r_conj) cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|,_33|administration_51|incidence_132|thrombocytopenia_170|._216 (l_pobj) studies_4\NNS\635850|NONE_0 (l_compound) toxicity_3\NN\13576101|four_14|subacute_9
D015790_D013921 CID cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_ccomp) thrombocytopenia_28\NN\14189204|in_170|,_137|administration_119|incidence_38|._46
C021341_D006402 NONE cefazedone_6\NN\0|and_4 (r_conj) cefonicid_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_24|hematologic_20|:_38|model_52|._96 (r_prep) effects_2\NNS\13245626|NONE_0 (l_appos) model_13\NN\5888929|the_76|hematologic_72|of_52|:_14|._44 (l_prep) of_14\IN\0|a_18|potential_16 (l_pobj) hematotoxicity_16\NN\0|NONE_0
C021341_D006402 NONE cefazedone_29\NN\0|400_41|mg/kg_33|or_17 (r_conj) cefonicid_23\NN\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|NONE_0 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) of_16\IN\0|50_4 (r_prep) %_15\NN\0|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) occurred_11\VBD\0|anemia_55|compromising_35|and_4|._99 (r_conj) was_3\VBD\0|NONE_0 (l_attr) compromising_6\NN\1035530|anemia_20|and_31|occurred_35|._134 (l_prep) of_7\IN\0|the_22|most_18 (l_pobj) cytopenias_9\NNS\14189204|NONE_0
C021341_D006402 NONE cefazedone)-treated_20\VBN\0|cefonicid_19|(_9 (r_amod) dogs_21\NNS\2083346|reproduced_71|;_41|period_46|compared_69|._136 (r_nsubj) showed_22\VBD\2137132|NONE_0 (l_ccomp) reproduced_10\VBN\1621555|;_30|dogs_71|period_117|compared_140|._207 (l_nsubjpass) syndrome_8\NN\5870365|upon_60|,_18|was_9|in_24
C021341_D006402 NONE cefazedone_11\NN\0|or_3 (r_conj) cefonicid_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|high_11 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_5\IN\0|the_19|to_41 (r_prep) administration_4\NN\1133281|that_9|can_64|hematotoxicity_75|and_161|provides_170 (r_nsubj) induce_15\VB\1627355|we_89|._172 (l_dobj) hematotoxicity_16\NN\0|that_84|administration_75|can_11|and_86|provides_95
C021341_D006402 NONE cefazedone_11\NN\0|or_3 (r_conj) cefonicid_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|high_11 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_5\IN\0|the_19|to_41 (r_prep) administration_4\NN\1133281|that_9|can_64|hematotoxicity_75|and_161|provides_170 (r_nsubj) induce_15\VB\1627355|we_89|._172 (l_dobj) hematotoxicity_16\NN\0|that_84|administration_75|can_11|and_86|provides_95 (l_amod) similar_17\JJ\0|NONE_0 (l_prep) to_18\IN\0|NONE_0 (l_pobj) dyscrasias_24\NNS\14052046|NONE_0
D015790_D064420 NONE cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|,_33|administration_51|incidence_132|thrombocytopenia_170|._216 (l_pobj) studies_4\NNS\635850|NONE_0 (l_compound) toxicity_3\NN\13576101|four_14|subacute_9
C021341_D009503 CID cefazedone_12\NN\0|or_3 (r_conj) cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_dobj) incidence_21\NN\13821570|in_132|,_99|administration_81|thrombocytopenia_38|._84 (l_prep) of_22\IN\0|a_27|dependent_20 (l_pobj) anemia_23\NN\14189204|NONE_0 (l_conj) neutropenia_25\NN\14196405|,_2
C021341_D013921 CID cefazedone_12\NN\0|or_3 (r_conj) cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_ccomp) thrombocytopenia_28\NN\14189204|in_170|,_137|administration_119|incidence_38|._46
D015790_D006402 NONE cefonicid_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_24|hematologic_20|:_38|model_52|._96 (r_prep) effects_2\NNS\13245626|NONE_0 (l_appos) model_13\NN\5888929|the_76|hematologic_72|of_52|:_14|._44 (l_prep) of_14\IN\0|a_18|potential_16 (l_pobj) hematotoxicity_16\NN\0|NONE_0
D015790_D006402 NONE cefonicid_23\NN\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|NONE_0 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) of_16\IN\0|50_4 (r_prep) %_15\NN\0|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) occurred_11\VBD\0|anemia_55|compromising_35|and_4|._99 (r_conj) was_3\VBD\0|NONE_0 (l_attr) compromising_6\NN\1035530|anemia_20|and_31|occurred_35|._134 (l_prep) of_7\IN\0|the_22|most_18 (l_pobj) cytopenias_9\NNS\14189204|NONE_0
D015790_D006402 NONE cefonicid_16\NN\0|(_10|cefazedone)-treated_19 (r_amod) dogs_21\NNS\2083346|reproduced_71|;_41|period_46|compared_69|._136 (r_nsubj) showed_22\VBD\2137132|NONE_0 (l_ccomp) reproduced_10\VBN\1621555|;_30|dogs_71|period_117|compared_140|._207 (l_nsubjpass) syndrome_8\NN\5870365|upon_60|,_18|was_9|in_24
D015790_D006402 NONE cefonicid_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|high_11 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_5\IN\0|the_19|to_41 (r_prep) administration_4\NN\1133281|that_9|can_64|hematotoxicity_75|and_161|provides_170 (r_nsubj) induce_15\VB\1627355|we_89|._172 (l_dobj) hematotoxicity_16\NN\0|that_84|administration_75|can_11|and_86|provides_95
D015790_D006402 NONE cefonicid_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|high_11 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_5\IN\0|the_19|to_41 (r_prep) administration_4\NN\1133281|that_9|can_64|hematotoxicity_75|and_161|provides_170 (r_nsubj) induce_15\VB\1627355|we_89|._172 (l_dobj) hematotoxicity_16\NN\0|that_84|administration_75|can_11|and_86|provides_95 (l_amod) similar_17\JJ\0|NONE_0 (l_prep) to_18\IN\0|NONE_0 (l_pobj) dyscrasias_24\NNS\14052046|NONE_0
D015790_D000740 CID cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_dobj) incidence_21\NN\13821570|in_132|,_99|administration_81|thrombocytopenia_38|._84 (l_prep) of_22\IN\0|a_27|dependent_20 (l_pobj) anemia_23\NN\14189204|NONE_0
D015790_D000740 CID cefonicid_23\NN\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|NONE_0 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) of_16\IN\0|50_4 (r_prep) %_15\NN\0|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) occurred_11\VBD\0|anemia_55|compromising_35|and_4|._99 (r_conj) was_3\VBD\0|NONE_0 (l_nsubj) anemia_2\NN\14189204|compromising_20|and_51|occurred_55|._154
C021341_D000740 CID cefazedone_12\NN\0|or_3 (r_conj) cefonicid_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_31|intravenous_27|to_27 (r_prep) administration_8\NN\1133281|in_51|,_18|incidence_81|thrombocytopenia_119|._165 (r_nsubj) caused_16\VBD\1617192|NONE_0 (l_dobj) incidence_21\NN\13821570|in_132|,_99|administration_81|thrombocytopenia_38|._84 (l_prep) of_22\IN\0|a_27|dependent_20 (l_pobj) anemia_23\NN\14189204|NONE_0
C021341_D000740 CID cefazedone_29\NN\0|400_41|mg/kg_33|or_17 (r_conj) cefonicid_23\NN\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|NONE_0 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) of_16\IN\0|50_4 (r_prep) %_15\NN\0|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) occurred_11\VBD\0|anemia_55|compromising_35|and_4|._99 (r_conj) was_3\VBD\0|NONE_0 (l_nsubj) anemia_2\NN\14189204|compromising_20|and_51|occurred_55|._154
14698717
D010672_D004827 NONE phenytoin_10\JJ\3550533|in_20 (r_compound) treatment_11\NN\654885|NONE_0 (l_prep) in_12\IN\13603305|phenytoin_20 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_amod) epileptic_14\JJ\10595647|some_5
D010672_D011605 NONE phenytoin_6\NN\3550533|NONE_0 (r_pobj) with_5\IN\0|in_15 (r_prep) treatment_4\NN\654885|to_3 (r_pobj) due_2\IN\5174653|acute_16|._57 (r_amod) psychosis_1\NN\14380140|NONE_0
D010672_D011605 NONE phenytoin_10\JJ\3550533|for_20 (r_compound) treatment_11\NN\654885|NONE_0 (r_dobj) following_9\VBG\8180190|NONE_0 (r_acl) psychosis_8\NN\14380140|who_14
D010672_D011605 NONE phenytoin_10\JJ\3550533|in_20 (r_compound) treatment_11\NN\654885|NONE_0 (r_pobj) following_9\VBG\8180190|that_11 (r_prep) occur_8\VBP\0|the_28|psychotic_24 (r_relcl) symptoms_6\NNS\5823932|that_19|may_77|result_95
D010672_D012640 NONE phenytoin_10\JJ\3550533|in_20 (r_compound) treatment_11\NN\654885|NONE_0 (r_pobj) following_9\VBG\8180190|that_11 (r_prep) occur_8\VBP\0|the_28|psychotic_24 (r_relcl) symptoms_6\NNS\5823932|that_19|may_77|result_95 (r_nsubj) be_17\VB\14625458|case_114|._57 (l_attr) result_20\NN\34213|that_114|symptoms_95|may_18 (l_amod) unrelated_24\JJ\0|the_33|direct_29|of_15|,_2 (l_prep) to_25\IN\0|NONE_0 (l_pobj) seizures_26\NNS\14081375|NONE_0
D010672_D014277 NONE phenytoin_10\JJ\3550533|for_20 (r_compound) treatment_11\NN\654885|NONE_0 (l_prep) for_12\IN\0|phenytoin_20 (l_pobj) neuralgia_14\NN\14322699|NONE_0
17931375
D006493_D003288 CID heparin_10\JJ\2718259|subcutaneous_13|on_18 (r_compound) injection_11\NN\320852|NONE_0 (l_prep) on_12\IN\0|subcutaneous_31|heparin_18 (l_pobj) bruising_13\VBG\69879|NONE_0
D006493_D003288 CID heparin_24\NN\2718259|NONE_0 (r_pobj) of_23\IN\0|the_27|subcutaneous_23 (r_prep) injection_22\NN\320852|NONE_0 (r_pobj) of_19\IN\0|the_19 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) following_16\VBG\8180190|the_54|of_43 (r_prep) effect_8\NN\34213|to_17 (l_prep) of_9\IN\0|the_11|following_43 (l_pobj) duration_11\NN\15113229|NONE_0 (l_prep) on_12\IN\0|injection_19 (l_pobj) bruising_13\VBG\69879|NONE_0
D006493_D003288 CID heparin_13\NN\2718259|NONE_0 (r_pobj) of_12\IN\0|the_27|subcutaneous_23 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) following_8\VBG\8180190|to_29|bruising_18 (r_prep) prevent_4\VB\0|different_21 (l_dobj) bruising_5\NN\69879|to_11|following_18
D006493_D003288 CID heparin_13\NN\2718259|NONE_0 (r_pobj) of_12\IN\0|the_27|subcutaneous_23 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) following_8\VBG\8180190|to_29|bruising_18 (r_prep) prevent_4\VB\0|different_21 (r_acl) methods_2\NNS\5616786|although_19|have_85|been_90|widely_95|and_110|described_114 (r_nsubjpass) studied_17\VBN\0|,_21|effect_27|is_95|little_98|._115 (r_advcl) documented_35\JJ\1000214|NONE_0 (l_nsubjpass) effect_22\NN\34213|studied_27|,_6|is_68|little_71|._88 (l_prep) of_23\IN\0|the_11 (l_pobj) duration_25\NN\15113229|NONE_0 (l_prep) on_26\IN\0|injection_19 (l_pobj) occurrence_28\NN\29378|NONE_0 (l_prep) of_29\IN\0|the_15 (l_pobj) bruising_30\VBG\69879|NONE_0
D006493_D003288 CID heparin_6\NN\2718259|areas_16 (r_pobj) on_4\IN\0|the_13 (r_prep) bruising_3\NN\69879|NONE_0
D006493_D003288 CID heparin_18\NN\2718259|NONE_0 (r_pobj) of_17\IN\0|the_32|subcutaneous_28 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) following_13\VBG\8180190|that_59|duration_44|effect_28 (r_prep) had_6\VBD\0|it_42|was_39|._87 (l_dobj) effect_8\NN\34213|that_31|duration_16|following_28 (l_prep) on_9\IN\0|an_10 (l_pobj) bruising_10\VBG\69879|NONE_0
D006493_D010146 CID heparin_10\JJ\2718259|subcutaneous_13|on_18 (r_compound) injection_11\NN\320852|NONE_0 (l_prep) on_12\IN\0|subcutaneous_31|heparin_18 (l_pobj) bruising_13\VBG\69879|NONE_0 (l_conj) pain_15\NN\14299637|and_4
D006493_D010146 CID heparin_24\NN\2718259|NONE_0 (r_pobj) of_23\IN\0|the_27|subcutaneous_23 (r_prep) injection_22\NN\320852|NONE_0 (r_pobj) of_19\IN\0|the_19 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) following_16\VBG\8180190|the_54|of_43 (r_prep) effect_8\NN\34213|to_17 (l_prep) of_9\IN\0|the_11|following_43 (l_pobj) duration_11\NN\15113229|NONE_0 (l_prep) on_12\IN\0|injection_19 (l_pobj) bruising_13\VBG\69879|NONE_0 (l_conj) pain_15\NN\14299637|and_4
D006493_D010146 CID heparin_13\NN\2718259|NONE_0 (r_pobj) of_12\IN\0|the_27|subcutaneous_23 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) following_8\VBG\8180190|to_29|bruising_18 (r_prep) prevent_4\VB\0|different_21 (l_dobj) bruising_5\NN\69879|to_11|following_18 (l_conj) pain_7\NN\14299637|and_4
D006493_D010146 CID heparin_13\NN\2718259|NONE_0 (r_pobj) of_12\IN\0|the_27|subcutaneous_23 (r_prep) injection_11\NN\320852|NONE_0 (r_pobj) following_8\VBG\8180190|to_29|bruising_18 (r_prep) prevent_4\VB\0|different_21 (r_acl) methods_2\NNS\5616786|although_19|have_85|been_90|widely_95|and_110|described_114 (r_nsubjpass) studied_17\VBN\0|,_21|effect_27|is_95|little_98|._115 (r_advcl) documented_35\JJ\1000214|NONE_0 (l_nsubjpass) effect_22\NN\34213|studied_27|,_6|is_68|little_71|._88 (l_prep) of_23\IN\0|the_11 (l_pobj) duration_25\NN\15113229|NONE_0 (l_prep) on_26\IN\0|injection_19 (l_pobj) occurrence_28\NN\29378|NONE_0 (l_prep) of_29\IN\0|the_15 (l_pobj) bruising_30\VBG\69879|NONE_0 (l_conj) pain_32\NN\14299637|and_4
D006493_D010146 CID heparin_18\NN\2718259|NONE_0 (r_pobj) of_17\IN\0|the_32|subcutaneous_28 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) following_13\VBG\8180190|that_59|duration_44|effect_28 (r_prep) had_6\VBD\0|it_42|was_39|._87 (l_dobj) effect_8\NN\34213|that_31|duration_16|following_28 (l_prep) on_9\IN\0|an_10 (l_pobj) bruising_10\VBG\69879|NONE_0 (l_conj) pain_12\NN\14299637|and_4
2696505
D009599_D006973 NONE nitroprusside_31\NN\0|NONE_0 (r_pobj) of_30\IN\0|NONE_0 (r_prep) discontinuation_29\NN\209943|NONE_0 (r_pobj) after_28\IN\0|associated_144|;_54|hypertension_44|was_31|in_18|._38 (r_prep) observed_24\VBN\2163746|NONE_0 (l_nsubjpass) hypertension_22\NN\14057371|associated_100|;_10|was_13|in_26|after_44|._82
D009599_D007022 CID nitroprusside_6\RB\0|and_4 (l_prep) for_7\IN\0|NONE_0 (l_pobj) hypotension_9\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_10\RB\0|-_13 (r_advmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypotension_13\NN\14057371|induced_46|and_26 (r_conj) hypotension_8\NN\14057371|in_41|,_20|were_50|in_64|._139
D009599_D007022 CID nitroprusside_10\RB\0|-_13 (r_advmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypotension_13\NN\14057371|induced_46|and_26
D009599_D016534 CID nitroprusside_31\NN\0|NONE_0 (r_pobj) of_30\IN\0|NONE_0 (r_prep) discontinuation_29\NN\209943|NONE_0 (r_pobj) after_28\IN\0|associated_144|;_54|hypertension_44|was_31|in_18|._38 (r_prep) observed_24\VBN\2163746|NONE_0 (l_ccomp) associated_3\VBN\628491|;_90|hypertension_100|was_113|in_126|after_144|._182 (l_advcl) increase_13\NN\13576355|infusion_62|was_53|with_38 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) rate_16\NN\13815152|NONE_0 (l_conj) output_19\NN\4007894|heart_23|and_12
D007741_D007022 CID labetalol_4\NN\2721160|NONE_0 (l_conj) nitroprusside_6\RB\0|and_4 (l_prep) for_7\IN\0|NONE_0 (l_pobj) hypotension_9\NN\14057371|NONE_0
D007741_D007022 CID labetalol_5\RB\2721160|-_9 (r_npadvmod) induced_7\VBN\1627355|and_20|hypotension_46 (r_amod) hypotension_8\NN\14057371|in_41|,_20|were_50|in_64|._139
D007741_D007022 CID labetalol_5\RB\2721160|-_9 (r_npadvmod) induced_7\VBN\1627355|and_20|hypotension_46 (r_amod) hypotension_8\NN\14057371|in_41|,_20|were_50|in_64|._139 (l_conj) hypotension_13\NN\14057371|induced_46|and_26
10579464
D003024_D002375 CID clozapine_2\NN\3713736|and_4 (r_conj) nra0160_0\NNP\0|significantly_22|catalepsy_44|in_54|,_61|exceed_94|._145 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_dobj) catalepsy_5\NN\14023236|nra0160_44|significantly_22|in_10|,_17|exceed_50|._101
D008694_D006948 CID methamphetamine_8\NN\2704153|NONE_0 (r_pobj) by_7\IN\0|in_25 (r_agent) induced_6\VBN\1627355|locomotor_24 (r_acl) hyperactivity_5\NN\14052403|nra0160_44|._54
D008694_D006948 CID map_10\NNP\4076846|(_1|)_3 (r_appos) methamphetamine_8\NN\2704153|NONE_0 (r_pobj) by_7\IN\0|in_25 (r_agent) induced_6\VBN\1627355|locomotor_24 (r_acl) hyperactivity_5\NN\14052403|nra0160_44|._54
C121249_D006948 NONE nra0160_0\NNP\0|hyperactivity_44|._98 (r_nsubj) antagonized_3\VBN\1787955|NONE_0 (l_dobj) hyperactivity_5\NN\14052403|nra0160_44|._54
D003024_D006948 NONE clozapine_2\NN\3713736|and_4 (r_conj) nra0160_0\NNP\0|hyperactivity_44|._98 (r_nsubj) antagonized_3\VBN\1787955|NONE_0 (l_dobj) hyperactivity_5\NN\14052403|nra0160_44|._54
C121249_D002375 CID nra0160_0\NNP\0|significantly_22|catalepsy_44|in_54|,_61|exceed_94|._145 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_dobj) catalepsy_5\NN\14023236|nra0160_44|significantly_22|in_10|,_17|exceed_50|._101
19356307
C032208_D003704 NONE alcohol_13\NN\7881800|NONE_0 (r_pobj) of_5\IN\0|the_26|dementia_17 (r_prep) effects_4\NNS\13245626|were_45|using_59|._138 (l_compound) dementia_3\NN\14395018|the_9|of_17
D012601_D008569 CID scopolamine_12\NN\14712692|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) impaired_10\VBN\258857|NONE_0
D012601_D008569 CID scopolamine_12\NN\14712692|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) impaired_10\VBN\258857|NONE_0 (r_amod) memory_9\NN\5926676|to_11 (r_dobj) improve_8\VB\126264|strong_18 (r_acl) ability_6\NN\4723816|oils_19 (r_dobj) showed_4\VBD\2137132|;_63|however_65|,_72|alcohol_85|deficit_106|only_142|,_146|and_148|improve_160|._211 (r_ccomp) relieved_20\VBD\205885|NONE_0 (l_dobj) deficit_22\NN\5113133|showed_106|;_43|however_41|,_34|alcohol_21|only_36|,_40|and_42|improve_54|._105 (l_prep) of_23\IN\0|the_12|in_22 (l_pobj) memory_25\NN\5926676|NONE_0
C032208_D008569 NONE alcohol_19\NN\7881800|showed_85|;_22|however_20|,_13|deficit_21|only_57|,_61|and_63|improve_75|._126 (r_nsubj) relieved_20\VBD\205885|NONE_0 (l_ccomp) showed_4\VBD\2137132|;_63|however_65|,_72|alcohol_85|deficit_106|only_142|,_146|and_148|improve_160|._211 (l_dobj) ability_6\NN\4723816|oils_19 (l_acl) improve_8\VB\126264|strong_18 (l_dobj) memory_9\NN\5926676|to_11 (l_amod) impaired_10\VBN\258857|NONE_0
C032208_D008569 NONE alcohol_19\NN\7881800|showed_85|;_22|however_20|,_13|deficit_21|only_57|,_61|and_63|improve_75|._126 (r_nsubj) relieved_20\VBD\205885|NONE_0 (l_dobj) deficit_22\NN\5113133|showed_106|;_43|however_41|,_34|alcohol_21|only_36|,_40|and_42|improve_54|._105 (l_prep) of_23\IN\0|the_12|in_22 (l_pobj) memory_25\NN\5926676|NONE_0
D012601_D003704 NONE scopolamine_9\NN\14712692|NONE_0 (r_pobj) by_8\IN\0|components_61|._14 (r_agent) induced_7\VBN\1627355|NONE_0 (l_nsubj) components_0\NNS\5867413|by_61|._75 (l_prep) of_1\IN\0|NONE_0 (l_pobj) dementia_6\NN\14395018|NONE_0
C008281_D003704 NONE limonene_8\NN\15068635|NONE_0 (r_nmod) alcohol_13\NN\7881800|NONE_0 (r_pobj) of_5\IN\0|the_26|dementia_17 (r_prep) effects_4\NNS\13245626|were_45|using_59|._138 (l_compound) dementia_3\NN\14395018|the_9|of_17
2273650
D012601_D000647 CID scopolamine_3\NN\14712692|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) produced_1\VBN\1617192|NONE_0 (r_acl) amnesia_0\NNP\5669934|were_50|by_64|given_76|,_121|and_123|facilitated_150
D012601_D000647 CID scopolamine_5\NN\14712692|similarly_20|partially_12|amnesia_55|,_62|but_64|failed_114 (r_nsubj) reversed_7\VBD\109660|NONE_0 (l_dobj) amnesia_12\NN\5669934|similarly_75|scopolamine_55|partially_43|,_7|but_9|failed_59
D012601_D000647 CID scopolamine_5\NN\14712692|similarly_20|partially_12|amnesia_55|,_62|but_64|failed_114 (r_nsubj) reversed_7\VBD\109660|NONE_0 (l_conj) failed_23\VBD\0|similarly_134|scopolamine_114|partially_102|amnesia_59|,_52|but_50 (l_xcomp) reverse_25\VB\13854649|significantly_52|cycloheximide_24|._41 (l_dobj) amnesia_30\NN\5669934|to_37
D012601_D000647 CID scopolamine_9\NN\14712692|-_11 (r_npadvmod) induced_11\VBN\1627355|the_16 (r_amod) amnesia_12\NN\5669934|similarly_75|scopolamine_55|partially_43|,_7|but_9|failed_59
D012601_D000647 CID scopolamine_9\NN\14712692|-_11 (r_npadvmod) induced_11\VBN\1627355|the_16 (r_amod) amnesia_12\NN\5669934|similarly_75|scopolamine_55|partially_43|,_7|but_9|failed_59 (r_dobj) reversed_7\VBD\109660|NONE_0 (l_conj) failed_23\VBD\0|similarly_134|scopolamine_114|partially_102|amnesia_59|,_52|but_50 (l_xcomp) reverse_25\VB\13854649|significantly_52|cycloheximide_24|._41 (l_dobj) amnesia_30\NN\5669934|to_37
D009270_D000647 NONE naloxone_37\NN\3808977|during_9 (r_dobj) administered_36\VBN\2436349|the_36|memory_32|in_15 (r_acl) retrieval_32\NN\13450862|morphine_37|also_28|._72 (r_dobj) facilitated_29\VBD\2547586|amnesia_150|were_100|by_86|given_74|,_29|and_27 (r_conj) reversed_7\VBN\109660|NONE_0 (l_nsubjpass) amnesia_0\NNP\5669934|were_50|by_64|given_76|,_121|and_123|facilitated_150
D009020_D000647 NONE morphine_9\NN\2707683|NONE_0 (r_pobj) by_8\IN\0|amnesia_64|were_14|given_12|,_57|and_59|facilitated_86 (r_agent) reversed_7\VBN\109660|NONE_0 (l_nsubjpass) amnesia_0\NNP\5669934|were_50|by_64|given_76|,_121|and_123|facilitated_150
D009020_D000647 NONE morphine_27\NN\2707683|also_9|retrieval_37|._109 (r_nsubj) facilitated_29\VBD\2547586|amnesia_150|were_100|by_86|given_74|,_29|and_27 (r_conj) reversed_7\VBN\109660|NONE_0 (l_nsubjpass) amnesia_0\NNP\5669934|were_50|by_64|given_76|,_121|and_123|facilitated_150
D003513_D000647 CID cycloheximide_5\NN\0|and_4 (r_conj) scopolamine_3\NN\14712692|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) produced_1\VBN\1617192|NONE_0 (r_acl) amnesia_0\NNP\5669934|were_50|by_64|given_76|,_121|and_123|facilitated_150
D003513_D000647 CID cycloheximide_22\NN\0|significantly_28|reverse_24|._65 (r_nsubj) failed_23\VBD\0|similarly_134|scopolamine_114|partially_102|amnesia_59|,_52|but_50 (r_conj) reversed_7\VBD\109660|NONE_0 (l_dobj) amnesia_12\NN\5669934|similarly_75|scopolamine_55|partially_43|,_7|but_9|failed_59
D003513_D000647 CID cycloheximide_22\NN\0|significantly_28|reverse_24|._65 (r_nsubj) failed_23\VBD\0|similarly_134|scopolamine_114|partially_102|amnesia_59|,_52|but_50 (l_xcomp) reverse_25\VB\13854649|significantly_52|cycloheximide_24|._41 (l_dobj) amnesia_30\NN\5669934|to_37
D003513_D000647 CID cycloheximide_27\RB\0|-_13 (r_advmod) induced_29\VBN\1627355|the_18 (r_amod) amnesia_30\NN\5669934|to_37 (r_dobj) reverse_25\VB\13854649|significantly_52|cycloheximide_24|._41 (r_xcomp) failed_23\VBD\0|similarly_134|scopolamine_114|partially_102|amnesia_59|,_52|but_50 (r_conj) reversed_7\VBD\109660|NONE_0 (l_dobj) amnesia_12\NN\5669934|similarly_75|scopolamine_55|partially_43|,_7|but_9|failed_59
D003513_D000647 CID cycloheximide_27\RB\0|-_13 (r_advmod) induced_29\VBN\1627355|the_18 (r_amod) amnesia_30\NN\5669934|to_37
18217897
D013792_D009369 NONE thalidomide_0\NNP\4166841|has_12|activity_37|in_46 (r_nsubj) limited_2\VBN\4019101|NONE_0 (l_prep) in_7\IN\13603305|thalidomide_46|has_34|activity_9 (l_pobj) lymphomas_15\NNS\14239918|NONE_0 (l_appos) trial_20\NN\786195|relapsed_66|indolent_43|hodgkin_30|:_13 (l_prep) of_21\IN\0|a_17|phase_15|ii_9 (l_pobj) cancer_23\NNP\14239425|NONE_0
D013792_D008228 NONE thalidomide_0\NNP\4166841|has_12|activity_37|in_46 (r_nsubj) limited_2\VBN\4019101|NONE_0 (l_prep) in_7\IN\13603305|thalidomide_46|has_34|activity_9 (l_pobj) lymphomas_15\NNS\14239918|NONE_0
D013792_D009101 NONE thalidomide_0\NNP\4166841|agent_35|._140 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|thalidomide_35|._105 (l_prep) with_5\IN\0|an_26|immunomodulatory_23 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|demonstrated_22 (l_pobj) myeloma_10\NN\14239425|NONE_0
C467567_D008223 NONE lenalidomide_31\NN\0|the_46|generation_35|immunomodulatory_24|,_2 (r_appos) agent_29\NN\7347|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) reported_23\VBN\831651|the_26|higher_22|activity_15 (r_acl) level_22\NN\4916342|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) contrast_17\NN\13854649|to_96|rate_59|and_4 (r_conj) demonstrate_4\VB\2137132|results_18|._205 (l_dobj) rate_8\NN\13815152|to_37|and_55|contrast_59 (l_prep) in_13\IN\13603305|an_55|important_52|response_42|to_28 (l_pobj) lymphomas_15\NNS\14239918|NONE_0
D013792_D008223 NONE thalidomide_0\NNP\4166841|agent_35|._140 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|thalidomide_35|._105 (l_prep) with_5\IN\0|an_26|immunomodulatory_23 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|demonstrated_22 (l_pobj) myeloma_10\NN\14239425|NONE_0 (l_conj) lymphoma_14\NN\14239918|multiple_30|,_14 (l_conj) lymphoma_17\NN\14239918|mantle_43|cell_36|and_22
D013792_D008223 NONE thalidomide_16\NN\4166841|between_99|,_67|patients_62|daily_19|with_25|tolerated_76|._118 (r_dobj) received_15\VBD\2210855|NONE_0 (l_nsubj) patients_8\NNS\9898892|between_37|,_5|thalidomide_62|daily_81|with_87|tolerated_138|._180 (l_prep) with_9\IN\0|24_12 (l_pobj) lymphomas_14\NNS\14239918|NONE_0
D013792_D008223 NONE thalidomide_12\NN\4166841|NONE_0 (r_pobj) to_9\IN\0|an_27|important_24|response_14|in_28 (r_prep) rate_8\NN\13815152|to_37|and_55|contrast_59 (l_prep) in_13\IN\13603305|an_55|important_52|response_42|to_28 (l_pobj) lymphomas_15\NNS\14239918|NONE_0
D013792_D007938 NONE thalidomide_0\NNP\4166841|has_12|activity_37|in_46 (r_nsubj) limited_2\VBN\4019101|NONE_0 (l_prep) in_7\IN\13603305|thalidomide_46|has_34|activity_9 (l_pobj) lymphomas_15\NNS\14239918|NONE_0 (l_appos) trial_20\NN\786195|relapsed_66|indolent_43|hodgkin_30|:_13 (l_prep) of_21\IN\0|a_17|phase_15|ii_9 (l_pobj) cancer_23\NNP\14239425|NONE_0 (l_conj) b._27\NNP\0|the_30|and_19 (l_compound) leukemia_25\NNP\14239918|group_9
D013792_D020522 NONE thalidomide_0\NNP\4166841|agent_35|._140 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|thalidomide_35|._105 (l_prep) with_5\IN\0|an_26|immunomodulatory_23 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|demonstrated_22 (l_pobj) myeloma_10\NN\14239425|NONE_0 (l_conj) lymphoma_14\NN\14239918|multiple_30|,_14
3070035
D002216_D051437 NONE captopril_2\NN\2673637|-_9 (r_npadvmod) induced_4\VBN\1627355|renal_8 (r_amod) insufficiency_6\NN\14462946|NONE_0
D002216_D051437 NONE captopril_4\NN\2673637|-_9 (r_npadvmod) induced_6\VBN\1627355|renal_8 (r_amod) failure_8\NN\66216|NONE_0
D002216_D058186 CID captopril_27\NN\2673637|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treatment_25\NN\654885|NONE_0 (r_pobj) following_24\VBG\8180190|sudden_39|of_18 (r_prep) deterioration_20\NN\14560612|who_21 (l_prep) of_21\IN\0|sudden_21|following_18 (l_pobj) function_23\NN\13783581|NONE_0
D002216_D006978 NONE captopril_2\NN\2673637|-_9 (r_npadvmod) induced_4\VBN\1627355|renal_8 (r_amod) insufficiency_6\NN\14462946|NONE_0 (r_pobj) of_1\IN\0|after_41|._108 (r_prep) reversibility_0\NN\4733640|NONE_0 (l_prep) after_7\IN\0|of_41|._67 (l_pobj) use_9\NN\407535|NONE_0 (l_prep) in_10\IN\13603305|prolonged_14 (l_pobj) case_13\NN\7283608|NONE_0 (l_prep) of_14\IN\0|an_16|unusual_13 (l_pobj) hypertension_16\NN\14057371|NONE_0
D002216_D006973 NONE captopril_27\NN\2673637|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treatment_25\NN\654885|NONE_0 (r_pobj) following_24\VBG\8180190|sudden_39|of_18 (r_prep) deterioration_20\NN\14560612|who_21 (r_dobj) developed_18\VBD\1753788|a_23|solitary_21|,_6 (r_relcl) kidney_15\NN\5333259|NONE_0 (r_pobj) to_12\IN\0|an_25|occluded_22|renal_13 (r_prep) artery_11\NN\5417975|NONE_0 (r_pobj) with_7\IN\0|severe_20 (r_prep) hypertension_6\NN\14057371|NONE_0
1987816
D008094_D011141 CID lithium_0\NN\14625458|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) polyuria_3\NN\14113228|related_21|._70
4008111
D000638_D012848 CID amiodarone_0\NN\2715941|-_10 (r_npadvmod) induced_2\VBN\1627355|sinoatrial_8|._24 (r_amod) block_4\NN\21939|NONE_0
D000638_D012848 CID amiodarone_7\NN\2715941|chronic_8|in_26 (r_compound) administration_8\NN\1133281|to_22 (r_pobj) due_4\JJ\5174653|we_29|block_6|,_88|syndrome_112|._153 (r_prep) observed_1\VBD\2163746|NONE_0 (l_dobj) block_3\NN\21939|we_23|due_6|,_94|syndrome_118|._159
D000638_D012848 CID amiodarone_5\NN\2715941|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) dosage_3\NN\13576355|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) reduction_0\NN\351485|in_47|._145 (r_nsubj) resulted_6\VBD\2633881|NONE_0 (l_prep) in_7\IN\13603305|reduction_47|._98 (l_pobj) disappearance_9\NN\42757|NONE_0 (l_prep) of_10\IN\0|the_18|and_24|persistence_32 (l_pobj) block_13\NN\21939|NONE_0
D000638_D013617 NONE amiodarone_7\NN\2715941|chronic_8|in_26 (r_compound) administration_8\NN\1133281|to_22 (r_pobj) due_4\JJ\5174653|we_29|block_6|,_88|syndrome_112|._153 (r_prep) observed_1\VBD\2163746|NONE_0 (l_dobj) syndrome_24\NN\5870365|we_141|block_118|due_112|,_24|._41 (l_conj) tachycardia_27\NN\14110674|white_36|and_21
D000638_D009202 NONE amiodarone_7\NN\2715941|chronic_8|in_26 (r_compound) administration_8\NN\1133281|to_22 (l_prep) in_9\IN\13603305|chronic_34|amiodarone_26 (l_pobj) boy_14\NN\9624168|NONE_0 (l_prep) with_15\IN\0|a_17|old_8 (l_pobj) cardiomyopathy_17\NN\14103288|NONE_0
D000638_D012804 NONE amiodarone_5\NN\2715941|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) dosage_3\NN\13576355|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) reduction_0\NN\351485|in_47|._145 (r_nsubj) resulted_6\VBD\2633881|NONE_0 (l_prep) in_7\IN\13603305|reduction_47|._98 (l_pobj) disappearance_9\NN\42757|NONE_0 (l_conj) persistence_16\NN\5053688|the_50|of_32|and_8 (l_prep) of_17\IN\0|the_16 (l_pobj) bradycardia_20\NNP\14110674|NONE_0
D000638_D014927 NONE amiodarone_7\NN\2715941|chronic_8|in_26 (r_compound) administration_8\NN\1133281|to_22 (r_pobj) due_4\JJ\5174653|we_29|block_6|,_88|syndrome_112|._153 (r_prep) observed_1\VBD\2163746|NONE_0 (l_dobj) syndrome_24\NN\5870365|we_141|block_118|due_112|,_24|._41
3425586
D003622_D000743 CID dapsone_0\NN\2716205|-_7 (r_npadvmod) associated_2\VBN\628491|heinz_11|body_17|hemolytic_22|in_39|._83 (r_amod) anemia_6\NN\14189204|NONE_0
D003622_D000743 CID dapsone_23\NN\2716205|NONE_0 (r_pobj) of_22\IN\0|a_7|associated_35 (r_prep) dose_21\NN\3740161|while_15 (r_dobj) taking_19\VBG\37396|woman_93|anemia_13|._83 (r_advcl) developed_12\VBD\1753788|NONE_0 (l_dobj) anemia_17\NN\14189204|woman_80|taking_13|._96
D003622_D000743 CID dapsone_21\NN\2716205|since_6|does_8|not_13|anemia_33|at_40 (r_nsubj) cause_24\VB\7323922|to_101|sensitivity_80|in_45|,_25 (l_dobj) anemia_26\NN\14189204|since_39|dapsone_33|does_25|not_20|at_7
D003622_D007918 NONE dapsone_23\NN\2716205|NONE_0 (r_pobj) of_22\IN\0|a_7|associated_35 (r_prep) dose_21\NN\3740161|while_15 (r_dobj) taking_19\VBG\37396|woman_93|anemia_13|._83 (r_advcl) developed_12\VBD\1753788|NONE_0 (l_nsubj) woman_2\NN\9605289|anemia_80|taking_93|._176 (l_conj) leprosy_11\NN\14127211|a_51|cambodian_49|with_33
D003622_D006461 NONE dapsone_23\NN\2716205|NONE_0 (r_pobj) of_22\IN\0|a_7|associated_35 (r_prep) dose_21\NN\3740161|while_15 (l_acl) associated_32\VBN\628491|a_42|of_35 (l_prep) with_33\IN\0|not_23|usually_19 (l_pobj) hemolysis_35\NN\13509528|NONE_0
15338796
D000420_D008173 NONE salbutamol_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|cumulative_17 (r_prep) doses_17\NNS\3740161|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) administration_14\NN\1133281|NONE_0 (r_pobj) after_13\IN\0|obstructive_25|lung_13 (r_prep) disease_12\NN\14061805|NONE_0
D000420_D014202 CID salbutamol_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|tremor_20|side_13|,_13|quantified_15|._54 (r_prep) effects_2\NNS\13245626|NONE_0 (l_compound) tremor_0\NNP\345926|side_7|of_20|,_33|quantified_35|._74
D000420_D014202 CID salbutamol_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|tremor_20|side_13 (r_prep) effects_4\NNS\13245626|to_21 (l_compound) tremor_2\JJ\345926|side_7|of_20
D000420_D014202 CID salbutamol_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|cumulative_17 (r_prep) doses_17\NNS\3740161|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) administration_14\NN\1133281|NONE_0 (r_pobj) after_13\IN\0|obstructive_25|lung_13 (r_prep) disease_12\NN\14061805|NONE_0 (r_pobj) with_9\IN\0|44_12 (r_prep) patients_8\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|determine_41|we_19|tremor_7|._99 (r_prep) assessed_4\VBD\670261|NONE_0 (l_dobj) tremor_5\NN\345926|determine_34|we_12|in_7|._106
D000420_D014202 CID salbutamol_0\NNP\0|significantly_11|severity_42|in_51|._86 (r_nsubj) increased_2\VBD\169651|NONE_0 (l_dobj) severity_4\NN\5036394|salbutamol_42|significantly_31|in_9|._44 (l_compound) tremor_3\NN\345926|NONE_0
3358181
D012312_D014693 CID ritodrine_6\JJ\0|NONE_0 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) after_5\IN\0|cesarean_17 (r_prep) section_4\NN\7020895|NONE_0 (r_pobj) during_2\IN\0|ventricular_29|:_47|interaction_49|._77 (r_prep) tachyarrhythmias_1\NNS\0|NONE_0
D010656_D007022 NONE phenylephrine_22\NN\2682038|such_8 (l_relcl) treat_24\VB\7570720|NONE_0 (l_dobj) patients_26\NNS\9898892|to_21|with_9 (l_amod) hypotensive_25\JJ\10405694|NONE_0
D012312_D002318 NONE ritodrine_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|an_12 (r_prep) infusion_13\NN\14589223|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) cessation_10\NN\7365849|even_11 (r_pobj) after_9\IN\0|serious_42|cardiovascular_34 (r_prep) complications_7\NNS\1073995|NONE_0
D010656_D013610 NONE phenylephrine_22\NN\2682038|such_8 (l_relcl) treat_24\VB\7570720|NONE_0 (l_prep) with_27\IN\0|to_30|patients_9 (l_pobj) tachycardia_28\NNS\14110674|NONE_0
D012312_D007752 NONE ritodrine_6\RB\0|NONE_0 (l_prep) for_7\IN\0|NONE_0 (l_pobj) labor_9\NN\7974025|NONE_0
D012312_D007752 NONE ritodrine_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|the_33|residual_29|betamimetic_20|and_13|effects_21 (r_prep) effects_17\NNS\13245626|NONE_0 (r_pobj) between_13\IN\0|NONE_0 (r_prep) interactions_12\NNS\37396|that_61|patients_56|may_9 (r_dobj) risk_11\VB\14541044|case_73|._126 (l_nsubj) patients_4\NNS\9898892|that_5|may_47|interactions_56 (l_acl) receiving_5\VBG\2210855|NONE_0 (l_dobj) ritodrine_6\RB\0|NONE_0 (l_prep) for_7\IN\0|NONE_0 (l_pobj) labor_9\NN\7974025|NONE_0
19581773
D012254_D004172 NONE ribavirin_21\RB\2725367|and_4 (r_conj) alpha-2b_19\CD\0|(_6|)_2 (r_conj) ifn_17\NNP\0|pegylated_22 (r_appos) interferon_15\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) of_11\IN\0|9_8 (r_prep) weeks_10\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|a_47|old_37|experienced_28|sudden_16|for_85|._114 (r_prep) diplopia_7\NN\14552802|NONE_0
D012254_D019698 NONE ribavirin_8\JJ\2725367|and_4 (r_conj) interferon_6\NN\2725367|pegylated_10|for_35 (r_nmod) treatment_9\NN\654885|NONE_0 (l_prep) for_10\IN\0|pegylated_45|interferon_35 (l_pobj) c._13\NNP\0|NONE_0
D012254_D019698 NONE ribavirin_21\RB\2725367|and_4 (r_conj) alpha-2b_19\CD\0|(_6|)_2 (r_conj) ifn_17\NNP\0|pegylated_22 (r_appos) interferon_15\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) of_11\IN\0|9_8 (r_prep) weeks_10\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|a_47|old_37|experienced_28|sudden_16|for_85|._114 (r_prep) diplopia_7\NN\14552802|NONE_0 (l_prep) for_22\IN\0|a_132|old_122|experienced_113|sudden_101|after_85|._29 (l_pobj) c_25\NNP\13714184|NONE_0
D012254_D019698 NONE ribavirin_21\RB\2725367|and_4 (r_conj) alpha-2b_19\CD\0|(_6|)_2 (r_conj) ifn_17\NNP\0|pegylated_22 (r_appos) interferon_15\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) of_11\IN\0|9_8 (r_prep) weeks_10\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|a_47|old_37|experienced_28|sudden_16|for_85|._114 (r_prep) diplopia_7\NN\14552802|NONE_0 (l_prep) for_22\IN\0|a_132|old_122|experienced_113|sudden_101|after_85|._29 (l_pobj) c_25\NNP\13714184|NONE_0 (l_appos) chc_27\NNP\0|chronic_21|hepatitis_13|(_1|)_3
D012254_D019698 NONE ribavirin_12\RB\2725367|pegylated_27|ifn_17|and_4|for_10 (r_conj) alpha-2b_10\CD\0|NONE_0 (l_prep) for_13\IN\0|pegylated_37|ifn_27|and_14|ribavirin_10 (l_pobj) chc_14\NNP\0|NONE_0
C417083_D004172 NONE alpha-2b_19\CD\0|(_6|)_2 (r_conj) ifn_17\NNP\0|pegylated_22 (r_appos) interferon_15\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) of_11\IN\0|9_8 (r_prep) weeks_10\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|a_47|old_37|experienced_28|sudden_16|for_85|._114 (r_prep) diplopia_7\NN\14552802|NONE_0
C417083_D009157 CID interferon_6\NN\2725367|pegylated_10|for_35 (r_nmod) treatment_9\NN\654885|NONE_0 (r_pobj) during_4\IN\0|of_21 (r_prep) development_0\NN\248977|NONE_0 (l_prep) of_1\IN\0|during_21 (l_pobj) myasthenia_3\NN\14187378|NONE_0
C417083_D009157 CID alpha-2b_10\CD\0|NONE_0 (r_pobj) of_7\IN\0|combination_20 (r_prep) therapy_6\NN\657604|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|the_22|ocular_18 (r_acl) myasthenia_2\NN\14187378|is_95|rarely_103
C417083_D009157 CID ifn_35\NNP\0|NONE_0 (r_compound) therapy_36\NN\657604|NONE_0 (r_pobj) of_34\IN\0|the_30|various_26|eye_18 (r_prep) complications_33\NNS\1073995|NONE_0 (r_pobj) of_29\IN\0|a_9 (r_prep) review_28\NN\5733583|NONE_0 (r_pobj) with_26\IN\0|reported_42|;_34|therefore_32|,_23|we_21|case_5|._61 (r_prep) present_23\VBP\28270|NONE_0 (l_ccomp) reported_18\VBN\831651|;_8|therefore_10|,_19|we_21|case_37|with_42|._103 (l_nsubjpass) myasthenia_2\NN\14187378|is_95|rarely_103
C417083_D019698 NONE interferon_6\NN\2725367|pegylated_10|for_35 (r_nmod) treatment_9\NN\654885|NONE_0 (l_prep) for_10\IN\0|pegylated_45|interferon_35 (l_pobj) c._13\NNP\0|NONE_0
C417083_D019698 NONE alpha-2b_19\CD\0|(_6|)_2 (r_conj) ifn_17\NNP\0|pegylated_22 (r_appos) interferon_15\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) of_11\IN\0|9_8 (r_prep) weeks_10\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|a_47|old_37|experienced_28|sudden_16|for_85|._114 (r_prep) diplopia_7\NN\14552802|NONE_0 (l_prep) for_22\IN\0|a_132|old_122|experienced_113|sudden_101|after_85|._29 (l_pobj) c_25\NNP\13714184|NONE_0
C417083_D019698 NONE alpha-2b_19\CD\0|(_6|)_2 (r_conj) ifn_17\NNP\0|pegylated_22 (r_appos) interferon_15\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) of_11\IN\0|9_8 (r_prep) weeks_10\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|a_47|old_37|experienced_28|sudden_16|for_85|._114 (r_prep) diplopia_7\NN\14552802|NONE_0 (l_prep) for_22\IN\0|a_132|old_122|experienced_113|sudden_101|after_85|._29 (l_pobj) c_25\NNP\13714184|NONE_0 (l_appos) chc_27\NNP\0|chronic_21|hepatitis_13|(_1|)_3
C417083_D019698 NONE alpha-2b_10\CD\0|NONE_0 (l_prep) for_13\IN\0|pegylated_37|ifn_27|and_14|ribavirin_10 (l_pobj) chc_14\NNP\0|NONE_0
C417083_D019698 NONE ifn_35\NNP\0|NONE_0 (r_compound) therapy_36\NN\657604|NONE_0 (r_pobj) of_34\IN\0|the_30|various_26|eye_18 (r_prep) complications_33\NNS\1073995|NONE_0 (r_pobj) of_29\IN\0|a_9 (r_prep) review_28\NN\5733583|NONE_0 (r_pobj) with_26\IN\0|reported_42|;_34|therefore_32|,_23|we_21|case_5|._61 (r_prep) present_23\VBP\28270|NONE_0 (l_ccomp) reported_18\VBN\831651|;_8|therefore_10|,_19|we_21|case_37|with_42|._103 (l_nsubjpass) myasthenia_2\NN\14187378|is_95|rarely_103 (l_acl) associated_3\VBN\628491|the_22|ocular_18 (l_prep) with_4\IN\0|NONE_0 (l_pobj) therapy_6\NN\657604|NONE_0 (l_prep) of_7\IN\0|combination_20 (l_pobj) alpha-2b_10\CD\0|NONE_0 (l_prep) for_13\IN\0|pegylated_37|ifn_27|and_14|ribavirin_10 (l_pobj) chc_14\NNP\0|NONE_0
D012254_D009157 CID ribavirin_8\JJ\2725367|and_4 (r_conj) interferon_6\NN\2725367|pegylated_10|for_35 (r_nmod) treatment_9\NN\654885|NONE_0 (r_pobj) during_4\IN\0|of_21 (r_prep) development_0\NN\248977|NONE_0 (l_prep) of_1\IN\0|during_21 (l_pobj) myasthenia_3\NN\14187378|NONE_0
D012254_D009157 CID ribavirin_12\RB\2725367|pegylated_27|ifn_17|and_4|for_10 (r_conj) alpha-2b_10\CD\0|NONE_0 (r_pobj) of_7\IN\0|combination_20 (r_prep) therapy_6\NN\657604|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|the_22|ocular_18 (r_acl) myasthenia_2\NN\14187378|is_95|rarely_103
9088814
D000527_D007022 CID e1-induced_5\JJ\0|prolonged_24|prostaglandin_14|and_23|haemodilution_27|on_41 (r_amod) hypotension_6\NN\14057371|NONE_0
D000527_D007022 CID e1_5\NN\0|NONE_0 (l_appos) hypotension_8\NN\14057371|prolonged_42|prostaglandin_32
D000527_D007022 CID pge1)-induced_7\JJ\0|(_1|and_26|haemodilution_30 (r_amod) hypotension_8\NN\14057371|prolonged_42|prostaglandin_32
D000527_D007022 CID pge1_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|hypotension_42|was_12|maintain_13|._73 (r_prep) induced_8\VBN\1627355|NONE_0 (l_nsubjpass) hypotension_1\NN\14057371|was_30|with_42|maintain_55|._115
D000527_D007022 CID pge1-induced_13\JJ\0|and_25|haemodilution_38 (r_amod) hypotension_14\NN\14057371|NONE_0
D003911_D020141 NONE dextran_23\NN\0|NONE_0 (r_amod) solution_24\NN\14586258|NONE_0 (r_pobj) of_22\IN\0|the_16|same_12 (r_prep) amount_21\NN\13329641|NONE_0 (r_pobj) with_18\IN\0|it_3 (r_prep) replacing_16\VBG\196485|ml_16|and_4 (r_conj) withdrawing_9\VBG\1835496|NONE_0 (r_pcomp) by_8\IN\0|haemodilution_45|was_13|,_103|and_105|were_134 (r_prep) produced_7\VBN\1617192|NONE_0 (l_nsubjpass) haemodilution_0\NN\0|was_32|by_45|,_148|and_150|were_179
D001663_D007022 NONE bilirubin_68\NN\14756039|and_10 (r_conj) ldh_65\NNP\0|,_2 (r_conj) sgpt_63\NNP\0|,_2 (r_appos) sgot_61\NNP\0|increases_55|._80 (r_nsubj) showed_69\VBD\2137132|showed_274|,_201|akbr_199|decrease_173|and_146|at_142|after_124|,_42|and_40 (r_conj) showed_23\VBD\2137132|NONE_0 (l_prep) after_42\IN\0|showed_150|,_77|akbr_75|decrease_49|and_22|at_18|,_82|and_84|showed_124 (l_pobj) start_44\NN\7290905|and_21|at_25|after_42 (l_prep) of_45\IN\0|the_10 (l_pobj) hypotension_46\NN\14057371|NONE_0
D000527_D008107 CID pge1-induced_13\JJ\0|and_25|haemodilution_38 (r_amod) hypotension_14\NN\14057371|NONE_0 (r_pobj) of_12\IN\0|120_8 (r_prep) min_11\NN\15154774|NONE_0 (r_pobj) of_7\IN\0|a_24|prolonged_22 (r_prep) combination_6\NN\7951464|that_17|would_88|impairment_100 (r_nsubj) cause_19\VB\7323922|results_127|._36 (l_dobj) impairment_20\NN\7296428|that_117|combination_100|would_12 (l_prep) of_21\IN\0|NONE_0 (l_pobj) function_23\NN\13783581|NONE_0
D000527_D020141 NONE e1-induced_5\JJ\0|prolonged_24|prostaglandin_14|and_23|haemodilution_27|on_41 (r_amod) hypotension_6\NN\14057371|NONE_0 (l_conj) haemodilution_8\NN\0|prolonged_51|prostaglandin_41|e1-induced_27|and_4|on_14
D000527_D020141 NONE e1_5\NN\0|NONE_0 (l_appos) hypotension_8\NN\14057371|prolonged_42|prostaglandin_32 (l_conj) haemodilution_10\NN\0|(_31|pge1)-induced_30|and_4
D000527_D020141 NONE pge1)-induced_7\JJ\0|(_1|and_26|haemodilution_30 (r_amod) hypotension_8\NN\14057371|prolonged_42|prostaglandin_32 (l_conj) haemodilution_10\NN\0|(_31|pge1)-induced_30|and_4
D000527_D020141 NONE pge1-induced_13\JJ\0|and_25|haemodilution_38 (r_amod) hypotension_14\NN\14057371|NONE_0 (l_conj) haemodilution_17\NN\0|pge1-induced_38|and_13
18726058
D010208_D003389 NONE papaverine_13\NN\3800001|NONE_0 (r_pobj) with_11\IN\0|a_12|few_10 (r_prep) cases_10\NNS\7283608|NONE_0 (r_pobj) in_7\IN\13603305|dysfunction_31|has_19|been_15|._38 (r_prep) described_6\VBN\1001294|NONE_0 (l_nsubjpass) dysfunction_3\NN\14204950|has_12|been_16|in_31|._69
D010208_D003389 NONE papaverine_8\NN\3800001|NONE_0 (r_pobj) from_7\IN\0|potential_33|nerve_15 (r_prep) deficits_6\NNS\5113133|to_33
D010208_D020301 NONE hydrochloride_1\NN\14817592|vasodilator_33|._109 (r_nsubj) is_2\VBZ\0|NONE_0 (l_attr) vasodilator_7\NN\3198383|hydrochloride_33|._76 (l_acl) used_8\VBD\0|a_28|acting_19 (l_xcomp) manage_10\VB\2524171|NONE_0 (l_dobj) vasospasm_11\NN\0|to_10|during_10
D010208_D020301 NONE papaverine_18\NN\3800001|who_21|for_11 (r_dobj) received_16\VBD\2210855|those_19 (l_prep) for_19\IN\0|who_32|papaverine_11 (l_pobj) vasospasm_20\NN\0|NONE_0
D010208_D020301 NONE papaverine_1\NN\3800001|was_11|as_20|._96 (r_nsubjpass) used_3\VBN\0|NONE_0 (l_prep) as_4\IN\14622893|papaverine_20|was_9|._76 (l_pobj) action_8\NN\30358|NONE_0 (l_acl) manage_10\VB\2524171|a_31|direct_29|therapeutic_22 (l_dobj) vasospasm_11\NN\0|to_10|in_10
D010208_D020301 NONE papaverine_1\NN\3800001|was_42|with_57|._173 (l_prep) for_2\IN\0|topical_19 (l_pobj) treatment_4\NN\654885|NONE_0 (l_prep) of_5\IN\0|the_14 (l_pobj) vasospasm_6\NN\0|NONE_0
17639754
D064704_D006470 CID levofloxacin_20\JJ\0|and_4 (r_conj) warfarin_18\NN\2718259|NONE_0 (r_pobj) between_17\IN\0|the_16 (r_prep) interaction_16\NN\37396|NONE_0 (r_pobj) of_14\IN\0|the_11 (r_prep) result_13\NN\34213|to_10 (r_attr) be_11\VB\14625458|that_15 (r_xcomp) appear_9\VBP\2604760|serious_36|bleeding_28 (r_relcl) complications_7\NNS\1073995|NONE_0 (l_compound) bleeding_6\NN\14285662|serious_8|appear_28
D014859_D006470 CID warfarin_18\NN\2718259|NONE_0 (r_pobj) between_17\IN\0|the_16 (r_prep) interaction_16\NN\37396|NONE_0 (r_pobj) of_14\IN\0|the_11 (r_prep) result_13\NN\34213|to_10 (r_attr) be_11\VB\14625458|that_15 (r_xcomp) appear_9\VBP\2604760|serious_36|bleeding_28 (r_relcl) complications_7\NNS\1073995|NONE_0 (l_compound) bleeding_6\NN\14285662|serious_8|appear_28
19473225
D000596_D010523 NONE acid_24\NN\14818238|its_26|related_14 (r_compound) glutamine_25\NN\14601829|and_35 (r_conj) glutamate_18\NN\15010703|although_9|were_55|ameliorate_71 (r_nsubjpass) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (r_advcl) is_3\VBZ\0|NONE_0 (l_nsubj) neuropathy_2\NN\14204950|still_14|factor_43|,_88|claimed_159|._198
D000596_D020258 NONE acid_24\NN\14818238|its_26|related_14 (r_compound) glutamine_25\NN\14601829|and_35 (r_conj) glutamate_18\NN\15010703|although_9|were_55|ameliorate_71 (r_nsubjpass) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (l_xcomp) ameliorate_29\VB\126264|although_80|glutamate_71|were_16 (l_dobj) neurotoxicity_31\NN\0|to_18
D018698_D010523 NONE glutamate_3\NN\15010703|term_5 (r_compound) supplementation_4\NN\5108947|protect_26|._80 (r_nsubj) failed_5\VBD\0|NONE_0 (l_xcomp) protect_7\VB\1127795|supplementation_26|._54 (l_prep) against_8\IN\0|to_11 (l_pobj) neurotoxicity_10\NN\0|NONE_0
D018698_D010523 NONE glutamate_18\NN\15010703|although_9|were_55|ameliorate_71 (r_nsubjpass) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (r_advcl) is_3\VBZ\0|NONE_0 (l_nsubj) neuropathy_2\NN\14204950|still_14|factor_43|,_88|claimed_159|._198
D018698_D010523 NONE glutamine_25\NN\14601829|and_35 (r_conj) glutamate_18\NN\15010703|although_9|were_55|ameliorate_71 (r_nsubjpass) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (r_advcl) is_3\VBZ\0|NONE_0 (l_nsubj) neuropathy_2\NN\14204950|still_14|factor_43|,_88|claimed_159|._198
D018698_D010523 NONE glutamate_9\NN\15010703|for_26 (r_compound) supplementation_10\NN\5108947|NONE_0 (l_prep) for_11\IN\0|glutamate_26 (l_pcomp) preventing_12\VBG\0|NONE_0 (l_dobj) neuropathy_17\NN\14204950|in_11
D018698_D010523 NONE glutamate_8\NN\15010703|at_26 (r_compound) supplementation_9\NN\5108947|that_15|protect_47 (r_nsubj) fails_14\VBZ\0|the_68 (l_xcomp) protect_16\VB\1127795|that_62|supplementation_47 (l_prep) against_17\IN\0|to_11 (l_pobj) neurotoxicity_19\NN\0|NONE_0
D018698_D020258 NONE glutamate_18\NN\15010703|although_9|were_55|ameliorate_71 (r_nsubjpass) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (l_xcomp) ameliorate_29\VB\126264|although_80|glutamate_71|were_16 (l_dobj) neurotoxicity_31\NN\0|to_18
D018698_D020258 NONE glutamine_25\NN\14601829|and_35 (r_conj) glutamate_18\NN\15010703|although_9|were_55|ameliorate_71 (r_nsubjpass) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (l_xcomp) ameliorate_29\VB\126264|although_80|glutamate_71|were_16 (l_dobj) neurotoxicity_31\NN\0|to_18
D018698_D010051 NONE glutamate_26\NN\15010703|NONE_0 (r_pobj) by_25\IN\0|were_110|:_27|23_25|had_22|been_18|,_43|at_45|,_92|and_94|received_105|._133 (r_agent) supplemented_24\VBN\182406|NONE_0 (l_ccomp) were_6\VBD\0|:_83|23_85|had_88|been_92|by_110|,_153|at_155|,_202|and_204|received_215|._243 (l_nsubj) patients_5\NNS\9898892|available_14 (l_compound) cancer_4\NN\14239425|three_14|ovarian_8
D017239_D010051 NONE pac_16\NNP\8324514|-_3 (r_npadvmod) containing_18\VBG\2632940|the_13|same_9 (r_amod) regimen_19\NN\5898568|NONE_0 (r_pobj) of_13\IN\0|six_11 (r_prep) cycles_12\NNS\15269513|NONE_0 (r_pobj) following_10\VBG\8180190|NONE_0 (r_prep) analysis_9\NN\633864|NONE_0 (r_pobj) for_8\IN\0|NONE_0 (r_prep) available_7\JJ\0|patients_14 (r_acomp) were_6\VBD\0|:_83|23_85|had_88|been_92|by_110|,_153|at_155|,_202|and_204|received_215|._243 (l_nsubj) patients_5\NNS\9898892|available_14 (l_compound) cancer_4\NN\14239425|three_14|ovarian_8
D017239_D020258 NONE paclitaxel_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|pac_17 (r_prep) chemotherapy_10\NN\661091|NONE_0 (r_pobj) for_9\IN\0|a_30|significant_28|limiting_16 (r_prep) factor_8\NN\7326557|neuropathy_43|still_29|,_45|claimed_116|._155 (r_attr) is_3\VBZ\0|NONE_0 (l_advcl) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (l_xcomp) ameliorate_29\VB\126264|although_80|glutamate_71|were_16 (l_dobj) neurotoxicity_31\NN\0|to_18
D017239_D020258 NONE pac_14\NNP\8324514|with_17 (r_appos) chemotherapy_10\NN\661091|NONE_0 (r_pobj) for_9\IN\0|a_30|significant_28|limiting_16 (r_prep) factor_8\NN\7326557|neuropathy_43|still_29|,_45|claimed_116|._155 (r_attr) is_3\VBZ\0|NONE_0 (l_advcl) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (l_xcomp) ameliorate_29\VB\126264|although_80|glutamate_71|were_16 (l_dobj) neurotoxicity_31\NN\0|to_18
D017239_D020258 NONE pac_30\NNP\8324514|NONE_0 (r_compound) neurotoxicity_31\NN\0|to_18
D017239_D010523 CID paclitaxel_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|peripheral_25 (r_prep) neurotoxicity_10\NN\0|NONE_0
D017239_D010523 CID paclitaxel_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|pac_17 (r_prep) chemotherapy_10\NN\661091|NONE_0 (r_pobj) for_9\IN\0|a_30|significant_28|limiting_16 (r_prep) factor_8\NN\7326557|neuropathy_43|still_29|,_45|claimed_116|._155 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) neuropathy_2\NN\14204950|still_14|factor_43|,_88|claimed_159|._198
D017239_D010523 CID pac_14\NNP\8324514|with_17 (r_appos) chemotherapy_10\NN\661091|NONE_0 (r_pobj) for_9\IN\0|a_30|significant_28|limiting_16 (r_prep) factor_8\NN\7326557|neuropathy_43|still_29|,_45|claimed_116|._155 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) neuropathy_2\NN\14204950|still_14|factor_43|,_88|claimed_159|._198
D017239_D010523 CID pac_30\NNP\8324514|NONE_0 (r_compound) neurotoxicity_31\NN\0|to_18 (r_dobj) ameliorate_29\VB\126264|although_80|glutamate_71|were_16 (r_xcomp) claimed_27\VBN\1011725|neuropathy_159|still_145|factor_116|,_71|._39 (r_advcl) is_3\VBZ\0|NONE_0 (l_nsubj) neuropathy_2\NN\14204950|still_14|factor_43|,_88|claimed_159|._198
D017239_D010523 CID pac_13\NNP\8324514|-_3 (r_npadvmod) induced_15\VBN\1627355|peripheral_8 (r_amod) neuropathy_17\NN\14204950|in_11
D017239_D010523 CID pac_21\NNP\8324514|NONE_0 (r_pobj) of_20\IN\0|peripheral_25 (r_prep) neurotoxicity_19\NN\0|NONE_0
435349
D013390_D005207 CID suxamethonium_0\JJ\0|infusion_14|and_28|observed_32|._55 (r_compound) rate_2\NN\13815152|NONE_0 (l_conj) observed_4\JJ\2163746|suxamethonium_32|infusion_18|and_4|._23 (l_dobj) fasciculations_5\NNS\14361664|NONE_0
D013390_D013746 NONE sch_20\NNP\0|when_5|mg_8|was_11 (r_nsubjpass) exceeded_24\VBN\0|either_108|when_101|there_96|response_74 (r_advcl) was_7\VBD\0|infusion_44|was_35|._98 (l_attr) response_10\NN\11410625|either_34|when_27|there_22|exceeded_74 (l_prep) to_11\IN\0|no_21|muscular_18 (l_pobj) stimulation_13\NN\242808|NONE_0 (l_compound) tetanic_12\JJ\0|of_20|or_39
3827439
D000666_D058186 CID amphotericin_6\JJ\2716866|NONE_0 (r_pobj) from_5\IN\0|recurrent_41|reversible_31|acute_20|renal_14|._17 (r_prep) failure_4\NN\66216|NONE_0
D000666_D058186 CID b_18\NNP\1355326|NONE_0 (r_pobj) of_16\IN\0|the_19 (r_prep) administration_15\NN\1133281|immediately_26|on_33 (r_dobj) following_13\VBG\8180190|acute_32|renal_26 (r_acl) failure_11\NN\66216|patient_89|._93
D000666_D058186 CID amphotericin_3\JJ\2716866|we_16|that_5|activate_71|._150 (r_advmod) propose_1\VBP\1010118|NONE_0 (l_conj) activate_15\VB\1641914|we_87|that_76|amphotericin_71|._79 (l_advcl) contributing_20\VBG\126264|,_103|in_101|,_50|may_48|feedback_18|,_10 (l_prep) to_21\IN\0|thereby_21 (l_pobj) failure_24\NN\66216|NONE_0
D000666_D005355 NONE b_18\NNP\1355326|NONE_0 (r_pobj) of_16\IN\0|the_19 (r_prep) administration_15\NN\1133281|immediately_26|on_33 (r_dobj) following_13\VBG\8180190|acute_32|renal_26 (r_acl) failure_11\NN\66216|patient_89|._93 (r_dobj) developed_8\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|failure_89|._182 (l_prep) with_2\IN\0|a_10|and_27|disseminated_31 (l_pobj) cirrhosis_4\NN\14116321|NONE_0
D000666_D013174 NONE b_18\NNP\1355326|NONE_0 (r_pobj) of_16\IN\0|the_19 (r_prep) administration_15\NN\1133281|immediately_26|on_33 (r_dobj) following_13\VBG\8180190|acute_32|renal_26 (r_acl) failure_11\NN\66216|patient_89|._93 (r_dobj) developed_8\VBD\1753788|NONE_0 (l_nsubj) patient_1\NN\9898892|failure_89|._182 (l_conj) disseminated_6\VBN\954608|a_41|with_31|and_4 (l_dobj) sporotrichosis_7\NN\14176895|NONE_0
20667451
D003474_D003072 NONE curcumin_0\NN\0|dysfunction_31|._117 (r_nsubj) ameliorates_1\VBZ\126264|NONE_0 (l_dobj) dysfunction_3\NN\14204950|curcumin_31|._86
D003474_D003072 NONE curcumin_14\NN\0|chronic_8 (r_compound) administration_15\NN\1133281|NONE_0 (r_pobj) of_12\IN\0|the_11|on_35 (r_prep) effect_11\NN\34213|to_19 (l_prep) on_16\IN\0|the_46|of_35 (l_pobj) impairment_23\NN\7296428|NONE_0
D003474_D003072 NONE curcumin_1\NN\0|concomitant_12 (r_compound) administration_2\NN\1133281|impairment_39|and_50|decreased_54|._131 (r_nsubj) prevented_3\VBD\0|NONE_0 (l_dobj) impairment_6\NN\7296428|administration_39|and_11|decreased_15|._92
D003474_D003072 NONE curcumin_4\NN\0|that_5|effect_24 (r_nsubj) has_5\VBZ\13888491|results_27|._209 (l_dobj) effect_7\NN\34213|that_29|curcumin_24 (l_prep) in_8\IN\13603305|beneficial_18 (l_pcomp) mitigating_9\VBG\894738|NONE_0 (l_dobj) deterioration_11\NN\14560612|NONE_0 (l_prep) of_12\IN\0|the_18 (l_pobj) functions_14\NNS\13783581|NONE_0
D003474_D003072 NONE curcumin_4\NN\0|that_5|can_9|be_13|as_27|phenobarbitone_73 (r_nsubjpass) considered_7\VBN\689344|findings_38|._160 (l_advcl) phenobarbitone_16\NN\2792049|that_78|curcumin_73|can_64|be_60|as_46 (l_prep) in_20\IN\13603305|to_44|and_26|therapy_8 (l_pcomp) preventing_21\VBG\0|NONE_0 (l_dobj) impairment_23\NN\7296428|NONE_0
D002220_D003072 CID carbamazepine_10\NN\0|and_4 (r_conj) phenobarbitone_8\NN\2792049|NONE_0 (r_pobj) in_7\IN\13603305|oxidative_17 (r_prep) damage_6\NN\7296428|cognitive_36|and_14|administered_43 (r_conj) dysfunction_3\NN\14204950|curcumin_31|._86
D002220_D003072 CID carbamazepine_6\NN\0|and_4 (r_conj) phenobarbitone_4\NN\2792049|the_25|antiepileptic_21|,_2 (r_conj) drugs_2\NNS\14778436|known_49|._99 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_acomp) known_9\JJ\0|drugs_49|._50 (l_xcomp) cause_11\VB\7323922|well_14 (l_dobj) impairment_13\NN\7296428|to_19
D002220_D003072 CID carbamazepine_19\NN\0|-_13 (r_npadvmod) induced_21\VBN\1627355|and_18 (r_conj) phenobarbitone-_17\JJ\0|cognitive_42|and_63|stress_77 (r_nmod) impairment_23\NN\7296428|NONE_0
D002220_D003072 CID carbamazepine_5\NN\0|and_4 (r_conj) phenobarbitone_3\NN\2792049|NONE_0 (r_pobj) of_2\IN\0|the_19|for_36 (r_prep) administration_1\NN\1133281|impairment_83|._157 (r_nsubj) caused_8\VBD\1617192|NONE_0 (l_dobj) impairment_11\NN\7296428|administration_83|._74 (l_prep) of_12\IN\0|a_25|significant_23 (l_pobj) learning_13\NN\5701944|stress_54 (l_conj) memory_15\NN\5926676|and_4|as_15
D002220_D003072 CID carbamazepine_24\NN\0|and_4 (r_conj) phenobarbitone_22\NN\2792049|NONE_0 (r_pobj) with_21\IN\0|without_38 (r_prep) treated_20\VBN\2376958|NONE_0 (r_acl) rats_19\NNS\2329401|NONE_0 (r_pobj) in_18\IN\13603305|oxidative_17 (r_prep) damage_17\NN\7296428|cognitive_34|and_14 (r_conj) functions_14\NNS\13783581|NONE_0
D002220_D003072 CID carbamazepine_18\NN\0|NONE_0 (r_compound) therapy_19\NN\657604|to_36|and_18|in_8 (r_conj) phenobarbitone_16\NN\2792049|that_78|curcumin_73|can_64|be_60|as_46 (l_prep) in_20\IN\13603305|to_44|and_26|therapy_8 (l_pcomp) preventing_21\VBG\0|NONE_0 (l_dobj) impairment_23\NN\7296428|NONE_0
D010634_D003072 CID phenobarbitone_8\NN\2792049|NONE_0 (r_pobj) in_7\IN\13603305|oxidative_17 (r_prep) damage_6\NN\7296428|cognitive_36|and_14|administered_43 (r_conj) dysfunction_3\NN\14204950|curcumin_31|._86
D010634_D003072 CID phenobarbitone_4\NN\2792049|the_25|antiepileptic_21|,_2 (r_conj) drugs_2\NNS\14778436|known_49|._99 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_acomp) known_9\JJ\0|drugs_49|._50 (l_xcomp) cause_11\VB\7323922|well_14 (l_dobj) impairment_13\NN\7296428|to_19
D010634_D003072 CID phenobarbitone-_17\JJ\0|cognitive_42|and_63|stress_77 (r_nmod) impairment_23\NN\7296428|NONE_0
D010634_D003072 CID phenobarbitone_3\NN\2792049|NONE_0 (r_pobj) of_2\IN\0|the_19|for_36 (r_prep) administration_1\NN\1133281|impairment_83|._157 (r_nsubj) caused_8\VBD\1617192|NONE_0 (l_dobj) impairment_11\NN\7296428|administration_83|._74 (l_prep) of_12\IN\0|a_25|significant_23 (l_pobj) learning_13\NN\5701944|stress_54 (l_conj) memory_15\NN\5926676|and_4|as_15
D010634_D003072 CID phenobarbitone_22\NN\2792049|NONE_0 (r_pobj) with_21\IN\0|without_38 (r_prep) treated_20\VBN\2376958|NONE_0 (r_acl) rats_19\NNS\2329401|NONE_0 (r_pobj) in_18\IN\13603305|oxidative_17 (r_prep) damage_17\NN\7296428|cognitive_34|and_14 (r_conj) functions_14\NNS\13783581|NONE_0
D010634_D003072 CID phenobarbitone_16\NN\2792049|that_78|curcumin_73|can_64|be_60|as_46 (l_prep) in_20\IN\13603305|to_44|and_26|therapy_8 (l_pcomp) preventing_21\VBG\0|NONE_0 (l_dobj) impairment_23\NN\7296428|NONE_0
12907309
C121465_D005334 NONE mpep_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|neuroprotective_23|,_7|antagonist_28|,_38|in_40 (r_prep) action_1\NN\30358|is_101|with_115|._189 (r_nsubjpass) associated_17\VBN\628491|NONE_0 (l_prep) with_18\IN\0|action_115|is_14|._74 (l_pobj) decrease_20\NN\7296428|NONE_0 (l_prep) in_21\IN\13603305|a_11 (l_pobj) outflow_23\NN\7407777|NONE_0 (l_conj) inhibition_25\NN\1068773|dopamine_21|and_4|in_27 (l_prep) of_26\IN\0|NONE_0 (l_pobj) hyperthermia_27\NN\14034177|NONE_0
C121465_D005334 NONE mpep_3\NNP\0|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) rendered_1\VBN\120316|NONE_0 (r_acl) neuroprotection_0\NNP\0|may_33|be_37|with_51|,_176|and_178|with_182|._213 (r_nsubjpass) associated_6\VBN\628491|NONE_0 (l_conj) with_29\IN\0|neuroprotection_182|may_149|be_145|with_131|,_6|and_4|._31 (l_pobj) decrease_31\NN\7296428|NONE_0 (l_prep) in_32\IN\13603305|a_11 (l_pobj) hyperthermia_33\NN\14034177|NONE_0
C121465_D020258 NONE mpep_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|neuroprotective_23|,_7|antagonist_28|,_38|in_40 (r_prep) action_1\NN\30358|is_101|with_115|._189 (l_prep) in_10\IN\13603305|neuroprotective_63|of_40|,_33|antagonist_12|,_2 (l_pobj) neurotoxicity_15\NN\0|NONE_0
D008694_D020258 NONE methamphetamine_11\NN\2704153|-_15 (r_npadvmod) induced_13\VBN\1627355|dopaminergic_8 (r_amod) neurotoxicity_15\NN\0|NONE_0
D008694_D064420 NONE methamphetamine_18\NN\2704153|-_15 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) toxicity_21\NN\13576101|NONE_0
C121465_D064420 NONE mpep_12\NNP\0|NONE_0 (r_pobj) by_11\IN\0|the_23|of_10 (r_prep) blockade_8\NN\952963|that_9|may_27|neurones_52 (r_nsubj) protect_14\VB\1127795|results_70|._70 (l_dobj) neurones_16\NNS\0|that_61|blockade_52|may_25 (l_prep) against_17\IN\0|dopaminergic_22 (l_pobj) toxicity_21\NN\13576101|NONE_0
D004298_D005334 NONE dopamine_22\NN\14807737|and_17|inhibition_21|in_48 (r_compound) outflow_23\NN\7407777|NONE_0 (l_conj) inhibition_25\NN\1068773|dopamine_21|and_4|in_27 (l_prep) of_26\IN\0|NONE_0 (l_pobj) hyperthermia_27\NN\14034177|NONE_0
D004298_D005334 NONE dopamine_15\NN\14807737|the_28|induced_8|in_16 (r_compound) efflux_16\NN\13482330|NONE_0 (r_pobj) of_10\IN\0|the_14|due_63 (r_prep) reduction_9\NN\351485|NONE_0 (r_pobj) with_7\IN\0|neuroprotection_51|may_18|be_14|,_125|and_127|with_131|._162 (r_prep) associated_6\VBN\628491|NONE_0 (l_conj) with_29\IN\0|neuroprotection_182|may_149|be_145|with_131|,_6|and_4|._31 (l_pobj) decrease_31\NN\7296428|NONE_0 (l_prep) in_32\IN\13603305|a_11 (l_pobj) hyperthermia_33\NN\14034177|NONE_0
D004298_D020258 NONE dopamine_22\NN\14807737|and_17|inhibition_21|in_48 (r_compound) outflow_23\NN\7407777|NONE_0 (r_pobj) in_21\IN\13603305|a_11 (r_prep) decrease_20\NN\7296428|NONE_0 (r_pobj) with_18\IN\0|action_115|is_14|._74 (r_prep) associated_17\VBN\628491|NONE_0 (l_nsubjpass) action_1\NN\30358|is_101|with_115|._189 (l_prep) in_10\IN\13603305|neuroprotective_63|of_40|,_33|antagonist_12|,_2 (l_pobj) neurotoxicity_15\NN\0|NONE_0
D008694_D005334 CID methamphetamine_11\NN\2704153|-_15 (r_npadvmod) induced_13\VBN\1627355|dopaminergic_8 (r_amod) neurotoxicity_15\NN\0|NONE_0 (r_pobj) in_10\IN\13603305|neuroprotective_63|of_40|,_33|antagonist_12|,_2 (r_prep) action_1\NN\30358|is_101|with_115|._189 (r_nsubjpass) associated_17\VBN\628491|NONE_0 (l_prep) with_18\IN\0|action_115|is_14|._74 (l_pobj) decrease_20\NN\7296428|NONE_0 (l_prep) in_21\IN\13603305|a_11 (l_pobj) outflow_23\NN\7407777|NONE_0 (l_conj) inhibition_25\NN\1068773|dopamine_21|and_4|in_27 (l_prep) of_26\IN\0|NONE_0 (l_pobj) hyperthermia_27\NN\14034177|NONE_0
D008694_D005334 CID methamphetamine_12\NN\2704153|-_15 (r_npadvmod) induced_14\VBN\1627355|the_20|dopamine_8|in_24 (r_amod) efflux_16\NN\13482330|NONE_0 (r_pobj) of_10\IN\0|the_14|due_63 (r_prep) reduction_9\NN\351485|NONE_0 (r_pobj) with_7\IN\0|neuroprotection_51|may_18|be_14|,_125|and_127|with_131|._162 (r_prep) associated_6\VBN\628491|NONE_0 (l_conj) with_29\IN\0|neuroprotection_182|may_149|be_145|with_131|,_6|and_4|._31 (l_pobj) decrease_31\NN\7296428|NONE_0 (l_prep) in_32\IN\13603305|a_11 (l_pobj) hyperthermia_33\NN\14034177|NONE_0
11391224
D003042_D006974 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) related_25\VBN\628491|acute_8|renal_14 (r_amod) failure_28\NN\66216|crescentic_63|,_34|and_32 (r_conj) glomerulonephritis_20\NN\14113798|schonlein_32|,_13 (r_conj) nephritis_17\NN\14113228|,_19 (r_conj) nephritis_12\NN\14113228|microangiopathy_23 (r_dobj) lupus_11\NN\14219661|13_73|cases_61|,_30|._115 (r_conj) included_2\VBD\0|NONE_0 (l_dobj) cases_3\NNS\7283608|13_12|,_31|lupus_61|._176 (l_prep) of_4\IN\0|NONE_0 (l_pobj) hypertension_6\NN\14057371|NONE_0
D003042_D058186 CID cocaine_23\NN\3492717|-_7 (r_npadvmod) related_25\VBN\628491|acute_8|renal_14 (r_amod) failure_28\NN\66216|crescentic_63|,_34|and_32
D003042_D011695 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) related_25\VBN\628491|acute_8|renal_14 (r_amod) failure_28\NN\66216|crescentic_63|,_34|and_32 (r_conj) glomerulonephritis_20\NN\14113798|schonlein_32|,_13 (r_conj) nephritis_17\NN\14113228|,_19
D003042_D008181 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) related_25\VBN\628491|acute_8|renal_14 (r_amod) failure_28\NN\66216|crescentic_63|,_34|and_32 (r_conj) glomerulonephritis_20\NN\14113798|schonlein_32|,_13 (r_conj) nephritis_17\NN\14113228|,_19 (r_conj) nephritis_12\NN\14113228|microangiopathy_23
D003042_D005921 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) related_25\VBN\628491|acute_8|renal_14 (r_amod) failure_28\NN\66216|crescentic_63|,_34|and_32 (r_conj) glomerulonephritis_20\NN\14113798|schonlein_32|,_13
D003042_D057049 NONE cocaine_23\NN\3492717|-_7 (r_npadvmod) related_25\VBN\628491|acute_8|renal_14 (r_amod) failure_28\NN\66216|crescentic_63|,_34|and_32 (r_conj) glomerulonephritis_20\NN\14113798|schonlein_32|,_13 (r_conj) nephritis_17\NN\14113228|,_19 (r_conj) nephritis_12\NN\14113228|microangiopathy_23 (r_dobj) lupus_11\NN\14219661|13_73|cases_61|,_30|._115 (l_nsubj) microangiopathy_9\NN\0|nephritis_23
14596845
D013395_D006948 CID sucrose_6\NN\14836642|that_28|had_23 (r_dobj) experienced_4\VBN\2108377|the_21 (r_relcl) animals_1\NNS\4475|hyperactive_58|in_70|compared_97|._335 (r_nsubj) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D013395_D006948 CID sucrose_25\NN\14836642|four_36|control_31|(_16|,_50|chow_59|,_97|chow_110|)_187 (r_appos) groups_19\NNS\2137|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|animals_97|hyperactive_39|in_27|._238 (r_prep) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D013395_D006948 CID sucrose_50\NN\14836642|,_16|or_14 (r_conj) amphetamine_44\NN\3248958|NONE_0 (r_pobj) with_43\IN\0|ad_16|libitum_13 (r_prep) chow_42\NN\7971582|four_146|control_141|(_126|sucrose_110|,_60|chow_51|,_13|)_77 (r_appos) groups_19\NNS\2137|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|animals_97|hyperactive_39|in_27|._238 (r_prep) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D000661_D006948 CID amphetamine_15\NN\3248958|NONE_0 (r_pobj) of_14\IN\0|a_11|low_9 (r_prep) dose_13\NN\3740161|NONE_0 (r_pobj) to_10\IN\0|behavioral_31|cross_20|-_15 (r_prep) sensitization_9\NN\14531772|diet_56|._42
D000661_D006948 CID amphetamine_24\NN\3248958|NONE_0 (r_pobj) of_23\IN\0|a_11|low_9 (r_prep) dose_22\NN\3740161|NONE_0 (r_pobj) to_19\IN\0|whether_98|rats_83|would_42|sensitization_14 (r_prep) show_14\VB\429048|study_77|._64 (l_dobj) sensitization_18\NN\14531772|whether_84|rats_69|would_28|to_14
D000661_D006948 CID amphetamine_14\NN\3248958|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) response_12\NN\11410625|NONE_0 (r_pobj) in_11\IN\13603305|animals_70|hyperactive_12|compared_27|._265 (r_prep) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D000661_D006948 CID amphetamine_30\NN\3248958|NONE_0 (r_compound) injection_31\NN\320852|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) followed_28\VBN\1835496|libitum_29|%_19|and_9|chow_5 (r_acl) sucrose_25\NN\14836642|four_36|control_31|(_16|,_50|chow_59|,_97|chow_110|)_187 (r_appos) groups_19\NNS\2137|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|animals_97|hyperactive_39|in_27|._238 (r_prep) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D000661_D006948 CID amphetamine_37\NN\3248958|NONE_0 (r_compound) injection_38\NN\320852|NONE_0 (r_pobj) by_36\IN\0|NONE_0 (r_agent) followed_35\VBN\1835496|cyclic_12 (r_acl) chow_34\NN\7971582|four_95|control_90|(_75|sucrose_59|,_9|,_38|chow_51|)_128 (r_appos) groups_19\NNS\2137|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|animals_97|hyperactive_39|in_27|._238 (r_prep) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D000661_D006948 CID amphetamine_44\NN\3248958|NONE_0 (r_pobj) with_43\IN\0|ad_16|libitum_13 (r_prep) chow_42\NN\7971582|four_146|control_141|(_126|sucrose_110|,_60|chow_51|,_13|)_77 (r_appos) groups_19\NNS\2137|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|animals_97|hyperactive_39|in_27|._238 (r_prep) were_9\VBD\0|NONE_0 (l_acomp) hyperactive_10\JJ\0|animals_58|in_12|compared_39|._277
D000661_D019966 NONE amphetamine_15\NN\3248958|NONE_0 (r_pobj) of_14\IN\0|a_11|low_9 (r_prep) dose_13\NN\3740161|NONE_0 (r_pobj) to_10\IN\0|behavioral_31|cross_20|-_15 (r_prep) sensitization_9\NN\14531772|diet_56|._42 (r_dobj) causes_5\VBZ\7323922|NONE_0 (l_nsubj) diet_1\NN\7560652|sensitization_56|._98 (l_acl) promoting_2\VBG\2556126|a_7 (l_dobj) dependency_4\NN\24720|NONE_0
19445921
C066201_D009203 NONE a_5\NN\13649268|salvianolic_17 (l_prep) on_6\IN\0|acid_7 (l_pobj) infarction_11\NN\14204950|NONE_0
C066201_D009203 NONE a_13\NN\13649268|salvianolic_17 (r_pobj) of_10\IN\0|the_31|cardioprotective_27|on_22 (r_prep) potential_9\NN\14481929|to_33 (l_prep) on_14\IN\0|the_53|cardioprotective_49|of_22 (l_pobj) infarction_19\NN\14204950|NONE_0
C066201_D009203 NONE a_9\DT\13649268|that_22 (r_appos) salvianolic_7\JJ\0|effect_80 (r_nsubj) has_13\VBZ\13888491|results_85|._87 (l_dobj) effect_17\NN\34213|salvianolic_80 (l_prep) against_18\IN\0|a_32|significant_30|protective_18 (l_pobj) infarction_23\NN\14204950|NONE_0
D000244_D012131 NONE adp_13\NNP\14964590|/_3 (r_nmod) o_15\NNP\14622893|decreased_44|control_22|and_8 (r_conj) ratio_11\NN\13815152|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) characterized_6\VBN\609683|mitochondrial_38|respiratory_24 (r_acl) dysfunction_5\NN\14204950|in_39|,_28|was_75|in_88|._117
D007545_D009203 CID isoproterenol_7\NN\3740161|-_13 (r_npadvmod) induced_9\VBN\1627355|myocardial_8|in_30 (r_amod) infarction_11\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_15\NN\3740161|-_13 (r_npadvmod) induced_17\VBN\1627355|myocardial_8|in_30 (r_amod) infarction_19\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_19\NN\3740161|-_13 (r_npadvmod) induced_21\VBN\1627355|myocardial_8 (r_amod) infarction_23\NN\14204950|NONE_0
D007545_D012131 NONE isoproterenol_19\NN\3740161|-_13 (r_npadvmod) treated_21\VBN\2376958|NONE_0 (r_amod) rats_22\NNS\2329401|NONE_0 (r_pobj) in_18\IN\13603305|in_127|,_116|dysfunction_88|was_13|._29 (r_prep) observed_17\VBN\2163746|NONE_0 (l_nsubjpass) dysfunction_5\NN\14204950|in_39|,_28|was_75|in_88|._117
C066201_D006331 NONE a_4\NN\13649268|of_20|for_2|dysfunction_80|and_114|improved_118 (r_appos) administration_0\NN\1133281|NONE_0 (l_conj) dysfunction_17\NN\14204950|of_100|a_80|for_78|and_34|improved_38
D007545_D006331 NONE isoproterenol_13\NN\3740161|-_13 (r_npadvmod) induced_15\VBN\1627355|attenuated_25|cardiac_8|and_28|injury_43 (r_amod) dysfunction_17\NN\14204950|of_100|a_80|for_78|and_34|improved_38
D007545_D009202 NONE isoproterenol_13\NN\3740161|-_13 (r_npadvmod) induced_15\VBN\1627355|attenuated_25|cardiac_8|and_28|injury_43 (r_amod) dysfunction_17\NN\14204950|of_100|a_80|for_78|and_34|improved_38 (l_conj) injury_20\NN\14052046|attenuated_68|induced_43|cardiac_35|and_15
D007545_D009202 NONE isoproterenol_8\NN\3740161|-_13 (r_npadvmod) induced_10\VBN\1627355|myocardial_8 (r_amod) damage_12\NN\7296428|NONE_0
C066201_D009202 NONE a_4\NN\13649268|of_20|for_2|dysfunction_80|and_114|improved_118 (r_appos) administration_0\NN\1133281|NONE_0 (l_conj) dysfunction_17\NN\14204950|of_100|a_80|for_78|and_34|improved_38 (l_conj) injury_20\NN\14052046|attenuated_68|induced_43|cardiac_35|and_15
C066201_D009202 NONE a_6\NN\13649268|salvianolic_17 (r_pobj) of_3\IN\0|the_20|protective_16|against_22 (r_prep) role_2\NN\719494|was_75|further_79|by_97|._129 (l_prep) against_7\IN\0|the_42|protective_38|of_22 (l_pobj) damage_12\NN\7296428|NONE_0
7930386
D002997_D012893 CID clomipramine_0\NNP\4482543|-_12 (r_npadvmod) induced_2\VBN\1627355|sleep_8 (r_amod) disturbance_4\NN\407535|does_12|not_17|action_52|._58
D002997_D012893 CID clomipramine_15\NN\4482543|NONE_0 (r_compound) administration_16\NN\1133281|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|to_42|role_27|,_2|,_38|on_40 (r_conj) examine_6\VB\0|study_24|was_18|._157 (l_dobj) role_8\NN\719494|to_15|,_25|induced_27|,_65|on_67 (l_prep) of_9\IN\0|the_9 (l_pobj) disturbance_11\NN\407535|NONE_0
9587734
D013390_D006947 CID suxamethonium_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_8 (r_prep) use_19\NN\407535|NONE_0 (r_pobj) following_17\VBG\8180190|a_75|of_68 (r_prep) case_5\NN\7283608|report_19|._139 (l_prep) of_6\IN\0|a_7|following_68 (l_pobj) arrest_8\NN\88481|NONE_0 (l_conj) death_11\NN\7296428|cardiac_30|and_15 (l_prep) as_12\IN\14622893|subsequent_17 (l_pobj) result_14\NN\34213|NONE_0 (l_prep) of_15\IN\0|a_9 (l_pobj) hyperkalaemia_16\NN\0|NONE_0
D013390_D006947 CID suxamethonium_35\NN\0|NONE_0 (r_pobj) of_34\IN\0|the_19 (r_prep) administration_33\NN\1133281|NONE_0 (r_pobj) following_31\VBG\8180190|no_104|of_95 (r_prep) signs_15\NNS\6643763|apart_80|,_16|there_14|._146 (l_prep) of_16\IN\0|no_9|following_95 (l_conj) of_21\IN\0|damage_10|or_3 (l_pobj) any_22\DT\0|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) conditions_28\NNS\14512817|NONE_0 (l_prep) for_29\IN\0|the_40|other_36|known_30|predisposing_24 (l_pobj) hyperkalaemia_30\NN\0|NONE_0
D013390_D001919 CID suxamethonium_5\NN\0|NONE_0 (l_appos) arrest_10\NN\88481|,_26 (l_amod) bradycardia_7\NN\14110674|cardiac_16
D013390_D004342 CID suxamethonium_11\NN\0|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) hypersensitivity_9\NN\14531772|NONE_0
D013390_D003643 NONE suxamethonium_0\NN\0|-_13 (r_npadvmod) induced_2\VBN\1627355|cardiac_8|and_23|death_27|following_33|._67 (r_amod) arrest_4\NN\88481|NONE_0 (l_conj) death_6\NN\7296428|induced_27|cardiac_19|and_4|following_6|._40
D013390_D003643 NONE suxamethonium_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_8 (r_prep) use_19\NN\407535|NONE_0 (r_pobj) following_17\VBG\8180190|a_75|of_68 (r_prep) case_5\NN\7283608|report_19|._139 (l_prep) of_6\IN\0|a_7|following_68 (l_pobj) arrest_8\NN\88481|NONE_0 (l_conj) death_11\NN\7296428|cardiac_30|and_15
D013390_D003643 NONE suxamethonium_11\NN\0|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) hypersensitivity_9\NN\14531772|NONE_0 (r_pobj) by_8\IN\0|that_26|death_17|was_11|,_36|associated_38 (r_agent) caused_7\VBN\1617192|it_36|is_33|._85 (l_nsubjpass) death_5\NN\7296428|that_9|was_6|by_17|,_53|associated_55
D013390_D006323 CID suxamethonium_0\NN\0|-_13 (r_npadvmod) induced_2\VBN\1627355|cardiac_8|and_23|death_27|following_33|._67 (r_amod) arrest_4\NN\88481|NONE_0
D013390_D006323 CID suxamethonium_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_8 (r_prep) use_19\NN\407535|NONE_0 (r_pobj) following_17\VBG\8180190|a_75|of_68 (r_prep) case_5\NN\7283608|report_19|._139 (l_prep) of_6\IN\0|a_7|following_68 (l_pobj) arrest_8\NN\88481|NONE_0
D013390_D006323 CID suxamethonium_5\NN\0|NONE_0 (l_appos) arrest_10\NN\88481|,_26
11752354
D004967_D009203 NONE estrogen_38\NN\14745635|NONE_0 (r_pobj) of_37\IN\0|the_9|,_11|and_13|presence_21 (r_prep) dose_36\NN\3740161|,_6|:_80|in_82|,_135|we_137|and_151|enrolled_155|._412 (r_dep) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27
D004967_D009203 NONE estrogen_38\NN\14745635|NONE_0 (r_pobj) of_37\IN\0|the_9|,_11|and_13|presence_21 (r_prep) dose_36\NN\3740161|,_6|:_80|in_82|,_135|we_137|and_151|enrolled_155|._412 (r_dep) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27 (l_prep) between_82\IN\0|a_30|first_28|myocardial_22 (l_pobj) 1990_83\CD\0|NONE_0 (l_conj) women_89\NNS\9605289|and_25|1995_21|and_16 (l_relcl) had_93\VBN\0|925_30|control_26 (l_dobj) infarction_96\NN\14204950|who_29|had_25|not_21|and_11|matched_24
D017135_D009203 NONE desogestrel_19\NN\0|third_24|-_19 (r_appos) generation_15\NN\7942152|oral_89 (r_nmod) contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27
D017135_D009203 NONE desogestrel_19\NN\0|third_24|-_19 (r_appos) generation_15\NN\7942152|oral_89 (r_nmod) contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27 (l_prep) between_82\IN\0|a_30|first_28|myocardial_22 (l_pobj) 1990_83\CD\0|NONE_0 (l_conj) women_89\NNS\9605289|and_25|1995_21|and_16 (l_relcl) had_93\VBN\0|925_30|control_26 (l_dobj) infarction_96\NN\14204950|who_29|had_25|not_21|and_11|matched_24
D003276_D009203 CID contraceptives_1\NNS\3183080|NONE_0 (l_conj) risk_4\NN\14541044|oral_28|and_8|._29 (l_prep) of_5\IN\0|the_9 (l_pobj) infarction_7\NN\14204950|NONE_0
D003276_D009203 CID contraceptives_7\NNS\3183080|NONE_0 (r_pobj) of_5\IN\0|the_8|and_23|risk_31 (r_prep) use_4\NN\407535|NONE_0 (l_conj) risk_10\NN\14541044|the_39|of_31|and_8 (l_prep) of_11\IN\0|the_9 (l_pobj) infarction_13\NN\14204950|NONE_0
D003276_D009203 CID contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27
D003276_D009203 CID contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27 (l_prep) between_82\IN\0|a_30|first_28|myocardial_22 (l_pobj) 1990_83\CD\0|NONE_0 (l_conj) women_89\NNS\9605289|and_25|1995_21|and_16 (l_relcl) had_93\VBN\0|925_30|control_26 (l_dobj) infarction_96\NN\14204950|who_29|had_25|not_21|and_11|matched_24
D003276_D009203 CID contraceptive_39\NN\3183080|NONE_0 (r_pobj) of_36\IN\0|any_9 (r_prep) type_35\NN\5839024|who_13|,_35|compared_40 (r_dobj) used_33\VBD\0|NONE_0 (r_relcl) women_31\NNS\9605289|NONE_0 (r_pobj) among_30\IN\0|myocardial_22 (r_prep) infarction_29\NN\14204950|NONE_0
D003276_D009203 CID contraceptives_5\NNS\3183080|who_14 (r_dobj) used_3\VBD\0|NONE_0 (r_relcl) women_1\NNS\9605289|NONE_0 (r_pobj) among_0\IN\0|,_40|ratio_51|interval_88|for_110|:_243 (r_prep) was_10\VBD\0|risk_192|was_222|among_236|._294 (r_ccomp) increased_53\VBN\169651|NONE_0 (l_nsubjpass) risk_48\NN\14541044|was_192|was_30|among_44|._102 (l_prep) of_49\IN\0|the_9 (l_pobj) infarction_51\NN\14204950|NONE_0
D003276_D009203 CID contraceptives_62\NNS\3183080|who_32 (r_dobj) used_57\VBD\0|NONE_0 (r_relcl) women_55\NNS\9605289|NONE_0 (r_pobj) among_54\IN\0|was_236|risk_44|was_14|._58 (r_prep) increased_53\VBN\169651|NONE_0 (l_nsubjpass) risk_48\NN\14541044|was_192|was_30|among_44|._102 (l_prep) of_49\IN\0|the_9 (l_pobj) infarction_51\NN\14204950|NONE_0
D003276_D009203 CID contraceptives_12\NNS\3183080|who_14|had_35 (r_dobj) used_10\VBD\0|NONE_0 (r_relcl) women_8\NNS\9605289|NONE_0 (r_pobj) among_7\IN\0|NONE_0 (r_prep) similar_6\JJ\0|risk_34|._97 (r_acomp) was_5\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|similar_34|._131 (l_prep) of_2\IN\0|the_9 (l_pobj) infarction_4\NN\14204950|NONE_0
C033273_D009203 NONE gestodene_21\NN\0|(_22|i.e._21|,_17|or_3|)_9|and_11|levonorgestrel_40 (r_conj) desogestrel_19\NN\0|third_24|-_19 (r_appos) generation_15\NN\7942152|oral_89 (r_nmod) contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27
C033273_D009203 NONE gestodene_21\NN\0|(_22|i.e._21|,_17|or_3|)_9|and_11|levonorgestrel_40 (r_conj) desogestrel_19\NN\0|third_24|-_19 (r_appos) generation_15\NN\7942152|oral_89 (r_nmod) contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27 (l_prep) between_82\IN\0|a_30|first_28|myocardial_22 (l_pobj) 1990_83\CD\0|NONE_0 (l_conj) women_89\NNS\9605289|and_25|1995_21|and_16 (l_relcl) had_93\VBN\0|925_30|control_26 (l_dobj) infarction_96\NN\14204950|who_29|had_25|not_21|and_11|matched_24
D011372_D009203 NONE progestagen_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_9|included_15 (r_prep) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27
D011372_D009203 NONE progestagen_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_9|included_15 (r_prep) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27 (l_prep) between_82\IN\0|a_30|first_28|myocardial_22 (l_pobj) 1990_83\CD\0|NONE_0 (l_conj) women_89\NNS\9605289|and_25|1995_21|and_16 (l_relcl) had_93\VBN\0|925_30|control_26 (l_dobj) infarction_96\NN\14204950|who_29|had_25|not_21|and_11|matched_24
D016912_D009203 NONE levonorgestrel_30\JJ\0|(_62|i.e._61|,_57|or_43|gestodene_40|)_31|and_29 (r_conj) desogestrel_19\NN\0|third_24|-_19 (r_appos) generation_15\NN\7942152|oral_89 (r_nmod) contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27
D016912_D009203 NONE levonorgestrel_30\JJ\0|(_62|i.e._61|,_57|or_43|gestodene_40|)_31|and_29 (r_conj) desogestrel_19\NN\0|third_24|-_19 (r_appos) generation_15\NN\7942152|oral_89 (r_nmod) contraceptives_33\NNS\3183080|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) included_11\VBN\0|the_24|of_15 (r_acl) type_8\NN\5839024|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) according_5\VBG\2657219|we_34|association_13|,_2|identified_309 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) identified_64\VBD\699815|we_343|association_322|,_311|according_309 (l_conj) enrolled_66\VBD\2471690|,_161|dose_155|:_75|in_73|,_20|we_18|and_4|._257 (l_dobj) women_68\NNS\9605289|18_6|through_9|,_187|year_198 (l_relcl) had_77\VBN\0|248_45 (l_dobj) infarction_81\NN\14204950|who_31|had_27 (l_prep) between_82\IN\0|a_30|first_28|myocardial_22 (l_pobj) 1990_83\CD\0|NONE_0 (l_conj) women_89\NNS\9605289|and_25|1995_21|and_16 (l_relcl) had_93\VBN\0|925_30|control_26 (l_dobj) infarction_96\NN\14204950|who_29|had_25|not_21|and_11|matched_24
7444978
D013307_D004409 CID streptomycin_48\NNS\2716866|NONE_0 (r_pobj) to_47\IN\0|more_15 (r_prep) sensitive_46\JJ\10488309|that_25|cochlea_16 (r_acomp) is_44\VBZ\0|NONE_0 (r_ccomp) indicating_40\VBG\952524|occurred_194|;_136|within_134|sensitivities_102|from_55|,_2|._131 (r_advcl) occurred_23\VBD\0|NONE_0 (l_ccomp) occurred_4\VBD\0|;_58|within_60|sensitivities_92|from_139|,_192|indicating_194|._325 (l_nsubj) movements_1\NNS\191142|in_37
D013307_D004409 CID streptomycin_48\NNS\2716866|NONE_0 (l_prep) than_49\IN\0|NONE_0 (l_pobj) site_51\NN\8673395|NONE_0 (l_amod) responsible_57\JJ\0|the_33|(_24|vestibular_23|)_2 (l_prep) for_58\IN\0|NONE_0 (l_pobj) dyskinesias_60\NNS\14084880|NONE_0
D013307_D003638 CID streptomycin_48\NNS\2716866|NONE_0 (r_pobj) to_47\IN\0|more_15 (r_prep) sensitive_46\JJ\10488309|that_25|cochlea_16 (r_acomp) is_44\VBZ\0|NONE_0 (r_ccomp) indicating_40\VBG\952524|occurred_194|;_136|within_134|sensitivities_102|from_55|,_2|._131 (r_advcl) occurred_23\VBD\0|NONE_0 (l_ccomp) occurred_4\VBD\0|;_58|within_60|sensitivities_92|from_139|,_192|indicating_194|._325 (l_nsubj) movements_1\NNS\191142|in_37 (l_conj) deafness_3\NN\14550797|abnormal_23|and_4
D013307_D020258 NONE streptomycin_11\NNS\2716866|NONE_0 (r_pobj) of_10\IN\0|neurotoxic_19 (r_prep) effects_9\NNS\13245626|NONE_0 (l_amod) neurotoxic_8\JJ\0|of_19
18544179
D005283_D009325 NONE fentanyl_1\NN\2707683|NONE_0 (r_dobj) omitting_0\VBG\471711|nausea_26|,_45|without_47|,_70|after_72|._105 (r_csubj) reduces_2\VBZ\441445|NONE_0 (l_dobj) nausea_3\NN\14299637|omitting_26|,_19|without_21|,_44|after_46|._79
D005283_D009325 NONE fentanyl_2\NN\2707683|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) omission_0\NN\70965|did_21|not_25|incidence_48|,_94|but_96|reduce_104|._279 (r_nsubj) reduce_5\VB\441445|NONE_0 (l_conj) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_conj) moderate_23\JJ\9605289|did_44|incidence_29|and/or_7|prior_26|,_116|to_118 (l_prep) to_24\TO\0|NONE_0 (l_pobj) nausea_26\NN\14299637|NONE_0
D005283_D009325 NONE fentanyl_37\NN\2707683|fentanyl_13|-_21 (r_nmod) dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_conj) moderate_23\JJ\9605289|did_44|incidence_29|and/or_7|prior_26|,_116|to_118 (l_prep) to_24\TO\0|NONE_0 (l_pobj) nausea_26\NN\14299637|NONE_0
D005283_D009325 NONE fentanyl_39\NN\2707683|fentanyl_13|-_8 (r_compound) dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_conj) moderate_23\JJ\9605289|did_44|incidence_29|and/or_7|prior_26|,_116|to_118 (l_prep) to_24\TO\0|NONE_0 (l_pobj) nausea_26\NN\14299637|NONE_0
D005283_D009325 NONE fentanyl_3\NN\2707683|the_8 (r_compound) groups_4\NNS\2137|NONE_0 (r_dobj) combining_0\VBG\7373277|benefits_63|,_101|reducing_103|(_208|p_209|decreased_284|._321 (r_csubj) revealed_5\VBD\2137132|NONE_0 (l_advcl) reducing_15\VBG\13447361|combining_103|benefits_40|,_2|(_105|p_106|decreased_181|._218 (l_dobj) nausea_17\NN\14299637|prior_31 (l_conj) vomiting_19\NN\116687|postoperative_25|and_4 (l_conj) nausea_21\NN\14299637|and_4
D005283_D009325 NONE fentanyl_3\NN\2707683|the_8 (r_compound) groups_4\NNS\2137|NONE_0 (r_dobj) combining_0\VBG\7373277|benefits_63|,_101|reducing_103|(_208|p_209|decreased_284|._321 (r_csubj) revealed_5\VBD\2137132|NONE_0 (l_advcl) decreased_57\VBN\169651|combining_284|benefits_221|,_183|reducing_181|(_76|p_75|._37 (l_nsubjpass) nausea_50\NN\14299637|while_6|was_25|from_39|(_55|p_56|)_65
C009250_D007022 NONE sevoflurane_9\NN\0|-_11 (r_npadvmod) sparing_11\VBG\2725714|no_15 (r_amod) effect_12\NN\34213|and_7|depression_33 (r_dobj) had_7\VBD\0|fentanyl_54|did_45|movement_13|but_4|._99 (l_conj) depression_16\NN\14373582|effect_33|and_26 (l_conj) hypotension_18\NN\14057371|increased_34|respiratory_24|,_2
C009250_D010146 NONE sevoflurane_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|omitting_72|nausea_46|,_27|without_25|,_2|._33 (r_prep) reduces_2\VBZ\441445|NONE_0 (l_prep) without_7\IN\0|omitting_47|nausea_21|,_2|,_23|after_25|._58 (l_pcomp) increasing_8\VBG\169651|NONE_0 (l_dobj) pain_9\NN\14299637|NONE_0
C009250_D010146 NONE sevoflurane_23\NN\0|in_24 (r_compound) anaesthesia_24\NN\14034177|NONE_0 (r_pobj) after_22\IN\0|the_15|first_11|24_5 (r_prep) h_21\NN\14622893|NONE_0 (r_pobj) in_17\IN\13603305|study_88|incidence_69|._81 (r_prep) examined_5\VBD\0|NONE_0 (l_dobj) incidence_7\NN\13821570|study_19|in_69|._150 (l_prep) of_10\IN\0|the_27|and_13|severity_9 (l_pobj) nausea_12\NN\14299637|NONE_0 (l_conj) vomiting_14\NN\116687|postoperative_25|and_4 (l_conj) pain_16\NN\14299637|and_4
D003907_D014839 NONE dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_dobj) incidence_19\NN\13821570|did_15|and/or_22|moderate_29|prior_55|,_145|to_147 (l_prep) of_20\IN\0|the_14 (l_pobj) vomiting_21\NN\116687|NONE_0
C009250_D001919 NONE sevoflurane_9\NN\0|-_11 (r_npadvmod) sparing_11\VBG\2725714|no_15 (r_amod) effect_12\NN\34213|and_7|depression_33 (r_dobj) had_7\VBD\0|fentanyl_54|did_45|movement_13|but_4|._99 (l_conj) depression_16\NN\14373582|effect_33|and_26 (l_conj) hypotension_18\NN\14057371|increased_34|respiratory_24|,_2 (l_conj) bradycardia_20\NN\14110674|and_4
C009250_D020250 NONE sevoflurane_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|of_44 (r_prep) advantages_1\NNS\5154517|NONE_0 (r_pobj) despite_0\IN\7501545|nausea_95|frequently_122|._132 (r_prep) occurs_15\VBZ\0|NONE_0 (l_nsubj) nausea_12\NN\14299637|despite_95|frequently_27|._37 (l_conj) vomiting_14\NN\116687|postoperative_25|and_4
C009250_D020250 NONE sevoflurane_23\NN\0|in_24 (r_compound) anaesthesia_24\NN\14034177|NONE_0 (r_pobj) after_22\IN\0|the_15|first_11|24_5 (r_prep) h_21\NN\14622893|NONE_0 (r_pobj) in_17\IN\13603305|study_88|incidence_69|._81 (r_prep) examined_5\VBD\0|NONE_0 (l_dobj) incidence_7\NN\13821570|study_19|in_69|._150 (l_prep) of_10\IN\0|the_27|and_13|severity_9 (l_pobj) nausea_12\NN\14299637|NONE_0 (l_conj) vomiting_14\NN\116687|postoperative_25|and_4
C009250_D020250 NONE sevoflurane_31\NN\0|an_54|unnecessary_51 (r_relcl) supplement_29\NN\6365467|to_46 (r_attr) be_23\VB\14625458|exacerbated_153|,_16|it_14|._83 (r_xcomp) appears_21\VBZ\2604760|NONE_0 (l_advcl) exacerbated_2\VBD\126264|,_137|it_139|be_153|._236 (l_dobj) nausea_4\NN\14299637|as_38|fentanyl_35|and_65|had_74 (l_conj) vomiting_6\VBG\116687|postoperative_25|and_4
C009250_D010149 NONE sevoflurane_31\NN\0|an_54|unnecessary_51 (r_relcl) supplement_29\NN\6365467|to_46 (r_attr) be_23\VB\14625458|exacerbated_153|,_16|it_14|._83 (r_xcomp) appears_21\VBZ\2604760|NONE_0 (l_advcl) exacerbated_2\VBD\126264|,_137|it_139|be_153|._236 (l_dobj) nausea_4\NN\14299637|as_38|fentanyl_35|and_65|had_74 (l_conj) vomiting_6\VBG\116687|postoperative_25|and_4 (l_prep) without_7\IN\0|NONE_0 (l_pobj) improvement_9\NN\7359599|NONE_0 (l_prep) in_10\IN\13603305|an_15 (l_pobj) pain_12\NN\14299637|NONE_0
C009250_D014839 NONE sevoflurane_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|omitting_72|nausea_46|,_27|without_25|,_2|._33 (r_prep) reduces_2\VBZ\441445|NONE_0 (l_dobj) nausea_3\NN\14299637|omitting_26|,_19|without_21|,_44|after_46|._79 (l_conj) vomiting_5\NN\116687|and_4
C009250_D009325 NONE sevoflurane_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|omitting_72|nausea_46|,_27|without_25|,_2|._33 (r_prep) reduces_2\VBZ\441445|NONE_0 (l_dobj) nausea_3\NN\14299637|omitting_26|,_19|without_21|,_44|after_46|._79
D003907_D009325 NONE dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_conj) moderate_23\JJ\9605289|did_44|incidence_29|and/or_7|prior_26|,_116|to_118 (l_prep) to_24\TO\0|NONE_0 (l_pobj) nausea_26\NN\14299637|NONE_0
D003907_D020250 NONE dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (r_conj) reduce_5\VB\441445|NONE_0 (l_dobj) incidence_8\NN\13821570|omission_48|did_27|not_23|,_46|but_48|reduce_56|._231 (l_prep) of_9\IN\0|the_22|overall_18 (l_pobj) nausea_11\NN\14299637|NONE_0 (l_conj) vomiting_13\NN\116687|postoperative_25|and_4
D003907_D020250 NONE dexamethasone_0\NNP\2721538|effect_33|._105 (r_nsubj) had_1\VBD\0|NONE_0 (l_dobj) effect_4\NN\34213|dexamethasone_33|._72 (l_prep) on_5\IN\0|no_22|significant_19 (l_pobj) incidence_7\NN\13821570|NONE_0 (l_prep) of_10\IN\0|the_26|or_12|severity_9 (l_pobj) nausea_12\NN\14299637|NONE_0 (l_conj) vomiting_14\NN\116687|postoperative_25|and_4
D005283_D014839 NONE fentanyl_1\NN\2707683|NONE_0 (r_dobj) omitting_0\VBG\471711|nausea_26|,_45|without_47|,_70|after_72|._105 (r_csubj) reduces_2\VBZ\441445|NONE_0 (l_dobj) nausea_3\NN\14299637|omitting_26|,_19|without_21|,_44|after_46|._79 (l_conj) vomiting_5\NN\116687|and_4
D005283_D014839 NONE fentanyl_2\NN\2707683|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) omission_0\NN\70965|did_21|not_25|incidence_48|,_94|but_96|reduce_104|._279 (r_nsubj) reduce_5\VB\441445|NONE_0 (l_conj) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_dobj) incidence_19\NN\13821570|did_15|and/or_22|moderate_29|prior_55|,_145|to_147 (l_prep) of_20\IN\0|the_14 (l_pobj) vomiting_21\NN\116687|NONE_0
D005283_D014839 NONE fentanyl_37\NN\2707683|fentanyl_13|-_21 (r_nmod) dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_dobj) incidence_19\NN\13821570|did_15|and/or_22|moderate_29|prior_55|,_145|to_147 (l_prep) of_20\IN\0|the_14 (l_pobj) vomiting_21\NN\116687|NONE_0
D005283_D014839 NONE fentanyl_39\NN\2707683|fentanyl_13|-_8 (r_compound) dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (l_dobj) incidence_19\NN\13821570|did_15|and/or_22|moderate_29|prior_55|,_145|to_147 (l_prep) of_20\IN\0|the_14 (l_pobj) vomiting_21\NN\116687|NONE_0
D005283_D012131 CID fentanyl_0\NNP\2707683|did_9|movement_41|but_50|had_54|._153 (r_nsubj) reduce_2\VB\441445|NONE_0 (l_conj) had_7\VBD\0|fentanyl_54|did_45|movement_13|but_4|._99 (l_conj) depression_16\NN\14373582|effect_33|and_26
D005283_D020250 CID fentanyl_2\NN\2707683|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) omission_0\NN\70965|did_21|not_25|incidence_48|,_94|but_96|reduce_104|._279 (r_nsubj) reduce_5\VB\441445|NONE_0 (l_dobj) incidence_8\NN\13821570|omission_48|did_27|not_23|,_46|but_48|reduce_56|._231 (l_prep) of_9\IN\0|the_22|overall_18 (l_pobj) nausea_11\NN\14299637|NONE_0 (l_conj) vomiting_13\NN\116687|postoperative_25|and_4
D005283_D020250 CID fentanyl_37\NN\2707683|fentanyl_13|-_21 (r_nmod) dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (r_conj) reduce_5\VB\441445|NONE_0 (l_dobj) incidence_8\NN\13821570|omission_48|did_27|not_23|,_46|but_48|reduce_56|._231 (l_prep) of_9\IN\0|the_22|overall_18 (l_pobj) nausea_11\NN\14299637|NONE_0 (l_conj) vomiting_13\NN\116687|postoperative_25|and_4
D005283_D020250 CID fentanyl_39\NN\2707683|fentanyl_13|-_8 (r_compound) dexamethasone_41\NN\2721538|NONE_0 (r_pobj) with_36\IN\0|17_4 (r_prep) %_35\NN\0|20_10|and_6 (r_conj) %_32\NN\0|NONE_0 (r_pobj) from_30\IN\0|,_57|respectively_59 (r_prep) discharge_29\NN\7283608|NONE_0 (r_pobj) to_28\IN\0|NONE_0 (r_prep) prior_27\RB\10675876|did_70|incidence_55|and/or_33|moderate_26|,_90|to_92 (r_advmod) reduce_17\VB\441445|omission_104|did_83|not_79|incidence_56|,_10|but_8|._175 (r_conj) reduce_5\VB\441445|NONE_0 (l_dobj) incidence_8\NN\13821570|omission_48|did_27|not_23|,_46|but_48|reduce_56|._231 (l_prep) of_9\IN\0|the_22|overall_18 (l_pobj) nausea_11\NN\14299637|NONE_0 (l_conj) vomiting_13\NN\116687|postoperative_25|and_4
D005283_D020250 CID fentanyl_3\NN\2707683|the_8 (r_compound) groups_4\NNS\2137|NONE_0 (r_dobj) combining_0\VBG\7373277|benefits_63|,_101|reducing_103|(_208|p_209|decreased_284|._321 (r_csubj) revealed_5\VBD\2137132|NONE_0 (l_advcl) reducing_15\VBG\13447361|combining_103|benefits_40|,_2|(_105|p_106|decreased_181|._218 (l_dobj) nausea_17\NN\14299637|prior_31 (l_conj) vomiting_19\NN\116687|postoperative_25|and_4
D005283_D020250 CID fentanyl_1\NN\2707683|as_3|nausea_35|and_100|had_109 (r_nsubj) exacerbated_2\VBD\126264|,_137|it_139|be_153|._236 (l_dobj) nausea_4\NN\14299637|as_38|fentanyl_35|and_65|had_74 (l_conj) vomiting_6\VBG\116687|postoperative_25|and_4
D005283_D001919 CID fentanyl_0\NNP\2707683|did_9|movement_41|but_50|had_54|._153 (r_nsubj) reduce_2\VB\441445|NONE_0 (l_conj) had_7\VBD\0|fentanyl_54|did_45|movement_13|but_4|._99 (l_conj) depression_16\NN\14373582|effect_33|and_26 (l_conj) hypotension_18\NN\14057371|increased_34|respiratory_24|,_2 (l_conj) bradycardia_20\NN\14110674|and_4
D005283_D010146 NONE fentanyl_1\NN\2707683|NONE_0 (r_dobj) omitting_0\VBG\471711|nausea_26|,_45|without_47|,_70|after_72|._105 (r_csubj) reduces_2\VBZ\441445|NONE_0 (l_prep) without_7\IN\0|omitting_47|nausea_21|,_2|,_23|after_25|._58 (l_pcomp) increasing_8\VBG\169651|NONE_0 (l_dobj) pain_9\NN\14299637|NONE_0
D005283_D010146 NONE fentanyl_11\NN\2707683|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) omission_9\NN\70965|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_prep) unaffected_6\JJ\0|severity_41|._38 (r_acomp) were_5\VBD\0|NONE_0 (l_nsubj) severity_1\NN\5036394|unaffected_41|._79 (l_compound) pain_0\NN\14299637|and_14|requirements_28
D005283_D010149 NONE fentanyl_1\NN\2707683|as_3|nausea_35|and_100|had_109 (r_nsubj) exacerbated_2\VBD\126264|,_137|it_139|be_153|._236 (l_dobj) nausea_4\NN\14299637|as_38|fentanyl_35|and_65|had_74 (l_conj) vomiting_6\VBG\116687|postoperative_25|and_4 (l_prep) without_7\IN\0|NONE_0 (l_pobj) improvement_9\NN\7359599|NONE_0 (l_prep) in_10\IN\13603305|an_15 (l_pobj) pain_12\NN\14299637|NONE_0
D005283_D007022 CID fentanyl_0\NNP\2707683|did_9|movement_41|but_50|had_54|._153 (r_nsubj) reduce_2\VB\441445|NONE_0 (l_conj) had_7\VBD\0|fentanyl_54|did_45|movement_13|but_4|._99 (l_conj) depression_16\NN\14373582|effect_33|and_26 (l_conj) hypotension_18\NN\14057371|increased_34|respiratory_24|,_2
C009250_D012131 NONE sevoflurane_9\NN\0|-_11 (r_npadvmod) sparing_11\VBG\2725714|no_15 (r_amod) effect_12\NN\34213|and_7|depression_33 (r_dobj) had_7\VBD\0|fentanyl_54|did_45|movement_13|but_4|._99 (l_conj) depression_16\NN\14373582|effect_33|and_26
17241784
D019821_D009135 CID statin_12\NN\3740161|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) associated_10\VBD\628491|progressive_49|with_28|._30 (r_acl) myopathy_1\NNS\14204950|NONE_0
D019821_D009135 CID statins_0\NNS\3740161|can_8|necrotizing_20|myopathy_32|._102 (r_nsubj) cause_2\VB\7323922|NONE_0 (l_ccomp) myopathy_5\NN\14204950|statins_32|can_24|necrotizing_12|._70
D019821_D009135 CID statins_9\NNS\3740161|whereby_8|may_8|myopathy_21 (r_nsubj) induce_11\VB\1627355|a_33|,_17|persists_25 (l_dobj) myopathy_13\NN\14204950|whereby_29|statins_21|may_13
D019821_D009135 CID statins_4\NNS\3740161|that_5|may_8|myopathy_40 (r_nsubj) initiate_6\VB\9632274|observations_38|._121 (l_dobj) myopathy_11\NN\14204950|that_45|statins_40|may_32
D019821_D009135 CID statins_13\NNS\3740161|NONE_0 (r_pobj) by_12\IN\0|the_14 (r_prep) induction_11\NN\7450842|may_16 (r_dobj) involve_9\VB\2676054|mechanism_48|uncertain_18|but_8|._168 (r_conj) is_5\VBZ\0|NONE_0 (l_nsubj) mechanism_1\NN\13446390|uncertain_30|but_40|involve_48|._216 (l_prep) of_2\IN\0|the_14 (l_pobj) myopathy_4\NN\14204950|NONE_0
D019821_-1 NONE statins_0\NNS\3740161|can_8|necrotizing_20|myopathy_32|._102 (r_nsubj) cause_2\VB\7323922|NONE_0 (l_ccomp) myopathy_5\NN\14204950|statins_32|can_24|necrotizing_12|._70 (l_conj) hyperckaemia_7\NN\0|and_4
19308880
D014635_D003221 CID acid_10\NN\14818238|NONE_0 (r_pobj) with_8\IN\0|a_39|serious_30|adverse_22|drug_14 (r_prep) reaction_7\NN\13446390|,_32|:_27|review_31|._78 (r_appos) confusion_0\NN\13972797|NONE_0
D014635_D003221 CID acid_10\NN\14818238|NONE_0 (r_pobj) with_8\IN\0|frequently_20 (r_prep) observed_7\VBD\2163746|an_36|adverse_33|drug_25 (r_acl) reaction_5\NN\13446390|confusion_29|._47 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) confusion_0\NN\13972797|reaction_29|._76
D014635_D003221 CID acid_17\NN\14818238|NONE_0 (r_pobj) with_15\IN\0|since_11 (r_prep) reported_12\VBN\831651|NONE_0 (r_acl) confusion_11\NN\13972797|NONE_0
D014635_D003221 CID acid_9\NN\14818238|NONE_0 (r_pobj) with_7\IN\0|:_39|cases_33|were_14|._41 (r_prep) reported_6\VBN\831651|NONE_0 (l_nsubjpass) cases_2\NNS\7283608|:_6|were_19|with_33|._74 (l_prep) of_3\IN\0|272_10 (l_pobj) confusion_4\NN\13972797|NONE_0
D014635_D003221 CID acid_10\NN\14818238|(_14|%_19|)_20 (r_compound) exposure_11\NN\5042871|NONE_0 (r_pobj) following_8\VBG\8180190|the_20|two_16|first_12 (r_prep) weeks_7\NNS\15113229|NONE_0 (r_pobj) during_3\IN\0|confusion_26|mostly_16|._67 (r_prep) occurred_2\VBD\0|NONE_0 (l_nsubj) confusion_0\NN\13972797|mostly_10|during_26|._93
D014635_D003221 CID acid_7\NN\14818238|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) confusion_4\NN\13972797|that_5|reaction_87
18182964
D003000_D006970 NONE clonidine_4\NN\2721160|NONE_0 (r_pobj) on_3\IN\0|drowsiness_22|common_7|,_12|but_14|resolved_28|._52 (r_prep) was_1\VBD\0|NONE_0 (l_nsubj) drowsiness_0\NN\14015731|common_15|on_22|,_34|but_36|resolved_50|._74
D003000_D006970 NONE clonidine_2\NN\2721160|NONE_0 (r_dobj) prescribing_1\VBG\748282|NONE_0 (r_acl) physicians_0\NNS\10305802|should_33|for_48|and_64|advise_68|._131 (r_nsubj) monitor_4\VB\10676877|NONE_0 (l_conj) advise_8\VB\813978|physicians_68|should_35|for_20|and_4|._63 (l_dobj) patients_9\NNS\9898892|NONE_0 (l_prep) about_10\IN\0|NONE_0 (l_pobj) likelihood_13\NN\4756172|NONE_0 (l_prep) of_14\IN\0|the_20|high_16 (l_pobj) drowsiness_16\NN\14015731|NONE_0
D003000_D001919 CID clonidine_10\NN\2721160|NONE_0 (r_pobj) with_9\IN\0|compared_15 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) subjects_7\NNS\6598915|NONE_0 (r_pobj) in_6\IN\13603305|more_30|of_15 (r_prep) incidents_3\NNS\7283608|there_16|._240 (l_prep) of_4\IN\0|more_15|in_15 (l_pobj) bradycardia_5\NN\14110674|NONE_0
D003000_D001919 CID clonidine_17\NN\2721160|NONE_0 (r_pobj) with_16\IN\0|not_12 (r_prep) treated_15\VBN\2376958|%_28|but_52|differences_83 (r_acl) those_13\DT\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) compared_11\VBN\644583|with_15 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) subjects_7\NNS\6598915|NONE_0 (r_pobj) in_6\IN\13603305|more_30|of_15 (r_prep) incidents_3\NNS\7283608|there_16|._240 (l_prep) of_4\IN\0|more_15|in_15 (l_pobj) bradycardia_5\NN\14110674|NONE_0
D003000_D001919 CID clonidine_2\NN\2721160|NONE_0 (r_dobj) prescribing_1\VBG\748282|NONE_0 (r_acl) physicians_0\NNS\10305802|should_33|for_48|and_64|advise_68|._131 (r_nsubj) monitor_4\VB\10676877|NONE_0 (l_prep) for_5\IN\0|physicians_48|should_15|and_16|advise_20|._83 (l_pobj) bradycardia_6\NN\14110674|NONE_0
D008774_D001289 NONE methylphenidate_12\NN\4320126|NONE_0 (l_prep) with_15\IN\0|in_12 (l_pobj) disorder_21\NN\14034177|NONE_0
D008774_D001289 NONE methylphenidate_12\NN\4320126|NONE_0 (l_prep) with_15\IN\0|in_12 (l_pobj) disorder_21\NN\14034177|NONE_0 (l_appos) adhd_23\NNP\14304060|hyperactivity_24|(_1|)_4
D008774_D001289 NONE methylphenidate_25\NN\4320126|to_23|n_9|,_2 (r_conj) clonidine_18\NN\2721160|in_95|,_51|children_45|were_26|randomly_21|._105 (r_xcomp) assigned_16\VBN\2475922|NONE_0 (l_nsubjpass) children_11\NNS\9622049|in_50|,_6|were_19|randomly_24|clonidine_45|._150 (l_prep) with_12\IN\0|122_13 (l_pobj) adhd_13\NNP\14304060|NONE_0
D008774_D001289 NONE methylphenidate_34\NN\4320126|and_4 (r_conj) clonidine_32\NN\2721160|(_10|n_9|29_5|)_3|,_2|(_30|n_31|32_35|,_38|or_40|placebo_43 (r_conj) methylphenidate_25\NN\4320126|to_23|n_9|,_2 (r_conj) clonidine_18\NN\2721160|in_95|,_51|children_45|were_26|randomly_21|._105 (r_xcomp) assigned_16\VBN\2475922|NONE_0 (l_nsubjpass) children_11\NNS\9622049|in_50|,_6|were_19|randomly_24|clonidine_45|._150 (l_prep) with_12\IN\0|122_13 (l_pobj) adhd_13\NNP\14304060|NONE_0
D008774_D001289 NONE methylphenidate_6\NN\4320126|NONE_0 (r_pobj) with_5\IN\0|alone_9|or_3 (r_conj) used_2\VBN\0|,_2|,_34 (r_acl) clonidine_0\NNP\2721160|safe_55|and_60|tolerated_69|._96 (r_nsubj) appears_8\VBZ\2604760|NONE_0 (l_conj) tolerated_12\VBN\802318|clonidine_69|safe_14|and_9|._27 (l_prep) in_13\IN\13603305|well_15 (l_pobj) adhd_15\NNP\14304060|NONE_0
D003000_D001289 NONE clonidine_0\NNP\2721160|NONE_0 (l_prep) for_1\IN\0|ii_46 (l_pobj) disorder_7\NN\14034177|NONE_0
D003000_D001289 NONE clonidine_7\NN\2721160|NONE_0 (r_pobj) of_6\IN\0|the_28|and_17|tolerability_13 (r_prep) safety_3\NN\13920835|to_15 (r_dobj) examine_1\VB\0|alone_54|or_60|with_63 (r_csubj) used_8\VBN\0|NONE_0 (l_conj) with_11\IN\0|examine_63|alone_9|or_3 (l_pobj) methylphenidate_12\NN\4320126|NONE_0 (l_prep) with_15\IN\0|in_12 (l_pobj) disorder_21\NN\14034177|NONE_0
D003000_D001289 NONE clonidine_7\NN\2721160|NONE_0 (r_pobj) of_6\IN\0|the_28|and_17|tolerability_13 (r_prep) safety_3\NN\13920835|to_15 (r_dobj) examine_1\VB\0|alone_54|or_60|with_63 (r_csubj) used_8\VBN\0|NONE_0 (l_conj) with_11\IN\0|examine_63|alone_9|or_3 (l_pobj) methylphenidate_12\NN\4320126|NONE_0 (l_prep) with_15\IN\0|in_12 (l_pobj) disorder_21\NN\14034177|NONE_0 (l_appos) adhd_23\NNP\14304060|hyperactivity_24|(_1|)_4
D003000_D001289 NONE clonidine_18\NN\2721160|in_95|,_51|children_45|were_26|randomly_21|._105 (r_xcomp) assigned_16\VBN\2475922|NONE_0 (l_nsubjpass) children_11\NNS\9622049|in_50|,_6|were_19|randomly_24|clonidine_45|._150 (l_prep) with_12\IN\0|122_13 (l_pobj) adhd_13\NNP\14304060|NONE_0
D003000_D001289 NONE clonidine_32\NN\2721160|(_10|n_9|29_5|)_3|,_2|(_30|n_31|32_35|,_38|or_40|placebo_43 (r_conj) methylphenidate_25\NN\4320126|to_23|n_9|,_2 (r_conj) clonidine_18\NN\2721160|in_95|,_51|children_45|were_26|randomly_21|._105 (r_xcomp) assigned_16\VBN\2475922|NONE_0 (l_nsubjpass) children_11\NNS\9622049|in_50|,_6|were_19|randomly_24|clonidine_45|._150 (l_prep) with_12\IN\0|122_13 (l_pobj) adhd_13\NNP\14304060|NONE_0
D003000_D001289 NONE clonidine_0\NNP\2721160|safe_55|and_60|tolerated_69|._96 (r_nsubj) appears_8\VBZ\2604760|NONE_0 (l_conj) tolerated_12\VBN\802318|clonidine_69|safe_14|and_9|._27 (l_prep) in_13\IN\13603305|well_15 (l_pobj) adhd_15\NNP\14304060|NONE_0
20528871
C104457_D006402 CID arag_8\NNP\0|NONE_0 (r_pobj) than_7\IN\0|the_16 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) for_4\IN\0|NONE_0 (r_prep) greater_3\JJR\0|toxicity_13|,_43|was_102|._145 (r_acomp) was_2\VBD\0|NONE_0 (l_nsubj) toxicity_1\NN\13576101|greater_13|,_56|was_115|._158
D005047_D015458 NONE etoposide_5\RB\0|,_2|in_32 (r_conj) nelarabine_3\NN\0|NONE_0 (l_prep) in_9\IN\13603305|,_34|etoposide_32 (l_pobj) leukaemia_18\NN\14239918|NONE_0 (l_conj) lymphoma_20\NN\14239918|relapsed_66|/_58|refractory_57|lymphoblastic_28|and_4
D005047_D015458 NONE etoposide_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|5_4|vp_14 (r_prep) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D005047_D015458 NONE vp_16\NNP\0|5_18|of_14 (r_appos) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D005047_D016399 NONE etoposide_5\RB\0|,_2|in_32 (r_conj) nelarabine_3\NN\0|NONE_0 (l_prep) in_9\IN\13603305|,_34|etoposide_32 (l_pobj) leukaemia_18\NN\14239918|NONE_0 (l_conj) lymphoma_20\NN\14239918|relapsed_66|/_58|refractory_57|lymphoblastic_28|and_4
D005047_D016399 NONE etoposide_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|5_4|vp_14 (r_prep) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D005047_D016399 NONE vp_16\NNP\0|5_18|of_14 (r_appos) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
C104457_D015458 NONE nelarabine_3\NN\0|NONE_0 (l_prep) in_9\IN\13603305|,_34|etoposide_32 (l_pobj) leukaemia_18\NN\14239918|NONE_0 (l_conj) lymphoma_20\NN\14239918|relapsed_66|/_58|refractory_57|lymphoblastic_28|and_4
C104457_D015458 NONE nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
C104457_D015458 NONE arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D003520_D015458 NONE cyclophosphamide_8\NN\0|,_6|and_4 (r_conj) etoposide_5\RB\0|,_2|in_32 (r_conj) nelarabine_3\NN\0|NONE_0 (l_prep) in_9\IN\13603305|,_34|etoposide_32 (l_pobj) leukaemia_18\NN\14239918|NONE_0 (l_conj) lymphoma_20\NN\14239918|relapsed_66|/_58|refractory_57|lymphoblastic_28|and_4
D003520_D015458 NONE cyclophosphamide_19\NN\0|(_9|)_6|and_4|cpm_18|and_23|chemotherapy_52 (r_conj) vp_16\NNP\0|5_18|of_14 (r_appos) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D003520_D015458 NONE cpm_21\NNP\0|(_27|)_24|and_22|cyclophosphamide_18|and_5|chemotherapy_34 (r_appos) vp_16\NNP\0|5_18|of_14 (r_appos) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
C104457_D016399 NONE nelarabine_3\NN\0|NONE_0 (l_prep) in_9\IN\13603305|,_34|etoposide_32 (l_pobj) leukaemia_18\NN\14239918|NONE_0 (l_conj) lymphoma_20\NN\14239918|relapsed_66|/_58|refractory_57|lymphoblastic_28|and_4
C104457_D016399 NONE nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
C104457_D016399 NONE arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D003520_D016399 NONE cyclophosphamide_8\NN\0|,_6|and_4 (r_conj) etoposide_5\RB\0|,_2|in_32 (r_conj) nelarabine_3\NN\0|NONE_0 (l_prep) in_9\IN\13603305|,_34|etoposide_32 (l_pobj) leukaemia_18\NN\14239918|NONE_0 (l_conj) lymphoma_20\NN\14239918|relapsed_66|/_58|refractory_57|lymphoblastic_28|and_4
D003520_D016399 NONE cyclophosphamide_19\NN\0|(_9|)_6|and_4|cpm_18|and_23|chemotherapy_52 (r_conj) vp_16\NNP\0|5_18|of_14 (r_appos) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D003520_D016399 NONE cpm_21\NNP\0|(_27|)_24|and_22|cyclophosphamide_18|and_5|chemotherapy_34 (r_appos) vp_16\NNP\0|5_18|of_14 (r_appos) d_12\SYM\15089472|NONE_0 (r_pobj) with_10\IN\0|(_7|)_2 (r_prep) arag_8\NNP\0|NONE_0 (r_appos) nelarabine_6\JJ\0|NONE_0 (r_pobj) of_5\IN\0|5_4 (r_prep) d_4\SYM\15089472|NONE_0 (r_pobj) of_2\IN\0|a_14 (r_prep) combination_1\NN\7951464|was_136|as_145|in_164|._238 (r_nsubjpass) used_28\VBN\0|NONE_0 (l_prep) in_32\IN\13603305|combination_164|was_28|as_19|._74 (l_pobj) children_34\NNS\9622049|NONE_0 (l_prep) with_35\IN\0|seven_15 (l_pobj) leukaemia_42\NN\14239918|NONE_0 (l_conj) lymphoma_44\NN\14239918|refractory_43|cell_18|or_3
D005047_D009422 NONE etoposide_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) synchrony_12\NN\13844690|NONE_0 (r_pobj) in_11\IN\13603305|salvage_16 (r_prep) therapy_10\NN\657604|NONE_0 (r_pobj) as_8\IN\14622893|arag_5 (r_prep) giving_6\VBG\1085793|NONE_0 (r_pcomp) of_5\IN\0|the_11 (r_prep) safety_4\NN\13920835|experience_24|,_89|monitored_138|._147 (r_dobj) supports_2\VBZ\407535|NONE_0 (l_advcl) monitored_24\VBN\2169352|experience_162|safety_138|,_49|._9 (l_nsubjpass) toxicity_20\NN\13576101|although_22|must_9|be_14|closely_17
D003520_D009422 NONE cyclophosphamide_16\NN\0|and_4 (r_conj) etoposide_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) synchrony_12\NN\13844690|NONE_0 (r_pobj) in_11\IN\13603305|salvage_16 (r_prep) therapy_10\NN\657604|NONE_0 (r_pobj) as_8\IN\14622893|arag_5 (r_prep) giving_6\VBG\1085793|NONE_0 (r_pcomp) of_5\IN\0|the_11 (r_prep) safety_4\NN\13920835|experience_24|,_89|monitored_138|._147 (r_dobj) supports_2\VBZ\407535|NONE_0 (l_advcl) monitored_24\VBN\2169352|experience_162|safety_138|,_49|._9 (l_nsubjpass) toxicity_20\NN\13576101|although_22|must_9|be_14|closely_17
C104457_D009422 CID arag_8\NNP\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) attributable_5\JJ\0|the_29|common_20|side_13 (r_amod) effects_4\NNS\13245626|neuropathy_74|._109 (r_nsubj) included_9\VBD\0|NONE_0 (l_dobj) neuropathy_17\NN\14204950|effects_74|._35
C104457_D009422 CID arag_7\NN\0|as_5 (r_dobj) giving_6\VBG\1085793|NONE_0 (r_pcomp) of_5\IN\0|the_11 (r_prep) safety_4\NN\13920835|experience_24|,_89|monitored_138|._147 (r_dobj) supports_2\VBZ\407535|NONE_0 (l_advcl) monitored_24\VBN\2169352|experience_162|safety_138|,_49|._9 (l_nsubjpass) toxicity_20\NN\13576101|although_22|must_9|be_14|closely_17
C104457_D059352 CID arag_8\NNP\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) attributable_5\JJ\0|the_29|common_20|side_13 (r_amod) effects_4\NNS\13245626|neuropathy_74|._109 (r_nsubj) included_9\VBD\0|NONE_0 (l_dobj) neuropathy_17\NN\14204950|effects_74|._35 (l_conj) pain_20\NN\14299637|grade_63|sensory_49|and_20
10704919
D017665_D006461 NONE hydroxyl_32\NN\14621446|(_24|)_8 (r_dobj) inactivated_30\VBN\1097743|effect_121|is_107|by_94|indicating_33|._114 (r_parataxis) prevented_6\VBN\0|NONE_0 (l_nsubjpass) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D017665_D006461 NONE hydroxyl_32\NN\14621446|(_24|)_8 (r_dobj) inactivated_30\VBN\1097743|effect_121|is_107|by_94|indicating_33|._114 (r_parataxis) prevented_6\VBN\0|NONE_0 (l_advcl) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (l_ccomp) related_42\VBN\628491|NONE_0 (l_nsubjpass) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D013629_D006461 CID tamoxifen_6\NN\2714883|NONE_0 (r_pobj) by_5\IN\0|hemolysis_40|related_16|._59 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubj) hemolysis_0\NNP\13509528|by_40|related_56|._99
D013629_D006461 CID tam_0\NNP\2954340|hemolysis_12|._68 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) hemolysis_2\NN\13509528|tam_12|._56
D013629_D006461 CID tam_13\NNP\2954340|hemolysis_18|._53 (r_nsubj) induces_14\VBZ\1627355|extension_81|variable_55|,_22|but_20 (r_conj) is_4\VBZ\0|NONE_0 (l_nsubj) extension_1\NN\15272029|variable_26|,_59|but_61|induces_81 (l_prep) of_2\IN\0|the_14 (l_pobj) hemolysis_3\NN\13509528|NONE_0
D013629_D006461 CID tam_13\NNP\2954340|hemolysis_18|._53 (r_nsubj) induces_14\VBZ\1627355|extension_81|variable_55|,_22|but_20 (l_dobj) hemolysis_16\NN\13509528|tam_18|._35
D013629_D006461 CID tam_4\NNP\2954340|NONE_0 (r_pobj) of_3\IN\0|the_21|hemolytic_17 (r_prep) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D013629_D006461 CID tam_4\NNP\2954340|NONE_0 (r_pobj) of_3\IN\0|the_21|hemolytic_17 (r_prep) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (r_nsubjpass) prevented_6\VBN\0|NONE_0 (l_advcl) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (l_ccomp) related_42\VBN\628491|NONE_0 (l_nsubjpass) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D013629_D006461 CID tam_36\NNP\2954340|-_3 (r_npadvmod) induced_38\VBN\1627355|NONE_0 (r_amod) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25 (r_nsubjpass) related_42\VBN\628491|NONE_0 (r_ccomp) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (r_advcl) prevented_6\VBN\0|NONE_0 (l_nsubjpass) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D013629_D006461 CID tam_36\NNP\2954340|-_3 (r_npadvmod) induced_38\VBN\1627355|NONE_0 (r_amod) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D013629_D006461 CID tam_17\NNP\2954340|-_3 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) hemolysis_20\NN\13509528|NONE_0
D013629_D006461 CID tam_3\NNP\2954340|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) caused_1\VBN\1617192|NONE_0 (r_acl) hemolysis_0\NNP\13509528|was_24|not_28|by_41|,_78|excluding_85|,_140|according_142|._194
D013629_D006461 CID tam_3\NNP\2954340|NONE_0 (r_pobj) by_2\IN\0|NONE_0 (r_agent) caused_1\VBN\1617192|NONE_0 (r_acl) hemolysis_0\NNP\13509528|was_24|not_28|by_41|,_78|excluding_85|,_140|according_142|._194 (r_nsubjpass) preceded_6\VBN\0|NONE_0 (l_prep) excluding_18\VBG\471711|hemolysis_85|was_61|not_57|by_44|,_7|,_55|according_57|._109 (l_pobj) mechanism_24\NN\13446390|also_38 (l_prep) of_25\IN\0|a_33|osmotic_23|type_15 (l_pobj) hemolysis_26\NN\13509528|NONE_0
D013629_D006461 CID tam_15\NNP\2954340|a_12|decreased_10|in_18|and_41 (r_compound) incorporation_16\NN\1237415|NONE_0 (r_pobj) to_12\IN\0|that_61|protection_52|is_11 (r_prep) related_11\VBN\628491|effects_69|avoided_134 (l_nsubjpass) protection_5\NN\407535|that_9|is_41|to_52 (l_prep) from_6\IN\0|the_15|by_15 (l_pobj) hemolysis_7\NN\13509528|NONE_0
D013629_D006461 CID tam_2\NNP\2954340|-_3 (r_npadvmod) induced_4\VBN\1627355|therefore_15|,_6|hemolysis_8|from_26|,_77|leading_79|._208 (r_amod) results_6\NNS\34213|NONE_0 (l_compound) hemolysis_5\NN\13509528|therefore_23|,_14|induced_8|from_18|,_69|leading_71|._200
D013629_D001943 NONE tamoxifen_0\NNP\2714883|drug_36|,_100|changes_110|._178 (r_nsubj) induces_18\VBZ\1627355|NONE_0 (l_nsubj) drug_7\NN\14778436|tamoxifen_36|,_64|changes_74|._142 (l_acl) prescribed_10\VBN\748282|the_36|antiestrogenic_32 (l_prep) in_11\IN\13603305|widely_18 (l_pobj) chemotherapy_13\NN\661091|NONE_0 (l_prep) of_14\IN\0|the_17 (l_pobj) cancer_16\NN\14239425|NONE_0
D013629_D001943 NONE tam_2\NNP\2954340|,_4 (r_appos) tamoxifen_0\NNP\2714883|drug_36|,_100|changes_110|._178 (r_nsubj) induces_18\VBZ\1627355|NONE_0 (l_nsubj) drug_7\NN\14778436|tamoxifen_36|,_64|changes_74|._142 (l_acl) prescribed_10\VBN\748282|the_36|antiestrogenic_32 (l_prep) in_11\IN\13603305|widely_18 (l_pobj) chemotherapy_13\NN\661091|NONE_0 (l_prep) of_14\IN\0|the_17 (l_pobj) cancer_16\NN\14239425|NONE_0
D011188_D006461 NONE k(+_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_12|)_6|from_8 (r_prep) leakage_9\NN\7407777|NONE_0 (r_pobj) by_7\IN\0|hemolysis_41|was_17|not_13|,_37|excluding_44|,_99|according_101|._153 (r_agent) preceded_6\VBN\0|NONE_0 (l_nsubjpass) hemolysis_0\NNP\13509528|was_24|not_28|by_41|,_78|excluding_85|,_140|according_142|._194
D011188_D006461 NONE k(+_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_12|)_6|from_8 (r_prep) leakage_9\NN\7407777|NONE_0 (r_pobj) by_7\IN\0|hemolysis_41|was_17|not_13|,_37|excluding_44|,_99|according_101|._153 (r_agent) preceded_6\VBN\0|NONE_0 (l_prep) excluding_18\VBG\471711|hemolysis_85|was_61|not_57|by_44|,_7|,_55|according_57|._109 (l_pobj) mechanism_24\NN\13446390|also_38 (l_prep) of_25\IN\0|a_33|osmotic_23|type_15 (l_pobj) hemolysis_26\NN\13509528|NONE_0
D013629_D000743 CID tamoxifen_0\NNP\2714883|drug_36|,_100|changes_110|._178 (r_nsubj) induces_18\VBZ\1627355|NONE_0 (l_dobj) changes_19\NNS\7283608|tamoxifen_110|drug_74|,_10|._68 (l_prep) in_20\IN\13603305|NONE_0 (l_pobj) shape_23\NN\5062748|NONE_0 (l_prep) of_24\IN\0|normal_21|discoid_14 (l_pobj) erythrocytes_25\NNS\5449268|NONE_0 (l_conj) anemia_28\NN\14189204|and_14
D013629_D000743 CID tam_2\NNP\2954340|,_4 (r_appos) tamoxifen_0\NNP\2714883|drug_36|,_100|changes_110|._178 (r_nsubj) induces_18\VBZ\1627355|NONE_0 (l_dobj) changes_19\NNS\7283608|tamoxifen_110|drug_74|,_10|._68 (l_prep) in_20\IN\13603305|NONE_0 (l_pobj) shape_23\NN\5062748|NONE_0 (l_prep) of_24\IN\0|normal_21|discoid_14 (l_pobj) erythrocytes_25\NNS\5449268|NONE_0 (l_conj) anemia_28\NN\14189204|and_14
D013629_D000743 CID tam_6\NNP\2954340|NONE_0 (r_pobj) of_5\IN\0|the_12|on_7 (r_prep) effects_4\NNS\13245626|work_19|,_45|attempting_47|._199 (r_dobj) evaluates_2\VBZ\670261|NONE_0 (l_advcl) attempting_12\VBG\2367363|work_66|effects_47|,_2|._152 (l_xcomp) identify_14\VB\699815|NONE_0 (l_dobj) mechanisms_17\NNS\13446390|to_27 (l_prep) on_18\IN\0|the_26|underlying_22|and_32|involvement_40 (l_pobj) anemia_23\NN\14189204|NONE_0
D013629_D000743 CID tam_19\NNP\2954340|-_3 (r_npadvmod) induced_21\VBN\1627355|hemolytic_8 (r_amod) anemia_23\NN\14189204|NONE_0
D013629_D000743 CID tam_13\NNP\2954340|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) promoted_11\VBN\2556126|mechanical_21 (r_acl) stability_10\NN\4777852|,_25|resulting_27 (r_dobj) decreased_8\VBD\169651|defects_51|shape_10|and_4|._77 (l_conj) resulting_15\VBG\2633881|stability_27|,_2 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) anemia_18\NN\14189204|NONE_0
D010100_D006461 NONE oxygen_7\NN\14622893|and_19|oxidation_34 (r_compound) consumption_8\NN\13440063|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) absence_5\NN\14449405|NONE_0 (r_pobj) by_4\IN\0|this_27|was_22|further_18|determined_63|._112 (r_agent) evidenced_3\VBN\1015244|NONE_0 (l_conj) determined_13\VBN\0|this_90|was_85|further_81|by_63|._49 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) parallel_15\NN\4743605|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) hemolysis_20\NN\13509528|NONE_0
D024502_D006461 NONE tocopherol_13\NN\14724645|NONE_0 (r_pobj) of_10\IN\0|low_19|and_30|acetate_51 (r_prep) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_nsubjpass) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D024502_D006461 NONE tocopherol_13\NN\14724645|NONE_0 (r_pobj) of_10\IN\0|low_19|and_30|acetate_51 (r_prep) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_advcl) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (l_ccomp) related_42\VBN\628491|NONE_0 (l_nsubjpass) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D024502_D006461 NONE t_17\NNP\14999913|alpha_24|-_19|(_7|)_1 (r_appos) tocopherol_13\NN\14724645|NONE_0 (r_pobj) of_10\IN\0|low_19|and_30|acetate_51 (r_prep) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_nsubjpass) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D024502_D006461 NONE t_17\NNP\14999913|alpha_24|-_19|(_7|)_1 (r_appos) tocopherol_13\NN\14724645|NONE_0 (r_pobj) of_10\IN\0|low_19|and_30|acetate_51 (r_prep) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_advcl) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (l_ccomp) related_42\VBN\628491|NONE_0 (l_nsubjpass) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D024502_D006461 NONE acetate_23\NN\15010703|low_70|of_51|and_21 (r_conj) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_nsubjpass) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D024502_D006461 NONE acetate_23\NN\15010703|low_70|of_51|and_21 (r_conj) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_advcl) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (l_ccomp) related_42\VBN\628491|NONE_0 (l_nsubjpass) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D024502_D006461 NONE tac_27\NNS\0|tocopherol_26|(_7|)_3 (r_appos) acetate_23\NN\15010703|low_70|of_51|and_21 (r_conj) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_nsubjpass) effect_2\NN\34213|is_14|by_27|inactivated_121|indicating_154|._235 (l_amod) hemolytic_1\JJ\0|the_4|of_17
D024502_D006461 NONE tac_27\NNS\0|tocopherol_26|(_7|)_3 (r_appos) acetate_23\NN\15010703|low_70|of_51|and_21 (r_conj) concentrations_9\NNS\4916342|NONE_0 (r_pobj) by_7\IN\0|effect_27|is_13|inactivated_94|indicating_127|._208 (r_agent) prevented_6\VBN\0|NONE_0 (l_advcl) indicating_34\VBG\952524|effect_154|is_140|by_127|inactivated_33|._81 (l_ccomp) related_42\VBN\628491|NONE_0 (l_nsubjpass) hemolysis_39\NN\13509528|that_17|is_10|not_13|to_25
D024505_D006461 NONE tocopherols_9\NNS\14724645|NONE_0 (r_pobj) by_8\IN\0|the_30|from_15 (r_prep) protection_5\NN\407535|that_9|is_41|to_52 (l_prep) from_6\IN\0|the_15|by_15 (l_pobj) hemolysis_7\NN\13509528|NONE_0
10683478
D001058_D006948 CID apomorphine_5\NN\3786417|-_11 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) hyperactivity_8\NN\14052403|NONE_0
D004298_D007035 NONE dopamine_28\NN\14807737|distinct_20 (r_relcl) changes_26\NNS\7283608|to_20 (r_dobj) produce_24\VB\7555863|to_30|hypothermia_20|,_9|and_7 (r_conj) induce_19\VB\1627355|its_15 (l_dobj) hypothermia_20\NN\14034177|to_10|,_11|and_13|produce_20
D001058_D007035 CID apomorphine_0\NNP\3786417|was_46|due_59|,_97|ability_103|._206 (r_nsubjpass) selected_8\VBN\697589|NONE_0 (l_dobj) ability_17\NN\4723816|apomorphine_103|was_57|due_44|,_6|._103 (l_acl) induce_19\VB\1627355|its_15 (l_dobj) hypothermia_20\NN\14034177|to_10|,_11|and_13|produce_20
D001058_D007035 CID apomorphine_11\NN\3786417|moreover_75|,_67|conditions_60|can_49|upon_38|._44 (l_prep) as_13\IN\14622893|to_20 (l_pobj) hypothermia_17\NN\14034177|such_21
D018491_D007035 NONE agonist_5\NN\0|,_26|,_7 (r_appos) apomorphine_0\NNP\3786417|was_46|due_59|,_97|ability_103|._206 (r_nsubjpass) selected_8\VBN\697589|NONE_0 (l_dobj) ability_17\NN\4723816|apomorphine_103|was_57|due_44|,_6|._103 (l_acl) induce_19\VB\1627355|its_15 (l_dobj) hypothermia_20\NN\14034177|to_10|,_11|and_13|produce_20
12041669
D000961_D000741 NONE globulin_1\NN\14736972|NONE_0 (l_prep) in_2\IN\13603305|antithymocyte_23|._59 (l_pobj) treatment_4\NN\654885|NONE_0 (l_prep) of_5\IN\0|the_14 (l_pobj) anemia_12\NN\14189204|NONE_0
D000961_D000741 NONE globulin_5\NN\14736972|NONE_0 (r_compound) therapy_6\NN\657604|who_36|antithymocyte_23|for_8|due_28 (r_dobj) received_3\VBD\2210855|a_14 (l_prep) for_7\IN\0|who_44|antithymocyte_31|therapy_8|due_20 (l_pobj) anemia_9\NN\14189204|NONE_0
D000961_D000741 NONE globulin_3\NN\14736972|of_17 (r_dobj) use_0\NN\407535|may_30|treatment_49|._101 (r_nsubj) be_5\VB\14625458|NONE_0 (l_attr) treatment_8\NN\654885|use_49|may_19|._52 (l_prep) of_9\IN\0|the_22|optimal_18 (l_pobj) anemia_16\NN\14189204|NONE_0
D010396_D000741 CID penicillamine_8\NN\3740161|-_13 (r_npadvmod) induced_10\VBN\1627355|aplastic_8 (r_amod) anemia_12\NN\14189204|NONE_0
D010396_D000741 CID penicillamine_14\NN\3740161|NONE_0 (r_compound) therapy_15\NN\657604|patient_95|is_8|._20 (r_nsubjpass) described_17\VBN\1001294|NONE_0 (l_nsubjpass) patient_1\NN\9898892|therapy_95|is_103|._115 (l_relcl) received_3\VBD\2210855|a_14 (l_prep) for_7\IN\0|who_44|antithymocyte_31|therapy_8|due_20 (l_pobj) anemia_9\NN\14189204|NONE_0
D010396_D000741 CID penicillamine_12\NN\3740161|-_13 (r_npadvmod) induced_14\VBN\1627355|aplastic_8 (r_amod) anemia_16\NN\14189204|NONE_0
12536034
D020888_D004832 CID vigabatrin_15\NN\0|and_4 (r_conj) carbamazepine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) administration_11\NN\1133281|NONE_0 (r_pobj) after_10\IN\0|authors_61|patients_39|._52 (r_prep) present_2\VBP\28270|NONE_0 (l_dobj) patients_4\NNS\9898892|authors_22|after_39|._91 (l_prep) with_5\IN\0|three_15 (l_pobj) epilepsy_9\NN\14085708|NONE_0
D005680_D004832 NONE acid_4\NN\14818238|-_4 (r_npadvmod) transmitted_6\VBN\2232190|thalamocortical_12 (r_amod) circuitry_8\NN\3278248|the_56|aminobutyric_46|for_19|._93 (r_compound) accounts_9\VBZ\6647206|NONE_0 (l_prep) for_10\IN\0|the_75|aminobutyric_65|circuitry_19|._74 (l_pobj) part_13\NN\31921|NONE_0 (l_prep) of_14\IN\0|a_13|major_11 (l_pobj) neurophysiology_17\NN\6081833|NONE_0 (l_prep) of_18\IN\0|the_31|underlying_27 (l_pobj) epilepsy_21\NN\14085708|NONE_0
D002220_D004832 CID carbamazepine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) administration_11\NN\1133281|NONE_0 (r_pobj) after_10\IN\0|authors_61|patients_39|._52 (r_prep) present_2\VBP\28270|NONE_0 (l_dobj) patients_4\NNS\9898892|authors_22|after_39|._91 (l_prep) with_5\IN\0|three_15 (l_pobj) epilepsy_9\NN\14085708|NONE_0
10365197
D003042_D019970 NONE cocaine_1\NN\3492717|-_7 (r_npadvmod) dependent_3\JJ\9627906|243_12|with_22|,_63|disorders_76 (r_amod) outpatients_4\NNS\10405694|were_97|on_111|._146 (l_prep) with_5\IN\0|243_34|dependent_22|,_41|disorders_54 (l_pobj) disorder_10\NN\14034177|NONE_0 (l_appos) cimd_12\NNP\0|induced_23|mood_15|(_1|)_4
D003042_D019970 NONE cocaine_6\NN\3492717|-_7 (r_npadvmod) induced_8\VBN\1627355|mood_8|(_22|cimd_23|)_27 (r_amod) disorder_10\NN\14034177|NONE_0 (l_appos) cimd_12\NNP\0|induced_23|mood_15|(_1|)_4
D003042_D001523 NONE cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|mood_8|:_21|rates_34|._106 (r_amod) disorder_4\NN\14034177|NONE_0 (l_appos) rates_7\NNS\13308999|induced_34|mood_26|:_13|._72 (l_conj) symptoms_10\NNS\5823932|prevalence_33|and_16|in_9 (l_amod) psychiatric_9\JJ\0|NONE_0
D003042_D001523 NONE cocaine_14\NN\3492717|-_7 (r_npadvmod) dependent_16\JJ\9627906|an_22|outpatient_19 (r_amod) sample_17\NN\5820620|NONE_0 (r_pobj) in_11\IN\13603305|prevalence_42|and_25|symptoms_9 (r_prep) rates_7\NNS\13308999|induced_34|mood_26|:_13|._72 (l_conj) symptoms_10\NNS\5823932|prevalence_33|and_16|in_9 (l_amod) psychiatric_9\JJ\0|NONE_0
D003042_D001523 NONE cocaine_1\NN\3492717|-_7 (r_npadvmod) dependent_3\JJ\9627906|243_12|with_22|,_63|disorders_76 (r_amod) outpatients_4\NNS\10405694|were_97|on_111|._146 (r_nsubjpass) compared_24\VBN\644583|NONE_0 (l_prep) on_25\IN\0|outpatients_111|were_14|._35 (l_pobj) measures_26\NNS\168237|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) symptoms_29\NNS\5823932|NONE_0 (l_amod) psychiatric_28\JJ\0|NONE_0
D003042_D001523 NONE cocaine_6\NN\3492717|-_7 (r_npadvmod) induced_8\VBN\1627355|mood_8|(_22|cimd_23|)_27 (r_amod) disorder_10\NN\14034177|NONE_0 (r_pobj) with_5\IN\0|243_34|dependent_22|,_41|disorders_54 (r_prep) outpatients_4\NNS\10405694|were_97|on_111|._146 (r_nsubjpass) compared_24\VBN\644583|NONE_0 (l_prep) on_25\IN\0|outpatients_111|were_14|._35 (l_pobj) measures_26\NNS\168237|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) symptoms_29\NNS\5823932|NONE_0 (l_amod) psychiatric_28\JJ\0|NONE_0
D003042_D019964 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|mood_8|:_21|rates_34|._106 (r_amod) disorder_4\NN\14034177|NONE_0
D003042_D019964 CID cocaine_14\NN\3492717|-_7 (r_npadvmod) dependent_16\JJ\9627906|an_22|outpatient_19 (r_amod) sample_17\NN\5820620|NONE_0 (r_pobj) in_11\IN\13603305|prevalence_42|and_25|symptoms_9 (r_prep) rates_7\NNS\13308999|induced_34|mood_26|:_13|._72 (r_appos) disorder_4\NN\14034177|NONE_0
D003042_D019964 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) dependent_3\JJ\9627906|243_12|with_22|,_63|disorders_76 (r_amod) outpatients_4\NNS\10405694|were_97|on_111|._146 (l_prep) with_5\IN\0|243_34|dependent_22|,_41|disorders_54 (l_pobj) disorder_10\NN\14034177|NONE_0
D003042_D019964 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) dependent_3\JJ\9627906|243_12|with_22|,_63|disorders_76 (r_amod) outpatients_4\NNS\10405694|were_97|on_111|._146 (l_conj) disorders_17\NNS\14034177|243_88|dependent_76|with_54|,_13
D003042_D019964 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) dependent_3\JJ\9627906|243_12|with_22|,_63|disorders_76 (r_amod) outpatients_4\NNS\10405694|were_97|on_111|._146 (l_conj) disorders_17\NNS\14034177|243_88|dependent_76|with_54|,_13 (l_conj) disorder_22\NN\14034177|other_33|mood_27|,_13|or_11
D003042_D019964 CID cocaine_6\NN\3492717|-_7 (r_npadvmod) induced_8\VBN\1627355|mood_8|(_22|cimd_23|)_27 (r_amod) disorder_10\NN\14034177|NONE_0
D003042_D019964 CID cocaine_6\NN\3492717|-_7 (r_npadvmod) induced_8\VBN\1627355|mood_8|(_22|cimd_23|)_27 (r_amod) disorder_10\NN\14034177|NONE_0 (r_pobj) with_5\IN\0|243_34|dependent_22|,_41|disorders_54 (r_prep) outpatients_4\NNS\10405694|were_97|on_111|._146 (l_conj) disorders_17\NNS\14034177|243_88|dependent_76|with_54|,_13
D003042_D019964 CID cocaine_6\NN\3492717|-_7 (r_npadvmod) induced_8\VBN\1627355|mood_8|(_22|cimd_23|)_27 (r_amod) disorder_10\NN\14034177|NONE_0 (r_pobj) with_5\IN\0|243_34|dependent_22|,_41|disorders_54 (r_prep) outpatients_4\NNS\10405694|were_97|on_111|._146 (l_conj) disorders_17\NNS\14034177|243_88|dependent_76|with_54|,_13 (l_conj) disorder_22\NN\14034177|other_33|mood_27|,_13|or_11
16160878
D014579_D001919 NONE ii_8\NNP\13741022|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) injection_4\NN\320852|intracerebroventricular_33|hypertension_25|and_54|stimulates_58|._104 (r_nsubj) causes_9\NNS\7323922|NONE_0 (l_dobj) hypertension_10\NN\14057371|intracerebroventricular_58|injection_25|and_29|stimulates_33|._79 (l_conj) bradycardia_12\NN\14110674|and_4
D003345_D010409 NONE corticosterone_35\NN\14752057|induced_15 (r_compound) level_36\NN\4916342|was_197|,_185|administration_171|effect_141|erection_73|,_43|and_41|._5 (r_conj) had_12\VBD\0|NONE_0 (l_dobj) erection_25\NN\14037619|was_124|,_112|administration_98|effect_68|,_30|and_32|level_73|._78
D014579_D006973 NONE ii_8\NNP\13741022|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) injection_4\NN\320852|intracerebroventricular_33|hypertension_25|and_54|stimulates_58|._104 (r_nsubj) causes_9\NNS\7323922|NONE_0 (l_dobj) hypertension_10\NN\14057371|intracerebroventricular_58|injection_25|and_29|stimulates_33|._79
D001058_D010409 CID apomorphine_21\NN\3786417|-_11 (r_npadvmod) induced_23\VBN\1627355|penile_8|and_24|behavior_37 (r_amod) erection_25\NN\14037619|was_124|,_112|administration_98|effect_68|,_30|and_32|level_73|._78
D014579_D001523 NONE ii_6\NNP\13741022|that_7|may_3|be_7|in_19 (r_nsubjpass) involved_9\VBN\2676054|data_30|._49 (l_prep) in_10\IN\13603305|that_26|ii_19|may_16|be_12 (l_pobj) aspects_12\NNS\5849789|NONE_0 (l_prep) of_13\IN\0|some_13 (l_pobj) disorders_15\NNS\14034177|NONE_0
D014579_D010409 NONE ii_11\NNP\13741022|NONE_0 (r_pobj) of_8\IN\0|the_27|central_23 (r_prep) administration_7\NN\1133281|was_26|,_14|effect_30|erection_98|,_128|and_130|level_171|._176 (r_nsubj) had_12\VBD\0|NONE_0 (l_dobj) erection_25\NN\14037619|was_124|,_112|administration_98|effect_68|,_30|and_32|level_73|._78
2385256
D008274_D009157 CID magnesium_6\NN\14625458|NONE_0 (r_compound) administration_7\NN\1133281|NONE_0 (r_pobj) after_5\IN\0|NONE_0 (r_prep) weakness_4\NN\14462666|NONE_0 (r_pobj) as_3\IN\14622893|NONE_0 (r_prep) presenting_2\VBG\2137132|myasthenia_18|._53 (r_acl) gravis_1\NN\0|NONE_0
D008274_D009157 CID magnesium_3\NN\14625458|NONE_0 (r_compound) administration_4\NN\1133281|NONE_0 (r_pobj) after_2\IN\0|NONE_0 (r_prep) paralysis_1\NN\14557898|although_9|has_41|been_45|in_60 (r_nsubjpass) described_7\VBN\1001294|,_50|it_52|has_55|not_59|previously_63|been_74|be_91|._142 (l_prep) in_8\IN\13603305|although_69|paralysis_60|has_19|been_15 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) gravis_13\NN\0|NONE_0
D008274_D009468 NONE magnesium_17\NN\14625458|parenteral_11|for_25 (r_compound) administration_18\NN\1133281|NONE_0 (r_pobj) after_15\IN\0|who_34|quadriplegic_13 (r_prep) became_12\VBD\146138|neuromuscular_26 (r_relcl) disease_10\NN\14061805|NONE_0
D008274_D011782 NONE magnesium_17\NN\14625458|parenteral_11|for_25 (r_compound) administration_18\NN\1133281|NONE_0 (r_pobj) after_15\IN\0|who_34|quadriplegic_13 (r_prep) became_12\VBD\146138|neuromuscular_26 (l_acomp) quadriplegic_14\JJ\10158756|who_21|after_13
D008274_D010243 NONE magnesium_3\NN\14625458|NONE_0 (r_compound) administration_4\NN\1133281|NONE_0 (r_pobj) after_2\IN\0|NONE_0 (r_prep) paralysis_1\NN\14557898|although_9|has_41|been_45|in_60
D008274_D020511 NONE magnesium_10\NN\14625458|NONE_0 (r_pobj) of_9\IN\0|the_26|neuromuscular_22 (r_prep) effects_8\NNS\13245626|NONE_0 (r_pobj) to_5\IN\0|unusually_20 (r_prep) sensitive_4\JJ\10488309|who_18 (r_acomp) are_2\VBP\13600404|NONE_0 (r_relcl) patients_0\NNS\9898892|should_79|be_86|of_99|._161 (r_nsubjpass) suspected_13\VBN\916909|NONE_0 (l_prep) of_14\IN\0|patients_99|should_20|be_13|._62 (l_pcomp) having_15\VBG\0|NONE_0 (l_dobj) disorder_18\NN\14034177|NONE_0 (l_prep) of_19\IN\0|an_23|underlying_20 (l_pobj) transmission_21\NN\121166|NONE_0
D008274_D011225 NONE magnesium_17\NN\14625458|parenteral_11|for_25 (r_compound) administration_18\NN\1133281|NONE_0 (l_prep) for_19\IN\0|parenteral_36|magnesium_25 (l_pobj) preeclampsia_20\NN\14191037|NONE_0
3076126
D009525_D009135 CID niacin_35\NN\15090742|or_3 (r_conj) gemfibrozil_33\NN\3740161|,_2 (r_conj) cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (r_acl) myopathy_0\NNP\14204950|NONE_0
D015248_D009135 CID gemfibrozil_33\NN\3740161|,_2 (r_conj) cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (r_acl) myopathy_0\NNP\14204950|NONE_0
D009525_D009212 NONE niacin_35\NN\15090742|or_3 (r_conj) gemfibrozil_33\NN\3740161|,_2 (r_conj) cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (l_prep) in_3\IN\13603305|,_32|and_34|reported_95 (l_pobj) cases_5\NNS\7283608|NONE_0 (l_prep) with_6\IN\0|some_11 (l_pobj) myoglobinuria_7\NNS\14299637|NONE_0
D016572_D009212 NONE cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (l_prep) in_3\IN\13603305|,_32|and_34|reported_95 (l_pobj) cases_5\NNS\7283608|NONE_0 (l_prep) with_6\IN\0|some_11 (l_pobj) myoglobinuria_7\NNS\14299637|NONE_0
D008148_D009135 NONE lovastatin_23\NN\3676175|NONE_0 (r_pobj) with_22\IN\0|in_66|,_27|has_25|been_21|rarely_16|,_15|in_28|._101 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (r_acl) myopathy_0\NNP\14204950|NONE_0
D009525_D051437 NONE niacin_35\NN\15090742|or_3 (r_conj) gemfibrozil_33\NN\3740161|,_2 (r_conj) cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (l_prep) in_10\IN\13603305|,_39|has_41|been_45|rarely_50|with_66|,_81|in_94|._167 (l_pobj) cases_12\NNS\7283608|NONE_0 (l_prep) with_13\IN\0|2_8 (l_pobj) failure_16\NN\66216|NONE_0
D008148_D051437 CID lovastatin_23\NN\3676175|NONE_0 (r_pobj) with_22\IN\0|in_66|,_27|has_25|been_21|rarely_16|,_15|in_28|._101 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (l_prep) in_10\IN\13603305|,_39|has_41|been_45|rarely_50|with_66|,_81|in_94|._167 (l_pobj) cases_12\NNS\7283608|NONE_0 (l_prep) with_13\IN\0|2_8 (l_pobj) failure_16\NN\66216|NONE_0
D008148_D009212 CID lovastatin_23\NN\3676175|NONE_0 (r_pobj) with_22\IN\0|in_66|,_27|has_25|been_21|rarely_16|,_15|in_28|._101 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (l_prep) in_3\IN\13603305|,_32|and_34|reported_95 (l_pobj) cases_5\NNS\7283608|NONE_0 (l_prep) with_6\IN\0|some_11 (l_pobj) myoglobinuria_7\NNS\14299637|NONE_0
D015248_D051437 NONE gemfibrozil_33\NN\3740161|,_2 (r_conj) cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (l_prep) in_10\IN\13603305|,_39|has_41|been_45|rarely_50|with_66|,_81|in_94|._167 (l_pobj) cases_12\NNS\7283608|NONE_0 (l_prep) with_13\IN\0|2_8 (l_pobj) failure_16\NN\66216|NONE_0
D016572_D009135 CID cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (r_acl) myopathy_0\NNP\14204950|NONE_0
D016572_D051437 NONE cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (l_prep) in_10\IN\13603305|,_39|has_41|been_45|rarely_50|with_66|,_81|in_94|._167 (l_pobj) cases_12\NNS\7283608|NONE_0 (l_prep) with_13\IN\0|2_8 (l_pobj) failure_16\NN\66216|NONE_0
D015248_D009212 NONE gemfibrozil_33\NN\3740161|,_2 (r_conj) cyclosporin_31\NN\0|NONE_0 (r_pobj) with_30\IN\0|concomitantly_22 (r_prep) treated_29\VBN\2376958|NONE_0 (r_acl) patients_27\NNS\9898892|especially_14 (r_pobj) in_26\IN\13603305|in_94|,_55|has_53|been_49|rarely_44|with_28|,_13|._73 (r_prep) reported_21\VBN\831651|in_95|,_63|and_61 (r_conj) associated_2\VBN\628491|,_2 (l_prep) in_3\IN\13603305|,_32|and_34|reported_95 (l_pobj) cases_5\NNS\7283608|NONE_0 (l_prep) with_6\IN\0|some_11 (l_pobj) myoglobinuria_7\NNS\14299637|NONE_0
1592014
D003042_D020521 NONE cocaine_8\NN\3492717|NONE_0 (r_pobj) of_7\IN\0|(_7|)_2 (r_prep) t1/2_5\NN\0|half_11|-_7 (r_appos) life_3\NN\13954253|the_9|short_37|,_42|but_44|occur_119 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) occur_29\VB\0|the_128|life_119|short_82|,_77|but_75 (l_nsubj) some_14\DT\0|can_67|hours_77|._97 (l_prep) of_15\IN\0|NONE_0 (l_pobj) consequences_17\NNS\34213|NONE_0 (l_prep) of_18\IN\0|the_17 (l_pobj) use_20\NN\407535|NONE_0 (l_prep) as_23\IN\14622893|its_14|,_7|,_23 (l_pobj) seizures_24\NNS\14081375|such_8 (l_conj) strokes_26\NNS\556313|and_4
C005618_D012640 CID benzoylecgonine_6\NN\0|NONE_0 (r_pobj) by_2\IN\0|seizures_17|._49 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|._66
C005618_D012640 CID benzoylecgonine_11\NN\0|the_33|major_29|of_12|be_17 (r_appos) metabolite_7\NN\20090|NONE_0 (r_pobj) of_4\IN\0|the_14 (r_prep) potential_3\NN\14481929|we_17|,_66|cause_71|._85 (r_dobj) evaluated_1\VBD\670261|NONE_0 (l_advcl) cause_17\VB\7323922|we_88|potential_71|,_5|._14 (l_dobj) seizures_18\NNS\14081375|to_9
C005618_D012640 CID be_13\VB\14625458|the_50|major_46|of_29|benzoylecgonine_17 (r_appos) metabolite_7\NN\20090|NONE_0 (r_pobj) of_4\IN\0|the_14 (r_prep) potential_3\NN\14481929|we_17|,_66|cause_71|._85 (r_dobj) evaluated_1\VBD\670261|NONE_0 (l_advcl) cause_17\VB\7323922|we_88|potential_71|,_5|._14 (l_dobj) seizures_18\NNS\14081375|to_9
C005618_D012640 CID be_0\VB\14625458|-_2 (r_advmod) induced_2\VBN\1627355|NONE_0 (r_amod) seizures_3\NNS\14081375|frequently_23|and_34|had_38|._123
C005618_D012640 CID be_23\NNP\14625458|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) induced_21\VBN\1627355|NONE_0 (r_acl) those_20\DT\0|characterized_70|,_2|multiple_42|,_68|and_70|resulted_81|._98 (r_nsubj) were_24\VBD\0|NONE_0 (l_advcl) characterized_7\VBN\609683|,_68|those_70|multiple_112|,_138|and_140|resulted_151|._168 (l_nsubjpass) seizures_4\NNS\14081375|whereas_24|were_9|best_14|as_33|and_66|resulted_70
C005618_D012640 CID be_0\VB\14625458|-_2 (r_advmod) injected_2\VBN\81072|have_27 (r_amod) rats_3\NNS\2329401|activity_65|without_104|._120 (l_relcl) have_7\VB\7846|injected_27 (l_dobj) seizures_8\NNS\14081375|that_18|did_13|not_9
C005618_D012640 CID be_0\VB\14625458|-_2 (r_advmod) injected_2\VBN\81072|have_27 (r_amod) rats_3\NNS\2329401|activity_65|without_104|._120 (r_nsubj) had_9\VBD\0|NONE_0 (l_prep) without_19\IN\0|rats_104|activity_39|._16 (l_pobj) seizures_20\NNS\14081375|NONE_0
C005618_D012640 CID be_5\VB\14625458|-_2 (r_advmod) induced_7\VBN\1627355|and_7 (r_conj) cocaine-_3\NN\0|NONE_0 (r_nmod) seizures_8\NNS\14081375|in_16
C005618_D012640 CID be_5\VB\14625458|-_2 (r_advmod) induced_7\VBN\1627355|and_7 (r_conj) cocaine-_3\NN\0|NONE_0 (r_nmod) seizures_8\NNS\14081375|in_16 (r_nsubj) differ_9\VBP\0|the_50 (r_relcl) finding_1\NN\43195|mechanism_96|and_135|emphasizes_139|._192 (r_nsubj) suggests_13\VBZ\1010118|NONE_0 (l_dobj) mechanism_17\NN\13446390|finding_96|and_39|emphasizes_43|._96 (l_prep) for_18\IN\0|one_14 (l_pobj) seizures_22\NNS\14081375|NONE_0
C005618_D012640 CID be_32\VB\14625458|importance_36|,_2 (r_conj) emphasizes_24\VBZ\943837|finding_139|mechanism_43|and_4|._53 (r_conj) suggests_13\VBZ\1010118|NONE_0 (l_nsubj) finding_1\NN\43195|mechanism_96|and_135|emphasizes_139|._192 (l_relcl) differ_9\VBP\0|the_50 (l_nsubj) seizures_8\NNS\14081375|in_16
C005618_D012640 CID be_32\VB\14625458|importance_36|,_2 (r_conj) emphasizes_24\VBZ\943837|finding_139|mechanism_43|and_4|._53 (r_conj) suggests_13\VBZ\1010118|NONE_0 (l_dobj) mechanism_17\NN\13446390|finding_96|and_39|emphasizes_43|._96 (l_prep) for_18\IN\0|one_14 (l_pobj) seizures_22\NNS\14081375|NONE_0
D003042_D003643 NONE cocaine_1\NN\3492717|-_7 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) seizures_4\NNS\14081375|whereas_24|were_9|best_14|as_33|and_66|resulted_70 (r_nsubjpass) characterized_7\VBN\609683|,_68|those_70|multiple_112|,_138|and_140|resulted_151|._168 (l_conj) resulted_16\VBD\2633881|whereas_94|seizures_70|were_61|best_56|as_37|and_4 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) death_18\NN\7296428|NONE_0
D003042_D003643 NONE cocaine_1\NN\3492717|-_7 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) seizures_4\NNS\14081375|whereas_24|were_9|best_14|as_33|and_66|resulted_70 (r_nsubjpass) characterized_7\VBN\609683|,_68|those_70|multiple_112|,_138|and_140|resulted_151|._168 (r_advcl) were_24\VBD\0|NONE_0 (l_conj) resulted_36\VBD\2633881|characterized_151|,_83|those_81|multiple_39|,_13|and_11|._17 (l_prep) in_37\IN\13603305|rarely_16 (l_pobj) death_38\NN\7296428|NONE_0
C005618_D003643 NONE be_23\NNP\14625458|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) induced_21\VBN\1627355|NONE_0 (r_acl) those_20\DT\0|characterized_70|,_2|multiple_42|,_68|and_70|resulted_81|._98 (r_nsubj) were_24\VBD\0|NONE_0 (l_advcl) characterized_7\VBN\609683|,_68|those_70|multiple_112|,_138|and_140|resulted_151|._168 (l_conj) resulted_16\VBD\2633881|whereas_94|seizures_70|were_61|best_56|as_37|and_4 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) death_18\NN\7296428|NONE_0
C005618_D003643 NONE be_23\NNP\14625458|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) induced_21\VBN\1627355|NONE_0 (r_acl) those_20\DT\0|characterized_70|,_2|multiple_42|,_68|and_70|resulted_81|._98 (r_nsubj) were_24\VBD\0|NONE_0 (l_conj) resulted_36\VBD\2633881|characterized_151|,_83|those_81|multiple_39|,_13|and_11|._17 (l_prep) in_37\IN\13603305|rarely_16 (l_pobj) death_38\NN\7296428|NONE_0
D003042_D012640 CID cocaine_4\NN\3492717|NONE_0 (r_compound) metabolite_5\NN\20090|the_12|in_27 (r_amod) benzoylecgonine_6\NN\0|NONE_0 (r_pobj) by_2\IN\0|seizures_17|._49 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|._66
D003042_D012640 CID cocaine_8\NN\3492717|NONE_0 (r_pobj) of_7\IN\0|(_7|)_2 (r_prep) t1/2_5\NN\0|half_11|-_7 (r_appos) life_3\NN\13954253|the_9|short_37|,_42|but_44|occur_119 (r_nsubj) is_9\VBZ\0|NONE_0 (l_conj) occur_29\VB\0|the_128|life_119|short_82|,_77|but_75 (l_nsubj) some_14\DT\0|can_67|hours_77|._97 (l_prep) of_15\IN\0|NONE_0 (l_pobj) consequences_17\NNS\34213|NONE_0 (l_prep) of_18\IN\0|the_17 (l_pobj) use_20\NN\407535|NONE_0 (l_prep) as_23\IN\14622893|its_14|,_7|,_23 (l_pobj) seizures_24\NNS\14081375|such_8
D003042_D012640 CID cocaine_9\NN\3492717|NONE_0 (r_pobj) of_8\IN\0|the_21|major_17|benzoylecgonine_12|be_29 (r_prep) metabolite_7\NN\20090|NONE_0 (r_pobj) of_4\IN\0|the_14 (r_prep) potential_3\NN\14481929|we_17|,_66|cause_71|._85 (r_dobj) evaluated_1\VBD\670261|NONE_0 (l_advcl) cause_17\VB\7323922|we_88|potential_71|,_5|._14 (l_dobj) seizures_18\NNS\14081375|to_9
D003042_D012640 CID cocaine_19\NN\3492717|NONE_0 (r_pobj) of_18\IN\0|equimolar_18 (r_prep) amounts_17\NNS\13329641|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) induced_14\VBN\1627355|NONE_0 (r_acl) those_13\DT\0|NONE_0 (r_pobj) than_12\IN\0|longer_17 (r_prep) latencies_11\NNS\15269513|NONE_0 (r_dobj) had_8\VBD\0|seizures_38|frequently_15|and_4|._85 (r_conj) occurred_4\VBD\0|NONE_0 (l_nsubj) seizures_3\NNS\14081375|frequently_23|and_34|had_38|._123
D003042_D012640 CID cocaine_1\NN\3492717|-_7 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) seizures_4\NNS\14081375|whereas_24|were_9|best_14|as_33|and_66|resulted_70
D003042_D012640 CID cocaine_15\NN\3492717|-_7 (r_npadvmod) injected_17\VBN\81072|NONE_0 (r_amod) animals_18\NNS\4475|NONE_0 (r_pobj) than_14\IN\0|more_24|locomotor_19 (r_prep) activity_13\NN\30358|rats_65|without_39|._55 (r_dobj) had_9\VBD\0|NONE_0 (l_nsubj) rats_3\NNS\2329401|activity_65|without_104|._120 (l_relcl) have_7\VB\7846|injected_27 (l_dobj) seizures_8\NNS\14081375|that_18|did_13|not_9
D003042_D012640 CID cocaine_15\NN\3492717|-_7 (r_npadvmod) injected_17\VBN\81072|NONE_0 (r_amod) animals_18\NNS\4475|NONE_0 (r_pobj) than_14\IN\0|more_24|locomotor_19 (r_prep) activity_13\NN\30358|rats_65|without_39|._55 (r_dobj) had_9\VBD\0|NONE_0 (l_prep) without_19\IN\0|rats_104|activity_39|._16 (l_pobj) seizures_20\NNS\14081375|NONE_0
D003042_D012640 CID cocaine-_3\NN\0|NONE_0 (r_nmod) seizures_8\NNS\14081375|in_16
D003042_D012640 CID cocaine-_3\NN\0|NONE_0 (r_nmod) seizures_8\NNS\14081375|in_16 (r_nsubj) differ_9\VBP\0|the_50 (r_relcl) finding_1\NN\43195|mechanism_96|and_135|emphasizes_139|._192 (r_nsubj) suggests_13\VBZ\1010118|NONE_0 (l_dobj) mechanism_17\NN\13446390|finding_96|and_39|emphasizes_43|._96 (l_prep) for_18\IN\0|one_14 (l_pobj) seizures_22\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_19\NN\3492717|-_7 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) seizures_22\NNS\14081375|NONE_0 (r_pobj) for_18\IN\0|one_14 (r_prep) mechanism_17\NN\13446390|finding_96|and_39|emphasizes_43|._96 (r_dobj) suggests_13\VBZ\1010118|NONE_0 (l_nsubj) finding_1\NN\43195|mechanism_96|and_135|emphasizes_139|._192 (l_relcl) differ_9\VBP\0|the_50 (l_nsubj) seizures_8\NNS\14081375|in_16
D003042_D012640 CID cocaine_19\NN\3492717|-_7 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) seizures_22\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_29\NN\3492717|a_2 (r_compound) metabolite_30\NN\20090|NONE_0 (r_pobj) of_27\IN\0|the_15 (r_prep) importance_26\NN\5138488|,_34|be_36 (r_dobj) emphasizes_24\VBZ\943837|finding_139|mechanism_43|and_4|._53 (r_conj) suggests_13\VBZ\1010118|NONE_0 (l_nsubj) finding_1\NN\43195|mechanism_96|and_135|emphasizes_139|._192 (l_relcl) differ_9\VBP\0|the_50 (l_nsubj) seizures_8\NNS\14081375|in_16
D003042_D012640 CID cocaine_29\NN\3492717|a_2 (r_compound) metabolite_30\NN\20090|NONE_0 (r_pobj) of_27\IN\0|the_15 (r_prep) importance_26\NN\5138488|,_34|be_36 (r_dobj) emphasizes_24\VBZ\943837|finding_139|mechanism_43|and_4|._53 (r_conj) suggests_13\VBZ\1010118|NONE_0 (l_dobj) mechanism_17\NN\13446390|finding_96|and_39|emphasizes_43|._96 (l_prep) for_18\IN\0|one_14 (l_pobj) seizures_22\NNS\14081375|NONE_0
1867351
D015767_D008288 NONE mefloquine_10\NN\2721948|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treatment_8\NN\654885|malaria_24|and_4 (r_conj) prophylaxis_6\NN\1077350|NONE_0 (l_compound) malaria_5\NN\14178913|and_20|treatment_24
21029050
D013390_D001049 CID succinylcholine_9\NN\3800001|NONE_0 (r_pobj) after_8\IN\0|gene_48|in_33|._51 (r_prep) mutations_2\NNS\4475|NONE_0 (l_prep) in_3\IN\13603305|gene_15|after_33|._84 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|NONE_0 (l_pobj) apnea_7\NN\14299637|NONE_0
D013390_D001049 CID succinylcholine_11\NN\3800001|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) action_9\NN\30358|NONE_0 (r_pobj) of_8\IN\0|a_21|prolonged_19 (r_prep) duration_7\NN\15113229|NONE_0 (r_pobj) with_4\IN\0|13_12 (r_prep) patients_3\NNS\9898892|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) eleven_0\CD\13745420|mutations_81|,_98|indicating_100|._175 (r_nsubj) had_12\VBD\0|NONE_0 (l_advcl) indicating_17\VBG\952524|eleven_100|mutations_19|,_2|._75 (l_ccomp) is_20\VBZ\0|NONE_0 (l_attr) reason_23\NN\9178821|that_26|this_21 (l_prep) for_24\IN\0|the_20|possible_16 (l_pobj) period_27\NN\13575869|NONE_0 (l_prep) of_28\IN\0|a_19|prolonged_17 (l_pobj) apnea_29\NN\14299637|NONE_0
322550
D009599_D007022 CID nitroprusside_8\RB\0|-_13 (r_advmod) induced_10\VBN\1627355|NONE_0 (r_amod) hypotension_11\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_1\JJ\0|NONE_0 (r_amod) infusion_2\NN\14589223|before_21|decrease_28|and_64|increased_82|._141 (r_nsubj) produced_3\VBD\1617192|NONE_0 (l_dobj) decrease_6\NN\7296428|before_49|infusion_28|and_36|increased_54|._113 (l_prep) in_7\IN\13603305|a_19|further_17 (l_pobj) pressure_10\NN\11419404|NONE_0
D009599_D007022 CID nitroprusside_0\NNP\0|decreases_33|,_130|but_132|change_144|._174 (r_nsubj) caused_1\VBD\1617192|NONE_0 (l_dobj) decreases_3\NNS\7296428|nitroprusside_33|,_97|but_99|change_111|._141 (l_prep) in_4\IN\13603305|significant_22 (l_pobj) pressure_7\NN\11419404|NONE_0
D009599_D007022 NONE nitroprusside_1\JJ\0|infusion_14|low_23|of_34 (r_amod) levels_4\NNS\4916342|NONE_0 (r_pobj) during_0\IN\0|do_49|not_52|markedly_56|dynamics_86|,_94|but_96|levels_105|produce_157|._227 (r_prep) alter_10\VB\0|NONE_0 (l_conj) produce_31\VBP\7555863|during_157|do_108|not_105|markedly_101|dynamics_71|,_63|but_61|levels_52|._70 (l_dobj) decreases_33\NNS\7296428|,_41|decreasing_33|,_17 (l_prep) in_34\IN\13603305|marked_17 (l_pobj) pressure_37\NN\11419404|NONE_0 (l_conj) output_40\NN\4007894|arterial_36|blood_27|and_12
D014867_D002303 NONE h2o_22\NNP\14618834|high_27|of_15|)_3 (r_punct) levels_16\NNS\4916342|during_105|do_56|not_53|markedly_49|dynamics_19|,_11|but_9|produce_52|._122 (r_conj) alter_10\VB\0|NONE_0 (l_conj) produce_31\VBP\7555863|during_157|do_108|not_105|markedly_101|dynamics_71|,_63|but_61|levels_52|._70 (l_dobj) decreases_33\NNS\7296428|,_41|decreasing_33|,_17 (l_prep) in_34\IN\13603305|marked_17 (l_pobj) pressure_37\NN\11419404|NONE_0 (l_conj) output_40\NN\4007894|arterial_36|blood_27|and_12
D014867_D007022 NONE h2o_22\NNP\14618834|high_27|of_15|)_3 (r_punct) levels_16\NNS\4916342|during_105|do_56|not_53|markedly_49|dynamics_19|,_11|but_9|produce_52|._122 (r_conj) alter_10\VB\0|NONE_0 (l_conj) produce_31\VBP\7555863|during_157|do_108|not_105|markedly_101|dynamics_71|,_63|but_61|levels_52|._70 (l_dobj) decreases_33\NNS\7296428|,_41|decreasing_33|,_17 (l_prep) in_34\IN\13603305|marked_17 (l_pobj) pressure_37\NN\11419404|NONE_0 (l_conj) output_40\NN\4007894|arterial_36|blood_27|and_12
D009599_D002303 NONE nitroprusside_1\JJ\0|NONE_0 (r_amod) infusion_2\NN\14589223|before_21|decrease_28|and_64|increased_82|._141 (r_nsubj) produced_3\VBD\1617192|NONE_0 (l_conj) increased_13\VBN\169651|before_103|infusion_82|decrease_54|and_18|._59 (l_conj) decreased_17\VBD\169651|significantly_39|rate_9|and_4 (l_dobj) output_19\NN\4007894|NONE_0
D009599_D002303 NONE nitroprusside_1\JJ\0|infusion_14|low_23|of_34 (r_amod) levels_4\NNS\4916342|NONE_0 (r_pobj) during_0\IN\0|do_49|not_52|markedly_56|dynamics_86|,_94|but_96|levels_105|produce_157|._227 (r_prep) alter_10\VB\0|NONE_0 (l_conj) produce_31\VBP\7555863|during_157|do_108|not_105|markedly_101|dynamics_71|,_63|but_61|levels_52|._70 (l_dobj) decreases_33\NNS\7296428|,_41|decreasing_33|,_17 (l_prep) in_34\IN\13603305|marked_17 (l_pobj) pressure_37\NN\11419404|NONE_0 (l_conj) output_40\NN\4007894|arterial_36|blood_27|and_12
3031535
D006220_D002375 CID haloperidol_28\NN\3713736|NONE_0 (r_pobj) by_27\IN\0|NONE_0 (r_agent) induced_26\VBN\1627355|whereas_56|neurons_35|important_23|in_13 (r_advcl) are_22\VBP\13600404|that_129|neurons_110|role_84|,_31 (r_advcl) have_6\VBP\7846|results_44|._151 (l_dobj) role_9\NN\719494|that_45|neurons_26|,_53|are_84 (l_prep) in_10\IN\13603305|an_18|important_15 (l_pobj) manifestation_12\NN\7321772|NONE_0 (l_prep) of_13\IN\0|the_18|induced_13 (l_pobj) catalepsy_14\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_28\NN\3713736|NONE_0 (r_pobj) by_27\IN\0|NONE_0 (r_agent) induced_26\VBN\1627355|whereas_56|neurons_35|important_23|in_13 (r_advcl) are_22\VBP\13600404|that_129|neurons_110|role_84|,_31 (l_prep) in_24\IN\13603305|whereas_43|neurons_22|important_10|induced_13 (l_pobj) catalepsy_25\NN\14023236|NONE_0
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN\0|NONE_0 (r_pobj) by_5\IN\0|involvement_33|._31 (r_agent) induced_4\VBN\1627355|NONE_0 (l_nsubj) involvement_1\NN\1080366|by_33|._64 (l_prep) in_2\IN\13603305|noradrenergic_26 (l_pobj) catalepsy_3\NN\14023236|NONE_0
D013759_D002375 CID thc_17\NNP\4017137|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|the_31|of_13 (r_acl) manifestation_12\NN\7321772|NONE_0 (l_prep) of_13\IN\0|the_18|induced_13 (l_pobj) catalepsy_14\NN\14023236|NONE_0
D013759_D002375 CID thc_17\NNP\4017137|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|the_31|of_13 (r_acl) manifestation_12\NN\7321772|NONE_0 (r_pobj) in_10\IN\13603305|an_18|important_15 (r_prep) role_9\NN\719494|that_45|neurons_26|,_53|are_84 (r_dobj) have_6\VBP\7846|results_44|._151 (l_advcl) are_22\VBP\13600404|that_129|neurons_110|role_84|,_31 (l_prep) in_24\IN\13603305|whereas_43|neurons_22|important_10|induced_13 (l_pobj) catalepsy_25\NN\14023236|NONE_0
9284778
D017402_D008107 NONE chlorofluorocarbons_14\NNS\14871968|NONE_0 (r_pobj) of_13\IN\0|sparing_20 (r_prep) substitutes_12\NNS\5695554|NONE_0 (r_pobj) as_8\IN\14622893|NONE_0 (r_prep) used_7\VBN\0|NONE_0 (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|of_17|._91 (r_acl) epidemic_0\NN\7435273|NONE_0 (l_prep) of_1\IN\0|caused_17|._108 (l_pobj) disease_3\NN\14061805|NONE_0
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD\0|NONE_0 (r_pobj) as_8\IN\14622893|the_13|same_9 (r_prep) way_7\NN\4916342|NONE_0 (r_pobj) in_4\IN\13603305|compounds_26|are_16|form_73|._186 (r_prep) metabolised_3\VBN\0|NONE_0 (l_advcl) form_14\VB\6286395|compounds_99|are_89|in_73|._113 (l_dobj) intermediates_18\NNS\14806838|to_40 (l_relcl) implicated_23\VBN\2677097|reactive_63|halide_38|,_18 (l_prep) in_24\IN\13603305|which_27|have_21|been_16 (l_pobj) hepatotoxicity_26\NN\0|NONE_0
D006221_D056486 NONE halothane_11\NN\3570838|NONE_0 (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\CD\0|NONE_0 (r_pobj) as_8\IN\14622893|the_13|same_9 (r_prep) way_7\NN\4916342|NONE_0 (r_pobj) in_4\IN\13603305|compounds_26|are_16|form_73|._186 (r_prep) metabolised_3\VBN\0|NONE_0 (l_advcl) form_14\VB\6286395|compounds_99|are_89|in_73|._113 (l_dobj) intermediates_18\NNS\14806838|to_40 (l_relcl) implicated_23\VBN\2677097|reactive_63|halide_38|,_18 (l_prep) in_24\IN\13603305|which_27|have_21|been_16 (l_pobj) hepatotoxicity_26\NN\0|NONE_0
D006221_D056486 NONE halothane_28\NN\3570838|NONE_0 (r_pobj) of_27\IN\0|the_19 (r_prep) hepatotoxicity_26\NN\0|NONE_0
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\0|123_9|)_6|and_4|(_35|hcfc_36|)_44 (r_conj) hcfc_23\NNP\14603497|(_1 (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|NONE_0 (r_pobj) of_20\IN\0|a_10 (r_prep) mixture_19\NN\19613|NONE_0 (r_pobj) to_17\IN\0|accidental_20 (r_prep) exposure_16\NN\5042871|who_32|had_28|had_24 (r_dobj) repeated_14\VBN\952524|nine_36|industrial_31 (r_relcl) workers_10\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_29|of_17 (r_prep) epidemic_3\NN\7435273|we_19|._205 (l_prep) of_4\IN\0|an_12|in_17 (l_pobj) disease_6\NN\14061805|NONE_0
C072959_D008107 CID 124_30\CD\0|NONE_0 (r_nummod) hcfc_29\NNP\14603497|123_45|)_42|and_40|1-chloro-1,2,2,2-tetrafluoroethane_36|(_1|)_8 (r_appos) hcfc_23\NNP\14603497|(_1 (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|NONE_0 (r_pobj) of_20\IN\0|a_10 (r_prep) mixture_19\NN\19613|NONE_0 (r_pobj) to_17\IN\0|accidental_20 (r_prep) exposure_16\NN\5042871|who_32|had_28|had_24 (r_dobj) repeated_14\VBN\952524|nine_36|industrial_31 (r_relcl) workers_10\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_29|of_17 (r_prep) epidemic_3\NN\7435273|we_19|._205 (l_prep) of_4\IN\0|an_12|in_17 (l_pobj) disease_6\NN\14061805|NONE_0
C072959_D008107 CID 124_8\CD\0|123_8|and_4 (r_conj) hcfcs_5\NNS\14603497|whether_8|can_18|in_29 (r_nsubj) result_10\VB\34213|to_38 (l_prep) in_11\IN\13603305|whether_37|hcfcs_29|can_11 (l_pobj) disease_14\NN\14061805|NONE_0
D014269_D056486 NONE trifluoroacetyl_16\NNS\0|NONE_0 (r_compound) halide_17\NN\15010703|reactive_25|,_20|implicated_38 (r_compound) intermediates_18\NNS\14806838|to_40 (l_relcl) implicated_23\VBN\2677097|reactive_63|halide_38|,_18 (l_prep) in_24\IN\13603305|which_27|have_21|been_16 (l_pobj) hepatotoxicity_26\NN\0|NONE_0
D014269_D056486 NONE trifluoroacetyl_17\NN\0|-_15 (r_npadvmod) altered_19\VBN\0|liver_8 (r_amod) proteins_21\NNS\14944888|that_35|are_9 (r_nsubjpass) involved_23\VBN\2676054|known_75|,_70|results_64|._8 (r_ccomp) suggest_15\VBP\1010118|NONE_0 (l_advcl) known_11\VBN\0|,_5|results_11|involved_75|._83 (l_nsubjpass) mechanism_3\NN\13446390|although_19|is_44|not_47 (l_prep) of_4\IN\0|the_20|exact_16 (l_pobj) hepatotoxicity_5\NN\0|NONE_0
C067411_D056486 NONE 124_9\CD\0|123_8|and_4 (r_conj) hcfcs_6\NNS\14603497|NONE_0 (r_pobj) to_5\IN\0|repeated_34|of_16 (r_prep) exposure_1\NN\5042871|can_46|in_57|._128 (r_nsubj) result_11\VB\34213|NONE_0 (l_prep) in_12\IN\13603305|exposure_57|can_11|._71 (l_pobj) injury_15\NN\14052046|NONE_0
C072959_D056486 NONE 124_9\CD\0|123_8|and_4 (r_conj) hcfcs_6\NNS\14603497|NONE_0 (r_pobj) to_5\IN\0|repeated_34|of_16 (r_prep) exposure_1\NN\5042871|can_46|in_57|._128 (r_nsubj) result_11\VB\34213|NONE_0 (l_prep) in_12\IN\13603305|exposure_57|can_11|._71 (l_pobj) injury_15\NN\14052046|NONE_0
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS\14603497|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|of_17|._91 (r_acl) epidemic_0\NN\7435273|NONE_0 (l_prep) of_1\IN\0|caused_17|._108 (l_pobj) disease_3\NN\14061805|NONE_0
D010126_D008107 NONE ozone_9\NN\14877585|-_5 (r_npadvmod) sparing_11\VBG\2725714|of_20 (r_amod) substitutes_12\NNS\5695554|NONE_0 (r_pobj) as_8\IN\14622893|NONE_0 (r_prep) used_7\VBN\0|NONE_0 (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|of_17|._91 (r_acl) epidemic_0\NN\7435273|NONE_0 (l_prep) of_1\IN\0|caused_17|._108 (l_pobj) disease_3\NN\14061805|NONE_0
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|NONE_0 (r_pobj) of_20\IN\0|a_10 (r_prep) mixture_19\NN\19613|NONE_0 (r_pobj) to_17\IN\0|accidental_20 (r_prep) exposure_16\NN\5042871|who_32|had_28|had_24 (r_dobj) repeated_14\VBN\952524|nine_36|industrial_31 (r_relcl) workers_10\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_29|of_17 (r_prep) epidemic_3\NN\7435273|we_19|._205 (l_prep) of_4\IN\0|an_12|in_17 (l_pobj) disease_6\NN\14061805|NONE_0
C067411_D008107 CID 123_24\CD\0|)_3|and_5|1-chloro-1,2,2,2-tetrafluoroethane_9|(_44|hcfc_45|)_53 (r_nummod) hcfc_23\NNP\14603497|(_1 (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\CD\0|NONE_0 (r_pobj) of_20\IN\0|a_10 (r_prep) mixture_19\NN\19613|NONE_0 (r_pobj) to_17\IN\0|accidental_20 (r_prep) exposure_16\NN\5042871|who_32|had_28|had_24 (r_dobj) repeated_14\VBN\952524|nine_36|industrial_31 (r_relcl) workers_10\NNS\7846|NONE_0 (r_pobj) in_7\IN\13603305|an_29|of_17 (r_prep) epidemic_3\NN\7435273|we_19|._205 (l_prep) of_4\IN\0|an_12|in_17 (l_pobj) disease_6\NN\14061805|NONE_0
C067411_D008107 CID 124_8\CD\0|123_8|and_4 (r_conj) hcfcs_5\NNS\14603497|whether_8|can_18|in_29 (r_nsubj) result_10\VB\34213|to_38 (l_prep) in_11\IN\13603305|whether_37|hcfcs_29|can_11 (l_pobj) disease_14\NN\14061805|NONE_0
8752018
D008094_D001714 NONE lithium_0\NN\14625458|treatment_29|._98 (r_nsubj) remains_1\VBZ\2684|NONE_0 (l_attr) treatment_6\NN\654885|lithium_29|._69 (l_prep) for_7\IN\0|a_23|line_15 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_36|acute_32 (l_pobj) disorder_15\NN\14034177|NONE_0
D008094_D001714 NONE lithium_10\NN\14625458|NONE_0 (r_pobj) from_9\IN\0|patients_9|divalproex_16 (r_prep) switching_6\VBG\191142|NONE_0 (l_dobj) patients_8\NNS\9898892|from_9|divalproex_25 (l_amod) bipolar_7\JJ\0|NONE_0
D008094_D001714 NONE lithium_8\NN\14625458|NONE_0 (r_pobj) of_7\IN\0|,_10|fully_19|,_37|with_39 (r_prep) substitution_6\NN\7337390|where_6|helpful_89 (r_nsubj) was_18\VBD\0|seven_93 (l_acomp) helpful_20\JJ\0|where_95|substitution_89 (l_prep) in_21\IN\13603305|extremely_18 (l_pcomp) reducing_22\VBG\13447361|NONE_0 (l_dobj) cognitive_24\JJ\0|NONE_0 (l_acl) attributed_31\VBN\670261|the_50|,_37|motivational_35 (l_prep) to_32\IN\0|NONE_0 (l_pobj) lithium_33\NN\14625458|NONE_0 (l_prep) in_34\IN\13603305|NONE_0 (l_pobj) patients_37\NNS\9898892|NONE_0 (l_amod) bipolar_36\JJ\0|our_4
D008094_D001714 NONE lithium_33\NN\14625458|NONE_0 (l_prep) in_34\IN\13603305|NONE_0 (l_pobj) patients_37\NNS\9898892|NONE_0 (l_amod) bipolar_36\JJ\0|our_4
D008094_D001714 NONE lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_amod) bipolar_14\JJ\0|experiencing_17
D008094_D011141 NONE lithium_15\NN\14625458|NONE_0 (r_pobj) of_14\IN\0|the_32|common_23|adverse_16|,_10|as_17 (r_prep) effects_13\NNS\13245626|NONE_0 (l_prep) as_18\IN\14622893|the_49|common_40|adverse_33|of_17|,_7 (l_pobj) polyuria_19\NN\14113228|such_8
D008094_D011141 NONE lithium_25\NN\14625458|subtle_7|side_8|as_26 (r_compound) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (r_nsubj) remain_40\VBP\2604760|NONE_0 (l_advcl) written_4\VBN\1697816|,_103|effects_130|understudied_220|._232 (l_prep) about_5\IN\0|although_31|much_22|has_17|been_13 (l_pobj) management_7\NN\1123598|NONE_0 (l_prep) of_8\IN\0|the_15 (l_pobj) effects_13\NNS\13245626|NONE_0 (l_prep) as_18\IN\14622893|the_49|common_40|adverse_33|of_17|,_7 (l_pobj) polyuria_19\NN\14113228|such_8
D014635_D003072 NONE sodium_13\NN\14625458|to_14 (r_dobj) divalproex_12\NN\0|by_15 (r_advcl) reduced_7\VBN\441445|associated_45|cognitive_34|._55 (r_acl) deficits_6\NNS\5113133|NONE_0
D014635_D003072 NONE sodium_13\NN\14625458|to_14|alleviate_10 (r_dobj) divalproex_12\NN\0|patients_25|from_16 (l_xcomp) alleviate_15\VB\205885|to_24|sodium_10 (l_dobj) impairments_20\NNS\7296428|to_43
D014635_D003072 NONE sodium_17\NN\14625458|NONE_0 (r_pobj) with_15\IN\0|of_39|,_29|fully_20|,_2 (r_prep) substitution_6\NN\7337390|where_6|helpful_89 (r_nsubj) was_18\VBD\0|seven_93 (l_acomp) helpful_20\JJ\0|where_95|substitution_89 (l_prep) in_21\IN\13603305|extremely_18 (l_pcomp) reducing_22\VBG\13447361|NONE_0 (l_dobj) cognitive_24\JJ\0|NONE_0 (l_conj) motivational_26\JJ\0|the_15|,_2|attributed_35 (l_conj) deficits_30\NNS\5113133|,_14|or_12
D014635_D003072 NONE sodium_6\NN\14625458|in_39|,_13|alternative_22|._144 (r_nsubj) was_7\VBD\0|NONE_0 (l_attr) alternative_10\NN\5788149|in_61|,_35|sodium_22|._122 (l_prep) to_11\IN\0|a_23|superior_21 (l_pobj) lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_acl) experiencing_16\VBG\2108377|bipolar_17 (l_dobj) deficits_18\NNS\5113133|NONE_0
D014635_D003072 NONE sodium_6\NN\14625458|in_39|,_13|alternative_22|._144 (r_nsubj) was_7\VBD\0|NONE_0 (l_attr) alternative_10\NN\5788149|in_61|,_35|sodium_22|._122 (l_prep) to_11\IN\0|a_23|superior_21 (l_pobj) lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_acl) experiencing_16\VBG\2108377|bipolar_17 (l_dobj) deficits_18\NNS\5113133|NONE_0 (l_conj) loss_20\NN\13252973|cognitive_20|,_2 (l_prep) of_21\IN\0|NONE_0 (l_pobj) creativity_22\NN\5616246|NONE_0
D014635_D003072 NONE sodium_6\NN\14625458|in_39|,_13|alternative_22|._144 (r_nsubj) was_7\VBD\0|NONE_0 (l_attr) alternative_10\NN\5788149|in_61|,_35|sodium_22|._122 (l_prep) to_11\IN\0|a_23|superior_21 (l_pobj) lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_acl) experiencing_16\VBG\2108377|bipolar_17 (l_dobj) deficits_18\NNS\5113133|NONE_0 (l_conj) loss_20\NN\13252973|cognitive_20|,_2 (l_prep) of_21\IN\0|NONE_0 (l_pobj) creativity_22\NN\5616246|NONE_0 (l_conj) impairments_26\NNS\7296428|,_17|and_15
D014635_D001714 NONE sodium_13\NN\14625458|to_14|alleviate_10 (r_dobj) divalproex_12\NN\0|patients_25|from_16 (r_advcl) switching_6\VBG\191142|NONE_0 (l_dobj) patients_8\NNS\9898892|from_9|divalproex_25 (l_amod) bipolar_7\JJ\0|NONE_0
D014635_D001714 NONE sodium_17\NN\14625458|NONE_0 (r_pobj) with_15\IN\0|of_39|,_29|fully_20|,_2 (r_prep) substitution_6\NN\7337390|where_6|helpful_89 (r_nsubj) was_18\VBD\0|seven_93 (l_acomp) helpful_20\JJ\0|where_95|substitution_89 (l_prep) in_21\IN\13603305|extremely_18 (l_pcomp) reducing_22\VBG\13447361|NONE_0 (l_dobj) cognitive_24\JJ\0|NONE_0 (l_acl) attributed_31\VBN\670261|the_50|,_37|motivational_35 (l_prep) to_32\IN\0|NONE_0 (l_pobj) lithium_33\NN\14625458|NONE_0 (l_prep) in_34\IN\13603305|NONE_0 (l_pobj) patients_37\NNS\9898892|NONE_0 (l_amod) bipolar_36\JJ\0|our_4
D014635_D001714 NONE sodium_6\NN\14625458|in_39|,_13|alternative_22|._144 (r_nsubj) was_7\VBD\0|NONE_0 (l_attr) alternative_10\NN\5788149|in_61|,_35|sodium_22|._122 (l_prep) to_11\IN\0|a_23|superior_21 (l_pobj) lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_amod) bipolar_14\JJ\0|experiencing_17
D008094_D003072 CID lithium_0\NN\14625458|-_7 (r_npadvmod) associated_2\VBN\628491|cognitive_11|reduced_45|._100 (r_amod) deficits_6\NNS\5113133|NONE_0
D008094_D003072 CID lithium_15\NN\14625458|NONE_0 (r_pobj) of_14\IN\0|the_32|common_23|adverse_16|,_10|as_17 (r_prep) effects_13\NNS\13245626|NONE_0 (r_pobj) of_8\IN\0|the_15 (r_prep) management_7\NN\1123598|NONE_0 (r_pobj) about_5\IN\0|although_31|much_22|has_17|been_13 (r_prep) written_4\VBN\1697816|,_103|effects_130|understudied_220|._232 (r_advcl) remain_40\VBP\2604760|NONE_0 (l_nsubj) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (l_prep) as_29\IN\14622893|subtle_33|lithium_26|side_18 (l_pobj) deficits_31\NNS\5113133|such_18
D008094_D003072 CID lithium_15\NN\14625458|NONE_0 (r_pobj) of_14\IN\0|the_32|common_23|adverse_16|,_10|as_17 (r_prep) effects_13\NNS\13245626|NONE_0 (r_pobj) of_8\IN\0|the_15 (r_prep) management_7\NN\1123598|NONE_0 (r_pobj) about_5\IN\0|although_31|much_22|has_17|been_13 (r_prep) written_4\VBN\1697816|,_103|effects_130|understudied_220|._232 (r_advcl) remain_40\VBP\2604760|NONE_0 (l_nsubj) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (l_prep) as_29\IN\14622893|subtle_33|lithium_26|side_18 (l_pobj) deficits_31\NNS\5113133|such_18 (l_conj) loss_33\NN\13252973|cognitive_20|,_2 (l_prep) of_34\IN\0|,_13|and_15|impairments_30 (l_pobj) creativity_35\NN\5616246|NONE_0
D008094_D003072 CID lithium_15\NN\14625458|NONE_0 (r_pobj) of_14\IN\0|the_32|common_23|adverse_16|,_10|as_17 (r_prep) effects_13\NNS\13245626|NONE_0 (r_pobj) of_8\IN\0|the_15 (r_prep) management_7\NN\1123598|NONE_0 (r_pobj) about_5\IN\0|although_31|much_22|has_17|been_13 (r_prep) written_4\VBN\1697816|,_103|effects_130|understudied_220|._232 (r_advcl) remain_40\VBP\2604760|NONE_0 (l_nsubj) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (l_prep) as_29\IN\14622893|subtle_33|lithium_26|side_18 (l_pobj) deficits_31\NNS\5113133|such_18 (l_conj) loss_33\NN\13252973|cognitive_20|,_2 (l_conj) impairments_39\NNS\7296428|of_30|,_17|and_15
D008094_D003072 CID lithium_25\NN\14625458|subtle_7|side_8|as_26 (r_compound) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (l_prep) as_29\IN\14622893|subtle_33|lithium_26|side_18 (l_pobj) deficits_31\NNS\5113133|such_18
D008094_D003072 CID lithium_25\NN\14625458|subtle_7|side_8|as_26 (r_compound) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (l_prep) as_29\IN\14622893|subtle_33|lithium_26|side_18 (l_pobj) deficits_31\NNS\5113133|such_18 (l_conj) loss_33\NN\13252973|cognitive_20|,_2 (l_prep) of_34\IN\0|,_13|and_15|impairments_30 (l_pobj) creativity_35\NN\5616246|NONE_0
D008094_D003072 CID lithium_25\NN\14625458|subtle_7|side_8|as_26 (r_compound) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (l_prep) as_29\IN\14622893|subtle_33|lithium_26|side_18 (l_pobj) deficits_31\NNS\5113133|such_18 (l_conj) loss_33\NN\13252973|cognitive_20|,_2 (l_conj) impairments_39\NNS\7296428|of_30|,_17|and_15
D008094_D003072 CID lithium_10\NN\14625458|NONE_0 (r_pobj) from_9\IN\0|patients_9|divalproex_16 (r_prep) switching_6\VBG\191142|NONE_0 (l_advcl) divalproex_12\NN\0|patients_25|from_16 (l_xcomp) alleviate_15\VB\205885|to_24|sodium_10 (l_dobj) impairments_20\NNS\7296428|to_43
D008094_D003072 CID lithium_8\NN\14625458|NONE_0 (r_pobj) of_7\IN\0|,_10|fully_19|,_37|with_39 (r_prep) substitution_6\NN\7337390|where_6|helpful_89 (r_nsubj) was_18\VBD\0|seven_93 (l_acomp) helpful_20\JJ\0|where_95|substitution_89 (l_prep) in_21\IN\13603305|extremely_18 (l_pcomp) reducing_22\VBG\13447361|NONE_0 (l_dobj) cognitive_24\JJ\0|NONE_0 (l_conj) motivational_26\JJ\0|the_15|,_2|attributed_35 (l_conj) deficits_30\NNS\5113133|,_14|or_12
D008094_D003072 CID lithium_33\NN\14625458|NONE_0 (r_pobj) to_32\IN\0|NONE_0 (r_prep) attributed_31\VBN\670261|the_50|,_37|motivational_35 (r_acl) cognitive_24\JJ\0|NONE_0 (l_conj) motivational_26\JJ\0|the_15|,_2|attributed_35 (l_conj) deficits_30\NNS\5113133|,_14|or_12
D008094_D003072 CID lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_acl) experiencing_16\VBG\2108377|bipolar_17 (l_dobj) deficits_18\NNS\5113133|NONE_0
D008094_D003072 CID lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_acl) experiencing_16\VBG\2108377|bipolar_17 (l_dobj) deficits_18\NNS\5113133|NONE_0 (l_conj) loss_20\NN\13252973|cognitive_20|,_2 (l_prep) of_21\IN\0|NONE_0 (l_pobj) creativity_22\NN\5616246|NONE_0
D008094_D003072 CID lithium_12\NN\14625458|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_acl) experiencing_16\VBG\2108377|bipolar_17 (l_dobj) deficits_18\NNS\5113133|NONE_0 (l_conj) loss_20\NN\13252973|cognitive_20|,_2 (l_prep) of_21\IN\0|NONE_0 (l_pobj) creativity_22\NN\5616246|NONE_0 (l_conj) impairments_26\NNS\7296428|,_17|and_15
D008094_D014202 NONE lithium_15\NN\14625458|NONE_0 (r_pobj) of_14\IN\0|the_32|common_23|adverse_16|,_10|as_17 (r_prep) effects_13\NNS\13245626|NONE_0 (l_prep) as_18\IN\14622893|the_49|common_40|adverse_33|of_17|,_7 (l_pobj) polyuria_19\NN\14113228|such_8 (l_conj) tremor_21\NN\345926|and_4
D008094_D014202 NONE lithium_25\NN\14625458|subtle_7|side_8|as_26 (r_compound) effects_27\NNS\13245626|written_130|,_27|understudied_90|._102 (r_nsubj) remain_40\VBP\2604760|NONE_0 (l_advcl) written_4\VBN\1697816|,_103|effects_130|understudied_220|._232 (l_prep) about_5\IN\0|although_31|much_22|has_17|been_13 (l_pobj) management_7\NN\1123598|NONE_0 (l_prep) of_8\IN\0|the_15 (l_pobj) effects_13\NNS\13245626|NONE_0 (l_prep) as_18\IN\14622893|the_49|common_40|adverse_33|of_17|,_7 (l_pobj) polyuria_19\NN\14113228|such_8 (l_conj) tremor_21\NN\345926|and_4
7516729
D014700_D001919 CID verapamil_6\NN\2938514|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) induced_4\VBN\1627355|dependent_22 (r_acl) bradycardia_3\NNS\14110674|was_33|by_49|._69
6727060
D008787_D005767 NONE metoclopramide_23\RB\0|after_14|he_8|for_15|in_45 (r_dobj) took_22\VBD\2367363|movements_97|in_78|._109 (l_prep) for_24\IN\0|after_29|he_23|metoclopramide_15|in_30 (l_pobj) disorder_26\NN\14034177|NONE_0
D008787_D004409 CID metoclopramide_7\NN\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) caused_5\VBN\1617192|tardive_19 (r_acl) dyskinesia_4\JJ\14084880|NONE_0
D008787_D004409 CID metoclopramide_23\RB\0|after_14|he_8|for_15|in_45 (r_dobj) took_22\VBD\2367363|movements_97|in_78|._109 (r_advcl) appeared_3\VBD\2604760|NONE_0 (l_nsubj) movements_2\NNS\191142|in_19|took_97|._206
D008787_D004409 CID metoclopramide_2\JJ\0|the_4 (r_compound) administration_3\NN\1133281|when_24|was_15 (r_nsubjpass) discontinued_5\VBN\0|,_12|movements_27|gradually_37|to_56|._80 (r_advcl) improved_11\VBD\126264|NONE_0 (l_nsubj) movements_9\NNS\191142|discontinued_27|,_15|gradually_10|to_29|._53
983936
D006854_D009202 NONE hydrocortisone_8\NN\14751417|,_6|and_4 (l_prep) on_9\IN\0|NONE_0 (l_pobj) injury_14\NN\14052046|NONE_0
D001241_D009202 NONE acid_3\NN\14818238|NONE_0 (l_conj) dipyridamole_5\NN\0|acetylsalicylic_22|,_2 (l_conj) hydrocortisone_8\NN\14751417|,_6|and_4 (l_prep) on_9\IN\0|NONE_0 (l_pobj) injury_14\NN\14052046|NONE_0
D004837_D009203 NONE epinephrine_9\NN\14807929|(_1 (r_amod) infusion_10\NN\14589223|diffuse_39|myocardial_31 (r_appos) injury_7\NN\14052046|NONE_0 (r_dobj) producing_4\VBG\1617192|NONE_0 (r_pcomp) for_3\IN\0|a_21|reproducible_19|)_61 (r_prep) model_2\NN\5888929|has_69|been_73|study_91|._211 (r_nsubjpass) developed_14\VBN\1753788|NONE_0 (l_advcl) study_16\VB\635850|model_91|has_22|been_18|._120 (l_dobj) effects_19\NNS\13245626|to_30 (l_prep) of_20\IN\0|the_29|cardioprotective_25 (l_pobj) agents_21\NNS\7347|NONE_0 (l_relcl) alter_26\VB\0|or_25|maneuvers_22 (l_dobj) evolution_28\NN\29677|which_22|might_16 (l_prep) of_29\IN\0|the_14 (l_pobj) infarction_32\NN\14204950|NONE_0
D004837_D009202 CID epinephrine_10\NN\14807929|-_11 (r_npadvmod) induced_12\VBN\1627355|myocardial_8|in_26 (r_amod) injury_14\NN\14052046|NONE_0
D004837_D009202 CID epinephrine_9\NN\14807929|(_1 (r_amod) infusion_10\NN\14589223|diffuse_39|myocardial_31 (r_appos) injury_7\NN\14052046|NONE_0
D004176_D009202 NONE dipyridamole_5\NN\0|acetylsalicylic_22|,_2 (l_conj) hydrocortisone_8\NN\14751417|,_6|and_4 (l_prep) on_9\IN\0|NONE_0 (l_pobj) injury_14\NN\14052046|NONE_0
11431197
D011899_D009395 CID ranitidine_0\NNP\14778019|-_10 (r_npadvmod) induced_2\VBN\1627355|acute_8|interstitial_14|in_37|._67 (r_amod) nephritis_5\NN\14113228|NONE_0
D011899_D009395 CID ranitidine_5\NN\14778019|-_10 (r_npadvmod) induced_7\VBN\1627355|acute_8|interstitial_14 (r_amod) nephritis_10\NN\14113228|NONE_0
12757899
D012834_D013226 NONE silver_3\NN\14821043|-_6 (r_npadvmod) stained_5\VBN\283090|and_12|neurons_32 (r_amod) ca3_6\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) extent_1\NN\13939892|was_57|after_78|._86 (r_nsubjpass) evaluated_12\VBN\670261|NONE_0 (l_prep) after_15\IN\0|extent_78|was_21|._8 (l_pobj) se_16\NNP\14724645|days_11
D008094_D013226 CID lithium_17\NN\14625458|-_7 (r_compound) pilocarpine_19\NN\14712692|-_11 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) se_22\NNP\14724645|NONE_0
D004958_D001930 NONE estradiol_0\NN\14749794|injury_46|but_78|in_86|._98 (r_nsubj) reduces_1\VBZ\441445|NONE_0 (l_dobj) injury_6\NN\14052046|estradiol_46|but_32|in_40|._52
D004958_D013226 NONE estradiol_7\NN\14749794|NONE_0 (r_pobj) of_4\IN\0|the_12|in_20|and_34|rats_60 (r_prep) effects_3\NNS\13245626|we_16|._116 (l_conj) rats_14\NNS\2329401|the_72|of_60|in_40|and_26 (l_acl) subjected_15\VBN\137313|ovariectomized_27|female_12 (l_prep) to_16\IN\0|NONE_0 (l_pobj) se_22\NNP\14724645|NONE_0
D007608_D013226 NONE acid_10\NN\14818238|-_4 (r_npadvmod) induced_12\VBN\1627355|kainic_12|se_28 (r_amod) status_13\NN\24720|NONE_0 (l_appos) se_16\NNP\14724645|kainic_40|induced_28 (l_amod) epilepticus_14\NN\0|(_12
D007608_D013226 NONE acid_10\NN\14818238|-_4 (r_npadvmod) induced_12\VBN\1627355|kainic_12|se_28 (r_amod) status_13\NN\24720|NONE_0 (l_appos) se_16\NNP\14724645|kainic_40|induced_28
D004958_D012640 NONE estradiol_0\NN\14749794|injury_46|but_78|in_86|._98 (r_nsubj) reduces_1\VBZ\441445|NONE_0 (l_dobj) injury_6\NN\14052046|estradiol_46|but_32|in_40|._52 (l_amod) induced_4\VBN\1627355|hippocampal_8|in_27 (l_npadvmod) seizure_2\NN\14081375|-_7
D004958_D012640 NONE estradiol_7\NN\14749794|NONE_0 (r_pobj) of_6\IN\0|the_12|on_13 (r_prep) effects_5\NNS\13245626|that_9|may_53|be_57|by_68 (l_prep) on_8\IN\0|the_25|of_13 (l_pobj) threshold_10\NN\15265518|NONE_0 (l_compound) seizure_9\NN\14081375|and_18|damage_22
D007608_D001930 NONE acid_10\NN\14818238|-_4 (r_npadvmod) induced_12\VBN\1627355|kainic_12|se_28 (r_amod) status_13\NN\24720|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|estrogens_62|rats_29|)_53|._54 (r_advcl) protect_1\VBP\1127795|NONE_0 (l_dobj) rats_3\NNS\2329401|estrogens_33|induced_29|)_82|._83 (l_prep) from_4\IN\0|ovariectomized_20 (l_pobj) injury_6\NN\14052046|NONE_0
D010862_D013226 CID pilocarpine_19\NN\14712692|-_11 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) se_22\NNP\14724645|NONE_0
8073369
D009538_D002543 CID nicotine_30\NN\14712692|all_4|treated_17 (r_nmod) chicks_34\NNS\1791625|NONE_0 (r_pobj) in_28\IN\13603305|seen_103|;_49|however_47|,_40|hemorrhage_20|._38 (r_prep) occurred_27\VBD\0|NONE_0 (l_nsubj) hemorrhage_26\NN\14285662|seen_83|;_29|however_27|,_20|in_20|._58
C007112_D001176 CID coniine_2\NN\0|however_9|,_2|has_8|produce_22|and_61|is_65|._102 (r_nsubj) failed_4\VBN\0|NONE_0 (l_xcomp) produce_6\VB\7555863|however_31|,_24|coniine_22|has_14|and_39|is_43|._80 (l_dobj) arthrogryposis_7\NN\0|to_11
C007112_D001176 CID coniine_15\RB\0|-_7 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) arthrogryposis_18\NN\0|NONE_0
D009538_D009140 NONE nicotine_7\NN\14712692|NONE_0 (r_compound) sulfate_8\NN\15010703|both_26|and_13 (r_conj) coniine_5\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|the_17 (r_acl) deformations_1\NNS\7420770|flexion_72|._112
D009538_D009140 NONE nicotine_7\NN\14712692|NONE_0 (r_compound) sulfate_8\NN\15010703|both_26|and_13 (r_conj) coniine_5\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|the_17 (r_acl) deformations_1\NNS\7420770|flexion_72|._112 (r_nsubj) were_9\VBD\0|NONE_0 (l_attr) flexion_11\NN\14034177|deformations_72|._40 (l_prep) of_14\IN\0|excessive_31|or_13|extension_10 (l_pobj) toes_18\NNS\5566097|NONE_0
C007112_D009140 NONE coniine_5\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|the_17 (r_acl) deformations_1\NNS\7420770|flexion_72|._112
C007112_D009140 NONE coniine_5\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|the_17 (r_acl) deformations_1\NNS\7420770|flexion_72|._112 (r_nsubj) were_9\VBD\0|NONE_0 (l_attr) flexion_11\NN\14034177|deformations_72|._40 (l_prep) of_14\IN\0|excessive_31|or_13|extension_10 (l_pobj) toes_18\NNS\5566097|NONE_0
15863244
D010894_D006345 NONE piroxicam_23\NN\3828465|selective_11|cox-2_39|based_55 (r_nmod) inhibitor_31\NN\20090|NONE_0 (r_pobj) to_22\IN\0|NONE_0 (r_prep) exposed_21\VBN\2110927|rat_12 (r_acl) fetuses_20\NNS\1471682|NONE_0 (r_pobj) for_18\IN\0|analysis_77|was_14|._116 (r_prep) performed_17\VBN\0|NONE_0 (l_nsubjpass) analysis_3\NN\633864|was_63|for_77|._193 (l_prep) for_4\IN\0|the_32|pooled_28|statistical_21 (l_pobj) defects_15\NNS\14462666|NONE_0
D010894_D009139 CID piroxicam_24\NN\3828465|NONE_0 (r_pobj) of_23\IN\0|the_17|highest_13 (r_prep) dose_22\NN\3740161|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|NONE_0 (r_acl) rats_17\NNS\2329401|NONE_0 (r_pobj) in_16\IN\13603305|toxicity_103|were_11|._50 (r_prep) found_15\VBN\13279262|NONE_0 (l_nsubjpass) toxicity_1\NN\13576101|were_92|in_103|._153 (l_appos) retardation_5\NN\7296428|maternal_39|,_22 (l_conj) increase_8\NN\13576355|intrauterine_37|growth_24|,_6|and_4 (l_prep) of_9\IN\0|NONE_0 (l_pobj) variations_13\NNS\7296428|NONE_0
D010894_D064420 NONE piroxicam_19\NN\3828465|NONE_0 (r_compound) study_20\NN\635850|and_14 (r_conj) dfu_17\NNP\0|selective_85|cyclooxygenase-2_57|in_29|--_2 (r_appos) inhibitors_11\NNS\20090|NONE_0 (r_pobj) of_4\IN\0|developmental_23 (r_prep) toxicity_3\NN\13576101|NONE_0
D010894_D064420 NONE piroxicam_17\NN\3828465|NONE_0 (r_pobj) of_11\IN\0|the_27|developmental_23|dfu_48 (r_prep) toxicity_10\NN\13576101|to_30
D010894_D064420 NONE piroxicam_24\NN\3828465|NONE_0 (r_pobj) of_23\IN\0|the_17|highest_13 (r_prep) dose_22\NN\3740161|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|NONE_0 (r_acl) rats_17\NNS\2329401|NONE_0 (r_pobj) in_16\IN\13603305|toxicity_103|were_11|._50 (r_prep) found_15\VBN\13279262|NONE_0 (l_nsubjpass) toxicity_1\NN\13576101|were_92|in_103|._153
C106876_D064420 NONE dfu_17\NNP\0|selective_85|cyclooxygenase-2_57|in_29|--_2 (r_appos) inhibitors_11\NNS\20090|NONE_0 (r_pobj) of_4\IN\0|developmental_23 (r_prep) toxicity_3\NN\13576101|NONE_0
C106876_D064420 NONE dfu_22\NNP\0|the_75|developmental_71|of_48 (r_conj) toxicity_10\NN\13576101|to_30
C106876_D064420 NONE phenyl-2(5h)-furanon_26\XX\0|NONE_0 (l_ccomp) was_5\VBD\0|;_94|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl_96|)_148|)_170 (l_xcomp) evaluate_7\VB\670261|aim_29 (l_dobj) toxicity_10\NN\13576101|to_30
C106876_D064420 NONE dfu_10\NNP\0|the_4|developmental_4|observed_27 (r_nmod) toxicity_12\NN\13576101|NONE_0
D010894_D009436 NONE piroxicam_23\NN\3828465|selective_11|cox-2_39|based_55 (r_nmod) inhibitor_31\NN\20090|NONE_0 (r_pobj) to_22\IN\0|NONE_0 (r_prep) exposed_21\VBN\2110927|rat_12 (r_acl) fetuses_20\NNS\1471682|NONE_0 (r_pobj) for_18\IN\0|analysis_77|was_14|._116 (r_prep) performed_17\VBN\0|NONE_0 (l_nsubjpass) analysis_3\NN\633864|was_63|for_77|._193 (l_prep) for_4\IN\0|the_32|pooled_28|statistical_21 (l_pobj) defects_15\NNS\14462666|NONE_0
D010894_D005317 CID piroxicam_24\NN\3828465|NONE_0 (r_pobj) of_23\IN\0|the_17|highest_13 (r_prep) dose_22\NN\3740161|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|NONE_0 (r_acl) rats_17\NNS\2329401|NONE_0 (r_pobj) in_16\IN\13603305|toxicity_103|were_11|._50 (r_prep) found_15\VBN\13279262|NONE_0 (l_nsubjpass) toxicity_1\NN\13576101|were_92|in_103|._153 (l_appos) retardation_5\NN\7296428|maternal_39|,_22
9495837
D012601_D000647 CID scopolamine_18\NN\14712692|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|NONE_0 (r_acl) amnesia_15\NN\5669934|to_11
D004025_D000647 CID dicyclomine_26\NN\0|mg_18|i.p._10|)_6|and_4 (r_conj) kg-1_22\NNP\0|(_6|in_44 (r_appos) scopolamine_18\NN\14712692|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|NONE_0 (r_acl) amnesia_15\NN\5669934|to_11
D000109_D000647 NONE acetylcholine_73\NN\14807558|extracellular_14 (r_amod) levels_75\NNS\4916342|NONE_0 (r_pobj) in_72\IN\13603305|an_12 (r_prep) increase_71\NN\13576355|NONE_0 (r_pobj) through_69\IN\0|NONE_0 (r_prep) /-)-pg-9_68\NFP\0|profiles_355|,_139|have_137|ratio_105|+_1|._66 (r_punct) shown_44\VBN\2137132|NONE_0 (l_dobj) ratio_48\NN\13815152|profiles_250|,_34|have_32|+_104|/-)-pg-9_105|._171 (l_relcl) be_53\VB\14625458|an_46|m4/m1_43|selectivity_37|of_19 (l_acomp) responsible_54\JJ\0|that_14|might_9 (l_prep) for_55\IN\0|NONE_0 (l_pobj) antinociception_57\NN\0|NONE_0 (l_conj) effect_63\NN\34213|the_41|and_21|induced_7 (l_amod) amnesic_62\JJ\10158756|the_9
C087567_D000647 NONE /-)-pg-9_2\.\0|(_2|+_1|able_34|._166 (r_nsubj) was_11\VBD\0|NONE_0 (l_acomp) able_12\JJ\0|(_36|+_35|/-)-pg-9_34|._132 (l_xcomp) prevent_14\VB\0|NONE_0 (l_dobj) amnesia_15\NN\5669934|to_11
C087567_D000647 NONE /-)-pg-9_5\NFP\0|(_2|+_1 (r_conj) of_2\IN\0|affinity_18|determined_48|deferens_93 (r_prep) profiles_1\NNS\6999802|,_216|have_218|ratio_250|+_354|/-)-pg-9_355|._421 (r_nsubj) shown_44\VBN\2137132|NONE_0 (l_dobj) ratio_48\NN\13815152|profiles_250|,_34|have_32|+_104|/-)-pg-9_105|._171 (l_relcl) be_53\VB\14625458|an_46|m4/m1_43|selectivity_37|of_19 (l_acomp) responsible_54\JJ\0|that_14|might_9 (l_prep) for_55\IN\0|NONE_0 (l_pobj) antinociception_57\NN\0|NONE_0 (l_conj) effect_63\NN\34213|the_41|and_21|induced_7 (l_amod) amnesic_62\JJ\10158756|the_9
C087567_D000647 NONE /-)-pg-9_68\NFP\0|profiles_355|,_139|have_137|ratio_105|+_1|._66 (r_punct) shown_44\VBN\2137132|NONE_0 (l_dobj) ratio_48\NN\13815152|profiles_250|,_34|have_32|+_104|/-)-pg-9_105|._171 (l_relcl) be_53\VB\14625458|an_46|m4/m1_43|selectivity_37|of_19 (l_acomp) responsible_54\JJ\0|that_14|might_9 (l_prep) for_55\IN\0|NONE_0 (l_pobj) antinociception_57\NN\0|NONE_0 (l_conj) effect_63\NN\34213|the_41|and_21|induced_7 (l_amod) amnesic_62\JJ\10158756|the_9
11875660
D001374_D009436 NONE 5-azacytidine_6\NN\0|NONE_0 (r_pobj) by_5\IN\0|at_17 (r_agent) induced_4\VBN\1627355|the_16 (r_acl) exencephaly_3\NNS\0|we_16|,_66|let_68|._156
17532790
D001971_D010300 NONE bromocriptine_36\NN\0|l_10|-_9|or_3 (r_conj) dopa_34\NNP\14601829|the_158|occurring_146|,_4|using_22 (r_appos) changes_8\NNS\7283608|in_42|,_22|we_20|._255 (l_acl) occurring_9\VBG\0|the_12|,_142|dopa_146|using_168 (l_prep) at_10\IN\14622893|NONE_0 (l_pobj) level_13\NN\4916342|NONE_0 (l_acl) obtained_17\VBN\2210855|the_38|protein_34|in_20 (l_prep) from_18\IN\0|NONE_0 (l_pobj) model_25\NN\5888929|NONE_0 (l_prep) of_26\IN\0|the_52|unilaterally_48|rat_10|treated_6 (l_pobj) pd_27\NNP\14625458|NONE_0
D007980_D004409 CID dopa_12\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) dyskinesia_15\NN\14084880|NONE_0
D007980_D004409 CID dopa_2\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_4\VBN\1627355|lid_20 (r_amod) dyskinesia_5\NN\14084880|among_20|._137
D007980_D004409 CID dopa_2\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_4\VBN\1627355|lid_20 (r_amod) dyskinesia_5\NN\14084880|among_20|._137 (l_appos) lid_7\NNP\5313679|induced_20
D007980_D004409 CID dopa_31\NNP\14601829|NONE_0 (r_pobj) with_28\IN\0|a_22|prolonged_20 (r_prep) treatment_27\NN\654885|NONE_0 (r_pobj) after_24\IN\0|that_48|in_37 (r_prep) arise_15\VBP\2623529|the_29|motor_25 (r_relcl) complications_13\NNS\1073995|NONE_0 (r_pobj) among_10\IN\0|dyskinesia_20|._117 (r_prep) is_9\VBZ\0|NONE_0 (l_nsubj) dyskinesia_5\NN\14084880|among_20|._137
D007980_D004409 CID dopa_31\NNP\14601829|NONE_0 (r_pobj) with_28\IN\0|a_22|prolonged_20 (r_prep) treatment_27\NN\654885|NONE_0 (r_pobj) after_24\IN\0|that_48|in_37 (r_prep) arise_15\VBP\2623529|the_29|motor_25 (r_relcl) complications_13\NNS\1073995|NONE_0 (r_pobj) among_10\IN\0|dyskinesia_20|._117 (r_prep) is_9\VBZ\0|NONE_0 (l_nsubj) dyskinesia_5\NN\14084880|among_20|._137 (l_appos) lid_7\NNP\5313679|induced_20
D007980_D004409 CID dopa_5\NNP\14601829|NONE_0 (r_pobj) with_2\IN\0|rats_13|allocated_17|._80 (r_prep) treated_1\VBD\2376958|NONE_0 (l_conj) allocated_7\VBN\2228698|rats_30|with_17|._63 (l_prep) to_8\IN\0|were_15 (l_pobj) groups_10\NNS\2137|NONE_0 (l_acl) based_11\VBN\0|two_11 (l_prep) on_12\IN\0|NONE_0 (l_pobj) presence_14\NN\13954253|NONE_0 (l_conj) absence_16\NN\14449405|the_16|or_3 (l_prep) of_17\IN\0|NONE_0 (l_pobj) lid_18\NNP\5313679|NONE_0
D016627_D010300 NONE 6-hydroxydopamine_21\CD\0|-_17 (r_compound) lesion_23\NN\14204950|NONE_0 (r_compound) rat_24\NN\2329401|the_42|unilaterally_38|of_10|treated_16 (r_compound) model_25\NN\5888929|NONE_0 (l_prep) of_26\IN\0|the_52|unilaterally_48|rat_10|treated_6 (l_pobj) pd_27\NNP\14625458|NONE_0
D007980_D010300 NONE dopa_2\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_4\VBN\1627355|lid_20 (r_amod) dyskinesia_5\NN\14084880|among_20|._137 (r_nsubj) is_9\VBZ\0|NONE_0 (l_prep) among_10\IN\0|dyskinesia_20|._117 (l_pobj) complications_13\NNS\1073995|NONE_0 (l_relcl) arise_15\VBP\2623529|the_29|motor_25 (l_prep) in_16\IN\13603305|that_11|after_37 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_nmod) disease_19\NN\14061805|(_8|pd_9|)_11
D007980_D010300 NONE dopa_2\NNP\14601829|l_2|-_1|-_4 (r_npadvmod) induced_4\VBN\1627355|lid_20 (r_amod) dyskinesia_5\NN\14084880|among_20|._137 (r_nsubj) is_9\VBZ\0|NONE_0 (l_prep) among_10\IN\0|dyskinesia_20|._117 (l_pobj) complications_13\NNS\1073995|NONE_0 (l_relcl) arise_15\VBP\2623529|the_29|motor_25 (l_prep) in_16\IN\13603305|that_11|after_37 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_nmod) pd_21\NNP\14625458|disease_9|(_1|)_2
D007980_D010300 NONE dopa_31\NNP\14601829|NONE_0 (r_pobj) with_28\IN\0|a_22|prolonged_20 (r_prep) treatment_27\NN\654885|NONE_0 (r_pobj) after_24\IN\0|that_48|in_37 (r_prep) arise_15\VBP\2623529|the_29|motor_25 (l_prep) in_16\IN\13603305|that_11|after_37 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_nmod) disease_19\NN\14061805|(_8|pd_9|)_11
D007980_D010300 NONE dopa_31\NNP\14601829|NONE_0 (r_pobj) with_28\IN\0|a_22|prolonged_20 (r_prep) treatment_27\NN\654885|NONE_0 (r_pobj) after_24\IN\0|that_48|in_37 (r_prep) arise_15\VBP\2623529|the_29|motor_25 (l_prep) in_16\IN\13603305|that_11|after_37 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_nmod) pd_21\NNP\14625458|disease_9|(_1|)_2
D007980_D010300 NONE dopa_34\NNP\14601829|the_158|occurring_146|,_4|using_22 (r_appos) changes_8\NNS\7283608|in_42|,_22|we_20|._255 (l_acl) occurring_9\VBG\0|the_12|,_142|dopa_146|using_168 (l_prep) at_10\IN\14622893|NONE_0 (l_pobj) level_13\NN\4916342|NONE_0 (l_acl) obtained_17\VBN\2210855|the_38|protein_34|in_20 (l_prep) from_18\IN\0|NONE_0 (l_pobj) model_25\NN\5888929|NONE_0 (l_prep) of_26\IN\0|the_52|unilaterally_48|rat_10|treated_6 (l_pobj) pd_27\NNP\14625458|NONE_0
11198499
C023754_D007022 CID tizanidine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_15|in_14 (r_prep) initiation_3\NN\7450842|NONE_0 (r_dobj) following_1\VBG\8180190|._132 (r_acl) hypotension_0\NN\14057371|NONE_0
C023754_D007022 CID tizanidine_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|the_13|for_35 (r_prep) addition_27\NN\3081021|NONE_0 (r_pobj) following_25\VBG\8180190|who_26|hypotension_12 (r_prep) developed_23\VBD\1753788|NONE_0 (l_dobj) hypotension_24\NN\14057371|who_14|following_12
D017706_D006973 NONE lisinopril_11\NN\2673637|NONE_0 (r_pobj) with_10\IN\0|chronically_20 (r_prep) treated_9\VBN\2376958|a_30|old_20|,_67 (r_acl) boy_7\NN\9624168|authors_30|control_88|._224 (r_dobj) present_2\VBP\28270|NONE_0 (l_advcl) control_20\VB\5190804|authors_118|boy_88|._136 (l_dobj) hypertension_21\NN\14057371|to_11
D000809_D009128 NONE angiotensin_14\NN\4522421|,_5 (r_appos) lisinopril_11\NN\2673637|NONE_0 (r_pobj) with_10\IN\0|chronically_20 (r_prep) treated_9\VBN\2376958|a_30|old_20|,_67 (r_acl) boy_7\NN\9624168|authors_30|control_88|._224 (r_dobj) present_2\VBP\28270|NONE_0 (l_advcl) control_20\VB\5190804|authors_118|boy_88|._136 (l_dobj) hypertension_21\NN\14057371|to_11 (l_relcl) developed_23\VBD\1753788|NONE_0 (l_prep) following_25\VBG\8180190|who_26|hypotension_12 (l_pobj) addition_27\NN\3081021|NONE_0 (l_prep) for_35\IN\0|the_48|of_35 (l_pobj) treatment_37\NN\654885|NONE_0 (l_prep) of_38\IN\0|the_14 (l_pobj) spasticity_39\NN\4770535|NONE_0
C023754_D006973 NONE tizanidine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_15|in_14 (r_prep) initiation_3\NN\7450842|NONE_0 (l_prep) in_6\IN\13603305|the_29|of_14 (l_pobj) patient_8\NN\9898892|NONE_0 (l_acl) treated_9\VBN\2376958|a_10 (l_prep) with_10\IN\0|NONE_0 (l_pobj) angiotensin_12\NN\4522421|NONE_0 (l_acl) converting_13\VBG\126264|an_15 (l_prep) for_16\IN\0|inhibitor_10 (l_pobj) hypertension_18\NN\14057371|NONE_0
C023754_D006973 NONE tizanidine_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|the_13|for_35 (r_prep) addition_27\NN\3081021|NONE_0 (r_pobj) following_25\VBG\8180190|who_26|hypotension_12 (r_prep) developed_23\VBD\1753788|NONE_0 (r_relcl) hypertension_21\NN\14057371|to_11
C023754_D006973 NONE tizanidine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_25|possible_21 (r_prep) interaction_2\NN\37396|should_60|be_67|in_75|prescribing_88|._167 (r_nsubjpass) kept_11\VBN\0|NONE_0 (l_advcl) prescribing_15\VBG\748282|interaction_88|should_28|be_21|in_13|._79 (l_xcomp) treat_18\VB\7570720|when_28|therapy_11 (l_dobj) hypertension_20\NN\14057371|to_16
D000809_D006973 NONE angiotensin_12\NN\4522421|NONE_0 (l_acl) converting_13\VBG\126264|an_15 (l_prep) for_16\IN\0|inhibitor_10 (l_pobj) hypertension_18\NN\14057371|NONE_0
D000809_D006973 NONE angiotensin_14\NN\4522421|,_5 (r_appos) lisinopril_11\NN\2673637|NONE_0 (r_pobj) with_10\IN\0|chronically_20 (r_prep) treated_9\VBN\2376958|a_30|old_20|,_67 (r_acl) boy_7\NN\9624168|authors_30|control_88|._224 (r_dobj) present_2\VBP\28270|NONE_0 (l_advcl) control_20\VB\5190804|authors_118|boy_88|._136 (l_dobj) hypertension_21\NN\14057371|to_11
C023754_D009128 NONE tizanidine_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|the_13|for_35 (r_prep) addition_27\NN\3081021|NONE_0 (l_prep) for_35\IN\0|the_48|of_35 (l_pobj) treatment_37\NN\654885|NONE_0 (l_prep) of_38\IN\0|the_14 (l_pobj) spasticity_39\NN\4770535|NONE_0
C023754_D009128 NONE tizanidine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_25|possible_21 (r_prep) interaction_2\NN\37396|should_60|be_67|in_75|prescribing_88|._167 (r_nsubjpass) kept_11\VBN\0|NONE_0 (l_advcl) prescribing_15\VBG\748282|interaction_88|should_28|be_21|in_13|._79 (l_xcomp) treat_18\VB\7570720|when_28|therapy_11 (l_dobj) hypertension_20\NN\14057371|to_16 (l_conj) spasticity_22\NN\4770535|either_23|or_3|in_11
D017706_D009128 NONE lisinopril_11\NN\2673637|NONE_0 (r_pobj) with_10\IN\0|chronically_20 (r_prep) treated_9\VBN\2376958|a_30|old_20|,_67 (r_acl) boy_7\NN\9624168|authors_30|control_88|._224 (r_dobj) present_2\VBP\28270|NONE_0 (l_advcl) control_20\VB\5190804|authors_118|boy_88|._136 (l_dobj) hypertension_21\NN\14057371|to_11 (l_relcl) developed_23\VBD\1753788|NONE_0 (l_prep) following_25\VBG\8180190|who_26|hypotension_12 (l_pobj) addition_27\NN\3081021|NONE_0 (l_prep) for_35\IN\0|the_48|of_35 (l_pobj) treatment_37\NN\654885|NONE_0 (l_prep) of_38\IN\0|the_14 (l_pobj) spasticity_39\NN\4770535|NONE_0
D000809_D007022 NONE angiotensin_12\NN\4522421|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treated_9\VBN\2376958|a_10 (r_acl) patient_8\NN\9898892|NONE_0 (r_pobj) in_6\IN\13603305|the_29|of_14 (r_prep) initiation_3\NN\7450842|NONE_0 (r_dobj) following_1\VBG\8180190|._132 (r_acl) hypotension_0\NN\14057371|NONE_0
D000809_D007022 NONE angiotensin_4\NN\4522421|NONE_0 (r_pobj) with_3\IN\0|adults_27|chronically_20 (r_prep) treated_2\VBN\2376958|may_54|ability_73|._162 (r_csubj) have_9\VB\7846|NONE_0 (l_dobj) ability_12\NN\4723816|treated_73|may_19|._89 (l_acl) respond_14\VB\2367363|a_21|limited_19 (l_prep) to_15\IN\0|to_11|blocked_63 (l_pobj) hypotension_16\NN\14057371|NONE_0
D000809_D007022 NONE angiotensin_14\NN\4522421|,_5 (r_appos) lisinopril_11\NN\2673637|NONE_0 (r_pobj) with_10\IN\0|chronically_20 (r_prep) treated_9\VBN\2376958|a_30|old_20|,_67 (r_acl) boy_7\NN\9624168|authors_30|control_88|._224 (r_dobj) present_2\VBP\28270|NONE_0 (l_advcl) control_20\VB\5190804|authors_118|boy_88|._136 (l_dobj) hypertension_21\NN\14057371|to_11 (l_relcl) developed_23\VBD\1753788|NONE_0 (l_dobj) hypotension_24\NN\14057371|who_14|following_12
D017706_D007022 CID lisinopril_11\NN\2673637|NONE_0 (r_pobj) with_10\IN\0|chronically_20 (r_prep) treated_9\VBN\2376958|a_30|old_20|,_67 (r_acl) boy_7\NN\9624168|authors_30|control_88|._224 (r_dobj) present_2\VBP\28270|NONE_0 (l_advcl) control_20\VB\5190804|authors_118|boy_88|._136 (l_dobj) hypertension_21\NN\14057371|to_11 (l_relcl) developed_23\VBD\1753788|NONE_0 (l_dobj) hypotension_24\NN\14057371|who_14|following_12
8423889
D000928_D009069 NONE antidepressant_20\JJ\3740161|the_4 (r_amod) fluoxetine_21\NN\4169152|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|NONE_0 (r_pobj) after_16\IN\0|the_94|increased_90|of_73|in_53 (r_prep) amount_4\NN\13329641|we_24|._127 (l_prep) of_5\IN\0|the_21|increased_17|in_20|after_73 (l_pobj) disability_7\NN\14547369|NONE_0
D004298_D010300 NONE dopamine_6\NN\14807737|-_8 (r_npadvmod) antagonistic_8\JJ\0|a_31|relevant_18|of_22|in_36 (r_amod) capacity_9\NN\5202497|NONE_0 (l_prep) in_12\IN\13603305|a_67|relevant_54|antagonistic_36|of_14 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_compound) disease_15\NN\14061805|parkinson_12
D005473_D009069 CID fluoxetine_5\NN\4169152|NONE_0 (r_amod) medication_6\NN\3247620|NONE_0 (r_pobj) after_4\IN\0|of_24|._27 (r_prep) increase_0\NNP\13576355|NONE_0 (l_prep) of_1\IN\0|after_24|._51 (l_pobj) disability_3\NN\14547369|NONE_0
D005473_D009069 CID fluoxetine_21\NN\4169152|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|NONE_0 (r_pobj) after_16\IN\0|the_94|increased_90|of_73|in_53 (r_prep) amount_4\NN\13329641|we_24|._127 (l_prep) of_5\IN\0|the_21|increased_17|in_20|after_73 (l_pobj) disability_7\NN\14547369|NONE_0
D005473_D010300 NONE fluoxetine_21\NN\4169152|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|NONE_0 (r_pobj) after_16\IN\0|the_94|increased_90|of_73|in_53 (r_prep) amount_4\NN\13329641|we_24|._127 (l_prep) in_8\IN\13603305|the_41|increased_37|of_20|after_53 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|four_14 (l_pobj) disease_15\NN\14061805|NONE_0
D005473_D010300 NONE fluoxetine_11\NN\4169152|NONE_0 (r_pobj) of_10\IN\0|a_53|relevant_40|antagonistic_22|in_14 (r_prep) capacity_9\NN\5202497|NONE_0 (l_prep) in_12\IN\13603305|a_67|relevant_54|antagonistic_36|of_14 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_compound) disease_15\NN\14061805|parkinson_12
D000928_D010300 NONE antidepressant_20\JJ\3740161|the_4 (r_amod) fluoxetine_21\NN\4169152|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|NONE_0 (r_pobj) after_16\IN\0|the_94|increased_90|of_73|in_53 (r_prep) amount_4\NN\13329641|we_24|._127 (l_prep) in_8\IN\13603305|the_41|increased_37|of_20|after_53 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|four_14 (l_pobj) disease_15\NN\14061805|NONE_0
1420741
D016572_D003424 NONE cyclosporin_16\NN\0|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) similar_14\JJ\0|immunosuppressive_29 (r_amod) properties_13\NNS\32613|NONE_0 (r_pobj) with_11\IN\0|an_14 (r_prep) antibiotic_10\NN\2716205|of_41|:_5|._67 (r_appos) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|:_36|antibiotic_41|._108 (l_pobj) disease_4\NN\14061805|NONE_0
D005672_D015212 NONE acid_13\NN\14818238|NONE_0 (r_pobj) of_11\IN\0|the_8|at_16 (r_prep) use_10\NN\407535|NONE_0 (l_prep) at_14\IN\14622893|the_24|of_16 (l_pobj) level_17\NN\4916342|NONE_0 (l_prep) in_18\IN\13603305|the_19|cytokine_15 (l_pobj) disease_21\NN\14061805|NONE_0
D005672_D003424 NONE acid_7\NN\14818238|NONE_0 (r_pobj) with_5\IN\0|crohn_16 (r_prep) disease_4\NN\14061805|NONE_0
D005672_D003424 NONE acid_28\NN\14818238|fusidic_8|in_15 (r_compound) treatment_29\NN\654885|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) tolerability_25\NN\0|the_25|and_4 (r_conj) pharmacodynamics_23\NNS\0|to_16 (r_dobj) estimate_21\VB\5802185|because_111|,_34|study_24|was_18|._118 (r_advcl) undertaken_19\VBN\1641914|NONE_0 (l_prep) because_0\IN\0|,_77|study_87|was_93|estimate_111|._229 (l_pobj) need_3\NN\13920835|of_7 (l_prep) for_4\IN\0|the_9 (l_pobj) development_6\NN\248977|NONE_0 (l_prep) of_7\IN\0|the_16 (l_pobj) treatments_9\NNS\654885|NONE_0 (l_prep) for_10\IN\0|new_15 (l_pobj) disease_13\NN\14061805|NONE_0
D005672_D003424 NONE acid_9\NN\14818238|that_13|fusidic_8|may_5|of_12|in_23 (r_nsubj) be_11\VB\14625458|results_58|._111 (l_prep) in_14\IN\13603305|that_36|fusidic_31|acid_23|may_18|of_11 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_compound) disease_20\NN\14061805|selected_32|chronic_23|active_15|crohn_8|is_48
18703024
D006220_D002375 CID haloperidol_3\NN\3713736|-_11 (r_npadvmod) induced_5\VBN\1627355|or_18|locomotion_36 (r_amod) catalepsy_6\NN\14023236|NONE_0
D016291_D002375 NONE mk-801-induced_8\JJ\0|NONE_0 (r_compound) locomotion_9\NN\4773351|induced_36|or_18 (r_conj) catalepsy_6\NN\14023236|NONE_0
11679859
D011346_D017109 CID prochlorperazine_3\NN\2719750|NONE_0 (r_pobj) of_2\IN\0|intravenous_27 (r_prep) administration_1\NN\1133281|does_79|not_84|incidence_99|._166 (r_nsubj) affect_12\VB\26192|NONE_0 (l_dobj) incidence_14\NN\13821570|administration_99|does_20|not_15|._67 (l_prep) of_15\IN\0|the_14 (l_pobj) akathisia_16\NN\0|NONE_0
D011346_D017109 CID prochlorperazine_12\NN\2719750|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) akathisia_7\NN\0|NONE_0
D011346_D017109 CID prochlorperazine_10\NN\2719750|when_5|was_17|by_34 (r_nsubjpass) administered_12\VBN\2436349|a_72|%_68|in_56 (r_advcl) reduction_3\NN\351485|was_157|not_161|._173 (l_prep) in_4\IN\13603305|a_16|%_12|administered_56 (l_pobj) incidence_6\NN\13821570|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) akathisia_8\NN\0|NONE_0
D011346_D014839 NONE prochlorperazine_8\NN\2719750|NONE_0 (l_prep) for_9\IN\0|NONE_0 (l_pobj) headache_10\NN\5829480|NONE_0 (l_conj) nausea_12\NN\14299637|,_2 (l_conj) vomiting_15\NN\116687|,_5|or_3
D011346_D009325 NONE prochlorperazine_8\NN\2719750|NONE_0 (l_prep) for_9\IN\0|NONE_0 (l_pobj) headache_10\NN\5829480|NONE_0 (l_conj) nausea_12\NN\14299637|,_2
D011346_D009325 NONE prochlorperazine_3\NN\2719750|NONE_0 (r_pobj) of_2\IN\0|the_13|in_20 (r_prep) efficacy_1\NN\5199286|likewise_69|did_78|not_82|affected_99|,_137|made_187|._191 (l_prep) in_4\IN\13603305|the_33|of_20 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) headache_8\NN\5829480|NONE_0 (l_conj) nausea_10\NN\14299637|and_4
D011346_D006261 NONE prochlorperazine_8\NN\2719750|NONE_0 (l_prep) for_9\IN\0|NONE_0 (l_pobj) headache_10\NN\5829480|NONE_0
D011346_D006261 NONE prochlorperazine_3\NN\2719750|NONE_0 (r_pobj) of_2\IN\0|the_13|in_20 (r_prep) efficacy_1\NN\5199286|likewise_69|did_78|not_82|affected_99|,_137|made_187|._191 (l_prep) in_4\IN\13603305|the_33|of_20 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) headache_8\NN\5829480|NONE_0
3828020
D010665_D002544 CID phenylpropanolamine_8\NN\2682038|NONE_0 (r_pobj) of_7\IN\0|a_19|single_17|oral_10 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) with_2\IN\0|cerebral_20|._46 (r_prep) infarction_1\NN\14204950|NONE_0
D010665_D002544 CID ppa_20\NNP\0|NONE_0 (r_pobj) of_19\IN\0|a_19|single_17|oral_10 (r_prep) dose_18\NN\3740161|NONE_0 (r_dobj) taking_14\VBG\37396|NONE_0 (r_pcomp) after_13\IN\0|who_35|infarction_11 (r_prep) suffered_9\VBD\2110220|a_18|young_16 (l_dobj) infarction_12\NN\14204950|who_24|after_11
2396046
D010634_D006528 NONE phenobarbital_35\NN\2792049|NONE_0 (r_dobj) containing_34\VBG\2632940|the_14|same_10 (r_acl) diet_33\NN\7560652|NONE_0 (r_dobj) fed_30\VBD\10373801|nodules_182|diet_92|,_88|developed_22|._42 (r_conj) fed_10\VBD\10373801|NONE_0 (l_nsubj) nodules_3\NNS\5264913|diet_90|,_94|developed_160|fed_182|._224 (l_conj) carcinomas_6\NNS\14239918|no_51|hepatic_48|preneoplastic_40|or_18|developed_11
D010634_D006528 NONE phenobarbital_35\NN\2792049|NONE_0 (r_dobj) containing_34\VBG\2632940|the_14|same_10 (r_acl) diet_33\NN\7560652|NONE_0 (r_dobj) fed_30\VBD\10373801|nodules_182|diet_92|,_88|developed_22|._42 (r_conj) fed_10\VBD\10373801|NONE_0 (l_advcl) developed_26\VBN\1753788|nodules_160|diet_70|,_66|fed_22|._64 (l_nsubj) nodule_21\NN\5264913|while_24|in_50 (l_conj) carcinoma_25\NN\14239918|one_48|preneoplastic_44|and_23
D010634_D006528 NONE phenobarbital_39\RB\2792049|-_13 (r_npadvmod) containing_41\VBG\2632940|the_18|devoid_19 (r_amod) diet_45\NN\7560652|NONE_0 (r_dobj) fed_37\VBD\10373801|incidence_167|%_93|,_84|respectively_82|,_70|fed_60|._52 (r_conj) was_9\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|%_74|,_83|respectively_85|,_97|fed_107|fed_167|._219 (l_prep) of_2\IN\0|the_14 (l_conj) of_6\IN\0|nodules_12|and_4 (l_pobj) carcinomas_8\NNS\14239918|NONE_0
D002794_D006528 CID choline_13\NN\15090742|-_7 (r_npadvmod) supplemented_15\VBN\182406|the_18|plain_14 (r_amod) diet_16\NN\7560652|nodules_90|,_4|developed_70|fed_92|._134 (r_dobj) fed_10\VBD\10373801|NONE_0 (l_nsubj) nodules_3\NNS\5264913|diet_90|,_94|developed_160|fed_182|._224 (l_conj) carcinomas_6\NNS\14239918|no_51|hepatic_48|preneoplastic_40|or_18|developed_11
D002794_D006528 CID choline_13\NN\15090742|-_7 (r_npadvmod) supplemented_15\VBN\182406|the_18|plain_14 (r_amod) diet_16\NN\7560652|nodules_90|,_4|developed_70|fed_92|._134 (r_dobj) fed_10\VBD\10373801|NONE_0 (l_advcl) developed_26\VBN\1753788|nodules_160|diet_70|,_66|fed_22|._64 (l_nsubj) nodule_21\NN\5264913|while_24|in_50 (l_conj) carcinoma_25\NN\14239918|one_48|preneoplastic_44|and_23
D002794_D006528 CID choline_23\NN\15090742|-_7 (r_npadvmod) devoid_25\JJ\0|the_18|plain_14 (r_amod) diet_26\NN\7560652|in_37|rats_34|,_4|and_6|%_12|,_21|in_23 (r_dobj) fed_20\VBD\10373801|incidence_107|%_33|,_24|respectively_22|,_10|fed_60|._112 (r_conj) was_9\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|%_74|,_83|respectively_85|,_97|fed_107|fed_167|._219 (l_prep) of_2\IN\0|the_14 (l_conj) of_6\IN\0|nodules_12|and_4 (l_pobj) carcinomas_8\NNS\14239918|NONE_0
D002794_D006528 CID choline_42\NN\15090742|-_7 (r_npadvmod) devoid_44\JJ\0|the_37|containing_19 (r_amod) diet_45\NN\7560652|NONE_0 (r_dobj) fed_37\VBD\10373801|incidence_167|%_93|,_84|respectively_82|,_70|fed_60|._52 (r_conj) was_9\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|%_74|,_83|respectively_85|,_97|fed_107|fed_167|._219 (l_prep) of_2\IN\0|the_14 (l_conj) of_6\IN\0|nodules_12|and_4 (l_pobj) carcinomas_8\NNS\14239918|NONE_0
9698967
D008619_D019954 NONE mepivacaine_43\NN\0|850_12 (r_amod) mg_45\NN\13717155|containing_3 (r_pobj) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0 (l_conj) agitation_11\NN\14373582|atrial_21|,_2 (l_conj) shouts_14\NNS\7109847|,_19
D004837_D004387 NONE adrenaline_47\NN\14807929|NONE_0 (r_dobj) containing_46\VBG\2632940|mg_3 (r_pcomp) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (l_prep) for_51\IN\0|asa_161|classification_157|ii_136|,_134|male_105|min_96|,_2 (l_pobj) correction_52\NN\248977|NONE_0 (l_prep) of_53\IN\0|NONE_0 (l_pobj) contracture_56\NN\369802|NONE_0
D008619_D004387 NONE mepivacaine_43\NN\0|850_12 (r_amod) mg_45\NN\13717155|containing_3 (r_pobj) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (l_prep) for_51\IN\0|asa_161|classification_157|ii_136|,_134|male_105|min_96|,_2 (l_pobj) correction_52\NN\248977|NONE_0 (l_prep) of_53\IN\0|NONE_0 (l_pobj) contracture_56\NN\369802|NONE_0
D008619_D011595 NONE mepivacaine_43\NN\0|850_12 (r_amod) mg_45\NN\13717155|containing_3 (r_pobj) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0 (l_conj) agitation_11\NN\14373582|atrial_21|,_2
D008619_D006973 CID mepivacaine_43\NN\0|850_12 (r_amod) mg_45\NN\13717155|containing_3 (r_pobj) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_prep) in_2\IN\13603305|an_12|,_17|accompanied_19|,_115 (l_pobj) pressure_4\NN\11419404|NONE_0
D004837_D014474 NONE adrenaline_47\NN\14807929|NONE_0 (r_dobj) containing_46\VBG\2632940|mg_3 (r_pcomp) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0 (l_conj) agitation_11\NN\14373582|atrial_21|,_2 (l_conj) shouts_14\NNS\7109847|,_19 (l_prep) of_17\IN\0|incomprehensible_33|and_9|loss_5 (l_pobj) consciousness_18\NN\5669934|NONE_0
D004837_D019954 NONE adrenaline_47\NN\14807929|NONE_0 (r_dobj) containing_46\VBG\2632940|mg_3 (r_pcomp) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0 (l_conj) agitation_11\NN\14373582|atrial_21|,_2 (l_conj) shouts_14\NNS\7109847|,_19
D008619_D001281 CID mepivacaine_43\NN\0|850_12 (r_amod) mg_45\NN\13717155|containing_3 (r_pobj) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0
D008619_D014474 NONE mepivacaine_43\NN\0|850_12 (r_amod) mg_45\NN\13717155|containing_3 (r_pobj) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0 (l_conj) agitation_11\NN\14373582|atrial_21|,_2 (l_conj) shouts_14\NNS\7109847|,_19 (l_prep) of_17\IN\0|incomprehensible_33|and_9|loss_5 (l_pobj) consciousness_18\NN\5669934|NONE_0
D004837_D006973 CID adrenaline_47\NN\14807929|NONE_0 (r_dobj) containing_46\VBG\2632940|mg_3 (r_pcomp) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_prep) in_2\IN\13603305|an_12|,_17|accompanied_19|,_115 (l_pobj) pressure_4\NN\11419404|NONE_0
D004837_D011595 NONE adrenaline_47\NN\14807929|NONE_0 (r_dobj) containing_46\VBG\2632940|mg_3 (r_pcomp) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0 (l_conj) agitation_11\NN\14373582|atrial_21|,_2
D004837_D001281 CID adrenaline_47\NN\14807929|NONE_0 (r_dobj) containing_46\VBG\2632940|mg_3 (r_pcomp) with_42\IN\0|axillary_15 (r_prep) block_41\NN\21939|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) performance_38\NN\6619065|NONE_0 (r_pobj) after_37\IN\0|12_7 (r_prep) min_36\NN\15154774|asa_65|classification_61|ii_40|,_38|male_9|,_94|for_96 (r_appos) group_28\NN\2137|increase_173|was_47|in_34|,_21|._183 (r_appos) observed_21\VBN\2163746|NONE_0 (l_nsubjpass) increase_1\NN\13576355|was_126|in_139|,_152|group_173|._356 (l_acl) accompanied_6\VBN\0|an_31|in_19|,_2|,_96 (l_agent) by_7\IN\0|NONE_0 (l_pobj) fibrillation_9\NN\14361664|NONE_0
1616457
D010424_D000647 CID pentobarbital_7\NN\2792049|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) caused_5\VBN\1617192|NONE_0 (r_acl) amnesia_4\NN\5669934|NONE_0
D010424_D000647 CID pentobarbital_15\NN\2792049|(_14|mg/kg_18|,_23 (r_nmod) ip_20\NNP\5999797|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) produced_13\VBN\1617192|NONE_0 (r_acl) amnesia_12\NN\5669934|NONE_0
12589964
D004317_D009202 CID doxorubicin_14\NN\2716866|-_11 (r_npadvmod) induced_16\VBN\1627355|cardiomyopathy_8 (r_amod) rats_18\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|myocardial_18 (r_prep) damage_12\NN\7296428|NONE_0
D004317_D009202 CID doxorubicin_14\NN\2716866|-_11 (r_npadvmod) induced_16\VBN\1627355|cardiomyopathy_8 (r_amod) rats_18\NNS\2329401|NONE_0 (l_amod) cardiomyopathy_17\NN\14103288|induced_8
D004317_D009202 CID doxorubicin_20\NN\2716866|NONE_0 (r_pobj) of_19\IN\0|a_12|rat_10|cardiomyopathy_29 (r_prep) model_18\NN\5888929|NONE_0 (r_pobj) in_15\IN\13603305|myocardial_18 (r_prep) damage_14\NN\7296428|NONE_0
D004317_D009202 CID doxorubicin_20\NN\2716866|NONE_0 (r_pobj) of_19\IN\0|a_12|rat_10|cardiomyopathy_29 (r_prep) model_18\NN\5888929|NONE_0 (l_appos) cardiomyopathy_23\NN\14103288|a_41|rat_39|of_29
D004317_D009202 CID dox)-induced_22\VBN\0|(_1 (r_amod) cardiomyopathy_23\NN\14103288|a_41|rat_39|of_29 (r_appos) model_18\NN\5888929|NONE_0 (r_pobj) in_15\IN\13603305|myocardial_18 (r_prep) damage_14\NN\7296428|NONE_0
D004317_D009202 CID dox)-induced_22\VBN\0|(_1 (r_amod) cardiomyopathy_23\NN\14103288|a_41|rat_39|of_29
D004317_D009202 CID dox_6\NNP\0|NONE_0 (r_pobj) after_5\IN\0|of_19 (r_prep) markers_1\NNS\21939|NONE_0 (r_pobj) among_0\IN\0|,_50|ctnt_52|ability_77|._177 (r_prep) showed_11\VBD\2137132|NONE_0 (l_dobj) ability_14\NN\4723816|among_77|,_27|ctnt_25|._100 (l_acl) detect_16\VB\2163746|the_24|greatest_20 (l_dobj) damage_18\NN\7296428|to_21
D004317_D066126 NONE dox_13\NNP\0|NONE_0 (r_pobj) after_12\IN\0|the_28|of_17|,_9 (r_prep) amount_7\NN\13329641|NONE_0 (r_pobj) between_5\IN\0|a_14 (r_prep) discrepancy_4\NN\4748836|although_21|there_12|due_68 (r_attr) was_2\VBD\0|,_155|it_157|likely_163|._411 (r_advcl) is_33\VBZ\0|NONE_0 (l_acomp) likely_34\JJ\0|was_163|,_8|it_6|._248 (l_ccomp) indicates_41\VBZ\952524|NONE_0 (l_conj) be_55\VB\14625458|that_117|ctnt_112|after_99|dox_93|damage_74|induced_29|and_21 (l_attr) marker_58\NN\21939|that_29|ctnt_24|should_19 (l_prep) for_59\IN\0|a_16|useful_14 (l_pobj) prediction_61\NN\5772356|NONE_0 (l_prep) of_62\IN\0|the_15 (l_pobj) cardiotoxicity_65\NN\0|NONE_0
D004317_D066126 NONE dox_40\NNP\0|that_24|ctnt_19|after_6|damage_19|induced_64|and_72|be_93 (r_nsubj) indicates_41\VBZ\952524|NONE_0 (l_conj) be_55\VB\14625458|that_117|ctnt_112|after_99|dox_93|damage_74|induced_29|and_21 (l_attr) marker_58\NN\21939|that_29|ctnt_24|should_19 (l_prep) for_59\IN\0|a_16|useful_14 (l_pobj) prediction_61\NN\5772356|NONE_0 (l_prep) of_62\IN\0|the_15 (l_pobj) cardiotoxicity_65\NN\0|NONE_0
D004317_D005355 NONE dox_8\NNP\0|NONE_0 (r_pobj) given_7\VBN\5892096|all_9 (r_prep) rats_6\NNS\2329401|NONE_0 (r_pobj) from_4\IN\0|NONE_0 (r_prep) hearts_3\NNS\496167|NONE_0 (r_pobj) of_2\IN\0|histological_24 (r_prep) evaluation_1\NN\874067|degrees_73|._122 (r_nsubj) revealed_9\VBD\2137132|NONE_0 (l_dobj) degrees_12\NNS\4916342|evaluation_73|._49 (l_prep) of_13\IN\0|significant_27|slight_15 (l_pobj) fibrosis_17\NN\14204950|NONE_0
D004317_D064420 NONE dox_3\NNP\0|the_4 (r_compound) rats_4\NNS\2329401|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) eighteen_0\CD\13745420|prematurely_30|of_42|during_62|._86 (r_nsubj) died_5\VBD\146138|NONE_0 (l_prep) of_7\IN\0|eighteen_42|prematurely_12|during_20|._44 (l_pobj) toxicity_9\NN\13576101|NONE_0
D004317_D006331 NONE doxorubicin_20\NN\2716866|NONE_0 (r_pobj) of_19\IN\0|a_12|rat_10|cardiomyopathy_29 (r_prep) model_18\NN\5888929|NONE_0 (r_pobj) in_15\IN\13603305|myocardial_18 (r_prep) damage_14\NN\7296428|NONE_0 (r_pobj) of_12\IN\0|the_14 (r_prep) diagnosis_11\NN\152018|NONE_0 (r_pobj) for_9\IN\0|we_54|value_23|,_97|and_99|examined_106 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) examined_27\VBD\0|we_160|value_129|for_106|,_9|and_7 (l_dobj) relationship_29\NN\31921|we_16|._157 (l_prep) with_35\IN\0|the_46|between_29 (l_pobj) development_37\NN\248977|NONE_0 (l_prep) of_38\IN\0|the_16 (l_pobj) disorders_40\NNS\14034177|NONE_0
D004317_D006331 NONE dox)-induced_22\VBN\0|(_1 (r_amod) cardiomyopathy_23\NN\14103288|a_41|rat_39|of_29 (r_appos) model_18\NN\5888929|NONE_0 (r_pobj) in_15\IN\13603305|myocardial_18 (r_prep) damage_14\NN\7296428|NONE_0 (r_pobj) of_12\IN\0|the_14 (r_prep) diagnosis_11\NN\152018|NONE_0 (r_pobj) for_9\IN\0|we_54|value_23|,_97|and_99|examined_106 (r_prep) investigated_1\VBD\644583|NONE_0 (l_conj) examined_27\VBD\0|we_160|value_129|for_106|,_9|and_7 (l_dobj) relationship_29\NN\31921|we_16|._157 (l_prep) with_35\IN\0|the_46|between_29 (l_pobj) development_37\NN\248977|NONE_0 (l_prep) of_38\IN\0|the_16 (l_pobj) disorders_40\NNS\14034177|NONE_0
D004317_D017202 NONE dox_6\NNP\0|NONE_0 (r_pobj) after_5\IN\0|of_19 (r_prep) markers_1\NNS\21939|NONE_0 (l_prep) of_2\IN\0|after_19 (l_pobj) injury_4\NN\14052046|NONE_0
11379838
D000928_D001714 CID antidepressant_0\NNP\3740161|-_14 (r_npadvmod) induced_2\VBN\1627355|in_14|:_33|identification_35|._65 (r_amod) mania_3\NN\9180259|NONE_0
D000928_D001714 CID antidepressant_0\NNP\3740161|-_14 (r_npadvmod) induced_2\VBN\1627355|in_14|:_33|identification_35|._65 (r_amod) mania_3\NN\9180259|NONE_0 (l_prep) in_4\IN\13603305|induced_14|:_19|identification_21|._51 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_amod) bipolar_5\JJ\0|NONE_0
D000928_D001714 CID antidepressants_10\NNS\3740161|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|NONE_0 (r_acl) mania_7\NN\9180259|NONE_0
D000928_D001714 CID antidepressants_10\NNS\3740161|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|NONE_0 (r_acl) mania_7\NN\9180259|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) switching_5\VBG\191142|NONE_0 (r_pcomp) of_4\IN\0|possible_15 (r_prep) risks_3\NNS\14541044|NONE_0 (r_pobj) about_1\IN\0|NONE_0 (r_prep) concerns_0\NNS\5682950|interfere_96|._184 (r_nsubj) continue_11\VBP\2367363|NONE_0 (l_xcomp) interfere_13\VB\2451370|concerns_96|._88 (l_prep) with_14\IN\0|to_13 (l_pobj) establishment_16\NN\235435|NONE_0 (l_prep) of_17\IN\0|the_18 (l_pobj) paradigm_21\NN\13803782|NONE_0 (l_prep) for_22\IN\0|an_30|optimal_27|treatment_19 (l_pobj) depression_24\NN\14373582|NONE_0
D000928_D001714 CID antidepressant_43\NN\3740161|NONE_0 (r_amod) therapy_44\NN\657604|NONE_0 (r_pobj) of_42\IN\0|NONE_0 (r_prep) type_41\NN\5839024|previous_25|manic_16|,_2|used_31|inhibitors_141|assessed_258 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2
D000928_D001714 CID antidepressant_43\NN\3740161|NONE_0 (r_amod) therapy_44\NN\657604|NONE_0 (r_pobj) of_42\IN\0|NONE_0 (r_prep) type_41\NN\5839024|previous_25|manic_16|,_2|used_31|inhibitors_141|assessed_258 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2 (l_conj) hypomanic_6\JJ\0|or_3
D000928_D001714 CID antidepressant_43\NN\3740161|NONE_0 (r_amod) therapy_44\NN\657604|NONE_0 (r_pobj) of_42\IN\0|NONE_0 (r_prep) type_41\NN\5839024|previous_25|manic_16|,_2|used_31|inhibitors_141|assessed_258 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16
D000928_D001714 CID antidepressant_43\NN\3740161|NONE_0 (r_amod) therapy_44\NN\657604|NONE_0 (r_pobj) of_42\IN\0|NONE_0 (r_prep) type_41\NN\5839024|previous_25|manic_16|,_2|used_31|inhibitors_141|assessed_258 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16 (l_prep) vs._30\IN\0|NONE_0 (l_pobj) ii_32\NNP\13741022|NONE_0
D000928_D001714 CID antidepressant_43\NN\3740161|NONE_0 (r_amod) therapy_44\NN\657604|NONE_0 (r_pobj) of_42\IN\0|NONE_0 (r_prep) type_41\NN\5839024|previous_25|manic_16|,_2|used_31|inhibitors_141|assessed_258 (r_appos) episodes_39\NNS\7283608|NONE_0 (l_amod) manic_38\JJ\0|previous_9|,_14|type_16|used_47|inhibitors_157|assessed_274
D000928_D001714 CID antidepressant_50\NN\3740161|NONE_0 (r_amod) drugs_51\NNS\14778436|NONE_0 (r_pobj) vs._49\IN\0|electroconvulsive_26|and_25 (r_prep) therapy_48\NN\657604|,_36 (r_dobj) used_45\VBN\0|previous_56|manic_47|,_33|type_31|inhibitors_110|assessed_227 (r_acl) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2
D000928_D001714 CID antidepressant_50\NN\3740161|NONE_0 (r_amod) drugs_51\NNS\14778436|NONE_0 (r_pobj) vs._49\IN\0|electroconvulsive_26|and_25 (r_prep) therapy_48\NN\657604|,_36 (r_dobj) used_45\VBN\0|previous_56|manic_47|,_33|type_31|inhibitors_110|assessed_227 (r_acl) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2 (l_conj) hypomanic_6\JJ\0|or_3
D000928_D001714 CID antidepressant_50\NN\3740161|NONE_0 (r_amod) drugs_51\NNS\14778436|NONE_0 (r_pobj) vs._49\IN\0|electroconvulsive_26|and_25 (r_prep) therapy_48\NN\657604|,_36 (r_dobj) used_45\VBN\0|previous_56|manic_47|,_33|type_31|inhibitors_110|assessed_227 (r_acl) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16
D000928_D001714 CID antidepressant_50\NN\3740161|NONE_0 (r_amod) drugs_51\NNS\14778436|NONE_0 (r_pobj) vs._49\IN\0|electroconvulsive_26|and_25 (r_prep) therapy_48\NN\657604|,_36 (r_dobj) used_45\VBN\0|previous_56|manic_47|,_33|type_31|inhibitors_110|assessed_227 (r_acl) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16 (l_prep) vs._30\IN\0|NONE_0 (l_pobj) ii_32\NNP\13741022|NONE_0
D000928_D001714 CID antidepressant_50\NN\3740161|NONE_0 (r_amod) drugs_51\NNS\14778436|NONE_0 (r_pobj) vs._49\IN\0|electroconvulsive_26|and_25 (r_prep) therapy_48\NN\657604|,_36 (r_dobj) used_45\VBN\0|previous_56|manic_47|,_33|type_31|inhibitors_110|assessed_227 (r_acl) episodes_39\NNS\7283608|NONE_0 (l_amod) manic_38\JJ\0|previous_9|,_14|type_16|used_47|inhibitors_157|assessed_274
D008094_D001714 NONE lithium_73\NN\14625458|mood_18|(_1|)_27 (r_appos) stabilizers_71\NNS\14806838|NONE_0 (r_pobj) of_69\IN\0|NONE_0 (r_prep) type_68\NN\5839024|and_4|,_54|and_56|temperament_60 (r_conj) use_66\NN\407535|particularly_64|,_52|selective_50|serotonin_40|reuptake_30|ssris_9|,_2|,_94 (r_conj) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2
D008094_D001714 NONE lithium_73\NN\14625458|mood_18|(_1|)_27 (r_appos) stabilizers_71\NNS\14806838|NONE_0 (r_pobj) of_69\IN\0|NONE_0 (r_prep) type_68\NN\5839024|and_4|,_54|and_56|temperament_60 (r_conj) use_66\NN\407535|particularly_64|,_52|selective_50|serotonin_40|reuptake_30|ssris_9|,_2|,_94 (r_conj) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2 (l_conj) hypomanic_6\JJ\0|or_3
D008094_D001714 NONE lithium_73\NN\14625458|mood_18|(_1|)_27 (r_appos) stabilizers_71\NNS\14806838|NONE_0 (r_pobj) of_69\IN\0|NONE_0 (r_prep) type_68\NN\5839024|and_4|,_54|and_56|temperament_60 (r_conj) use_66\NN\407535|particularly_64|,_52|selective_50|serotonin_40|reuptake_30|ssris_9|,_2|,_94 (r_conj) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16
D008094_D001714 NONE lithium_73\NN\14625458|mood_18|(_1|)_27 (r_appos) stabilizers_71\NNS\14806838|NONE_0 (r_pobj) of_69\IN\0|NONE_0 (r_prep) type_68\NN\5839024|and_4|,_54|and_56|temperament_60 (r_conj) use_66\NN\407535|particularly_64|,_52|selective_50|serotonin_40|reuptake_30|ssris_9|,_2|,_94 (r_conj) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16 (l_prep) vs._30\IN\0|NONE_0 (l_pobj) ii_32\NNP\13741022|NONE_0
D008094_D001714 NONE lithium_73\NN\14625458|mood_18|(_1|)_27 (r_appos) stabilizers_71\NNS\14806838|NONE_0 (r_pobj) of_69\IN\0|NONE_0 (r_prep) type_68\NN\5839024|and_4|,_54|and_56|temperament_60 (r_conj) use_66\NN\407535|particularly_64|,_52|selective_50|serotonin_40|reuptake_30|ssris_9|,_2|,_94 (r_conj) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (l_amod) manic_38\JJ\0|previous_9|,_14|type_16|used_47|inhibitors_157|assessed_274
D017367_D001714 CID inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2
D017367_D001714 CID inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2 (l_conj) hypomanic_6\JJ\0|or_3
D017367_D001714 CID inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16
D017367_D001714 CID inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16 (l_prep) vs._30\IN\0|NONE_0 (l_pobj) ii_32\NNP\13741022|NONE_0
D017367_D001714 CID inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (l_amod) manic_38\JJ\0|previous_9|,_14|type_16|used_47|inhibitors_157|assessed_274
D017367_D001714 CID ssris_62\NNPS\2718811|particularly_55|,_43|selective_41|serotonin_31|reuptake_21|,_7|use_9|,_103 (r_appos) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2
D017367_D001714 CID ssris_62\NNPS\2718811|particularly_55|,_43|selective_41|serotonin_31|reuptake_21|,_7|use_9|,_103 (r_appos) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (r_pobj) with_10\IN\0|patients_67|were_14|._525 (r_prep) compared_9\VBN\644583|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|were_53|with_67|._592 (l_relcl) experienced_2\VBD\2108377|NONE_0 (l_dobj) switch_7\NN\3096960|who_37 (l_amod) manic_4\JJ\0|a_2 (l_conj) hypomanic_6\JJ\0|or_3
D017367_D001714 CID ssris_62\NNPS\2718811|particularly_55|,_43|selective_41|serotonin_31|reuptake_21|,_7|use_9|,_103 (r_appos) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16
D017367_D001714 CID ssris_62\NNPS\2718811|particularly_55|,_43|selective_41|serotonin_31|reuptake_21|,_7|use_9|,_103 (r_appos) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) number_35\NN\5107765|did_94|,_2 (r_appos) those_11\DT\0|NONE_0 (l_relcl) did_13\VBD\0|,_92|number_94 (l_prep) on_15\IN\0|who_12|not_4 (l_pobj) variables_17\NNS\2452|NONE_0 (l_prep) including_18\VBG\0|several_18 (l_pobj) age_19\NN\4916342|NONE_0 (l_conj) sex_21\NN\13440063|,_2 (l_conj) diagnosis_23\NN\152018|,_2 (l_appos) iv_27\NNP\13741022|NONE_0 (l_appos) i_29\PRP\14622893|(_16|dsm_15|-_12|bipolar_8|)_16 (l_prep) vs._30\IN\0|NONE_0 (l_pobj) ii_32\NNP\13741022|NONE_0
D017367_D001714 CID ssris_62\NNPS\2718811|particularly_55|,_43|selective_41|serotonin_31|reuptake_21|,_7|use_9|,_103 (r_appos) inhibitors_60\NNS\20090|previous_166|manic_157|,_143|type_141|used_110|assessed_117 (r_appos) episodes_39\NNS\7283608|NONE_0 (l_amod) manic_38\JJ\0|previous_9|,_14|type_16|used_47|inhibitors_157|assessed_274
D017367_D001714 CID ssris_29\NNS\2718811|NONE_0 (r_pobj) with_28\IN\0|NONE_0 (r_prep) treated_27\VBN\2376958|NONE_0 (r_acl) patients_26\NNS\9898892|NONE_0 (r_pobj) of_25\IN\0|the_13 (r_prep) subgroup_24\NN\31264|NONE_0 (r_pobj) of_22\IN\0|24_4 (r_prep) %_21\NN\0|)_55 (r_pobj) in_19\IN\13603305|(_14|(_5|and_4|;_61|%_65|episodes_93|,_101 (r_prep) experienced_42\JJ\2108377|all_102 (r_parataxis) patients_11\NNS\9898892|NONE_0 (r_pobj) of_9\IN\0|27_4|and_133|%_139 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|switches_40|episodes_178|._186 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) switches_0\NNS\3096960|in_40|episodes_218|._226 (l_prep) to_1\IN\0|NONE_0 (l_pobj) hypomania_2\NN\0|NONE_0
D017367_D001714 CID ssris_29\NNS\2718811|NONE_0 (r_pobj) with_28\IN\0|NONE_0 (r_prep) treated_27\VBN\2376958|NONE_0 (r_acl) patients_26\NNS\9898892|NONE_0 (r_pobj) of_25\IN\0|the_13 (r_prep) subgroup_24\NN\31264|NONE_0 (r_pobj) of_22\IN\0|24_4 (r_prep) %_21\NN\0|)_55 (r_pobj) in_19\IN\13603305|(_14|(_5|and_4|;_61|%_65|episodes_93|,_101 (r_prep) experienced_42\JJ\2108377|all_102 (r_parataxis) patients_11\NNS\9898892|NONE_0 (r_pobj) of_9\IN\0|27_4|and_133|%_139 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|switches_40|episodes_178|._186 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) switches_0\NNS\3096960|in_40|episodes_218|._226 (l_prep) to_1\IN\0|NONE_0 (l_pobj) hypomania_2\NN\0|NONE_0 (l_conj) mania_4\NN\9180259|or_3
D017367_D001714 CID ssris_29\NNS\2718811|NONE_0 (r_pobj) with_28\IN\0|NONE_0 (r_prep) treated_27\VBN\2376958|NONE_0 (r_acl) patients_26\NNS\9898892|NONE_0 (r_pobj) of_25\IN\0|the_13 (r_prep) subgroup_24\NN\31264|NONE_0 (r_pobj) of_22\IN\0|24_4 (r_prep) %_21\NN\0|)_55 (r_pobj) in_19\IN\13603305|(_14|(_5|and_4|;_61|%_65|episodes_93|,_101 (r_prep) experienced_42\JJ\2108377|all_102 (l_dobj) episodes_44\NNS\7283608|(_107|(_98|and_97|in_93|;_32|%_28|,_8 (l_amod) manic_43\JJ\0|NONE_0
D017367_D001714 CID ssris_29\NNS\2718811|NONE_0 (r_pobj) with_28\IN\0|NONE_0 (r_prep) treated_27\VBN\2376958|NONE_0 (r_acl) patients_26\NNS\9898892|NONE_0 (r_pobj) of_25\IN\0|the_13 (r_prep) subgroup_24\NN\31264|NONE_0 (r_pobj) of_22\IN\0|24_4 (r_prep) %_21\NN\0|)_55 (r_pobj) in_19\IN\13603305|(_14|(_5|and_4|;_61|%_65|episodes_93|,_101 (r_prep) experienced_42\JJ\2108377|all_102 (r_parataxis) patients_11\NNS\9898892|NONE_0 (r_pobj) of_9\IN\0|27_4|and_133|%_139 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|switches_40|episodes_178|._186 (r_prep) occurred_5\VBD\0|NONE_0 (l_npadvmod) episodes_56\NNS\7283608|switches_218|in_178|._8 (l_amod) hypomanic_55\JJ\0|experienced_12
7977601
11206082
D005680_D012640 NONE gaba(a_24\NNP\0|other_6|)_6|receptor_8 (r_nmod) ligands_27\NNS\20090|NONE_0 (r_pobj) of_22\IN\0|various_32|pharmacological_24 (r_prep) effects_21\NNS\13245626|NONE_0 (r_pobj) to_18\IN\0|differentially_25 (r_prep) sensitive_17\JJ\10488309|lines_105|also_20|._78 (r_acomp) are_14\VBP\13600404|NONE_0 (l_nsubj) lines_2\NNS\8426461|also_85|sensitive_105|._183 (l_acl) selected_3\VBN\697589|two_16|mouse_12 (l_prep) for_4\IN\0|NONE_0 (l_pobj) sensitivities_6\NNS\5651971|NONE_0 (l_prep) to_7\IN\0|differential_27 (l_pobj) seizures_13\NNS\14081375|NONE_0
D005680_D012640 NONE gaba(a_44\NNP\0|the_4|receptor_8|benzodiazepine_17 (r_nmod) site_48\NN\8673395|NONE_0 (r_pobj) of_42\IN\0|an_19|inverse_16 (r_prep) agonist_41\NN\0|methyl_59|beta_52|-_48|ccm_17|)_14|,_13 (r_appos) carboline-3-carboxylate_32\NN\0|NONE_0 (r_pobj) of_28\IN\0|a_24|single_22|i.p._15 (r_prep) injection_27\NN\320852|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) seizures_21\NNS\14081375|NONE_0
D001569_D012640 NONE benzodiazepine_47\NN\3771443|the_21|gaba(a_17|receptor_9 (r_amod) site_48\NN\8673395|NONE_0 (r_pobj) of_42\IN\0|an_19|inverse_16 (r_prep) agonist_41\NN\0|methyl_59|beta_52|-_48|ccm_17|)_14|,_13 (r_appos) carboline-3-carboxylate_32\NN\0|NONE_0 (r_pobj) of_28\IN\0|a_24|single_22|i.p._15 (r_prep) injection_27\NN\320852|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) seizures_21\NNS\14081375|NONE_0
C036150_D012640 CID carboline_10\NN\0|-_9 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) seizures_13\NNS\14081375|NONE_0
C036150_D012640 CID carboline-3-carboxylate_32\NN\0|NONE_0 (r_pobj) of_28\IN\0|a_24|single_22|i.p._15 (r_prep) injection_27\NN\320852|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) seizures_21\NNS\14081375|NONE_0
C036150_D012640 CID ccm_36\NNP\0|methyl_42|beta_35|-_31|)_3|,_4|agonist_17 (r_appos) carboline-3-carboxylate_32\NN\0|NONE_0 (r_pobj) of_28\IN\0|a_24|single_22|i.p._15 (r_prep) injection_27\NN\320852|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) seizures_21\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin-_25\NN\0|after_51 (r_amod) seizures_30\NNS\14081375|the_68|vigilance_64|,_48|and_46
D010433_D012640 CID pentylenetetrazol_27\NN\3740161|-_17 (r_npadvmod) induced_29\VBN\1627355|and_22 (r_conj) picrotoxin-_25\NN\0|after_51 (r_amod) seizures_30\NNS\14081375|the_68|vigilance_64|,_48|and_46
D003975_D012640 NONE diazepam_2\NN\2830852|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) anxiolysis_5\NN\0|we_29|with_11|,_43|sedation_62|._182 (r_dobj) measured_1\VBD\697589|NONE_0 (l_dobj) sedation_17\NN\14034177|we_91|anxiolysis_62|with_51|,_19|._120 (l_prep) by_18\IN\0|induced_17 (l_pcomp) recording_19\VBG\6791372|NONE_0 (l_dobj) states_22\NNS\8491826|NONE_0 (l_conj) seizures_30\NNS\14081375|the_68|vigilance_64|,_48|and_46
D003975_D012640 NONE diazepam_14\NN\2830852|-_8 (r_npadvmod) induced_16\VBN\1627355|by_17 (r_amod) sedation_17\NN\14034177|we_91|anxiolysis_62|with_51|,_19|._120 (l_prep) by_18\IN\0|induced_17 (l_pcomp) recording_19\VBG\6791372|NONE_0 (l_dobj) states_22\NNS\8491826|NONE_0 (l_conj) seizures_30\NNS\14081375|the_68|vigilance_64|,_48|and_46
18951540
D007980_D004409 CID levodopa_5\NN\14604959|-_8 (r_npadvmod) induced_7\VBN\1627355|in_20 (r_amod) dyskinesias_8\NNS\14084880|NONE_0
D007980_D010300 NONE levodopa_5\NN\14604959|-_8 (r_npadvmod) induced_7\VBN\1627355|in_20 (r_amod) dyskinesias_8\NNS\14084880|NONE_0 (l_prep) in_9\IN\13603305|induced_20 (l_pobj) disease_12\NN\14061805|NONE_0
17879945
D019438_D050197 CID ritonavir_5\VBZ\4013993|NONE_0 (r_compound) treatment_6\NN\654885|that_15|formation_43|to_66 (r_nsubj) increases_7\VBZ\13576355|we_57|have_54|previously_49|._95 (l_dobj) formation_10\NN\7938773|that_58|treatment_43|to_23 (l_compound) lesion_9\NN\14204950|atherosclerotic_16|in_17
4027862
D003891_D003693 CID desipramine_0\NN\4482543|-_11 (r_npadvmod) induced_2\VBN\1627355|at_17|._66 (r_amod) delirium_3\NN\14391660|NONE_0
D003891_D003693 CID desipramine_7\NNP\4482543|patient_30|delirium_24|was_56|._89 (r_nsubj) developed_8\VBD\1753788|NONE_0 (l_dobj) delirium_10\NN\14391660|patient_54|desipramine_24|was_32|._65
7862923
D002220_D019965 NONE carbamazepine_0\NNP\0|was_14|to_27|among_65|._198 (r_nsubjpass) switched_2\VBN\138508|NONE_0 (l_prep) among_8\IN\0|carbamazepine_65|was_51|to_38|._133 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) psychotic_18\JJ\10595647|six_48|difficult_44|schizophrenic_25|using_19
D002220_D012559 NONE carbamazepine_0\NNP\0|was_14|to_27|among_65|._198 (r_nsubjpass) switched_2\VBN\138508|NONE_0 (l_prep) among_8\IN\0|carbamazepine_65|was_51|to_38|._133 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) schizophrenic_15\JJ\10490141|six_23|difficult_19|psychotic_25|using_44
D003024_D019965 NONE clozapine_26\NN\3713736|or_3 (r_conj) chlorpromazine_24\NN\3713736|,_2 (r_conj) haloperidol_22\NN\3713736|concomitantly_14 (r_dobj) using_20\VBG\418025|six_67|difficult_63|schizophrenic_44|psychotic_19 (r_acl) patients_19\NNS\9898892|NONE_0 (l_amod) psychotic_18\JJ\10595647|six_48|difficult_44|schizophrenic_25|using_19
D002746_D012559 NONE chlorpromazine_24\NN\3713736|,_2 (r_conj) haloperidol_22\NN\3713736|concomitantly_14 (r_dobj) using_20\VBG\418025|six_67|difficult_63|schizophrenic_44|psychotic_19 (r_acl) patients_19\NNS\9898892|NONE_0 (l_amod) schizophrenic_15\JJ\10490141|six_23|difficult_19|psychotic_25|using_44
C036006_D012559 NONE oxcarbazepine_7\NN\0|NONE_0 (r_pobj) to_3\IN\0|carbamazepine_27|was_13|among_38|._171 (r_prep) switched_2\VBN\138508|NONE_0 (l_prep) among_8\IN\0|carbamazepine_65|was_51|to_38|._133 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) schizophrenic_15\JJ\10490141|six_23|difficult_19|psychotic_25|using_44
D006220_D019965 NONE haloperidol_22\NN\3713736|concomitantly_14 (r_dobj) using_20\VBG\418025|six_67|difficult_63|schizophrenic_44|psychotic_19 (r_acl) patients_19\NNS\9898892|NONE_0 (l_amod) psychotic_18\JJ\10595647|six_48|difficult_44|schizophrenic_25|using_19
D002746_D019965 NONE chlorpromazine_24\NN\3713736|,_2 (r_conj) haloperidol_22\NN\3713736|concomitantly_14 (r_dobj) using_20\VBG\418025|six_67|difficult_63|schizophrenic_44|psychotic_19 (r_acl) patients_19\NNS\9898892|NONE_0 (l_amod) psychotic_18\JJ\10595647|six_48|difficult_44|schizophrenic_25|using_19
C036006_D019965 NONE oxcarbazepine_7\NN\0|NONE_0 (r_pobj) to_3\IN\0|carbamazepine_27|was_13|among_38|._171 (r_prep) switched_2\VBN\138508|NONE_0 (l_prep) among_8\IN\0|carbamazepine_65|was_51|to_38|._133 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) psychotic_18\JJ\10595647|six_48|difficult_44|schizophrenic_25|using_19
D003024_D012559 NONE clozapine_26\NN\3713736|or_3 (r_conj) chlorpromazine_24\NN\3713736|,_2 (r_conj) haloperidol_22\NN\3713736|concomitantly_14 (r_dobj) using_20\VBG\418025|six_67|difficult_63|schizophrenic_44|psychotic_19 (r_acl) patients_19\NNS\9898892|NONE_0 (l_amod) schizophrenic_15\JJ\10490141|six_23|difficult_19|psychotic_25|using_44
D006220_D012559 NONE haloperidol_22\NN\3713736|concomitantly_14 (r_dobj) using_20\VBG\418025|six_67|difficult_63|schizophrenic_44|psychotic_19 (r_acl) patients_19\NNS\9898892|NONE_0 (l_amod) schizophrenic_15\JJ\10490141|six_23|difficult_19|psychotic_25|using_44
18221780
D016202_D010146 NONE nmda_3\NNP\0|antagonist_5|of_28 (r_compound) enhancement_5\NN\248977|NONE_0 (r_pobj) in_2\IN\13603305|sex_16|in_60|:_99|comparisons_101|._140 (r_prep) differences_1\NNS\4723816|NONE_0 (l_prep) in_9\IN\13603305|sex_76|in_60|:_39|comparisons_41|._80 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_18|capsaicin_16 (l_pobj) pain_15\NN\14299637|NONE_0
D016202_D010146 NONE nmda_9\NNP\0|and_17|morphine_21 (r_compound) antagonists_10\NNS\7846|NONE_0 (r_pobj) between_8\IN\0|a_33|dimorphic_22|in_38 (r_prep) interaction_7\NN\37396|findings_42|._143 (l_prep) in_13\IN\13603305|a_71|dimorphic_60|between_38 (l_pobj) model_17\NN\5888929|NONE_0 (l_compound) pain_16\NN\14299637|a_13|persistent_11|distinguished_23
D002211_D059787 NONE capsaicin_11\NN\15032661|a_2|of_16 (r_compound) model_12\NN\5888929|NONE_0 (r_pobj) in_9\IN\13603305|sex_76|in_60|:_39|comparisons_41|._80 (r_prep) differences_1\NNS\4723816|NONE_0 (l_appos) comparisons_17\NNS\635850|sex_117|in_101|in_41|:_2|._39 (l_prep) to_18\IN\0|NONE_0 (l_pobj) models_20\NNS\5888929|NONE_0 (l_prep) of_21\IN\0|two_11 (l_pobj) pain_23\NN\14299637|NONE_0
D009020_D059787 NONE morphine_7\NN\2707683|NONE_0 (r_compound) antihyperalgesia_8\NN\0|NONE_0 (r_pobj) of_6\IN\0|nmda_28|antagonist_23 (r_prep) enhancement_5\NN\248977|NONE_0 (r_pobj) in_2\IN\13603305|sex_16|in_60|:_99|comparisons_101|._140 (r_prep) differences_1\NNS\4723816|NONE_0 (l_appos) comparisons_17\NNS\635850|sex_117|in_101|in_41|:_2|._39 (l_prep) to_18\IN\0|NONE_0 (l_pobj) models_20\NNS\5888929|NONE_0 (l_prep) of_21\IN\0|two_11 (l_pobj) pain_23\NN\14299637|NONE_0
D009020_D059787 NONE morphine_21\NN\2707683|NONE_0 (r_pobj) of_20\IN\0|the_28|antinociceptive_24 (r_prep) effects_19\NNS\13245626|in_90|antagonists_40|to_20|._61 (r_dobj) enhance_16\VBP\227165|NONE_0 (l_prep) in_0\IN\13603305|antagonists_50|effects_90|to_110|._151 (l_pobj) models_3\NNS\5888929|,_6 (l_compound) pain_2\NN\14299637|acute_6
D009020_D059787 NONE morphine_2\NN\2707683|NONE_0 (r_compound) antinociception_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|by_28 (r_prep) enhancement_0\NN\248977|was_60|in_69|,_119|with_121|._177 (r_nsubjpass) seen_7\VBN\2106506|NONE_0 (l_prep) in_8\IN\13603305|enhancement_69|was_9|,_50|with_52|._108 (l_pobj) males_10\NNS\15388|NONE_0 (l_prep) in_13\IN\13603305|both_23|and_12|females_8 (l_pobj) models_17\NNS\5888929|NONE_0 (l_compound) pain_16\NN\14299637|the_10|acute_6
D009020_D059787 NONE morphine_12\NN\2707683|nmda_21|and_4 (r_conj) antagonists_10\NNS\7846|NONE_0 (r_pobj) between_8\IN\0|a_33|dimorphic_22|in_38 (r_prep) interaction_7\NN\37396|findings_42|._143 (l_prep) in_13\IN\13603305|a_71|dimorphic_60|between_38 (l_pobj) model_17\NN\5888929|NONE_0 (l_relcl) distinguished_21\VBN\618878|a_36|persistent_34|pain_23 (l_prep) from_22\IN\0|that_26|can_21|be_17 (l_pobj) those_23\DT\0|NONE_0 (l_acl) observed_24\VBN\2163746|NONE_0 (l_prep) in_25\IN\13603305|NONE_0 (l_pobj) models_28\NNS\5888929|NONE_0 (l_compound) pain_27\NN\14299637|acute_6
D003915_D059787 NONE dextromethorphan_5\NNP\0|NONE_0 (r_pobj) by_4\IN\0|of_28 (r_prep) enhancement_0\NN\248977|was_60|in_69|,_119|with_121|._177 (r_nsubjpass) seen_7\VBN\2106506|NONE_0 (l_prep) in_8\IN\13603305|enhancement_69|was_9|,_50|with_52|._108 (l_pobj) males_10\NNS\15388|NONE_0 (l_prep) in_13\IN\13603305|both_23|and_12|females_8 (l_pobj) models_17\NNS\5888929|NONE_0 (l_compound) pain_16\NN\14299637|the_10|acute_6
D002211_D010146 NONE capsaicin_11\NN\15032661|a_2|of_16 (r_compound) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_18|capsaicin_16 (l_pobj) pain_15\NN\14299637|NONE_0
D002211_D006930 CID capsaicin_11\NN\15032661|NONE_0 (r_pobj) of_10\IN\0|in_13 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) by_8\IN\0|to_49|,_38|hyperalgesia_25|was_12|,_72|immersed_103|._188 (r_agent) induced_7\VBN\1627355|NONE_0 (l_nsubjpass) hyperalgesia_5\NN\0|to_24|,_13|was_13|by_25|,_97|immersed_128|._213
D016202_D059787 NONE nmda_3\NNP\0|antagonist_5|of_28 (r_compound) enhancement_5\NN\248977|NONE_0 (r_pobj) in_2\IN\13603305|sex_16|in_60|:_99|comparisons_101|._140 (r_prep) differences_1\NNS\4723816|NONE_0 (l_appos) comparisons_17\NNS\635850|sex_117|in_101|in_41|:_2|._39 (l_prep) to_18\IN\0|NONE_0 (l_pobj) models_20\NNS\5888929|NONE_0 (l_prep) of_21\IN\0|two_11 (l_pobj) pain_23\NN\14299637|NONE_0
D016202_D059787 NONE aspartate_11\NNP\0|methyl_9|(_10|nmda_11|)_15 (r_nmod) antagonists_15\NNS\7846|in_50|effects_40|to_60|._101 (r_nsubj) enhance_16\VBP\227165|NONE_0 (l_prep) in_0\IN\13603305|antagonists_50|effects_90|to_110|._151 (l_pobj) models_3\NNS\5888929|,_6 (l_compound) pain_2\NN\14299637|acute_6
D016202_D059787 NONE nmda_13\NNP\0|methyl_20|aspartate_11|(_1|)_4 (r_nmod) antagonists_15\NNS\7846|in_50|effects_40|to_60|._101 (r_nsubj) enhance_16\VBP\227165|NONE_0 (l_prep) in_0\IN\13603305|antagonists_50|effects_90|to_110|._151 (l_pobj) models_3\NNS\5888929|,_6 (l_compound) pain_2\NN\14299637|acute_6
D016202_D059787 NONE nmda_9\NNP\0|and_17|morphine_21 (r_compound) antagonists_10\NNS\7846|NONE_0 (r_pobj) between_8\IN\0|a_33|dimorphic_22|in_38 (r_prep) interaction_7\NN\37396|findings_42|._143 (l_prep) in_13\IN\13603305|a_71|dimorphic_60|between_38 (l_pobj) model_17\NN\5888929|NONE_0 (l_relcl) distinguished_21\VBN\618878|a_36|persistent_34|pain_23 (l_prep) from_22\IN\0|that_26|can_21|be_17 (l_pobj) those_23\DT\0|NONE_0 (l_acl) observed_24\VBN\2163746|NONE_0 (l_prep) in_25\IN\13603305|NONE_0 (l_pobj) models_28\NNS\5888929|NONE_0 (l_compound) pain_27\NN\14299637|acute_6
D009020_D010146 NONE morphine_7\NN\2707683|NONE_0 (r_compound) antihyperalgesia_8\NN\0|NONE_0 (r_pobj) of_6\IN\0|nmda_28|antagonist_23 (r_prep) enhancement_5\NN\248977|NONE_0 (r_pobj) in_2\IN\13603305|sex_16|in_60|:_99|comparisons_101|._140 (r_prep) differences_1\NNS\4723816|NONE_0 (l_prep) in_9\IN\13603305|sex_76|in_60|:_39|comparisons_41|._80 (l_pobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_18|capsaicin_16 (l_pobj) pain_15\NN\14299637|NONE_0
D009020_D010146 NONE morphine_12\NN\2707683|nmda_21|and_4 (r_conj) antagonists_10\NNS\7846|NONE_0 (r_pobj) between_8\IN\0|a_33|dimorphic_22|in_38 (r_prep) interaction_7\NN\37396|findings_42|._143 (l_prep) in_13\IN\13603305|a_71|dimorphic_60|between_38 (l_pobj) model_17\NN\5888929|NONE_0 (l_compound) pain_16\NN\14299637|a_13|persistent_11|distinguished_23
17261653
D003000_D001919 CID clonidine_0\NNP\2721160|-_9|bradycardia_18|in_30 (r_npadvmod) induced_2\VBN\1627355|%_59|._133 (l_dobj) bradycardia_3\NN\14110674|clonidine_18|-_9|in_12
7858459
C007744_D020258 NONE fluorocitrate_16\NN\0|and_4 (r_conj) fluoroacetate_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|a_23|krebs_21|cycle_15|,_34|deficiency_45 (r_prep) blockade_12\NN\952963|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) due_7\JJ\5174653|pathogenesis_52|may_7|._128 (r_acomp) be_6\VB\14625458|NONE_0 (l_nsubj) pathogenesis_1\NN\13533470|may_45|due_52|._180 (l_prep) of_2\IN\0|the_17 (l_pobj) neurotoxicity_4\NN\0|NONE_0
D002955_D020258 NONE acid_2\NN\14818238|because_16|unlikely_9 (r_nsubj) was_3\VBD\0|,_49|neurotoxicity_51|5-fluorouracil_82|was_97|highly_101|._117 (r_advcl) suspected_21\VBN\916909|NONE_0 (l_nsubjpass) neurotoxicity_12\NN\0|was_51|,_2|5-fluorouracil_31|was_46|highly_50|._66
D005472_D009369 NONE 5-fluorouracil_3\CD\0|/_14 (r_punct) folinic_5\JJ\0|dose_20|infusion_13 (r_amod) therapy_8\NN\657604|has_8|recently_12|regimen_38|._65 (r_nsubj) become_11\VBN\146138|NONE_0 (l_attr) regimen_14\NN\5898568|therapy_38|has_30|recently_26|._27 (l_prep) for_15\IN\0|a_18|popular_16 (l_pobj) cancers_17\NNS\14239425|NONE_0
D005472_D003128 CID 5-fluorouracil_35\CD\0|NONE_0 (r_punct) of_34\IN\0|the_23|first_19|day_7|and_18 (r_prep) dose_29\NN\3740161|folinic_35|acid_43 (r_nmod) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (l_prep) into_16\IN\0|then_12|,_16|lasting_18 (l_pobj) coma_19\NN\5678932|NONE_0
D005472_D003221 CID 5-fluorouracil_10\CD\0|NONE_0 (r_punct) of_9\IN\0|a_21|dose_14|and_18|acid_30 (r_prep) infusion_8\NN\14589223|NONE_0 (r_pobj) by_3\IN\0|confusion_18|._58 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubj) confusion_1\NN\13972797|by_18|._76
D005472_D003221 CID 5-fluorouracil_35\CD\0|NONE_0 (r_punct) of_34\IN\0|the_23|first_19|day_7|and_18 (r_prep) dose_29\NN\3740161|folinic_35|acid_43 (r_nmod) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (r_conj) developed_1\VBD\1753788|NONE_0 (l_dobj) symptoms_4\NNS\5823932|he_30|,_61|and_63|lapsed_72|._205 (l_prep) of_5\IN\0|acute_26|neurologic_20 (l_pobj) confusion_7\NN\13972797|NONE_0
D005472_D003221 CID 5-fluorouracil_35\CD\0|NONE_0 (r_punct) of_34\IN\0|the_23|first_19|day_7|and_18 (r_prep) dose_29\NN\3740161|folinic_35|acid_43 (r_nmod) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (r_conj) developed_1\VBD\1753788|NONE_0 (l_dobj) symptoms_4\NNS\5823932|he_30|,_61|and_63|lapsed_72|._205 (l_prep) of_5\IN\0|acute_26|neurologic_20 (l_pobj) confusion_7\NN\13972797|NONE_0 (l_conj) disorientation_9\NN\5896733|mental_18|,_2
D002955_D009369 NONE acid_6\NN\14818238|NONE_0 (r_compound) infusion_7\NN\14589223|dose_33|folinic_13 (r_compound) therapy_8\NN\657604|has_8|recently_12|regimen_38|._65 (r_nsubj) become_11\VBN\146138|NONE_0 (l_attr) regimen_14\NN\5898568|therapy_38|has_30|recently_26|._27 (l_prep) for_15\IN\0|a_18|popular_16 (l_pobj) cancers_17\NNS\14239425|NONE_0
D002955_D003128 CID acid_38\NN\14818238|dose_43|folinic_8 (r_compound) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (l_prep) into_16\IN\0|then_12|,_16|lasting_18 (l_pobj) coma_19\NN\5678932|NONE_0
D005463_D020258 NONE fluoroacetate_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|a_23|krebs_21|cycle_15|,_34|deficiency_45 (r_prep) blockade_12\NN\952963|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) due_7\JJ\5174653|pathogenesis_52|may_7|._128 (r_acomp) be_6\VB\14625458|NONE_0 (l_nsubj) pathogenesis_1\NN\13533470|may_45|due_52|._180 (l_prep) of_2\IN\0|the_17 (l_pobj) neurotoxicity_4\NN\0|NONE_0
D013831_D020258 NONE thiamine_18\NN\15090742|,_19|or_21|deficiency_52 (r_compound) deficiency_19\NN\14449126|a_68|krebs_66|cycle_60|by_45|,_11 (r_conj) blockade_12\NN\952963|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) due_7\JJ\5174653|pathogenesis_52|may_7|._128 (r_acomp) be_6\VB\14625458|NONE_0 (l_nsubj) pathogenesis_1\NN\13533470|may_45|due_52|._180 (l_prep) of_2\IN\0|the_17 (l_pobj) neurotoxicity_4\NN\0|NONE_0
D005472_D020258 NONE 5-fluorouracil_18\CD\0|was_82|,_33|neurotoxicity_31|was_15|highly_19|._35 (r_punct) suspected_21\VBN\916909|NONE_0 (l_nsubjpass) neurotoxicity_12\NN\0|was_51|,_2|5-fluorouracil_31|was_46|highly_50|._66
D005472_D020258 NONE 5-fluorouracil_3\CD\0|NONE_0 (r_punct) neurotoxicity_4\NN\0|NONE_0
D002945_D013274 NONE cisplatinum_11\NN\0|chemotherapy_27 (l_appos) hours_24\NNS\15118228|,_54|etoposide_52 (l_conj) acid_28\NN\14818238|m2/24_25|)_14|and_12 (l_prep) for_29\IN\0|folinic_13 (l_pobj) adenocarcinoma_33\NN\14242337|NONE_0
D002955_D001523 NONE acid_38\NN\14818238|dose_43|folinic_8 (r_compound) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (r_conj) developed_1\VBD\1753788|NONE_0 (l_dobj) symptoms_4\NNS\5823932|he_30|,_61|and_63|lapsed_72|._205 (l_prep) of_5\IN\0|acute_26|neurologic_20 (l_pobj) confusion_7\NN\13972797|NONE_0 (l_conj) disorientation_9\NN\5896733|mental_18|,_2 (l_conj) irritability_11\NN\7552087|and_4
D002955_D003221 CID acid_13\NN\14818238|a_51|dose_44|of_30|and_12 (r_conj) infusion_8\NN\14589223|NONE_0 (r_pobj) by_3\IN\0|confusion_18|._58 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubj) confusion_1\NN\13972797|by_18|._76
D002955_D003221 CID acid_38\NN\14818238|dose_43|folinic_8 (r_compound) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (r_conj) developed_1\VBD\1753788|NONE_0 (l_dobj) symptoms_4\NNS\5823932|he_30|,_61|and_63|lapsed_72|._205 (l_prep) of_5\IN\0|acute_26|neurologic_20 (l_pobj) confusion_7\NN\13972797|NONE_0
D002955_D003221 CID acid_38\NN\14818238|dose_43|folinic_8 (r_compound) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (r_conj) developed_1\VBD\1753788|NONE_0 (l_dobj) symptoms_4\NNS\5823932|he_30|,_61|and_63|lapsed_72|._205 (l_prep) of_5\IN\0|acute_26|neurologic_20 (l_pobj) confusion_7\NN\13972797|NONE_0 (l_conj) disorientation_9\NN\5896733|mental_18|,_2
D005047_D013274 NONE etoposide_13\NN\0|,_2|hours_52 (r_conj) cisplatinum_11\NN\0|chemotherapy_27 (l_appos) hours_24\NNS\15118228|,_54|etoposide_52 (l_conj) acid_28\NN\14818238|m2/24_25|)_14|and_12 (l_prep) for_29\IN\0|folinic_13 (l_pobj) adenocarcinoma_33\NN\14242337|NONE_0
D002955_D013274 NONE acid_28\NN\14818238|m2/24_25|)_14|and_12 (l_prep) for_29\IN\0|folinic_13 (l_pobj) adenocarcinoma_33\NN\14242337|NONE_0
C007419_D020258 NONE dihydrouracil_22\VBN\0|NONE_0 (r_compound) dehydrogenase_23\NN\0|NONE_0 (r_compound) deficiency_24\NN\14449126|thiamine_52|,_33|or_31 (r_conj) deficiency_19\NN\14449126|a_68|krebs_66|cycle_60|by_45|,_11 (r_conj) blockade_12\NN\952963|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) due_7\JJ\5174653|pathogenesis_52|may_7|._128 (r_acomp) be_6\VB\14625458|NONE_0 (l_nsubj) pathogenesis_1\NN\13533470|may_45|due_52|._180 (l_prep) of_2\IN\0|the_17 (l_pobj) neurotoxicity_4\NN\0|NONE_0
D005472_D013274 NONE 5-fluorouracil_18\CD\0|,_12|dose_5|(_15|mg_22|/_24 (r_punct) m2/24_23\NN\0|)_11|and_13|acid_25 (r_compound) hours_24\NNS\15118228|,_54|etoposide_52 (l_conj) acid_28\NN\14818238|m2/24_25|)_14|and_12 (l_prep) for_29\IN\0|folinic_13 (l_pobj) adenocarcinoma_33\NN\14242337|NONE_0
D005472_D001523 NONE 5-fluorouracil_35\CD\0|NONE_0 (r_punct) of_34\IN\0|the_23|first_19|day_7|and_18 (r_prep) dose_29\NN\3740161|folinic_35|acid_43 (r_nmod) infusion_39\NN\14589223|NONE_0 (r_pobj) during_26\IN\0|for_27 (r_prep) lasting_21\VBG\2704349|then_30|into_18|,_2 (r_advcl) lapsed_15\VBD\124442|he_102|symptoms_72|,_11|and_9|._133 (r_conj) developed_1\VBD\1753788|NONE_0 (l_dobj) symptoms_4\NNS\5823932|he_30|,_61|and_63|lapsed_72|._205 (l_prep) of_5\IN\0|acute_26|neurologic_20 (l_pobj) confusion_7\NN\13972797|NONE_0 (l_conj) disorientation_9\NN\5896733|mental_18|,_2 (l_conj) irritability_11\NN\7552087|and_4
2234245
D003676_D064420 NONE desferrioxamine_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_17|higher_13 (r_prep) doses_8\NNS\3740161|NONE_0 (r_dobj) receiving_5\VBG\2210855|NONE_0 (r_acl) patients_4\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|toxicity_18|or_58|coincided_61|._131 (r_prep) appeared_2\VBD\2604760|NONE_0 (l_nsubj) toxicity_1\NN\13576101|in_18|or_76|coincided_79|._149
D003676_D014786 NONE desferrioxamine_8\NN\0|NONE_0 (r_dobj) receiving_7\VBG\2210855|hemodialyzed_22 (r_acl) patients_6\NNS\9898892|NONE_0 (r_pobj) in_4\IN\13603305|ocular_29|._50 (r_prep) toxicity_3\NN\13576101|NONE_0
D003676_D014786 NONE desferrioxamine_10\NN\0|NONE_0 (r_dobj) receiving_9\VBG\2210855|41_25|hemodialyzed_22|weekly_50 (r_acl) patients_8\NNS\9898892|period_32 (r_pobj) during_0\IN\0|for_118|were_137|for_152|._189 (r_prep) monitored_25\VBN\2169352|NONE_0 (l_prep) for_26\IN\0|during_152|for_34|were_15|._37 (l_pobj) detection_27\NN\5708432|NONE_0 (l_prep) of_28\IN\0|NONE_0 (l_pobj) toxicity_30\NN\13576101|NONE_0
D003676_D014786 NONE desferrioxamine_15\NN\0|NONE_0 (r_dobj) receiving_14\VBG\2210855|hemodialyzed_22 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|an_27|infrequent_24 (r_prep) complication_10\NN\1073995|that_47|toxicity_30|not_18 (r_attr) is_6\VBZ\0|data_40|._84 (l_nsubj) toxicity_5\NN\13576101|that_17|not_12|complication_30
D003676_D034381 NONE desferrioxamine_0\NNP\0|NONE_0 (r_compound) withdrawal_1\NN\7206096|in_20|,_100|and_102|reversal_117|._181 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_conj) reversal_22\NN\199130|withdrawal_117|in_97|,_17|and_15|._64 (l_prep) of_23\IN\0|a_20|complete_18 (l_pcomp) hearing_24\NN\1184814|NONE_0 (l_dobj) loss_25\NN\13252973|in_5|in_40
D003676_D006311 NONE desferrioxamine_8\NN\0|NONE_0 (r_dobj) receiving_7\VBG\2210855|hemodialyzed_22 (r_acl) patients_6\NNS\9898892|NONE_0 (r_pobj) in_4\IN\13603305|ocular_29|._50 (r_prep) toxicity_3\NN\13576101|NONE_0
D003676_D006311 NONE desferrioxamine_10\NN\0|NONE_0 (r_dobj) receiving_9\VBG\2210855|41_25|hemodialyzed_22|weekly_50 (r_acl) patients_8\NNS\9898892|period_32 (r_pobj) during_0\IN\0|for_118|were_137|for_152|._189 (r_prep) monitored_25\VBN\2169352|NONE_0 (l_prep) for_26\IN\0|during_152|for_34|were_15|._37 (l_pobj) detection_27\NN\5708432|NONE_0 (l_prep) of_28\IN\0|NONE_0 (l_pobj) toxicity_30\NN\13576101|NONE_0
D003676_D006311 NONE desferrioxamine_15\NN\0|NONE_0 (r_dobj) receiving_14\VBG\2210855|hemodialyzed_22 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|an_27|infrequent_24 (r_prep) complication_10\NN\1073995|that_47|toxicity_30|not_18 (r_attr) is_6\VBZ\0|data_40|._84 (l_nsubj) toxicity_5\NN\13576101|that_17|not_12|complication_30
-1_D064420 NONE aluminium_19\NN\14625458|or_3 (r_conj) ferritin_17\NN\14728724|serum_22 (r_nmod) levels_21\NNS\4916342|NONE_0 (r_pobj) of_16\IN\0|the_18 (r_prep) normalization_15\NN\1123598|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) coincided_12\VBD\2604477|toxicity_79|in_61|or_3|._70 (r_conj) appeared_2\VBD\2604760|NONE_0 (l_nsubj) toxicity_1\NN\13576101|in_18|or_76|coincided_79|._149
17437408
D010862_D012640 CID pilocarpine_11\NN\14712692|-_11 (r_npadvmod) induced_13\VBN\1627355|in_17 (r_amod) seizures_14\NNS\14081375|NONE_0
18020536
D001569_D004244 CID bzds_4\NNP\0|/_4 (r_nmod) rds_6\NNS\0|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) use_2\NN\407535|however_9|,_2|was_16|with_31|,_45|inability_47|._238 (r_nsubjpass) associated_8\VBN\628491|NONE_0 (l_prep) with_9\IN\0|however_40|,_33|use_31|was_15|,_14|inability_16|._207 (l_pobj) dizziness_10\NN\14299637|NONE_0
D001569_D005221 CID bzds_4\NNP\0|/_4 (r_nmod) rds_6\NNS\0|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) use_2\NN\407535|however_9|,_2|was_16|with_31|,_45|inability_47|._238 (r_nsubjpass) associated_8\VBN\628491|NONE_0 (l_npadvmod) inability_12\NN\23271|however_56|,_49|use_47|was_31|with_16|,_2|._191 (l_acl) sleep_14\VB\14034177|NONE_0 (l_prep) after_15\IN\0|to_9 (l_pcomp) awaking_16\VBG\146138|and_82|with_86 (l_prep) at_17\IN\14622893|in_23|during_39 (l_pobj) night_18\NN\15113229|NONE_0 (l_conj) tiredness_20\NN\14015731|and_4
D001569_D003866 CID bzds_4\NNP\0|/_4 (r_nmod) rds_6\NNS\0|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) use_2\NN\407535|however_9|,_2|was_16|with_31|,_45|inability_47|._238 (r_nsubjpass) associated_8\VBN\628491|NONE_0 (l_npadvmod) inability_12\NN\23271|however_56|,_49|use_47|was_31|with_16|,_2|._191 (l_acl) sleep_14\VB\14034177|NONE_0 (l_prep) after_15\IN\0|to_9 (l_conj) with_31\IN\0|awaking_86|and_4 (l_pobj) symptoms_34\NNS\5823932|NONE_0
D001569_D007319 CID bzds_4\NNP\0|/_4 (r_nmod) rds_6\NNS\0|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) use_2\NN\407535|however_9|,_2|was_16|with_31|,_45|inability_47|._238 (r_nsubjpass) associated_8\VBN\628491|NONE_0 (l_npadvmod) inability_12\NN\23271|however_56|,_49|use_47|was_31|with_16|,_2|._191 (l_acl) sleep_14\VB\14034177|NONE_0
9625142
D001663_D000744 NONE bilirubin_21\NN\14756039|NONE_0 (r_pobj) in_19\IN\13603305|a_19|gradual_17|and_19|decrease_25 (r_prep) increase_18\NN\13576355|returned_87|,_22|there_20|._138 (l_conj) decrease_24\NN\7296428|a_44|gradual_42|in_25|and_6 (l_prep) in_25\IN\13603305|a_11 (l_pobj) concentration_27\NN\4916342|NONE_0 (l_acl) caused_28\VBN\1617192|hemoglobin_25 (l_agent) by_29\IN\0|NONE_0 (l_pobj) anemia_33\NN\14189204|NONE_0
D047090_D000744 NONE lactam_11\NN\0|the_9 (r_compound) antibiotic_12\NN\2716205|NONE_0 (r_dobj) withholding_8\VBG\360757|NONE_0 (r_pcomp) after_7\IN\0|although_58|transaminases_45|gradually_31|to_12 (r_prep) returned_4\VBD\1835496|,_65|there_67|increase_87|._225 (r_advcl) was_15\VBD\0|NONE_0 (l_attr) increase_18\NN\13576355|returned_87|,_22|there_20|._138 (l_conj) decrease_24\NN\7296428|a_44|gradual_42|in_25|and_6 (l_prep) in_25\IN\13603305|a_11 (l_pobj) concentration_27\NN\4916342|NONE_0 (l_acl) caused_28\VBN\1617192|hemoglobin_25 (l_agent) by_29\IN\0|NONE_0 (l_pobj) anemia_33\NN\14189204|NONE_0
D002443_D000744 CID ceftriaxone_11\NN\2996840|NONE_0 (r_pobj) by_10\IN\0|hepatitis_75|._14 (r_prep) induced_9\VBN\1627355|NONE_0 (l_nsubj) hepatitis_1\NNP\14127211|by_75|._89 (l_appos) anemia_5\NN\14189204|acute_38|,_23
D002443_-1 NONE ceftriaxone_11\NN\2996840|NONE_0 (r_pobj) by_10\IN\0|hepatitis_75|._14 (r_prep) induced_9\VBN\1627355|NONE_0 (l_nsubj) hepatitis_1\NNP\14127211|by_75|._89 (l_appos) anemia_5\NN\14189204|acute_38|,_23 (l_conj) erythroblastocytopenia_8\NN\0|autoimmune_33|hemolytic_22|,_6|and_4
D002443_D056486 CID ceftriaxone_11\NN\2996840|NONE_0 (r_pobj) by_10\IN\0|hepatitis_75|._14 (r_prep) induced_9\VBN\1627355|NONE_0 (l_nsubj) hepatitis_1\NNP\14127211|by_75|._89
D002443_D056486 CID ceftriaxone_12\NN\2996840|NONE_0 (r_dobj) ingesting_10\VBG\0|shortly_14 (r_pcomp) after_9\IN\0|man_38|hepatitis_18|._32 (r_prep) developed_5\VBD\1753788|NONE_0 (l_dobj) hepatitis_7\NN\14127211|man_20|after_18|._50
D001663_-1 NONE bilirubin_21\NN\14756039|NONE_0 (r_pobj) in_19\IN\13603305|a_19|gradual_17|and_19|decrease_25 (r_prep) increase_18\NN\13576355|returned_87|,_22|there_20|._138 (l_conj) decrease_24\NN\7296428|a_44|gradual_42|in_25|and_6 (l_prep) in_25\IN\13603305|a_11 (l_pobj) concentration_27\NN\4916342|NONE_0 (l_acl) caused_28\VBN\1617192|hemoglobin_25 (l_agent) by_29\IN\0|NONE_0 (l_pobj) anemia_33\NN\14189204|NONE_0 (l_conj) erythroblastocytopenia_35\NN\0|an_35|autoimmune_32|hemolytic_21|and_4
D047090_-1 NONE lactam_11\NN\0|the_9 (r_compound) antibiotic_12\NN\2716205|NONE_0 (r_dobj) withholding_8\VBG\360757|NONE_0 (r_pcomp) after_7\IN\0|although_58|transaminases_45|gradually_31|to_12 (r_prep) returned_4\VBD\1835496|,_65|there_67|increase_87|._225 (r_advcl) was_15\VBD\0|NONE_0 (l_attr) increase_18\NN\13576355|returned_87|,_22|there_20|._138 (l_conj) decrease_24\NN\7296428|a_44|gradual_42|in_25|and_6 (l_prep) in_25\IN\13603305|a_11 (l_pobj) concentration_27\NN\4916342|NONE_0 (l_acl) caused_28\VBN\1617192|hemoglobin_25 (l_agent) by_29\IN\0|NONE_0 (l_pobj) anemia_33\NN\14189204|NONE_0 (l_conj) erythroblastocytopenia_35\NN\0|an_35|autoimmune_32|hemolytic_21|and_4
16403073
D007654_D016171 CID ketoconazole_0\NNP\0|pointes_33|without_41|._95 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) pointes_4\FW\831651|ketoconazole_33|without_8|._62
D007654_D016171 CID ketoconazole_24\RB\0|for_13 (r_dobj) taking_23\VBG\37396|NONE_0 (r_pcomp) after_22\IN\0|pointes_14 (r_prep) torsades_16\NNS\0|who_51|interval_13|and_4 (l_dobj) pointes_18\FW\831651|after_14
D007654_D016171 CID ketoconazole_24\RB\0|for_13 (r_dobj) taking_23\VBG\37396|NONE_0 (r_pcomp) after_22\IN\0|pointes_14 (r_prep) torsades_16\NNS\0|who_51|interval_13|and_4 (l_dobj) pointes_18\FW\831651|after_14 (l_appos) tdp_20\NN\0|de_12|(_1|)_3
D007654_D016171 CID ketoconazole_13\RB\0|that_53|by_48|,_2|may_19|interval_34|and_43|induce_47 (r_nsubj) prolong_16\VB\317700|we_89 (l_conj) induce_20\VB\1627355|that_100|by_95|,_49|ketoconazole_47|may_28|interval_13|and_4 (l_dobj) tdp._21\NN\0|NONE_0
D007654_D008133 CID ketoconazole_24\RB\0|for_13 (r_dobj) taking_23\VBG\37396|NONE_0 (r_pcomp) after_22\IN\0|pointes_14 (r_prep) torsades_16\NNS\0|who_51|interval_13|and_4 (r_conj) developed_9\VBD\1753788|a_41|with_33 (l_dobj) interval_14\NN\33615|who_38|and_9|torsades_13
D007654_D008133 CID ketoconazole_5\JJ\0|when_5|is_13|to_29 (r_nsubjpass) administered_7\VBN\2436349|this_46|for_35|._72 (l_prep) to_8\IN\0|when_34|ketoconazole_29|is_16 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) factors_12\NNS\7326557|NONE_0 (l_prep) for_13\IN\0|risk_13 (l_pobj) syndrome_17\NN\5870365|NONE_0
D007654_D009181 NONE ketoconazole_24\RB\0|for_13 (r_dobj) taking_23\VBG\37396|NONE_0 (l_prep) for_25\IN\0|ketoconazole_13 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) infection_29\NN\14052046|NONE_0
D007654_D003324 NONE ketoconazole_24\RB\0|for_13 (r_dobj) taking_23\VBG\37396|NONE_0 (r_pcomp) after_22\IN\0|pointes_14 (r_prep) torsades_16\NNS\0|who_51|interval_13|and_4 (r_conj) developed_9\VBD\1753788|a_41|with_33 (r_relcl) woman_3\NN\9605289|we_12|._171 (l_prep) with_4\IN\0|a_8|developed_33 (l_pobj) disease_7\NN\14061805|NONE_0
3341566
D009599_D007022 CID nitroprusside_10\RB\0|-_13 (r_advmod) induced_12\VBN\1627355|sodium_21|in_20 (r_amod) hypotension_13\NN\14057371|NONE_0
D009599_D007022 CID snp_21\NNP\11493266|the_4 (r_compound) group_22\NN\2137|NONE_0 (r_pobj) in_19\IN\13603305|NONE_0 (r_prep) that_18\DT\0|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) compared_16\VBN\644583|NONE_0 (r_prep) higher_15\RBR\0|during_107|output_64|lower_39|._42 (r_acomp) was_8\VBD\0|NONE_0 (l_prep) during_0\IN\0|output_43|lower_68|higher_107|._149 (l_pobj) hypotension_4\NN\14057371|NONE_0
D009599_D007022 CID snp_7\NNP\11493266|hem_8 (r_compound) groups_8\NNS\2137|NONE_0 (r_pobj) in_3\IN\13603305|mm_6|,_25|respectively_27|,_39|during_41|p_61|._78 (r_prep) hg_2\NNP\14625458|NONE_0 (l_prep) during_12\IN\0|mm_47|in_41|,_16|respectively_14|,_2|p_20|._37 (l_pobj) hypotension_13\NN\14057371|NONE_0
D009599_D006470 NONE nitroprusside_10\RB\0|-_13 (r_advmod) induced_12\VBN\1627355|sodium_21|in_20 (r_amod) hypotension_13\NN\14057371|NONE_0 (r_pobj) during_8\IN\0|NONE_0 (r_prep) than_7\IN\0|variation_39|greater_26|during_18|._71 (r_prep) is_3\VBZ\0|NONE_0 (l_prep) during_5\IN\0|variation_21|greater_8|than_18|._89 (l_pobj) hemorrhage_6\NN\14285662|NONE_0
D009599_D006470 NONE nitroprusside_28\NN\0|pressure_120|was_111|to_97|for_85|._26 (r_advcl) decreased_4\VBN\169651|NONE_0 (l_prep) for_9\IN\0|pressure_35|was_26|to_12|nitroprusside_85|._111 (l_pobj) minutes_11\NNS\6502378|NONE_0 (l_prep) by_13\IN\0|30_18 (l_pobj) hemorrhage_14\NN\14285662|either_10|or_24|by_27
D009599_D006470 NONE nitroprusside_28\NN\0|pressure_120|was_111|to_97|for_85|._26 (r_advcl) decreased_4\VBN\169651|NONE_0 (l_prep) for_9\IN\0|pressure_35|was_26|to_12|nitroprusside_85|._111 (l_pobj) minutes_11\NNS\6502378|NONE_0 (l_prep) by_13\IN\0|30_18 (l_pobj) hemorrhage_14\NN\14285662|either_10|or_24|by_27 (l_appos) hem_16\NNP\3264542|NONE_0
D009599_D006470 NONE snp_30\NNP\11493266|(_1|,_3|7_9|)_10 (r_dep) n_32\CC\14622893|NONE_0 (r_npadvmod) nitroprusside_28\NN\0|pressure_120|was_111|to_97|for_85|._26 (r_advcl) decreased_4\VBN\169651|NONE_0 (l_prep) for_9\IN\0|pressure_35|was_26|to_12|nitroprusside_85|._111 (l_pobj) minutes_11\NNS\6502378|NONE_0 (l_prep) by_13\IN\0|30_18 (l_pobj) hemorrhage_14\NN\14285662|either_10|or_24|by_27
D009599_D006470 NONE snp_30\NNP\11493266|(_1|,_3|7_9|)_10 (r_dep) n_32\CC\14622893|NONE_0 (r_npadvmod) nitroprusside_28\NN\0|pressure_120|was_111|to_97|for_85|._26 (r_advcl) decreased_4\VBN\169651|NONE_0 (l_prep) for_9\IN\0|pressure_35|was_26|to_12|nitroprusside_85|._111 (l_pobj) minutes_11\NNS\6502378|NONE_0 (l_prep) by_13\IN\0|30_18 (l_pobj) hemorrhage_14\NN\14285662|either_10|or_24|by_27 (l_appos) hem_16\NNP\3264542|NONE_0
D009599_D006470 NONE snp_21\NNP\11493266|the_4 (r_compound) group_22\NN\2137|NONE_0 (r_pobj) in_19\IN\13603305|NONE_0 (r_prep) that_18\DT\0|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) compared_16\VBN\644583|NONE_0 (r_prep) higher_15\RBR\0|during_107|output_64|lower_39|._42 (r_acomp) was_8\VBD\0|NONE_0 (l_prep) during_0\IN\0|output_43|lower_68|higher_107|._149 (l_pobj) hypotension_4\NN\14057371|NONE_0 (l_amod) induced_3\VBN\1627355|NONE_0 (l_npadvmod) hem_1\NNP\3264542|-_3
D009599_D006470 NONE snp_17\NNP\11493266|the_4 (r_compound) group_18\NN\2137|NONE_0 (r_pobj) in_15\IN\13603305|NONE_0 (r_prep) hg_14\NNP\14625458|+/-_11|2.0_7|p_21 (r_appos) mm_13\NN\13649268|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) compared_8\VBN\644583|mm_24|in_18|,_2|._67 (r_prep) hg_2\NNP\14625458|NONE_0 (l_prep) in_3\IN\13603305|mm_6|,_16|compared_18|._85 (l_pobj) group_6\NN\2137|NONE_0 (l_compound) hem_5\NNP\3264542|the_4
D009599_D006470 NONE snp_7\NNP\11493266|hem_8 (r_compound) groups_8\NNS\2137|NONE_0 (l_nmod) hem_5\NNP\3264542|snp_8
15009014
D001285_D006940 NONE atropine_16\NN\14712692|NONE_0 (r_pobj) by_10\IN\0|increases_50|were_20|also_15|._177 (r_agent) abolished_9\VBN\0|NONE_0 (l_nsubjpass) increases_2\NNS\13576355|were_30|also_35|by_50|._227 (l_prep) in_3\IN\13603305|the_21|evoked_17 (l_pobj) flow_6\NN\7311115|NONE_0
D002211_D006940 CID capsaicin_0\NNS\15032661|to_30|induced_54|._129 (r_nsubj) applied_7\VBN\0|NONE_0 (l_conj) induced_13\VBN\1627355|capsaicin_54|to_24|._75 (l_dobj) increases_14\NNS\13576355|provoked_47 (l_prep) in_15\IN\13603305|and_33 (l_pobj) flow_20\NN\7311115|NONE_0
19058010
D007545_D009203 CID isoproterenol_9\JJ\3740161|NONE_0 (r_pobj) in_8\IN\13603305|tea_30 (r_prep) combination_7\NN\7951464|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) effect_0\NN\34213|infarction_82|._100 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_dobj) infarction_12\NN\14204950|effect_82|._18
D007545_D009203 CID isoproterenol_37\NN\3740161|NONE_0 (r_pobj) in_36\IN\13603305|atpases_8 (r_prep) bound_34\VBN\13863771|the_157|combined_153|of_136|on_109|,_94|weight_87 (r_acl) effects_9\NNS\13245626|to_28 (r_dobj) investigate_6\VB\644583|study_19|was_13|iso)-induced_201|._243 (r_xcomp) aimed_4\VBN\1987160|NONE_0 (l_parataxis) iso)-induced_39\VBN\0|study_220|was_214|investigate_201|._42 (l_dobj) infarction_41\NN\14204950|(_25
D007545_D009203 CID iso)-induced_39\VBN\0|study_220|was_214|investigate_201|._42 (l_dobj) infarction_41\NN\14204950|(_25
D007545_D009203 CID iso_14\NN\0|NONE_0 (r_pobj) during_13\IN\0|the_61|synergistic_57|protective_45|of_27 (r_prep) effect_6\NN\34213|findings_45|induced_45|._82 (r_dobj) indicate_2\VBP\952524|NONE_0 (l_ccomp) induced_15\VBN\1627355|findings_90|effect_45|._37 (l_dobj) infarction_17\NN\14204950|NONE_0
D010936_D009203 NONE tea_3\NN\7881800|in_30 (r_nmod) combination_7\NN\7951464|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) effect_0\NN\34213|infarction_82|._100 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_dobj) infarction_12\NN\14204950|effect_82|._18
D010936_D009203 NONE tea_12\NN\7881800|NONE_0 (r_pobj) of_10\IN\0|the_21|combined_17|on_27|,_42|weight_49|bound_136 (r_prep) effects_9\NNS\13245626|to_28 (r_dobj) investigate_6\VB\644583|study_19|was_13|iso)-induced_201|._243 (r_xcomp) aimed_4\VBN\1987160|NONE_0 (l_parataxis) iso)-induced_39\VBN\0|study_220|was_214|investigate_201|._42 (l_dobj) infarction_41\NN\14204950|(_25
D010936_D009203 NONE tea_9\NN\7881800|NONE_0 (r_pobj) of_7\IN\0|the_34|synergistic_30|protective_18|during_27 (r_prep) effect_6\NN\34213|findings_45|induced_45|._82 (r_dobj) indicate_2\VBP\952524|NONE_0 (l_ccomp) induced_15\VBN\1627355|findings_90|effect_45|._37 (l_dobj) infarction_17\NN\14204950|NONE_0
D014810_D009203 NONE e_6\NN\14724645|green_22|and_12 (r_conj) tea_3\NN\7881800|in_30 (r_nmod) combination_7\NN\7951464|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) effect_0\NN\34213|infarction_82|._100 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_dobj) infarction_12\NN\14204950|effect_82|._18
D014810_D009203 NONE e_15\NN\14724645|green_22|and_12 (r_conj) tea_12\NN\7881800|NONE_0 (r_pobj) of_10\IN\0|the_21|combined_17|on_27|,_42|weight_49|bound_136 (r_prep) effects_9\NNS\13245626|to_28 (r_dobj) investigate_6\VB\644583|study_19|was_13|iso)-induced_201|._243 (r_xcomp) aimed_4\VBN\1987160|NONE_0 (l_parataxis) iso)-induced_39\VBN\0|study_220|was_214|investigate_201|._42 (l_dobj) infarction_41\NN\14204950|(_25
D014810_D009203 NONE e_12\NN\14724645|green_22|and_12 (r_conj) tea_9\NN\7881800|NONE_0 (r_pobj) of_7\IN\0|the_34|synergistic_30|protective_18|during_27 (r_prep) effect_6\NN\34213|findings_45|induced_45|._82 (r_dobj) indicate_2\VBP\952524|NONE_0 (l_ccomp) induced_15\VBN\1627355|findings_90|effect_45|._37 (l_dobj) infarction_17\NN\14204950|NONE_0
2096243
C017367_D019965 CID carmofur_0\NN\0|-_8 (r_npadvmod) induced_2\VBN\1627355|organic_8|mental_16|._32 (r_amod) disorders_5\NNS\14034177|NONE_0
C017367_D019965 CID carmofur_19\NN\0|-_8 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) leukoencephalopathy_22\NN\0|NONE_0 (r_pobj) of_18\IN\0|the_10 (r_prep) onset_17\NN\7325190|NONE_0 (r_pobj) after_15\IN\0|the_22|prognostic_18 (r_prep) period_14\NN\13575869|NONE_0 (r_pobj) in_11\IN\13603305|a_21|old_11 (r_prep) female_10\NN\15388|NONE_0 (r_pobj) in_5\IN\13603305|disorder_22|was_13|._104 (r_prep) observed_4\VBN\2163746|NONE_0 (l_nsubjpass) disorder_2\NN\14034177|was_9|in_22|._126
C017367_D056784 CID carmofur_19\NN\0|-_8 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) leukoencephalopathy_22\NN\0|NONE_0
C017367_D056784 CID carmofur_2\NN\0|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) leukoencephalopathy_5\JJ\0|consequently_31|,_19|may_20|uncommonly_24|in_42|._95
C017367_D010554 NONE carmofur_2\NN\0|-_8 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) leukoencephalopathy_5\JJ\0|consequently_31|,_19|may_20|uncommonly_24|in_42|._95 (r_nsubj) result_8\VB\34213|NONE_0 (l_prep) in_9\IN\13603305|consequently_73|,_61|leukoencephalopathy_42|may_22|uncommonly_18|._53 (l_pobj) syndrome_12\NN\5870365|NONE_0
3676049
D007530_D007022 CID isoflurane_6\RB\3570838|-_10 (r_npadvmod) induced_8\VBN\1627355|in_20 (r_amod) hypotension_9\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_12\RB\3570838|-_10 (r_npadvmod) induced_14\VBN\1627355|in_20 (r_amod) hypotension_15\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_19\NN\3570838|NONE_0 (r_pobj) of_18\IN\0|the_9 (r_prep) dose_17\NN\3740161|NONE_0 (r_dobj) increasing_15\VBG\169651|NONE_0 (r_pcomp) by_14\IN\0|hypotension_57|was_12|,_36|and_38|maintained_42|._97 (r_prep) induced_13\VBN\1627355|NONE_0 (l_nsubjpass) hypotension_1\NN\14057371|was_45|by_57|,_93|and_95|maintained_99|._154
D008628_D007022 NONE hg_11\NNP\14625458|NONE_0 (r_pobj) of_6\IN\0|an_15|average_12 (r_prep) map_5\NNP\4076846|NONE_0 (r_pobj) to_2\IN\0|controlled_23 (r_prep) hypotension_1\NN\14057371|was_45|by_57|,_93|and_95|maintained_99|._154
D014978_D013345 NONE xenon-133_24\.\0|flow_143|were_123|after_99|by_64 (r_punct) measured_4\VBN\697589|NONE_0 (l_prep) after_9\IN\0|flow_44|were_24|by_35|xenon-133_99 (l_pobj) haemorrhage_12\NN\14285662|days_28
D010100_D007022 NONE oxygen_8\NN\14622893|NONE_0 (r_pobj) for_7\IN\0|cerebral_24|metabolic_15 (r_prep) rate_6\NN\13815152|cerebral_43|blood_34|and_23 (r_conj) flow_2\NN\7311115|were_44|during_58|._170 (r_nsubjpass) measured_10\VBN\697589|NONE_0 (l_prep) during_11\IN\0|flow_58|were_14|._112 (l_pobj) hypotension_15\NN\14057371|NONE_0
D007530_D002532 NONE isoflurane_6\RB\3570838|-_10 (r_npadvmod) induced_8\VBN\1627355|in_20 (r_amod) hypotension_9\NN\14057371|NONE_0 (l_prep) in_10\IN\13603305|induced_20 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) subjected_12\VBN\137313|NONE_0 (l_prep) for_15\IN\0|to_11 (l_pobj) aneurysms_17\NNS\14057371|NONE_0
D007530_D002532 NONE isoflurane_12\RB\3570838|-_10 (r_npadvmod) induced_14\VBN\1627355|in_20 (r_amod) hypotension_15\NN\14057371|NONE_0 (l_prep) in_16\IN\13603305|induced_20 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_acl) subjected_19\VBN\137313|10_12 (l_prep) to_20\IN\0|NONE_0 (l_pobj) craniotomy_21\NN\671351|NONE_0 (l_prep) for_22\IN\0|NONE_0 (l_pobj) clipping_23\NN\6400510|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) aneurysm_27\NN\14057371|NONE_0
D007530_D000783 NONE isoflurane_7\JJ\3570838|the_4 (r_amod) concentration_8\NN\4916342|after_50|was_14|to_26|._34 (r_nsubjpass) reduced_10\VBN\441445|NONE_0 (l_prep) after_0\IN\0|concentration_50|was_64|to_76|._84 (l_pobj) clipping_2\NN\6400510|NONE_0 (l_prep) of_3\IN\0|the_13 (l_pobj) aneurysm_5\NN\14057371|NONE_0
D010100_D002532 NONE oxygen_8\NN\14622893|NONE_0 (r_pobj) for_7\IN\0|cerebral_24|metabolic_15 (r_prep) rate_6\NN\13815152|cerebral_43|blood_34|and_23 (r_conj) flow_2\NN\7311115|were_44|during_58|._170 (r_nsubjpass) measured_10\VBN\697589|NONE_0 (l_prep) during_11\IN\0|flow_58|were_14|._112 (l_pobj) hypotension_15\NN\14057371|NONE_0 (l_prep) in_16\IN\13603305|induced_20 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_acl) subjected_19\VBN\137313|10_12 (l_prep) to_20\IN\0|NONE_0 (l_pobj) craniotomy_21\NN\671351|NONE_0 (l_prep) for_22\IN\0|NONE_0 (l_pobj) clipping_23\NN\6400510|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) aneurysm_27\NN\14057371|NONE_0
10706004
D011188_D003866 NONE k)-atpase_28\NNP\0|NONE_0 (r_pobj) of_23\IN\0|deteriorated_36|na+-binding_23 (r_prep) properties_22\NNS\32613|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) consequence_18\NN\34213|NONE_0 (r_pobj) as_16\IN\14622893|by_46|from_19 (r_prep) accompanied_9\VBN\0|a_26|reversible_24 (l_agent) by_10\IN\0|from_27|as_46 (l_pobj) na+-extrusion_12\NN\0|NONE_0 (l_amod) depressed_11\JJ\1819147|NONE_0
D009569_D003866 NONE no_2\JJ\7204911|-_2 (r_compound) synthase_4\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) inhibition_0\NN\1068773|hypertension_47|._194 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_dobj) hypertension_8\NN\14057371|inhibition_47|._147 (l_acl) accompanied_9\VBN\0|a_26|reversible_24 (l_agent) by_10\IN\0|from_27|as_46 (l_pobj) na+-extrusion_12\NN\0|NONE_0 (l_amod) depressed_11\JJ\1819147|NONE_0
D019331_D006973 NONE ester_49\NN\14727670|40_42|mg_39|/_37|/_34|day_33 (r_appos) kg_40\NNS\13717155|NONE_0 (r_pobj) with_36\IN\0|synthase_20 (r_prep) inhibition_35\NN\1068773|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_prep) rats_30\NNS\2329401|NONE_0 (r_pobj) in_29\IN\13603305|for_96 (r_prep) induced_28\VBN\1627355|assess_159|,_80|we_78|response_63|._120 (r_advcl) studied_14\VBD\0|NONE_0 (l_dobj) response_16\NN\11410625|assess_96|,_17|we_15|induced_63|._183 (l_prep) of_17\IN\0|the_13 (l_pobj) k)-atpase_22\NNP\0|NONE_0 (l_prep) to_23\IN\0|cardiac_22|(_14|na_13|,_11 (l_pobj) hypertension_27\NN\14057371|NONE_0
D019331_D006973 NONE name_53\NNP\6284225|arginine_25|methyl_16|)_4 (r_appos) ester_49\NN\14727670|40_42|mg_39|/_37|/_34|day_33 (r_appos) kg_40\NNS\13717155|NONE_0 (r_pobj) with_36\IN\0|synthase_20 (r_prep) inhibition_35\NN\1068773|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_prep) rats_30\NNS\2329401|NONE_0 (r_pobj) in_29\IN\13603305|for_96 (r_prep) induced_28\VBN\1627355|assess_159|,_80|we_78|response_63|._120 (r_advcl) studied_14\VBD\0|NONE_0 (l_dobj) response_16\NN\11410625|assess_96|,_17|we_15|induced_63|._183 (l_prep) of_17\IN\0|the_13 (l_pobj) k)-atpase_22\NNP\0|NONE_0 (l_prep) to_23\IN\0|cardiac_22|(_14|na_13|,_11 (l_pobj) hypertension_27\NN\14057371|NONE_0
D012964_D003866 NONE na+-extrusion_12\NN\0|NONE_0 (l_amod) depressed_11\JJ\1819147|NONE_0
D012964_D003866 NONE na+-binding_21\NN\0|deteriorated_13|of_23 (r_compound) properties_22\NNS\32613|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) consequence_18\NN\34213|NONE_0 (r_pobj) as_16\IN\14622893|by_46|from_19 (r_prep) accompanied_9\VBN\0|a_26|reversible_24 (l_agent) by_10\IN\0|from_27|as_46 (l_pobj) na+-extrusion_12\NN\0|NONE_0 (l_amod) depressed_11\JJ\1819147|NONE_0
D012964_D003866 NONE na_26\UH\14625458|the_5|(_1|,_2 (r_nmod) k)-atpase_28\NNP\0|NONE_0 (r_pobj) of_23\IN\0|deteriorated_36|na+-binding_23 (r_prep) properties_22\NNS\32613|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) consequence_18\NN\34213|NONE_0 (r_pobj) as_16\IN\14622893|by_46|from_19 (r_prep) accompanied_9\VBN\0|a_26|reversible_24 (l_agent) by_10\IN\0|from_27|as_46 (l_pobj) na+-extrusion_12\NN\0|NONE_0 (l_amod) depressed_11\JJ\1819147|NONE_0
D009569_D006973 CID oxide_17\NN\14818238|NONE_0 (r_npadvmod) deficient_18\JJ\0|nitric_13 (r_amod) hypertension_19\NN\14057371|NONE_0
D009569_D006973 CID no_2\DT\7204911|NONE_0 (r_det) synthesis_3\NN\13446390|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) inhibition_0\NN\1068773|hypertension_45|._57 (r_nsubj) induces_4\VBZ\1627355|NONE_0 (l_dobj) hypertension_6\NN\14057371|inhibition_45|._12
D009569_D006973 CID no_24\JJ\7204911|-_2 (r_npadvmod) deficient_26\JJ\0|NONE_0 (r_amod) hypertension_27\NN\14057371|NONE_0
D009569_D006973 CID no_32\JJ\7204911|-_2 (r_compound) synthase_34\NN\0|with_20 (r_compound) inhibition_35\NN\1068773|NONE_0 (r_pobj) by_31\IN\0|NONE_0 (r_prep) rats_30\NNS\2329401|NONE_0 (r_pobj) in_29\IN\13603305|for_96 (r_prep) induced_28\VBN\1627355|assess_159|,_80|we_78|response_63|._120 (r_advcl) studied_14\VBD\0|NONE_0 (l_dobj) response_16\NN\11410625|assess_96|,_17|we_15|induced_63|._183 (l_prep) of_17\IN\0|the_13 (l_pobj) k)-atpase_22\NNP\0|NONE_0 (l_prep) to_23\IN\0|cardiac_22|(_14|na_13|,_11 (l_pobj) hypertension_27\NN\14057371|NONE_0
D009569_D006973 CID no_2\JJ\7204911|-_2 (r_compound) synthase_4\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) inhibition_0\NN\1068773|hypertension_47|._194 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_dobj) hypertension_8\NN\14057371|inhibition_47|._147
D000255_D006973 NONE atp_4\NNP\14964590|and_4 (r_conj) sodium_2\NN\14625458|of_26 (r_nmod) affinities_5\NNS\11426530|NONE_0 (r_pobj) of_1\IN\0|during_58|._110 (r_prep) changes_0\NNS\7283608|NONE_0 (l_prep) during_13\IN\0|of_58|._52 (l_conj) after_15\IN\0|and_4 (l_pobj) hypertension_19\NN\14057371|NONE_0
D000255_D006973 NONE atp_20\NNP\14964590|-_3 (r_npadvmod) binding_22\VBG\4688246|the_8 (r_amod) site_23\NN\8673395|NONE_0 (r_pobj) of_18\IN\0|higher_16 (r_prep) affinity_17\NN\11426530|to_10 (r_pobj) due_14\IN\5174653|(_25|na_24|,_22|k)-atpase_21|,_2|,_46 (r_prep) increased_12\VBD\169651|after_64|,_32|the_30|of_17|revealed_62|._104 (r_parataxis) activity_6\NN\30358|NONE_0 (l_prep) after_0\IN\0|,_32|the_34|of_47|increased_64|revealed_126|._168 (l_pobj) recovery_1\NN\7357388|NONE_0 (l_prep) from_2\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
D000255_D006973 NONE atp_33\NNP\14964590|NONE_0 (r_pobj) for_32\IN\0|the_21|lowered_17|km_9 (r_prep) value_31\NN\5856066|NONE_0 (r_pobj) from_27\IN\0|as_12 (r_prep) revealed_26\VBN\2137132|after_126|,_94|the_92|of_79|increased_62|._42 (r_advcl) activity_6\NN\30358|NONE_0 (l_prep) after_0\IN\0|,_32|the_34|of_47|increased_64|revealed_126|._168 (l_pobj) recovery_1\NN\7357388|NONE_0 (l_prep) from_2\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
D012964_D006973 NONE sodium_2\NN\14625458|of_26 (r_nmod) affinities_5\NNS\11426530|NONE_0 (r_pobj) of_1\IN\0|during_58|._110 (r_prep) changes_0\NNS\7283608|NONE_0 (l_prep) during_13\IN\0|of_58|._52 (l_conj) after_15\IN\0|and_4 (l_pobj) hypertension_19\NN\14057371|NONE_0
D012964_D006973 NONE na_10\UH\14625458|the_13|cardiac_9|(_1|,_2 (r_nmod) k)-atpase_12\NNP\0|NONE_0 (r_pobj) of_6\IN\0|sodium_26 (r_prep) affinities_5\NNS\11426530|NONE_0 (r_pobj) of_1\IN\0|during_58|._110 (r_prep) changes_0\NNS\7283608|NONE_0 (l_prep) during_13\IN\0|of_58|._52 (l_conj) after_15\IN\0|and_4 (l_pobj) hypertension_19\NN\14057371|NONE_0
D012964_D006973 NONE sodium_9\NN\14625458|intracellular_14 (r_compound) level_10\NN\4916342|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) elevation_6\NN\7445480|in_35|,_2|was_40|in_55|._72 (r_nsubjpass) documented_12\VBN\1000214|NONE_0 (l_prep) in_0\IN\13603305|,_33|elevation_35|was_75|in_90|._107 (l_pobj) models_2\NNS\5888929|NONE_0 (l_prep) of_3\IN\0|several_15 (l_pobj) hypertension_4\NN\14057371|NONE_0
D012964_D006973 NONE na+_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|transmembraneous_27 (r_prep) transport_9\NN\3575240|NONE_0 (r_pobj) in_7\IN\13603305|NONE_0 (r_prep) disturbances_6\NNS\407535|NONE_0 (r_pobj) of_5\IN\0|the_20|molecular_16 (r_prep) basis_4\NN\13790712|to_24 (r_dobj) assess_1\VB\5220461|,_79|we_81|response_96|induced_159|._279 (r_advcl) studied_14\VBD\0|NONE_0 (l_dobj) response_16\NN\11410625|assess_96|,_17|we_15|induced_63|._183 (l_prep) of_17\IN\0|the_13 (l_pobj) k)-atpase_22\NNP\0|NONE_0 (l_prep) to_23\IN\0|cardiac_22|(_14|na_13|,_11 (l_pobj) hypertension_27\NN\14057371|NONE_0
D012964_D006973 NONE na_20\UH\14625458|cardiac_9|(_1|,_2|to_13 (r_nmod) k)-atpase_22\NNP\0|NONE_0 (l_prep) to_23\IN\0|cardiac_22|(_14|na_13|,_11 (l_pobj) hypertension_27\NN\14057371|NONE_0
D012964_D006973 NONE na_9\NNP\14625458|(_1|,_2|k)-atpase_3|,_22|due_24|,_70 (r_npadvmod) increased_12\VBD\169651|after_64|,_32|the_30|of_17|revealed_62|._104 (r_parataxis) activity_6\NN\30358|NONE_0 (l_prep) after_0\IN\0|,_32|the_34|of_47|increased_64|revealed_126|._168 (l_pobj) recovery_1\NN\7357388|NONE_0 (l_prep) from_2\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
D012964_D006973 NONE na+-extrusion_12\NN\0|NONE_0 (r_pobj) by_10\IN\0|from_27|as_46 (r_agent) accompanied_9\VBN\0|a_26|reversible_24 (r_acl) hypertension_8\NN\14057371|inhibition_47|._147
D012964_D006973 NONE na+-binding_21\NN\0|deteriorated_13|of_23 (r_compound) properties_22\NNS\32613|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) consequence_18\NN\34213|NONE_0 (r_pobj) as_16\IN\14622893|by_46|from_19 (r_prep) accompanied_9\VBN\0|a_26|reversible_24 (r_acl) hypertension_8\NN\14057371|inhibition_47|._147
D012964_D006973 NONE na_26\UH\14625458|the_5|(_1|,_2 (r_nmod) k)-atpase_28\NNP\0|NONE_0 (r_pobj) of_23\IN\0|deteriorated_36|na+-binding_23 (r_prep) properties_22\NNS\32613|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) consequence_18\NN\34213|NONE_0 (r_pobj) as_16\IN\14622893|by_46|from_19 (r_prep) accompanied_9\VBN\0|a_26|reversible_24 (r_acl) hypertension_8\NN\14057371|inhibition_47|._147
D011188_D006973 NONE k)-atpase_12\NNP\0|NONE_0 (r_pobj) of_6\IN\0|sodium_26 (r_prep) affinities_5\NNS\11426530|NONE_0 (r_pobj) of_1\IN\0|during_58|._110 (r_prep) changes_0\NNS\7283608|NONE_0 (l_prep) during_13\IN\0|of_58|._52 (l_conj) after_15\IN\0|and_4 (l_pobj) hypertension_19\NN\14057371|NONE_0
D011188_D006973 NONE k)-atpase_22\NNP\0|NONE_0 (l_prep) to_23\IN\0|cardiac_22|(_14|na_13|,_11 (l_pobj) hypertension_27\NN\14057371|NONE_0
D011188_D006973 NONE k)-atpase_11\NNP\0|(_4|na_3|,_1|,_19|due_21|,_67 (r_nsubj) increased_12\VBD\169651|after_64|,_32|the_30|of_17|revealed_62|._104 (r_parataxis) activity_6\NN\30358|NONE_0 (l_prep) after_0\IN\0|,_32|the_34|of_47|increased_64|revealed_126|._168 (l_pobj) recovery_1\NN\7357388|NONE_0 (l_prep) from_2\IN\0|NONE_0 (l_pobj) hypertension_3\NN\14057371|NONE_0
D011188_D006973 NONE k)-atpase_28\NNP\0|NONE_0 (r_pobj) of_23\IN\0|deteriorated_36|na+-binding_23 (r_prep) properties_22\NNS\32613|NONE_0 (r_pobj) of_19\IN\0|a_14 (r_prep) consequence_18\NN\34213|NONE_0 (r_pobj) as_16\IN\14622893|by_46|from_19 (r_prep) accompanied_9\VBN\0|a_26|reversible_24 (r_acl) hypertension_8\NN\14057371|inhibition_47|._147
10737864
D003000_D001919 CID clonidine_14\NN\2721160|NONE_0 (r_pobj) given_12\VBN\5892096|withdrawal_41 (r_prep) induces_15\VBZ\1627355|given_107|pattern_34|,_27|and_25 (l_dobj) withdrawal_17\NN\7206096|given_41 (l_conj) bradycardia_19\NNP\14110674|sympathetic_27|and_4
D003000_D001919 CID clonidine_24\NN\2721160|developmental_12|on_34 (r_poss) effects_27\NNS\13245626|that_31|would_50|other_68 (r_nsubj) mirror_35\VB\4069276|exhibits_218|,_105|we_103|._17 (r_ccomp) hypothesized_22\VBD\719734|NONE_0 (l_ccomp) exhibits_5\VBZ\6733939|,_113|we_115|mirror_218|._235 (l_conj) induces_15\VBZ\1627355|given_107|pattern_34|,_27|and_25 (l_dobj) withdrawal_17\NN\7206096|given_41 (l_conj) bradycardia_19\NNP\14110674|sympathetic_27|and_4
D003000_D001919 CID clonidine_19\NN\2721160|-_9 (r_npadvmod) induced_21\VBN\1627355|NONE_0 (r_amod) bradycardia_22\NN\14110674|baseline_44|cardiac_35|and_22
12617329
D014508_D007674 NONE urea_10\NN\14727670|and_4 (r_conj) creatinine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_19|in_23 (r_prep) concentrations_6\NNS\4916342|and_52|glutathione_64 (r_dobj) measuring_4\VBG\407535|and_118|by_122 (r_pcomp) by_3\IN\0|nephrotoxicity_28|was_13|._176 (r_prep) assessed_2\VBN\670261|NONE_0 (l_nsubjpass) nephrotoxicity_0\NN\0|was_15|by_28|._204
D006170_D007674 NONE arabic_6\JJ\6986894|NONE_0 (r_pobj) with_4\IN\0|on_16 (r_prep) treatment_3\NN\654885|NONE_0 (l_prep) on_7\IN\0|with_16 (l_pobj) nephrotoxicity_9\NN\0|NONE_0
D006170_D007674 NONE arabic_14\JJ\6986894|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) rats_11\NNS\2329401|NONE_0 (r_pobj) of_10\IN\0|on_24 (r_prep) treatment_9\NN\654885|NONE_0 (l_prep) on_15\IN\0|of_24 (l_pobj) failure_18\NN\66216|NONE_0 (l_acl) induced_19\VBN\1627355|acute_20|renal_14 (l_agent) by_20\IN\0|NONE_0 (l_pobj) nephrotoxicity_25\NN\0|NONE_0
D006170_D007674 NONE arabic_6\JJ\6986894|gum_4 (r_amod) treatment_7\NN\654885|that_16|has_10|amelioration_31 (r_nsubj) induced_9\VBN\1627355|it_51|could_48|be_42|._102 (l_dobj) amelioration_12\NN\248977|that_47|treatment_31|has_21 (l_prep) of_13\IN\0|a_22|modest_20 (l_pobj) some_14\DT\0|NONE_0 (l_prep) of_15\IN\0|NONE_0 (l_pobj) indices_20\NNS\13850304|NONE_0 (l_prep) of_21\IN\0|the_41|histological_37 (l_pobj) nephrotoxicity_23\NN\0|NONE_0
D005839_D007683 NONE gm_1\NNP\13717155|-_2 (r_npadvmod) induced_3\VBN\1627355|the_7|proximal_8|tubular_17 (r_amod) necrosis_6\NN\11444117|be_21|._123
D005839_D007683 NONE gm_16\NNP\13717155|with_12|than_28 (r_dobj) given_15\VBN\5892096|NONE_0 (r_acl) rats_14\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|less_12 (r_prep) severe_12\JJ\0|to_20 (r_acomp) be_9\VB\14625458|necrosis_21|._102 (r_xcomp) appeared_7\VBD\2604760|NONE_0 (l_nsubj) necrosis_6\NN\11444117|be_21|._123
D005839_D007683 NONE gm_25\NNP\13717155|NONE_0 (r_pobj) given_24\VBN\5892096|NONE_0 (r_acl) those_23\DT\0|NONE_0 (r_pobj) in_22\IN\13603305|NONE_0 (r_prep) than_21\IN\0|gm_28|with_16 (r_prep) given_15\VBN\5892096|NONE_0 (r_acl) rats_14\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|less_12 (r_prep) severe_12\JJ\0|to_20 (r_acomp) be_9\VB\14625458|necrosis_21|._102 (r_xcomp) appeared_7\VBD\2604760|NONE_0 (l_nsubj) necrosis_6\NN\11444117|be_21|._123
D005839_D007674 NONE gentamicin_8\NN\2716866|in_26 (r_amod) nephrotoxicity_9\NN\0|NONE_0
D005839_D007674 NONE gentamicin_21\NN\2716866|(_11|gm_12|)_14 (r_nmod) nephrotoxicity_25\NN\0|NONE_0
D005839_D007674 NONE gm_23\NNP\13717155|gentamicin_12|(_1|)_2 (r_nmod) nephrotoxicity_25\NN\0|NONE_0
D005839_D007674 NONE gm_22\NNP\13717155|NONE_0 (r_compound) nephrotoxicity_23\NN\0|NONE_0
D006170_D058186 CID arabic_14\JJ\6986894|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) rats_11\NNS\2329401|NONE_0 (r_pobj) of_10\IN\0|on_24 (r_prep) treatment_9\NN\654885|NONE_0 (l_prep) on_15\IN\0|of_24 (l_pobj) failure_18\NN\66216|NONE_0
D005839_D058186 CID gentamicin_21\NN\2716866|(_11|gm_12|)_14 (r_nmod) nephrotoxicity_25\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|acute_20|renal_14 (r_acl) failure_18\NN\66216|NONE_0
D005839_D058186 CID gm_23\NNP\13717155|gentamicin_12|(_1|)_2 (r_nmod) nephrotoxicity_25\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|acute_20|renal_14 (r_acl) failure_18\NN\66216|NONE_0
D006170_D007683 NONE arabic_20\JJ\6986894|together_18 (r_pobj) with_18\IN\0|gm_12|than_16 (r_prep) given_15\VBN\5892096|NONE_0 (r_acl) rats_14\NNS\2329401|NONE_0 (r_pobj) in_13\IN\13603305|less_12 (r_prep) severe_12\JJ\0|to_20 (r_acomp) be_9\VB\14625458|necrosis_21|._102 (r_xcomp) appeared_7\VBD\2604760|NONE_0 (l_nsubj) necrosis_6\NN\11444117|be_21|._123
D003404_D007674 NONE creatinine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_19|in_23 (r_prep) concentrations_6\NNS\4916342|and_52|glutathione_64 (r_dobj) measuring_4\VBG\407535|and_118|by_122 (r_pcomp) by_3\IN\0|nephrotoxicity_28|was_13|._176 (r_prep) assessed_2\VBN\670261|NONE_0 (l_nsubjpass) nephrotoxicity_0\NN\0|was_15|by_28|._204
D005978_D007674 NONE glutathione_16\NN\0|concentrations_64|and_12 (r_conj) measuring_4\VBG\407535|and_118|by_122 (r_pcomp) by_3\IN\0|nephrotoxicity_28|was_13|._176 (r_prep) assessed_2\VBN\670261|NONE_0 (l_nsubjpass) nephrotoxicity_0\NN\0|was_15|by_28|._204
D005978_D007674 NONE gsh_18\NNP\0|reduced_21|in_5|,_25 (r_appos) glutathione_16\NN\0|concentrations_64|and_12 (r_conj) measuring_4\VBG\407535|and_118|by_122 (r_pcomp) by_3\IN\0|nephrotoxicity_28|was_13|._176 (r_prep) assessed_2\VBN\670261|NONE_0 (l_nsubjpass) nephrotoxicity_0\NN\0|was_15|by_28|._204
6466532
D006024_D001919 NONE glycopyrrolate_3\NN\0|NONE_0 (l_prep) in_6\IN\13603305|i.v._33|and_13|atropine_9 (l_pobj) prevention_8\NN\1073995|NONE_0 (l_prep) of_9\IN\0|the_15 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D006024_D001919 NONE glycopyrrolate_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_18|before_117|,_152|prevent_157 (r_prep) effectiveness_1\NN\5190804|,_259|was_261|._272 (l_acl) prevent_27\VB\0|the_175|of_157|before_40|,_5 (l_dobj) arrhythmia_28\NN\14103288|to_11|following_27 (l_conj) bradycardia_30\NNP\14110674|and_4
D001285_D001919 NONE atropine_5\NN\14712692|i.v._24|and_4|in_9 (r_conj) glycopyrrolate_3\NN\0|NONE_0 (l_prep) in_6\IN\13603305|i.v._33|and_13|atropine_9 (l_pobj) prevention_8\NN\1073995|NONE_0 (l_prep) of_9\IN\0|the_15 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D001285_D001919 NONE atropine_12\NN\14712692|micrograms_20|and_4 (r_conj) kg-1_10\NNS\0|NONE_0 (r_dobj) glycopyrrolate_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_18|before_117|,_152|prevent_157 (r_prep) effectiveness_1\NN\5190804|,_259|was_261|._272 (l_acl) prevent_27\VB\0|the_175|of_157|before_40|,_5 (l_dobj) arrhythmia_28\NN\14103288|to_11|following_27 (l_conj) bradycardia_30\NNP\14110674|and_4
D013390_D001145 NONE suxamethonium_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|repeated_15 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) following_13\VBG\8180190|and_16|arrhythmias_12 (r_prep) bradycardia_10\NN\14110674|NONE_0 (l_conj) arrhythmias_12\NNS\14103288|and_4|following_12
D013390_D001145 NONE suxamethonium_35\NN\0|NONE_0 (r_pobj) of_34\IN\0|repeated_15 (r_prep) doses_33\NNS\3740161|NONE_0 (r_pobj) following_31\VBG\8180190|to_38|arrhythmia_27 (r_prep) prevent_27\VB\0|the_175|of_157|before_40|,_5 (l_dobj) arrhythmia_28\NN\14103288|to_11|following_27
D013390_D001919 CID suxamethonium_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|repeated_15 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) following_13\VBG\8180190|and_16|arrhythmias_12 (r_prep) bradycardia_10\NN\14110674|NONE_0
D013390_D001919 CID suxamethonium_35\NN\0|NONE_0 (r_pobj) of_34\IN\0|repeated_15 (r_prep) doses_33\NNS\3740161|NONE_0 (r_pobj) following_31\VBG\8180190|to_38|arrhythmia_27 (r_prep) prevent_27\VB\0|the_175|of_157|before_40|,_5 (l_dobj) arrhythmia_28\NN\14103288|to_11|following_27 (l_conj) bradycardia_30\NNP\14110674|and_4
D001285_D001145 NONE atropine_5\NN\14712692|i.v._24|and_4|in_9 (r_conj) glycopyrrolate_3\NN\0|NONE_0 (l_prep) in_6\IN\13603305|i.v._33|and_13|atropine_9 (l_pobj) prevention_8\NN\1073995|NONE_0 (l_prep) of_9\IN\0|the_15 (l_pobj) bradycardia_10\NN\14110674|NONE_0 (l_conj) arrhythmias_12\NNS\14103288|and_4|following_12
D001285_D001145 NONE atropine_12\NN\14712692|micrograms_20|and_4 (r_conj) kg-1_10\NNS\0|NONE_0 (r_dobj) glycopyrrolate_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_18|before_117|,_152|prevent_157 (r_prep) effectiveness_1\NN\5190804|,_259|was_261|._272 (l_acl) prevent_27\VB\0|the_175|of_157|before_40|,_5 (l_dobj) arrhythmia_28\NN\14103288|to_11|following_27
D006024_D001145 NONE glycopyrrolate_3\NN\0|NONE_0 (l_prep) in_6\IN\13603305|i.v._33|and_13|atropine_9 (l_pobj) prevention_8\NN\1073995|NONE_0 (l_prep) of_9\IN\0|the_15 (l_pobj) bradycardia_10\NN\14110674|NONE_0 (l_conj) arrhythmias_12\NNS\14103288|and_4|following_12
D006024_D001145 NONE glycopyrrolate_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_18|before_117|,_152|prevent_157 (r_prep) effectiveness_1\NN\5190804|,_259|was_261|._272 (l_acl) prevent_27\VB\0|the_175|of_157|before_40|,_5 (l_dobj) arrhythmia_28\NN\14103288|to_11|following_27
9199746
D014640_D013290 NONE vancomycin_14\NNP\2716866|and_4 (l_prep) for_15\IN\0|NONE_0 (l_pobj) endophthalmitis_20\NN\0|NONE_0
D000583_D064420 NONE amikacin_4\RB\0|NONE_0 (l_nsubj) toxicity_1\NN\13576101|._36
D000617_D009877 NONE aminoglycosides_2\NNS\0|although_22|have_16|substantially_21|prognosis_51 (r_nsubj) improved_5\VBN\126264|,_44|infarction_54|may_65|recovery_88|._96 (l_dobj) prognosis_7\NN\6748969|although_73|aminoglycosides_51|have_35|substantially_30 (l_prep) in_8\IN\13603305|visual_17 (l_pobj) endophthalmitis_9\NN\0|NONE_0
D019793_D013684 NONE fluorescein_1\NN\14598383|NONE_0 (r_amod) angiography_2\NN\904623|fundus_19|closure_40|._66 (r_nsubj) confirmed_3\VBD\0|NONE_0 (l_dobj) closure_6\NN\280853|fundus_59|angiography_40|._26 (l_conj) telangiectasis_8\NN\0|macular_30|capillary_22|and_4
D000583_D013290 NONE amikacin_6\JJ\0|following_26 (r_prep) presumed_5\VBN\719734|NONE_0 (l_prep) following_9\VBG\8180190|amikacin_26 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) amikacin_12\JJ\0|NONE_0 (l_conj) vancomycin_14\NNP\2716866|and_4 (l_prep) for_15\IN\0|NONE_0 (l_pobj) endophthalmitis_20\NN\0|NONE_0
D000583_D013290 NONE amikacin_12\JJ\0|NONE_0 (l_conj) vancomycin_14\NNP\2716866|and_4 (l_prep) for_15\IN\0|NONE_0 (l_pobj) endophthalmitis_20\NN\0|NONE_0
D000617_D007238 NONE aminoglycosides_2\NNS\0|although_22|have_16|substantially_21|prognosis_51 (r_nsubj) improved_5\VBN\126264|,_44|infarction_54|may_65|recovery_88|._96 (r_advcl) impair_14\VB\258857|NONE_0 (l_nsubj) infarction_12\NN\14204950|improved_54|,_10|may_11|recovery_34|._42
D000583_D012164 CID amikacin_6\JJ\0|following_26 (l_pobj) toxicity_8\NN\13576101|NONE_0
D000583_D012164 CID amikacin_12\JJ\0|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treatment_10\NN\654885|NONE_0 (r_pobj) following_9\VBG\8180190|amikacin_26 (r_prep) presumed_5\VBN\719734|NONE_0 (l_prep) amikacin_6\JJ\0|following_26 (l_pobj) toxicity_8\NN\13576101|NONE_0
D014640_D012164 NONE vancomycin_14\NNP\2716866|and_4 (r_conj) amikacin_12\JJ\0|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treatment_10\NN\654885|NONE_0 (r_pobj) following_9\VBG\8180190|amikacin_26 (r_prep) presumed_5\VBN\719734|NONE_0 (l_prep) amikacin_6\JJ\0|following_26 (l_pobj) toxicity_8\NN\13576101|NONE_0
17175308
D020123_D007674 NONE srl_13\NNP\0|NONE_0 (r_pobj) with_12\IN\0|cohort_38|was_12|as_9|,_30|due_32|)_82 (r_prep) treated_11\VBN\2376958|NONE_0 (l_prep) due_18\IN\5174653|cohort_70|was_44|with_32|as_23|,_2|)_50 (l_pobj) nephropathy_22\NN\14573196|to_21 (l_advmod) can_24\VB\3094503|chronic_31|allograft_23|(_1|(_5|n_6
D020123_D011507 CID sirolimus_4\VB\0|NONE_0 (r_pobj) to_3\TO\0|in_13 (r_prep) conversion_2\NN\7359599|NONE_0 (r_pobj) after_1\IN\0|._60 (r_prep) proteinuria_0\NNP\14299637|NONE_0
D020123_D011507 CID sirolimus_11\NN\0|NONE_0 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) of_10\IN\0|a_14 (r_prep) consequence_9\NN\34213|NONE_0 (r_pobj) as_7\IN\14622893|recently_40|,_32|proteinuria_30|has_18|been_14|,_37|remained_66|._82 (r_prep) reported_6\VBN\831651|NONE_0 (l_nsubjpass) proteinuria_3\NN\14299637|recently_10|,_2|has_12|been_16|as_30|,_67|remained_96|._112
D020123_D011507 CID srl_18\NN\0|NONE_0 (r_compound) conversion_19\NN\7359599|NONE_0 (r_pobj) after_17\IN\0|proteinuria_12 (r_prep) displayed_14\VBD\2137132|who_17|or_3 (l_dobj) proteinuria_16\NN\14299637|after_12
D020123_D011507 CID srl_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_8|as_7 (r_prep) use_6\NN\407535|NONE_0 (r_pobj) after_4\IN\0|proteinuria_23|common_7|._64 (r_prep) was_2\VBD\0|NONE_0 (l_nsubj) proteinuria_1\NN\14299637|common_16|after_23|._87
D020123_D051436 NONE srl_13\NNP\0|NONE_0 (r_pobj) with_12\IN\0|cohort_38|was_12|as_9|,_30|due_32|)_82 (r_prep) treated_11\VBN\2376958|NONE_0 (l_prep) due_18\IN\5174653|cohort_70|was_44|with_32|as_23|,_2|)_50 (l_pobj) nephropathy_22\NN\14573196|to_21
3750012
D010396_D001172 NONE penicillamine_4\NN\3740161|NONE_0 (l_conj) therapy_7\NN\657604|and_16 (l_prep) for_8\IN\0|chloroquine_20 (l_pobj) arthritis_10\NN\14171682|NONE_0
D010396_D001172 NONE penicillamine_16\NN\3740161|NONE_0 (l_conj) therapy_19\NN\657604|and_16 (l_prep) for_20\IN\0|chloroquine_20 (l_pobj) arthritis_22\NN\14171682|NONE_0
D002738_D001172 NONE chloroquine_6\NN\2721948|for_20 (r_amod) therapy_7\NN\657604|and_16 (l_prep) for_8\IN\0|chloroquine_20 (l_pobj) arthritis_10\NN\14171682|NONE_0
D002738_D001172 NONE chloroquine_18\NN\2721948|for_20 (r_compound) therapy_19\NN\657604|and_16 (l_prep) for_20\IN\0|chloroquine_20 (l_pobj) arthritis_22\NN\14171682|NONE_0
D002738_D009157 CID chloroquine_6\NN\2721948|for_20 (r_amod) therapy_7\NN\657604|and_16 (r_conj) penicillamine_4\NN\3740161|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|myasthenia_18|._72 (r_acl) gravis_1\NN\0|NONE_0
D002738_D009157 CID chloroquine_18\NN\2721948|for_20 (r_compound) therapy_19\NN\657604|and_16 (r_conj) penicillamine_16\NN\3740161|NONE_0 (r_pobj) after_15\IN\0|who_54|gravis_7 (r_prep) had_7\VBD\0|a_21|unique_19 (l_dobj) gravis_14\NN\0|who_47|after_7
D010396_D009157 CID penicillamine_4\NN\3740161|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|myasthenia_18|._72 (r_acl) gravis_1\NN\0|NONE_0
D010396_D009157 CID penicillamine_16\NN\3740161|NONE_0 (r_pobj) after_15\IN\0|who_54|gravis_7 (r_prep) had_7\VBD\0|a_21|unique_19 (l_dobj) gravis_14\NN\0|who_47|after_7
18186898
D019259_D009135 CID lamivudine_24\NN\3834836|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) augmented_22\VBN\153263|which_37|is_31|by_18|and_4 (r_conj) triggered_18\VBN\1641914|mitochondrial_35 (r_relcl) dysfunction_15\NN\14204950|NONE_0 (r_pobj) from_13\IN\0|that_70|dysfunction_43|may_18|have_14 (r_prep) resulted_12\VBN\2633881|we_72|._100 (l_nsubj) dysfunction_7\NN\14204950|that_27|may_25|have_29|from_43 (l_conj) myopathy_9\NNS\14204950|patient_34|tubular_24|and_4
D016559_D000138 NONE tacrolimus_1\NN\0|although_9|was_11|be_28|and_80|replaced_88 (r_nsubjpass) suspected_3\VBN\916909|NONE_0 (l_xcomp) be_5\VB\14625458|although_37|tacrolimus_28|was_17|and_52|replaced_60 (l_attr) cause_7\NN\7323922|to_10 (l_prep) of_8\IN\0|the_10 (l_pobj) acidosis_14\NN\14204950|NONE_0
D016559_D000138 NONE tacrolimus_1\NN\0|although_9|was_11|be_28|and_80|replaced_88 (r_nsubjpass) suspected_3\VBN\916909|NONE_0 (l_conj) replaced_17\VBN\1631072|although_97|tacrolimus_88|was_77|be_60|and_8 (l_agent) by_18\IN\0|was_13 (l_pobj) sirolimus_19\NN\0|NONE_0 (l_conj) acidosis_21\NN\14204950|,_2
D020123_D000138 NONE sirolimus_19\NN\0|NONE_0 (r_pobj) by_18\IN\0|was_13 (r_agent) replaced_17\VBN\1631072|although_97|tacrolimus_88|was_77|be_60|and_8 (r_conj) suspected_3\VBN\916909|NONE_0 (l_xcomp) be_5\VB\14625458|although_37|tacrolimus_28|was_17|and_52|replaced_60 (l_attr) cause_7\NN\7323922|to_10 (l_prep) of_8\IN\0|the_10 (l_pobj) acidosis_14\NN\14204950|NONE_0
D020123_D000138 NONE sirolimus_19\NN\0|NONE_0 (l_conj) acidosis_21\NN\14204950|,_2
D019259_D005198 CID lamivudine_24\NN\3834836|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) augmented_22\VBN\153263|which_37|is_31|by_18|and_4 (r_conj) triggered_18\VBN\1641914|mitochondrial_35 (r_relcl) dysfunction_15\NN\14204950|NONE_0 (r_pobj) from_13\IN\0|that_70|dysfunction_43|may_18|have_14 (r_prep) resulted_12\VBN\2633881|we_72|._100 (l_nsubj) dysfunction_7\NN\14204950|that_27|may_25|have_29|from_43
D016559_D009135 CID tacrolimus_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|which_19|is_13|and_14|augmented_18 (r_agent) triggered_18\VBN\1641914|mitochondrial_35 (r_relcl) dysfunction_15\NN\14204950|NONE_0 (r_pobj) from_13\IN\0|that_70|dysfunction_43|may_18|have_14 (r_prep) resulted_12\VBN\2633881|we_72|._100 (l_nsubj) dysfunction_7\NN\14204950|that_27|may_25|have_29|from_43 (l_conj) myopathy_9\NNS\14204950|patient_34|tubular_24|and_4
D019259_D028361 NONE lamivudine_24\NN\3834836|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) augmented_22\VBN\153263|which_37|is_31|by_18|and_4 (r_conj) triggered_18\VBN\1641914|mitochondrial_35 (r_relcl) dysfunction_15\NN\14204950|NONE_0
D016559_D028361 NONE tacrolimus_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|which_19|is_13|and_14|augmented_18 (r_agent) triggered_18\VBN\1641914|mitochondrial_35 (r_relcl) dysfunction_15\NN\14204950|NONE_0
D016559_D005198 CID tacrolimus_20\NN\0|NONE_0 (r_pobj) by_19\IN\0|which_19|is_13|and_14|augmented_18 (r_agent) triggered_18\VBN\1641914|mitochondrial_35 (r_relcl) dysfunction_15\NN\14204950|NONE_0 (r_pobj) from_13\IN\0|that_70|dysfunction_43|may_18|have_14 (r_prep) resulted_12\VBN\2633881|we_72|._100 (l_nsubj) dysfunction_7\NN\14204950|that_27|may_25|have_29|from_43
D019259_D006509 NONE lamivudine_0\NNP\3834836|was_11|because_21|._82 (r_nsubjpass) added_2\VBN\156601|NONE_0 (l_prep) because_3\IN\0|lamivudine_21|was_10|._61 (l_pobj) infection_9\NN\14052046|of_23
16330293
12084448
D007069_D009207 CID ifosfamide_27\NN\0|NONE_0 (r_pobj) of_26\IN\0|the_13|for_14 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) after_23\IN\0|myoclonus_45 (r_prep) disabling_14\VBG\126264|a_50|of_43 (l_dobj) myoclonus_16\NN\14360459|after_45
D007069_D009207 CID ifosfamide_12\JJ\0|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) infusion_10\NN\14589223|NONE_0 (r_pobj) during_9\IN\0|the_26|of_13|,_29|findings_49|following_109 (r_prep) presence_6\NN\13954253|in_30|,_6|associated_208|._238 (r_nsubj) suggest_31\VBP\1010118|NONE_0 (l_ccomp) associated_36\VBN\628491|in_238|,_214|presence_208|._30 (l_nsubjpass) myoclonus_34\NN\14360459|that_14|is_10|with_24
D007069_D009207 CID ifx_41\NNP\0|NONE_0 (r_pobj) of_40\IN\0|the_8 (r_prep) use_39\NN\407535|NONE_0 (r_pobj) with_37\IN\0|that_38|myoclonus_24|is_14 (r_prep) associated_36\VBN\628491|in_238|,_214|presence_208|._30 (l_nsubjpass) myoclonus_34\NN\14360459|that_14|is_10|with_24
D007069_D001927 CID ifosfamide_0\NNP\0|presenting_26|._51 (r_compound) encephalopathy_1\NN\14084880|NONE_0
D007069_D010954 NONE ifosfamide_27\NN\0|NONE_0 (r_pobj) of_26\IN\0|the_13|for_14 (r_prep) infusion_25\NN\14589223|NONE_0 (l_prep) for_28\IN\0|the_27|of_14 (l_pobj) plasmacytoma_29\NN\14235200|NONE_0
D007069_D020820 NONE ifosfamide_0\NNP\0|presenting_26|._51 (r_compound) encephalopathy_1\NN\14084880|NONE_0 (l_acl) presenting_2\VBG\2137132|ifosfamide_26|._25 (l_prep) with_3\IN\0|NONE_0 (l_pobj) asterixis_4\NNS\0|NONE_0
D007069_D020820 NONE ifosfamide_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_19 (r_prep) administration_1\NN\1133281|was_29|and_46|resolved_76 (r_nsubjpass) discontinued_5\VBN\0|NONE_0 (l_conj) resolved_12\VBD\352826|administration_76|was_47|and_30 (l_nsubj) asterixis_11\NNS\0|within_16|completely_19|._29
D007069_D020820 NONE ifosfamide_12\JJ\0|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) infusion_10\NN\14589223|NONE_0 (r_pobj) during_9\IN\0|the_26|of_13|,_29|findings_49|following_109 (r_prep) presence_6\NN\13954253|in_30|,_6|associated_208|._238 (l_prep) of_7\IN\0|the_13|during_13|,_42|findings_62|following_122 (l_pobj) asterixis_8\NNS\0|NONE_0
D007069_D020820 NONE ifx_41\NNP\0|NONE_0 (r_pobj) of_40\IN\0|the_8 (r_prep) use_39\NN\407535|NONE_0 (r_pobj) with_37\IN\0|that_38|myoclonus_24|is_14 (r_prep) associated_36\VBN\628491|in_238|,_214|presence_208|._30 (r_ccomp) suggest_31\VBP\1010118|NONE_0 (l_nsubj) presence_6\NN\13954253|in_30|,_6|associated_208|._238 (l_prep) of_7\IN\0|the_13|during_13|,_42|findings_62|following_122 (l_pobj) asterixis_8\NNS\0|NONE_0
15458908
D020849_D005705 NONE raloxifene_0\NNP\0|did_11|not_15|risk_28|,_71|disease_85|._215 (r_nsubj) increase_3\VB\13576355|NONE_0 (l_dep) disease_20\NN\14061805|raloxifene_85|did_74|not_70|risk_57|,_14|._130
D020849_D005705 NONE raloxifene_0\NNP\0|was_11|with_26|,_75|but_77|was_87 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_conj) was_13\VBD\0|raloxifene_87|was_76|with_61|,_12|but_10 (l_attr) risk_16\NN\14541044|there_23|._87 (l_prep) for_17\IN\0|no_18|increased_15 (l_pobj) cataracts_18\NNS\14252864|NONE_0 (l_conj) disease_21\NN\14061805|,_14
D020849_D054556 CID raloxifene_11\NN\0|:_40|during_38|,_2|was_11|with_26|._138 (r_nsubjpass) associated_13\VBN\628491|NONE_0 (l_prep) with_14\IN\0|:_66|during_64|,_28|raloxifene_26|was_15|._112 (l_pobj) risk_17\NN\14541044|NONE_0 (l_prep) for_18\IN\0|an_18|increased_15 (l_pobj) thromboembolism_20\NN\14100769|NONE_0
D020849_D054556 CID raloxifene_0\NNP\0|was_11|with_26|,_75|but_77|was_87 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|raloxifene_26|was_15|,_49|but_51|was_61 (l_pobj) risk_6\NN\14541044|NONE_0 (l_prep) for_7\IN\0|an_18|increased_15 (l_pobj) thromboembolism_9\NN\14100769|NONE_0
D020849_D004714 NONE raloxifene_0\NNP\0|did_11|not_15|risk_28|,_71|disease_85|._215 (r_nsubj) increase_3\VB\13576355|NONE_0 (l_dep) disease_20\NN\14061805|raloxifene_85|did_74|not_70|risk_57|,_14|._130 (l_appos) ci_27\NNP\13635336|gallbladder_33|(_13|rr_12|;_6 (l_appos) hyperplasia_34\NN\14365950|%_27|1.3_18|)_15|,_14
D020849_D004714 NONE raloxifene_0\NNP\0|was_11|with_26|,_75|but_77|was_87 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_conj) was_13\VBD\0|raloxifene_87|was_76|with_61|,_12|but_10 (l_attr) risk_16\NN\14541044|there_23|._87 (l_prep) for_17\IN\0|no_18|increased_15 (l_pobj) cataracts_18\NNS\14252864|NONE_0 (l_conj) disease_21\NN\14061805|,_14 (l_conj) hyperplasia_24\NN\14365950|gallbladder_33|,_14
D020849_D002386 NONE raloxifene_0\NNP\0|did_11|not_15|risk_28|,_71|disease_85|._215 (r_nsubj) increase_3\VB\13576355|NONE_0 (l_dobj) risk_4\NN\14541044|raloxifene_28|did_17|not_13|,_43|disease_57|._187 (l_prep) for_5\IN\0|NONE_0 (l_pobj) cataracts_6\NNS\14252864|NONE_0
D020849_D002386 NONE raloxifene_0\NNP\0|was_11|with_26|,_75|but_77|was_87 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_conj) was_13\VBD\0|raloxifene_87|was_76|with_61|,_12|but_10 (l_attr) risk_16\NN\14541044|there_23|._87 (l_prep) for_17\IN\0|no_18|increased_15 (l_pobj) cataracts_18\NNS\14252864|NONE_0
D020849_D010024 NONE raloxifene_4\NNP\0|,_21|trial_63|,_68 (r_compound) evaluation_5\NNP\874067|NONE_0 (r_pobj) of_3\IN\0|the_22|multiple_18 (r_prep) outcomes_2\NNPS\7291312|women_112|with_118|._135 (r_nsubj) enrolled_17\VBD\2471690|NONE_0 (l_prep) with_21\IN\0|outcomes_118|women_6|._17 (l_pobj) osteoporosis_22\NN\14204950|NONE_0
D020849_D016889 NONE raloxifene_0\NNP\0|did_11|not_15|risk_28|,_71|disease_85|._215 (r_nsubj) increase_3\VB\13576355|NONE_0 (l_dep) disease_20\NN\14061805|raloxifene_85|did_74|not_70|risk_57|,_14|._130 (l_appos) ci_27\NNP\13635336|gallbladder_33|(_13|rr_12|;_6 (l_appos) hyperplasia_34\NN\14365950|%_27|1.3_18|)_15|,_14 (l_appos) %_40\NN\0|endometrial_35|(_11 (l_conj) cancer_49\NN\14239425|rr_40|;_34|95_32|0.4_25|,_17|or_15|;_14|%_18
D020849_D016889 NONE raloxifene_0\NNP\0|was_11|with_26|,_75|but_77|was_87 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_conj) was_13\VBD\0|raloxifene_87|was_76|with_61|,_12|but_10 (l_attr) risk_16\NN\14541044|there_23|._87 (l_prep) for_17\IN\0|no_18|increased_15 (l_pobj) cataracts_18\NNS\14252864|NONE_0 (l_conj) disease_21\NN\14061805|,_14 (l_conj) hyperplasia_24\NN\14365950|gallbladder_33|,_14 (l_conj) cancer_28\NN\14239425|endometrial_40|,_17|or_15
17491223
D017256_D017202 NONE sestamibi_46\NNP\0|photon_17 (r_nmod) emission_50\NN\44455|NONE_0 (r_dobj) using_43\VBG\418025|ischemia_10|,_2 (r_conj) detecting_36\VBG\635012|NONE_0 (l_dobj) ischemia_41\NN\14195315|,_8|using_10
D004280_D017202 CID dobutamine_14\NN\0|-_10 (r_npadvmod) induced_16\VBN\1627355|myocardial_8 (r_amod) ischemia_18\NN\14195315|NONE_0
D004280_D017202 CID dobutamine_8\NN\0|-_10 (r_npadvmod) induced_10\VBN\1627355|myocardial_8 (r_amod) ischemia_12\NN\14195315|NONE_0
D004280_D017202 CID dobutamine_37\NN\0|-_10 (r_npadvmod) induced_39\VBN\1627355|myocardial_8 (r_amod) ischemia_41\NN\14195315|,_8|using_10
D017256_D007511 NONE sestamibi_46\NNP\0|photon_17 (r_nmod) emission_50\NN\44455|NONE_0 (r_dobj) using_43\VBG\418025|ischemia_10|,_2 (r_conj) detecting_36\VBG\635012|NONE_0 (r_pcomp) for_35\IN\0|to_172|value_141|,_39|compared_34|,_2|computed_99 (r_prep) assess_3\VB\5220461|:_5|._368 (l_conj) computed_51\VBD\632627|to_271|value_240|,_138|compared_133|,_101|for_99 (l_advcl) assess_60\VB\5220461|tomography_49 (l_dobj) presence_62\NN\13954253|to_14 (l_prep) of_65\IN\0|the_24|or_11|absence_8 (l_pobj) ischemia_66\NN\14195315|NONE_0
D004280_D007511 NONE dobutamine_37\NN\0|-_10 (r_npadvmod) induced_39\VBN\1627355|myocardial_8 (r_amod) ischemia_41\NN\14195315|,_8|using_10 (r_dobj) detecting_36\VBG\635012|NONE_0 (r_pcomp) for_35\IN\0|to_172|value_141|,_39|compared_34|,_2|computed_99 (r_prep) assess_3\VB\5220461|:_5|._368 (l_conj) computed_51\VBD\632627|to_271|value_240|,_138|compared_133|,_101|for_99 (l_advcl) assess_60\VB\5220461|tomography_49 (l_dobj) presence_62\NN\13954253|to_14 (l_prep) of_65\IN\0|the_24|or_11|absence_8 (l_pobj) ischemia_66\NN\14195315|NONE_0
10091617
D012642_D010300 NONE selegiline_0\NNP\0|-_10|hypotension_28|:_62|study_79|._118 (r_advmod) induced_2\VBN\1627355|NONE_0 (l_dobj) hypotension_4\NN\14057371|selegiline_28|-_18|:_34|study_51|._90 (l_prep) in_5\IN\13603305|postural_21 (l_pobj) disease_8\NN\14061805|NONE_0
D012642_D010300 NONE selegiline_30\NN\0|to_17 (r_dobj) receive_27\VB\2210855|NONE_0 (r_xcomp) randomized_25\VBN\278117|an_65|increased_62|in_42 (r_acl) mortality_15\NN\5054863|trial_25|and_99|compared_110 (r_dobj) found_12\VBD\13279262|NONE_0 (l_nsubj) trial_11\NN\786195|mortality_25|and_124|compared_135 (l_nmod) group_7\NNP\2137|(_6|ukpdrg_7|)_13 (l_compound) disease_5\NNP\14061805|parkinson_12|research_8
D012642_D010300 NONE selegiline_30\NN\0|to_17 (r_dobj) receive_27\VB\2210855|NONE_0 (r_xcomp) randomized_25\VBN\278117|an_65|increased_62|in_42 (r_acl) mortality_15\NN\5054863|trial_25|and_99|compared_110 (l_prep) in_16\IN\13603305|an_23|increased_20|randomized_42 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
D012642_D010300 NONE selegiline_30\NN\0|to_17 (r_dobj) receive_27\VB\2210855|NONE_0 (r_xcomp) randomized_25\VBN\278117|an_65|increased_62|in_42 (r_acl) mortality_15\NN\5054863|trial_25|and_99|compared_110 (l_prep) in_16\IN\13603305|an_23|increased_20|randomized_42 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0 (l_appos) pd_23\NNP\14625458|parkinson_21|(_1|)_2
D012642_D010300 NONE selegiline_17\RB\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|pd_12 (r_acl) patients_15\NNS\9898892|NONE_0 (l_compound) pd_14\NNP\14625458|receiving_12
D012642_D010300 NONE selegiline_18\NN\0|NONE_0 (r_pobj) on_17\IN\0|which_42|was_36|in_25 (r_prep) marked_10\VBN\1296462|systolic_43|orthostatic_34|,_45|lost_59 (l_prep) in_11\IN\13603305|which_17|was_11|on_25 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_compound) pd_15\NNP\14625458|20_3
D007980_D007024 NONE dopa_11\NNP\14601829|with_22|and_6 (r_conj) therapy_5\NN\657604|that_5|was_35|with_50 (r_nsubjpass) associated_13\VBN\628491|recently_63|,_55|we_53|._106 (l_prep) with_14\IN\0|that_55|therapy_50|was_15 (l_pobj) hypotension_18\NN\14057371|NONE_0
D007980_D007024 NONE dopa_13\NNP\14601829|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) combination_9\NN\7951464|NONE_0 (r_pobj) in_8\IN\13603305|that_16 (r_prep) selegiline_7\NN\0|is_38|with_52 (r_nsubjpass) associated_15\VBN\628491|our_67|previous_63 (l_prep) with_16\IN\0|selegiline_52|is_14 (l_pobj) hypotension_19\NN\14057371|NONE_0
D012642_D007024 CID selegiline_0\NNP\0|-_10|hypotension_28|:_62|study_79|._118 (r_advmod) induced_2\VBN\1627355|NONE_0 (l_dobj) hypotension_4\NN\14057371|selegiline_28|-_18|:_34|study_51|._90
D012642_D007024 CID selegiline_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|and_16|dopa_22 (r_prep) therapy_5\NN\657604|that_5|was_35|with_50 (r_nsubjpass) associated_13\VBN\628491|recently_63|,_55|we_53|._106 (l_prep) with_14\IN\0|that_55|therapy_50|was_15 (l_pobj) hypotension_18\NN\14057371|NONE_0
D012642_D007024 CID selegiline_25\NN\0|NONE_0 (r_pobj) of_24\IN\0|NONE_0 (r_prep) withdrawal_23\NN\7206096|NONE_0 (r_pobj) by_22\IN\0|which_20|was_14 (r_agent) abolished_21\VBN\0|selective_53|systolic_43|orthostatic_34 (r_relcl) hypotension_18\NN\14057371|NONE_0
D012642_D007024 CID selegiline_29\NN\0|in_11 (r_dobj) stopping_28\VBG\3323703|NONE_0 (l_prep) in_30\IN\13603305|selegiline_11 (l_pobj) expectation_32\NN\5941423|NONE_0 (l_acl) shed_36\VB\3859280|the_32 (l_prep) on_38\IN\0|that_27|this_22|might_17|light_6 (l_pobj) mechanisms_40\NNS\13446390|NONE_0 (l_relcl) causes_45\VBZ\7323922|the_33 (l_dobj) hypotension_47\NN\14057371|by_37|drug_24
D012642_D007024 CID selegiline_18\NN\0|NONE_0 (r_pobj) on_17\IN\0|which_42|was_36|in_25 (r_prep) marked_10\VBN\1296462|systolic_43|orthostatic_34|,_45|lost_59 (r_relcl) hypotension_7\NN\14057371|tilt_33|._133
D012642_D007024 CID selegiline_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) withdrawal_7\NN\7206096|days_11 (r_pobj) after_6\IN\0|hypotension_35|was_23|and_31|abolished_43|._93 (r_prep) ameliorated_3\VBN\126264|NONE_0 (l_nsubjpass) hypotension_1\NN\14057371|was_12|after_35|and_66|abolished_78|._128
D012642_D007024 CID selegiline_1\NN\0|NONE_0 (r_dobj) stopping_0\VBG\3323703|also_20|significantly_25|pressures_87|._159 (r_csubj) reduced_4\VBD\441445|NONE_0 (l_dobj) pressures_11\NNS\11419404|stopping_87|also_67|significantly_62|._72
D012642_D007024 CID selegiline_7\NN\0|is_38|with_52 (r_nsubjpass) associated_15\VBN\628491|our_67|previous_63 (l_prep) with_16\IN\0|selegiline_52|is_14 (l_pobj) hypotension_19\NN\14057371|NONE_0
D007980_D010300 NONE dopa_36\NN\14601829|with_14|._44 (r_nsubj) compared_37\VBN\644583|trial_135|mortality_110|and_11 (r_conj) found_12\VBD\13279262|NONE_0 (l_nsubj) trial_11\NN\786195|mortality_25|and_124|compared_135 (l_nmod) group_7\NNP\2137|(_6|ukpdrg_7|)_13 (l_compound) disease_5\NNP\14061805|parkinson_12|research_8
D007980_D010300 NONE dopa_36\NN\14601829|with_14|._44 (r_nsubj) compared_37\VBN\644583|trial_135|mortality_110|and_11 (r_conj) found_12\VBD\13279262|NONE_0 (l_dobj) mortality_15\NN\5054863|trial_25|and_99|compared_110 (l_prep) in_16\IN\13603305|an_23|increased_20|randomized_42 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
D007980_D010300 NONE dopa_36\NN\14601829|with_14|._44 (r_nsubj) compared_37\VBN\644583|trial_135|mortality_110|and_11 (r_conj) found_12\VBD\13279262|NONE_0 (l_dobj) mortality_15\NN\5054863|trial_25|and_99|compared_110 (l_prep) in_16\IN\13603305|an_23|increased_20|randomized_42 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0 (l_appos) pd_23\NNP\14625458|parkinson_21|(_1|)_2
D007980_D010300 NONE dopa_43\NN\14601829|alone_5 (r_dobj) taking_40\VBG\37396|NONE_0 (r_acl) those_39\DT\0|NONE_0 (r_pobj) with_38\IN\0|dopa_14|._30 (r_prep) compared_37\VBN\644583|trial_135|mortality_110|and_11 (r_conj) found_12\VBD\13279262|NONE_0 (l_nsubj) trial_11\NN\786195|mortality_25|and_124|compared_135 (l_nmod) group_7\NNP\2137|(_6|ukpdrg_7|)_13 (l_compound) disease_5\NNP\14061805|parkinson_12|research_8
D007980_D010300 NONE dopa_43\NN\14601829|alone_5 (r_dobj) taking_40\VBG\37396|NONE_0 (r_acl) those_39\DT\0|NONE_0 (r_pobj) with_38\IN\0|dopa_14|._30 (r_prep) compared_37\VBN\644583|trial_135|mortality_110|and_11 (r_conj) found_12\VBD\13279262|NONE_0 (l_dobj) mortality_15\NN\5054863|trial_25|and_99|compared_110 (l_prep) in_16\IN\13603305|an_23|increased_20|randomized_42 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
D007980_D010300 NONE dopa_43\NN\14601829|alone_5 (r_dobj) taking_40\VBG\37396|NONE_0 (r_acl) those_39\DT\0|NONE_0 (r_pobj) with_38\IN\0|dopa_14|._30 (r_prep) compared_37\VBN\644583|trial_135|mortality_110|and_11 (r_conj) found_12\VBD\13279262|NONE_0 (l_dobj) mortality_15\NN\5054863|trial_25|and_99|compared_110 (l_prep) in_16\IN\13603305|an_23|increased_20|randomized_42 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0 (l_appos) pd_23\NNP\14625458|parkinson_21|(_1|)_2
2951327
D005996_D007022 CID nitroglycerin_103\NN\15015501|or_3 (r_conj) hydralazine_101\NN\2721160|NONE_0 (r_pobj) by_100\IN\0|NONE_0 (r_agent) induced_99\VBN\1627355|comparable_23 (r_acl) hypotension_98\NN\14057371|NONE_0
D009638_D007022 NONE norepinephrine_76\NN\14807929|the_4|release_15|(_28 (r_amod) rate_78\NN\13815152|NONE_0 (r_pobj) of_74\IN\0|no_16 (r_prep) augmentation_73\NN\7356676|no_22|and_7|min_72|)_75 (r_conj) tachycardia_70\NN\14110674|93_84|1_77|p_74|,_57|or_55|%_44|but_7 (r_conj) +/-_45\NN\0|pressure_163|+/-_39|,_5|observed_182|._278 (r_appos) was_29\VBD\0|NONE_0 (l_conj) observed_90\VBN\2163746|pressure_345|+/-_221|,_187|+/-_182|._96 (l_advcl) is_93\VBZ\0|were_21|,_8 (l_prep) in_94\IN\13603305|which_9 (l_pobj) contrast_95\NN\13854649|NONE_0 (l_prep) to_96\IN\0|NONE_0 (l_pobj) hypotension_98\NN\14057371|NONE_0
D005996_D013610 NONE nitroglycerin_103\NN\15015501|or_3 (r_conj) hydralazine_101\NN\2721160|NONE_0 (r_pobj) by_100\IN\0|NONE_0 (r_agent) induced_99\VBN\1627355|comparable_23 (r_acl) hypotension_98\NN\14057371|NONE_0 (r_pobj) to_96\IN\0|NONE_0 (r_prep) contrast_95\NN\13854649|NONE_0 (r_pobj) in_94\IN\13603305|which_9 (r_prep) is_93\VBZ\0|were_21|,_8 (r_advcl) observed_90\VBN\2163746|pressure_345|+/-_221|,_187|+/-_182|._96 (r_conj) was_29\VBD\0|NONE_0 (l_appos) +/-_45\NN\0|pressure_163|+/-_39|,_5|observed_182|._278 (l_conj) tachycardia_70\NN\14110674|93_84|1_77|p_74|,_57|or_55|%_44|but_7
D006830_D013610 NONE hydralazine_101\NN\2721160|NONE_0 (r_pobj) by_100\IN\0|NONE_0 (r_agent) induced_99\VBN\1627355|comparable_23 (r_acl) hypotension_98\NN\14057371|NONE_0 (r_pobj) to_96\IN\0|NONE_0 (r_prep) contrast_95\NN\13854649|NONE_0 (r_pobj) in_94\IN\13603305|which_9 (r_prep) is_93\VBZ\0|were_21|,_8 (r_advcl) observed_90\VBN\2163746|pressure_345|+/-_221|,_187|+/-_182|._96 (r_conj) was_29\VBD\0|NONE_0 (l_appos) +/-_45\NN\0|pressure_163|+/-_39|,_5|observed_182|._278 (l_conj) tachycardia_70\NN\14110674|93_84|1_77|p_74|,_57|or_55|%_44|but_7
D009638_D013610 NONE norepinephrine_76\NN\14807929|the_4|release_15|(_28 (r_amod) rate_78\NN\13815152|NONE_0 (r_pobj) of_74\IN\0|no_16 (r_prep) augmentation_73\NN\7356676|no_22|and_7|min_72|)_75 (r_conj) tachycardia_70\NN\14110674|93_84|1_77|p_74|,_57|or_55|%_44|but_7
D006830_D007022 CID hydralazine_101\NN\2721160|NONE_0 (r_pobj) by_100\IN\0|NONE_0 (r_agent) induced_99\VBN\1627355|comparable_23 (r_acl) hypotension_98\NN\14057371|NONE_0
19657887
D000431_D004417 CID alcohol_9\NN\7881800|NONE_0 (r_pobj) of_8\IN\0|the_14 (r_prep) ingestion_7\NN\13440063|NONE_0 (r_pobj) after_5\IN\0|1_7 (r_prep) hour_4\NN\15154774|NONE_0 (r_pobj) in_0\IN\13603305|,_50|he_52|malaise_65|._124 (r_prep) developed_12\VBD\1753788|NONE_0 (l_dobj) malaise_13\NN\14446652|in_65|,_15|he_13|._59 (l_prep) with_14\IN\0|NONE_0 (l_pobj) flushing_15\NN\281101|NONE_0 (l_prep) of_16\IN\0|NONE_0 (l_pobj) face_18\NN\5225090|NONE_0 (l_conj) tachycardia_20\NN\14110674|the_10|,_2 (l_conj) dyspnea_23\NN\14299637|,_6|and_4
D000431_D013610 CID alcohol_9\NN\7881800|NONE_0 (r_pobj) of_8\IN\0|the_14 (r_prep) ingestion_7\NN\13440063|NONE_0 (r_pobj) after_5\IN\0|1_7 (r_prep) hour_4\NN\15154774|NONE_0 (r_pobj) in_0\IN\13603305|,_50|he_52|malaise_65|._124 (r_prep) developed_12\VBD\1753788|NONE_0 (l_dobj) malaise_13\NN\14446652|in_65|,_15|he_13|._59 (l_prep) with_14\IN\0|NONE_0 (l_pobj) flushing_15\NN\281101|NONE_0 (l_prep) of_16\IN\0|NONE_0 (l_pobj) face_18\NN\5225090|NONE_0 (l_conj) tachycardia_20\NN\14110674|the_10|,_2
D000431_D005483 CID alcohol_9\NN\7881800|NONE_0 (r_pobj) of_8\IN\0|the_14 (r_prep) ingestion_7\NN\13440063|NONE_0 (r_pobj) after_5\IN\0|1_7 (r_prep) hour_4\NN\15154774|NONE_0 (r_pobj) in_0\IN\13603305|,_50|he_52|malaise_65|._124 (r_prep) developed_12\VBD\1753788|NONE_0 (l_dobj) malaise_13\NN\14446652|in_65|,_15|he_13|._59 (l_prep) with_14\IN\0|NONE_0 (l_pobj) flushing_15\NN\281101|NONE_0 (l_prep) of_16\IN\0|NONE_0 (l_pobj) face_18\NN\5225090|NONE_0
D004221_D013610 NONE disulfiram_7\NN\3740161|-_10 (r_npadvmod) like_9\JJ\5839024|with_14 (r_amod) syndrome_10\NN\5870365|after_45|,_31|he_29|._99 (l_prep) with_11\IN\0|like_14 (l_pcomp) flushing_12\NN\281101|NONE_0 (l_conj) tachycardia_14\NN\14110674|,_2|after_38
D004221_D005483 NONE disulfiram_7\NN\3740161|-_10 (r_npadvmod) like_9\JJ\5839024|with_14 (r_amod) syndrome_10\NN\5870365|after_45|,_31|he_29|._99 (l_prep) with_11\IN\0|like_14 (l_pcomp) flushing_12\NN\281101|NONE_0
D004221_D007022 NONE disulfiram_7\NN\3740161|-_10 (r_npadvmod) like_9\JJ\5839024|with_14 (r_amod) syndrome_10\NN\5870365|after_45|,_31|he_29|._99 (l_prep) with_11\IN\0|like_14 (l_pcomp) flushing_12\NN\281101|NONE_0 (l_conj) tachycardia_14\NN\14110674|,_2|after_38 (l_conj) hypotension_18\NN\14057371|,_15|and_13
2071257
D012601_D000647 NONE scopolamine_13\NN\14712692|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) caused_11\VBN\1617192|NONE_0 (r_acl) amnesia_10\NN\5669934|NONE_0
D005997_D008569 NONE glycerylphosphorylcholine_15\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_12|on_51 (r_prep) effects_9\NNS\13245626|to_12 (l_prep) on_23\IN\0|the_63|of_51 (l_pobj) impairment_25\NN\7296428|NONE_0
D005997_D008569 NONE gfc_21\NNP\0|l_43|-_42|alpha_41|-_36 (r_appos) glycerylphosphorylcholine_15\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_12|on_51 (r_prep) effects_9\NNS\13245626|to_12 (l_prep) on_23\IN\0|the_63|of_51 (l_pobj) impairment_25\NN\7296428|NONE_0
D012601_D008569 CID scopolamine_28\NN\14712692|NONE_0 (r_pobj) by_27\IN\0|NONE_0 (r_agent) induced_26\VBN\1627355|memory_18 (r_acl) impairment_25\NN\7296428|NONE_0
D012601_D008569 CID scopolamine_20\NN\14712692|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_agent) induced_18\VBN\1627355|of_24 (r_acl) impairment_13\NN\7296428|to_14 (l_prep) of_14\IN\0|induced_24 (l_pobj) attention_15\NN\5701944|NONE_0 (l_conj) memory_17\NN\5926676|and_4
D005997_D000647 NONE phosphorylcholine_8\NN\0|NONE_0 (r_pobj) of_1\IN\0|on_38|._70 (r_prep) effect_0\NN\34213|NONE_0 (l_prep) on_9\IN\0|of_38|._32 (l_pobj) amnesia_10\NN\5669934|NONE_0
2375138
D008874_D006323 CID midazolam_2\RB\2830852|-_9 (r_npadvmod) associated_4\VBN\628491|possible_33|intramuscular_24|cardiorespiratory_11|and_36|death_40|._45 (r_amod) arrest_6\NN\88481|NONE_0
D008874_D006323 CID midazolam_17\NN\2830852|NONE_0 (r_pobj) of_16\IN\0|intramuscular_29 (r_prep) administration_15\NN\1133281|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) associated_12\VBN\628491|the_63|first_59|published_53|of_38 (r_acl) case_6\NN\7283608|report_37|._100 (l_prep) of_7\IN\0|the_25|first_21|published_15|associated_38 (l_pobj) arrest_9\NN\88481|NONE_0
D008874_D003643 NONE midazolam_2\RB\2830852|-_9 (r_npadvmod) associated_4\VBN\628491|possible_33|intramuscular_24|cardiorespiratory_11|and_36|death_40|._45 (r_amod) arrest_6\NN\88481|NONE_0 (l_conj) death_8\NN\7296428|possible_73|intramuscular_64|associated_40|cardiorespiratory_29|and_4|._5
D008874_D003643 NONE midazolam_17\NN\2830852|NONE_0 (r_pobj) of_16\IN\0|intramuscular_29 (r_prep) administration_15\NN\1133281|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) associated_12\VBN\628491|the_63|first_59|published_53|of_38 (r_acl) case_6\NN\7283608|report_37|._100 (l_prep) of_7\IN\0|the_25|first_21|published_15|associated_38 (l_pobj) arrest_9\NN\88481|NONE_0 (l_conj) death_11\NN\7296428|cardiorespiratory_29|and_4
1436384
C070935_D020258 NONE ly274614_13\NNP\0|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_prep) rodents_11\NNS\1886756|NONE_0 (r_pobj) in_10\IN\13603305|striatal_26|dopamine_17 (r_prep) neurons_9\NNS\5430628|NONE_0 (r_pobj) toward_6\IN\0|induced_22 (r_prep) neurotoxicity_5\NN\0|NONE_0
C070935_D020258 NONE ly274614_23\NNP\0|that_5|antagonist_29 (r_nsubj) is_24\VBZ\0|that_144|effect_124|receptors_28|and_18 (r_conj) involves_18\VBZ\2676054|the_115 (l_nsubj) effect_8\NN\34213|that_20|receptors_96|and_106|is_124 (l_amod) neurotoxic_7\JJ\0|the_4|of_18
D000661_D020258 CID amphetamine_2\NN\3248958|-_11 (r_npadvmod) induced_4\VBN\1627355|toward_22 (r_amod) neurotoxicity_5\NN\0|NONE_0
D000661_D020258 CID amphetamine_10\NN\3248958|related_16|toward_34 (r_nmod) compounds_13\NNS\5869584|NONE_0 (r_pobj) of_9\IN\0|the_22|neurotoxic_18 (r_prep) effect_8\NN\34213|that_20|receptors_96|and_106|is_124 (l_amod) neurotoxic_7\JJ\0|the_4|of_18
D000596_D020258 NONE acid_18\NN\14818238|an_20|excitatory_17 (r_compound) antagonist_19\NN\7846|,_27 (r_appos) ly274614_13\NNP\0|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_prep) rodents_11\NNS\1886756|NONE_0 (r_pobj) in_10\IN\13603305|striatal_26|dopamine_17 (r_prep) neurons_9\NNS\5430628|NONE_0 (r_pobj) toward_6\IN\0|induced_22 (r_prep) neurotoxicity_5\NN\0|NONE_0
D004298_D020258 NONE dopamine_8\NN\14807737|striatal_9|in_17 (r_compound) neurons_9\NNS\5430628|NONE_0 (r_pobj) toward_6\IN\0|induced_22 (r_prep) neurotoxicity_5\NN\0|NONE_0
D004298_D020258 NONE dopamine_16\NN\14807737|nigrostriatal_14 (r_compound) neurons_17\NNS\5430628|NONE_0 (r_pobj) toward_14\IN\0|amphetamine_34|related_18 (r_prep) compounds_13\NNS\5869584|NONE_0 (r_pobj) of_9\IN\0|the_22|neurotoxic_18 (r_prep) effect_8\NN\34213|that_20|receptors_96|and_106|is_124 (l_amod) neurotoxic_7\JJ\0|the_4|of_18
D016202_D020258 NONE nmda_19\NNP\0|NONE_0 (r_compound) receptors_20\NNS\5225602|that_116|effect_96|and_10|is_28 (r_dobj) involves_18\VBZ\2676054|the_115 (l_nsubj) effect_8\NN\34213|that_20|receptors_96|and_106|is_124 (l_amod) neurotoxic_7\JJ\0|the_4|of_18
D016202_D020258 NONE nmda_26\NNP\0|an_3|receptor_5|with_25 (r_compound) antagonist_28\NN\7846|that_34|ly274614_29 (r_attr) is_24\VBZ\0|that_144|effect_124|receptors_28|and_18 (r_conj) involves_18\VBZ\2676054|the_115 (l_nsubj) effect_8\NN\34213|that_20|receptors_96|and_106|is_124 (l_amod) neurotoxic_7\JJ\0|the_4|of_18
12443032
D003042_D002637 CID cocaine_0\NN\3492717|pain_22 (r_nsubj) related_1\VBN\628491|:_18|are_20|we_24|tip_38|?_55 (l_dobj) pain_3\NN\14299637|cocaine_22
D003042_D002637 CID cocaine_6\NN\3492717|NONE_0 (r_pobj) of_5\IN\0|the_13|produce_14 (r_prep) tendency_4\NN\6193203|in_19|,_6|be_51|._162 (l_acl) produce_8\VB\7555863|the_27|of_14 (l_dobj) pain_10\NN\14299637|to_17
D003042_D002637 CID cocaine_6\NN\3492717|NONE_0 (r_pobj) of_5\IN\0|the_13|produce_14 (r_prep) tendency_4\NN\6193203|in_19|,_6|be_51|._162 (r_nsubj) ought_11\MD\0|NONE_0 (l_xcomp) be_13\VB\14625458|in_70|,_57|tendency_51|._111 (l_advcl) faced_22\VBN\2439281|to_46|in_40 (l_prep) with_23\IN\0|when_11 (l_pobj) victim_26\NN\9630641|NONE_0 (l_prep) of_27\IN\0|a_15|young_13|is_18 (l_pobj) pain_29\NN\14299637|NONE_0
D003042_D002637 CID cocaine_7\NN\3492717|NONE_0 (r_compound) use_8\NN\407535|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) related_5\VBN\628491|the_28|of_14 (r_acl) mechanism_1\NN\13446390|is_47|and_60|discussed_87 (l_prep) of_2\IN\0|the_14|related_14 (l_pobj) pain_4\NN\14299637|NONE_0
11135224
D017239_D002289 NONE paclitaxel_0\NNP\0|NONE_0 (l_conj) cisplatin_2\NN\0|,_2|._142 (l_conj) chemotherapy_7\NN\661091|,_30|and_28 (l_prep) within_8\IN\0|combination_25 (l_pobj) approach_12\NN\940842|NONE_0 (l_prep) in_13\IN\13603305|a_41|multidisciplinary_39|therapeutic_21 (l_pobj) carcinoma_18\NN\14239918|NONE_0
D017239_D002289 NONE paclitaxel_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) toxicity_15\NN\13576101|response_19|,_6|and_4 (r_conj) rate_12\NN\13815152|the_26|,_11 (r_conj) feasibility_9\NN\5152150|to_17|treat_100 (r_dobj) determine_7\VB\0|objective_31|._136 (l_xcomp) treat_26\VB\7570720|to_117|feasibility_100 (l_dobj) nsclc_28\NN\0|to_20
D017239_D002289 NONE paclitaxel_30\NN\0|NONE_0 (r_pobj) of_29\IN\0|a_14|(_14|m(2_22|)_25 (r_prep) combination_28\NN\7951464|NONE_0 (r_pobj) with_26\IN\0|patients_110|were_13|given_46|)_76|on_78|,_86|cisplatin_88|)_109|given_111|)_141|on_143|,_151|and_153|gemcitabine_157|given_182|._247 (r_prep) treated_25\VBN\2376958|NONE_0 (l_nsubjpass) patients_7\NNS\9898892|were_97|with_110|given_156|)_186|on_188|,_196|cisplatin_198|)_219|given_221|)_251|on_253|,_261|and_263|gemcitabine_267|given_292|._357 (l_prep) with_8\IN\0|five_45|consecutive_40|naive_15 (l_pobj) nsclc_11\NNP\0|NONE_0
D017239_D002289 NONE paclitaxel_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_16|,_24|and_26|gemcitabine_30 (r_prep) combination_1\NN\7951464|is_54|well_57|and_72|shows_76|._115 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_conj) shows_13\VBZ\429048|combination_76|is_22|well_19|and_4|._39 (l_prep) in_16\IN\13603305|activity_9 (l_pobj) nsclc_18\NNP\0|NONE_0
C056507_D064420 NONE gemcitabine_23\NN\0|NONE_0 (r_compound) combination_24\NN\7951464|a_41|,_29|cisplatin_27 (r_conj) paclitaxel_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) toxicity_15\NN\13576101|response_19|,_6|and_4
D002945_D002289 NONE cisplatin_2\NN\0|,_2|._142 (l_conj) chemotherapy_7\NN\661091|,_30|and_28 (l_prep) within_8\IN\0|combination_25 (l_pobj) approach_12\NN\940842|NONE_0 (l_prep) in_13\IN\13603305|a_41|multidisciplinary_39|therapeutic_21 (l_pobj) carcinoma_18\NN\14239918|NONE_0
D002945_D002289 NONE cisplatin_0\NN\0|-_9 (r_npadvmod) based_2\VBN\0|chemotherapy_6 (r_amod) combinations_4\NNS\7951464|quality_21|._98 (r_nsubj) improve_5\VBP\126264|NONE_0 (l_dobj) quality_6\NN\24264|combinations_21|._77 (l_prep) in_11\IN\13603305|of_21 (l_pobj) carcinoma_16\NN\14239918|NONE_0
D002945_D002289 NONE cisplatin_0\NN\0|-_9 (r_npadvmod) based_2\VBN\0|chemotherapy_6 (r_amod) combinations_4\NNS\7951464|quality_21|._98 (r_nsubj) improve_5\VBP\126264|NONE_0 (l_dobj) quality_6\NN\24264|combinations_21|._77 (l_prep) in_11\IN\13603305|of_21 (l_pobj) carcinoma_16\NN\14239918|NONE_0 (l_appos) nsclc_18\NNP\0|advanced_39|nonsmall_30|lung_16|(_1|)_5
D002945_D002289 NONE cisplatin_20\NN\0|a_14|,_2|combination_27 (r_conj) paclitaxel_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) toxicity_15\NN\13576101|response_19|,_6|and_4 (r_conj) rate_12\NN\13815152|the_26|,_11 (r_conj) feasibility_9\NN\5152150|to_17|treat_100 (r_dobj) determine_7\VB\0|objective_31|._136 (l_xcomp) treat_26\VB\7570720|to_117|feasibility_100 (l_dobj) nsclc_28\NN\0|to_20
D002945_D002289 NONE cisplatin_47\NN\0|patients_198|were_101|with_88|given_42|)_12|on_10|,_2|)_21|given_23|)_53|on_55|,_63|and_65|gemcitabine_69|given_94|._159 (r_conj) treated_25\VBN\2376958|NONE_0 (l_nsubjpass) patients_7\NNS\9898892|were_97|with_110|given_156|)_186|on_188|,_196|cisplatin_198|)_219|given_221|)_251|on_253|,_261|and_263|gemcitabine_267|given_292|._357 (l_prep) with_8\IN\0|five_45|consecutive_40|naive_15 (l_pobj) nsclc_11\NNP\0|NONE_0
D002945_D002289 NONE cisplatin_5\NN\0|,_2 (r_conj) paclitaxel_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_16|,_24|and_26|gemcitabine_30 (r_prep) combination_1\NN\7951464|is_54|well_57|and_72|shows_76|._115 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_conj) shows_13\VBZ\429048|combination_76|is_22|well_19|and_4|._39 (l_prep) in_16\IN\13603305|activity_9 (l_pobj) nsclc_18\NNP\0|NONE_0
D017239_D064420 NONE paclitaxel_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) toxicity_15\NN\13576101|response_19|,_6|and_4
D002945_D064420 NONE cisplatin_20\NN\0|a_14|,_2|combination_27 (r_conj) paclitaxel_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) toxicity_15\NN\13576101|response_19|,_6|and_4
C056507_D002289 NONE gemcitabine_5\NN\0|NONE_0 (r_compound) combination_6\NN\7951464|within_25 (r_compound) chemotherapy_7\NN\661091|,_30|and_28 (l_prep) within_8\IN\0|combination_25 (l_pobj) approach_12\NN\940842|NONE_0 (l_prep) in_13\IN\13603305|a_41|multidisciplinary_39|therapeutic_21 (l_pobj) carcinoma_18\NN\14239918|NONE_0
C056507_D002289 NONE gemcitabine_23\NN\0|NONE_0 (r_compound) combination_24\NN\7951464|a_41|,_29|cisplatin_27 (r_conj) paclitaxel_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) toxicity_15\NN\13576101|response_19|,_6|and_4 (r_conj) rate_12\NN\13815152|the_26|,_11 (r_conj) feasibility_9\NN\5152150|to_17|treat_100 (r_dobj) determine_7\VB\0|objective_31|._136 (l_xcomp) treat_26\VB\7570720|to_117|feasibility_100 (l_dobj) nsclc_28\NN\0|to_20
C056507_D002289 NONE gemcitabine_65\NN\0|patients_267|were_170|with_157|given_111|)_81|on_79|,_71|cisplatin_69|)_48|given_46|)_16|on_14|,_6|and_4|given_25|._90 (r_conj) treated_25\VBN\2376958|NONE_0 (l_nsubjpass) patients_7\NNS\9898892|were_97|with_110|given_156|)_186|on_188|,_196|cisplatin_198|)_219|given_221|)_251|on_253|,_261|and_263|gemcitabine_267|given_292|._357 (l_prep) with_8\IN\0|five_45|consecutive_40|naive_15 (l_pobj) nsclc_11\NNP\0|NONE_0
C056507_D002289 NONE gemcitabine_8\NN\0|the_46|of_30|,_6|and_4 (r_conj) combination_1\NN\7951464|is_54|well_57|and_72|shows_76|._115 (r_nsubjpass) tolerated_11\VBN\802318|NONE_0 (l_conj) shows_13\VBZ\429048|combination_76|is_22|well_19|and_4|._39 (l_prep) in_16\IN\13603305|activity_9 (l_pobj) nsclc_18\NNP\0|NONE_0
3403780
D000082_D017093 NONE paracetamol_0\NN\0|-_11 (r_npadvmod) associated_2\VBN\628491|,_15|acidosis_27|._62 (r_amod) coma_3\NN\5678932|NONE_0 (l_appos) acidosis_6\NN\14204950|associated_27|,_12|._35 (l_conj) failure_11\NN\66216|metabolic_38|,_20
D000082_D003128 NONE paracetamol_0\NN\0|-_11 (r_npadvmod) associated_2\VBN\628491|,_15|acidosis_27|._62 (r_amod) coma_3\NN\5678932|NONE_0
D000082_D058186 CID paracetamol_13\JJ\0|NONE_0 (r_compound) ingestion_14\NN\13440063|NONE_0 (r_pobj) following_12\VBG\8180190|acute_40|renal_34|and_20|failure_8 (r_prep) failure_8\NN\66216|case_40|,_14|is_60|._72 (l_conj) failure_11\NN\66216|acute_32|renal_26|and_12|following_8
D000082_D058186 NONE paracetamol_0\NN\0|-_11 (r_npadvmod) associated_2\VBN\628491|,_15|acidosis_27|._62 (r_amod) coma_3\NN\5678932|NONE_0 (l_appos) acidosis_6\NN\14204950|associated_27|,_12|._35 (l_conj) failure_11\NN\66216|metabolic_38|,_20
D000082_D000138 CID paracetamol_0\NN\0|-_11 (r_npadvmod) associated_2\VBN\628491|,_15|acidosis_27|._62 (r_amod) coma_3\NN\5678932|NONE_0 (l_appos) acidosis_6\NN\14204950|associated_27|,_12|._35
D000082_D000138 CID paracetamol_13\JJ\0|NONE_0 (r_compound) ingestion_14\NN\13440063|NONE_0 (r_pobj) following_12\VBG\8180190|acute_40|renal_34|and_20|failure_8 (r_prep) failure_8\NN\66216|case_40|,_14|is_60|._72 (r_nsubjpass) presented_16\VBN\2137132|NONE_0 (l_nsubjpass) case_1\NN\7283608|,_26|failure_40|is_100|._112 (l_prep) of_2\IN\0|a_7 (l_pobj) acidosis_4\NN\14204950|NONE_0
D000082_D017114 CID paracetamol_13\JJ\0|NONE_0 (r_compound) ingestion_14\NN\13440063|NONE_0 (r_pobj) following_12\VBG\8180190|acute_40|renal_34|and_20|failure_8 (r_prep) failure_8\NN\66216|case_40|,_14|is_60|._72 (l_conj) failure_11\NN\66216|acute_32|renal_26|and_12|following_8
2632720
D006854_D006973 NONE cortisol_8\NN\14751417|plasma_24|urinary_13 (r_compound) levels_9\NNS\4916342|in_54|had_7|been_11|following_25|demonstrated_98|._179 (r_nsubjpass) achieved_12\VBN\2524171|NONE_0 (l_conj) demonstrated_22\VBD\2137132|in_152|levels_98|had_91|been_87|following_73|._81 (l_dobj) hypertension_23\NN\14057371|NONE_0
D007654_D003480 NONE ketoconazole_16\JJ\0|NONE_0 (r_pobj) with_15\IN\0|a_18|term_11 (r_prep) basis_14\NN\13790712|NONE_0 (r_pobj) on_9\IN\0|patients_41|developed_39|._71 (r_prep) treated_8\VBN\2376958|NONE_0 (l_nsubj) patients_3\NNS\9898892|on_41|developed_80|._112 (l_prep) with_4\IN\0|14_12 (l_pobj) syndrome_7\NN\5870365|NONE_0
D007654_D006973 CID ketoconazole_7\JJ\0|prolonged_10 (r_compound) treatment_8\NN\654885|NONE_0 (r_pobj) of_5\IN\0|a_15 (r_prep) complication_4\NN\1073995|NONE_0 (r_pobj) as_2\IN\14622893|arterial_22|._53 (r_prep) hypertension_1\NN\14057371|NONE_0
D007654_D006973 CID ketoconazole_16\JJ\0|NONE_0 (r_pobj) with_15\IN\0|a_18|term_11 (r_prep) basis_14\NN\13790712|NONE_0 (r_pobj) on_9\IN\0|patients_41|developed_39|._71 (r_prep) treated_8\VBN\2376958|NONE_0 (l_advcl) developed_17\VBN\1753788|patients_80|on_39|._32 (l_dobj) hypertension_19\NN\14057371|NONE_0
D007654_D006973 CID ketoconazole_14\JJ\0|,_20|yet_22|monitoring_52 (r_compound) therapy_15\NN\657604|NONE_0 (r_dobj) following_13\VBG\8180190|in_79|levels_25|had_18|been_14|demonstrated_73|._154 (r_prep) achieved_12\VBN\2524171|NONE_0 (l_conj) demonstrated_22\VBD\2137132|in_152|levels_98|had_91|been_87|following_73|._81 (l_dobj) hypertension_23\NN\14057371|NONE_0
D007654_D006973 CID ketoconazole_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|high_11 (r_prep) doses_10\NNS\3740161|NONE_0 (r_pobj) with_8\IN\0|term_15 (r_prep) treatment_7\NN\654885|that_15|may_42|blockade_60 (r_nsubj) induce_14\VB\1627355|findings_75|._72 (l_dobj) blockade_16\NN\952963|that_75|treatment_60|may_18 (l_acl) leading_17\VBG\4339291|enzyme_16 (l_prep) to_18\IN\0|NONE_0 (l_pobj) hypertension_22\NN\14057371|NONE_0
17042910
C065179_D006973 NONE atorvastatin_5\NN\3676175|NONE_0 (r_pobj) of_4\IN\0|oxidant_16|in_16|._64 (r_prep) effects_3\NNS\13245626|NONE_0 (l_prep) in_6\IN\13603305|oxidant_32|of_16|._48 (l_pobj) hypertension_10\NN\14057371|NONE_0
C065179_D006973 NONE atorvastatin_0\NNP\3676175|properties_41|._204 (r_nsubj) possesses_4\VBZ\8209687|NONE_0 (l_dobj) properties_6\NNS\32613|atorvastatin_41|._163 (l_relcl) reported_10\VBN\831651|pleiotropic_38 (l_xcomp) improve_12\VB\126264|that_27|have_22|been_17 (l_prep) through_15\IN\0|to_32|function_9 (l_pobj) availability_17\NN\4718563|NONE_0 (l_prep) of_18\IN\0|increased_23 (l_pobj) production_23\NN\30358|NONE_0 (l_prep) in_24\IN\13603305|no_30|reduced_23|o2-_15 (l_pobj) forms_26\NNS\6286395|NONE_0 (l_prep) of_27\IN\0|various_14 (l_pobj) hypertension_28\NN\14057371|NONE_0
C065179_D006973 NONE ato_2\NNP\0|)_3 (r_appos) atorvastatin_0\NNP\3676175|properties_41|._204 (r_nsubj) possesses_4\VBZ\8209687|NONE_0 (l_dobj) properties_6\NNS\32613|atorvastatin_41|._163 (l_relcl) reported_10\VBN\831651|pleiotropic_38 (l_xcomp) improve_12\VB\126264|that_27|have_22|been_17 (l_prep) through_15\IN\0|to_32|function_9 (l_pobj) availability_17\NN\4718563|NONE_0 (l_prep) of_18\IN\0|increased_23 (l_pobj) production_23\NN\30358|NONE_0 (l_prep) in_24\IN\13603305|no_30|reduced_23|o2-_15 (l_pobj) forms_26\NNS\6286395|NONE_0 (l_prep) of_27\IN\0|various_14 (l_pobj) hypertension_28\NN\14057371|NONE_0
D013481_D006973 NONE superoxide_19\NN\14971519|NONE_0 (r_advmod) increased_18\VBN\169651|(_120|hypertension_106|is_93|by_76|and_4 (r_conj) characterized_5\VBN\609683|production_117 (l_nsubjpass) hypertension_3\NN\14057371|(_14|is_13|by_30|and_102|increased_106
D013481_D006973 NONE o2-_21\NNPS\0|(_1|)_3|._15 (r_nmod) production_23\NN\30358|characterized_117 (r_appos) dexamethasone_0\NNP\2721538|NONE_0 (l_parataxis) characterized_5\VBN\609683|production_117 (l_nsubjpass) hypertension_3\NN\14057371|(_14|is_13|by_30|and_102|increased_106
D013481_D006973 NONE o2-_22\JJ\0|no_15|reduced_8|in_15 (r_compound) production_23\NN\30358|NONE_0 (l_prep) in_24\IN\13603305|no_30|reduced_23|o2-_15 (l_pobj) forms_26\NNS\6286395|NONE_0 (l_prep) of_27\IN\0|various_14 (l_pobj) hypertension_28\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone_7\NN\2721538|-_13 (r_npadvmod) induced_9\VBN\1627355|in_21 (r_amod) hypertension_10\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone_0\NNP\2721538|NONE_0 (l_parataxis) characterized_5\VBN\609683|production_117 (l_nsubjpass) hypertension_3\NN\14057371|(_14|is_13|by_30|and_102|increased_106
D003907_D006973 CID dex)-induced_2\JJ\0|NONE_0 (r_amod) hypertension_3\NN\14057371|(_14|is_13|by_30|and_102|increased_106
D009569_D006973 NONE oxide_12\NN\14818238|(_6|no_7|)_9 (r_nmod) deficiency_16\NN\14449126|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|endothelial_24 (r_acl) dysfunction_8\NN\14204950|NONE_0 (r_pobj) by_6\IN\0|(_44|hypertension_30|is_17|and_72|increased_76 (r_agent) characterized_5\VBN\609683|production_117 (l_nsubjpass) hypertension_3\NN\14057371|(_14|is_13|by_30|and_102|increased_106
D009569_D006973 NONE no_14\NNP\7204911|oxide_7|(_1|)_2 (r_intj) deficiency_16\NN\14449126|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|endothelial_24 (r_acl) dysfunction_8\NN\14204950|NONE_0 (r_pobj) by_6\IN\0|(_44|hypertension_30|is_17|and_72|increased_76 (r_agent) characterized_5\VBN\609683|production_117 (l_nsubjpass) hypertension_3\NN\14057371|(_14|is_13|by_30|and_102|increased_106
D009569_D006973 NONE no_19\DT\7204911|reduced_7|o2-_15|in_30 (r_amod) production_23\NN\30358|NONE_0 (l_prep) in_24\IN\13603305|no_30|reduced_23|o2-_15 (l_pobj) forms_26\NNS\6286395|NONE_0 (l_prep) of_27\IN\0|various_14 (l_pobj) hypertension_28\NN\14057371|NONE_0
3780846
D006220_D009127 CID haloperidol_7\NN\3713736|in_36|,_2|was_29|in_38|._186 (r_nsubjpass) used_14\VBN\0|NONE_0 (l_prep) in_15\IN\13603305|in_74|,_40|haloperidol_38|was_9|._148 (l_pobj) order_16\NN\7168131|NONE_0 (l_acl) block_18\VB\21939|NONE_0 (l_conj) estimate_24\VB\5802185|to_44|activation_18|and_7 (l_dobj) degree_27\NN\4916342|to_21 (l_prep) of_28\IN\0|the_16|real_12 (l_pobj) tolerance_30\NN\5032565|NONE_0 (l_prep) to_31\IN\0|the_14 (l_pobj) rigidity_33\NN\5023233|NONE_0
D006220_D009127 CID haloperidol_0\NNP\3713736|rigidity_25|._48 (r_nsubj) enhanced_1\VBD\227165|NONE_0 (l_dobj) rigidity_3\NN\5023233|haloperidol_25|._23
D009020_D009127 CID morphine_14\NN\2707683|NONE_0 (r_pobj) by_13\IN\0|in_12 (r_agent) produced_12\VBN\1617192|the_22|muscular_18 (r_acl) rigidity_11\NN\5023233|NONE_0
D009020_D009127 CID morphine_10\NN\2707683|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) produced_8\VBN\1617192|the_22|muscular_18 (r_acl) rigidity_7\NN\5023233|NONE_0
D009020_D009127 CID morphine_9\NN\2707683|NONE_0 (r_pobj) of_8\IN\0|a_12|test_10|(_12|mg/kg_16|)_26 (r_prep) dose_7\NN\3740161|controls_22 (r_dobj) given_4\VBN\5892096|rigidity_66|._123 (r_csubj) showed_15\VBD\2137132|NONE_0 (l_dobj) rigidity_18\NN\5023233|given_66|._57
D009020_D009127 CID morphine_6\NN\2707683|NONE_0 (r_pobj) with_5\IN\0|rats_25|for_12|and_14|withdrawn_18|h_38|showed_40|showed_118|._248 (r_prep) treated_1\VBD\2376958|NONE_0 (l_conj) showed_27\VBD\2137132|rats_143|for_130|with_118|and_104|withdrawn_100|h_80|showed_78|._130 (l_dobj) rigidity_29\NN\5023233|half_29|after_9
D009020_D009127 CID morphine_35\NN\2707683|NONE_0 (r_pobj) of_34\IN\0|the_14|test_10|was_17|group_86 (r_prep) dose_33\NN\3740161|NONE_0 (r_pobj) after_30\IN\0|half_38|rigidity_9 (r_prep) showed_27\VBD\2137132|rats_143|for_130|with_118|and_104|withdrawn_100|h_80|showed_78|._130 (l_dobj) rigidity_29\NN\5023233|half_29|after_9
D009020_D009127 CID morphine_16\NN\2707683|NONE_0 (r_pobj) of_15\IN\0|an_10|in_12 (r_prep) action_14\NN\30358|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) due_11\JJ\5174653|to_6 (r_acomp) be_10\VB\14625458|which_20|is_14 (r_xcomp) assumed_8\VBN\719734|,_11|,_58 (r_relcl) rigidity_4\NN\5023233|that_5|can_79|be_83|by_98
D009020_D018476 CID morphine_6\NN\2707683|NONE_0 (r_pobj) with_5\IN\0|rats_25|for_12|and_14|withdrawn_18|h_38|showed_40|showed_118|._248 (r_prep) treated_1\VBD\2376958|NONE_0 (l_conj) showed_27\VBD\2137132|rats_143|for_130|with_118|and_104|withdrawn_100|h_80|showed_78|._130 (l_prep) after_30\IN\0|half_38|rigidity_9 (l_pobj) dose_33\NN\3740161|NONE_0 (l_relcl) was_37\VBD\0|the_31|test_27|of_17|group_69 (l_conj) were_46\VBD\0|that_57|not_48|less_30|and_4 (l_acomp) akinetic_47\JJ\0|NONE_0
D009020_D018476 CID morphine_35\NN\2707683|NONE_0 (r_pobj) of_34\IN\0|the_14|test_10|was_17|group_86 (r_prep) dose_33\NN\3740161|NONE_0 (l_relcl) was_37\VBD\0|the_31|test_27|of_17|group_69 (l_conj) were_46\VBD\0|that_57|not_48|less_30|and_4 (l_acomp) akinetic_47\JJ\0|NONE_0
3693336
D014229_D003866 NONE triazolam_0\NNP\2830852|-_9|episodes_24|._74 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) episodes_4\NNS\7283608|triazolam_24|-_15|._50 (l_prep) in_8\IN\13603305|brief_34|of_19 (l_pobj) patient_11\NN\9898892|NONE_0 (l_amod) depressed_10\JJ\1819147|a_2
D014229_D003866 NONE triazolam_3\NN\2830852|NONE_0 (r_pobj) of_2\IN\0|large_12 (r_prep) doses_1\NNS\3740161|repeatedly_19|episodes_44|._90 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_dobj) episodes_7\NNS\7283608|doses_44|repeatedly_25|._46 (l_prep) in_10\IN\13603305|brief_24|of_9 (l_pobj) woman_14\NN\9605289|NONE_0 (l_amod) depressed_12\JJ\1819147|a_2|elderly_10
D014229_D001714 CID triazolam_0\NNP\2830852|-_9|episodes_24|._74 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) episodes_4\NNS\7283608|triazolam_24|-_15|._50 (l_prep) of_5\IN\0|brief_15|in_19 (l_pobj) mania_7\NN\9180259|NONE_0
D014229_D001714 CID triazolam_3\NN\2830852|NONE_0 (r_pobj) of_2\IN\0|large_12 (r_prep) doses_1\NNS\3740161|repeatedly_19|episodes_44|._90 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_dobj) episodes_7\NNS\7283608|doses_44|repeatedly_25|._46 (l_prep) of_8\IN\0|brief_15|in_9 (l_pobj) mania_9\NN\9180259|NONE_0
D014229_D001714 CID triazolam_10\NN\2830852|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) action_8\NN\30358|NONE_0 (r_pobj) of_7\IN\0|the_13 (r_prep) duration_6\NN\15113229|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) coincident_3\JJ\0|excitement_15|._51 (r_acomp) was_2\VBD\0|NONE_0 (l_nsubj) excitement_1\NN\7527352|coincident_15|._66 (l_amod) manic_0\JJ\0|NONE_0
12523465
C022189_D006212 CID zonisamide_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|visual_22|._26 (r_acl) hallucinations_1\NNS\14376855|NONE_0
C022189_D006212 CID zonisamide_29\NN\0|NONE_0 (r_amod) treatment_30\NN\654885|NONE_0 (r_pobj) after_28\IN\0|status_7 (r_prep) altered_25\VBD\0|who_50|hallucinations_19|and_4 (r_conj) experienced_20\VBD\2108377|three_19 (r_relcl) patients_18\NNS\9898892|reported_63|,_20|we_18|begun_112|._141 (r_dobj) describe_16\VBP\1001294|NONE_0 (l_advcl) reported_6\VBN\831651|,_43|we_45|patients_63|begun_175|._204 (l_nsubjpass) hallucinations_2\NNS\14376855|although_16|have_15|not_20|been_24|as_38
C022189_D006212 CID zonisamide_29\NN\0|NONE_0 (r_amod) treatment_30\NN\654885|NONE_0 (r_pobj) after_28\IN\0|status_7 (r_prep) altered_25\VBD\0|who_50|hallucinations_19|and_4 (r_conj) experienced_20\VBD\2108377|three_19 (l_dobj) hallucinations_23\NNS\14376855|who_31|and_15|altered_19
C022189_D012640 NONE zonisamide_0\NNP\0|drug_45|._89 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) drug_7\NN\14778436|zonisamide_45|._44 (l_acl) used_8\VBN\0|a_36|spectrum_28|antiepileptic_19 (l_xcomp) treat_10\VB\7570720|NONE_0 (l_dobj) types_12\NNS\5839024|to_17 (l_prep) of_13\IN\0|various_14 (l_pobj) seizures_14\NNS\14081375|NONE_0
15649445
D012110_D004409 CID reserpine_1\NN\2721160|haloperidol_25|treatments_37|uptake_84|and_91|elicit_95|._130 (r_nsubj) change_6\VBP\7283608|NONE_0 (l_conj) elicit_12\VBP\1617192|reserpine_95|haloperidol_70|treatments_58|uptake_11|and_4|._35 (l_dobj) dyskinesia_14\NN\14084880|NONE_0
D012110_D004409 CID reserpine-_0\NNP\0|models_76|._196 (l_conj) dyskinesia_6\NN\14084880|and_34
D012110_D004409 CID reserpine-_0\NNP\0|models_76|._196 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_attr) models_10\NNS\5888929|reserpine-_76|._120 (l_prep) of_11\IN\0|putative_23|animal_14|related_58 (l_pobj) dyskinesia_13\JJ\14084880|NONE_0
D012110_D004409 CID reserpine-_0\NNP\0|models_76|._196 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_attr) models_10\NNS\5888929|reserpine-_76|._120 (l_prep) of_11\IN\0|putative_23|animal_14|related_58 (l_pobj) dyskinesia_13\JJ\14084880|NONE_0 (l_appos) td_15\NN\0|tardive_20
D012110_D004409 CID reserpine_12\NN\2721160|NONE_0 (r_pobj) by_10\IN\0|in_63|,_43|authors_37|dyskinesia_11|._68 (r_prep) induced_7\VBD\1627355|NONE_0 (l_dobj) dyskinesia_9\NN\14084880|in_52|,_32|authors_26|by_11|._79
D018698_D004409 NONE glutamate_9\NN\15010703|synaptosomal_19 (r_compound) uptake_10\NN\13440063|reserpine_84|haloperidol_59|treatments_47|and_7|elicit_11|._46 (r_dobj) change_6\VBP\7283608|NONE_0 (l_conj) elicit_12\VBP\1617192|reserpine_95|haloperidol_70|treatments_58|uptake_11|and_4|._35 (l_dobj) dyskinesia_14\NN\14084880|NONE_0
D018698_D004409 NONE glutamate_5\NN\15010703|NONE_0 (r_compound) uptake_6\NN\13440063|NONE_0 (r_pobj) in_4\IN\13603305|a_11 (r_prep) decrease_3\NN\7296428|importantly_15|,_4|negatively_40|with_51|._108 (r_nsubj) correlates_7\VBZ\5857459|NONE_0 (l_prep) with_9\IN\0|importantly_66|,_55|decrease_51|negatively_11|._57 (l_pobj) increase_11\NN\13576355|NONE_0 (l_prep) in_12\IN\13603305|an_12 (l_pobj) incidence_14\NN\13821570|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) diskinesia_17\NN\0|NONE_0
D006220_D004409 CID haloperidol_4\NN\3713736|reserpine_25|treatments_12|uptake_59|and_66|elicit_70|._105 (r_compound) change_6\VBP\7283608|NONE_0 (l_conj) elicit_12\VBP\1617192|reserpine_95|haloperidol_70|treatments_58|uptake_11|and_4|._35 (l_dobj) dyskinesia_14\NN\14084880|NONE_0
D006220_D004409 CID haloperidol_2\NN\3713736|-_11 (r_npadvmod) induced_4\VBN\1627355|orofacial_8 (r_amod) dyskinesia_6\NN\14084880|and_34
D006220_D004409 CID haloperidol_2\NN\3713736|-_11 (r_npadvmod) induced_4\VBN\1627355|orofacial_8 (r_amod) dyskinesia_6\NN\14084880|and_34 (r_conj) reserpine-_0\NNP\0|models_76|._196 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_attr) models_10\NNS\5888929|reserpine-_76|._120 (l_prep) of_11\IN\0|putative_23|animal_14|related_58 (l_pobj) dyskinesia_13\JJ\14084880|NONE_0
D006220_D004409 CID haloperidol_2\NN\3713736|-_11 (r_npadvmod) induced_4\VBN\1627355|orofacial_8 (r_amod) dyskinesia_6\NN\14084880|and_34 (r_conj) reserpine-_0\NNP\0|models_76|._196 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_attr) models_10\NNS\5888929|reserpine-_76|._120 (l_prep) of_11\IN\0|putative_23|animal_14|related_58 (l_pobj) dyskinesia_13\JJ\14084880|NONE_0 (l_appos) td_15\NN\0|tardive_20
D006220_D004409 CID haloperidol_15\NN\3713736|subchronic_11 (r_compound) administration_16\NN\1133281|acute_43|and_27|to_15 (r_conj) reserpine_12\NN\2721160|NONE_0 (r_pobj) by_10\IN\0|in_63|,_43|authors_37|dyskinesia_11|._68 (r_prep) induced_7\VBD\1627355|NONE_0 (l_dobj) dyskinesia_9\NN\14084880|in_52|,_32|authors_26|by_11|._79
18631865
D020123_D051436 NONE rapamycin_16\NNS\0|mtor_11|,_27|sirolimus_40|,_49 (r_nmod) inhibitors_20\NNS\20090|NONE_0 (r_pobj) of_15\IN\0|mammalian_17 (r_prep) target_14\NN\7258332|NONE_0 (r_pobj) to_12\IN\0|from_28|in_74 (r_prep) conversion_8\NN\7359599|NONE_0 (l_prep) in_25\IN\13603305|from_102|to_74 (l_pobj) recipients_28\NNS\9764201|NONE_0 (l_prep) with_29\IN\0|renal_28|transplant_22 (l_pobj) nephropathy_32\NN\14573196|NONE_0
D020123_D051436 NONE sirolimus_23\NN\0|rapamycin_40|mtor_29|,_13|,_9 (r_appos) inhibitors_20\NNS\20090|NONE_0 (r_pobj) of_15\IN\0|mammalian_17 (r_prep) target_14\NN\7258332|NONE_0 (r_pobj) to_12\IN\0|from_28|in_74 (r_prep) conversion_8\NN\7359599|NONE_0 (l_prep) in_25\IN\13603305|from_102|to_74 (l_pobj) recipients_28\NNS\9764201|NONE_0 (l_prep) with_29\IN\0|renal_28|transplant_22 (l_pobj) nephropathy_32\NN\14573196|NONE_0
D020123_D011507 CID sirolimus_5\NN\0|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) due_3\JJ\5174653|whether_24|proteinuria_16 (r_acomp) was_2\VBD\0|unsolved_89|observed_136|._241 (l_nsubj) proteinuria_1\NN\14299637|whether_8|due_16
D020123_D011507 CID sirolimus_5\NN\0|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) due_3\JJ\5174653|whether_24|proteinuria_16 (r_acomp) was_2\VBD\0|unsolved_89|observed_136|._241 (r_csubj) remained_14\VBD\2604760|NONE_0 (l_advcl) observed_22\VBN\2163746|was_136|unsolved_47|._105 (l_nsubjpass) proteinuria_19\NN\14299637|until_17|has_12|been_16|during_30|in_55
D020123_D011507 CID sirolimus_24\NN\0|NONE_0 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) during_23\IN\0|until_47|proteinuria_30|has_18|been_14|in_25 (r_prep) observed_22\VBN\2163746|was_136|unsolved_47|._105 (r_advcl) remained_14\VBD\2604760|NONE_0 (l_csubj) was_2\VBD\0|unsolved_89|observed_136|._241 (l_nsubj) proteinuria_1\NN\14299637|whether_8|due_16
D020123_D011507 CID sirolimus_24\NN\0|NONE_0 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) during_23\IN\0|until_47|proteinuria_30|has_18|been_14|in_25 (r_prep) observed_22\VBN\2163746|was_136|unsolved_47|._105 (l_nsubjpass) proteinuria_19\NN\14299637|until_17|has_12|been_16|during_30|in_55
D020123_D011507 CID sirolimus_34\NN\0|de_10 (r_nmod) novo_36\NNP\0|who_26 (r_dobj) received_33\VBD\2210855|NONE_0 (r_relcl) patients_31\NNS\9898892|NONE_0 (r_pobj) in_30\IN\13603305|transplantation_20|and_4 (r_conj) in_26\IN\13603305|until_72|proteinuria_55|has_43|been_39|during_25 (r_prep) observed_22\VBN\2163746|was_136|unsolved_47|._105 (r_advcl) remained_14\VBD\2604760|NONE_0 (l_csubj) was_2\VBD\0|unsolved_89|observed_136|._241 (l_nsubj) proteinuria_1\NN\14299637|whether_8|due_16
D020123_D011507 CID sirolimus_34\NN\0|de_10 (r_nmod) novo_36\NNP\0|who_26 (r_dobj) received_33\VBD\2210855|NONE_0 (r_relcl) patients_31\NNS\9898892|NONE_0 (r_pobj) in_30\IN\13603305|transplantation_20|and_4 (r_conj) in_26\IN\13603305|until_72|proteinuria_55|has_43|been_39|during_25 (r_prep) observed_22\VBN\2163746|was_136|unsolved_47|._105 (l_nsubjpass) proteinuria_19\NN\14299637|until_17|has_12|been_16|during_30|in_55
1085609
D007538_D012640 CID isoniazid_6\NN\2716205|NONE_0 (r_amod) therapy_7\NN\657604|to_13 (r_pobj) due_4\IN\5174653|neonatal_43|pyridoxine_34|responsive_23|._24 (r_amod) convulsions_3\NNS\14081375|NONE_0
D007538_D012640 CID isoniazid_6\NN\2716205|therapy_10 (r_pobj) on_5\IN\0|a_20|old_11|daily_30|because_47 (r_prep) infant_4\NN\9918248|was_87|after_100|._127 (r_nsubjpass) admitted_18\VBN\822367|NONE_0 (l_prep) after_19\IN\0|infant_100|was_13|._27 (l_pobj) days_21\NNS\15140892|NONE_0 (l_prep) of_22\IN\0|4_7 (l_pobj) fits_24\NNS\7518132|NONE_0
D007538_D012640 CID isoniazid_19\NN\2716205|an_51|of_38 (r_relcl) aetiology_13\NN\7326557|NONE_0 (r_dobj) suggesting_11\VBG\1010118|fits_70|within_58|,_2|._82 (r_advcl) ceased_2\VBD\0|NONE_0 (l_nsubj) fits_1\NNS\7518132|within_12|,_68|suggesting_70|._152
D011736_D012640 NONE pyridoxine_1\NN\15090742|neonatal_9|responsive_11|due_34|._58 (r_nmod) convulsions_3\NNS\14081375|NONE_0
D011736_D012640 NONE pyridoxine_9\NN\15090742|NONE_0 (r_dobj) administering_7\VBG\2436349|NONE_0 (r_pcomp) of_6\IN\0|4_8 (r_prep) hours_5\NNS\15118228|NONE_0 (r_pobj) within_3\IN\0|fits_12|,_56|suggesting_58|._140 (r_prep) ceased_2\VBD\0|NONE_0 (l_nsubj) fits_1\NNS\7518132|within_12|,_68|suggesting_70|._152
D011736_D012640 NONE pyridoxine_15\JJ\15090742|secondary_22 (r_compound) deficiency_16\NN\14449126|NONE_0 (r_pobj) of_14\IN\0|an_13|isoniazid_38 (r_prep) aetiology_13\NN\7326557|NONE_0 (r_dobj) suggesting_11\VBG\1010118|fits_70|within_58|,_2|._82 (r_advcl) ceased_2\VBD\0|NONE_0 (l_nsubj) fits_1\NNS\7518132|within_12|,_68|suggesting_70|._152
D007538_D014376 NONE isoniazid_6\NN\2716205|therapy_10 (r_pobj) on_5\IN\0|a_20|old_11|daily_30|because_47 (r_prep) infant_4\NN\9918248|was_87|after_100|._127 (l_prep) because_13\IN\0|a_67|old_58|on_47|daily_17 (l_pobj) tuberculosis_16\NN\14127211|of_12
891050
D004176_D001002 NONE dipyridamole_6\NN\0|,_2 (r_conj) heparin_4\JJ\2718259|NONE_0 (r_pobj) with_3\IN\0|she_16|was_12|;_43|and_45|rose_98 (r_prep) treated_2\VBN\2376958|NONE_0 (l_conj) rose_20\VBD\13112664|she_114|was_110|with_98|;_55|and_53 (l_conj) stopped_37\VBN\0|after_133|,_105|output_91|above_79|;_67|and_65|._7 (l_prep) after_28\IN\0|,_25|treatment_36|was_46 (l_pobj) onset_30\NN\7325190|months_17 (l_prep) of_31\IN\0|the_10 (l_pobj) anuria_32\NN\14061805|NONE_0
D003276_D006463 CID contraceptives_17\NNS\3183080|NONE_0 (r_dobj) taking_15\VBG\37396|a_8 (r_acl) woman_14\NN\9605289|NONE_0 (r_pobj) in_12\IN\13603305|the_36|hemolytic_32|uremic_22|(_6|hus_5|)_2 (r_prep) syndrome_8\NN\5870365|NONE_0
D003276_D006463 CID contraceptives_17\NNS\3183080|NONE_0 (r_dobj) taking_15\VBG\37396|a_8 (r_acl) woman_14\NN\9605289|NONE_0 (r_pobj) in_12\IN\13603305|the_36|hemolytic_32|uremic_22|(_6|hus_5|)_2 (r_prep) syndrome_8\NN\5870365|NONE_0 (l_appos) hus_10\NNP\0|the_31|hemolytic_27|uremic_17|(_1|)_3|in_5
D006493_D001002 NONE heparin_4\JJ\2718259|NONE_0 (r_pobj) with_3\IN\0|she_16|was_12|;_43|and_45|rose_98 (r_prep) treated_2\VBN\2376958|NONE_0 (l_conj) rose_20\VBD\13112664|she_114|was_110|with_98|;_55|and_53 (l_conj) stopped_37\VBN\0|after_133|,_105|output_91|above_79|;_67|and_65|._7 (l_prep) after_28\IN\0|,_25|treatment_36|was_46 (l_pobj) onset_30\NN\7325190|months_17 (l_prep) of_31\IN\0|the_10 (l_pobj) anuria_32\NN\14061805|NONE_0
7199841
C004616_D010243 CID ce_11\NN\14625458|seven_3|35_10 (r_nmod) %_15\NN\0|NONE_0 (r_pobj) of_8\IN\0|subarachnoid_23 (r_prep) injection_7\NN\320852|that_27 (r_dobj) received_5\VBD\2210855|the_20|20_16|)_65 (r_relcl) animals_3\NNS\4475|NONE_0 (r_pobj) of_0\IN\0|developed_90|limb_105|._119 (r_prep) paralysis_21\NN\14557898|NONE_0
D002045_D010243 NONE bupivacaine_6\NN\0|that_14 (r_dobj) received_5\VBD\2210855|the_17 (r_relcl) animals_3\NNS\4475|NONE_0 (r_pobj) of_1\IN\0|,_40|saline_49 (r_prep) none_0\NN\15228378|to_88|._129 (r_nsubj) titrated_14\VBN\489837|NONE_0 (l_prep) to_15\IN\0|none_88|._41 (l_pobj) paralysis_23\NN\14557898|NONE_0
C004616_D013118 CID ce_12\NNP\14625458|that_31 (r_dobj) received_9\VBD\2210855|the_17 (r_relcl) animals_7\NNS\4475|NONE_0 (r_pobj) of_5\IN\0|the_20|15_16|spinal_13 (r_prep) cords_4\NNS\4489008|NONE_0 (r_pobj) of_0\IN\0|NONE_0 (r_prep) 13_14\CD\13745420|,_2|necrosis_18 (r_nsubj) showed_15\VBD\2137132|;_23|roots_35|normal_71|._77 (l_dobj) necrosis_17\NN\11444117|,_20|13_18
11256525
D000588_D001002 NONE amine_26\NN\14951377|and_4 (r_conj) furosemide_24\NN\3214670|dose_5 (r_nmod) infusion_27\NN\14589223|NONE_0 (r_pobj) despite_20\IN\7501545|which_25|hours_6 (r_prep) lasted_17\VBD\2704349|a_23|sudden_21|,_8 (r_relcl) anuria_14\NN\14061805|NONE_0
D019808_D006331 NONE losartan_5\NN\0|due_35|was_9|._23 (l_compound) dysfunction_4\NN\14204950|NONE_0
D000809_D012078 NONE angiotensin_24\NN\4522421|the_10|(_19|ras_20|)_23 (r_compound) system_25\NN\3575240|NONE_0 (r_pobj) of_20\IN\0|a_20|strong_18 (r_prep) activation_19\NN\13561719|NONE_0 (r_pobj) in_16\IN\13603305|in_107|,_92|stenosis_77|certainly_19|._60 (r_prep) resulted_15\VBD\2633881|NONE_0 (l_nsubj) stenosis_6\NN\14204950|in_30|,_15|certainly_58|in_77|._137
D019808_D001002 CID losartan_4\NN\0|NONE_0 (r_amod) administration_5\NN\1133281|in_15 (r_dobj) following_3\VBG\8180190|repeated_26|transient_17|._69 (r_prep) anuria_2\NN\14061805|NONE_0
D019808_D001002 CID losartan_27\NN\0|NONE_0 (r_amod) administration_28\NN\1133281|NONE_0 (r_pobj) after_26\IN\0|who_47|episodes_29 (r_prep) developed_20\VBD\1753788|a_54|solitary_52|and_36|insufficiency_18 (l_dobj) episodes_22\NNS\7283608|who_18|after_29 (l_prep) of_23\IN\0|two_13 (l_pobj) anuria_25\NN\14061805|NONE_0
D019808_D001002 CID losartan_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|50_6 (r_prep) mg_7\NN\13717155|NONE_0 (r_pobj) of_5\IN\0|the_15|first_11 (r_prep) dose_4\NN\3740161|surprisingly_24|,_12|in_35|._127 (r_nsubj) resulted_10\VBD\2633881|NONE_0 (l_prep) in_11\IN\13603305|surprisingly_59|,_47|dose_35|._92 (l_pobj) anuria_14\NN\14061805|NONE_0
D019808_D001002 CID losartan_7\NN\0|later_19|,_14|by_12|,_2|was_9|again_24|and_30|developed_78 (r_nsubjpass) prescribed_9\VBN\748282|NONE_0 (l_conj) developed_22\VBD\1753788|later_97|,_92|by_90|,_80|losartan_78|was_69|again_54|and_48 (l_dobj) episode_25\NN\7283608|after_63|,_33|patient_27|._44 (l_prep) of_26\IN\0|a_17|second_15|lasting_20 (l_pobj) anuria_28\NN\14061805|NONE_0
D019808_D014652 NONE losartan_12\NN\0|that_44|can_9|complications_38|and_90|used_104 (r_nsubj) cause_14\VB\7323922|the_66 (l_dobj) complications_17\NNS\1073995|that_82|losartan_38|can_29|and_52|used_66 (l_prep) in_18\IN\13603305|serious_33|unexpected_25 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) disease_22\NN\14061805|NONE_0
D005665_D001002 NONE furosemide_24\NN\3214670|dose_5 (r_nmod) infusion_27\NN\14589223|NONE_0 (r_pobj) despite_20\IN\7501545|which_25|hours_6 (r_prep) lasted_17\VBD\2704349|a_23|sudden_21|,_8 (r_relcl) anuria_14\NN\14061805|NONE_0
D019808_D051436 NONE losartan_27\NN\0|NONE_0 (r_amod) administration_28\NN\1133281|NONE_0 (r_pobj) after_26\IN\0|who_47|episodes_29 (r_prep) developed_20\VBD\1753788|a_54|solitary_52|and_36|insufficiency_18 (r_relcl) kidney_14\NN\5333259|NONE_0 (l_conj) insufficiency_18\NN\14462946|a_36|solitary_34|and_18|developed_18
D000809_D006333 NONE angiotensin_24\NN\4522421|the_10|(_19|ras_20|)_23 (r_compound) system_25\NN\3575240|NONE_0 (r_pobj) of_20\IN\0|a_20|strong_18 (r_prep) activation_19\NN\13561719|NONE_0 (r_pobj) in_16\IN\13603305|in_107|,_92|stenosis_77|certainly_19|._60 (r_prep) resulted_15\VBD\2633881|NONE_0 (l_nsubj) stenosis_6\NN\14204950|in_30|,_15|certainly_58|in_77|._137 (l_acl) combined_7\VBN\2630189|renal_22|artery_16 (l_prep) with_8\IN\0|NONE_0 (l_pobj) failure_10\NN\66216|NONE_0
D000804_D014652 NONE ii_9\NNP\13741022|receptor_3 (r_compound) antagonist_11\NN\7846|the_28|angiotensin_24 (r_compound) losartan_12\NN\0|that_44|can_9|complications_38|and_90|used_104 (r_nsubj) cause_14\VB\7323922|the_66 (l_dobj) complications_17\NNS\1073995|that_82|losartan_38|can_29|and_52|used_66 (l_prep) in_18\IN\13603305|serious_33|unexpected_25 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) disease_22\NN\14061805|NONE_0
D019808_D006973 NONE losartan_27\NN\0|NONE_0 (r_amod) administration_28\NN\1133281|NONE_0 (r_pobj) after_26\IN\0|who_47|episodes_29 (r_prep) developed_20\VBD\1753788|a_54|solitary_52|and_36|insufficiency_18 (r_relcl) kidney_14\NN\5333259|NONE_0 (r_pobj) with_11\IN\0|a_31|old_21|hypertensive_17 (r_prep) man_10\NN\9605289|NONE_0 (l_amod) hypertensive_9\JJ\10405694|a_14|old_4|with_17
3412544
D010615_D014516 NONE phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (l_conj) ureter_14\NN\5250659|the_18|renal_14|,_2|associated_18 (l_conj) bladder_16\NN\5515670|or_3
D010615_D014516 NONE phenacetin_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|,_13|increased_26 (r_prep) consumption_11\NN\13440063|NONE_0 (l_relcl) increased_17\VBD\169651|of_26|,_13 (l_conj) for_30\IN\0|which_81|also_75|risk_56|but_8 (l_pobj) cancer_32\NN\14239425|not_17
D010615_D007680 CID phenacetin_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|,_13|increased_26 (r_prep) consumption_11\NN\13440063|NONE_0 (l_relcl) increased_17\VBD\169651|of_26|,_13 (l_dobj) risk_19\NN\14541044|which_25|also_19|but_48|for_56 (l_prep) for_20\IN\0|the_9 (l_pobj) cancer_21\NN\14239425|NONE_0 (l_prep) of_22\IN\0|NONE_0 (l_pobj) pelvis_25\NN\5578911|NONE_0 (l_conj) bladder_27\NN\5515670|the_21|renal_17|and_4
D010615_D007680 NONE phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (l_conj) ureter_14\NN\5250659|the_18|renal_14|,_2|associated_18 (l_conj) bladder_16\NN\5515670|or_3
D000082_D007681 NONE paracetamol_1\JJ\0|does_5|cancer_29|?_63 (r_nsubj) cause_2\VB\7323922|NONE_0 (l_dobj) cancer_4\NN\14239425|does_34|paracetamol_29|?_34 (l_conj) necrosis_8\NN\11444117|urothelial_37|or_19
D000082_D007681 NONE paracetamol_24\NNP\0|either_21|or_3 (r_conj) phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (r_pobj) of_9\IN\0|renal_35|papillary_29|or_10|cancer_7 (r_prep) necrosis_6\NN\11444117|NONE_0
D000082_D007681 NONE paracetamol_12\JJ\0|NONE_0 (r_compound) consumption_13\NN\13440063|NONE_0 (r_pobj) from_11\IN\0|an_18|increased_15|for_29|or_58|any_61 (r_prep) risk_10\NN\14541044|to_29 (l_prep) for_14\IN\0|an_47|increased_44|from_29|or_29|any_32 (l_pobj) necrosis_17\NN\11444117|NONE_0
D000082_D001749 NONE paracetamol_24\NNP\0|either_21|or_3 (r_conj) phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (l_conj) ureter_14\NN\5250659|the_18|renal_14|,_2|associated_18 (l_conj) bladder_16\NN\5515670|or_3
D000082_D014516 NONE paracetamol_24\NNP\0|either_21|or_3 (r_conj) phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (l_conj) ureter_14\NN\5250659|the_18|renal_14|,_2|associated_18 (l_conj) bladder_16\NN\5515670|or_3
D000082_D014516 NONE paracetamol_12\JJ\0|NONE_0 (r_compound) consumption_13\NN\13440063|NONE_0 (r_pobj) from_11\IN\0|an_18|increased_15|for_29|or_58|any_61 (r_prep) risk_10\NN\14541044|to_29 (r_dobj) substantiate_7\VB\0|NONE_0 (r_xcomp) unable_5\JJ\0|by_21|,_10|we_8|was_138|._198 (r_acomp) were_4\VBD\0|NONE_0 (l_advcl) was_25\VBD\0|by_159|,_148|we_146|unable_138|._60 (l_attr) suggestion_27\NN\5833840|although_21|there_12 (l_prep) of_28\IN\0|a_13 (l_pobj) association_30\NN\8008335|NONE_0 (l_prep) with_31\IN\0|an_15 (l_pobj) cancer_32\NN\14239425|NONE_0 (l_prep) of_33\IN\0|NONE_0 (l_pobj) ureter_35\NN\5250659|NONE_0
D000082_D014523 NONE paracetamol_1\JJ\0|does_5|cancer_29|?_63 (r_nsubj) cause_2\VB\7323922|NONE_0 (l_dobj) cancer_4\NN\14239425|does_34|paracetamol_29|?_34
D000082_D007680 NONE paracetamol_24\NNP\0|either_21|or_3 (r_conj) phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (l_conj) ureter_14\NN\5250659|the_18|renal_14|,_2|associated_18 (l_conj) bladder_16\NN\5515670|or_3
D000082_D009369 NONE paracetamol_12\JJ\0|NONE_0 (r_compound) consumption_13\NN\13440063|NONE_0 (r_pobj) from_11\IN\0|an_18|increased_15|for_29|or_58|any_61 (r_prep) risk_10\NN\14541044|to_29 (l_conj) any_19\DT\0|an_79|increased_76|from_61|for_32|or_3 (l_prep) of_20\IN\0|NONE_0 (l_pobj) cancers_22\NNS\14239425|NONE_0
D010615_D007681 CID phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (r_pobj) of_9\IN\0|renal_35|papillary_29|or_10|cancer_7 (r_prep) necrosis_6\NN\11444117|NONE_0
D010615_D007681 CID phenacetin_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|,_13|increased_26 (r_prep) consumption_11\NN\13440063|NONE_0 (r_pobj) by_10\IN\0|risk_62|was_29|20-fold_8|._130 (r_agent) increased_7\VBN\169651|NONE_0 (l_nsubjpass) risk_1\NN\14541044|was_33|20-fold_54|by_62|._192 (l_prep) of_2\IN\0|the_9 (l_pobj) necrosis_5\NN\11444117|NONE_0
D010615_D001749 CID phenacetin_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|,_13|increased_26 (r_prep) consumption_11\NN\13440063|NONE_0 (l_relcl) increased_17\VBD\169651|of_26|,_13 (l_dobj) risk_19\NN\14541044|which_25|also_19|but_48|for_56 (l_prep) for_20\IN\0|the_9 (l_pobj) cancer_21\NN\14239425|NONE_0 (l_prep) of_22\IN\0|NONE_0 (l_pobj) pelvis_25\NN\5578911|NONE_0 (l_conj) bladder_27\NN\5515670|the_21|renal_17|and_4
D010615_D001749 NONE phenacetin_22\JJ\2707683|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) consumption_19\NN\13440063|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_36|renal_32|,_20|ureter_18 (r_acl) pelvis_12\NN\5578911|NONE_0 (l_conj) ureter_14\NN\5250659|the_18|renal_14|,_2|associated_18 (l_conj) bladder_16\NN\5515670|or_3
9862868
D004997_D002780 CID estradiol_9\NNP\14749794|(_10|ee_11|)_13|and_25|extrahepatic_29 (r_nmod) treatment_13\NN\654885|by_39 (r_nmod) cholestasis_16\NN\14052403|we_100|models_88|determine_53|._84 (r_dobj) used_1\VBD\0|NONE_0 (l_dobj) models_3\NNS\5888929|we_12|cholestasis_88|determine_141|._172 (l_prep) of_4\IN\0|rat_11 (l_pobj) cholestasis_6\NN\14052403|NONE_0
D004997_D002780 CID ee_11\NNP\6125041|estradiol_11|(_1|)_2|and_14|extrahepatic_18 (r_nmod) treatment_13\NN\654885|by_39 (r_nmod) cholestasis_16\NN\14052403|we_100|models_88|determine_53|._84 (r_dobj) used_1\VBD\0|NONE_0 (l_dobj) models_3\NNS\5888929|we_12|cholestasis_88|determine_141|._172 (l_prep) of_4\IN\0|rat_11 (l_pobj) cholestasis_6\NN\14052403|NONE_0
D004997_D001651 NONE estradiol_9\NNP\14749794|(_10|ee_11|)_13|and_25|extrahepatic_29 (r_nmod) treatment_13\NN\654885|by_39 (r_nmod) cholestasis_16\NN\14052403|we_100|models_88|determine_53|._84
D004997_D001651 NONE ee_11\NNP\6125041|estradiol_11|(_1|)_2|and_14|extrahepatic_18 (r_nmod) treatment_13\NN\654885|by_39 (r_nmod) cholestasis_16\NN\14052403|we_100|models_88|determine_53|._84
2008831
D008755_D000787 NONE methylergonovine_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|intracoronary_29 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|were_60|in_73|without_163|._202 (r_nsubjpass) studied_8\VBN\0|NONE_0 (l_prep) without_25\IN\0|effects_163|were_103|in_90|._39 (l_pobj) angina_26\NN\14171682|NONE_0 (l_appos) pectoris_27\NN\0|NONE_0
D008755_D013035 NONE methylergonovine_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|a_22|low_9 (r_prep) dose_17\NN\3740161|NONE_0 (r_pobj) of_13\IN\0|an_27|intracoronary_24 (r_prep) injection_12\NN\320852|which_27 (r_dobj) use_9\VBP\407535|spasm_31|provocation_25|,_8|,_75 (r_relcl) tests_6\NNS\5798043|that_23|sensitivity_102|and_132|be_188 (l_compound) spasm_4\NN\14299637|provocation_6|,_23|use_31|,_106
D008755_D000788 NONE methylergonovine_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|direct_36|intracoronary_29|in_20 (r_prep) administration_4\NN\1133281|NONE_0 (l_prep) in_7\IN\13603305|direct_56|intracoronary_49|of_20 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_conj) without_11\IN\0|and_4 (l_pobj) angina_13\NN\14171682|NONE_0
D008755_D000788 NONE methylergonovine_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|intracoronary_29 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|were_60|in_73|without_163|._202 (r_nsubjpass) studied_8\VBN\0|NONE_0 (l_prep) in_9\IN\13603305|effects_73|were_13|without_90|._129 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|21_12 (l_pobj) angina_14\NN\14171682|NONE_0
D008755_D000788 NONE methylergonovine_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|a_22|low_9 (r_prep) dose_17\NN\3740161|NONE_0 (r_pobj) of_13\IN\0|an_27|intracoronary_24 (r_prep) injection_12\NN\320852|which_27 (r_dobj) use_9\VBP\407535|spasm_31|provocation_25|,_8|,_75 (r_relcl) tests_6\NNS\5798043|that_23|sensitivity_102|and_132|be_188 (r_nsubj) have_21\VBP\7846|results_129|._149 (l_dobj) sensitivity_24\NN\5651971|that_125|tests_102|and_30|be_86 (l_prep) in_25\IN\13603305|a_19|high_17 (l_pobj) angina_27\NN\14171682|NONE_0
D008755_D002637 NONE methylergonovine_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|intracoronary_29 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|were_60|in_73|without_163|._202 (r_nsubjpass) studied_8\VBN\0|NONE_0 (l_prep) in_9\IN\13603305|effects_73|were_13|without_90|._129 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|21_12 (l_pobj) angina_14\NN\14171682|NONE_0 (l_conj) patients_17\NNS\9898892|variant_22|and_7 (l_prep) with_18\IN\0|22_12 (l_pobj) pain_21\NN\14299637|and_5|in_9
17020434
D001241_D020521 NONE aspirin_24\NN\2707683|that_5|risk_26|by_31 (r_nsubj) reduces_26\VBZ\441445|that_72|warfarin_67|risk_46|by_31|,_25|and_23 (r_conj) reduces_13\VBZ\441445|data_90|have_25|._81 (l_dobj) risk_15\NN\14541044|that_26|warfarin_21|by_15|,_21|and_23|reduces_46 (l_prep) of_16\IN\0|the_9 (l_pobj) stroke_17\NN\556313|NONE_0
D001241_D020521 NONE aspirin_12\NN\2707683|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) preventing_14\VBG\0|NONE_0 (l_dobj) strokes_15\NNS\556313|NONE_0
D014812_D004617 NONE k_16\NNP\13608598|antagonist_2 (r_compound) drugs_18\NNS\14778436|NONE_0 (r_pobj) as_14\IN\14622893|as_13|in_30 (r_prep) efficient_13\JJ\0|to_9 (l_prep) in_19\IN\13603305|as_43|as_30 (l_pobj) prevention_21\NN\1073995|NONE_0 (l_prep) of_22\IN\0|the_15 (l_pobj) events_24\NNS\23100|NONE_0
C081309_D004617 NONE irbesartan_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|the_52|w_41|(_39|atrial_38|clopidogrel_18|)_49|study_51 (r_prep) trial_8\NN\786195|has_63|is_94|._188 (r_nsubj) demonstrated_19\VBN\2137132|NONE_0 (l_ccomp) is_22\VBZ\0|trial_94|has_31|._94 (l_acomp) superior_23\JJ\9623038|that_17|warfarin_12 (l_xcomp) platelet_25\NN\5432736|NONE_0 (l_prep) in_32\IN\13603305|to_47|therapy_35|clopidogrel_26|)_2 (l_pobj) events_37\NNS\23100|prevention_22
C479958_D001281 NONE idraparinux_0\NNP\0|is_36|being_39|in_55|._91 (r_nsubjpass) evaluated_9\VBN\670261|NONE_0 (l_prep) in_10\IN\13603305|idraparinux_55|is_19|being_16|._36 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) fibrillation_14\NN\14361664|NONE_0
D000809_D001281 NONE angiotensin_0\NN\4522421|-_11 (r_npadvmod) converting_2\VBG\126264|enzyme_11|and_29|drugs_66 (r_amod) inhibitors_4\NNS\20090|promise_59|._117 (r_nsubj) hold_12\VBP\812274|NONE_0 (l_dobj) promise_13\NN\6684383|inhibitors_59|._58 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) fibrillation_16\NN\14361664|NONE_0
D000804_D020257 NONE ii_7\CD\13741022|angiotensin_12|blocking_12 (r_nummod) drugs_11\NNS\14778436|converting_66|enzyme_55|and_37 (r_conj) inhibitors_4\NNS\20090|promise_59|._117 (r_nsubj) hold_12\VBP\812274|NONE_0 (l_dobj) promise_13\NN\6684383|inhibitors_59|._58 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) fibrillation_16\NN\14361664|NONE_0 (l_prep) through_17\IN\0|atrial_20 (l_pobj) remodelling_19\NN\0|NONE_0
D014859_D004617 NONE warfarin_21\NN\2718259|that_5|superior_12 (r_nsubj) is_22\VBZ\0|trial_94|has_31|._94 (l_acomp) superior_23\JJ\9623038|that_17|warfarin_12 (l_xcomp) platelet_25\NN\5432736|NONE_0 (l_prep) in_32\IN\13603305|to_47|therapy_35|clopidogrel_26|)_2 (l_pobj) events_37\NNS\23100|prevention_22
C426686_D004617 NONE ximelagatran_0\NN\0|was_49|be_62|,_143|but_145|withdrawn_167|._217 (r_nsubjpass) found_9\VBN\13279262|NONE_0 (l_xcomp) be_11\VB\14625458|ximelagatran_62|was_13|,_81|but_83|withdrawn_105|._155 (l_acomp) efficient_13\JJ\0|to_9 (l_prep) in_19\IN\13603305|as_43|as_30 (l_pobj) prevention_21\NN\1073995|NONE_0 (l_prep) of_22\IN\0|the_15 (l_pobj) events_24\NNS\23100|NONE_0
D000804_D001281 NONE ii_7\CD\13741022|angiotensin_12|blocking_12 (r_nummod) drugs_11\NNS\14778436|converting_66|enzyme_55|and_37 (r_conj) inhibitors_4\NNS\20090|promise_59|._117 (r_nsubj) hold_12\VBP\812274|NONE_0 (l_dobj) promise_13\NN\6684383|inhibitors_59|._58 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) fibrillation_16\NN\14361664|NONE_0
D014859_D001281 NONE warfarin_21\NN\2718259|that_5|superior_12 (r_nsubj) is_22\VBZ\0|trial_94|has_31|._94 (r_ccomp) demonstrated_19\VBN\2137132|NONE_0 (l_nsubj) trial_8\NN\786195|has_63|is_94|._188 (l_compound) clopidogrel_7\NNP\0|the_34|w_23|(_21|atrial_20|with_18|)_67|study_69 (l_compound) fibrillation_6\NNP\14361664|NONE_0
C055162_D004617 NONE clopidogrel_7\NNP\0|the_34|w_23|(_21|atrial_20|with_18|)_67|study_69 (r_compound) trial_8\NN\786195|has_63|is_94|._188 (r_nsubj) demonstrated_19\VBN\2137132|NONE_0 (l_ccomp) is_22\VBZ\0|trial_94|has_31|._94 (l_acomp) superior_23\JJ\9623038|that_17|warfarin_12 (l_xcomp) platelet_25\NN\5432736|NONE_0 (l_prep) in_32\IN\13603305|to_47|therapy_35|clopidogrel_26|)_2 (l_pobj) events_37\NNS\23100|prevention_22
C055162_D004617 NONE clopidogrel_28\JJ\0|to_21|therapy_9|)_24|in_26 (r_dobj) platelet_25\NN\5432736|NONE_0 (l_prep) in_32\IN\13603305|to_47|therapy_35|clopidogrel_26|)_2 (l_pobj) events_37\NNS\23100|prevention_22
D001241_D001281 NONE aspirin_30\NN\2707683|plus_5 (r_conj) clopidogrel_28\JJ\0|to_21|therapy_9|)_24|in_26 (r_dobj) platelet_25\NN\5432736|NONE_0 (r_xcomp) superior_23\JJ\9623038|that_17|warfarin_12 (r_acomp) is_22\VBZ\0|trial_94|has_31|._94 (r_ccomp) demonstrated_19\VBN\2137132|NONE_0 (l_nsubj) trial_8\NN\786195|has_63|is_94|._188 (l_compound) clopidogrel_7\NNP\0|the_34|w_23|(_21|atrial_20|with_18|)_67|study_69 (l_compound) fibrillation_6\NNP\14361664|NONE_0
D014812_D056486 NONE k_16\NNP\13608598|antagonist_2 (r_compound) drugs_18\NNS\14778436|NONE_0 (r_pobj) as_14\IN\14622893|as_13|in_30 (r_prep) efficient_13\JJ\0|to_9 (r_acomp) be_11\VB\14625458|ximelagatran_62|was_13|,_81|but_83|withdrawn_105|._155 (r_xcomp) found_9\VBN\13279262|NONE_0 (l_conj) withdrawn_30\VBN\1835496|ximelagatran_167|was_118|be_105|,_24|but_22|._50 (l_prep) because_31\IN\0|has_28|been_24|recently_19 (l_pobj) tests_36\NNS\5798043|of_27 (l_compound) function_35\NN\13783581|abnormal_15
C426686_D056486 CID ximelagatran_0\NN\0|was_49|be_62|,_143|but_145|withdrawn_167|._217 (r_nsubjpass) found_9\VBN\13279262|NONE_0 (l_conj) withdrawn_30\VBN\1835496|ximelagatran_167|was_118|be_105|,_24|but_22|._50 (l_prep) because_31\IN\0|has_28|been_24|recently_19 (l_pobj) tests_36\NNS\5798043|of_27 (l_compound) function_35\NN\13783581|abnormal_15
C055162_D001281 NONE clopidogrel_7\NNP\0|the_34|w_23|(_21|atrial_20|with_18|)_67|study_69 (l_compound) fibrillation_6\NNP\14361664|NONE_0
C055162_D001281 NONE clopidogrel_28\JJ\0|to_21|therapy_9|)_24|in_26 (r_dobj) platelet_25\NN\5432736|NONE_0 (r_xcomp) superior_23\JJ\9623038|that_17|warfarin_12 (r_acomp) is_22\VBZ\0|trial_94|has_31|._94 (r_ccomp) demonstrated_19\VBN\2137132|NONE_0 (l_nsubj) trial_8\NN\786195|has_63|is_94|._188 (l_compound) clopidogrel_7\NNP\0|the_34|w_23|(_21|atrial_20|with_18|)_67|study_69 (l_compound) fibrillation_6\NNP\14361664|NONE_0
C081309_D001281 NONE irbesartan_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|the_52|w_41|(_39|atrial_38|clopidogrel_18|)_49|study_51 (r_prep) trial_8\NN\786195|has_63|is_94|._188 (l_compound) clopidogrel_7\NNP\0|the_34|w_23|(_21|atrial_20|with_18|)_67|study_69 (l_compound) fibrillation_6\NNP\14361664|NONE_0
D000809_D020257 NONE angiotensin_0\NN\4522421|-_11 (r_npadvmod) converting_2\VBG\126264|enzyme_11|and_29|drugs_66 (r_amod) inhibitors_4\NNS\20090|promise_59|._117 (r_nsubj) hold_12\VBP\812274|NONE_0 (l_dobj) promise_13\NN\6684383|inhibitors_59|._58 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) fibrillation_16\NN\14361664|NONE_0 (l_prep) through_17\IN\0|atrial_20 (l_pobj) remodelling_19\NN\0|NONE_0
D001241_D004617 NONE aspirin_30\NN\2707683|plus_5 (r_conj) clopidogrel_28\JJ\0|to_21|therapy_9|)_24|in_26 (r_dobj) platelet_25\NN\5432736|NONE_0 (l_prep) in_32\IN\13603305|to_47|therapy_35|clopidogrel_26|)_2 (l_pobj) events_37\NNS\23100|prevention_22
D014859_D020521 NONE warfarin_12\NN\2718259|that_5|risk_21|by_36|,_42|and_44|reduces_67 (r_nsubj) reduces_13\VBZ\441445|data_90|have_25|._81 (l_dobj) risk_15\NN\14541044|that_26|warfarin_21|by_15|,_21|and_23|reduces_46 (l_prep) of_16\IN\0|the_9 (l_pobj) stroke_17\NN\556313|NONE_0
D014859_D020521 NONE warfarin_8\VB\2718259|overall_32|,_25|in_23|,_2|superior_12|,_53|with_55|._92 (r_nsubj) is_9\VBZ\0|NONE_0 (l_acomp) superior_10\JJ\9623038|overall_44|,_37|in_35|,_14|warfarin_12|,_41|with_43|._80 (l_prep) to_11\IN\0|NONE_0 (l_pobj) aspirin_12\NN\2707683|NONE_0 (l_prep) in_13\IN\13603305|NONE_0 (l_pcomp) preventing_14\VBG\0|NONE_0 (l_dobj) strokes_15\NNS\556313|NONE_0
11745184
D004999_D001943 NONE wr-2721_7\NNP\0|cisplatin_15|(_8|)_19 (r_nmod) amifostine_9\NN\0|NONE_0 (r_pobj) of_4\IN\0|a_17|ii_9|for_39|:_70|e8188_117|._123 (r_prep) trial_3\NN\786195|NONE_0 (l_prep) for_11\IN\0|a_56|ii_48|of_39|:_31|e8188_78|._84 (l_pobj) carcinoma_14\NN\14239918|NONE_0
D004999_D001943 NONE amifostine_9\NN\0|NONE_0 (r_pobj) of_4\IN\0|a_17|ii_9|for_39|:_70|e8188_117|._123 (r_prep) trial_3\NN\786195|NONE_0 (l_prep) for_11\IN\0|a_56|ii_48|of_39|:_31|e8188_78|._84 (l_pobj) carcinoma_14\NN\14239918|NONE_0
D004999_D001943 NONE amifostine_10\NN\0|plus_5 (r_conj) cisplatin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_16 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) of_4\IN\0|a_17|ii_9 (r_prep) study_3\NN\635850|was_54|in_68|,_145|but_147|regimen_183 (r_nsubjpass) conducted_12\VBN\2436349|NONE_0 (l_prep) in_13\IN\13603305|study_68|was_14|,_77|but_79|regimen_115 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) carcinoma_19\NN\14239918|NONE_0
D002945_D020258 NONE cisplatin_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|although_50|effect_25|has_18|been_14 (r_prep) observed_8\VBN\2163746|,_23|toxicities_43|have_135|use_152|._191 (r_advcl) limited_31\VBN\4019101|NONE_0 (l_nsubj) toxicities_16\NNS\13576101|observed_43|,_20|have_92|use_109|._148 (l_acl) associated_17\VBN\628491|the_29|limiting_20 (l_prep) with_18\IN\0|NONE_0 (l_pcomp) cisplatin_19\NN\0|NONE_0 (l_preconj) nephrotoxicity_23\NN\0|NONE_0 (l_conj) ototoxicity_25\NN\0|(_23|e.g._22|,_18|,_2|)_30 (l_conj) neurotoxicity_28\NN\0|,_6|and_4
D002945_D020258 NONE cisplatin_19\NN\0|NONE_0 (l_preconj) nephrotoxicity_23\NN\0|NONE_0 (l_conj) ototoxicity_25\NN\0|(_23|e.g._22|,_18|,_2|)_30 (l_conj) neurotoxicity_28\NN\0|,_6|and_4
D002945_D001943 NONE cisplatin_5\NN\0|wr-2721_15|(_23|)_34 (r_nmod) amifostine_9\NN\0|NONE_0 (r_pobj) of_4\IN\0|a_17|ii_9|for_39|:_70|e8188_117|._123 (r_prep) trial_3\NN\786195|NONE_0 (l_prep) for_11\IN\0|a_56|ii_48|of_39|:_31|e8188_78|._84 (l_pobj) carcinoma_14\NN\14239918|NONE_0
D002945_D001943 NONE cisplatin_0\NNP\0|activity_32|used_46|._116 (r_nsubj) has_1\VBZ\13888491|NONE_0 (l_advcl) used_6\VBN\0|cisplatin_46|activity_14|._70 (l_prep) as_7\IN\14622893|when_10 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|second-_32|line_15 (l_pobj) carcinoma_17\NN\14239918|NONE_0
D002945_D001943 NONE cisplatin_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|although_50|effect_25|has_18|been_14 (r_prep) observed_8\VBN\2163746|,_23|toxicities_43|have_135|use_152|._191 (r_advcl) limited_31\VBN\4019101|NONE_0 (l_dobj) use_33\NN\407535|observed_152|,_129|toxicities_109|have_17|._39 (l_prep) as_34\IN\14622893|its_8 (l_pobj) treatment_36\NN\654885|NONE_0 (l_prep) for_37\IN\0|a_12 (l_pobj) carcinoma_39\NN\14239918|NONE_0
D002945_D001943 NONE cisplatin_19\NN\0|NONE_0 (r_pcomp) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_29|limiting_20 (r_acl) toxicities_16\NNS\13576101|observed_43|,_20|have_92|use_109|._148 (r_nsubj) limited_31\VBN\4019101|NONE_0 (l_dobj) use_33\NN\407535|observed_152|,_129|toxicities_109|have_17|._39 (l_prep) as_34\IN\14622893|its_8 (l_pobj) treatment_36\NN\654885|NONE_0 (l_prep) for_37\IN\0|a_12 (l_pobj) carcinoma_39\NN\14239918|NONE_0
D002945_D001943 NONE cisplatin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_16 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) of_4\IN\0|a_17|ii_9 (r_prep) study_3\NN\635850|was_54|in_68|,_145|but_147|regimen_183 (r_nsubjpass) conducted_12\VBN\2436349|NONE_0 (l_prep) in_13\IN\13603305|study_68|was_14|,_77|but_79|regimen_115 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) carcinoma_19\NN\14239918|NONE_0
D002945_D006311 CID cisplatin_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|although_50|effect_25|has_18|been_14 (r_prep) observed_8\VBN\2163746|,_23|toxicities_43|have_135|use_152|._191 (r_advcl) limited_31\VBN\4019101|NONE_0 (l_nsubj) toxicities_16\NNS\13576101|observed_43|,_20|have_92|use_109|._148 (l_acl) associated_17\VBN\628491|the_29|limiting_20 (l_prep) with_18\IN\0|NONE_0 (l_pcomp) cisplatin_19\NN\0|NONE_0 (l_preconj) nephrotoxicity_23\NN\0|NONE_0 (l_conj) ototoxicity_25\NN\0|(_23|e.g._22|,_18|,_2|)_30
D002945_D006311 CID cisplatin_19\NN\0|NONE_0 (l_preconj) nephrotoxicity_23\NN\0|NONE_0 (l_conj) ototoxicity_25\NN\0|(_23|e.g._22|,_18|,_2|)_30
D002945_D006311 CID cisplatin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|early_13 (r_prep) trials_1\NNS\786195|also_35|reduced_152|._159 (r_nsubj) suggested_7\VBD\1010118|NONE_0 (l_ccomp) reduced_24\VBN\441445|trials_152|also_117|._7 (l_nsubjpass) incidence_10\NN\13821570|that_9|were_88 (l_prep) of_13\IN\0|the_27|and_13|severity_9 (l_pobj) nephrotoxicity_17\NN\0|NONE_0 (l_conj) ototoxicity_19\NN\0|induced_24|,_2
D002945_D006311 CID cisplatin_14\NN\0|-_9 (r_advmod) induced_16\VBN\1627355|,_22|ototoxicity_24 (r_amod) nephrotoxicity_17\NN\0|NONE_0 (l_conj) ototoxicity_19\NN\0|induced_24|,_2
D004999_D006311 NONE amifostine_5\NN\0|and_4 (r_conj) cisplatin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|early_13 (r_prep) trials_1\NNS\786195|also_35|reduced_152|._159 (r_nsubj) suggested_7\VBD\1010118|NONE_0 (l_ccomp) reduced_24\VBN\441445|trials_152|also_117|._7 (l_nsubjpass) incidence_10\NN\13821570|that_9|were_88 (l_prep) of_13\IN\0|the_27|and_13|severity_9 (l_pobj) nephrotoxicity_17\NN\0|NONE_0 (l_conj) ototoxicity_19\NN\0|induced_24|,_2
D004999_D009369 NONE amifostine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_13 (r_prep) addition_16\NN\3081021|NONE_0 (r_pobj) with_14\IN\0|effect_59|was_13|._58 (r_prep) observed_13\VBN\2163746|NONE_0 (l_nsubjpass) effect_5\NN\34213|was_46|with_59|._117 (l_amod) protective_4\JJ\0|neither_16|a_8|nor_18|reduced_22 (l_npadvmod) tumor_2\NN\14234074|-_5
D004999_D064420 NONE amifostine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_13 (r_prep) addition_16\NN\3081021|NONE_0 (r_pobj) with_14\IN\0|effect_59|was_13|._58 (r_prep) observed_13\VBN\2163746|NONE_0 (l_nsubjpass) effect_5\NN\34213|was_46|with_59|._117 (l_conj) reduced_7\VBN\441445|neither_38|a_30|protective_22|nor_4 (l_dobj) toxicity_8\NN\13576101|to_9
D002945_D064420 NONE cisplatin_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|although_50|effect_25|has_18|been_14 (r_prep) observed_8\VBN\2163746|,_23|toxicities_43|have_135|use_152|._191 (r_advcl) limited_31\VBN\4019101|NONE_0 (l_nsubj) toxicities_16\NNS\13576101|observed_43|,_20|have_92|use_109|._148
D002945_D064420 NONE cisplatin_19\NN\0|NONE_0 (r_pcomp) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|the_29|limiting_20 (r_acl) toxicities_16\NNS\13576101|observed_43|,_20|have_92|use_109|._148
D002945_D064420 NONE cisplatin_20\VB\0|NONE_0 (r_acl) amifostine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_13 (r_prep) addition_16\NN\3081021|NONE_0 (r_pobj) with_14\IN\0|effect_59|was_13|._58 (r_prep) observed_13\VBN\2163746|NONE_0 (l_nsubjpass) effect_5\NN\34213|was_46|with_59|._117 (l_conj) reduced_7\VBN\441445|neither_38|a_30|protective_22|nor_4 (l_dobj) toxicity_8\NN\13576101|to_9
D002945_D009422 CID cisplatin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|early_13 (r_prep) trials_1\NNS\786195|also_35|reduced_152|._159 (r_nsubj) suggested_7\VBD\1010118|NONE_0 (l_ccomp) reduced_24\VBN\441445|trials_152|also_117|._7 (l_nsubjpass) incidence_10\NN\13821570|that_9|were_88 (l_prep) of_13\IN\0|the_27|and_13|severity_9 (l_pobj) nephrotoxicity_17\NN\0|NONE_0 (l_conj) ototoxicity_19\NN\0|induced_24|,_2 (l_conj) neuropathy_22\NN\14204950|,_6|and_4
D002945_D009422 CID cisplatin_14\NN\0|-_9 (r_advmod) induced_16\VBN\1627355|,_22|ototoxicity_24 (r_amod) nephrotoxicity_17\NN\0|NONE_0 (l_conj) ototoxicity_19\NN\0|induced_24|,_2 (l_conj) neuropathy_22\NN\14204950|,_6|and_4
D004999_D007674 NONE amifostine_5\NN\0|and_4 (r_conj) cisplatin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|early_13 (r_prep) trials_1\NNS\786195|also_35|reduced_152|._159 (r_nsubj) suggested_7\VBD\1010118|NONE_0 (l_ccomp) reduced_24\VBN\441445|trials_152|also_117|._7 (l_nsubjpass) incidence_10\NN\13821570|that_9|were_88 (l_prep) of_13\IN\0|the_27|and_13|severity_9 (l_pobj) nephrotoxicity_17\NN\0|NONE_0
D004999_D009422 NONE amifostine_5\NN\0|and_4 (r_conj) cisplatin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|early_13 (r_prep) trials_1\NNS\786195|also_35|reduced_152|._159 (r_nsubj) suggested_7\VBD\1010118|NONE_0 (l_ccomp) reduced_24\VBN\441445|trials_152|also_117|._7 (l_nsubjpass) incidence_10\NN\13821570|that_9|were_88 (l_prep) of_13\IN\0|the_27|and_13|severity_9 (l_pobj) nephrotoxicity_17\NN\0|NONE_0 (l_conj) ototoxicity_19\NN\0|induced_24|,_2 (l_conj) neuropathy_22\NN\14204950|,_6|and_4
D002945_D007674 CID cisplatin_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|although_50|effect_25|has_18|been_14 (r_prep) observed_8\VBN\2163746|,_23|toxicities_43|have_135|use_152|._191 (r_advcl) limited_31\VBN\4019101|NONE_0 (l_nsubj) toxicities_16\NNS\13576101|observed_43|,_20|have_92|use_109|._148 (l_acl) associated_17\VBN\628491|the_29|limiting_20 (l_prep) with_18\IN\0|NONE_0 (l_pcomp) cisplatin_19\NN\0|NONE_0 (l_preconj) nephrotoxicity_23\NN\0|NONE_0
D002945_D007674 CID cisplatin_19\NN\0|NONE_0 (l_preconj) nephrotoxicity_23\NN\0|NONE_0
D002945_D007674 CID cisplatin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|early_13 (r_prep) trials_1\NNS\786195|also_35|reduced_152|._159 (r_nsubj) suggested_7\VBD\1010118|NONE_0 (l_ccomp) reduced_24\VBN\441445|trials_152|also_117|._7 (l_nsubjpass) incidence_10\NN\13821570|that_9|were_88 (l_prep) of_13\IN\0|the_27|and_13|severity_9 (l_pobj) nephrotoxicity_17\NN\0|NONE_0
D002945_D007674 CID cisplatin_14\NN\0|-_9 (r_advmod) induced_16\VBN\1627355|,_22|ototoxicity_24 (r_amod) nephrotoxicity_17\NN\0|NONE_0
D002945_D009369 NONE cisplatin_20\VB\0|NONE_0 (r_acl) amifostine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_13 (r_prep) addition_16\NN\3081021|NONE_0 (r_pobj) with_14\IN\0|effect_59|was_13|._58 (r_prep) observed_13\VBN\2163746|NONE_0 (l_nsubjpass) effect_5\NN\34213|was_46|with_59|._117 (l_amod) protective_4\JJ\0|neither_16|a_8|nor_18|reduced_22 (l_npadvmod) tumor_2\NN\14234074|-_5
8410052
D010862_D002544 CID pilocarpine_10\NN\14712692|-_11 (r_npadvmod) induced_12\VBN\1627355|prolonged_22 (r_amod) status_13\NN\24720|NONE_0 (r_pobj) by_8\IN\0|infarcts_57|were_12|epilepticus_40|._51 (r_agent) evoked_7\VBN\1617192|NONE_0 (l_nsubjpass) infarcts_0\NNS\14204950|were_45|by_57|epilepticus_97|._108 (l_prep) in_1\IN\13603305|NONE_0 (l_pobj) reticulata_5\NNS\0|NONE_0
D010862_D013226 CID pilocarpine_10\NN\14712692|-_11 (r_npadvmod) induced_12\VBN\1627355|prolonged_22 (r_amod) status_13\NN\24720|NONE_0 (r_pobj) by_8\IN\0|infarcts_57|were_12|epilepticus_40|._51 (r_agent) evoked_7\VBN\1617192|NONE_0 (l_advmod) epilepticus_14\NN\0|infarcts_97|were_52|by_40|._11
D019344_D001480 NONE lactate_10\NN\14850483|NONE_0 (r_pobj) of_9\IN\0|at_11 (r_prep) infusion_8\NN\14589223|or_31|by_34 (r_pobj) by_7\IN\0|injury_34|was_13|._71 (r_agent) produced_6\VBN\1617192|NONE_0 (l_nsubjpass) injury_1\NN\14052046|was_21|by_34|._105 (l_prep) in_2\IN\13603305|focal_13 (l_pobj) cortex_4\NN\5462674|NONE_0
14657095
D000666_D006333 CID b_20\NNP\1355326|NONE_0 (r_pobj) with_18\IN\0|who_101|failure_34|after_26|for_26 (r_prep) developed_5\VBD\1753788|a_14 (l_dobj) failure_12\NN\66216|who_67|after_8|with_34|for_60
D000666_D006333 CID amb_22\NNP\0|amphotericin_16 (r_appos) b_20\NNP\1355326|NONE_0 (r_pobj) with_18\IN\0|who_101|failure_34|after_26|for_26 (r_prep) developed_5\VBD\1753788|a_14 (l_dobj) failure_12\NN\66216|who_67|after_8|with_34|for_60
D000666_D006333 CID amb._12\NN\0|NONE_0 (r_pobj) for_11\IN\0|after_35|posaconazole_29|was_16 (r_prep) substituted_10\VBN\126264|NONE_0 (r_advcl) resolved_6\VBD\352826|his_54|echocardiographic_50|and_18|failure_8 (r_acl) abnormalities_2\NNS\14034177|NONE_0 (l_conj) failure_5\NN\66216|his_46|echocardiographic_42|and_10|resolved_8
D000666_D064420 NONE amb._12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_45|rare_41 (r_prep) toxicity_10\NN\13576101|to_49
C101425_D006333 NONE posaconazole_8\NN\0|after_6|was_13|for_29 (r_nsubjpass) substituted_10\VBN\126264|NONE_0 (r_advcl) resolved_6\VBD\352826|his_54|echocardiographic_50|and_18|failure_8 (r_acl) abnormalities_2\NNS\14034177|NONE_0 (l_conj) failure_5\NN\66216|his_46|echocardiographic_42|and_10|resolved_8
D000666_D003047 NONE b_20\NNP\1355326|NONE_0 (r_pobj) with_18\IN\0|who_101|failure_34|after_26|for_26 (r_prep) developed_5\VBD\1753788|a_14 (l_prep) for_24\IN\0|who_127|failure_60|after_52|with_26 (l_pobj) coccidioidomycosis_26\NN\14176895|NONE_0
D000666_D003047 NONE amb_22\NNP\0|amphotericin_16 (r_appos) b_20\NNP\1355326|NONE_0 (r_pobj) with_18\IN\0|who_101|failure_34|after_26|for_26 (r_prep) developed_5\VBD\1753788|a_14 (l_prep) for_24\IN\0|who_127|failure_60|after_52|with_26 (l_pobj) coccidioidomycosis_26\NN\14176895|NONE_0
D000666_D002311 CID b_6\NNP\1355326|amphotericin_13 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) related_3\VBN\628491|reversible_34|dilated_23|._33 (r_acl) cardiomyopathy_2\NN\14103288|NONE_0
D000666_D002311 CID b_20\NNP\1355326|NONE_0 (r_pobj) with_18\IN\0|who_101|failure_34|after_26|for_26 (r_prep) developed_5\VBD\1753788|a_14 (l_dobj) failure_12\NN\66216|who_67|after_8|with_34|for_60 (l_amod) cardiomyopathy_7\NN\14103288|dilated_8|heart_39
D000666_D002311 CID amb_22\NNP\0|amphotericin_16 (r_appos) b_20\NNP\1355326|NONE_0 (r_pobj) with_18\IN\0|who_101|failure_34|after_26|for_26 (r_prep) developed_5\VBD\1753788|a_14 (l_dobj) failure_12\NN\66216|who_67|after_8|with_34|for_60 (l_amod) cardiomyopathy_7\NN\14103288|dilated_8|heart_39
2334618
D009020_D013610 NONE morphine_26\NN\2707683|NONE_0 (r_compound) infusion_27\NN\14589223|the_13 (r_compound) group_28\NN\2137|NONE_0 (r_pobj) in_24\IN\13603305|ventricular_45|ectopic_33|(_19|p_18|)_2 (r_prep) beats_17\NNS\8289449|(_43|p_42|)_26|and_24 (r_conj) tachyarrhythmias_7\NNS\0|NONE_0
D009020_D018879 CID morphine_26\NN\2707683|NONE_0 (r_compound) infusion_27\NN\14589223|the_13 (r_compound) group_28\NN\2137|NONE_0 (r_pobj) in_24\IN\13603305|ventricular_45|ectopic_33|(_19|p_18|)_2 (r_prep) beats_17\NNS\8289449|(_43|p_42|)_26|and_24
D002045_D001049 NONE bupivacaine_34\NN\0|NONE_0 (r_pobj) of_31\IN\0|a_33|continuous_31|extradural_20 (r_prep) infusion_30\NN\14589223|NONE_0 (r_dobj) receiving_26\VBG\2210855|five_14|mean_65|in_78 (r_acl) patients_25\NNS\9898892|five_87|receiving_73|mean_23|and_9 (r_conj) patients_10\NNS\9898892|NONE_0 (r_pobj) between_8\IN\0|incidence_59|was_13|._234 (r_prep) compared_7\VBN\644583|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_46|between_59|._293 (l_prep) of_2\IN\0|the_14 (l_pobj) apnoea_5\NN\0|NONE_0
D009020_D001049 NONE morphine_17\NN\2707683|NONE_0 (r_pobj) of_16\IN\0|a_27|continuous_25|i.v._14 (r_prep) infusion_15\NN\14589223|NONE_0 (r_dobj) receiving_11\VBG\2210855|five_14|mean_50|and_64|patients_73 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) between_8\IN\0|incidence_59|was_13|._234 (r_prep) compared_7\VBN\644583|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_46|between_59|._293 (l_prep) of_2\IN\0|the_14 (l_pobj) apnoea_5\NN\0|NONE_0
D009020_D020181 CID morphine_25\NN\2707683|a_2 (r_compound) infusion_26\NN\14589223|who_19 (r_dobj) had_23\VBD\0|NONE_0 (r_relcl) patients_21\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|obstructive_94|frequently_11|._39 (r_prep) occurred_17\VBD\0|NONE_0 (l_nsubj) obstructive_1\JJ\0|frequently_83|in_94|._133 (l_appos) p_3\NN\14622893|both_18|(_1 (l_conj) apnoea_10\NN\0|0.05_18|)_14|and_12
D009020_D020182 CID morphine_25\NN\2707683|a_2 (r_compound) infusion_26\NN\14589223|who_19 (r_dobj) had_23\VBD\0|NONE_0 (r_relcl) patients_21\NNS\9898892|NONE_0 (r_pobj) in_20\IN\13603305|obstructive_94|frequently_11|._39 (r_prep) occurred_17\VBD\0|NONE_0 (l_nsubj) obstructive_1\JJ\0|frequently_83|in_94|._133 (l_appos) p_3\NN\14622893|both_18|(_1 (l_conj) apnoea_10\NN\0|0.05_18|)_14|and_12
8437969
D002927_D007938 NONE cimetidine_27\NN\14778019|while_36|hour_17 (r_dobj) receiving_23\VBG\2210855|developed_67|,_48|episodes_40 (r_advcl) recurrent_14\JJ\0|a_76|old_66|with_58|and_44|history_37|._108 (r_appos) man_4\NN\9605289|NONE_0 (l_prep) with_5\IN\0|a_18|old_8|and_14|history_21|recurrent_58|._166 (l_pobj) leukemia_6\NN\14239918|NONE_0
D002927_D001145 NONE cimetidine_6\NN\14778019|NONE_0 (r_compound) administration_7\NN\1133281|NONE_0 (r_pobj) to_5\IN\0|arrhythmias_36|were_24|temporally_19 (r_prep) related_4\VBN\628491|,_36|after_50|,_67|and_69|recur_81|._114 (l_nsubjpass) arrhythmias_1\NNS\14103288|were_12|temporally_17|to_36
D011899_D001145 NONE ranitidine_18\NN\14778019|NONE_0 (r_compound) treatment_19\NN\654885|NONE_0 (r_pobj) during_17\IN\0|did_14|not_10 (r_prep) recur_16\VB\339934|related_81|,_45|after_31|,_14|and_12|._33 (r_conj) disappeared_9\VBD\0|NONE_0 (l_ccomp) related_4\VBN\628491|,_36|after_50|,_67|and_69|recur_81|._114 (l_nsubjpass) arrhythmias_1\NNS\14103288|were_12|temporally_17|to_36
D002927_D054138 CID cimetidine_7\NN\14778019|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|sinus_13|._46 (r_acl) arrest_1\NN\88481|NONE_0
D002927_D054138 CID cimetidine_27\NN\14778019|while_36|hour_17 (r_dobj) receiving_23\VBG\2210855|developed_67|,_48|episodes_40 (r_advcl) recurrent_14\JJ\0|a_76|old_66|with_58|and_44|history_37|._108 (l_appos) episodes_17\NNS\7283608|developed_27|,_8|receiving_40 (l_prep) of_18\IN\0|brief_15 (l_pobj) arrest_21\NN\88481|NONE_0
D002927_D054138 CID cimetidine_14\NN\14778019|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|the_40|first_36|reported_30|of_16 (r_acl) case_5\NN\7283608|this_27|._67 (l_prep) of_6\IN\0|the_24|first_20|reported_14|associated_16 (l_pobj) arrest_8\NN\88481|NONE_0
D002927_D001919 CID cimetidine_7\NN\14778019|NONE_0 (r_pobj) of_6\IN\0|intermittent_35|intravenous_22 (r_prep) infusions_5\NNS\14589223|NONE_0 (r_pobj) of_2\IN\0|the_19 (r_prep) administration_1\NN\1133281|is_67|infrequently_70|with_94|._134 (r_nsubjpass) associated_10\VBN\628491|NONE_0 (l_prep) with_11\IN\0|administration_94|is_27|infrequently_24|._40 (l_pobj) development_13\NN\248977|NONE_0 (l_prep) of_14\IN\0|the_16 (l_pobj) bradyarrhythmias_15\NNS\0|NONE_0
D002927_D006331 NONE cimetidine_27\NN\14778019|while_36|hour_17 (r_dobj) receiving_23\VBG\2210855|developed_67|,_48|episodes_40 (r_advcl) recurrent_14\JJ\0|a_76|old_66|with_58|and_44|history_37|._108 (r_appos) man_4\NN\9605289|NONE_0 (l_conj) history_9\NN\15120823|a_39|old_29|with_21|and_7|recurrent_37|._145 (l_prep) of_10\IN\0|no_11 (l_pobj) disease_12\NN\14061805|NONE_0
2870085
C047847_D002637 NONE flestolol_6\NN\0|NONE_0 (r_compound) infusion_7\NN\14589223|in_44|,_12|was_9|be_22|._69 (r_nsubjpass) found_9\VBN\13279262|NONE_0 (l_xcomp) be_11\VB\14625458|in_66|,_34|infusion_22|was_13|._47 (l_acomp) safe_12\JJ\4340750|to_6 (l_conj) effective_14\JJ\0|and_4 (l_prep) in_15\IN\13603305|NONE_0 (l_pcomp) controlling_16\VBG\0|NONE_0 (l_dobj) pain_18\NN\14299637|NONE_0
C047847_D013610 NONE flestolol_0\NNP\0|attenuation_36|._84 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) attenuation_6\NN\7427337|flestolol_36|._48 (l_prep) of_7\IN\0|a_29|dependent_22 (l_pobj) tachycardia_11\NN\14110674|NONE_0
D007545_D013610 CID isoproterenol_8\NN\3740161|-_13 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) tachycardia_11\NN\14110674|NONE_0
C047847_D013617 NONE flestolol_0\NNP\0|effectively_10|rate_36|in_41|._90 (r_nsubj) reduced_2\VBD\441445|NONE_0 (l_prep) in_5\IN\13603305|flestolol_41|effectively_31|rate_5|._49 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) tachyarrhythmia_9\NN\0|NONE_0
C047847_D000789 NONE flestolol_6\NN\0|NONE_0 (r_compound) infusion_7\NN\14589223|in_44|,_12|was_9|be_22|._69 (r_nsubjpass) found_9\VBN\13279262|NONE_0 (l_prep) in_0\IN\13603305|,_32|infusion_44|was_53|be_66|._113 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) angina_4\NN\14171682|NONE_0
7053303
D002927_D003704 CID cimetidine_10\NN\14778019|possibly_16|to_3 (r_pobj) due_8\IN\5174653|one_30|of_21 (r_amod) case_4\NN\7283608|there_19|._209 (l_prep) of_5\IN\0|one_9|due_21 (l_pobj) dementia_6\NN\14395018|NONE_0
D002927_D003704 CID cimetidine_40\JJ\14778019|NONE_0 (r_compound) levels_41\NNS\4916342|who_19|above_7 (r_dobj) had_39\VBD\0|liver_28 (r_relcl) disease_37\NN\14061805|NONE_0 (r_pobj) without_33\IN\0|13_12 (r_prep) patients_32\NNS\9898892|NONE_0 (r_pobj) of_30\IN\0|a_8 (r_prep) group_29\NN\2137|NONE_0 (r_pobj) in_27\IN\13603305|(_58|with_57|hr_17|)_2 (r_prep) cimetidine_10\NN\14778019|possibly_16|to_3 (r_pobj) due_8\IN\5174653|one_30|of_21 (r_amod) case_4\NN\7283608|there_19|._209 (l_prep) of_5\IN\0|one_9|due_21 (l_pobj) dementia_6\NN\14395018|NONE_0
D002927_D003704 CID cimetidine_3\NN\14778019|high_5|alone_18 (r_compound) levels_4\NNS\4916342|thus_22|,_18|do_13|not_16|always_20|dementia_34|._42 (r_nsubj) induce_9\VB\1627355|NONE_0 (l_dobj) dementia_10\NN\14395018|thus_56|,_52|levels_34|do_21|not_18|always_14|._8
D002927_D008107 NONE cimetidine_10\NN\14778019|possibly_16|to_3 (l_prep) in_27\IN\13603305|(_58|with_57|hr_17|)_2 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) without_33\IN\0|13_12 (l_pobj) disease_37\NN\14061805|NONE_0
D002927_D008107 NONE cimetidine_40\JJ\14778019|NONE_0 (r_compound) levels_41\NNS\4916342|who_19|above_7 (r_dobj) had_39\VBD\0|liver_28 (r_relcl) disease_37\NN\14061805|NONE_0
D002927_D007674 NONE cimetidine_10\NN\14778019|possibly_16|to_3 (l_prep) in_27\IN\13603305|(_58|with_57|hr_17|)_2 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) without_33\IN\0|13_12 (l_pobj) disease_37\NN\14061805|NONE_0
D002927_D007674 NONE cimetidine_40\JJ\14778019|NONE_0 (r_compound) levels_41\NNS\4916342|who_19|above_7 (r_dobj) had_39\VBD\0|liver_28 (r_relcl) disease_37\NN\14061805|NONE_0
12921865
D005680_D012640 NONE acid_21\NN\14818238|that_48|positively_43 (l_appos) receptor_26\NN\5225602|the_38|aminobutyric_28|(_10|gaba(a_9|)_3|)_2 (l_prep) against_27\IN\0|NONE_0 (l_pobj) increase_29\NN\13576355|NONE_0 (l_prep) in_30\IN\13603305|the_13 (l_pobj) sensitivity_31\NN\5651971|NONE_0 (l_prep) to_32\IN\0|NONE_0 (l_pobj) effects_35\NNS\13245626|NONE_0 (l_prep) of_36\IN\0|the_23|convulsant_19 (l_pobj) cocaine_37\NN\3492717|NONE_0 (l_acl) engendered_38\VBN\1645601|NONE_0 (l_agent) by_39\IN\0|NONE_0 (l_pobj) administration_42\NN\1133281|NONE_0 (l_appos) kindling_45\NN\15101361|repeated_41|cocaine_32|(_9|)_8 (l_compound) seizure_44\NN\14081375|NONE_0
D005680_D012640 NONE gaba(a_23\NNP\0|the_29|aminobutyric_19|(_1|)_6|)_7|receptor_9 (r_appos) acid_21\NN\14818238|that_48|positively_43 (l_appos) receptor_26\NN\5225602|the_38|aminobutyric_28|(_10|gaba(a_9|)_3|)_2 (l_prep) against_27\IN\0|NONE_0 (l_pobj) increase_29\NN\13576355|NONE_0 (l_prep) in_30\IN\13603305|the_13 (l_pobj) sensitivity_31\NN\5651971|NONE_0 (l_prep) to_32\IN\0|NONE_0 (l_pobj) effects_35\NNS\13245626|NONE_0 (l_prep) of_36\IN\0|the_23|convulsant_19 (l_pobj) cocaine_37\NN\3492717|NONE_0 (l_acl) engendered_38\VBN\1645601|NONE_0 (l_agent) by_39\IN\0|NONE_0 (l_pobj) administration_42\NN\1133281|NONE_0 (l_appos) kindling_45\NN\15101361|repeated_41|cocaine_32|(_9|)_8 (l_compound) seizure_44\NN\14081375|NONE_0
D005680_D012640 NONE gaba(a_4\NN\0|these_15|positive_9|)_6 (r_nmod) modulators_6\NNS\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) all_0\DT\0|expression_56|,_86|inhibited_133|._170 (r_nsubj) suppressed_7\VBD\2510337|NONE_0 (l_dobj) expression_9\NN\4679549|all_56|,_30|inhibited_77|._114 (l_prep) of_10\IN\0|the_15 (l_pobj) seizures_12\NNS\14081375|NONE_0
D013256_D001523 NONE steroids_1\NNS\14727670|actions_37|._117 (r_nsubj) demonstrate_2\VBP\2137132|NONE_0 (l_dobj) actions_4\NNS\30358|steroids_37|._80 (l_relcl) have_6\VBP\7846|pharmacological_29 (l_dobj) relevance_7\NN\13791389|that_10 (l_prep) for_8\IN\0|NONE_0 (l_pobj) host_10\NN\9605289|NONE_0 (l_prep) of_11\IN\0|a_7 (l_pobj) disorders_15\NNS\14034177|NONE_0
D011280_D012640 NONE allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
D011280_D012640 NONE pregnan-20-one_6\NNP\0|NONE_0 (r_advmod) 3alpha_2\CD\0|(_1|)_36|,_37|pregnanolone_39 (r_appos) allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
D011280_D012640 NONE pregnanolone_9\NN\0|(_40|3alpha_39|)_3|,_2 (r_appos) allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
D011280_D012640 NONE pregnan-20-one_15\NNP\0|and_16|ganaxolone_20 (r_parataxis) pregnanolone_9\NN\0|(_40|3alpha_39|)_3|,_2 (r_appos) allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
D011280_D012640 NONE allopregnanolone_24\NN\0|NONE_0 (r_pobj) of_23\IN\0|a_23|synthetic_21 (r_prep) derivative_22\NN\5802185|(_13|)_80 (r_appos) ganaxolone_18\NN\0|pregnan-20-one_20|and_4 (r_conj) pregnanolone_9\NN\0|(_40|3alpha_39|)_3|,_2 (r_appos) allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
D011280_D012640 NONE allopregnanolone_16\NN\0|whereas_13|development_46 (r_nsubj) inhibited_19\VBD\2510337|all_133|expression_77|,_47|._37 (r_advcl) suppressed_7\VBD\2510337|NONE_0 (l_dobj) expression_9\NN\4679549|all_56|,_30|inhibited_77|._114 (l_prep) of_10\IN\0|the_15 (l_pobj) seizures_12\NNS\14081375|NONE_0
C105051_D012640 NONE ganaxolone_18\NN\0|pregnan-20-one_20|and_4 (r_conj) pregnanolone_9\NN\0|(_40|3alpha_39|)_3|,_2 (r_appos) allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
C105051_D012640 NONE pregnan-20-one_31\NNP\0|NONE_0 (r_appos) 3alpha_25\CD\0|NONE_0 (r_appos) allopregnanolone_24\NN\0|NONE_0 (r_pobj) of_23\IN\0|a_23|synthetic_21 (r_prep) derivative_22\NN\5802185|(_13|)_80 (r_appos) ganaxolone_18\NN\0|pregnan-20-one_20|and_4 (r_conj) pregnanolone_9\NN\0|(_40|3alpha_39|)_3|,_2 (r_appos) allopregnanolone_0\NN\0|were_218|for_230|._397 (r_nsubjpass) tested_34\VBN\670261|NONE_0 (l_prep) for_35\IN\0|allopregnanolone_230|were_12|._167 (l_pobj) ability_37\NN\4723816|NONE_0 (l_acl) suppress_39\VB\2510337|their_17 (l_dobj) expression_41\NN\4679549|to_16 (l_appos) effect_44\NN\34213|the_31|(_16 (l_conj) development_47\NN\248977|anticonvulsant_27|)_6|and_4 (l_prep) of_52\IN\0|(_27|effect_8|)_2 (l_pobj) seizures_56\NNS\14081375|NONE_0
C105051_D012640 NONE ganaxolone_18\NN\0|only_26|and_4 (r_conj) allopregnanolone_16\NN\0|whereas_13|development_46 (r_nsubj) inhibited_19\VBD\2510337|all_133|expression_77|,_47|._37 (r_advcl) suppressed_7\VBD\2510337|NONE_0 (l_dobj) expression_9\NN\4679549|all_56|,_30|inhibited_77|._114 (l_prep) of_10\IN\0|the_15 (l_pobj) seizures_12\NNS\14081375|NONE_0
D013256_D009422 NONE steroids_1\NNS\14727670|actions_37|._117 (r_nsubj) demonstrate_2\VBP\2137132|NONE_0 (l_dobj) actions_4\NNS\30358|steroids_37|._80 (l_relcl) have_6\VBP\7846|pharmacological_29 (l_dobj) relevance_7\NN\13791389|that_10 (l_prep) for_8\IN\0|NONE_0 (l_pobj) host_10\NN\9605289|NONE_0 (l_prep) of_11\IN\0|a_7 (l_pobj) disorders_15\NNS\14034177|NONE_0
D013256_D012640 NONE steroids_4\NNS\14727670|NONE_0 (l_prep) against_5\IN\0|neuroactive_21 (l_pobj) seizures_9\NNS\14081375|NONE_0
D013256_D012640 NONE steroid_13\NN\14727670|to_57 (l_relcl) modulate_16\VBP\1724459|two_69|endogenous_65|one_50|synthetic_46|neuroactive_36 (l_dobj) acid_21\NN\14818238|that_48|positively_43 (l_appos) receptor_26\NN\5225602|the_38|aminobutyric_28|(_10|gaba(a_9|)_3|)_2 (l_prep) against_27\IN\0|NONE_0 (l_pobj) increase_29\NN\13576355|NONE_0 (l_prep) in_30\IN\13603305|the_13 (l_pobj) sensitivity_31\NN\5651971|NONE_0 (l_prep) to_32\IN\0|NONE_0 (l_pobj) effects_35\NNS\13245626|NONE_0 (l_prep) of_36\IN\0|the_23|convulsant_19 (l_pobj) cocaine_37\NN\3492717|NONE_0 (l_acl) engendered_38\VBN\1645601|NONE_0 (l_agent) by_39\IN\0|NONE_0 (l_pobj) administration_42\NN\1133281|NONE_0 (l_appos) kindling_45\NN\15101361|repeated_41|cocaine_32|(_9|)_8 (l_compound) seizure_44\NN\14081375|NONE_0
D003042_D012640 CID cocaine_6\NN\3492717|kindled_8|-_15 (r_compound) seizures_9\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_37\NN\3492717|NONE_0 (l_acl) engendered_38\VBN\1645601|NONE_0 (l_agent) by_39\IN\0|NONE_0 (l_pobj) administration_42\NN\1133281|NONE_0 (l_appos) kindling_45\NN\15101361|repeated_41|cocaine_32|(_9|)_8 (l_compound) seizure_44\NN\14081375|NONE_0
D003042_D012640 CID cocaine_41\NN\3492717|repeated_9|(_23|kindling_32|)_40 (r_compound) administration_42\NN\1133281|NONE_0 (l_appos) kindling_45\NN\15101361|repeated_41|cocaine_32|(_9|)_8 (l_compound) seizure_44\NN\14081375|NONE_0
D003042_D012640 CID cocaine_53\NN\3492717|-_7 (r_npadvmod) kindled_55\VBN\2764245|in_17 (r_amod) seizures_56\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_10\NN\3492717|NONE_0 (r_pobj) of_7\IN\0|daily_21 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) by_4\IN\0|kindled_30|were_13|for_44|._54 (r_agent) induced_3\VBN\1627355|NONE_0 (l_csubjpass) kindled_0\VBN\2764245|were_17|by_30|for_74|._84 (l_dobj) seizures_1\NNS\14081375|NONE_0
16904497
D014221_D011128 NONE triamcinolone_16\NN\14751417|NONE_0 (r_pobj) of_15\IN\0|epidural_19 (r_prep) injection_14\NN\320852|NONE_0 (r_pobj) by_12\IN\0|possibly_16 (r_agent) caused_11\VBN\1617192|a_43|of_34 (r_acl) report_5\NN\6470073|case_10|._102 (l_prep) of_6\IN\0|a_9|caused_34 (l_pobj) syndrome_9\NN\5870365|NONE_0
D002045_D011128 CID bupivacaine_18\NN\0|and_4 (r_conj) triamcinolone_16\NN\14751417|NONE_0 (r_pobj) of_15\IN\0|epidural_19 (r_prep) injection_14\NN\320852|NONE_0 (r_pobj) by_12\IN\0|possibly_16 (r_agent) caused_11\VBN\1617192|a_43|of_34 (r_acl) report_5\NN\6470073|case_10|._102 (l_prep) of_6\IN\0|a_9|caused_34 (l_pobj) syndrome_9\NN\5870365|NONE_0
D013256_D010146 NONE steroid_16\NN\14727670|epidural_9 (r_compound) injection_17\NN\320852|NONE_0 (r_pobj) for_14\IN\0|woman_53|was_14|._30 (r_prep) scheduled_13\VBN\704690|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_39|for_53|._83 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) pain_11\NN\14299637|NONE_0
D013256_D011128 NONE steroid_5\NN\14727670|epidural_9 (r_compound) injection_6\NN\320852|NONE_0 (r_pobj) after_3\IN\0|equina_16|:_32|report_41|._47 (r_prep) syndrome_2\NN\5870365|NONE_0
D013256_D009422 NONE steroid_10\NN\14727670|epidural_9 (r_compound) injections_11\NNS\320852|NONE_0 (r_pobj) after_8\IN\0|continued_49|for_29 (r_prep) vigilance_4\NN\5650579|clinical_35|and_14 (l_prep) for_5\IN\0|continued_20|after_29 (l_pobj) deterioration_7\NN\14560612|NONE_0
D013256_D011843 NONE steroid_11\NN\14727670|epidural_9|,_18|medications_25 (r_compound) injections_12\NNS\320852|physical_35|,_19 (r_conj) therapy_8\NN\657604|methods_50|._87 (r_attr) are_6\VBP\13600404|NONE_0 (l_nsubj) methods_2\NNS\5616786|therapy_50|._137 (l_prep) of_3\IN\0|conventional_31|treatment_18 (l_pobj) radiculopathy_5\NN\0|NONE_0
D013256_D017116 NONE steroid_16\NN\14727670|epidural_9 (r_compound) injection_17\NN\320852|NONE_0 (r_pobj) for_14\IN\0|woman_53|was_14|._30 (r_prep) scheduled_13\VBN\704690|NONE_0 (l_nsubjpass) woman_4\NN\9605289|was_39|for_53|._83 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) pain_11\NN\14299637|NONE_0
12596116
D015282_D000860 NONE octreotide_0\NNP\0|-_10|hypoxemia_19|._77 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) hypoxemia_3\NN\0|octreotide_19|-_9|._58
D015282_D006976 CID octreotide_0\NNP\0|-_10|hypoxemia_19|._77 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) hypoxemia_3\NN\0|octreotide_19|-_9|._58 (l_conj) hypertension_6\NN\14057371|and_14|in_13
D015282_D006976 CID octreotide_10\NN\0|hypertension_72|after_49|,_10|enhance_15|._48 (r_advmod) developed_2\VBD\1753788|NONE_0 (l_nsubj) hypertension_1\NN\14057371|after_23|octreotide_72|,_82|enhance_87|._120
D015282_D005402 NONE octreotide_10\NN\0|hypertension_72|after_49|,_10|enhance_15|._48 (r_advmod) developed_2\VBD\1753788|NONE_0 (l_advcl) enhance_13\VB\227165|hypertension_87|after_64|octreotide_15|,_5|._33 (l_dobj) resolution_14\NN\6470073|to_11 (l_prep) of_15\IN\0|NONE_0 (l_pobj) fistula_17\NN\14253124|NONE_0
16337777
D010862_D004833 CID pilocarpine_49\NN\14712692|the_4|of_18 (r_amod) model_50\NN\5888929|NONE_0 (l_prep) of_51\IN\0|the_22|pilocarpine_18 (l_pobj) epilepsy_54\NN\14085708|NONE_0
D010862_D013226 NONE pilocarpine_49\NN\14712692|the_4|of_18 (r_amod) model_50\NN\5888929|NONE_0 (r_pobj) of_47\IN\0|the_18|chronic_14 (r_prep) phase_46\NN\15113229|NONE_0 (r_pobj) in_43\IN\13603305|to_137|abnormalities_126 (r_prep) provoke_18\VB\1617192|NONE_0 (r_xcomp) sufficient_16\JJ\0|whether_70|generation_52|would_9 (r_acomp) be_15\VB\14625458|in_98|,_85|we_83|._222 (l_nsubj) generation_8\NN\7942152|whether_18|would_43|sufficient_52 (l_prep) during_11\IN\0|increased_27|of_6 (l_pobj) epilepticus_13\NN\0|NONE_0
D010862_D004827 NONE pilocarpine_12\NN\14712692|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|the_35|experimental_31|of_12 (r_acl) model_7\NN\5888929|NONE_0 (l_prep) of_8\IN\0|the_23|experimental_19|induced_12 (l_pobj) epilepsy_9\NN\14085708|NONE_0
18503483
D016559_D020968 CID tacrolimus_2\NN\0|-_10 (r_npadvmod) associated_4\VBN\628491|brachial_11 (r_amod) neuritis_6\NN\14336539|NONE_0
C107135_D020968 NONE everolimus_10\NN\0|NONE_0 (r_pobj) to_9\TO\0|in_14 (r_prep) conversion_8\NN\7359599|NONE_0 (r_pobj) after_7\IN\0|of_43|--_72|report_79|._114 (r_prep) recovery_0\NN\7357388|NONE_0 (l_prep) of_1\IN\0|after_43|--_115|report_122|._157 (l_pobj) neuritis_6\NN\14336539|NONE_0
11334364
D000082_D066126 NONE acetaminophen_13\RB\2707683|-_13 (r_advmod) induced_15\VBN\1627355|,_22|toxicity_48 (r_amod) nephrotoxicity_16\NN\0|NONE_0 (l_conj) toxicity_22\NN\13576101|induced_48|,_26 (l_conj) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24
D000082_D066126 NONE acetaminophen_16\RB\2707683|to_11|toxicity_74 (r_advmod) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_conj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
D000082_D066126 NONE aap)-induced_18\VBN\0|(_1|,_27|amiodarone_29 (r_compound) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60 (r_nmod) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_conj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
D000638_D066126 NONE amiodarone_18\NN\2715941|-_10 (r_npadvmod) induced_20\VBN\1627355|lung_8|and_22|cardiotoxicity_46 (r_amod) toxicity_22\NN\13576101|induced_48|,_26 (l_conj) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24
D000638_D066126 NONE amiodarone_21\NN\2715941|(_30|aap)-induced_29|,_2 (r_appos) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60 (r_nmod) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_conj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
D000638_D066126 NONE ami)-induced_23\JJ\0|nephrotoxicity_28|(_1|lung_13|,_26|and_28|doxorubicin_32 (r_amod) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_conj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
D000638_D007674 NONE amiodarone_18\NN\2715941|-_10 (r_npadvmod) induced_20\VBN\1627355|lung_8|and_22|cardiotoxicity_46 (r_amod) toxicity_22\NN\13576101|induced_48|,_26 (r_conj) nephrotoxicity_16\NN\0|NONE_0
D000638_D007674 NONE amiodarone_21\NN\2715941|(_30|aap)-induced_29|,_2 (r_appos) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
D000638_D007674 NONE ami)-induced_23\JJ\0|nephrotoxicity_28|(_1|lung_13|,_26|and_28|doxorubicin_32 (r_amod) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_nmod) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
C511402_D009336 NONE extract_35\NN\14589223|NONE_0 (r_pobj) by_28\IN\0|induced_23 (r_prep) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24 (r_conj) toxicity_22\NN\13576101|induced_48|,_26 (r_conj) nephrotoxicity_16\NN\0|NONE_0 (r_pobj) during_12\IN\0|associated_46|apoptotic_35|cell_12 (r_prep) deaths_11\NNS\7296428|vivo_69|of_53 (l_amod) apoptotic_7\JJ\0|associated_11|cell_23|during_35 (l_conj) necrotic_9\JJ\0|and_4
C511402_D009336 NONE gspe_31\NNP\0|NONE_0 (r_pobj) by_30\IN\0|which_35|was_29|effectively_20 (r_agent) blocked_29\VBN\1476483|in_52 (r_relcl) necrosis_20\NN\11444117|NONE_0
C511402_D008171 NONE extract_35\NN\14589223|NONE_0 (r_pobj) by_28\IN\0|induced_23 (r_prep) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24 (r_conj) toxicity_22\NN\13576101|induced_48|,_26
C511402_D008171 NONE extract_10\NN\14589223|NONE_0 (r_pobj) of_5\IN\0|the_12|prevent_55 (r_prep) ability_4\NN\4723816|study_19|._207 (l_acl) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74
C511402_D008171 NONE gspe_12\NNP\0|ih636_43|proanthocyanidin_26|(_1|)_4 (r_appos) extract_10\NN\14589223|NONE_0 (r_pobj) of_5\IN\0|the_12|prevent_55 (r_prep) ability_4\NN\4723816|study_19|._207 (l_acl) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74
D000082_D007674 CID acetaminophen_13\RB\2707683|-_13 (r_advmod) induced_15\VBN\1627355|,_22|toxicity_48 (r_amod) nephrotoxicity_16\NN\0|NONE_0
D000082_D007674 CID acetaminophen_16\RB\2707683|to_11|toxicity_74 (r_advmod) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_nmod) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
D000082_D007674 CID aap)-induced_18\VBN\0|(_1|,_27|amiodarone_29 (r_compound) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
D000638_D009336 CID amiodarone_18\NN\2715941|-_10 (r_npadvmod) induced_20\VBN\1627355|lung_8|and_22|cardiotoxicity_46 (r_amod) toxicity_22\NN\13576101|induced_48|,_26 (r_conj) nephrotoxicity_16\NN\0|NONE_0 (r_pobj) during_12\IN\0|associated_46|apoptotic_35|cell_12 (r_prep) deaths_11\NNS\7296428|vivo_69|of_53 (l_amod) apoptotic_7\JJ\0|associated_11|cell_23|during_35 (l_conj) necrotic_9\JJ\0|and_4
D000638_D009336 CID ami_11\NNP\0|,_2 (r_conj) aap_9\NNP\0|all_24|the_20|,_11|as_4 (r_appos) drugs_4\NNS\14778436|interestingly_23|,_10|death_51|in_57|._148 (r_nsubj) induced_14\VBD\1627355|NONE_0 (l_prep) in_17\IN\13603305|interestingly_80|,_67|drugs_57|death_6|._91 (l_pobj) addition_18\NN\3081021|NONE_0 (l_prep) to_19\IN\0|NONE_0 (l_pobj) necrosis_20\NN\11444117|NONE_0
C511402_D017695 NONE gspe_30\NNP\0|than_17 (r_compound) preexposure_31\NN\0|NONE_0 (r_pobj) of_29\IN\0|the_12 (r_prep) absence_28\NN\14449405|NONE_0 (r_pobj) in_26\IN\13603305|a_62|of_52|by_23 (r_prep) variety_17\NN\7951464|NONE_0 (r_pobj) with_15\IN\0|massive_22|tissue_14 (r_prep) damage_14\NN\7296428|NONE_0
D000638_D008171 CID amiodarone_18\NN\2715941|-_10 (r_npadvmod) induced_20\VBN\1627355|lung_8|and_22|cardiotoxicity_46 (r_amod) toxicity_22\NN\13576101|induced_48|,_26
D000638_D008171 CID amiodarone_21\NN\2715941|(_30|aap)-induced_29|,_2 (r_appos) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60 (r_nmod) toxicity_25\NN\13576101|to_85|acetaminophen_74
D000638_D008171 CID ami)-induced_23\JJ\0|nephrotoxicity_28|(_1|lung_13|,_26|and_28|doxorubicin_32 (r_amod) toxicity_25\NN\13576101|to_85|acetaminophen_74
D004317_D007674 NONE doxorubicin_24\NN\2716866|-_11 (r_npadvmod) induced_26\VBN\1627355|by_23 (r_amod) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24 (r_conj) toxicity_22\NN\13576101|induced_48|,_26 (r_conj) nephrotoxicity_16\NN\0|NONE_0
D004317_D007674 NONE doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (r_conj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_nmod) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
D004317_D007674 NONE dox)-induced_30\JJ\0|(_1|in_28 (r_amod) cardiotoxicity_31\NN\0|NONE_0 (r_dobj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (r_conj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_nmod) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
D000082_D009336 CID acetaminophen_13\RB\2707683|-_13 (r_advmod) induced_15\VBN\1627355|,_22|toxicity_48 (r_amod) nephrotoxicity_16\NN\0|NONE_0 (r_pobj) during_12\IN\0|associated_46|apoptotic_35|cell_12 (r_prep) deaths_11\NNS\7296428|vivo_69|of_53 (l_amod) apoptotic_7\JJ\0|associated_11|cell_23|during_35 (l_conj) necrotic_9\JJ\0|and_4
D000082_D009336 CID aap_9\NNP\0|all_24|the_20|,_11|as_4 (r_appos) drugs_4\NNS\14778436|interestingly_23|,_10|death_51|in_57|._148 (r_nsubj) induced_14\VBD\1627355|NONE_0 (l_prep) in_17\IN\13603305|interestingly_80|,_67|drugs_57|death_6|._91 (l_pobj) addition_18\NN\3081021|NONE_0 (l_prep) to_19\IN\0|NONE_0 (l_pobj) necrosis_20\NN\11444117|NONE_0
C511402_D007674 NONE extract_35\NN\14589223|NONE_0 (r_pobj) by_28\IN\0|induced_23 (r_prep) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24 (r_conj) toxicity_22\NN\13576101|induced_48|,_26 (r_conj) nephrotoxicity_16\NN\0|NONE_0
C511402_D007674 NONE extract_10\NN\14589223|NONE_0 (r_pobj) of_5\IN\0|the_12|prevent_55 (r_prep) ability_4\NN\4723816|study_19|._207 (l_acl) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_nmod) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
C511402_D007674 NONE gspe_12\NNP\0|ih636_43|proanthocyanidin_26|(_1|)_4 (r_appos) extract_10\NN\14589223|NONE_0 (r_pobj) of_5\IN\0|the_12|prevent_55 (r_prep) ability_4\NN\4723816|study_19|._207 (l_acl) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_nmod) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60
D004317_D008171 NONE doxorubicin_24\NN\2716866|-_11 (r_npadvmod) induced_26\VBN\1627355|by_23 (r_amod) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24 (r_conj) toxicity_22\NN\13576101|induced_48|,_26
D004317_D008171 NONE doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (r_conj) toxicity_25\NN\13576101|to_85|acetaminophen_74
D004317_D008171 NONE dox)-induced_30\JJ\0|(_1|in_28 (r_amod) cardiotoxicity_31\NN\0|NONE_0 (r_dobj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (r_conj) toxicity_25\NN\13576101|to_85|acetaminophen_74
D000082_D008171 NONE acetaminophen_13\RB\2707683|-_13 (r_advmod) induced_15\VBN\1627355|,_22|toxicity_48 (r_amod) nephrotoxicity_16\NN\0|NONE_0 (l_conj) toxicity_22\NN\13576101|induced_48|,_26
D000082_D008171 NONE acetaminophen_16\RB\2707683|to_11|toxicity_74 (r_advmod) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74
D000082_D008171 NONE aap)-induced_18\VBN\0|(_1|,_27|amiodarone_29 (r_compound) nephrotoxicity_19\NN\0|(_27|ami)-induced_28|lung_41|,_54|and_56|doxorubicin_60 (r_nmod) toxicity_25\NN\13576101|to_85|acetaminophen_74
D004317_D009336 CID doxorubicin_24\NN\2716866|-_11 (r_npadvmod) induced_26\VBN\1627355|by_23 (r_amod) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24 (r_conj) toxicity_22\NN\13576101|induced_48|,_26 (r_conj) nephrotoxicity_16\NN\0|NONE_0 (r_pobj) during_12\IN\0|associated_46|apoptotic_35|cell_12 (r_prep) deaths_11\NNS\7296428|vivo_69|of_53 (l_amod) apoptotic_7\JJ\0|associated_11|cell_23|during_35 (l_conj) necrotic_9\JJ\0|and_4
D004317_D009336 CID dox_13\NNP\0|and_4 (r_conj) ami_11\NNP\0|,_2 (r_conj) aap_9\NNP\0|all_24|the_20|,_11|as_4 (r_appos) drugs_4\NNS\14778436|interestingly_23|,_10|death_51|in_57|._148 (r_nsubj) induced_14\VBD\1627355|NONE_0 (l_prep) in_17\IN\13603305|interestingly_80|,_67|drugs_57|death_6|._91 (l_pobj) addition_18\NN\3081021|NONE_0 (l_prep) to_19\IN\0|NONE_0 (l_pobj) necrosis_20\NN\11444117|NONE_0
C511402_D066126 NONE extract_35\NN\14589223|NONE_0 (r_pobj) by_28\IN\0|induced_23 (r_prep) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24
C511402_D066126 NONE extract_10\NN\14589223|NONE_0 (r_pobj) of_5\IN\0|the_12|prevent_55 (r_prep) ability_4\NN\4723816|study_19|._207 (l_acl) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_conj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
C511402_D066126 NONE gspe_12\NNP\0|ih636_43|proanthocyanidin_26|(_1|)_4 (r_appos) extract_10\NN\14589223|NONE_0 (r_pobj) of_5\IN\0|the_12|prevent_55 (r_prep) ability_4\NN\4723816|study_19|._207 (l_acl) prevent_15\VB\0|the_67|of_55 (l_dobj) toxicity_25\NN\13576101|to_85|acetaminophen_74 (l_conj) doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
D004317_D066126 CID doxorubicin_24\NN\2716866|-_11 (r_npadvmod) induced_26\VBN\1627355|by_23 (r_amod) cardiotoxicity_27\NN\0|induced_46|lung_38|and_24
D004317_D066126 CID doxorubicin_28\NN\2716866|nephrotoxicity_60|(_33|ami)-induced_32|lung_19|,_6|and_4 (l_dobj) cardiotoxicity_31\NN\0|NONE_0
D004317_D066126 CID dox)-induced_30\JJ\0|(_1|in_28 (r_amod) cardiotoxicity_31\NN\0|NONE_0
19346865
D008795_D007239 NONE metronidazole_4\NN\2723292|they_21|had_16|been_12|(_14|dosage_21|)_68|treat_73|._110 (r_dobj) taking_3\VBG\37396|NONE_0 (l_advcl) treat_23\VB\7570720|they_94|had_89|been_85|metronidazole_73|(_59|dosage_52|)_5|._37 (l_dobj) infection_25\NN\14052046|to_13
D008795_D001927 CID metronidazole_5\NN\2723292|-_13 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) encephalopathy_8\NN\14084880|NONE_0 (r_pobj) in_4\IN\13603305|reversible_38|inferior_27|colliculus_18|:_39|findings_60|._138 (r_prep) lesion_3\NN\14204950|NONE_0
D008795_D001927 CID metronidazole_5\NN\2723292|-_13 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) encephalopathy_8\NN\14084880|NONE_0
D008795_D001927 CID metronidazole_9\NN\2723292|-_13 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) encephalopathy_12\NN\14084880|NONE_0 (r_pobj) in_8\IN\13603305|reversible_39|inferior_28|colliculus_19 (r_prep) lesions_7\NNS\14204950|to_42|,_47|focus_52
D008795_D001927 CID metronidazole_9\NN\2723292|-_13 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) encephalopathy_12\NN\14084880|NONE_0
D008795_D001927 CID metronidazole_20\NN\2723292|-_13 (r_npadvmod) induced_22\VBN\1627355|(_23|range_28|;_33|years_41 (r_amod) encephalopathy_23\NN\14084880|NONE_0
D008795_D001927 CID metronidazole_11\NN\2723292|-_13 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) encephalopathy_14\NN\14084880|NONE_0 (r_pobj) for_10\IN\0|the_19 (r_prep) characteristic_9\NN\5849040|NONE_0 (r_pobj) as_7\IN\14622893|lesions_28|could_20|be_14|,_62|next_64|._103 (r_prep) considered_6\VBN\689344|NONE_0 (l_nsubjpass) lesions_3\NNS\14204950|could_8|be_14|as_28|,_90|next_92|._131
D008795_D001927 CID metronidazole_11\NN\2723292|-_13 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) encephalopathy_14\NN\14084880|NONE_0
3970039
D003520_D002277 CID cyclophosphamide_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|risk_22|._54 (r_nsubj) increases_2\VBZ\13576355|NONE_0 (l_dobj) risk_4\NN\14541044|therapy_22|._32 (l_prep) of_5\IN\0|the_9 (l_pobj) carcinoma_6\NN\14239918|NONE_0 (l_prep) of_7\IN\0|NONE_0 (l_pobj) bladder_9\NN\5515670|NONE_0
D000477_D015470 CID agents_4\NNS\7347|NONE_0 (r_pobj) with_2\IN\0|patients_17 (r_prep) treated_1\VBN\2376958|risk_49|,_101|and_103|associated_151 (r_csubj) have_5\VBP\7846|NONE_0 (l_dobj) risk_8\NN\14541044|treated_49|,_52|and_54|associated_102 (l_prep) of_9\IN\0|an_18|increased_15 (l_pobj) development_10\NN\248977|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) leukemia_14\NN\14239918|NONE_0
D000477_D015470 CID agents_19\NNS\7347|are_24|with_39|._85 (r_nsubjpass) associated_23\VBN\628491|treated_151|risk_102|,_50|and_48 (r_conj) have_5\VBP\7846|NONE_0 (l_dobj) risk_8\NN\14541044|treated_49|,_52|and_54|associated_102 (l_prep) of_9\IN\0|an_18|increased_15 (l_pobj) development_10\NN\248977|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) leukemia_14\NN\14239918|NONE_0
D000477_D009369 NONE agents_31\NNS\7347|immunosuppressive_49|,_26|,_6 (r_appos) drugs_27\NNS\14778436|NONE_0 (r_pobj) of_25\IN\0|the_8|in_60 (r_prep) use_24\NN\407535|is_18|,_6|should_105|be_112|for_124|._202 (r_nsubjpass) reserved_41\VBN\2213690|data_264|are_190|still_186|being_180|,_165|and_163 (r_conj) collected_14\VBN\2281093|NONE_0 (l_nsubjpass) data_0\NNS\7951464|are_74|still_78|being_84|,_99|and_101|reserved_264 (l_prep) on_1\IN\0|NONE_0 (l_pobj) risk_5\NN\14541044|NONE_0 (l_prep) of_6\IN\0|the_28|possible_24|increased_15 (l_pobj) malignancy_7\NN\14070360|NONE_0
D003520_D001172 NONE cyclophosphamide_17\NN\0|and_4 (r_conj) azathioprine_15\NN\3740161|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|several_64|term_51|of_38|and_47 (r_acl) studies_7\NNS\635850|there_34|have_28|increased_148|._157 (l_prep) of_8\IN\0|several_26|term_13|treated_38|and_85 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) arthritis_12\NN\14171682|NONE_0
D000477_D001172 NONE agents_31\NNS\7347|immunosuppressive_49|,_26|,_6 (r_appos) drugs_27\NNS\14778436|NONE_0 (r_pobj) of_25\IN\0|the_8|in_60 (r_prep) use_24\NN\407535|is_18|,_6|should_105|be_112|for_124|._202 (r_nsubjpass) reserved_41\VBN\2213690|data_264|are_190|still_186|being_180|,_165|and_163 (r_conj) collected_14\VBN\2281093|NONE_0 (l_nsubjpass) data_0\NNS\7951464|are_74|still_78|being_84|,_99|and_101|reserved_264 (l_prep) on_1\IN\0|NONE_0 (l_pobj) risk_5\NN\14541044|NONE_0 (l_prep) of_6\IN\0|the_28|possible_24|increased_15 (l_pobj) malignancy_7\NN\14070360|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) arthritis_10\NN\14171682|NONE_0
D000477_D001172 NONE agents_31\NNS\7347|immunosuppressive_49|,_26|,_6 (r_appos) drugs_27\NNS\14778436|NONE_0 (r_pobj) of_25\IN\0|the_8|in_60 (r_prep) use_24\NN\407535|is_18|,_6|should_105|be_112|for_124|._202 (l_prep) in_33\IN\13603305|the_68|of_60 (l_pobj) treatment_35\NN\654885|NONE_0 (l_prep) of_36\IN\0|the_14 (l_pobj) arthritis_38\NN\14171682|NONE_0
D003520_D009369 NONE cyclophosphamide_17\NN\0|and_4 (r_conj) azathioprine_15\NN\3740161|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|several_64|term_51|of_38|and_47 (r_acl) studies_7\NNS\635850|there_34|have_28|increased_148|._157 (r_attr) been_2\VBN\0|NONE_0 (l_conj) increased_29\VBN\169651|there_182|have_176|studies_148|._9 (l_nsubjpass) incidence_20\NN\13821570|is_40|not_43 (l_prep) of_21\IN\0|the_14 (l_pobj) most_22\JJS\0|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) cancers_26\NNS\14239425|NONE_0
D003520_D001749 CID cyclophosphamide_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|risk_22|._54 (r_nsubj) increases_2\VBZ\13576355|NONE_0 (l_dobj) risk_4\NN\14541044|therapy_22|._32 (l_prep) of_5\IN\0|the_9 (l_pobj) carcinoma_6\NN\14239918|NONE_0 (l_prep) of_7\IN\0|NONE_0 (l_pobj) bladder_9\NN\5515670|NONE_0
D000477_D008228 CID agents_4\NNS\7347|NONE_0 (r_pobj) with_2\IN\0|patients_17 (r_prep) treated_1\VBN\2376958|risk_49|,_101|and_103|associated_151 (r_csubj) have_5\VBP\7846|NONE_0 (l_conj) associated_23\VBN\628491|treated_151|risk_102|,_50|and_48 (l_prep) with_24\IN\0|agents_39|are_15|._46 (l_pobj) development_26\NN\248977|NONE_0 (l_prep) of_27\IN\0|the_16 (l_pobj) lymphoma_32\NN\14239918|NONE_0
D000477_D008228 CID agents_19\NNS\7347|are_24|with_39|._85 (r_nsubjpass) associated_23\VBN\628491|treated_151|risk_102|,_50|and_48 (l_prep) with_24\IN\0|agents_39|are_15|._46 (l_pobj) development_26\NN\248977|NONE_0 (l_prep) of_27\IN\0|the_16 (l_pobj) lymphoma_32\NN\14239918|NONE_0
D001379_D009369 NONE azathioprine_15\NN\3740161|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|several_64|term_51|of_38|and_47 (r_acl) studies_7\NNS\635850|there_34|have_28|increased_148|._157 (r_attr) been_2\VBN\0|NONE_0 (l_conj) increased_29\VBN\169651|there_182|have_176|studies_148|._9 (l_nsubjpass) incidence_20\NN\13821570|is_40|not_43 (l_prep) of_21\IN\0|the_14 (l_pobj) most_22\JJS\0|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) cancers_26\NNS\14239425|NONE_0
D001379_D001172 NONE azathioprine_15\NN\3740161|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|several_64|term_51|of_38|and_47 (r_acl) studies_7\NNS\635850|there_34|have_28|increased_148|._157 (l_prep) of_8\IN\0|several_26|term_13|treated_38|and_85 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) arthritis_12\NN\14171682|NONE_0
D001379_D008228 CID azathioprine_21\NN\3740161|both_27|alkylating_22|and_4 (r_conj) agents_19\NNS\7347|are_24|with_39|._85 (r_nsubjpass) associated_23\VBN\628491|treated_151|risk_102|,_50|and_48 (l_prep) with_24\IN\0|agents_39|are_15|._46 (l_pobj) development_26\NN\248977|NONE_0 (l_prep) of_27\IN\0|the_16 (l_pobj) lymphoma_32\NN\14239918|NONE_0
D001379_D015470 NONE azathioprine_21\NN\3740161|both_27|alkylating_22|and_4 (r_conj) agents_19\NNS\7347|are_24|with_39|._85 (r_nsubjpass) associated_23\VBN\628491|treated_151|risk_102|,_50|and_48 (r_conj) have_5\VBP\7846|NONE_0 (l_dobj) risk_8\NN\14541044|treated_49|,_52|and_54|associated_102 (l_prep) of_9\IN\0|an_18|increased_15 (l_pobj) development_10\NN\248977|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) leukemia_14\NN\14239918|NONE_0
2266990
D008454_D001068 CID mazindol_4\NN\0|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) attributable_2\JJ\0|side_13 (r_amod) effects_1\NNS\13245626|appetite_52 (r_nsubj) included_5\VBN\0|;_112|dosage_123|was_130|in_142|._160 (l_dobj) appetite_7\NN\7485475|effects_52
D008454_D001068 CID mazindol_35\NN\0|NONE_0 (r_amod) dosage_36\NN\13576355|included_123|;_11|was_7|in_19|._37 (r_nsubjpass) reduced_38\VBN\441445|NONE_0 (l_ccomp) included_5\VBN\0|;_112|dosage_123|was_130|in_142|._160 (l_dobj) appetite_7\NN\7485475|effects_52
D008454_D020388 NONE mazindol_7\NN\0|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) dystrophy_10\NN\14151139|NONE_0
D008454_D020388 NONE mazindol_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|a_28|12-month_26|controlled_17|,_11|inhibitor_49|,_58 (r_prep) trial_5\NN\786195|we_35|in_66|._100 (r_dobj) conducted_1\VBD\2436349|NONE_0 (l_prep) in_16\IN\13603305|we_101|trial_66|._34 (l_pobj) boys_18\NNS\9624168|NONE_0 (l_prep) with_19\IN\0|83_8 (l_pobj) dystrophy_21\NN\14151139|NONE_0
D008454_D020388 NONE mazindol_0\JJ\0|NONE_0 (r_compound) doses_1\NNS\3740161|not_6|progression_19|._64 (r_nsubj) slow_3\VBP\151689|NONE_0 (l_dobj) progression_5\NN\8457976|doses_19|not_13|._45 (l_prep) of_6\IN\0|the_16 (l_pobj) weakness_7\NN\14462666|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) dystrophy_10\NN\14151139|NONE_0
D008454_D014987 CID mazindol_4\NN\0|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) attributable_2\JJ\0|side_13 (r_amod) effects_1\NNS\13245626|appetite_52 (r_nsubj) included_5\VBN\0|;_112|dosage_123|was_130|in_142|._160 (l_dobj) appetite_7\NN\7485475|effects_52 (l_appos) mouth_14\NN\5610008|decreased_30|(_11|%_8|)_7|,_6|,_11|change_24
D008454_D014987 CID mazindol_35\NN\0|NONE_0 (r_amod) dosage_36\NN\13576355|included_123|;_11|was_7|in_19|._37 (r_nsubjpass) reduced_38\VBN\441445|NONE_0 (l_ccomp) included_5\VBN\0|;_112|dosage_123|was_130|in_142|._160 (l_dobj) appetite_7\NN\7485475|effects_52 (l_appos) mouth_14\NN\5610008|decreased_30|(_11|%_8|)_7|,_6|,_11|change_24
D008454_D018908 NONE mazindol_0\JJ\0|NONE_0 (r_compound) doses_1\NNS\3740161|not_6|progression_19|._64 (r_nsubj) slow_3\VBP\151689|NONE_0 (l_dobj) progression_5\NN\8457976|doses_19|not_13|._45 (l_prep) of_6\IN\0|the_16 (l_pobj) weakness_7\NN\14462666|NONE_0
D008454_D012817 CID mazindol_4\NN\0|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) attributable_2\JJ\0|side_13 (r_amod) effects_1\NNS\13245626|appetite_52 (r_nsubj) included_5\VBN\0|;_112|dosage_123|was_130|in_142|._160 (l_dobj) appetite_7\NN\7485475|effects_52 (l_appos) change_21\NN\7283608|decreased_54|(_35|%_32|)_31|,_30|mouth_24|,_13 (l_conj) symptoms_29\NNS\5823932|behavioral_46|(_28|%_25|)_24|,_23|and_21
D008454_D012817 CID mazindol_35\NN\0|NONE_0 (r_amod) dosage_36\NN\13576355|included_123|;_11|was_7|in_19|._37 (r_nsubjpass) reduced_38\VBN\441445|NONE_0 (l_ccomp) included_5\VBN\0|;_112|dosage_123|was_130|in_142|._160 (l_dobj) appetite_7\NN\7485475|effects_52 (l_appos) change_21\NN\7283608|decreased_54|(_35|%_32|)_31|,_30|mouth_24|,_13 (l_conj) symptoms_29\NNS\5823932|behavioral_46|(_28|%_25|)_24|,_23|and_21
6861444
D009638_D006973 CID noradrenaline_3\NN\14807929|NONE_0 (r_pobj) of_2\IN\0|intrarenal_20 (r_prep) infusion_1\NN\14589223|hypertension_33|at_46|._101 (r_nsubj) caused_4\VBD\1617192|NONE_0 (l_dobj) hypertension_5\NN\14057371|infusion_33|at_13|._68
D009638_D006973 CID noradrenaline_8\NN\14807929|chronic_19|intrarenal_11 (r_amod) infusion_9\NN\14589223|NONE_0 (r_pobj) after_5\IN\0|NONE_0 (r_prep) hypertension_4\NN\14057371|that_5|is_61|by_73
D009638_D006973 CID noradrenaline_18\NN\14807929|NONE_0 (r_dobj) circulating_17\VBG\1835496|NONE_0 (r_pcomp) of_16\IN\0|higher_14 (r_prep) levels_15\NNS\4916342|and_36|by_40 (r_pobj) by_12\IN\0|that_78|hypertension_73|is_12 (r_agent) produced_11\VBN\1617192|results_85|._129 (l_nsubjpass) hypertension_4\NN\14057371|that_5|is_61|by_73
137340
D010830_D006948 NONE physostigmine_12\NN\14712692|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) attenuated_10\VBN\224901|hyperactivity_49|was_35|by_19|and_4|._27 (r_conj) potentiated_6\VBN\229605|NONE_0 (l_nsubjpass) hyperactivity_4\NN\14052403|was_14|by_30|and_45|attenuated_49|._76
D012701_D006948 NONE serotonin_22\NN\14807737|a_2 (r_compound) depletor_23\NN\0|on_100|,_83|pretreatment_81|,_14|,_8|change_32|._59 (r_nsubj) caused_25\VBD\1617192|NONE_0 (l_dobj) change_28\NN\7283608|on_132|,_115|pretreatment_113|,_46|depletor_32|,_24|._27 (l_prep) in_29\IN\13603305|no_22|significant_19 (l_pobj) hyperactivity_31\NN\14052403|NONE_0
D009388_D006948 NONE neostigmine_6\NN\2718084|both_25|and_4|,_11|penetrate_26 (r_conj) methscopolamine_4\NN\0|in_18|,_7|,_79|effect_88|._136 (r_nsubj) had_18\VBD\0|NONE_0 (l_dobj) effect_20\NN\34213|in_106|,_95|methscopolamine_88|,_9|._48 (l_prep) on_21\IN\0|no_10 (l_pobj) hyperactivity_23\NN\14052403|NONE_0
D012601_D006948 CID scopolamine_8\NN\14712692|NONE_0 (r_pobj) by_7\IN\0|hyperactivity_30|was_16|and_15|attenuated_19|._46 (r_agent) potentiated_6\VBN\229605|NONE_0 (l_nsubjpass) hyperactivity_4\NN\14052403|was_14|by_30|and_45|attenuated_49|._76
D010134_D006948 NONE chlorophenylalamine_9\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) pretreatment_5\NN\0|on_19|,_2|,_67|depletor_81|,_89|change_113|._140 (r_nsubj) caused_25\VBD\1617192|NONE_0 (l_dobj) change_28\NN\7283608|on_132|,_115|pretreatment_113|,_46|depletor_32|,_24|._27 (l_prep) in_29\IN\13603305|no_22|significant_19 (l_pobj) hyperactivity_31\NN\14052403|NONE_0
D019832_D006948 NONE methscopolamine_4\NN\0|in_18|,_7|,_79|effect_88|._136 (r_nsubj) had_18\VBD\0|NONE_0 (l_dobj) effect_20\NN\34213|in_106|,_95|methscopolamine_88|,_9|._48 (l_prep) on_21\IN\0|no_10 (l_pobj) hyperactivity_23\NN\14052403|NONE_0
D009020_D006948 CID morphine_5\NN\2707683|-_8 (r_npadvmod) induced_7\VBN\1627355|in_17 (r_amod) increase_8\NN\13576355|NONE_0 (l_prep) in_9\IN\13603305|induced_17 (l_pobj) activity_11\NN\30358|NONE_0
D009020_D006948 CID morphine_7\NN\2707683|-_8 (r_npadvmod) induced_9\VBN\1627355|the_13|in_17 (r_amod) increase_10\NN\13576355|NONE_0 (l_prep) in_11\IN\13603305|the_30|induced_17 (l_pobj) activity_13\NN\30358|NONE_0
D009020_D006948 CID morphine_7\NN\2707683|-_8 (r_compound) hc1_9\NNP\0|NONE_0 (r_pobj) of_6\IN\0|10_9 (r_prep) mg/kg_5\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_32|subcutaneous_28 (r_prep) administration_2\NN\1133281|increase_61|._99 (r_nsubj) produced_10\VBD\1617192|NONE_0 (l_dobj) increase_13\NN\13576355|administration_61|._38 (l_prep) in_14\IN\13603305|a_18|marked_16 (l_pobj) activity_16\NN\30358|NONE_0
D009020_D006948 CID morphine_1\NN\2707683|-_8 (r_npadvmod) induced_3\VBN\1627355|the_13 (r_amod) hyperactivity_4\NN\14052403|was_14|by_30|and_45|attenuated_49|._76
D009020_D006948 CID morphine_26\NN\2707683|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_agent) produced_24\VBN\1617192|the_18 (r_acl) hyperactivity_23\NN\14052403|NONE_0
227508
D008750_D007022 CID methyldopa_8\NN\2721160|NONE_0 (r_pobj) of_3\IN\0|the_23|hypotensive_19 (r_prep) effect_2\NN\34213|was_37|also_41|partially_46|by_65|._76 (l_amod) hypotensive_1\JJ\10405694|the_4|of_19
D003000_D006973 NONE clonidine_17\NN\2721160|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) produced_14\VBN\1617192|blood_30|and_15|rate_5 (r_acl) pressure_10\NN\11419404|NONE_0 (r_pobj) in_8\IN\13603305|the_13 (r_prep) decrease_7\NN\7296428|in_55|,_38|hypertensive_22|,_75|inhibited_104|._153 (r_dobj) rats_5\NNS\2329401|NONE_0 (l_amod) hypertensive_4\JJ\10405694|in_33|,_16|decrease_22|,_97|inhibited_126|._175
D003000_D006973 NONE clonidine_7\NN\2721160|membranes_47 (r_preconj) in_0\IN\13603305|,_85|did_87|not_91|binding_121|,_152|and_154|influence_196 (l_pobj) membranes_2\NNS\4188643|clonidine_47 (l_prep) from_3\IN\0|brain_16 (l_pobj) rats_6\NNS\2329401|NONE_0 (l_amod) hypertensive_5\JJ\10405694|NONE_0
D003000_D006973 NONE clonidine_42\NN\2721160|-_9 (r_npadvmod) suppressible_44\NN\0|of_21 (r_amod) binding_45\NN\4688246|naloxone_71|did_41|not_37|)_41|._42 (r_dobj) influence_41\VB\5190804|in_196|,_111|did_109|not_105|binding_75|,_44|and_42 (r_conj) influence_18\VB\5190804|NONE_0 (l_prep) in_0\IN\13603305|,_85|did_87|not_91|binding_121|,_152|and_154|influence_196 (l_pobj) membranes_2\NNS\4188643|clonidine_47 (l_prep) from_3\IN\0|brain_16 (l_pobj) rats_6\NNS\2329401|NONE_0 (l_amod) hypertensive_5\JJ\10405694|NONE_0
-1_D006973 NONE nalozone_31\NN\0|NONE_0 (r_pobj) by_30\IN\0|NONE_0 (r_agent) reversed_29\VBN\109660|micrograms_32|,_19|was_17|or_3|,_20|mg/kg_31 (r_conj) inhibited_27\VBN\2510337|in_159|,_142|hypertensive_126|decrease_104|,_29|._49 (r_conj) rats_5\NNS\2329401|NONE_0 (l_amod) hypertensive_4\JJ\10405694|in_33|,_16|decrease_22|,_97|inhibited_126|._175
-1_D006973 NONE 3h]-naloxone_23\CD\0|NONE_0 (r_pobj) of_21\IN\0|stereoselective_24 (r_prep) binding_20\NN\4688246|in_121|,_36|did_34|not_30|,_31|and_33|influence_75 (r_dobj) influence_18\VB\5190804|NONE_0 (l_prep) in_0\IN\13603305|,_85|did_87|not_91|binding_121|,_152|and_154|influence_196 (l_pobj) membranes_2\NNS\4188643|clonidine_47 (l_prep) from_3\IN\0|brain_16 (l_pobj) rats_6\NNS\2329401|NONE_0 (l_amod) hypertensive_5\JJ\10405694|NONE_0
-1_D006973 NONE 3h]-dihydroergocryptine_48\CD\0|(_24|1_25 (r_nummod) nm_51\NNP\13649268|NONE_0 (r_pobj) of_46\IN\0|suppressible_21 (r_prep) binding_45\NN\4688246|naloxone_71|did_41|not_37|)_41|._42 (r_dobj) influence_41\VB\5190804|in_196|,_111|did_109|not_105|binding_75|,_44|and_42 (r_conj) influence_18\VB\5190804|NONE_0 (l_prep) in_0\IN\13603305|,_85|did_87|not_91|binding_121|,_152|and_154|influence_196 (l_pobj) membranes_2\NNS\4188643|clonidine_47 (l_prep) from_3\IN\0|brain_16 (l_pobj) rats_6\NNS\2329401|NONE_0 (l_amod) hypertensive_5\JJ\10405694|NONE_0
D009270_D006973 NONE naloxone_30\NN\3808977|did_30|not_34|binding_71|)_112|._113 (r_nsubj) influence_41\VB\5190804|in_196|,_111|did_109|not_105|binding_75|,_44|and_42 (r_conj) influence_18\VB\5190804|NONE_0 (l_prep) in_0\IN\13603305|,_85|did_87|not_91|binding_121|,_152|and_154|influence_196 (l_pobj) membranes_2\NNS\4188643|clonidine_47 (l_prep) from_3\IN\0|brain_16 (l_pobj) rats_6\NNS\2329401|NONE_0 (l_amod) hypertensive_5\JJ\10405694|NONE_0
D009270_D007022 NONE naloxone_14\NN\3808977|NONE_0 (r_pobj) by_13\IN\0|effect_65|was_28|also_24|partially_19|._11 (r_agent) reversed_12\VBN\109660|NONE_0 (l_nsubjpass) effect_2\NN\34213|was_37|also_41|partially_46|by_65|._76 (l_amod) hypotensive_1\JJ\10405694|the_4|of_19
16680561
C476217_D006261 CID cinacalcet_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|when_27|desipramine_12|%_29 (r_prep) receiving_12\VBG\2210855|NONE_0 (r_pcomp) than_10\IN\0|NONE_0 (r_prep) alone_9\RB\0|adverse_52|following_37 (r_amod) events_4\NNS\23100|subjects_26 (r_dobj) reported_2\VBD\831651|,_130|frequent_141|nausea_160|have_181|been_186|for_200|._258 (r_ccomp) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98 (l_conj) headache_31\NN\5829480|(_12|and_4|)_8
C476217_D006261 CID cinacalcet_43\NN\0|either_22|or_3 (r_conj) desipramine_41\NN\4482543|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) treated_38\VBN\2376958|NONE_0 (r_acl) patients_37\NNS\9898892|NONE_0 (r_pobj) for_36\IN\0|reported_200|,_70|frequent_59|nausea_40|have_19|been_14|._58 (r_prep) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98 (l_conj) headache_31\NN\5829480|(_12|and_4|)_8
C476217_D009325 CID cinacalcet_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|when_27|desipramine_12|%_29 (r_prep) receiving_12\VBG\2210855|NONE_0 (r_pcomp) than_10\IN\0|NONE_0 (r_prep) alone_9\RB\0|adverse_52|following_37 (r_amod) events_4\NNS\23100|subjects_26 (r_dobj) reported_2\VBD\831651|,_130|frequent_141|nausea_160|have_181|been_186|for_200|._258 (r_ccomp) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98
C476217_D009325 CID cinacalcet_43\NN\0|either_22|or_3 (r_conj) desipramine_41\NN\4482543|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) treated_38\VBN\2376958|NONE_0 (r_acl) patients_37\NNS\9898892|NONE_0 (r_pobj) for_36\IN\0|reported_200|,_70|frequent_59|nausea_40|have_19|been_14|._58 (r_prep) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98
D003891_D006261 CID desipramine_8\NN\4482543|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) treatment_6\NN\654885|NONE_0 (r_dobj) following_5\VBG\8180190|adverse_15|alone_37 (r_acl) events_4\NNS\23100|subjects_26 (r_dobj) reported_2\VBD\831651|,_130|frequent_141|nausea_160|have_181|been_186|for_200|._258 (r_ccomp) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98 (l_conj) headache_31\NN\5829480|(_12|and_4|)_8
D003891_D006261 CID desipramine_13\NN\4482543|when_15|with_12|%_41 (r_dobj) receiving_12\VBG\2210855|NONE_0 (r_pcomp) than_10\IN\0|NONE_0 (r_prep) alone_9\RB\0|adverse_52|following_37 (r_amod) events_4\NNS\23100|subjects_26 (r_dobj) reported_2\VBD\831651|,_130|frequent_141|nausea_160|have_181|been_186|for_200|._258 (r_ccomp) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98 (l_conj) headache_31\NN\5829480|(_12|and_4|)_8
D003891_D006261 CID desipramine_41\NN\4482543|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) treated_38\VBN\2376958|NONE_0 (r_acl) patients_37\NNS\9898892|NONE_0 (r_pobj) for_36\IN\0|reported_200|,_70|frequent_59|nausea_40|have_19|been_14|._58 (r_prep) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98 (l_conj) headache_31\NN\5829480|(_12|and_4|)_8
D003891_D009325 CID desipramine_8\NN\4482543|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) treatment_6\NN\654885|NONE_0 (r_dobj) following_5\VBG\8180190|adverse_15|alone_37 (r_acl) events_4\NNS\23100|subjects_26 (r_dobj) reported_2\VBD\831651|,_130|frequent_141|nausea_160|have_181|been_186|for_200|._258 (r_ccomp) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98
D003891_D009325 CID desipramine_13\NN\4482543|when_15|with_12|%_41 (r_dobj) receiving_12\VBG\2210855|NONE_0 (r_pcomp) than_10\IN\0|NONE_0 (r_prep) alone_9\RB\0|adverse_52|following_37 (r_amod) events_4\NNS\23100|subjects_26 (r_dobj) reported_2\VBD\831651|,_130|frequent_141|nausea_160|have_181|been_186|for_200|._258 (r_ccomp) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98
D003891_D009325 CID desipramine_41\NN\4482543|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) treated_38\VBN\2376958|NONE_0 (r_acl) patients_37\NNS\9898892|NONE_0 (r_pobj) for_36\IN\0|reported_200|,_70|frequent_59|nausea_40|have_19|been_14|._58 (r_prep) reported_35\VBN\831651|NONE_0 (l_nsubjpass) nausea_29\NN\14299637|reported_160|,_30|frequent_19|have_21|been_26|for_40|._98
7881871
D011692_D011507 CID aminonucleoside_12\NN\0|puromycin_10|(_16|pan)-induced_17 (r_nmod) nephropathy_15\NN\14573196|NONE_0 (r_pobj) of_9\IN\0|the_17 (r_prep) pathogenesis_8\NN\13533470|NONE_0 (r_pobj) in_6\IN\13603305|species_29|have_21|been_16|,_80|with_82|._138 (r_prep) implicated_5\VBN\2677097|NONE_0 (l_prep) with_17\IN\0|species_111|have_103|been_98|in_82|,_2|._56 (l_pcomp) reducing_20\VBG\13447361|NONE_0 (l_dobj) proteinuria_22\NN\14299637|antioxidants_40|significantly_27
D011692_D011507 CID pan)-induced_14\JJ\0|puromycin_27|aminonucleoside_17|(_1 (r_amod) nephropathy_15\NN\14573196|NONE_0 (r_pobj) of_9\IN\0|the_17 (r_prep) pathogenesis_8\NN\13533470|NONE_0 (r_pobj) in_6\IN\13603305|species_29|have_21|been_16|,_80|with_82|._138 (r_prep) implicated_5\VBN\2677097|NONE_0 (l_prep) with_17\IN\0|species_111|have_103|been_98|in_82|,_2|._56 (l_pcomp) reducing_20\VBG\13447361|NONE_0 (l_dobj) proteinuria_22\NN\14299637|antioxidants_40|significantly_27
D011692_D011507 CID pan_14\NNP\3101986|NONE_0 (r_compound) nephropathy_15\NN\14573196|NONE_0 (r_pobj) in_13\IN\13603305|the_23|proteinuric_19 (r_prep) injury_12\NN\14052046|NONE_0
D010100_D011507 NONE oxygen_1\NN\14622893|reactive_9 (r_compound) species_2\NNS\7992450|have_8|been_13|in_29|,_109|with_111|._167 (r_nsubjpass) implicated_5\VBN\2677097|NONE_0 (l_prep) with_17\IN\0|species_111|have_103|been_98|in_82|,_2|._56 (l_pcomp) reducing_20\VBG\13447361|NONE_0 (l_dobj) proteinuria_22\NN\14299637|antioxidants_40|significantly_27
D010100_D007674 NONE oxygen_1\NN\14622893|reactive_9 (r_compound) species_2\NNS\7992450|have_8|been_13|in_29|,_109|with_111|._167 (r_nsubjpass) implicated_5\VBN\2677097|NONE_0 (l_prep) in_6\IN\13603305|species_29|have_21|been_16|,_80|with_82|._138 (l_pobj) pathogenesis_8\NN\13533470|NONE_0 (l_prep) of_9\IN\0|the_17 (l_pobj) nephropathy_15\NN\14573196|NONE_0
D011692_D007674 CID aminonucleoside_7\NN\0|-_15 (r_advmod) induced_9\VBN\1627355|puromycin_26 (r_amod) nephropathy_10\NN\14573196|NONE_0
D011692_D007674 CID aminonucleoside_12\NN\0|puromycin_10|(_16|pan)-induced_17 (r_nmod) nephropathy_15\NN\14573196|NONE_0
D011692_D007674 CID pan)-induced_14\JJ\0|puromycin_27|aminonucleoside_17|(_1 (r_amod) nephropathy_15\NN\14573196|NONE_0
D011692_D007674 CID pan_14\NNP\3101986|NONE_0 (r_compound) nephropathy_15\NN\14573196|NONE_0
16740173
6666578
D010396_D001018 CID penicillamine_2\NN\3740161|-_13|angiopathy_22|in_33|._40 (r_compound) induced_4\VBN\1627355|NONE_0 (l_advmod) angiopathy_5\NN\14204950|penicillamine_22|-_9|in_11|._18
9249847
D014700_D013611 CID verapamil_7\NN\2938514|catheter_14|in_32|and_81|cardiomyopathy_104 (r_nmod) ablation_10\NN\671351|NONE_0 (r_pobj) after_6\IN\0|iatrogenically_74|tachycardia_12|._124 (r_prep) induced_1\VBD\1627355|NONE_0 (l_dobj) tachycardia_5\NN\14110674|iatrogenically_62|after_12|._136
D014700_D013611 CID verapamil_10\NN\2938514|unidirectional_13|antegrade_28|of_44 (r_nmod) block_14\NN\21939|NONE_0 (r_pobj) after_9\IN\0|junctional_24|escape_13|after_71 (r_prep) beats_8\NNS\8289449|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|without_23|,_2|,_128 (r_acl) qrs_0\UH\0|attack_183|._189 (r_nsubj) established_22\VBD\2426171|NONE_0 (l_dobj) attack_25\NN\955060|qrs_183|._6 (l_compound) avrt_24\NN\0|frequent_9
D014700_D002311 NONE verapamil_7\NN\2938514|catheter_14|in_32|and_81|cardiomyopathy_104 (r_nmod) ablation_10\NN\671351|NONE_0 (l_conj) cardiomyopathy_24\NN\14103288|verapamil_104|catheter_90|in_72|and_23
D014700_D014927 NONE verapamil_7\NN\2938514|catheter_14|in_32|and_81|cardiomyopathy_104 (r_nmod) ablation_10\NN\671351|NONE_0 (l_prep) in_11\IN\13603305|verapamil_32|catheter_18|and_49|cardiomyopathy_72 (l_pobj) patient_13\NN\9898892|NONE_0 (l_prep) with_14\IN\0|a_10 (l_pobj) syndrome_20\NN\5870365|NONE_0
3107448
D005905_D003924 NONE glyburide_18\NN\2719105|NONE_0 (r_amod) therapy_19\NN\657604|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) initiation_16\NN\7450842|soon_11 (r_pobj) after_15\IN\0|patients_88|syndrome_14|._37 (r_prep) developed_7\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|syndrome_74|after_88|._125 (l_prep) with_2\IN\0|two_13 (l_pobj) mellitus_6\NN\0|NONE_0
D005905_D056486 CID glyburide_0\NN\2719105|-_9 (r_npadvmod) induced_2\VBN\1627355|._17 (r_amod) hepatitis_3\NN\14127211|NONE_0
D005905_D056486 CID glyburide_1\NN\2719105|NONE_0 (r_pobj) for_0\IN\0|,_13|sulfonylurea_35|,_47|reports_64|._95 (r_prep) exist_15\VBP\0|NONE_0 (l_nsubj) reports_12\NNS\6470073|for_64|,_51|sulfonylurea_29|,_17|._31 (l_prep) of_13\IN\0|two_18|brief_14 (l_pobj) hepatotoxicity_14\NN\0|NONE_0
D005905_D056486 CID glyburide_18\NN\2719105|NONE_0 (r_amod) therapy_19\NN\657604|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) initiation_16\NN\7450842|soon_11 (r_pobj) after_15\IN\0|patients_88|syndrome_14|._37 (r_prep) developed_7\VBD\1753788|NONE_0 (l_dobj) syndrome_13\NN\5870365|patients_74|after_14|._51
D005905_D056486 CID glyburide_0\NNP\2719105|can_10|illness_46|._69 (r_nsubj) produce_2\VB\7555863|NONE_0 (l_dobj) illness_8\NN\14052046|glyburide_46|can_36|._23
D013453_D056486 NONE sulfonylureas_14\NNS\2719105|NONE_0 (r_pobj) with_13\IN\0|hepatotoxicity_69|,_55|common_44|,_38|has_36|been_32|infrequently_13|._18 (r_prep) reported_10\VBN\831651|NONE_0 (l_nsubjpass) hepatotoxicity_3\NN\0|,_14|common_25|,_31|has_33|been_37|infrequently_56|with_69|._87
D013453_D056486 NONE sulfonylurea_7\NN\2719105|for_35|,_22|,_12|reports_29|._60 (r_nsubj) exist_15\VBP\0|NONE_0 (l_nsubj) reports_12\NNS\6470073|for_64|,_51|sulfonylurea_29|,_17|._31 (l_prep) of_13\IN\0|two_18|brief_14 (l_pobj) hepatotoxicity_14\NN\0|NONE_0
6387529
D003975_D000379 NONE diazepam_3\NN\2830852|NONE_0 (r_pobj) of_2\IN\0|behavioral_19|and_12|propranolol_16|._75 (r_prep) effects_1\NNS\13245626|NONE_0 (l_conj) propranolol_5\NN\0|behavioral_35|of_16|and_4|._59 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) disorder_10\NN\14034177|NONE_0 (l_conj) agoraphobia_12\NNP\14381416|panic_19|and_4
D003975_D000379 NONE diazepam_6\NN\2830852|NONE_0 (r_pobj) of_5\IN\0|oral_11|(_12|dose_20|and_78 (r_prep) doses_4\NNS\3740161|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|dose_124 (r_nsubj) propranolol_27\NN\0|dose_47|were_157|in_175|._225 (r_advcl) investigated_58\VBN\644583|NONE_0 (l_nsubjpass) dose_37\NN\3740161|propranolol_47|were_110|in_128|._178 (l_prep) on_47\IN\0|a_41|median_39|of_27|for_13|)_2 (l_pobj) performance_49\NN\6619065|NONE_0 (l_prep) of_50\IN\0|psychological_26 (l_pobj) patients_51\NNS\9898892|NONE_0 (l_prep) with_52\IN\0|NONE_0 (l_pobj) disorders_54\NNS\14034177|NONE_0 (l_conj) agoraphobia_56\NNP\14381416|panic_20|and_4
D011433_D000379 NONE propranolol_5\NN\0|behavioral_35|of_16|and_4|._59 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) disorder_10\NN\14034177|NONE_0 (l_conj) agoraphobia_12\NNP\14381416|panic_19|and_4
D011433_D000379 NONE propranolol_27\NN\0|dose_47|were_157|in_175|._225 (r_advcl) investigated_58\VBN\644583|NONE_0 (l_nsubjpass) dose_37\NN\3740161|propranolol_47|were_110|in_128|._178 (l_prep) on_47\IN\0|a_41|median_39|of_27|for_13|)_2 (l_pobj) performance_49\NN\6619065|NONE_0 (l_prep) of_50\IN\0|psychological_26 (l_pobj) patients_51\NNS\9898892|NONE_0 (l_prep) with_52\IN\0|NONE_0 (l_pobj) disorders_54\NNS\14034177|NONE_0 (l_conj) agoraphobia_56\NNP\14381416|panic_20|and_4
D003975_D008569 CID diazepam_12\NN\2830852|NONE_0 (r_pobj) for_11\IN\0|NONE_0 (r_prep) greater_10\JJR\0|decrease_13|._37 (r_acomp) was_9\VBD\0|drugs_54|recall_24|but_17 (r_conj) impaired_2\VBD\258857|NONE_0 (l_dobj) recall_5\NN\7185325|drugs_30|but_7|was_24
D003975_D016584 NONE diazepam_3\NN\2830852|NONE_0 (r_pobj) of_2\IN\0|behavioral_19|and_12|propranolol_16|._75 (r_prep) effects_1\NNS\13245626|NONE_0 (l_conj) propranolol_5\NN\0|behavioral_35|of_16|and_4|._59 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) disorder_10\NN\14034177|NONE_0
D003975_D016584 NONE diazepam_6\NN\2830852|NONE_0 (r_pobj) of_5\IN\0|oral_11|(_12|dose_20|and_78 (r_prep) doses_4\NNS\3740161|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|dose_124 (r_nsubj) propranolol_27\NN\0|dose_47|were_157|in_175|._225 (r_advcl) investigated_58\VBN\644583|NONE_0 (l_nsubjpass) dose_37\NN\3740161|propranolol_47|were_110|in_128|._178 (l_prep) on_47\IN\0|a_41|median_39|of_27|for_13|)_2 (l_pobj) performance_49\NN\6619065|NONE_0 (l_prep) of_50\IN\0|psychological_26 (l_pobj) patients_51\NNS\9898892|NONE_0 (l_prep) with_52\IN\0|NONE_0 (l_pobj) disorders_54\NNS\14034177|NONE_0
D011433_D008569 CID propranolol_14\NN\0|NONE_0 (r_advcl) diazepam_12\NN\2830852|NONE_0 (r_pobj) for_11\IN\0|NONE_0 (r_prep) greater_10\JJR\0|decrease_13|._37 (r_acomp) was_9\VBD\0|drugs_54|recall_24|but_17 (r_conj) impaired_2\VBD\258857|NONE_0 (l_dobj) recall_5\NN\7185325|drugs_30|but_7|was_24
D011433_D016584 NONE propranolol_5\NN\0|behavioral_35|of_16|and_4|._59 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) disorder_10\NN\14034177|NONE_0
D011433_D016584 NONE propranolol_27\NN\0|dose_47|were_157|in_175|._225 (r_advcl) investigated_58\VBN\644583|NONE_0 (l_nsubjpass) dose_37\NN\3740161|propranolol_47|were_110|in_128|._178 (l_prep) on_47\IN\0|a_41|median_39|of_27|for_13|)_2 (l_pobj) performance_49\NN\6619065|NONE_0 (l_prep) of_50\IN\0|psychological_26 (l_pobj) patients_51\NNS\9898892|NONE_0 (l_prep) with_52\IN\0|NONE_0 (l_pobj) disorders_54\NNS\14034177|NONE_0
18083142
D004298_D001008 NONE dopamine_9\NN\14807737|hydroxylase_14|mice_45 (r_compound) knockout_13\NN\10787470|NONE_0 (r_pobj) of_8\IN\0|the_16 (r_prep) performance_7\NN\6619065|in_32|,_19|we_17|in_98|examine_133|._211 (r_dobj) evaluated_5\VBD\670261|NONE_0 (l_advcl) examine_36\VB\0|in_165|,_152|we_150|performance_133|in_35|._78 (l_dobj) contribution_38\NN\786195|to_15 (l_prep) of_39\IN\0|the_17 (l_pobj) signaling_41\NN\33020|NONE_0 (l_prep) to_42\IN\0|noradrenergic_24 (l_pobj) anxiety_46\NN\14373582|NONE_0
D004298_D001008 NONE dopamine_17\NN\14807737|a_2|beta_9|-_13 (r_nmod) hydroxylase_20\NN\0|(_12|dbh_13|)_16 (r_nmod) inhibitor_24\NN\20090|of_49|,_36 (r_appos) administration_12\NN\1133281|NONE_0 (r_pobj) following_11\VBG\8180190|anxiety_44|was_36|also_32|in_16|._83 (r_prep) attenuated_6\VBN\224901|NONE_0 (l_nsubjpass) anxiety_3\NN\14373582|was_8|also_12|in_28|following_44|._127
D015016_D001008 NONE yohimbine_48\NN\0|the_24|alpha(2_20|)_13 (r_appos) antagonist_47\NN\7846|the_50|antagonist_37|and_17 (r_conj) prazosin_42\NN\2698769|while_30|effect_54 (r_nsubj) had_49\VBD\0|that_238|with_220|,_79 (r_advcl) pretreatment_10\NN\0|in_68|,_16|we_14|._246 (l_prep) with_11\IN\0|that_18|,_141|had_220 (l_pobj) antagonist_17\NN\7846|NONE_0 (l_acl) propranolol_18\NN\0|the_40|adrenergic_31|receptor_20 (l_dobj) behavior_26\NN\407535|in_9 (l_amod) like_25\JJ\5839024|blocked_32|induced_16 (l_npadvmod) anxiety_23\NN\14373582|-_7
D011433_D001008 NONE propranolol_18\NN\0|the_40|adrenergic_31|receptor_20 (l_dobj) behavior_26\NN\407535|in_9 (l_amod) like_25\JJ\5839024|blocked_32|induced_16 (l_npadvmod) anxiety_23\NN\14373582|-_7
D003042_D001008 CID cocaine_12\NN\3492717|-_7 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) anxiety_15\NN\14373582|NONE_0
D003042_D001008 CID cocaine_4\NN\3492717|underlying_11|rewarding_10 (r_poss) effects_7\NNS\13245626|while_52|mechanisms_42|have_8|been_13|extensively_26 (r_nsubjpass) studied_10\VBN\0|,_19|attention_26|has_36|been_40|to_50|._121 (r_advcl) paid_17\VBN\2199590|NONE_0 (l_dative) to_18\IN\0|studied_50|,_31|attention_24|has_14|been_10|._71 (l_pobj) states_22\NNS\8491826|NONE_0 (l_acl) induced_23\VBN\1627355|the_33|unpleasant_29|behavioral_18 (l_agent) by_24\IN\0|NONE_0 (l_pobj) cocaine_25\NN\3492717|NONE_0 (l_prep) as_28\IN\14622893|,_7 (l_pobj) anxiety_29\NN\14373582|such_8
D003042_D001008 CID cocaine_25\NN\3492717|NONE_0 (l_prep) as_28\IN\14622893|,_7 (l_pobj) anxiety_29\NN\14373582|such_8
D003042_D001008 CID cocaine_43\NN\3492717|-_7 (r_npadvmod) induced_45\VBN\1627355|NONE_0 (r_amod) anxiety_46\NN\14373582|NONE_0
D003042_D001008 CID cocaine_4\NN\3492717|that_5|dependently_13|behavior_48|,_82|measured_87 (r_nsubj) increased_8\VBN\169651|:_41|we_39|._108 (l_dobj) behavior_12\NN\407535|that_53|cocaine_48|dependently_35|,_34|measured_39 (l_amod) like_11\JJ\5839024|in_14 (l_npadvmod) anxiety_9\NN\14373582|NONE_0
D003042_D001008 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) anxiety_3\NN\14373582|was_8|also_12|in_28|following_44|._127
D003042_D001008 CID cocaine_20\NN\3492717|-_7 (r_npadvmod) induced_22\VBN\1627355|blocked_16|like_16 (r_amod) behavior_26\NN\407535|in_9 (l_amod) like_25\JJ\5839024|blocked_32|induced_16 (l_npadvmod) anxiety_23\NN\14373582|-_7
D003042_D001008 CID cocaine_14\NN\3492717|-_7 (r_npadvmod) induced_16\VBN\1627355|in_16 (r_amod) anxiety_17\NN\14373582|NONE_0
D011224_D001008 NONE prazosin_42\NN\2698769|while_30|effect_54 (r_nsubj) had_49\VBD\0|that_238|with_220|,_79 (r_advcl) pretreatment_10\NN\0|in_68|,_16|we_14|._246 (l_prep) with_11\IN\0|that_18|,_141|had_220 (l_pobj) antagonist_17\NN\7846|NONE_0 (l_acl) propranolol_18\NN\0|the_40|adrenergic_31|receptor_20 (l_dobj) behavior_26\NN\407535|in_9 (l_amod) like_25\JJ\5839024|blocked_32|induced_16 (l_npadvmod) anxiety_23\NN\14373582|-_7
D009638_D001008 NONE norepinephrine_0\NN\14807929|through_25 (r_compound) signaling_1\VBG\33020|critical_47|._97 (r_nsubj) is_7\VBZ\0|NONE_0 (l_acomp) critical_8\JJ\0|signaling_47|._50 (l_prep) for_9\IN\0|NONE_0 (l_pobj) expression_10\NN\4679549|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) anxiety_15\NN\14373582|NONE_0
D009638_D001008 NONE norepinephrine_22\NN\14807929|which_11 (r_dobj) lack_21\VBP\14449126|(_22|dbh_21|-/-_17|)_14|,_8|,_24 (r_relcl) mice_18\NNS\2329401|dopamine_45|hydroxylase_31 (r_appos) knockout_13\NN\10787470|NONE_0 (r_pobj) of_8\IN\0|the_16 (r_prep) performance_7\NN\6619065|in_32|,_19|we_17|in_98|examine_133|._211 (r_dobj) evaluated_5\VBD\670261|NONE_0 (l_advcl) examine_36\VB\0|in_165|,_152|we_150|performance_133|in_35|._78 (l_dobj) contribution_38\NN\786195|to_15 (l_prep) of_39\IN\0|the_17 (l_pobj) signaling_41\NN\33020|NONE_0 (l_prep) to_42\IN\0|noradrenergic_24 (l_pobj) anxiety_46\NN\14373582|NONE_0
D009638_D001008 NONE ne_24\NNP\14622893|NONE_0 (r_appos) norepinephrine_22\NN\14807929|which_11 (r_dobj) lack_21\VBP\14449126|(_22|dbh_21|-/-_17|)_14|,_8|,_24 (r_relcl) mice_18\NNS\2329401|dopamine_45|hydroxylase_31 (r_appos) knockout_13\NN\10787470|NONE_0 (r_pobj) of_8\IN\0|the_16 (r_prep) performance_7\NN\6619065|in_32|,_19|we_17|in_98|examine_133|._211 (r_dobj) evaluated_5\VBD\670261|NONE_0 (l_advcl) examine_36\VB\0|in_165|,_152|we_150|performance_133|in_35|._78 (l_dobj) contribution_38\NN\786195|to_15 (l_prep) of_39\IN\0|the_17 (l_pobj) signaling_41\NN\33020|NONE_0 (l_prep) to_42\IN\0|noradrenergic_24 (l_pobj) anxiety_46\NN\14373582|NONE_0
D004221_D001008 NONE disulfiram_14\NN\3740161|NONE_0 (r_pobj) of_13\IN\0|,_13|inhibitor_49 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) following_11\VBG\8180190|anxiety_44|was_36|also_32|in_16|._83 (r_prep) attenuated_6\VBN\224901|NONE_0 (l_nsubjpass) anxiety_3\NN\14373582|was_8|also_12|in_28|following_44|._127
3173180
D008795_D006463 CID metronidazole_7\NN\2723292|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treatment_5\NN\654885|NONE_0 (r_pobj) after_4\IN\0|uraemic_17|._34 (r_prep) syndrome_3\NN\5870365|NONE_0
D008795_D006463 CID metronidazole_19\NN\2723292|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treatment_17\NN\654885|NONE_0 (r_pobj) after_16\IN\0|who_46|syndrome_9 (r_prep) developed_10\VBD\1753788|six_17 (l_dobj) syndrome_15\NN\5870365|who_37|after_9
D008795_D006463 CID metronidazole_4\NN\2723292|NONE_0 (r_pobj) of_3\IN\0|the_16|in_17 (r_prep) involvement_2\NN\1080366|while_10|is_81|not_84|firmly_100 (l_prep) in_5\IN\13603305|the_33|of_17 (l_pobj) aetiology_7\NN\7326557|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) syndrome_13\NN\5870365|NONE_0
D008795_D006463 CID metronidazole_4\NN\2723292|NONE_0 (r_pobj) of_3\IN\0|the_16|in_17 (r_prep) involvement_2\NN\1080366|while_10|is_81|not_84|firmly_100 (r_nsubjpass) established_16\VBN\2426171|,_18|action_24|link_188|._274 (r_advcl) suggest_43\VBP\1010118|NONE_0 (l_nsubj) action_20\NN\30358|established_24|,_6|link_164|._250 (l_conj) evidence_33\NN\5816287|the_84|of_73|in_60 (l_prep) of_34\IN\0|the_22|reported_18 (l_pobj) changes_36\NNS\7283608|NONE_0 (l_prep) in_37\IN\13603305|oxidation_18 (l_pobj) syndrome_42\NN\5870365|NONE_0
D008795_D006463 CID metronidazole_4\NN\2723292|NONE_0 (r_pobj) of_3\IN\0|the_16|in_17 (r_prep) involvement_2\NN\1080366|while_10|is_81|not_84|firmly_100 (r_nsubjpass) established_16\VBN\2426171|,_18|action_24|link_188|._274 (r_advcl) suggest_43\VBP\1010118|NONE_0 (l_dobj) link_46\NN\13792579|established_188|,_170|action_164|._86 (l_prep) between_47\IN\0|a_16|possible_14 (l_pobj) treatment_49\NN\654885|NONE_0 (l_conj) cases_52\NNS\7283608|metronidazole_33|and_9 (l_prep) of_53\IN\0|some_11 (l_pobj) syndrome_58\NN\5870365|NONE_0
D008795_D006463 CID metronidazole_48\NN\2723292|and_24|cases_33 (r_amod) treatment_49\NN\654885|NONE_0 (r_pobj) between_47\IN\0|a_16|possible_14 (r_prep) link_46\NN\13792579|established_188|,_170|action_164|._86 (r_dobj) suggest_43\VBP\1010118|NONE_0 (l_advcl) established_16\VBN\2426171|,_18|action_24|link_188|._274 (l_nsubjpass) involvement_2\NN\1080366|while_10|is_81|not_84|firmly_100 (l_prep) in_5\IN\13603305|the_33|of_17 (l_pobj) aetiology_7\NN\7326557|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) syndrome_13\NN\5870365|NONE_0
D008795_D006463 CID metronidazole_48\NN\2723292|and_24|cases_33 (r_amod) treatment_49\NN\654885|NONE_0 (r_pobj) between_47\IN\0|a_16|possible_14 (r_prep) link_46\NN\13792579|established_188|,_170|action_164|._86 (r_dobj) suggest_43\VBP\1010118|NONE_0 (l_nsubj) action_20\NN\30358|established_24|,_6|link_164|._250 (l_conj) evidence_33\NN\5816287|the_84|of_73|in_60 (l_prep) of_34\IN\0|the_22|reported_18 (l_pobj) changes_36\NNS\7283608|NONE_0 (l_prep) in_37\IN\13603305|oxidation_18 (l_pobj) syndrome_42\NN\5870365|NONE_0
D008795_D006463 CID metronidazole_48\NN\2723292|and_24|cases_33 (r_amod) treatment_49\NN\654885|NONE_0 (l_conj) cases_52\NNS\7283608|metronidazole_33|and_9 (l_prep) of_53\IN\0|some_11 (l_pobj) syndrome_58\NN\5870365|NONE_0
2578334
D001564_D011230 CID benzo[a]-pyrene_53\NN\0|the_23|three_19|,_2|,_27|nitrosourea_40 (r_appos) carcinogens_51\NNS\20090|NONE_0 (r_pobj) by_48\IN\0|NONE_0 (r_agent) induced_47\VBN\1627355|the_30|of_20 (r_acl) phase_43\NN\15113229|NONE_0 (r_pobj) during_41\IN\0|5-azc_70|was_18|to_8|._181 (r_prep) given_38\VBN\5892096|NONE_0 (l_nsubjpass) 5-azc_24\CD\0|was_52|to_62|during_70|._251 (l_advcl) test_1\VB\5798043|,_129|5-azacytidine_131|(_145|)_151|mg/kg_157|,_163|inhibitor_168|,_196 (l_dobj) validity_3\NN\4782878|to_12 (l_prep) of_4\IN\0|the_13 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_acl) plays_11\VBZ\7007684|the_43 (l_prep) in_15\IN\13603305|that_52|hypomethylation_47|role_5 (l_pobj) initiation_17\NN\7450842|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) process_20\NN\407535|NONE_0
D008770_D011230 CID nitrosourea_65\NN\0|the_63|three_59|,_42|benzo[a]-pyrene_40|,_13 (r_appos) carcinogens_51\NNS\20090|NONE_0 (r_pobj) by_48\IN\0|NONE_0 (r_agent) induced_47\VBN\1627355|the_30|of_20 (r_acl) phase_43\NN\15113229|NONE_0 (r_pobj) during_41\IN\0|5-azc_70|was_18|to_8|._181 (r_prep) given_38\VBN\5892096|NONE_0 (l_nsubjpass) 5-azc_24\CD\0|was_52|to_62|during_70|._251 (l_advcl) test_1\VB\5798043|,_129|5-azacytidine_131|(_145|)_151|mg/kg_157|,_163|inhibitor_168|,_196 (l_dobj) validity_3\NN\4782878|to_12 (l_prep) of_4\IN\0|the_13 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_acl) plays_11\VBZ\7007684|the_43 (l_prep) in_15\IN\13603305|that_52|hypomethylation_47|role_5 (l_pobj) initiation_17\NN\7450842|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) process_20\NN\407535|NONE_0
D019813_D011230 CID 1,2-dimethylhydrazine_71\CD\0|(_15|mg/kg_11|)_6|and_4 (r_conj) 60_67\CD\13745420|methyl_22|-_16|n_15|-_14|1,2-dmh_37|mg/kg_51 (r_appos) nitrosourea_65\NN\0|the_63|three_59|,_42|benzo[a]-pyrene_40|,_13 (r_appos) carcinogens_51\NNS\20090|NONE_0 (r_pobj) by_48\IN\0|NONE_0 (r_agent) induced_47\VBN\1627355|the_30|of_20 (r_acl) phase_43\NN\15113229|NONE_0 (r_pobj) during_41\IN\0|5-azc_70|was_18|to_8|._181 (r_prep) given_38\VBN\5892096|NONE_0 (l_nsubjpass) 5-azc_24\CD\0|was_52|to_62|during_70|._251 (l_advcl) test_1\VB\5798043|,_129|5-azacytidine_131|(_145|)_151|mg/kg_157|,_163|inhibitor_168|,_196 (l_dobj) validity_3\NN\4782878|to_12 (l_prep) of_4\IN\0|the_13 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_acl) plays_11\VBZ\7007684|the_43 (l_prep) in_15\IN\13603305|that_52|hypomethylation_47|role_5 (l_pobj) initiation_17\NN\7450842|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) process_20\NN\407535|NONE_0
D019813_D011230 CID 1,2-dmh_73\NNP\0|methyl_59|-_53|n_52|-_51|60_37|mg/kg_14 (r_appos) nitrosourea_65\NN\0|the_63|three_59|,_42|benzo[a]-pyrene_40|,_13 (r_appos) carcinogens_51\NNS\20090|NONE_0 (r_pobj) by_48\IN\0|NONE_0 (r_agent) induced_47\VBN\1627355|the_30|of_20 (r_acl) phase_43\NN\15113229|NONE_0 (r_pobj) during_41\IN\0|5-azc_70|was_18|to_8|._181 (r_prep) given_38\VBN\5892096|NONE_0 (l_nsubjpass) 5-azc_24\CD\0|was_52|to_62|during_70|._251 (l_advcl) test_1\VB\5798043|,_129|5-azacytidine_131|(_145|)_151|mg/kg_157|,_163|inhibitor_168|,_196 (l_dobj) validity_3\NN\4782878|to_12 (l_prep) of_4\IN\0|the_13 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_acl) plays_11\VBZ\7007684|the_43 (l_prep) in_15\IN\13603305|that_52|hypomethylation_47|role_5 (l_pobj) initiation_17\NN\7450842|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) process_20\NN\407535|NONE_0
D001374_D011230 CID 5-azacytidine_0\RB\0|initiation_26|._72 (r_nsubj) potentiates_1\VBZ\229605|NONE_0 (l_dobj) initiation_2\NN\7450842|5-azacytidine_26|._46 (l_acl) induced_3\VBN\1627355|NONE_0 (l_agent) by_4\IN\0|NONE_0 (l_pobj) carcinogens_5\NNS\20090|NONE_0
D001374_D011230 CID 5-azacytidine_22\JJ\0|test_131|,_2|(_14|)_20|mg/kg_26|,_32|inhibitor_37|,_65 (r_punct) 5-azc_24\CD\0|was_52|to_62|during_70|._251 (l_advcl) test_1\VB\5798043|,_129|5-azacytidine_131|(_145|)_151|mg/kg_157|,_163|inhibitor_168|,_196 (l_dobj) validity_3\NN\4782878|to_12 (l_prep) of_4\IN\0|the_13 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_acl) plays_11\VBZ\7007684|the_43 (l_prep) in_15\IN\13603305|that_52|hypomethylation_47|role_5 (l_pobj) initiation_17\NN\7450842|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) process_20\NN\407535|NONE_0
D001374_D011230 CID 5-azc_24\CD\0|was_52|to_62|during_70|._251 (l_advcl) test_1\VB\5798043|,_129|5-azacytidine_131|(_145|)_151|mg/kg_157|,_163|inhibitor_168|,_196 (l_dobj) validity_3\NN\4782878|to_12 (l_prep) of_4\IN\0|the_13 (l_pobj) hypothesis_6\NN\7162194|NONE_0 (l_acl) plays_11\VBZ\7007684|the_43 (l_prep) in_15\IN\13603305|that_52|hypomethylation_47|role_5 (l_pobj) initiation_17\NN\7450842|NONE_0 (l_prep) of_18\IN\0|the_15 (l_pobj) process_20\NN\407535|NONE_0
8669433
D010615_D007676 CID phenacetin_16\NN\2707683|NONE_0 (r_pobj) with_15\IN\0|a_13 (r_prep) comparison_14\NN\635850|habitual_76|of_63|as_46|:_4|._26 (r_appos) use_1\NN\407535|NONE_0 (l_prep) as_4\IN\14622893|habitual_30|of_17|:_42|comparison_46|._72 (l_pobj) factor_7\NN\7326557|NONE_0 (l_prep) for_8\IN\0|a_14|risk_12 (l_pobj) failure_11\NN\66216|NONE_0
D010615_D007676 CID phenacetin_14\NN\2707683|NONE_0 (r_pobj) of_13\IN\0|habitual_13 (r_prep) use_12\NN\407535|that_14|is_18|with_32|,_112|with_114 (r_nsubjpass) associated_16\VBN\628491|studies_84|._137 (l_prep) with_17\IN\0|that_46|use_32|is_14|,_80|with_82 (l_pobj) development_19\NN\248977|NONE_0 (l_prep) of_20\IN\0|the_16 (l_pobj) failure_23\NN\66216|NONE_0
D010615_D007676 CID phenacetin_14\NN\2707683|NONE_0 (r_pobj) of_13\IN\0|habitual_13 (r_prep) use_12\NN\407535|that_14|is_18|with_32|,_112|with_114 (r_nsubjpass) associated_16\VBN\628491|studies_84|._137 (l_prep) with_17\IN\0|that_46|use_32|is_14|,_80|with_82 (l_pobj) development_19\NN\248977|NONE_0 (l_prep) of_20\IN\0|the_16 (l_pobj) failure_23\NN\66216|NONE_0 (l_conj) disease_29\NN\14061805|chronic_42|renal_34|and_20
D010615_D007676 CID phenacetin_14\NN\2707683|NONE_0 (r_pobj) of_13\IN\0|habitual_13 (r_prep) use_12\NN\407535|that_14|is_18|with_32|,_112|with_114 (r_nsubjpass) associated_16\VBN\628491|studies_84|._137 (l_prep) with_17\IN\0|that_46|use_32|is_14|,_80|with_82 (l_pobj) development_19\NN\248977|NONE_0 (l_prep) of_20\IN\0|the_16 (l_pobj) failure_23\NN\66216|NONE_0 (l_conj) disease_29\NN\14061805|chronic_42|renal_34|and_20 (l_appos) esrd_31\NNP\0|stage_21|renal_15|(_1|)_4
D010615_D007676 CID phenacetin_5\NN\2707683|that_10|may_29|to_44|,_65|with_67 (r_nsubj) contribute_9\VB\126264|studies_59|._105 (l_prep) to_10\IN\0|that_54|phenacetin_44|may_15|,_21|with_23 (l_pobj) burden_12\NN\5832264|NONE_0 (l_prep) of_13\IN\0|the_11 (l_pobj) esrd_14\NNP\0|NONE_0
D000082_D007676 NONE acetaminophen_3\NN\2707683|NONE_0 (r_pobj) of_2\IN\0|habitual_13|as_17|:_59|comparison_63|._89 (r_prep) use_1\NN\407535|NONE_0 (l_prep) as_4\IN\14622893|habitual_30|of_17|:_42|comparison_46|._72 (l_pobj) factor_7\NN\7326557|NONE_0 (l_prep) for_8\IN\0|a_14|risk_12 (l_pobj) failure_11\NN\66216|NONE_0
D000082_D007676 NONE acetaminophen_27\NN\2707683|NONE_0 (r_pobj) of_26\IN\0|habitual_13 (r_prep) use_25\NN\407535|that_14|is_21|also_24|with_40|,_75|with_77 (r_nsubjpass) associated_30\VBN\628491|however_160|,_153|studies_132|._91 (l_prep) with_31\IN\0|that_54|use_40|is_19|also_16|,_35|with_37 (l_pobj) failure_34\NN\66216|NONE_0
D000082_D007676 NONE acetaminophen_27\NN\2707683|NONE_0 (r_pobj) of_26\IN\0|habitual_13 (r_prep) use_25\NN\407535|that_14|is_21|also_24|with_40|,_75|with_77 (r_nsubjpass) associated_30\VBN\628491|however_160|,_153|studies_132|._91 (l_prep) with_31\IN\0|that_54|use_40|is_19|also_16|,_35|with_37 (l_pobj) failure_34\NN\66216|NONE_0 (l_conj) esrd_36\NNP\0|chronic_26|renal_18|and_4
D000082_D007676 NONE acetaminophen_7\RB\2707683|both_20|and_4 (r_conj) phenacetin_5\NN\2707683|that_10|may_29|to_44|,_65|with_67 (r_nsubj) contribute_9\VB\126264|studies_59|._105 (l_prep) to_10\IN\0|that_54|phenacetin_44|may_15|,_21|with_23 (l_pobj) burden_12\NN\5832264|NONE_0 (l_prep) of_13\IN\0|the_11 (l_pobj) esrd_14\NNP\0|NONE_0
D000082_D007676 NONE acetaminophen_6\NN\2707683|NONE_0 (r_pobj) of_5\IN\0|habitual_13|alone_17 (r_prep) use_4\NN\407535|that_14|risk_41 (r_nsubj) increases_8\VBZ\13576355|the_57 (l_dobj) risk_10\NN\14541044|that_55|use_41 (l_prep) of_11\IN\0|the_9 (l_pobj) esrd_12\NNP\0|NONE_0
8741744
D009538_D009069 NONE nicotine_29\NN\14712692|NONE_0 (r_pobj) by_28\IN\0|NONE_0 (r_agent) caused_27\VBN\1617192|the_54|early_50|(_44|min_39|)_36|field_29|locomotor_23|(_19|kg(-1_27|)_32|,_33|i.m._35|)_39 (r_acl) hypoactivity_26\NN\0|compared_120|,_84|lesions_82|,_53|enhanced_55|._160
D009538_D009069 NONE nicotine_48\NN\14712692|-_8 (r_npadvmod) induced_50\VBN\1627355|the_32|later_28|(_22|min_14 (r_amod) hyperactivity_51\NN\14052403|,_13|and_15|raised_19 (r_dobj) enhanced_39\VBD\227165|compared_175|,_139|lesions_137|hypoactivity_55|,_2|._105 (r_advcl) blunted_14\VBD\224901|NONE_0 (l_dobj) hypoactivity_26\NN\0|compared_120|,_84|lesions_82|,_53|enhanced_55|._160
D009538_D006948 CID nicotine_29\NN\14712692|NONE_0 (r_pobj) by_28\IN\0|NONE_0 (r_agent) caused_27\VBN\1617192|the_54|early_50|(_44|min_39|)_36|field_29|locomotor_23|(_19|kg(-1_27|)_32|,_33|i.m._35|)_39 (r_acl) hypoactivity_26\NN\0|compared_120|,_84|lesions_82|,_53|enhanced_55|._160 (r_dobj) blunted_14\VBD\224901|NONE_0 (l_advcl) enhanced_39\VBD\227165|compared_175|,_139|lesions_137|hypoactivity_55|,_2|._105 (l_dobj) hyperactivity_51\NN\14052403|,_13|and_15|raised_19
D009538_D006948 CID nicotine_48\NN\14712692|-_8 (r_npadvmod) induced_50\VBN\1627355|the_32|later_28|(_22|min_14 (r_amod) hyperactivity_51\NN\14052403|,_13|and_15|raised_19
2894766
D012460_D002305 CID sulfasalazine_29\NN\0|term_5 (r_compound) therapy_30\NN\657604|who_42|was_38|for_8 (r_dobj) receiving_25\VBG\2210855|a_27|old_17|,_10 (r_relcl) man_21\NN\9605289|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) developed_15\VBN\1753788|positive_24 (r_acl) autoantibodies_14\NNS\15027189|echocardiographic_62|of_35|,_15|and_13 (r_conj) evidence_7\NN\5816287|pneumonitis_60|,_49|bilateral_47|pleural_37|,_20|._171 (l_prep) of_8\IN\0|echocardiographic_27|,_20|and_22|autoantibodies_35 (l_pobj) tamponade_10\NN\14507951|NONE_0
D012460_D008180 CID sulfasalazine_0\NNP\0|-_13 (r_npadvmod) induced_2\VBN\1627355|lupus_8|._27 (r_amod) erythematosus_4\NN\0|NONE_0
D012460_D008180 CID sulfasalazine_7\RB\0|-_13 (r_npadvmod) induced_9\VBN\1627355|,_13|manifested_21 (r_amod) lupus_10\NN\14219661|that_43|patient_34
D012460_D008180 CID sulfasalazine_3\NN\0|who_8|treat_17 (r_dobj) use_2\VBP\407535|NONE_0 (r_relcl) physicians_0\NNS\10305802|should_83|aware_93|._151 (r_nsubj) be_12\VB\14625458|NONE_0 (l_acomp) aware_13\JJ\0|physicians_93|should_10|._58 (l_prep) of_14\IN\0|NONE_0 (l_pobj) signs_16\NNS\6643763|NONE_0 (l_prep) of_17\IN\0|the_10 (l_pobj) syndrome_22\NN\5870365|NONE_0
D012460_D008180 CID sulfasalazine_18\NN\0|-_13 (r_npadvmod) induced_20\VBN\1627355|lupus_8 (r_amod) syndrome_22\NN\5870365|NONE_0
D012460_D012700 NONE sulfasalazine_7\RB\0|-_13 (r_npadvmod) induced_9\VBN\1627355|,_13|manifested_21 (r_amod) lupus_10\NN\14219661|that_43|patient_34 (l_relcl) manifested_13\VBD\1015244|induced_21|,_8 (l_prep) with_14\IN\0|which_17|in_53 (l_pobj) serositis_15\NN\0|NONE_0
D012460_D003093 NONE sulfasalazine_29\NN\0|term_5 (r_compound) therapy_30\NN\657604|who_42|was_38|for_8 (r_dobj) receiving_25\VBG\2210855|a_27|old_17|,_10 (l_prep) for_31\IN\0|who_50|was_46|therapy_8 (l_pobj) colitis_34\NN\14336539|NONE_0
D012460_D011014 CID sulfasalazine_29\NN\0|term_5 (r_compound) therapy_30\NN\657604|who_42|was_38|for_8 (r_dobj) receiving_25\VBG\2210855|a_27|old_17|,_10 (r_relcl) man_21\NN\9605289|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) developed_15\VBN\1753788|positive_24 (r_acl) autoantibodies_14\NNS\15027189|echocardiographic_62|of_35|,_15|and_13 (r_conj) evidence_7\NN\5816287|pneumonitis_60|,_49|bilateral_47|pleural_37|,_20|._171 (r_appos) effusions_4\NNS\6880249|NONE_0 (l_dep) pneumonitis_0\NNP\14336539|,_11|bilateral_13|pleural_23|,_40|evidence_60|._231
D012460_D010996 CID sulfasalazine_29\NN\0|term_5 (r_compound) therapy_30\NN\657604|who_42|was_38|for_8 (r_dobj) receiving_25\VBG\2210855|a_27|old_17|,_10 (r_relcl) man_21\NN\9605289|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) developed_15\VBN\1753788|positive_24 (r_acl) autoantibodies_14\NNS\15027189|echocardiographic_62|of_35|,_15|and_13 (r_conj) evidence_7\NN\5816287|pneumonitis_60|,_49|bilateral_47|pleural_37|,_20|._171 (r_appos) effusions_4\NNS\6880249|NONE_0
D012460_D015212 NONE sulfasalazine_3\NN\0|who_8|treat_17 (r_dobj) use_2\VBP\407535|NONE_0 (l_xcomp) treat_5\VB\7570720|who_25|sulfasalazine_17 (l_dobj) patients_6\NNS\9898892|to_9 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disease_10\NN\14061805|NONE_0
D012460_D015212 NONE sulfasalazine_18\NN\0|-_13 (r_npadvmod) induced_20\VBN\1627355|lupus_8 (r_amod) syndrome_22\NN\5870365|NONE_0 (r_pobj) of_17\IN\0|the_10 (r_prep) signs_16\NNS\6643763|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) aware_13\JJ\0|physicians_93|should_10|._58 (r_acomp) be_12\VB\14625458|NONE_0 (l_nsubj) physicians_0\NNS\10305802|should_83|aware_93|._151 (l_relcl) use_2\VBP\407535|NONE_0 (l_xcomp) treat_5\VB\7570720|who_25|sulfasalazine_17 (l_dobj) patients_6\NNS\9898892|to_9 (l_prep) with_7\IN\0|NONE_0 (l_pobj) disease_10\NN\14061805|NONE_0
19729346
D010098_D010146 NONE oxycodone_18\NN\0|NONE_0 (r_pobj) of_14\IN\0|a_20|single_18|10-mg_11|in_31 (r_prep) dose_13\NN\3740161|NONE_0 (r_pobj) of_9\IN\0|the_52|objective_48|neurocognitive_23 (r_prep) effects_8\NNS\13245626|study_59|)_91|,_92|and_94|years_120|adults_127|._195 (r_dobj) measured_2\VBD\697589|NONE_0 (l_dobj) adults_39\NNS\7846|study_186|effects_127|)_36|,_35|and_33|years_7|._68 (l_relcl) suffering_43\VBG\14322699|NONE_0 (l_prep) from_44\IN\0|who_23|were_19|not_14 (l_pobj) pain_49\NN\14299637|NONE_0
D010098_D059350 NONE oxycodone_30\NN\0|NONE_0 (r_pobj) of_26\IN\0|a_13|10-mg_11 (r_prep) dose_25\NN\3740161|NONE_0 (r_pobj) to_22\IN\0|NONE_0 (r_prep) response_21\NN\11410625|NONE_0 (r_pobj) in_20\IN\13603305|NONE_0 (r_prep) changes_19\NNS\7283608|who_76|are_72|not_68|from_54 (r_dobj) suffering_11\VBG\14322699|healthy_33|older_25 (l_prep) from_12\IN\0|who_22|are_18|not_14|changes_54 (l_pobj) pain_14\NN\14299637|NONE_0
14513889
D007654_D009422 NONE ketoconazole_0\NNP\0|-_12|sequelae_32|._40 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) sequelae_4\NNS\14501726|ketoconazole_32|-_20|._8
20633755
D013390_D001049 CID suxamethonium_0\NNS\0|apnea_32|._86 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) apnea_3\NN\14299637|suxamethonium_32|._54
D013390_D001049 CID suxamethonium_0\JJ\0|apnea_31|._134 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) apnea_3\NN\14299637|suxamethonium_31|._103
D009943_D001049 CID poisons_17\NNS\20090|NONE_0 (r_pobj) by_12\IN\0|in_53|enzyme_24|gets_17 (r_agent) deactivated_11\VBN\1097743|NONE_0 (r_relcl) patients_5\NNS\9898892|NONE_0 (r_pobj) in_4\IN\13603305|prolonged_16 (r_prep) apnea_3\NN\14299637|suxamethonium_31|._103
D009943_D001049 CID compound_14\NN\5869584|NONE_0 (r_pobj) by_12\IN\0|suicidal_17 (r_prep) attempt_11\NN\407535|NONE_0 (r_pobj) about_9\IN\0|the_16 (r_prep) information_8\NN\6598915|because_12|was_50|from_64 (r_nsubjpass) concealed_16\VBN\0|apnea_91|._32 (r_advcl) ensued_5\VBD\2633881|NONE_0 (l_nsubj) apnea_1\NN\14299637|concealed_91|._123
8319760
D000804_D009404 NONE ii_43\NNP\13741022|a_20|angiotensin_12|receptor_3|,_22|at_24 (r_compound) antagonist_45\NN\7846|induced_159|was_101|markedly_97|by_78|)_35|,_34|._45 (r_appos) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0
D000804_D011507 NONE ii_43\NNP\13741022|a_20|angiotensin_12|receptor_3|,_22|at_24 (r_compound) antagonist_45\NN\7846|induced_159|was_101|markedly_97|by_78|)_35|,_34|._45 (r_appos) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8
D001806_D009404 NONE urea_17\NN\14727670|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) increase_13\NN\13576355|and_4 (r_conj) hypercholesterolemia_11\NN\14299637|,_2 (r_conj) hypoalbuminemia_9\NN\0|,_2 (r_conj) proteinuria_7\NN\14299637|such_8 (r_pobj) as_6\IN\14622893|nephrotic_25 (r_prep) syndromes_4\NNS\5870365|NONE_0
D019808_D009401 NONE 753_1\CD\0|NONE_0 (r_nummod) dup_0\NN\0|development_21|._79 (r_nsubj) prevents_2\VBZ\0|NONE_0 (l_dobj) development_4\NN\248977|dup_21|._58 (l_prep) of_5\IN\0|the_16 (l_pobj) nephrosis_10\NN\14304060|puromycin_34
D000804_D006937 NONE ii_43\NNP\13741022|a_20|angiotensin_12|receptor_3|,_22|at_24 (r_compound) antagonist_45\NN\7846|induced_159|was_101|markedly_97|by_78|)_35|,_34|._45 (r_appos) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2 (l_conj) hypercholesterolemia_11\NN\14299637|,_2
D011692_D009401 NONE aminonucleoside_7\NN\0|-_15 (r_advmod) induced_9\VBN\1627355|NONE_0 (r_amod) nephrosis_10\NN\14304060|puromycin_34
D011692_D009401 NONE aminonucleoside_17\NN\0|-_15 (r_advmod) induced_19\VBN\1627355|NONE_0 (r_amod) nephrosis_20\NN\14304060|puromycin_34
D011692_D009404 CID aminonucleoside_26\NN\0|appearance_172|,_44|in_34|by_26 (r_advmod) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0
D019808_D006937 NONE 753_35\CD\0|NONE_0 (r_nummod) dup_34\NN\0|(_8 (r_nmod) losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2 (l_conj) hypercholesterolemia_11\NN\14299637|,_2
D019808_D006937 NONE losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2 (l_conj) hypercholesterolemia_11\NN\14299637|,_2
D019808_D011507 NONE 753_35\CD\0|NONE_0 (r_nummod) dup_34\NN\0|(_8 (r_nmod) losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8
D019808_D011507 NONE losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8
D011692_D006937 CID aminonucleoside_26\NN\0|appearance_172|,_44|in_34|by_26 (r_advmod) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2 (l_conj) hypercholesterolemia_11\NN\14299637|,_2
D019808_D034141 NONE 753_35\CD\0|NONE_0 (r_nummod) dup_34\NN\0|(_8 (r_nmod) losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2
D019808_D034141 NONE losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2
D001806_D011507 NONE urea_17\NN\14727670|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) increase_13\NN\13576355|and_4 (r_conj) hypercholesterolemia_11\NN\14299637|,_2 (r_conj) hypoalbuminemia_9\NN\0|,_2 (r_conj) proteinuria_7\NN\14299637|such_8
D000809_D009401 NONE angiotensin_10\NN\4522421|the_10|in_19 (r_compound) system_11\NN\3575240|NONE_0 (l_prep) in_12\IN\13603305|the_29|angiotensin_19 (l_pobj) development_14\NN\248977|NONE_0 (l_prep) of_15\IN\0|the_16 (l_pobj) nephrosis_20\NN\14304060|puromycin_34
D001806_D034141 NONE urea_17\NN\14727670|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) increase_13\NN\13576355|and_4 (r_conj) hypercholesterolemia_11\NN\14299637|,_2 (r_conj) hypoalbuminemia_9\NN\0|,_2
D000804_D034141 NONE ii_43\NNP\13741022|a_20|angiotensin_12|receptor_3|,_22|at_24 (r_compound) antagonist_45\NN\7846|induced_159|was_101|markedly_97|by_78|)_35|,_34|._45 (r_appos) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2
D011692_D011507 CID aminonucleoside_26\NN\0|appearance_172|,_44|in_34|by_26 (r_advmod) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8
D011692_D034141 CID aminonucleoside_26\NN\0|appearance_172|,_44|in_34|by_26 (r_advmod) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0 (l_prep) as_6\IN\14622893|nephrotic_25 (l_pobj) proteinuria_7\NN\14299637|such_8 (l_conj) hypoalbuminemia_9\NN\0|,_2
D019808_D009404 NONE 753_35\CD\0|NONE_0 (r_nummod) dup_34\NN\0|(_8 (r_nmod) losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0
D019808_D009404 NONE losartan_37\NN\0|NONE_0 (r_pobj) of_33\IN\0|oral_20 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) by_30\IN\0|induced_81|was_23|markedly_19|)_43|,_44|antagonist_78|._123 (r_agent) inhibited_29\VBN\2510337|NONE_0 (l_ccomp) induced_19\VBN\1627355|was_58|markedly_62|by_81|)_124|,_125|antagonist_159|._204 (l_nsubj) appearance_1\NN\4723816|,_128|in_138|by_146|aminonucleoside_172 (l_prep) of_2\IN\0|the_15 (l_pobj) syndromes_4\NNS\5870365|NONE_0
D001806_D006937 NONE urea_17\NN\14727670|NONE_0 (r_pobj) in_14\IN\13603305|NONE_0 (r_prep) increase_13\NN\13576355|and_4 (r_conj) hypercholesterolemia_11\NN\14299637|,_2
11147747
D018490_D014549 CID antidepressants_1\NNS\3740161|NONE_0 (l_conj) incontinence_4\NN\13473097|serotonergic_41|and_12|._12
D018490_D014549 CID antidepressants_8\NNS\3740161|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) secondary_5\JJ\8426461|NONE_0 (r_amod) incontinence_4\NN\13473097|that_5|could_55|be_61|by_73
D020280_D014549 CID sertraline_22\NN\4169152|the_59|selective_55|serotonin_45|inhibitors_26|and_4|,_10|as_20|third_25 (r_conj) paroxetine_20\NN\0|NONE_0 (r_pobj) to_14\IN\0|who_37|secondary_10 (r_prep) developed_11\VBD\1753788|2_22|female_20 (l_dobj) secondary_13\JJ\8426461|who_27|to_10 (l_compound) incontinence_12\NN\13473097|NONE_0
C047426_D014549 CID venlafaxine_10\NN\0|while_13 (r_dobj) taking_9\VBG\37396|who_35|incontinence_19 (r_advcl) experienced_6\VBD\2108377|2_20|male_18 (l_dobj) incontinence_7\NN\13473097|who_16|taking_19
C047426_D014549 CID venlafaxine_35\NNP\0|NONE_0 (r_pobj) on_34\IN\0|who_31|effect_7 (r_prep) developed_30\VBD\1753788|a_12 (r_relcl) third_28\NN\13732295|the_84|selective_80|serotonin_70|inhibitors_51|and_29|sertraline_25|,_15|as_5 (r_conj) paroxetine_20\NN\0|NONE_0 (r_pobj) to_14\IN\0|who_37|secondary_10 (r_prep) developed_11\VBD\1753788|2_22|female_20 (l_dobj) secondary_13\JJ\8426461|who_27|to_10 (l_compound) incontinence_12\NN\13473097|NONE_0
D017374_D014549 CID paroxetine_20\NN\0|NONE_0 (r_pobj) to_14\IN\0|who_37|secondary_10 (r_prep) developed_11\VBD\1753788|2_22|female_20 (l_dobj) secondary_13\JJ\8426461|who_27|to_10 (l_compound) incontinence_12\NN\13473097|NONE_0
D016651_D014549 CID carbonate_12\NN\15010703|patients_34|were_25|also_20 (r_dobj) taking_10\VBG\37396|the_35|3_31 (r_relcl) cases_5\NNS\7283608|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) 2_1\CD\13741022|NONE_0 (r_pobj) in_0\IN\13603305|,_85|both_87|could_101|have_107|to_124|._143 (r_prep) contributed_23\VBN\126264|NONE_0 (l_prep) to_24\IN\0|in_124|,_39|both_37|could_23|have_17|._19 (l_pobj) incontinence_26\NN\13473097|NONE_0
D012701_D014549 NONE serotonin_17\NN\14807737|the_14|selective_10|inhibitors_19|and_41|sertraline_45|,_55|as_65|third_70 (r_compound) paroxetine_20\NN\0|NONE_0 (r_pobj) to_14\IN\0|who_37|secondary_10 (r_prep) developed_11\VBD\1753788|2_22|female_20 (l_dobj) secondary_13\JJ\8426461|who_27|to_10 (l_compound) incontinence_12\NN\13473097|NONE_0
20882060
D009496_D002375 NONE neurotensin_3\NN\0|NONE_0 (l_prep) on_4\IN\0|pallidal_21 (l_pobj) catalepsy_9\NN\14023236|NONE_0
D009496_D002375 NONE neurotensin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|bilateral_20 (r_prep) infusions_1\NNS\14589223|catalepsy_92|in_102|._109 (r_nsubj) reversed_8\VBD\109660|NONE_0 (l_dobj) catalepsy_13\NN\14023236|infusions_92|in_10|._17
D006220_D002375 CID haloperidol_5\NN\3713736|-_11 (r_npadvmod) induced_7\VBN\1627355|parkinsonian_8|:_30|studies_68 (r_amod) catalepsy_9\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_9\NN\3713736|-_11 (r_npadvmod) induced_11\VBN\1627355|parkinsonian_8 (r_amod) catalepsy_13\NN\14023236|infusions_92|in_10|._17
D006220_D010302 NONE haloperidol_12\NN\3713736|-_11 (r_npadvmod) induced_14\VBN\1627355|parkinsonian_8 (r_amod) symptoms_16\NNS\5823932|NONE_0
D009496_D010302 NONE neurotensin_10\NN\0|NONE_0 (l_prep) on_11\IN\0|pallidal_21 (l_pobj) symptoms_16\NNS\5823932|NONE_0
3496378
D014217_D056486 CID troleandomycin_3\NN\0|-_14 (r_npadvmod) induced_5\VBN\1627355|acute_8 (r_amod) hepatitis_7\NN\14127211|NONE_0
D014217_D056486 CID troleandomycin_9\NN\0|in_8|-_14 (r_npadvmod) induced_11\VBN\1627355|a_33 (r_relcl) patient_6\NN\9898892|NONE_0 (r_pobj) of_4\IN\0|the_9 (r_prep) case_3\NN\7283608|we_14|followed_63|._106 (r_dobj) report_1\VBP\6470073|NONE_0 (l_ccomp) followed_14\VBN\1835496|we_77|case_63|._43 (l_nsubjpass) hepatitis_12\NN\14127211|was_10|by_23
D014217_D056486 CID troleandomycin_8\NN\0|-_14 (r_npadvmod) induced_10\VBN\1627355|acute_8 (r_amod) hepatitis_12\NN\14127211|that_67|cholestasis_52|can_40
D014217_D002779 CID troleandomycin_3\NN\0|-_14 (r_npadvmod) induced_5\VBN\1627355|acute_8 (r_amod) hepatitis_7\NN\14127211|NONE_0 (r_pobj) after_2\IN\0|prolonged_22|._44 (r_prep) cholestasis_1\NN\14052403|NONE_0
D014217_D002779 CID troleandomycin_9\NN\0|in_8|-_14 (r_npadvmod) induced_11\VBN\1627355|a_33 (r_relcl) patient_6\NN\9898892|NONE_0 (r_pobj) of_4\IN\0|the_9 (r_prep) case_3\NN\7283608|we_14|followed_63|._106 (r_dobj) report_1\VBP\6470073|NONE_0 (l_ccomp) followed_14\VBN\1835496|we_77|case_63|._43 (l_agent) by_15\IN\0|hepatitis_23|was_13 (l_pobj) cholestasis_18\NN\14052403|NONE_0
D014217_D002779 CID troleandomycin_8\NN\0|-_14 (r_npadvmod) induced_10\VBN\1627355|acute_8 (r_amod) hepatitis_12\NN\14127211|that_67|cholestasis_52|can_40 (r_dobj) follow_7\VB\1835496|observation_56|._45 (l_nsubj) cholestasis_5\NN\14052403|that_15|can_12|hepatitis_52
D014217_D007565 CID troleandomycin_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) after_2\IN\0|jaundice_18|for_39|and_50|associated_58|._91 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) jaundice_0\NN\14299637|after_18|for_57|and_68|associated_76|._109
D014217_D004802 CID troleandomycin_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_pobj) after_2\IN\0|jaundice_18|for_39|and_50|associated_58|._91 (r_prep) occurred_1\VBD\0|NONE_0 (l_conj) associated_11\VBN\628491|jaundice_76|after_58|for_19|and_8|._33 (l_prep) with_12\IN\0|was_15 (l_pobj) hypereosinophilia_13\NNS\0|NONE_0
16005948
D003042_D064420 NONE cocaine_3\NN\3492717|NONE_0 (r_compound) toxicity_4\NN\13576101|NONE_0
-1_D064420 NONE gnc92h2_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|the_16|higher_12|mg/kg_16|)_21|,_22|reduced_55|,_72|seizures_74 (r_prep) dose_10\NN\3740161|NONE_0 (r_pobj) with_7\IN\0|blockade_42|was_13|._130 (r_prep) observed_6\VBN\2163746|NONE_0 (l_nsubjpass) blockade_1\NN\952963|was_29|with_42|._172 (l_prep) of_2\IN\0|significant_21 (l_pobj) toxicity_4\NN\13576101|NONE_0
-1_D003643 NONE gnc92h2_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|the_16|higher_12|mg/kg_16|)_21|,_22|reduced_55|,_72|seizures_74 (r_prep) dose_10\NN\3740161|NONE_0 (l_appos) seizures_28\NNS\14081375|the_90|higher_86|of_74|mg/kg_58|)_53|,_52|reduced_19|,_2 (l_prt) up_29\IN\153263|by_20 (l_prep) to_30\TO\0|NONE_0 (l_pobj) %_32\NN\0|NONE_0 (l_conj) death_34\NN\7296428|77_8|and_4
-1_D003643 NONE gnc92h2_2\NNP\0|importantly_13|,_2|death_18|injection_42|._51 (r_nsubj) prevented_3\VBD\0|NONE_0 (l_dobj) death_4\NN\7296428|importantly_31|,_20|gnc92h2_18|injection_24|._33
D003042_D062787 NONE cocaine_4\NN\3492717|NONE_0 (r_pobj) of_3\IN\0|the_16|illicit_12 (r_prep) use_2\NN\407535|in_25 (r_nsubj) continues_5\VBZ\2367363|elusive_77|._84 (l_prep) in_6\IN\13603305|use_25 (l_pobj) proportions_8\NNS\13824815|NONE_0 (l_conj) treatment_10\NN\654885|epidemic_25|and_4 (l_prep) for_11\IN\0|NONE_0 (l_pobj) overdose_13\NN\84738|NONE_0
D003042_D003643 NONE cocaine_3\NN\3492717|NONE_0 (r_compound) toxicity_4\NN\13576101|NONE_0 (r_pobj) of_2\IN\0|significant_21 (r_prep) blockade_1\NN\952963|was_29|with_42|._172 (r_nsubjpass) observed_6\VBN\2163746|NONE_0 (l_prep) with_7\IN\0|blockade_42|was_13|._130 (l_pobj) dose_10\NN\3740161|NONE_0 (l_appos) seizures_28\NNS\14081375|the_90|higher_86|of_74|mg/kg_58|)_53|,_52|reduced_19|,_2 (l_prt) up_29\IN\153263|by_20 (l_prep) to_30\TO\0|NONE_0 (l_pobj) %_32\NN\0|NONE_0 (l_conj) death_34\NN\7296428|77_8|and_4
D003042_D003643 NONE cocaine_8\NN\3492717|even_10 (r_compound) injection_9\NN\320852|importantly_55|,_44|gnc92h2_42|death_24|._9 (r_dobj) prevented_3\VBD\0|NONE_0 (l_dobj) death_4\NN\7296428|importantly_31|,_20|gnc92h2_18|injection_24|._33
-1_D062787 NONE gnc92h2_6\NNP\0|NONE_0 (r_pobj) of_1\IN\0|as_47|._87 (r_prep) evaluation_0\NN\874067|NONE_0 (l_prep) as_7\IN\14622893|of_47|._40 (l_pobj) immunotherapy_9\NN\661091|NONE_0 (l_prep) for_10\IN\0|an_17 (l_pobj) overdose_12\NN\84738|NONE_0
-1_D062787 NONE gnc92h2_7\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_26|therapeutic_22 (r_prep) potential_2\NN\14481929|was_46|using_59|._92 (r_nsubjpass) examined_9\VBN\0|NONE_0 (l_advcl) using_10\VBG\418025|potential_59|was_13|._33 (l_dobj) model_12\NN\5888929|NONE_0 (l_prep) of_13\IN\0|a_8 (l_pobj) overdose_15\NN\84738|NONE_0
-1_D062787 NONE gnc92h2_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|the_24|important_20|as_11 (r_prep) potential_5\NN\14481929|results_30|._67 (l_prep) as_8\IN\14622893|the_35|important_31|of_11 (l_pobj) tool_11\NN\3563967|NONE_0 (l_prep) against_12\IN\0|a_19|therapeutic_17 (l_pobj) overdose_14\NN\84738|NONE_0
-1_D012640 NONE gnc92h2_12\NNP\0|NONE_0 (r_pobj) of_11\IN\0|the_16|higher_12|mg/kg_16|)_21|,_22|reduced_55|,_72|seizures_74 (r_prep) dose_10\NN\3740161|NONE_0 (l_appos) seizures_28\NNS\14081375|the_90|higher_86|of_74|mg/kg_58|)_53|,_52|reduced_19|,_2
D003042_D012640 CID cocaine_3\NN\3492717|NONE_0 (r_compound) toxicity_4\NN\13576101|NONE_0 (r_pobj) of_2\IN\0|significant_21 (r_prep) blockade_1\NN\952963|was_29|with_42|._172 (r_nsubjpass) observed_6\VBN\2163746|NONE_0 (l_prep) with_7\IN\0|blockade_42|was_13|._130 (l_pobj) dose_10\NN\3740161|NONE_0 (l_appos) seizures_28\NNS\14081375|the_90|higher_86|of_74|mg/kg_58|)_53|,_52|reduced_19|,_2
11897407
D007545_D009203 CID isoproterenol_6\NN\3740161|-_13 (r_npadvmod) induced_8\VBN\1627355|myocardial_8|in_30 (r_amod) infarction_10\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_22\NN\3740161|-_13 (r_npadvmod) induced_24\VBN\1627355|acute_8|myocardial_14 (r_amod) infarction_27\NN\14204950|NONE_0
C067171_D009203 NONE glucarate_2\NN\0|NONE_0 (l_prep) for_3\IN\0|99mtc_16|-_11|._68 (l_pobj) detection_4\NN\5708432|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) infarction_10\NN\14204950|NONE_0
C067171_D009203 NONE glucarate_2\NN\0|easy_14|,_29|stable_31|and_47|used_55|._151 (r_nsubj) was_3\VBD\0|NONE_0 (l_conj) used_14\VBN\0|glucarate_55|easy_41|,_26|stable_24|and_8|._96 (l_xcomp) study_16\VB\635850|was_12 (l_dobj) biodistribution_18\NN\0|to_13 (l_prep) in_19\IN\13603305|its_20 (l_pobj) rats_20\NNS\2329401|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) infarction_27\NN\14204950|NONE_0
D005937_D007238 NONE acid_9\NN\14818238|NONE_0 (r_pobj) on_7\IN\0|NONE_0 (r_prep) based_6\VBN\0|a_39|new_37|avid_25 (r_acl) radiopharmaceutical_5\NN\3920989|was_43|in_56|._100 (l_amod) avid_4\JJ\0|a_14|new_12|based_25 (l_npadvmod) infarct_2\NN\14204950|-_7
D007545_D007238 NONE isoproterenol_18\NN\3740161|NONE_0 (r_pobj) with_17\IN\0|can_23|be_19|easily_16 (r_prep) obtained_16\VBN\2210855|model_94|ligation_46|._27 (r_conj) implies_7\VBZ\943837|NONE_0 (l_nsubj) model_2\NN\5888929|ligation_48|obtained_94|._121 (l_acl) used_3\VBN\0|the_17|animal_13 (l_xcomp) produce_5\VB\7555863|NONE_0 (l_dobj) infarction_6\NN\14204950|to_11
D007545_D007238 NONE isoproterenol_12\JJ\3740161|NONE_0 (r_compound) administration_13\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|18_5 (r_prep) h_10\NN\14622893|that_38|rats_29|infarct_11 (r_npadvmod) developed_6\VBD\1753788|studies_35|._60 (l_dobj) infarct_8\NN\14204950|that_27|rats_18|h_11
567256
D004054_D000230 NONE diethylstilbestrol_25\NN\14749794|NONE_0 (r_pobj) with_24\IN\0|the_10 (r_prep) liver_23\NN\5298729|NONE_0
D004054_D008113 CID diethylstilbestrol_6\NN\14749794|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|the_10 (r_acl) liver_3\NN\5298729|NONE_0
D004054_D008113 CID diethylstilbestrol_25\NN\14749794|NONE_0 (r_pobj) with_24\IN\0|the_10 (r_prep) liver_23\NN\5298729|NONE_0 (r_pobj) of_21\IN\0|a_37|differentiated_30 (r_prep) adenocarcinoma_20\NN\14242337|NONE_0 (r_pobj) for_15\IN\0|who_21|had_17|been_13|for_78 (r_prep) treated_14\VBN\2376958|a_31|old_21 (r_relcl) man_10\NN\9605289|NONE_0 (r_pobj) in_5\IN\13603305|angiosarcoma_35|._132 (r_prep) occurred_4\VBD\0|NONE_0 (l_nsubj) angiosarcoma_0\NNP\14239425|in_35|._167 (l_prep) of_1\IN\0|NONE_0 (l_pobj) liver_3\NN\5298729|NONE_0
D004054_D008113 NONE diethylstilbestrol_25\NN\14749794|NONE_0 (r_pobj) with_24\IN\0|the_10 (r_prep) liver_23\NN\5298729|NONE_0
D004054_D006394 CID diethylstilbestrol_6\NN\14749794|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|the_10 (r_acl) liver_3\NN\5298729|NONE_0
D004054_D006394 CID diethylstilbestrol_25\NN\14749794|NONE_0 (r_pobj) with_24\IN\0|the_10 (r_prep) liver_23\NN\5298729|NONE_0 (r_pobj) of_21\IN\0|a_37|differentiated_30 (r_prep) adenocarcinoma_20\NN\14242337|NONE_0 (r_pobj) for_15\IN\0|who_21|had_17|been_13|for_78 (r_prep) treated_14\VBN\2376958|a_31|old_21 (r_relcl) man_10\NN\9605289|NONE_0 (r_pobj) in_5\IN\13603305|angiosarcoma_35|._132 (r_prep) occurred_4\VBD\0|NONE_0 (l_nsubj) angiosarcoma_0\NNP\14239425|in_35|._167 (l_prep) of_1\IN\0|NONE_0 (l_pobj) liver_3\NN\5298729|NONE_0
15515654
D003676_D034381 NONE dfo_5\NNP\0|contributing_6|in_24 (r_poss) role_8\NN\719494|NONE_0 (l_prep) in_9\IN\13603305|dfo_24|contributing_18 (l_pobj) development_11\NN\248977|NONE_0 (l_prep) of_12\IN\0|the_16 (l_pobj) impairment_14\NN\7296428|NONE_0
D003676_D006311 NONE dfo_6\NNP\0|NONE_0 (r_pobj) than_5\IN\0|NONE_0 (r_prep) other_4\JJ\0|no_20|ototoxic_17|,_2|,_14 (r_amod) factor_2\NN\7326557|present_28|._58 (l_compound) ototoxic_1\JJ\0|no_3|,_15|other_17|,_31
D003676_D006319 CID dfo_6\NNP\0|or_14|withdrawal_27 (r_compound) reduction_7\NN\351485|NONE_0 (r_pobj) to_5\IN\0|subjects_34|were_15|._40 (r_prep) submitted_4\VBN\1952898|NONE_0 (l_nsubjpass) subjects_0\NNS\6598915|were_19|to_34|._74 (l_prep) with_1\IN\0|NONE_0 (l_pobj) snhl_2\NNP\0|NONE_0
18162529
D004967_D006966 NONE estrogen_20\NN\14745635|-_8 (r_npadvmod) induced_22\VBN\1627355|the_13|lh_8 (r_amod) surge_24\NN\7405893|pulsatile_51|lh_41|and_28 (r_conj) secretion_17\NN\13526110|two_75|neuroendocrine_71|necessary_45|:_15 (r_appos) parameters_9\NNS\5858936|whether_64|hyperprolactinemia_48 (r_dobj) inhibited_6\VBD\2510337|we_51|first_48|._128 (l_nsubj) hyperprolactinemia_5\NN\0|whether_16|parameters_48
D013469_D006966 CID sulpiride_7\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|chronic_27 (r_acl) hyperprolactinemia_1\NN\0|frequency_96|,_128|but_130|in_139|._189
D012313_D006966 NONE acid_5\NN\14818238|hypothalamic_54|prolactin_41|messenger_22|,_11|signaling_23 (r_compound) levels_6\NNS\4916342|dependent_110|._132 (l_conj) signaling_9\NN\33020|hypothalamic_77|prolactin_64|messenger_45|acid_23|,_12 (l_conj) inhibition_13\NN\1068773|prolactin_44|,_25|and_23 (l_amod) hyperprolactinemic_12\JJ\0|of_30
D004298_D006966 NONE dopamine_5\NN\14807737|NONE_0 (r_compound) antagonist_6\NN\7846|the_13 (r_compound) sulpiride_7\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|chronic_27 (r_acl) hyperprolactinemia_1\NN\0|frequency_96|,_128|but_130|in_139|._189
D013256_D006966 NONE steroid_14\NN\14727670|-_7 (r_npadvmod) dependent_16\JJ\9627906|a_10 (r_amod) manner_17\NN\4916342|NONE_0 (r_pobj) in_12\IN\13603305|that_69|frequency_53|is_43|by_30 (r_prep) inhibited_8\VBN\2510337|data_39|._69 (l_agent) by_9\IN\0|that_39|frequency_23|is_13|in_30 (l_pobj) hyperprolactinemia_11\NN\0|NONE_0
D004958_D006966 NONE estradiol_22\NN\14749794|NONE_0 (r_pobj) on_21\IN\0|NONE_0 (r_prep) dependent_20\JJ\9627906|levels_110|._22 (r_acomp) are_19\VBP\13600404|NONE_0 (l_nsubj) levels_6\NNS\4916342|dependent_110|._132 (l_conj) signaling_9\NN\33020|hypothalamic_77|prolactin_64|messenger_45|acid_23|,_12 (l_conj) inhibition_13\NN\1068773|prolactin_44|,_25|and_23 (l_amod) hyperprolactinemic_12\JJ\0|of_30
D004958_D006966 NONE estradiol_30\NN\14749794|NONE_0 (r_pobj) of_29\IN\0|chronic_19|low_11 (r_prep) levels_28\NNS\4916342|NONE_0 (r_pobj) of_25\IN\0|the_13 (r_prep) presence_24\NN\13954253|only_12 (r_pobj) in_22\IN\13603305|hyperprolactinemia_139|frequency_43|,_11|but_9|._50 (r_conj) caused_8\VBD\1617192|NONE_0 (l_nsubj) hyperprolactinemia_1\NN\0|frequency_96|,_128|but_130|in_139|._189
11587867
D014750_-1 NONE vincristine_28\NN\3917455|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) exposed_26\VBN\2110927|NONE_0 (r_acl) areas_25\NNS\8630985|NONE_0 (r_pobj) in_24\IN\13603305|pseudocystic_28|,_31|accompanied_33 (r_prep) transformation_23\NN\7296428|of_44|as_16
D014750_D054198 NONE vincristine_9\NN\3917455|accidental_23|intrathecal_12|in_25 (r_compound) instillation_10\NN\320852|NONE_0 (l_prep) in_11\IN\13603305|accidental_48|intrathecal_37|vincristine_25 (l_pobj) girl_15\NN\10787470|NONE_0 (l_prep) with_16\IN\0|a_18|5-year_16|old_9 (l_pobj) leucemia_20\NN\0|NONE_0
D014750_D054198 NONE vincristine_9\NN\3917455|accidental_23|intrathecal_12|in_25 (r_compound) instillation_10\NN\320852|NONE_0 (l_prep) in_11\IN\13603305|accidental_48|intrathecal_37|vincristine_25 (l_pobj) girl_15\NN\10787470|NONE_0 (l_prep) with_16\IN\0|a_18|5-year_16|old_9 (l_pobj) leucemia_20\NN\0|NONE_0 (l_conj) man_25\NN\9605289|recurrent_57|acute_47|lymphoblastic_41|and_18 (l_prep) with_26\IN\0|a_18|57-year_16|old_8 (l_pobj) lymphoma_28\NN\14239918|NONE_0
D014750_D009410 CID vincristine_28\NN\3917455|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) exposed_26\VBN\2110927|NONE_0 (r_acl) areas_25\NNS\8630985|NONE_0 (r_pobj) in_24\IN\13603305|pseudocystic_28|,_31|accompanied_33 (r_prep) transformation_23\NN\7296428|of_44|as_16 (r_conj) degeneration_14\NN\29677|investigations_55|._173 (l_prep) of_15\IN\0|as_28|transformation_44 (l_pobj) myelin_16\NN\14864360|NONE_0 (l_conj) axons_18\NNS\5464104|and_4
D014750_D003711 CID vincristine_28\NN\3917455|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) exposed_26\VBN\2110927|NONE_0 (r_acl) areas_25\NNS\8630985|NONE_0 (r_pobj) in_24\IN\13603305|pseudocystic_28|,_31|accompanied_33 (r_prep) transformation_23\NN\7296428|of_44|as_16 (r_conj) degeneration_14\NN\29677|investigations_55|._173 (l_prep) of_15\IN\0|as_28|transformation_44 (l_pobj) myelin_16\NN\14864360|NONE_0 (l_conj) axons_18\NNS\5464104|and_4
D014750_D001927 NONE vincristin_6\NN\0|accidental_23|intrathecal_12|:_25|report_29 (r_compound) administration_7\NN\1133281|to_37 (r_pobj) due_2\IN\5174653|fatal_26|._78 (r_prep) myeloencephalopathy_1\NN\0|NONE_0
2312209
D007548_D009336 NONE dinitrate_22\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_19 (r_prep) administration_19\NN\1133281|NONE_0 (r_pobj) following_17\VBG\8180190|necrosis_73|infarction_32|sublingually_58|._70 (r_prep) suffered_8\VBD\2110220|NONE_0 (l_nsubj) necrosis_7\NN\11444117|infarction_41|following_73|sublingually_131|._143
D007548_D009203 CID dinitrate_7\NN\0|NONE_0 (r_pobj) of_5\IN\0|sublingual_26 (r_prep) administration_4\NN\1133281|NONE_0 (r_dobj) following_2\VBG\8180190|myocardial_22|._59 (r_prep) infarction_1\NN\14204950|NONE_0
D007548_D009203 CID dinitrate_22\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_19 (r_prep) administration_19\NN\1133281|NONE_0 (r_pobj) following_17\VBG\8180190|necrosis_73|infarction_32|sublingually_58|._70 (r_prep) suffered_8\VBD\2110220|NONE_0 (l_dobj) infarction_12\NN\14204950|necrosis_41|following_32|sublingually_90|._102
6229975
D013999_D007238 NONE timolol_17\NN\2832168|the_4 (r_compound) group_18\NN\2137|NONE_0 (r_pobj) in_15\IN\13603305|unchanged_10 (r_prep) remained_13\VBD\2604760|after_67|,_48|size_40|in_25|and_4|._39 (r_conj) increased_7\VBD\169651|NONE_0 (l_punct) ,_4\,\0|after_19|size_8|in_23|and_44|remained_48|._87 (l_punct) infarction_3\NN\14204950|NONE_0
D013999_D009203 NONE timolol_8\NN\2832168|term_5|after_18 (r_compound) treatment_9\NN\654885|NONE_0 (l_prep) after_10\IN\0|term_23|timolol_18 (l_pobj) infarction_12\NN\14204950|NONE_0
D013999_D009203 NONE timolol_6\NN\2832168|term_5|on_18 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) of_2\IN\0|the_11|after_45 (r_prep) effect_1\NN\34213|was_80|by_94|in_103|timolol_164|._176 (l_prep) after_11\IN\0|the_56|of_45 (l_pobj) infarction_13\NN\14204950|NONE_0
D013999_D009203 NONE timolol_33\NN\2832168|effect_164|was_84|by_70|in_61|._12 (r_conj) evaluated_15\VBN\670261|NONE_0 (l_nsubjpass) effect_1\NN\34213|was_80|by_94|in_103|timolol_164|._176 (l_prep) after_11\IN\0|the_56|of_45 (l_pobj) infarction_13\NN\14204950|NONE_0
D013999_D001919 NONE timolol_6\NN\2832168|-_7 (r_npadvmod) induced_8\VBN\1627355|and_20|increase_39 (r_amod) bradycardia_9\NN\14110674|NONE_0
10901305
D007649_D004204 NONE ketamine_7\NN\3054098|NONE_0 (l_prep) to_8\IN\0|NONE_0 (l_pobj) manipulation_9\NN\157081|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) fracture_12\NN\14285662|NONE_0 (l_conj) dislocation_14\NN\7367812|the_16|or_3
D007649_D050723 NONE ketamine_0\NN\3054098|NONE_0 (l_dobj) sedation_1\NN\14034177|._78 (l_prep) for_2\IN\0|NONE_0 (l_pobj) reduction_4\NN\351485|NONE_0 (l_prep) of_5\IN\0|the_14 (l_pobj) fractures_8\NNS\14285662|NONE_0
D007649_D050723 NONE ketamine_14\NN\3054098|NONE_0 (l_prep) for_15\IN\0|NONE_0 (l_pobj) sedation_16\NN\14034177|NONE_0 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) treatment_19\NN\654885|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) fractures_23\NNS\14285662|NONE_0
D007649_D050723 NONE ketamine_7\NN\3054098|NONE_0 (l_prep) to_8\IN\0|NONE_0 (l_pobj) manipulation_9\NN\157081|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) fracture_12\NN\14285662|NONE_0
D007649_D050723 NONE ketamine_0\NNP\3054098|reliably_9|quickly_31|sedation_57|._176 (r_nsubj) provided_7\VBD\2199590|NONE_0 (l_dobj) sedation_9\NN\14034177|ketamine_57|reliably_48|quickly_26|._119 (l_acl) facilitate_12\VB\2547586|adequate_33 (l_dobj) reduction_14\NN\351485|to_30|effectively_27 (l_prep) of_15\IN\0|the_14 (l_pobj) fractures_18\NNS\14285662|NONE_0
7988234
D017706_D000799 CID lisinopril_6\NN\2673637|NONE_0 (r_compound) therapy_7\NN\657604|NONE_0 (r_pobj) to_5\IN\0|a_34|of_24 (r_prep) history_1\NN\15120823|was_54|._66 (l_prep) of_2\IN\0|a_10|to_24 (l_pobj) angioedema_3\NN\14316714|NONE_0
D008790_D000799 CID metoprolol_6\NN\2832168|NONE_0 (r_pobj) of_5\IN\0|the_31|intravenous_27 (r_prep) administration_4\NN\1133281|NONE_0 (r_dobj) following_1\VBG\8180190|._54 (r_prep) angioedema_0\NNP\14316714|NONE_0
D008790_D000799 CID metoprolol_12\NN\2832168|during_71|,_14|was_11|,_20|resulting_22|._52 (r_nsubjpass) given_14\VBN\5892096|NONE_0 (l_advcl) resulting_16\VBG\2633881|during_93|,_36|metoprolol_22|was_11|,_2|._30 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) angioedema_19\NN\14316714|NONE_0
D013256_D000799 NONE steroids_7\NNS\14727670|NONE_0 (r_pobj) with_5\IN\0|angioedema_34|after_14|._59 (r_prep) resolved_2\VBD\352826|NONE_0 (l_nsubj) angioedema_1\NN\14316714|after_20|with_34|._93
D004155_D000799 NONE diphenhydramine_9\NN\2720725|intravenous_25|and_4 (r_conj) steroids_7\NNS\14727670|NONE_0 (r_pobj) with_5\IN\0|angioedema_34|after_14|._59 (r_prep) resolved_2\VBD\352826|NONE_0 (l_nsubj) angioedema_1\NN\14316714|after_20|with_34|._93
2054792
D004317_D009369 NONE adriamycin_2\NNS\0|NONE_0 (r_pobj) of_1\IN\0|combined_14|._79 (r_prep) effect_0\NN\34213|NONE_0 (l_acl) combined_3\VBN\2630189|of_14|._65 (l_prep) on_8\IN\0|with_29 (l_pobj) tumor_9\NN\14234074|NONE_0
D004317_D005334 NONE adriamycin_2\NNS\0|NONE_0 (r_pobj) of_1\IN\0|combined_14|._79 (r_prep) effect_0\NN\34213|NONE_0 (l_acl) combined_3\VBN\2630189|of_14|._65 (l_prep) with_4\IN\0|on_29 (l_pobj) hyperthermia_7\NN\14034177|NONE_0
D004317_D005334 NONE adriamycin_3\NNP\0|-_10 (r_npadvmod) mediated_5\VBN\761713|antitumor_9|and_28|toxicities_46 (r_amod) activity_7\NN\30358|NONE_0 (l_conj) toxicities_11\NNS\13576101|mediated_46|antitumor_37|and_18 (l_prep) by_12\IN\0|normal_25|tissue_18 (l_pobj) hyperthermia_15\NN\14034177|NONE_0
D004317_D005334 NONE adriamycin_13\NNP\0|-_10 (r_npadvmod) mediated_15\VBN\761713|both_16|antitumor_9|and_28|effects_43 (r_amod) activity_17\NN\30358|hyperthermia_85|._31 (r_dobj) enhanced_11\VBD\227165|NONE_0 (l_nsubj) hyperthermia_2\NN\14034177|activity_85|._116
D004317_D005334 NONE adriamycin_7\NNP\0|-_10 (r_npadvmod) mediated_9\VBN\761713|antitumor_9 (r_amod) effect_11\NN\34213|while_69|hyperthermia_52 (r_dobj) enhances_6\VBZ\227165|thus_36|,_32|,_45|toxicity_61|is_70|also_73|,_87|and_89|eroded_162 (l_nsubj) hyperthermia_5\NN\14034177|while_17|effect_52
D004317_D064420 NONE adriamycin_3\NNP\0|-_10 (r_npadvmod) mediated_5\VBN\761713|antitumor_9|and_28|toxicities_46 (r_amod) activity_7\NN\30358|NONE_0 (l_conj) toxicities_11\NNS\13576101|mediated_46|antitumor_37|and_18
D004317_D064420 NONE adriamycin_7\NNP\0|-_10 (r_npadvmod) mediated_9\VBN\761713|antitumor_9 (r_amod) effect_11\NN\34213|while_69|hyperthermia_52 (r_dobj) enhances_6\VBZ\227165|thus_36|,_32|,_45|toxicity_61|is_70|also_73|,_87|and_89|eroded_162 (r_advcl) increased_18\VBN\169651|NONE_0 (l_nsubjpass) toxicity_15\NN\13576101|thus_97|,_93|enhances_61|,_16|is_9|also_12|,_26|and_28|eroded_101
20621845
D002122_D014652 NONE chloride_18\NN\14818238|NONE_0 (l_appos) injury_22\NN\14052046|calcium_44
D002122_D014652 NONE cacl(2))-induced_20\VBN\0|(_1|arterial_17 (r_amod) injury_22\NN\14052046|calcium_44
D002122_D017545 CID cacl2-induced_14\VBN\0|thoracic_14|aortic_23|in_39 (r_amod) aneurysm_17\NN\14057371|degeneration_52
D002122_D017545 CID chloride_18\NN\14818238|NONE_0 (r_pobj) by_16\IN\0|to_59|model_40|and_54|explore_61 (r_prep) establish_5\VB\2426171|study_22|was_16|,_189|metalloproteinases_198|._280 (l_dobj) model_8\NN\5888929|to_19|by_40|and_94|explore_101 (l_prep) of_9\IN\0|a_12|rat_10 (l_pobj) aneurysm_12\NN\14057371|NONE_0
D002122_D017545 CID chloride_18\NN\14818238|NONE_0 (r_pobj) by_16\IN\0|to_59|model_40|and_54|explore_61 (r_prep) establish_5\VB\2426171|study_22|was_16|,_189|metalloproteinases_198|._280 (l_dobj) model_8\NN\5888929|to_19|by_40|and_94|explore_101 (l_prep) of_9\IN\0|a_12|rat_10 (l_pobj) aneurysm_12\NN\14057371|NONE_0 (l_appos) taa_14\NNP\0|thoracic_26|aortic_17|(_1|)_3
D002122_D017545 CID chloride_18\NN\14818238|NONE_0 (r_pobj) by_16\IN\0|to_59|model_40|and_54|explore_61 (r_prep) establish_5\VB\2426171|study_22|was_16|,_189|metalloproteinases_198|._280 (r_xcomp) designed_3\VBN\1631534|NONE_0 (l_conj) metalloproteinases_39\NNS\0|study_220|was_214|establish_198|,_9|._82 (l_conj) inhibitors_46\NNS\20090|matrix_54|(_28|mmps_27|)_23|and_21 (l_prep) in_50\IN\13603305|their_36|endogenous_30|(_8|timps_7|)_2 (l_pobj) formation_52\NN\7938773|NONE_0 (l_compound) taa_51\NNP\0|NONE_0
D002122_D017545 CID cacl(2))-induced_20\VBN\0|(_1|arterial_17 (r_amod) injury_22\NN\14052046|calcium_44 (r_appos) chloride_18\NN\14818238|NONE_0 (r_pobj) by_16\IN\0|to_59|model_40|and_54|explore_61 (r_prep) establish_5\VB\2426171|study_22|was_16|,_189|metalloproteinases_198|._280 (l_dobj) model_8\NN\5888929|to_19|by_40|and_94|explore_101 (l_prep) of_9\IN\0|a_12|rat_10 (l_pobj) aneurysm_12\NN\14057371|NONE_0
D002122_D017545 CID cacl(2))-induced_20\VBN\0|(_1|arterial_17 (r_amod) injury_22\NN\14052046|calcium_44 (r_appos) chloride_18\NN\14818238|NONE_0 (r_pobj) by_16\IN\0|to_59|model_40|and_54|explore_61 (r_prep) establish_5\VB\2426171|study_22|was_16|,_189|metalloproteinases_198|._280 (l_dobj) model_8\NN\5888929|to_19|by_40|and_94|explore_101 (l_prep) of_9\IN\0|a_12|rat_10 (l_pobj) aneurysm_12\NN\14057371|NONE_0 (l_appos) taa_14\NNP\0|thoracic_26|aortic_17|(_1|)_3
D002122_D017545 CID cacl(2))-induced_20\VBN\0|(_1|arterial_17 (r_amod) injury_22\NN\14052046|calcium_44 (r_appos) chloride_18\NN\14818238|NONE_0 (r_pobj) by_16\IN\0|to_59|model_40|and_54|explore_61 (r_prep) establish_5\VB\2426171|study_22|was_16|,_189|metalloproteinases_198|._280 (r_xcomp) designed_3\VBN\1631534|NONE_0 (l_conj) metalloproteinases_39\NNS\0|study_220|was_214|establish_198|,_9|._82 (l_conj) inhibitors_46\NNS\20090|matrix_54|(_28|mmps_27|)_23|and_21 (l_prep) in_50\IN\13603305|their_36|endogenous_30|(_8|timps_7|)_2 (l_pobj) formation_52\NN\7938773|NONE_0 (l_compound) taa_51\NNP\0|NONE_0
D002122_D017545 CID )_9\-RRB-\0|study_52|model_28|by_22 (r_punct) establishes_2\VBZ\2426171|NONE_0 (l_dobj) model_5\NN\5888929|study_24|by_6|)_28 (l_compound) taa_4\NNP\0|a_2
1835291
D009241_D029424 NONE bromide_5\NN\14904359|NONE_0 (r_pobj) of_3\IN\0|acute_30|bronchodilating_24|in_40|._80 (r_prep) effects_2\NNS\13245626|NONE_0 (l_prep) in_8\IN\13603305|acute_70|bronchodilating_64|of_40|._40 (l_pobj) disease_12\NN\14061805|NONE_0
D009241_D029424 NONE bromide_9\NN\14904359|ipratropium_12|(_16|micrograms_20|)_30|and_32|tablets_62 (r_compound) aerosol_10\NN\11439690|NONE_0 (r_pobj) of_7\IN\0|a_14|single_12|titrated_91 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) of_3\IN\0|the_27|bronchodilator_23 (r_prep) effects_2\NNS\13245626|were_173|in_187|._306 (r_nsubjpass) compared_37\VBN\644583|NONE_0 (l_prep) in_38\IN\13603305|effects_187|were_14|._119 (l_pobj) study_48\NN\635850|NONE_0 (l_prep) in_49\IN\13603305|a_51|blind_42|,_37|controlled_27|crossover_16 (l_pobj) patients_51\NNS\9898892|NONE_0 (l_prep) with_52\IN\0|21_12 (l_pobj) disease_58\NN\14061805|NONE_0
D009241_D029424 NONE ipratropium_4\NN\0|that_5|bronchodilator_29|in_67 (r_nsubj) is_5\VBZ\0|results_30|._99 (l_prep) in_13\IN\13603305|that_72|ipratropium_67|bronchodilator_38 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) obstruction_18\NN\4341686|NONE_0
D013806_D029424 NONE theophylline_7\NN\2905612|ipratropium_24|and_4 (r_conj) bromide_5\NN\14904359|NONE_0 (r_pobj) of_3\IN\0|acute_30|bronchodilating_24|in_40|._80 (r_prep) effects_2\NNS\13245626|NONE_0 (l_prep) in_8\IN\13603305|acute_70|bronchodilating_64|of_40|._40 (l_pobj) disease_12\NN\14061805|NONE_0
D013806_D029424 NONE theophylline_19\NN\2905612|acting_7 (r_amod) tablets_20\NNS\4233405|ipratropium_74|bromide_62|(_46|micrograms_42|)_32|and_30 (r_conj) aerosol_10\NN\11439690|NONE_0 (r_pobj) of_7\IN\0|a_14|single_12|titrated_91 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) of_3\IN\0|the_27|bronchodilator_23 (r_prep) effects_2\NNS\13245626|were_173|in_187|._306 (r_nsubjpass) compared_37\VBN\644583|NONE_0 (l_prep) in_38\IN\13603305|effects_187|were_14|._119 (l_pobj) study_48\NN\635850|NONE_0 (l_prep) in_49\IN\13603305|a_51|blind_42|,_37|controlled_27|crossover_16 (l_pobj) patients_51\NNS\9898892|NONE_0 (l_prep) with_52\IN\0|21_12 (l_pobj) disease_58\NN\14061805|NONE_0
D013806_D029424 NONE theophylline_12\NN\2905612|NONE_0 (r_pobj) than_10\IN\0|a_29|potent_22 (r_prep) bronchodilator_9\NN\3740161|that_34|ipratropium_29|in_38 (r_attr) is_5\VBZ\0|results_30|._99 (l_prep) in_13\IN\13603305|that_72|ipratropium_67|bronchodilator_38 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) obstruction_18\NN\4341686|NONE_0
D013806_D005767 CID theophylline_9\JJ\2905612|NONE_0 (r_amod) use_10\NN\407535|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) experienced_7\VBN\2108377|NONE_0 (r_acl) those_6\DT\0|were_11|,_2|did_41|systems_93|._100 (r_nsubj) involve_12\VB\2676054|NONE_0 (l_dobj) systems_17\NNS\3575240|were_104|,_95|those_93|did_52|._7
D013806_D002318 CID theophylline_9\JJ\2905612|NONE_0 (r_amod) use_10\NN\407535|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) experienced_7\VBN\2108377|NONE_0 (r_acl) those_6\DT\0|were_11|,_2|did_41|systems_93|._100 (r_nsubj) involve_12\VB\2676054|NONE_0 (l_dobj) systems_17\NNS\3575240|were_104|,_95|those_93|did_52|._7
347884
D006220_D019967 NONE haloperidol_6\NN\3713736|NONE_0 (r_pobj) with_5\IN\0|the_23|double_19|blind_12 (r_prep) study_4\NN\635850|NONE_0 (r_pobj) in_0\IN\13603305|,_42|substances_49|were_60|be_74|._184 (r_prep) found_11\VBN\13279262|NONE_0 (l_xcomp) be_13\VB\14625458|in_74|,_32|substances_25|were_14|._110 (l_acomp) effective_15\JJ\0|to_13 (l_prep) in_16\IN\13603305|highly_17 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) syndromes_21\NNS\5870365|NONE_0 (l_acl) belonging_22\VBG\7526757|psychotic_20 (l_prep) to_24\IN\0|predominantly_14 (l_pobj) group_27\NN\2137|NONE_0
2445283
D012254_D000740 CID ribavirin_7\NN\2725367|that_5|effect_27|,_58|and_60|managed_129 (r_nsubj) has_8\VBZ\13888491|from_47|,_29|we_27 (l_conj) managed_31\VBN\2524171|that_134|ribavirin_129|effect_102|,_71|and_69 (l_nsubjpass) anemia_20\NN\14189204|can_46|be_50|easily_53|._67
D012254_D006478 NONE ribavirin_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|antiviral_17 (r_prep) effect_3\NN\34213|and_14|in_20|._64 (r_conj) tolerance_0\NN\5032565|NONE_0 (l_prep) in_6\IN\13603305|and_34|effect_20|._44 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) fever_11\NN\14299637|NONE_0
D012254_D006478 NONE ribavirin_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|antiviral_17 (r_prep) effect_3\NN\34213|and_14 (r_conj) tolerance_0\NN\5032565|was_44|in_56|._141 (r_nsubjpass) studied_7\VBN\0|NONE_0 (l_prep) in_8\IN\13603305|tolerance_56|was_12|._85 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|6_11 (l_pobj) fever_14\NN\14299637|NONE_0
D012254_D006478 NONE ribavirin_5\NN\2725367|NONE_0 (r_pobj) of_4\IN\0|antiviral_17 (r_prep) effect_3\NN\34213|and_14 (r_conj) tolerance_0\NN\5032565|was_44|in_56|._141 (r_nsubjpass) studied_7\VBN\0|NONE_0 (l_prep) in_8\IN\13603305|tolerance_56|was_12|._85 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|6_11 (l_pobj) fever_14\NN\14299637|NONE_0 (l_appos) ahf_16\NNP\0|argentine_29|hemorrhagic_19|(_1|)_3|of_5
D012254_D006478 NONE ribavirin_7\NN\2725367|that_5|effect_27|,_58|and_60|managed_129 (r_nsubj) has_8\VBZ\13888491|from_47|,_29|we_27 (l_dobj) effect_11\NN\34213|that_32|ribavirin_27|,_31|and_33|managed_102 (l_prep) in_12\IN\13603305|an_20|antiviral_17 (l_pobj) cases_14\NNS\7283608|NONE_0 (l_prep) of_15\IN\0|advanced_15 (l_pobj) ahf_16\NNP\0|NONE_0
D012254_D006478 NONE ribavirin_5\RB\2725367|NONE_0 (r_pobj) of_4\IN\0|the_31|possible_27|beneficial_18|during_13 (r_prep) effect_3\NN\34213|is_51|._63 (l_prep) during_6\IN\0|the_44|possible_40|beneficial_31|of_13 (l_pobj) days_9\NNS\15140892|NONE_0 (l_prep) of_10\IN\0|the_17|initial_13 (l_pobj) ahf_11\NNP\0|NONE_0
D012254_D014766 NONE ribavirin_2\RB\2725367|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) administration_0\NN\1133281|in_37|._110 (r_nsubj) resulted_3\VBD\2633881|NONE_0 (l_prep) in_4\IN\13603305|administration_37|._73 (l_pobj) neutralization_6\NN\231567|NONE_0 (l_prep) of_7\IN\0|a_17|and_11|drop_17 (l_pobj) viremia_8\NN\14204950|NONE_0
17854040
D012964_D006509 NONE na_9\TO\14625458|mutations_59|virus_19|._173 (r_aux) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_amod) infected_17\JJ\2316868|with_18
D012964_D006509 NONE na_9\TO\14625458|mutations_59|virus_19|._173 (r_aux) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_prep) with_19\IN\0|infected_18 (l_conj) without_21\IN\0|and_4 (l_pobj) implications_27\NNS\5774614|NONE_0 (l_conj) patients_40\NNS\9898892|:_83|for_68 (l_amod) infected_37\VBN\2316868|african_15
D012964_D006509 NONE na_21\NN\14625458|carriers_11|with_20 (r_aux) ve_22\VB\0|an_116|exploratory_113|investigate_92|strains_35 (r_acl) study_4\NN\635850|this_24|._207 (l_acl) investigate_6\VB\644583|an_24|exploratory_21|strains_57|ve_92 (l_dobj) virus_12\NN\9312843|to_48 (l_compound) b_11\NN\1355326|resistant_20
D012964_D006509 NONE na_21\TO\14625458|patients_27 (r_aux) ve_22\VB\0|NONE_0 (l_dobj) patients_29\NNS\9898892|na_27 (l_amod) infected_28\VBN\2316868|NONE_0
D012964_D015658 NONE na_9\TO\14625458|mutations_59|virus_19|._173 (r_aux) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_prep) with_19\IN\0|infected_18 (l_conj) without_21\IN\0|and_4 (l_pobj) implications_27\NNS\5774614|NONE_0 (l_punct) :_26\:\0|for_15|patients_83 (l_punct) infection_25\NN\14052046|NONE_0
D012964_D015658 NONE na_9\TO\14625458|mutations_59|virus_19|._173 (r_aux) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_prep) with_19\IN\0|infected_18 (l_conj) without_21\IN\0|and_4 (l_pobj) implications_27\NNS\5774614|NONE_0 (l_conj) patients_40\NNS\9898892|:_83|for_68 (l_amod) infected_37\VBN\2316868|african_15
D012964_D015658 NONE na_21\NN\14625458|carriers_11|with_20 (r_aux) ve_22\VB\0|an_116|exploratory_113|investigate_92|strains_35 (r_acl) study_4\NN\635850|this_24|._207 (r_attr) was_1\VBD\0|NONE_0 (l_punct) ._41\.\0|this_231|study_207 (l_punct) in_37\IN\13603305|NONE_0 (l_punct) infection_36\NN\14052046|patients_27
D012964_D015658 NONE na_21\TO\14625458|patients_27 (r_aux) ve_22\VB\0|NONE_0 (l_dobj) patients_29\NNS\9898892|na_27 (l_amod) infected_28\VBN\2316868|NONE_0
D019259_D015658 NONE lamivudine_3\NN\3834836|-_10|in_22 (r_compound) resistance_5\NN\37396|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|NONE_0 (r_acl) mutations_0\NNS\4475|na_59|virus_78|._232 (r_nsubj) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_prep) with_19\IN\0|infected_18 (l_conj) without_21\IN\0|and_4 (l_pobj) implications_27\NNS\5774614|NONE_0 (l_punct) :_26\:\0|for_15|patients_83 (l_punct) infection_25\NN\14052046|NONE_0
D019259_D015658 NONE lamivudine_3\NN\3834836|-_10|in_22 (r_compound) resistance_5\NN\37396|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|NONE_0 (r_acl) mutations_0\NNS\4475|na_59|virus_78|._232 (r_nsubj) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_prep) with_19\IN\0|infected_18 (l_conj) without_21\IN\0|and_4 (l_pobj) implications_27\NNS\5774614|NONE_0 (l_conj) patients_40\NNS\9898892|:_83|for_68 (l_amod) infected_37\VBN\2316868|african_15
D019259_D015658 NONE lamivudine_7\JJ\3834836|-_10 (r_npadvmod) resistant_9\JJ\0|b_20 (r_amod) virus_12\NN\9312843|to_48 (r_dobj) investigate_6\VB\644583|an_24|exploratory_21|strains_57|ve_92 (r_acl) study_4\NN\635850|this_24|._207 (r_attr) was_1\VBD\0|NONE_0 (l_punct) ._41\.\0|this_231|study_207 (l_punct) in_37\IN\13603305|NONE_0 (l_punct) infection_36\NN\14052046|patients_27
D019259_D015658 NONE lamivudine_19\NN\3834836|selected_9|-_10 (r_compound) na_21\NN\14625458|carriers_11|with_20 (r_aux) ve_22\VB\0|an_116|exploratory_113|investigate_92|strains_35 (r_acl) study_4\NN\635850|this_24|._207 (r_attr) was_1\VBD\0|NONE_0 (l_punct) ._41\.\0|this_231|study_207 (l_punct) in_37\IN\13603305|NONE_0 (l_punct) infection_36\NN\14052046|patients_27
D019259_D015658 NONE lamivudine_1\NN\3834836|-_10 (r_npadvmod) resistant_3\JJ\0|hbv_15 (r_amod) strains_4\NNS\7358060|were_8|in_22|and_76|patients_109|._117 (r_nsubjpass) detected_6\VBN\2163746|NONE_0 (l_conj) patients_28\NNS\9898892|strains_109|were_101|in_87|and_33|._8 (l_amod) infected_27\VBN\2316868|20_14
D019259_D015658 NONE lamivudine_14\NN\3834836|-_10 (r_npadvmod) resistant_16\JJ\0|hbv_15|in_18 (r_amod) strains_17\NNS\7358060|NONE_0 (l_prep) in_18\IN\13603305|hbv_33|resistant_18 (l_pcomp) ve_22\VB\0|NONE_0 (l_dobj) patients_29\NNS\9898892|na_27 (l_amod) infected_28\VBN\2316868|NONE_0
D019259_D015658 NONE lamivudine_22\NN\3834836|when_5|-_10|treatment_57 (r_npadvmod) containing_24\VBG\2632940|widespread_62|of_41 (r_advcl) emergence_16\NN\7290905|NONE_0 (r_pobj) in_14\IN\13603305|whether_59|mutations_23|could_13|applied_152 (r_prep) result_13\VB\34213|to_63|be_60 (l_conj) applied_38\VBN\0|whether_211|mutations_175|could_165|in_152 (l_advcl) is_45\VBZ\0|regimens_56|become_47|widely_40|in_25|,_10 (l_acomp) likely_46\JJ\0|as_11|this_8 (l_xcomp) have_48\VB\7846|NONE_0 (l_dobj) implications_50\NNS\5774614|to_18 (l_prep) in_51\IN\13603305|potential_23 (l_pobj) management_53\NN\1123598|NONE_0 (l_prep) of_54\IN\0|the_15 (l_pobj) patients_61\NNS\9898892|NONE_0 (l_amod) infected_60\VBN\2316868|NONE_0
D019259_D006509 NONE lamivudine_3\NN\3834836|-_10|in_22 (r_compound) resistance_5\NN\37396|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|NONE_0 (r_acl) mutations_0\NNS\4475|na_59|virus_78|._232 (r_nsubj) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_amod) infected_17\JJ\2316868|with_18
D019259_D006509 NONE lamivudine_3\NN\3834836|-_10|in_22 (r_compound) resistance_5\NN\37396|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|NONE_0 (r_acl) mutations_0\NNS\4475|na_59|virus_78|._232 (r_nsubj) ve_10\VB\0|NONE_0 (l_dobj) virus_13\NN\9312843|mutations_78|na_19|._154 (l_appos) patients_18\NNS\9898892|b_23|(_15|hbv_14|)_11 (l_prep) with_19\IN\0|infected_18 (l_conj) without_21\IN\0|and_4 (l_pobj) implications_27\NNS\5774614|NONE_0 (l_conj) patients_40\NNS\9898892|:_83|for_68 (l_amod) infected_37\VBN\2316868|african_15
D019259_D006509 NONE lamivudine_7\JJ\3834836|-_10 (r_npadvmod) resistant_9\JJ\0|b_20 (r_amod) virus_12\NN\9312843|to_48 (l_compound) b_11\NN\1355326|resistant_20
D019259_D006509 NONE lamivudine_19\NN\3834836|selected_9|-_10 (r_compound) na_21\NN\14625458|carriers_11|with_20 (r_aux) ve_22\VB\0|an_116|exploratory_113|investigate_92|strains_35 (r_acl) study_4\NN\635850|this_24|._207 (l_acl) investigate_6\VB\644583|an_24|exploratory_21|strains_57|ve_92 (l_dobj) virus_12\NN\9312843|to_48 (l_compound) b_11\NN\1355326|resistant_20
D019259_D006509 NONE lamivudine_1\NN\3834836|-_10 (r_npadvmod) resistant_3\JJ\0|hbv_15 (r_amod) strains_4\NNS\7358060|were_8|in_22|and_76|patients_109|._117 (r_nsubjpass) detected_6\VBN\2163746|NONE_0 (l_prep) in_7\IN\13603305|strains_22|were_14|and_54|patients_87|._95 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_compound) b_16\NNP\1355326|15_35|infected_27|chronic_18
D019259_D006509 NONE lamivudine_1\NN\3834836|-_10 (r_npadvmod) resistant_3\JJ\0|hbv_15 (r_amod) strains_4\NNS\7358060|were_8|in_22|and_76|patients_109|._117 (r_nsubjpass) detected_6\VBN\2163746|NONE_0 (l_conj) patients_28\NNS\9898892|strains_109|were_101|in_87|and_33|._8 (l_amod) infected_27\VBN\2316868|20_14
D019259_D006509 NONE lamivudine_14\NN\3834836|-_10 (r_npadvmod) resistant_16\JJ\0|hbv_15|in_18 (r_amod) strains_17\NNS\7358060|NONE_0 (l_prep) in_18\IN\13603305|hbv_33|resistant_18 (l_pcomp) ve_22\VB\0|NONE_0 (l_dobj) patients_29\NNS\9898892|na_27 (l_amod) infected_28\VBN\2316868|NONE_0
D019259_D006509 NONE lamivudine_22\NN\3834836|when_5|-_10|treatment_57 (r_npadvmod) containing_24\VBG\2632940|widespread_62|of_41 (r_advcl) emergence_16\NN\7290905|NONE_0 (r_pobj) in_14\IN\13603305|whether_59|mutations_23|could_13|applied_152 (r_prep) result_13\VB\34213|to_63|be_60 (l_conj) applied_38\VBN\0|whether_211|mutations_175|could_165|in_152 (l_advcl) is_45\VBZ\0|regimens_56|become_47|widely_40|in_25|,_10 (l_acomp) likely_46\JJ\0|as_11|this_8 (l_xcomp) have_48\VB\7846|NONE_0 (l_dobj) implications_50\NNS\5774614|to_18 (l_prep) in_51\IN\13603305|potential_23 (l_pobj) management_53\NN\1123598|NONE_0 (l_prep) of_54\IN\0|the_15 (l_pobj) patients_61\NNS\9898892|NONE_0 (l_amod) infected_60\VBN\2316868|NONE_0
7468724
D013726_D007752 NONE terbutaline_4\JJ\0|for_22 (r_compound) treatment_5\NN\654885|NONE_0 (l_prep) for_6\IN\0|terbutaline_22 (l_pobj) labor_8\NN\7974025|NONE_0
D013726_D007752 NONE terbutaline_11\NN\0|NONE_0 (l_prep) for_12\IN\0|NONE_0 (l_pobj) labor_14\NN\7974025|NONE_0
D013726_D002318 CID terbutaline_4\JJ\0|for_22 (r_compound) treatment_5\NN\654885|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|cardiovascular_29|._55 (r_acl) complications_1\NNS\1073995|NONE_0
D013726_D002318 CID terbutaline_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treated_9\VBN\2376958|160_13 (r_acl) patients_8\NNS\9898892|NONE_0 (r_pobj) in_4\IN\13603305|complications_23|._67 (r_prep) occurred_3\VBD\0|NONE_0 (l_nsubj) complications_2\NNS\1073995|in_23|._90
7269015
D003520_D003556 NONE cyclophosphamide_13\NN\0|-_16 (r_npadvmod) induced_15\VBN\1627355|both_36|and_21 (r_conj) radiation_11\NN\11452218|NONE_0 (r_nmod) cystitis_16\NN\14566129|busulfan_66|and_48 (r_conj) cystitis_8\NN\14566129|NONE_0
D003520_D003556 NONE cyclophosphamide_13\NN\0|-_16 (r_npadvmod) induced_15\VBN\1627355|both_36|and_21 (r_conj) radiation_11\NN\11452218|NONE_0 (r_nmod) cystitis_16\NN\14566129|busulfan_66|and_48
D002066_D006470 CID busulfan_0\NNS\0|-_8 (r_npadvmod) induced_2\VBN\1627355|hemorrhagic_8|._28 (r_amod) cystitis_4\NN\14566129|NONE_0
D002066_D006470 CID busulfan_4\NNS\0|-_8 (r_npadvmod) induced_6\VBN\1627355|a_11|hemorrhage_8 (r_amod) cystitis_8\NN\14566129|NONE_0
D002066_D002277 NONE busulfan_7\NNS\0|NONE_0 (r_pobj) of_6\IN\0|the_19|known_15 (r_prep) tendency_5\NN\6193203|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) view_1\NN\6208021|induce_42 (r_pobj) in_0\IN\13603305|,_96|cytology_115|is_124|in_137|._169 (l_advcl) induce_9\VB\1627355|view_42 (l_dobj) atypia_11\NN\0|to_19 (l_conj) carcinoma_13\NN\14239918|cellular_20|and_4|in_10
D002066_D003556 CID busulfan_0\NNS\0|-_8 (r_npadvmod) induced_2\VBN\1627355|hemorrhagic_8|._28 (r_amod) cystitis_4\NN\14566129|NONE_0
D002066_D003556 CID busulfan_4\NNS\0|-_8 (r_npadvmod) induced_6\VBN\1627355|a_11|hemorrhage_8 (r_amod) cystitis_8\NN\14566129|NONE_0
D002066_D003556 CID busulfan_7\NNS\0|and_18|cystitis_66 (r_amod) cystitis_8\NN\14566129|NONE_0
D002066_D003556 CID busulfan_7\NNS\0|and_18|cystitis_66 (r_amod) cystitis_8\NN\14566129|NONE_0 (l_conj) cystitis_16\NN\14566129|busulfan_66|and_48
15899738
D003401_D001281 CID creatine_5\NN\14601829|monohydrate_9 (r_compound) supplementation_7\NN\5108947|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|lone_25|atrial_20|._52 (r_acl) fibrillation_2\NN\14361664|NONE_0
D003401_D001145 NONE creatine_5\NN\14601829|reports_20|have_12|._41 (l_prep) to_6\IN\0|NONE_0 (l_pobj) development_8\NN\248977|NONE_0 (l_prep) of_9\IN\0|the_16 (l_pobj) arrhythmia_10\NN\14103288|NONE_0
12615818
D017373_D011085 NONE acetate_1\NN\15010703|estradiol_30|is_49|in_61|for_71|and_122|is_126|._189 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0
D017373_D011085 NONE acetate_1\NN\15010703|estradiol_30|is_49|in_61|for_71|and_122|is_126|._189 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0 (l_appos) pcos_36\NNP\0|polycystic_27|ovary_16|(_1|)_4
D017373_D011085 NONE cpa_7\NNP\9761403|/_3 (r_nmod) ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0
D017373_D011085 NONE cpa_7\NNP\9761403|/_3 (r_nmod) ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0 (l_appos) pcos_36\NNP\0|polycystic_27|ovary_16|(_1|)_4
D017373_D011085 NONE cpa_42\NNP\9761403|/_3 (r_nmod) ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0 (r_pobj) of_38\IN\0|the_9 (r_prep) risk_37\NN\14541044|to_16 (r_dobj) estimate_35\VB\5802185|using_196|we_151|analysis_129|years_38|._47 (r_advcl) conducted_7\VBD\2436349|NONE_0 (l_npadvmod) years_27\NNS\15144371|using_158|we_113|analysis_91|estimate_38|._85 (l_prep) with_28\IN\0|15_16 (l_pobj) acne_29\NN\14171682|NONE_0 (l_conj) hirsutism_31\NN\4683453|,_2 (l_conj) pcos_33\NNP\0|or_3
D017373_D011085 NONE cpa_13\NNP\9761403|/_3 (r_nmod) ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|the_18|of_10 (l_pobj) women_17\NNS\9605289|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) acne_19\NN\14171682|NONE_0 (l_conj) hirsutism_21\NN\4683453|,_2 (l_conj) pcos_23\NNP\0|or_3
D003276_D054556 NONE contraceptives_23\NNS\3183080|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) compared_18\VBN\644583|studies_99|have_91|risk_60|._62 (r_prep) demonstrated_3\VBN\2137132|NONE_0 (l_dobj) risk_6\NN\14541044|studies_39|have_31|compared_60|._122 (l_prep) of_7\IN\0|an_18|increased_15 (l_pobj) thromboembolism_9\NN\14100769|NONE_0
D003276_D054556 NONE contraceptives_23\NNS\3183080|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) compared_18\VBN\644583|studies_99|have_91|risk_60|._62 (r_prep) demonstrated_3\VBN\2137132|NONE_0 (l_dobj) risk_6\NN\14541044|studies_39|have_31|compared_60|._122 (l_prep) of_7\IN\0|an_18|increased_15 (l_pobj) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3|associated_5
D004997_D006628 NONE estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0 (l_conj) hirsutism_24\NN\4683453|and_4
D004997_D006628 NONE ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0 (l_conj) hirsutism_24\NN\4683453|and_4
D004997_D006628 NONE ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0 (r_pobj) of_38\IN\0|the_9 (r_prep) risk_37\NN\14541044|to_16 (r_dobj) estimate_35\VB\5802185|using_196|we_151|analysis_129|years_38|._47 (r_advcl) conducted_7\VBD\2436349|NONE_0 (l_npadvmod) years_27\NNS\15144371|using_158|we_113|analysis_91|estimate_38|._85 (l_prep) with_28\IN\0|15_16 (l_pobj) acne_29\NN\14171682|NONE_0 (l_conj) hirsutism_31\NN\4683453|,_2
D004997_D006628 NONE ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|the_18|of_10 (l_pobj) women_17\NNS\9605289|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) acne_19\NN\14171682|NONE_0 (l_conj) hirsutism_21\NN\4683453|,_2
D017373_D000152 NONE acetate_1\NN\15010703|estradiol_30|is_49|in_61|for_71|and_122|is_126|._189 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0
D017373_D000152 NONE cpa_7\NNP\9761403|/_3 (r_nmod) ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0
D017373_D000152 NONE cpa_42\NNP\9761403|/_3 (r_nmod) ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0 (r_pobj) of_38\IN\0|the_9 (r_prep) risk_37\NN\14541044|to_16 (r_dobj) estimate_35\VB\5802185|using_196|we_151|analysis_129|years_38|._47 (r_advcl) conducted_7\VBD\2436349|NONE_0 (l_npadvmod) years_27\NNS\15144371|using_158|we_113|analysis_91|estimate_38|._85 (l_prep) with_28\IN\0|15_16 (l_pobj) acne_29\NN\14171682|NONE_0
D017373_D000152 NONE cpa_13\NNP\9761403|/_3 (r_nmod) ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|the_18|of_10 (l_pobj) women_17\NNS\9605289|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) acne_19\NN\14171682|NONE_0
D017373_D006628 NONE acetate_1\NN\15010703|estradiol_30|is_49|in_61|for_71|and_122|is_126|._189 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0 (l_conj) hirsutism_24\NN\4683453|and_4
D017373_D006628 NONE cpa_7\NNP\9761403|/_3 (r_nmod) ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0 (l_conj) hirsutism_24\NN\4683453|and_4
D017373_D006628 NONE cpa_42\NNP\9761403|/_3 (r_nmod) ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0 (r_pobj) of_38\IN\0|the_9 (r_prep) risk_37\NN\14541044|to_16 (r_dobj) estimate_35\VB\5802185|using_196|we_151|analysis_129|years_38|._47 (r_advcl) conducted_7\VBD\2436349|NONE_0 (l_npadvmod) years_27\NNS\15144371|using_158|we_113|analysis_91|estimate_38|._85 (l_prep) with_28\IN\0|15_16 (l_pobj) acne_29\NN\14171682|NONE_0 (l_conj) hirsutism_31\NN\4683453|,_2
D017373_D006628 NONE cpa_13\NNP\9761403|/_3 (r_nmod) ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|the_18|of_10 (l_pobj) women_17\NNS\9605289|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) acne_19\NN\14171682|NONE_0 (l_conj) hirsutism_21\NN\4683453|,_2
D004997_D054556 CID estradiol_14\NN\14749794|the_103|of_94|._58 (r_appos) risk_1\NN\14541044|NONE_0 (l_prep) of_2\IN\0|the_9|estradiol_94|._152 (l_pobj) thromboembolism_4\NN\14100769|NONE_0
D004997_D054556 CID ee_17\NNP\6125041|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0
D004997_D054556 CID ee_17\NNP\6125041|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3|associated_5
D004997_D054556 CID ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0
D004997_D054556 CID ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) with_9\IN\0|confounding_79 (r_prep) associated_8\VBN\628491|an_25|increased_22|of_7 (r_acl) risk_5\NN\14541044|we_34|have_31|excluded_138|._146 (l_prep) of_6\IN\0|an_18|increased_15|associated_7 (l_pobj) vte_7\NNP\0|NONE_0
D004997_D011085 NONE estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0
D004997_D011085 NONE estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0 (l_appos) pcos_36\NNP\0|polycystic_27|ovary_16|(_1|)_4
D004997_D011085 NONE ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0
D004997_D011085 NONE ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_conj) is_26\VBZ\0|acetate_126|estradiol_96|is_77|in_65|for_55|and_4|._63 (l_attr) option_30\NN\6480506|also_17 (l_prep) for_31\IN\0|a_19|treatment_17 (l_pobj) syndrome_34\NN\5870365|NONE_0 (l_appos) pcos_36\NNP\0|polycystic_27|ovary_16|(_1|)_4
D004997_D011085 NONE ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0 (r_pobj) of_38\IN\0|the_9 (r_prep) risk_37\NN\14541044|to_16 (r_dobj) estimate_35\VB\5802185|using_196|we_151|analysis_129|years_38|._47 (r_advcl) conducted_7\VBD\2436349|NONE_0 (l_npadvmod) years_27\NNS\15144371|using_158|we_113|analysis_91|estimate_38|._85 (l_prep) with_28\IN\0|15_16 (l_pobj) acne_29\NN\14171682|NONE_0 (l_conj) hirsutism_31\NN\4683453|,_2 (l_conj) pcos_33\NNP\0|or_3
D004997_D011085 NONE ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|the_18|of_10 (l_pobj) women_17\NNS\9605289|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) acne_19\NN\14171682|NONE_0 (l_conj) hirsutism_21\NN\4683453|,_2 (l_conj) pcos_23\NNP\0|or_3
D017373_D054556 CID acetate_9\NN\15010703|cyproterone_12 (r_oprd) prescribed_7\VBD\748282|NONE_0 (r_acl) women_6\NNS\9605289|NONE_0 (r_pobj) in_5\IN\13603305|venous_23 (r_prep) thromboembolism_4\NN\14100769|NONE_0
D017373_D054556 CID cpa_15\NNP\9761403|/_3 (r_nmod) ee_17\NNP\6125041|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0
D017373_D054556 CID cpa_15\NNP\9761403|/_3 (r_nmod) ee_17\NNP\6125041|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|venous_29|(_6|vte_5|)_2 (r_acl) thromboembolism_9\NN\14100769|NONE_0 (l_appos) vte_11\NNP\0|venous_24|(_1|)_3|associated_5
D017373_D054556 CID cpa_42\NNP\9761403|/_3 (r_nmod) ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0
D017373_D054556 CID cpa_13\NNP\9761403|/_3 (r_nmod) ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) with_9\IN\0|confounding_79 (r_prep) associated_8\VBN\628491|an_25|increased_22|of_7 (r_acl) risk_5\NN\14541044|we_34|have_31|excluded_138|._146 (l_prep) of_6\IN\0|an_18|increased_15|associated_7 (l_pobj) vte_7\NNP\0|NONE_0
D004997_D000152 NONE estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0
D004997_D000152 NONE ee_9\NNP\6125041|(_5|)_2 (r_appos) estradiol_5\NN\14749794|acetate_30|is_19|in_31|for_41|and_92|is_96|._159 (r_nsubjpass) licensed_12\VBN\803325|NONE_0 (l_prep) for_16\IN\0|acetate_71|estradiol_41|is_22|in_10|and_51|is_55|._118 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) of_19\IN\0|the_14 (l_pobj) women_20\NNS\9605289|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) acne_22\NN\14171682|NONE_0
D004997_D000152 NONE ee_44\NNP\6125041|NONE_0 (r_pobj) with_41\IN\0|NONE_0 (r_prep) associated_40\VBN\628491|NONE_0 (r_acl) vte_39\NNP\0|NONE_0 (r_pobj) of_38\IN\0|the_9 (r_prep) risk_37\NN\14541044|to_16 (r_dobj) estimate_35\VB\5802185|using_196|we_151|analysis_129|years_38|._47 (r_advcl) conducted_7\VBD\2436349|NONE_0 (l_npadvmod) years_27\NNS\15144371|using_158|we_113|analysis_91|estimate_38|._85 (l_prep) with_28\IN\0|15_16 (l_pobj) acne_29\NN\14171682|NONE_0
D004997_D000152 NONE ee_15\NNP\6125041|NONE_0 (r_pobj) of_12\IN\0|the_8|in_10 (r_prep) use_11\NN\407535|NONE_0 (l_prep) in_16\IN\13603305|the_18|of_10 (l_pobj) women_17\NNS\9605289|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) acne_19\NN\14171682|NONE_0
12483326
D002945_D009916 NONE cisplatin_11\NN\0|NONE_0 (r_pcomp) than_10\IN\0|milder_20|side_13|,_14 (r_prep) effects_9\NNS\13245626|to_20 (r_dobj) have_6\VB\7846|generally_34|,_25|carboplatin_23|is_11|known_84|._89 (r_xcomp) said_4\VBN\940384|NONE_0 (l_ccomp) known_20\JJ\0|generally_118|,_109|carboplatin_107|is_95|have_84|._5 (l_auxpass) are_18\VBP\13600404|well_4 (l_nsubj) toxicity_17\NN\13576101|NONE_0
D002945_D005128 NONE cisplatin_11\NN\0|NONE_0 (r_pcomp) than_10\IN\0|milder_20|side_13|,_14 (r_prep) effects_9\NNS\13245626|to_20 (r_dobj) have_6\VB\7846|generally_34|,_25|carboplatin_23|is_11|known_84|._89 (r_xcomp) said_4\VBN\940384|NONE_0 (l_ccomp) known_20\JJ\0|generally_118|,_109|carboplatin_107|is_95|have_84|._5 (l_auxpass) are_18\VBP\13600404|well_4 (l_nsubj) toxicity_17\NN\13576101|NONE_0
D016190_D005909 NONE carboplatin_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|intracarotid_23|for_15 (r_prep) injection_7\NN\320852|NONE_0 (l_prep) for_10\IN\0|intracarotid_38|of_15 (l_pobj) glioblastomas_12\NNS\14236743|NONE_0
D016190_D005909 NONE carboplatin_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|an_26|intracarotid_23|for_15|in_43 (r_prep) injection_8\NN\320852|man_29|._78 (l_prep) for_11\IN\0|an_41|intracarotid_38|of_15|in_28 (l_pobj) glioblastomas_13\NNS\14236743|NONE_0
D016190_D005128 NONE carboplatin_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|intracarotid_23|for_15 (r_prep) injection_7\NN\320852|NONE_0 (r_pobj) after_5\IN\0|severe_35|ocular_28|._71 (r_prep) toxicity_4\NN\13576101|NONE_0
D016190_D005128 NONE carboplatin_2\NN\0|generally_11|,_2|is_12|have_23|known_107|._112 (r_nsubjpass) said_4\VBN\940384|NONE_0 (l_ccomp) known_20\JJ\0|generally_118|,_109|carboplatin_107|is_95|have_84|._5 (l_auxpass) are_18\VBP\13600404|well_4 (l_nsubj) toxicity_17\NN\13576101|NONE_0
D016190_D005128 NONE carboplatin_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|intracarotid_23|,_14|reported_38 (r_prep) injection_14\NN\320852|NONE_0 (r_pobj) after_12\IN\0|however_69|,_62|we_60|case_43|._75 (r_prep) experienced_3\VBD\2108377|NONE_0 (l_dobj) case_5\NN\7283608|however_26|,_19|we_17|after_43|._118 (l_prep) of_6\IN\0|a_7 (l_pobj) toxicity_11\NN\13576101|NONE_0
D016190_D005128 NONE carboplatin_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|intracarotid_23 (r_prep) injection_3\NN\320852|when_29 (r_dobj) performing_1\VBG\407535|,_48|we_50|must_53|aware_61|._110 (r_advcl) be_9\VB\14625458|NONE_0 (l_acomp) aware_10\JJ\0|performing_61|,_13|we_11|must_8|._49 (l_prep) of_11\IN\0|NONE_0 (l_pobj) toxicity_16\NN\13576101|NONE_0
D016190_D009916 NONE carboplatin_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|intracarotid_23|for_15 (r_prep) injection_7\NN\320852|NONE_0 (r_pobj) after_5\IN\0|severe_35|ocular_28|._71 (r_prep) toxicity_4\NN\13576101|NONE_0
D016190_D009916 NONE carboplatin_2\NN\0|generally_11|,_2|is_12|have_23|known_107|._112 (r_nsubjpass) said_4\VBN\940384|NONE_0 (l_ccomp) known_20\JJ\0|generally_118|,_109|carboplatin_107|is_95|have_84|._5 (l_auxpass) are_18\VBP\13600404|well_4 (l_nsubj) toxicity_17\NN\13576101|NONE_0
D016190_D009916 NONE carboplatin_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|intracarotid_23|,_14|reported_38 (r_prep) injection_14\NN\320852|NONE_0 (r_pobj) after_12\IN\0|however_69|,_62|we_60|case_43|._75 (r_prep) experienced_3\VBD\2108377|NONE_0 (l_dobj) case_5\NN\7283608|however_26|,_19|we_17|after_43|._118 (l_prep) of_6\IN\0|a_7 (l_pobj) toxicity_11\NN\13576101|NONE_0
D016190_D064420 NONE carboplatin_7\NN\0|NONE_0 (r_amod) toxicity_8\NN\13576101|NONE_0
7292072
D003891_D017180 CID desipramine_4\JJ\4482543|NONE_0 (r_amod) toxicity_5\NN\13576101|NONE_0 (r_pobj) in_3\IN\13603305|variant_32|ventricular_24|._23 (r_prep) tachycardia_2\NN\14110674|NONE_0
D003891_D017180 CID desipramine_10\NN\4482543|NONE_0 (r_amod) toxicity_11\NN\13576101|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) induced_8\VBN\1627355|variant_32|ventricular_24 (r_acl) tachycardia_7\NN\14110674|NONE_0
D003891_D064420 NONE desipramine_4\JJ\4482543|NONE_0 (r_amod) toxicity_5\NN\13576101|NONE_0
D003891_D064420 NONE desipramine_10\NN\4482543|NONE_0 (r_amod) toxicity_11\NN\13576101|NONE_0
9401499
D013988_D000741 CID ticlopidine_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|aplastic_8|:_23|report_25|._86 (r_amod) anemia_4\NN\14189204|NONE_0
D013988_D000741 CID ticlopidine_8\NN\0|-_11 (r_npadvmod) induced_10\VBN\1627355|aplastic_8 (r_amod) anemia_12\NN\14189204|NONE_0
D013988_D000741 CID ticlopidine_2\NN\0|-_11 (r_npadvmod) induced_4\VBN\1627355|aplastic_8|with_24 (r_amod) anemia_6\NN\14189204|NONE_0
D013988_D000380 CID ticlopidine_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) initiation_7\NN\7450842|weeks_12 (r_pobj) after_6\IN\0|agranulocytosis_36|,_31 (r_prep) occurred_1\VBD\0|examination_65|is_114|._128 (l_nsubj) agranulocytosis_0\NN\14189204|after_36|,_67
9195768
D018170_D010292 CID sumatriptan_7\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_8 (r_prep) use_4\NN\407535|NONE_0 (r_dobj) following_2\VBG\8180190|atypical_20 (r_prep) sensations_1\NNS\5708432|common_61|,_67|but_69|of_73|._92
17147461
D000804_D011507 NONE ii_52\CD\13741022|angiotensin_12|receptor_3 (r_compound) blockers_54\NNS\10101634|converting_56|enzyme_45|or_27 (r_conj) inhibitors_49\NNS\20090|NONE_0 (r_pobj) of_44\IN\0|NONE_0 (r_prep) use_43\NN\407535|close_52|of_35|,_2|occurs_99 (r_conj) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_prep) of_37\IN\0|close_17|,_33|use_35|occurs_134 (l_pobj) proteinuria_38\NN\14299637|NONE_0
D000804_D011507 NONE ii_52\CD\13741022|angiotensin_12|receptor_3 (r_compound) blockers_54\NNS\10101634|converting_56|enzyme_45|or_27 (r_conj) inhibitors_49\NNS\20090|NONE_0 (r_pobj) of_44\IN\0|NONE_0 (r_prep) use_43\NN\407535|close_52|of_35|,_2|occurs_99 (r_conj) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_advcl) occurs_57\VBZ\0|close_151|of_134|,_101|use_99 (l_nsubj) proteinuria_56\NN\14299637|if_3|and_19|withdrawal_23|needed_37
D000809_D011507 NONE angiotensin_45\NN\4522421|-_11 (r_npadvmod) converting_47\VBG\126264|enzyme_11|or_29|blockers_56 (r_amod) inhibitors_49\NNS\20090|NONE_0 (r_pobj) of_44\IN\0|NONE_0 (r_prep) use_43\NN\407535|close_52|of_35|,_2|occurs_99 (r_conj) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_prep) of_37\IN\0|close_17|,_33|use_35|occurs_134 (l_pobj) proteinuria_38\NN\14299637|NONE_0
D000809_D011507 NONE angiotensin_45\NN\4522421|-_11 (r_npadvmod) converting_47\VBG\126264|enzyme_11|or_29|blockers_56 (r_amod) inhibitors_49\NNS\20090|NONE_0 (r_pobj) of_44\IN\0|NONE_0 (r_prep) use_43\NN\407535|close_52|of_35|,_2|occurs_99 (r_conj) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_advcl) occurs_57\VBZ\0|close_151|of_134|,_101|use_99 (l_nsubj) proteinuria_56\NN\14299637|if_3|and_19|withdrawal_23|needed_37
D020123_D011507 CID sirolimus_0\NNP\0|-_9 (r_npadvmod) associated_2\VBN\628491|and_23|dysfunction_33|._44 (r_amod) proteinuria_3\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_11\NN\0|that_32|,_28|under_26|,_2|is_10|with_24 (r_nsubjpass) associated_13\VBN\628491|however_79|,_72|reports_61|._55 (l_prep) with_14\IN\0|that_56|,_52|under_50|,_26|sirolimus_24|is_14 (l_pobj) proteinuria_15\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_3\NN\0|-_9 (r_npadvmod) associated_5\VBN\628491|NONE_0 (r_amod) proteinuria_6\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_22|molecular_18|on_13 (r_prep) effects_19\NNS\13245626|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) knowledge_15\NN\23100|NONE_0 (r_pobj) by_14\IN\0|occur_60|,_38|occurrence_30|could_19|be_13|,_64|use_70|._305 (r_agent) minimised_13\VBN\831651|NONE_0 (l_dep) use_27\NN\407535|occur_130|,_108|occurrence_100|could_89|be_83|by_70|,_6|._235 (l_appos) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_prep) of_37\IN\0|close_17|,_33|use_35|occurs_134 (l_pobj) proteinuria_38\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_22|molecular_18|on_13 (r_prep) effects_19\NNS\13245626|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) knowledge_15\NN\23100|NONE_0 (r_pobj) by_14\IN\0|occur_60|,_38|occurrence_30|could_19|be_13|,_64|use_70|._305 (r_agent) minimised_13\VBN\831651|NONE_0 (l_dep) use_27\NN\407535|occur_130|,_108|occurrence_100|could_89|be_83|by_70|,_6|._235 (l_appos) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_advcl) occurs_57\VBZ\0|close_151|of_134|,_101|use_99 (l_nsubj) proteinuria_56\NN\14299637|if_3|and_19|withdrawal_23|needed_37
D020123_D011507 CID sirolimus_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|the_8|in_13|,_47|monitoring_55 (r_prep) use_27\NN\407535|occur_130|,_108|occurrence_100|could_89|be_83|by_70|,_6|._235 (l_appos) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_prep) of_37\IN\0|close_17|,_33|use_35|occurs_134 (l_pobj) proteinuria_38\NN\14299637|NONE_0
D020123_D011507 CID sirolimus_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|the_8|in_13|,_47|monitoring_55 (r_prep) use_27\NN\407535|occur_130|,_108|occurrence_100|could_89|be_83|by_70|,_6|._235 (l_appos) monitoring_36\NN\879759|the_63|of_55|in_42|,_8 (l_advcl) occurs_57\VBZ\0|close_151|of_134|,_101|use_99 (l_nsubj) proteinuria_56\NN\14299637|if_3|and_19|withdrawal_23|needed_37
D020123_D058186 NONE sirolimus_11\NN\0|that_32|,_28|under_26|,_2|is_10|with_24 (r_nsubjpass) associated_13\VBN\628491|however_79|,_72|reports_61|._55 (l_prep) with_14\IN\0|that_56|,_52|under_50|,_26|sirolimus_24|is_14 (l_pobj) proteinuria_15\NN\14299637|NONE_0 (l_conj) dysfunction_19\NN\14204950|and_16
D020123_D058186 NONE sirolimus_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|the_28|acute_24|renal_18|(_26|as_32|)_60 (r_acl) dysfunction_3\NN\14204950|may_74|due_81|._170
D020123_D007674 CID sirolimus_0\NNP\0|-_9 (r_npadvmod) associated_2\VBN\628491|and_23|dysfunction_33|._44 (r_amod) proteinuria_3\NN\14299637|NONE_0 (l_conj) dysfunction_6\NN\14204950|associated_33|and_10|._11
D020123_D007674 CID sirolimus_0\NNP\0|advance_41|._135 (r_nsubj) represents_1\VBZ\2664769|NONE_0 (l_dobj) advance_5\NN\7311115|sirolimus_41|._94 (l_prep) in_6\IN\13603305|a_28|major_26|therapeutic_20 (l_pobj) prevention_8\NN\1073995|NONE_0 (l_prep) of_9\IN\0|the_15 (l_pobj) rejection_13\NN\30358|NONE_0 (l_conj) nephropathy_17\NN\14573196|acute_54|allograft_42|and_22
D020123_D007674 CID sirolimus_1\NN\0|because_8|does_10|not_15|vasomotor_29|effects_53 (r_nsubj) share_4\VB\13329641|,_77|it_79|has_82|been_86|drug_121|._126 (r_advcl) designated_18\VBN\0|NONE_0 (l_oprd) drug_24\NN\14778436|share_121|,_44|it_42|has_39|been_35|._5 (l_amod) nephrotoxic_23\JJ\0|a_7|'_5|'_16
12464714
D004878_D006970 NONE ergotamine_19\NNP\14712692|/_10 (r_nmod) caffeine_21\NN\14712692|and_15 (r_conj) rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (l_appos) nausea_34\NN\14299637|the_154|common_145|adverse_138|(_123|>_112|,_47 (l_conj) somnolence_42\NN\14015731|(_19|4.2_18|)_6|and_4
D004878_D004244 NONE ergotamine_19\NNP\14712692|/_10 (r_nmod) caffeine_21\NN\14712692|and_15 (r_conj) rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (r_nsubj) were_25\VBD\0|NONE_0 (l_attr) dizziness_26\NN\14299637|events_104|respectively_19|,_7|,_24|._77
D002110_D008881 NONE caffeine_13\NN\14712692|crossover_88|of_67|._20 (l_prep) in_14\IN\13603305|mg_30|ergotamine_20|/_10 (l_pobj) migraine_15\NN\14326607|NONE_0
D002110_D008881 NONE caffeine_22\NN\14712692|2_18 (r_appos) ergotamine_18\NN\14712692|NONE_0 (r_pobj) to_16\IN\0|mg_10 (r_prep) tablet_15\NN\4233405|1_20 (r_amod) rizatriptan_12\JJ\0|NONE_0 (r_pobj) for_10\IN\0|the_15 (r_prep) preference_9\NN\7497473|study_19|tablets_79|in_87|._154 (r_dobj) assessed_7\VBD\670261|NONE_0 (l_prep) in_26\IN\13603305|study_106|preference_87|tablets_8|._67 (l_pobj) patients_28\NNS\9898892|NONE_0 (l_acl) treating_29\VBG\2376958|439_13 (l_dobj) attack_33\NN\955060|NONE_0 (l_compound) migraine_32\JJ\14326607|a_9|single_7|with_16
C093622_D010146 NONE rizatriptan_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|2_4 (r_prep) h_10\NN\14622893|percent_37|free_7|,_19|compared_21|,_90|being_104|._142 (r_npadvmod) were_6\VBD\0|NONE_0 (l_acomp) free_8\JJ\7942152|percent_30|h_7|,_26|compared_28|,_97|being_111|._149 (l_npadvmod) pain_7\NN\14299637|NONE_0
C093622_D010146 NONE rizatriptan_31\JJ\0|superior_18|within_27 (r_nsubj) being_32\VBG\24720|percent_141|free_111|h_104|,_85|compared_83|,_14|._38 (r_advcl) were_6\VBD\0|NONE_0 (l_acomp) free_8\JJ\7942152|percent_30|h_7|,_26|compared_28|,_97|being_111|._149 (l_npadvmod) pain_7\NN\14299637|NONE_0
C093622_D010146 NONE rizatriptan_6\NN\0|NONE_0 (r_dobj) taking_5\VBG\37396|NONE_0 (r_acl) patients_4\NNS\9898892|NONE_0 (r_pobj) of_3\IN\0|36_4 (r_prep) %_2\NN\0|free_43|at_48|and_55|had_59|,_122|compared_124|._191 (r_nsubj) were_7\VBD\0|NONE_0 (l_acomp) free_9\JJ\7942152|%_43|at_5|and_12|had_16|,_79|compared_81|._148 (l_npadvmod) pain_8\NN\14299637|NONE_0
C093622_D004244 CID rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (r_nsubj) were_25\VBD\0|NONE_0 (l_attr) dizziness_26\NN\14299637|events_104|respectively_19|,_7|,_24|._77
D002110_D012001 NONE caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2 (l_conj) phonophobia_19\NNS\14382238|,_2|and_27|for_31
C093622_D012001 NONE rizatriptan_0\NNP\0|also_16|superior_21|h_177|._213 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) superior_3\JJ\9623038|rizatriptan_21|also_5|h_156|._192 (l_prep) to_4\IN\0|NONE_0 (l_pobj) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2 (l_conj) phonophobia_19\NNS\14382238|,_2|and_27|for_31
D002110_D014839 NONE caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2
D002110_D004244 NONE caffeine_21\NN\14712692|and_15 (r_conj) rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (r_nsubj) were_25\VBD\0|NONE_0 (l_attr) dizziness_26\NN\14299637|events_104|respectively_19|,_7|,_24|._77
D012701_D008881 NONE 5-ht(1b/1d_4\CD\0|)_10 (r_nummod) receptor_6\NN\5225602|a_24|selective_22|with_17 (r_compound) agonist_7\NN\0|rizatriptan_48|._95 (l_prep) with_8\IN\0|a_41|selective_39|receptor_17 (l_pobj) absorption_11\NN\13558490|NONE_0 (l_conj) onset_14\NN\7325190|rapid_32|oral_26|and_10 (l_prep) in_17\IN\13603305|early_22|of_10 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) of_21\IN\0|the_20|acute_16 (l_pobj) migraine_22\NN\14326607|NONE_0
D004878_D014839 NONE ergotamine_5\NN\14712692|/_10|in_20 (r_nmod) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2
C093622_D006261 NONE rizatriptan_19\JJ\0|NONE_0 (r_dobj) preferring_18\VBG\1777210|NONE_0 (r_acl) patients_17\NNS\9898892|NONE_0 (r_pobj) of_16\IN\0|67.3_6 (r_prep) %_15\NN\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) cited_12\VBN\730052|the_42|important_33|for_16|,_2 (r_acl) reason_8\NN\9178821|relief_42|._128 (r_attr) was_4\VBD\0|NONE_0 (l_nsubj) relief_1\NN\7492516|reason_42|._170 (l_prep) of_2\IN\0|faster_14 (l_pobj) headache_3\NN\5829480|NONE_0
D004878_D008881 NONE ergotamine_11\NN\14712692|mg_10|/_10|in_20 (r_nmod) caffeine_13\NN\14712692|crossover_88|of_67|._20 (l_prep) in_14\IN\13603305|mg_30|ergotamine_20|/_10 (l_pobj) migraine_15\NN\14326607|NONE_0
D004878_D008881 NONE ergotamine_18\NN\14712692|NONE_0 (r_pobj) to_16\IN\0|mg_10 (r_prep) tablet_15\NN\4233405|1_20 (r_amod) rizatriptan_12\JJ\0|NONE_0 (r_pobj) for_10\IN\0|the_15 (r_prep) preference_9\NN\7497473|study_19|tablets_79|in_87|._154 (r_dobj) assessed_7\VBD\670261|NONE_0 (l_prep) in_26\IN\13603305|study_106|preference_87|tablets_8|._67 (l_pobj) patients_28\NNS\9898892|NONE_0 (l_acl) treating_29\VBG\2376958|439_13 (l_dobj) attack_33\NN\955060|NONE_0 (l_compound) migraine_32\JJ\14326607|a_9|single_7|with_16
C093622_D009325 CID rizatriptan_0\NNP\0|also_16|superior_21|h_177|._213 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) superior_3\JJ\9623038|rizatriptan_21|also_5|h_156|._192 (l_prep) to_4\IN\0|NONE_0 (l_pobj) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0
C093622_D009325 CID rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (l_appos) nausea_34\NN\14299637|the_154|common_145|adverse_138|(_123|>_112|,_47
C093622_D020795 NONE rizatriptan_0\NNP\0|also_16|superior_21|h_177|._213 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) superior_3\JJ\9623038|rizatriptan_21|also_5|h_156|._192 (l_prep) to_4\IN\0|NONE_0 (l_pobj) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2 (l_conj) phonophobia_19\NNS\14382238|,_2|and_27|for_31 (l_conj) photophobia_21\NNS\14382238|or_3
D002110_D009325 NONE caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0
D002110_D009325 NONE caffeine_21\NN\14712692|and_15 (r_conj) rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (l_appos) nausea_34\NN\14299637|the_154|common_145|adverse_138|(_123|>_112|,_47
D004878_D012001 NONE ergotamine_5\NN\14712692|/_10|in_20 (r_nmod) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2 (l_conj) phonophobia_19\NNS\14382238|,_2|and_27|for_31
D002110_D020795 NONE caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2 (l_conj) phonophobia_19\NNS\14382238|,_2|and_27|for_31 (l_conj) photophobia_21\NNS\14382238|or_3
D004878_D020795 NONE ergotamine_5\NN\14712692|/_10|in_20 (r_nmod) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2 (l_conj) phonophobia_19\NNS\14382238|,_2|and_27|for_31 (l_conj) photophobia_21\NNS\14382238|or_3
C093622_D006970 NONE rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (l_appos) nausea_34\NN\14299637|the_154|common_145|adverse_138|(_123|>_112|,_47 (l_conj) somnolence_42\NN\14015731|(_19|4.2_18|)_6|and_4
D004878_D009325 NONE ergotamine_5\NN\14712692|/_10|in_20 (r_nmod) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0
D004878_D009325 NONE ergotamine_19\NNP\14712692|/_10 (r_nmod) caffeine_21\NN\14712692|and_15 (r_conj) rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (l_appos) nausea_34\NN\14299637|the_154|common_145|adverse_138|(_123|>_112|,_47
C093622_D014839 NONE rizatriptan_0\NNP\0|also_16|superior_21|h_177|._213 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) superior_3\JJ\9623038|rizatriptan_21|also_5|h_156|._192 (l_prep) to_4\IN\0|NONE_0 (l_pobj) caffeine_7\NN\14712692|NONE_0 (l_prep) in_8\IN\13603305|ergotamine_20|/_10 (l_pobj) proportions_10\NNS\13824815|NONE_0 (l_prep) of_11\IN\0|the_16 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) nausea_15\NN\14299637|NONE_0 (l_conj) vomiting_17\VBG\116687|no_11|,_2
D002110_D010146 NONE caffeine_22\NN\14712692|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|24.3_6 (r_acl) %_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) compared_14\VBN\644583|percent_58|free_28|h_21|,_2|,_69|being_83|._121 (r_prep) were_6\VBD\0|NONE_0 (l_acomp) free_8\JJ\7942152|percent_30|h_7|,_26|compared_28|,_97|being_111|._149 (l_npadvmod) pain_7\NN\14299637|NONE_0
D002110_D010146 NONE caffeine_35\NN\14712692|NONE_0 (r_pobj) on_32\IN\0|NONE_0 (r_prep) patients_31\NNS\9898892|NONE_0 (r_pobj) of_30\IN\0|20_4 (r_prep) %_29\NN\0|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) compared_26\VBN\644583|%_124|free_81|at_76|and_69|had_65|,_2|._67 (r_prep) were_7\VBD\0|NONE_0 (l_acomp) free_9\JJ\7942152|%_43|at_5|and_12|had_16|,_79|compared_81|._148 (l_npadvmod) pain_8\NN\14299637|NONE_0
D002110_D006261 NONE caffeine_29\NN\14712692|who_25 (r_dobj) preferred_26\VBD\1777210|NONE_0 (r_relcl) patients_24\NNS\9898892|NONE_0 (r_pobj) of_23\IN\0|54.2_6 (r_prep) %_22\NN\0|and_8 (r_conj) rizatriptan_19\JJ\0|NONE_0 (r_dobj) preferring_18\VBG\1777210|NONE_0 (r_acl) patients_17\NNS\9898892|NONE_0 (r_pobj) of_16\IN\0|67.3_6 (r_prep) %_15\NN\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) cited_12\VBN\730052|the_42|important_33|for_16|,_2 (r_acl) reason_8\NN\9178821|relief_42|._128 (r_attr) was_4\VBD\0|NONE_0 (l_nsubj) relief_1\NN\7492516|reason_42|._170 (l_prep) of_2\IN\0|faster_14 (l_pobj) headache_3\NN\5829480|NONE_0
C093622_D008881 NONE rizatriptan_7\JJ\0|NONE_0 (r_pobj) for_6\IN\0|NONE_0 (r_prep) preference_5\NN\7497473|and_4 (r_conj) efficacy_3\NN\5199286|NONE_0 (r_pobj) of_2\IN\0|crossover_21|caffeine_67|._87 (r_prep) comparison_1\NN\635850|NONE_0 (l_conj) caffeine_13\NN\14712692|crossover_88|of_67|._20 (l_prep) in_14\IN\13603305|mg_30|ergotamine_20|/_10 (l_pobj) migraine_15\NN\14326607|NONE_0
C093622_D008881 NONE rizatriptan_0\NNP\0|agonist_48|._143 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agonist_7\NN\0|rizatriptan_48|._95 (l_prep) with_8\IN\0|a_41|selective_39|receptor_17 (l_pobj) absorption_11\NN\13558490|NONE_0 (l_conj) onset_14\NN\7325190|rapid_32|oral_26|and_10 (l_prep) in_17\IN\13603305|early_22|of_10 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) of_21\IN\0|the_20|acute_16 (l_pobj) migraine_22\NN\14326607|NONE_0
C093622_D008881 NONE rizatriptan_12\JJ\0|NONE_0 (r_pobj) for_10\IN\0|the_15 (r_prep) preference_9\NN\7497473|study_19|tablets_79|in_87|._154 (r_dobj) assessed_7\VBD\670261|NONE_0 (l_prep) in_26\IN\13603305|study_106|preference_87|tablets_8|._67 (l_pobj) patients_28\NNS\9898892|NONE_0 (l_acl) treating_29\VBG\2376958|439_13 (l_dobj) attack_33\NN\955060|NONE_0 (l_compound) migraine_32\JJ\14326607|a_9|single_7|with_16
D004878_D010146 NONE ergotamine_20\NN\14712692|/_10|0.001_30 (r_nmod) caffeine_22\NN\14712692|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|24.3_6 (r_acl) %_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) compared_14\VBN\644583|percent_58|free_28|h_21|,_2|,_69|being_83|._121 (r_prep) were_6\VBD\0|NONE_0 (l_acomp) free_8\JJ\7942152|percent_30|h_7|,_26|compared_28|,_97|being_111|._149 (l_npadvmod) pain_7\NN\14299637|NONE_0
D004878_D010146 NONE ergotamine_33\NNP\14712692|/_10|0.001_30 (r_nmod) caffeine_35\NN\14712692|NONE_0 (r_pobj) on_32\IN\0|NONE_0 (r_prep) patients_31\NNS\9898892|NONE_0 (r_pobj) of_30\IN\0|20_4 (r_prep) %_29\NN\0|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) compared_26\VBN\644583|%_124|free_81|at_76|and_69|had_65|,_2|._67 (r_prep) were_7\VBD\0|NONE_0 (l_acomp) free_9\JJ\7942152|%_43|at_5|and_12|had_16|,_79|compared_81|._148 (l_npadvmod) pain_8\NN\14299637|NONE_0
D004878_D006261 NONE ergotamine_27\NN\14712692|/_10 (r_nmod) caffeine_29\NN\14712692|who_25 (r_dobj) preferred_26\VBD\1777210|NONE_0 (r_relcl) patients_24\NNS\9898892|NONE_0 (r_pobj) of_23\IN\0|54.2_6 (r_prep) %_22\NN\0|and_8 (r_conj) rizatriptan_19\JJ\0|NONE_0 (r_dobj) preferring_18\VBG\1777210|NONE_0 (r_acl) patients_17\NNS\9898892|NONE_0 (r_pobj) of_16\IN\0|67.3_6 (r_prep) %_15\NN\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) cited_12\VBN\730052|the_42|important_33|for_16|,_2 (r_acl) reason_8\NN\9178821|relief_42|._128 (r_attr) was_4\VBD\0|NONE_0 (l_nsubj) relief_1\NN\7492516|reason_42|._170 (l_prep) of_2\IN\0|faster_14 (l_pobj) headache_3\NN\5829480|NONE_0
D002110_D006970 NONE caffeine_21\NN\14712692|and_15 (r_conj) rizatriptan_17\NN\0|NONE_0 (r_pobj) after_16\IN\0|incidence_34|or_22|%_16 (r_prep) >_7\XX\0|the_42|common_33|adverse_26|(_11|,_65|nausea_112 (r_appos) events_4\NNS\23100|respectively_85|,_97|dizziness_104|,_128|._181 (l_appos) nausea_34\NN\14299637|the_154|common_145|adverse_138|(_123|>_112|,_47 (l_conj) somnolence_42\NN\14015731|(_19|4.2_18|)_6|and_4
18619688
D004317_D003643 NONE adriamycin_0\NNP\0|-_10 (r_advmod) induced_2\VBN\1627355|cardiomyocyte_19 (r_amod) death_5\NN\7296428|role_25|in_30|._61
D004317_D003643 NONE adriamycin_17\NNS\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|death_75|role_50|in_45|._21 (r_advcl) plays_3\VBZ\7007684|NONE_0 (l_nsubj) death_2\NN\7296428|role_25|in_30|induced_75|._96
C025946_D006333 NONE 3-methyladenine_2\LS\0|:_2|,_21 (r_appos) methods_0\NNS\5616786|inhibitor_43|was_66|in_75|._129 (r_nsubjpass) used_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|methods_75|inhibitor_32|was_9|._54 (l_pobj) model_18\NN\5888929|NONE_0 (l_compound) failure_17\NN\66216|a_8|heart_6|of_14|induced_22
C025946_D006333 NONE 3ma_4\VBN\0|NONE_0 (r_appos) 3-methyladenine_2\LS\0|:_2|,_21 (r_appos) methods_0\NNS\5616786|inhibitor_43|was_66|in_75|._129 (r_nsubjpass) used_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|methods_75|inhibitor_32|was_9|._54 (l_pobj) model_18\NN\5888929|NONE_0 (l_compound) failure_17\NN\66216|a_8|heart_6|of_14|induced_22
D004317_D006333 CID adriamycin_0\NNP\0|-_10 (r_advmod) induced_2\VBN\1627355|cardiomyocyte_19 (r_amod) death_5\NN\7296428|role_25|in_30|._61 (r_nsubj) plays_6\VBZ\7007684|NONE_0 (l_prep) in_10\IN\13603305|death_30|role_5|._31 (l_pobj) model_13\NN\5888929|NONE_0 (l_prep) of_14\IN\0|a_12|rat_10 (l_pobj) failure_16\NN\66216|NONE_0
D004317_D006333 CID adriamycin_7\NNS\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|mechanisms_36|underlying_25|heart_14 (r_acl) failure_4\NN\66216|complicated_39|._68
D004317_D006333 CID adriamycin_20\NNS\0|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_agent) induced_18\VBN\1627355|the_33|of_17 (r_acl) progression_14\NN\8457976|NONE_0 (l_prep) of_15\IN\0|the_16|induced_17 (l_pobj) failure_17\NN\66216|NONE_0
D004317_D006333 CID adriamycin_20\NNS\0|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_agent) induced_18\VBN\1627355|the_33|of_17 (r_acl) progression_14\NN\8457976|NONE_0 (r_pobj) in_12\IN\13603305|whether_31|autophagy_23|was_13 (r_prep) involved_11\VBN\2676054|to_37|,_66|develop_83 (r_ccomp) investigate_7\VB\644583|aim_25|._169 (l_advcl) develop_26\VB\1753788|to_120|involved_83|,_17 (l_dobj) strategy_30\NN\5902545|so_41|that_38|we_33|can_30 (l_prep) for_31\IN\0|a_27|novel_25|treatment_19 (l_pobj) failure_33\NN\66216|NONE_0
D004317_D006333 CID adriamycin_23\NNS\0|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) induced_21\VBN\1627355|a_30|heart_28|failure_22|of_8 (r_acl) model_18\NN\5888929|NONE_0 (l_compound) failure_17\NN\66216|a_8|heart_6|of_14|induced_22
D004317_D006333 CID adriamycin_17\NNS\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|death_75|role_50|in_45|._21 (r_advcl) plays_3\VBZ\7007684|NONE_0 (l_prep) in_7\IN\13603305|death_30|role_5|induced_45|._66 (l_pobj) pathogenesis_9\NN\13533470|NONE_0 (l_prep) of_10\IN\0|the_17 (l_pobj) failure_12\NN\66216|NONE_0
D004317_D006333 CID adriamycin_13\NNS\0|NONE_0 (r_pobj) by_12\IN\0|via_14 (r_agent) caused_11\VBN\1617192|heart_14 (r_acl) failure_10\NN\66216|NONE_0
11250767
D011441_D005921 CID propylthiouracil_13\NN\14727670|NONE_0 (l_relcl) developed_25\VBD\1753788|NONE_0 (l_nsubj) syndrome_17\NN\5870365|in_10 (l_prep) of_18\IN\0|a_11 (l_pobj) pericarditis_19\NN\14338942|NONE_0 (l_conj) fever_21\NN\14299637|,_2 (l_conj) glomerulonephritis_24\NN\14113798|,_6|and_4
D011441_D010493 CID propylthiouracil_0\NNP\14727670|-_16 (r_npadvmod) induced_2\VBN\1627355|staining_20|antineutrophil_29|cytoplasmic_44|positive_69|in_89|._121 (r_amod) vasculitis_11\NN\14336539|NONE_0 (l_prep) in_12\IN\13603305|induced_89|staining_69|antineutrophil_60|cytoplasmic_45|positive_20|._32 (l_pobj) conjunction_13\NN\5048123|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) pericarditis_15\NN\14338942|NONE_0
D011441_D010493 CID propylthiouracil_5\NN\14727670|-_16 (r_npadvmod) induced_7\VBN\1627355|manifesting_19 (r_amod) vasculitis_8\NN\14336539|NONE_0 (l_acl) manifesting_9\VBG\1015244|induced_19 (l_prep) with_10\IN\0|NONE_0 (l_pobj) pericarditis_11\NN\14338942|NONE_0
D011441_D010493 CID propylthiouracil_13\NN\14727670|NONE_0 (l_relcl) developed_25\VBD\1753788|NONE_0 (l_nsubj) syndrome_17\NN\5870365|in_10 (l_prep) of_18\IN\0|a_11 (l_pobj) pericarditis_19\NN\14338942|NONE_0
D011441_D010493 CID uracil_20\NN\14964590|propylthio-_12 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|mpo_30|positive_20 (r_acl) vasculitis_16\NN\14336539|NONE_0 (r_pobj) in_9\IN\13603305|no_33|prior_30|of_16 (r_prep) reports_6\NNS\6470073|review_25|._104 (l_prep) of_7\IN\0|no_17|prior_14|in_16 (l_pobj) pericarditis_8\NN\14338942|NONE_0
D011441_D010493 CID uracil_14\NN\14964590|NONE_0 (r_compound) therapy_15\NN\657604|NONE_0 (r_appos) propylthio-_13\VB\0|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) attributable_11\JJ\0|the_53|initial_49|of_27 (r_amod) manifestation_5\NN\7321772|pericarditis_32|may_19|._83 (r_attr) be_2\VB\14625458|NONE_0 (l_nsubj) pericarditis_0\NNP\14338942|may_13|manifestation_32|._115
D011441_D006980 NONE propylthiouracil_13\NN\14727670|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|the_54|first_50|case_44|of_32 (r_acl) report_5\NN\6470073|we_26|._144 (l_prep) of_6\IN\0|the_22|first_18|case_12|treated_32 (l_pobj) woman_8\NN\9605289|NONE_0 (l_prep) with_9\IN\0|a_8 (l_pobj) hyperthyroidism_10\NN\14059928|NONE_0
D011441_D014657 NONE propylthiouracil_0\NNP\14727670|-_16 (r_npadvmod) induced_2\VBN\1627355|staining_20|antineutrophil_29|cytoplasmic_44|positive_69|in_89|._121 (r_amod) vasculitis_11\NN\14336539|NONE_0
D011441_D014657 NONE propylthiouracil_5\NN\14727670|-_16 (r_npadvmod) induced_7\VBN\1627355|manifesting_19 (r_amod) vasculitis_8\NN\14336539|NONE_0
D011441_D014657 NONE uracil_20\NN\14964590|propylthio-_12 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) associated_17\VBN\628491|mpo_30|positive_20 (r_acl) vasculitis_16\NN\14336539|NONE_0
D011441_D014657 NONE uracil_14\NN\14964590|NONE_0 (r_compound) therapy_15\NN\657604|NONE_0 (r_appos) propylthio-_13\VB\0|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) attributable_11\JJ\0|the_53|initial_49|of_27 (r_amod) manifestation_5\NN\7321772|pericarditis_32|may_19|._83 (l_prep) of_6\IN\0|the_26|initial_22|attributable_27 (l_pobj) vasculitis_10\NN\14336539|NONE_0
D011441_D005334 CID propylthiouracil_13\NN\14727670|NONE_0 (l_relcl) developed_25\VBD\1753788|NONE_0 (l_nsubj) syndrome_17\NN\5870365|in_10 (l_prep) of_18\IN\0|a_11 (l_pobj) pericarditis_19\NN\14338942|NONE_0 (l_conj) fever_21\NN\14299637|,_2
11706060
D019344_D000163 NONE lactate_8\NN\14850483|in_8 (r_dobj) elevates_6\VBZ\2391803|combined_58|therapy_34|cardiomyopathy_19|and_4|._47 (l_prep) in_9\IN\13603305|lactate_8 (l_pobj) mice_12\NNS\2329401|NONE_0 (l_compound) aids_11\NNP\13974317|transgenic_11
D019344_D000163 NONE lactate_18\NN\14850483|NONE_0 (l_prep) in_22\IN\13603305|elevated_29|plasma_20|(_5|la_4|)_2 (l_pobj) aids_23\NNP\13974317|NONE_0
D019344_D000163 NONE la_20\NNP\14625458|elevated_25|plasma_16|(_1|)_2|in_4 (r_appos) lactate_18\NN\14850483|NONE_0 (l_prep) in_22\IN\13603305|elevated_29|plasma_20|(_5|la_4|)_2 (l_pobj) aids_23\NNP\13974317|NONE_0
D019344_D000163 NONE la_10\NNP\14625458|NONE_0 (l_prep) in_11\IN\13603305|elevated_12 (l_pobj) mice_14\NNS\2329401|NONE_0 (l_compound) transgenic_13\JJ\0|NONE_0 (l_compound) aids_12\NNP\13974317|NONE_0
D019259_D000163 NONE lamivudine_43\NN\3834836|NONE_0 (r_pobj) of_40\IN\0|the_22|haart_18 (r_prep) combination_39\NN\7951464|NONE_0 (r_pobj) with_36\IN\0|determine_164|,_115|mice_75|were_13|._109 (r_prep) treated_35\VBN\2376958|NONE_0 (l_nsubjpass) mice_15\NNS\2329401|determine_89|,_40|were_62|with_75|._184 (l_compound) aids_14\NNP\13974317|old_26|hemizygous_22|transgenic_11|pol_26
D019344_D009202 NONE lactate_8\NN\14850483|in_8 (r_dobj) elevates_6\VBZ\2391803|combined_58|therapy_34|cardiomyopathy_19|and_4|._47 (r_conj) causes_3\VBZ\7323922|NONE_0 (l_advmod) cardiomyopathy_4\NN\14103288|combined_39|therapy_15|and_15|elevates_19|._66
D019344_D009202 NONE lactate_18\NN\14850483|NONE_0 (r_pobj) in_15\IN\13603305|cm_8|and_4 (r_conj) in_9\IN\13603305|therapy_30|is_14|through_67|._114 (l_pobj) cm_12\NNP\13649268|and_4|in_8 (l_amod) cardiomyopathy_10\NN\14103288|(_15|)_18
D019344_D009202 NONE lactate_18\NN\14850483|NONE_0 (r_pobj) in_15\IN\13603305|cm_8|and_4 (r_conj) in_9\IN\13603305|therapy_30|is_14|through_67|._114 (l_pobj) cm_12\NNP\13649268|and_4|in_8
D019344_D009202 NONE la_20\NNP\14625458|elevated_25|plasma_16|(_1|)_2|in_4 (r_appos) lactate_18\NN\14850483|NONE_0 (r_pobj) in_15\IN\13603305|cm_8|and_4 (r_conj) in_9\IN\13603305|therapy_30|is_14|through_67|._114 (l_pobj) cm_12\NNP\13649268|and_4|in_8 (l_amod) cardiomyopathy_10\NN\14103288|(_15|)_18
D019344_D009202 NONE la_20\NNP\14625458|elevated_25|plasma_16|(_1|)_2|in_4 (r_appos) lactate_18\NN\14850483|NONE_0 (r_pobj) in_15\IN\13603305|cm_8|and_4 (r_conj) in_9\IN\13603305|therapy_30|is_14|through_67|._114 (l_pobj) cm_12\NNP\13649268|and_4|in_8
D019344_D009202 NONE la_41\NNP\14625458|NONE_0 (r_pobj) of_39\IN\0|NONE_0 (r_prep) determination_38\NN\43195|at_227|,_194|mice_192|echocardiography_177|,_6|and_4|._26 (r_conj) underwent_7\VBD\109660|NONE_0 (l_dobj) echocardiography_8\RB\177127|at_50|,_17|mice_15|,_171|and_173|determination_177|._203 (l_appos) quantitation_10\NN\0|,_2 (l_prep) of_11\IN\0|encoding_58 (l_pobj) abundance_12\NN\5108740|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) markers_15\NNS\21939|NONE_0 (l_prep) of_16\IN\0|molecular_18 (l_pobj) cm_17\NNP\13649268|NONE_0
D019344_D009202 NONE la_10\NNP\14625458|NONE_0 (r_pobj) with_8\IN\0|mitochondrial_17 (r_prep) cm_7\NNP\13649268|that_43|haart_27
D019344_D028361 NONE lactate_18\NN\14850483|NONE_0 (r_pobj) in_15\IN\13603305|cm_8|and_4 (r_conj) in_9\IN\13603305|therapy_30|is_14|through_67|._114 (r_prep) implicated_8\VBN\2677097|NONE_0 (l_prep) through_24\IN\0|therapy_97|is_81|in_67|._47 (l_pobj) mechanisms_25\NNS\13446390|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) dysfunction_28\NN\14204950|NONE_0
D019344_D028361 NONE la_20\NNP\14625458|elevated_25|plasma_16|(_1|)_2|in_4 (r_appos) lactate_18\NN\14850483|NONE_0 (r_pobj) in_15\IN\13603305|cm_8|and_4 (r_conj) in_9\IN\13603305|therapy_30|is_14|through_67|._114 (r_prep) implicated_8\VBN\2677097|NONE_0 (l_prep) through_24\IN\0|therapy_97|is_81|in_67|._47 (l_pobj) mechanisms_25\NNS\13446390|NONE_0 (l_prep) of_26\IN\0|NONE_0 (l_pobj) dysfunction_28\NN\14204950|NONE_0
D019469_D000163 NONE indinavir_46\NNS\4013993|zidovudine_28|,_18|,_6|and_4 (r_conj) lamivudine_43\NN\3834836|NONE_0 (r_pobj) of_40\IN\0|the_22|haart_18 (r_prep) combination_39\NN\7951464|NONE_0 (r_pobj) with_36\IN\0|determine_164|,_115|mice_75|were_13|._109 (r_prep) treated_35\VBN\2376958|NONE_0 (l_nsubjpass) mice_15\NNS\2329401|determine_89|,_40|were_62|with_75|._184 (l_compound) aids_14\NNP\13974317|old_26|hemizygous_22|transgenic_11|pol_26
D002118_D009202 NONE calcium_30\NN\14625458|sarcoplasmic_13|[_15|serca2_16|]_22|)_23 (r_compound) atpase_31\NNP\0|(_84|ventricular_83|mrna_71|factor_38|and_25 (r_conj) encoding_21\VBG\614489|of_58 (r_parataxis) quantitation_10\NN\0|,_2 (l_prep) of_11\IN\0|encoding_58 (l_pobj) abundance_12\NN\5108740|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) markers_15\NNS\21939|NONE_0 (l_prep) of_16\IN\0|molecular_18 (l_pobj) cm_17\NNP\13649268|NONE_0
D015215_D000163 NONE zidovudine_41\NN\3834836|,_10|,_22|and_24|indinavir_28 (r_nmod) lamivudine_43\NN\3834836|NONE_0 (r_pobj) of_40\IN\0|the_22|haart_18 (r_prep) combination_39\NN\7951464|NONE_0 (r_pobj) with_36\IN\0|determine_164|,_115|mice_75|were_13|._109 (r_prep) treated_35\VBN\2376958|NONE_0 (l_nsubjpass) mice_15\NNS\2329401|determine_89|,_40|were_62|with_75|._184 (l_compound) aids_14\NNP\13974317|old_26|hemizygous_22|transgenic_11|pol_26
9100294
D020748_D018376 CID 5967_14\CD\0|NONE_0 (r_prep) 40_12\CD\13745420|NONE_0 (r_nummod) ro_11\NNP\6894544|a_31|channel_17|,_2 (r_appos) blocker_9\NN\10101634|that_27|,_19|alterations_44 (r_nsubj) induced_16\VBD\1627355|investigation_72|._92 (l_dobj) alterations_18\NNS\7283608|that_71|blocker_44|,_25
D009543_D018376 CID nifedipine_29\NN\2938514|and_4 (r_conj) verapamil_27\NN\2938514|only_9 (r_pobj) for_26\IN\0|statistically_31 (r_prep) significant_24\JJ\0|incidence_28|._45 (r_acomp) was_22\VBD\0|incidence_135|was_93|after_80|,_21|but_19 (r_conj) observed_7\VBN\2163746|NONE_0 (l_nsubjpass) incidence_2\NN\13821570|was_42|after_55|,_114|but_116|was_135 (l_prep) of_3\IN\0|a_16|low_14 (l_pobj) malformations_5\NNS\14213199|NONE_0
D002118_D018376 NONE calcium_7\NN\14625458|NONE_0 (r_compound) channel_8\NN\6251781|NONE_0 (r_compound) blockers_9\NNS\10101634|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) exposed_5\VBN\2110927|cardiovascular_42|in_15|._35 (r_acl) alterations_1\NNS\7283608|NONE_0
D002118_D018376 NONE calcium_7\NN\14625458|new_4 (r_compound) channel_8\NN\6251781|a_14|,_15|ro_17 (r_compound) blocker_9\NN\10101634|that_27|,_19|alterations_44 (r_nsubj) induced_16\VBD\1627355|investigation_72|._92 (l_dobj) alterations_18\NNS\7283608|that_71|blocker_44|,_25
D002118_D018376 NONE calcium_10\NN\14625458|NONE_0 (r_compound) channel_11\NN\6251781|in_17 (r_compound) blockers_12\NNS\10101634|that_21|malformations_42 (r_nsubj) induce_15\VBP\1627355|the_56 (l_dobj) malformations_17\NNS\14213199|that_63|blockers_42
D002118_D018376 NONE calcium_7\NN\14625458|NONE_0 (r_compound) channel_8\NN\6251781|these_14 (r_compound) blockers_9\NNS\10101634|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) one_4\CD\13741022|rats_23|were_18|during_38|._163 (r_dobj) administered_3\VBN\2436349|NONE_0 (l_prep) during_10\IN\0|rats_61|were_56|one_38|._125 (l_pobj) period_12\NN\13575869|NONE_0 (l_prep) of_13\IN\0|the_11 (l_pobj) morphogenesis_15\NN\13489037|NONE_0 (l_conj) offspring_18\NN\10235549|cardiac_30|and_8 (l_acl) examined_19\VBD\0|the_14 (l_prep) on_20\IN\0|NONE_0 (l_pobj) day_21\NN\15154774|NONE_0 (l_prep) of_23\IN\0|20_3 (l_pobj) gestation_24\NN\15116532|NONE_0 (l_prep) for_25\IN\0|NONE_0 (l_pobj) malformations_27\NNS\14213199|NONE_0
D002118_D018376 NONE calcium_15\NN\14625458|NONE_0 (r_compound) channel_16\NN\6251781|the_17|four_13 (r_compound) blockers_17\NNS\10101634|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) each_11\DT\0|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) exposure_9\NN\5042871|NONE_0 (r_pobj) after_8\IN\0|incidence_55|was_13|,_59|but_61|was_80 (r_prep) observed_7\VBN\2163746|NONE_0 (l_nsubjpass) incidence_2\NN\13821570|was_42|after_55|,_114|but_116|was_135 (l_prep) of_3\IN\0|a_16|low_14 (l_pobj) malformations_5\NNS\14213199|NONE_0
D014700_D018376 CID verapamil_27\NN\2938514|only_9 (r_pobj) for_26\IN\0|statistically_31 (r_prep) significant_24\JJ\0|incidence_28|._45 (r_acomp) was_22\VBD\0|incidence_135|was_93|after_80|,_21|but_19 (r_conj) observed_7\VBN\2163746|NONE_0 (l_nsubjpass) incidence_2\NN\13821570|was_42|after_55|,_114|but_116|was_135 (l_prep) of_3\IN\0|a_16|low_14 (l_pobj) malformations_5\NNS\14213199|NONE_0
16867021
C052075_D006948 NONE thp_6\NNP\0|mg/kg_18|i.p._24|)_28|reduced_30|locomotor_38 (r_nmod) time_16\NN\7308889|on_86|,_50|,_4|distance_6|and_24|speed_36|._52 (r_npadvmod) traveled_19\VBD\0|NONE_0 (l_prep) on_0\IN\0|,_36|time_86|,_90|distance_92|and_110|speed_122|._138 (l_pobj) hyperactivity_4\NN\14052403|NONE_0
C052075_D006948 NONE thp_0\NNP\0|profile_36|climbing_167|._183 (r_nsubj) exhibited_1\VBD\2632167|NONE_0 (l_dobj) profile_6\NN\6999802|thp_36|climbing_131|._147 (l_prep) by_7\IN\0|an_30|like_13 (l_pcomp) potentiating_8\VBG\229605|NONE_0 (l_conj) reducing_14\VBG\13447361|catalepsy_11|,_2 (l_dobj) hyperactivity_18\NN\14052403|and_14|reducing_18
C052075_D002375 CID thioperamide_13\JJ\0|(_22|5_21|i.c.v._12|)_6|and_4|(_19|mg/kg_23|)_33 (r_conj) microg_9\NN\0|r)-alpha_35|-_27|ramh_9 (r_parataxis) methylhistamine_3\NN\0|(_10|,_79|se_85|did_88|not_92|catalepsy_102|._111 (r_nsubj) cause_27\VB\7323922|NONE_0 (l_dobj) catalepsy_28\NN\14023236|(_112|methylhistamine_102|,_23|se_17|did_14|not_10|._9
C052075_D002375 CID thp_15\NNP\0|(_1|)_3 (r_appos) thioperamide_13\JJ\0|(_22|5_21|i.c.v._12|)_6|and_4|(_19|mg/kg_23|)_33 (r_conj) microg_9\NN\0|r)-alpha_35|-_27|ramh_9 (r_parataxis) methylhistamine_3\NN\0|(_10|,_79|se_85|did_88|not_92|catalepsy_102|._111 (r_nsubj) cause_27\VB\7323922|NONE_0 (l_dobj) catalepsy_28\NN\14023236|(_112|methylhistamine_102|,_23|se_17|did_14|not_10|._9
C052075_D002375 CID thp_0\NNP\0|profile_36|climbing_167|._183 (r_nsubj) exhibited_1\VBD\2632167|NONE_0 (l_dobj) profile_6\NN\6999802|thp_36|climbing_131|._147 (l_prep) by_7\IN\0|an_30|like_13 (l_pcomp) potentiating_8\VBG\229605|NONE_0 (l_dobj) catalepsy_12\NN\14023236|,_9|reducing_11
D001058_D006948 NONE apomorphine_21\NN\3786417|NONE_0 (r_dobj) reducing_20\VBG\13447361|hyperactivity_18|and_4 (r_conj) reducing_14\VBG\13447361|catalepsy_11|,_2 (l_dobj) hyperactivity_18\NN\14052403|and_14|reducing_18
D000661_D006948 CID amphetamine_1\NN\3248958|-_11 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) hyperactivity_4\NN\14052403|NONE_0
D000661_D006948 CID amphetamine_15\NN\3248958|-_11 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) hyperactivity_18\NN\14052403|and_14|reducing_18
D006220_D006948 NONE haloperidol_9\NN\3713736|-_11 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) catalepsy_12\NN\14023236|,_9|reducing_11 (r_dobj) potentiating_8\VBG\229605|NONE_0 (l_conj) reducing_14\VBG\13447361|catalepsy_11|,_2 (l_dobj) hyperactivity_18\NN\14052403|and_14|reducing_18
D001058_D002375 NONE apomorphine_19\NN\3786417|-_11 (r_npadvmod) induced_21\VBN\1627355|climbing_8|and_26|activities_60 (r_amod) behavior_23\NN\407535|to_118|effect_105 (r_dobj) study_6\VB\635850|study_22|was_16|._176 (l_dobj) effect_8\NN\34213|to_13|behavior_105 (l_prep) of_9\IN\0|the_11 (l_pobj) ligands_12\NNS\20090|NONE_0 (l_prep) on_13\IN\0|histamine_32|h(3)-receptor_22 (l_pobj) catalepsy_17\NN\14023236|NONE_0
D001058_D002375 NONE apomorphine_12\NN\3786417|while_6|were_60|for_70 (r_nsubjpass) used_26\VBN\0|catalepsy_124|was_114|by_102|,_73|._74 (r_advcl) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) catalepsy_0\NNP\14023236|was_10|by_22|,_51|used_124|._198
D001058_D002375 NONE apomorphine_21\NN\3786417|NONE_0 (r_dobj) reducing_20\VBG\13447361|hyperactivity_18|and_4 (r_conj) reducing_14\VBG\13447361|catalepsy_11|,_2 (r_conj) potentiating_8\VBG\229605|NONE_0 (l_dobj) catalepsy_12\NN\14023236|,_9|reducing_11
D006220_D002375 CID haloperidol_4\NN\3713736|NONE_0 (r_pobj) by_3\IN\0|catalepsy_22|was_12|,_29|used_102|._176 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) catalepsy_0\NNP\14023236|was_10|by_22|,_51|used_124|._198
D006220_D002375 CID haloperidol_4\NN\3713736|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) prior_2\RB\10675876|1_4|h_2|in_30|._92 (r_advmod) resulted_5\VBD\2633881|NONE_0 (l_prep) in_6\IN\13603305|1_34|h_32|prior_30|._62 (l_pobj) increase_11\NN\13576355|NONE_0 (l_prep) in_12\IN\13603305|a_26|dependent_19|(_23|p_24|)_32 (l_pobj) catalepsy_14\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_9\NN\3713736|-_11 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) catalepsy_12\NN\14023236|,_9|reducing_11
D000661_D002375 NONE amphetamine_25\NN\3248958|-_11 (r_npadvmod) induced_27\VBN\1627355|locomotor_8|in_29 (r_amod) activities_29\NNS\30358|induced_60|climbing_52|and_34 (r_conj) behavior_23\NN\407535|to_118|effect_105 (r_dobj) study_6\VB\635850|study_22|was_16|._176 (l_dobj) effect_8\NN\34213|to_13|behavior_105 (l_prep) of_9\IN\0|the_11 (l_pobj) ligands_12\NNS\20090|NONE_0 (l_prep) on_13\IN\0|histamine_32|h(3)-receptor_22 (l_pobj) catalepsy_17\NN\14023236|NONE_0
D000661_D002375 NONE amphetamine_19\NN\3248958|(_21|mg/kg_16|)_6|and_4 (r_conj) apomorphine_12\NN\3786417|while_6|were_60|for_70 (r_nsubjpass) used_26\VBN\0|catalepsy_124|was_114|by_102|,_73|._74 (r_advcl) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) catalepsy_0\NNP\14023236|was_10|by_22|,_51|used_124|._198
D000661_D002375 NONE amphetamine_15\NN\3248958|-_11 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) hyperactivity_18\NN\14052403|and_14|reducing_18 (r_dobj) reducing_14\VBG\13447361|catalepsy_11|,_2 (r_conj) potentiating_8\VBG\229605|NONE_0 (l_dobj) catalepsy_12\NN\14023236|,_9|reducing_11
D006632_D002375 NONE histamine_10\NN\14739004|h(3)-receptor_10|on_32 (r_nmod) ligands_12\NNS\20090|NONE_0 (l_prep) on_13\IN\0|histamine_32|h(3)-receptor_22 (l_pobj) catalepsy_17\NN\14023236|NONE_0
C069357_D002375 NONE methylhistamine_3\NN\0|(_10|,_79|se_85|did_88|not_92|catalepsy_102|._111 (r_nsubj) cause_27\VB\7323922|NONE_0 (l_dobj) catalepsy_28\NN\14023236|(_112|methylhistamine_102|,_23|se_17|did_14|not_10|._9
C069357_D002375 NONE ramh_5\NNP\0|r)-alpha_26|-_18|microg_9 (r_appos) methylhistamine_3\NN\0|(_10|,_79|se_85|did_88|not_92|catalepsy_102|._111 (r_nsubj) cause_27\VB\7323922|NONE_0 (l_dobj) catalepsy_28\NN\14023236|(_112|methylhistamine_102|,_23|se_17|did_14|not_10|._9
19269743
D002211_D010146 CID capsaicin_9\NN\15032661|-_9 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) pain_12\NN\14299637|NONE_0
D002211_D010146 CID capsaicin_21\NN\15032661|NONE_0 (r_pobj) of_20\IN\0|three_12|microg_29 (r_prep) doses_19\NNS\3740161|NONE_0 (r_pobj) of_17\IN\0|intradermal_23|separated_52 (r_prep) injections_16\NNS\320852|in_93|,_52|volunteers_32|)_89|,_90|given_97|._179 (r_dobj) received_14\VBD\2210855|NONE_0 (l_prep) in_0\IN\13603305|,_41|volunteers_61|injections_93|)_182|,_183|given_190|._272 (l_pobj) order_1\NN\7168131|NONE_0 (l_acl) address_3\VB\6355894|NONE_0 (l_dobj) memory_8\NN\5926676|to_26 (l_compound) pain_7\NN\14299637|term_5
D002211_D010146 CID capsaicin_11\NN\15032661|(_16|p<0.001_22|)_29 (r_compound) doses_12\NNS\3740161|NONE_0 (r_pobj) across_10\IN\0|to_53|reliably_50|magnitude_23|,_37|regardless_39 (r_prep) discriminate_5\VB\650353|NONE_0 (l_dobj) magnitude_7\NN\4916342|to_30|reliably_27|across_23|,_60|regardless_62 (l_compound) pain_6\NN\14299637|and_15|duration_19
84204
D002927_D008107 NONE cimetidine_19\FW\14778019|both_64|renal_59|(_31|p_30|)_14|,_13|as_3 (r_conj) dysfunction_8\NN\14204950|patients_34|._125
D002927_D003221 CID cimetidine_7\NN\14778019|-_10 (r_npadvmod) associated_9\VBN\628491|mental_11 (r_amod) confusion_11\NN\13972797|NONE_0
D002927_D003221 CID cimetidine_3\NN\14778019|-_10 (r_npadvmod) associated_5\VBN\628491|mental_11 (r_amod) confusion_7\NN\13972797|NONE_0
D002927_D051437 NONE cimetidine_19\FW\14778019|both_64|renal_59|(_31|p_30|)_14|,_13|as_3 (r_conj) dysfunction_8\NN\14204950|patients_34|._125
11027905
D016202_D009437 NONE aspartate_13\NNP\0|(_10|nmda_11|)_15|,_28|as_35 (r_nmod) antagonists_17\NNS\7846|that_33|,_29|may_31|effective_38 (r_nsubj) be_24\VB\14625458|studies_91|have_83|._96 (l_acomp) effective_25\JJ\0|that_71|antagonists_38|,_9|may_7 (l_prep) in_26\IN\13603305|NONE_0 (l_pcomp) improving_27\VBG\126264|NONE_0 (l_dobj) analgesia_29\NN\14034177|NONE_0 (l_prep) in_30\IN\13603305|opioid_17 (l_pobj) syndromes_33\NNS\5870365|NONE_0 (l_prep) as_36\IN\14622893|difficult_31|pain_21|,_7 (l_pobj) pain_38\NN\14299637|such_20
D016202_D009437 NONE nmda_15\NNP\0|aspartate_11|(_1|)_4|,_17|as_24 (r_nmod) antagonists_17\NNS\7846|that_33|,_29|may_31|effective_38 (r_nsubj) be_24\VB\14625458|studies_91|have_83|._96 (l_acomp) effective_25\JJ\0|that_71|antagonists_38|,_9|may_7 (l_prep) in_26\IN\13603305|NONE_0 (l_pcomp) improving_27\VBG\126264|NONE_0 (l_dobj) analgesia_29\NN\14034177|NONE_0 (l_prep) in_30\IN\13603305|opioid_17 (l_pobj) syndromes_33\NNS\5870365|NONE_0 (l_prep) as_36\IN\14622893|difficult_31|pain_21|,_7 (l_pobj) pain_38\NN\14299637|such_20
D016202_D010146 NONE aspartate_13\NNP\0|(_10|nmda_11|)_15|,_28|as_35 (r_nmod) antagonists_17\NNS\7846|that_33|,_29|may_31|effective_38 (r_nsubj) be_24\VB\14625458|studies_91|have_83|._96 (l_acomp) effective_25\JJ\0|that_71|antagonists_38|,_9|may_7 (l_prep) in_26\IN\13603305|NONE_0 (l_pcomp) improving_27\VBG\126264|NONE_0 (l_dobj) analgesia_29\NN\14034177|NONE_0 (l_prep) in_30\IN\13603305|opioid_17 (l_pobj) syndromes_33\NNS\5870365|NONE_0 (l_compound) pain_32\NN\14299637|difficult_10|,_14|as_21
D016202_D010146 NONE nmda_15\NNP\0|aspartate_11|(_1|)_4|,_17|as_24 (r_nmod) antagonists_17\NNS\7846|that_33|,_29|may_31|effective_38 (r_nsubj) be_24\VB\14625458|studies_91|have_83|._96 (l_acomp) effective_25\JJ\0|that_71|antagonists_38|,_9|may_7 (l_prep) in_26\IN\13603305|NONE_0 (l_pcomp) improving_27\VBG\126264|NONE_0 (l_dobj) analgesia_29\NN\14034177|NONE_0 (l_prep) in_30\IN\13603305|opioid_17 (l_pobj) syndromes_33\NNS\5870365|NONE_0 (l_compound) pain_32\NN\14299637|difficult_10|,_14|as_21
D007649_D009437 NONE ketamine_21\NN\3054098|such_8 (r_pobj) as_20\IN\14622893|aspartate_35|(_25|nmda_24|)_20|,_7 (r_prep) antagonists_17\NNS\7846|that_33|,_29|may_31|effective_38 (r_nsubj) be_24\VB\14625458|studies_91|have_83|._96 (l_acomp) effective_25\JJ\0|that_71|antagonists_38|,_9|may_7 (l_prep) in_26\IN\13603305|NONE_0 (l_pcomp) improving_27\VBG\126264|NONE_0 (l_dobj) analgesia_29\NN\14034177|NONE_0 (l_prep) in_30\IN\13603305|opioid_17 (l_pobj) syndromes_33\NNS\5870365|NONE_0 (l_prep) as_36\IN\14622893|difficult_31|pain_21|,_7 (l_pobj) pain_38\NN\14299637|such_20
D007649_D009437 NONE ketamine_0\NNP\3054098|can_9|analgesia_30|._93 (r_nsubj) improve_2\VB\126264|NONE_0 (l_dobj) analgesia_4\NN\14034177|ketamine_30|can_21|._63 (l_prep) in_5\IN\13603305|morphine_19 (l_pobj) syndromes_8\NNS\5870365|NONE_0 (l_prep) as_11\IN\14622893|difficult_31|pain_21|,_7 (l_pobj) pain_13\NN\14299637|such_20
D007649_D010146 NONE ketamine_21\NN\3054098|such_8 (r_pobj) as_20\IN\14622893|aspartate_35|(_25|nmda_24|)_20|,_7 (r_prep) antagonists_17\NNS\7846|that_33|,_29|may_31|effective_38 (r_nsubj) be_24\VB\14625458|studies_91|have_83|._96 (l_acomp) effective_25\JJ\0|that_71|antagonists_38|,_9|may_7 (l_prep) in_26\IN\13603305|NONE_0 (l_pcomp) improving_27\VBG\126264|NONE_0 (l_dobj) analgesia_29\NN\14034177|NONE_0 (l_prep) in_30\IN\13603305|opioid_17 (l_pobj) syndromes_33\NNS\5870365|NONE_0 (l_compound) pain_32\NN\14299637|difficult_10|,_14|as_21
D007649_D010146 NONE ketamine_7\NN\3054098|NONE_0 (r_pobj) of_6\IN\0|subhypnotic_18|(_12|0.25_13|)_37 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) of_3\IN\0|a_13|slow_11 (r_prep) bolus_2\NN\13899404|was_66|to_76|._195 (r_nsubjpass) given_16\VBN\5892096|NONE_0 (l_dative) to_17\IN\0|bolus_76|was_10|._119 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_relcl) was_23\VBD\0|10_30|cancer_27 (l_nsubj) pain_22\NN\14299637|unrelieved_9|in_32
D007649_D010146 NONE ketamine_0\NN\3054098|significantly_35|intensity_66|in_76|._116 (r_nsubj) reduced_8\VBD\441445|NONE_0 (l_dobj) intensity_11\NN\5090441|ketamine_66|significantly_31|in_10|._50 (l_compound) pain_10\NN\14299637|the_4
D007649_D010146 NONE ketamine_0\NNP\3054098|can_9|analgesia_30|._93 (r_nsubj) improve_2\VB\126264|NONE_0 (l_dobj) analgesia_4\NN\14034177|ketamine_30|can_21|._63 (l_prep) in_5\IN\13603305|morphine_19 (l_pobj) syndromes_8\NNS\5870365|NONE_0 (l_compound) pain_7\NN\14299637|difficult_10|,_14|as_21
D007649_D009369 NONE ketamine_4\NN\3054098|NONE_0 (l_prep) in_5\IN\13603305|intravenous_21 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_compound) cancer_6\NN\14239425|on_16
D007649_D009369 NONE ketamine_7\NN\3054098|NONE_0 (r_pobj) of_6\IN\0|subhypnotic_18|(_12|0.25_13|)_37 (r_prep) doses_5\NNS\3740161|NONE_0 (r_pobj) of_3\IN\0|a_13|slow_11 (r_prep) bolus_2\NN\13899404|was_66|to_76|._195 (r_nsubjpass) given_16\VBN\5892096|NONE_0 (l_dative) to_17\IN\0|bolus_76|was_10|._119 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_compound) cancer_19\NN\14239425|10_3|was_27
D009020_D009369 NONE morphine_9\NN\2707683|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) on_8\IN\0|cancer_16 (r_prep) patients_7\NNS\9898892|NONE_0 (l_compound) cancer_6\NN\14239425|on_16
D009020_D009369 NONE morphine_26\NN\2707683|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_prep) unrelieved_24\JJ\0|pain_9|in_23 (r_acomp) was_23\VBD\0|10_30|cancer_27 (r_relcl) patients_20\NNS\9898892|NONE_0 (l_compound) cancer_19\NN\14239425|10_3|was_27
D009020_D009437 NONE morphine_3\NN\2707683|in_19 (r_compound) analgesia_4\NN\14034177|ketamine_30|can_21|._63 (l_prep) in_5\IN\13603305|morphine_19 (l_pobj) syndromes_8\NNS\5870365|NONE_0 (l_prep) as_11\IN\14622893|difficult_31|pain_21|,_7 (l_pobj) pain_13\NN\14299637|such_20
D009020_D010146 NONE morphine_4\NN\2707683|NONE_0 (r_pobj) to_3\IN\0|not_15 (r_prep) responsive_2\JJ\0|NONE_0 (r_amod) pain_0\NN\14299637|often_35|problematic_41|._52
D009020_D010146 NONE morphine_26\NN\2707683|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_prep) unrelieved_24\JJ\0|pain_9|in_23 (r_acomp) was_23\VBD\0|10_30|cancer_27 (l_nsubj) pain_22\NN\14299637|unrelieved_9|in_32
D009020_D010146 NONE morphine_3\NN\2707683|in_19 (r_compound) analgesia_4\NN\14034177|ketamine_30|can_21|._63 (l_prep) in_5\IN\13603305|morphine_19 (l_pobj) syndromes_8\NNS\5870365|NONE_0 (l_compound) pain_7\NN\14299637|difficult_10|,_14|as_21
3409645
D008727_D007172 CID methotrexate_23\NNP\2722166|NONE_0 (r_pobj) of_22\IN\0|the_11 (r_prep) taking_21\NN\37396|impotence_117|common_98|and_57|found_49|and_8|._22 (r_conj) was_1\VBD\0|NONE_0 (l_nsubj) impotence_0\NN\4723816|common_19|and_60|found_68|and_109|taking_117|._139
7234705
D011342_D008133 NONE procainamide_5\NN\0|that_5|can_13|syndrome_51|with_60 (r_nsubj) produce_7\VB\7555863|cases_40|._84 (l_dobj) syndrome_14\NN\5870365|that_56|procainamide_51|can_38|with_9
D011342_D018879 NONE procainamide_6\NN\0|in_33|,_2|was_13|orally_30|for_37|._114 (r_nsubjpass) administered_8\VBN\2436349|NONE_0 (l_prep) for_10\IN\0|in_70|,_39|procainamide_37|was_24|orally_7|._77 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) contractions_16\NNS\358931|NONE_0
D011342_D017180 CID procainamide_0\NNP\0|-_12|tachycardia_46|._57 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) tachycardia_5\NN\14110674|procainamide_46|-_34|._11
D011342_D017180 CID procainamide_3\RB\0|-_12 (r_advmod) induced_5\VBN\1627355|polymorphous_8|ventricular_21 (r_amod) tachycardia_8\NNS\14110674|NONE_0
D011342_D017180 CID procainamide_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|400_7 (r_prep) mg_15\IN\13717155|NONE_0 (r_pobj) of_11\IN\0|intravenous_27|for_33 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) after_8\IN\0|in_64|,_48|tachycardia_21|._120 (r_prep) appeared_7\VBD\2604760|NONE_0 (l_nsubj) tachycardia_6\NN\14110674|in_43|,_27|after_21|._141
D011342_D017180 CID procainamide_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|400_7 (r_prep) mg_15\IN\13717155|NONE_0 (r_pobj) of_11\IN\0|intravenous_27|for_33 (r_prep) administration_10\NN\1133281|NONE_0 (l_prep) for_18\IN\0|intravenous_60|of_33 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) of_21\IN\0|the_14 (l_pobj) tachycardia_24\NN\14110674|NONE_0
D011342_D017180 CID procainamide_16\NN\0|NONE_0 (r_amod) therapy_17\NN\657604|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) continuation_14\NN\407535|NONE_0 (r_pobj) despite_13\IN\7501545|,_44|tachycardia_71|did_83|not_87|._98 (r_prep) reoccur_24\VB\0|in_167|,_145|pacemaker_119|was_109|and_96|,_93 (l_nsubj) tachycardia_21\NN\14110674|despite_71|,_27|did_12|not_16|._27
D011342_D017180 CID procainamide_5\NN\0|that_5|can_13|syndrome_51|with_60 (r_nsubj) produce_7\VB\7555863|cases_40|._84 (l_prep) with_15\IN\0|that_65|procainamide_60|can_47|syndrome_9 (l_pobj) tachycardia_18\NN\14110674|NONE_0
D011342_D001282 NONE procainamide_6\NN\0|in_33|,_2|was_13|orally_30|for_37|._114 (r_nsubjpass) administered_8\VBN\2436349|NONE_0 (l_prep) for_10\IN\0|in_70|,_39|procainamide_37|was_24|orally_7|._77 (l_pobj) treatment_11\NN\654885|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) contractions_16\NNS\358931|NONE_0 (l_conj) flutter_19\NN\331950|chronic_53|premature_45|ventricular_35|or_10
1549199
D007980_D011618 NONE levodopa_13\RB\14604959|-_8 (r_npadvmod) induced_15\VBN\1627355|,_17|disturbances_25 (r_amod) psychosis_16\NN\14380140|orthostatic_42|,_19
D007980_D064420 NONE levodopa_9\NN\14604959|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) for_8\IN\0|NONE_0 (r_prep) dose_7\NN\3740161|NONE_0 (r_dobj) starting_6\NN\457382|no_18|single_15 (r_acl) correct_5\JJ\138508|while_25|there_19 (r_attr) is_2\VBZ\0|,_55|individuals_62|can_74|be_78|on_89|,_139|following_141|._268 (r_advcl) started_16\VBN\0|NONE_0 (l_prep) following_27\VBG\8180190|is_141|,_86|individuals_79|can_67|be_63|on_52|,_2|._127 (l_pobj) rule_30\NN\5835747|NONE_0 (l_relcl) attempt_33\VB\407535|the_24|general_20 (l_xcomp) titrate_35\VB\489837|not_18|to_14 (l_dobj) levodopa_38\NN\14604959|to_21 (l_relcl) lead_49\VB\5155821|carbidopa_58|-_49|to_39|,_13|"_12 (l_prep) to_50\IN\0|which_15|can_9 (l_pobj) toxicity_51\NN\13576101|NONE_0
D007980_D064420 NONE levodopa_38\NN\14604959|to_21 (l_relcl) lead_49\VB\5155821|carbidopa_58|-_49|to_39|,_13|"_12 (l_prep) to_50\IN\0|which_15|can_9 (l_pobj) toxicity_51\NN\13576101|NONE_0
D007980_D020447 CID levodopa_13\RB\14604959|-_8 (r_npadvmod) induced_15\VBN\1627355|,_17|disturbances_25 (r_amod) psychosis_16\NN\14380140|orthostatic_42|,_19 (l_conj) disturbances_19\NNS\407535|induced_25|,_8 (l_conj) parasomnias_21\NNS\0|sleep_22|or_3
D002230_D064420 NONE carbidopa_36\NN\0|-_9|to_19|,_45|"_46|lead_58 (r_compound) levodopa_38\NN\14604959|to_21 (l_relcl) lead_49\VB\5155821|carbidopa_58|-_49|to_39|,_13|"_12 (l_prep) to_50\IN\0|which_15|can_9 (l_pobj) toxicity_51\NN\13576101|NONE_0
D007980_D007024 CID levodopa_13\RB\14604959|-_8 (r_npadvmod) induced_15\VBN\1627355|,_17|disturbances_25 (r_amod) psychosis_16\NN\14380140|orthostatic_42|,_19 (r_conj) hypotension_11\NN\14057371|gastrointestinal_40|,_14
D007980_D012893 NONE levodopa_13\RB\14604959|-_8 (r_npadvmod) induced_15\VBN\1627355|,_17|disturbances_25 (r_amod) psychosis_16\NN\14380140|orthostatic_42|,_19 (l_conj) disturbances_19\NNS\407535|induced_25|,_8
D007980_D005767 CID levodopa_13\RB\14604959|-_8 (r_npadvmod) induced_15\VBN\1627355|,_17|disturbances_25 (r_amod) psychosis_16\NN\14380140|orthostatic_42|,_19 (r_conj) hypotension_11\NN\14057371|gastrointestinal_40|,_14 (r_conj) disorders_8\NNS\14034177|such_25
18308784
C035054_D007859 NONE rg1_1\NNP\0|impairment_17|._90 (r_nsubj) restores_2\VBZ\1631072|NONE_0 (l_dobj) impairment_4\NN\7296428|rg1_17|._73 (l_prep) of_5\IN\0|the_15|induced_12 (l_pobj) learning_6\VBG\5701944|NONE_0
C035054_D007859 NONE rg1_0\NNP\0|NONE_0 (l_advcl) ameliorate_11\VB\126264|,_55|._38 (l_dobj) impairment_14\NN\7296428|as_81|,_36|could_34
C035054_D007859 NONE rg1_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_11|on_7 (r_prep) effect_9\NN\34213|to_19 (l_prep) on_12\IN\0|the_18|of_7 (l_pobj) impairment_14\NN\7296428|NONE_0
D009020_D007859 CID morphine_10\NN\2707683|chronic_8|in_24 (r_compound) administration_11\NN\1133281|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|the_27|of_12 (r_acl) impairment_4\NN\7296428|rg1_17|._73 (l_prep) of_5\IN\0|the_15|induced_12 (l_pobj) learning_6\VBG\5701944|NONE_0
D009020_D007859 CID morphine_17\NN\2707683|chronic_8|and_24|mechanism_32 (r_compound) administration_18\NN\1133281|NONE_0 (r_pobj) by_15\IN\0|learning_20 (r_prep) impairment_14\NN\7296428|NONE_0
D036145_D007859 NONE ginsenoside_4\NN\0|NONE_0 (r_pobj) as_2\IN\14622893|,_45|could_47|impairment_81 (r_prep) ameliorate_11\VB\126264|,_55|._38 (l_dobj) impairment_14\NN\7296428|as_81|,_36|could_34
18768591
D004317_D034141 CID doxorubicin_0\NNP\2716866|NONE_0 (r_compound) treatment_1\NN\654885|in_19|)_86|and_88|15/44_92|._215 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_conj) 15/44_21\CD\0|treatment_92|in_73|)_6|and_4|._123 (l_prep) of_22\IN\0|NONE_0 (l_pobj) mice_25\NNS\2329401|NONE_0 (l_acl) leading_26\VBG\4339291|sgk1(-/-_15|)_7 (l_prep) to_27\IN\0|NONE_0 (l_pobj) syndrome_30\NN\5870365|NONE_0 (l_prep) with_31\IN\0|severe_26|nephrotic_19 (l_pobj) ascites_32\NNS\14204950|NONE_0 (l_conj) lipidemia_34\NN\14299637|,_2 (l_conj) hypoalbuminemia_37\VB\0|,_6|and_4
D000450_D009404 NONE aldosterone_1\NN\14751863|plasma_7 (r_compound) levels_2\NNS\4916342|in_17|and_53|followed_61|._124 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_prep) in_4\IN\13603305|levels_17|and_36|followed_44|._107 (l_pobj) mice_6\NNS\2329401|NONE_0 (l_amod) nephrotic_5\JJ\0|of_15
D012964_D007674 NONE sodium_7\NN\14625458|epithelial_11|retention_39 (r_compound) channel_8\NN\6251781|NONE_0 (r_pobj) to_5\IN\0|nephropathy_18|._81 (r_prep) leads_4\VBZ\5155821|NONE_0 (l_nsubj) nephropathy_3\NN\14573196|to_18|._99
D000450_D005355 NONE aldosterone_1\NN\14751863|-_11 (r_npadvmod) sensitive_3\JJ\10488309|the_16|kinase_46 (r_amod) sgk1_10\NNP\0|has_5|been_9|participate_23|._135 (r_nsubjpass) shown_13\VBN\2137132|NONE_0 (l_xcomp) participate_15\VB\2367363|sgk1_23|has_18|been_14|._112 (l_conj) mediate_23\VB\761713|to_49|in_34|and_7 (l_dobj) fibrosis_25\NN\14204950|to_17
D004317_D011507 CID doxorubicin_0\NNP\2716866|NONE_0 (r_compound) treatment_1\NN\654885|in_19|)_86|and_88|15/44_92|._215 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_prep) in_3\IN\13603305|treatment_19|)_67|and_69|15/44_73|._196 (l_pobj) proteinuria_5\NN\14299637|NONE_0
D014508_D009404 NONE urea_8\NN\14727670|serum_6 (r_compound) concentrations_9\NNS\4916342|during_52|,_13|faster_39|in_46|than_64|)_80 (r_nsubj) increased_10\VBD\169651|NONE_0 (l_prep) during_0\IN\0|,_39|concentrations_52|faster_91|in_98|than_116|)_132 (l_pobj) course_2\NN\883297|NONE_0 (l_prep) of_3\IN\0|the_11 (l_pobj) syndrome_5\NN\5870365|NONE_0
D004317_D001201 CID doxorubicin_0\NNP\2716866|NONE_0 (r_compound) treatment_1\NN\654885|in_19|)_86|and_88|15/44_92|._215 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_conj) 15/44_21\CD\0|treatment_92|in_73|)_6|and_4|._123 (l_prep) of_22\IN\0|NONE_0 (l_pobj) mice_25\NNS\2329401|NONE_0 (l_acl) leading_26\VBG\4339291|sgk1(-/-_15|)_7 (l_prep) to_27\IN\0|NONE_0 (l_pobj) syndrome_30\NN\5870365|NONE_0 (l_prep) with_31\IN\0|severe_26|nephrotic_19 (l_pobj) ascites_32\NNS\14204950|NONE_0
D004317_D009404 CID doxorubicin_8\NN\2716866|-_11 (r_npadvmod) induced_10\VBN\1627355|nephrotic_8 (r_amod) syndrome_12\NN\5870365|NONE_0
D004317_D009404 CID doxorubicin_0\NNP\2716866|NONE_0 (r_compound) treatment_1\NN\654885|in_19|)_86|and_88|15/44_92|._215 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_conj) 15/44_21\CD\0|treatment_92|in_73|)_6|and_4|._123 (l_prep) of_22\IN\0|NONE_0 (l_pobj) mice_25\NNS\2329401|NONE_0 (l_acl) leading_26\VBG\4339291|sgk1(-/-_15|)_7 (l_prep) to_27\IN\0|NONE_0 (l_pobj) syndrome_30\NN\5870365|NONE_0
D012964_D016055 NONE sodium_7\NN\14625458|epithelial_11|retention_39 (r_compound) channel_8\NN\6251781|NONE_0 (l_appos) retention_12\NN\809465|epithelial_50|sodium_39
D004317_D005355 NONE doxorubicin_0\NNP\2716866|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) nephropathy_3\NN\14573196|to_18|._99 (r_nsubj) leads_4\VBZ\5155821|NONE_0 (l_prep) to_5\IN\0|nephropathy_18|._81 (l_pobj) channel_8\NN\6251781|NONE_0 (l_appos) retention_12\NN\809465|epithelial_50|sodium_39 (l_conj) fibrosis_15\NN\14204950|(_44|enac)-dependent_43|volume_27|and_10
D004317_D006949 CID doxorubicin_0\NNP\2716866|NONE_0 (r_compound) treatment_1\NN\654885|in_19|)_86|and_88|15/44_92|._215 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_conj) 15/44_21\CD\0|treatment_92|in_73|)_6|and_4|._123 (l_prep) of_22\IN\0|NONE_0 (l_pobj) mice_25\NNS\2329401|NONE_0 (l_acl) leading_26\VBG\4339291|sgk1(-/-_15|)_7 (l_prep) to_27\IN\0|NONE_0 (l_pobj) syndrome_30\NN\5870365|NONE_0 (l_prep) with_31\IN\0|severe_26|nephrotic_19 (l_pobj) ascites_32\NNS\14204950|NONE_0 (l_conj) lipidemia_34\NN\14299637|,_2
D004317_D007674 NONE doxorubicin_0\NNP\2716866|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) nephropathy_3\NN\14573196|to_18|._99
D004317_D016055 NONE doxorubicin_0\NNP\2716866|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) nephropathy_3\NN\14573196|to_18|._99 (r_nsubj) leads_4\VBZ\5155821|NONE_0 (l_prep) to_5\IN\0|nephropathy_18|._81 (l_pobj) channel_8\NN\6251781|NONE_0 (l_appos) retention_12\NN\809465|epithelial_50|sodium_39
D012964_D005355 NONE sodium_7\NN\14625458|epithelial_11|retention_39 (r_compound) channel_8\NN\6251781|NONE_0 (l_appos) retention_12\NN\809465|epithelial_50|sodium_39 (l_conj) fibrosis_15\NN\14204950|(_44|enac)-dependent_43|volume_27|and_10
1967484
D013469_D004409 NONE sulpiride_11\NN\0|thought_51|,_2|-_9|dyskinesia_26 (r_npadvmod) induced_13\VBN\1627355|have_44|been_49|occasionally_63|._75 (l_dobj) dyskinesia_15\JJ\14084880|thought_77|,_28|sulpiride_26|-_17
D013469_D010302 NONE sulpiride_11\NN\0|thought_51|,_2|-_9|dyskinesia_26 (r_npadvmod) induced_13\VBN\1627355|have_44|been_49|occasionally_63|._75 (l_dobj) dyskinesia_15\JJ\14084880|thought_77|,_28|sulpiride_26|-_17 (l_conj) parkinsonism_17\NN\14085708|tardive_23|and_4
D013469_D004421 CID sulpiride_0\NNP\0|-_9|dystonia_26|._34 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dystonia_4\NN\0|sulpiride_26|-_17|._8
D013469_D004421 CID sulpiride_17\NN\0|NONE_0 (r_compound) therapy_18\NN\657604|NONE_0 (r_dobj) starting_16\VBG\457382|NONE_0 (r_pcomp) after_15\IN\0|who_60|dystonia_25|within_16 (r_prep) developed_8\VBD\1753788|a_22|old_12 (l_dobj) dystonia_11\NN\0|who_35|within_9|after_25
D013469_D004421 CID sulpiride_8\NN\0|-_9 (r_npadvmod) induced_10\VBN\1627355|tardive_8 (r_amod) dystonia_12\NN\0|NONE_0
12707296
D006854_D006973 NONE cortisol_7\NN\14751417|-_8 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) hypertension_10\NN\14057371|NONE_0
D006854_D006973 NONE cortisol_12\NN\14751417|-_8 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) hypertension_15\NN\14057371|NONE_0
D006854_D006973 NONE cortisol_3\NN\14751417|-_8 (r_npadvmod) induced_5\VBN\1627355|in_18 (r_amod) increases_6\NNS\13576355|that_22|are_28|not_32|with_47 (l_prep) in_7\IN\13603305|induced_18 (l_pobj) pressure_9\NN\11419404|NONE_0
D001120_D006973 NONE arginine_2\NN\14605787|in_19|with_29|._63 (r_compound) transport_3\NN\3575240|NONE_0 (l_prep) with_6\IN\0|arginine_29|in_10|._34 (l_pobj) hypertension_10\NN\14057371|NONE_0
D001120_D006973 NONE arginine_4\NN\14605787|l_2|-_1|-_8 (r_compound) nitric_6\NN\0|a_23|deficient_21|oxide_7 (r_compound) system_8\NN\3575240|is_7|in_21|._53 (r_nsubjpass) implicated_10\VBN\2677097|NONE_0 (l_prep) in_11\IN\13603305|system_21|is_14|._32 (l_pobj) hypertension_15\NN\14057371|NONE_0
D001120_D006973 NONE arginine_19\NN\14605787|the_6|transport_9 (r_compound) system_21\NN\3575240|NONE_0 (r_pobj) in_15\IN\13603305|NONE_0 (r_prep) abnormalities_14\NNS\14034177|NONE_0 (r_pobj) with_13\IN\0|that_69|increases_47|are_19|not_15 (r_prep) associated_12\VBN\628491|we_70|._64 (l_nsubjpass) increases_6\NNS\13576355|that_22|are_28|not_32|with_47 (l_prep) in_7\IN\13603305|induced_18 (l_pobj) pressure_9\NN\11419404|NONE_0
D009569_D006973 NONE oxide_7\NN\14818238|a_30|deficient_28|nitric_7 (r_compound) system_8\NN\3575240|is_7|in_21|._53 (r_nsubjpass) implicated_10\VBN\2677097|NONE_0 (l_prep) in_11\IN\13603305|system_21|is_14|._32 (l_pobj) hypertension_15\NN\14057371|NONE_0
2440413
D005680_D012640 NONE gaba_24\NNP\14601829|-_4 (r_compound) a_26\NNP\13649268|the_9|linked_11|chloride_18 (r_nmod) channel_31\NN\6251781|that_127|site_118|hch_47|may_43 (r_attr) be_22\VB\14625458|data_101|._46 (l_nsubj) site_7\NN\8673395|that_9|hch_71|may_75|channel_118 (l_amod) responsible_8\JJ\0|the_9|h_52 (l_prep) for_9\IN\0|NONE_0 (l_pobj) decrease_11\NN\7296428|NONE_0 (l_prep) in_12\IN\13603305|the_13 (l_pobj) activity_14\NN\30358|NONE_0 (l_compound) seizure_13\NN\14081375|NONE_0
C034818_D012640 CID carboline-3-carboxylate_36\NNP\0|3-mercaptopropionic_82|mpa_56|,_52|bicuculline_50|bcc_37|,_33|(_46|str_47|)_50 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
C034818_D012640 CID carboline-3-carboxylate_36\NNP\0|3-mercaptopropionic_82|mpa_56|,_52|bicuculline_50|bcc_37|,_33|(_46|str_47|)_50 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
C034818_D012640 CID dmcm_38\NNP\0|methyl_56|6,7-dimethoxy-4-ethyl_49|-_28|b_27|-_26|(_1|)_4|,_5|or_7|strychnine_10 (r_appos) carboline-3-carboxylate_36\NNP\0|3-mercaptopropionic_82|mpa_56|,_52|bicuculline_50|bcc_37|,_33|(_46|str_47|)_50 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
C034818_D012640 CID dmcm_38\NNP\0|methyl_56|6,7-dimethoxy-4-ethyl_49|-_28|b_27|-_26|(_1|)_4|,_5|or_7|strychnine_10 (r_appos) carboline-3-carboxylate_36\NNP\0|3-mercaptopropionic_82|mpa_56|,_52|bicuculline_50|bcc_37|,_33|(_46|str_47|)_50 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D001640_D012640 CID bicuculline_26\NN\0|3-mercaptopropionic_32|mpa_6|,_2|bcc_13|,_17|carboline-3-carboxylate_50|(_96|str_97|)_100 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D001640_D012640 CID bicuculline_26\NN\0|3-mercaptopropionic_32|mpa_6|,_2|bcc_13|,_17|carboline-3-carboxylate_50|(_96|str_97|)_100 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D001640_D012640 CID bcc_28\NNP\0|3-mercaptopropionic_45|mpa_19|,_15|bicuculline_13|,_4|carboline-3-carboxylate_37|(_83|str_84|)_87 (r_appos) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D001640_D012640 CID bcc_28\NNP\0|3-mercaptopropionic_45|mpa_19|,_15|bicuculline_13|,_4|carboline-3-carboxylate_37|(_83|str_84|)_87 (r_appos) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D013331_D012640 CID strychnine_42\NN\14712692|methyl_66|6,7-dimethoxy-4-ethyl_59|-_38|b_37|-_36|(_11|dmcm_10|)_6|,_5|or_3 (r_conj) carboline-3-carboxylate_36\NNP\0|3-mercaptopropionic_82|mpa_56|,_52|bicuculline_50|bcc_37|,_33|(_46|str_47|)_50 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D013331_D012640 CID strychnine_42\NN\14712692|methyl_66|6,7-dimethoxy-4-ethyl_59|-_38|b_37|-_36|(_11|dmcm_10|)_6|,_5|or_3 (r_conj) carboline-3-carboxylate_36\NNP\0|3-mercaptopropionic_82|mpa_56|,_52|bicuculline_50|bcc_37|,_33|(_46|str_47|)_50 (r_conj) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D013331_D012640 CID str_44\NNP\0|3-mercaptopropionic_129|mpa_103|,_99|bicuculline_97|bcc_84|,_80|carboline-3-carboxylate_47|(_1|)_3 (r_appos) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D013331_D012640 CID str_44\NNP\0|3-mercaptopropionic_129|mpa_103|,_99|bicuculline_97|bcc_84|,_80|carboline-3-carboxylate_47|(_1|)_3 (r_appos) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D015097_D012640 CID acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D015097_D012640 CID acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D015097_D012640 CID mpa_23\NNP\0|3-mercaptopropionic_26|,_4|bicuculline_6|bcc_19|,_23|carboline-3-carboxylate_56|(_102|str_103|)_106 (r_appos) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (r_nsubj) was_46\VBD\0|NONE_0 (l_ccomp) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (l_nsubjpass) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D015097_D012640 CID mpa_23\NNP\0|3-mercaptopropionic_26|,_4|bicuculline_6|bcc_19|,_23|carboline-3-carboxylate_56|(_102|str_103|)_106 (r_appos) acid_21\NN\14818238|NONE_0 (r_pobj) to_19\IN\0|NONE_0 (r_pcomp) due_18\IN\5174653|seizure_17 (r_prep) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D010433_D012640 CID ptz_27\NNP\0|NONE_0 (r_pobj) to_24\TO\0|to_30|threshold_10 (r_prep) decrease_21\VB\7296428|hexachlorocyclohexane_103|has_18|been_14|)_50 (l_dobj) threshold_23\NN\15265518|to_20|to_10 (l_compound) seizure_22\NN\14081375|NONE_0
D010433_D012640 CID ptz_13\NNP\0|-_3 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) seizures_16\NNS\14081375|NONE_0
D010433_D012640 CID ptz_4\NNP\0|to_3 (r_pobj) due_2\IN\5174653|seizure_17 (r_amod) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D010433_D012640 CID ptz_4\NNP\0|to_3 (r_pobj) due_2\IN\5174653|seizure_17 (r_amod) activity_1\NN\30358|was_41|significantly_45 (r_nsubjpass) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (r_ccomp) was_46\VBD\0|NONE_0 (l_nsubj) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D010433_D012640 CID ptz_14\NNP\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|seizure_17 (r_acl) activity_11\NN\30358|NONE_0 (l_compound) seizure_10\NN\14081375|induced_17
D010433_D012640 CID ptz_14\NNP\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|seizure_17 (r_acl) activity_11\NN\30358|NONE_0 (r_pobj) to_9\IN\0|that_25|tolerance_20|may_10|h_46|,_63|decreased_129 (r_prep) occur_8\VB\0|data_32|._144 (l_advcl) decreased_36\VBN\169651|that_154|tolerance_149|may_139|to_129|h_83|,_66 (l_nsubjpass) response_26\NN\11410625|since_10|is_51 (l_prep) to_27\IN\0|the_13 (l_pobj) agents_34\NNS\7347|NONE_0 (l_amod) inducing_33\VBG\42311|only_23|these_18|two_12 (l_npadvmod) seizure_31\NN\14081375|-_7
D001556_D012640 NONE hexachlorocyclohexane_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|differential_21|on_41|._78 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_9\IN\0|differential_62|of_41|._37 (l_pobj) seizures_13\NNS\14081375|NONE_0
D001556_D012640 NONE lindane_7\NN\14919948|gamma_29|-_24 (r_appos) hexachlorocyclohexane_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|differential_21|on_41|._78 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_9\IN\0|differential_62|of_41|._37 (l_pobj) seizures_13\NNS\14081375|NONE_0
D001556_D012640 NONE hexachlorocyclohexane_2\NN\0|has_85|been_89|decrease_103|)_153 (r_nsubjpass) shown_19\VBN\2137132|NONE_0 (l_xcomp) decrease_21\VB\7296428|hexachlorocyclohexane_103|has_18|been_14|)_50 (l_dobj) threshold_23\NN\15265518|to_20|to_10 (l_compound) seizure_22\NN\14081375|NONE_0
D001556_D012640 NONE hch_6\NNP\0|gamma_35|-_30|(_7|)_3|,_4|ingredient_17|,_54 (r_appos) hexachlorocyclohexane_2\NN\0|has_85|been_89|decrease_103|)_153 (r_nsubjpass) shown_19\VBN\2137132|NONE_0 (l_xcomp) decrease_21\VB\7296428|hexachlorocyclohexane_103|has_18|been_14|)_50 (l_dobj) threshold_23\NN\15265518|to_20|to_10 (l_compound) seizure_22\NN\14081375|NONE_0
D001556_D012640 NONE lindane_15\NN\14919948|NONE_0 (r_pobj) of_12\IN\0|the_22|active_18 (r_prep) ingredient_11\NN\3081021|gamma_52|-_47|(_24|hch_17|)_14|,_13|,_37 (r_appos) hexachlorocyclohexane_2\NN\0|has_85|been_89|decrease_103|)_153 (r_nsubjpass) shown_19\VBN\2137132|NONE_0 (l_xcomp) decrease_21\VB\7296428|hexachlorocyclohexane_103|has_18|been_14|)_50 (l_dobj) threshold_23\NN\15265518|to_20|to_10 (l_compound) seizure_22\NN\14081375|NONE_0
D001556_D012640 NONE hch_7\NNP\0|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) exposure_3\NN\5042871|NONE_0 (r_pobj) after_2\IN\0|3_4|and_28|increase_43 (r_prep) h_1\NN\14622893|24_88|after_93|)_141|._142 (l_conj) increase_10\VB\13576355|3_47|after_43|and_15 (l_prep) to_12\IN\0|conversely_30|threshold_10 (l_pobj) seizures_16\NNS\14081375|NONE_0
D001556_D012640 NONE hch_24\NNP\0|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) exposure_20\NN\5042871|NONE_0 (r_pobj) after_19\IN\0|h_93|24_5|)_48|._49 (r_prep) h_18\NN\14622893|NONE_0 (l_dep) h_1\NN\14622893|24_88|after_93|)_141|._142 (l_conj) increase_10\VB\13576355|3_47|after_43|and_15 (l_prep) to_12\IN\0|conversely_30|threshold_10 (l_pobj) seizures_16\NNS\14081375|NONE_0
D001556_D012640 NONE hch_30\NNP\0|NONE_0 (r_pobj) of_25\IN\0|intraperitoneal_31 (r_prep) administration_24\NN\1133281|NONE_0 (r_pobj) after_22\IN\0|in_103|,_90|severity_84|was_30|in_19|h_2|._58 (r_prep) tested_15\VBN\670261|NONE_0 (l_nsubjpass) severity_5\NN\5036394|in_19|,_6|was_54|in_65|h_82|after_84|._142 (l_prep) of_6\IN\0|the_13 (l_pobj) response_7\NN\11410625|NONE_0 (l_prep) to_8\IN\0|NONE_0 (l_pobj) agents_13\NNS\7347|NONE_0 (l_amod) inducing_12\VBG\42311|other_14 (l_npadvmod) seizure_10\NN\14081375|-_7
D001556_D012640 NONE hch_8\NNP\0|NONE_0 (r_pobj) of_5\IN\0|the_19 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) after_2\IN\0|hour_5|,_37|activity_43|was_79 (r_prep) increased_18\VBN\169651|,_9|regardless_11|,_40|while_42|h_51|response_84|was_93|._105 (l_nsubjpass) activity_11\NN\30358|hour_48|after_43|,_6|was_36 (l_prep) of_12\IN\0|the_13 (l_pobj) agents_16\NNS\7347|NONE_0 (l_amod) inducing_15\VBG\42311|NONE_0 (l_npadvmod) seizure_13\NN\14081375|-_7
D001556_D012640 NONE hch_31\NNP\0|24_17|after_12 (r_appos) h_27\NN\14622893|increased_51|,_42|regardless_40|,_11|while_9|response_33|was_42|._54 (r_dep) observed_36\VBN\2163746|NONE_0 (l_advcl) increased_18\VBN\169651|,_9|regardless_11|,_40|while_42|h_51|response_84|was_93|._105 (l_nsubjpass) activity_11\NN\30358|hour_48|after_43|,_6|was_36 (l_prep) of_12\IN\0|the_13 (l_pobj) agents_16\NNS\7347|NONE_0 (l_amod) inducing_15\VBG\42311|NONE_0 (l_npadvmod) seizure_13\NN\14081375|-_7
D001556_D012640 NONE hch_22\NNP\0|NONE_0 (r_pobj) after_19\IN\0|24_5 (r_prep) h_18\NN\14622893|that_71|tolerance_66|may_56|to_46|,_17|decreased_83 (r_npadvmod) occur_8\VB\0|data_32|._144 (l_prep) to_9\IN\0|that_25|tolerance_20|may_10|h_46|,_63|decreased_129 (l_pobj) activity_11\NN\30358|NONE_0 (l_compound) seizure_10\NN\14081375|induced_17
D001556_D012640 NONE hch_22\NNP\0|NONE_0 (r_pobj) after_19\IN\0|24_5 (r_prep) h_18\NN\14622893|that_71|tolerance_66|may_56|to_46|,_17|decreased_83 (r_npadvmod) occur_8\VB\0|data_32|._144 (l_advcl) decreased_36\VBN\169651|that_154|tolerance_149|may_139|to_129|h_83|,_66 (l_nsubjpass) response_26\NN\11410625|since_10|is_51 (l_prep) to_27\IN\0|the_13 (l_pobj) agents_34\NNS\7347|NONE_0 (l_amod) inducing_33\VBG\42311|only_23|these_18|two_12 (l_npadvmod) seizure_31\NN\14081375|-_7
D001556_D012640 NONE hch_20\NNP\0|that_80|site_71|may_4|channel_47 (r_nsubj) be_22\VB\14625458|data_101|._46 (l_nsubj) site_7\NN\8673395|that_9|hch_71|may_75|channel_118 (l_amod) responsible_8\JJ\0|the_9|h_52 (l_prep) for_9\IN\0|NONE_0 (l_pobj) decrease_11\NN\7296428|NONE_0 (l_prep) in_12\IN\13603305|the_13 (l_pobj) activity_14\NN\30358|NONE_0 (l_compound) seizure_13\NN\14081375|NONE_0
D010852_D012640 CID picrotoxin_6\NN\0|and_4|ptx_12 (r_conj) ptz_4\NNP\0|to_3 (r_pobj) due_2\IN\5174653|seizure_17 (r_amod) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D010852_D012640 CID picrotoxin_6\NN\0|and_4|ptx_12 (r_conj) ptz_4\NNP\0|to_3 (r_pobj) due_2\IN\5174653|seizure_17 (r_amod) activity_1\NN\30358|was_41|significantly_45 (r_nsubjpass) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (r_ccomp) was_46\VBD\0|NONE_0 (l_nsubj) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D010852_D012640 CID ptx_8\NNP\0|and_16|picrotoxin_12 (r_appos) ptz_4\NNP\0|to_3 (r_pobj) due_2\IN\5174653|seizure_17 (r_amod) activity_1\NN\30358|was_41|significantly_45 (l_compound) seizure_0\NN\14081375|due_17
D010852_D012640 CID ptx_8\NNP\0|and_16|picrotoxin_12 (r_appos) ptz_4\NNP\0|to_3 (r_pobj) due_2\IN\5174653|seizure_17 (r_amod) activity_1\NN\30358|was_41|significantly_45 (r_nsubjpass) decreased_12\VBN\169651|;_9|however_11|,_18|activity_28|not_182|different_186|._208 (r_ccomp) was_46\VBD\0|NONE_0 (l_nsubj) activity_17\NN\30358|decreased_28|;_19|however_17|,_10|not_154|different_158|._180 (l_compound) seizure_16\NN\14081375|due_17
D010852_D012640 CID ptx_16\NNP\0|and_4 (r_conj) ptz_14\NNP\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|seizure_17 (r_acl) activity_11\NN\30358|NONE_0 (l_compound) seizure_10\NN\14081375|induced_17
D010852_D012640 CID ptx_16\NNP\0|and_4 (r_conj) ptz_14\NNP\0|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|seizure_17 (r_acl) activity_11\NN\30358|NONE_0 (r_pobj) to_9\IN\0|that_25|tolerance_20|may_10|h_46|,_63|decreased_129 (r_prep) occur_8\VB\0|data_32|._144 (l_advcl) decreased_36\VBN\169651|that_154|tolerance_149|may_139|to_129|h_83|,_66 (l_nsubjpass) response_26\NN\11410625|since_10|is_51 (l_prep) to_27\IN\0|the_13 (l_pobj) agents_34\NNS\7347|NONE_0 (l_amod) inducing_33\VBG\42311|only_23|these_18|two_12 (l_npadvmod) seizure_31\NN\14081375|-_7
1527456
D008012_D014012 NONE lignocaine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|intratympanic_27 (r_prep) instillation_5\NN\320852|NONE_0 (r_pobj) by_3\IN\0|of_12|2_56|through_67|._92 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|by_12|2_68|through_79|._104 (l_pobj) tinnitus_2\NN\14299637|NONE_0
D008012_D014012 NONE lidocaine_9\NN\3681148|NONE_0 (r_appos) lignocaine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|intratympanic_27 (r_prep) instillation_5\NN\320852|NONE_0 (r_pobj) by_3\IN\0|of_12|2_56|through_67|._92 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) of_1\IN\0|by_12|2_68|through_79|._104 (l_pobj) tinnitus_2\NN\14299637|NONE_0
D008012_D014012 NONE lignocaine_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|intratympanic_27 (r_prep) instillation_10\NN\320852|NONE_0 (r_pobj) by_8\IN\0|ist_4 (r_prep) treating_6\VBG\2376958|NONE_0 (l_dobj) ist_7\NNP\0|by_4
D008012_D014012 NONE lidocaine_14\NN\3681148|NONE_0 (r_appos) lignocaine_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|intratympanic_27 (r_prep) instillation_10\NN\320852|NONE_0 (r_pobj) by_8\IN\0|ist_4 (r_prep) treating_6\VBG\2376958|NONE_0 (l_dobj) ist_7\NNP\0|by_4
2515254
D005996_D008881 CID nitroglycerin_11\NN\15015501|NONE_0 (r_pobj) of_10\IN\0|a_39|one_37|sided_33|frontotemporal_27 (r_prep) application_9\NN\947128|patients_45|._100 (r_dobj) received_4\VBD\2210855|NONE_0 (l_nsubj) patients_3\NNS\9898892|application_45|._145 (l_compound) migraine_2\NN\14326607|twenty_14|common_7
D005996_D008881 CID nitroglycerin_7\NN\15015501|NONE_0 (r_pobj) by_6\IN\0|attacks_21|were_13|in_17|._83 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) attacks_3\NNS\955060|were_8|by_21|in_38|._104 (l_compound) migraine_2\NN\14326607|early_12|onset_6
D005996_D008881 CID nitroglycerin_13\NN\15015501|NONE_0 (r_pobj) with_11\IN\0|an_22|early_19|onset_13 (r_prep) attack_10\NN\955060|who_29 (r_dobj) developed_6\VBD\1753788|20_26|migraine_23|,_6|,_65 (r_relcl) patients_3\NNS\9898892|subsequently_25|drug_94|in_99|._145 (l_compound) migraine_2\NN\14326607|20_3|,_17|developed_23|,_88
D005996_D008881 CID nitroglycerin_7\NN\15015501|NONE_0 (r_pobj) of_6\IN\0|the_29|inducing_16 (r_prep) effect_5\NN\34213|thus_27|depend_33|,_90|suggesting_92|._198 (l_amod) inducing_4\VBG\42311|the_13|of_16 (l_npadvmod) migraine_2\NN\14326607|-_8
D005996_D008881 CID nitroglycerin_7\NN\15015501|NONE_0 (r_pobj) of_6\IN\0|the_29|inducing_16 (r_prep) effect_5\NN\34213|thus_27|depend_33|,_90|suggesting_92|._198 (r_nsubj) seems_8\VBZ\2604760|NONE_0 (l_advcl) suggesting_21\VBG\1010118|thus_119|effect_92|depend_59|,_2|._106 (l_ccomp) is_26\VBZ\0|NONE_0 (l_prep) of_27\IN\0|that_34|region_10 (l_pobj) importance_29\NN\5138488|NONE_0 (l_prep) in_30\IN\13603305|crucial_19 (l_pobj) development_32\NN\248977|NONE_0 (l_prep) of_33\IN\0|the_16 (l_pobj) crisis_36\NN\14411243|NONE_0 (l_compound) migraine_35\JJ\14326607|a_2
D005996_D010146 NONE nitroglycerin_7\NN\15015501|NONE_0 (r_pobj) of_6\IN\0|the_29|inducing_16 (r_prep) effect_5\NN\34213|thus_27|depend_33|,_90|suggesting_92|._198 (r_nsubj) seems_8\VBZ\2604760|NONE_0 (l_xcomp) depend_10\VB\2604760|thus_60|effect_33|,_57|suggesting_59|._165 (l_prep) on_11\IN\0|to_10 (l_pobj) stimulation_13\NN\242808|NONE_0 (l_prep) of_14\IN\0|direct_19 (l_pobj) site_17\NN\8673395|NONE_0 (l_prep) of_18\IN\0|the_18|habitual_14 (l_pobj) pain_19\NN\14299637|NONE_0
20080983
D003042_D012893 CID cocaine_23\NN\3492717|chronic_8 (r_compound) users_24\NNS\7846|NONE_0 (r_pobj) in_21\IN\13603305|daytime_19 (r_prep) sleepiness_20\NN\14015731|dosed_37|on_21
D003042_D012893 CID cocaine_18\NN\3492717|abstinent_10 (r_compound) users_19\NNS\7846|NONE_0 (r_pobj) in_16\IN\13603305|daytime_19 (r_prep) sleepiness_15\NN\14015731|NONE_0
C048833_D012893 NONE modafinil_15\NN\0|NONE_0 (l_conj) sleepiness_20\NN\14015731|dosed_37|on_21
C048833_D012893 NONE modafinil_0\NNP\0|was_10|with_25|,_61|measured_66|._177 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_advcl) measured_10\VBN\697589|modafinil_66|was_56|with_41|,_5|._111 (l_conj) decrease_22\NN\7296428|as_73|by_61|,_27|and_25 (l_prep) in_23\IN\13603305|a_30|significant_21 (l_pobj) sleepiness_26\NN\14015731|NONE_0
C048833_D012893 NONE modafinil_3\NN\0|sleep_29|,_34|normalizes_36|._126 (r_nsubj) promotes_4\VBZ\2556126|NONE_0 (l_conj) normalizes_8\VBZ\109660|modafinil_36|sleep_7|,_2|._90 (l_conj) decreases_13\VBZ\7296428|architecture_18|,_6|and_4 (l_dobj) sleepiness_15\NN\14015731|NONE_0
3125768
D015760_D009127 CID alfentanil_4\NN\0|-_10 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) rigidity_7\NN\5023233|NONE_0
D015760_D009127 CID alfentanil_8\NN\0|-_10 (r_npadvmod) induced_10\VBN\1627355|in_17 (r_amod) rigidity_11\NN\5023233|NONE_0
D015760_D009127 CID alfentanil_9\NN\0|that_39|rigidity_34|should_25|be_18|,_10|and_12|,_15|used_48 (r_advcl) prevented_7\VBN\0|observations_45|._126 (l_nsubjpass) rigidity_4\NN\5023233|that_5|should_9|be_16|alfentanil_34|,_44|and_46|,_49|used_82
C032943_D009127 NONE metocurine_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|when_28|rigidity_23|was_14 (r_prep) abolished_8\VBN\0|variables_49|to_30|._25 (l_nsubjpass) rigidity_6\NN\5023233|when_5|was_9|with_23
20698227
C473478_D006461 CID sunitinib_16\JJ\0|such_8 (r_pobj) as_15\IN\14622893|angiogenesis_29 (r_prep) inhibitors_13\NNS\20090|NONE_0 (r_pobj) of_11\IN\0|a_9 (r_prep) number_10\NN\5107765|have_66|been_71|cause_85|._106 (r_nsubjpass) found_21\VBN\13279262|ribavirin_131|has_121|been_117|inhibit_103 (l_advcl) cause_23\VB\7323922|number_85|have_19|been_14|._21 (l_dobj) hemolysis_25\NN\13509528|to_15
D012254_D006461 NONE ribavirin_1\RB\2725367|has_10|been_14|inhibit_28|found_131 (r_nsubjpass) found_4\VBN\13279262|NONE_0 (l_conj) found_21\VBN\13279262|ribavirin_131|has_121|been_117|inhibit_103 (l_advcl) cause_23\VB\7323922|number_85|have_19|been_14|._21 (l_dobj) hemolysis_25\NN\13509528|to_15
C471405_D006461 CID sorafenib_18\NNS\0|and_4 (r_conj) sunitinib_16\JJ\0|such_8 (r_pobj) as_15\IN\14622893|angiogenesis_29 (r_prep) inhibitors_13\NNS\20090|NONE_0 (r_pobj) of_11\IN\0|a_9 (r_prep) number_10\NN\5107765|have_66|been_71|cause_85|._106 (r_nsubjpass) found_21\VBN\13279262|ribavirin_131|has_121|been_117|inhibit_103 (l_advcl) cause_23\VB\7323922|number_85|have_19|been_14|._21 (l_dobj) hemolysis_25\NN\13509528|to_15
C100416_D019698 NONE 2a_14\CD\0|NONE_0 (r_pobj) by_10\IN\0|infected_45|were_13|._46 (r_agent) treated_9\VBN\2376958|NONE_0 (l_csubjpass) infected_3\VBN\2316868|were_32|by_45|._91 (l_prep) with_4\IN\0|patients_30|chronically_21 (l_pobj) virus_7\NN\9312843|NONE_0
D012254_D019698 NONE ribavirin_16\RB\2725367|pegylated_34|interferon_24|alpha_13|and_4 (r_conj) 2a_14\CD\0|NONE_0 (r_pobj) by_10\IN\0|infected_45|were_13|._46 (r_agent) treated_9\VBN\2376958|NONE_0 (l_csubjpass) infected_3\VBN\2316868|were_32|by_45|._91 (l_prep) with_4\IN\0|patients_30|chronically_21 (l_pobj) virus_7\NN\9312843|NONE_0
D012254_D019698 NONE ribavirin_16\RB\2725367|soluble_20|and_4 (r_conj) markers_14\NNS\21939|NONE_0 (r_dobj) angiogenesis_12\NN\13489037|NONE_0 (r_pobj) between_11\IN\0|a_7 (r_prep) link_10\NN\13792579|NONE_0 (r_dobj) investigating_8\VBG\575741|the_34|first_30|in_18 (r_acl) study_4\NN\635850|this_18|induced_96 (r_attr) is_1\VBZ\0|NONE_0 (l_advcl) induced_17\VBD\1627355|this_114|study_96 (l_dobj) anemia_18\NN\14189204|and_36|find_53 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) c_23\NNP\13714184|NONE_0
D012254_D000740 NONE ribavirin_16\RB\2725367|soluble_20|and_4 (r_conj) markers_14\NNS\21939|NONE_0 (r_dobj) angiogenesis_12\NN\13489037|NONE_0 (r_pobj) between_11\IN\0|a_7 (r_prep) link_10\NN\13792579|NONE_0 (r_dobj) investigating_8\VBG\575741|the_34|first_30|in_18 (r_acl) study_4\NN\635850|this_18|induced_96 (r_attr) is_1\VBZ\0|NONE_0 (l_advcl) induced_17\VBD\1627355|this_114|study_96 (l_dobj) anemia_18\NN\14189204|and_36|find_53
D012254_D000743 NONE ribavirin_8\RB\2725367|NONE_0 (r_pobj) for_7\IN\0|NONE_0 (r_prep) treatment_6\NN\654885|NONE_0 (r_pobj) of_5\IN\0|a_9|associated_27 (r_prep) target_4\NN\7258332|can_22|angiogenesis_18|?_61 (l_acl) associated_9\VBN\628491|a_36|of_27 (l_dobj) anemia_11\NN\14189204|NONE_0
18261172
D000806_D007674 NONE acei_5\NNP\0|/_4|arb_5|and_17|patients_21|monitored_30 (r_nmod) therapy_8\NN\657604|NONE_0 (r_pobj) with_4\IN\0|srl_19|should_15|be_8|and_61|increased_65|._92 (r_prep) used_3\VBN\0|NONE_0 (l_conj) increased_15\VBD\169651|srl_84|should_80|be_73|with_65|and_4|._27 (l_dobj) dysfunction_17\NN\14204950|NONE_0
D020123_D011507 CID sirolimus_6\NN\0|-_9 (r_npadvmod) based_8\VBN\0|in_24 (r_amod) immunosuppression_9\NN\13973990|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) switch_4\NN\3096960|NONE_0 (r_pobj) after_3\IN\0|of_15|._90 (r_prep) development_0\NN\248977|NONE_0 (l_prep) of_1\IN\0|after_15|._105 (l_pobj) proteinuria_2\NN\14299637|NONE_0
D020123_D011507 CID sirolmus_7\NN\0|immunosuppressive_28|(_10|is_9|effects_33 (r_nsubj) lacks_11\VBZ\14449126|;_25|however_27|,_34|proteinuria_36|has_68|been_72|following_86|._117 (r_ccomp) reported_23\VBN\831651|NONE_0 (l_nsubjpass) proteinuria_17\NN\14299637|lacks_36|;_11|however_9|,_2|has_32|been_36|following_50|._81
D020123_D011507 CID srl_9\NNP\0|)_17|drug_15|(_1|)_3 (r_appos) sirolmus_7\NN\0|immunosuppressive_28|(_10|is_9|effects_33 (r_nsubj) lacks_11\VBZ\14449126|;_25|however_27|,_34|proteinuria_36|has_68|been_72|following_86|._117 (r_ccomp) reported_23\VBN\831651|NONE_0 (l_nsubjpass) proteinuria_17\NN\14299637|lacks_36|;_11|however_9|,_2|has_32|been_36|following_50|._81
D020123_D011507 CID srl_20\NNP\0|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) associated_18\VBN\628491|NONE_0 (r_acl) proteinuria_17\NN\14299637|lacks_36|;_11|however_9|,_2|has_32|been_36|following_50|._81
D020123_D011507 CID srl_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|the_29|of_15 (r_acl) incidence_5\NN\13821570|in_32|,_6|unknown_48|._55 (l_prep) of_6\IN\0|the_14|associated_15 (l_pobj) proteinuria_7\NN\14299637|NONE_0
D020123_D011507 CID srl_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) switch_10\NN\3096960|NONE_0 (r_pobj) after_9\IN\0|thus_61|,_57|proteinuria_55|may_43|in_31|._89 (r_prep) develop_4\VB\1753788|NONE_0 (l_nsubj) proteinuria_2\NN\14299637|thus_6|,_2|may_12|in_24|after_55|._144
D020123_D011507 CID srl_0\NNP\0|should_4|be_11|with_19|and_80|increased_84|._111 (r_nsubjpass) used_3\VBN\0|NONE_0 (l_prep) with_4\IN\0|srl_19|should_15|be_8|and_61|increased_65|._92 (l_pobj) therapy_8\NN\657604|NONE_0 (l_acl) monitored_11\VBD\2169352|acei_30|/_26|arb_25|and_13|patients_9 (l_prep) for_12\IN\0|NONE_0 (l_pobj) proteinuria_13\NN\14299637|NONE_0
D057911_D007674 NONE arb_7\NNP\9882007|acei_5|/_1|and_12|patients_16|monitored_25 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) with_4\IN\0|srl_19|should_15|be_8|and_61|increased_65|._92 (r_prep) used_3\VBN\0|NONE_0 (l_conj) increased_15\VBD\169651|srl_84|should_80|be_73|with_65|and_4|._27 (l_dobj) dysfunction_17\NN\14204950|NONE_0
D057911_D011507 NONE blocker_6\NN\10101634|(_8|arb_9|)_12 (r_nmod) therapy_10\NN\657604|ace_54|and_40 (r_conj) inhibitor_1\NN\20090|development_78|._89 (r_nsubj) reduced_11\VBN\441445|NONE_0 (l_dobj) development_13\NN\248977|inhibitor_78|._11 (l_compound) proteinuria_12\NN\14299637|NONE_0
D057911_D011507 NONE arb_8\NNP\9882007|blocker_9|(_1|)_3 (r_nmod) therapy_10\NN\657604|ace_54|and_40 (r_conj) inhibitor_1\NN\20090|development_78|._89 (r_nsubj) reduced_11\VBN\441445|NONE_0 (l_dobj) development_13\NN\248977|inhibitor_78|._11 (l_compound) proteinuria_12\NN\14299637|NONE_0
D057911_D011507 NONE arb_7\NNP\9882007|acei_5|/_1|and_12|patients_16|monitored_25 (r_compound) therapy_8\NN\657604|NONE_0 (l_acl) monitored_11\VBD\2169352|acei_30|/_26|arb_25|and_13|patients_9 (l_prep) for_12\IN\0|NONE_0 (l_pobj) proteinuria_13\NN\14299637|NONE_0
D000806_D011507 NONE inhibitor_1\NN\20090|development_78|._89 (r_nsubj) reduced_11\VBN\441445|NONE_0 (l_dobj) development_13\NN\248977|inhibitor_78|._11 (l_compound) proteinuria_12\NN\14299637|NONE_0
D000806_D011507 NONE acei_5\NNP\0|/_4|arb_5|and_17|patients_21|monitored_30 (r_nmod) therapy_8\NN\657604|NONE_0 (l_acl) monitored_11\VBD\2169352|acei_30|/_26|arb_25|and_13|patients_9 (l_prep) for_12\IN\0|NONE_0 (l_pobj) proteinuria_13\NN\14299637|NONE_0
D020123_D007674 NONE sirolmus_7\NN\0|immunosuppressive_28|(_10|is_9|effects_33 (r_nsubj) lacks_11\VBZ\14449126|;_25|however_27|,_34|proteinuria_36|has_68|been_72|following_86|._117 (l_dobj) effects_13\NNS\13245626|immunosuppressive_61|(_43|is_42|sirolmus_33 (l_amod) nephrotoxic_12\JJ\0|NONE_0
D020123_D007674 NONE srl_9\NNP\0|)_17|drug_15|(_1|)_3 (r_appos) sirolmus_7\NN\0|immunosuppressive_28|(_10|is_9|effects_33 (r_nsubj) lacks_11\VBZ\14449126|;_25|however_27|,_34|proteinuria_36|has_68|been_72|following_86|._117 (l_dobj) effects_13\NNS\13245626|immunosuppressive_61|(_43|is_42|sirolmus_33 (l_amod) nephrotoxic_12\JJ\0|NONE_0
D020123_D007674 NONE srl_20\NNP\0|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) associated_18\VBN\628491|NONE_0 (r_acl) proteinuria_17\NN\14299637|lacks_36|;_11|however_9|,_2|has_32|been_36|following_50|._81 (r_nsubjpass) reported_23\VBN\831651|NONE_0 (l_ccomp) lacks_11\VBZ\14449126|;_25|however_27|,_34|proteinuria_36|has_68|been_72|following_86|._117 (l_dobj) effects_13\NNS\13245626|immunosuppressive_61|(_43|is_42|sirolmus_33 (l_amod) nephrotoxic_12\JJ\0|NONE_0
D020123_D007674 NONE srl_0\NNP\0|should_4|be_11|with_19|and_80|increased_84|._111 (r_nsubjpass) used_3\VBN\0|NONE_0 (l_conj) increased_15\VBD\169651|srl_84|should_80|be_73|with_65|and_4|._27 (l_dobj) dysfunction_17\NN\14204950|NONE_0
7834920
D007538_D014397 NONE isoniazid_9\NN\2716205|patient_53|regimen_24|and_4|and_37|discovered_45|._142 (l_prep) for_10\IN\0|NONE_0 (l_pobj) tuberculosis_12\NN\14127211|NONE_0
D012293_D005921 CID rifampin_6\NN\2716205|intermittent_13|for_17 (r_amod) therapy_7\NN\657604|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|NONE_0 (r_acl) glomerulonephritis_2\NN\14113798|crescentic_22|._91
D012293_D005921 CID rifampin_17\NN\2716205|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|a_10 (r_acl) patient_14\NN\9898892|NONE_0 (r_pobj) in_12\IN\13603305|an_74|unusual_71|of_55|had_39 (r_prep) finding_6\NN\43195|study_25|._162 (l_prep) of_7\IN\0|an_19|unusual_16|in_55|had_94 (l_pobj) glomerulonephritis_11\NN\14113798|NONE_0
D012293_D005921 CID rifampin_20\NN\2716205|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|a_10 (r_acl) patient_17\NN\9898892|NONE_0 (r_pobj) in_15\IN\13603305|the_113|unusual_109|of_90 (r_prep) occurrence_5\NN\29378|report_29|._135 (l_prep) of_6\IN\0|the_23|unusual_19|in_90 (l_pobj) glomerulonephritis_9\NN\14113798|NONE_0
D012293_D005921 CID rifampin_20\NN\2716205|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) treated_18\VBN\2376958|a_10 (r_acl) patient_17\NN\9898892|NONE_0 (r_pobj) in_15\IN\13603305|the_113|unusual_109|of_90 (r_prep) occurrence_5\NN\29378|report_29|._135 (l_prep) of_6\IN\0|the_23|unusual_19|in_90 (l_pobj) glomerulonephritis_9\NN\14113798|NONE_0 (l_prep) with_10\IN\0|progressive_31 (l_pobj) crescents_11\NNS\13867641|NONE_0 (l_conj) glomerulonephritis_14\NN\14113798|and_14
D012293_D014397 NONE rifampin_6\NN\2716205|intermittent_13|for_17 (r_amod) therapy_7\NN\657604|NONE_0 (l_prep) for_8\IN\0|intermittent_30|rifampin_17 (l_pobj) tuberculosis_10\NN\14127211|NONE_0
D012293_D014397 NONE rifampin_7\NN\2716205|NONE_0 (r_pobj) of_6\IN\0|a_19|10-month_17 (r_prep) regimen_5\NN\5898568|patient_29|and_20|isoniazid_24|and_61|discovered_69|._166 (r_dobj) underwent_2\VBD\109660|NONE_0 (l_conj) isoniazid_9\NN\2716205|patient_53|regimen_24|and_4|and_37|discovered_45|._142 (l_prep) for_10\IN\0|NONE_0 (l_pobj) tuberculosis_12\NN\14127211|NONE_0
D007538_D051437 NONE isoniazid_9\NN\2716205|patient_53|regimen_24|and_4|and_37|discovered_45|._142 (r_conj) underwent_2\VBD\109660|NONE_0 (l_conj) discovered_15\VBN\2163746|patient_98|regimen_69|and_49|isoniazid_45|and_8|._97 (l_xcomp) developed_18\VBN\1753788|was_23 (l_dobj) signs_19\NNS\6643763|to_18|have_15|after_41 (l_prep) of_20\IN\0|NONE_0 (l_pobj) failure_23\NN\66216|NONE_0
D012293_D051437 CID rifampin_7\NN\2716205|NONE_0 (r_pobj) of_6\IN\0|a_19|10-month_17 (r_prep) regimen_5\NN\5898568|patient_29|and_20|isoniazid_24|and_61|discovered_69|._166 (r_dobj) underwent_2\VBD\109660|NONE_0 (l_conj) discovered_15\VBN\2163746|patient_98|regimen_69|and_49|isoniazid_45|and_8|._97 (l_xcomp) developed_18\VBN\1753788|was_23 (l_dobj) signs_19\NNS\6643763|to_18|have_15|after_41 (l_prep) of_20\IN\0|NONE_0 (l_pobj) failure_23\NN\66216|NONE_0
11928786
D016642_D062787 NONE zyban_0\NNP\0|toxicity_57|._77 (r_nsubj) caused_1\VBD\1617192|NONE_0 (l_dobj) toxicity_6\NN\13576101|zyban_57|._20 (l_prep) in_7\IN\13603305|significant_53|neurological_41 (l_pobj) overdose_8\NN\84738|NONE_0
D016642_D064420 NONE bupropion_0\NNP\0|(_10|zyban_11|)_16|._26 (r_nmod) toxicity_4\NN\13576101|NONE_0
D016642_D064420 NONE zyban_2\NNP\0|bupropion_11|(_1|)_5|._15 (r_nmod) toxicity_4\NN\13576101|NONE_0
D000241_D012640 NONE adenosine_14\NN\14964367|NONE_0 (r_pobj) with_13\IN\0|was_25|successfully_21 (r_prep) treated_12\VBN\2376958|seizures_83|were_74|with_61|._22 (r_conj) treated_3\VBN\2376958|NONE_0 (l_nsubjpass) seizures_1\NNS\14081375|were_9|with_22|treated_83|._105
D003975_D013610 NONE diazepam_5\NN\2830852|NONE_0 (l_conj) tachycardia_9\NN\14110674|and_18
D016642_D002318 NONE zyban_0\NNP\0|toxicity_57|._77 (r_nsubj) caused_1\VBD\1617192|NONE_0 (l_dobj) toxicity_6\NN\13576101|zyban_57|._20
D016642_D020258 NONE zyban_0\NNP\0|toxicity_57|._77 (r_nsubj) caused_1\VBD\1617192|NONE_0 (l_dobj) toxicity_6\NN\13576101|zyban_57|._20
D000241_D013610 NONE adenosine_14\NN\14964367|NONE_0 (r_pobj) with_13\IN\0|was_25|successfully_21 (r_prep) treated_12\VBN\2376958|seizures_83|were_74|with_61|._22 (r_conj) treated_3\VBN\2376958|NONE_0 (l_prep) with_4\IN\0|seizures_22|were_13|treated_61|._83 (l_pobj) diazepam_5\NN\2830852|NONE_0 (l_conj) tachycardia_9\NN\14110674|and_18
D003975_D012640 NONE diazepam_5\NN\2830852|NONE_0 (r_pobj) with_4\IN\0|seizures_22|were_13|treated_61|._83 (r_prep) treated_3\VBN\2376958|NONE_0 (l_nsubjpass) seizures_1\NNS\14081375|were_9|with_22|treated_83|._105
3560095
D005480_D001171 NONE flurbiprofen_0\NNP\3828465|NONE_0 (l_prep) in_1\IN\13603305|._49 (l_pobj) treatment_3\NN\654885|NONE_0 (l_prep) of_4\IN\0|the_14 (l_pobj) arthritis_7\NN\14171682|NONE_0
D005480_D001171 NONE flurbiprofen_13\JJ\3828465|NONE_0 (r_pobj) with_12\IN\0|who_17|were_13|at_18|day_47 (r_prep) treated_11\VBN\2376958|juvenile_40|rheumatoid_31|,_11 (r_relcl) arthritis_7\NN\14171682|NONE_0
D005480_D001168 NONE flurbiprofen_13\JJ\3828465|NONE_0 (r_pobj) with_12\IN\0|who_17|were_13|at_18|day_47 (r_prep) treated_11\VBN\2376958|juvenile_40|rheumatoid_31|,_11 (r_relcl) arthritis_7\NN\14171682|NONE_0 (r_pobj) with_4\IN\0|four_14|,_103 (r_prep) patients_3\NNS\9898892|decreases_144|._218 (r_nsubj) had_26\VBD\0|NONE_0 (l_dobj) decreases_29\NNS\7296428|patients_144|._74 (l_prep) in_32\IN\13603305|significant_36|from_14|after_23 (l_pobj) indices_35\NNS\13850304|NONE_0 (l_compound) arthritis_34\NN\14171682|6_2
8701950
D001241_D000743 NONE aspirin_20\NN\2707683|,_2 (r_conj) corticosteroids_18\NNS\14745635|fresh_33|plasma_20|,_2 (r_conj) replacement_16\NN\196485|of_65|,_22 (r_appos) discontinuation_4\NN\209943|in_15|,_2|to_141|._162 (r_nsubj) led_24\VBD\3202760|NONE_0 (l_prep) to_25\IN\0|in_156|,_143|discontinuation_141|._21 (l_pobj) resolution_26\NN\6470073|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) maha_28\NNP\9654687|NONE_0
D016572_D000743 NONE a_19\NNP\13649268|in_103|,_54|fk506_52|does_46|not_41|._64 (l_appos) drug_28\NN\14778436|react_54|with_48|cyclosporin_43|cya_28|,_24 (l_acl) known_30\VBN\0|an_35|suppressive_25 (l_xcomp) induce_32\VB\1627355|already_17 (l_dobj) maha_33\NNP\9654687|to_10
D016572_D000743 NONE cya_21\NN\0|react_26|with_20|cyclosporin_15|,_4|drug_28 (r_appos) a_19\NNP\13649268|in_103|,_54|fk506_52|does_46|not_41|._64 (l_appos) drug_28\NN\14778436|react_54|with_48|cyclosporin_43|cya_28|,_24 (l_acl) known_30\VBN\0|an_35|suppressive_25 (l_xcomp) induce_32\VB\1627355|already_17 (l_dobj) maha_33\NNP\9654687|to_10
D016559_D000743 CID fk506_4\NNP\0|anemia_20|._26 (r_dobj) complicating_3\VBG\126264|NONE_0 (l_nsubj) anemia_2\NN\14189204|fk506_20|._46
D016559_D000743 CID tacrolimus_6\NNP\0|NONE_0 (r_nmod) therapy_8\NN\657604|(_13 (r_appos) fk506_4\NNP\0|anemia_20|._26 (r_dobj) complicating_3\VBG\126264|NONE_0 (l_nsubj) anemia_2\NN\14189204|fk506_20|._46
D016559_D000743 CID fk506_17\NNP\0|tacrolimus_7 (r_nmod) therapy_21\NN\657604|NONE_0 (r_pobj) under_16\IN\0|2_25|solid_23|organ_17 (r_prep) recipients_15\NNS\9764201|NONE_0 (r_pobj) in_11\IN\13603305|3_55|of_44 (r_prep) episodes_3\NNS\7283608|we_14|._113 (l_prep) of_4\IN\0|3_11|in_44 (l_pobj) anemia_7\NN\14189204|NONE_0
D016559_D000743 CID fk506_17\NNP\0|tacrolimus_7 (r_nmod) therapy_21\NN\657604|NONE_0 (r_pobj) under_16\IN\0|2_25|solid_23|organ_17 (r_prep) recipients_15\NNS\9764201|NONE_0 (r_pobj) in_11\IN\13603305|3_55|of_44 (r_prep) episodes_3\NNS\7283608|we_14|._113 (l_prep) of_4\IN\0|3_11|in_44 (l_pobj) anemia_7\NN\14189204|NONE_0 (l_appos) maha_9\NNP\9654687|microangiopathic_35|hemolytic_18|(_1|)_4
D016559_D000743 CID tacrolimus_19\NNP\0|fk506_7 (r_nmod) therapy_21\NN\657604|NONE_0 (r_pobj) under_16\IN\0|2_25|solid_23|organ_17 (r_prep) recipients_15\NNS\9764201|NONE_0 (r_pobj) in_11\IN\13603305|3_55|of_44 (r_prep) episodes_3\NNS\7283608|we_14|._113 (l_prep) of_4\IN\0|3_11|in_44 (l_pobj) anemia_7\NN\14189204|NONE_0
D016559_D000743 CID tacrolimus_19\NNP\0|fk506_7 (r_nmod) therapy_21\NN\657604|NONE_0 (r_pobj) under_16\IN\0|2_25|solid_23|organ_17 (r_prep) recipients_15\NNS\9764201|NONE_0 (r_pobj) in_11\IN\13603305|3_55|of_44 (r_prep) episodes_3\NNS\7283608|we_14|._113 (l_prep) of_4\IN\0|3_11|in_44 (l_pobj) anemia_7\NN\14189204|NONE_0 (l_appos) maha_9\NNP\9654687|microangiopathic_35|hemolytic_18|(_1|)_4
D016559_D000743 CID fk506_6\NNP\0|NONE_0 (r_pobj) of_5\IN\0|,_43|replacement_65 (r_prep) discontinuation_4\NN\209943|in_15|,_2|to_141|._162 (r_nsubj) led_24\VBD\3202760|NONE_0 (l_prep) to_25\IN\0|in_156|,_143|discontinuation_141|._21 (l_pobj) resolution_26\NN\6470073|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) maha_28\NNP\9654687|NONE_0
D016559_D000743 CID fk506_6\NNP\0|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) reintroduction_4\NN\7217349|in_16|,_2|to_28|._55 (r_nsubj) led_7\VBD\3202760|NONE_0 (l_prep) to_8\IN\0|in_44|,_30|reintroduction_28|._27 (l_pobj) recurrence_10\NN\7342049|NONE_0 (l_prep) of_11\IN\0|rapid_17 (l_pobj) maha_12\NNP\9654687|NONE_0
D016559_D000743 CID fk506-associated_0\VBN\0|NONE_0 (r_amod) maha_1\NNP\9654687|probably_8|rare_17|but_22|be_42
D016559_D000743 CID fk506_9\NNP\0|in_51|,_2|does_6|not_11|a_52|._116 (r_nsubj) seem_12\VB\2604760|NONE_0 (l_oprd) a_19\NNP\13649268|in_103|,_54|fk506_52|does_46|not_41|._64 (l_appos) drug_28\NN\14778436|react_54|with_48|cyclosporin_43|cya_28|,_24 (l_acl) known_30\VBN\0|an_35|suppressive_25 (l_xcomp) induce_32\VB\1627355|already_17 (l_dobj) maha_33\NNP\9654687|to_10
D000305_D000743 NONE corticosteroids_18\NNS\14745635|fresh_33|plasma_20|,_2 (r_conj) replacement_16\NN\196485|of_65|,_22 (r_appos) discontinuation_4\NN\209943|in_15|,_2|to_141|._162 (r_nsubj) led_24\VBD\3202760|NONE_0 (l_prep) to_25\IN\0|in_156|,_143|discontinuation_141|._21 (l_pobj) resolution_26\NN\6470073|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) maha_28\NNP\9654687|NONE_0
D004176_D000743 NONE dipyridamole_23\NN\0|,_6|and_4 (r_conj) aspirin_20\NN\2707683|,_2 (r_conj) corticosteroids_18\NNS\14745635|fresh_33|plasma_20|,_2 (r_conj) replacement_16\NN\196485|of_65|,_22 (r_appos) discontinuation_4\NN\209943|in_15|,_2|to_141|._162 (r_nsubj) led_24\VBD\3202760|NONE_0 (l_prep) to_25\IN\0|in_156|,_143|discontinuation_141|._21 (l_pobj) resolution_26\NN\6470073|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) maha_28\NNP\9654687|NONE_0
18809400
D008063_D010523 NONE acid_7\NN\14818238|that_18|might_5|risk_22|and_103|encourage_107 (r_nsubj) reduce_9\VB\441445|findings_46|._142 (l_dobj) risk_11\NN\14541044|that_40|acid_22|might_17|and_81|encourage_85 (l_prep) of_12\IN\0|the_9 (l_pcomp) developing_13\VBG\13541167|NONE_0 (l_dobj) toxicity_16\NN\13576101|NONE_0
D017239_D028361 NONE paclitaxel_7\NN\0|both_19|and_4 (r_conj) cisplatin_5\NN\0|that_10|impairment_51 (r_nsubj) cause_8\VBP\7323922|results_55|._116 (l_dobj) impairment_11\NN\7296428|that_61|cisplatin_51
D017239_D028361 NONE paclitaxel_11\NN\0|both_8|and_11|cisplatin_15 (r_pobj) in_10\IN\13603305|an_27|early_24|common_18 (r_prep) event_8\NN\23100|in_56|toxicity_28|induced_39|._60 (r_attr) is_4\VBZ\0|NONE_0 (l_nsubj) toxicity_3\NN\13576101|in_28|event_28|induced_67|._88
D002945_D020258 NONE cisplatin_13\NN\0|both_23|paclitaxel_15|and_4 (r_conj) in_10\IN\13603305|an_27|early_24|common_18 (r_prep) event_8\NN\23100|in_56|toxicity_28|induced_39|._60 (r_attr) is_4\VBZ\0|NONE_0 (l_advcl) induced_14\VBN\1627355|in_95|toxicity_67|event_39|._21 (l_dobj) neurotoxicity_15\NN\0|NONE_0
D017239_D020258 NONE paclitaxel_11\NN\0|both_8|and_11|cisplatin_15 (r_pobj) in_10\IN\13603305|an_27|early_24|common_18 (r_prep) event_8\NN\23100|in_56|toxicity_28|induced_39|._60 (r_attr) is_4\VBZ\0|NONE_0 (l_advcl) induced_14\VBN\1627355|in_95|toxicity_67|event_39|._21 (l_dobj) neurotoxicity_15\NN\0|NONE_0
D008063_D001480 NONE acid_10\NN\14818238|NONE_0 (r_pobj) of_6\IN\0|the_13|in_21 (r_prep) efficacy_5\NN\5199286|and_58|apoptosis_62 (l_prep) in_11\IN\13603305|the_34|of_21 (l_pcomp) preventing_12\VBG\0|NONE_0 (l_dobj) damage_14\NN\7296428|NONE_0
D008063_D001480 NONE acid_34\NN\14818238|toxic_30|and_17 (r_conj) agents_29\NNS\7347|NONE_0 (r_pobj) to_27\IN\0|NONE_0 (r_prep) exposure_26\NN\5042871|NONE_0 (r_pobj) after_25\IN\0|the_60|and_47|morphology_27|of_16 (r_prep) function_19\NN\13783581|and_8 (r_conj) apoptosis_16\NN\11486178|efficacy_62|and_4 (r_conj) investigating_3\VBG\575741|approach_17|._206 (l_dobj) efficacy_5\NN\5199286|and_58|apoptosis_62 (l_prep) in_11\IN\13603305|the_34|of_21 (l_pcomp) preventing_12\VBG\0|NONE_0 (l_dobj) damage_14\NN\7296428|NONE_0
D017239_D010523 CID paclitaxel_32\NN\0|NONE_0 (r_pobj) to_31\IN\0|(_22|drg_21|)_18|sensory_16 (r_prep) neurons_30\NNS\5430628|dorsal_35|root_28 (r_appos) ganglion_25\NN\5462674|NONE_0 (r_pobj) of_22\IN\0|primary_17 (r_prep) cultures_21\NNS\7966140|NONE_0 (r_dobj) exposing_19\VBG\2110927|NONE_0 (r_pcomp) by_18\IN\0|that_41|closely_36|in_18|drugs_158 (r_prep) mimic_13\VBP\10200365|an_77|in_74|vitro_71|of_59 (r_relcl) model_5\NN\5888929|we_20|induced_22|._256 (r_dobj) used_1\VBD\0|NONE_0 (l_xcomp) induced_8\VBD\1627355|we_42|model_22|._234 (l_dobj) neuropathy_10\NN\14204950|NONE_0
D002945_D010523 CID cisplatin_34\NN\0|and_4 (r_conj) paclitaxel_32\NN\0|NONE_0 (r_pobj) to_31\IN\0|(_22|drg_21|)_18|sensory_16 (r_prep) neurons_30\NNS\5430628|dorsal_35|root_28 (r_appos) ganglion_25\NN\5462674|NONE_0 (r_pobj) of_22\IN\0|primary_17 (r_prep) cultures_21\NNS\7966140|NONE_0 (r_dobj) exposing_19\VBG\2110927|NONE_0 (r_pcomp) by_18\IN\0|that_41|closely_36|in_18|drugs_158 (r_prep) mimic_13\VBP\10200365|an_77|in_74|vitro_71|of_59 (r_relcl) model_5\NN\5888929|we_20|induced_22|._256 (r_dobj) used_1\VBD\0|NONE_0 (l_xcomp) induced_8\VBD\1627355|we_42|model_22|._234 (l_dobj) neuropathy_10\NN\14204950|NONE_0
D008063_D009410 NONE acid_7\NN\14818238|if_16|neuroprotective_8|induced_45|,_66|plays_92 (r_nsubj) is_8\VBZ\0|study_40|._230 (l_advcl) plays_18\VBZ\7007684|if_108|acid_92|neuroprotective_84|induced_47|,_26 (l_dobj) role_21\NN\719494|if_41|damage_24|,_39|and_41|depend_93 (l_prep) in_22\IN\13603305|a_16|critical_14 (l_pobj) cascade_25\NN\9475292|NONE_0
D008063_D009410 NONE acid_35\NN\14818238|NONE_0 (r_pobj) of_31\IN\0|neuroprotective_24 (r_prep) effects_30\NNS\13245626|if_19|on_36 (r_nsubj) depend_36\VBP\2604760|if_134|damage_117|role_93|,_54|and_52 (r_conj) plays_18\VBZ\7007684|if_108|acid_92|neuroprotective_84|induced_47|,_26 (l_dobj) role_21\NN\719494|if_41|damage_24|,_39|and_41|depend_93 (l_prep) in_22\IN\13603305|a_16|critical_14 (l_pobj) cascade_25\NN\9475292|NONE_0
D002945_D028361 NONE cisplatin_5\NN\0|that_10|impairment_51 (r_nsubj) cause_8\VBP\7323922|results_55|._116 (l_dobj) impairment_11\NN\7296428|that_61|cisplatin_51
D002945_D028361 NONE cisplatin_13\NN\0|both_23|paclitaxel_15|and_4 (r_conj) in_10\IN\13603305|an_27|early_24|common_18 (r_prep) event_8\NN\23100|in_56|toxicity_28|induced_39|._60 (r_attr) is_4\VBZ\0|NONE_0 (l_nsubj) toxicity_3\NN\13576101|in_28|event_28|induced_67|._88
D008063_D020258 NONE acid_3\NN\14818238|damage_28|._92 (r_nsubj) prevents_4\VBZ\0|NONE_0 (l_dobj) damage_6\NN\7296428|acid_28|._64 (l_conj) neurotoxicity_8\NN\0|mitochondrial_25|and_4|in_14
D008063_D020258 NONE acid_7\NN\14818238|if_16|neuroprotective_8|induced_45|,_66|plays_92 (r_nsubj) is_8\VBZ\0|study_40|._230 (l_advcl) induced_12\VBN\1627355|if_61|acid_45|neuroprotective_37|,_21|plays_47 (l_dobj) neurotoxicity_13\NN\0|NONE_0
D008063_D020258 NONE acid_35\NN\14818238|NONE_0 (r_pobj) of_31\IN\0|neuroprotective_24 (r_prep) effects_30\NNS\13245626|if_19|on_36 (r_nsubj) depend_36\VBP\2604760|if_134|damage_117|role_93|,_54|and_52 (r_conj) plays_18\VBZ\7007684|if_108|acid_92|neuroprotective_84|induced_47|,_26 (r_advcl) is_8\VBZ\0|study_40|._230 (l_advcl) induced_12\VBN\1627355|if_61|acid_45|neuroprotective_37|,_21|plays_47 (l_dobj) neurotoxicity_13\NN\0|NONE_0
D008063_D020258 NONE acid_3\NN\14818238|effects_28|induced_57 (r_nsubj) exerts_4\VBZ\1158872|:_92|it_94|toxicity_123|and_132|induces_136|._249 (l_conj) induced_9\VBN\1627355|acid_57|effects_29 (l_dobj) neurotoxicity_10\NN\0|NONE_0
D008063_D009422 NONE acid_3\NN\14818238|damage_28|._92 (r_nsubj) prevents_4\VBZ\0|NONE_0 (l_dobj) damage_6\NN\7296428|acid_28|._64 (l_prep) in_9\IN\13603305|mitochondrial_39|and_18|neurotoxicity_14 (l_pobj) neuropathy_12\NN\14204950|NONE_0
D008063_D028361 NONE acid_3\NN\14818238|damage_28|._92 (r_nsubj) prevents_4\VBZ\0|NONE_0 (l_dobj) damage_6\NN\7296428|acid_28|._64
D008063_D028361 NONE acid_7\NN\14818238|if_16|neuroprotective_8|induced_45|,_66|plays_92 (r_nsubj) is_8\VBZ\0|study_40|._230 (l_advcl) plays_18\VBZ\7007684|if_108|acid_92|neuroprotective_84|induced_47|,_26 (l_nsubj) damage_17\NN\7296428|if_17|role_24|,_63|and_65|depend_117
D008063_D028361 NONE acid_35\NN\14818238|NONE_0 (r_pobj) of_31\IN\0|neuroprotective_24 (r_prep) effects_30\NNS\13245626|if_19|on_36 (r_nsubj) depend_36\VBP\2604760|if_134|damage_117|role_93|,_54|and_52 (r_conj) plays_18\VBZ\7007684|if_108|acid_92|neuroprotective_84|induced_47|,_26 (l_nsubj) damage_17\NN\7296428|if_17|role_24|,_63|and_65|depend_117
D008063_D028361 NONE acid_3\NN\14818238|effects_28|induced_57 (r_nsubj) exerts_4\VBZ\1158872|:_92|it_94|toxicity_123|and_132|induces_136|._249 (r_ccomp) rescues_16\VBZ\45907|NONE_0 (l_dobj) toxicity_19\NN\13576101|exerts_123|:_31|it_29|and_9|induces_13|._126
11961407
D011692_D011507 CID pan_21\NNP\3101986|NONE_0 (r_compound) injection_22\NN\320852|NONE_0 (r_pobj) after_20\IN\0|5_34|80_16 (r_prep) days_19\NNS\15140892|tissues_57|were_49|at_35|include_34|._215 (r_npadvmod) analyzed_2\VBN\0|NONE_0 (l_advcl) include_26\VB\0|tissues_91|were_83|at_69|days_34|._181 (l_dobj) phase_30\NN\15113229|so_32|as_29|to_26 (l_prep) of_31\IN\0|both_21|the_16|acute_12|associated_15|(_55|days_56 (l_pobj) proteinuria_32\NN\14299637|NONE_0
D011692_D011507 CID pan_21\NNP\3101986|NONE_0 (r_compound) injection_22\NN\320852|NONE_0 (r_pobj) after_20\IN\0|5_34|80_16 (r_prep) days_19\NNS\15140892|tissues_57|were_49|at_35|include_34|._215 (r_npadvmod) analyzed_2\VBN\0|NONE_0 (l_advcl) include_26\VB\0|tissues_91|were_83|at_69|days_34|._181 (l_dobj) phase_30\NN\15113229|so_32|as_29|to_26 (l_appos) days_39\NNS\15140892|both_77|the_72|acute_68|of_56|associated_41|(_1 (l_conj) phase_47\NN\15113229|5_22|)_18|and_16 (l_prep) of_48\IN\0|the_18|chronic_14|associated_15 (l_pobj) proteinuria_49\NN\14299637|NONE_0
D014443_D009401 NONE tyrosine_2\NN\14601829|glepp1_16|receptor_9|ptpro_22|in_29|._49 (r_compound) phosphatase_3\NN\14732946|NONE_0 (l_prep) in_7\IN\13603305|glepp1_45|receptor_38|tyrosine_29|ptpro_7|._20 (l_pobj) nephrosis_10\NN\14304060|NONE_0
D011692_D005921 NONE pan_21\NNP\3101986|NONE_0 (r_compound) injection_22\NN\320852|NONE_0 (r_pobj) after_20\IN\0|5_34|80_16 (r_prep) days_19\NNS\15140892|tissues_57|were_49|at_35|include_34|._215 (r_npadvmod) analyzed_2\VBN\0|NONE_0 (l_advcl) include_26\VB\0|tissues_91|were_83|at_69|days_34|._181 (l_dobj) phase_30\NN\15113229|so_32|as_29|to_26 (l_appos) days_39\NNS\15140892|both_77|the_72|acute_68|of_56|associated_41|(_1 (l_conj) phase_47\NN\15113229|5_22|)_18|and_16 (l_acl) associated_50\VBN\628491|the_33|chronic_29|of_15 (l_prep) with_51\IN\0|NONE_0 (l_pobj) glomerulosclerosis_52\NN\0|NONE_0
D011692_D009401 CID pan_9\NNP\3101986|rat_4 (r_compound) nephrosis_10\NN\14304060|NONE_0
D011692_D009401 CID aminonucleoside_1\JJ\0|puromycin_10 (r_amod) nephrosis_2\NN\14304060|was_10|by_22|aminonucleoside_71|._107
D011692_D009401 CID aminonucleoside_11\NN\0|nephrosis_71|was_61|by_49|._36 (r_advmod) induced_4\VBN\1627355|NONE_0 (l_nsubjpass) nephrosis_2\NN\14304060|was_10|by_22|aminonucleoside_71|._107
D011692_D009401 CID pan_13\NNP\3101986|NONE_0 (r_appos) aminonucleoside_11\NN\0|nephrosis_71|was_61|by_49|._36 (r_advmod) induced_4\VBN\1627355|NONE_0 (l_nsubjpass) nephrosis_2\NN\14304060|was_10|by_22|aminonucleoside_71|._107
11581460
D005283_D009127 NONE fentanyl_5\NN\2707683|NONE_0 (r_compound) administration_6\NN\1133281|NONE_0 (r_pobj) of_4\IN\0|various_30|reported_22|side_13 (r_prep) effects_3\NNS\13245626|rigidity_54|._116 (r_nsubj) include_7\VBP\0|NONE_0 (l_dobj) rigidity_10\NN\5023233|effects_54|._62
D005283_D001745 CID fentanyl_22\NN\2707683|NONE_0 (r_pobj) of_21\IN\0|continuous_20 (r_prep) infusion_20\NN\14589223|NONE_0 (r_pobj) of_18\IN\0|a_9 (r_prep) result_17\NN\34213|NONE_0 (r_pobj) as_15\IN\14622893|hydronephrosis_15 (r_prep) mimicking_13\VBG\1742886|renal_31|pelvocalyceal_25 (r_acl) dilatation_12\NN\14034177|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) leading_8\VBG\4339291|2_37|of_29 (r_acl) cases_3\NNS\7283608|here_8|,_4|are_149|._161 (l_prep) of_4\IN\0|2_8|leading_29 (l_pobj) retention_7\NN\809465|NONE_0
D005283_D006869 NONE fentanyl_22\NN\2707683|NONE_0 (r_pobj) of_21\IN\0|continuous_20 (r_prep) infusion_20\NN\14589223|NONE_0 (r_pobj) of_18\IN\0|a_9 (r_prep) result_17\NN\34213|NONE_0 (r_pobj) as_15\IN\14622893|hydronephrosis_15 (r_prep) mimicking_13\VBG\1742886|renal_31|pelvocalyceal_25 (l_dobj) hydronephrosis_14\NN\14204950|as_15
D005283_D001919 CID fentanyl_5\NN\2707683|NONE_0 (r_compound) administration_6\NN\1133281|NONE_0 (r_pobj) of_4\IN\0|various_30|reported_22|side_13 (r_prep) effects_3\NNS\13245626|rigidity_54|._116 (r_nsubj) include_7\VBP\0|NONE_0 (l_dobj) rigidity_10\NN\5023233|effects_54|._62 (l_conj) hypotension_12\NN\14057371|chest_21|wall_15|,_2 (l_conj) depression_15\NN\14373582|,_14 (l_conj) bradycardia_18\NN\14110674|respiratory_28|,_6|and_4
D005283_D016055 CID fentanyl_12\NN\2707683|NONE_0 (r_pobj) of_11\IN\0|continuous_32|intravenous_21 (r_prep) infusion_10\NN\14589223|NONE_0 (r_pobj) of_7\IN\0|a_9 (r_prep) result_6\NN\34213|NONE_0 (r_pobj) as_4\IN\14622893|bladder_27|of_9 (r_prep) retention_1\NN\809465|:_77|case_81|._93 (l_prep) of_2\IN\0|bladder_18|as_9 (l_pobj) urine_3\NN\14853947|NONE_0
D005283_D007022 CID fentanyl_5\NN\2707683|NONE_0 (r_compound) administration_6\NN\1133281|NONE_0 (r_pobj) of_4\IN\0|various_30|reported_22|side_13 (r_prep) effects_3\NNS\13245626|rigidity_54|._116 (r_nsubj) include_7\VBP\0|NONE_0 (l_dobj) rigidity_10\NN\5023233|effects_54|._62 (l_conj) hypotension_12\NN\14057371|chest_21|wall_15|,_2
D005283_D012131 CID fentanyl_5\NN\2707683|NONE_0 (r_compound) administration_6\NN\1133281|NONE_0 (r_pobj) of_4\IN\0|various_30|reported_22|side_13 (r_prep) effects_3\NNS\13245626|rigidity_54|._116 (r_nsubj) include_7\VBP\0|NONE_0 (l_dobj) rigidity_10\NN\5023233|effects_54|._62 (l_conj) hypotension_12\NN\14057371|chest_21|wall_15|,_2 (l_conj) depression_15\NN\14373582|,_14
2024540
D004656_D006333 NONE enalapril_11\NN\2673637|NONE_0 (r_pobj) of_10\IN\0|in_26 (r_prep) safety_9\NN\13920835|and_34|analysis_30|of_21|:_2|._105 (l_prep) in_14\IN\13603305|of_26 (l_pobj) phase_18\NN\15113229|NONE_0 (l_prep) of_19\IN\0|the_28|initial_24|treatment_16 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) failure_24\NN\66216|NONE_0
D000806_D007022 CID inhibitors_10\NNS\20090|NONE_0 (r_appos) enzyme_6\NN\14723628|into_24 (r_dobj) converting_5\VBG\126264|NONE_0 (l_prep) into_11\IN\0|enzyme_24 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_25|adjunctive_21 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) failure_20\NN\66216|NONE_0 (l_conj) cases_22\NNS\7283608|congestive_26|heart_15|,_2 (l_prep) of_23\IN\0|NONE_0 (l_pobj) hypotension_25\NN\14057371|NONE_0
D000806_D007022 CID inhibitor_7\NN\20090|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) safety_3\NN\13920835|to_14 (r_dobj) assess_1\VB\5220461|trial_96|was_102|that_115|compared_120|._212 (r_advcl) designed_19\VBN\1631534|NONE_0 (l_prep) compared_21\VBD\644583|assess_120|trial_24|was_18|that_5|._92 (l_pobj) incidence_23\NN\13821570|NONE_0 (l_prep) of_26\IN\0|the_27|and_13|severity_9 (l_pobj) hypotension_28\NN\14057371|NONE_0
D000806_D006333 NONE inhibitors_10\NNS\20090|NONE_0 (r_appos) enzyme_6\NN\14723628|into_24 (r_dobj) converting_5\VBG\126264|NONE_0 (l_prep) into_11\IN\0|enzyme_24 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_25|adjunctive_21 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) failure_20\NN\66216|NONE_0
D004656_D007022 NONE enalapril_8\NN\2673637|the_18|ace_14 (r_appos) inhibitor_7\NN\20090|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) safety_3\NN\13920835|to_14 (r_dobj) assess_1\VB\5220461|trial_96|was_102|that_115|compared_120|._212 (r_advcl) designed_19\VBN\1631534|NONE_0 (l_prep) compared_21\VBD\644583|assess_120|trial_24|was_18|that_5|._92 (l_pobj) incidence_23\NN\13821570|NONE_0 (l_prep) of_26\IN\0|the_27|and_13|severity_9 (l_pobj) hypotension_28\NN\14057371|NONE_0
D004656_D007022 NONE enalapril_3\RB\2673637|who_13 (r_dobj) received_2\VBD\2210855|NONE_0 (r_relcl) patients_0\NNS\9898892|hypotension_104|._170 (r_nsubj) experienced_4\VBD\2108377|NONE_0 (l_dobj) hypotension_11\NN\14057371|patients_104|._66
D011224_D007022 CID prazosin_14\NN\2698769|-_8 (r_npadvmod) controlled_16\VBN\0|a_36|multicenter_34|,_23|randomized_21|,_11 (r_amod) trial_17\NN\786195|assess_96|was_6|that_19|compared_24|._116 (r_nsubjpass) designed_19\VBN\1631534|NONE_0 (l_prep) compared_21\VBD\644583|assess_120|trial_24|was_18|that_5|._92 (l_pobj) incidence_23\NN\13821570|NONE_0 (l_prep) of_26\IN\0|the_27|and_13|severity_9 (l_pobj) hypotension_28\NN\14057371|NONE_0
D011224_D007022 CID prazosin_21\NN\2698769|who_13 (r_dobj) received_20\VBD\2210855|the_17 (r_relcl) patients_18\NNS\9898892|NONE_0 (r_pobj) than_16\IN\0|clinically_79|(_7|%_3|)_2 (r_prep) hypotension_11\NN\14057371|patients_104|._66
D011224_D006333 NONE prazosin_13\NN\2698769|and_4 (r_conj) enalapril_11\NN\2673637|NONE_0 (r_pobj) of_10\IN\0|in_26 (r_prep) safety_9\NN\13920835|and_34|analysis_30|of_21|:_2|._105 (l_prep) in_14\IN\13603305|of_26 (l_pobj) phase_18\NN\15113229|NONE_0 (l_prep) of_19\IN\0|the_28|initial_24|treatment_16 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) failure_24\NN\66216|NONE_0
19300402
D001920_D003929 NONE bradykinin_0\NN\0|receptors_11|and_33|inhibitors_59|in_70|and_85|streptozotocin_89 (r_compound) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) chemotherapy_15\NN\661091|NONE_0 (l_conj) model_20\NN\5888929|and_28 (l_compound) rat_19\NN\2329401|diabetic_20 (l_compound) neuropathy_18\NN\14204950|NONE_0
D013311_D006930 CID streptozotocin_11\NNS\0|bradykinin_89|receptors_78|and_56|inhibitors_30|in_19|and_4 (r_conj) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62
D013311_D006930 CID streptozotocin_1\JJ\0|-_14 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) hyperalgesia_4\NN\0|NONE_0
D013311_D006930 CID streptozotocin_1\JJ\0|-_14 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) hyperalgesia_4\NN\0|NONE_0 (r_pobj) in_0\IN\13603305|,_38|synthase_53|in_75|,_115|induced_140|seemed_172 (r_prep) participates_9\VBZ\2367363|NONE_0 (l_advcl) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (l_dobj) hyperalgesia_21\NN\0|whereas_31|in_23|-_9
D014750_D006930 CID vincristine_9\NN\3917455|NONE_0 (r_pobj) in_8\IN\13603305|bradykinin_70|receptors_59|and_37|inhibitors_11|and_15|streptozotocin_19 (r_prep) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62
D014750_D006930 CID vincristine_26\NN\3917455|NONE_0 (r_pobj) by_25\IN\0|NONE_0 (r_agent) produced_24\VBN\1617192|NONE_0 (r_acl) hyperalgesia_23\NN\0|NONE_0
D014750_D006930 CID vincristine_18\NN\3917455|NONE_0 (r_pobj) in_17\IN\13603305|whereas_8|-_14|hyperalgesia_23 (r_prep) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (r_advcl) participates_9\VBZ\2367363|NONE_0 (l_prep) in_0\IN\13603305|,_38|synthase_53|in_75|,_115|induced_140|seemed_172 (l_pobj) hyperalgesia_4\NN\0|NONE_0
D014750_D006930 CID vincristine_18\NN\3917455|NONE_0 (r_pobj) in_17\IN\13603305|whereas_8|-_14|hyperalgesia_23 (r_prep) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (l_dobj) hyperalgesia_21\NN\0|whereas_31|in_23|-_9
D001920_D009437 NONE bradykinin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|small_12 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|concomitant_27 (r_prep) administration_3\NN\1133281|therefore_23|,_14|can_92|effective_99|,_143|in_150|._166 (r_nsubj) be_16\VB\14625458|NONE_0 (l_acomp) effective_17\JJ\0|therefore_122|,_113|administration_99|can_7|,_44|in_51|._67 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) alleviation_19\NN\7492516|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) pain_22\NN\14299637|NONE_0
D013311_D003929 CID streptozotocin_11\NNS\0|bradykinin_89|receptors_78|and_56|inhibitors_30|in_19|and_4 (r_conj) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) chemotherapy_15\NN\661091|NONE_0 (l_conj) model_20\NN\5888929|and_28 (l_compound) rat_19\NN\2329401|diabetic_20 (l_compound) neuropathy_18\NN\14204950|NONE_0
D009569_D003929 NONE oxide_5\NN\14818238|nitric_7 (r_compound) synthase_6\NN\0|NONE_0 (r_compound) inhibitors_7\NNS\20090|bradykinin_59|receptors_48|and_26|in_11|and_26|streptozotocin_30 (r_conj) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) chemotherapy_15\NN\661091|NONE_0 (l_conj) model_20\NN\5888929|and_28 (l_compound) rat_19\NN\2329401|diabetic_20 (l_compound) neuropathy_18\NN\14204950|NONE_0
D014750_D003929 NONE vincristine_9\NN\3917455|NONE_0 (r_pobj) in_8\IN\13603305|bradykinin_70|receptors_59|and_37|inhibitors_11|and_15|streptozotocin_19 (r_prep) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) chemotherapy_15\NN\661091|NONE_0 (l_conj) model_20\NN\5888929|and_28 (l_compound) rat_19\NN\2329401|diabetic_20 (l_compound) neuropathy_18\NN\14204950|NONE_0
D001920_D006930 NONE bradykinin_0\NN\0|receptors_11|and_33|inhibitors_59|in_70|and_85|streptozotocin_89 (r_compound) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62
D001920_D006930 NONE bradykinin_9\NN\0|NONE_0 (r_compound) receptors_10\NNS\5225602|NONE_0 (r_pobj) of_8\IN\0|and_24|synthase_41|but_50 (r_prep) inhibition_7\NN\1068773|that_5|activity_90|hyperalgesia_116 (r_nsubj) reduces_21\VBZ\441445|results_134|._29 (l_dobj) hyperalgesia_23\NN\0|that_121|inhibition_116|activity_26
D001920_D006930 NONE bradykinin_19\NN\0|neuronal_43|no_34|synthase_31|as_3 (r_conj) activation_15\NN\13561719|inducible_47|no_37|and_25 (r_conj) synthase_10\NN\0|NONE_0 (r_pobj) of_7\IN\0|both_14 (r_prep) products_6\NNS\3076708|that_10|are_92|in_105 (r_nsubjpass) involved_21\VBN\2676054|it_124|was_121|also_117|._48 (l_prep) in_22\IN\13603305|that_115|products_105|are_13 (l_pobj) hyperalgesia_23\NN\0|NONE_0
D001920_D006930 NONE bradykinin_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|pronociceptive_24 (r_prep) activity_12\NN\30358|NONE_0 (r_pobj) in_10\IN\13603305|in_75|,_37|synthase_22|,_40|induced_65|seemed_97 (r_prep) participates_9\VBZ\2367363|NONE_0 (l_prep) in_0\IN\13603305|,_38|synthase_53|in_75|,_115|induced_140|seemed_172 (l_pobj) hyperalgesia_4\NN\0|NONE_0
D001920_D006930 NONE bradykinin_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|pronociceptive_24 (r_prep) activity_12\NN\30358|NONE_0 (r_pobj) in_10\IN\13603305|in_75|,_37|synthase_22|,_40|induced_65|seemed_97 (r_prep) participates_9\VBZ\2367363|NONE_0 (l_advcl) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (l_dobj) hyperalgesia_21\NN\0|whereas_31|in_23|-_9
D001920_D006930 NONE bradykinin_22\NN\0|activate_21|._58 (r_nsubj) seemed_23\VBD\2604760|in_172|,_134|synthase_119|in_97|,_57|induced_32 (r_conj) participates_9\VBZ\2367363|NONE_0 (l_prep) in_0\IN\13603305|,_38|synthase_53|in_75|,_115|induced_140|seemed_172 (l_pobj) hyperalgesia_4\NN\0|NONE_0
D001920_D006930 NONE bradykinin_22\NN\0|activate_21|._58 (r_nsubj) seemed_23\VBD\2604760|in_172|,_134|synthase_119|in_97|,_57|induced_32 (r_conj) participates_9\VBZ\2367363|NONE_0 (l_advcl) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (l_dobj) hyperalgesia_21\NN\0|whereas_31|in_23|-_9
D009569_D009437 NONE no_12\DT\7204911|synthase_3 (r_det) inhibitors_14\NNS\20090|receptor_37|and_16 (r_conj) antagonists_10\NNS\7846|NONE_0 (r_dobj) bradykinin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|small_12 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|concomitant_27 (r_prep) administration_3\NN\1133281|therefore_23|,_14|can_92|effective_99|,_143|in_150|._166 (r_nsubj) be_16\VB\14625458|NONE_0 (l_acomp) effective_17\JJ\0|therefore_122|,_113|administration_99|can_7|,_44|in_51|._67 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) alleviation_19\NN\7492516|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) pain_22\NN\14299637|NONE_0
D009569_D006930 NONE oxide_5\NN\14818238|nitric_7 (r_compound) synthase_6\NN\0|NONE_0 (r_compound) inhibitors_7\NNS\20090|bradykinin_59|receptors_48|and_26|in_11|and_26|streptozotocin_30 (r_conj) antagonists_2\NNS\7846|hyperalgesia_91|._153 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) hyperalgesia_13\NN\0|antagonists_91|._62
D009569_D006930 NONE no_13\DT\7204911|inducible_10 (r_det) synthase_14\NN\0|of_41|and_17|but_9 (r_conj) inhibition_7\NN\1068773|that_5|activity_90|hyperalgesia_116 (r_nsubj) reduces_21\VBZ\441445|results_134|._29 (l_dobj) hyperalgesia_23\NN\0|that_121|inhibition_116|activity_26
D009569_D006930 NONE no_18\DT\7204911|not_13|neuronal_9|synthase_3 (r_det) activity_20\NN\30358|that_95|inhibition_90|hyperalgesia_26 (r_nsubj) reduces_21\VBZ\441445|results_134|._29 (l_dobj) hyperalgesia_23\NN\0|that_121|inhibition_116|activity_26
D009569_D006930 NONE no_9\DT\7204911|inducible_10|and_12|activation_37 (r_compound) synthase_10\NN\0|NONE_0 (r_pobj) of_7\IN\0|both_14 (r_prep) products_6\NNS\3076708|that_10|are_92|in_105 (r_nsubjpass) involved_21\VBN\2676054|it_124|was_121|also_117|._48 (l_prep) in_22\IN\13603305|that_115|products_105|are_13 (l_pobj) hyperalgesia_23\NN\0|NONE_0
D009569_D006930 NONE no_13\DT\7204911|neuronal_9|synthase_3|as_31|bradykinin_34 (r_det) activation_15\NN\13561719|inducible_47|no_37|and_25 (r_conj) synthase_10\NN\0|NONE_0 (r_pobj) of_7\IN\0|both_14 (r_prep) products_6\NNS\3076708|that_10|are_92|in_105 (r_nsubjpass) involved_21\VBN\2676054|it_124|was_121|also_117|._48 (l_prep) in_22\IN\13603305|that_115|products_105|are_13 (l_pobj) hyperalgesia_23\NN\0|NONE_0
D009569_D006930 NONE no_7\DT\7204911|inducible_10 (r_compound) synthase_8\NN\0|in_53|,_15|in_22|,_62|induced_87|seemed_119 (r_nsubj) participates_9\VBZ\2367363|NONE_0 (l_prep) in_0\IN\13603305|,_38|synthase_53|in_75|,_115|induced_140|seemed_172 (l_pobj) hyperalgesia_4\NN\0|NONE_0
D009569_D006930 NONE no_7\DT\7204911|inducible_10 (r_compound) synthase_8\NN\0|in_53|,_15|in_22|,_62|induced_87|seemed_119 (r_nsubj) participates_9\VBZ\2367363|NONE_0 (l_advcl) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (l_dobj) hyperalgesia_21\NN\0|whereas_31|in_23|-_9
D009569_D006930 NONE no_27\DT\7204911|neuronal_9|synthase_3 (r_det) pathway_29\NN\5483677|to_33 (r_dobj) activate_25\VB\1641914|bradykinin_21|._37 (r_xcomp) seemed_23\VBD\2604760|in_172|,_134|synthase_119|in_97|,_57|induced_32 (r_conj) participates_9\VBZ\2367363|NONE_0 (l_prep) in_0\IN\13603305|,_38|synthase_53|in_75|,_115|induced_140|seemed_172 (l_pobj) hyperalgesia_4\NN\0|NONE_0
D009569_D006930 NONE no_27\DT\7204911|neuronal_9|synthase_3 (r_det) pathway_29\NN\5483677|to_33 (r_dobj) activate_25\VB\1641914|bradykinin_21|._37 (r_xcomp) seemed_23\VBD\2604760|in_172|,_134|synthase_119|in_97|,_57|induced_32 (r_conj) participates_9\VBZ\2367363|NONE_0 (l_advcl) induced_20\VBN\1627355|in_140|,_102|synthase_87|in_65|,_25|seemed_32 (l_dobj) hyperalgesia_21\NN\0|whereas_31|in_23|-_9
11642480
D015283_D003865 NONE citalopram_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|by_16 (r_prep) treatment_6\NN\654885|NONE_0 (l_prep) by_9\IN\0|with_16 (l_pobj) boy_14\NN\9624168|NONE_0 (l_prep) with_15\IN\0|a_18|old_8 (l_pobj) depression_17\NN\14373582|NONE_0
D015283_D003866 NONE citalopram_7\NN\0|NONE_0 (r_pobj) on_6\IN\0|a_23|depressed_21 (r_prep) adolescent_5\NN\9622049|NONE_0 (l_amod) depressed_4\JJ\1819147|a_2|on_21
D015283_D004409 CID citalopram_7\NN\0|NONE_0 (r_pobj) on_6\IN\0|a_23|depressed_21 (r_prep) adolescent_5\NN\9622049|NONE_0 (r_pobj) in_2\IN\13603305|palpebral_20|._39 (r_prep) twitching_1\VBG\14360459|NONE_0
D015283_D004409 CID citalopram_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|by_16 (r_prep) treatment_6\NN\654885|NONE_0 (l_prep) by_9\IN\0|with_16 (l_pobj) boy_14\NN\9624168|NONE_0 (l_prep) with_15\IN\0|a_18|old_8 (l_pobj) depression_17\NN\14373582|NONE_0 (l_relcl) exhibited_19\VBD\2632167|major_21 (l_dobj) twitching_21\NN\14360459|who_24|during_10
15859940
D016572_D057049 CID cyclosporine_18\NN\0|mainly_10 (r_pobj) to_17\IN\0|NONE_0 (r_prep) secondary_15\JJ\8426461|drug_14|,_2 (r_amod) related_13\VBN\628491|that_68|cause_45 (r_acomp) was_11\VBD\0|we_68|._50 (l_nsubj) cause_7\NN\7323922|that_23|related_45 (l_prep) of_8\IN\0|the_24|frequent_15 (l_pobj) microangiopathy_10\NN\0|NONE_0
D016572_D064420 NONE cyclosporine_7\NN\0|related_9|(_1|,_34|status_49 (r_nmod) toxicity_11\NN\13576101|causes_55|._62
D016559_D064420 NONE tacrolimus_9\NN\0|,_2 (r_conj) cyclosporine_7\NN\0|related_9|(_1|,_34|status_49 (r_nmod) toxicity_11\NN\13576101|causes_55|._62
8595686
D013874_D010146 NONE thiopentone_0\NN\0|for_25|._75 (r_compound) pretreatment_1\NN\0|NONE_0 (l_prep) for_2\IN\0|thiopentone_25|._50 (l_pobj) pain_5\NN\14299637|NONE_0
D013874_D010146 NONE thiopentone_17\NN\0|whereas_8|only_12|severity_29 (r_nsubj) reduces_19\VBZ\441445|that_125|lidocaine_120|incidence_98 (r_advcl) reduces_4\VBZ\441445|we_27|._130 (l_dobj) incidence_6\NN\13821570|that_27|lidocaine_22|reduces_98 (l_prep) of_9\IN\0|the_27|and_13|severity_9 (l_pobj) pain_12\NN\14299637|NONE_0
D015742_D010146 CID propofol_3\JJ\0|injection_9|in_24 (r_amod) pain_5\NN\14299637|NONE_0
D015742_D010146 CID propofol_3\JJ\0|injection_9|in_24 (r_amod) pain_5\NN\14299637|study_38|._50
D015742_D010146 CID propofol_10\JJ\0|injection_9|in_24 (r_amod) pain_12\NN\14299637|NONE_0
D008012_D010146 NONE lidocaine_3\NN\3681148|that_5|incidence_22|reduces_120 (r_nsubj) reduces_4\VBZ\441445|we_27|._130 (l_dobj) incidence_6\NN\13821570|that_27|lidocaine_22|reduces_98 (l_prep) of_9\IN\0|the_27|and_13|severity_9 (l_pobj) pain_12\NN\14299637|NONE_0
11263551
D016572_-1 NONE cyclosporine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|a_30|rare_28|side_12 (r_prep) effect_16\NN\34213|syndrome_42|and_37|diagnosed_55|._135 (r_attr) is_10\VBZ\0|NONE_0 (l_nsubj) syndrome_6\NNP\5870365|effect_42|and_79|diagnosed_97|._177 (l_appos) cips_8\NNP\0|the_49|inhibitor_33|pain_15|(_1|)_4
D016559_-1 NONE tacrolimus_20\NN\0|or_3 (r_conj) cyclosporine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|a_30|rare_28|side_12 (r_prep) effect_16\NN\34213|syndrome_42|and_37|diagnosed_55|._135 (r_attr) is_10\VBZ\0|NONE_0 (l_nsubj) syndrome_6\NNP\5870365|effect_42|and_79|diagnosed_97|._177 (l_appos) cips_8\NNP\0|the_49|inhibitor_33|pain_15|(_1|)_4
D016559_D010146 CID tacrolimus_5\VB\0|NONE_0 (r_compound) trough_6\NN\9366017|cyclosporine-_28 (r_compound) levels_7\NNS\4916342|NONE_0 (r_pobj) of_2\IN\0|the_14|and_45|administration_53 (r_prep) reduction_1\NN\351485|to_110|._127 (r_nsubj) led_15\VBD\3202760|NONE_0 (l_prep) to_16\IN\0|reduction_110|._17 (l_pobj) relief_17\NN\7492516|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) pain_19\NN\14299637|NONE_0
D016559_D010146 CID tacrolimus_20\NN\0|or_3 (r_conj) cyclosporine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|a_30|rare_28|side_12 (r_prep) effect_16\NN\34213|syndrome_42|and_37|diagnosed_55|._135 (r_attr) is_10\VBZ\0|NONE_0 (l_nsubj) syndrome_6\NNP\5870365|effect_42|and_79|diagnosed_97|._177 (l_compound) pain_5\NNP\14299637|the_34|inhibitor_18|(_14|cips_15|)_19
D016572_D010146 CID cyclosporine-_3\NN\0|trough_28 (r_nmod) levels_7\NNS\4916342|NONE_0 (r_pobj) of_2\IN\0|the_14|and_45|administration_53 (r_prep) reduction_1\NN\351485|to_110|._127 (r_nsubj) led_15\VBD\3202760|NONE_0 (l_prep) to_16\IN\0|reduction_110|._17 (l_pobj) relief_17\NN\7492516|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) pain_19\NN\14299637|NONE_0
D016572_D010146 CID cyclosporine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|a_30|rare_28|side_12 (r_prep) effect_16\NN\34213|syndrome_42|and_37|diagnosed_55|._135 (r_attr) is_10\VBZ\0|NONE_0 (l_nsubj) syndrome_6\NNP\5870365|effect_42|and_79|diagnosed_97|._177 (l_compound) pain_5\NNP\14299637|the_34|inhibitor_18|(_14|cips_15|)_19
D002118_D010146 NONE calcium_12\NN\14625458|NONE_0 (r_compound) channel_13\NN\6251781|NONE_0 (r_compound) blockers_14\NNS\10101634|NONE_0 (r_pobj) of_11\IN\0|the_19 (r_prep) administration_10\NN\1133281|the_67|of_53|and_8 (r_conj) reduction_1\NN\351485|to_110|._127 (r_nsubj) led_15\VBD\3202760|NONE_0 (l_prep) to_16\IN\0|reduction_110|._17 (l_pobj) relief_17\NN\7492516|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) pain_19\NN\14299637|NONE_0
2572625
C013295_D056486 NONE thienodiazepine_27\NN\0|a_2 (r_amod) derivative_28\NN\5802185|a_157|developed_143|,_20 (r_appos) patient_6\NN\9898892|NONE_0 (l_relcl) developed_8\VBD\1753788|a_14|,_123|derivative_143 (l_dobj) hepatitis_10\NN\14127211|who_20|with_10|after_59
C013295_D047508 NONE thienodiazepine_27\NN\0|a_2 (r_amod) derivative_28\NN\5802185|a_157|developed_143|,_20 (r_appos) patient_6\NN\9898892|NONE_0 (l_relcl) developed_8\VBD\1753788|a_14|,_123|derivative_143 (l_prep) with_11\IN\0|who_30|hepatitis_10|after_49 (l_pobj) necrosis_14\NN\11444117|NONE_0
C084599_D056486 CID clotiazepam_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|acute_8|._23 (r_amod) hepatitis_4\NN\14127211|NONE_0
C084599_D056486 CID clotiazepam_24\NN\0|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) administration_22\NN\1133281|NONE_0 (r_pobj) of_21\IN\0|the_10 (r_prep) onset_20\NN\7325190|months_17 (r_pobj) after_18\IN\0|who_79|hepatitis_59|with_49 (r_prep) developed_8\VBD\1753788|a_14|,_123|derivative_143 (l_dobj) hepatitis_10\NN\14127211|who_20|with_10|after_59
C084599_D056486 CID clotiazepam_9\NN\0|chemically_22 (r_xcomp) related_7\VBN\628491|the_58|of_39|,_13 (r_acl) administration_1\NN\1133281|,_76|did_78|not_82|with_96|and_110|induce_122|._153 (r_nsubj) interfere_13\VB\2451370|NONE_0 (l_conj) induce_19\VB\1627355|administration_122|,_46|did_44|not_40|with_26|and_12|._31 (l_dobj) relapse_21\NN\66636|did_19|not_15 (l_prep) of_22\IN\0|any_12 (l_pobj) hepatitis_23\NN\14127211|NONE_0
C084599_D056486 CID clotiazepam_4\NN\0|that_5|can_12|hepatitis_29|and_39|suggests_43 (r_nsubj) induce_6\VB\1627355|observation_39|._121 (l_dobj) hepatitis_8\NN\14127211|that_34|clotiazepam_29|can_17|and_10|suggests_14
C084599_D056486 CID clotiazepam_4\NN\0|that_5|can_12|hepatitis_29|and_39|suggests_43 (r_nsubj) induce_6\VB\1627355|observation_39|._121 (l_conj) suggests_10\VBZ\1010118|that_48|clotiazepam_43|can_31|hepatitis_14|and_4 (l_ccomp) is_13\VBZ\0|NONE_0 (l_attr) hepatotoxicity_16\NN\0|that_23|there_18
C084599_D056486 CID clotiazepam_18\NN\0|NONE_0 (r_pobj) between_17\IN\0|cross_21 (r_prep) hepatotoxicity_16\NN\0|that_23|there_18 (r_attr) is_13\VBZ\0|NONE_0 (r_ccomp) suggests_10\VBZ\1010118|that_48|clotiazepam_43|can_31|hepatitis_14|and_4 (r_conj) induce_6\VB\1627355|observation_39|._121 (l_dobj) hepatitis_8\NN\14127211|that_34|clotiazepam_29|can_17|and_10|suggests_14
C084599_D056486 CID clotiazepam_18\NN\0|NONE_0 (r_pobj) between_17\IN\0|cross_21 (r_prep) hepatotoxicity_16\NN\0|that_23|there_18
C084599_D047508 NONE clotiazepam_24\NN\0|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) administration_22\NN\1133281|NONE_0 (r_pobj) of_21\IN\0|the_10 (r_prep) onset_20\NN\7325190|months_17 (r_pobj) after_18\IN\0|who_79|hepatitis_59|with_49 (r_prep) developed_8\VBD\1753788|a_14|,_123|derivative_143 (l_prep) with_11\IN\0|who_30|hepatitis_10|after_49 (l_pobj) necrosis_14\NN\11444117|NONE_0
D001569_D056486 NONE benzodiazepines_4\NNS\3771443|NONE_0 (r_pobj) of_2\IN\0|the_19|,_26|related_39 (r_prep) administration_1\NN\1133281|,_76|did_78|not_82|with_96|and_110|induce_122|._153 (r_nsubj) interfere_13\VB\2451370|NONE_0 (l_conj) induce_19\VB\1627355|administration_122|,_46|did_44|not_40|with_26|and_12|._31 (l_dobj) relapse_21\NN\66636|did_19|not_15 (l_prep) of_22\IN\0|any_12 (l_pobj) hepatitis_23\NN\14127211|NONE_0
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|and_12 (r_conj) clotiazepam_18\NN\0|NONE_0 (r_pobj) between_17\IN\0|cross_21 (r_prep) hepatotoxicity_16\NN\0|that_23|there_18 (r_attr) is_13\VBZ\0|NONE_0 (r_ccomp) suggests_10\VBZ\1010118|that_48|clotiazepam_43|can_31|hepatitis_14|and_4 (r_conj) induce_6\VB\1627355|observation_39|._121 (l_dobj) hepatitis_8\NN\14127211|that_34|clotiazepam_29|can_17|and_10|suggests_14
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|and_12 (r_conj) clotiazepam_18\NN\0|NONE_0 (r_pobj) between_17\IN\0|cross_21 (r_prep) hepatotoxicity_16\NN\0|that_23|there_18
10406016
C007789_D007249 NONE fucoidan_0\NNP\0|-_8 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|evidence_15|,_67|had_69|._176 (r_nsubj) exhibited_4\VBD\2632167|NONE_0 (l_conj) had_13\VBD\0|rats_69|evidence_54|,_2|._107 (l_conj) tended_18\VBD\2604760|hematomas_15|,_6|and_4 (l_xcomp) have_20\VB\7846|NONE_0 (l_dobj) inflammation_22\NN\14299637|to_13|after_45
C007789_D020141 CID fucoidan_0\NNP\0|-_8 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|evidence_15|,_67|had_69|._176 (r_nsubj) exhibited_4\VBD\2632167|NONE_0 (l_dobj) evidence_5\NN\5816287|rats_15|,_52|had_54|._161 (l_prep) of_6\IN\0|NONE_0 (l_pobj) clotting_9\NN\13518963|NONE_0
C007789_D020141 CID fucoidan_0\NNP\0|-_8 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|evidence_15|,_67|had_69|._176 (r_nsubj) exhibited_4\VBD\2632167|NONE_0 (l_dobj) evidence_5\NN\5816287|rats_15|,_52|had_54|._161 (l_prep) of_6\IN\0|NONE_0 (l_pobj) clotting_9\NN\13518963|NONE_0 (l_conj) hemodilution_11\NN\0|impaired_28|blood_19|and_4
C007789_D001925 NONE fucoidan_5\RB\0|we_38|in_71|._184 (l_relcl) reported_10\VBN\831651|the_53|sulfated_49|polysaccharide_40|,_17|,_44 (l_xcomp) reduce_12\VB\441445|which_27|has_21|been_17 (l_dobj) damage_15\NN\7296428|to_29
C007789_D002543 NONE fucoidan_2\JJ\0|on_19 (r_compound) treatment_3\NN\654885|NONE_0 (l_prep) on_4\IN\0|fucoidan_19 (l_pobj) hemorrhage_9\NN\14285662|NONE_0
C007789_D002543 NONE fucoidan_5\RB\0|we_38|in_71|._184 (r_dobj) tested_1\VBD\670261|NONE_0 (l_prep) in_17\IN\13603305|we_109|fucoidan_71|._113 (l_pobj) model_20\NN\5888929|NONE_0 (l_prep) of_21\IN\0|a_12|rat_10|induced_28 (l_pobj) hemorrhage_23\NN\14285662|NONE_0
C007789_D006406 NONE fucoidan_0\NNP\0|-_8 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|evidence_15|,_67|had_69|._176 (r_nsubj) exhibited_4\VBD\2632167|NONE_0 (l_conj) had_13\VBD\0|rats_69|evidence_54|,_2|._107 (l_dobj) hematomas_15\NNS\14317720|,_9|and_11|tended_15
C007789_D006406 NONE fucoidan_0\NNP\0|-_8 (r_npadvmod) treated_2\VBN\2376958|NONE_0 (r_amod) rats_3\NNS\2329401|evidence_15|,_67|had_69|._176 (r_nsubj) exhibited_4\VBD\2632167|NONE_0 (l_conj) had_13\VBD\0|rats_69|evidence_54|,_2|._107 (l_conj) tended_18\VBD\2604760|hematomas_15|,_6|and_4 (l_xcomp) have_20\VB\7846|NONE_0 (l_dobj) inflammation_22\NN\14299637|to_13|after_45 (l_prep) in_23\IN\13603305|less_18 (l_pobj) vicinity_25\NN\8648322|NONE_0 (l_prep) of_26\IN\0|the_13 (l_pobj) hematoma_28\NN\14317720|NONE_0
12820454
D016729_D000740 CID acetate_6\NN\15010703|patients_34|and_93|evaluated_102|._238 (r_dobj) received_2\VBD\2210855|NONE_0 (l_conj) evaluated_32\VBN\670261|patients_136|acetate_102|and_9|._136 (l_prep) for_33\IN\0|were_15|by_11 (l_pobj) anemia_34\NN\14189204|NONE_0
D016729_D000740 CID a_10\NNP\13649268|cab_30|[_26|leuprolide_25|(_6|)_1|mg_8|,_10|intramuscularly_12|,_27|days_38 (r_appos) acetate_6\NN\15010703|patients_34|and_93|evaluated_102|._238 (r_dobj) received_2\VBD\2210855|NONE_0 (l_conj) evaluated_32\VBN\670261|patients_136|acetate_102|and_9|._136 (l_prep) for_33\IN\0|were_15|by_11 (l_pobj) anemia_34\NN\14189204|NONE_0
D005485_D000740 CID flutamide_23\NN\0|mg_3|,_9|,_14|per_16 (r_nmod) tid_25\NN\0|every_37|28_31|plus_23 (r_conj) days_19\NNS\15140892|cab_68|[_64|leuprolide_63|(_44|a_38|)_37|mg_30|,_28|intramuscularly_26|,_11 (r_appos) acetate_6\NN\15010703|patients_34|and_93|evaluated_102|._238 (r_dobj) received_2\VBD\2210855|NONE_0 (l_conj) evaluated_32\VBN\670261|patients_136|acetate_102|and_9|._136 (l_prep) for_33\IN\0|were_15|by_11 (l_pobj) anemia_34\NN\14189204|NONE_0
2476560
D001556_D012532 NONE lindane_12\NN\14919948|initiated_50|;_16|most_14|._60 (r_dobj) consider_11\VBP\689344|NONE_0 (l_ccomp) initiated_5\VBN\1617192|;_34|most_36|lindane_50|._110 (l_nsubjpass) treatment_0\NN\654885|is_22|usually_25|by_43 (l_prep) for_1\IN\0|NONE_0 (l_pobj) scabies_2\NNS\14174549|NONE_0
D001556_D012532 NONE hexachloride_16\NN\0|(_15|)_12|treatment_18 (r_appos) lindane_12\NN\14919948|initiated_50|;_16|most_14|._60 (r_dobj) consider_11\VBP\689344|NONE_0 (l_ccomp) initiated_5\VBN\1617192|;_34|most_36|lindane_50|._110 (l_nsubjpass) treatment_0\NN\654885|is_22|usually_25|by_43 (l_prep) for_1\IN\0|NONE_0 (l_pobj) scabies_2\NNS\14174549|NONE_0
D001556_D000741 CID lindane_4\NN\14919948|evidence_30|is_21 (r_dobj) accumulating_2\VBG\2281093|can_26|toxic_33|and_69|associated_80|._112 (r_csubj) be_6\VB\14625458|NONE_0 (l_conj) associated_16\VBN\628491|accumulating_80|can_54|toxic_47|and_11|._32 (l_prep) with_17\IN\0|may_18|be_14 (l_pobj) anaemia_19\NN\14299637|NONE_0
D001556_D002493 CID lindane_4\NN\14919948|evidence_30|is_21 (r_dobj) accumulating_2\VBG\2281093|can_26|toxic_33|and_69|associated_80|._112 (r_csubj) be_6\VB\14625458|NONE_0 (l_acomp) toxic_7\JJ\0|accumulating_33|can_7|and_36|associated_47|._79 (l_prep) to_8\IN\0|NONE_0 (l_pobj) system_12\NN\3575240|NONE_0
3560096
D011188_D006947 NONE potassium_8\NN\14625458|to_16 (r_dobj) effect_6\NN\34213|NONE_0 (r_xcomp) known_4\VBN\0|no_21|other_18 (r_acl) medications_3\NNS\3247620|as_12|had_44|been_48|concomitantly_59 (r_nsubjpass) given_11\VBN\5892096|,_19|course_26|suggestive_46|._125 (r_advcl) is_18\VBZ\0|NONE_0 (l_acomp) suggestive_19\JJ\0|given_46|,_27|course_20|._79 (l_prep) of_20\IN\0|NONE_0 (l_pobj) relationship_27\NN\31921|NONE_0 (l_prep) between_28\IN\0|a_32|cause_30 (l_pobj) sulindac_29\NN\3828465|NONE_0 (l_conj) hyperkalemia_31\NN\14299637|and_4
D007213_D006947 CID indomethacin_17\NN\3828465|such_8 (r_pobj) as_16\IN\14622893|(_13|)_7 (r_prep) nsaid_13\NNP\2721538|nonsteroidal_38|antiinflammatory_25 (r_appos) agents_11\NNS\7347|NONE_0 (r_pobj) of_8\IN\0|a_15 (r_prep) complication_7\NN\1073995|NONE_0 (r_pobj) as_5\IN\14622893|hyperkalemia_42|has_29|recently_25|been_16|._86 (r_prep) recognized_4\VBN\686447|NONE_0 (l_nsubjpass) hyperkalemia_0\NNP\14299637|has_13|recently_17|been_26|as_42|._128
D013467_D006947 CID sulindac_3\NN\3828465|NONE_0 (r_compound) therapy_4\NN\657604|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|._32 (r_acl) hyperkalemia_0\NNP\14299637|NONE_0
D013467_D006947 CID sulindac_22\NN\3828465|NONE_0 (r_compound) administration_23\NN\1133281|NONE_0 (r_pobj) of_21\IN\0|8_7 (r_prep) days_20\NNS\15140892|NONE_0 (r_pobj) within_16\IN\0|hyperkalemia_53 (r_prep) developed_15\VBD\1753788|we_74|patients_60|._55 (l_nsubj) hyperkalemia_6\VBD\14299637|within_53
D013467_D006947 CID sulindac_29\NN\3828465|NONE_0 (l_conj) hyperkalemia_31\NN\14299637|and_4
1009330
D011206_D003556 CID iodine_10\NN\14622893|kanamycin_32|-_23|and_13 (r_conj) colistin_6\NN\0|NONE_0 (r_nmod) irrigations_11\NNS\1057200|NONE_0 (r_pobj) of_3\IN\0|a_18|high_16 (r_prep) percentage_2\NN\13815742|were_65|with_81|and_103|suggested_107|._157 (r_nsubjpass) associated_13\VBN\628491|NONE_0 (l_prep) with_14\IN\0|percentage_81|were_16|and_22|suggested_26|._76 (l_pobj) cystitis_16\NN\14566129|NONE_0
C004658_D003556 NONE choloroaniline_10\NN\0|the_26|degradation_22 (r_appos) product_7\NN\3076708|that_21|not_28|factor_46 (r_nsubj) is_11\VBZ\0|results_65|have_57|._84 (l_attr) factor_15\NN\7326557|that_67|product_46|not_18 (l_prep) in_16\IN\13603305|a_21|significant_19 (l_pobj) cystitis_22\NN\14566129|NONE_0
C010882_D003556 CID digluconate_19\NN\0|NONE_0 (r_npadvmod) associated_20\VBN\628491|erosive_11 (r_amod) cystitis_22\NN\14566129|NONE_0
D003091_D003556 CID colistin_6\NN\0|NONE_0 (r_nmod) irrigations_11\NNS\1057200|NONE_0 (r_pobj) of_3\IN\0|a_18|high_16 (r_prep) percentage_2\NN\13815742|were_65|with_81|and_103|suggested_107|._157 (r_nsubjpass) associated_13\VBN\628491|NONE_0 (l_prep) with_14\IN\0|percentage_81|were_16|and_22|suggested_26|._76 (l_pobj) cystitis_16\NN\14566129|NONE_0
C005253_D003556 NONE picloxydine_0\NNP\0|NONE_0 (r_compound) irrigations_1\NNS\1057200|have_24|but_67|have_93 (r_nsubj) appeared_2\VBD\2604760|NONE_0 (l_xcomp) have_4\VB\7846|irrigations_24|but_43|have_69 (l_dobj) incidence_7\NN\13821570|to_16 (l_prep) of_8\IN\0|a_18|lower_16 (l_pobj) cystitis_10\NN\14566129|NONE_0
D007612_D003556 CID kanamycin_4\NN\2716866|-_9|and_19|iodine_32 (r_compound) colistin_6\NN\0|NONE_0 (r_nmod) irrigations_11\NNS\1057200|NONE_0 (r_pobj) of_3\IN\0|a_18|high_16 (r_prep) percentage_2\NN\13815742|were_65|with_81|and_103|suggested_107|._157 (r_nsubjpass) associated_13\VBN\628491|NONE_0 (l_prep) with_14\IN\0|percentage_81|were_16|and_22|suggested_26|._76 (l_pobj) cystitis_16\NN\14566129|NONE_0
19387625
D002211_D006930 CID capsaicin_7\NN\15032661|-_9 (r_npadvmod) induced_9\VBN\1627355|secondary_8 (r_amod) hyperalgesia_11\NN\0|NONE_0
D002211_D006930 CID capsaicin_16\NN\15032661|-_9 (r_npadvmod) induced_18\VBN\1627355|secondary_8 (r_amod) hyperalgesia_20\NN\0|NONE_0
D002211_D006930 CID capsaicin_20\NN\15032661|-_9 (r_npadvmod) untreated_22\VBN\0|,_9|control_11 (r_amod) condition_25\NN\24720|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) that_18\DT\0|NONE_0 (r_pobj) to_17\IN\0|very_13 (r_prep) similar_16\JJ\0|that_79|magnitude_70 (r_acomp) is_14\VBZ\0|furthermore_97|,_86|it_84|was_81|._65 (l_nsubj) magnitude_7\NN\4916342|that_9|similar_70 (l_prep) of_8\IN\0|the_14 (l_pobj) modulation_10\NN\7044917|NONE_0 (l_prep) in_11\IN\13603305|attentional_23 (l_pobj) hyperalgesia_13\NN\0|NONE_0
D002211_D006930 CID capsaicin_7\NN\15032661|and_20|modulation_36 (r_compound) treatment_8\NN\654885|NONE_0 (r_pobj) between_6\IN\0|no_15 (r_prep) interaction_5\NN\37396|NONE_0 (r_dobj) showing_3\VBG\6887726|findings_10|,_2|affect_152|._205 (r_csubj) suggest_12\VBP\1010118|NONE_0 (l_ccomp) affect_22\VB\26192|findings_162|,_154|showing_152|._53 (l_nsubj) hyperalgesia_18\NN\0|that_33|might_27|pain_51|through_56
D002211_D006930 CID capsaicin_14\NN\15032661|-_9 (r_npadvmod) induced_16\VBN\1627355|secondary_8|and_31|attention_35 (r_amod) hyperalgesia_18\NN\0|that_33|might_27|pain_51|through_56
D002211_D010146 NONE capsaicin_7\NN\15032661|-_9 (r_npadvmod) induced_9\VBN\1627355|secondary_8 (r_amod) hyperalgesia_11\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|perceived_25|pain_15 (r_prep) intensity_5\NN\5090441|NONE_0 (l_compound) pain_4\NN\14299637|perceived_10|in_15
D002211_D010146 NONE capsaicin_16\NN\15032661|-_9 (r_npadvmod) induced_18\VBN\1627355|secondary_8 (r_amod) hyperalgesia_20\NN\0|NONE_0 (r_pobj) in_15\IN\13603305|NONE_0 (r_prep) attention_14\NN\5701944|NONE_0 (r_pobj) by_13\IN\0|that_45|how_40|ratings_21|are_13 (r_agent) affected_12\VBN\126264|however_61|,_54|it_52|is_49|not_46|._65 (l_nsubjpass) ratings_10\NNS\5733583|that_24|how_19|are_8|by_21 (l_compound) intensity_9\NN\5090441|NONE_0 (l_compound) pain_8\NN\14299637|NONE_0
D002211_D010146 NONE capsaicin_7\NN\15032661|and_20|modulation_36 (r_compound) treatment_8\NN\654885|NONE_0 (r_pobj) between_6\IN\0|no_15 (r_prep) interaction_5\NN\37396|NONE_0 (r_dobj) showing_3\VBG\6887726|findings_10|,_2|affect_152|._205 (r_csubj) suggest_12\VBP\1010118|NONE_0 (l_ccomp) affect_22\VB\26192|findings_162|,_154|showing_152|._53 (l_dobj) pain_24\NN\14299637|that_84|hyperalgesia_51|might_24|through_5
D002211_D010146 NONE capsaicin_14\NN\15032661|-_9 (r_npadvmod) induced_16\VBN\1627355|secondary_8|and_31|attention_35 (r_amod) hyperalgesia_18\NN\0|that_33|might_27|pain_51|through_56 (r_nsubj) affect_22\VB\26192|findings_162|,_154|showing_152|._53 (l_dobj) pain_24\NN\14299637|that_84|hyperalgesia_51|might_24|through_5
18821488
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16\NNP\0|the_60|methylbutyl)amino]-_25|(_38 (r_nmod) wr242511_18\NNP\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) following_4\VBG\8180190|in_18|)_135|._136 (r_prep) toxicity_0\NN\13576101|NONE_0
C068820_D064420 NONE wr242511_18\NNP\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) following_4\VBG\8180190|in_18|)_135|._136 (r_prep) toxicity_0\NN\13576101|NONE_0
C068820_D064420 NONE wr242511_4\NNP\0|that_5|should_9|not_16|be_20|as_31|dissociated_138 (r_nsubjpass) pursued_8\VBN\10192926|it_44|is_41|._168 (l_advcl) dissociated_27\VBN\2431320|that_143|wr242511_138|should_129|not_122|be_118|as_107 (l_prep) from_28\IN\0|unless_84|characteristics_65|can_32|be_28|successfully_25 (l_pobj) those_29\DT\0|NONE_0 (l_acl) producing_30\VBG\1617192|NONE_0 (l_dobj) toxicity_32\NN\13576101|NONE_0
C068820_D011041 NONE wr242511_4\NNP\0|that_5|should_9|not_16|be_20|as_31|dissociated_138 (r_nsubjpass) pursued_8\VBN\10192926|it_44|is_41|._168 (l_prep) as_9\IN\14622893|that_36|wr242511_31|should_22|not_15|be_11|dissociated_107 (l_pobj) pretreatment_11\NN\0|NONE_0 (l_prep) for_12\IN\0|a_15 (l_pobj) poisoning_14\NN\14034177|NONE_0
C068820_D006456 CID wr242511_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|minutes_22 (r_prep) postinjection_9\NN\0|furthermore_73|,_62|hemoglobinuria_50|was_35|,_44|and_46|occurred_64 (r_dobj) noted_5\VBN\1009240|NONE_0 (l_nsubjpass) hemoglobinuria_3\NN\14299637|furthermore_23|,_12|was_15|postinjection_50|,_94|and_96|occurred_114
C080436_D064420 NONE 8-aminoquinoline_8\JJ\0|NONE_0 (r_compound) 8-[(4-amino_9\CD\0|-_11 (r_compound) l_11\NN\13616054|-_1 (r_compound) methylbutyl)amino]-_13\NN\0|the_35|hexyloxy)-6-methoxy-4-methylquinoline_25|(_63 (r_punct) wr242511_18\NNP\0|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) following_4\VBG\8180190|in_18|)_135|._136 (r_prep) toxicity_0\NN\13576101|NONE_0
C068820_D008708 NONE wr242511_4\NNP\0|NONE_0 (l_relcl) produced_7\VBD\1617192|,_8|,_92 (l_dobj) methemoglobinemia_9\NN\0|which_27|in_33
3782049
D008972_D058186 CID molindone_18\NN\3713736|NONE_0 (r_compound) administration_19\NN\1133281|NONE_0 (r_pobj) following_17\VBG\8180190|massive_58|and_35|failure_8 (r_prep) rhabdomyolysis_11\NN\0|to_22 (l_conj) failure_16\NN\66216|massive_50|and_27|following_8
D008972_D012206 CID molindone_6\NN\3713736|NONE_0 (r_compound) administration_7\NN\1133281|NONE_0 (r_pobj) following_5\VBG\8180190|massive_23 (r_prep) rhabdomyolysis_4\NN\0|NONE_0
D008972_D012206 CID molindone_18\NN\3713736|NONE_0 (r_compound) administration_19\NN\1133281|NONE_0 (r_pobj) following_17\VBG\8180190|massive_58|and_35|failure_8 (r_prep) rhabdomyolysis_11\NN\0|to_22
D008972_D012559 NONE molindone_18\NN\3713736|NONE_0 (r_compound) administration_19\NN\1133281|NONE_0 (r_pobj) following_17\VBG\8180190|massive_58|and_35|failure_8 (r_prep) rhabdomyolysis_11\NN\0|to_22 (r_dobj) illustrate_9\VB\955601|case_47|is_15|._103 (r_xcomp) reported_7\VBN\831651|NONE_0 (l_nsubjpass) case_1\NN\7283608|is_32|illustrate_47|._150 (l_prep) of_2\IN\0|the_9 (l_pobj) patient_5\NN\9898892|NONE_0 (l_amod) schizophrenic_4\JJ\10490141|a_2
8690168
D006497_D003928 NONE sulphate_3\NN\15010703|-_8 (r_npadvmod) associated_5\VBN\628491|heparan_17|anionic_11|in_25 (r_amod) sites_7\NNS\8673395|NONE_0 (l_prep) in_8\IN\13603305|heparan_42|associated_25|anionic_14 (l_pobj) membrane_12\NN\4188643|NONE_0 (l_prep) of_13\IN\0|the_33|glomerular_29|basement_18 (l_pobj) rats_14\NNS\2329401|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) nephropathy_20\NN\14573196|NONE_0
D013311_D003928 CID streptozotocin_16\NNS\0|-_14 (r_npadvmod) induced_18\VBN\1627355|diabetic_8 (r_amod) nephropathy_20\NN\14573196|NONE_0
C015445_D003920 NONE blue_38\JJ\4959672|NONE_0 (r_dobj) employing_33\VBG\0|sites_160|were_118|in_105|after_88|,_2|._42 (r_advcl) studied_12\VBN\0|NONE_0 (l_prep) after_17\IN\0|sites_72|were_30|in_17|,_86|employing_88|._130 (l_pobj) induction_18\NN\7450842|months_13 (l_prep) of_19\IN\0|by_12 (l_pobj) diabetes_20\NNS\14075199|NONE_0
D013311_D003920 NONE streptozotocin_22\NNS\0|and_15|in_19 (r_pobj) by_21\IN\0|of_12 (r_prep) induction_18\NN\7450842|months_13 (l_prep) of_19\IN\0|by_12 (l_pobj) diabetes_20\NNS\14075199|NONE_0
D013311_D003920 NONE streptozotocin_4\JJ\0|-_14 (r_amod) diabetic_6\JJ\10595647|with_14
D006497_D003920 NONE sulphate_1\NN\15010703|-_8 (r_npadvmod) associated_3\VBN\628491|heparan_17|anionic_11|in_25 (r_amod) sites_5\NNS\8673395|were_42|in_55|after_72|,_158|employing_160|._202 (r_nsubjpass) studied_12\VBN\0|NONE_0 (l_prep) after_17\IN\0|sites_72|were_30|in_17|,_86|employing_88|._130 (l_pobj) induction_18\NN\7450842|months_13 (l_prep) of_19\IN\0|by_12 (l_pobj) diabetes_20\NNS\14075199|NONE_0
D006497_D003920 NONE sulphate_18\NN\15010703|NONE_0 (r_compound) charge_19\NN\972621|a_27|reduced_25|heparan_17|barrier_7|/_14 (r_compound) density_22\NN\4941325|that_124|in_119|is_8|at_17 (r_nsubjpass) found_24\VBN\13279262|we_147|._68 (l_prep) in_3\IN\13603305|that_5|density_119|is_127|at_136 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) diabetic_6\JJ\10595647|with_14
1468485
D015237_D006470 NONE alpha_14\NN\6828818|NONE_0 (r_pobj) of_11\IN\0|physiological_38|and_17|instillation_13 (r_prep) saline_8\NN\14849367|NONE_0 (r_pobj) with_6\IN\0|bladder_19 (r_prep) irrigation_5\NN\1057200|NONE_0 (r_pobj) including_3\VBG\0|conservative_24|,_2|,_97 (r_prep) treatment_1\NN\654885|control_128|._146 (r_nsubj) failed_16\VBD\0|NONE_0 (l_xcomp) control_19\VB\5190804|treatment_128|._18 (l_dobj) hemorrhage_20\NN\14285662|to_19|totally_16
D003520_D006470 CID cyclophosphamide_7\NN\0|-_16 (r_npadvmod) induced_9\VBN\1627355|intractable_29|hemorrhagic_8 (r_amod) cystitis_11\NN\14566129|NONE_0
D003520_D006470 CID cyclophosphamide_10\NN\0|for_25 (r_compound) therapy_11\NN\657604|to_20 (r_pobj) due_8\IN\5174653|we_53|case_41|._60 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|due_41|._101 (l_prep) of_4\IN\0|a_7 (l_pobj) cystitis_7\NN\14566129|NONE_0
D003520_D006470 CID cyclophosphamide_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_14 (r_prep) treatment_14\NN\654885|NONE_0 (r_pobj) in_12\IN\13603305|a_19|safe_17 (r_prep) alternative_11\NN\5788149|in_49|,_40|form_33|can_17|cystitis_69|._77 (r_dobj) offer_8\VB\7160883|NONE_0 (l_dobj) cystitis_20\NN\14566129|in_118|,_109|form_102|can_86|alternative_69|._8
D010100_D006470 NONE oxygen_1\NN\14622893|hyperbaric_11|for_15|._87 (r_compound) therapy_2\NN\657604|NONE_0 (l_prep) for_3\IN\0|hyperbaric_26|oxygen_15|._72 (l_pobj) control_4\NN\5190804|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) cystitis_11\NN\14566129|NONE_0
D010100_D003556 NONE oxygen_1\NN\14622893|hyperbaric_11|for_15|._87 (r_compound) therapy_2\NN\657604|NONE_0 (l_prep) for_3\IN\0|hyperbaric_26|oxygen_15|._72 (l_pobj) control_4\NN\5190804|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) cystitis_11\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_7\NN\0|-_16 (r_npadvmod) induced_9\VBN\1627355|intractable_29|hemorrhagic_8 (r_amod) cystitis_11\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_10\NN\0|for_25 (r_compound) therapy_11\NN\657604|to_20 (r_pobj) due_8\IN\5174653|we_53|case_41|._60 (r_prep) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|due_41|._101 (l_prep) of_4\IN\0|a_7 (l_pobj) cystitis_7\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_14 (r_prep) treatment_14\NN\654885|NONE_0 (r_pobj) in_12\IN\13603305|a_19|safe_17 (r_prep) alternative_11\NN\5788149|in_49|,_40|form_33|can_17|cystitis_69|._77 (r_dobj) offer_8\VB\7160883|NONE_0 (l_dobj) cystitis_20\NN\14566129|in_118|,_109|form_102|can_86|alternative_69|._8
D003520_D014890 NONE cyclophosphamide_10\NN\0|for_25 (r_compound) therapy_11\NN\657604|to_20 (l_prep) for_12\IN\0|cyclophosphamide_25 (l_pobj) granulomatosis_15\NN\0|NONE_0
88336
D002719_D013375 NONE chlormethiazole_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|high_11 (r_prep) doses_4\NNS\3740161|patients_23|for_25|,_56|and_58|took_66 (r_dobj) received_2\VBD\2210855|NONE_0 (l_prep) for_7\IN\0|patients_48|doses_25|,_31|and_33|took_41 (l_pobj) symptoms_10\NNS\5823932|NONE_0
D002719_D003128 CID chlormethiazole_10\NN\0|NONE_0 (r_compound) intoxication_11\NN\14034177|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) those_8\DT\0|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) two_6\CD\13741022|nitrazepam_24|and_4 (r_conj) overdose_4\NN\84738|NONE_0 (r_pobj) with_2\IN\0|the_12 (r_prep) patient_1\NN\9898892|to_94|,_125|showing_127|._210 (r_nsubj) conformed_12\VBD\0|NONE_0 (l_prep) to_13\IN\0|patient_94|,_31|showing_33|._116 (l_pobj) criteria_15\NNS\13577171|NONE_0 (l_prep) of_16\IN\0|the_13 (l_pobj) coma_19\NN\5678932|'_7|'_4
D009567_D013375 NONE nitrazepam_19\NN\2830852|NONE_0 (r_pobj) of_18\IN\0|a_20|suicidal_18 (r_prep) overdose_17\NN\84738|one_20|._22 (r_dobj) took_14\VBD\2367363|patients_89|doses_66|for_41|,_10|and_8 (r_conj) received_2\VBD\2210855|NONE_0 (l_prep) for_7\IN\0|patients_48|doses_25|,_31|and_33|took_41 (l_pobj) symptoms_10\NNS\5823932|NONE_0
D000431_D062787 NONE alcohol_8\NN\7881800|NONE_0 (r_compound) withdrawal_9\NN\7206096|NONE_0 (r_compound) symptoms_10\NNS\5823932|NONE_0 (r_pobj) for_7\IN\0|patients_48|doses_25|,_31|and_33|took_41 (r_prep) received_2\VBD\2210855|NONE_0 (l_conj) took_14\VBD\2367363|patients_89|doses_66|for_41|,_10|and_8 (l_dobj) overdose_17\NN\84738|one_20|._22
D000431_D013375 NONE alcohol_8\NN\7881800|NONE_0 (r_compound) withdrawal_9\NN\7206096|NONE_0 (r_compound) symptoms_10\NNS\5823932|NONE_0
D009567_D003128 CID nitrazepam_3\JJ\2830852|and_20|two_24 (r_amod) overdose_4\NN\84738|NONE_0 (r_pobj) with_2\IN\0|the_12 (r_prep) patient_1\NN\9898892|to_94|,_125|showing_127|._210 (r_nsubj) conformed_12\VBD\0|NONE_0 (l_prep) to_13\IN\0|patient_94|,_31|showing_33|._116 (l_pobj) criteria_15\NNS\13577171|NONE_0 (l_prep) of_16\IN\0|the_13 (l_pobj) coma_19\NN\5678932|'_7|'_4
D002719_D062787 NONE chlormethiazole_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|high_11 (r_prep) doses_4\NNS\3740161|patients_23|for_25|,_56|and_58|took_66 (r_dobj) received_2\VBD\2210855|NONE_0 (l_conj) took_14\VBD\2367363|patients_89|doses_66|for_41|,_10|and_8 (l_dobj) overdose_17\NN\84738|one_20|._22
D002719_D062787 NONE chlormethiazole_10\NN\0|NONE_0 (r_compound) intoxication_11\NN\14034177|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) those_8\DT\0|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) two_6\CD\13741022|nitrazepam_24|and_4 (r_conj) overdose_4\NN\84738|NONE_0
D009567_D062787 CID nitrazepam_19\NN\2830852|NONE_0 (r_pobj) of_18\IN\0|a_20|suicidal_18 (r_prep) overdose_17\NN\84738|one_20|._22
D009567_D062787 CID nitrazepam_3\JJ\2830852|and_20|two_24 (r_amod) overdose_4\NN\84738|NONE_0
9334596
D013739_D020018 CID testosterone_5\NN\14747587|NONE_0 (r_pobj) for_4\IN\0|patient_21|was_13|screened_30|._135 (r_prep) screened_3\VBN\2533282|NONE_0 (l_conj) screened_9\VBN\2533282|patient_51|was_43|for_30|._105 (l_prep) on_12\IN\0|were_28|for_14 (l_pobj) basis_14\NN\13790712|NONE_0 (l_prep) of_15\IN\0|the_10 (l_pobj) desire_18\NN\26192|NONE_0
D013739_D020018 CID testosterone_22\NN\14747587|or_3 (r_conj) gynecomastia_20\NN\14501726|low_19|sexual_15|,_2 (r_conj) desire_18\NN\26192|NONE_0
D013739_D020018 CID testosterone_1\NN\14747587|in_18 (r_dobj) determining_0\VBG\0|would_93|have_99|%_113|._215 (l_prep) in_3\IN\13603305|testosterone_18 (l_pobj) cases_4\NNS\7283608|only_8 (l_prep) of_5\IN\0|NONE_0 (l_pobj) desire_8\NN\26192|NONE_0
D013739_D020018 CID testosterone_23\NN\14747587|NONE_0 (r_pobj) with_21\IN\0|the_10 (r_prep) cases_20\NNS\7283608|NONE_0 (r_pobj) of_18\IN\0|40_4 (r_prep) %_17\NN\0|determining_113|would_20|have_14|._102 (r_dobj) missed_15\VBN\0|NONE_0 (l_csubj) determining_0\VBG\0|would_93|have_99|%_113|._215 (l_prep) in_3\IN\13603305|testosterone_18 (l_pobj) cases_4\NNS\7283608|only_8 (l_prep) of_5\IN\0|NONE_0 (l_pobj) desire_8\NN\26192|NONE_0
D013739_D020018 CID testosterone_8\NN\14747587|that_25|before_20|be_13|in_32|but_96|measured_111 (r_nsubjpass) determined_10\VBN\0|we_57|now_54|._134 (l_prep) in_12\IN\13603305|that_57|before_52|testosterone_32|be_19|but_64|measured_79 (l_pobj) cases_13\NNS\7283608|only_8 (l_prep) of_14\IN\0|NONE_0 (l_pobj) desire_17\NN\26192|NONE_0
D013739_D020018 CID testosterone_14\NN\14747587|and/or_7 (r_conj) gynecomastia_12\NN\14501726|low_19|sexual_15|,_2 (r_conj) desire_10\NN\26192|NONE_0
D013739_D007027 NONE testosterone_5\NN\14747587|the_14|other_10|low_4 (r_compound) levels_6\NNS\4916342|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) most_0\JJS\0|result_52|._373 (r_nsubj) seemed_7\VBD\2604760|NONE_0 (l_xcomp) result_9\VB\34213|most_52|._321 (l_prep) from_10\IN\0|to_10|because_41 (l_pobj) dysfunction_13\NN\14204950|NONE_0
D001971_D006966 NONE bromocriptine_13\NN\0|and_4 (l_prep) for_14\IN\0|NONE_0 (l_pobj) hyperprolactinemia_15\NN\0|NONE_0
D013739_D006177 NONE testosterone_5\NN\14747587|NONE_0 (r_pobj) for_4\IN\0|patient_21|was_13|screened_30|._135 (r_prep) screened_3\VBN\2533282|NONE_0 (l_conj) screened_9\VBN\2533282|patient_51|was_43|for_30|._105 (l_prep) on_12\IN\0|were_28|for_14 (l_pobj) basis_14\NN\13790712|NONE_0 (l_prep) of_15\IN\0|the_10 (l_pobj) desire_18\NN\26192|NONE_0 (l_conj) gynecomastia_20\NN\14501726|low_19|sexual_15|,_2
D013739_D006177 NONE testosterone_22\NN\14747587|or_3 (r_conj) gynecomastia_20\NN\14501726|low_19|sexual_15|,_2
D013739_D006177 NONE testosterone_14\NN\14747587|and/or_7 (r_conj) gynecomastia_12\NN\14501726|low_19|sexual_15|,_2
D013739_D010911 NONE testosterone_6\NN\14747587|NONE_0 (r_compound) determination_7\NN\43195|NONE_0 (r_pobj) after_5\IN\0|tumors_23|were_16|._32 (r_prep) discovered_4\VBN\2163746|NONE_0 (l_nsubjpass) tumors_2\NNS\14234074|were_7|after_23|._55
C004648_D007006 NONE heptylate_5\NN\0|NONE_0 (l_conj) gonadotropin_9\NN\5407119|testosterone_42|or_19 (l_prep) for_10\IN\0|human_29|chorionic_23 (l_pobj) hypogonadism_11\NN\14076126|NONE_0
C004648_D006966 NONE heptylate_5\NN\0|NONE_0 (l_conj) gonadotropin_9\NN\5407119|testosterone_42|or_19 (l_prep) for_10\IN\0|human_29|chorionic_23 (l_pobj) hypogonadism_11\NN\14076126|NONE_0 (l_conj) bromocriptine_13\NN\0|and_4 (l_prep) for_14\IN\0|NONE_0 (l_pobj) hyperprolactinemia_15\NN\0|NONE_0
D001971_D007006 NONE bromocriptine_13\NN\0|and_4 (r_conj) hypogonadism_11\NN\14076126|NONE_0
D013739_D007172 NONE testosterone_6\NN\14747587|NONE_0 (r_pobj) of_4\IN\0|the_12|in_50 (r_prep) results_3\NNS\34213|we_16|and_117|compared_121|,_151|results_153|._374 (l_prep) in_10\IN\13603305|the_62|of_50 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_acl) referred_13\VBD\730052|1,022_15 (l_prep) because_14\IN\0|NONE_0 (l_pobj) dysfunction_17\NN\14204950|of_12
D013739_D007172 NONE testosterone_5\NN\14747587|the_14|other_10|low_4 (r_compound) levels_6\NNS\4916342|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) most_0\JJS\0|result_52|._373 (r_nsubj) seemed_7\VBD\2604760|NONE_0 (l_xcomp) result_9\VB\34213|most_52|._321 (l_prep) because_14\IN\0|to_51|from_41 (l_conj) have_24\VB\7846|of_57|hormone_29|and_7 (l_dobj) role_28\NN\719494|to_21 (l_prep) in_29\IN\13603305|only_18|a_13|small_11 (l_pobj) dysfunction_31\NN\14204950|NONE_0
D013739_D007172 NONE testosterone_6\NN\14747587|NONE_0 (r_pobj) of_4\IN\0|in_39 (r_prep) effects_3\NNS\13245626|low_20|and_4 (l_prep) in_10\IN\13603305|of_39 (l_pobj) dysfunction_12\NN\14204950|NONE_0
1919871
D000082_D007681 CID paracetamol_22\JJ\0|and_4|in_12 (r_conj) aspirin_20\NN\2707683|NONE_0 (r_pobj) with_19\IN\0|continuous_31|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) during_13\IN\0|NONE_0 (r_prep) developed_12\VBN\1753788|a_42|decreased_40|urinary_30|concentrating_22 (r_acl) ability_11\NN\4723816|renal_69|papillary_63|(_44|rpn_43|)_40|and_38|._111 (r_conj) necrosis_2\NN\11444117|NONE_0
D000082_D007681 CID paracetamol_22\JJ\0|and_4|in_12 (r_conj) aspirin_20\NN\2707683|NONE_0 (r_pobj) with_19\IN\0|continuous_31|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) during_13\IN\0|NONE_0 (r_prep) developed_12\VBN\1753788|a_42|decreased_40|urinary_30|concentrating_22 (r_acl) ability_11\NN\4723816|renal_69|papillary_63|(_44|rpn_43|)_40|and_38|._111 (r_conj) necrosis_2\NN\11444117|NONE_0 (l_appos) rpn_4\NNP\0|renal_26|papillary_20|(_1|)_3|and_5|ability_43|._154
D001241_D007681 CID aspirin_20\NN\2707683|NONE_0 (r_pobj) with_19\IN\0|continuous_31|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) during_13\IN\0|NONE_0 (r_prep) developed_12\VBN\1753788|a_42|decreased_40|urinary_30|concentrating_22 (r_acl) ability_11\NN\4723816|renal_69|papillary_63|(_44|rpn_43|)_40|and_38|._111 (r_conj) necrosis_2\NN\11444117|NONE_0
D001241_D007681 CID aspirin_20\NN\2707683|NONE_0 (r_pobj) with_19\IN\0|continuous_31|term_15 (r_prep) treatment_18\NN\654885|NONE_0 (r_pobj) during_13\IN\0|NONE_0 (r_prep) developed_12\VBN\1753788|a_42|decreased_40|urinary_30|concentrating_22 (r_acl) ability_11\NN\4723816|renal_69|papillary_63|(_44|rpn_43|)_40|and_38|._111 (r_conj) necrosis_2\NN\11444117|NONE_0 (l_appos) rpn_4\NNP\0|renal_26|papillary_20|(_1|)_3|and_5|ability_43|._154
8955532
D003911_D006973 NONE dextran_15\NN\0|NONE_0 (r_pobj) of_11\IN\0|before_31 (r_prep) clearance_10\NN\5089947|NONE_0 (l_prep) before_16\IN\0|of_31 (l_conj) during_18\IN\0|and_4 (l_pobj) hypertension_23\NN\14057371|NONE_0
D001920_D006973 NONE bradykinin_4\NN\0|NONE_0 (l_prep) in_7\IN\13603305|receptors_10 (l_pobj) disruption_8\NN\1066163|NONE_0 (l_prep) during_15\IN\0|of_27 (l_pobj) hypertension_17\NN\14057371|NONE_0
D001920_D006973 NONE bradykinin_15\NN\0|NONE_0 (r_pobj) of_14\IN\0|synthesis_18|/_9 (r_prep) release_13\NN\3748886|NONE_0 (r_pobj) of_10\IN\0|the_9 (r_prep) role_9\NN\719494|to_17|activate_43 (r_dobj) determine_7\VB\0|goal_26|._145 (l_xcomp) activate_17\VB\1641914|to_60|role_43 (l_prep) in_20\IN\13603305|to_25|receptors_10 (l_pobj) disruption_21\NN\1066163|NONE_0 (l_prep) during_28\IN\0|of_27 (l_pobj) hypertension_30\NN\14057371|NONE_0
D001920_D006973 NONE bradykinin_23\NN\0|NONE_0 (r_pobj) of_22\IN\0|the_22|synthesis_18|/_9 (r_prep) release_21\NN\3748886|NONE_0 (r_pobj) to_17\IN\0|is_15|not_12|activate_42 (r_prep) related_16\VBN\628491|findings_93|._71 (l_auxpass) is_14\VBZ\0|not_3|to_15|activate_57 (l_nsubj) disruption_4\NN\1066163|that_5 (l_prep) during_11\IN\0|of_27 (l_pobj) hypertension_13\NN\14057371|NONE_0
D010656_D006973 CID phenylephrine_19\NN\2682038|-_13 (r_npadvmod) induced_21\VBN\1627355|acute_8|in_27 (r_amod) hypertension_23\NN\14057371|NONE_0
C065679_D006973 NONE hoe-140_30\NNP\0|and_4|microm_13 (r_conj) vehicle_28\NN\3100490|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treated_26\VBN\2376958|NONE_0 (r_acl) rats_25\NNS\2329401|NONE_0 (r_pobj) in_24\IN\13603305|induced_27|acute_19 (r_prep) hypertension_23\NN\14057371|NONE_0
19037603
D019259_D012216 NONE lamivudine_3\NN\3834836|NONE_0 (r_pobj) of_2\IN\0|prophylactic_17|with_14|._80 (r_prep) use_1\NN\407535|NONE_0 (l_prep) with_4\IN\0|prophylactic_31|of_14|._66 (l_pobj) therapy_7\NN\657604|NONE_0 (l_prep) for_8\IN\0|chronic_34|immunosuppressive_26 (l_pobj) disorders_10\NNS\14034177|NONE_0
D019259_D012216 NONE lamivudine_18\NN\3834836|NONE_0 (r_pobj) of_17\IN\0|the_32|prophylactic_28|in_14 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) of_13\IN\0|the_18 (r_prep) effectiveness_12\NN\5190804|NONE_0 (r_pobj) concerning_10\VBG\0|to_25|experience_11 (r_prep) report_7\VB\6470073|objective_31|patients_155|._190 (r_xcomp) was_5\VBD\0|NONE_0 (l_attr) patients_30\NNS\9898892|objective_186|report_155|._35 (l_prep) with_31\IN\0|)_20|positive_18 (l_pobj) disease_33\NN\14061805|NONE_0
D019259_D012216 NONE lamivudine_23\JJ\3834836|immunosuppressive_35 (r_compound) therapies_24\NNS\657604|NONE_0 (r_pobj) on_18\IN\0|who_9 (r_prep) were_17\VBD\0|rheumatologic_28|,_6 (r_relcl) diseases_14\NNS\14061805|NONE_0
D006514_D012216 NONE antigen_24\NN\20090|NONE_0 (r_pobj) in_19\IN\13603305|the_46|prophylactic_42|of_14 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) of_13\IN\0|the_18 (r_prep) effectiveness_12\NN\5190804|NONE_0 (r_pobj) concerning_10\VBG\0|to_25|experience_11 (r_prep) report_7\VB\6470073|objective_31|patients_155|._190 (r_xcomp) was_5\VBD\0|NONE_0 (l_attr) patients_30\NNS\9898892|objective_186|report_155|._35 (l_prep) with_31\IN\0|)_20|positive_18 (l_pobj) disease_33\NN\14061805|NONE_0
D006514_D012216 NONE ag_27\NNP\14821043|virus_27|surface_21 (r_appos) antigen_24\NN\20090|NONE_0 (r_pobj) in_19\IN\13603305|the_46|prophylactic_42|of_14 (r_prep) administration_16\NN\1133281|NONE_0 (r_pobj) of_13\IN\0|the_18 (r_prep) effectiveness_12\NN\5190804|NONE_0 (r_pobj) concerning_10\VBG\0|to_25|experience_11 (r_prep) report_7\VB\6470073|objective_31|patients_155|._190 (r_xcomp) was_5\VBD\0|NONE_0 (l_attr) patients_30\NNS\9898892|objective_186|report_155|._35 (l_prep) with_31\IN\0|)_20|positive_18 (l_pobj) disease_33\NN\14061805|NONE_0
D006514_D012216 NONE ag_9\NNP\14821043|positive_3|with_21 (r_nmod) patients_11\NNS\9898892|from_51|,_21|,_110|were_112|retrospectively_117|._141 (l_prep) with_12\IN\0|ag_21|positive_18 (l_pobj) diseases_14\NNS\14061805|NONE_0
809711
D005996_D007022 CID nitroglycerin_0\NNP\15015501|has_14|been_18|reduce_32 (r_nsubjpass) shown_3\VBN\2137132|,_71|effect_76|in_95|by_106|._162 (r_ccomp) potentiated_17\VBN\229605|NONE_0 (l_agent) by_21\IN\0|shown_106|,_35|effect_30|in_11|._56 (l_pobj) agents_22\NNS\7347|NONE_0 (l_relcl) reverse_24\VBP\13854649|NONE_0 (l_dobj) hypotension_28\NN\14057371|that_35
D005996_D007022 CID nitroglycerin_25\NN\15015501|-_13 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) hypotension_28\NN\14057371|that_35
D005996_D009203 NONE nitroglycerin_9\NN\15015501|NONE_0 (r_pobj) of_7\IN\0|the_23|beneficial_19|in_29 (r_prep) effects_6\NNS\13245626|NONE_0 (l_prep) in_10\IN\13603305|the_52|beneficial_48|of_29 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) infarction_15\NN\14204950|NONE_0
D005996_D009203 NONE nitroglycerin_0\NNP\15015501|has_14|been_18|reduce_32 (r_nsubjpass) shown_3\VBN\2137132|,_71|effect_76|in_95|by_106|._162 (l_xcomp) reduce_5\VB\441445|nitroglycerin_32|has_18|been_14 (l_prep) during_10\IN\0|to_31|elevation_10 (l_pobj) infarction_13\NN\14204950|NONE_0
D005996_D009203 NONE nitroglycerin_25\NN\15015501|-_13 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) hypotension_28\NN\14057371|that_35 (r_dobj) reverse_24\VBP\13854649|NONE_0 (r_relcl) agents_22\NNS\7347|NONE_0 (r_pobj) by_21\IN\0|shown_106|,_35|effect_30|in_11|._56 (r_agent) potentiated_17\VBN\229605|NONE_0 (l_ccomp) shown_3\VBN\2137132|,_71|effect_76|in_95|by_106|._162 (l_xcomp) reduce_5\VB\441445|nitroglycerin_32|has_18|been_14 (l_prep) during_10\IN\0|to_31|elevation_10 (l_pobj) infarction_13\NN\14204950|NONE_0
D005996_D009203 NONE nitroglycerin_9\NN\15015501|patients_75|+/-_80 (r_dobj) received_7\VBD\2210855|NONE_0 (l_nsubj) patients_1\NNS\9898892|nitroglycerin_75|+/-_155 (l_prep) with_2\IN\0|ten_13 (l_pobj) infarctions_6\NNS\14204950|NONE_0
D005996_D009203 NONE nitroglycerin_8\NN\15015501|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) phenylephrine_6\NN\2682038|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) addition_4\NN\3081021|that_5|not_46|beneficial_50 (r_nsubj) is_9\VBZ\0|results_64|._79 (l_acomp) beneficial_11\JJ\0|that_55|addition_50|not_4 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) infarction_20\NN\14204950|NONE_0
D010656_D009203 NONE phenylephrine_2\NN\2682038|NONE_0 (l_prep) of_3\IN\0|NONE_0 (l_pobj) effects_6\NNS\13245626|NONE_0 (l_prep) in_10\IN\13603305|the_52|beneficial_48|of_29 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) infarction_15\NN\14204950|NONE_0
D010656_D009203 NONE phenylephrine_6\NN\2682038|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) addition_4\NN\3081021|that_5|not_46|beneficial_50 (r_nsubj) is_9\VBZ\0|results_64|._79 (l_acomp) beneficial_11\JJ\0|that_55|addition_50|not_4 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) infarction_20\NN\14204950|NONE_0
17600377
C524754_D009410 NONE coumarate_17\NN\0|that_16|maltolyl_11|candidate_37 (r_nsubj) is_18\VBZ\0|results_63|,_47|study_41|._162 (l_attr) candidate_22\NN\10450303|that_53|maltolyl_48|coumarate_37 (l_relcl) characterized_29\VBN\609683|a_70|effective_56|against_36 (l_agent) by_30\IN\0|that_22|is_17 (l_pobj) death_34\NN\7296428|NONE_0
D012601_D003072 CID scopolamine_17\NN\14712692|-_11 (r_npadvmod) injected_19\VBN\81072|NONE_0 (r_amod) rats_20\NNS\2329401|and_5|in_9 (r_pobj) in_16\IN\13603305|cognitive_18 (r_prep) decline_15\NN\13458571|whether_53|coumarate_34|could_24
C544092_D003072 NONE beta_24\NN\6828818|NONE_0 (r_pobj) in_22\IN\13603305|rats_9|and_4 (r_conj) in_16\IN\13603305|cognitive_18 (r_prep) decline_15\NN\13458571|whether_53|coumarate_34|could_24
C544092_D003072 NONE 42)-infused_34\VBN\0|NONE_0 (r_amod) rats_35\NNS\2329401|amyloid_35 (r_dobj) beta_31\NN\6828818|coumarate_178|was_168|attenuate_155|._31 (r_advcl) found_5\VBN\13279262|NONE_0 (l_xcomp) attenuate_7\VB\224901|coumarate_23|was_13|beta_155|._186 (l_dobj) deficits_9\NNS\5113133|to_23
C524754_D003704 NONE coumarate_7\NN\0|a_29|novel_27|,_13|,_9 (r_appos) compound_2\NN\5869584|deficits_53|and_62|shows_66|._132 (r_nsubj) attenuates_9\VBZ\224901|NONE_0 (l_conj) shows_13\VBZ\429048|compound_66|deficits_13|and_4|._66 (l_dobj) effects_15\NNS\13245626|NONE_0 (l_prep) in_16\IN\13603305|neuroprotective_24 (l_amod) vitro_17\FW\0|NONE_0 (l_conj) in_19\IN\13603305|and_4 (l_pobj) models_22\NNS\5888929|NONE_0 (l_compound) dementia_21\NN\14395018|NONE_0
C524754_D003072 NONE coumarate_7\NN\0|a_29|novel_27|,_13|,_9 (r_appos) compound_2\NN\5869584|deficits_53|and_62|shows_66|._132 (r_nsubj) attenuates_9\VBZ\224901|NONE_0 (l_dobj) deficits_11\NNS\5113133|compound_53|and_9|shows_13|._79
C524754_D003072 NONE coumarate_11\NN\0|whether_19|could_10|decline_34 (r_nsubj) improve_13\VB\126264|in_73|,_53|we_51 (l_dobj) decline_15\NN\13458571|whether_53|coumarate_34|could_24
C524754_D003072 NONE coumarate_3\NN\0|was_10|attenuate_23|beta_178|._209 (r_nsubjpass) found_5\VBN\13279262|NONE_0 (l_xcomp) attenuate_7\VB\224901|coumarate_23|was_13|beta_155|._186 (l_dobj) deficits_9\NNS\5113133|to_23
C524754_D003072 NONE coumarate_17\NN\0|that_16|maltolyl_11|candidate_37 (r_nsubj) is_18\VBZ\0|results_63|,_47|study_41|._162 (l_attr) candidate_22\NN\10450303|that_53|maltolyl_48|coumarate_37 (l_relcl) characterized_29\VBN\609683|a_70|effective_56|against_36 (l_agent) by_30\IN\0|that_22|is_17 (l_pobj) death_34\NN\7296428|NONE_0 (l_conj) decline_37\NN\13458571|spread_38|neuronal_31|and_16 (l_prep) of_38\IN\0|progressive_20 (l_pobj) function_40\NN\13783581|NONE_0
C524754_D000544 NONE coumarate_17\NN\0|that_16|maltolyl_11|candidate_37 (r_nsubj) is_18\VBZ\0|results_63|,_47|study_41|._162 (l_attr) candidate_22\NN\10450303|that_53|maltolyl_48|coumarate_37 (l_prep) against_23\IN\0|a_34|effective_20|characterized_36 (l_pobj) disease_26\NN\14061805|NONE_0
10526274
C056507_D064420 NONE gem_1\NNP\2743547|(_1|)_3|may_5|rate_27|,_61|with_63|._135 (r_nsubj) obtain_4\VB\2210855|NONE_0 (l_prep) with_17\IN\0|(_64|gem_63|)_60|may_58|rate_36|,_2|._72 (l_pobj) toxicity_19\NN\13576101|NONE_0
C056507_D064420 NONE gem_12\NNP\2743547|NONE_0 (r_pobj) of_11\IN\0|the_16|in_15 (r_prep) combination_10\NN\7951464|NONE_0 (r_pobj) of_8\IN\0|the_26|and_13|toxicity_9 (r_prep) efficacy_5\NN\5199286|in_25|were_155|._168 (l_conj) toxicity_7\NN\13576101|the_17|and_4|of_9
C030852_D064420 NONE vnb_14\NNP\0|and_4 (r_conj) gem_12\NNP\2743547|NONE_0 (r_pobj) of_11\IN\0|the_16|in_15 (r_prep) combination_10\NN\7951464|NONE_0 (r_pobj) of_8\IN\0|the_26|and_13|toxicity_9 (r_prep) efficacy_5\NN\5199286|in_25|were_155|._168 (l_conj) toxicity_7\NN\13576101|the_17|and_4|of_9
D002945_D064420 NONE cisplatin_28\NN\0|NONE_0 (r_dobj) receiving_27\VBG\2210855|NONE_0 (r_pcomp) to_26\IN\0|some_22 (r_prep) contraindication_25\NN\5819149|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) those_22\DT\0|advanced_18|or_3 (r_conj) nsclc_20\NNP\0|NONE_0 (r_pobj) with_18\IN\0|elderly_17 (r_prep) patients_17\NNS\9898892|NONE_0 (r_pobj) in_15\IN\13603305|the_31|of_15 (r_prep) combination_10\NN\7951464|NONE_0 (r_pobj) of_8\IN\0|the_26|and_13|toxicity_9 (r_prep) efficacy_5\NN\5199286|in_25|were_155|._168 (l_conj) toxicity_7\NN\13576101|the_17|and_4|of_9
D002945_D002289 NONE cisplatin_20\NN\0|who_19|can_15|not_12 (r_dobj) receive_19\VB\2210855|70_41|or_32|older_29|or_23|patients_20 (r_relcl) years_11\NNS\15144371|gemcitabine_77|._55 (r_npadvmod) age_9\NN\4916342|NONE_0 (l_nsubj) gemcitabine_0\NNP\0|years_77|._132 (l_conj) vinorelbine_2\NN\0|plus_5 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_compound) carcinoma_7\NN\14239918|nonsmall_19
D002945_D002289 NONE cisplatin_28\NN\0|NONE_0 (r_dobj) receiving_27\VBG\2210855|NONE_0 (r_pcomp) to_26\IN\0|some_22 (r_prep) contraindication_25\NN\5819149|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) those_22\DT\0|advanced_18|or_3 (r_conj) nsclc_20\NNP\0|NONE_0
D002945_D002289 NONE cisplatin_33\NN\0|NONE_0 (r_dobj) receiving_32\VBG\2210855|NONE_0 (r_pcomp) to_31\IN\0|some_22 (r_prep) contraindication_30\NN\5819149|who_13 (r_dobj) had_28\VBD\0|11_31|age_23|but_8 (r_conj) were_21\VBD\0|years_13|and_7 (r_conj) /=_16\NFP\0|patients_65|were_36|,_23|were_10|._95 (r_punct) included_8\VBN\0|NONE_0 (l_nsubjpass) patients_3\NNS\9898892|were_29|,_42|were_55|/=_65|._160 (l_prep) with_4\IN\0|nine_14 (l_pobj) nsclc_6\NNP\0|NONE_0
C030852_D002289 NONE vinorelbine_2\NN\0|plus_5 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_compound) carcinoma_7\NN\14239918|nonsmall_19
C030852_D002289 NONE vnb_14\NNP\0|and_4 (r_conj) gem_12\NNP\2743547|NONE_0 (r_pobj) of_11\IN\0|the_16|in_15 (r_prep) combination_10\NN\7951464|NONE_0 (l_prep) in_15\IN\13603305|the_31|of_15 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|elderly_17 (l_pobj) nsclc_20\NNP\0|NONE_0
C056507_D002289 NONE gemcitabine_0\NNP\0|years_77|._132 (l_conj) vinorelbine_2\NN\0|plus_5 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_compound) carcinoma_7\NN\14239918|nonsmall_19
C056507_D002289 NONE gem_12\NNP\2743547|NONE_0 (r_pobj) of_11\IN\0|the_16|in_15 (r_prep) combination_10\NN\7951464|NONE_0 (l_prep) in_15\IN\13603305|the_31|of_15 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|elderly_17 (l_pobj) nsclc_20\NNP\0|NONE_0
6692345
D005200_D063646 NONE fanft_16\NNP\0|in_21 (r_compound) carcinogenesis_17\NN\0|NONE_0
D005200_D063646 NONE fanft_30\NNP\0|NONE_0 (r_pobj) on_29\IN\0|aspirin_17|in_9 (r_prep) effect_28\NN\34213|that_15|not_38|due_42 (r_nsubj) is_34\VBZ\0|that_149|mechanisms_134|are_123|in_110|,_56|and_54 (r_conj) involved_14\VBN\2676054|NONE_0 (l_prep) in_15\IN\13603305|that_39|mechanisms_24|are_13|,_54|and_56|is_110 (l_pobj) carcinogenesis_17\NN\0|NONE_0
D001241_D063646 NONE aspirin_26\NN\2707683|on_17|in_26 (r_poss) effect_28\NN\34213|that_15|not_38|due_42 (r_nsubj) is_34\VBZ\0|that_149|mechanisms_134|are_123|in_110|,_56|and_54 (r_conj) involved_14\VBN\2676054|NONE_0 (l_prep) in_15\IN\13603305|that_39|mechanisms_24|are_13|,_54|and_56|is_110 (l_pobj) carcinogenesis_17\NN\0|NONE_0
D005200_D013274 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|the_22|-_16|to_70 (r_prep) administration_3\NN\1133281|in_102|._210 (r_nsubj) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|administration_102|._108 (l_pobj) incidence_17\NN\13821570|NONE_0 (l_conj) induction_27\NN\7450842|a_74|reduced_72|of_54|but_18 (l_prep) of_28\IN\0|a_24|concomitant_22 (l_pobj) tumors_30\NNS\14234074|NONE_0
D005200_D013274 CID fanft_9\NNP\0|NONE_0 (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|the_22|-_16|to_70 (r_prep) administration_3\NN\1133281|in_102|._210 (r_nsubj) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|administration_102|._108 (l_pobj) incidence_17\NN\13821570|NONE_0 (l_conj) induction_27\NN\7450842|a_74|reduced_72|of_54|but_18 (l_prep) of_28\IN\0|a_24|concomitant_22 (l_pobj) tumors_30\NNS\14234074|NONE_0
D005200_D013274 CID fanft_19\NNP\0|-_5 (r_npadvmod) induced_21\VBN\1627355|bladder_8 (r_amod) carcinomas_23\NNS\14239918|NONE_0 (r_pobj) of_18\IN\0|a_20|reduced_18|but_36|induction_54 (r_prep) incidence_17\NN\13821570|NONE_0 (l_conj) induction_27\NN\7450842|a_74|reduced_72|of_54|but_18 (l_prep) of_28\IN\0|a_24|concomitant_22 (l_pobj) tumors_30\NNS\14234074|NONE_0
D001241_D001749 NONE aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|the_22|-_16|to_70 (r_prep) administration_3\NN\1133281|in_102|._210 (r_nsubj) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|administration_102|._108 (l_pobj) incidence_17\NN\13821570|NONE_0 (l_prep) of_18\IN\0|a_20|reduced_18|but_36|induction_54 (l_pobj) carcinomas_23\NNS\14239918|NONE_0
D001241_D013274 NONE aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|the_22|-_16|to_70 (r_prep) administration_3\NN\1133281|in_102|._210 (r_nsubj) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|administration_102|._108 (l_pobj) incidence_17\NN\13821570|NONE_0 (l_conj) induction_27\NN\7450842|a_74|reduced_72|of_54|but_18 (l_prep) of_28\IN\0|a_24|concomitant_22 (l_pobj) tumors_30\NNS\14234074|NONE_0
D005200_D001749 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|the_22|-_16|to_70 (r_prep) administration_3\NN\1133281|in_102|._210 (r_nsubj) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|administration_102|._108 (l_pobj) incidence_17\NN\13821570|NONE_0 (l_prep) of_18\IN\0|a_20|reduced_18|but_36|induction_54 (l_pobj) carcinomas_23\NNS\14239918|NONE_0
D005200_D001749 CID fanft_9\NNP\0|NONE_0 (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7\NNP\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) aspirin_5\NN\2707683|NONE_0 (r_pobj) of_4\IN\0|the_22|-_16|to_70 (r_prep) administration_3\NN\1133281|in_102|._210 (r_nsubj) resulted_13\VBD\2633881|NONE_0 (l_prep) in_14\IN\13603305|administration_102|._108 (l_pobj) incidence_17\NN\13821570|NONE_0 (l_prep) of_18\IN\0|a_20|reduced_18|but_36|induction_54 (l_pobj) carcinomas_23\NNS\14239918|NONE_0
D005200_D001749 CID fanft_19\NNP\0|-_5 (r_npadvmod) induced_21\VBN\1627355|bladder_8 (r_amod) carcinomas_23\NNS\14239918|NONE_0
2950248
D004176_D017202 NONE dipyridamole_0\NNP\0|-_12 (r_npadvmod) induced_2\VBN\1627355|myocardial_8|._27 (r_amod) ischemia_4\NN\14195315|NONE_0
D004176_D017202 NONE dipyridamole_16\NN\0|preoperative_13 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_14\IN\0|a_14|side_12 (r_prep) effect_13\NN\34213|NONE_0 (r_pobj) as_10\IN\14622893|to_56|,_40|this_38|has_33|not_29|previously_25|been_14|,_53|demonstrated_114|._186 (r_prep) reported_9\VBN\831651|NONE_0 (l_advcl) demonstrated_27\VBN\2137132|to_170|,_154|this_152|has_147|not_143|previously_139|been_128|as_114|,_61|._72 (l_nsubjpass) ischemia_24\NN\14195315|although_41|has_9|been_13|occur_34
D004176_D017202 NONE dipyridamole_20\NN\0|-_12 (r_dep) induced_22\VBN\1627355|myocardial_8 (r_amod) ischemia_24\NN\14195315|although_41|has_9|been_13|occur_34
D004176_D003324 NONE dipyridamole_16\NN\0|preoperative_13 (r_compound) therapy_17\NN\657604|NONE_0 (r_pobj) of_14\IN\0|a_14|side_12 (r_prep) effect_13\NN\34213|NONE_0 (r_pobj) as_10\IN\14622893|to_56|,_40|this_38|has_33|not_29|previously_25|been_14|,_53|demonstrated_114|._186 (r_prep) reported_9\VBN\831651|NONE_0 (l_advcl) demonstrated_27\VBN\2137132|to_170|,_154|this_152|has_147|not_143|previously_139|been_128|as_114|,_61|._72 (l_xcomp) occur_29\VB\0|although_75|ischemia_34|has_25|been_21 (l_prep) with_34\IN\0|to_31|in_22 (l_pobj) disease_37\NN\14061805|NONE_0
D004176_D003324 NONE dipyridamole_20\NN\0|-_12 (r_dep) induced_22\VBN\1627355|myocardial_8 (r_amod) ischemia_24\NN\14195315|although_41|has_9|been_13|occur_34 (r_nsubjpass) demonstrated_27\VBN\2137132|to_170|,_154|this_152|has_147|not_143|previously_139|been_128|as_114|,_61|._72 (l_xcomp) occur_29\VB\0|although_75|ischemia_34|has_25|been_21 (l_prep) with_34\IN\0|to_31|in_22 (l_pobj) disease_37\NN\14061805|NONE_0
D004176_D007511 NONE dipyridamole_23\NN\0|-_12 (r_npadvmod) induced_25\VBN\1627355|the_17 (r_amod) ischemia_26\NN\14195315|NONE_0
D004176_D000787 CID dipyridamole_10\NN\0|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) administration_7\NN\1133281|NONE_0 (r_pobj) after_6\IN\0|angina_58|in_42|._114 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) angina_0\NNP\14171682|after_58|in_100|._172
18791946
D002939_D015746 CID ciprofloxacin_16\NNS\2716866|NONE_0 (r_pobj) of_14\IN\0|3-day_21|for_22 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|man_46|with_33|._89 (r_prep) reported_5\VBN\831651|NONE_0 (l_prep) with_6\IN\0|man_13|after_33|._122 (l_pobj) pain_8\NN\14299637|NONE_0
D002939_D000743 CID ciprofloxacin_7\NNS\2716866|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|severe_47|and_23|anaemia_8 (r_acl) thrombocytopenia_1\JJ\14189204|:_69|a_71|case_73|with_85|._103 (l_conj) anaemia_4\NN\14299637|severe_39|and_15|associated_8
D002939_D000743 CID ciprofloxacin_5\NNS\2716866|that_5|may_14|thrombocytopenia_47|,_86|in_93 (r_nsubj) precipitate_7\VB\15046900|report_36|._147 (l_dobj) thrombocytopenia_11\JJ\14189204|that_52|ciprofloxacin_47|may_33|,_39|in_46 (l_conj) anaemia_14\NN\14299637|threatening_44|and_15
D002939_D013921 CID ciprofloxacin_7\NNS\2716866|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|severe_47|and_23|anaemia_8 (r_acl) thrombocytopenia_1\JJ\14189204|:_69|a_71|case_73|with_85|._103
D002939_D013921 CID ciprofloxacin_5\NNS\2716866|that_5|may_14|thrombocytopenia_47|,_86|in_93 (r_nsubj) precipitate_7\VB\15046900|report_36|._147 (l_dobj) thrombocytopenia_11\JJ\14189204|that_52|ciprofloxacin_47|may_33|,_39|in_46
D002939_D014552 NONE ciprofloxacin_16\NNS\2716866|NONE_0 (r_pobj) of_14\IN\0|3-day_21|for_22 (r_prep) administration_13\NN\1133281|NONE_0 (l_prep) for_17\IN\0|3-day_43|of_22 (l_pobj) suspect_19\NN\7846|NONE_0 (l_prep) of_20\IN\0|a_10 (l_pobj) infection_23\NN\14052046|NONE_0
D002939_D007565 CID ciprofloxacin_16\NNS\2716866|NONE_0 (r_pobj) of_14\IN\0|3-day_21|for_22 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|man_46|with_33|._89 (r_prep) reported_5\VBN\831651|NONE_0 (l_prep) with_6\IN\0|man_13|after_33|._122 (l_pobj) pain_8\NN\14299637|NONE_0 (l_conj) jaundice_10\NN\14299637|abdominal_19|and_4
17344566
D013974_D007037 NONE thyroxine_7\NN\5413241|with_36|._91 (l_compound) taking_6\VBG\37396|a_31|old_21|and_17|simvastatin_21 (l_nsubj) male_5\NN\15388|NONE_0 (l_amod) hypothyroid_4\JJ\0|NONE_0
D013974_D009135 NONE thyroxine_7\NN\5413241|with_36|._91 (r_nsubj) presented_10\VBD\2137132|NONE_0 (l_prep) with_11\IN\0|thyroxine_36|._55 (l_pobj) syndrome_15\NN\5870365|NONE_0 (l_conj) myonecrosis_17\NN\11486708|compartment_25|and_4
D019821_D009135 NONE simvastatin_0\NNP\3676175|-_11 (r_npadvmod) induced_2\VBN\1627355|compartment_22|and_43|myonecrosis_47|associated_59|._89 (r_amod) syndrome_6\NN\5870365|NONE_0 (l_conj) myonecrosis_8\NN\11486708|induced_47|compartment_25|and_4|associated_12|._42
D019821_D009135 NONE simvastatin_9\NN\3676175|a_52|old_42|taking_21|and_4 (r_conj) thyroxine_7\NN\5413241|with_36|._91 (r_nsubj) presented_10\VBD\2137132|NONE_0 (l_prep) with_11\IN\0|thyroxine_36|._55 (l_pobj) syndrome_15\NN\5870365|NONE_0 (l_conj) myonecrosis_17\NN\11486708|compartment_25|and_4
D019821_D007037 NONE simvastatin_0\NNP\3676175|-_11 (r_npadvmod) induced_2\VBN\1627355|compartment_22|and_43|myonecrosis_47|associated_59|._89 (r_amod) syndrome_6\NN\5870365|NONE_0 (l_acl) associated_9\VBN\628491|induced_59|compartment_37|and_16|myonecrosis_12|._30 (l_prep) with_10\IN\0|NONE_0 (l_pobj) hypothyroidism_11\NN\14059928|NONE_0
D019821_D007037 NONE simvastatin_9\NN\3676175|a_52|old_42|taking_21|and_4 (r_conj) thyroxine_7\NN\5413241|with_36|._91 (l_compound) taking_6\VBG\37396|a_31|old_21|and_17|simvastatin_21 (l_nsubj) male_5\NN\15388|NONE_0 (l_amod) hypothyroid_4\JJ\0|NONE_0
D019821_D003161 CID simvastatin_0\NNP\3676175|-_11 (r_npadvmod) induced_2\VBN\1627355|compartment_22|and_43|myonecrosis_47|associated_59|._89 (r_amod) syndrome_6\NN\5870365|NONE_0
D019821_D003161 CID simvastatin_9\NN\3676175|a_52|old_42|taking_21|and_4 (r_conj) thyroxine_7\NN\5413241|with_36|._91 (r_nsubj) presented_10\VBD\2137132|NONE_0 (l_prep) with_11\IN\0|thyroxine_36|._55 (l_pobj) syndrome_15\NN\5870365|NONE_0
D013974_D003161 NONE thyroxine_7\NN\5413241|with_36|._91 (r_nsubj) presented_10\VBD\2137132|NONE_0 (l_prep) with_11\IN\0|thyroxine_36|._55 (l_pobj) syndrome_15\NN\5870365|NONE_0
